<SEC-DOCUMENT>0001140361-19-017070.txt : 20190923
<SEC-HEADER>0001140361-19-017070.hdr.sgml : 20190923
<ACCEPTANCE-DATETIME>20190923060819
ACCESSION NUMBER:		0001140361-19-017070
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		36
FILED AS OF DATE:		20190923
DATE AS OF CHANGE:		20190923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-233659
		FILM NUMBER:		191106214

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>nt10002526x6_f1a.htm
<DESCRIPTION>F-1/A
<TEXT>
<html>
<head>
    <title> </title>
 <meta content="text/html; charset=UTF-8">
 <meta name="GeneratedBy" content="Summit Financial Printing, LLC" version="1.32">
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 6.3.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body>
<!-- 100-regcov -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>As </b><b>filed with</b><b> the Securities and Exchange Commission on </b><b>September </b><b>23</b><b>,</b><b> 2019</b></p>


<p class="regno" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: right; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>Registration No. 333-</b><b>233659</b><b> </b></p>

			<div style="clear: both;"></div></div>

<div class="block-frill" style="width: 100%; margin-left: 0%; ">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>

<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>UNITED STATES<br></b><b>SECURITIES AND EXCHANGE COMMISSION<br></b><b><font style="font-size: 10.67px;">Washington, D.C. 20549</font></b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>

<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>Amendment No. 1 to<br></b><b>FORM F-1<br></b><b>REGISTRATION STATEMENT<br></b><b>UNDER<br></b><b>THE SECURITIES ACT OF 1933</b></p>

				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -2.67px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16px; line-height: 12.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 1.33px; margin-bottom: 0px; "><b>ADC THERAPEUTICS SA<br></b><font style="font-size: 10.67px;">(Exact name of Registrant as specified in its charter)</font></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><b>Not Applicable<br></b><font style="font-size: 10.67px;">(Translation of Registrant&#8217;s name into English)</font></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="32%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><b>Switzerland</b></div>
							</td>
							<td width="34%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; "><b>2834</b></div>
							</td>
							<td width="34%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; "><b>Not Applicable</b></div>
							</td>
						</tr>
						<tr>
							<td width="32%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">(State or other jurisdiction of<br> incorporation or organization)</div>
							</td>
							<td width="34%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">(Primary Standard Industrial<br> Classification Code Number)</div>
							</td>
							<td width="34%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">(I.R.S. Employer<br> Identification No.)</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><b>Biop&#244;le<br> </b><b>Route de la Corniche 3B<br> </b><b>1066 Epalinges<br> </b><b>Switzerland<br> </b><b>+41 21 653 02 00<br></b>(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><b>ADC Therapeutics America, Inc.<br> </b><b>430 Mountain Avenue, 4th Floor<br> </b><b>Murray Hill, NJ 07974<br> </b><b>(908) 546-5556<br></b>(Name, address, including zip code, and telephone number, including area code, of agent for service)</p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><i><b>Copies to:</b></i></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="23%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><b>Deanna L. Kirkpatrick<br> </b><b>Yasin Keshvargar<br> </b><b>Davis Polk &amp; Wardwell LLP<br> </b><b>450 Lexington Avenue<br> </b><b>New York, NY 10017<br> </b><b>(212) 450-4000</b></div>
							</td>
							<td width="26%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; "><b>Dieter Gericke<br> </b><b>Benjamin Leisinger<br> </b><b>Homburger AG<br> </b><b>Hardstrasse 201<br> </b><b>CH-8005 Zurich,<br> </b><b>Switzerland<br> </b><b>+41 43 222 10 00</b></div>
							</td>
							<td width="26%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; "><b>Jacques Iffland<br> </b><b>Lenz &amp; Staehelin<br> </b><b>Route de Ch&#234;ne 30<br> </b><b>CH-1211 Geneva 6,<br> </b><b>Switzerland<br> </b><b>+41 58 450 70 00</b></div>
							</td>
							<td width="26%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; "><b>Richard Segal<br> </b><b>Divakar Gupta<br> </b><b>Alison Haggerty<br> </b><b>Cooley LLP<br> </b><b>500 Boylston Street<br> </b><b>Boston, MA 02116<br> </b><b>(617) 937-2300</b></div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 5.33px; margin-bottom: 0px; "><b>Approximate date of commencement of proposed sale to the public: </b>As soon as practicable after the effective date of this registration statement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font> </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font> </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font> </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font> </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company &#9746; </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="font-size: 1.33px;">&#8201;</font><font style="font-family: wingdings">o</font> </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">&#8224; The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 17%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><b>CALCULATION OF REGISTRATION FEE</b></p>
				<div class="calc" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: -8px; margin-top: 0px; "> </div></div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-top: 1pt solid #000000; border-bottom: 1pt solid #000000; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="56%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; border-right: 1px solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.83px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 1.83px; "><b>Title of each class of securities to be registered</b></div></td>
	<td colspan="3" width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; border-right: 1px solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 1.83px; padding-right: 1.83px; margin-right: 0px;"><div class="group-p" style="padding-left: 1.83px; padding-right: 1.83px; "><b>Proposed maximum<br> </b><b>aggregate offering price</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)</sup></b></div></td>
	<td colspan="3" width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 1.83px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 1.83px; padding-right: 0px; "><b>Amount of registration fee</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></b></div></td>
</tr>

					<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; border-right: 1px solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.83px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 1.83px; ">
Common shares, par value CHF 0.064 per share
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="20%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 244,103,600 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; border-right: 1px solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 29,586 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="calc" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: -8px; margin-top: 0px; "> </div><br></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Includes 1,224,600 common shares granted pursuant to the underwriters&#8217; option to purchase additional common shares.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(3)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Filing fees in the amount of $18,180.00 were previously paid.
</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 5.33px; margin-bottom: 0px; "><b>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall </b><b>file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the </b><b>Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to such </b><b>Section 8(a), may determine.</b></p>
			<div style="clear: both;"></div></div>



<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>



<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 101-cov -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-redherring" style="width: 100%; margin-left: 0%; ">
				<p class="unknown" style="color: #fc0014; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</p>
			</div>



<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="h1" style="color: #fc0014; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>SUBJECT TO COMPLETION DATED </i><i>SEPTEMBER 23</i><i>, 2019<br></i><i>PRELIMINARY PROSPECTUS</i></p>


<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><i>8,164,000</i><i> </i><i>Shares</i></p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="logo_adc.jpg" alt="" style="height: 68.40px; width: 139.20px; scale: ">&#8201;<br></p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; line-height: 22px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><i><b>ADC THERAPEUTICS SA<br></b></i><i><b>&nbsp;&nbsp;<br></b></i><i>Common Shares</i></p>
				<div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>

<p class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>We are offering </b></i><i><b>8,164,000 </b></i><i><b>of our common shares. This is our initial public offering and no public </b></i><i><b>market currently exists for our common shares. We anticipate that the initial public offering price will </b></i><i><b>be between $</b></i><i><b>23.00</b></i><i><b> and $</b></i><i><b>26.00</b></i><i><b> per common share.</b></i></p>


<p class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Our</b></i><i><b> common shares</b></i><i><b> have been approved for listing</b></i><i><b> on </b></i><i><b>the New York Stock Exchange (&#147;NYSE&#148;) </b></i><i><b>under </b></i><i><b>the symbol &#147;ADCT.&#148;</b></i></p>

				<div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>We are an &#147;emerging growth company&#148; as defined under U.S. federal securities laws and, as such, </b></i><i><b>may elect to comply with reduced public company reporting requirements for this and future filings. </b></i><i><b>See &#147;Prospectus Summary&#8212;Implications of Being an Emerging Growth Company.&#148;</b></i></p>
				<div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 16px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Investing in our common shares involves a high degree of risk. See &#147;Risk Factors&#148; </b></i><i><b>beginning on page</b></i><i><b> </b></i><i><b><a href="#tRF">11</a></b></i><i><b> </b></i><i><b>of this prospectus.</b></i></p>
				<div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or </b></i><i><b>disapproved of these securities or determined if this prospectus is truthful or complete. Any </b></i><i><b>representation to the contrary is a criminal offense. </b></i></p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 12px; margin-bottom: 12px; " div="yes"></p><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 2.67px; margin-top: 0px; "> </div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="66%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 13.13px; ">&#160;</div></td>
	<td colspan="3" width="19%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 13.13px; padding-right: 13.13px; "><i><b>PER SHARE</b></i></div></td>
	<td colspan="3" width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 13.13px; padding-right: 0px; "><i><b>TOTAL</b></i></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="66%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 13.13px; "><i>Initial public offering price</i></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><i>$</i></div></td><td width="16%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><i>&nbsp;&nbsp;&nbsp;&nbsp;</i><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><i>$</i></div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><i>&nbsp;&nbsp;&nbsp;&nbsp;</i></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="66%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 13.13px; "><i>Underwriting discounts and commissions</i><i><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></i></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><i>$</i></div></td><td width="16%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><i>$</i></div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="66%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 13.13px; "><i>Proceeds, before expenses, to us</i></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><i>$</i></div></td><td width="16%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><i>$</i></div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 16%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; "><i>(1)</i></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; "><i>See &#147;Underwriters&#148; for a description of all compensation payable to the underwriters.</i></td></tr></table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>We have granted the underwriters an option for a period of 30 days to purchase up to an </i><i>additional</i><i> 1,224,600</i><i> common shares.</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><i>Astra</i><i>Zeneca, Redmile Group,</i><i> LLC and certain </i><i>of our other</i><i> existing shareholders and/or their</i><i> </i><i>respective</i><i> affiliated entities have indicated an interest in purchasing up to approximately $115 </i><i>million of the common shares being offered in this offering at the initial public offering price and </i><i>on the same terms as the other purchasers in this offering. However, because indications of </i><i>interest are not binding agreements or commitments to purchase, the underwriters could </i><i>determine to sell more, fewer or no shares to any of these potential purchasers, and any of these </i><i>potential purchasers could determine to purchase more, fewer or no shares in this offering.</i> </p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>The underwriters expect to deliver the common shares against payment in New York, New York </i><i>on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.</i></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="37%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i>MORGAN STANLEY</i></div>
							</td>
							<td width="45%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; "><i>BofA MERRILL LYNCH</i></div>
							</td>
							<td width="18%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; "><i>COWEN</i></div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.</i></p>
			</div><div style="clear: both"></div>



<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 102-toc -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>TABLE OF CONTENTS</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<a name="TOC"></a><table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tPS">Prospectus Summary</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tPS">1</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tRF">Risk Factors</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tRF">11</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tCSR">Cautionary Statement Regarding Forward-Looking Statements</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tCSR">72</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tMID">Market and Industry Data</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tMID">74</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tUP">Use of Proceeds</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tUP">75</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tDP">Dividend Policy</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tDP">77</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tC">Capitalization</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tC">78</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tD">Dilution</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tD">80</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tSCF">Selected Consolidated Financial Data</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tSCF">82</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tMDA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tMDA">84</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tB">Business</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tB">102</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tM">Management</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tM">171</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tS">Principal Shareholders</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tS">181</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tRPT">Related Party Transactions</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tRPT">184</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tDSC">Description of Share Capital and Articles of Association</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tDSC">187</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tCOSL">Comparison of Swiss Law and Delaware Law</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tCOSL">199</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tCSE">Common Shares Eligible for Future Sale</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tCSE">207</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tT">Taxation</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tT">209</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tU">Underwriters</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tU">217</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tEO">Expenses of the Offering</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tEO">226</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tLM">Legal Matters</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tLM">227</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tE">Experts</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tE">227</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tEJ">Enforcement of Judgments</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tEJ">228</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#tWYC">Where You Can Find More Information</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#tWYC">229</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7px; "><a href="#fFINTOC">Index to Financial Statements</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fFINTOC">F-1</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are organized under the laws of Switzerland and our registered office and domicile is located in Epalinges, Canton of Vaud, Switzerland. Moreover, a number of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. See &#147;Enforcement of Judgments&#148; for additional information.</p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless otherwise indicated or the context otherwise requires, all references in this prospectus to &#147;ADC Therapeutics,&#148; &#147;ADCT,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;our,&#148; &#147;ours,&#148; &#147;us&#148; or similar terms refer to ADC Therapeutics SA and its consolidated subsidiaries.</p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We own various trademark registrations and applications, and unregistered trademarks, including ADC Therapeutics, ADCT and our corporate logo. All other trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and &#8482; symbols, but such </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">i</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#146; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#147;IFRS&#148;). None of the consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States (&#147;U.S. GAAP&#148;). The terms &#147;dollar,&#148; &#147;USD&#148; or &#147;$&#148; refer to U.S. dollars and the term &#147;Swiss franc&#148; and &#147;CHF&#148; refer to the legal currency of Switzerland, unless otherwise indicated. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts listed are due to rounding.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our historical audited consolidated financial statements as of and for the years ended December 31, 2018 and December 31, 2017 have been restated. See Notes 1 and 25 to the audited consolidated financial statements included elsewhere in this prospectus.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The financial information should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our fiscal year ends on December 31. References in this prospectus to a fiscal year, such as &#147;fiscal year 2018,&#148; relate to our fiscal year ended on December 31 of that calendar year.</p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We and the underwriters have not authorized anyone to provide any information or to make any representations other than as contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we may have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Neither we nor the underwriters are making an offer to sell the common shares in any jurisdiction where the offer or sale is not permitted. This offering is being made in the United States and elsewhere solely on the basis of the information contained in this prospectus. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of the common shares. Our business, financial condition, results of operations and prospects may have changed since the date on the front cover of this prospectus. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of common shares and the distribution of this prospectus outside the United States.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Until &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (25 days after the date of this prospectus), all dealers that effect transactions in the </i><i>common shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in </i><i>addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their </i><i>unsold allotments or subscriptions.</i></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are incorporated as a Swiss stock corporation (<i>soci&#233;t&#233; anonyme</i>) under the laws of Switzerland, and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules of the U.S. Securities and Exchange Commission (the &#147;SEC&#148;), we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;).</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">ii</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 103-summary -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tPS"></a><b>PROSPECTUS SUMMARY </b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>This summary highlights information contained elsewhere in this prospectus. This summary may not contain all the </i><i>information that may be important to you, and we urge you to read this entire prospectus carefully, including the &#147;Risk </i><i>Factors,&#148; &#147;Business&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; </i><i>sections and our consolidated financial statements, including the notes thereto, included elsewhere in this prospectus, </i><i>before deciding to invest in our common shares.</i></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Overview</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.87px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (&#147;ADCs&#148;) for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation pyrrolobenzodiazepine (&#147;PBD&#148;) technology to which we have proprietary rights for our targets. We are leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises three clinical-stage product candidates, ADCT-402, ADCT-301 and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, ADCT-301 and ADCT-601, and two preclinical product candidates, ADCT-701 and ADCT-901. We retain worldwide development and commercialization rights to all of our product candidates, other than ADCT-301 for which we have a collaboration and license agreement with Genmab A/S (&#147;Genmab&#148;). </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.87px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our two lead product candidates, ADCT-402 and ADCT-301, have demonstrated significant clinical activity in heavily pre-treated patients, while maintaining manageable tolerability profiles. We are evaluating ADCT-402 in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (&#147;DLBCL&#148;). In August 2019, we achieved the targeted enrollment for this clinical trial and, as of August 2, 2019, have observed a 41.7% overall response rate (&#147;ORR&#148;) in the first 96 patients treated with ADCT-402. Previously, we completed a 183-patient Phase 1 clinical trial of ADCT-402 for the treatment of relapsed or refractory non-Hodgkin lymphoma (&#147;NHL&#148;) that showed a 41.4% ORR in patients with DLBCL at the initial dose for the Phase 2 clinical trial. If the pivotal Phase 2 clinical trial of ADCT-402 is successful, we intend to submit a biologics license application (&#147;BLA&#148;) to the U.S. Food and Drug Administration (&#147;FDA&#148;) in the second half of 2020. In addition, we have begun patient enrollment in a pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory Hodgkin lymphoma (&#147;HL&#148;). We have completed enrollment of a 133-patient Phase 1 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and NHL that has shown an 86.5% ORR in patients with HL at the initial dose planned for the Phase 2 clinical trial. We believe that our pivotal Phase 2 clinical trial of ADCT-301, if successful, will support a BLA submission in the first half of 2022. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.85px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Antibody drug conjugates are an established therapeutic approach in oncology used to selectively deliver potent chemotherapeutic cytotoxins directly to tumor cells, with the goal of maximizing activity in tumor cells while minimizing toxicity to healthy cells. The antibody component is designed to selectively bind to a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment. Upon binding to the antigen, most ADC molecules are internalized by the cell where the cytotoxic warhead is released causing cell death.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.87px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">PBD warheads have a different mechanism of action than other warheads because they create cross-links in the cancer cells&#146; DNA that do not distort the DNA helix, potentially evading the cells&#146; natural DNA repair mechanisms. They have been shown preclinically to be approximately 100 times more potent than warheads used in currently marketed ADCs. Our ADCs use next-generation PBD technology, which is designed to produce warheads that are less hydrophobic, causing them to be easier to conjugate and, based on preclinical data, have less off-target toxicity, than first-generation PBD warheads. Preclinical studies have further shown that our next-generation PBD warheads have improved therapeutic indices compared to first-generation PBDs. We believe that this mechanism of action has the potential to allow our ADCs to achieve significant clinical activity and durable responses in difficult-to-treat patients. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.85px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We were founded in 2011 as a spinoff from Spirogen Ltd. (&#147;Spirogen&#148;), which was founded in 2000 and was an early innovator in PBD-based ADC research. Our co-founder and CEO, Dr. Christopher Martin, was a founder and the CEO of Spirogen until its sale to AstraZeneca plc in 2013. We leverage Dr. Martin&#146;s decades-long experience in the development and evolution of PBD-based ADC research. Our senior management team also brings extensive experience in oncology research and development, clinical development, chemistry, manufacturing and controls (&#147;CMC&#148;) and regulatory and compliance, having held senior positions in such companies as AstraZeneca plc, Celgene Corporation, Daiichi Sankyo Company, Genentech, Inc., Genmab, and Wyeth Pharmaceuticals, Inc. Our board of directors includes former senior executives of AstraZeneca plc, GlaxoSmithKline plc, Pfizer Inc., F. Hoffmann-La Roche AG and Serono S.A.</p>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">1</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since inception, we have raised $558.6 million in gross cash proceeds from equity financings. Our headquarters are based in Lausanne, Switzerland, our research and development team is based in London, our clinical development team is based in New Jersey and in Lausanne, and our CMC team is based in the San Francisco Bay Area.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>The Potential of </b><b>Our Next-Generation PBD-Based Antibody Drug Conjugates</b><b> </b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Cytotoxic Potency</i>. The PBD dimer warheads used in our ADCs have been shown preclinically to be approximately 100 times more potent than other warheads used in marketed ADCs, such as auristatin, maytansine and calicheamicin. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Activity</i><i> in Tumors with Low-Expressing Targets</i>. The high potency of our PBD-based warheads means that, compared to other warheads, fewer molecules of warhead should be needed to be internalized into the cancer cell to kill it. We believe that the potency of our PBD-based warheads may allow us to develop ADCs that target antigens with low expression levels in the tumor microenvironment, potentially increasing the range of cancers amenable to treatment with ADCs. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Durable Responses</i>. Our PBD-based ADCs create <i>inter</i>strand cross-links in the target cells&#8217; DNA. As PBD cross-links are non-distortive, they are designed to be able to evade the cells&#8217; DNA repair mechanisms that result in limited clinical responses and relapses. We believe that this may contribute to the durability of the responses that we have observed in our clinical trials. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Bystander Effect</i>. Since our PBD-based warheads are cell-permeable, they may be able to diffuse into adjacent cells and kill them in an antigen-independent manner. We believe that this may allow us to develop ADCs that target antigens with heterogeneous expression levels in the tumor microenvironment, potentially increasing the range of cancers amenable to treatment with ADCs. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Immunogenic Cell Death</i>. PBD warheads have been observed to induce immunogenic cell death, whereby a cancer cell&#8217;s death expresses certain stress signals that induce the body&#8217;s anti-tumor immune response through the activation of T cells and antigen-presenting cells. This opens up the potential for combining our ADCs with other therapies, particularly with immuno-oncology therapies such as checkpoint inhibitors, that are specifically designed to activate the patient&#8217;s own immune system to combat cancer. </td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Pipeline</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_barchart1.jpg" alt="" style="height: 261.24px; width: 609.84px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">*We believe that our Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL and our Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL are pivotal clinical trials (i.e., a clinical trial intended to serve as the basis for BLA submission). Therefore, we believe that the Phase 3 clinical trials of ADCT-402 for the treatment of relapsed or refractory DLBCL and of ADCT-301 for the treatment of relapsed or refractory HL will be post-marketing confirmatory clinical trials. **We retain worldwide development and commercialization rights to ADCT-301, subject to our collaboration and license agreement with Genmab. See &#147;Business&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#148; </p>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">2</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>ADCT-402 </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our lead product candidate, ADCT-402, is an ADC targeting CD19-expressing cancers. We are developing ADCT-402 for the treatment of relapsed or refractory NHL, both when used as a monotherapy and when used in combination with other therapies. The following summary provides key information about ADCT-402: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have completed a 183-patient Phase 1 clinical trial of ADCT-402 for the treatment of relapsed or refractory NHL, including 137 patients with relapsed or refractory DLBCL. In this clinical trial, ADCT-402 demonstrated significant clinical activity, while maintaining a manageable tolerability profile. More specifically, we observed: </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">in heavily pre-treated patients with relapsed or refractory DLBCL who have received a median of </font><font style="font-size: 13.33px;">three prior lines of therapy</font><font style="font-size: 13.33px;">:</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="80px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a 42.3% ORR across all doses;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="80px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a 41.4% ORR at the initial dose in our pivotal Phase 2 clinical trial; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">a 46.7% ORR in heavily pre-treated patients with relapsed or refractory MCL who have received a </font><font style="font-size: 13.33px;">median of four prior lines of therapy; and </font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">a 78.6% ORR in heavily pre-treated patients with relapsed or refractory FL who have received a </font><font style="font-size: 13.33px;">median of four prior lines of therapy. </font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ADCT-402 is being evaluated in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL, for which we anticipate reporting response rate data in the second quarter of 2020. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">As of August 2, 2019, we observed a 41.7% ORR in the first 96 patients treated with ADCT-402.</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ADCT-402 is also being evaluated in a Phase 1b clinical trial in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and mantle cell lymphoma (&#147;MCL&#148;), for which we anticipate reporting safety and efficacy data in the fourth quarter of 2020. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">In addition, ADCT-402 is being evaluated in a Phase 1b clinical trial in combination with durvalumab for the treatment of relapsed or refractory DLBCL, MCL and follicular lymphoma (&#147;FL&#148;), for which we anticipate reporting safety and efficacy data in the fourth quarter of 2020. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">If our pivotal Phase 2 clinical trial is successful, we intend to submit a BLA for ADCT-402 for the treatment of relapsed or refractory DLBCL in the second half of 2020. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We retain worldwide development and commercialization rights to ADCT-402. If approved, we intend to commercialize ADCT-402 in the United States through our own commercial infrastructure and to selectively pursue strategic collaborations in other geographies. </td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>ADCT-301 </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our second lead product candidate, ADCT-301, is an ADC targeting CD25-expressing cancers. We are developing ADCT-301 for the treatment of relapsed or refractory HL, NHL and solid tumors. The following summary provides key information about ADCT-301: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Enrollment has been completed in a 133-patient Phase 1 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and NHL, including 77 patients with relapsed or refractory HL. In this clinical trial, as of April 14, 2019, ADCT-301 demonstrated significant clinical activity, while maintaining a manageable tolerability profile. More specifically, we observed: </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">in heavily pre-treated patients with relapsed or refractory HL who have received a median of five </font><font style="font-size: 13.33px;">prior lines of therapy</font><font style="font-size: 13.33px;">:</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="80px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a 70.7% ORR across all doses;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="80px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an 86.5% ORR at the initial dose planned in our pivotal Phase 2 clinical trial; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">a 44.0% ORR in heavily pre-treated patients with relapsed or refractory T-cell lymphoma who </font><font style="font-size: 13.33px;">have received a median of four prior lines of therapy. </font></td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">3</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have begun patient enrollment in a pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL, for which we anticipate reporting response rate data in the fourth quarter of 2021. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ADCT-301 is being evaluated in a Phase 1b clinical trial for the treatment of selected advanced solid tumors.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We intend to advance ADCT-301 through clinical development to support a BLA submission for the treatment of relapsed or refractory HL in the first half of 2022. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We retain worldwide development and commercialization rights to ADCT-301, subject to our collaboration and license agreement with Genmab. </td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our </b><b>Strategy</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Key elements of our strategy are outlined below: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Advance our lead product candidate, ADCT-402, to BLA submission in the second half of 2020. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Advance our second lead product candidate, ADCT-301, to support BLA submission in the first half of 2022. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Advance our two clinical-stage solid tumor product candidates, with the potential to address multiple indications in areas of high unmet medical need. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Continue to build a diverse and balanced portfolio of product candidates to address high unmet medical needs in oncology by leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Maximize the commercial potential of our product candidates. </td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Associated with Our Business</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ability to implement our business strategy is subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following this prospectus summary. These risks include, among others:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have incurred net losses during all fiscal periods since our inception, have no products approved for commercial sale and anticipate that we will continue to incur substantial net losses for the foreseeable future.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have concentrated our research and development efforts on PBD-based ADCs, and our future success depends heavily on the successful development of this therapeutic approach.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Our current product candidates are in various stages of development, and it is possible that none of our product candidates will ever become commercial products.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">A clinical hold on any of our clinical trials may result in delays of our clinical development timeline. In the past, certain of our clinical trials have been subject to clinical holds prior to the dosing of the first patient and partial clinical holds after the dosing of the first patient.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Our product candidates may cause undesirable side effects or have other properties that may delay or prevent their development or regulatory approval or limit their commercial potential.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The regulatory review and approval processes of the FDA, the European Medicines Agency (&#147;EMA&#148;) and comparable regulatory authorities in other jurisdictions are lengthy, time consuming and inherently unpredictable. If we are unable to obtain, or if there are delays in obtaining, regulatory approval for our product candidates, we will not be able to commercialize our product candidates and our ability to generate revenue will be materially impaired.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have never commercialized a product and we currently have no sales force, marketing or distribution capabilities and may lack the necessary expertise, personnel and resources to successfully commercialize our product candidates.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We face substantial competition, which may result in others discovering, developing or commercializing products, treatment methods and/or technologies before or more successfully than we do.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">4</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Our rights to ADCT-301 are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will maintain the rights to develop or commercialize ADCT-301.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We rely on third parties for the manufacture, production, storage and distribution of our product candidates. Our dependence on these third parties may impair the clinical advancement and commercialization of our product candidates.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Issued patents covering one or more of our product candidates or technologies, including ADCT-402, ADCT-301 or the technology we use in our product candidates, could be found invalid or unenforceable if challenged in court.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">If we fail to attract and retain senior management and key scientific personnel or fail to adequately plan for succession, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have identified a material weakness in our internal control over financial reporting. If we are unable to remediate this material weakness or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our common shares.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Company and Corporate Information</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We were incorporated as a Swiss limited liability company (<i>soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</i>) on June 6, 2011 and converted into a Swiss stock corporation (<i>soci&#233;t&#233; anonyme</i>) under the laws of Switzerland on October 13, 2015. We have two subsidiaries: ADC Therapeutics (UK) Limited and ADC Therapeutics America, Inc. Our principal executive office is located at Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland and our telephone number is +41 21 653 02 00. Our website is www.adctherapeutics.com. The reference to our website is an inactive textual reference only and information contained therein or connected thereto are not incorporated into this prospectus or the registration statement of which it forms a part.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Share Capital Reorganization</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Immediately prior to the completion of this offering, our outstanding share capital will consist of 65,088,000 common shares. Prior to the completion of this offering, we intend to complete the remaining steps in our share capital reorganization. Our share capital reorganization consists of (i) an increase of the par value of each of our Class A common shares and Class B, C, D and E preferred shares from CHF 100 per share to CHF 1,000 per share, against the conversion of distributable reserves into share capital (the &#147;Par Value Increase&#148;), which was effected on August 28, 2019, (ii) a one-to-15,625 share split of all issued shares and reclassification of our issued Class A common shares into common shares (the &#147;Share Split&#148;), which was effected on September 19, 2019, and (iii) a conversion on a one-to-one basis of our issued Class B, C, D and E preferred shares into common shares (the &#147;Conversion,&#148; and together with the Par Value Increase and the Share Split, the &#147;Share Capital Reorganization&#148;), which will be effected immediately prior to the completion of this offering. See &#147;Description of Share Capital and Articles of Association&#8212;Share Capital.&#148;</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Implications of Being an Emerging Growth Company</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging growth company, we may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a requirement to have only two years of audited financial statements in addition to any required interim financial statements and correspondingly reduced disclosure in the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in the registration statement of which this prospectus forms a part;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the &#147;Sarbanes-Oxley Act&#148;); and</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">5</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to the extent that we no longer qualify as a foreign private issuer, (i) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (ii) exemptions from the requirements of holding a non-binding advisory vote on executive compensation, including golden parachute compensation.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the previous three years; and (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common shares that are held by non-affiliates exceeds $700.0 million as of the prior June 30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>. We may choose to take advantage of some but not all of these reduced burdens. For example, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. This transition period is only applicable under U.S. GAAP. As a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required or permitted by the International Accounting Standards Board.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Implications of Being a Foreign Private Issuer</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are also considered a &#147;foreign private issuer.&#148; Accordingly, upon consummation of this offering, we will report under the Exchange Act as a non-U.S. company with foreign private issuer status. This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i) the majority of our executive officers or directors are U.S. citizens or residents, (ii) more than 50% of our assets are located in the United States or (iii) our business is administered principally in the United States. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In this prospectus, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company and a foreign private issuer. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities.</p>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">6</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>THE OFFERING</b></p>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">Common shares offered by us</div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">
8,164,000 shares.
</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 298.67px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 13.33px; text-indent: -13.33px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">Option to purchase additional common shares offered by us</div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">
We have granted the underwriters an option for a period of 30 days to purchase up to 1,224,600 additional common shares.
</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 298.67px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 13.33px; text-indent: -13.33px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">Common shares to be outstanding immediately after this offering</div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">
73,252,000 shares (or 74,476,600 shares if the underwriters exercise their option to purchase additional common shares in full).
</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">Use of proceeds</div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">
We estimate that the net proceeds to us from this offering will be approximately $178.3 million, or approximately $205.9 million if the underwriters exercise their option to purchase additional common shares in full, assuming an initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</div>

<p class="sum2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 320px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: (i) to advance ADCT-402 through the completion of the ongoing pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL and the other ongoing clinical trials and to commence preparations for a clinical trial that we anticipate will be a post-marketing confirmatory clinical trial if ADCT-402 is approved on the basis of Phase 2 data; (ii) to advance ADCT-301 through the completion of the ongoing pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL and the other ongoing clinical trial and to commence and advance potential combination clinical trials; (iii) to advance ADCT-602 through the completion of the ongoing Phase 1/2 clinical trial for the treatment of relapsed or refractory ALL; (iv) to advance ADCT-601 through the completion of the ongoing Phase 1 clinical trial for the treatment of selected advanced solid tumors; (v) to commence the scale up of commercial operations in the United States for ADCT-402 and to fund our commercial-scale CMC plans for ADCT-402 and ADCT-301; (vi) to fund the research and development of our preclinical product candidates and preclinical pipeline; and (vii) for working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for a more complete description of the intended use of proceeds from this offering.</p>

				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">Risk factors</div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our common shares.</div>
			</div><div style="clear: both"></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">7</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">Directed share program</div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">
At our request, the underwriters have reserved 5% of the common shares offered by this prospectus, for sale, at the initial public offering price, to our employees and to friends, professional contacts and family members of our employees and directors. If purchased by these persons, these shares will not be subject to a lock-up restriction, except in the case of shares purchased by any officer, which will be subject to a 180-day lock-up restriction described under &#147;Underwriters.&#148; The number of common shares available for sale to the general public will be reduced by the number of reserved common shares sold to these individuals. Any reserved common shares that are not so purchased will be offered by the underwriters to the general public on the same basis as the other common shares offered by this prospectus. See &#147;Underwriters.&#148;
</div>
				<div style="clear: both;"></div><div class="rmk" style="float: left; width: 312px; margin-top: 8px; padding-right: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">NYSE symbol</div>
				<div class="rmk" style="overflow: hidden; margin-top: 8px; color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-bottom: 0px; ">&#147;ADCT&#148;</div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The number of common shares that will be outstanding after this offering is based on 65,088,000 common shares, which is the number of common shares outstanding immediately prior to the completion of this offering and excludes:</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
9,104,000 of our common shares reserved for future issuance under our 2019 Equity Incentive Plan, which will become effective in connection with this offering; and
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
1,583,875 common shares we hold in treasury, net of the delivery of an estimated 968,750 common shares (subject to adjustments for final tax and social security deductions) that we expect to deliver to participants of our 2014 Incentive Plan to settle outstanding awards thereunder in connection with this offering.
</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless otherwise indicated, all information contained in this prospectus assumes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the Share Capital Reorganization;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the filing and effectiveness of our amended and restated articles of association, which will occur immediately prior to the completion of this offering;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
no exercise of the option granted to the underwriters to purchase up to 1,224,600 additional common shares in connection with this offering;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
an initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">no purchase of common shares in this offering by directors, officers or existing shareholders;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
the issuance and repurchase of 140 Class A common shares (2,187,500 common shares after giving effect to the Share Capital Reorganization) on September 19, 2019, for the settlement of share grants and equity-linked instruments for directors, officers, employees and consultants;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
the delivery to participants of our 2014 Incentive Plan of an estimated 968,750 common shares (subject to adjustments for final tax and social security deductions), which we currently hold in treasury, to settle outstanding awards under our 2014 Incentive Plan in connection with this offering; and
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">no issuance of any common shares reserved for future issuance under our 2019 Equity Incentive Plan, as described in the immediately preceding paragraph.</td></tr></table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">AstraZeneca, Redmile Group, LLC and certain of our other existing shareholders and/or their respective affiliated entities have indicated an interest in purchasing up to approximately $115 million of the common shares being offered in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to any of these potential purchasers, and any of these potential purchasers could determine to purchase more, fewer or no shares in this offering. </p>

			</div><div style="clear: both"></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">8</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>SUMMARY CONSOLIDATED FINANCIAL DATA</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following summary consolidated financial data should be read in conjunction with &#147;Selected Consolidated Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements, including the notes thereto, included elsewhere in this prospectus. The summary consolidated income statement data for the years ended December 31, 2018 and 2017 are derived from our audited consolidated financial statements included elsewhere in this prospectus. The summary consolidated income statement data for the six months ended June 30, 2019 and 2018 and the consolidated balance sheet data as of June 30, 2019 are derived from our unaudited interim consolidated financial statements included elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same basis as our audited consolidated financial statements and include all normal recurring adjustments that we consider necessary for a fair statement of our financial position and operating results as of the dates and for the periods presented. Our historical results are not necessarily indicative of the results that may be expected in the future, and our results for the six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our audited consolidated financial statements are prepared in accordance with IFRS and presented in USD. Our unaudited interim consolidated financial statements are prepared in compliance with IAS 34 and presented in USD.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.98px; padding-right: 9.98px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.98px; padding-right: 0px; "><i><b>Restated</b></i></div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.98px; padding-right: 9.98px; "><b>Six Months Ended June 30,</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.98px; padding-right: 0px; "><b>Year Ended December 31,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">&#160;</div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.98px; padding-right: 9.98px; "><b>2019</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.98px; padding-right: 9.98px; "><b>2018</b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.98px; padding-right: 9.98px; "><b>2018</b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 9.98px; padding-right: 0px; "><b>2017</b></div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; "><b>Consolidated Income Statement Data:</b></div></td>
	<td colspan="12" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 9.98px; padding-right: 0px; "><b>(in USD thousands except for share and per share data)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Contract revenue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,340</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">625</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,140</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,803</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(46,572</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(60,133</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(118,313</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(85,530</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(6,592</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(3,969</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(8,768</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7,943</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Operating loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(50,824</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(63,477</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(125,941</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(91,670</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Financial income</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,306</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,641</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,856</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,031</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Financial expense</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(68</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(156</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">213</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">825</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Loss before taxes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,659</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,680</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,872</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,814</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Income tax expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(199</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(224</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(48</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Loss for the period</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(49,858</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(61,828</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (0.84 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (1.07 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Weighted-average number of shares used to compute basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 59,122,324 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 57,968,750 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 58,250,000 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 48,989,383 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Pro forma basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (0.83 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (2.09 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.98px; ">Weighted-average number of shares used to compute pro forma basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 59,725,949 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 58,853,625 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
See Note 23 to our audited consolidated financial statements and Note 13 to our unaudited interim consolidated financial statements included elsewhere in this prospectus for a description of the method used to compute basic and diluted net loss per share. These figures have been retroactively adjusted to give effect to the Share Split, which was effected on September 19, 2019.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
The pro forma information gives effect to the following: (i) our issuance and sale of an aggregate of 77 Class E preferred shares (1,203,125 common shares after giving effect to the Share Capital Reorganization) on July 5, 2019; (ii) the delivery of 23.368 Class A common shares (365,125 common shares after the Share Capital Reorganization) by certain of our directors and officers for the settlement of the 2013 Promissory Notes and the 2016 Promissory Notes; (iii) our issuance and repurchase of 140 Class A common shares (2,187,500 common shares after giving effect to the Share Capital Reorganization) on September 19, 2019, for the settlement of share grants and equity-linked instruments for directors, officers, employees and consultants; (iv) the delivery to participants of our 2014 Incentive Plan of an estimated 968,750 common shares (subject to adjustments for final tax and social security deductions), which
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">9</p>

			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 98%; margin-left: 0%; padding-left: 1%; padding-right: 1%; border: solid 1pt black; padding-bottom: 20px;">

<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">we currently hold in treasury, to settle outstanding awards under our 2014 Incentive Plan in connection with this offering and the related payment by us of an estimated $10 million in tax and social security liabilities on behalf of participants of our 2014 Incentive Plan; (v) the Par Value Increase; and (vi) the Conversion, as if each such event occurred on the first day of the period presented (other than with respect to (i)). </p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(3)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">On January 1, 2019, we adopted IFRS 16 &#147;Leases,&#148; the impact of which is described in Note 3 to our unaudited interim consolidated financial statements.</td></tr></table><div style="clear: both"></div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.29px; padding-right: 0px; "><b>As of </b><b>June</b><b> 3</b><b>0</b><b>, 201</b><b>9</b></div></td>
</tr>
<tr>
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.29px; padding-right: 8.29px; "><b>Actual</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.29px; padding-right: 8.29px; "><b>Pro Forma</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></b></div></td>
	<td colspan="3" width="25%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 8.29px; padding-right: 0px; "><b>Pro Forma As Adjusted</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)(3)</sup></b></div></td>
</tr>
<tr>
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; "><b>Consolidated Balance Sheet Data:</b></div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 8.29px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">182,156</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 172,156 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 350,473 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Total assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">200,839</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 190,839 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 369,156 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Share capital</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">424</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 4,362 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 4,887 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Share premium</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">527,083</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 588,742 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 766,534 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Shares to be issued</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">26,641</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> &#8212; </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> &#8212; </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Other reserves</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 5,835 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (43,121 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (43,121 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Cumulative translation adjustments</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(51</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (51 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (51 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Accumulated losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> (381,943 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> (381,943 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> (381,943 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="45%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 8.29px; ">Total equity</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">177,989</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 167,989 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="22%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 346,306 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
The pro forma information gives effect to the following adjustments: (i) our issuance and sale of an aggregate of 77 Class E preferred shares (1,203,125 common shares after giving effect to the Share Capital Reorganization) on July 5, 2019; (ii)  the delivery of 23.368 Class A common shares (365,125 common shares after the Share Capital Reorganization) by certain of our directors and officers for the settlement of the 2013 Promissory Notes and the 2016 Promissory Notes; (iii) our issuance and repurchase of 140 Class A common shares (2,187,500 common shares after giving effect to the Share Capital Reorganization) on September 19, 2019, for the settlement of share grants and equity-linked instruments for directors, officers, employees and consultants; (iv) the delivery to participants of our 2014 Incentive Plan of an estimated 968,750 common shares (subject to adjustments for final tax and social security deductions), which we currently hold in treasury, to settle outstanding awards under our 2014 Incentive Plan in connection with this offering and the related payment by us of an estimated $10 million in tax and social security liabilities on behalf of participants of our 2014 Incentive Plan; (v) the Par Value Increase; and (vi) the Conversion.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
The pro forma as adjusted information gives effect to the pro forma adjustments described in footnote (1) above and our issuance and sale of 8,164,000 common shares in this offering at the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(3)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
The pro forma as adjusted information is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, total assets and total equity by $7.6 million, assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each 1,000,000 share increase or decrease in the number of common shares offered by us would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, total assets and total equity by $22.8 million, assuming the assumed initial public offering price of $24.50 per common share, the midpoint of the price range set forth on the cover page of this prospectus remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>





<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">10</p>
			</div>


<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 104-risk -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tRF"></a><b>RISK FACTORS</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Investing in our common shares involves a high degree of risk. You should carefully consider the risks and </i><i>uncertainties described below together with all of the other information contained in this prospectus, including </i><i>our consolidated financial statements </i><i>including the notes thereto, included elsewhere in</i><i> this prospectus, before </i><i>deciding to invest in our common shares. If any of the events or developments described below were to occur, </i><i>our business, results of operations, financial condition and prospects could suffer materially, the trading price of </i><i>our common shares could decline and you could lose all or part of your investment. The risks and uncertainties </i><i>described below are not the only ones we face. Additional risks and uncertainties not presently known to us or </i><i>that we currently believe to be immaterial may also adversely affect our business. If any of the following risks </i><i>occur, our business, results of operations, financial condition and prospects could be materially and adversely </i><i>affected.</i></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Our Financial Position and Capital Requirements</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>We have incurred net losses during all fiscal periods since our inception, have no products approved for </b></i><i><b>commercial sale and anticipate that we will continue to incur substantial net losses for the foreseeable future.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a clinical-stage biotechnology company and have a history of net losses. For the years ended December 31, 2018 and 2017, our net loss was $123.1 million and $89.9 million, respectively. For the six months ended June 30, 2019, our net loss was $49.9 million. As of June 30, 2019, we had accumulated net losses of $381.9 million. Our net losses have resulted principally from costs incurred in our research and development activities and personnel expenses.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect to continue to incur significant expenses and increasing net losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval for and commercialize our product candidates. We anticipate that our expenses will increase substantially as we:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">conduct and complete the pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
conduct and complete the pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">conduct and complete the Phase 1b clinical trials of ADCT-402 and ADCT-301 for the treatment of other indications and Phase 1 clinical trials for our other product candidates, as well as any subsequent clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">commence and conduct any required post-marketing confirmatory clinical trials for any of our product candidates in anticipation of potential accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory agencies in other jurisdictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expand our research and development efforts for our preclinical product candidates and research pipeline;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">seek regulatory approval for our product candidates from applicable regulatory authorities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">invest in our late-stage clinical development, manufacturing and commercialization activities, including launching commercial sales, marketing and distribution operations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">continue to prepare, file, prosecute, maintain, protect and enforce our intellectual property rights and claims;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">add clinical, scientific, operational, financial and management information systems and personnel; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">operate as a public company.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Even if we obtain regulatory approval of and are successful in commercializing one or more of our product candidates, we may incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our net losses may fluctuate significantly from quarter to quarter and from year to year.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">11</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may never achieve or sustain profitability.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not know when or whether we will become profitable. To date, we have not commercialized any products or generated any revenues from the sale of products. We do not expect to generate any product revenues in the foreseeable future. To become and remain profitable, we must succeed in developing, obtaining regulatory approval for and commercializing one or more of our product candidates. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, discovering and developing additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, establishing commercialization capabilities for any approved products and achieving market acceptance for any approved products. We may never succeed in these activities. Even if we succeed in these activities, we may never generate revenue in an amount sufficient to achieve profitability.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because of the numerous risks and uncertainties associated with biotechnology product development and commercialization, we are unable to accurately predict whether and when we will achieve profitability. If we are required by the FDA, the EMA or any comparable regulatory authority in other jurisdictions to perform preclinical studies or clinical trials in addition to those we currently expect to conduct, or if there are any delays or complications in completing preclinical studies of our product candidates or, if preclinical studies are successful, in submitting an investigational new drug application (&#147;IND&#148;) to the FDA, manufacturing clinical trial supplies and completing clinical trials for our product candidates, our expenses could increase substantially and our ability to achieve profitability could be further delayed.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Even if we achieve profitability, we may not be able to sustain profitability in subsequent periods. After we achieve profitability, if ever, we expect to continue to engage in substantial research and development activities and to incur substantial expenses to develop and commercialize additional product candidates. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our revenues, expenses and profitability.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our failure to achieve or sustain profitability would depress our market value and could impair our ability to execute our business plan, raise capital, develop additional product candidates or continue our operations. A decline in the value of our company could cause our shareholders to lose all or part of their investment.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have a limited operating history and have never generated any revenue from product sales, which may </b></i><i><b>make it difficult to evaluate the success of our business to date and to assess our future viability. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We were incorporated in 2011, and our operations to date have been largely focused on developing our product candidates, including conducting preclinical studies and clinical trials, raising capital and building our management team and infrastructure. We have not yet demonstrated an ability to obtain regulatory approvals, manufacture products on a commercial scale, or partner with contract manufacturing organizations (&#147;CMOs&#148;) to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Additionally, the markets for our product candidates are competitive. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products. Moreover, we will need to eventually transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Even after the completion of this offering, we will require substantial additional capital to execute our </b></i><i><b>business plan. Our inability to obtain this capital when needed could force us to delay, limit, reduce or </b></i><i><b>terminate our product development efforts or our establishment of late-stage development and </b></i><i><b>commercialization capabilities.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since our inception, we have used substantial amounts of cash. The development of biotechnology product candidates is capital intensive and we expect that we will continue to expend substantial resources for the foreseeable future to develop and commercialize our current and future product candidates, particularly as we conduct and complete the pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL, conduct and complete the pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL, conduct and complete the Phase 1b clinical trials of ADCT-402 and ADCT-301 for the treatment of other indications and Phase 1 clinical trials for our other product candidates and commence and conduct any </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">12</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">required post-marketing confirmatory clinical trials. Our expenditures in the foreseeable future may include costs associated with conducting research and development activities, conducting preclinical studies and clinical trials, obtaining regulatory approvals, undertaking late-stage commercialization activities, establishing our sales and marketing capabilities, manufacturing and selling approved products and potentially acquiring new technologies.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To date, we have financed our operations primarily through equity financings. Since inception, we have raised $558.6 million in gross cash proceeds from equity financings. As of June 30, 2019, we had $182.2 million in cash and cash equivalents. We believe that we have sufficient financial resources to fund our projected operating requirements for at least the next twelve months. Based on our current business plan, we estimate that the net proceeds we receive from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our projected operating requirements through at least the next 24 months. However, our projected operating requirements may change as a result of many factors currently unknown to us and we may require additional capital sooner than anticipated. Furthermore, because the outcome of our current and planned clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. For example, our costs will increase if we experience any delays in our current and planned clinical trials.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our future capital requirements, both in the near- and long-term, depend on many factors, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the progress, results and costs of our pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL and our pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the progress, results and costs of our clinical trials of ADCT-402 and ADCT-301 for the treatment of other indications and for our other product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the progress, results and costs of any required post-marketing confirmatory clinical trials for any product candidates that receive accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory agencies in other jurisdictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the scope, progress, results and costs of researching and developing product candidates in our research pipeline, including conducting preclinical studies and clinical trials of such product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs of outsourced manufacturing of our product candidates, which are complex biological molecules, for clinical trials and in preparation for regulatory approval and commercialization;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the outcome, timing and costs of obtaining regulatory approvals for our product candidates if the requisite clinical trials are successful;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the size of the markets for approved indications in territories in which we receive regulatory approval, if any;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing and costs of commercialization activities for our product candidates, if any are approved for sale, including establishing our sales and marketing capabilities and engaging in the marketing, sales and distribution of our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the revenue, if any, received from the commercialization of our product candidates, if any are approved for sale;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to maintain and establish collaboration, licensing or other arrangements and the financial terms of such agreements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs involved in preparing, filing, prosecuting, maintaining, protecting and enforcing our intellectual property rights and claims, including any litigation costs and the outcome of such litigation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing and amount of milestone payments we receive under our collaboration agreements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs involved in maintaining and improving the technology we use in our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our efforts to enhance operational systems and hire additional personnel, including personnel to support the development of our product candidates and to satisfy our obligations as a public company;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">13</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the effect of competing technological and market developments; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the types of available sources of private and/or public market financing.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not have any committed external source of funds, and additional funds may not be available when we need them or on terms that are acceptable to us. Further, as a Swiss company, we have less flexibility to raise capital, particularly in a quick and efficient manner, as compared to U.S. companies. See &#147;&#8212;Risks Related to Our Common Shares and This Offering&#8212;Our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs.&#148; If adequate funds are not available to us on a timely basis or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development efforts or our establishment of late-stage development and commercialization capabilities.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require </b></i><i><b>us to relinquish rights to our intellectual property or product candidates on unfavorable terms.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless and until we can generate sufficient revenue to finance our cash requirements, which may never happen, we may seek additional capital through a variety of means, including through public and private equity offerings and debt financings, credit and loan facilities and additional collaborations. If we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that are senior to or otherwise adversely affect your rights as a shareholder. If we raise additional capital through the sale of debt securities or through entering into credit or loan facilities, we may be restricted in our ability to take certain actions, such as incurring additional debt, making capital expenditures, acquiring or licensing intellectual property rights, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. If we raise additional capital through collaborations with third parties, we may be required to relinquish valuable rights to our intellectual property or product candidates or we may be required to grant licenses for our intellectual property or product candidates on unfavorable terms. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development efforts or our establishment of late-stage development and commercialization capabilities or we may be required to grant rights to third parties to develop and market our product candidates that we would otherwise prefer to develop and market ourselves.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our ability to use tax loss carryforwards in Switzerland may be limited.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of December 31, 2018, we reported $329.3 million in tax loss carryforwards from previous financial years for Swiss corporate income tax purposes. Such tax loss carryforwards could be used to offset future taxable income. However, if not used, tax loss carryforwards expire seven years after the tax year in which they were incurred. Due to our limited income, there is a high risk that our tax loss carryforwards will expire in part or in their entirety and cannot be used to offset future taxable income for Swiss corporate income tax purposes.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, any tax loss carryforwards that we report in our tax returns are subject to review and confirmation by the competent Swiss tax authorities in their tax assessment of the tax year for which the tax loss carryforwards are used to offset taxable income. Consequently, we are exposed to the risk that the competent Swiss tax authorities may not accept the reported tax loss carryforwards in part or in their entirety. Any limitations in our ability to use tax loss carryforwards to offset taxable income could adversely affect our financial condition.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Changes in tax laws or the interpretation of tax laws could have a material impact on our financial condition.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The tax administration of the Canton of Vaud has confirmed in advance tax rulings that, up to and including the 2019 tax period, which ends on December 31, 2019, we are eligible for the base company regime, which is a privileged tax regime that applies if certain requirements, such as maximum thresholds for Swiss source income and expenses, are satisfied. Due to the Swiss corporate tax law reform that has been enacted and will take effect on January 1, 2020, all Swiss cantons, including the Canton of Vaud, will abolish the base company regime as of January 1, 2020, which will subject us to the standard cantonal taxation regime and, consequently, result in a significantly higher effective tax rate for us. The standard effective corporate tax rate in Epalinges, Canton of Vaud, can change from time to time. However, we expect that the standard combined (federal, cantonal, communal) effective corporate income tax rate, except for dividend income for which we could claim a </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">14</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">participation exemption, for 2020 in Epalinges will be approximately 13.7%, which is higher than the combined (federal, cantonal, communal) effective corporate income tax rate of approximately 9% to 11% under the base company regime in 2018.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, in view of the ongoing implementation of the OECD G20 Base Erosion and Profit Shifting Project and the European Union anti-avoidance tax package, the existing transfer pricing system and our intercompany relationships could be challenged by the competent tax authorities, resulting in additional taxes, interest and penalties in case of profit add-backs, non-deductible expenses or objections to the transfer pricing documentation. A focus area is the taxation and allocation of profits generated from intangibles where the DEMPE (Development, Enhancement, Maintenance, Protection and Exploitation) functions will become more relevant compared to the pure bearing of costs. This may impact the taxation of our group profits and may impact our effective tax rate. These and other changes in tax laws or the interpretation of tax laws could have a material adverse effect on our financial condition.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Exchange rate fluctuations may materially affect our results of operations and financial condition.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We operate internationally and are exposed to fluctuations in foreign exchange rates between the U.S. dollar and other currencies, particularly the British pound, the Euro and the Swiss franc. Our reporting currency is the U.S. dollar and, as a result, financial line items are converted into U.S. dollars at the applicable foreign exchange rates. As our business grows, we expect that at least some of our revenues and expenses will be denominated in currencies other than the U.S. dollar. Therefore, unfavorable developments in the value of the U.S. dollar relative to other relevant currencies could adversely affect our business and financial condition.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are subject to risks related to the accounting treatment of our pension and other post-employment benefit </b></i><i><b>plans.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We provide retirement benefits to our employees as required by Swiss law by means of a pension fund that is maintained by a life insurance company. The life insurance company operates a pension plan for all of our employees as a defined benefit plan under International Accounting Standard (&#147;IAS&#148;) 19. As of December 31, 2018, we reported an employee benefit obligation, before deduction of plan assets, of $4.4 million in accordance with IAS 19. As of June 30, 2019, we reported an employee benefit obligation, before deduction of plan assets, of $4.9 million in accordance with IAS 19. The obligation represents our projected obligations towards current and future pensioners discounted at an annual rate of 0.85%. Under Swiss statutory rules and pursuant to our contract with the group life assurance provider, all risks including investment risk are fully covered. That said, no underfunding exists under Swiss law. The variance between Swiss statutory rules and the IFRS is apparent in many Swiss companies, and the IFRS obligation of our pension plan does not necessarily reflect a true payment obligation under Swiss law because Swiss law allows us to maintain flexibility to adjust benefit levels under the plans and we could use this flexibility to mitigate any liability. For more information, see Note 2.8 (Significant accounting policies&#8212;Employee benefits) and Note 17 (Pension obligations) to the consolidated audited financial statements included elsewhere in this prospectus. However, should the Swiss statutory rules at any time require a determination that our pension plan is significantly underfunded, we could be obliged to make additional contributions into the pension plan in addition to our obligation to make regular contributions as defined in the pension plan regulation. If such risk materializes, this could have a material adverse effect on our financial position or results of operations.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to the Development of Our Product Candidates</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>We have concentrated our research and development efforts on PBD-based ADCs, and our future success </b></i><i><b>depends heavily on the successful development of this therapeutic approach.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ADCs use next-generation PBD warheads, which have a different mechanism of action than warheads used in currently approved ADCs. Although multiple PBD-based ADCs are being developed, none have been approved for sale in the United States or in the European Union. Any failures or setbacks involving PBD technology or PBD-based ADCs, whether developed by us or third parties, including adverse events, could have a detrimental impact on our product candidates and our research pipeline. For example, we or another party may uncover a previously unknown risk associated with PBD or other issues that may be more problematic than we currently believe, which may prolong the period of observation required for obtaining, or result in the failure to obtain, regulatory approval or may necessitate additional clinical testing. If the PBD warhead technology that we </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">15</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">use is not safe in certain product candidates, we would be required to abandon or redesign all of our current product candidates, which could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our current product candidates are in various stages of development, and it is possible that none of our </b></i><i><b>product candidates will ever become commercial products.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our success depends heavily on the successful further development of our current and future product candidates and our research pipeline and regulatory approval of our current and future product candidates, all of which are subject to risks and uncertainties beyond our control. We are currently conducting a pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL and a pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL. However, the FDA may ultimately disagree that these Phase 2 clinical trials are sufficient for regulatory approval if, for example, we fail to show a sufficient response rate or duration of response (&#147;DoR&#148;). We are also conducting Phase 1b clinical trials of ADCT-402 and ADCT-301 for the treatment of other indications as well as Phase 1 clinical trials for our other product candidates. There can be no assurance that any of our product candidates will prove to be safe, effective or commercially viable treatments for cancer.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we discontinue development of a product candidate, we will not receive the anticipated revenues from that product candidate and we may not receive any return on our investment in that product candidate. We may discontinue a product candidate for clinical reasons if it does not prove to be safe and effective for its targeted indications. For example, in the past, we and other companies in our field have discontinued the development of product candidates that did not achieve the necessary efficacy at tolerated doses required for patient benefit. In addition, there may be important facts about the safety, efficacy and risk versus benefit of our product candidates that are not known to us at this time. Any unexpected safety events or our failure to generate sufficient data in our clinical trials to demonstrate efficacy may cause a product candidate to fail clinical development. Furthermore, even if that product candidate meets its safety and efficacy endpoints, we may discontinue its development for various reasons, such as changes in the competitive environment or the standard of care and the prioritization of our resources.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Due to the uncertain and time-consuming clinical development and regulatory approval process, we may not successfully develop any of our product candidates and may choose to discontinue the development of any of our product candidates. Therefore, it is possible that none of our current product candidates will ever become commercial products. Our failure to develop and commercialize our current and future product candidates could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Positive and promising results from preclinical studies and early-stage clinical trials may not be predictive of results from late-stage clinical trials or from clinical trials of the same product candidates for the treatment of other indications. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Late-stage clinical trials could differ in significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, efficacy endpoints, dosing regimen and statistical design. Moreover, success in clinical trials in a particular indication does not guarantee that a product candidate will be successful for the treatment of other indications. Many companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials after achieving encouraging or positive results in early-stage development. There can be no assurance that we will not face similar setbacks in our ongoing or planned late-stage clinical trials, including in our pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL, our pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and any subsequent or post-marketing confirmatory clinical trials. Therefore, despite positive results observed in early-stage clinical trials, our product candidates may fail to demonstrate sufficient efficacy in our pivotal or post-marketing confirmatory clinical trials.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Preliminary interim or &#147;top-line&#148; data that we announce or publish from time to time may change as more </b></i><i><b>data become available and are subject to audit and verification procedures that could result in material </b></i><i><b>changes in the final data. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time, we may publish preliminary interim or &#147;top-line&#148; data from clinical trials. Positive preliminary data may not be predictive of such trial&#146;s subsequent or overall results. Preliminary data are subject </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">16</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">to the risk that one or more of the outcomes may materially change as more data become available. Additionally, preliminary data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Therefore, positive preliminary results in any ongoing clinical trial may not be predictive of such results in the completed trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, preliminary data that we report may differ from future results from the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to preliminary data could significantly harm our business prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Delays in the commencement and completion of clinical trials could increase costs and delay or prevent </b></i><i><b>regulatory approval and commercialization of our product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We cannot guarantee that clinical trials of our product candidates will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of the clinical trial process, and other events may cause us to temporarily or permanently stop a clinical trial. Events that may prevent successful or timely commencement and completion of clinical development include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">negative preclinical data;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delays in receiving the required regulatory clearance from the appropriate regulatory authorities to commence clinical trials or amend clinical trial protocols, including any objections to our INDs or protocol amendments from the FDA;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delays in reaching, or a failure to reach, a consensus with regulatory authorities on study design;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delays in reaching, or a failure to reach, an agreement on acceptable terms with prospective clinical research organizations (&#147;CROs&#148;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">difficulties in obtaining required Institutional Review Board (&#147;IRB&#148;) or ethics committee approval at each clinical trial site;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">challenges in recruiting and enrolling suitable patients that meet the study criteria to participate in clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the inability to enroll a sufficient number of patients in clinical trials to ensure adequate statistical power to detect statistically significant treatment effects;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">imposition of a clinical hold by regulatory authorities or IRBs for any reason, including safety concerns and noncompliance with regulatory requirements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">failure by CROs, other third parties or us to adhere to clinical trial requirements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">failure to perform in accordance with the FDA&#8217;s good clinical practices (&#147;GCP&#148;) or applicable regulatory guidelines in other jurisdictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the inability to manufacture adequate quantities of a product candidate or other materials necessary in accordance with current Good Manufacturing Practices (&#147;cGMPs&#148;) to conduct clinical trials, including, for example, delays in the testing, validation, manufacturing delays or failures at our CROs and delivery of the product candidates to the clinical trial sites;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">lower than anticipated patient retention rates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">difficulties in maintaining contact with patients after treatment, resulting in incomplete data;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ambiguous or negative interim results;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our CROs or clinical trial sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a clinical trial;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">17</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">unforeseen safety issues, including occurrence of treatment emergent adverse events (&#147;TEAEs&#148;) associated with the product candidate that are viewed to outweigh the product candidate&#8217;s potential benefits;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">lack of adequate funding to continue the clinical trial.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a clinical trial. If we are not able to successfully complete clinical trials, we will not be able to obtain regulatory approval and will not be able to commercialize our product candidates.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>A clinical hold on any of our clinical trials may result in delays </b></i><i><b>of </b></i><i><b>our clinical development timeline.</b></i><i><b> In the </b></i><i><b>past, certain of our clinical trials have been subject to clinical holds prior to the dosing of the first patient and </b></i><i><b>partial clinical holds after the dosing of the first patient.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In October 2017, the FDA placed a partial clinical hold on our Phase 1 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and NHL after we informed the FDA that two patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome and one patient with HL was diagnosed with polyradiculopathy. In consultation with the FDA, we amended the clinical trial protocol and in January 2018, the FDA lifted the partial clinical hold without condition. In the future, other cases of Guillain&#8211;Barr&#233; syndrome may arise which may also result in partial or full clinical holds.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In connection with seeking clearance of our INDs for ADCT-601 and ADCT-602, we were subject to clinical holds prior to the dosing of the first patient in these clinical trials. For ADCT-602, the FDA required additional data to support the stability of the product candidate at low doses. For ADCT-601, the FDA had questions regarding the novel linker technology, the stability of the product candidate and the clinical trial protocol. The FDA subsequently lifted these clinical holds, and for ADCT-601, we must submit a protocol amendment before we commence Phase 1b of the clinical trial.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There can be no assurance that our current or future clinical trials will not be subject to partial or full clinical holds, which could delay or impair the commencement and completion of our clinical trials and the regulatory approval of our product candidates.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we experience delays or difficulties in patient enrollment for clinical trials, our research and development </b></i><i><b>efforts and the receipt of necessary regulatory approvals could be significantly delayed or prevented.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Commencement and successful and timely completion of clinical trials require us to enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA or comparable regulatory authorities in other jurisdictions. Any delay or difficulty in patient enrollment could significantly delay or otherwise hinder our research and development efforts and delay or prevent receipt of necessary regulatory approvals.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Patient enrollment is affected by many factors, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the size and nature of the patient population;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the severity of the disease under investigation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the eligibility criteria for the study in question, including any misjudgment of, and resultant adjustment to, the appropriate ranges applicable to the exclusion and inclusion criteria;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the number of clinical trial sites and the proximity of prospective patients to those sites;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the nature, severity and frequency of adverse side effects associated with our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the standard of care in the diseases under investigation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the commitment of our clinical investigators to identify eligible patients;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">competing studies or trials with similar eligibility criteria;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the patient referral practices of physicians; and</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">18</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including perception of ADCs generally and of PBD-based ADCs specifically.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In particular, some of our clinical trials will seek to enroll patients with characteristics that are found in a small population. For example, our pivotal Phase 2 clinical trial of ADCT-402 will seek to enroll patients with DLBCL who have failed or are intolerant to two or more multi-agent systemic treatment regimens, while our pivotal Phase 2 clinical trial of ADCT-301 will seek to enroll patients with HL who have failed three prior lines of therapy, including brentuximab vedotin and a checkpoint inhibitor approved for HL. Our clinical trials will compete with those for other product candidates in the same therapeutic areas as our product candidates. This competition will reduce the number and types of patients available to us, as some patients who might have opted to enroll in our clinical trials may instead opt to enroll in one being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites used by some of our competitors, which will reduce the number of patients who are available for our clinical trials in these clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and antibody therapy, rather than to participate in our clinical trials. In addition, patients may also be unwilling to participate in our clinical trials because of negative publicity from adverse events in the biotechnology industry. Challenges in recruiting and enrolling suitable patients to participate in clinical trials could increase costs, affect the timing and outcome of our planned clinical trials and result in delays to our current development plan for our product candidates.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our product candidates may cause undesirable side effects or have other properties that may delay or prevent </b></i><i><b>their development or regulatory approval or limit their commercial potential.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Undesirable side effects caused by our product candidates or by ADCs developed by others could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in more restrictive labeling or the denial of regulatory approval by the FDA, EMA or other regulatory authorities and potential product liability claims. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial. Many compounds developed in the biotechnology industry that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented their further development.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In our clinical trials, we have observed certain class toxicities associated with our PBD-based warheads, including elevated liver enzymes, skin rash, and effusions and edema. In addition, in our Phase 1 clinical trial of ADCT-402 for the treatment of relapsed or refractory NHL and pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL, reported Grade &#8805;3 TEAEs included neutrophil count decreased, platelet count decreased, gamma-glutamyltransferase increased and anemia, while in our Phase 1 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and NHL, reported Grade &#8805;3 TEAEs include gamma-glutamyltransferase increased, maculopapular rash, alanine aminotransferase increased and anemia.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, in the past, certain patients with HL treated with ADCT-301 have reported Guillain&#8211;Barr&#233; syndrome. In August and September 2017, in our Phase 1 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and NHL, we informed the FDA that two patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome and one patient with HL was diagnosed with polyradiculopathy. The FDA issued a partial clinical hold on our clinical trial, pursuant to which we suspended the enrollment of new patients but continued the treatment of enrolled patients who would derive a clinical benefit from continued treatment with ADCT-301. We amended the clinical trial protocol and informed consent to include, among other things, additional risk factors to patient screening, additional exclusion criteria and routine neurologic evaluation prior to and during the clinical trial to monitor the occurrence of Guillain&#8211;Barr&#233; syndrome. In January 2018, the FDA lifted the partial clinical hold without condition. In September 2018, we informed the FDA that two additional patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome. We voluntarily suspended patient enrollment and undertook a detailed safety review of our clinical trial in accordance with our clinical trial protocol and submitted it to the FDA. Upon review, in October 2018, the FDA agreed that we can resume patient enrollment and made certain recommendations, including the expansion of the HL 30 &#956;g/kg dose cohort to ten additional patients, the continued assessment of pharmacokinetics and regulatory T-cell profiles in the clinical trial and that we consult with the FDA regarding the decision of final dose selection before closing the 30 &#956;g/kg dose cohort. We subsequently implemented the FDA&#146;s recommendations. No incidence of Guillain&#8211;Barr&#233; syndrome has been reported for NHL or solid tumor patients treated with ADCT-301 and no further incidence of Guillain&#8211;Barr&#233; </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">19</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">syndrome has been reported in patients with HL treated with ADCT-301 since October 2018. However, there can be no assurance that patients treated with ADCT-301 will not experience Guillain&#8211;Barr&#233; syndrome or other serious adverse side effects in the future and there can be no assurance that the FDA, EMA or comparable regulatory authorities in other jurisdictions will not place clinical holds on our current or future clinical trials, the result of which could delay or prevent us from obtaining regulatory approval for ADCT-301. Even if approved, ADCT-301 may carry boxed warnings or precautions regarding the risk of Guillain&#8211;Barr&#233; syndrome.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For our current and future clinical trials, we have contracted with and expect to continue to contract with CROs experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, they may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials and which could jeopardize regulatory approval.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be uncovered with a significantly larger number of patients exposed to the drug. For example, while ADCT-402 and ADCT-301 have demonstrated manageable tolerability profiles thus far, there can be no assurance that these and our other product candidates will not cause more severe side effects in a greater proportion of patients.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, some of our product candidates are developed or intended to be used in combination with other therapies. Currently, we are conducting Phase 1b clinical trials of ADCT-402 in combination with ibrutinib and in combination with durvalumab. Ibrutinib and durvalumab may cause undesirable side effects. Common side effects of ibrutinib include pneumonia, upper respiratory tract infection, low neutrophil count, low platelet count, rash and edema. Common side effects of durvalumab include fatigue, musculoskeletal pain, nausea and rash. Combining ADCT-402 with ibrutinib or durvalumab may cause additional, different or more severe side effects than either ADCT-402 or ibrutinib or durvalumab used as monotherapies. In addition, ADCT-402 and these other therapies may have common toxicities, such as edema. When used in combination, the severity and frequency of such undesirable side effects may be greater than the cumulative severity and frequency of such side effects when the therapies are used as monotherapies. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In our Phase 1b clinical trial of ADCT-402 in combination with ibrutinib, one dose-limiting toxicity (&#147;DLT&#148;) of Death Not Otherwise Specified was observed in a patient treated with ADCT-402 at the 90 &#181;g/kg dose level in combination with ibrutinib. The investigator assessed the death as unlikely to be related to ADCT-402 and as possibly being related to ibrutinib, the disease and/or comorbidities. There can be no assurance that patients in our combination clinical trials will not experience serious adverse side effects, including death, in the future. The uncertainty resulting from the use of our product candidates in combination with other therapies may make it difficult to accurately predict side effects in clinical trials.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we or others identify undesirable side effects caused by our product candidates or those of our competitors, a number of potentially significant negative consequences could result, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may encounter delays or difficulties in enrolling patients for our clinical trials due to a negative perception of our product candidates&#8217; safety and tolerability profile;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we and/or regulatory authorities may temporarily or permanently put our clinical trials on hold;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may be unable to obtain regulatory approval for our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory authorities may withdraw or limit their approvals of our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory authorities may require the addition of labeling statements, such as a contraindication, boxed warnings or additional warnings;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the FDA may require development of a Risk Evaluation and Mitigation Strategy with Elements to Assure Safe Use as a condition of approval;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may decide to remove our product candidates from the marketplace;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may be subject to regulatory investigations and government enforcement actions;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">20</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we could be sued and held liable for harm caused to patients, including as a result of hospital errors; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our reputation may suffer.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could substantially increase commercialization costs.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may expend our resources to pursue particular product candidates and fail to capitalize on product </b></i><i><b>candidates that may be more profitable or for which there is a greater likelihood of success.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because we have limited financial resources and personnel, we focus on the development of specific product candidates based on our product development strategy. As a result, we may forgo or delay the pursuit of other product candidates that later prove to have greater commercial potential. Decision making about which product candidates to prioritize involves inherent subjectivity and/or uncertainty. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business and financial condition. Our spending on current and future research programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through partnering, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not be successful in our efforts to develop additional product candidates and build up our research </b></i><i><b>pipeline.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A key element of our development strategy is to build a robust pipeline of PBD-based ADCs targeting both novel and clinically validated cancer targets for the treatment of hematological malignancies and solid tumors. Our license and collaboration agreement with MedImmune Limited (&#147;MedImmune&#148;) allows us to develop PBD-based ADCs against 11 targets. See &#147;Business&#8212;License and Collaboration Agreements&#8212;MedImmune License and Collaboration Agreement.&#148; We have selected all 11 targets under this agreement. There can be no assurance that these targets will yield safe, effective and commercially viable product candidates. If we wish to develop ADCs for additional targets, we must secure additional licenses from MedImmune, which we may not be able to obtain at a reasonable cost or on reasonable terms, if at all.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We also pursue research programs involving non-ADC product candidates. However, we may be unable to identify suitable additional product candidates for clinical development, which would limit our ability to develop product candidates and our ability to obtain revenues from commercializing any such product candidates. Even if we are successful in continuing to build our research pipeline, the potential product candidates that we identify may fail in clinical development or commercialization. For example, they may not demonstrate sufficient efficacy or may demonstrate harmful side effects or other characteristics that make them unlikely to receive regulatory approval and achieve market acceptance.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our research and development activities could be affected or delayed as a result of possible restrictions on </b></i><i><b>animal testing.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials in humans. We conduct preclinical studies of our product candidates in rats, mice, dogs and non-human primates. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed or become more expensive.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">21</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to the Regulatory Approval of Our Product Candidates</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>The regulatory review and approval processes of the FDA, EMA and comparable regulatory authorities in </b></i><i><b>other jurisdictions are lengthy, time consuming and inherently unpredictable. If we are unable to obtain, or if </b></i><i><b>there are delays in obtaining, regulatory approval for our product candidates, we will not be able to </b></i><i><b>commercialize our product candidates and our ability to generate revenue will be materially impaired.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our product candidates must be approved by the FDA in the United States, by the EMA in the European Union and by comparable regulatory authorities in other jurisdictions in other jurisdictions prior to commercialization. In order to obtain regulatory approval for the commercial sale of any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that the product candidate is safe and effective for use in each target indication and that manufacturing of the product candidate is robust and reproducible. The time required to obtain approval by the FDA, EMA and comparable regulatory authorities in other jurisdictions is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors. Of the large number of drugs in development in the United States, only a small percentage will successfully complete the FDA regulatory approval process and will be commercialized. Accordingly, there can be no assurance that any of our product candidates will receive regulatory approval in the United States, the European Union or other jurisdictions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Regulatory authorities have substantial discretion in the approval process. They may refuse to accept any application and may decide that our data are insufficient for approval and require additional clinical trials or other studies. Therefore, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, EMA or any comparable regulatory authority in other jurisdictions. For example, while we may designate certain of our clinical trials as &#147;pivotal,&#148; the FDA, EMA and other comparable regulatory authorities in other jurisdictions may not agree with such designation. For example, we believe that our Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL and that our Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL, if successful, may support accelerated approval by the FDA. However, the FDA has not opined on whether these Phase 2 clinical trials will in fact be sufficient to support regulatory approval. Therefore, there can be no assurance that these clinical trials will be viewed as sufficient by the FDA, EMA and other comparable regulatory authorities in other jurisdictions to support regulatory approval. Accordingly, our assumptions about Phase 3 clinical trials of ADCT-402 for the treatment of relapsed or refractory DLBCL and ADCT-301 for the treatment of relapsed or refractory HL being post-marketing confirmatory clinical trials may be inaccurate, and we may need to conduct Phase 3 clinical trials for these and any other of our product candidates prior to receiving regulatory approval from the FDA and comparable regulatory authorities in other jurisdictions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated, we may incur significant additional costs and the regulatory approval of our product candidates may be delayed or prevented. For example, the FDA, EMA or comparable regulatory authorities in other jurisdictions may express safety concerns due to the partial clinical hold that was issued but subsequently lifted for ADCT-301 and may require additional preclinical studies or clinical trials. In such instance, our progress in the development of ADCT-301 may be significantly delayed or stopped and the associated costs may be significantly increased. Furthermore, additional clinical trials or other testing could shorten any periods during which we may have the exclusive right to commercialize our product candidates and could allow our competitors to bring products to market before we do, which may prevent the successful commercialization of our product candidates. Therefore, positive or promising results from clinical trials of our product candidates do not guarantee regulatory approval by the FDA, EMA or any comparable regulatory authority in other jurisdictions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, the process and time required to obtain regulatory approval differ by jurisdiction. In many countries outside the United States, a drug must be approved for reimbursement before it can be approved for sale in that country. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services at market rates. Under certain circumstances, we may be required to report some of these relationships to the FDA, EMA or comparable regulatory authorities in other jurisdictions, which could conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA, </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">22</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">EMA or comparable regulatory authorities in other jurisdictions may, therefore, question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could delay, or result in the rejection of, our marketing applications.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To date, regulatory approval has not been obtained for any product candidate based on the PBD technology used in our product candidates in any jurisdiction, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval in any jurisdiction. Because our product candidates are based on next-generation PBD technology, the regulatory approval process for our product candidates can be more expensive and take longer than that for our competitors&#146; better known or more extensively studied product candidates. It is difficult to determine the time and resources required to obtain regulatory approvals for our product candidates in the United States, the European Union or other major markets. In addition, we may gain regulatory approval for our product candidates in some but not all of the jurisdictions for which we seek approval or for some but not all of the target indications for which we seek approval, resulting in limited commercial opportunity for the approved product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Applications for regulatory approval and regulatory approval of our product candidates could be delayed or be denied for many reasons, including but not limited to the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the FDA, EMA or comparable regulatory authorities in other jurisdictions may disagree with the number, design or implementation of our clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the population studied in the clinical trial may not be considered sufficiently broad or representative to assure safety in the full population for which we seek approval;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the FDA, EMA or comparable regulatory authorities in other jurisdictions may disagree with our interpretation of data from preclinical studies or clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the data collected from clinical trials of our product candidates may not meet the level of statistical or clinical significance required by the FDA, EMA or comparable regulatory authorities in other jurisdictions or may otherwise not be sufficient to support the submission of a BLA, Marketing Authorization Application (&#147;MAA&#148;) or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the FDA, EMA or comparable regulatory authorities in other jurisdictions may not accept data generated by our preclinical service providers and clinical trial sites;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the FDA, EMA or comparable regulatory authorities in other jurisdictions may require us to conduct additional preclinical studies and clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may be unable to demonstrate to the FDA, EMA or comparable regulatory authorities in other jurisdictions that a product candidate&#8217;s response rate, DoR or risk-benefit ratio for its proposed indication is acceptable;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the FDA, EMA or comparable regulatory authorities in other jurisdictions may fail to approve the manufacturing processes, test procedures and specifications applicable to the manufacture of our product candidates, the facilities of third-party manufacturers with which we contract for clinical or commercial supplies may fail to maintain a compliance status acceptable to the FDA, EMA or comparable regulatory authorities or the EMA or comparable regulatory authorities may fail to approve facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we or any third-party service providers may be unable to demonstrate compliance with cGMPs to the satisfaction of the FDA, EMA or comparable regulatory authorities in other jurisdictions, which could result in delays in regulatory approval or require us to withdraw or recall products and interrupt commercial supply of our products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the approval policies or regulations of the FDA, EMA or comparable regulatory authorities in other jurisdictions may change in a manner rendering our clinical data insufficient for approval; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">political factors surrounding the approval process, such as government shutdowns and political instability.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">23</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any of these factors, many of which are beyond our control, may result in our failing to obtain regulatory approval for any of our product candidates, which would significantly harm our business, financial condition and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We intend to seek accelerated approval for some of our product candidates, which may not lead to a faster </b></i><i><b>development or regulatory review or approval process, and does not increase the likelihood that the product </b></i><i><b>candidates will receive marketing approval.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the FDA&#146;s accelerated approval program, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. We intend to seek accelerated approval for some of our product candidates on the basis of ORR with an acceptable DoR, a surrogate endpoint that we believe is reasonably likely to predict clinical benefit. However, full approval of another product for the same indication as any of our product candidates for which we are seeking accelerated approval may make accelerated approval of our product candidates more difficult.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For drugs granted accelerated approval, post-marketing confirmatory clinical trials are required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory clinical trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. If any of our competitors were to receive full approval on the basis of a confirmatory clinical trial for an indication for which we are seeking accelerated approval before we receive accelerated approval, the indication we are seeking may no longer qualify as a condition for which there is an unmet medical end and accelerated approval of our product candidate would be more difficult. Moreover, the FDA may withdraw approval of our product candidate approved under the accelerated approval pathway if, for example:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the clinical trial(s) required to verify the predicted clinical benefit of a product candidates fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the product candidate;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">other evidence demonstrates that a product candidate is not shown to be safe or effective under the conditions of use;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we fail to conduct any required post-marketing confirmatory clinical trial with due diligence; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we disseminate false or misleading promotional materials relating to the relevant product candidate.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Breakthrough Therapy Designations or Fast Track Designations by the FDA, or comparable designations by </b></i><i><b>foreign regulatory authorities, for our product candidates may not lead to a faster development or regulatory </b></i><i><b>review or approval process and do not increase the likelihood that a product candidate would receive </b></i><i><b>regulatory approval.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not currently have Breakthrough Therapy Designation or Fast Track Designation for any of our product candidates. We may seek such designations, and comparable designations by foreign regulatory authorities, for one or more of our product candidates for the treatment of certain indications. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for development. A Fast Track Designation may be available if a product candidate is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA has broad discretion whether or not to grant Breakthrough Therapy Designation or Fast Track Designation. Accordingly, even if we believe, after completing early clinical trials, that one of our product candidates meets the criteria for such designations, the FDA may disagree and instead determine not to make </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">24</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">such designations. Even if we receive such designation for a product candidate, it may not result in a faster development process, review or approval compared to conventional FDA procedures and does not guarantee ultimate approval by the FDA. Many drugs that have received such designations have failed to obtain ultimate approval by the FD<font style="text-transform: uppercase;">A</font>. In addition, the FDA may decide to rescind such designations if it determines that our product candidates no longer meet the conditions for qualification, including as a result of the product candidates&#146; failure to meet endpoints in any clinical trial.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have received orphan drug designation from the FDA for ADCT-402 for the treatment of DLBCL and </b></i><i><b>MCL, and we may seek it for our other product candidates. However, we may be unable to maintain the </b></i><i><b>benefits associated with the designation and may not receive the designation for our other product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that meet the following criteria: (i) they are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union or they are intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product and (ii) where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. The FDA&#146;s determination of whether two ADCs are the same product for purposes of orphan drug exclusivity is based on a determination of sameness of the monoclonal antibody element and the functional element of the conjugated molecule. Two ADCs are deemed to be the same product if the complementarity determining region sequences of the antibody and the functional element of the conjugated molecule are the same. A difference in either of those two elements can result in a determination that the molecules are different.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity for the orphan indication following drug or biological product approval, provided that the criteria for orphan designation are still applicable at the time of the granting of the marketing authorization. This period may be reduced to six years if, at the end of the fifth year, the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. However, orphan drug designation neither shortens the development time or regulatory review time of a drug or therapeutic biologic nor gives the drug or therapeutic biologic any advantage in the regulatory review or approval process.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have received orphan drug designation in the United States for ADCT-402 for the treatment of DLBCL and MCL in 2017. We may pursue orphan drug designation for one or more of our other product candidates. However, obtaining an orphan drug designation can be difficult, and we may not be successful in doing so. Even if we obtain orphan drug designation for our product candidates in specific indications, we may not be the first to obtain regulatory approval of these product candidates for the orphan-designated indication. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Furthermore, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different ADCs with different monoclonal antibody elements or functional elements of the conjugated molecule can be approved for </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">25</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same ADC with the same monoclonal antibody element and functional element of the conjugated molecule for the same condition if the FDA concludes that the later ADC is safer, more effective or makes a major contribution to patient care. Our inability to obtain orphan drug designation for any product candidates for the treatment of rare cancers and/or our inability to maintain that designation for the duration of the applicable exclusivity period, could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are required to comply with comprehensive and ongoing regulatory requirements for any product </b></i><i><b>candidates that receive regulatory approval, including conducting post-marketing confirmatory clinical trials </b></i><i><b>for any product candidates that receive accelerated approval.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any product candidates for which we receive accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory authorities in other jurisdictions based on data from clinical trials that use single-arm designs are required to undergo one or more confirmatory clinical trials. If such a product candidate fails to meet its safety and efficacy endpoints in such confirmatory clinical trials, the regulatory authority may withdraw its conditional approval. There is no assurance that any such product will successfully advance through its confirmatory clinical trial(s). Therefore, even if a product candidate receives accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory authorities, such approval may be withdrawn at a later date.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, any product candidates for which we receive regulatory approval in a particular jurisdiction and the activities associated with their commercialization, including testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, will be subject to comprehensive regulation by the FDA, EMA or comparable regulatory authorities in other jurisdictions. These requirements include, without limitation, submissions of safety and other post-marketing information and reports, registration and listing requirements, the FDA&#146;s cGMP requirements or comparable requirements in foreign jurisdictions, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA, EMA or comparable regulatory authorities in other jurisdictions, requirements regarding the distribution of samples to physicians, tracking and reporting of payments to physicians and other healthcare providers and recordkeeping.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA, EMA or comparable regulatory authorities in other jurisdictions may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product .In the United States, the FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA also imposes stringent restrictions on manufacturers&#146; communications regarding use of their products and, if we promote our products beyond their approved indications or in a manner inconsistent with the approved labeling, we may be subject to enforcement action for off-label promotion. Violations of the U.S. Federal Food, Drug, and Cosmetic Act (the &#147;FDCA&#148;) relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the later discovery of previously unknown problems with an approved product, including adverse events of unanticipated severity or frequency, or with manufacturing operations or processes, or failure to comply with regulatory requirements, may result in, among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">restrictions on the marketing or manufacturing of the product;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">withdrawal of the product from the market or voluntary or mandatory product recalls;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">fines, restitution or disgorgement of profits or revenues;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">warning or untitled letters;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">requirements to conduct post-marketing studies or clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">holds on clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">refusal by the FDA, EMA or comparable regulatory authorities in other jurisdictions to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">26</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">product seizure or detention;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">refusal to permit the import or export of products; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">injunctions or the imposition of civil or criminal penalties.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The policies of the FDA, EMA and comparable regulatory authorities in other jurisdictions may change and additional regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or to the adoption of new requirements, or not able to maintain regulatory compliance, we may lose any regulatory approval that may have been obtained. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad, as the regulatory environment changes rapidly. For example, certain policies of the current U.S. Presidential Administration may impact our business and industry. Namely, the current U.S. Presidential Administration has taken several executive actions that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight activities, such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to the Commercialization of Our Product Candidates</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>We have never commercialized a product and we currently have no sales force, marketing or distribution </b></i><i><b>capabilities and may lack the necessary expertise, personnel and resources to successfully commercialize our </b></i><i><b>product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We currently have no sales, marketing or commercial product distribution capabilities and have no experience in commercializing products. If any of our product candidates is approved by the FDA, EMA or comparable regulatory authorities in other jurisdictions, we will need to develop internal sales, marketing and distribution capabilities to commercialize such products, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. Given our initial focus on relapsed and refractory cancer patient populations, we intend to commercialize ADCT-402, if approved, in the United States using a focused and highly specialized sales and marketing team with a focus on hematologists and oncologists.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are costs and risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. We must also compete with other biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Alternatively, we may wish to establish collaborations with third parties to maximize the potential of our product candidates in some or all jurisdictions in which a product candidate has been approved. The biotechnology industries are characterized by intense competition. Therefore, we may not be successful in entering into such commercialization arrangements with third parties on favorable terms, or at all. In addition, we may have limited control over such third parties, and any of them may fail to devote the necessary resources and attention to sell, market and distribute our products effectively.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There can be no assurance that we will be able to develop in-house sales, marketing and distribution capacities or establish or maintain relationships with third parties to perform these services. As a result, we may not successfully commercialize any product in any jurisdiction.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our product candidates are complex and difficult to manufacture. We could experience manufacturing </b></i><i><b>problems that result in delays in our development or commercialization programs.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are four manufacturing streams for the manufacture of one of our product candidates: the antibody, the PBD-based payload, the ADC drug substance and the drug product. Because our PBD-based payload is completely synthetic, considerable synthetic chemistry efforts must be undertaken to develop manufacturing processes for our PBD-based payloads. Although we believe we have access to scalable cGMP-compliant </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">27</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">manufacturing processes for the PBD-based payloads used for our product candidates, our preparation of the process for commercial scale manufacturing is ongoing and is not yet complete for ADCT-402 and ADCT-301. In addition, because the antibodies used in our product candidates are biologics, there are risks inherent in their manufacture and their conjugation to the PBD-based warhead. There can be no assurance that we will not experience production problems in our manufacturing process. Moreover, scaling up manufacturing techniques used for the manufacture of an ADC product candidate at a clinical scale to commercial quantities may be difficult and may delay our ability to commercialize our product candidates, if approved.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Problems with the manufacturing process, including even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs. In the past, we have received a batch of one of our product candidates that did not meet our specifications. There can be no assurance that CMOs will be able to manufacture product candidates and/or components of product candidates that meet our specifications, which could delay our clinical trials and the regulatory approval and commercialization of our product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We currently rely on and expect to continue to rely on third parties for the manufacturing and supply of our product candidates. As a result, components of our product candidates are manufactured at different locations, and disruptions, delays and other difficulties may arise in the shipping and transportation of these components, resulting in delayed or failed components.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the FDA, EMA and comparable regulatory authorities in other jurisdictions may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, EMA or comparable regulatory authorities in other jurisdictions may prohibit the distribution of a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures and product recalls.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Growth in the costs and expenses of components or raw materials may also adversely influence our business, results of operations and financial condition. Supply sources could be interrupted from time to time and, if interrupted, it is not certain that supplies could be resumed, whether in part or in whole, within a reasonable timeframe and at an acceptable cost, or at all. We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could cause reputational damage. Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of any product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of operations and prospects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing processes or facilities also could restrict our ability to meet market demand for any products we develop and commercialize.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our commercial success depends upon attaining significant market acceptance of our product candidates, if </b></i><i><b>approved, among physicians, patients, patient advocacy groups third-party payors and the medical community.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we obtain regulatory approval for any of our current or future product candidates, that product candidate may nevertheless not gain sufficient market acceptance among physicians, patients, patient advocacy groups, third-party payors and the medical community. For example, they may prefer current, well-established cancer treatments, such as chemotherapy and radiation therapy, to the exclusion of our product candidates or may prefer </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">28</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">other novel product candidates rather than our product candidates. Efforts to educate physicians, patients, patient advocacy groups and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and may not receive a satisfactory return on our investment into the research and development of those product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The degree of market acceptance of any approved products depends on a number of factors, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the safety and efficacy of the product, as demonstrated in clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the indications for which the product is approved and the labeling approved by regulatory authorities for use with the product, including any warnings that may be required in the labeling;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to offer our products for sale at competitive prices;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the perceptions of physician, patient and patient advocacy group of ADCs generally and PBD-based ADCs specifically;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the treatment&#8217;s cost, safety, efficacy, convenience and ease of administration compared to that of alternative treatments;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">acceptance by physicians, patients and patient advocacy groups of the product as a safe and effective treatment;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the availability of coverage and adequate reimbursement by third-party payors, including cost-sharing programs such as copays and deductibles;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">patients&#8217; willingness to pay out-of-pocket in the absence of coverage and/or adequate reimbursement from third-party payors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the effectiveness of our and our competitors&#8217; sales and marketing efforts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to establish sales, marketing and commercial product distribution capabilities or to partner with third parties with such capabilities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the nature, severity and frequency of adverse side effects;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any restrictions on the use of our products together with other medications;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">publication of any post-approval data on the safety and effectiveness of the product; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the success of randomized post-marketing commitment studies to confirm the benefit-risk ratio of the product.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Market acceptance of our product candidates is heavily dependent on patients&#146; and physicians&#146; perception that our product candidates are safe and effective treatments for their targeted indications. The perceptions of any product are influenced by perceptions of competitors&#146; products that are in the same class or that have a similar mechanism of action. As a result, adverse public perception of our competitors&#146; ADC products may negatively impact the market acceptance of our product candidates. If any approved products are not accepted by the market to the extent that we expect, we may not be able to generate significant product revenues and may not become or remain profitable.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The market opportunities for our product candidates may be smaller than we estimate and any approval that </b></i><i><b>we obtain may be based on a narrower definition of the patient population.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Cancer therapies are sometimes characterized as first line, second line or third line. When cancer is detected early enough, first-line therapy is sometimes adequate to cure the cancer or prolong life without a cure. When first-line therapy proves unsuccessful, second-line therapy may be administered. When second-line therapy proves unsuccessful, third-line therapy may be administered. We expect that regulatory approval as third-line therapies will be sought for ADCT-402 and ADCT-301 for the treatment of relapsed or refractory DLBCL and HL, respectively. Subsequently, for those products that prove to be sufficiently beneficial, if any, regulatory approval as second-line therapies may be sought, as monotherapy or in combination with other therapies. However, there can be no assurance that our product candidates, even if approved as third-line therapies, would be approved as second-line therapies. In addition, we may have to conduct additional clinical trials prior to gaining approval as second-line therapies.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">29</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive third-line therapy and who have the potential to benefit from treatment with our product candidates, are based on estimates derived from a variety of sources, including scientific literature, surveys of clinicians and healthcare professionals and other forms of market research. However, the ultimate market opportunity for our product candidates will depend on, among other things, the final labeling for such product candidates as agreed with the FDA, EMA or comparable regulatory authorities in other jurisdictions, acceptance by the medical community and patient access and drug pricing and reimbursement. The number of patients who can be treated with our product candidates may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which would materially and adversely affect our results of operations and our business.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Regulatory agencies actively enforce the laws and regulations prohibiting the promotion of drugs for off-label </b></i><i><b>uses. If we are found to have improperly promoted off-label use, we may become subject to significant </b></i><i><b>liability.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA, EMA and comparable regulatory authorities in other jurisdictions strictly regulate the promotional claims that may be made about prescription drug products, such as our product candidates, if approved. While physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications, a product may not be promoted for uses that are not approved by the applicable regulatory authority as reflected in the product&#146;s approved labeling or for uses inconsistent with the product&#146;s approved labeling. For example, if we receive regulatory approval for ADCT-402 for the treatment of relapsed or refractory DLBCL in patients who have failed two or more treatment regimens, at least one of which must have contained rituximab, physicians, in their professional medical judgment, may nevertheless prescribe either drug product to their patients in a manner that is inconsistent with the approved labeling. In addition, although we believe our warhead may provide for superior efficacy as compared to marketed ADCs, without head-to-head data, we will be unable to make comparative claims for our product candidates, if approved. If we are found to have promoted such off-label use or made such unsubstantiated comparative claims, we may become subject to significant liability under the FDCA and other statutory authorities, such as laws prohibiting false claims for reimbursement. The U.S. government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our products, if approved, we could become subject to significant liability, which would harm our reputation and negatively impact our financial condition.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are developing certain of our product candidates in combination with other therapies, and regulatory </b></i><i><b>approval, safety or supply issues with these other therapies may delay or prevent the development and </b></i><i><b>approval of our product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Currently, we are evaluating the use of ADCT-402 in combination with ibrutinib and in combination with durvalumab and plan to evaluate the use of ADCT-301 in combination with checkpoint inhibitors. In the future, we may explore the use of these or our other product candidates in combination with other therapies. If we choose to develop a product candidate for use in combination with an approved therapy, we are subject to the risk that the FDA, EMA or comparable regulatory authorities in other jurisdictions could revoke approval of, or that safety, efficacy, manufacturing or supply issues could arise with, the therapy used in combination with our product candidate. If the therapies we use in combination with our product candidates are replaced as the standard of care, the FDA, EMA or comparable regulatory authorities in other jurisdictions may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our product candidates, if approved, being removed from the market or being less successful commercially.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Where we develop a product candidate for use in combination with a therapy that has not been approved by the FDA, EMA or comparable regulatory authorities in other jurisdictions, we will not be able to market our product candidate for use in combination with such an unapproved therapy, unless and until the unapproved therapy receives regulatory approval. Currently, we are evaluating the use of ADCT-402 in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL and in combination with durvalumab for the treatment of relapsed or refractory DLBCL, MCL and FL. However, ibrutinib has not been approved by the FDA for the treatment of DLBCL, and durvalumab has not been approved by the FDA for the treatment of </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">30</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">DLBCL, MCL, or FL. Therefore, even if ADCT-402 receives regulatory approval, we cannot market it for use in combination with ibrutinib or durvalumab unless and until they are approved for the indications that we are targeting. These unapproved therapies face the same risks described with respect to our product candidates currently in development, including serious adverse effects and delays in their clinical trials. In addition, other companies may also develop their products or product candidates in combination with the unapproved therapies with which we are developing our product candidates for use in combination. Any setbacks in these companies&#146; clinical trials, including the emergence of serious adverse effects, may delay or prevent the development and approval of our product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the FDA, EMA or comparable regulatory authorities in other jurisdictions do not approve or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain regulatory approval of or to commercialize such product candidates in combination with these therapies.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Coverage and reimbursement may be limited or unavailable for our product candidates, which could make it </b></i><i><b>difficult to sell our products profitably.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors is essential for most patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products. We cannot be certain that coverage and adequate reimbursement will be available for any of our product candidates, if approved, or that reimbursement policies will not reduce the demand for any of our product candidates, if approved. If coverage and adequate reimbursement are not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a product is:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a covered benefit under its health plan;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">safe, effective and medically necessary;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">appropriate for the specific patient;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">cost-effective; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">neither experimental nor investigational.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If coverage and adequate reimbursement of our future products, if any, is unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability. Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage and reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services (&#147;CMS&#148;), which decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not always, follow the CMS&#146;s decisions regarding coverage and reimbursement. It is difficult to predict what third-party payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Further, one payor&#146;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate reimbursement for that product. We may need to conduct expensive pharmaco-economic studies in order to </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">31</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">demonstrate the medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be considered medically necessary or cost-effective. In addition to third-party payors, professional organizations and patient advocacy groups such as the National Comprehensive Cancer Network and the American Society of Clinical Oncology can influence decisions about reimbursement for new medicines by determining standards for care. Therefore, it is possible that any of our product candidates, even if approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize the product candidates profitably.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Reimbursement agencies in Europe may be more restrictive than payors in the United States. For example, a number of cancer products have been approved for reimbursement in the United States but not in certain European countries. In Europe, pricing and reimbursement schemes vary widely from country to country and may require additional clinical trials. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Other countries require the completion of additional health technology assessments that compare the cost-effectiveness of a particular product candidate to currently available therapies. In addition, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product, may adopt a system of direct or indirect controls on the profitability of the company placing the product on the market or monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. Furthermore, many countries in the European Union have increased the amount of discounts required on pharmaceutical products, and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, and prescription products in particular, has become increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no assurance that any country that has reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. Accordingly, the reimbursement for any products in Europe may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Healthcare reform legislation and other changes in the healthcare industry and in healthcare spending may </b></i><i><b>adversely affect our business model.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our revenue prospects could be affected by changes in healthcare spending and policies in the United States, the European Union and any other potential jurisdictions we may seek to commercialize our product candidates, if approved. We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">32</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress enacted the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, the &#147;Health Care Reform Act&#148;), which included changes to the coverage and reimbursement of drug products under government healthcare programs such as:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must pay to the federal government;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">created a licensure framework for follow-on biologic products.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since its enactment, there have been judicial and congressional challenges to certain aspects of the Health Care Reform Act as well as recent efforts by the current U.S. Presidential Administration to repeal or replace certain aspects of the Health Care Reform Act. For example, in 2017, the U.S. Congress enacted the Tax Cuts and Jobs Act (the &#147;TCJA&#148;), which eliminated the tax-based shared responsibility payment imposed by the Health Care Reform Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; On December 14, 2018, the U.S. District Court for the Northern District of Texas held that the individual mandate is a critical and inseverable feature of the Health Care Reform Act, and therefore, because it was repealed by the TCJA, the remaining provisions of the Health Care Reform Act are invalid as well. While the enforcement of the judgment is stayed pending appeal and the current U.S. Presidential Administration and the CMS have stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals and other efforts to repeal and replace the Health Care Reform Act will impact the Health Care Reform Act. Since the enactment of the TCJA, there have been additional amendments to certain provisions of the Health Care Reform Act, and the current U.S. Presidential Administration and Congress may continue to seek to modify, repeal or otherwise invalidate all, or certain other provisions of, the Health Care Reform Act. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and prospects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2017, the U.S. Congress enacted the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act (the &#147;Right to Try Act&#148;). The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">33</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act of 2011 (the &#147;Budget Control Act&#148;), which included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 absent additional congressional action. In 2012, the U.S. Congress enacted the American Taxpayer Relief Act which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the current U.S. Presidential Administration&#146;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the current U.S. Presidential Administration released a &#147;Blueprint&#148; to lower drug prices and reduce out-of-pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. In addition, CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of treatment. Prescription drugs and biological products that are in violation of these requirements will be included on a public list. Any adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing healthcare legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the demand for any products for which we may obtain regulatory approval;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to set a price that we believe is fair for our products;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">34</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to obtain coverage and reimbursement approval for a product;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to generate revenues and achieve or maintain profitability; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the level of taxes that we are required to pay.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We face substantial competition, which may result in others discovering, developing or commercializing </b></i><i><b>products, treatment methods and/or technologies before or more successfully than we do.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The biotechnology industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future. Our competitors include large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Many of our competitors have significantly greater financial resources and capabilities in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through strategic collaborations with large and established companies. Furthermore, mergers and acquisitions in the biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">With respect to our current and potential future product candidates, we believe that our ability to compete effectively and develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">advance the technology we use in our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">obtain, maintain, protect and enforce intellectual property protection for our technologies and product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">obtain required government and other public and private approvals on a timely basis;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">attract and retain key personnel;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">execute our research and development plans;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">commercialize effectively;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">obtain and maintain coverage and reimbursement for our products in approved indications;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">obtain adequate funding for our activities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">comply with applicable laws, regulations and regulatory requirements and restrictions with respect to the commercialization of our products, including with respect to any changed or increased regulatory restrictions; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">enter into additional strategic collaborations to advance the development and commercialization of our product candidates.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many companies are active in the oncology market and are developing or marketing products for the specific therapeutic markets that we target, including both antibody and non-antibody-based therapies. Similarly, we also face competition from other companies and institutions that continue to invest in innovation in the ADC field including new payload classes, new conjugation approaches and new targeting moieties. Specifically, we are aware of multiple companies with ADC technologies that may be competitive to our product candidates, including, but not limited to, AbbVie, Inc., Astellas Pharma Inc., AstraZeneca plc, BioAtla, LLC, Bristol-Myers Squibb Company, CytomX Therapeutics, Daiichi Sankyo Company, Eli Lilly and Company, Genentech, Inc., Genmab, ImmunoGen, Inc., Immunomedics, Inc., Mersana Therapeutics Inc., Millennium Pharmaceuticals, Inc., MorphoSys AG, Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Seattle Genetics, Inc., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Ltd and Wyeth Pharmaceuticals, Inc. Currently, there are five approved ADCs: (i) brentuximab vedotin (Adcetris&#174;), marketed by Seattle Genetics, Inc. and Takeda Pharmaceutical Company Ltd, (ii) ado-trastuzumab emtansine (Kadcyla&#174;), marketed by Genentech, </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">35</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Inc., (iii) inotuzumab ozogamicin (Besponsa&#174;), marketed by Pfizer Inc., (iv) gemtuzumab ozogamicin (Mylotarg&#174;), also marketed by Pfizer Inc. and (v) polatuzumab vedotin (Polivy&#174;), marketed by Genentech, Inc. In addition, as of 2018, there are approximately 175 ADCs in development, the vast majority of which are being developed for the treatment of cancer.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the relapsed or refractory DLBCL setting, for which we are developing ADCT-402, current third-line treatment options include CAR T-cell therapy (&#147;CAR-T&#148;), allogeneic stem cell transplant and chemotherapy using small molecules. Recently, Polivy&#174; was approved for third-line use in combination with bendamustine and a rituximab product. In addition, we expect new competitors, including tafasitamab (MOR208) and bispecific antibodies, to enter the market as treatment options for such patients. In the relapsed or refractory HL setting, for which we are developing ADCT-301, current third-line treatment options include chemotherapy, immunotherapy and Adcetris&#174;. In addition, we expect changes to the treatment paradigm, such as the movement of Adcetris&#174; to earlier lines of therapy and the potential expanded use of checkpoint inhibitors, and new entrants such as bispecific antibodies. We expect to compete on relative improved safety, tolerability, efficacy, convenience and cost compared to other treatment options. However, there can be no assurance that our product candidates would be able to compete effectively.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop, which would render our products obsolete or noncompetitive. Our competitors also may obtain FDA, EMA or regulatory approval in other jurisdictions for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. We anticipate that we will face increased competition in the future as additional companies enter our market and scientific developments surrounding other cancer therapies continue to accelerate.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products or biosimilars. Generic products are currently on the market for the indications that we are pursuing, and biosimilars and additional generic products are expected to become available over the coming years. In the United States, the Biologics Price Competition and Innovation Act of 2009 (the &#147;BPCIA&#148;), included as a subtitle in the Health Care Reform Act, established a pathway for the FDA approval of follow-on biologics and provides a twelve-year data exclusivity period for reference products and an additional six-month exclusivity period if pediatric studies are conducted. It is unclear how the Health Care Reform Act repeal efforts discussed above, including the 2018 federal district court case, and subsequent appeals, if any, will impact the biosimilar framework created by the Health Care Reform Act and thus, our business. In Europe, the EMA has issued guidelines for approving products through an abbreviated pathway, and biosimilars have been approved in Europe. If a biosimilar version of one of our potential products is approved in the United States or Europe, it could have a negative effect on sales and gross profits of the potential product and our financial condition.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Our Relationship with Third Parties</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Our rights to ADCT-301 are subject to our collaboration and license agreement with Genmab, and there can </b></i><i><b>be no assurance that we will maintain the rights to develop or commercialize ADCT-301.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our collaboration and license agreement with Genmab requires a divestment of ADCT-301, in which Genmab has a 25% interest, following database lock for the Phase 1/2 clinical trial. See &#147;Business&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#148; The agreement sets out a defined process to facilitate the divestment of ADCT-301 by licensing the rights thereto to a third party, subject to Genmab&#146;s right of first opportunity to negotiate to acquire ADCT-301 in full. This process includes the opportunity for both parties to bid for the license rights alongside third parties. Both parties are required to use commercially reasonable efforts to complete and maximize the value obtained in this process. Therefore, our rights to ADCT-301 are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will apply for regulatory approval of or commercialize ADCT-301.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">36</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We rely on third parties to conduct preclinical </b></i><i><b>studies and/or</b></i><i><b> clinical trials of our product candidates. If they </b></i><i><b>do not properly and successfully perform their obligations to us, we may not be able to obtain regulatory </b></i><i><b>approvals for our product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We rely, and we expect that we will continue to rely, on CROs and other third parties to assist in managing, monitoring and otherwise carrying out preclinical studies and clinical trials of our product candidates. We currently rely on third parties to manage and conduct our clinical trials of ADCT-402 and ADCT-301. As a result of our reliance on CROs and other third parties, we have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than we would otherwise have if we relied entirely upon our own staff. These CROs and other third parties are not our employees and we have limited control over the amount of time and resources that they dedicate to our product candidates. In addition, communications with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">have staffing difficulties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">fail to comply with contractual obligations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">experience regulatory compliance issues;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">undergo changes in priorities or become financially distressed; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">form relationships with other entities, some of which may be our competitors.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If these third parties do not successfully carry out their duties under their agreements, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to clinical trial protocols or to regulatory requirements, or if they otherwise fail to comply with clinical trial protocols or meet expected deadlines, the clinical trials of our product candidates may not meet regulatory requirements. Specifically, the FDA, EMA and comparable regulatory authorities in other jurisdictions require compliance with regulations and standards, including GCP, for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical trials to assure that the data and results are credible and accurate and that the rights, integrity and confidentiality of study participants are protected. Although we rely, and intend to continue to rely, on third parties to conduct our clinical trials, they are not our employees, and we are responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan, protocol, legal and regulatory requirements and scientific standards. Our reliance on these third parties for research and development activities will reduce our control over these activities, but will not relieve us of our responsibilities. If our CROs and other third-party research and development partners fail to comply with applicable GCPs or other regulatory requirements, the clinical data generated in our clinical trials may be deemed unreliable and preclinical development activities or clinical trials may be extended, delayed, suspended or terminated.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We compete with many other companies for the resources of these third parties. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our product candidates. The third parties with whom we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. If any of our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur in our clinical trials, which can materially impact our ability to meet our desired clinical development timelines. There can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, results of operations, financial condition and prospects.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">37</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We rely </b></i><i><b>on third parties for the manufacture, production, storage and distribution of our product candidates. </b></i><i><b>Our dependence on these third parties may impair the clinical advancement and commercialization of our </b></i><i><b>product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We currently rely on and expect to continue to rely on third parties for the manufacturing and supply of our product candidates, and such reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. There are four manufacturing streams for the manufacture of one of our product candidates: the antibody, the PBD-based payload, the ADC drug substance and the drug product. In addition, we contract with specialized analytical laboratories for lot release and stability testing of our product candidates. For the foreseeable future, we expect to continue to rely on such third parties for the manufacture, production, storage and distribution of our product candidates on a clinical or, if any of our product candidates receives regulatory approval, on a commercial scale. If our agreements with these third parties expire or are terminated, there is no guarantee that we would be able to negotiate new agreements with them or other third parties on equally favorable terms as the current agreements, or at all.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Reliance on third-party providers may expose us to different risks than if we were to manufacture and supply product candidates ourselves. The facilities used by our CMOs or other third-party manufacturers to manufacture our product candidates must be approved by the EMA and comparable regulatory authorities in other jurisdictions, and the FDA requires our CMOs or other third-party manufacturers to maintain a compliance status acceptable to the FDA, pursuant to inspections that will be conducted after we submit the marketing application to the applicable regulatory authorities. Although we have auditing rights with all our manufacturing counterparties, we do not have control over a supplier&#146;s or manufacturer&#146;s compliance with these laws, regulations, applicable cGMP standards and other laws and regulations, such as those related to environmental health and safety matters. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If our CMOs or other third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA and comparable regulatory authorities in other jurisdictions, or if the quality or accuracy of the manufacturing and quality control data they obtain is compromised due to their failure to adhere to protocols or to regulatory requirements, we will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of our CMOs or other third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If a CMO or other third-party manufacturer cannot maintain a compliance status acceptable to the FDA, or if the EMA or a comparable regulatory authority in another jurisdiction does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates and that obtained approvals could be revoked, which would adversely affect our business and reputation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Due to the complexity to manufacture our product candidates and the small quantities of product candidates needed for clinical trials and regulatory submission purposes, we contract with one CMO for each component of our product candidates and/or the same CMO for multiple components of our product candidates or services involved in manufacturing our product candidates. We cannot ensure that these CMOs will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of exclusive CMOs exposes us to several risks, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delays or stoppages in product shipments for our product candidates, including loss shipments and cross-border logistical complications, resulting in delayed and lost shipments;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delays to the development timelines for our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an inability to commence or continue clinical trials of product candidates under development;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">interruption of supply resulting from modifications to a CMO&#8217;s operations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delays or stoppage in manufacturing or shipment due to a CMO&#8217;s bankruptcy, winding up, reorganization or similar corporate failures or financial distress;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delays in product shipments resulting from uncorrected defects, reliability issues, or a CMO&#8217;s variation in a component;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">38</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a lack of long-term arrangements for key components;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">difficulty and cost associated with locating and qualifying alternative CMOs for our components or raw materials in a timely manner;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">production delays related to the evaluation and testing of components from alternative CMOs, and corresponding regulatory qualifications;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">delay in delivery due to our CMOs&#8217; prioritizing other customer orders over ours;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">damage to our reputation caused by defective product candidates produced by our CMOs; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">potential price increases.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The failure of one or more CMOs to supply product candidates and/or components of product candidates that meet our specifications could delay our clinical trials and the regulatory approval and commercialization of our product candidates. A CMO may not be able to correct batch failures in a reasonable timeframe, if at all, which may require us to seek replacement CMOs. In the past, we have received a batch of one of our product candidates that did not meet our specifications. There can be no assurance that CMOs will be able to manufacture product candidates and/or components of product candidates that meet our specifications, which could delay our clinical trials and the regulatory approval and commercialization of our product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Establishing additional or replacement CMOs could take a substantial amount of time and it may be difficult to establish replacement CMOs who meet regulatory requirements. In general, there are relatively few alternative CMOs that are able to manufacture our product candidates under cGMP. If we have to switch to a replacement CMO, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. If we are able to find a replacement CMO, the replacement CMO would need to be qualified and may require additional regulatory authority approval, which could result in further delay regulatory approval and commercialization of our product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, third-party providers may breach, terminate or decline to renew agreements they have with us because of factors beyond our control, such as their own financial difficulties or business priorities, international trade restrictions and financial costs, potentially at a time that is costly or otherwise inconvenient for us or our partners. In such cases, we would face the challenge of transferring complicated manufacturing techniques to other CMOs. We may incur significant costs and be required to devote significant time to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. A transfer of the manufacturing process for our product candidates would be time-consuming, and we or our partners may not be able to achieve such transfer. If we are unable to find an adequate replacement or another acceptable solution in time, clinical trials of our product candidates could be delayed or our commercial activities could be harmed.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our third-party manufacturers may be unable to successfully scale up manufacturing of our product </b></i><i><b>candidates in sufficient quality and quantity, which may impair the clinical advancement and </b></i><i><b>commercialization of our product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to conduct clinical trials of our product candidates and commercialize any approved product candidates, our manufacturing partners need to manufacture them in large quantities. However, they may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. Furthermore, due to the specific nature of our ADCs&#146; components and availability of production capacity, there is significant lead time required by our third-party manufacturers to provide us with the needed manufacturing services. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of these product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting products may be delayed or not obtained, which could significantly harm our business. Supply sources could be interrupted from time to time and, if interrupted, it is not certain that supplies could be resumed (whether in part or in whole) within a </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">39</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">reasonable timeframe and at an acceptable cost, or at all. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not be successful in establishing commercialization collaborations, which could adversely affect our </b></i><i><b>ability to commercialize our product candidates, if approved.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect to commercialize our product candidates, if approved, in the United States and to collaborate with strategic third parties to commercialize our product candidates outside of the United States. We may not be successful in entering into such marketing and distribution arrangements with third parties or in entering in such marketing and distribution arrangements with third parties on favorable terms. Moreover, such arrangements are complex and time consuming to negotiate, document and implement and they may require substantial resources to maintain.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, it is possible that a collaborator may not devote sufficient resources to the commercialization of our product candidates or may otherwise fail in its commercialization efforts, in which event the commercialization of such product candidates could be delayed or terminated and our business could be substantially harmed. In addition, the terms of any collaboration or other arrangement that we establish may not be favorable to us or may not be perceived as favorable, which may negatively impact our business, financial condition, results of operations and prospects. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We </b></i><i><b>collaborate</b></i><i><b> with third parties in the research, development and commercialization of certain of our </b></i><i><b>product candidates and may enter into other collaborations in the future for our other product candidates. If </b></i><i><b>our </b></i><i><b>collaborators</b></i><i><b> do not perform as expected or if we are unable to maintain existing or establish additional </b></i><i><b>collaborations, our ability to develop and commercialize our product candidates may be adversely affected.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time, we may enter into collaboration agreements with third parties that have experience in product development, manufacturing and/or commercialization for other product candidates and/or research programs. We may face significant competition in seeking appropriate partners for our product candidates, and the negotiation process may be time-consuming and complex. In order for us to successfully partner our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Even if we are successful in our efforts to establish collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. If we fail to establish and maintain collaborations related to our product candidates, we could bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise for which we have not budgeted. This could negatively affect the development and commercialization of our product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In such collaborations, we will depend on the performance of our collaborators. Our collaborators may fail to perform their obligations under the collaboration agreements or may not perform their obligations in a timely manner. If conflicts arise between our collaborators and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Furthermore, our collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. In addition, we cannot control the amount and timing of resources our collaborators may devote to our product candidates. They may separately pursue competing products, therapeutic approaches or technologies to develop treatments for the diseases targeted by us. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our product candidates. Even if our collaborators continue their contributions to the strategic collaborations, they may nevertheless determine not to actively pursue the development or commercialization of any resulting products. Additionally, if our collaborators pursue different clinical or regulatory strategies with their product candidates based on similar technology as used in our product candidates, adverse events with their product candidates could negatively affect our product candidates. Any of these developments could harm our product development efforts.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may be subject to exclusivity and other governance provisions within a collaboration agreement that may prevent us from pursuing certain alternative product candidates and exercising complete control over our </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">40</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">product candidates&#146; development and commercialization. For example, our collaboration and license agreement with Genmab requires a divestment of ADCT-301, in which Genmab has a 25% interest, following database lock for the Phase 1/2 clinical trial. See &#147;Business&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#148; In addition, our collaborators will likely have customary termination rights under these agreements. Any termination of an agreement by the relevant collaborators could affect our ability to develop further such product candidates or adversely affect how we are perceived in scientific and financial communities. Therefore, if our collaborators terminate or breach our agreements with them, or otherwise fail to complete their obligations in a timely manner, it may have a detrimental effect on our financial position by reducing or eliminating the potential for us to receive technology access and license fees, milestones and royalties, reimbursement of development costs, as well as possibly requiring us to devote additional efforts and incur costs associated with pursuing internal development of product candidates. Furthermore, if our collaborators do not prioritize and commit sufficient resources to our product candidates, we or our partners may be unable to develop or commercialize these product candidates, which would limit our ability to generate revenue and become profitable.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Intellectual Property</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>If we are unable to obtain, maintain or protect our intellectual property rights in any products or technologies </b></i><i><b>we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, third </b></i><i><b>parties could develop and commercialize products and technology similar or identical to ours, and we may not </b></i><i><b>be able to compete effectively in our market.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our success depends in significant part on our own and any of our licensors&#146; ability to obtain, maintain and protect patents and other intellectual property rights and operate without infringing, misappropriating, or otherwise violating the intellectual property rights of others. To protect our proprietary position, we have filed numerous patent applications both in the United States and in foreign jurisdictions to obtain patent rights to inventions we have developed that are important to our business, including ADCT-402 and ADCT-301. We have also licensed from third parties rights to patents and other intellectual property, including from MedImmune with respect to the PBD technology we use for our PBD-based ADCs, from Synaffix B.V. (&#147;Synaffix&#148;) for site-specific conjugation technology we use in ADCT-601 and ADCT-701, from Genmab with respect to the antibody we use in ADCT-301 and from other parties for some of our other product candidates and related technology. If we or our current or future licensors are unable to obtain or maintain patent protection with respect to such inventions and technology, our business, financial condition, results of operations and prospects could be materially harmed.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The patent prosecution process is expensive, time-consuming and complex, and we and our current or future licensors may not be able to prepare, file, prosecute, maintain and enforce all necessary or desirable patent applications at a reasonable cost or in a timely manner. Patents may be invalidated and patent applications may not be granted for a number of reasons, including known and unknown prior art (including our own prior art), deficiencies in the patent applications or the lack of novelty of the underlying inventions or technology. It is also possible that we or our current and future licensors will fail to identify patentable aspects of inventions made in the course of research, development and commercialization activities in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research, development and commercialization activities, such as our employees, corporate collaborators, outside scientific collaborators, CROs, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such activities before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our current or future licensors were the first to make the inventions claimed in our owned or licensed patents or patent applications, or that we or our current or future licensors were the first to file for patent protection of such inventions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Moreover, in some circumstances, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering technology that we license from third parties, and are reliant on our licensors. For example, pursuant to our agreements with MedImmune and Genmab, MedImmune and Genmab retain control of the preparation, filing, prosecution, maintenance, enforcement and defense of certain of the patents and patent applications licensed to us. Therefore, these patents </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">41</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">and applications may not be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our current or future licensors fail to prosecute, maintain, enforce or defend such patents and other intellectual property rights, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, or lose rights to those patents or patent applications, the rights that we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#146; patent rights are highly uncertain. For example, there is significant uncertainty, and there has been much litigation, regarding what is considered patentable subject matter under U.S. patent law, including with respect to diagnostics. Our owned and licensed pending and future patent applications may not result in patents being issued which protect the products or technologies we develop, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Moreover, the patent examination process may require us or our current and future licensors to narrow the scope of the claims of our owned or licensed pending and future patent applications, which may limit the scope of patent protection that may be obtained. Additionally, the scope of patent protection can be reinterpreted after issuance. Even if our owned or licensed pending and future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or in-license may be challenged, narrowed, circumvented or invalidated by third parties in court or in patent offices in the United States and abroad. Our owned or licensed patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then, only to the extent the issued claims cover the technology. Our competitors or other third parties may also be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (&#147;USPTO&#148;). We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate an opposition, interference, reexamination, post-grant review, <i>inter partes</i> review, nullification or derivation action in court or before patent offices, or other proceedings challenging the inventorship, validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. An adverse determination in any such proceeding or litigation could reduce the scope of, or invalidate, the patent rights we own or license, allow third parties to commercialize the products or technologies we develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or our current or future licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in foreign patent offices, that challenge priority of invention or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of the product candidates and technologies we develop, including ADCT-402 or ADCT-301. Such proceedings also may result in substantial cost and require significant time and attention from our scientific and management personnel, even if the eventual outcome is favorable to us. Consequently, there can be no assurance that any product candidates or technology we develop will be protectable or remain protected by valid and enforceable patents. In addition, if the breadth or strength of protection provided by our patents or patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our current and future licensors were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications on or before March 15, 2013, an interference proceeding in the United States </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">42</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Issued patents covering one or more of our product candidates or technologies, including ADCT-402, </b></i><i><b>ADCT-301 or the technology we use in our product candidates, could be found invalid or unenforceable if </b></i><i><b>challenged in court.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To protect our competitive position, we may, from time to time, resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable and expensive, and many of our or our licensors&#146; or collaboration partners&#146; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaboration partners can. Accordingly, despite our or our licensors&#146; or collaboration partners&#146; efforts, we or our licensors or collaboration partners may not prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the United States and the European Union. We may fail in enforcing our rights, in which case third parties, including our competitors, may be permitted to use our technology without being required to pay us any license fees.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties, including our competitors, to commercialize or use our product candidates and technologies, including the PBD technology we use in our product candidates, and then compete directly with us, without payment to us.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we or one of our current or future licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. A claim for unenforceability could involve an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or the European Patent Office or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO or an equivalent foreign body, even outside the context of litigation. Potential proceedings include reexamination, post-grant review, <i>inter parte</i>s review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technology or any product candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we or our licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or certain aspects of the PBD technology we use in our product candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects. Further, litigation could result in substantial costs and diversion of management resources, regardless of the outcome, and this could harm our business and financial results. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which </b></i><i><b>could be expensive, time-consuming and unsuccessful.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Competitors and other third parties may infringe, misappropriate or otherwise violate our issued patents or other intellectual property or the patents or other intellectual property of our licensors, or we or our licensors may be required to defend against claims of infringement, misappropriation or other violations of intellectual </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">43</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">property held by third parties. In addition, our patents or the patents of our licensors may become involved in inventorship or priority disputes. To counter infringement, misappropriation or other unauthorized use, we or our licensors may be required to file infringement claims, which can be expensive and time-consuming. Any claims we or our licensors assert against perceived infringers could provoke these parties to assert counterclaims alleging that we or our licensors infringe their patents or that our or our licensors&#146; patents are invalid or unenforceable. In a patent infringement proceeding, a court may decide that a patent of ours or one of our licensors&#146; is invalid or unenforceable, in whole or in part, construe the patent&#146;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#146; patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly. We may find it impractical or undesirable to enforce our intellectual property rights against some third parties. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our or our licensors&#146; patents or patent applications. If we or our licensors are unsuccessful in any interference proceedings to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated or held unenforceable. If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority of inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or narrowing of our owned or licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common shares.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we fail to comply with our obligations in the agreements under which we license intellectual property rights </b></i><i><b>from third parties or otherwise experience disruptions to our business relationships with our licensors, we </b></i><i><b>could lose the ability to continue the development and commercialization of our product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are party to a number of intellectual property and technology licenses that are important to our business. For example, the PBD technology we use to generate our PBD-based ADCs was developed by, and is licensed on a target-exclusive basis from, MedImmune. All of our ADC product candidates and research programs utilize a PBD-based warhead. In addition, we license certain patents and know-how relating to the antibodies used and incorporated into ADCT-301 from Genmab and those used and incorporated into our other product candidates from other third-party licensors. For more information regarding these agreements, see &#147;Business&#8212;License and Collaboration Agreements.&#148; If we fail to comply with our obligations under these or our other agreements, including payment and diligence terms, our current and future licensors may have the right to terminate these agreements, in which event we may not be able to develop, manufacture, market or sell any product that is covered by these agreements or may face other penalties under these agreements. Such an occurrence could adversely affect the value of the product candidates being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all, or cause us to lose our rights under these agreements, including our rights to intellectual property or technology important to our development programs. Accordingly, termination of these agreements may require us to cease the development of our product candidates, including ADCT-402 or ADCT-301.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the scope of rights granted under the license agreement and other interpretation-related issues;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">44</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the sublicensing of patent and other rights under our existing collaborative development relationships and any collaboration relationships we might enter into in the future;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current and future licensors and us; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the priority of invention of patented technology.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the agreements under which we license intellectual property or technology from third parties are generally complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreements. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not be successful in obtaining additional intellectual property rights necessary or required to further </b></i><i><b>develop our product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses from such third-party intellectual property holders. Moreover, we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of product candidates we may develop. In addition, many of our patents are co-owned with MedImmune, which licenses its interest in such patents to us. With respect to any patents we co-own with third parties, we may require licenses to such co-owners&#146; interest to such patents. In addition, we may need the cooperation of any co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. We may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for product candidates we develop, including ADCT-402 or ADCT-301. The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development or commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. As a result, we may be unable to obtain any such licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, including ADCT-402 or ADCT-301, which could significantly harm our business, financial condition, results of operations and prospects. In addition, even if we obtain a license, it may be non-exclusive, thereby giving third parties, including our competitors, access to the same technologies licensed to us. In addition, any license we obtain could require us to make substantial licensing and royalty payments. If we are unable to obtain an exclusive license to any third-party or co-owned patents or patent applications, such parties may be able to license their rights to other third parties, including our competitors, and such third parties could market competing products and technology. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">45</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Third parties may initiate legal proceedings against us alleging that we infringe, misappropriate, or otherwise </b></i><i><b>violate their intellectual property rights or we may initiate legal proceedings against third parties to challenge </b></i><i><b>the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be </b></i><i><b>uncertain and could have an adverse effect on the success of our business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our and our current or future licensors&#146; proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Third parties may initiate legal proceedings against us or our current and future licensors alleging that we or our current and future licensors infringe, misappropriate or otherwise violate their intellectual property rights. In addition, we and our licensors have initiated, and we and our current and future licensors may in the future initiate, legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, reexaminations, <i>inter partes</i> reviews or derivation proceedings in the United States or other jurisdictions. These proceedings can be expensive and time-consuming, and many of our or our current and future licensors&#146; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our current and future licensors. Numerous U.S.- and foreign-issued patents and pending patent applications which are owned by third parties exist in the fields in which we are pursuing our product candidates. We are aware of a patent family with issued claims that could be construed to cover the linker in ADCT-601 and ADCT-701. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are, and in the future, we may identify, other third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of one or more of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Parties making infringement, misappropriation or other intellectual property claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates, including ADCT-402 or ADCT-301. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources. In addition, even if we believe any third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of validity, enforceability, priority or non-infringement. A court of competent jurisdiction could hold that such third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such third-party U.S. patents in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. An unfavorable outcome could require us or our current and future licensors to cease using the related technology or developing or commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our current and future licensors a license on commercially reasonable terms or at all. Even if we or our current and future licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our current and future licensors, and it could require us to make substantial licensing and royalty payments. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed a patent. A finding of infringement, misappropriation or other violation of third-party intellectual property could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">46</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may be subject to claims by third parties asserting that we or our employees, consultants or advisors have </b></i><i><b>misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual </b></i><i><b>property.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many of our employees, consultants, and advisors, including our senior management, were previously employed at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and/or non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending against any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Intellectual property litigation or proceedings could cause us to spend substantial resources and distract our </b></i><i><b>personnel.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of our common shares to decline. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon, misappropriating or otherwise violating our intellectual property. Any of the foregoing events could harm our business, financial condition, results of operation and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect </b></i><i><b>our product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or the interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs. The Leahy-Smith Act includes provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">47</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review,<i> inter partes</i> review and derivation proceedings. In addition, assuming that other requirements for patentability are met, prior to March 15, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Obtaining and maintaining patent protection depends on compliance with various procedural, document </b></i><i><b>submission, fee payment and other requirements imposed by governmental patent agencies, and our patent </b></i><i><b>protection could be reduced or eliminated for non-compliance with these requirements.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patent or patent application are due to be paid to the USPTO and various government patent agencies outside of the United States in several stages over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can, in some cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our current and future licensors fail to maintain the patents and patent applications covering our product candidates, our patent protection could be reduced or eliminated and our competitors might be better able to enter the market with competing products or technology, which could have a material adverse effect on our business, financial condition, results of operation and prospects. </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we do not obtain patent term extension for any product candidates we may develop, our business may be </b></i><i><b>materially harmed.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Patents have a limited lifespan. Due to the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. At the time of the expiration of any relevant patents, the underlying technology covered by such patents can be used by any third party, including competitors. Although the patent term extensions under the Drug Price Competition and Patent Term Restoration Action of 1984 (the &#147;Hatch-Waxman Amendments&#148;) in the United States may be available to extend the patent term, we cannot provide any assurances that any such patent term extension will be obtained and, if so, for how long.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">48</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">candidates are commercialized. Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or the regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may not be able to protect our intellectual property rights throughout the world.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our owned or licensed intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. For example, in some jurisdictions, including Europe, it is more difficult to obtain patents protecting a medical method of use, and any such patents we are able to obtain in such jurisdictions may issue with narrower scope than their U.S. counterparts. Consequently, we and our current and future licensors may not be able to prevent third parties from practicing our owned or licensed inventions in all countries outside the United States, or from selling or importing products made using our owned or licensed inventions in and into the United States or other jurisdictions. Competitors may use our owned or licensed technologies to develop their own products in jurisdictions where we have not obtained patent protection and, further, may export otherwise infringing products to territories where we and our current and future licensors have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, including ADCT-402 or ADCT-301, and our owned and licensed patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us and our current and future licensors to stop the infringement of our owned or licensed patents or marketing of competing products in violation of our owned or licensed intellectual property and proprietary rights generally. Proceedings to enforce our owned or licensed intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our and our current or future licensors&#146; efforts and attention from other aspects of our business, could put our owned or licensed patents at risk of being invalidated or interpreted narrowly, could put our and our current or future licensors&#146; patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our current and future licensors. We or our current and future licensors may not prevail in any lawsuits that we or our current and future licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our and our current and future licensors&#146; efforts to enforce intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our current and future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">49</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we are unable to protect our confidential information and trade secrets, our business and competitive </b></i><i><b>position would be harmed.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Trade secrets can be difficult to protect. We seek to protect these trade secrets, in part, by entering into non-disclosure, confidentiality and invention assignment agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality agreements with our employees and consultants. However, there can be no assurance that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have a material adverse effect on our business.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques, and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. If a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us. Failure on our part to adequately protect our trade secrets or confidential information could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If our trademarks and trade names are not adequately protected, then we may not be able to build name </b></i><i><b>recognition in our markets and our business may be adversely affected.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our registered or unregistered trademarks or trade names may be challenged, circumvented, declared generic or determined to be infringing on other marks. There can be no assurance that competitors will not infringe our trademarks, that we will have adequate resources to enforce our trademarks or that any of our current or future trademark applications will be approved. During trademark registration proceedings, we may receive rejections and, although we are given an opportunity to respond, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and in proceedings before comparable agencies in many foreign jurisdictions, trademarks are examined for registrability against prior pending and registered third-party trademarks, and third parties are given an opportunity to oppose registration of pending trademark applications and/or to seek cancellation of registered trademarks. Applications to register our trademarks may be finally rejected, and opposition or cancellation proceedings may be filed against our trademarks, which may necessitate a change in branding strategy if such rejections and proceedings cannot be overcome or resolved. For example, in some jurisdictions the applicable trademark office has rejected our corporate name for registration, or a third party has objected to a published application for a product trademark, which, in some cases, has caused us to abandon or limit our applications, and/or rely more on the registration for our corporate logo.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Intellectual property rights do not necessarily address all potential threats. </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we license or may own in the future;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">50</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may not develop additional proprietary technologies that are patentable;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the patents of others may harm our business; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Should any of these events occur, they could have a material adverse effect on our business, results of operations, financial condition and prospects. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Our Business and Industry</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>If we fail to attract and retain senior management and key scientific personnel or fail to adequately plan for </b></i><i><b>succession, we may be unable to successfully develop our product candidates, conduct our clinical trials and </b></i><i><b>commercialize our product candidates.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ability to compete in the highly competitive biotechnology industry depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on the performance and expertise of members of our senior management and key scientific personnel, including our co-founder and CEO, Dr. Christopher Martin, who was a co-founder of Spirogen Ltd., the company that developed the PBD technology that we use for all of our ADC product candidates and research programs. The loss of the services of Dr. Martin or any of our other senior management members, other key employees and scientific and medical advisors could impede the achievement of our research, development and commercialization objectives. Dr. Martin and other members of our senior management are employed pursuant to employment agreements with no term and that require advance notice (twelve months for Dr. Martin) for termination, but Dr. Martin and each of these other persons may terminate their employment with us at any time. In addition, laws and regulations on executive compensation, including legislation in our home country, Switzerland, may restrict our ability to attract, motivate and retain the required level of qualified personnel. In Switzerland, legislation affecting public companies has been passed that, among other things, (i) imposes an annual binding shareholders&#146; &#147;say-on-pay&#148; vote with respect to the compensation of the members of (a) the executive committee and (b) the board of directors, (ii) prohibits severance, advances, transaction premiums and similar payments to executive officers and directors, and (iii) requires companies to specify various compensation-related matters in their articles of association, thus requiring them to be approved by a shareholders&#146; vote. Moreover, the United Kingdom&#146;s potential exit from the European Union may result in difficulties in attracting and retaining qualified personnel for our research and development laboratories in London. We do not maintain &#147;key person&#148; insurance for any of our executives or other employees.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, our failure to put in place adequate succession plans for senior and key management roles or the failure of key employees to successfully transition into new roles could have an adverse effect on our business and operating results. The unexpected or abrupt departure of one or more of our key personnel and the failure to effectively transfer knowledge and effect smooth key personnel transitions may have an adverse effect on our business resulting from the loss of such person&#146;s skills, knowledge of our business, and years of industry experience. If we cannot effectively manage leadership transitions and management changes in the future, our reputation and future business prospects could be adversely affected.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Competition for skilled personnel is intense, particularly in the biotechnology industry. We are headquartered in Lausanne, Switzerland, and maintain research and development laboratories in London, clinical development operations in New Jersey and in Lausanne, and CMC operations in the San Francisco Bay Area. At each of these locations, we face competition for personnel from other companies, universities, public and private research </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">51</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">institutions and other organizations. This competition may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous biotechnology companies for similar personnel. This possibility is further compounded by the novel nature of our product candidates, as fewer people are trained in or are experienced with product candidates of this type. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed or may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may encounter difficulties in managing our growth and expanding our operations successfully.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As we seek to advance our product candidates through clinical trials and commercialization, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities. In addition, as our operations expand, we expect that we will need to manage additional relationships with various collaborators, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management. Our management may have to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to these growth activities, including identifying, recruiting, integrating, maintaining and motivating additional employees, managing our research and development efforts effectively, including the clinical trials and the FDA&#146;s, EMA&#146;s or comparable regulatory authority in other jurisdictions&#146; review process for our product candidates, while complying with our contractual obligations to contractors and other third parties and improving our operational, financial and management controls, reporting systems and procedures.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to effectively manage our research and development efforts and hire, train and integrate additional management, administrative and sales and marketing personnel. Due to our limited financial resources, we may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company or could disrupt our operations.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed or that we can find qualified replacements. Furthermore, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we do not achieve our projected development and commercialization goals in the timeframes we announce </b></i><i><b>and expect, the commercialization of any of our product candidates may be delayed, and our business will be </b></i><i><b>harmed.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the regulatory submissions or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical trials, receipt of regulatory approval or the commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our available capital resources or capital constraints we experience;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">52</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to identify and enroll patients who meet clinical trial eligibility criteria;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our receipt of approvals by the FDA, EMA and comparable regulatory authorities in other jurisdictions, and the timing thereof;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">other actions, decisions or rules issued by regulators;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to manufacture and supply clinical trial materials to our clinical sites on a timely basis;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the efforts of our collaborators with respect to the commercialization of our products; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the securing of, costs related to, and timing issues associated with, commercial product manufacturing as well as sales and marketing activities.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of any of our product candidates may be delayed, and our business, results of operations, financial condition and prospects may be adversely affected.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Failure to comply with health and data protection laws and regulations could lead to government enforcement </b></i><i><b>actions, private litigation and/or adverse publicity and could negatively affect our operating results and </b></i><i><b>business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We receive, generate and store significant and increasing volumes of sensitive information, such as employee and patient data. In addition, we actively seek access to medical information, including patient data, through research and development collaborations or otherwise. We have legal and contractual obligations regarding the protection of confidentiality and appropriate use of personal data. We and any potential collaborators may be subject to federal, state, local and foreign laws and regulations that apply to the collection, use, retention, protection, disclosure, transfer and other processing of personal data. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (for example, Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#147;HITECH&#148;). Depending on the facts and circumstances, we could be subject to civil, criminal and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Several foreign jurisdictions, including the European Union, its member states and Australia, among others, have adopted legislation and regulations that increase or change the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in these jurisdictions. In the United States, the state of California enacted legislation, the California Consumer Privacy Act, effective January 1, 2020, that increases the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in the state of California. These laws and regulations are complex and change frequently, at times due to changes in political climate, and existing laws and regulations are subject to different and conflicting interpretations, which adds to the complexity of processing personal data from these jurisdictions. These laws have the potential to increase costs of compliance, risks of noncompliance and penalties for noncompliance. The Regulation 2016/679, known as the General Data Protection Regulation (&#147;GDPR&#148;), as well as European Union member state implementing legislations, apply to the collection and processing of personal data, including health-related information, by companies located in the European Union, or in certain circumstances, by companies located outside of the European Union and processing personal information of individuals located in the European Union.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">53</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, they are subject to legal challenges and uncertainty about compliance with European Union data protection laws remains.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue. The GDPR has increased our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional potential mechanisms to ensure compliance with the new European Union data protection rules.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions, which could include civil, criminal and administrative penalties, private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#146; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our current and future operations are subject to applicable fraud and abuse, transparency, government price </b></i><i><b>reporting, privacy and security, and other healthcare laws. If we are unable to comply, or do not fully comply, </b></i><i><b>with such laws, we could face substantial penalties.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. The healthcare laws that may affect our ability to operate include, but are not limited to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Federal civil and criminal false claims laws, such as the False Claims Act (&#147;FCA&#148;), which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">54</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="bl" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">pharmaceutical companies have been prosecuted under the FCA in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">HIPAA, as amended by HITECH, and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Health Care Reform Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments and other transfers of value provided to physicians and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">55</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our drug candidates, if approved. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering and use of our drug candidates, if approved, to be in violation of applicable laws.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other health care laws. If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#146;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our employees, agents, contractors or collaborators may engage in misconduct or other improper activities.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, agents, contractors or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, environmental, competition, and patient privacy and other privacy laws and regulations. Misconduct by these parties could include intentional failures to comply with FDA, EMA or other applicable regulations, provide accurate information to the FDA, EMA and comparable regulatory authorities in other jurisdictions, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, EMA or comparable regulatory authorities in other jurisdictions. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results and reputation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we are subject to the Foreign Corrupt Practices Act (&#147;FCPA&#148;) and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">56</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">regulations, particularly given the high level of complexity of these laws. We have provisions in our Code of Business Conduct and Ethics and certain controls in place that are designed to mitigate the risk of non-compliance with anti-corruption and anti-bribery laws, and we are developing an anti-corruption policy and implementing procedures. However, it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions stemming from a failure to comply with these laws or regulations. Violations of these laws and regulations could result in, among other things, administrative, civil and criminal fines and sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, exclusion from participation in federal healthcare programs including Medicare and Medicaid, implementation of compliance programs, integrity oversight and reporting obligations, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We and our third-party contractors must comply with environmental, health and safety laws and regulations. </b></i><i><b>A failure to comply with these laws and regulations could expose us to significant costs or liabilities.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In particular, our product candidates use PBDs, which are highly potent cytotoxins that require special handling by our and our contractors&#146; staff. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of biological or hazardous materials or wastes, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Product liability lawsuits could cause us to incur substantial liabilities and to limit development and/or </b></i><i><b>commercialization of any products that we may develop.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We face an inherent risk of product liability as a result of the clinical testing of our product candidates in human clinical trials and will face an even greater risk if we commercialize any products that we successfully develop. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. In particular, we believe that our highly potent PBD-based ADCs may increase our potential exposure to product liability claims. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">decreased demand for our product candidates or products that we may develop;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">injury to our reputation and significant negative media attention;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">withdrawal of clinical trial sites and/or study participants;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">57</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">significant costs to defend the related litigations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a diversion of management&#8217;s time and our resources to pursue our business strategy;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">substantial monetary awards to study participants or patients;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">product recalls, withdrawals or labeling, marketing or promotional restrictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">loss of revenue;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the inability to commercialize our product candidates that we may develop; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a decline in the price of our common shares.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We currently carry product liability insurance covering our clinical trials in the amount of $10 million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In such instance, we may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If we engage in acquisitions and/or commercial collaborations in the future, we will incur a variety of costs </b></i><i><b>and we may never realize the anticipated benefits of such acquisitions.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may acquire technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. Such efforts may never result in a transaction, and any future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, research programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, research programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources and personnel than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Even if we are able to successfully identify and acquire or in-license new products, product candidates, research programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, research programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us or that we inadequately assess. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or fails to reach its forecasted commercial potential, or that the integration of a product, product candidate, research program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, acquisitions create other uncertainties and risks, particularly when the acquisition takes the form of a merger or other business consolidation. We may encounter unexpected difficulties, or incur unexpected costs, in connection with transition activities and integration efforts, which include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">high acquisition costs;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">58</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the need to incur substantial debt or engage in dilutive issuances of equity securities to pay for acquisitions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the potential disruption of our historical business and our activities under our collaboration agreements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the strain on, and need to expand, our existing operational, technical, financial and administrative infrastructure;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our lack of experience in late-stage product development and commercialization;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the difficulties in assimilating employees and corporate cultures;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the difficulties in hiring qualified personnel and establishing necessary development and/or commercialization capabilities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the failure to retain key management and other personnel;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the challenges in controlling additional costs and expenses in connection with and as a result of the acquisition;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the need to write down assets or recognize impairment charges;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the diversion of our management&#8217;s attention to integration of operations and corporate and administrative infrastructures; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any unanticipated liabilities for activities of or related to the acquired business or its operations, products or product candidates.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we fail to integrate or otherwise manage an acquired business successfully and in a timely manner, resulting operating inefficiencies could increase our costs more than we planned, could negatively impact the market price of our common shares and could otherwise distract us from execution of our strategy.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our internal computer systems, or those of our partners, third-party CROs or other contractors or consultants, </b></i><i><b>may fail or suffer security breaches, which could result in a material disruption of our product development </b></i><i><b>programs and significant monetary losses.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Despite the implementation of security measures, our internal computer systems and those of our current or future partners, third-party CROs and other contractors and consultants have been subject to attacks by, and may be vulnerable to damage from, various methods, including cybersecurity attacks, breaches, or other technological failures which can include, among other things, computer viruses, malicious codes, employee theft or misuse, unauthorized access attempts including third parties gaining access to systems using stolen or inferred credentials, denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and telecommunication and electrical failures. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of keystroke loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering and/or other means. If a failure, accident or security breach were to occur and cause interruptions in our, our partners&#146; or our CROs&#146; operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, a material disruption of our programs and/or significant monetary losses. For example, the loss of clinical trial or CMC data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach to running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the GDPR and relevant member state law in the European Union or HIPAA and other relevant state and federal privacy laws in the United States. Moreover, because we maintain sensitive company data on our computer networks, including our intellectual property and proprietary business information, any such security breach may compromise information stored on our networks and may result in significant data losses or theft of our intellectual property or proprietary business information. We currently carry cybersecurity liability insurance in the amount of CHF 5 million in the aggregate. However, our current cybersecurity liability insurance, and any such insurance that we may obtain in the future, may not cover the damages we would sustain based on any breach of our computer security protocols or other cybersecurity attack. To the extent that </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">59</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, our reputation could be harmed and we could incur significant liabilities and the further development of our product candidates could be disrupted.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our business is subject to economic, political, regulatory and other risks associated with conducting business </b></i><i><b>internationally.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because we plan to market our products, if approved, outside of the United States, our business is subject to risks associated with conducting business internationally. In addition, we and a number of our suppliers are located outside the United States. Our future results could be harmed by a variety of factors, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">global trends toward pharmaceutical pricing;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">differing regulatory requirements for drug approvals in non-U.S. countries;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">differing reimbursement, pricing and insurance regimes;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">potentially reduced protection for, and complexities and difficulties in obtaining, maintaining, protecting and enforcing, intellectual property rights;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">difficulties in compliance with non-U.S. laws and regulations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in non-U.S. regulations and customs, tariffs and trade barriers;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in non-U.S. currency exchange rates and currency controls;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">negative consequences from changes in tax laws;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">workforce uncertainty in countries where labor unrest is more common than in the United States;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">difficulties associated with staffing and managing international operations, including differing labor relations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The United Kingdom&#146;s withdrawal from the European Union may have a negative effect on global economic </b></i><i><b>conditions, financial markets and our business.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On June 23, 2016, the United Kingdom held a referendum on its membership in the European Union, in which United Kingdom voters approved an exit from the European Union (&#147;Brexit&#148;). On March 29, 2017, the United Kingdom formally notified the European Council pursuant to Article 50 of the Treaty of Lisbon of its intention to leave the European Union. In January and March 2019, the U.K. Parliament voted against a draft withdrawal agreement negotiated between the United Kingdom and the European Union. On April 10, 2019, the European Union granted an extension to the withdrawal process until October 31, 2019 or the first day of the month after the withdrawal agreement is passed, whichever comes first.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Brexit imposes new regulatory costs and challenges that may have a material adverse effect on us and our operations. While the date on which Brexit is to occur is uncertain, we may face decreased chances to obtain market approval for our products in the European Union, including the possibility that the EMA will not accept </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">60</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">data from our clinical trials conducted in the United Kingdom or will only do so if we comply with certain conditions. Conversely, since a significant proportion of the United Kingdom&#146;s regulatory framework affecting the pharmaceutical and biotechnological industry is derived from European Union directives and regulations, Brexit could materially alter the regulatory regime with respect to our product candidates in the United Kingdom, which may increase the time and costs associated with obtaining regulatory approval from the relevant authorities. It may also be time-consuming and expensive for us to alter our internal operations in order to comply with new regulations. Altered regulations could also add time and expense to the process by which our product candidates receive regulatory approval in the United Kingdom and the European Union.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, following the Brexit vote, the European Union moved the EMA&#146;s headquarters from the United Kingdom to the Netherlands. This transition may cause disruption in the administrative and medical scientific links between the EMA and the UK Medicines and Healthcare products Regulatory Agency, including delays in granting clinical trial authorization or marketing authorization, disruption of import and export of active substance and other components of new drug formulations and disruption of the supply chain for clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We or the third parties upon whom we depend may be adversely affected by natural disasters, and our </b></i><i><b>business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition, medical epidemic, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully use our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or the interruption of our business operations for a substantial period of time.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, there can be no assurance that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs and commercialization efforts may be harmed. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Risks Related to Our Common Shares and This Offering</b></p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>There was no public market for our common shares prior to this offering, and an active market in our </b></i><i><b>common shares may not develop.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Before this offering, there was no public trading market for our common shares. We cannot predict the extent to which an active market for our common shares will develop or be sustained after this offering. If a market for our common shares does not develop or is not sustained, it may be difficult for shareholders to sell their shares at an attractive price, or at all. Further, an inactive market may also impair our ability to raise capital by selling our common shares and may impair our ability to enter into collaborations or acquire companies or products by using our common shares as consideration.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we cannot predict the prices at which our common shares will trade. The initial public offering price of our common shares was agreed between us and the underwriters based on a number of factors, including market conditions in effect at the time of this offering, which may not be indicative of the price at which our common shares will trade following completion of this offering. It is possible that in one or more future periods, our results of operations may be below the expectations of public market analysts and investors and, as a result of these and other factors, the price of our common shares may fall.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The market price of our common shares may be volatile and may fluctuate due to factors beyond our control.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The initial public offering price for our common shares will be determined by negotiations between us and the representatives of the underwriters and may not be indicative of prices that will prevail in the trading market. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">61</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The market price of shares of our common shares could be subject to wide fluctuations in response to many risk factors listed in this &#147;Risk Factors&#148; section, and others beyond our control, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">results and timing of preclinical studies and clinical trials of our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">results of clinical trials of our competitors&#8217; products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">public concern relating to the commercial value or safety of any of our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our inability to adequately protect our proprietary rights, including patents, trademarks and trade secrets;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our inability to raise additional capital and the terms on which we raise it;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">commencement or termination of any strategic collaboration or licensing arrangement;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory developments, including actions with respect to our products or our competitors&#8217; products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">actual or anticipated fluctuations in our financial condition and operating results;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">publication of research reports by securities analysts about us or our competitors or our industry;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">additions and departures of key personnel;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the passage of legislation or other regulatory developments affecting us or our industry;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">fluctuations in the valuation of companies perceived by investors to be comparable to us;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">sales of our common shares by us, our insiders or our other shareholders;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">speculation in the press or investment community;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">announcement or expectation of additional financing efforts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in market conditions for biopharmaceutical stocks; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in general market and economic conditions.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the stock market has historically experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. As a result of this volatility, our investors may not be able to sell their common shares at or above the initial public offering price. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry or our product candidates, or to a lesser extent, our markets. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This risk is especially relevant for biotechnology companies, which have experienced significant stock price volatility in recent years. Securities litigation could result in substantial costs and divert our management&#146;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our operating results may fluctuate significantly or may fall below the expectations of investors or securities </b></i><i><b>analysts, each of which may cause the price of our common shares to fluctuate or decline.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect our operating results to be subject to fluctuations by numerous factors, including:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">variations in the level of expense related to the ongoing development of our product candidates or research pipeline;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or existing or future collaborators or licensing partners;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">62</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements, or the termination or modification of any such existing or future arrangements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any intellectual property infringement lawsuit or any opposition, interference, cancellation or other intellectual-property-related proceeding in which we may become involved;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">additions and departures of key personnel;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regulatory developments affecting our product candidates or those of our competitors; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changes in general market and economic conditions.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If our operating results fall below the expectations of investors or securities analysts, the price of our common shares could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our common shares to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our existing shareholders will continue to be able to exercise significant influence over us, and their interests </b></i><i><b>may conflict with the interests of other shareholders.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Following completion of this offering, our existing shareholders are expected to own approximately 88.9% of our common shares (or approximately 87.4% if the underwriters exercise their option to purchase additional common shares in full), excluding any common shares purchased by any such holders in this offering. As a result, these shareholders, if acting together, would be able to influence or control matters requiring approval by our shareholders, including the election of directors and the approval of certain types of capital increases, statutory mergers or other extraordinary transactions.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">AstraZeneca, Redmile Group, LLC and certain of our other existing shareholders and/or their respective affiliated entities have indicated an interest in purchasing up to approximately $115 million of the common shares being offered in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to any of these potential purchasers, and any of these potential purchasers could determine to purchase more, fewer or no shares in this offering. The calculations above do not reflect any potential purchases by these potential purchasers.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, our articles of association will contain provisions stating that if an individual or legal entity acquires common shares and, as a result, directly or indirectly, has voting rights with respect to more than 15% of the registered share capital recorded in the commercial register, the registered shares exceeding the limit of 15% shall be entered in the share register as shares without voting rights. However, any shareholders holding more than 15% prior to the filing and effectiveness of our amended and restated articles of association will remain registered with voting rights for such shares. This may, in certain instances, allow our existing shareholders to exercise more influence over us than our other shareholders despite holding the same amount of common shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To the extent that the interests of our existing shareholders may differ from the interests of our other shareholders, the latter may be disadvantaged by any action that our existing shareholders may seek to pursue. In addition, the concentration of ownership may have the effect of delaying, preventing or deterring a change of control of us, could deprive our shareholders of an opportunity to receive a premium for their common shares as part of a sale of our company and might ultimately affect the market price of our common shares. See &#147;Principal Shareholders.&#148;</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">63</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely </b></i><i><b>affect the price of our common shares.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Future sales of a substantial number of our common shares, or the perception that such sales will occur, could cause a decline in the market price of our common shares. Following the completion of this offering, based on an initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, we will have 73,252,000 common shares outstanding based on 65,088,000 common shares issued and outstanding immediately prior to completion of this offering and accounting for the Share Capital Reorganization. This includes the common shares in this offering, which may be resold in the public market immediately upon the closing of this offering without restriction, unless purchased by our affiliates. Approximately 54.3% of the common shares outstanding are expected to be held by affiliates (assuming no exercise of the underwriters&#146; option to purchase additional common shares and no purchases of common shares in this offering by our affiliates). All of these common shares will be subject to the lock-up agreements described in the &#147;Underwriters&#148; section of this prospectus. However, Morgan Stanley &amp; Co. LLC and BofA Securities, Inc., on behalf of the underwriters, can waive the provisions of these lock-up agreements by written consent, in their sole discretion, and allow the sale of these shares at any time. After the end of such lock-up agreements or if such lock-up agreements are waived, if these shareholders sell substantial amounts of common shares in the public market or if the market perceives that such sales may occur, the market price of our common shares and our ability to raise capital through an issue of equity securities in the future could be adversely affected.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain of our shareholders have granted a security interest in at least some of our shares beneficially owned by them to secure certain of their debt instruments, each of which may include default provisions. In the event of a default under any such debt instruments, the secured parties may foreclose upon any and all shares pledged to them, the occurrence of which may result in the sale of substantial amounts of our common shares in the public market, which could adversely affect the market price of our common shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, following the completion of this offering, we intend to cease any new grants under our existing equity incentive plans and adopt a new equity incentive plan under which we would have the discretion to grant a broad range of equity-based awards to eligible participants. We intend to register all common shares that we may issue under this equity compensation plan. Once we register these common shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the &#147;Underwriters&#148; section of this prospectus. If a large number of our common shares or securities convertible into our common shares are sold in the public market after they become eligible for sale, the sales could reduce the trading price of our common shares and impede our ability to raise future capital.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Swiss law, shareholders may receive certain pre-emptive rights to subscribe on a <i>pro rata</i> basis for issuances of equity or other securities that are convertible into equity. However, due to the laws and regulations in certain jurisdictions, shareholders in certain jurisdictions may not be able to exercise such rights, unless the company registers or otherwise qualifies the rights offering, including by complying with prospectus requirements under the laws of that jurisdiction. There can be no assurance that we will take any action to register or otherwise qualify an offering of subscription rights or shares under the laws of any jurisdiction where the offering of such rights is restricted, other than the United States. If shareholders in such jurisdictions are unable to exercise their subscription rights, their ownership interest will be diluted.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>You will incur immediate and substantial dilution as a result of this offering.</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The initial public offering price of our common shares will be substantially higher than the pro forma as adjusted net tangible book value per common share after the completion of this offering. Therefore, if you purchase common shares in this offering, you will pay a price per common share that substantially exceeds the pro forma as adjusted net tangible book value per common share after this offering. To the extent options under our future incentive plans are exercised, you will incur further dilution. Based on an initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of $19.89 per common share, representing the difference between the pro forma as adjusted net tangible book value per common share and the assumed initial public offering price. In addition, purchasers of common shares in this offering will have contributed approximately 25.2% of the aggregate price paid by all purchasers of our common shares, but will own only approximately 11.1% of our common shares outstanding after this offering.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">64</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Moreover, we issued options in the past to acquire common shares at prices significantly below the assumed initial public offering price. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. See &#147;Dilution.&#148;</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We currently intend to use the net proceeds from this offering as described in &#147;Use of Proceeds.&#148; However, our board of directors and our management retains broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common shares. Our failure to apply these funds effectively could result in financial losses, which could have a material adverse effect on our business, results of operations, financial condition and prospects, cause the price of our common shares to decline and delay the development of our product candidates.</p>

<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Participation in this offering by our existing shareholders and/or their affiliated entities may reduce the public </b></i><i><b>float for our common shares.</b></i></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">AstraZeneca, Redmile Group, LLC and certain of our other existing shareholders and/or their respective affiliated entities have indicated an interest in purchasing up to approximately $115 million of the common shares being offered in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to any of these potential purchasers, and any of these potential purchasers could determine to purchase more, fewer or no shares in this offering. If such potential purchasers are allocated and purchase all or a portion of the shares in which they have indicated an interest in this offering or more shares, such purchase would reduce the public float of our shares, which could have an adverse impact on the liquidity of our ordinary shares and depress the price at which you may be able to sell common shares purchased in this offering.</p>

				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have never paid dividends and do not expect to pay any dividends in the foreseeable future.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have not paid any cash dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend to reinvest any earnings in our business and do not anticipate declaring or paying any cash dividends until we have an established revenue stream to support continuing dividends. In addition, any proposal for the payment of future dividends will be at the discretion of our board of directors after taking into account various factors including our business prospects, liquidity requirements, financial performance and new product development. Furthermore, payment of future dividends is subject to certain limitations pursuant to our current and future debt instruments, Swiss law and our amended and restated articles of association. See &#147;Description of Share Capital and Articles of Association.&#148; Accordingly, investors cannot rely on dividend income from our common shares, and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about </b></i><i><b>our business, the price of our common shares and our trading volume could decline.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The trading market for our common shares will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or too few securities or industry analysts commence coverage of our company, the trading price for our common shares would likely be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research about our business, the price of our common shares would likely decline. In addition, if our operating results fail to meet the forecast of analysts, the price of our common shares would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common shares could decrease, which might cause the price of our common shares and trading volume to decline.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The implementation of the authorized share capital increase may be challenged or blocked.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior to this offering, we will need to obtain a shareholder resolution for, among other things, the increase in authorized share capital necessary to source the common shares to be sold in this offering. Even if we get this approval, as with all share capital increases in Switzerland, (i) a third party, such as shareholders or creditors, </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">65</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">may at least temporarily block the registration of the capital increase in the commercial register of the Canton of Vaud and request the competent court to grant a preliminary injunction in a summary proceeding in which we would be entitled to appear, and (ii) a shareholder may challenge the underlying shareholders&#146; resolution within two months after such shareholders&#146; meeting and, therefore, prevent or delay the completion of this offering. There can be no assurance that the implementation of the authorized share capital increase will not be challenged or blocked.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The rights of our shareholders may be different from the rights of shareholders in companies governed by the </b></i><i><b>laws of U.S. jurisdictions.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a Swiss corporation. Our corporate affairs are governed by our articles of association and by the laws governing companies, including listed companies, incorporated in Switzerland. The rights of our shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations of shareholders and directors of companies governed by the laws of U.S. jurisdictions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the performance of its duties, our board of directors is required by Swiss law to consider the interests of our company, our shareholders, our employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, shareholders&#146; interests. Swiss law limits the ability of our shareholders to challenge resolutions made or other actions taken by our board of directors in court. Our shareholders generally are not permitted to file a suit to reverse a decision or an action taken by our board of directors, but are instead only permitted to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder claims against a member of our board of directors for breach of fiduciary duty would have to be brought to the competent courts in Epalinges, Canton of Vaud, Switzerland, or where the relevant member of our board of directors is domiciled. In addition, under Swiss law, any claims by our shareholders against us must be brought exclusively to the competent courts in Epalinges, Canton of Vaud, Switzerland. A further summary of applicable Swiss company law is contained in this prospectus, see &#147;Description of Share Capital and Articles of Association&#148; and &#147;Comparison of Swiss Law and Delaware Law.&#148; However, there can be no assurance that Swiss law will not change in the future, which could adversely affect the rights of our shareholders, or that Swiss law will protect our shareholders in a similar fashion as under U.S. corporate law principles.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and </b></i><i><b>otherwise manage ongoing capital needs.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Swiss law reserves for approval by shareholders certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment of dividends and cancellation of treasury shares must be approved by shareholders. Swiss law also requires that our shareholders themselves resolve to, or authorize our board of directors to, increase our share capital. While our shareholders may authorize share capital that can be issued by our board of directors without additional shareholder approval, Swiss law limits this authorization to 50% of the issued share capital at the time of the authorization. The authorization, furthermore, has a limited duration of up to two years and must be renewed by the shareholders from time to time thereafter in order to be available for raising capital. Additionally, subject to specified exceptions, including exceptions explicitly described in our amended and restated articles of association, Swiss law grants pre-emptive subscription rights to existing shareholders to subscribe for new issuances of shares. Swiss law also does not provide as much flexibility in the various rights and regulations that can attach to different categories of shares as do the laws of some other jurisdictions. These Swiss law requirements relating to our capital management may limit our flexibility, and situations may arise where greater flexibility would have provided benefits to our shareholders. See &#147;Description of Share Capital and Articles of Association&#148; and &#147;Comparison of Swiss Law and Delaware Law.&#148;</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our shares are not listed in Switzerland, our home jurisdiction. As a result, our shareholders will not benefit </b></i><i><b>from certain provisions of Swiss law that are designed to protect shareholders in a public takeover offer or a </b></i><i><b>change-of-control transaction.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because our common shares will be listed exclusively on the NYSE and not in Switzerland, our shareholders will not benefit from the protection afforded by certain provisions of Swiss law that are designed to protect shareholders in the event of a public takeover offer or a change-of-control transaction. For example, Article 120 of the Swiss Financial Market Infrastructure Act and its implementing provisions require investors to </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">66</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">disclose their interest in our company if they reach, exceed or fall below certain ownership thresholds. Similarly, the Swiss takeover regime imposes a duty on any person or group of persons who acquires more than one-third of a company&#146;s voting rights to make a mandatory offer for all of the company&#146;s outstanding listed equity securities. In addition, the Swiss takeover regime imposes certain restrictions and obligations on bidders in a voluntary public takeover offer that are designed to protect shareholders. However, these protections are applicable only to issuers that list their equity securities in Switzerland and, because our common shares will be listed exclusively on the NYSE, will not be applicable to us. Furthermore, since Swiss law restricts our ability to implement rights plans or U.S.-style &#147;poison pills,&#148; our ability to resist an unsolicited takeover attempt or to protect minority shareholders in the event of a change of control transaction may be limited. Therefore, our shareholders may not be protected in the same degree in a public takeover offer or a change-of-control transaction as are shareholders in a Swiss company listed in Switzerland.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against us or our executive </b></i><i><b>officers or members of our board of directors.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are organized under the laws of Switzerland and our registered office and domicile is located in Epalinges, Canton of Vaud, Switzerland. Moreover, a number of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the Swiss Federal Act on Private International Law (&#147;PILA&#148;). This statute provides that the application of provisions of non-Swiss law by the courts in Switzerland shall be precluded if the result is incompatible with Swiss public policy. Also, certain mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Switzerland and the United States do not have a treaty providing for reciprocal recognition and enforcement of judgments in civil and commercial matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the PILA. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the non-Swiss court had jurisdiction pursuant to the PILA;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment of such non-Swiss court has become final and non-appealable;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment does not contravene Swiss public policy;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">no proceeding involving the same parties and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state, and this decision is recognizable in Switzerland.</td></tr></table><div style="clear: both"></div>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Anti-takeover provisions in our amended and restated articles of association could make an acquisition of us, </b></i><i><b>which may be beneficial to our shareholders, more difficult.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our amended and restated articles of association contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us that shareholders may consider favorable, including transactions in which our shareholders may receive a premium for their shares. Our amended and restated articles of association, which will become effective upon the closing of this offering, include provisions that:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
in certain cases, allow our board of directors to place up to 36,000,000 common shares and rights to acquire an additional 22,350,000 common shares (in aggregate, 79.7% of the expected share capital after completion of this offering) with affiliates or third parties, without existing shareholders having statutory pre-emptive rights in relation to this share placement;
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">67</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">allow our board of directors not to record any acquirer of common shares, or several acquirers acting in concert, in our share register as a shareholder with voting rights with respect to more than 15% of our share capital as set forth in the commercial register;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">limit the size of our board of directors to ten members; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">require two-thirds of the votes represented at a shareholder meeting for amending or repealing the above-mentioned voting and recording restrictions, for amending the provision setting a maximum board size or providing for indemnification of our directors and members of our executive committee and for removing the chairman or any member of the board of directors before the end of his or her term of office.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These and other provisions, alone or together, could delay or prevent takeovers and changes in control. See &#147;Description of Share Capital and Articles of Association.&#148; These provisions could also limit the price that investors might be willing to pay in the future for our common shares, thereby depressing the market price of our common shares.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We will be a foreign private issuer, and, as a result, we will not be subject to certain rules and obligations that </b></i><i><b>are applicable to a U.S. domestic public company</b></i><i><b> and will not be subject to certain NYSE corporate </b></i><i><b>governance listing standards that are applicable to a NYSE-listed U.S. domestic public company</b></i><i><b>.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon consummation of this offering, we will report under the Exchange Act as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we intend to furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i) the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii) the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities, and liability for insiders who profit from trades made in a short period of time; and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four months after the end of each financial year, while U.S. domestic issuers are required to file their annual report on Form 10-K in less time. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, because we will be a foreign private issuer, we will elect to comply with our home country governance requirements and certain exemptions thereunder, rather than complying with certain of the NYSE corporate governance listing standards that are applicable to U.S. companies listed on the NYSE. For example, we are exempt from NYSE listing standards that require a listed U.S. company to have (i) a majority of the board of directors consist of independent directors, (ii) regularly scheduled executive sessions with only independent directors and (iii) a compensation committee and a nomination and corporate governance committee consist entirely of independent directors. In accordance with our NYSE listing, our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act and Rule 10A-3 of the Exchange Act, both of which are also applicable to NYSE-listed U.S. companies. Because we are a foreign private issuer, however, our audit committee is not subject to additional NYSE listing standards applicable to NYSE-listed U.S. companies, including an affirmative determination that all members of the audit committee are &#147;independent.&#148; Furthermore, NYSE listing standards generally require NYSE-listed U.S. companies to, among other things, seek shareholder approval for the implementation of certain equity compensation plans and issuances of securities, which we are not required to follow as a foreign private issuer. Accordingly, our shareholders may not have the same protections afforded to shareholders of companies that are not foreign private issuers. For an overview of our corporate governance principles, see &#147;Description of Share Capital and Articles of Association.&#148; </p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#146;s </b></i><i><b>domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We qualify as a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We may no longer be a foreign private issuer as of June 30, 2020 (the end of our second fiscal quarter in the fiscal year </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">68</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">after this offering), which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers, as of January 1, 2021. In order to maintain our current status as a foreign private issuer, either (a) a majority of our common shares must be either directly or indirectly owned of record by nonresidents of the United States or (b)(i) a majority of our executive officers or directors may not be United States citizens or residents, (ii) more than 50% of our assets cannot be located in the United States and (iii) our business must be administered principally outside the United States. If we lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would be more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We are an emerging growth company, and we cannot be certain if the reduced reporting requirements </b></i><i><b>applicable to emerging growth companies will make our common shares less attractive to investors.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, (i) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (ii) reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and (iii) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation. In addition, as an emerging growth company, we are required to provide only two years of audited financial statements and two years of selected financial data in our initial registration statement, compared to three and five years, respectively, for comparable data reported by other public companies</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common shares held by non-affiliates exceeds $700 million as of any June 30 (the end of our second fiscal quarter) before that time or if we have total annual gross revenues of $1.07 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31 (our fiscal year end) or, if we issue more than $1.0 billion in non-convertible debt during any three-year period before that time, we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the price of our common shares may be more volatile. When these exemptions cease to apply, we expect to incur additional expenses and devote increased management effort toward ensuring compliance with them, and we cannot predict or estimate the amount or timing of such additional costs.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>As a result of being a public company, we will incur additional costs, and we may not manage to comply with </b></i><i><b>our internal control procedures and corporate governance structures.</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To comply with the requirements imposed on us as a public company, we will incur significant legal, insurance, accounting and other expenses that we did not incur as a private company. The increased costs may require us to reduce costs in other areas of our business. In addition, our board of directors, management and administrative staff will be required to perform additional tasks. For example, in anticipation of becoming a public company, we will need to adopt additional internal controls and disclosure controls and procedures, retain </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">69</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">a transfer agent, adopt an insider trading policy and bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and may divert management&#146;s time and attention from research and development activities. These laws, regulations and standards are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters, enforcement proceedings and higher costs necessitated by ongoing revisions to disclosure and governing practices, which could have a material adverse impact on our business, financial condition, results of operations and prospects.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We have identified a material weakness in our internal control over financial reporting. If we are unable to </b></i><i><b>remediate this material weakness or otherwise fail to maintain an effective system of internal controls, we may </b></i><i><b>not be able to accurately or timely report our financial condition or results of operations, which may adversely </b></i><i><b>affect our business and the price of our common shares.</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have identified a material weakness in our internal control over financial reporting. A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In June 2019, we identified an error related to the calculation of the expense charge for our historical share purchase plans, which, in accordance with IFRS 2, were required to be accounted for as if they were share option plans. While the share purchase plans were properly accounted for on the balance sheet, there was a material understatement of the share-based compensation expense, and the related disclosures were incomplete. This required a restatement of our previously issued consolidated financial statements as of and for the years ended December 31, 2018 and December 31, 2017. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The material weakness arose from a lack of effective internal controls to ensure the appropriate accounting policy was applied to the share purchase plans. Specifically, despite accounting policies being in place, there were insufficient procedures and controls to ensure that the policies were appropriately implemented and that there was proper presentation and disclosure within the financial statements. We have taken steps to remediate the material weakness and to enhance our overall control environment, including implementing changes in our internal control over financial reporting with regard to complex accounting matters such as share-based compensation plans.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, as a foreign private issuer, we currently are not required to comply with the Sarbanes-Oxley Act. As a result, neither our management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act. Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We cannot assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to remediate the control deficiencies that led to this material weakness in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses.</p>
				<p class="frisk" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>We may have been a passive foreign investment company for U.S. federal income tax purposes (a </b></i><i><b>&#147;PFIC&#148;) </b></i><i><b>for our 2018 taxable year and it is possible that we will be a PFIC in future taxable years. If we are a PFIC, </b></i><i><b>our U.S. shareholders may be subject to adverse U.S. federal income tax consequences.</b></i><i><b> </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), we will be a PFIC for any taxable year in which, after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of passive income or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. Passive income generally </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">70</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">includes dividends, interest, certain non-active rents and royalties, and capital gains. We may have been a PFIC for our 2018 taxable year and it is possible that we will be a PFIC for one or more subsequent taxable years. Whether we will be a PFIC in 2019 or any future years is uncertain because, among other things, (i) we currently own, and will own after the completion of this offering, a substantial amount of passive assets, including cash, (ii) the timing of our recognition of active income for U.S. federal income tax purposes, which may differ from the timing of the recognition of such income for financial accounting purposes, may result in our recognizing minimal amounts of active income for U.S. federal income tax purposes in certain taxable years, (iii) the license and joint collaboration agreement with MedImmune for the joint clinical development of MEDI3726 has been our sole source of active income, but MedImmune discontinued the joint clinical development of MEDI3726 in the first half of 2019, and there can be no assurance that we will be able to enter into another licensing or collaboration agreement and (iv) the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may be determined in substantial part by our market capitalization, which may vary substantially over time. Moreover, the determination of whether we were a PFIC in 2018 or will be a PFIC for 2019 or any other year in which our common shares are not publicly traded for the entirety of such year depends in substantial part on whether we are a controlled foreign corporation for U.S. federal income tax purposes (a &#147;CFC&#148;) for either or both of those years, and we believe that, if we were a CFC in 2018 or are a CFC in 2019, it is likely that we would be considered a PFIC in such year. Although we do not believe that we were a CFC in 2018 and do not expect to be a CFC in 2019, the determination of PFIC status depends on the ownership of our common shares after the application of certain attribution rules under the Code, and we do not have all of the information necessary to make a definitive determination that we were not and will not be a CFC. Accordingly there can be no assurance that we will not be a PFIC for 2019 or any future taxable year.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are a PFIC for any taxable year during which a U.S. investor holds common shares, we generally will continue to be treated as a PFIC with respect to that U.S. investor for all succeeding years during which the U.S. investor holds common shares, even if we cease to meet the threshold requirements for PFIC status. Such a U.S. investor may be subject to adverse U.S. federal income tax consequences, including (i) the treatment of all or a portion of any gain on disposition as ordinary income, (ii) the application of a deferred interest charge on such gain and on the receipt of certain dividends and (iii) compliance with certain reporting requirements. If we are a PFIC for any taxable year, the foregoing rules will also apply to a U.S. Holder&#146;s indirect interest in any PFIC in which we hold a direct or indirect interest (a &#147;Lower-tier PFIC&#148;). If we determine that we are a PFIC for any taxable year, we will use our commercially reasonable efforts to, and currently expect to, provide the information necessary for U.S. Holders to make a qualified electing fund elections (&#147;QEF Elections&#148;), which could mitigate the adverse U.S. federal income tax consequence of the PFIC rules. We also currently expect that we will provide the information necessary for U.S. Holders to make a QEF Election with respect to any Lower-tier PFIC, but there can be no assurance that we will be able to provide such information. See &#147;Taxation&#8212;Material U.S. Federal Income Tax Consequences for U.S. Holders.&#148;</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">71</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 105-caution -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tCSR"></a><b>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this prospectus can be identified by the use of forward-looking words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;will&#148; and &#147;potential,&#148; among others.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Forward-looking statements appear in a number of places in this prospectus and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management&#146;s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section entitled &#147;Risk Factors&#148; in this prospectus. These forward-looking statements include, among others:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the commencement, timing, progress and results of our research and development programs, preclinical studies and clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing of IND, BLA, MAA and other regulatory submissions with the FDA, EMA or comparable regulatory authorities in other jurisdictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the proposed clinical development pathway for our lead product candidates, ADCT-402 and ADCT-301, and our other product candidates, and the acceptability of the results of clinical trials for regulatory approval of such product candidates by the FDA, EMA or comparable regulatory authorities in other jurisdictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">assumptions relating to the identification of serious adverse, undesirable or unacceptable side effects related to our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing of and our ability to obtain and maintain regulatory approval for our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our intent and plan for the commercialization of ADCT-402 and, subject to our collaboration and license agreement with Genmab, of ADCT-301, if approved;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our expectations regarding the size of the patient populations amenable to treatment with our product candidates, if approved as well as initial lines of therapy;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">assumptions relating to the rate and degree of market acceptance of any approved product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the pricing and reimbursement of our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to identify and develop additional product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our competitive position and the development of and projections relating to our competitors or our industry;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to raise capital when needed in order to continue our research and development programs or commercialization efforts;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to identify and successfully enter into strategic collaborations in the future;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to obtain, maintain, protect and enforce intellectual property protection for our product candidates, and the scope of such protection;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">72</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to attract and retain qualified key management and technical personnel; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a foreign private issuer. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. The forward-looking statements contained in this prospectus are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act which does not extend to initial public offerings. You should read this prospectus and the documents that we have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">73</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tMID"></a><b>MARKET AND INDUSTRY DATA</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. These data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. We caution you not to give undue weight to such projections, assumptions and estimates.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">74</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tUP"></a><b>USE OF PROCEEDS</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We estimate that the net proceeds from the issuance and sale of 8,164,000 common shares by us in this offering will be approximately $178.3 million, or approximately $205.9 million if the underwriters exercise their option to purchase additional common shares in full, at the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Each $1.00 increase or decrease in the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the net proceeds to us by $7.6 million, assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each 1,000,000 share increase or decrease in the number of common shares offered by us would increase or decrease the net proceeds to us by $22.8 million, assuming the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of June 30, 2019, we had cash and cash equivalents of $182.2 million. We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
approximately $50 million to advance ADCT-402 through the completion of the ongoing pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL, to advance ADCT-402 through the completion of the ongoing Phase 1b combination clinical trials with ibrutinib and with durvalumab and potential other combination trials and to commence preparations for a clinical trial that we anticipate will be a post-marketing confirmatory clinical trial if ADCT-402 is approved on the basis of Phase 2 data;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
approximately $35 million to advance ADCT-301 through the completion of the ongoing pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL, to advance ADCT-301 through the completion of the ongoing Phase 1b clinical trial for the treatment of selected advanced solid tumors and to commence and advance potential combination clinical trials for ADCT-301 in these and other indications;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
approximately $5 million to advance ADCT-602 through the completion of the ongoing Phase 1/2 clinical trial for the treatment of relapsed or refractory ALL;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
approximately $20 million to advance ADCT-601 through the completion of the ongoing Phase 1 clinical trial for the treatment of selected advanced solid tumors;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
approximately $100 million to commence the scale up of commercial operations in the United States for ADCT-402 and to fund our commercial-scale CMC plans for ADCT-402 and ADCT-301;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
approximately $20 million to fund the research and development of our preclinical product candidates and preclinical pipeline; and
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the remainder to fund working capital and other general corporate purposes.</td></tr></table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Based on the planned use of proceeds above, we estimate that the net proceeds we receive from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our projected operating requirements through at least the next 24 months. However, due to the uncertainties inherent in the product development process, it is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. The amount and timing of our actual expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing and success of our current and future preclinical studies and clinical trials, the timing and outcome of regulatory submissions and the nature of our late-stage manufacturing and commercialization activities for our product candidates. In addition, we might decide to postpone or not pursue certain preclinical studies or clinical trials if the net proceeds from this offering and our other sources of cash are less than expected.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">75</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The expected net proceeds from this offering, together with our existing cash and cash equivalents, will not be sufficient for us to advance our product candidates through regulatory approval, and we will need to raise additional capital to complete the development and potential commercialization of our product candidates. We expect to finance our cash needs primarily through equity offerings and potentially through debt financings, collaborations, license and development agreements.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our management will retain broad discretion in the application of the net proceeds we receive from our initial public offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds. Pending the use of the proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation instruments, including short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict whether the proceeds invested will yield a favorable return.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">76</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tDP"></a><b>DIVIDEND POLICY </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have never declared or paid cash dividends on our share capital. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Swiss law, any dividend must be approved by our shareholders. In addition, our auditors must confirm that the dividend proposal of our board of directors to the shareholders conforms to Swiss statutory law and our amended and restated articles of association. A Swiss corporation may pay dividends only if it has sufficient distributable profits from the previous business year (<i>b&#233;n&#233;fice de l&#146;exercice</i>) or brought forward from previous business years (<i>report des b&#233;n&#233;fices</i>) or if it has distributable reserves (<i>r&#233;serves &#224; libre disposition</i>), each as evidenced by its audited stand-alone statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and its articles of association have been deducted. Distributable reserves are generally booked either as free reserves (<i>r&#233;serves libres</i>) or as reserves from capital contributions (<i>apports de capital</i>). Distributions out of share capital, which is the aggregate par value of a corporation&#146;s issued shares, may be made only by way of a share capital reduction. See &#147;Description of Share Capital and Articles of Association.&#148;</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">77</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tC"></a><b>CAPITALIZATION</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth our cash and cash equivalents and our total capitalization as of June 30, 2019:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">on an actual basis;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
on a pro forma basis to give effect to the following adjustments: (i) our issuance and sale of an aggregate of 77 Class E preferred shares (1,203,125 common shares after giving effect to the Share Capital Reorganization) on July 5, 2019; (ii) the delivery of 23.368 Class A common shares (365,125 common shares after the Share Capital Reorganization) by certain of our directors and officers for the settlement of the 2013 Promissory Notes and the 2016 Promissory Notes; (iii) our issuance and repurchase of 140 Class A common shares (2,187,500 common shares after giving effect to the Share Capital Reorganization) on September 19, 2019, for the settlement of share grants and equity-linked instruments for directors, officers, employees and consultants; (iv) the delivery to participants of our 2014 Incentive Plan of an estimated 968,750 common shares (subject to adjustments for final tax and social security deductions), which we currently hold in treasury, to settle outstanding awards under our 2014 Incentive Plan in connection with this offering and the related payment by us of an estimated $10 million in tax and social security liabilities on behalf of participants of our 2014 Incentive Plan; (v) the Par Value Increase; and (vi) the Conversion; and
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
on a pro forma as adjusted basis to give effect to the pro forma adjustments described immediately above and our issuance and sale of 8,164,000 common shares in this offering at the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">You should read this table in conjunction with our consolidated financial statements, including the notes thereto, included in this prospectus as well as &#147;Use of Proceeds,&#148; &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148;</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.68px; padding-right: 0px; "><b>As of </b><b>June</b><b> 3</b><b>0</b><b>, 201</b><b>9</b></div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.68px; padding-right: 3.68px; "><b>Actual</b></div></td>
	<td colspan="3" width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.68px; padding-right: 3.68px; "><b>Pro Forma</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.68px; padding-right: 0px; "><b>Pro Forma As<br> </b><b>Adjusted</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></b></div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.68px; padding-right: 0px; "><b>(in USD thousands except for share and per share data)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">182,156</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 172,156 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 350,473 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Lease liability (long-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,289</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 4,289 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 4,289 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Shareholders&#8217; equity:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">
Common shares; 12,515,625 shares issued and outstanding, actual, par value CHF 0.0064 per share; 65,088,000 shares issued and outstanding, pro forma, par value CHF 0.064 per share; 73,252,000 shares issued and outstanding, pro forma as adjusted, par value CHF 0.064 per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">84</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 4,362 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 4,887 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">
Preferred shares; 50,765,625 shares issued and outstanding, actual, par value CHF 0.0064 per share; no shares issued and outstanding, pro forma; no shares issued and outstanding, pro forma as adjusted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup>
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">340</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> &#8212; </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> &#8212; </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">
Share premium
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 527,083 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 588,742 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 766,534 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Shares to be issued</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">26,641</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> &#8212; </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> &#8212; </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Other reserves</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,835</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (43,121 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (43,121 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Cumulative translation adjustments</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(51</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (51 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (51 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Accumulated losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(381,943</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> (381,943 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> (381,943 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Total equity</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">177,989</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 167,989 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 346,306 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.68px; ">Total capitalization</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">182,278</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 172,278 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 350,595 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
The pro forma as adjusted information is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma amount of each of cash and cash equivalents, total equity and total capitalization by $7.6 million, assuming that the number
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">78</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each 1,000,000 share increase or decrease in the number of common shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the pro forma amount of each of cash and cash equivalents, total equity and total capitalization by $22.8 million, assuming the assumed initial public offering price of $24.50 per common share, the midpoint of the price range set forth on the cover page of this prospectus remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">
(2)
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
The par value of common shares, actual, has been retroactively adjusted to give effect to the Share Split, which was effected on September 19, 2019. The par value of common shares, pro forma, has been adjusted to give effect to the pro forma adjustments described above, as a result of which the par value is CHF 0.064 per common share.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">
(3)
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
The par value of preferred shares, actual, has been retroactively adjusted to give effect to the Share Split, which was effected on September 19, 2019.
</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Other than as set forth in the pro forma adjustments and reflected in the table above, there have been no material changes to our capitalization since June 30, 2019. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">79</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tD"></a><b>DILUTION</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If you invest in our common shares, your interest will be diluted to the extent of the difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common shares immediately after this offering.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Net tangible book value is determined by dividing our tangible net worth (defined as total assets, less intangible net assets, less total liabilities) by the number of our common shares outstanding. Our historical net tangible book value as of June 30, 2019 was $169.6 million, or $2.68 per share (on a fully diluted basis), after giving effect to the Share Split. After giving effect to the following adjustments: (i) our issuance and sale of an aggregate of 77 Class E preferred shares (1,203,125 common shares after giving effect to the Share Capital Reorganization) on July 5, 2019; (ii) the delivery of 23.368 Class A common shares (365,125 common shares after the Share Capital Reorganization) by certain of our directors and officers for the settlement of the 2013 Promissory Notes and the 2016 Promissory Notes, (iii) our issuance and repurchase of 140 Class A common shares (2,187,500 common shares after giving effect to the Share Capital Reorganization) on September 19, 2019, for the settlement of share grants and equity-linked instruments for directors, officers, employees and consultants; (iv) the delivery to participants of our 2014 Incentive Plan of an estimated 968,750 common shares (subject to adjustments for final tax and social security deductions), which we currently hold in treasury, to settle outstanding awards under our 2014 Incentive Plan in connection with this offering and the related payment by us of an estimated $10 million in tax and social security liabilities on behalf of participants of our 2014 Incentive Plan; (v) the Par Value Increase; and (vi) the Conversion, the pro forma net tangible book value as of June 30, 2019 was $159.6 million, or $2.45 per common share.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After giving effect to our issuance and sale of 8,164,000 common shares in this offering at the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, the pro forma as adjusted net tangible book value as of June 30, 2019 would have been $337.9 million, or $4.61 per common share. This amount represents an immediate increase in pro forma net tangible book value of $2.16 per common share to our existing shareholders and an immediate dilution in pro forma net tangible book value of $19.89 per common share to new investors.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table illustrates this dilution on a per common share basis:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.67px; ">Assumed initial public offering price per common share</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 24.50 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.67px; ">Historical net tangible book value per share as of June 30, 2019</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.68 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.67px; ">Decrease in net tangible book value per share as of June 30, 2019 attributable to pro forma adjustments</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 0.23 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.67px; ">Pro forma net tangible book value per common share as of June 30, 2019</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.45 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.67px; ">Increase in pro forma net tangible book value per share attributable to new investors participating in this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 2.16 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.67px; ">Pro forma as adjusted net tangible book value per common share after giving effect to this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 4.61 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.67px; ">Dilution per common share to investors participating in this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 19.89 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted net tangible book value per common share after this offering by $0.10 per share and dilution per common share to new investors participating in this offering by $0.10 per share, assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of common shares we are offering. Each 1,000,000 share increase in the number of common shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value per common share after this offering by $0.24 per share and decrease the dilution per common share to new investors participating in this offering by $0.24 per share, assuming the assumed initial public offering price of $24.50 per share, the midpoint of the price range set forth on the cover </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">80</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each 1,000,000 share decrease in the number of common shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per common share after this offering by $0.25 per share and increase the dilution per common share to new investors participating in this offering by $0.25 per share, assuming the assumed initial public offering price of $24.50 per common share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the underwriters exercise their option to purchase an additional 1,224,600 common shares in this offering, the pro forma as adjusted net tangible book value per common share after this offering would increase to $4.91 per share, representing an immediate increase in pro forma as adjusted net tangible book value per common share of $2.46 per share to existing shareholders and immediate dilution of $19.59 in pro forma as adjusted net tangible book value per common share to new investors participating in this offering.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes as of June 30, 2019, on the pro forma as adjusted basis described above, the number of common shares, the total consideration and the average price per common share (1) paid to us by existing shareholders and (2) to be paid by investors purchasing common shares in this offering at the assumed initial public offering price of $24.50 per common share, which is the midpoint of the price range set forth on the cover page on this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.33px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.33px; padding-right: 2.33px; "><b>Shares Purchased</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.33px; padding-right: 2.33px; "><b>Total Consideration</b></div></td>
	<td colspan="3" width="19%" rowspan="2" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.33px; padding-right: 0px; "><b>Weighted-</b><b>Average Price<br> </b><b>Per Common<br> </b><b>Share</b></div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.33px; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.33px; padding-right: 2.33px; "><b>Number</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.33px; padding-right: 2.33px; "><b>Percent</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.33px; padding-right: 2.33px; "><b>Amount</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.33px; padding-right: 2.33px; "><b>Percent</b></div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.33px; ">&#160;</div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.33px; padding-right: 0px; "><b>(in USD thousands except for share and per share data) </b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.33px; ">Existing shareholders before this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 65,088,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 88.9 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 593,104 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 74.8 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="16%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9.11 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.33px; ">Investors participating in this offering</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 8,164,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 11.1 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 200,018 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 25.2 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">$</div></td><td width="16%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 24.5 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.33px; "><b>Total</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 73,252,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">100</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 793,122 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">100</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="16%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The table above assumes no exercise of the underwriters&#146; option to purchase additional common shares in this offering. If the underwriters&#146; option to purchase additional common shares is exercised in full, the number of common shares held by existing shareholders would be reduced to 87.4% of the total number of common shares outstanding after this offering, and the number of common shares held by new investors participating in the offering would be increased to 12.6% of the total number of common shares outstanding after this offering.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, AstraZeneca, Redmile Group, LLC and certain of our other existing shareholders and/or their respective affiliated entities have indicated an interest in purchasing up to approximately $115 million of the common shares being offered in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to any of these potential purchasers, and any of these potential purchasers could determine to purchase more, fewer or no shares in this offering. The table above does not reflect any potential purchases by these potential purchasers.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To the extent that any outstanding options under our future incentive plans are exercised, new options are issued under our share-based compensation plans or we issue additional common shares in the future, there will be further dilution to investors participating in this offering.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">81</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tSCF"></a><b>SELECTED CONSOLIDATED FINANCIAL DATA</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following selected consolidated financial data should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements, including the notes thereto, included elsewhere in this prospectus. The selected consolidated income statement data for the years ended December 31, 2018 and 2017 are derived from our audited consolidated financial statements included elsewhere in this prospectus. The selected consolidated income statement data for the six months ended June 30, 2019 and 2018 and the consolidated balance sheet data as of June 30, 2019 are derived from our unaudited interim consolidated financial statements included elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same basis as our audited consolidated financial statements and include all normal recurring adjustments that we consider necessary for a fair statement of our financial position and operating results as of the dates and for the periods presented. Our historical results are not necessarily indicative of the results that may be expected in the future, and our results for the six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our audited consolidated financial statements are prepared in accordance with IFRS and presented in USD. Our unaudited interim consolidated financial statements are prepared in compliance with IAS 34 and presented in USD.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.98px; padding-right: 3.98px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.98px; padding-right: 0px; "><i><b>Restated</b></i></div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.98px; padding-right: 3.98px; "><b>Six Months Ended June 30,</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.98px; padding-right: 0px; "><b>Year Ended December 31,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.98px; padding-right: 3.98px; "><b>2019</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.98px; padding-right: 3.98px; "><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.98px; padding-right: 3.98px; "><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.98px; padding-right: 0px; "><b>2017</b></div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 3.98px; "><b>Consolidated Income Statement Data:</b></div></td>
	<td colspan="12" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.98px; padding-right: 0px; "><b>(in USD thousands except for share and per share data)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Contract revenue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,340</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">625</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,140</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,803</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(46,572</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(60,133</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(118,313</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(85,530</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(6,592</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(3,969</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(8,768</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7,943</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Operating loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(50,824</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(63,477</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(125,941</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(91,670</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Financial income</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,306</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,641</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,856</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,031</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Financial expense</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(68</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(156</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">213</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">825</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Loss before taxes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,659</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,680</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,872</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,814</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Income tax expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(199</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(224</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(48</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Loss for the period</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(49,858</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(61,828</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (0.84 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (1.07 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Weighted-average number of shares used to compute basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 59,122,324 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 57,968,750 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 58,250,000 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 48,989,383 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Pro forma basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (0.83 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> (2.09 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.98px; ">Weighted-average number of shares used to compute pro forma basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 59,725,949 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 58,853,625 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
See Note 23 to our audited consolidated financial statements and Note 13 to our unaudited interim consolidated financial statements included elsewhere in this prospectus for a description of the method used to compute basic and diluted net loss per share. These figures have been retroactively adjusted to give effect to the Share Split, which was effected on September 19, 2019.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
The pro forma information gives effect to the following adjustments: (i) our issuance and sale of an aggregate of 77 Class E preferred shares (1,203,125 common shares after giving effect to the Share Capital Reorganization) on July 5, 2019; (ii) the delivery of 23.368 Class A common shares (365,125 common shares after the Share Capital Reorganization) by certain of our directors and officers for the settlement of the 2013 Promissory Notes and the 2016 Promissory Notes; (iii) our issuance and repurchase of 140 Class A common shares (2,187,500 common shares after giving effect to the Share Capital Reorganization) on September 19, 2019, for the settlement of share grants and equity-linked instruments for directors, officers, employees and consultants; (iv) the delivery to participants of our 2014 Incentive Plan of an estimated 968,750 common shares (subject to adjustments for final tax and social security deductions), which we currently hold in treasury, to settle outstanding awards under our 2014 Incentive Plan in connection with this offering and the related payment by us of an estimated $10 million in tax and social security liabilities on behalf of participants of our 2014 Incentive Plan; (v) the Par Value Increase; and (vi) the Conversion, as if each event occurred on the first day of the period presented (other than with respect to (i)).
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">82</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(3)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">On January 1, 2019, we adopted IFRS 16 &#147;Leases,&#148; the impact of which is described in Note 3 to our unaudited interim consolidated financial statements.</td></tr></table><div style="clear: both"></div>
				<table align="20" width="94%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.93px; padding-right: 2.93px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.93px; padding-right: 0px; "><i><b>Restated</b></i></div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.93px; padding-right: 2.93px; "><b>As of June 30,</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.93px; padding-right: 0px; "><b>As of December 31,</b></div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.93px; padding-right: 2.93px; "><b>2019</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.93px; padding-right: 2.93px; "><b>2018</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.93px; padding-right: 0px; "><b>2017</b></div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2.93px; "><b>Consolidated Balance Sheet Data:</b></div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.93px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">182,156</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">138,807</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Total assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">200,839</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">150,558</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">271,949</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Share capital</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">424</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">401</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">397</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Share premium</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">527,083</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,268</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,296</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Shares to be issued</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">26,641</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Other reserves</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,835</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,702</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,426</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Cumulative translation adjustments</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(51</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(43</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">36</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Accumulated losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(381,943</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(332,085</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(208,989</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.93px; ">Total equity</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">177,989</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">126,243</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">249,166</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">83</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 106-mda -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tMDA"></a><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND<br> </b><b>RESULTS OF OPERATIONS </b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>You should read the following discussion of our financial condition and results of operations in conjunction with </i><i>the section titled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements, including </i><i>the notes thereto, included elsewhere in this prospectus. In addition to historical information, the following </i><i>discussion and analysis contains forward-looking statements that reflect our plans, estimates and beliefs. Our </i><i>actual results and the timing of events could differ materially from those anticipated in the forward-looking </i><i>statements. Factors that could cause or contribute to these differences include those discussed below and </i><i>elsewhere in this prospectus, particularly in the sections titled &#147;Risk Factors&#148; and &#147;Cautionary Statement </i><i>Regarding Forward-Looking Statements.&#148; The audited consolidated financial statements as of and for the years </i><i>ended December 31, 2018 and 2017 were prepared in accordance with the IFRS.</i><i> </i><i>The unaudited interim </i><i>consolidated financial statements as of and for the six months ended</i><i> </i><i>June 30, 2019 and 2018 were prepared in </i><i>compliance with IAS 34 and presented in USD.</i></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Overview</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted ADCs for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation PBD technology to which we have proprietary rights for our targets. We are leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises three clinical-stage product candidates, ADCT-402, ADCT-301 and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, ADCT-301 and ADCT-601, and two preclinical product candidates, ADCT-701 and ADCT-901. We retain worldwide development and commercialization rights to all of our product candidates, other than ADCT-301 for which we have a collaboration and license agreement with Genmab.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our two lead product candidates, ADCT-402 and ADCT-301, have demonstrated significant clinical activity in heavily pre-treated patients, while maintaining manageable tolerability profiles. We are evaluating ADCT-402 in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL. In August 2019, we achieved the targeted enrollment for this clinical trial and, as of August 2, 2019, have observed a 41.7% ORR in the first 96 patients treated with ADCT-402. Previously, we completed a 183-patient Phase 1 clinical trial of ADCT-402 for the treatment of relapsed or refractory NHL that showed a 41.4% ORR in patients with DLBCL at the initial dose for the Phase 2 clinical trial. If the pivotal Phase 2 clinical trial of ADCT-402 is successful, we intend to submit a BLA to the FDA in the second half of 2020. In addition, we have begun patient enrollment in a pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL. We have completed enrollment of a 133-patient Phase 1 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and NHL that has shown an 86.5% ORR in patients with HL at the initial dose planned for the Phase 2 clinical trial. We believe that our pivotal Phase 2 clinical trial of ADCT-301, if successful, will support a BLA submission in the first half of 2022.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We began our operations in 2011. Since then, our operations have focused on organizing and staffing our company, business planning, raising capital and conducting research and development, including preclinical studies and clinical trials. We do not have any products approved for sale. We have funded our operations primarily through equity financing and, to a lesser extent, through revenue from license and collaboration agreements. Since inception, we have raised $558.6 million in gross cash proceeds from equity financings, and a total of $30.0 million from a collaboration agreement. As of June 30, 2019, we had cash and cash equivalents of $182.2 million.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since our inception, we have incurred net losses, which have been significant in recent periods. For the years ended December 31, 2018 and 2017, our net loss was $123.1 million and $89.9 million, respectively. For the six months ended June 30, 2019 and 2018, our net losses were $49.9 million and $61.8 million, respectively. We expect to continue incurring significant expenses and substantial net losses over the next several years as we advance our product candidates and research programs, apply for regulatory approval for our product candidates and, subject to obtaining such approval, commercialize any approved products. Our future profitability will be dependent upon the successful development, approval and commercialization of our product candidates and achieving a level of revenues adequate to support our cost structure. We may never achieve profitability and, unless and until we do, we will continue to need to raise additional capital. Our net losses may fluctuate </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">84</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">significantly from period to period and year to year, depending principally on the timing of our clinical trials, our expenditures on other research and development activities, the timing and amount of our CMC costs and, subject to obtaining regulatory approval for our product candidates, revenues generated from the commercialization of any approved products. We anticipate that our expenses will increase substantially in connection with our ongoing activities, as we:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">conduct and complete the pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
conduct and complete the pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">conduct and complete the Phase 1b clinical trials of ADCT-402 and ADCT-301 for the treatment of other indications and Phase 1 clinical trials for our other product candidates, as well as any subsequent clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">commence and conduct any required post-marketing confirmatory clinical trials for any of our product candidates in anticipation of potential accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory agencies in other jurisdictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expand our research and development efforts for our preclinical product candidates and research pipeline;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">seek regulatory approval for our product candidates from applicable regulatory authorities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">invest in our late-stage clinical development, manufacturing and commercialization activities, including launching commercial sales, marketing and distribution operations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">continue to prepare, file, prosecute, maintain, protect and enforce our intellectual property rights and claims;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">add clinical, scientific, operational, financial and management information systems and personnel; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">operate as a public company.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are subject to a number of risks comparable to those of other similar companies, including dependence on key individuals; the need to develop product candidates with the required safety and efficacy profile to seek regulatory approval and be commercially viable; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the research and development of our product candidates and research pipeline.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Financial Operations Overview</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Product Revenue</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To date, we have not generated any revenue from the sale of product candidates. Our ability to generate product revenue and to become profitable will depend upon our ability to successfully develop, obtain regulatory approval for and commercialize our lead product candidates, ADCT-402 and ADCT-301, and our other product candidates. Because of the numerous risks and uncertainties associated with product development and regulatory approval, we are unable to predict the amount or timing of product revenue.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Contract Revenue</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2013, we entered into a license and joint collaboration agreement with MedImmune related to the joint clinical development of MEDI3726. To date, we have recognized minimal contract revenue, which has consisted of upfront license payments received in 2013 and a milestone payment received in 2016 under this agreement. In addition, we have, in the past, received cost reimbursement payments under this agreement, which were offset against the related expenses and were not reported as revenue. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In accordance with IFRS, revenue arising from the provision of services under a license or collaboration agreement is recognized by reference to the stage of completion of the transaction at the end of the reporting period. This method requires judgment on the part of management and, in particular, requires management to make a reliable estimate of total transaction revenue, the stage of completion and the costs to complete the </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">85</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">transaction. As a result of the discontinuance of the joint clinical development of MEDI3726 in June 2019, as of June 30, 2019, we had no non-refundable upfront payment (consisting of deferred revenue and presented as a contract liability in our consolidated balance sheet) remaining.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Research and Development Expenses</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research and development expenses consist principally of:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">salaries for research and development staff and related expenses, including share-based compensation expense;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">costs for production of preclinical and clinical-stage product candidates by CMOs;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">fees and other costs paid to contract research organizations in connection with the performance of preclinical studies and clinical trials;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">costs of related facilities, materials and equipment;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">costs associated with depreciation of right-of-use assets;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">costs associated with obtaining and maintaining patents and other intellectual property; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">amortization and depreciation of tangible and intangible fixed assets used to develop our product candidates.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research and development costs are expensed in the period in which they are incurred. From our inception to June 30, 2019, we have incurred $376.2 million in total research and development expenses. For the years ended December 31, 2018 and 2017, our research and development costs were $118.3 million and $85.5 million, respectively. The increase is principally due to increased cost associated with the clinical trials for our lead product candidates, ADCT-402 and ADCT-301, and, to a lesser extent, clinical trials for our other clinical-stage product candidates. The increase is also due to increased expenses associated with our preclinical product candidates and our research pipeline. For the next six months ended June 30, 2019 and 2018, our research and development costs were $46.6 million and $60.1 million, respectively. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect that our total research and development expenses will increase substantially in future periods. Our research and development expenses primarily relate to the following key programs:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>ADCT-402</i>. Our pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL, our Phase 1b clinical trial of ADCT-402 in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL, and our Phase 1b clinical trial of ADCT-402 in combination with durvalumab for the treatment of relapsed or refractory DLBCL, MCL and FL.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>ADCT-301</i>. Our pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and our Phase 1b clinical trial of ADCT-301 for the treatment of selected advanced solid tumors.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Other development programs</i>. Our other research and development expenses related to our Phase 1/2 clinical trial of ADCT-602 for the treatment of relapsed or refractory ALL, ADCT-601 for the treatment of selected advanced solid tumors and our preclinical studies of ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. The expenses mainly consist of salaries, costs for production of our product candidates and costs paid to contract research organizations in conjunction with clinical trials and preclinical studies.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our research and development expenses may vary substantially from period to period based on the timing of our research and development activities, including due to timing of commencement of clinical trials and enrollment of patients in clinical trials. Research and development expenses are expected to increase as we advance the clinical development of our lead product candidates, ADCT-402 and ADCT-301, and further advance the research and development of our other product candidates. The successful development of our product candidates is uncertain.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">86</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our research and development expenses for our clinical-stage product candidates, preclinical product candidates and research pipeline for the years ended December 31, 2018 and 2017 and for the six months ended June 30, 2019 and 2018.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.39px; padding-right: 2.39px; "><b>Six Months Ended June 30,</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.39px; padding-right: 2.39px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.39px; padding-right: 2.39px; "><b>Year Ended December 31,</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.39px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.39px; padding-right: 2.39px; "><b>2019</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.39px; padding-right: 2.39px; "><b>2018</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.39px; padding-right: 2.39px; "><b>Change</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.39px; padding-right: 2.39px; "><b>2018</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.39px; padding-right: 2.39px; "><b>2017</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.39px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">&#160;</div></td>
	<td colspan="18" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.39px; padding-right: 0px; "><b>(unaudited)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">&#160;</div></td>
	<td colspan="18" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.39px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">ADCT-402</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">18,820</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">19,336</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(515</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">45,701</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">28,907</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">16,794</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">ADCT-301</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13,880</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">15,010</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,130</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">29,374</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">20,042</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">9,332</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">ADCT-602</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">563</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,782</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(3,220</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,162</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8,402</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,240</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">ADCT-601</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,937</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,743</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(3,806</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">14,250</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7,654</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,595</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">MEDI3726</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">683</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,555</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(872</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,389</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,539</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(150</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">Preclinical product candidates and<br> research pipeline</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">9,689</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">13,707</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(4,018</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">20,437</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">17,986</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2,451</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.39px; ">Total</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">46,572</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">60,133</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(13,561</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">118,313</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">85,530</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">32,782</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the cost of manufacturing clinical supplies, and establishing commercial supplies, of any product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the number and characteristics of product candidates that we pursue;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the cost, timing and outcomes of regulatory approvals;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the cost and timing of establishing sales, marketing and distribution capabilities; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the terms and timing of any collaboration, licensing or other arrangements that we may establish, including any required milestone and royalty payments thereunder.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A change in the outcome of any of these variables with respect to the development of our lead product candidates, ADCT-402 and ADCT-301, or any other current or future product candidates could mean a significant change in the costs and timing associated with the development of such product candidate. For example, if we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated or if we experience significant delays in enrollment in any clinical trials, we could incur significant additional costs and the clinical development timeline for our product candidates may be delayed.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>General and Administrative Expenses</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">General and administrative expenses include employee expenses, general and administrative costs (including in particular professional fees, telecommunications costs, communications costs and IT costs), general and administrative costs charged by related parties (including telecommunications costs), depreciation of property, depreciation of right-of-use assets, plant and equipment, amortization of intangible assets, facility expenses and travel expenses. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect to incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, additional insurance expenses, investor relations activities and other administrative and professional services.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Financial Income and Expenses</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Financial income primarily consists of interest received from banks on our cash balances. Our policy is to invest funds in low-risk investments such as interest-bearing bank deposits and money market funds with maturities not exceeding three months. We expect to continue this treasury policy. Financial expense consists principally of commercial banking fees.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">87</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Taxation</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are subject to corporate taxation in Switzerland. We are also subject to taxation in other jurisdictions in which we operate, in particular, the United States and the United Kingdom, where our two wholly-owned subsidiaries are incorporated.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are entitled under Swiss laws to carry forward any losses incurred for a period of seven years, which could be used to offset future taxable income. As of December 31, 2018, we had tax loss carryforwards totaling $329.3 million that can be carried forward through future periods with the latest period ending in 2025. There is no certainty that we will make sufficient profits to be able to utilize these tax loss carryforwards in full.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Results of Operations</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Comparison of the Six Months Ended June 30, 2019 and June 30, 2018</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our results of operations for the six months ended June 30, 2019 and 2018:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.25px; padding-right: 4.25px; "><b>Six Months Ended June 30,</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.25px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.25px; padding-right: 4.25px; "><b>2019</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.25px; padding-right: 4.25px; "><b>2018</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.25px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.25px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Contract revenue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,340</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">625</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,715</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(46,572</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(60,133</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13,561</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(6,592</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(3,969</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(2,623</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Operating loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(50,824</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(63,477</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">12,653</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Financial income</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,306</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,641</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(335</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Financial expense</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(68</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(224</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Loss before taxes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,659</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,680</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">12,021</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Income tax expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(199</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(51</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.25px; ">Loss for the period</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(49,858</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(61,828</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">11,970</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Contract Revenue</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Contract revenue increased to $2.3 million for the six months ended June 30, 2019 from $0.6 million for the six months ended June 30, 2018, an increase of $1.7 million. The increase was due to the recognition, as a result of the discontinuance of the joint clinical development of MEDI3726 in June 2019, of the remaining non-refundable upfront payment (consisting of deferred revenue and presented as a contract liability in our consolidated balance sheet) of $2.3 million that existed as of December 31, 2018.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Research and Development Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our research and development expenses for the six months ended June 30, 2019 and 2018:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.89px; padding-right: 3.89px; "><b>Six Months Ended June 30,</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.89px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.89px; padding-right: 3.89px; "><b>2019</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.89px; padding-right: 3.89px; "><b>2018</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.89px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.89px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">External R&amp;D costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">33,112</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">48,304</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(15,192</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Employee expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10,531</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8,762</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,769</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Administrative and general costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,139</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">915</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">224</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Depreciation of property, plant and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">194</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">38</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Depreciation of right-of-use assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">398</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">398</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Amortization of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">9</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Impairment of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">227</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(227</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Facility expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">49</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">405</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(356</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Travel expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">692</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">864</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(172</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Laboratory supplies</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">451</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">492</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(41</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">46,572</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">60,133</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(13,561</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our research and development expenses decreased to $46.6 million for the six months ended June 30, 2019 from $60.1 million for the six months ended June 30, 2018, a decrease of $13.6 million, or 23%. The decrease was primarily due to a decrease in CMC costs as the clinical trials advance.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">88</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>General and Administrative Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our general and administrative expenses for the six months ended June 30, 2019 and 2018:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.40px; padding-right: 4.40px; "><b>Six Months Ended June 30,</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.40px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.40px; padding-right: 4.40px; "><b>2019</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.40px; padding-right: 4.40px; "><b>2018</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.40px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.40px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">Employee expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,530</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,245</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">285</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">Administrative and general costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,477</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,387</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,090</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">General and administrative costs charged by related parties</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">22</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(22</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">Depreciation of property, plant and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">75</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">75</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">Depreciation of right-of-use assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">115</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">115</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">Amortization of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">Facility expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">32</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">100</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(68</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">Travel expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">356</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">136</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">220</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.40px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">6,592</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">3,969</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">2,623</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our general and administrative expenses for the six months ended June 30, 2019 increased to $6.6 million from $4.0 million for the six months ended June 30, 2018, an increase of $2.6 million, or 66%. The increase was primarily due to costs incurred to prepare for this offering.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Financial Income</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Financial income decreased to $1.3 million for the six months ended June 30, 2019 from $1.6 million for the six months ended June 30, 2018, primarily due to lower cash balances.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Income Tax Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Income tax expenses increased to $0.2 million for the six months ended June 30, 2019 from $0.1 million for the six months ended June 30, 2018. This increase was primarily due to our internal arrangements to reimburse our subsidiaries for the services they render on a cost-plus-margin basis. The net profit at each subsidiary is subject to local income tax and gives rise to minimal amounts of tax expense.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Comparison of the Years Ended December 31, 2018 and December 31, 2017</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our results of operations for the years ended December 31, 2018 and 2017:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.51px; padding-right: 4.51px; "><i><b>Restated</b></i></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.51px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.51px; padding-right: 4.51px; "><b>Year Ended December 31,</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.51px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.51px; padding-right: 4.51px; "><b>2018</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.51px; padding-right: 4.51px; "><b>2017</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.51px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.51px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">Contract revenue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,140</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,803</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(663</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(118,313</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(85,530</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(32,783</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(8,768</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7,943</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(825</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">Operating loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(125,941</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(91,670</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(34,271</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">Financial income</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,856</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,031</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,825</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">213</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">825</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(612</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">Loss before taxes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,872</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,814</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(33,058</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">Income tax expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(224</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(48</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(176</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.51px; ">Loss for the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(33,234</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Contract Revenue</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Contract revenue decreased to $1.1 million for the year ended December 31, 2018 from $1.8 million for the year ended December 31, 2017, a decrease of $0.7 million, or 39%. The decrease was due to a lower recognition of deferred revenue. Revenue is recognized over the expected period in which work is performed, in proportion to the related costs. The lower recognition of deferred revenue for the year ended December 31, 2018 was attributable to a pause in patient enrollment in the clinical trial of MEDI3726. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a result of the recognition of $1.1 million in contract revenue for the year ended December 31, 2018, the non-refundable upfront payment (consisting of deferred revenue and presented as a contract liability in our consolidated balance sheet) decreased to $2.3 million for the year ended December 31, 2018 from $3.5 million for the year ended December 31, 2017.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">89</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Research and Development Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our research and development expenses for the years ended December 31, 2018 and 2017:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.88px; padding-right: 4.88px; "><i><b>Restated</b></i></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.88px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.88px; padding-right: 4.88px; "><b>Year Ended December 31,</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.88px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.88px; padding-right: 4.88px; "><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.88px; padding-right: 4.88px; "><b>2017</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.88px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.88px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">External R&amp;D costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">93,185</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">69,347</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">23,837</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Employee expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">19,246</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">11,951</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7,295</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Administrative and general costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,953</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,742</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">211</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Depreciation of property, plant and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">330</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">191</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">139</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Amortization of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">17</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Impairment of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">227</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">227</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Facility expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">832</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">550</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">282</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Travel expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,563</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">981</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">582</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Laboratory supplies</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">960</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">755</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">204</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.88px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">118,313</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">85,530</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">32,782</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our research and development expenses increased to $118.3 million for the year ended December 31, 2018 from $85.5 million for the year ended December 31, 2017, an increase of $32.8 million, or 38%. The increase was primarily due to increased clinical trial costs for our lead product candidates, including the commencement of our pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL and the development of a commercial supply chain for ADCT-402, and to a lesser extent, increased research and development costs for our other product candidates and our research pipeline.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>General and Administrative Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our general and administrative expenses for the years ended December 31, 2018 and 2017:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.03px; padding-right: 5.03px; "><i><b>Restated</b></i></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.03px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.03px; padding-right: 5.03px; "><b>Year Ended December 31,</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.03px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.03px; padding-right: 5.03px; "><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.03px; padding-right: 5.03px; "><b>2017</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.03px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.03px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">Employee expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,936</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,760</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">176</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">Administrative and general costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,131</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,630</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">501</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">General and administrative costs charged by related parties</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">38</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">41</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">Depreciation of property, plant and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">158</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">137</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">21</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">Amortization of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">Facility expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">224</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">202</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">21</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">Travel expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">273</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">173</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">100</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.03px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">8,768</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">7,943</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">825</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our general and administrative expenses for the year ended December 31, 2018 increased to $8.8 million from $7.9 million for the year ended December 31, 2017, an increase of $0.8 million, or 10%. The increase was primarily due to an increased number of general and administrative employees and related expenses.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Financial Income</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Financial income increased to $2.9 million for the year ended December 31, 2018 from $1.0 million for the year ended December 31, 2017, primarily due to an increased amount of cash on deposit and increased interest rates.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Income Tax Expenses</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Income tax expenses increased to $0.2 million for the year ended December 31, 2018 from a minimal amount for the year ended December 31, 2017. This increase was primarily due to our internal arrangements to reimburse our foreign subsidiaries in the United States and the United Kingdom for the services they render on a cost-plus-margin basis. The net profit at each subsidiary is subject to local income tax and gives rise to minimal amounts of tax expense.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">90</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Liquidity and Capital Resources</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since inception, we have incurred significant net losses. To date, we have not generated any product revenue and we have financed our operations through equity financings and additional funds provided by collaborations. As of June 30, 2019, we had cash and cash equivalents of $182.2 million.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our primary uses of capital are, and we expect will continue to be, research and development expenses, compensation and related expenses and other operating expenses, including rent. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We expect to incur substantial expenses in connection with the advancement of our pivotal clinical trials and BLA preparations for our lead product candidates, ADCT-402 and ADCT-301, and the development of our other product candidates and our research pipeline.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We plan to continue to fund our operating needs through the net proceeds of this offering, additional equity financings and/or other forms of financing. We may also pursue strategic collaborations for clinical development and commercialization of our product candidates in various geographical markets. The sale of additional equity would result in additional dilution to our shareholders. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Cash Flows</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Comparison of the Six Months Ended June 30, 2019 and June 30, 2018</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our cash flows for the six months ended June 30, 2019 and 2018:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.70px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.70px; padding-right: 3.70px; "><b>Six Months Ended June 30,</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.70px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.70px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.70px; padding-right: 3.70px; "><b>2019</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.70px; padding-right: 3.70px; "><b>2018</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.70px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.70px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.70px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.70px; ">Net cash provided by (used in):<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.70px; ">Operating activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(55,688</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,494</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,806</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.70px; ">Investing activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,907</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(531</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,376</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.70px; ">Financing activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">100,931</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">100,944</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.70px; ">Net change in cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">43,336</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(62,038</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">105,374</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Net Cash Used in Operating Activities</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Net cash used in operating activities decreased to $55.7 million for the six months ended June 30, 2019 from $61.5 million for the six months ended June 30, 2018, a decrease of $5.8 million, or 9%. The increase is primarily due to a decrease in CMC costs.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Net Cash Used in Investing Activities</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Net cash used in investing activities increased to $1.9 million for the six months ended June 30, 2019 from $0.5 million for the six months ended June 30, 2018, an increase of $1.4 million, or 259%. The increase is primarily due to an increase in investments in intangible assets. Net cash used in investing activities for the six months ended June 30, 2019 and 2018 consisted of payments for purchases of tangible and intangible assets.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Net Cash Provided by / Used in Financing Activities</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Net cash provided by financing activities was $100.9 million for the six months ended June 30, 2019 compared to $13 thousand net cash used in financing activities for the six months ended June 30, 2018. Net cash provided by financing activities for the six months ended June 30, 2019 primarily resulted from the issuance and sale of Class E preferred shares.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">91</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Comparison of the Years Ended December 31, 2018 and December 31, 2017</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our cash flows for the years ended December 31, 2018 and 2017:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.96px; padding-right: 3.95px; "><i><b>Restated</b></i></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.95px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.96px; padding-right: 3.95px; "><b>Year Ended December 31,</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.95px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.96px; padding-right: 3.95px; "><b>2018</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.95px; padding-right: 3.95px; "><b>2017</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.95px; padding-right: 0px; "><b>Change</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.96px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">Net cash provided by (used in):<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">Operating activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(121,362</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(74,945</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(46,417</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">Investing activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,506</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(3,248</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">742</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">Financing activities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(24</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">197,239</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(197,263</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.96px; ">Net change in cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(123,892</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">119,046</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">(242,938</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Net Cash Used in Operating Activities</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Net cash used in operating activities increased to $121.4 million for the year ended December 31, 2018 from $74.9 million for the year ended December 31, 2017, an increase of $46.4 million, or 62%. The increase is primarily due to increased research and development activity.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Net Cash Used in Investing Activities</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Net cash used in investing activities decreased to $2.5 million for the year ended December 31, 2018 from $3.2 million for the year ended December 31, 2017, a decrease of $0.7 million, or 22%. The decrease is primarily due to decreased investment in intangible assets of $1.0 million. Net cash used in investing activities for the years ended December 31, 2018 and 2017 consisted of payments for purchases of tangible and intangible assets.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Net Cash Provided by / Used in Financing Activities</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Net cash used in financing activities was $24 thousand for the year ended December 31, 2018 compared to $197.2 million of net cash provided by financing activities for the year ended December 31, 2017. Net cash provided by financing activities for the year ended December 31, 2017 primarily resulted from the sale of Class E preferred shares.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Operating Capital Requirements</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or commence clinical trials of, and seek regulatory approval for, our product candidates, including confirmatory clinical trials following any conditional or accelerated approval that our product candidates may receive. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. Furthermore, following the completion of this offering, we expect to incur additional costs associated with operating as a public company in the United States. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. We believe that the net proceeds of this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 24 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the progress, results and costs of our pivotal Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL and our pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the progress, results and costs of our clinical trials of ADCT-402 and ADCT-301 for the treatment of other indications and for our other product candidates;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">92</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the progress, results and costs of any required post-marketing confirmatory clinical trials for any product candidates that receive accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory agencies in other jurisdictions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the scope, progress, results and costs of researching and developing product candidates in our research pipeline, including conducting preclinical studies and clinical trials of such product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs of outsourced manufacturing of our product candidates, which are complex biological molecules, for clinical trials and in preparation for regulatory approval and commercialization;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the outcome, timing and costs of obtaining regulatory approvals for our product candidates if the requisite clinical trials are successful;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the size of the markets for approved indications in territories in which we receive regulatory approval, if any;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing and costs of commercialization activities for our product candidates, if any are approved for sale, including establishing our sales and marketing capabilities and engaging in the marketing, sales and distribution of our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the revenue, if any, received from the commercialization of our product candidates, if any are approved for sale;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our ability to maintain and establish collaboration, licensing or other arrangements and the financial terms of such agreements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs involved in preparing, filing, prosecuting, maintaining, protecting and enforcing our intellectual property rights and claims, including any litigation costs and the outcome of such litigation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the timing and amount of milestone payments we receive under our collaboration agreements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the costs involved in maintaining and improving the technology we use in our product candidates;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our efforts to enhance operational systems and hire additional personnel, including personnel to support the development of our product candidates and to satisfy our obligations as a public company;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the effect of competing technological and market developments; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the types of available sources of private and/or public market financing.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, convertible debt financings, strategic collaborations and licensing arrangements. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we raise funds through additional strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us or issue and sell our common </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">93</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">shares, which may result in dilution to our shareholders. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For more information as to the risks associated with our future funding needs, see &#147;Risk Factors.&#148;</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Contractual Obligations and Other Commitments</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into various agreements with collaborators, including in-licensing and manufacturing agreements. These agreements provide for us to make milestone and royalty payments that are conditional principally on success, and that are spread over various stages of development and commercialization, including achieving preclinical proof of concept, filing an IND or other regulatory submissions, commencing or completing multiple clinical development stages, obtaining regulatory approval in multiple countries, and achieving various levels of commercial sales. As of December 31, 2018, the aggregate amount of such potential milestone payments, under all such collaboration agreements, was $331.1 million. Of this total, $144.1 million would become payable upon achieving milestones up to and including regulatory approval of a product candidate and $187.0 million would become payable after commencing sales of a product candidate. The timing of these payments, and whether they become due, is conditional on achieving the applicable milestones.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our only other significant financial contractual obligations are future minimum lease payments under non-cancellable operating leases, which as of December 31, 2018, amounted to $4.4 million.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table summarizes our future minimum lease payments under non-cancellable operating leases as of payment due date by period as of December 31, 2018:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.96px; ">&#160;</div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.96px; padding-right: 0px; "><b>Payments Due By Period</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></b><b> </b></div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.96px; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.96px; padding-right: 2.96px; "><b>Total </b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.96px; padding-right: 2.96px; "><b>Less than 1 year </b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.96px; padding-right: 2.96px; "><b>1-3 years </b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.96px; padding-right: 2.96px; "><b>3-5 years</b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.96px; padding-right: 0px; "><b>More than 5 years</b></div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.96px; ">&#160;</div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.96px; padding-right: 0px; "><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.96px; ">Operating leases</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">4,378</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,084</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2,075</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,088</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">131</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.96px; ">Total<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">4,378</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1,084</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">2,075</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">1,088</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">131</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">The amounts of contractual obligations set forth in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. The table does not include obligations under agreements that we can cancel without a significant penalty.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Excludes collaboration agreements described in the preceding paragraphs above.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Internal Control Over Financial Reporting</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In June 2019, we identified an error related to the calculation of the expense charge for our historical share purchase plans, which, in accordance with IFRS 2, were required to be accounted for as if they were share option plans. While the share purchase plans were properly accounted for on the balance sheet, there was a material understatement of the share-based compensation expense, and the related disclosures were incomplete. This required a restatement of our previously issued consolidated financial statements as of and for the years ended December 31, 2018 and December 31, 2017. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The material weakness arose from a lack of effective internal controls to ensure the appropriate accounting policy was applied to the share purchase plans. Specifically, despite accounting policies being in place, there were insufficient procedures and controls to ensure that the policies were appropriately implemented and that there was proper presentation and disclosure within the financial statements. We have taken steps to remediate </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">94</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">the material weakness and to enhance our overall control environment, including implementing changes in our internal control over financial reporting with regard to complex accounting matters such as share-based compensation plans.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, as a foreign private issuer, we currently are not required to comply with the Sarbanes-Oxley Act. As a result, neither our management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act. Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We cannot assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to remediate the control deficiencies that led to this material weakness in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. See &#147;Risk Factors&#8212;Risks Related to Our Common Shares and This Offering&#8212;We have identified a material weakness in our internal control over financial reporting. If we are unable to remediate this material weakness or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our common shares.&#148;</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Off-Balance Sheet Arrangements</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements or commitments.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our market risk arises primarily from our exposure to fluctuation in currency exchange rates and to a significantly lesser extent, our exposure to interest rate movements. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of June 30, 2019, we had cash and cash equivalents of $182.2 million, which consisted exclusively of bank and money market deposits. Such interest-earning instruments carry a degree of interest rate risk. However, historical fluctuations of interest income have not been significant and have been principally impacted by the change in our cash balances as opposed to changes in interest rates received on the cash balances.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While we operate internationally and are exposed to foreign exchange risk arising from various currency exposures, primarily with respect to British pounds, Euros and Swiss francs, our foreign exchange risk is minimal. We primarily pay invoices in U.S. dollars and hold cash principally in U.S. dollars. Differences in exchange rates accounted for $0.2 million in income for the year ended December 31, 2018, $0.8 million in income for the year ended December 31, 2017, $0.1 million in loss for the six months ended June 30, 2019 and $0.2 million in income for the six months ended June 30, 2018. A hypothetical 10% change in exchange rates during any of the periods presented would not have had a material impact on our consolidated financial statements. For more information, see Note 3.1 to our audited consolidated financial statements included elsewhere in this prospectus.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations for the periods presented.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Critical Accounting Policies and Significant Judgments and Estimates</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Revenue Recognition</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Revenue is measured at the fair value of the consideration received or receivable for the sale of services in the ordinary course of our activities. Revenue is shown net of value-added tax, rebates and discounts and after intra-company sales.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">95</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We apply the five-step model to contracts only when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Performance Obligation Satisfied to the State of Completion</b></i><i><b>&#8212;</b></i><i><b>Deferred Contract Revenue Amortization</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue is recognized according to the stage of completion of the transaction at the end of the period using the cost input method. Under this method, revenue is recognized in the accounting periods in which the services are rendered. The recognition of revenue on this basis provides full information on the extent of service activity and performance during a period.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To be able to estimate the outcome of a transaction reliably, we must be able to make a reliable estimate of total transaction revenue, the stage of completion and the costs to complete the transaction. The stage of completion is determined as the proportion of the transaction costs incurred for services rendered to date compared to the estimated total transaction costs.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Research and Development Expenses</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research expenditure is recognized in expense in the year in which it is incurred. Internal development expenditure is capitalized only if it meets the recognition criteria of IAS 38 &#147;Intangible Assets.&#148; Where regulatory and other uncertainties are such that the criteria are not met, which is almost invariably the case prior to approval of the drug by the relevant regulatory authority, the expenditure is recognized in the income statement. Where, however, recognition criteria are met, internal development expenditure is capitalized and amortized on a straight-line basis over its useful economic life.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Current, Deferred Income Tax and Tax Credit</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The tax expense for the period comprises current and deferred tax. Tax is recognized in the income statement, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In these cases, the related tax is recognized in other comprehensive income or directly in equity, respectively.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where we and our subsidiaries operate and generate taxable income. We periodically evaluate positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. We establish provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Taxes on income are accrued in the same periods as the revenues and expenses to which they relate. Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. The deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit nor loss. Deferred income tax is determined using tax rates that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">96</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences or the unused tax losses can be utilized.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Deferred income tax assets from R&amp;D tax credit carryforwards are recognized to the extent that the national tax authority confirms the eligibility of such a claim and that the realization of the related tax benefit through future taxable profits is probable.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income taxes assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Employee Benefits</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Pension Obligations</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We operate defined benefit and defined contribution pension schemes in accordance with the local conditions and practices in the countries in which we operate. The schemes are generally funded through payments to insurance companies or trustee-administered funds, determined by periodic actuarial calculations. A defined contribution plan is a pension plan under which we pay fixed contributions into a separate entity (a fund) and have no legal or constructive obligations to pay further contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to the employees&#146; service in previous, current and future periods. A defined benefit plan is a pension plan that is not a defined contribution plan. Typically, defined benefit plans define an amount of pension benefit that an employee will receive on retirement, usually dependent on one or more factors such as age, years of service and compensation. However, as is the case with many Swiss pension plans, although the amount of ultimate pension benefit is not defined, certain legal obligations of the plan nevertheless create constructive obligations on the employer to pay further contributions to fund an eventual deficit. This results in the plan being accounted for as a defined benefit plan under IFRS.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The liability recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity that approximate to the terms of the related pension obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The current service cost of the defined benefit plan, recognized in the income statement in employee benefit expense, except where included in the cost of an asset, reflects the increase in the defined benefit obligation resulting from employee service in the current year.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Past service costs, resulting from a plan amendment or curtailment, are recognized immediately in the income statement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The net interest cost is calculated by applying the discount rate to the net balance of the present value of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expenses in the income statement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are charged or credited to equity in other comprehensive income in the period in which they arise.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For defined contribution plans, we pay contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. Once the contributions have been paid, we have no further payment obligations. The contributions are recognized as employee benefit expenses when they are due and are included in staff costs. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">97</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Share-Based Compensation Expense</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The fair value of shares or options granted, respectively, under share purchase or share option plans is recognized as an employee share-based compensation expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the shares or options granted:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">including any market performance conditions (e.g. our share price);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">excluding the impact of any service and non-market performance vesting conditions (e.g. employee performance targets or remaining our or our subsidiaries&#8217; employee over a specified time period); and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">including the impact of any non-vesting conditions (e.g. the requirement for employees to save or hold shares for a specific period of time).</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, we revise our estimate of the number of options that are expected to vest based on the non-market vesting and service conditions. We recognize the impact of the revision to original estimate, if any, in profit or loss, with a corresponding adjustment to equity.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The proceeds received net of any directly attributable transaction costs are credited directly to equity. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The application of our accounting policy for share-based compensation is described below for each of our plans. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>2016 Share Purchase Plan</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On November 18, 2016, we implemented the 2016 Share Purchase Plan to provide participants the opportunity to buy our shares in accordance with plan rules, which specified the purchase price. </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For the years ended December 31, 2018 and 2017, participants acquired 36 and 0 Class A common shares (562,500 and 0 common shares after giving effect to the Share Capital Reorganization), respectively. For the six months ended June 30, 2019 and 2018, participants acquired 6 and 3 Class A common shares (93,750 and 46,875 common shares after giving effect to the Share Capital Reorganization), respectively. The 2016 Share Purchase Plan does not oblige us to buy back the shares issued. Participants paid the par value of the Class A common shares in cash and settled the balance between the purchase price and the par value in the form of a promissory note. These promissory notes bear interest and have a term of ten years, and we have the right of recourse. In accordance with IFRS, we have accounted for these share purchases as if they were non-recourse and therefore, in substance, share options. To effect this, we have deemed the strike price to be equal to the purchase price plus accumulated interest up to the expected date of exercise, and the life of the share options to be equivalent to the period remaining until a likely Liquidity Event (as defined herein) and we have offset the amount of outstanding promissory notes against the share premium. A Liquidity Event is the first to occur of four possible events: (i) the acquisition of us by a third-party buyer, (ii) our merger with another entity, (iii) the sale of substantially all our assets to a third-party buyer, or (iv) an initial public offering. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The terms also include leaver provisions, giving us a call right over 100%, 75%, 50% or 25% if the date of termination occurs after the first, second, third or fourth anniversary of the award, respectively. As such, the respective shares vest 25% annually from the date of grant over a four-year period. We have the right to repurchase the shares over a four-year call period. However, we intend to waive this call right for the period after completion of this offering. Since we have not in the past demonstrated any practice of doing so, the plan is considered as equity settled under IFRS 2.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have used an independent valuation firm to calculate the fair value of the award grants per participant. As our call rights expire 25% annually from the date of grant over a four-year period, we annually take a charge for the entire portion of the award grants that expire in the year and for a portion of the partially-earned award grants for which the call rights have not yet expired, on a <i>pro rata</i> basis. This results in a front-loaded charge to the income statement. In all cases, the charge to the income statement results in a corresponding credit being booked to &#147;Other reserves&#148; within equity.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The contractual term of each award granted is ten years. The cumulative amount credited to &#147;Other reserves&#148; as of December 31, 2018 and 2017 was $3.5 million and $3.1 million, respectively. The expense recognized for services received for the years ended December 31, 2018 and 2017 was $0.4 million and $0.7 million, respectively. The cumulative amount credited to &#147;Other reserves&#148; as of June 30, 2019 and 2018 </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">98</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">was $3.6 million and $3.3 million, respectively. The expense recognized for services received for the six months ended June 30, 2019 and 2018 was $0.1 million and $0.2 million, respectively.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The fair value at grant date is independently determined using an adjusted form of the Black-Scholes option pricing model, taking into account the strike price, the term of the award, the impact of material dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk-free interest rate for the term of the award and the correlations and volatilities of the shares of peer group companies. The assumptions used in an adjusted form of the Black-Scholes option pricing model for awards granted are as follows:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 11.91px; ">&#160;</div>
							</td>
							<td colspan="2" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 11.91px; padding-right: 0px; "><b>Year </b><b>E</b><b>nded December 31,</b></div>
							</td>
						</tr>
						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 11.91px; ">&#160;</div>
							</td>
							<td width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 11.91px; padding-right: 11.91px; "><b>2018</b></div>
							</td>
							<td width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 11.91px; padding-right: 0px; "><b>2017</b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 11.91px; ">Weighted average share price (in USD)</div>
							</td>
							<td width="22%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 11.91px; ">
0.4 to 1.0
</div>
							</td>
							<td width="11%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 0px; ">&#8212;</div>
							</td>
						</tr>
						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 11.91px; ">Strike price (in USD)</div>
							</td>
							<td width="22%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 11.91px; ">
2.06 to 2.1
</div>
							</td>
							<td width="11%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 0px; ">&#8212;</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 11.91px; ">Expected volatility (%)</div>
							</td>
							<td width="22%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 11.91px; ">170.0 to 233.10</div>
							</td>
							<td width="11%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 0px; ">&#8212;</div>
							</td>
						</tr>
						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 11.91px; ">Award life (years)</div>
							</td>
							<td width="22%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 11.91px; ">0.83 to 1.33</div>
							</td>
							<td width="11%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 0px; ">&#8212;</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 11.91px; ">Expected dividend yield (%)</div>
							</td>
							<td width="22%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 11.91px; ">&#8212;</div>
							</td>
							<td width="11%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 0px; ">&#8212;</div>
							</td>
						</tr>
						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 11.91px; ">Risk-free interest rate (%)</div>
							</td>
							<td width="22%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 11.91px; ">2.32 to 2.60</div>
							</td>
							<td width="11%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 11.91px; padding-right: 0px; ">&#8212;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To derive a value for the Class A common share price at grant date, the independent valuers applied an adjusted form of the Black-Scholes option pricing model, which derives the implied equity value for one type of equity security from a contemporaneous transaction involving another type of security. This approach considered the timing, amount, liquidation preferences and dividend rights of issues of preference shares. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The expected volatility was based on historical volatility and selected volatility determined by median values observed among comparable public companies.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The award life is based on the time interval between the date of grant and the date at which, when making the grant, we expected a Liquidity Event to occur.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>2014 Incentive Plan</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the 2014 Incentive Plan, we may grant options to plan participants entitling them to acquire upon the occurrence of a Liquidity Event a defined number of Class A common shares at a defined strike prices or an equivalent cash amount. The strike price is set by us at the fair market value of the underlying Class A common shares on the date of grant. The awards for senior employees vest 25% annually from the date of grant over a four-year period. In the event that a Liquidity Event takes place before the end of a plan participant&#146;s vesting period, all of the awards granted to that plan participant vest as of the date of the Liquidity Event. In addition, we have granted junior employees share option awards effective January 1, 2017 and 2018, which vest 100% upon the occurrence of a Liquidity Event. Fair value of the awards is measured at each reporting date using an adjusted form of the Black-Scholes option pricing model, taking into account the terms and conditions upon which the awards were granted.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We will be required to settle the awards under the 2014 Incentive Plan upon the occurrence of a Liquidity Event, such as this offering. Upon completion of this offering, we have determined that the awards outstanding under the 2014 Incentive Plan will be settled in common shares rather than in cash. Therefore, the plan has been accounted for as equity settled under IFRS 2.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have used an independent valuation firm to calculate the fair value of the award grants per participant. Awards vest 25% annually from the date of grant over a four-year period, we annually take a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the income statement. For non-vested awards, we annually take a <i>pro rata</i> charge to the income statement over the period up to the anticipated date of our initial public offering. In all cases, the charge to the income statement results in a corresponding credit being booked to &#147;Other reserves&#148; within equity.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The contractual term of each award granted is ten years. The cumulative amount credited to &#147;Other reserves&#148; with respect to the 2014 Incentive Plan is $1.9 million and $1.8 million as of December 31, 2018 and 2017, respectively. The expense recognized for services received during the years ended December 31, 2018 and </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">99</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">2017 was $0.1 million and $0.3 million, respectively. The cumulative amount credited to &#147;Other reserves&#148; with respect to the 2014 Incentive Plan is $1.9 million and $1.8 million as of June 30, 2019 and 2018, respectively. The expense recognized for services received during the six months ended June 30, 2019 and 2018 was $20 thousand and $0.1 million, respectively.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The fair value at grant date is independently determined using an adjusted form of the Black-Scholes option model that takes into account the strike price, the term of the award, the impact of material dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk-free interest rate for the term of the award and the correlations and volatilities of the shares of peer group companies.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The assumptions used in an adjusted form of the Black-Scholes option pricing model for awards granted are as follows:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2.85px; ">&#160;</div>
							</td>
							<td colspan="2" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.85px; padding-right: 0px; "><b>Year </b><b>E</b><b>nded December 31,</b></div>
							</td>
						</tr>
						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2.85px; ">&#160;</div>
							</td>
							<td width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.85px; padding-right: 2.85px; "><b>2018</b></div>
							</td>
							<td width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.85px; padding-right: 0px; "><b>2017</b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2.85px; ">Weighted average share price (in USD)</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 2.85px; ">
0.6 to 1.5
</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 0px; ">
0.1 to 0.9
</div>
							</td>
						</tr>
						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2.85px; ">Strike price (in USD)</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 2.85px; ">
20.8
</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 0px; ">
10.7 / 20.8
</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2.85px; ">Expected volatility (%)</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 2.85px; ">146.40 to 201.90</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 0px; ">130.40 to 235.20</div>
							</td>
						</tr>
						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2.85px; ">Award life (years)</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 2.85px; ">1.02 to 1.75</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 0px; ">0.91 to 2.16</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2.85px; ">Expected dividend yield (%)</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 2.85px; ">&#8212;</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 0px; ">&#8212;</div>
							</td>
						</tr>
						<tr>
							<td width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2.85px; ">Risk-free interest rate (%)</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 2.85px; ">1.84 to 2.57</div>
							</td>
							<td width="17%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2.85px; padding-right: 0px; ">0.82 to 1.66</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To derive a value for the Class A common share price at grant date, the independent valuers applied an adjusted form of the Black-Scholes option pricing model, which derives the implied equity value for one type of equity security from a contemporaneous transaction involving another type of security. This approach considered the timing, amount, liquidation preferences and dividend rights of issues of preference shares. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The expected volatility was based on historical volatility and selected volatility was based on median values observed among comparable public companies. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The award life was based on the time interval between the date of grant and the date at which, when making the grant, we expected a Liquidity Event to occur.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>2013 Share Purchase Plan</i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Participants acquired 100 Class A common shares (1,562,500 common shares after giving effect to the Share Capital Reorganization) pursuant to share purchase agreements executed in September 2013 at a purchase price determined by the board of directors. There is no contractual obligation on our part to buy back the shares issued. Participants paid the par value of the Class A common shares in cash and settled the balance between the purchase price and the par value in the form of a promissory note. These promissory notes bear interest and have a term of ten years, and we have the right of recourse. We had a right to repurchase the shares until December 31, 2015. Given that we did not exercise such right, the plan has been accounted for as equity settled under IFRS 2.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All expenses relating to the 2013 Share Purchase Plan were recognized in the years ended December 31, 2013 to December 31, 2015. The cumulative amount included in &#147;Other reserves&#148; in respect of this plan as of December 31, 2018 and 2017 and as of June 30, 2019 and 2018 was $1.4 million.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Leases</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From January 1, 2019, leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Company. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset&#146;s useful life and the lease term on a straight-line basis.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee&#146;s incremental borrowing rate is used, being the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">100</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Right-of-use assets are measured at cost and are comprised of the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the amount of the initial measurement of lease liability;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any lease payments made at or before the commencement date less any lease incentives received;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any initial direct costs, and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">restoration costs.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Recent Accounting Pronouncements</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">See Note 2 to our audited consolidated financial statements and Note 3 to our unaudited interim consolidated financial statements for a description of recent accounting pronouncements applicable to our consolidated financial statements.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On January 1, 2019, we adopted IFRS 16, &#147;Leases,&#148; pursuant to which leases are recognized as a right-of-use asset and a corresponding liability at the adoption date. For the six months ended June 30, 2019, we applied the modified retrospective approach, which requires the recognition of the cumulative effect of initially applying IFRS 16 as of January 1, 2019 to accumulative losses. For the six months ended June 30, 2019, we recorded $5.4 million in right-of-use assets and corresponding lease liability. See Note 3 to our unaudited interim consolidated financial statements for more information.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>JOBS Act</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. This transition period is only applicable under U.S. GAAP. As a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required or permitted by the International Accounting Standards Board.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we intend to rely on certain of these exemptions, including without limitation, (i) providing an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board, regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common shares that are held by non-affiliates exceeds $700.0 million as of the prior June 30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">101</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 107-business -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tB"></a><b>BUSINESS</b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Overview</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted ADCs for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation PBD technology to which we have proprietary rights for our targets. We are leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises three clinical-stage product candidates, ADCT-402, ADCT-301 and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, ADCT-301 and ADCT-601, and two preclinical product candidates, ADCT-701 and ADCT-901. We retain worldwide development and commercialization rights to all of our product candidates, other than ADCT-301 for which we have a collaboration and license agreement with Genmab. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our two lead product candidates, ADCT-402 and ADCT-301, have demonstrated significant clinical activity in heavily pre-treated patients, while maintaining manageable tolerability profiles. We are evaluating ADCT-402 in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL. In August 2019, we achieved the targeted enrollment for this clinical trial and, as of August 2, 2019, have observed a 41.7% ORR in the first 96 patients treated with ADCT-402. Previously, we completed a 183-patient Phase 1 clinical trial of ADCT-402 for the treatment of relapsed or refractory NHL that showed a 41.4% ORR in patients with DLBCL at the initial dose for the Phase 2 clinical trial. If the pivotal Phase 2 clinical trial of ADCT-402 is successful, we intend to submit a BLA to the FDA in the second half of 2020. In addition, we have begun patient enrollment in a pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL. We have completed enrollment of a 133-patient Phase 1 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and NHL that has shown an 86.5% ORR in patients with HL at the initial dose planned for the Phase 2 clinical trial. We believe that our pivotal Phase 2 clinical trial of ADCT-301, if successful, will support a BLA submission in the first half of 2022. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Antibody drug conjugates are an established therapeutic approach in oncology used to selectively deliver potent chemotherapeutic cytotoxins directly to tumor cells, with the goal of maximizing activity in tumor cells while minimizing toxicity to healthy cells. The antibody component is designed to selectively bind to a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment. Upon binding to the antigen, most ADC molecules are internalized by the cell where the cytotoxic warhead is released causing cell death.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">PBD warheads have a different mechanism of action than other warheads because they create cross-links in the cancer cells&#146; DNA that do not distort the DNA helix, potentially evading the cells&#146; natural DNA repair mechanisms. They have been shown preclinically to be approximately 100 times more potent than warheads used in currently marketed ADCs. Our ADCs use next-generation PBD technology, which is designed to produce warheads that are less hydrophobic, causing them to be easier to conjugate and, based on preclinical data, have less off-target toxicity, than first-generation PBD warheads. Preclinical studies have further shown that our next-generation PBD warheads have improved therapeutic indices compared to first-generation PBDs. We believe that this mechanism of action has the potential to allow our ADCs to achieve significant clinical activity and durable responses in difficult-to-treat patients. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We were founded in 2011 as a spinoff from Spirogen, which was founded in 2000 and was an early innovator in PBD-based ADC research. Our co-founder and CEO, Dr. Christopher Martin, was a founder and the CEO of Spirogen until its sale to AstraZeneca plc in 2013. We leverage Dr. Martin&#146;s decades-long experience in the development and evolution of PBD-based ADC research. Our senior management team also brings extensive experience in oncology research and development, clinical development, CMC and regulatory and compliance, having held senior positions in such companies as AstraZeneca plc, Celgene Corporation, Daiichi Sankyo Company, Genentech, Inc., Genmab, and Wyeth Pharmaceuticals, Inc. Our board of directors includes former senior executives of AstraZeneca plc, GlaxoSmithKline plc, Pfizer Inc., F. Hoffmann-La Roche AG and Serono S.A.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">102</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since inception, we have raised $558.6 million in gross cash proceeds from equity financings. Our headquarters are based in Lausanne, Switzerland, our research and development team is based in London, our clinical development team is based in New Jersey and in Lausanne, and our CMC team is based in the San Francisco Bay Area. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Pipeline</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our research and development operations have generated a diverse and balanced portfolio. Our hematology franchise comprises three clinical-stage product candidates, ADCT-402, ADCT-301 and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, ADCT-301 and ADCT-601, and two preclinical product candidates, ADCT-701 and ADCT-901. The figure below summarizes key information about our product candidates:</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_barchart1.jpg" alt="" style="height: 257.09px; width: 600.16px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">*We believe that our Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL and our Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL are pivotal clinical trials (i.e., a clinical trial intended to serve as the basis for BLA submission). Therefore, we believe that the Phase 3 clinical trials of ADCT-402 for the treatment of relapsed or refractory DLBCL and of ADCT-301 for the treatment of relapsed or refractory HL will be post-marketing confirmatory clinical trials. **We retain worldwide development and commercialization rights to ADCT-301, subject to our collaboration and license agreement with Genmab. See &#147;&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#148; </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, our preclinical research pipeline consists of research programs focused on five ADC targets (one hematological and four solid tumor targets) and ten XDC targets (four hematological and six solid tumor targets), with the goal of selecting clinical candidates for further development. We refer to those targets for which we are exploring the use of non-antibody protein scaffolds and peptides to deliver potent PBD cytotoxins to tumor cells as &#147;XDC targets.&#148;</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Strengths</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We are a pioneer in developing highly potent and targeted PBD-based ADCs. We believe that our team, with decades of experience in this field, is well positioned to advance PBD-based ADCs for the benefit of cancer patients.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Our two lead product candidates, ADCT-402 and ADCT-301, have demonstrated strong clinical activity in heavily pre-treated patients, while maintaining manageable tolerability profiles, and we are advancing the clinical development of our lead product candidates to support BLA submissions in DLBCL and HL, respectively, in the second half of 2020 and the first half of 2022, respectively.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We are advancing a broad pipeline of four clinical-stage product candidates addressing multiple areas of unmet medical need across hematological malignancies and solid tumors, leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We retain worldwide development and commercialization rights to our product candidates, except for ADCT-301 for which we have a collaboration and license agreement with Genmab.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">103</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Our experienced CMC team is highly proficient in the manufacturing of PBD-based ADCs and has developed a robust commercial supply chain for ADCT-402 that is in the late stages of CMC validation.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Strategy</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our near-term goal is to leverage our expertise in next-generation PBD technology to develop and deliver innovative therapies to patients suffering from severe diseases who lack adequate treatment options, with a focus on oncology and immuno-oncology. Our long-term vision is to broaden the use of our ADCs to an extensive range of hematological and solid tumor indications, while also advancing any approved products through the treatment paradigm to become standard-of-care treatments in earlier lines of therapy. Key elements of our strategy to achieve our near-term goal and long-term vision include:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Advance our lead product candidate, ADCT-402, to BLA submission in </i><i>the second half of 2020</i>. Based on promising results from our 183-patient Phase 1 clinical trial, we are currently evaluating ADCT-402 in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL, and, if successful, we intend to submit a BLA in the second half of 2020.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
<i>Advance our second lead product candidate, ADCT-301, to support BLA submission in </i><i>the first half of </i><i>2022</i>. Based on promising results from our 133-patient Phase 1 clinical trial that recently completed enrollment, we are currently evaluating ADCT-301 in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL that, if successful, may form the basis for a BLA submission in the first half of 2022.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Advance our two clinical-stage </i><i>solid tumor </i><i>product candidates</i><i>, with the potential to address multiple </i><i>indications in areas of high unmet medical need</i>. Our PBD-based ADCs have multiple mechanisms of action that we believe make them suitable for targeting solid tumors. We are therefore evaluating ADCT-301, which targets the CD25-expressing Tregs that are part of the immunosuppressive tumor microenvironment, as a novel immuno-oncology approach for the treatment of various solid tumors. We are also evaluating ADCT-601, which targets AXL-expressing solid tumors, for the treatment of various solid tumors.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Continue to build a divers</i><i>e</i><i> and balanced portfolio of product candidates to address high unmet </i><i>medical needs in oncology by leveraging our R&amp;D strengths, our disciplined approach to target </i><i>selection and our preclinical and clinical development strategy</i>. In addition to the lead indications that we are pursuing for ADCT-402 and ADCT-301, we are also evaluating these two product candidates in various other disease settings, such as other NHL indications and, in the case of ADCT-301, multiple solid tumors, both as monotherapies and when used in combination with other therapies. Furthermore, we are advancing our other product candidates, including ADCT-602, and research programs through preclinical and clinical development. To strike an optimized risk-reward balance, we intend to address both hematological malignancies and solid tumors, across both clinically validated and novel cancer targets.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Maximize the commercial potential of our product candidates.</i> We currently hold worldwide development and commercialization rights to all of our product candidates, other than ADCT-301 for which we have a collaboration and license agreement with Genmab. We intend to commercialize ADCT-402 in the United States through our own infrastructure and to selectively pursue strategic collaborations in other geographies. We plan to build a U.S. sales and marketing team with a focus on hematologists and oncologists to support the commercialization of ADCT-402, if approved, which will serve as the foundation of our U.S. commercialization efforts for our other product candidates in our hematology franchise.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Overview of Antibody Drug Conjugates</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled fashion and which are usually classified as either hematological malignancies or solid tumors. In 2018, there were an estimated 18.1 million new cases of cancer and 9.6 million cancer-related deaths. Global spending on cancer treatment surpassed $133 billion in 2017 and is expected to exceed $200 billion by 2022, driven by an aging population and the development of improved treatment options. According to the National Cancer Institute, in the United States, most newly launched cancer treatments were priced at more than $100,000 per patient for one year of treatment. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">104</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The most common cancer treatments typically include a combination of surgery, radiation therapy and chemotherapy. In addition, several novel targeted therapies have also been approved. Each of these treatments have certain benefits but also certain limitations and may not be suitable for all patients. ADCs can complement other forms of treatment and are an important part of the cancer treatment paradigm.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Antibody drug conjugates are an established therapeutic approach in oncology used to selectively deliver potent chemotherapeutic cytotoxins directly to tumor cells, with the goal of maximizing activity in tumor cells while minimizing toxicity to healthy cells. An ADC consists of three components: (i) a monoclonal antibody that selectively targets a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment; (ii) a cytotoxic molecule, often referred to as the toxin or the warhead, that kills the target cell; and (iii) a chemical linker that joins together the antibody and the warhead. The warhead and the linker are together referred to as the payload. The figure below shows the three components of an ADC.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram1.jpg" alt="" style="height: 196.91px; width: 225.31px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Schematic representation of an ADC, showing its three components.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Because the antibody is designed to selectively target a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment, an ADC will bind preferentially to those cells that express the specific antigen. Upon binding to the antigen, most ADC molecules are internalized by the cell where the cytotoxic warhead is released through either cleavage of the linker or degradation of the entire antibody by cellular processes. Once a sufficient number of cytotoxic molecules have been released intracellularly, apoptosis occurs when the cell next attempts to replicate.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Components of Antibody Drug Conjugates</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Monoclonal Antibodies</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The first component of an ADC is the monoclonal antibody, which is a highly specific targeting agent that selectively binds to a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment. Since ADCs are designed to selectively target an antigen that is expressed in the tumor microenvironment, ADCs have less effect on cells that do not express the target antigen. Due to this specificity, the cytotoxins used in ADCs can be much more potent than those used in traditional chemotherapies, allowing normally systemically intolerable doses of cytotoxins to be directed at tumors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In an ADC, two significant factors are considered in the selection of the antigen to which the antibody is targeted: (i) the preferential expression on tumor cells or other cells in the tumor microenvironment; and (ii) the level of antigen expression on these cells. As a result, it is generally recognized that high and consistent (i.e., homogeneous) antigen expression throughout the tumor microenvironment correlates with higher efficacy of the ADC. By contrast, the ability to achieve a therapeutic concentration of cytotoxins in the target cell diminishes as the level of antigen expression decreases.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Chemotherapeutic Warheads</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The second component of an ADC is the cytotoxic warhead, or the cell-killing toxin. Cytotoxins commonly used in ADCs include tubulin inhibitors, such as maytansines and auristatins, and DNA-damaging toxins, such as calicheamicin. Because a warhead is conjugated to an antibody that selectively targets the tumor </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">105</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">microenvironment, ADCs can use cytotoxins at levels that are normally too potent to be used as a stand-alone therapy. Once an ADC is internalized by the target cell, the warhead is released and ultimately causes cell death via a warhead-specific mechanism. Some warheads have the additional ability to diffuse into and kill neighboring cells in the tumor microenvironment. This bystander effect can be useful in enhancing the efficacy of ADCs in tumors with heterogeneous antigen expression by providing a mechanism to kill neighboring tumor cells that do not express the target antigen.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Chemical Linkers</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The third component of an ADC is the chemical linker used to attach the warhead to the antibody. The chemical linker directly affects the efficacy, safety and tolerability of an ADC. Before an ADC is internalized by the target cell, it is critical that the chemical linker provides a stable connection between the warhead and the antibody in systemic circulation, as premature release of the warhead can cause significant off-target toxicity. After an ADC is internalized by the target cell, it is critical that the warhead is released from the antibody to promote rapid and efficient cell killing.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Linkers used in ADCs fall into two categories: cleavable and non-cleavable. Cleavable linkers release the warhead intracellularly after proteolytic cleavage of the linker by intracellular enzymes such as cathepsin or after weakening of the linker by the intracellular environment. In contrast, non-cleavable linkers are resistant to this type of cleavage and instead rely on the degradation of the entire antibody. As a result, the released payload in ADCs that use non-cleavable linkers remains attached to a fragment of the antibody, which limits the warhead&#146;s permeability to adjacent cells, reducing the bystander effect and potentially the ADC&#146;s efficacy in tumors with heterogeneous target antigen expression.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Key Strengths and Attributes of Antibody Drug Conjugates</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Antibody drug conjugates are an important part of the cancer treatment paradigm for the following reasons:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Selective Targeting</i>. Traditional chemotherapies are unable to distinguish between healthy cells and tumor cells. As a result, these therapies typically have a narrow therapeutic window (i.e., the dose range that can treat disease effectively without causing unacceptable toxic side effects). In contrast, ADCs, through their use of antigen-specific antibodies, target tumor cells or other cells in the tumor microenvironment with greater selectivity than do traditional chemotherapies. This selective targeting allows ADCs to use potent cytotoxins at dose levels that otherwise would not be tolerable. As a result, ADCs can represent a highly effective treatment approach while maintaining manageable side effects.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Wide Addressable Patient Population.</i> ADCs represent a treatment approach that expands the treatment options available to cancer patients. Many therapies are not appropriate for certain patient populations. For example, surgery is not used when the cancer is widespread, chemotherapy may not be appropriate when the patient is too sick to tolerate or does not respond to available chemotherapeutics, stem cell transplant may not be appropriate when the patient is frail, and some novel targeted therapies such as CAR-T (i.e., a type of treatment in which a patient&#8217;s T cells are modified in the laboratory so they will attack cancer cells) may not be appropriate when there is significant comorbidity. As a result of these limitations, there remains a significant unmet medical need for patients for whom other treatment options are inappropriate or ineffective.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Potential in Relapsed or Refractory Patients</i>. Traditional therapies typically have limited effectiveness for patients who exhibit relapsed (i.e., the cancer returns after an initial positive response to treatment) or refractory (i.e., the cancer is resistant to treatment) cancers. In contrast, some ADCs have proven efficacious in such patient populations while maintaining a manageable tolerability profile. Therefore, ADCs represent an important part of the cancer treatment paradigm, expanding the treatment options available to patients suffering from relapsed or refractory cancers.</td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The Antibody Drug Conjugates Landscape</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Currently, there are five approved ADCs: (i) brentuximab vedotin (Adcetris&#174;), marketed by Seattle Genetics, Inc. and Takeda Pharmaceutical Company Ltd, (ii) ado-trastuzumab emtansine (Kadcyla&#174;), marketed by Genentech, Inc., (iii) inotuzumab ozogamicin (Besponsa&#174;), marketed by Pfizer Inc., (iv) gemtuzumab ozogamicin (Mylotarg&#174;), marketed by Pfizer Inc., and (v) polatuzumab vedotin (Polivy&#174;), marketed by Genentech, Inc. We believe that the commercial success of previously approved ADCs demonstrates ADCs&#146; potential to become an important part of the cancer treatment paradigm.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">106</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While ADCs are an important part of the cancer treatment paradigm, there are certain challenges in developing ADCs that achieve the optimal therapeutic index (i.e., the balance between efficacy and tolerability). These challenges include (i) developing warheads that are sufficiently potent to target cancers with low or heterogeneous antigen expression without causing unacceptable toxic side effects, (ii) designing linkers that are stable in systemic circulation but that release the warhead once the ADC has been internalized by the target cell, and (iii) creating ADCs that achieve durable responses. We believe that our expertise in ADC research and development and access to next-generation PBD technology enables us to develop ADCs that overcome these challenges.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our Next-Generation PBD-Based Antibody Drug Conjugates</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We develop ADCs that use next-generation PBD warhead technology. Using this technology, we have developed a diverse and balanced portfolio of highly targeted ADCs with potential for improved therapeutic indices that may allow us to broaden the scope of addressable cancer patients for whom treatment with ADCs is feasible or appropriate.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">PBDs are a class of antibiotic or anti-tumor molecules. First-generation PBDs, developed in the early 2000s, were originally used as stand-alone chemotherapeutics. They were subsequently explored for use as ADC warheads. However, these first-generation PBD warheads&#146; hydrophobicity generally resulted in manufacturability issues and they exhibited significant toxicities that resulted in very narrow therapeutic indices. In contrast, our ADCs use next-generation PBD technology, which is designed to produce warheads that are less hydrophobic, causing them to be easier to conjugate and, based on preclinical data, have less off-target toxicity, than first-generation PBD warheads. Through further in-house development of conjugation technology and highly stable linker design, we aim to develop PBD-based ADCs that achieve significant clinical activity and durable responses in difficult-to-treat patients.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our ADCs use PBD dimer warheads, which are two PBD monomer molecules bonded together. Once inside a target cell, these PBD dimers bind irreversibly to DNA without distorting the double helix, potentially evading DNA repair mechanisms that can otherwise reduce ADCs&#146; effectiveness. PBD dimers do this by covalently binding two guanines from opposite DNA strands in the minor groove, forming highly cytotoxic <i>inter</i>strand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication, and ultimately resulting in cell death. The figure below shows the mechanism of action of our PBD-based ADCs.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram2.jpg" alt="" style="height: 241.40px; width: 459.13px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The mechanism of action of our PBD-based ADCs.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">107</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe that our ADCs, using next-generation PBD technology, have the potential to become an important part of the cancer treatment paradigm due to their following potential benefits:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Cytotoxic Potency</i>. The PBD dimer warheads used in our ADCs have been shown preclinically to be approximately 100 times more potent than other warheads used in currently marketed ADCs, such as auristatin, maytansine and calicheamicin. The figure below shows the relative <i>in vitro</i> cytotoxic potency of various ADC warheads and common chemotherapeutics in comparison to a PBD dimer. Despite their potency, however, the PBD dimer warheads used in our ADCs have demonstrated a manageable tolerability profile in our preclinical studies and clinical trials to date.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram3.jpg" alt="" style="height: 244.24px; width: 449.67px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The relative <i>in vitro</i> cytotoxic potency of various ADC warheads (in red) and common chemotherapeutics (in black) in comparison to a PBD dimer. &#147;IC50&#148; means the drug concentration causing 50% inhibition of the desired activity, and &#147;M&#148; means molar. Source: Spirogen, a subsidiary of AstraZeneca plc.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Activ</i><i>ity</i><i> in Tumors with Low-Expressing Targets</i>. Tumor cells typically require a threshold number of warhead molecules to be internalized for efficient cell killing. The high potency of our PBD-based warheads means that, compared to other warheads, fewer molecules of warhead should be needed to be internalized into the cancer cell to kill it. In cancer cells with low levels of antigen expression, ADCs with less potent warheads cannot bind in sufficient quantities to be effective. We believe that the potency of our PBD-based warheads may allow us to develop ADCs that target antigens with low expression levels in the tumor microenvironment, potentially increasing the range of cancers amenable to treatment with ADCs.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Durable Responses</i>. Cross-links in DNA occur when an agent reacts with two nucleotides of DNA, forming a covalent linkage between them. The cross-links can occur in the same strand (i.e., <i>intra</i>strand) or between opposite strands of DNA (i.e., <i>inter</i>strand). Our PBD-based ADCs create <i>inter</i>strand cross-links in the target cells&#8217; DNA. These <i>inter</i>strand cross-links persist in target cells and can lie dormant, potentially for weeks. We believe that this allows our ADCs to target slowly proliferating cancer cells, including cancer stem cells. The persistence of the <i>inter</i>strand cross-links is explained by the fact that these cross-links do not distort the DNA helix. Cells have natural DNA repair mechanisms that detect structural changes to DNA, including those caused by cytotoxic warheads, and repair the DNA back to its original state. Warheads that create <i>intra</i>strand cross-links, and even some warheads that create <i>inter</i>strand cross-links such as calicheamicin, distort the DNA helix, triggering the cells&#8217; DNA repair mechanisms, thereby reducing their efficacy and leading to drug resistance. As PBD cross-links are non-distortive, they are designed to be able to evade the cells&#8217; DNA repair mechanisms. In addition, tumor cells also induce the expression of certain transporter proteins (i.e., proteins that are able to transport warheads across the membrane outside the tumor cell) or the activation of detoxifying mechanisms that lead to inactive toxins. These potential resistance mechanisms limit traditional ADCs&#8217; efficacy, resulting in limited clinical responses and relapses. Based on data to date, very few resistance mechanisms have been reported for PBDs. We believe that all of these factors may contribute to the durability of the responses that we have observed in our clinical trials.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">108</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Bystander Effect</i>. The bystander effect occurs when a released warhead is able to diffuse into and kill neighboring cells in the tumor microenvironment, irrespective of those cells&#8217; antigen expression. Upon binding to the target antigen and internalization of our ADCs into the tumor cell, the warhead is designed to induce apoptosis. This is followed by the release of free PBD dimers into the tumor microenvironment. Since our PBD-based warheads are cell-permeable, they may be able to diffuse into adjacent cells and kill them in an antigen-independent manner. We believe that this may allow us to develop ADCs that target antigens with heterogeneous expression levels in the tumor microenvironment, potentially increasing the range of cancers amenable to treatment with ADCs. Once the PBD is released into circulation outside the tumor microenvironment, it is rapidly excreted with a short half-life, thus limiting overall systemic toxicity. We believe that this results in our ADCs&#8217; bystander effect being controlled and generally limited to tumor cells.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><i>Immunogenic Cell Death</i>. PBD warheads have been observed to induce immunogenic cell death, whereby a cancer cell&#8217;s death expresses certain stress signals that induce the body&#8217;s anti-tumor immune response through the activation of T cells and antigen-presenting cells. This opens up the potential for combining our ADCs with other therapies, particularly with immuno-oncology therapies such as checkpoint inhibitors, that are specifically designed to activate the patient&#8217;s own immune system to combat cancer.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Target Selection Strategy</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">While PBD warheads offer distinct benefits, they are not suitable for targeting all antigens expressed on a tumor or in the tumor microenvironment. Based on our extensive experience with PBD warheads, we have developed a disciplined target selection strategy, which involves:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">analysis of the relative overexpression of the target antigen on the membrane of cancer cells (as compared to healthy cells) and other target characteristics, such as internalization (i.e., how rapidly the antigen migrates from the membrane to the inside of the cell), recycling (i.e., whether or not the antigen recycles back to the membrane once internalized) and shedding (i.e., whether the antigen is cleaved off from the membrane to form a soluble antigen sink in the extracellular space and/or circulation) properties;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review of whether an ADC that targets the antigen has the potential to address a clear unmet medical need and whether there is an established development path with the potential for accelerated regulatory approval;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">extensive in-house research and development focused on identifying preclinical <i>in vivo</i> activity and on- and off-target toxicity to determine the therapeutic index of a PBD-based ADC aimed at the antigen target; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">determination of the potential product candidate&#8217;s placement in the overall risk-reward profile of our portfolio.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our target selection strategy aims to optimize the balance between risk and reward associated with clinical development and commercialization by covering both hematological and solid tumor indications and both clinically validated and novel cancer targets. Consistent with this strategy, we initially focused on clinically validated targets in hematological indications, as they represented the fastest route to achieve clinical proof of concept. Since then, we have expanded our focus to novel targets and in solid tumor indications.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">109</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since inception, we have evaluated more than 170 targets and are currently pursuing 11 ADC targets and 10 XDC targets for further development. The figure below shows the ADC targets for our current research and development programs.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram4.jpg" alt="" style="height: 284.95px; width: 323.76px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">ADC targets for our current research and development programs, which include both clinically validated and novel cancer targets in both hematological and solid tumor targets. Unlabeled circles represent undisclosed targets.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Development Strategy</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Once we have selected a target antigen that we believe is suitable for ADC development, we undertake research and development to advance the ADC through clinical development. Our development strategy involves:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">selecting the clinical product candidate that represents the optimal combination of antibody, linker and PBD dimer. We compare multiple candidates with different combinations of the target-specific antibodies, linkers and linker positions, conjugation chemistry and the PBD warhead. Our objective is to nominate product candidates that exhibit the optimal balance between efficacy and safety in preclinical models.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">advancing our product candidates through IND-enabling preclinical studies, focusing on rapid execution of required pharmacology studies, non-clinical toxicology and pharmacokinetic studies and cGMP manufacturing of Phase 1 clinical material. Our efficient approach to preclinical development is evidenced by the following:</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">We have consistently completed IND-enabling preclinical studies in </font><font style="font-size: 13.33px;">13 to 22</font><font style="font-size: 13.33px;"> months following </font><font style="font-size: 13.33px;">selection of the clinical product candidate.</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">Since 2015, we have submitted five INDs and worked with our collaborators to submit two </font><font style="font-size: 13.33px;">additional INDs</font><font style="font-size: 13.33px;"> for our product candidates</font><font style="font-size: 13.33px;">.</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">designing clinical trials to efficiently advance our product candidates towards regulatory submission and potential approval. Our clinical trials have the following features:</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">Our Phase 1 clinical trials enroll patients with different cancers that express the target antigen on </font><font style="font-size: 13.33px;">the tumor cells or other cells in the tumor microenvironment. This allows us to conduct small </font><font style="font-size: 13.33px;">dose-expansion studies simultaneously with dose-escalation studies, enabling signal searching and </font><font style="font-size: 13.33px;">dose selection prior to concluding Phase 1 clinical trials. We have successfully used this method in </font><font style="font-size: 13.33px;">our Phase 1 clinical trials for ADCT-402 and ADCT-301, which resulted in the early identification </font><font style="font-size: 13.33px;">of DLBCL and HL as the initial indications to pursue in our pivotal Phase 2 clinical trials, </font><font style="font-size: 13.33px;">respectively. In addition, our approach allows us to identify opportunities that may expand the </font><font style="font-size: 13.33px;">market opportunity for our product candidates. For example, while we are pursuing DLBCL as the </font></td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">110</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="ebl" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 80px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">lead indication for ADCT-402, we believe that the data generated from the Phase 1 clinical trial may allow us to more efficiently advance evaluations of ADCT-402 for the treatment of other indications, such as MCL and FL, in pivotal clinical trials.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">Our Phase 1 clinical trials involve a wide range of dosing regimens. Because the PBD cross-links </font><font style="font-size: 13.33px;">persist in tumor cells, it is important to find the dose levels and intervals that result in optimal </font><font style="font-size: 13.33px;">tumor shrinkage while minimizing cumulative toxicities due to accumulation of the cross-links </font><font style="font-size: 13.33px;">between doses. The wide range of dosing regimens in our Phase 1 clinical trials enables us to </font><font style="font-size: 13.33px;">select the dose level to be used in pivotal clinical trials without the need for separate dose-range </font><font style="font-size: 13.33px;">finding studies.</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">Our clinical trials are designed to balance risk and reward by enrolling patients with both cancers </font><font style="font-size: 13.33px;">that are difficult to treat and those that are more responsive to treatment.</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">encouraging close collaboration between our preclinical and clinical teams. For example, when our clinical team provides emerging pharmacokinetic data to our preclinical team, this strengthens the predictive value of our preclinical animal models when switching between indications, such as from hematological tumors to solid tumors with ADCT-301. Our preclinical team also analyze biomarkers that correlate with patient outcomes taken by our clinical team to monitor their pharmacodynamics effects and to inform patient selection and dosing strategies.</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Product Candidates</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are leveraging next-generation PBD technology, to which we have proprietary rights for our targets, to develop a diverse and balanced portfolio of product candidates. Our hematology franchise comprises three clinical-stage product candidates, including our lead product candidate, ADCT-402, which we are evaluating in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL, and our second lead product candidate, ADCT-301, which we are evaluating in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL. Our solid tumor franchise comprises two clinical-stage product candidates and two preclinical product candidates.</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Hematology Franchise</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our hematology franchise comprises three clinical-stage product candidates for the treatment of various hematological malignancies, including lymphoma and leukemia. The figure below summarizes the clinical-stage product candidates in our hematology franchise.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_barchart2.jpg" alt="" style="height: 146.16px; width: 609.84px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">*We believe that our Phase 2 clinical trial of ADCT-402 for the treatment of relapsed or refractory DLBCL and our Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL are pivotal clinical trials (i.e., a clinical trial intended to serve as the basis for BLA submission). Therefore, we believe that the Phase 3 clinical trials of ADCT-402 for the treatment of relapsed or refractory DLBCL and of ADCT-301 for the treatment of relapsed or refractory HL will be post-marketing confirmatory clinical trials. **We retain worldwide development and commercialization rights to ADCT-301, subject to our collaboration and license agreement with Genmab. See &#147;&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#148;</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The Lymphoma Disease Setting</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Lymphoma is a group of several closely related blood cancers that develop in the lymphatic system, an interconnected network of vessels and nodes that circulate a fluid called lymph. The lymph is rich in lymphocytes, a type of white blood cells that help the body fight off infections and other diseases. Lymphoma occurs when lymphocytes become cancerous and are typically classified into two groups: non-Hodgkin lymphoma and Hodgkin lymphoma.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">111</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Non-Hodgkin Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Non-Hodgkin lymphoma is a heterogeneous group of cancers of the lymphatic system that is characterized by the overproduction and accumulation of lymphocytes, either B lymphocytes (&#147;B cells&#148;) or T lymphocytes (&#147;T cells&#148;). These cancerous lymphocytes travel to and accumulate in other organs, including the lymph nodes, bone marrow and spleen, and disrupt these organs&#146; normal functioning. In 2018, there were an estimated 125,000 total new cases of NHL in the United States, France, Germany, Italy, Spain and the United Kingdom (&#147;Europe&#148;). The various types of NHL are distinguished by the characteristics of the cancer cells associated with each disease type. The designations &#147;indolent&#148; (i.e., slow growing) and &#147;aggressive&#148; (i.e., fast growing) are often applied to types of NHL based on the diseases&#146; progression and prognosis. The figure below shows the distribution of NHL in the United States and Europe.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -2.67px; margin-bottom: 0px; "><img src="nt10002526x6_piechart1.jpg" alt="" style="height: 246.13px; width: 409.07px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -8px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The distribution of NHL in the United States and Europe. Figures represent the estimated total number of new cases of the respective diseases in 2018.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 10.67px; margin-bottom: 0px; "><i>Diffuse Large B-Cell Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Diffuse large B-cell lymphoma is an aggressive type of NHL that develops from the B cells in the lymphatic system. It is the most common type of NHL, with an estimated 50,000 total new cases of <i>de novo</i> or transformed DLBCL in the United States and Europe in 2018. If left untreated, DLBCL is rapidly fatal.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Treatments for DLBCL can be divided into first-line, second-line and third-line and later therapies. The figure below shows the current DLBCL treatment landscape.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><img src="nt10002526x6_diagram5.jpg" alt="" style="height: 259.92px; width: 599.64px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -8px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Current DLBCL treatment landscape. Patient population data presented are for the United States, France, Germany, Italy, Spain and the United Kingdom. Not all relapsing patients will receive treatment. The blue box represents the initial potential addressable patient population for ADCT-402, if approved as a third-line therapy. The green boxes represent the potential addressable patient population for ADCT-402, if approved as a second-line therapy in combination with other therapies.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">112</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">First-line therapy generally involves chemotherapy with a rituximab backbone, such as R-CHOP (i.e., a chemotherapy regimen consisting of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone, plus rituximab). Although first-line therapy is effective in some patients, approximately 40% of patients require second-line therapy.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Second-line therapy depends on whether the patient is eligible for stem cell transplant. Eligibility is determined by a patient&#146;s physical fitness and response to high-dose salvage chemotherapy. For the patients who are ineligible for stem cell transplant, second-line therapy involves chemotherapy. Of the approximately 40% of patients that require treatment in the second-line setting, approximately 70% will relapse.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Approximately 20% of patients diagnosed with DLBCL will receive third-line therapy. Current third-line therapies include CAR-T. However, given its serious and potentially fatal side effects, such as cytokine release syndrome and neurological toxicity, patients who are ineligible to receive autologous stem cell transplant as a second-line therapy will likely also be ineligible to receive CAR-T. Other third-line therapies include allogeneic stem cell transplant (i.e., transplant involving a healthy donor&#146;s stem cells) and chemotherapy using small molecules. However, given that stem cell transplant requires patients to be physically fit, the proportion of eligible patients is small. Furthermore, the efficacy of chemotherapy regimens is limited, with the majority of patients failing to achieve a durable response. Recently, Polivy&#174;, a CD79b-directed ADC, received accelerated approval for third-line use in combination with bendamustine and a rituximab product. Despite this, however, the limited treatment options and generally poor outcomes observed in patients with relapsed or refractory DLBCL highlights the urgent need for alternative treatment strategies. We are developing ADCT-402 to address this unmet medical need.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The table below presents information about the competitive landscape of approved treatments and treatments in development for relapsed or refractory DLBCL:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="17%" rowspan="2" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.78px; "><b>Treatment</b></div>
							</td>
							<td width="14%" rowspan="2" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.78px; padding-right: 1.78px; "><b>Relapsed</b><b> or<br></b><b>Refractory </b><b>DLBCL<br></b><b>Patients </b><b>Excluded</b></div>
							</td>
							<td colspan="3" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.78px; padding-right: 1.78px; "><b>Response Rate*</b></div>
							</td>
							<td width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.78px; padding-right: 1.78px; "><b>Duration of Response*<br></b><b>(months)</b></div>
							</td>
							<td width="19%" rowspan="2" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.78px; padding-right: 0px; "><b>Common Grade</b><b> </b><b>&#8805;</b><b>3</b><br><b>TEAEs</b><b>*</b><br><b>(%)</b></div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.78px; padding-right: 1.78px; "><b>Complete<br></b><b>Response</b></div>
							</td>
							<td width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.78px; padding-right: 1.78px; "><b>Partial<br></b><b>Response</b></div>
							</td>
							<td width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.78px; padding-right: 1.78px; "><b>Overall<br></b><b>Response Rate</b></div>
							</td>
							<td width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.78px; padding-right: 1.78px; "><b>Median<br></b><b>(CR Patients / PR Patients)</b></div>
							</td>
						</tr>


						<tr>
							<td width="17%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-indent: -10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 10.67px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.78px; "><b>Polatuzumab vedotin<br></b><b>(Polivy</b><b>&#174;</b><b>)***</b></div>
							</td>
							<td width="14%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">**</div>
							</td>
							<td width="8%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">15%</div>
							</td>
							<td width="8%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">37%</div>
							</td>
							<td width="12%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">52%</div>
							</td>
							<td width="22%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">5.2<br>(** / **)</div>
							</td>
							<td width="19%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 0px; ">Neutropenia (40%)<br>Thrombocytopenia (18%)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.78px; "><b>MOR208***</b></div>
							</td>
							<td width="14%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">**</div>
							</td>
							<td width="8%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">6%</div>
							</td>
							<td width="8%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">20%</div>
							</td>
							<td width="12%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">26%</div>
							</td>
							<td width="22%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">20.1<br>(** / **)</div>
							</td>
							<td width="19%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 0px; ">Neutropenia (17%)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-indent: -10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 10.67px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.78px; "><b>Polatuzumab vedotin<br></b><b>(Polivy&#174;) in<br></b><b>combination with<br></b><b>rituximab </b><b>plus<br></b><b>bendamustine</b></div>
							</td>
							<td width="14%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">SCT eligible;<br>transformed DLBCL</div>
							</td>
							<td width="8%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">50%</div>
							</td>
							<td width="8%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">13%</div>
							</td>
							<td width="12%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">63%</div>
							</td>
							<td width="22%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">**<br>(** / **)</div>
							</td>
							<td width="19%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 0px; ">Neutropenia (42%)<br>Thrombocytopenia (40%)<br>Anemia (24%)<br>Pneumonia (16%)<br>Lymphopenia (13%)</div>
							</td>
						</tr>
						<tr>
							<td width="17%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-indent: -10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 10.67px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.78px; "><b>MOR208 in<br></b><b>combination with<br></b><b>lenalidomide***</b></div>
							</td>
							<td width="14%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">
SCT eligible;<br>four or more prior lines<br>of therapy;<br>double-hit and<br> triple-hit<br>DLBCL
</div>
							</td>
							<td width="8%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">43%</div>
							</td>
							<td width="8%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">17%</div>
							</td>
							<td width="12%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">60%</div>
							</td>
							<td width="22%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 1.78px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 1.78px; ">21.7<br>(** / **)</div>
							</td>
							<td width="19%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.78px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.78px; padding-right: 0px; ">Neutropenia (48%)<br>Thrombocytopenia (17%)<br>Febrile neutropenia (13%)</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Information about the competitive landscape for the treatment of relapsed or refractory DLBCL. *Response rate data, duration of response data and TEAEs data are derived from different clinical trials conducted at different points in time: polatuzumab vedotin (Polivy&#174;) (NCT01290549); MOR208 (NCT01685008); polatuzumab vedotin (Polivy&#174;) in combination with rituximab plus bendamustine (NCT02257567); and MOR208 in combination with lenalidomide (NCT02399085). Clinical trials vary in clinical trial design and patient inclusion criteria. Head-to-head clinical trials of these treatment options have not been conducted. **Not reported. ***Treatments that have not been approved. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Follicular Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Follicular lymphoma is an indolent type of NHL that develops from B cells in the lymphatic system. It is the second most common type of NHL, with an estimated 23,000 total new cases in the United States and Europe in 2018. FL is a highly variable disease, with uncertain prognosis and varying periods of progression.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Common therapies for FL include R-CHOP and R-CVP (i.e., a chemotherapy regimen consisting of cyclophosphamide, vincristine sulfate and prednisone, plus rituximab). Although first-line therapy is effective in some patients, approximately 45% of patients require second-line therapy. These patients have limited treatment </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">113</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">options. Generally, intensive chemotherapy regimens are not acceptable due to their toxicity, but less intensive chemotherapy regimens are not effective in such patients. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory FL highlights the urgent need for alternative treatment strategies. We are developing ADCT-402 to address this unmet medical need.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Mantle Cell Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Mantle cell lymphoma is an aggressive type of NHL that develops from B cells in the mantle zone of the lymphatic system. It is a rare type of NHL, with an estimated 6,000 total new cases in the United States and Europe in 2018. If left untreated, MCL is rapidly fatal.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Common therapies for MCL include R-CHOP or R-DHAP (i.e., a chemotherapy regimen consisting of dexamethasone, cytarabine and cisplatin, plus rituximab). Although first-line therapy is effective in some patients, approximately 70% of patients require second-line therapy. These patients have limited treatment options. The efficacy of current second-line therapies is limited, with the majority of patients failing to achieve a durable response. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory MCL highlights the urgent need for alternative treatment strategies. We are developing ADCT-402 to address this unmet medical need.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>T-Cell Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">T-cell lymphoma is a group of aggressive NHLs that develops from the T cells of the lymphatic system. They are a rare type of NHL, with an estimated 11,000 total new cases in the United States and Europe in 2018. T-cell lymphoma comprises a diverse group of diseases with differing prognoses.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Common therapies for T-cell lymphoma include chemotherapy, such as CHOP (i.e., a chemotherapy regimen consisting of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone) and CHOP-like regimens alone or in combination with other approved chemotherapeutics. Although first-line therapy is effective in some patients, approximately 70% of patients require second-line therapy. These patients have limited treatment options. The efficacy of current second-line therapies is limited, with the majority of patients failing to achieve a durable response. The National Comprehensive Cancer Network guidelines suggest that relapsed or refectory patients enroll in clinical trials, rather than receive treatment via standard therapy. In our experience, investigators have repeatedly stressed that novel therapies that are able to achieve an ORR above 40% are highly relevant and warrant further clinical development. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory T-cell lymphoma highlights the urgent need for alternative treatment strategies. Therefore, there is a significant unmet medical need for patients with relapsed or refractory T-cell lymphoma. We are developing ADCT-301 to address this unmet medical need.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Hodgkin Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Hodgkin lymphoma is a rare but highly curable type of neoplasm of the lymph nodes. These lymphoid malignancies travel to other organs, such as the liver, lungs and bone marrow, and disrupt these organs&#146; normal functioning. In 2015, there were an estimated 16,500 total new cases of HL in the United States and Europe. Patients diagnosed with HL generally have good prognoses, with a five-year overall survival rate of approximately 87%.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">114</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Treatments for HL can be divided into first-line, second-line and third-line and later therapies. The figure below shows the current HL treatment landscape.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram6.jpg" alt="" style="height: 259.16px; width: 598.12px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Current HL treatment landscape. Patient population data presented are for the United States, France, Germany, Italy, Spain and the United Kingdom. Not all relapsing patients will receive treatment. The blue box represents the initial potential addressable patient population for ADCT-301, if approved as a third-line therapy. The green boxes represent the potential addressable patient population for ADCT-301, if approved as a second-line therapy in combination with other therapies.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">First-line therapy generally involves ABVD (i.e., a chemotherapy regimen consisting of doxorubicin, bleomycin (which may be substituted by Adcetris&#174;, a CD30-directed ADC), vinblastine and dacarbazine), which may be combined with radiotherapy. Although first-line therapy is effective in most patients, approximately 15-20% of patients require second-line therapy.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Second-line therapy depends on whether the patient is eligible for stem cell transplant. Eligibility is determined by the patient&#146;s physical fitness and response to salvage chemotherapy regimens not received in first-line therapy. For the patients who are ineligible for stem cell transplant, second-line therapy involves a chemotherapy regimen not already administered or Adcetris&#174;, with or without bendamustine. Of the approximately 15% of patients that require treatment in the second-line setting, approximately 50% will relapse.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Approximately 8% of patients diagnosed with HL will receive third-line therapy. Current third-line therapies include an alternative chemotherapy regimen not previously used or immunotherapy with Adcetris&#174;. Although Adcetris&#174; and checkpoint inhibitors have achieved relatively high ORRs compared to traditional chemotherapy regimens, these therapies are moving into earlier lines of treatment. Other third-line chemotherapy regimens involving bendamustine, everolimus or lenalidomide have only shown limited efficacy. Other therapies include allogeneic stem cell transplantation. However, given that stem cell transplant requires patients to be physically fit, the proportion of eligible patients is small. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory HL highlights the urgent need for alternative treatment strategies. We are developing ADCT-301 to address this unmet medical need.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The Leukemia Disease Setting</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Leukemia is a group of several closely related blood cancers that develop in the bone marrow. Once the marrow cell undergoes a leukemic change, the leukemia cells may grow and survive better than healthy cells. Over time, the leukemia cells crowd out or suppress the development of healthy cells. Leukemia is classified into four groups: acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Acute Lymphoblastic Leukemia</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Acute lymphoblastic leukemia is an aggressive form of blood cancer, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as leukemic blasts. These leukemic blasts are overproduced in the bone marrow affecting the synthesis of normal blood cells, causing a decrease in red blood </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">115</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">cells, platelets and normal white blood cells. In 2016, there were an estimated 9,000 total new cases of ALL in the United States and Europe. ALL develops rapidly throughout the bone marrow and peripheral blood within a few days or a few weeks of the first symptoms. If left untreated, ALL is rapidly fatal.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Common therapies for ALL include multidrug chemotherapy regimens using available generic chemotherapeutics. Although first-line therapy is effective in some patients, approximately 30%-40% of patients require second-line therapy. For these patients, treatment options include targeted therapies such as tisagenlecleucel (Kymriah&#174;), a CD19-directed genetically modified autologous T cell immunotherapy, blinatumomab (Blincyto&#174;), a bispecific T-cell engager targeting CD19, and Besponsa&#174;, a CD22-directed ADC. However, there remains a significant unmet medical need for patients who exhibit relapsed or refractory ALL due to the heterogeneity of and the existence of different subgroups within ALL. We are developing ADCT-602 to address this unmet medical need.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADCT-402: PBD-Based ADC Targeting CD19</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Overview</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our lead product candidate, ADCT-402, or loncastuximab tesirine, is an ADC targeting CD19-expressing cancers. We are developing ADCT-402 for the treatment of relapsed or refractory NHL, both when used as a monotherapy and when used in combination with other therapies. The following summary provides key information about ADCT-402:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have completed a 183-patient Phase 1 clinical trial of ADCT-402 for the treatment of relapsed or refractory NHL, including 137 patients with relapsed or refractory DLBCL. In this clinical trial, ADCT-402 demonstrated significant clinical activity, while maintaining a manageable tolerability profile. More specifically, we observed: </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">in heavily pre-treated patients with relapsed or refractory DLBCL who have received a median of </font><font style="font-size: 13.33px;">three prior lines of therapy:</font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="80px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a 42.3% ORR across all doses;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="80px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a 41.4% ORR at the initial dose in our pivotal Phase 2 clinical trial; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">a 46.7% ORR in heavily pre-treated patients with relapsed or refractory MCL who have received a </font><font style="font-size: 13.33px;">median of four prior lines of therapy; and</font><font style="font-size: 13.33px;"> </font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">a 78.6% ORR in heavily pre-treated patients with relapsed or refractory FL who have received a </font><font style="font-size: 13.33px;">median of four prior lines of therapy.</font><font style="font-size: 13.33px;"> </font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ADCT-402 is being evaluated in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL, for which we anticipate reporting response rate data in the second quarter of 2020. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">As of August 2, 2019, we observed a 41.7% ORR in the first 96 patients treated with ADCT-402.</font><font style="font-size: 13.33px;"> </font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ADCT-402 is also being evaluated in a Phase 1b clinical trial in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and mantle cell lymphoma (&#147;MCL&#148;), for which we anticipate reporting safety and efficacy data in the fourth quarter of 2020. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">In addition, ADCT-402 is being evaluated in a Phase 1b clinical trial in combination with durvalumab for the treatment of relapsed or refractory DLBCL, MCL and follicular lymphoma (&#147;FL&#148;), for which we anticipate reporting safety and efficacy data in the fourth quarter of 2020. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">If our pivotal Phase 2 clinical trial is successful, we intend to submit a BLA for ADCT-402 for the treatment of relapsed or refractory DLBCL in the second half of 2020. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Of the estimated 50,000 total patients diagnosed with DLBCL each year in the United States and Europe, approximately 40% will exhibit relapsed or refractory DLBCL. We believe that the treatment of relapsed or refractory DLBCL remains an area of high unmet medical need. We expect that we would launch ADCT-402, if approved, as a third-line therapy for the treatment of DLBCL. As there is currently no leading therapeutic option for this patient population, we estimate that the initial addressable patient population is approximately 10,000 patients per year in the United States and Europe. One recent entrant into third-line therapy for DLBCL is CAR-T, which, while having demonstrated strong efficacy, is associated with significant toxicity and cost, limiting its market acceptance and accessibility. Recently, Polivy&#174; received accelerated approval for third-line </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">116</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">use in combination with bendamustine and a rituximab product. However, we believe that there remains a significant opportunity for ADCT-402 as a third-line therapy for the treatment of DLBCL, if approved. In addition, we are undertaking two combination trials of ADCT-402 with ibrutinib and with durvalumab, respectively, which, if successful, may enable ADCT-402 to be used as a second-line therapy for the treatment of DLBCL in combination with these therapies, which may increase the addressable patient population to approximately 20,000 patients per year in the United States and Europe. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to DLBCL, we are evaluating ADCT-402 for the treatment of relapsed or refractory FL and MCL in combination with other therapies. Of the estimated 23,000 total patients diagnosed with FL each year in the United States and Europe, approximately 45% will exhibit relapsed or refractory FL. Of the estimated 6,000 total patients who are diagnosed with MCL each year in the United States and Europe, approximately 70% will exhibit relapsed or refractory MCL. We believe that the treatment of relapsed or refractory FL and MCL remain areas of high unmet medical need. We intend to develop ADCT-402 as a therapeutic option for relapsed or refractory MCL and FL to address the high unmet medical needs of these patient populations.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Structure and Mechanism of Action</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT-402 is composed of a humanized monoclonal antibody (RB4v1.2) directed against human CD19 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. Once bound to a CD19-expressing cell, it is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication and ultimately resulting in cell death. The figure below shows the structure of ADCT-402.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram7.jpg" alt="" style="height: 152.41px; width: 288.73px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Visual representation of ADCT-402.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The human CD19 antigen is involved in the recognition, binding and adhesion processes of cells, mediating direct interactions between surfaces of different cell types and pathogen recognition. CD19 is expressed only on B cells (i.e., a type of white blood cell that plays a significant role in protecting the body from infection by producing antibodies) throughout all stages of B cell development and differentiation. Its expression is maintained in high levels in hematologic B cell malignancies, including NHL and certain types of leukemia. For example, CD19 is expressed in activated B cells and memory B cells in DLBCL, in na&#239;ve B cells in MCL, and in memory B cells in FL.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe that CD19 is an attractive target for ADCs developed to treat hematological malignancies for the following reasons:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">CD19 is a clinically validated target for the treatment of B cell malignancies.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">CD19 is expressed in B cell lineage at an earlier stage compared to CD20, which is another well-known target for the treatment of hematological malignancies.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The CD19 antigen is rapidly internalized by the cell. Therefore, it is an effective target for ADC therapy since ADCs bind only to antigens on the cell surface and the ADCs must be internalized to release the warhead inside the cell.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The CD19 antigen does not shed into the circulation. Therefore, there are no, or very low, levels of soluble CD19 to compete for binding of the ADC.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">117</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Phase 1 Clinical Trial in Relapsed or Refractory Non-Hodgkin Lymphoma</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have conducted a Phase 1, open-label, dose escalation and dose expansion clinical trial of the safety and tolerability of ADCT-402, used as monotherapy, in 183 patients with relapsed or refractory B-cell lineage NHL, which includes <i>de novo</i> and transformed DLBCL, FL, chronic lymphocytic leukemia, MCL, marginal zone B-cell lymphoma, Burkitt&#146;s lymphoma and lymphoplasmacytic lymphoma (collectively, &#147;B-NHL&#148;). We conducted the clinical trial at 12 sites in the United States and Europe, pursuant to an IND accepted by the FDA in December 2015. The first patient was dosed in March 2016. The results of the clinical trial showed encouraging anti-tumor activity and manageable tolerability profile in patients with relapsed or refractory B-NHL. The clinical trial&#146;s design and our main findings are summarized below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trial Design</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objectives of the dose escalation stage of the clinical trial were to (i) evaluate the safety and tolerability, and determine, as appropriate, the maximum tolerated dose (&#147;MTD&#148;) of ADCT-402 in patients with relapsed or refractory B-NHL and (ii) determine the recommended dose(s) of ADCT-402 for the dose expansion stage of the clinical trial. The primary objective of the dose expansion stage was to evaluate the safety and tolerability of ADCT-402 at the dose level(s) recommended from the results of the dose escalation stage. The secondary objectives of the clinical trial were to (i) evaluate the clinical activity of ADCT-402, as measured by ORR, DoR, overall survival (&#147;OS&#148;) and progression-free survival (&#147;PFS&#148;), (ii) characterize the pharmacokinetic profile of ADCT-402 and the free warhead SG3199 and (iii) evaluate anti-drug antibodies (&#147;ADAs&#148;) in patients&#146; blood before, during and after treatment with ADCT-402.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial enrolled patients with pathologically confirmed relapsed or refractory B-NHL who had failed or were intolerant to established therapy or for whom no other treatment options were available. Of the 183 patients who participated in the clinical trial, 139 patients were diagnosed with relapsed or refractory DLBCL, 15 patients were diagnosed with relapsed or refractory MCL, 14 patients were diagnosed with FL and the remaining 15 patients were diagnosed with other forms of relapsed or refractory B-NHL. The median age of the patients was 63, the minimum age was 20 and the maximum age was 87. The table below presents information about the patients&#146; prior lines of therapy.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Patient Characteristics</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Number of previous chemotherapies received, median (minimum, maximum)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 &nbsp;(1,13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Response to first-line chemotherapy, n (%)<br></div></td>
	<td colspan="1" width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Relapsed</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">115 (62.8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Refractory</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">43 (23.5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Response to last-line chemotherapy, n (%)<br></div></td>
	<td colspan="1" width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Relapsed</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">66 (36.1</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Refractory</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">109 (59.6</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Prior stem cell transplant, n (%)<br></div></td>
	<td colspan="1" width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Yes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">42 (23.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">No</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">141 (77.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Information about the patients&#146; prior lines of therapy.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the dose escalation stage, patients received intravenous infusions of ADCT-402, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose was 15 &#181;g/kg and the highest allowed dose was planned at 300 &#181;g/kg. Dose escalation was conducted using a 3+3 design with oversight by a Dose Escalation Steering Committee (&#147;DESC&#148;). In the dose expansion stage, patients received 120 &#181;g/kg and 150 &#181;g/kg doses on the first day of each 21-day treatment cycle. The dose levels were determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. In this clinical trial, response to treatment was determined as complete response (&#147;CR&#148;), partial response (&#147;PR&#148;), stable disease (&#147;SD&#148;) or progressive disease (&#147;PD&#148;), based on the 2014 Lugano Classification Criteria.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trial Results</i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Diffuse Large B-Cell Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For patients with relapsed or refractory DLBCL (n=139), the median prior lines of therapy received was three. The median number of treatment cycles received was two and the maximum number of treatment cycles received was 13. The median duration of treatment was 64 days.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main observed safety and tolerability findings in patients with relapsed or refractory DLBCL were as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The MTD was not reached in the dose escalation stage.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">118</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Grade &#8805;3 TEAEs were reported in 108 patients, or 77.7% of patients. The table below presents the most common Grade &#8805;3 TEAEs that were reported in more than 5% of patients.</td></tr></table><div style="clear: both"></div>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="36%" rowspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 5.16px; "><b>Grade &#8805;3 TEAEs*, n (%)</b></div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 0px; "><b>Dose Levels</b></div></td>
</tr>
<tr>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 5.16px; "><b>&#8804;90 &#181;g/kg<br> </b><b>(n=10)</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 5.16px; "><b>120 &#181;g/kg<br> </b><b>(n=32)</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.16px; padding-right: 5.15px; "><b>150 &#181;g/kg<br> </b><b>(n=70)</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.15px; padding-right: 5.15px; "><b>200 &#181;g/kg<br> </b><b>(n=27)</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.15px; padding-right: 0px; "><b>All Doses<br> </b><b>(n=139)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Gamma-glutamyltransferase increased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 &nbsp;(10.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 &nbsp;(21.9</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">12 &nbsp;(17.1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 &nbsp;(25.9</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">27 &nbsp;(19.4</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Anemia</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (20.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (9.4</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">11 (15.7</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (11.1</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">19 (13.7</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Neutrophil count decreased** </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (10.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (12.5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 (11.4</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6 (22.2</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">19 (13.7</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Platelet count decreased** </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (6.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6 (8.3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6 (22.2</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">14 (10.1</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Disease progression</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (6.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 (11.4</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 (7.2</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Hypokalemia</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 (11.4</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (3.7</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">9 (6.5</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Alkaline phosphatase increased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (10.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (9.4</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (4.3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (3.7</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 (5.8</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Lymphocyte count decreased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (6.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (5.7</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (7.4</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 (5.8</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Alanine aminotransferase increased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (6.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (4.3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (7.4</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 (5.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">Fatigue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (6.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (2.9</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (11.1</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 (5.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; ">White blood cell count decreased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (6.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (4.3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (7.4</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 (5.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="36%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.16px; "><b>Patients with any Grade &#8805;3 TEAEs</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>4</b><b> (40.0</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>24</b><b> (75.0</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>5</b><b>6</b><b> (</b><b>80.0</b><b></b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>24</b><b> (88.9</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>10</b><b>8</b><b> (7</b><b>7.7</b><b></b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The most common Grade &#8805;3 TEAEs for various administered dose levels. *Grade refers to the severity of the adverse event, with grade 1 adverse events generally including mild or asymptomatic conditions or clinical or diagnostic observations only, grade 2 adverse events generally including moderate events or minimal, local or non-invasive intervention events, grade 3 adverse events generally including severe or medically significant events that are not immediately life-threatening, events requiring hospitalization or prolongation of hospitalization or disabling events and grade 4 adverse events generally including life-threatening consequences or urgent intervention events. **Based on laboratory abnormality reporting.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">TEAEs in 26 patients, or 18.7% of patients, led to treatment discontinuation.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In our analysis, we highlight certain efficacy data for dose levels above &#8805;120 &#181;g/kg because (i) 120 &#181;g/kg was the dose level at which the first significant activity signal was observed and (ii) the majority of the patients were treated at dose levels &#8805;120 &#181;g/kg. The main observed efficacy findings from the Phase 1 clinical trial in patients with relapsed or refractory DLBCL were as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Across all dose levels, 32 patients, or 23.4% of patients, achieved a complete response and another 26 patients, or 19.0% of patients, achieved a partial response, resulting in an ORR of 58/137, or 42.3%. At dose levels &#8805;120 &#956;g/kg, 31 patients, or 24.4% of patients, achieved a complete response and another 25 patients, or 19.7% of patients, achieved a partial response, resulting in an ORR of 56/127, or 44.1%. In our post-hoc subset analysis that excluded patients with double-hit or triple-hit disease and patients with primary refractory and early relapsed disease, at dose levels &#8805;120 &#956;g/kg, 18 patients, or 45.0% of patients, achieved a complete response and another 8 patients, or 20.0% of patients, achieved a partial response, resulting in an ORR of 26/40, or 65.0%. The tables below show the response rate data and the effect of tumor characteristics, age and response to prior therapy on response rate data at dose levels &#8805;120 &#181;g/kg.</td></tr></table><div style="clear: both"></div>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="41%" rowspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 3.89px; "><b>Best Overall Response, n (%)</b></div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 0px; "><b>Dose Levels</b></div></td>
</tr>
<tr>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 3.89px; "><b>&#8804;90 &#181;g/kg<br> </b><b>(n=10)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 3.89px; "><b>120 &#181;g/kg<br> </b><b>(n=32)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 3.89px; "><b>150 &#181;g/kg<br> </b><b>(n=70)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 3.89px; "><b>200 &#181;g/kg<br> </b><b>(n=25)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 0px; "><b>All Doses<br> </b><b>(n=137)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Complete response (CR)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 &nbsp;(10.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6 &nbsp;(18.8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">15 &nbsp;(21.4</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 &nbsp;(40.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">32 (23.4</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Partial response (PR)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (10.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 (25.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">14 (20.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (12.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">26 (19.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Stable disease</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (20.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 (21.9</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">12 (17.1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (8.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">23 (16.8</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Progressive disease</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6 (60.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 (31.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">28 (40.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 (40.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">54 (39.4</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Not evaluable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (3.1</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (1.4</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (1.5</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; "><b>Overall response rate (CR + PR)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>2</b><b> (20.0</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>14</b><b> (43.8</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>2</b><b>9</b><b> (4</b><b>1.4</b><b></b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>13</b><b> (52.0</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>5</b><b>8</b><b> </b><b>&nbsp;</b><b>(4</b><b>2.3</b><b></b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response rate data. &#147;Not evaluable&#148; means that the patient met the criteria for inclusion in the efficacy analysis set, but the only scan obtained for disease assessment was indeterminate. As specified in the protocol definition of the efficacy analysis set, two patients were excluded from the efficacy analysis as they only received a single dose of study drug and did not have documented progression of disease at any point.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">119</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">

						<tr>
							<td width="33%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Tumor Characteristics</b></div>
							</td>
							<td width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">&#160;</div>
							</td>
							<td width="36%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Overall Response Rate,<br> </b><b>responders/total (%)</b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="33%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Bulky disease*</div>
							</td>
							<td width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Absent</div>
							</td>
							<td width="36%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">52/109 (47.7)</div>
							</td>
						</tr>
						<tr>
							<td width="33%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div>
							</td>
							<td width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Present</div>
							</td>
							<td width="36%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">4/18 (22.2), including 2/18 (11.1) CR</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="33%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Double-hit or triple-hit disease**</div>
							</td>
							<td width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Absent</div>
							</td>
							<td width="36%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">51/105 (48.6)</div>
							</td>
						</tr>
						<tr>
							<td width="33%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div>
							</td>
							<td width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Present</div>
							</td>
							<td width="36%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">5/22 (22.7), including 3/22 (13.6) CR</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="33%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Transformed disease***</div>
							</td>
							<td width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">No</div>
							</td>
							<td width="36%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">40/96 (41.7)</div>
							</td>
						</tr>
						<tr>
							<td width="33%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div>
							</td>
							<td width="22%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Yes</div>
							</td>
							<td width="36%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">16/31 (51.6), including 9/31 (29.0) CR</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">

						<tr>
							<td width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Age</b></div>
							</td>
							<td width="53%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Overall Response Rate,<br> </b><b>responders/total (%)</b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Less than 65</div>
							</td>
							<td width="53%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">25/69 (36.2), including 16/69 (23.2) CR</div>
							</td>
						</tr>
						<tr>
							<td width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">65-74</div>
							</td>
							<td width="53%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">18/36 (50.0), including 11/36 (30.6) CR</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 2px; ">More than 74</div>
							</td>
							<td width="53%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 2px; padding-right: 0px; ">13/22 (59.1), including 4/22 (18.2) CR</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Response to Prior Therapy</b></div></td>
	<td colspan="1" width="24%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="3" width="26%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Overall Response Rate,<br> </b><b>responders/total (%)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Response to first-line therapy</div></td>
	<td colspan="1" width="24%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Complete response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="23%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">32/49 &nbsp;(65.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Partial response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="23%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">12/33 (36.4</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Overall response rate</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="23%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">44/82 (53.7</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">No response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="23%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">12/44 (27.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Response to most recent therapy</div></td>
	<td colspan="1" width="24%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Complete response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="23%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">16/21 (76.2</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Partial response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="23%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">9/24 (37.5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Overall response rate</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="23%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">25/45 (55.6</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="24%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">No response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="23%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">31/82 (37.8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Overall response rate data by various baseline patient characteristics at dose levels &#8805;120 &#181;g/kg. *Bulky disease is recorded for patients whose cancerous masses measure at least 10 cm in diameter. **Double-hit and triple-hit DLBCL are rare subtypes of DLBCL characterized by two or three recurrent chromosome translocations and are generally associated with poor prognosis. ***Transformed disease is recorded for patients who had another type of lymphoma that progressed to become DLBCL.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Across all dose levels, the median DoR was not reached for patients who achieved a complete response (indicating that more than half of the patients continued to show a complete response as of their most recent assessment) and 2.86 months for patients who achieved a partial response, for an overall DoR of 4.47 months. At dose levels &#8805;120 &#181;g/kg, the median DoR was not reached for patients who achieved a complete response (indicating that more than half of the patients continued to show a complete response as of their most recent assessment) and was 2.69 months for patients who achieved a partial response, for an overall DoR of 4.17 months. In our post-hoc subset analysis that excluded patients with double-hit or triple-hit disease and patients with primary refractory and early relapsed disease, at dose levels &#8805;120 &#956;g/kg, the median DoR was 10.6 months for patients who achieved a complete response and was 2.1 months for patients who achieved a partial response, for an overall DoR of 4.1 months. The figure below shows the DoR by response at dose levels &#8805;120 &#181;g/kg.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart1.jpg" alt="" style="height: 211.20px; width: 425.33px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Duration of response by response at dose levels &#8805;120 &#181;g/kg.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">120</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Mantle Cell Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For patients with relapsed or refractory MCL (n=15), the median prior lines of therapy received was four. The median number of treatment cycles received was two and the maximum number of treatment cycles received was 11. The median duration of treatment was 65 days.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main observed safety and tolerability findings in patients with relapsed or refractory MCL were similar in nature, frequency and severity to those in patients with relapsed or refractory DLBCL. The main observed efficacy findings from the Phase 1 clinical trial in patients with relapsed or refractory MCL were as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Across all dose levels, five patients, or 33.3% of patients, achieved a complete response and another two patients, or 13.3% of patients, achieved a partial response, resulting in an ORR of 7/15, or 46.7%.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The median DoR was not reached (indicating that more than half of the patients continued to show a complete response as of their most recent assessment).</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Follicular Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For patients with relapsed or refractory FL (n=14), the median prior lines of therapy received was four. The median number of treatment cycles received was three and the maximum number of treatment cycles received was 12. The median duration of treatment was 79 days.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main observed safety and tolerability findings in patients with relapsed or refractory FL were similar in nature, frequency and severity to those in patients with relapsed or refractory DLBCL. The main efficacy findings from the Phase 1 clinical trial in patients with relapsed or refractory FL were as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Across all dose levels, nine patients, or 64.3% of patients, achieved a complete response and another two patients, or 14.3% of patients, achieved a partial response, resulting in an ORR of 11/14, or 78.6%.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The median DoR was not reached (indicating that more than half of the patients continued to show a complete response as of their most recent assessment).</td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Diffuse Large B-Cell Lymphoma</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are currently conducting a Phase 2, multi-center, open-label, single-arm clinical trial to evaluate the safety and efficacy of ADCT-402 in patients with relapsed or refractory DLBCL, as defined according to the 2016 World Health Organization classification to include DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma and high-grade B-cell lymphoma. We are conducting the clinical trial at 37 sites in the United States and Europe, pursuant to an IND accepted by the FDA in December 2015 and an additional protocol submitted in April 2018. The first patient was dosed in August 2018. We anticipate reporting response rate data in the second quarter of 2020. The clinical trial&#146;s design is summarized below.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Clinical Trial Design</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objective of the Phase 2 clinical trial is to evaluate the efficacy of ADCT-402 in patients with relapsed or refractory DLBCL, measured by ORR based on the 2014 Lugano Classification Criteria. The secondary objectives are to (i) characterize the safety profile of ADCT-402, (ii) characterize the pharmacokinetic profile of ADCT-402, (iii) evaluate the immunogenicity of ADCT-402 and (iv) evaluate the impact of ADCT-402 treatment on health-related quality of life (&#147;HRQoL&#148;). </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial enrolled patients with pathologically confirmed relapsed or refractory DLBCL who have previously received two or more multi-agent systemic treatment regimens. As of August 2019, we enrolled 140 patients and achieved the targeted enrollment for this clinical trial. On May 1, 2019, as part of the interim analysis for futility, we analyzed the safety and efficacy data for the first 52 patients in the clinical trial. On August 2, 2019, we updated the safety and efficacy data for these patients and analyzed the efficacy data for the first 96 patients in the clinical trial. Of the first 52 patients in the clinical trial, the median age of the patients was 63, the minimum age was 24 and the maximum age was 84. The table below presents information about these patients&#146; prior lines of therapy. </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">121</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Patient Characteristics</b></div></td>
	<td colspan="1" width="42%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 0px; ">&#160;</div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Number of previous chemotherapies received, median (minimum, maximum)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 3 &nbsp;&nbsp;(2,&nbsp;7 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Response to first-line chemotherapy, n (%)<br></div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Relapsed</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">32 &nbsp;&nbsp;(61.5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Refractory</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">16 &nbsp;&nbsp;(30.8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Response to last-line chemotherapy, n (%)<br></div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Relapsed</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">16 &nbsp;&nbsp;(30.8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Refractory</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">27 &nbsp;&nbsp;(51.9</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Prior stem cell transplant, n (%)<br></div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Yes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">9 &nbsp;&nbsp;(17.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">No</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">43 &nbsp;&nbsp;(82.7</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Information about the first 52 patients&#146; prior lines of therapy.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial is using a two-stage design, with an interim analysis for futility based on data collected from the first 52 patients. The results of the interim analysis for futility showed that the clinical trial met the criteria to continue to full enrollment. Patients receive a 150 &#181;g/kg dose on the first day of each 21-day treatment cycle for two treatment cycles, followed by a reduction to a 75 &#181;g/kg dose on the first day of each 21-day treatment cycle. The decision for initial dosing at the 150 &#181;g/kg dose level was predicated on higher observed and predicted ORR as compared to lower dose levels. The decision to reduce the dose level after two treatment cycles is based on the rapid onset of initial response observed in the majority of patients in the Phase 1 clinical trial and the desire to optimize the risk-benefit profile for patients. Therefore, the dosing regimen is selected to optimize the frequency of objective response, while permitting continued exposure with manageable toxicity to optimize the durability of response. In this clinical trial, response to treatment will be determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Interim Data</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On August 2, 2019, we updated the safety and efficacy data for the first 52 patients in the clinical trial and analyzed the efficacy data for the first 96 patients in the clinical trial. Unless otherwise indicated, the data presented are as of August 2, 2019. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main observed safety and tolerability findings were as follows: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">With regard to the 52-patient cohort, Grade &#8805;3 TEAEs were reported in 48 patients, or 73.1% of patients. The table below presents the most common Grade &#8805;3 TEAEs that were reported in more than 5% of patients. </td></tr></table><div style="clear: both"></div>
				<table align="40" width="80%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">&#160;</div></td>
	<td colspan="8" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.30px; padding-right: 0px; "><b>Cohort</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 3.30px; "><b>Grade </b><b>&#8805;</b><b>3 TEAEs*, n (%)</b></div></td>
	<td colspan="8" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.30px; padding-right: 0px; "><b>52-Patient Cohort<br></b><b>(n=52)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">Neutrophil count decreased**</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">16 &nbsp;&nbsp;(30.8</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">Gamma-glutamyltransferase increased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">12 &nbsp;&nbsp;(23.1</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">Platelet count decreased**</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 &nbsp;&nbsp;(19.2</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">Anemia</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6 &nbsp;&nbsp;(11.5</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">White blood cell count decreased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 &nbsp;&nbsp;(7.7</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">Hypercalcemia</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 &nbsp;&nbsp;(7.7</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">Hypokalemia</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 &nbsp;&nbsp;(5.8</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; ">Lymphocyte count decreased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 &nbsp;&nbsp;(5.8</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.30px; "><b>Patients with any Grade </b><b>&#8805;</b><b>3 TEAEs</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>3</b><b>8 &nbsp;&nbsp;(73.1</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The most common Grade &#8805;3 TEAEs. *Grade refers to the severity of the adverse event, with grade 1 adverse events generally including mild or asymptomatic conditions or clinical or diagnostic observations only, grade 2 adverse events generally including moderate events or minimal, local or non-invasive intervention events, grade 3 adverse events generally including severe or medically significant events that are not immediately life-threatening, events requiring hospitalization or prolongation of hospitalization or disabling events and grade 4 adverse events generally including life-threatening consequences or urgent intervention events. **Based on laboratory abnormality reporting. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">With regard to the 52-patient cohort, TEAEs in 10 patients, or 19.2% of patients, led to treatment discontinuation.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">122</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have not completed a comprehensive review of the safety data with respect to the 96-patient cohort. However, based on our continuous review of the safety data, we did not observe any significant safety findings with respect to the nature or severity of Grade &#8805;3 TEAEs in the 96-patient cohort that we did not observe in the 52-patient cohort.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main observed efficacy findings were as follows: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">With regard to the 52-patient cohort, 10 patients, or 19.2% of patients, achieved a complete response and another 14 patients, or 26.9% of patients, achieved a partial response, resulting in an ORR of 24/52, or 46.2%. With regard to the 96-patient cohort, 16 patients, or 16.7% of patients, achieved a complete response and another 24 patients, or 25.0% of patients, achieved a partial response, resulting in an ORR of 40/96, or 41.7%. The table below shows the response rate data for the respective cohorts.</td></tr></table><div style="clear: both"></div>
				<table align="40" width="80%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.94px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.94px; padding-right: 0px; "><b>Cohort</b></div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 3.94px; "><b>Best Overall Response, n (%)</b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.94px; padding-right: 3.94px; "><b>52-Patient Cohort<br></b><b>(n=52)</b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.94px; padding-right: 0px; "><b>96-Patient Cohort<br></b><b>(n=96)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.94px; ">Complete response (CR) </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 &nbsp;&nbsp;(19.2</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">16 &nbsp;&nbsp;(16.7</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.94px; ">Partial response (PR) </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">14 &nbsp;&nbsp;(26.9</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">24 &nbsp;&nbsp;(25.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.94px; ">Stable disease</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 &nbsp;&nbsp;(19.2</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">16 &nbsp;&nbsp;(16.7</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.94px; ">Progressive disease</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 &nbsp;&nbsp;(19.2</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">20 &nbsp;&nbsp;(20.8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.94px; ">Not evaluable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 &nbsp;&nbsp;(15.4</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">20 &nbsp;&nbsp;(20.8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.94px; "><b>Overall response rate (CR + PR)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="13%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>24 &nbsp;&nbsp;(46.2</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>40 &nbsp;&nbsp;(41.7</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response rate data for the 52-patient and 96-patient cohorts. &#8220;Not evaluable&#8221; means that the patient met the criteria for inclusion in the efficacy analysis set, but the only scan obtained for disease assessment was indeterminate. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Due to the mechanism of action of PBD warheads, we believe that the anti-tumor effects of ADCT-402 are realized over time. As such, we believe that the data presented as of August 2, 2019 may not reflect the data that would be obtained if the same 96 patients were evaluated at a later date. For example, when evaluated at a later date, patients who initially achieved partial responses may achieve complete responses and patients who initially displayed stable disease may achieve partial or complete responses. In the Phase 1 clinical trial of ADCT-402 for relapsed or refractory NHL, we observed nine DLBCL patients who initially achieved partial responses subsequently achieve complete responses, four DLBCL patients who initially displayed stable disease subsequently achieve complete responses and three DLBCL patients who initially displayed stable disease subsequently achieve partial responses. Therefore, we believe that ADCT-402 may exhibit greater anti-tumor activity as we continue to follow the 96-patient cohort in the clinical trial.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Pathway to Regulatory Approval</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Following our end-of-Phase 1 meeting with the FDA, we have commenced a Phase 2 clinical trial, which, if successful, we believe will form the basis of a BLA submission for accelerated approval of ADCT-402 for the treatment of relapsed or refractory DLBCL in patients who have failed two or more treatment regimens. However, the FDA has not opined on whether our Phase 2 clinical trial will in fact be sufficient to support such submission. Based on our current clinical development timeline, we anticipate submitting a BLA for ADCT-402 in the second half of 2020.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Combination Clinical Trials</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Phase 1b Combination </i><i>Clinical</i><i> Trial with Ibrutinib</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Ibrutinib is a small-molecule inhibitor of Bruton&#146;s tyrosin kinase (&#147;BTK&#148;), a mediator of the B cell receptor signaling pathway implicated in the pathogenesis of B cell cancers. BTK&#146;s role in signaling results in activation of pathways necessary for B cell tracking, chemotaxis and adhesion. Ibrutinib forms a covalent bond with cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. Nonclinical studies have shown that ibrutinib inhibits malignant B cell proliferation and survival <i>in vivo</i> as well as cell migration and substrate adhesion <i>in vitro</i>. Currently, ibrutinib is indicated for the treatment of several types of B-NHL, including MCL.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">123</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Both ADCT-402 and ibrutinib have demonstrated clinical activity as single agents for the treatment of relapsed or refractory B-NHL, including DLBCL and MCL. In addition, in our preclinical studies in DLBCL models, we have observed synergistic effects when ADCT-402 and ibrutinib were used in combination. We believe that combining these two targeted agents with different mechanisms of action has the potential to increase clinical activity compared to either agent alone.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are conducting a Phase 1b open-label, single-arm dose escalation and dose expansion clinical trial of the safety and tolerability of ADCT-402, used in combination with ibrutinib, in patients with relapsed or refractory DLBCL or MCL. We are conducting the clinical trial at six sites in the United States and Europe, pursuant to an IND accepted by the FDA in December 2015 and an additional protocol submitted in July 2018. The first patient was dosed in February 2019. The clinical trial&#146;s design is summarized below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trial Design</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objectives of the clinical trial are to (i) characterize the safety and tolerability of ADCT-402 in combination with ibrutinib and (ii) identify the MTD, recommended dose and dose schedule for future clinical trials. The secondary objectives are to (i) evaluate the anti-tumor effect of the combination of ADCT-402 with ibrutinib, (ii) characterize the pharmacokinetic profile of ADCT-402 when given in combination with ibrutinib and (iii) evaluate the immunogenicity of ADCT-402 when given in combination with ibrutinib.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory DLBCL who have failed or are intolerant to available standard therapy and patients with pathologically confirmed relapsed or refractory MCL who have received at least one prior line of therapy. The clinical trial is expected to enroll approximately 60 patients.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the dose escalation stage, patients receive ibrutinib at 560 mg/per day and receive intravenous infusions of ADCT-402, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose of ADCT-402 is 60 &#181;g/kg and the highest allowed dose will be 150 &#181;g/kg. Dose escalation is conducted using a 3+3 design with oversight by a DESC. The initial dose escalation cohort received ADCT-402 concurrently with ibrutinib for two treatment cycles and may then continue ibrutinib therapy for up to one year. Depending on the safety and tolerability results from the initial cohort, subsequent cohorts may receive either ADCT-402 with concurrent ibrutinib or ADCT-402 followed by ibrutinib. In the dose expansion stage, patients receive ADCT-402 at the recommended dose determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. The dose expansion stage may have two cohorts, one for DLBCL and one for MCL, to obtain additional safety and preliminary anti-tumor activity information at the MTD and recommended dose for future clinical trials. In this clinical trial, response to treatment will be determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Interim Data</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The dose-escalation stage of the Phase 1 clinical trial is ongoing. As of August 14, 2019, three DLBCL patients have been treated with ADCT-402 at the 60 &#181;g/kg dose level in combination with ibrutinib and two DLBCL patients have been treated with ADCT-402 at the 90 &#181;g/kg dose level in combination with ibrutinib. From a safety perspective, one out of the five patients reported a Grade &#8805;3 TEAE, which was also a DLT, of Death Not Otherwise Specified in a patient treated with ADCT-402 at the 90 &#181;g/kg dose level in combination with ibrutinib. The investigator assessed the death as unlikely to be related to ADCT-402 and as possibly being related to ibrutinib, the disease and/or comorbidities. Three patients treated with ADCT-402 at the 60 &#181;g/kg dose level and one patient treated with ADCT-402 at the 90 &#181;g/kg dose level have been assessed for response to treatment and all patients achieved complete responses.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Phase 1b Combination Clinical Trial with Durvalumab</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Durvalumab is a human monoclonal antibody that blocks the interaction of PD-L1 with PD1 on T cells and CD80 on other immune cells. Blockade of PD-L1/PD1 and PD-L1/CD80 interactions releases the inhibition of immune responses, including those that may result in tumor elimination. Nonclinical studies have shown that durvalumab stimulates the anti-tumor immune response by binding to PD-L1 and shifting the balance toward an anti-tumor response. To date, durvalumab has been given either as monotherapy or in combination with other anti-cancer agents to more than 6,000 patients as part of ongoing clinical trials.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">124</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Both ADCT-402 and durvalumab have shown clinical activity as single agents for the treatment of relapsed or refractory B-NHL, including DLBCL, MCL and FL. In addition, in preclinical studies, PBD-based ADCs have been observed to induce immunogenic cell death and exhibit synergistic effects when used in combination with checkpoint inhibitors. We believe that combining these two types of targeted agents with different mechanisms of action has the potential to increase clinical activity compared to either agent alone. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are conducting a Phase 1b open-label, single-arm dose escalation and dose expansion clinical trial of the safety and tolerability of ADCT-402, used in combination with durvalumab, in patients with advanced DLBCL, MCL or FL. We are conducting the clinical trial at 10 sites in the United States and Europe, pursuant to an IND accepted by the FDA in December 2015 and an additional protocol submitted in August 2018. The first patient was dosed in February 2019. The clinical trial&#146;s design is summarized below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trial Design</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objectives of the clinical trial are to (i) characterize the safety and tolerability of ADCT-402 in combination with durvalumab and (ii) identify the recommended dose and dose schedule for future studies. The secondary objectives are to (i) evaluate the anti-tumor effect of the combination of ADCT-402 with durvalumab, (ii) characterize the pharmacokinetic profile of ADCT-402 when given in combination with durvalumab and (iii) evaluate the immunogenicity of ADCT-402 when given in combination with durvalumab.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory DLBCL, MCL or FL who have failed or are intolerant to available standard therapy. The clinical trial is expected to enroll approximately 75 patients.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the dose escalation stage, patients receive a 1500 mg dose of durvalumab every four weeks and receive intravenous infusions of ADCT-402, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose of ADCT-402 is 90 &#181;g/kg and the highest allowed dose will be 150 &#181;g/kg. Dose escalation is conducted using a 3+3 design with oversight by a DESC. The initial dose escalation cohort received ADCT-402 for two cycles. However, patients who have not achieved a completed response or progressed at the fifteenth week disease assessment may receive two additional doses of ADCT-402. In the dose expansion stage, patients receive ADCT-402 at the recommended dose determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. The dose expansion stage may have up to three cohorts, one for DLBCL, one for MCL and one for FL, to obtain additional safety and preliminary anti-tumor activity information at the MTD and recommended dose for expansion. In this clinical trial, response to treatment will be determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Interim Data</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The dose-escalation stage of the Phase 1 clinical trial is ongoing. As of August 14, 2019, three patients have been treated with ADCT-402 at the 90 &#181;g/kg dose level in combination with durvalumab and three patients have been treated with ADCT-402 at the 120 &#181;g/kg dose level in combination with durvalumab. From a safety perspective, four out of the six patients reported one or more Grade &#8805;3 TEAEs, including vomiting, acute kidney injury, generalized muscle weakness and pneumonia. No DLT has been observed. Three patients treated with ADCT-402 at the 90 &#181;g/kg dose level have been assessed for response to treatment, out of which one FL patient achieved a partial response and the remaining assessed patients displayed progressive disease.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADCT-301: PBD-Based ADC Targeting CD25</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Overview</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our second lead product candidate, ADCT-301, or camidanlumab tesirine, is an ADC targeting CD25-expressing cancers. We are developing ADCT-301 for the treatment of relapsed or refractory HL, NHL and solid tumors. The following summary provides key information about ADCT-301:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Enrollment has been completed in a 133-patient Phase 1 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL and NHL, including 77 patients with relapsed or refractory HL. In this clinical trial, as of April 14, 2019, ADCT-301 demonstrated significant clinical activity, while maintaining a manageable tolerability profile. More specifically, we observed: </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">in heavily pre-treated patients with relapsed or refractory HL who have received a median of five </font><font style="font-size: 13.33px;">prior lines of therapy:</font></td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">125</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="80px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a 70.7% ORR across all doses;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="80px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an 86.5% ORR at the initial dose planned in our pivotal Phase 2 clinical trial; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; vertical-align: top; text-align: left; ">&#9675;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8px; text-align: left; "><font style="font-size: 13.33px;">a 44.0% ORR in heavily pre-treated patients with relapsed or refractory T-cell lymphoma who </font><font style="font-size: 13.33px;">have received a median of four prior lines of therapy.</font><font style="font-size: 13.33px;"> </font></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We have begun patient enrollment in a pivotal Phase 2 clinical trial of ADCT-301 for the treatment of relapsed or refractory HL, for which we anticipate reporting response rate data in the fourth quarter of 2021.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ADCT-301 is being evaluated in a Phase 1b clinical trial for the treatment of selected advanced solid tumors.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We intend to advance ADCT-301 through clinical development to support a BLA submission for the treatment of relapsed or refractory HL in the first half of 2022. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">We retain worldwide development and commercialization rights to ADCT-301, subject to our collaboration and license agreement with Genmab.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Of the estimated 16,500 total patients diagnosed with HL each year in the United States and Europe, approximately 15-20% will exhibit relapsed or refractory HL. We believe that the treatment of relapsed or refractory HL remains an area of high unmet medical need. We are developing ADCT-301 as a third-line therapy for the treatment of HL. As there is currently no leading therapeutic option for this patient population, we estimate that the initial addressable patient population is approximately 1,300 patients per year in the United States and Europe. Recently, the entry of the Adcetris&#174; has altered the treatment landscape in earlier lines of therapy. However, we believe that there remains a significant opportunity for ADCT-301 as a third-line therapy for the treatment of HL, if approved. In the future, we intend to undertake additional clinical trials in combination with other therapies, such as PD1-targeting agents, with the potential to enable ADCT-301 to be used as a second-line therapy for the treatment of HL, which may increase the addressable patient population to approximately 2,500 patients per year in the United States and Europe.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to HL, we are evaluating ADCT-301 for the treatment of relapsed or refractory T-cell lymphoma. Of the estimated 11,000 total patients diagnosed with T-cell lymphoma each year in the United States and Europe, approximately 70% will exhibit relapsed or refractory T-cell lymphoma. We believe that the treatment of relapsed or refractory T-cell lymphoma remains an area of high unmet medical need. We intend to develop ADCT-301 as a therapeutic option for relapsed or refractory T-cell lymphoma to address the high unmet medical need of this patient population.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Structure and Mechanism of Action</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT-301 is composed of a human monoclonal antibody (HuMax&#174;-TAC) directed against human CD25 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. Once bound to a CD25-expressing cell, it is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication and ultimately resulting in cell death. The figure below shows a visual representation of ADCT-301 and its mechanism of action.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram11.jpg" alt="" style="height: 163.77px; width: 317.13px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Visual representation of ADCT-301.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">126</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">CD25, or T cell activation antigen, is the alpha chain of IL-2R. In normal human tissue, expression of CD25 is mainly limited to activated T cells and activated B cells. CD25 is involved in autoimmunity, organ transplantation, and graft rejection, and Tregs are involved in the prevention of autoimmune processes. The preponderance of CD25-expressing cells in hematological malignancies and the relationship between increased CD25 expression and poor prognosis raises the possibility of using an anti-CD25 antibody to deliver a potent cytotoxin to these cells in patients.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe that CD25 is an attractive target for ADCs developed to treat hematological malignancies and solid tumors for the following reasons:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">CD25 expression in healthy human tissue is mainly limited to activated T cells and activated B cells.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">CD25 is expressed in a wide range of hematological malignancies.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The importance of CD25 overexpression as a prognosticator in hematological malignancies has been shown in multiple indications, including DLBCL.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">CD25 positive Treg cells have been shown to play a role in undermining anti-tumor immune functions.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The safety profiles of monoclonal antibodies directed against CD25 have been well characterized.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Clinical proof of concept for treatment of CD25 positive malignancies has been established using radio-immunoconjugates and immunotoxins incorporating the anti-CD25 antibodies.</td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Phase 1 Clinical Trial in Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are conducting a Phase 1, open-label, dose escalation and dose expansion clinical trial of the safety and tolerability of ADCT-301, used as monotherapy, in patients with relapsed or refractory HL or NHL. We have completed enrollment of the HL part of the clinical trial, having treated 77 patients with relapsed or refractory HL, and are continuing enrollment for the NHL part of the clinical trial, having enrolled 51 patients with relapsed or refractory NHL as of April 14, 2019. We are conducting the clinical trial at 12 sites in the United States and Europe, pursuant to an IND accepted by the FDA in April 2015. The first patient was dosed in October 2015. The results of the clinical trial showed encouraging anti-tumor activity and manageable tolerability profile in patients with relapsed or refractory HL or NHL. The clinical trial&#146;s design and our main findings are summarized below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trial Design</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objectives of the dose escalation stage of the clinical trial were to (i) evaluate the safety and tolerability, and determine, as appropriate, the MTD of ADCT-301 in patients with relapsed or refractory HL or NHL and (ii) determine the recommended dose(s) of ADCT-301 for the dose expansion stage of the clinical trial. The primary objective of the dose expansion stage was to evaluate the safety and tolerability of ADCT-301 at the dose level(s) recommended from the results of the dose escalation stage. The secondary objectives of the clinical trial were to (i) evaluate the clinical activity of ADCT-301, as measured by ORR, DoR, OS and PFS, (ii) characterize the pharmacokinetic profile of ADCT-301 and the free warhead SG3199 and (iii) evaluate ADAs in patients&#146; blood before, during and after treatment with ADCT-301.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial enrolled patients with pathologically confirmed relapsed or refractory HL who have failed or were intolerant to brentuximab vedotin and have received a checkpoint inhibitor and is enrolling patients with pathologically confirmed relapsed or refractory NHL who have failed or were intolerant to any established therapy. As of April 14, 2019, of the 128 patients who participated in the clinical trial, 77 were diagnosed with relapsed or refractory HL and the remaining 51 were diagnosed with relapsed or refractory NHL, including 29 patients with relapsed or refractory T-cell lymphoma. The median age of the patients was 51, the minimum age was 19 and the maximum age was 88. The median age of HL patients was 38, the minimum age was 19 and the maximum age was 80. The table below presents information about the patients&#146; prior lines of therapy for all patients in the clinical trial and for HL patients.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Patient Characteristics</b><b> </b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Number of previous systemic therapies received, median (minimum, maximum)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 &nbsp;(1,15</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Prior stem cell transplant, n (%)<br></div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Yes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">57 (44.5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">No</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">71 (55.5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Information about the patients&#146; prior lines of therapy.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">127</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Patient Characteristics of HL Patients</b></div></td>
	<td colspan="1" width="42%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 0px; ">&#160;</div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Number of previous systemic therapies received, median (minimum, maximum)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 &nbsp;&nbsp;(2,15</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Prior stem cell transplant, n (%)</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Yes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">47 &nbsp;&nbsp;(61.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Autologous stem cell transplant</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">39 &nbsp;&nbsp;(50.6</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Allogenic stem cell transplant</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 &nbsp;&nbsp;(3.9</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">Both autologous and allogenic stem cell transplant</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 &nbsp;&nbsp;(6.5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2px; padding-right: 2px; ">No</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">30 &nbsp;&nbsp;(39.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Information about the HL patients&#146; prior lines of therapy.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the dose escalation stage, patients received intravenous infusion of ADCT-301, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose was 3 &#181;g/kg and the highest given dose was 300 &#181;g/kg. Dose escalation was conducted using a continual reassessment method with oversight by a DESC. The MTD was defined as the highest dose level that has at least a 60% probability that the DLT rate is less than 30%. In the dose expansion stage, patients with HL received 30 &#181;g/kg or 45 &#181;g/kg doses on the first day of each 21-day treatment cycle, while patients with T-cell lymphoma receive 60 &#181;g/kg or 80 &#181;g/kg doses on the first day of each 21-day treatment cycle. These dose levels were determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. In this clinical trial, response to treatment is determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trial Results</i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Hodgkin Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For patients with relapsed or refractory HL (n=77), the median prior lines of therapy received was five. The median number of treatment cycles received was three and the maximum number of treatment cycles received was 15. The median duration of treatment was 50 days.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main observed safety and tolerability findings in patients with relapsed or refractory HL were as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The MTD was not reached in the dose escalation stage.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Grade &#8805;3 TEAEs were reported in 51 patients, or 66.2% of patients. The table below presents the most common Grade &#8805;3 TEAEs that are reported in more than 5% of patients.</td></tr></table><div style="clear: both"></div>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="41%" rowspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 3.89px; "><b>Grade &#8805;3 TEAEs, n (%)</b></div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 0px; "><b>Dose Levels</b></div></td>
</tr>
<tr>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 3.89px; "><b>&#8804;20 &#181;g/kg<br> </b><b>(n=3)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 3.89px; "><b>30 &#181;g/kg<br> </b><b>(n=20)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 3.89px; "><b>45 &#181;g/kg<br> </b><b>(n=37)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 3.89px; "><b>&#8805;60 &#181;g/kg<br> </b><b>(n=17)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.89px; padding-right: 0px; "><b>All Doses<br> </b><b>(n=77)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Gamma-glutamyltransferase increased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 &nbsp;(33.3</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 &nbsp;(10.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (8.1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 &nbsp;(41.2</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13 &nbsp;(16.9</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Maculopapular rash</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (33.3</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (10.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 &nbsp;(21.6</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (11.8</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13 (16.9</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Alanine aminotransferase increased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (8.1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (23.5</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 (9.1</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Anemia</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (33.3</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (10.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (8.1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6 (7.8</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Aspartate aminotransferase increased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (2.7</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (23.5</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 (6.5</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Guillain&#8211;Barr&#233; syndrome</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (5.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (5.4</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (5.9</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (5.2</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; ">Lipase increased</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (5.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (8.1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (5.2</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.89px; "><b>Patients with any Grade &#8805;3 TEAEs</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>2</b><b> (66.7</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>12</b><b> (60.0</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>25</b><b> (67.6</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>12</b><b> (70.6</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>51</b><b> (66.2</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The most common Grade &#8805;3 TEAEs for various administered dose levels.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In August and September 2017, we informed the FDA that two patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome and one HL patient was diagnosed with polyradiculopathy. The FDA issued a partial clinical hold on our clinical trial, pursuant to which we suspended the enrollment of new patients but continued the treatment of enrolled patients who would derive a clinical benefit from continued treatment with ADCT-301. We amended the clinical trial protocol and informed consent to include, among other things, additional risk factors to patient screening, additional exclusion criteria and routine neurologic evaluation prior to and during the clinical trial to monitor the occurrence of </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">128</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Guillain&#8211;Barr&#233; syndrome. In January 2018, the FDA lifted the partial clinical hold without condition. As of May 2019, one patient diagnosed with Guillain&#8211;Barr&#233; syndrome achieved a partial response and is alive, the other patient diagnosed with Guillain&#8211;Barr&#233; syndrome achieved a complete response and underwent, but died from complications related to, allogeneic stem cell transplant, and the patient diagnosed with polyradiculopathy achieved a complete response and is alive.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In September 2018, we informed the FDA that two additional patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome. We voluntarily suspended patient enrollment and undertook a detailed safety review of our clinical trial in accordance with our clinical trial protocol and submitted it to the FDA. Upon review, in October 2018, the FDA agreed that we can resume patient enrollment and made certain recommendations, including the expansion of the HL 30 &#956;g/kg dose cohort to ten additional patients, the continued assessment of pharmacokinetics and regulatory T-cell profiles in the clinical trial and that we consult with the FDA regarding the decision of final dose selection before closing the 30 &#956;g/kg dose cohort. We subsequently implemented the FDA&#146;s recommendations. As of May 2019, the two patients diagnosed with Guillain&#8211;Barr&#233; syndrome achieved a complete response and are alive.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There has been no incidence of Guillain&#8211;Barr&#233; syndrome in patients with NHL, acute leukemia or solid tumors treated with ADCT-301. Scientific literature suggests that patients with HL have a higher incidence of Guillain&#8211;Barr&#233; syndrome. Since October 2018, there have been no further incidence of Guillain&#8211;Barr&#233; syndrome in patients with HL treated with ADCT-301.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">TEAEs in 20 patients, or 26.0% of patients, led to treatment discontinuation.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In our analysis, we highlight certain efficacy data for the 45 &#181;g/kg dose level because it is the initial dose level that will be administered in our pivotal Phase 2 clinical trial. The main observed efficacy findings in patients with relapsed or refractory HL were as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Across all dose levels, 30 patients, or 40.0% of patients, achieved a complete response and another 23 patients, or 30.7% of patients, achieved a partial response, resulting in an ORR of 53/75, or 70.7%. The tables below show the response rate data and the effect of prior therapies on response rate data at the 45 &#181;g/kg dose level.</td></tr></table><div style="clear: both"></div>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="41%" rowspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4.26px; "><b>Best Overall Response, n (%)</b></div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.26px; padding-right: 0px; "><b>Dose Levels</b></div></td>
</tr>
<tr>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.26px; padding-right: 4.26px; "><b>&#8804;20 &#181;g/kg<br> </b><b>(n=3)</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.26px; padding-right: 4.26px; "><b>30 &#181;g/kg<br> </b><b>(n=18)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.26px; padding-right: 4.26px; "><b>45 &#181;g/kg<br> </b><b>(n=37)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.26px; padding-right: 4.26px; "><b>&#8805;60 &#181;g/kg<br> </b><b>(n=17)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.26px; padding-right: 0px; "><b>All Doses<br> </b><b>(n=75)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.26px; ">Complete response (CR)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 &nbsp;(27.8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">18 &nbsp;(48.6</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 &nbsp;(41.1</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">30 &nbsp;(40.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.26px; ">Partial response (PR)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 &nbsp;(33.3</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (22.2</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">14 (37.8</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (23.5</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">23 (30.7</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.26px; ">Stable disease</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (33.3</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6 (33.3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (5.9</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 (10.7</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.26px; ">Progressive disease</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (11.1</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 (13.5</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (23.5</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">11 (14.7</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.26px; ">Not evaluable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (33.3</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (11.1</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (5.9</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (4.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.26px; "><b>Overall response rate (CR + PR)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1</b><b> (33.3</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>9</b><b> (50.0</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>32</b><b> (86.5</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>11</b><b> (64.7</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>53</b><b> (70.7</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response rate data for various administered dose levels. &#147;Not evaluable&#148; means that the patient met the criteria for inclusion in the efficacy analysis set, but the only scan obtained for disease assessment was indeterminate. As specified in the protocol definition of the efficacy analysis set, two patients were excluded from the efficacy analysis as they only received a single dose of study drug and sufficient time has not passed for scans to determine response to treatment.</p>
				<table align="40" width="88%" style="margin-top: 4px; margin-left: 8%; border-collapse: collapse; ">

						<tr>
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4.31px; "><b>Prior Therapy</b></div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.31px; padding-right: 0px; "><b>Overall Response Rate<br> </b><b>responders/total (%)</b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.31px; ">Brentuximab vedotin</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.31px; padding-right: 0px; ">32/37 (86.5)</div>
							</td>
						</tr>
						<tr>
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.31px; ">Brentuximab vedotin and checkpoint inhibitor</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.31px; padding-right: 0px; ">23/26 (88.5)</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.31px; ">Stem cell transplant</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.31px; padding-right: 0px; ">16/18 (88.9)</div>
							</td>
						</tr>
						<tr>
							<td width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.31px; ">Brentuximab vedotin, checkpoint inhibitor and stem cell transplant</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.31px; padding-right: 0px; ">13/14 (92.9)</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Overall response rate data by prior therapy at the 45 &#181;g/kg dose level.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Across all dose levels, the median DoR was 8.1 months for patients who achieved a complete response and 5.1 months for patients who achieved a partial response, for an overall DoR of 6.4 months. At the </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">129</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="bl" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">45 &#181;g/kg dose level, the median DoR was 7.2 months for patients who achieved a complete response and 5.6 months for patients who achieved a partial response, for an overall DoR of 6.6 months. The figure below shows the DoR by response at the 45 &#181;g/kg dose level.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart2.jpg" alt="" style="height: 245.33px; width: 428px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Duration of response by response at the 45 &#181;g/kg dose level. Circles represent censored patients.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>T-Cell Lymphoma</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For patients with relapsed or refractory T-cell lymphoma (n=29), the median prior lines of therapy received was four. The median number of treatment cycles received was three and the maximum number of treatment cycles received was seven. The median duration of treatment was 38 days.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main observed safety and tolerability findings from the Phase 1 clinical trial in patients with relapsed or refractory T-cell lymphoma were as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The MTD was not reached in the dose escalation stage.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Grade &#8805;3 TEAEs were reported in 23 patients, or 79.3% of patients. The most common Grade &#8805;3 TEAEs, reported in more than 5% of patients, included hypercalcemia (10.3%), acute kidney injury (6.9%), back pain (6.9%), dehydration (6.9%), gamma-glutamyltransferase increased (6.9%), lung infection (6.9%), platelet count decreased (6.9%), pyrexia (6.9%), rash (6.9%) and maculopapular rash (6.9%).</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">TEAEs in two patients, or 6.9% of patients, led to treatment discontinuation.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The main observed efficacy findings from the Phase 1 clinical trial in patients with relapsed or refractory T-cell lymphoma were as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Across all dose levels, two patients, or 8.0% of patients, achieved a complete response and another nine patients, or 36.0% of patients, achieved a partial response, resulting in an ORR of 11/25, or 44.0%.</td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Hodgkin Lymphoma</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are currently conducting a Phase 2, multi-center, open-label, single-arm clinical trial to evaluate the safety and efficacy of ADCT-301 in patients with relapsed or refractory HL. We are conducting the clinical trial pursuant to an IND accepted by the FDA in April 2015 and an additional protocol submitted in March 2019. We began enrolling patients in September 2019, and we anticipate that the first patient in this clinical trial will be treated with ADCT-301 in the fourth quarter of 2019. We anticipate reporting response rate data in the fourth quarter of 2021. The clinical trial&#146;s design is summarized below.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objective of the Phase 2 clinical trial is to evaluate the efficacy of ADCT-301 in patients with relapsed or refractory HL, measured by ORR based on the 2014 Lugano Classification Criteria. The secondary </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">130</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">objectives are to (i) characterize additional efficacy endpoints of ADCT-301, including DoR, complete response rate, PFS and OS, (ii) characterize the safety profile of ADCT-301, (iii) characterize the pharmacokinetic profile of ADCT-301 and (iv) evaluate the impact of ADCT-301 treatment on HRQoL.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory HL who have failed three prior lines of therapy, including brentuximab vedotin and a checkpoint inhibitor approved for HL, such as nivolumab or pembrolizumab. The clinical trial is expected to enroll approximately 100 patients.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the clinical trial, patients will receive a 45 &#181;g/kg dose on the first day of each 21-day treatment cycle for two treatment cycles and will receive a 30 &#181;g/kg dose on the first day of each 21-day treatment cycle for subsequent treatment cycles. The decision for the initial dose level is based on the following observations from our Phase 1 clinical trial: (i) the favorable ORR and complete response rate together with a manageable tolerability profile, (ii) the high fraction of patients with HL who could tolerate at least two cycles of ADCT-301 before an AE leading to a dose delay or modification occurred and (iii) the ability to manage some of the severe TEAEs at this dose level. The decision to reduce the subsequent dose level is based on the ability to mitigate the frequency and severity of AEs foreseen in patients treated with the 45 &#181;g/kg dose level beyond two treatment cycles and the significant clinical activity observed at the 30 &#181;g/kg dose level. Therefore, the dosing regimen is selected to optimize potential response to treatment, while maintaining a manageable tolerability profile. Because of the ORR observed in the Phase 1 clinical trial of ADCT-301 in patients with HL and the anticipated recruitment projections, we do not believe that an interim futility analysis is warranted. In this clinical trial, response to treatment will be determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Pathway to Regulatory Approval</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Following our end-of-Phase 1 meeting with the FDA, we have commenced a Phase 2 clinical trial, which, if successful, we believe will form the basis of a BLA submission for accelerated approval of ADCT-301 for the treatment of relapsed or refractory HL in patients who have failed or were intolerant to brentuximab vedotin and a checkpoint inhibitor approved for HL. However, the FDA has not opined on whether our Phase 2 clinical trial will in fact be sufficient to support such submission. Based on our current clinical development timeline, we anticipate having data to support a BLA submission in the first half of 2022.</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADCT-602: PBD-Based ADC Targeting CD22</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT-602 is an ADC targeting CD22-expressing hematological malignancies. We have entered into a collaboration agreement with MD Anderson Cancer Center, pursuant to which they are conducting a Phase 1/2 clinical trial of ADCT-602 for the treatment of relapsed or refractory ALL.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Of the estimated 9,000 total patients diagnosed with ALL each year in the United States and Europe, approximately 30% will exhibit relapsed or refractory ALL. We believe that the treatment of relapsed or refractory ALL remains an area of high unmet medical need. New therapies for the treatment of ALL, such as Kymriah&#174;, Blincyto&#174; and Besponsa&#174;, are providing additional treatment options for patients with relapsed or refractory ALL. However, the heterogeneity of ALL and the existence of different subgroups within the disease mean there remains a high unmet medical need for portions of the ALL patient population. We intend to develop ADCT-602 as a therapeutic option for relapsed or refractory ALL to address the high unmet medical need of this patient population.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Structure and Mechanism of Action</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT-602 is composed of a humanized monoclonal antibody (hLL2-C220) directed against human CD22 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. Once bound to a CD22-expressing cell, it is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication and ultimately resulting in cell death. The figure below shows the structure of ADCT-602.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">131</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram8.jpg" alt="" style="height: 196.35px; width: 330.53px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Visual representation of ADCT-602.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The human CD22 antigen plays a pivotal role in the recognition, binding and adhesion processes of cells. CD22 is only expressed on B cells throughout all stages of B cell development and differentiation. Its expression is maintained in high levels in hematological B cell malignancies, including in NHL and certain types of leukemia, including B-cell ALL. We believe that CD22 is an attractive target for ADCs developed to treat hematological malignancies for the following reasons:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The CD22 antigen is rapidly internalized by the cell.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An increasing number of reports describe the outgrowth of CD19-negative tumor cells in patients who initially respond to CD19-targeted therapy. We believe that given CD22&#8217;s broad and favorable expression profile, it may be a viable alternative B cell marker to CD19 for the targeted delivery of highly potent cytotoxic drugs.</td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Preclinical Studies</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Preclinical Efficacy Studies</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the <i>in vivo</i> efficacy of ADCT-602 in the Ramos xenograft model, in which mice received a single dose of (i) ADCT-602 at 0.3 mg/kg, (ii) ADCT-602 at 1 mg/kg, (iii) a non-targeted ADC at 1 mg/kg, or (iv) a vehicle control. We observed that ADCT-602 exhibited dose-dependent anti-tumor activity, while the non-targeted ADC and the vehicle control did not demonstrate any significant anti-tumor activity. The table below summarizes the response data and the figures below show the mean tumor volume in the Ramos xenograft model and the Kaplan-Meier plot from the Ramos xenograft model.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.51px; ">&#160;</div></td>
	<td colspan="12" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.51px; padding-right: 0px; "><b>n (%)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 3.51px; "><b>Response</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.51px; padding-right: 3.51px; "><b>ADCT-602<br> </b><b>0.3 mg/kg<br> </b><b>(n=10)</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.51px; padding-right: 3.51px; "><b>ADCT-602<br> </b><b>1 mg/kg<br> </b><b>(n=10)</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.51px; padding-right: 3.51px; "><b>Non-Targeted ADC<br> </b><b>1 mg/kg<br> </b><b>(n=10)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.51px; padding-right: 0px; "><b>Vehicle Control<br> </b><b>(n=10)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.51px; ">Complete response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10 &nbsp;(100.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.51px; ">Partial response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.51px; ">Tumor-free survivor</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">9 (90.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response data obtained in the Ramos xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">132</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart3.jpg" alt="" style="height: 215.84px; width: 418.43px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The anti-tumor activity of ADCT-602 in the Ramos xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart4.jpg" alt="" style="height: 219.63px; width: 488.48px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The Kaplan-Meier plot of the activity of ADCT-602 in the Ramos xenograft model. Data represent Kaplan-Meier survival curves for each group of mice.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Preclinical Safety Studies</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the toxicity of ADCT-602 primarily in non-human primates and with a single-dose MTD study in rats. In non-human primates, ADCT-602 was observed to be well tolerated at the 0.6 mg/kg dose. Toxicity was characterized by dose-dependent reversible myelosuppression, bodyweight loss, lymphocyte depletion with loss of germinal centers and CD20-positive cells and nephropathy. In rats, the MTD for ADCT-602 was 2 mg/kg.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Phase 1/2 Clinical Trial in Relapsed or Refractory Acute Lymphoblastic Leukemia</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are conducting a Phase 1/2, open-label, dose escalation and dose expansion clinical trial of the safety and anti-tumor activity of ADCT-602, used as monotherapy, in patients with relapsed or refractory ALL. We are conducting the clinical trial at one site in the United States, pursuant to an IND accepted by the FDA in July 2018. The first patient was dosed in November 2018. The clinical trial&#146;s design is summarized below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 6.67px; margin-bottom: 0px; "><i>Clinical Trial Design</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objectives of the dose escalation stage are to (i) evaluate the safety and tolerability, and determine, as appropriate, the MTD of ADCT-602 in patients with relapsed or refractory ALL and (ii) determine the recommended dose(s) of ADCT-602 for the dose expansion stage. The primary objective of the dose expansion stage is to evaluate the efficacy of ADCT-602 at the dose level(s) recommended from the results of the dose escalation stage. The secondary objectives of the clinical trial are to (i) evaluate the clinical activity of ADCT-602, as measured by ORR, DoR, OS and PFS, (ii) characterize the pharmacokinetic profile of ADCT-602 and the free warhead SG3199, (iii) evaluate the immunogenicity of ADCT-602 and (iv) characterize the effect of ADCT-602 exposure on the QT interval.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">133</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory B-ALL and patients with pathologically confirmed relapsed or refractory Ph+ ALL who have failed either first- or second-generation tyrosine kinase inhibitor. The clinical trial is expected to enroll approximately 65 patients.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the dose escalation stage, patients receive intravenous infusions of ADCT-602, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose of ADCT-602 is 30 &#181;g/kg and the highest allowed dose will be 150 &#181;g/kg. Dose escalation is conducted using a 3+3 design with oversight by a DESC. In the dose expansion stage, patients receive ADCT-602 at the recommended dose determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. Dose expansion is conducted according to Simon&#146;s Minimax two-stage design. In the first stage, 22 patients (including six patients treated at the MTD in the dose escalation stage) will be dosed. If there are four or fewer responses in these patients, the clinical trial will stop. Otherwise, 19 additional patients will be dosed for a total of 41 patients. In this clinical trial, response to treatment will be determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 6.67px; margin-bottom: 0px; "><i>Interim Data</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The dose-escalation stage of the Phase 1/2 clinical trial is ongoing. As of June 7, 2019, five patients have been treated with ADCT-602: three at the 30 &#181;g/kg dose level and two at the 60 &#181;g/kg dose level. From a safety perspective, no DLT has been observed. Three patients treated at the 30 &#181;g/kg dose level have been assessed for response to treatment, out of which one patient achieved a complete response and the remaining assessed patients displayed progressive disease.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Solid Tumor Franchise</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our solid tumor franchise comprises two clinical-stage product candidates and two preclinical product candidates for the treatment of various solid tumor cancers, including colorectal cancer, head and neck cancer, non-small cell lung cancer, gastric and esophageal cancers, pancreatic cancer, bladder cancer, renal cell carcinoma, melanoma, triple negative breast cancer and ovarian cancer. The figure below summarizes the product candidates in our solid tumor franchise.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_barchart3.jpg" alt="" style="height: 141.65px; width: 619.52px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">*In certain cases, a Phase 2 clinical trial may be a pivotal clinical trial (i.e., a clinical trial intended to serve as the basis for BLA submission). **We retain worldwide development and commercialization rights to ADCT-301, subject to our collaboration and license agreement with Genmab. See &#147;&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#148;</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">134</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>The Solid Tumor Disease Setting</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are many different types of solid tumors and they account for the majority of cancers. The most commonly diagnosed solid tumor cancers include lung cancer, prostate cancer, breast cancer and colorectal cancer. The figure below presents the most common types of solid tumor cancers in the United States. The prognosis and treatment of solid tumor cancers vary based on the type of cancer.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_barchart4.jpg" alt="" style="height: 204px; width: 548.53px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The most common solid tumor cancers in the United States. Source: National Cancer Institute.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Despite recent significant advances in the treatment of some solid tumor cancers, there remains a high medical need for novel therapies. One of the significant recent advances in the treatment of solid tumor cancers is the introduction of PD1 and PD-L1 checkpoint inhibitors, such as pembrolizumab (Keytruda&#174;), that leverages the body&#146;s immune system to attack tumor cells. However, only 45% of cancer patients are eligible for treatment with checkpoint inhibitors and only 12% of cancer patients respond to treatment with checkpoint inhibitors. We are developing product candidates directed at different targets from those targeted by checkpoint inhibitors. We believe that our product candidates may enhance the efficacy of checkpoint inhibitors when they are used in combination and may provide a treatment option for patients who are not eligible for or do not respond to treatment with checkpoint inhibitors. We believe that there is a significant opportunity for our product candidates to address the high unmet medical need of these patient populations.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADCT-301: PBD-Based ADC Targeting CD25</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to ADCT-301&#146;s hematological indications, we are also exploring its use as a novel immuno-oncology approach for the treatment of solid tumor cancers. ADCT-301 targets CD25 proteins expressed on Tregs, which contribute to the immunosuppressive tumor microenvironment in a variety of cancers, including colorectal, ovarian, lung, pancreatic cancers and melanoma, by allowing the tumor to evade immune surveillance. In recent years, a number of companies have begun exploring the therapeutic potential of approaches that deplete or reduce Tregs in the tumor microenvironment, while restoring the activity of cytotoxic T effector cells. These approaches usually use a single mechanism of action. In contrast, ADCT-301 has three mechanisms of action that may enhance anti-tumor activity. First, ADCT-301 directly targets Tregs, with the goal of causing cell death. Second, after the target cell&#146;s death, the PBD warhead is designed to diffuse into the tumor microenvironment, creating a bystander effect. Third, we believe that the target cell&#146;s death triggers immunogenic cell death, which boosts the body&#146;s anti-tumor immune response. We believe that these effects may further be enhanced by combining ADCT-301 with a checkpoint inhibitor. The figure below shows ADCT-301&#146;s proposed mechanisms of action in solid tumors.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">135</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram9.jpg" alt="" style="height: 324px; width: 586.67px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">ADCT-301&#146;s proposed mechanisms of action in solid tumors.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Preclinical Immuno-Oncology Studies in Solid Tumors</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Preclinical Efficacy Studies</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Preclinical immuno-oncology models rely on mice that have a functional immune system and can only use murine cancer cells. The antibody in ADCT-301 does not bind to murine Tregs or any murine cell line expressing CD25 and thus cannot be used in preclinical immuno-oncology models. We therefore created the surrogate antibody Sur301, which binds to murine CD25, using the same PBD warhead as ADCT-301.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the <i>in vivo</i> efficacy of Sur301 in the CD25 negative MC38 syngeneic model, in which mice received (i) one dose of Sur301 at various dose levels, alone or in combination with three doses of an anti-PD1 antibody, or (ii) either three doses of an anti-PD1 antibody, a non-targeted ADC or a vehicle control. We observed that Sur301 exhibited strong and durable anti-tumor activity when used in monotherapy as a single dose at 0.5 mg/kg and 1 mg/kg. Furthermore, we observed that combining a low dose of Sur301 (0.1 mg/kg) with the anti-PD1 antibody resulted in anti-tumor activity was synergistic (i.e., the total effect of the combined drug is greater than the sum of the individual effects of each drug). The figures below show the mean tumor volume in the CD25 negative MC38 syngeneic model and the synergistic effect of Sur301 and the anti-PD1 antibody.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart5.jpg" alt="" style="height: 191.04px; width: 481.92px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -5.33px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The anti-tumor activity of Sur301 in the CD25 negative MC38 syngeneic model. Data represent the mean tumor volume &#177; SEM for each group of mice.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">136</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart6.jpg" alt="" style="height: 188.53px; width: 422.80px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -10.67px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The synergistic effect of Sur301 and the anti-PD1 antibody in the CD25 negative MC38 syngeneic model. Data represent the mean tumor volume &#177; SEM for each group of mice.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.60px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, the tumor-free survivors from our preclinical studies were re-challenged by being re-grafted with MC38 cancer cells. These re-grafted tumor-free survivors did not develop any tumor, suggesting that immunological memory was induced by treatment with Sur301, both alone or in combination with an anti-PD1 antibody. The figure below shows the mean tumor volume in the re-challenge of tumor-free survivors.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart7.jpg" alt="" style="height: 185.84px; width: 511.52px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -5.33px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The immunological memory induced by Sur301 in the re-challenge of tumor-free survivors. Treatments indicated represent the treatment that the tumor-free survivors received before the re-challenge. Data represent the mean tumor volume &#177; SEM for each group of mice. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.60px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Finally, we undertook a preclinical study to assess Sur301&#146;s mechanism of action by removing CD8 positive T effector cells, which generally play an important role in anti-tumor immunity. Mice were treated with a CD8-depleting antibody to remove these cells before they were treated with Sur301, alone or in combination with an anti-PD1 antibody. We observed that the anti-tumor activity of Sur301 was lost when CD8 positive T effector cells were depleted, indicating these cells play a key role in Sur301&#146;s anti-tumor activity. The figure below shows the mean tumor volume in mice treated with a CD8-depleting antibody.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><img src="nt10002526x6_linechart8.jpg" alt="" style="height: 230.92px; width: 506.92px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -13.33px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The anti-tumor activity of Sur301 depends on CD8 positive T effector cells. Data represent the mean tumor volume &#177; SEM for each group of mice.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">137</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The conclusions from our preclinical studies with Sur301 suggest that targeting CD25 positive Tregs in the tumor microenvironment with ADCT-301 may be an attractive approach to induce an effective anti-tumor response, especially when combined with checkpoint inhibitors, because:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Sur301 exhibited strong and durable anti-tumor activity in a CD25 negative solid tumor model when tested alone at 0.5 mg/kg and 1 mg/kg dose levels;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Sur301 exhibited strong synergistic effects when tested at a low dose level in combination with an anti-PD1 regimen;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Sur301&#8217;s observed anti-tumor activity was dependent on CD8 T effector cells; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Sur301 was associated with immunological memory in our re-challenge of tumor-free survivors.</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Preclinical Safety Studies</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the toxicity of ADCT-301 primarily in non-human primates and with a single-dose MTD study in mice and rats. In non-human primates, ADCT-301 was observed to be well tolerated at 0.15 mg/kg. Toxicity was characterized by dose-dependent myelosuppression, increased liver enzymes, inflammation of the gastrointestinal tract, reduced bodyweight, nephropathy and skin toxicity. In mice and rats, the MTD for ADCT-301 was 9 mg/kg and 2 mg/kg, respectively.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Phase 1b Clinical Trial in Selected Advanced Solid Tumors</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are conducting a Phase 1b, open-label, dose escalation and dose expansion clinical trial of the safety and tolerability of ADCT-301 used as monotherapy, in patients with selected advanced solid tumors, defined as those that literature evidence indicates contains CD25 positive Tregs, such as colorectal cancer, head and neck cancer, non-small cell lung cancer, gastric and esophageal cancers, pancreatic cancer, bladder cancer, renal cell carcinoma, melanoma, triple negative breast cancer and ovarian cancer. We are conducting the clinical trial at five sites in the United States and Europe, pursuant to an IND accepted by the FDA in June 2018. The first patient was dosed in January 2019. The clinical trial&#146;s design is summarized below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trial Design</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objectives of the clinical trial are to (i) evaluate the safety and tolerability of ADCT-301 in patients with selected advanced solid tumors and (ii) identify the recommended dose and dose schedule for future studies in patients with selected advanced solid tumors. The secondary objectives are to (i) evaluate the preliminary anti-tumor activity of ADCT-301, (ii) characterize the pharmacokinetic profile of ADCT-301 and (iii) evaluate the immunogenicity of ADCT-301.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory solid tumor malignancy that is locally advanced or metastatic at the time of screening and who have failed or are intolerant to existing therapies. The clinical trial is expected to enroll approximately 62 patients, with approximately 32 patients for the dose escalation stage and approximately 30 patients for the dose expansion stage.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the dose escalation stage, patients will receive intravenous infusion of ADCT-301, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose will be 20 &#181;g/kg and the highest allowed dose will be 300 &#181;g/kg. Dose escalation will be conducted using a 3+3 design with oversight by a DESC. In the dose expansion stage, patients will receive ADCT-301 at the recommended dose determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. The dose expansion stage may have two cohorts, one for an indication for which ADCT-301 was shown in the dose escalation stage to have preliminary activity and one for a basket arm with the same indications allowed in the dose escalations stage. In this clinical trial, response to treatment will be determined as CR, PR, SD or PD, based on Response Evaluation Criteria in Solid Tumors (&#147;RECIST&#148;) and immune RECIST (&#147;iRECIST&#148;).</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Interim Data</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The dose-escalation stage of the Phase 1b clinical trial is ongoing. As of August 23, 2019, 16 patients have been treated with ADCT-301: three at the 20 &#181;g/kg dose level, five at the 30 &#181;g/kg dose level, five at the 45 &#181;g/kg dose level and three at the 60 &#181;g/kg dose level. From a safety perspective, three patients reported one or more Grade &#8805;3 TEAEs, including maculopapular rash, anemia and gastrointestinal bleeding. No DLTs have been observed. Three </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">138</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">patients treated at the 20 &#181;g/kg dose level, four patients treated at the 30 &#181;g/kg dose level, three patients treated at the 45 &#181;g/kg dose level and two patients treated at the 60 &#181;g/kg dose level have been assessed for response to treatment, out of which two patients at the 20 &#181;g/kg dose level and two patients at the 30 &#181;g/kg dose level displayed stable disease and the remaining assessed patients displayed progressive disease.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADCT-601: PBD-Based ADC Targeting AXL</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT-601 is an ADC targeting AXL-expressing cancers. Currently, we are conducting a Phase 1 clinical trial of ADCT-601 for the treatment of selected advanced tumors.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Structure and Mechanism of Action</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT-601 is composed of a humanized monoclonal antibody (1H12-HAKB) directed against human AXL and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. Once bound to an AXL-expressing cell, it is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication and ultimately resulting in cell death. The figure below shows the structure of ADCT-601. ADCT-601 also features the following unique technologies:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">ADCT-601 uses Glycoconnect<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> site-specific conjugation technology, which allows for fast and stable conjugation of the warhead to the antibody.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The PBD payload of ADCT-601 contains a unique spacer, Hydraspace<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>, which we have shown to provide an additional improvement in therapeutic index in preclinical models.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_diagram10.jpg" alt="" style="height: 170.99px; width: 324.80px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -6.67px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Visual representation of ADCT-601.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">AXL plays a pivotal role in various physiological and pathological processes. We believe that AXL is an attractive target for ADCs developed to treat solid tumors the following reasons:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">AXL is highly overexpressed or ectopically expressed in a multitude of solid tumors, including in lung, breast, prostate, pancreas, glioma and esophageal cancers. Its overexpression is maintained in both primary tumors and metastasis.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">AXL expression in healthy tissues is significantly lower than that in tumor cells.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">AXL is expressed on M2 macrophages, which are part of the immunosuppressive tumor microenvironment.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Expression and activation of AXL is associated with poor clinical prognosis in many tumor indications and several studies suggest that expression of AXL is induced by both targeted and chemotherapy drugs. Therefore, AXL-based therapies may be efficacious even where traditional therapies have failed.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">AXL is prevalent in tumors resistant to anti-PD1 therapy, and pre-clinical data have shown the benefit of combining AXL-targeted therapies with immunotherapies.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The extracellular portion of AXL can be cleaved off from the membrane to generate soluble AXL (&#147;sAXL&#148;), which can be detected in serum. Recent studies suggest that sAXL can be a potential circulating biomarker in certain tumors, representing a potentially attractive biomarker for clinical use.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">139</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Preclinical Studies</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Preclinical Efficacy Studies</i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Breast Cancer</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the <i>in vivo</i> efficacy of ADCT-601 in the MDA-MB-231 xenograft model, in which mice received a single dose of (i) ADCT-601 at 1 mg/kg, (ii) a non-targeted ADC at 1 mg/kg, or (iii) a vehicle control. We observed that ADCT-601 exhibited potent and sustained anti-tumor activity, while the non-targeted ADC and the vehicle control did not exhibit any significant anti-tumor activity. The table below summarizes the response data, and the figures below show the mean tumor volume in the MDA-MB-231 xenograft model and the Kaplan-Meier plot from the MDA-MB-231 xenograft model.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="62%" rowspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2.54px; "><b>Response</b></div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2.54px; padding-right: 0px; "><b>n (%)</b></div></td>
</tr>
<tr>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2.54px; padding-right: 2.54px; "><b>ADCT-601<br> </b><b>1 mg/kg<br> </b><b>(n=10)</b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2.54px; padding-right: 2.54px; "><b>Non-Targeted ADC<br> </b><b>1 mg/kg<br> </b><b>(n=10)</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2.54px; padding-right: 0px; "><b>Vehicle Control<br> </b><b>(n=10)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.54px; ">Complete response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 &nbsp;(40.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.54px; ">Partial response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 (50.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.54px; ">Tumor-free survivor</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4 (40.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response data obtained in the MDA-MB-231 xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart9.jpg" alt="" style="height: 211.11px; width: 436.41px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: -5.33px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The anti-tumor activity of ADCT-601 in the MDA-MB-231 xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart10.jpg" alt="" style="height: 220px; width: 473.33px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The Kaplan-Meier plot of the activity of ADCT-601 in the MDA-MB-231 xenograft model. Data represent Kaplan-Meier survival curves for each group of mice.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">140</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Esophageal Cancer</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the <i>in vivo</i> efficacy of ADCT-601 in the ES0195 patient-derived xenograft model, in which mice received a single dose of (i) ADCT-601 at 1 mg/kg, (ii) a non-targeted ADC at 1 mg/kg, or (iii) a vehicle control. We observed that ADCT-601 exhibited potent and sustained anti-tumor activity, while the non-targeted ADC and the vehicle control did not exhibit any significant anti-tumor activity. The table below summarizes the response data and the figures below show the mean tumor volume in the ES0195 patient-derived xenograft model and the Kaplan-Meier plot from the ES0195 patient-derived xenograft model.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="54%" rowspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 6.54px; "><b>Response</b></div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 6.54px; padding-right: 0px; "><b>n (%)</b></div></td>
</tr>
<tr>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 6.54px; padding-right: 6.54px; "><b>ADCT-601<br> </b><b>1 mg/kg<br> </b><b>(n=8)</b></div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 6.54px; padding-right: 6.54px; "><b>Non-Targeted ADC<br> </b><b>1 mg/kg<br> </b><b>(n=8)</b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 6.54px; padding-right: 0px; "><b>Vehicle Control<br> </b><b>(n=8)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.54px; ">Complete response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 &nbsp;(25.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.54px; ">Partial response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 (62.5</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.54px; ">Tumor-free survivor</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 (25.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response data obtained in the ES0195 patient-derived xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart11.jpg" alt="" style="height: 211.11px; width: 463.87px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The anti-tumor activity of ADCT-601 in the ES0195 patient-derived xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart12.jpg" alt="" style="height: 209.21px; width: 446.83px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The Kaplan-Meier plot of the activity of ADCT-601 in the ES0195 patient-derived xenograft model. Data represent Kaplan-Meier survival curves for each group of mice. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">141</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Pancreatic Cancer</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the in vivo efficacy of ADCT-601 and that of AXL-107-MMAE, an AXL-targeted ADC similar to HuMax-AXL-ADC, which is currently in Phase 1/2 development by a third party for multiple types of solid tumors, in the PAXF1657 pancreatic cancer patient-derived xenograft model, in which mice received a single dose of (i) ADCT-601 at 0.075 mg/kg, (ii) ADCT-601 at 0.15 mg/kg, (iii) ADCT-601 at 0.3 mg/kg, (iv) AXL-107-MMAE at 0.3 mg/kg, (v) AXL-107-MMAE at 4 mg/kg, or (vi) a control vehicle. We observed that ADCT-601 exhibited dose-dependent anti-tumor activity and superior anti-tumor activity compared to AXL-107-MMAE when tested at the same low dose of 0.3 mg/kg. The table below summarizes the response data and the figures below show the mean tumor volume in the PAXF1657 xenograft model and the Kaplan-Meier plot from the PAXF1657 patient-derived xenograft model. </p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="26%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.16px; ">&#160;</div></td>
	<td colspan="18" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.16px; padding-right: 0px; "><b>n (%)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="26%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 3.16px; "><b>Response</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.16px; padding-right: 3.16px; "><b>ADCT-601<br></b><b>0.075 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.16px; padding-right: 3.16px; "><b>ADCT-601</b><br><b>0.15 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.16px; padding-right: 3.16px; "><b>ADCT-601</b><br><b>0.3 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.16px; padding-right: 3.16px; "><b>AXL-107-MMAE</b><br><b>0.3 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.16px; padding-right: 3.16px; "><b>AXL-107-MMAE</b><br><b>4 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.16px; padding-right: 0px; "><b>Vehicle Control</b><br><b>&nbsp;&nbsp;&nbsp;<br></b><b>(n=8)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="26%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.16px; ">Complete response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 &nbsp;(37.5</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 &nbsp;(100.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="26%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.16px; ">Partial response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1 (12.5</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="26%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.16px; ">Tumor-free survivor</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (37.5</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="12%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8 (100.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response data obtained in the PAXF1657 patient-derived xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart13.jpg" alt="" style="height: 188.39px; width: 470.49px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The anti-tumor activity of ADCT-601 in the PAXF1657 patient-derived xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart14.jpg" alt="" style="height: 209.21px; width: 443.99px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The Kaplan-Meier plot of the activity of ADCT-601 in the PAXF1657 patient-derived xenograft model. Data represent Kaplan-Meier survival curves for each group of mice.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">142</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Preclinical Safety Studies</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the toxicity of ADCT-601 primarily in non-human primates and with a single-dose MTD study in rats. In non-human primates, toxicity was observed in the immune system, bone marrow, kidney, mammary glands (females only), reproductive tract and skin. Most microscopic findings were not reversible after a six-week recovery phase, except for the morphologic effect on the hematopoietic system in the bone marrow in both sexes, and the immune system (spleen, thymus and gut-associated lymphoid tissue) in males. In rats, the MTD for ADCT-601 was 6 mg/kg.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Phase 1 Clinical Trial in Selected Advanced Solid Tumors</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are conducting a Phase 1, open-label, dose escalation and dose expansion clinical trial of the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601, used as monotherapy, in patients with selected advanced solid or metastatic tumors, including triple-negative breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and soft tissue sarcoma. We are conducting the clinical trial at four sites in the United States and Europe, pursuant to an IND accepted by the FDA in December 2018. The first patient was dosed in January 2019. The clinical trial&#146;s design is summarized below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clincial Trial Design</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objectives of the clinical trial are to (i) evaluate the safety and tolerability of ADCT-601 in patients with selected advanced solid tumors and (ii) identify the recommended dose and dose schedule for future studies in patients with selected advanced solid tumors. The secondary objectives are to (i) evaluate the preliminary anti-tumor activity of ADCT-601, (ii) characterize the pharmacokinetic profile of ADCT-601 and (iii) evaluate the immunogenicity of ADCT-601.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory solid tumor malignancy that is locally advanced or metastatic at the time of screening and who have failed or are intolerant to existing therapies. The clinical trial is expected to enroll approximately 75 patients, with approximately 30 patients for the dose escalation stage and approximately 45 patients for the dose expansion stage.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the dose escalation stage, patients will receive intravenous infusion of ADCT-601, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose will be 50 &#181;g/kg and the highest allowed dose will be 600 &#181;g/kg. Dose escalation will be conducted using a 3+3 design with oversight by a DESC. In the dose expansion stage, patients will receive ADCT-601 at the recommended dose determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. The dose expansion stage may have up to three cohorts, one for each of three indications for which ADCT-601 was shown in the dose escalation stage to have preliminary activity. In this clinical trial, response to treatment will be determined as CR, PR, SD or PD, based on RECIST and iRECIST.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Interim Data</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The dose-escalation stage of the Phase 1 clinical trial is ongoing. As of August 3, 2019, 15 patients have been treated with ADCT-601: three at the 50 &#181;g/kg dose level, six at the 100 &#181;g/kg dose level and six at the 150 &#181;g/kg dose level. From a safety perspective, eight out of the 15 patients experienced one or more Grade &#8805;3 TEAEs, including pain, abdominal pain, hematuria, gamma-glutamyltransferase increased and anemia. One DLT of Grade 3 hematuria has been observed. Three patients treated at the 50 &#181;g/kg dose level, six patients treated at the 100 &#181;g/kg dose level and one patient treated at the 150 &#181;g/kg dose level have been assessed for response to treatment, out of which one patient achieved a partial response at the 50 &#181;g/kg dose level, four patients displayed stable disease at the 100 &#181;g/kg dose level, one patient displayed stable disease at the 150 &#181;g/kg dose level and the remaining assessed patients displayed progressive disease.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Preclinical Solid Tumor Product Candidates</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>ADCT-701: PBD-Based ADC Targeting DLK-1</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT-701 is an ADC targeting DLK-1-expressing cancers. We are developing ADCT-701 for the treatment of advanced solid tumors with high unmet medical needs, including hepatocellular carcinoma, neuroblastoma and small cell lung cancer (&#147;SCLC&#148;). ADCT-701 is composed of a humanized monoclonal antibody (HuBa-1-3D) </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">143</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">directed against human DLK-1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. DLK-1 is widely expressed during fetal development, but its expression is highly restricted in adults. However, DKL-1 is expressed in adults in several tumors, such as neuroblastoma, hepatocellular carcinoma (&#147;HCC&#148;), SCLC and acute myeloid leukemia. We believe that DLK-1 is an attractive target for ADC development as (i) DLK-1 is selectively expressed in a wide range of malignancies but is restrictively expressed in healthy organs, (ii) DLK-1 in HCC cells manifest cancer stem cell-like properties, such as chemo-resistance, self-renewal ability and xenograft tumorigenesis, indicating DLK-1&#146;s potential to be a prognostic biomarker in HCC, and (iii) DLK-1 knockdown has been observed to suppress <i>in vivo</i> tumor growth and delay cell cycle progression. Currently, we are conducting preclinical development of ADCT-701 and expect to submit an IND in the fourth quarter of 2020.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the <i>in vivo</i> efficacy of ADCT-701 in the LI1097 patient-derived hepatocellular carcinoma xenograft model, in which mice received a single dose of (i) ADCT-701 at 0.1 mg/kg, (ii) ADCT-701 at 0.3 mg/kg, (iii) ADCT-701 at 1 mg/kg, (iv) a non-targeted ADC at 1 mg/kg, or (v) a vehicle control. We observed that ADCT-701 exhibited potent, specific and dose-dependent anti-tumor activity, while the non-targeted ADC and the vehicle control did not exhibit any significant anti-tumor activity. The table below summarizes the response data and the figure below shows the mean tumor volume in the LI1097 patient-derived xenograft model.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.85px; ">&#160;</div></td>
	<td colspan="15" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.85px; padding-right: 0px; "><b>n (%)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 3.85px; "><b>Response</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.85px; padding-right: 3.85px; "><b>ADCT-701</b><br><b>0.1 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.85px; padding-right: 3.85px; "><b>ADCT-701</b><br><b>0.3 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.85px; padding-right: 3.85px; "><b>ADCT-701</b><br><b>1 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.85px; padding-right: 3.85px; "><b>Non-Targeted ADC</b><br><b>1 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.85px; padding-right: 0px; "><b>Vehicle Control<br></b><b>&nbsp;&nbsp;&nbsp;<br></b><b>(n=8)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.85px; ">Complete response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 &nbsp;(37.5</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.85px; ">Partial response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3 (62.5</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="38%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.85px; ">Tumor-free survivor</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response data obtained in the LI1097 patient-derived xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart16.jpg" alt="" style="height: 259.31px; width: 278.08px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The anti-tumor activity of ADCT-701 in the LI1097 patient-derived xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">144</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>ADCT-901: PBD-Based ADC Targeting KAAG1</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT-901 is an ADC targeting KAAG1-expressing cancers. We are developing ADCT-901 for the treatment of advanced solid tumors with high unmet medical needs, including platinum resistant ovarian cancer and triple negative breast cancer. ADCT-901 is composed of a humanized monoclonal antibody (3A4) directed against human KAAG1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. KAAG1 is a novel tumor-associated antigen expressed in a high percentage of ovarian tumors and triple negative breast cancer, with restricted expression in healthy cells. We believe that KAAG1 is an attractive target for ADC development as (i) it is an intracellular target by definition, but becomes exposed on the membrane of tumor cells, (ii) it has high expression in tumors with high unmet medical need, including ovarian cancer and triple negative breast cancer, while its expression on healthy tissue is very restricted and (iii) it internalizes and co-localizes with lysosomal-associated membrane protein 1, a lysosomal marker, which shows that the target is efficiently transported to the cellular compartment where efficient release of the cytotoxin is expected. Currently, we are conducting preclinical development of ADCT-901 and expect to submit an IND in the second quarter of 2020.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We evaluated the <i>in vivo</i> efficacy of ADCT-901 in the CTG-0703 patient-derived ovarian cancer xenograft model, in which mice received a single dose of (i) ADCT-901 at 1 mg/kg, (ii) a non-targeted ADC at 1 mg/kg, or (iii) a vehicle control. We observed that ADCT-901 exhibited potent and specific anti-tumor activity, while the non-targeted ADC and the vehicle control did not exhibit any significant anti-tumor activity. The table below summarizes the response data and the figure below shows the mean tumor volume in the CTG-0703 patient-derived xenograft model.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.72px; ">&#160;</div></td>
	<td colspan="9" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.72px; padding-right: 0px; "><b>n (%)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.72px; "><b>Response</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.72px; padding-right: 4.71px; "><b>ADCT-901</b><br><b>1 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.71px; padding-right: 4.71px; "><b>Non-Targeted ADC</b><br><b>1 mg/kg</b><br><b>(n=8)</b></div></td>
	<td colspan="3" width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.71px; padding-right: 0px; "><b>Vehicle Control<br></b><b>&nbsp;&nbsp;&nbsp;<br></b><b>(n=8)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.72px; ">Complete response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 &nbsp;(0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.72px; ">Partial response</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7 &nbsp;(87.5</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.72px; ">Tumor-free survivor</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0 (0.0</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Response data obtained in the CTG-0703 patient-derived xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><img src="nt10002526x6_linechart15.jpg" alt="" style="height: 241.63px; width: 267.87px; scale: ">&#8201;<br></p>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">The anti-tumor activity of ADCT-901 in the CTG-0703 patient-derived xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">145</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Our Research Pipeline</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to our product candidates described above, we have selected five additional ADC targets (one hematological and four solid tumor targets) and ten XDC targets (four hematological and six solid tumor targets) for which we are conducting preclinical research, with the aim of selecting clinical candidates for further development. For the XDC product candidates, we are exploring different non-antibody protein scaffolds as well as peptides for tumor targeting.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are also testing complementary technologies to expand the therapeutic index of our product candidates. For example, we are investigating novel conjugation and linker technologies to maximize the benefits of the PBD dimer technology. As an example, we benchmarked multiple site-specific conjugation technologies and identified GlycoConnect<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>/Hydraspace technology (licensed from Synaffix) to provide the enhanced therapeutic index for ADCT-601 and ADCT-701 that we observed in preclinical models. We continue to explore alternative conjugation and linker strategies as they become available and determine whether there is any merit in utilizing them in product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Moreover, we are exploring the development of ADCs that use tumor-conditional binding approaches, such as antibody masking, which depends on the unique proteolytic environment in the tumor. These tumor-specific proteases can be used to remove masking peptides engineered on a masked antibody. Such masked antibodies will not bind to healthy tissue expressing the target and will not bind to soluble target shed into circulation (as there is no expression of the tumor specific proteases and the mask prevents binding to target). However, once in the tumor microenvironment, tumor-specific proteases release the masking peptide from the antibody and it will bind to the target on the tumor cell membrane, allowing internalization of the ADC into the tumor. Another tumor conditional binding approach relies on the pH difference between tumor (more acidic) and healthy tissue (neutral pH), as it is possible to raise and select antibodies that only bind to their antigen at acidic pH, while there is little to no binding at neutral pH. Hence, we believe that ADCs developed using such antibodies will only bind to target expressed in the tumor and leave healthy tissue unaffected.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Chemistry, Manufacturing and Controls</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We believe that the manufacture of ADCs requires considerable expertise, know-how and resources. Since our inception, we have made significant financial and human resource investments to become a leader in the industry for ADC chemistry, manufacture and control processes. Currently, we have a 29 person, in-house team, based in the San Francisco Bay Area, overseeing our CMC operations for each of our product candidates.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not own or operate, and do not plan to own or operate, manufacturing infrastructure for the manufacture of clinical or commercial supply of our product candidates. Instead, we contract with third party cGMP-compliant CMOs that have the facilities and capabilities to manufacture on our behalf the intermediate components and the final product candidates for use in clinical trials and future commercial supply. Our in-house team oversees all aspects of the CMO manufacturing process, including defining the scope of work and monitoring all aspects of the manufacturing process to ensure that they meet our specifications and quality requirements, including conducting routine site visits and audits. We also contract with external specialist quality control and stability-testing organizations to monitor the quality of the materials manufactured by the CMOs.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Recently, we have commenced implementation of the commercial supply chain to meet the requirements for potential accelerated approvals of BLAs for ADCT-402 and ADCT-301. For ADCT-402, we are in the late stages of validating the commercial supply chain. For ADCT-301, we have contracted to initiate the validation of the commercial supply chain in early 2020.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>License and Collaboration Agreements</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>MedImmune License and Collaboration Agreement</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2011, we (then operating under the name ADCT S&#224;rl) entered into a license and collaboration agreement with Spirogen (since renamed ADC Products UK Ltd.), pursuant to which Spirogen granted us access to its next-generation PBD-based warhead and linker technology. In connection with AstraZeneca plc&#146;s acquisition of Spirogen S&#224;rl (which was at the time the direct parent company of Spirogen) and the transfer of certain of Spirogen&#146;s intellectual property to Spirogen S&#224;rl, including its PBD-based warhead and linker technology, the agreement was subsequently amended and restated in October 2013 (with retroactive effect to September 2011), with Spirogen S&#224;rl also becoming a party to such agreement. Spirogen S&#224;rl subsequently transferred the PBD </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">146</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">technology to MedImmune Limited, which, together with MedImmune LLC, is the global biologics research and development arm of AstraZeneca plc. Thereafter, Spirogen S&#224;rl transferred its rights and obligations under the agreement to MedImmune and the agreement was subsequently amended and restated again in May 2016 (with retroactive effect to September 2011), with MedImmune replacing Spirogen S&#224;rl as the licensor thereunder.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the agreement, MedImmune has granted us an exclusive, worldwide license under certain patent rights and related know-how to make, have made, use, sell, offer for sale and import product candidates in the field of human therapeutics and diagnostics that consist of (i) PBD-based molecules directly conjugated to an antibody (i.e., ADCs with a PBD-based warhead) that specifically bind to up to 11 approved targets (&#147;ADC Targets&#148;), and (ii) PBD-based molecules conjugated to a non-antibody (i.e., targeting-moiety conjugates with a PBD-based warhead) that specifically bind to up to ten approved targets (&#147;XDC Targets&#148;). As of the date hereof, there are 11 approved ADC Targets subject to the license, including CD19 (the target of ADCT-402) and CD25 (the target of ADCT-301), and ten approved XDC Targets subject to the license.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the agreement, we have the right to grant sublicenses to affiliates and, subject to MedImmune&#146;s approval (not to be unreasonably withheld), third parties. In addition, with respect to each licensed target, we have agreed to use commercially reasonable efforts to develop and commercialize at least one product and submit an IND application with the FDA (or its equivalent in another jurisdiction) for one product within 48 months after formal designation of the target as an approved replacement target, which we have done with respect to CD19 and CD25 upon submitting the IND applications for ADCT-402 and ADCT-301, respectively.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As consideration for the rights granted to us under the agreement, in 2011 we paid Spirogen an up-front licensing fee of $2.5 million. No further payments in consideration for the grant of such rights are required to be paid to Spirogen or MedImmune under the agreement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">With respect to patents conceived during the course of our exercise of our rights under the agreement, rights are allocated as follows under the agreement: (i) we own any such patent that claims an antibody that binds to one of the ADC Targets approved under the agreement, (ii) we and MedImmune jointly own any such patent claiming any PBD-based ADC, with us owning the exclusive right to exploit such patent during the term of the agreement and (iii) MedImmune owns any such patent that claims a PBD or any PBD attached to an antibody that does not bind to one of the ADC Targets approved under the agreement. In addition, we have the right to prosecute and maintain all patents described in clauses (i) and (ii) above and are responsible for the costs of prosecuting and maintaining such patents. The ownership of any patents conceived during our exercise of our rights under the agreement in connection with non-ADC Targets will be determined under U.S. patent law.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless earlier terminated, the agreement terminates on the date of expiration of the last to expire licensed patent right that covers a product being exploited under the license. The agreement (including the licenses granted thereunder) will terminate upon our material breach of any provision of the agreement that is not cured within an applicable cure period.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Genmab Collaboration and License Agreement</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In June 2013, we entered into a collaboration and license agreement with Genmab to collaborate on the development of ADCT-301, which uses Genmab&#146;s HuMax&#174;-TAC antibody that targets CD25.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the agreement, Genmab has granted us an exclusive, worldwide license or sublicense, as applicable, to certain patents covering, and know-how relating to, the HuMax&#174;-TAC antibody to make, develop, use, sell, offer for sale and import ADCT-301 for the treatment of conditions and diseases in humans.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We were not required to pay any up-front licensing fees, and are not required to pay any ongoing royalty fees or milestone or other payments, to Genmab under the agreement. Rather, under the terms of the agreement, each party initially had a 50% interest in ADCT-301 and, subject to the oversight of the joint steering committee established thereunder, we were responsible for the execution of the preclinical work plan, together with technical support from Genmab. Upon the joint steering committee&#146;s approval of the proposed IND application and clinical work plan for ADCT-301 in March 2015, Genmab exercised its option under the agreement to retain a 25% interest in ADCT-301 rather than pay us a specified fee necessary to retain its 50% interest. As a result of such exercise, we are the sole developing party, have the casting vote on the joint steering committee and have assumed all costs for the future development of ADCT-301 until the completion of a Phase 1/2 clinical trial based upon an agreed clinical plan framework. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">147</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may choose to discontinue our funding obligations under the agreement at any time upon prior written notice to Genmab. In such case, Genmab may choose to take over the development of ADCT-301 in return for increasing its interest in ADCT-301 from 25% to 75%, with us retaining a 25% interest and the licenses and sublicenses granted to us under the agreement terminating. If Genmab does not choose to take over the development of ADCT-301, the divestment process referred to below will be initiated immediately, unless the parties mutually agree to terminate the agreement. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Following database lock for the Phase 1/2 clinical trial, the agreement sets out a defined process to facilitate the divestment of ADCT-301 by licensing the rights thereto to us, Genmab or a third party, subject to Genmab&#146;s right of first opportunity to negotiate to acquire ADCT-301 in full. This process includes the opportunity for both parties to bid for the license rights alongside third parties. Both parties are required to use commercially reasonable efforts to complete and maximize the value obtained in this process.If Genmab does not exercise its right of first opportunity and the divestment process is not successfully completed (or some other arrangement is not made) within a specified period of time, the agreement will be terminated. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the agreement, all patents directed to ADCT-301 that arose from the activities under the preclinical or clinical work plan (irrespective of the identity of the inventors) are our sole property, and we are responsible for the costs of prosecuting and maintaining such patents. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Unless earlier terminated (including, as described above), the agreement will expire upon the earlier of (i) following database lock for the Phase 1/2 clinical trial, upon (x) the execution of an agreement between Genmab and us documenting Genmab&#146;s exercise of its option to acquire our share of ADCT-301 in full or (y) the consummation of the divestment of ADCT-301 by licensing the rights thereto to a third party (or to either us or Genmab) and (ii) the expiration of the last valid patent claim included in any of the intellectual property claiming ADCT-301 (whether licensed by Genmab to us or by us to Genmab) that would preclude a third party from developing, making, using, selling and importing ADCT-301 in any country. Either party may terminate the agreement upon breach by the other party of any material provision of the agreement that is not cured within an applicable cure period. Either party may terminate the agreement upon written notice thereof upon the occurrence of certain insolvency events with respect to the other party.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon termination of the agreement, the licenses and sublicenses granted thereunder will terminate and we will be required to grant to Genmab a non-exclusive, worldwide, fully paid-up license to any claims in any new patents in any jurisdiction (irrespective of the identity of the inventors) arising from the activities under the preclinical work plan or clinical work plan to the extent that such claims are directed to ADCT-301 (or other antibody drug conjugates making use of Genmab&#146;s CD25 antibody). Any proceeds from such patents will be shared between the parties as set forth in the agreement.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Synaffix Commercial License Agreement</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In October 2016, we entered into a commercial license agreement with Synaffix, under which we obtained a non-exclusive, royalty-bearing, sublicensable, worldwide license under certain patent rights and related know-how owned by Synaffix relating to site-specific conjugation technology to research, develop, manufacture, use, sell, import, distribute, commercialize and market antibody-drug conjugates for human therapeutic use that bind to three selected targets, including ADCT-601 and ADCT-701.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In consideration for the rights granted under the agreement, we paid an upfront fee and two additional six-figure fees upon our selection of licensed products binding specific targets, and are required to pay a one-time fee upon the acceptance of a BLA (or foreign equivalent) for a licensed product, payments in the high eight figures upon the achievement of certain milestones (of which we have already paid a high six-figure amount) and tiered royalties in the low single-digit percentages on net sales of licensed products.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The agreement remains in effect on a country-by-country and licensed product-by-licensed product basis until the expiration of the last-to-expire valid claim in a patent licensed under the agreement covering such product in such country. Upon the expiration of the agreement for each licensed product in each country, the licenses granted to us for such product in such country will become fully paid-up and perpetual. We may terminate the agreement in its entirety or on a licensed product-by-licensed product basis at any time. Either party may terminate the agreement, subject to a specified notice and cure period, for a breach by the other party of a material provision of the agreement or upon an insolvency-related event experienced by the other party.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">148</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Bergenbio License Agreement</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In July 2014, we entered into a license agreement with Bergenbio AS (&#147;Bergenbio&#148;) under which we obtained an exclusive, royalty-bearing, sublicensable (subject to certain restrictions), worldwide license in certain patent rights and related know-how owned by Bergenbio relating to certain AXL-targeting antibodies used in ADCT-601 to conduct research, develop, make, use, sell, offer for sale, import and otherwise commercialize products for the treatment and/or prevention of diseases in humans (with an exception for certain types of products), as well as a similar non-exclusive license relating to companion diagnostics for such licensed products.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In consideration for the rights granted under the agreement we paid an upfront fee, and we also paid a one-time low six-figure fee upon the filing of an IND application for ADCT-601 in 2018. Additionally, we are required to make payments in the low eight figures per licensed product upon the achievement of certain milestones, an additional one-time low eight-figure payment upon the achievement of a specified commercialization milestone, and tiered royalties in the mid-single digit percentages on net sales of licensed products.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The agreement remains in effect on a country-by-country and licensed product-by-licensed product basis until the latest of (i) the expiration of the last-to-expire valid claim in a patent covering such product licensed under the agreement in such country, (ii) the expiration of any other exclusivity protection of such licensed product in such country and (iii) the ten-year anniversary of the first commercial sale of such licensed product in such country. Upon the expiration of the agreement for each licensed product in each country, the licenses granted to us for such product in such country will become fully paid-up and irrevocable. We may terminate the agreement at any time effective immediately upon providing written notice to Bergenbio. Either party may terminate the agreement, subject to specified notice and cure periods, for a material breach by the other party of the agreement or upon an insolvency-related event experienced by the other party. Bergenbio may terminate the agreement, subject to a specified notice and cure period, if we fail to undertake any reasonable steps in the development and/or commercialization of at least one licensed product for a period of more than six consecutive months.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Intellectual Property</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our success depends in part on our ability to obtain and maintain proprietary protection for our technology, programs and know-how related to our business, defend and enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual property rights of others. We seek to protect our proprietary position by, among other things, exclusively licensing and filing U.S. and foreign patent applications related to our technology, existing and planned programs and improvements that are important to the development of our business, where patent protection is available. We also rely on trade secrets, know-how, continuing technological innovation and confidential information to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Notwithstanding these efforts, we cannot be sure that patents will be granted with respect to any patent applications we have licensed or filed or may license or file in the future, and we cannot be sure that any patents we have licensed or patents that may be licensed or granted to us in the future will not be challenged, invalidated, or circumvented or that such patents will be commercially useful in protecting our technology. Moreover, trade secrets can be difficult to protect. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, we or our licensors may be subject to claims that former employees, collaborators, or other third parties have an interest in our owned or in-licensed patents or other intellectual property as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third party co-owners&#146; interest in such patent applications, such co-owners may be able to license their rights to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents that issue </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">149</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">from such patent applications against third parties, and such cooperation may not be provided to us. For more information regarding the risks related to intellectual property, please see &#147;Risk Factors&#8212;Risks Related to Intellectual Property.&#148;</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Patent Portfolio</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.60px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The term of individual utility patents depends upon the countries in which they are granted. In most countries, including the United States, the utility patent term is generally 20 years from the earliest claimed filing date of a non-provisional utility patent application in the applicable country. United States provisional utility patent applications are not eligible to become issued patents until, among other things, non-provisional patent applications are filed within 12 months of the filing date of the applicable provisional patent applications and the failure to file such non-provisional patent applications within such timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. In the United States, a patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent having an earlier expiration date. In certain circumstances, U.S. patents can also be eligible for patent term extension; for more information, see &#147;&#8212;Government Regulation&#8212;Regulatory Approval in the United States&#8212;U.S. Patent Term Restoration and Marketing Exclusivity.&#148; The expiration dates referred to below are without regard to potential patent term adjustment or extension that may be available to us.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.60px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In general, our licensed, owned or co-owned patents relate to our ADC products, the underlying antibodies, the PBD-based warhead, the linker used to connect such PBD warheads to the antibodies to form an ADC, modifications of the antibodies to enhance efficacy, and the methods to formulate, co-formulate, use and administer or co-administer such ADCs.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>&#147;PBD Warhead,&#148; &#147;PBD Warhead with Linker&#148; and Linker Patent Protection</i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.60px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of August 31, 2019, with respect to the PBD-based warhead and ADC technology we use to develop our product candidates, we have exclusively licensed from MedImmune 16 patent families directed to different aspects of the chemistry of the PBD molecules and methods of using the molecules in the treatment of proliferative diseases. These families include approximately 17 issued U.S. utility patents, 16 granted European patents, 12 granted Japanese patents, six granted Chinese patents, and 57 granted utility patents in other jurisdictions, along with 16 pending utility patent applications in non-U.S. jurisdictions. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2021 and 2033.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.60px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of August 31, 2019, with respect to the &#147;PBD warhead with linker&#148; or linker technology we use to develop our product candidates, we have exclusively licensed from MedImmune 23 patent families directed to different aspects of the chemistry of the &#147;PBD with linker&#148; or linker molecules. Some of these patent families offer generic protection to the ADCs as well. These families include approximately 18 issued U.S. utility patents, 17 granted European patents, 20 granted Japanese patents, eight granted Chinese patents and 99 granted utility patents in other jurisdictions, along with 10 pending U.S. non-provisional utility patent applications and 126 pending utility patent applications in other jurisdictions. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2031 and 2038. The issued utility patents, and any utility patents granted from applications, more specifically directed to the &#147;PBD warhead with linker&#148; or linker present in ADCT-301, ADCT-402 and ADCT-602 are expected to expire between 2031 and 2033. Any utility patents granted from applications more specifically directed to the &#147;PBD warhead with linker&#148; or linker present in ADCT-601 are expected to expire in 2038.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For more information on the license and collaboration agreement with MedImmune, see &#147;&#8212;License and Collaboration Agreements&#8212;MedImmune License and Collaboration Agreement.&#148;</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Antibody and Product-Specific Patent Protection</i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 10.67px; margin-bottom: 0px; "><i>ADCT-402</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The antibody for ADCT-402 is in the public domain.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Patents more specifically directed to the ADCT-402 ADC are co-owned by us and MedImmune, with us having the exclusive right to exploit the relevant patents during the term of our license and collaboration agreement with MedImmune. As of August 31, 2019, there are seven such patent families directed to the ADC </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">150</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">product, methods of using the ADC as a single agent or in combination with other named molecules in the treatment of proliferative diseases, and dosing regimens. The family having issued claims directed to the ADCT-402 composition includes one issued U.S. utility patent, one granted utility patent in each of Europe, Japan and China and one pending U.S. non-provisional utility patent application, along with five granted utility patents and three pending utility patent applications in other jurisdictions. The other families include three pending U.S. provisional utility patent applications and nine pending utility patent applications in other jurisdictions (including three Patent Cooperation Treaty (&#147;PCT&#148;) applications). These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2033 and 2039.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>ADCT-301</i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of August 31, 2019, with respect to the antibody for ADCT-301, we exclusively license an antibody utility patent family from Genmab that includes approximately four issued U.S. utility patents, one pending U.S. non-provisional utility patent application and 14 granted patents in foreign jurisdictions. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2023 and 2024. For more information on the collaboration and license agreement with Genmab, see &#147;&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#148;</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The patents more specifically directed to the ADCT-301 ADC are co-owned by us and MedImmune, with us having the exclusive right to exploit the relevant patents during the term of our license and collaboration agreement with MedImmune. As of August 31, 2019, there are 12 such patent families directed to the ADC product, methods of using the ADC as a single agent or in combination with other named molecules in the treatment of proliferative diseases, and dosing regimens. The family having issued claims directed to the ADCT-301 composition includes one issued U.S. utility patent, one granted utility patent in each of Europe, Japan, and China, and four granted utility patents and four pending utility patent applications in other jurisdictions. The other families include three pending U.S. non-provisional utility patent applications, three pending European utility patent applications, one pending utility patent application in each of Japan and China, and 19 pending utility patent applications in other jurisdictions (including four PCT applications). These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2033 and 2039. </p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>ADCT-602</i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of August 31, 2019, we and MedImmune co-own three patent families relating specifically to the ADCT-602 ADC, along with methods of using the ADC as a single agent or in combination with other named molecules in the treatment of proliferative diseases; we have the exclusive right to exploit the relevant patents during the term of our license and collaboration agreement with MedImmune. The family having issued claims directed to the ADCT-602 composition includes one issued U.S. utility patent and one granted utility patent in each of Europe, Japan and China, along with five granted utility patents and four pending utility patent applications in other jurisdictions. The other families include one pending U.S. non-provisional utility patent application, one pending utility patent application in each of Europe, Japan, and China, and 13 pending utility patent applications in other jurisdictions (including one PCT application). These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2033 and 2038. We also exclusively license one patent family from MedImmune relating to the ADCT-602 ADC. This family includes one pending U.S. non-provisional utility patent application and one pending utility patent application in each of Europe, Japan, China, and India. Any utility patents granted from such applications are expected to expire in 2036.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>ADCT-601</i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of August 31, 2019, we and MedImmune co-own two patent families relating specifically to the ADCT-601 ADC, along with methods of using the ADC as a single agent or in combination with other named molecules in the treatment of proliferative diseases; we have the exclusive right to exploit the relevant patents during the term of our license and collaboration agreement with MedImmune. The family directed to the ADCT-601 ADC contains one pending U.S. non-provisional utility patent application, one pending utility patent application in each of Europe, Japan and China, and eight pending utility patent applications in other jurisdictions, and the family directed to methods of use contains one pending U.S. non-provisional utility patent application and five pending utility patent applications in other jurisdictions (including one PCT application). Any utility patents granted from such applications are expected to expire in 2038. </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">151</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Additionally, we license several patent families relating to ADCT-601. As of August 31, 2019, this includes two patent families exclusively licensed from Bergenbio relating to the ADCT-601 antibody moiety as a product. These families include one issued U.S. utility patent, one allowed European utility patent, one pending U.S. non-provisional utility patent application, and one pending utility patent application in each of Europe, Japan and China, along with four pending utility patent applications in other jurisdictions. The issued utility patent, and any utility patents granted from such applications, are expected to expire between 2035 and 2036. We also non-exclusively license patent families from Synaffix relating to processes for producing ADCs with the ADCT-601 linker technology and linker synthesis intermediates. These families include six issued U.S. utility patents, five granted European utility patents, one granted Japanese utility patent, two granted Chinese utility patents and two granted Indian utility patents, along with three pending U.S. non-provisional utility patent application, two pending European utility patent application, four pending Japanese utility patent applications and four pending Chinese utility patent applications. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2031 and 2037. Additionally, we exclusively license one patent family from MedImmune relating to the ADCT-601 ADC that contains one pending PCT application, which is being entered into the national phase in the United States, Europe, Japan, China and India. Any utility patents granted from these applications are expected to expire in 2038. For more information on the license agreements with Synaffix and Bergenbio, see &#147;&#8212;License and Collaboration Agreements&#8212;Synaffix Commercial License Agreement&#148; and &#147;&#8212;License and Collaboration Agreements&#8212;Bergenbio License Agreement.&#148;</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Competition</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The biotechnology industry, and the oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. While we believe that our technology, intellectual property, know-how, scientific expertise and leadership team provide us with certain competitive advantages, we face potential competition from many sources, including major pharmaceutical and biotechnology companies, academic institutions and public and private research organizations. Many competitors and potential competitors have substantially greater scientific, research and product development capabilities, as well as greater financial, marketing and human resources than we do.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Many companies are active in the oncology market and are developing or marketing products for the specific therapeutic markets that we target, including both antibody and non-antibody-based therapies. Similarly, we also face competition from other companies and institutions that continue to invest in innovation in the ADC field including new payload classes, new conjugation approaches and new targeting moieties. Specifically, we are aware of multiple companies with ADC technologies that may be competitive to our product candidates, including, but not limited to, AbbVie, Inc., Astellas Pharma Inc., AstraZeneca plc, BioAtla, LLC, Bristol-Myers Squibb Company, CytomX Therapeutics, Daiichi Sankyo Company, Eli Lilly and Company, Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Immunomedics, Inc., Mersana Therapeutics Inc., Millennium Pharmaceuticals, Inc., MorphoSys AG, Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Seattle Genetics, Inc., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Ltd and Wyeth Pharmaceuticals, Inc. Currently, there are five approved ADCs: (i) brentuximab vedotin (Adcetris&#174;), marketed by Seattle Genetics, Inc. and Takeda Pharmaceutical Company Ltd, (ii) ado-trastuzumab emtansine (Kadcyla&#174;), marketed by Genentech, Inc., (iii) inotuzumab ozogamicin (Besponsa&#174;), marketed by Pfizer Inc., (iv) gemtuzumab ozogamicin (Mylotarg&#174;), also marketed by Pfizer Inc. and (v) polatuzumab vedotin (Polivy&#174;), marketed by Genentech, Inc. In addition, as of 2018, there are approximately 175 ADCs in development, the vast majority of which are being developed for the treatment of cancer.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the relapsed or refractory DLBCL setting, for which we are developing ADCT-402, current third-line treatment options include CAR-T, allogeneic stem cell transplant and chemotherapy using small molecules. Recently, Polivy&#174; was approved for third-line use in combination with bendamustine and a rituximab product. In addition, we expect new competitors, including MOR208 and bispecific antibodies, to enter the market as treatment options for such patients. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the relapsed or refractory HL setting, for which we are developing ADCT-301, current third-line treatment options include chemotherapy, immunotherapy and Adcetris&#174;. In addition, we expect changes to the treatment paradigm, such as the movement of Adcetris&#174; to earlier lines of therapy and the potential expanded use of checkpoint inhibitors, and new entrants such as bispecific antibodies.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any product candidates that we successfully develop and commercialize may compete directly with approved therapies and any new therapies that may be approved in the future. Competition will be based on their </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">152</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">safety and effectiveness, the timing and scope of marketing approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price levels and discounts offered, patent position and other factors. Our competitors may succeed in developing competing products before we do, obtaining marketing approval for products and gaining acceptance for such products in the same markets that we are targeting.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Government Regulation</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, such as our investigational medicines and any future investigational medicines. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Regulatory Approval in the United States</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDCA, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the FDCA that governs the approval of new drug applications (&#147;NDAs&#148;). Biological products, such as our ADC product candidates, are approved for marketing under provisions of the Public Health Service Act (the &#147;PHSA&#148;), via a BLA. However, the application process and requirements for approval of BLAs are very similar to those for NDAs, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our investigational medicines and any future investigational medicines must be approved by the FDA pursuant to a BLA before they may be legally marketed in the United States. The process generally involves the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including studies conducted in accordance with GLP requirements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">approval by an IRB or independent ethics committee at each clinical trial site before each clinical trial may be commenced;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">submission to the FDA of a BLA;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, strength, quality and purity;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the BLA to assure compliance with GCPs and integrity of the clinical data;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">payment of any user fees for FDA review of the BLA;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">153</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">compliance with any post-approval requirements, including REMS, where applicable, and post-approval studies required by the FDA as a condition of approval.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Preclinical Studies</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as <i>in vitro </i>and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trials</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, clinical trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">154</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the product candidate, and, if possible, early evidence of effectiveness. Phase 1 clinical trials may be designated as Phase 1a, which may involve dose escalation to determine the maximum tolerated dose, or Phase 1b, which may involve dose expansion at one or more dose levels to determine the recommended dose level for Phase 2 clinical trials.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product, and provide an adequate basis for product labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These Phases may overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose-expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional Phase 1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in selected subpopulation(s).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are disease-affected patients and, as a result, considerably more information on clinical activity may be collectedduring such trials than during Phase 1 clinical trials for non-oncology therapies. A single Phase 3 or Phase 2 trial with other confirmatory evidence may be sufficient in rare instances to provide substantial evidence of effectiveness (generally subject to the requirement of additional post-approval studies).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including noncompliance with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency, and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>FDA Review Process</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Following completion of the clinical trials, the results of preclinical studies and clinical trials are submitted to the FDA as part of a BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic or drug may be marketed in the United States.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The cost of preparing and submitting a BLA is substantial. Under the Prescription Drug User Fee Act, as amended (the &#147;PDUFA&#148;), each BLA must be accompanied by a substantial user fee. The FDA adjusts the </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">155</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. The applicant under an approved BLA is also subject to an annual program fee.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA reviews all submitted BLAs before it accepts them for filing and may request additional information. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA for a new molecular entity and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be extended by FDA requests for additional information or clarification.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA also may audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety and efficacy. Additionally, the FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally follows such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After the FDA evaluates a BLA, it will issue either an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy (&#147;REMS&#148;) to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#146;s safe use (&#147;ETASU&#148;). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#146;s safety or efficacy.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Orphan Drug Designation</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">156</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for off-label uses, the competitor&#146;s product could be used for the orphan indication despite another product&#146;s orphan exclusivity.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">FDA&#146;s determination of whether two ADCs are the same product for purposes of orphan drug exclusivity is based on a determination of sameness of the monoclonal antibody element and the functional element of the conjugated molecule. Two ADCs are deemed to be the same product if the complementarity determining region sequences of the antibody and the functional element of the conjugated molecule are the same. A difference in either of those two elements can result in a determination that the molecules are different.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Expedited Development and Review Programs</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a new biologic candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#146;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#146;s BLA before the application is complete. This &#147;rolling review&#148; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the biologic candidate. The FDA must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#146;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">157</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#146;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or approval process.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Additional Controls for Biologics</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Pediatric Information</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Pediatric Research Equity Act, or PREA, BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted. However, beginning in 2020, PREA will apply to BLAs for orphan-designated biologics if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA has determined is substantially relevant to the growth or progression of a pediatric cancer. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Best Pharmaceuticals for Children Act (the &#147;BPCA&#148;) provides a six-month extension of any exclusivity&#8212;patent or non-patent&#8212;for a biologic if certain conditions are met. Conditions for exclusivity include </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">158</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">the FDA&#146;s determination that information relating to the use of a new biologic in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Post-Approval Requirements</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Adverse event reporting and submission of periodic safety summary reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a biologic product&#146;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">fines, warning or other enforcement-related letters or holds on post-approval clinical studies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">product seizure or detention, or refusal to permit the import or export of products; or </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">injunctions or the imposition of civil or criminal penalties.</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>U.S. Patent Term Restoration and Marketing Exclusivity</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Depending upon the timing, duration, and specifics of FDA approval of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch Waxman Amendments. The Hatch Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent term extension, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term extension period is generally one half the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for such an extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we or are licensors may apply for </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">159</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">patent term extension for our owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. However, an extension might not be granted because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The BPCIA created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#147;First licensure&#148; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Regulatory Approval in the European Union</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The EMA is a decentralized scientific agency of the European Union. It coordinates the evaluation and monitoring of centrally authorized medicinal products. It is responsible for the scientific evaluation of applications for EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors. The EMA decentralizes its scientific assessment of medicines by working through a network of about 4,500 experts throughout the European Union, nominated by the member states. The EMA draws on resources of over 40 National Competent Authorities of European Union member states.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The process regarding approval of medicinal products in the European Union follows roughly the same lines as in the United States and likewise generally involves satisfactorily completing each of the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU Good Laboratory Practice regulations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">submission to the relevant national authorities of a clinical trial application (&#147;CTA&#148;) for each trial in humans, which must be approved before the trial may begin in each country where patient enrollment is planned;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">submission to the relevant competent authorities of a MAA, which includes the data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities, including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMP;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">160</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the product.</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Preclinical Studies</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess the quality and potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of the compounds for testing must comply with the relevant international, EU and national legislation, regulations and guidelines. The results of the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Clinical Trials</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the Clinical Trials Directive 2001/20/EC, as amended (the &#147;Clinical Trials Directive&#148;), a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, approval must be obtained from the competent national authority of each European Union member state in which a clinical trial is planned to be conducted. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier and further supporting information prescribed by the Clinical Trials Directive and other applicable guidance documents including but not being limited to the clinical trial protocol. Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical trial application in that country.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Directive 2001/20/EC will be replaced by Regulation (EU) No. 536/2014, which became effective on June 16, 2014. The Regulation introduces an authorization procedure based on a single submission via a single EU portal, an assessment procedure leading to a single decision, as well as transparency requirements (the proactive publication of clinical trial data in the EU database). Since October 2016, based on its Policy 0070, the EMA has been publishing clinical data submitted by pharmaceutical companies to support their MAA for human medicines under this centralized procedure.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Manufacturing and import into the EU of investigational medicinal products is subject to the holding of appropriate authorizations and must be carried out in accordance with cGMP.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Review and Approval</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Authorization to market a product in the European Union member states proceeds under one of four procedures: a centralized authorization procedure, a mutual recognition procedure, a decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics fall under the centralized procedure, only this procedure will be described here.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain drugs, including medicinal products developed by means of biotechnological processes, must be approved via the centralized authorization procedure for marketing authorization. A successful application under the centralized authorization procedure results in a marketing authorization from the European Commission, which is automatically valid in all European Union member states. The other European Economic Area member states (namely Norway, Iceland and Liechtenstein) are also obligated to recognize the European Commission decision. The EMA and the European Commission administer the centralized authorization procedure.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the centralized authorization procedure, the Committee for Medicinal Products for Human Use (the &#147;CHMP&#148;) serves as the scientific committee that renders opinions about the safety, efficacy and quality of human products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#146;s national drug authority, with one of them appointed to act as Rapporteur for the co-ordination of the evaluation with the possible assistance of a further member of the CHMP acting as a Co-Rapporteur. After approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP is required to issue an opinion within 210 days of receipt of a valid application, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data. The process is complex and involves extensive consultation with the regulatory authorities of member states and a number of experts. Once the procedure is completed, a European Public Assessment Report is produced. If the CHMP concludes that the quality, safety and efficacy of </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">161</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">the medicinal product is sufficiently proven, it adopts a positive opinion. The CHMP&#146;s opinion is sent to the European Commission, which uses the opinion as the basis for its decision whether or not to grant a marketing authorization. If the opinion is negative, information is given as to the grounds on which this conclusion was reached.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">After a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for failure to adhere to the conditions of the marketing authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Conditional Approval and Accelerated Assessment</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As per Article 14(7) of Regulation (EC) 726/2004, a medicine that would fulfill an unmet medical need may, if its immediate availability is in the interest of public health, be granted a conditional marketing authorization on the basis of less complete clinical data than are normally required, subject to specific obligations being imposed on the authorization holder. These specific obligations are to be reviewed annually by the EMA. The list of these obligations shall be made publicly accessible. Such an authorization shall be valid for one year, on a renewable basis.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">When an application is submitted for a marketing authorization in respect of a drug for human use which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure pursuant to Article 14(9) of Regulation (EC) 726/2004. Under the accelerated assessment procedure, the CHMP is required to issue an opinion within 150 days of receipt of a valid application, subject to clock stops. We believe that some of the disease indications in which our product candidates are currently being or may be developed in the future qualify for this provision, and we will take advantage of this provision as appropriate.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Period of Authorization and Renewals</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A marketing authorization is initially valid for five years and may then be renewed on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder shall provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variants introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization shall cease to be valid (the so-called sunset clause).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Without prejudice to the law on the protection of industrial and commercial property, marketing authorizations for new medicinal products benefit from an 8+2+1 year period of regulatory protection. This regime consists of a regulatory data protection period of eight years plus a concurrent market exclusivity of 10 years plus an additional market exclusivity of one further year if, during the first eight years of those 10 years, the marketing approval holder obtains an approval for one or more new therapeutic indications which, during the scientific evaluation prior to their approval, are determined to bring a significant clinical benefit in comparison with existing therapies. Under the current rules, a third party may reference the preclinical and clinical data of the reference product beginning eight years after first approval, but the third party may market a generic version of the reference product after only 10 (or 11) years have lapsed.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Orphan Drug Designation</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Regulation (EC) 141/2000 states that a drug shall be designated as an orphan drug if its sponsor can establish (i) that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union when the application is made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">162</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">investment; and (ii) that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Regulation (EC) 847/2000 sets out criteria for the designation of orphan drugs. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a 10-year period of market exclusivity, which means that no similar medicinal product can be authorized in the same indication. This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify continued market exclusivity. In addition, derogation from market exclusivity may be granted on an individual basis in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product or demonstration of &#147;clinically relevant superiority&#148; by a similar medicinal product. Medicinal products designated as orphan drugs pursuant to Regulation (EC) 141/2000 are eligible for incentives made available by the European Union and by the member states to support research into, and the development and availability of, orphan drugs.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the MAA of a medicinal product designated as an orphan drug pursuant to Regulation (EC) 141/2000 includes the results of all studies conducted in compliance with an agreed PIP, and a corresponding statement is subsequently included in the marketing authorization granted, the 10-year period of market exclusivity will be extended to 12 years.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>European Data Collection and Processing</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The collection, transfer, processing and other use of personal information, including health data, in the European Union is governed by the GDPR, which came into effect in May 2018. This directive imposes several requirements relating to (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside the European Economic Area, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union member states may result in fines and other administrative penalties. The GDPR introduces new data protection requirements in the EU and substantial fines for breaches of the data protection rules. The GDPR and related data protection laws may impose additional responsibility and liability in relation to personal data that we collect and process and we may be required to put in place additional mechanisms ensuring compliance with such rules. This may be onerous and adversely affect our business, financial condition, results of operations, and prospects.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Marketing</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Much like the Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Payments made to physicians in certain European Union member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">163</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>International Regulation</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA or European Commission approval.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Other Healthcare Laws and Regulations and Legislative Reform</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Healthcare and Privacy Laws and Regulations</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. The healthcare laws that may affect our ability to operate include, but are not limited to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Federal civil and criminal false claims laws, such as the FCA, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">HIPAA, as amended by HITECH, and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates that perform services for </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">164</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="bl" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 53.33px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Health Care Reform Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments and other transfers of value provided to physicians and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#146;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Legislative Reform</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress enacted the Health Care Reform Act, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as:</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">165</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must pay to the federal government;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">created a licensure framework for follow-on biologic products.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since its enactment, there have been judicial and congressional challenges to certain aspects of the Health Care Reform Act as well as recent efforts by the current U.S. Presidential Administration to repeal or replace certain aspects of the Health Care Reform Act. For example, in 2017, the U.S. Congress enacted the TCJA, which eliminated the tax-based shared responsibility payment imposed by the Health Care Reform Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; On December 14, 2018, the U.S. District Court for the Northern District of Texas held that the individual mandate is a critical and inseverable feature of the Health Care Reform Act, and therefore, because it was repealed by the TCJA, the remaining provisions of the Health Care Reform Act are invalid as well. While the enforcement of the judgment is stayed pending appeal and the current U.S. Presidential Administration and the CMS have stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals and other efforts to repeal and replace the Health Care Reform Act will impact the Health Care Reform Act. Since the enactment of the TCJA, there have been additional amendments to certain provisions of the Health Care Reform Act, and the current U.S. Presidential Administration and Congress may continue to seek to modify, repeal or otherwise invalidate all, or certain other provisions of, the Health Care Reform Act. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and prospects.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2017, the U.S. Congress enacted the Right to Try Act. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act, which </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">166</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 absent additional congressional action. In 2012, the U.S. Congress enacted the American Taxpayer Relief Act which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the current U.S. Presidential Administration&#146;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the current U.S. Presidential Administration released a &#147;Blueprint&#148; to lower drug prices and reduce out-of-pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. In addition, CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of treatment. Prescription drugs and biological products that are in violation of these requirements will be included on a public list. Any adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Environmental, Health and Safety Laws and Regulations</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In particular, our product candidates use PBDs, which are highly potent cytotoxins that require special handling by our and our contractors&#146; staff. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources. Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">167</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Pharmaceutical Coverage, Pricing and Reimbursement</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors is essential for most patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a product is:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a covered benefit under its health plan;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">safe, effective and medically necessary;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">appropriate for the specific patient;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">cost-effective; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">neither experimental nor investigational.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If coverage and adequate reimbursement of our future products, if any, is unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability. Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage and reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, which decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not always, follow the CMS&#146;s decisions regarding coverage and reimbursement. It is difficult to predict what third-party payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Further, one payor&#146;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate reimbursement for that product. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be considered medically necessary or cost-effective. In addition to third-party payors, professional organizations and patient advocacy groups such as the National Comprehensive Cancer Network and the American Society of Clinical Oncology can influence decisions about reimbursement for new medicines by determining standards for care. Therefore, it is possible that any of our product candidates, even if approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize the product candidates profitably.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Reimbursement agencies in Europe may be more restrictive than payors in the United States. For example, a number of cancer products have been approved for reimbursement in the United States but not in certain European countries. In Europe, pricing and reimbursement schemes vary widely from country to country. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Other countries require the completion of additional health technology assessments that compare the cost-effectiveness of a particular product candidate to currently available therapies. In addition, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product, may adopt a system of direct or </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">168</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">indirect controls on the profitability of the company placing the product on the market or monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. Furthermore, many countries in the European Union have increased the amount of discounts required on pharmaceutical products, and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, and prescription products in particular, has become increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no assurance that any country that has reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. Accordingly, the reimbursement for any products in Europe may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Facilities</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We do not own any real property. We believe that our leased facilities meet our present needs and are continuously reviewing our space requirements. The table below sets forth the sizes and uses of our leased facilities:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>Location</b></div>
							</td>
							<td width="27%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>Primary Function</b></div>
							</td>
							<td width="27%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>Approximate Size</b></div>
							</td>
						</tr>


						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Biop&#244;le<br> Route de la Corniche 3B<br> 1066 Epalinges<br> Switzerland</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Office</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">518 m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">430 Mountain Avenue, 4th Floor<br> Murray Hill, New Jersey 07974<br> United States</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Office</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">1038 m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">42 New Road<br> London, E1 2AX<br> United Kingdom</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Office and laboratory</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">284 m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">1510 Fashion Island Boulevard, Suite 205<br> San Mateo, California 94404<br> United States</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Office</div>
							</td>
							<td width="27%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">390 m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are not aware of any environmental issues or other constraints that would materially impact the intended use of our facilities.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">169</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Employees</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of July 31, 2019, we had 125 personnel, 87 of whom have an advanced academic degree (Diploma/Master, D.Phil., Ph.D., M.D.). As of July 31, 2019, 72 of our employees were located in the United States, 23 in Switzerland and 30 in the United Kingdom. We are not subject to collective bargaining agreements or similar labor contracts and do not have a workers&#146; council. We believe that our relationship with our employees is good.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Legal Proceedings</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The results of litigation and claims cannot be predicted with certainty. As of the date of this prospectus, we do not believe that we are party to any claim or litigation, the outcome of which would, individually or in the aggregate, be reasonably expected to have a material adverse effect on our business.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">170</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 108-management -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tM"></a><b>MANAGEMENT</b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Executive Officers and Board of Directors</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table presents information about our executive officers and directors immediately following the pricing of this offering and prior to the listing of our common shares on the NYSE. The term of each of our directors is one year and, accordingly, will expire at our annual general meeting of shareholders to be held in 2020. Ages are as of the date of this prospectus.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="31%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; "><b>Name</b></div></td>
	<td colspan="3" width="56%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>Position</b><b>(s)</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>Age</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; "><b>Executive Officers and Directors<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="54%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Christopher Martin</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Chief Executive Officer and Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">61</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Michael Forer</div></td>
	<td colspan="3" width="56%" valign="top" align="justify" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Executive Vice President, Chief Financial Officer and Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">54</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Jay Feingold</div></td>
	<td colspan="3" width="56%" valign="top" align="justify" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: justify; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Senior Vice President, Chief Medical Officer &amp; Head of Oncology</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">63</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Patrick van Berkel</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Senior Vice President, Research and Development</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">51</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Richard Onyett</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Vice President, Business Development</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">72</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Dominique Graz</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">General Counsel and Company Secretary</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">58</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Peter Greaney</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Head of Corporate Development</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">40</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">St&#233;phane Henchoz</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Director of Finance</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">51</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Susan Romanus</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Chief Compliance Officer</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">54</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; "><b>Non-Executive Directors<br></b></div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Peter B. Corr</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Chairman and Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">71</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Stephen Evans-Freke</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">67</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Peter Hug</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">
61
</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Thomas Pfisterer</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">37</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Thomas M. Rinderknecht</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">65</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Tyrell J. Rivers</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">46</div></td>
</tr>
<tr>
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Jacques Theurillat</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">60</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="31%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Barrie Ward</div></td>
	<td colspan="3" width="56%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Director</div></td>
	<td colspan="3" width="13%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4px; padding-right: 0px; ">80</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<p class="ftnote" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; line-height: 12px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; ">Unless otherwise indicated, the current business address for our executive officers and directors and our non-executive directors is ADC Therapeutics SA, Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Executive Officers</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Christopher Martin</b>,<b> D.Phil.</b>, has been an Executive Director of our board of directors since our formation and has been our Chief Executive Officer since June 2015. From 2000 to 2013, Dr. Martin was co-founder and Chief Executive Officer of Spirogen, which was acquired by AstraZeneca plc in 2013, at which point he became a member of both MedImmune&#146;s management leadership team and AstraZeneca plc&#146;s senior leaders group. Prior to this acquisition, Dr. Martin led numerous Spirogen collaboration transactions, including agreements with Genentech, Inc. and Seattle Genetics, Inc. He is currently a Non-Executive Chairman of Tokamak Energy Ltd. Dr. Martin holds a B.Sc. in chemical engineering from Aston University, a D.Phil. in engineering science from Oxford University and an M.B.A. from the International Institute for Management Development and is a Fellow of the Institution of Chemical Engineers.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Michael Forer</b>,<b> LL.B.</b>, has been Vice Chairman of our board of directors and our Executive Vice President since June 2015 and our Chief Financial Officer since March 2016. From our formation to 2015, Mr. Forer was our Chief Executive Officer. From 2009 to 2013, Mr. Forer was a board member and Executive Director of Spirogen. Previously, Mr. Forer was the Managing Director for the investment activities of Auven Therapeutics Holdings L.P. and the co-founder and Managing Director of Rosetta Capital Limited, after starting his career at Rothschild Asset Management. Mr. Forer holds a B.A. in economics from the University of Western Ontario, an LL.B. from the University of British Columbia and a Diploma in international business from the University of Copenhagen.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Jay Feingold</b>,<b> M.D.</b>,<b> Ph.D.</b>, has been our Senior Vice President, Chief Medical Officer and Head of Oncology Clinical Development since September 2014. From 2010 to 2014, he was Vice President of U.S. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">171</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Medical Affairs and Chairman of the Global Medical Affairs Oversight Committee at Daiichi Sankyo Company, Ltd. From 2007 to 2010, Dr. Feingold was Vice President of Global Oncology Clinical Development and Global Therapy Area Director of Oncology at Wyeth Pharmaceuticals, Inc. Dr. Feingold holds a B.S. in biology from Stony Brook University and an M.D. and Ph.D. from the Albert Einstein College of Medicine and was trained in pediatrics and pediatric hematology and oncology at the University of California Los Angeles Center for the Health Sciences.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Patrick van Berkel</b>,<b> Ph.D.</b>, has been our Senior Vice President of Research &amp; Development since August 2012. From 2003 to 2012, Dr. van Berkel served in various roles at Genmab A/S, including as Vice President of Antibody Technology and Vice President of Chemistry, Manufacturing and Control, Research and Development and as Director of Technology for the Antibody Technology division. Dr. van Berkel holds a B.S. in chemistry from the University of Nijmegen and a Ph.D. in chemistry from the University of Leiden.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Richard Onyett</b> has been our Vice President of Business Development since April 2014. From July 2006 to January 2012, Mr. Onyett was the Commercial Director at Spirogen Limited and Commercial Director at Oxogen Limited. Previously, he was Senior Vice President of Business Development of KuDOS Pharmaceuticals Limited, Senior Vice President of Corporate Development at Epidauros GmbH and Senior Vice President of Corporate Development at Anthra Pharmaceuticals Inc. Mr. Onyett holds a B.Sc. in biological sciences from the University of Nottingham and a M.Sc. in general virology from the University of Birmingham.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Dominique Graz</b>,<b> Dr. iur.</b>, has been our General Counsel and Company Secretary since April 2018. From 2016 to 2018, Mr. Graz was an independent counsel at Python. From 2003 to 2016, Mr. Graz was the group general counsel and secretary to the board of Firmenich International SA. Mr. Graz holds a masters in law and a Dr. iur. from the University of Lausanne and is admitted to the bar of the Canton of Vaud, Switzerland.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Peter Greaney</b>,<b> Ph.D.</b>, has been our Head of Corporate Development since September 2018. From 2006 to 2018, he served in various positions at Celgene Corporation, including as Director of Business Development, Strategy and Operations and Associate Director of Business Development. Dr. Greaney holds a B.S. in cell biology from the University of East Anglia and a Ph.D. in molecular and cellular biology from the University of Nottingham.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>St&#233;phane Henchoz</b> has been our Director of Finance since September 2014. From 1991 to 2013, Mr. Henchoz held senior leadership roles at Merck Serono S.A., including as Controlling Manager for the Research and Development Function, Financial Controller for the IT function in Geneva, Associate Manager at the Corporate Strategic Management Department in Geneva and Regional Financial Analyst for the Latin America region in Uruguay. Mr. Henchoz holds a B.S. in economics and finance from Haute &#201;cole de Gestion de Gen&#232;ve.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Susan Romanus</b> has been our Chief Compliance Officer since June 2018. From 2015 to 2018, she served as Vice President, Compliance at Taiho Oncology, Inc. From 2009 to 2012, she served as Vice President, Chief Ethics &amp; Compliance Officer at Daiichi Sankyo Company. Ms. Romanus holds a B.S. in biochemistry and cell biology from the University of California San Diego and an M.B.A. from the University of San Diego and a certificate in change leadership from Cornell University.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Non-Executive Directors</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Peter B. Corr</b>,<b> </b><b>M.D.</b>,<b> </b><b>Ph.D.</b>, has been the Chairman of our board of directors since June 2011. He is the co-founder and Managing General Partner of Auven Therapeutics Management L.L.L.P. From 2000 to 2006, he held various senior positions at Pfizer Inc., including Executive Vice President for Science and Technology, Executive Vice President for Global Research and Development and President for Worldwide Development. In addition to our board of directors, Dr. Corr also serves as Co-Founder and Chairman of the board of directors of Imvax Inc. and as a member of the board of directors of Analytica Limited. Dr. Corr holds a B.S. in pharmacy from Albany College of Pharmacy and Health Sciences and an M.D. and Ph.D. from Georgetown University School of Medicine.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Stephen Evans-Freke</b>,<b> LL.B.</b>, has been a Non-Executive Director of our board of directors since June 2011. He is the co-founder and Managing General Partner of Auven Therapeutics Management L.L.L.P. Mr. Evans-Freke was also the co-founder, Chairman and Chief Executive Officer of Sugen, Inc. until its sale to Pharmacia Corporation. Previously, Mr. Evans-Freke was the President of PaineWebber Development Corporation, Managing Director of BliteEastman PaineWebber Inc. and a member of the board of directors of </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">172</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">PaineWebber, Inc. In addition, he was the co-founder of CIBUS Global LLC, Fibrogen, Inc. and Royalty Pharma AG. Mr. Evans-Freke holds a LL.B. from Cambridge University.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Peter Hug</b>,<b> Ph.D.</b>, has been a Non-Executive Director of our board of directors since June 2019. From 1983 to 2018, Dr. Hug served in various positions at F. Hoffmann-La Roche Ltd., including as head of Roche Pharma EEMEA region, head of Roche Pharma Europe region and Executive Vice President of Roche Pharma Partnering. In addition to our board of directors, Dr. Hug also serves as a member of the board of directors of Swiss Post Ltd. Dr. Hug holds a Ph.D. in economics from the University of Basel.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Thomas Pfisterer</b> has been a Non-Executive Director of our board of directors since October 2016. Since 2015, Mr. Pfisterer has headed the direct investment activities of the WILD Family Office. From 2011 to 2015, Mr. Pfisterer served as the head of strategic development of WILD Flavors GmbH, where he directed the company&#146;s global M&amp;A activities. Previously, Mr. Pfisterer also worked in the investment banking division of Morgan Stanley Bank AG. In addition to our board of directors, Mr. Pfisterer also serves as a Non-Executive Director of Sermonix Pharmaceuticals Inc., InSphero AG, Stade Fran&#231;ais Paris SASP and Imvax Inc. Mr. Pfisterer holds a B.A. in economics and a B.A. in administration finance from the University of St. Gallen and a M.Phil. in finance from Cambridge University.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Thomas M. Rinderknecht</b>,<b> Ph.D.</b>, has been a Non-Executive director of our board of directors since May 2016. Since 2008, Dr. Rinderknecht has been a senior partner at the law firm Badertscher Rechtsanw&#228;lte AG. In addition to our board of directors, Dr. Rinderknecht also serves as a member of the board of directors of Chocoladefabriken Lindt &amp; Spr&#252;ngli AG, Canyon Pharmaceuticals AG, APR Applied Pharma Research SA and several other firms in the media, hotel and industry sectors. Dr. Rinderknecht holds a masters in law and a Ph.D. in law from the University of Zurich and is admitted to the bar of the Canton of Zug, Switzerland.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Tyrell J. Rivers</b>,<b> Ph.D.</b>, has been a Non-Executive Director of our board of directors since June 2018. Since 2014, Dr. Rivers has been an Executive Director within AstraZeneca&#146;s Corporate Development Group. From 2009 to 2014, Dr. Rivers was at MedImmune Ventures specializing in biotechnology investing. In addition to our board of directors, Dr. Rivers also serves as a member of the board of directors of Armaron Bio Ltd, Cerapedics, Inc., Corvidia Therapeutics, Inc. and Viela Bio, Inc. Dr. Rivers holds a B.S. in chemical engineering from the Massachusetts Institute of Technology, a M.S. in engineering from the University of Texas at Austin, an M.B.A. from New York University Stern School of Business and a Ph.D. in chemical engineering from the University of Texas at Austin.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Jacques Theurillat</b>,<b> LL.B.</b>, has been a Non-Executive Director of our board of directors since July 2015. Since 2016, he has been a partner at the Sofinnova Crossover Fund. From 2008 to 2015, Mr. Theurillat served as the Chief Executive Officer of Ares Life Sciences AG. Previously, Mr. Theurillat was the Chief Financial Officer of Serono S.A. In addition to our board of directors, Mr. Theurillat also serves as a member of the board of directors of Vifor Pharma AG, Mudipharma Ltd and CNH Industrial N.V. Mr. Theurillat holds an LL.B. from both Madrid University and Geneva University, an M.B.A. from Centro Estudios Financieros and a Swiss federal diploma in tax.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Barrie Ward</b>,<b> Ph.D.</b>, has been a Non-Executive Director of our board of directors since September 2014. Since 2007, Dr. Ward has been a member of the board of supervisory directors of Pharming Group N.V. From 1999 to 2006, Dr. Ward served as Chief Executive Officer of KuDOS Pharmaceuticals Ltd. Previously, Dr. Ward held various positions at GlaxoSmithKline plc. Dr. Ward holds a B.Sc. and a Ph.D. in microbial biochemistry from the University of Bath.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Board Composition and Election of Directors After This Offering</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our board of directors is composed of ten members. Each director is elected for a one-year term. The current members of our board of directors were appointed at our annual general meeting of shareholders on June 28, 2019 to serve until our first annual general meeting of shareholders as a public company in 2020.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a foreign private issuer under the rules of the SEC. As a result, in accordance with the NYSE listing standards, we will rely on home country governance requirements and certain exemptions there under rather than on the stock exchange corporate governance requirements, including the requirement that within one year of the completion of this offering we have a board that is composed of a majority of independent directors. There are no family relationships among any of our directors or executive officers. For an overview of our corporate governance principles, see &#147;Description of Share Capital and Articles of Association.&#148;</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">173</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Committees of the Board of Directors</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our board of directors will establish three separate committees at or prior to the closing of this offering: an audit committee, a compensation committee and a nomination and corporate governance committee.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Audit Committee</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The audit committee, which is expected to consist of Jacques Theurillat (chair), Stephen Evans-Freke and Thomas M. Rinderknecht, will assist our board of directors in overseeing our accounting and financial reporting processes and the audits of our consolidated financial statements. In addition, the audit committee will be directly responsible for the compensation, retention and oversight of the work of our independent registered public accounting firm that our shareholders elect as our external auditors. The audit committee will consist exclusively of members of our board of directors who are financially literate, and each of Jacques Theurillat, Stephen Evans-Freke and Thomas M. Rinderknecht is considered an &#147;audit committee financial expert&#148; as defined by the SEC. Our audit committee complies with Rule 10A-3(b)(1) of the Exchange Act, taking into account applicable transition periods under Rule 10A-3(b)(1)(iv)(A). Our board of directors has determined that each of Jacques Theurillat and Thomas M. Rinderknecht satisfy the &#147;independence&#148; requirements set forth in Rule 10A-3 under the Exchange Act. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The audit committee will be governed by a charter that complies with the NYSE listing standards that apply to us. The audit committee will have the responsibility to, among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">pre-approve the audit services and non-audit services (including the fees and terms thereof) to be provided by the independent auditor pursuant to pre-approval policies and procedures;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">evaluate the independent auditor&#8217;s qualifications, performance and independence, and present its conclusions with respect to the independent auditor to the board of directors on at least an annual basis;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">confirm and evaluate the rotation of the audit partners on the audit engagement team as required by law;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">at least annually, review management&#8217;s plans with respect to the responsibilities, budget and staffing of the internal audit function and its plans for the implementation of the internal audit function, if any;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review and discuss with management and the independent auditor the annual audited consolidated and stand-alone financial statements and unaudited quarterly financial statements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review with management, personnel responsible for the design and implementation of the internal audit function and the independent auditor (i) any analyses or other written communications prepared by management and/or the independent auditor setting forth significant financial reporting issues and judgments made in connection with the preparation of the financial statements, (ii) the Company&#8217;s critical accounting policies and practices, (iii) the effect of regulatory and accounting initiatives, as well as off-balance sheet transactions and structures, on the Company&#8217;s financial statements and (iv) any major issues regarding accounting principles and financial statement presentations;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review the type and presentation of information included in the earnings press releases, as well as financial information and earnings guidance provided to analysts and rating agencies, and may review earnings press releases prior to public dissemination;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">in conjunction with the chief executive officer and chief financial officer, review disclosure controls and procedures and internal control over financial reporting;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review policies and practices with respect to risk assessment and risk management; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review any major litigation or investigations against the Company that may have a material impact on the Company&#8217;s financial statements.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The audit committee will meet as often as it determines is appropriate to carry out its responsibilities, but in any event will meet at least four times per year. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">174</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Compensation Committee</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The compensation committee, which is expected to consist of Barrie Ward (chair), Peter B. Corr and Stephen Evans-Freke, will support our board of directors in establishing and reviewing the compensation and benefits strategy and guidelines as well as in preparing the proposals to the annual general meeting of shareholders regarding the compensation of the members of the board of directors and the executive officers. The compensation committee may submit proposals to the board of directors on other compensation-related matters. Swiss law requires that we have a compensation committee, so in accordance with NYSE listing standards, we will follow home country requirements with respect to the compensation committee. As a result, our practice will vary from NYSE listing standards, which set forth certain requirements as to the responsibilities, composition and independence of compensation committees for domestic issuers. Swiss law requires that our board of directors submit the aggregate amount of compensation of all members of our board of directors and of all executive officers to a binding shareholder vote every year. Commencing with our annual general meeting of shareholders in 2020, the members of the compensation committee will be elected by our annual general meeting of shareholders. The board of directors will appoint the chair of the compensation committee and fill any vacancies until the following annual general meeting of shareholders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The compensation committee will have the responsibility to, among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regularly review and make recommendations to the board of directors regarding our compensation and benefits strategy and guidelines;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">prepare the proposals to the shareholders&#8217; meeting regarding the compensation of the members of the board of directors and the executive committee;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">regularly review and make recommendations to the board of directors regarding the compensation of the members of the board of directors and of the executive committee;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review and approve the recommendation of our chief executive officer regarding the fixed and variable compensation, including incentive plan participation and benefits, of the members of the management team other than members of the executive committee; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review and make recommendations to the board of directors regarding our compensation and benefits plans (cash and/or equity-based plans) and, where appropriate or required, make recommendations to adopt, amend and terminate such plans; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to the extent not delegated by the compensation committee to a different body or a third party, administer our compensation and benefits plans (other than equity-based plans); and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review and assess risks arising from our employee compensation policies and practices and whether any such risks are reasonably likely to have a material adverse effect on us.</td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Nomination and Corporate Governance Committee</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The nomination and corporate governance committee, which is expected to consist of Stephen Evans-Freke (chair), Peter Hug and Thomas M. Rinderknecht will be responsible for director and board committee nominations, succession planning, performance evaluation and reviewing and amending, if required, our corporate governance framework and guidelines. The members of the nomination and corporate governance committee and its chair will be appointed by our board of directors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The nomination and corporate governance committee will have the responsibility to, among other things:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">determine selection criteria for the succession of the members of the board of directors and board committees, our chief executive officer, our chief financial officer and our executive vice president, and establish such succession planning (including for the event of the incapacitation, retirement or removal of such individuals) by making recommendations to the board of directors; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">oversee searches and identify qualified individuals for membership on the board of directors and for the position of chief executive officer; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">recommend individuals for membership on the board of directors and board committees and for the position of chief executive officer; </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">175</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">at least annually, prepare the board of directors&#8217; assessment of the performance of the board of directors and board committees and of our chief executive officer and review the recommendations of the other board committees based on their evaluation of their own performance; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review the recommendations of the other board committees based on their self-evaluations and discuss its self-evaluation with the board of directors; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">monitor and assess developments and trends in corporate governance to the extent that these do not have an impact on the activities and tasks of the audit and finance committee or the compensation committee; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">review proposals to be made to the board of directors for the amendment of our amended and restated articles of association, our organizational regulations, any other rules or regulations and the Code of Conduct; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">periodically review and reassess the adequacy of the Code of Conduct and recommend any proposed changes to the board of directors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">periodically review and assess the adequacy of the charter of the nomination and corporate governance committee and recommend any proposed changes to the board of directors for approval; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">if it deems advisable, develop and recommend to the board of directors corporate governance guidelines for the Company, and, if such guidelines are adopted, periodically review and reassess the adequacy of such guidelines, consider any requests for waivers of such guidelines and make recommendations to the board of directors regarding amendments and request for waivers; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">oversee compliance with the Code of Conduct and report on such compliance to the board of directors. </td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Code of Business Conduct and Ethics</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In connection with this offering, we will adopt a Code of Business Conduct and Ethics (the &#147;Code of Conduct&#148;), that is applicable to all of our employees, executive officers and directors. At or prior to the closing of this offering, the Code of Conduct will be available on our website <i>www.adctherapeutics.com.</i> Our board of directors will be responsible for overseeing the Code of Conduct and will be required to approve any waivers of the Code of Conduct. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed in our annual report on Form 20-F. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Corporate Governance Practices</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a &#147;foreign private issuer,&#148; as defined by the SEC, we are permitted to follow home country corporate governance practices, instead of certain corporate governance standards required by the NYSE for U.S. companies. Accordingly, we intend to follow Swiss corporate governance rules in lieu of certain of the NYSE&#146;s corporate governance requirements. The significant differences between our Swiss corporate governance rules and the NYSE&#146;s corporate governance requirements are set forth below:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Exemption from the requirement that a majority of the board of directors be comprised of independent directors and that there be regularly scheduled meetings with only the independent directors present. Swiss law does not have such a requirement.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Exemption from the requirements that the compensation committee and the nomination and corporate governance committee be comprised of independent directors. Swiss law does not have such requirements.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Exemption from quorum requirements applicable to meetings of shareholders. Swiss law does not require such quorum requirements.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Exemption from the requirement that independent directors meet at regularly scheduled executive sessions. Swiss law does not have such a requirement.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Exemption from the requirement that listed companies adopt and disclose corporate governance guidelines that cover certain minimum specified subjects related to director qualifications and responsibilities. Swiss law does not require the adoption or disclosure of such guidelines. </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">176</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Exemption from the requirement to disclose within four business days of any determination to grant a waiver of the Code of Conduct to directors and executive officers. Although we will require approval by our board of directors for any such waiver, we may choose not to disclose the waiver in the manner set forth in the NYSE listing standards.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Exemption from the requirement to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans. Our amended and restated articles of association will provide that our board of directors is authorized, in certain instances, to issue a certain number of common shares without re-approval by our shareholders. </td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Compensation of Directors and Executive Officers</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For the year ended December 31, 2018, the aggregate compensation paid to the members of our board of directors and our executive officers for services in all capacities, including retirement and similar benefits, was $4.9 million. Pursuant to Swiss law, beginning at our first annual meeting as a public company in 2020, we will be required to submit the aggregate amount of compensation of our board of directors and the aggregate amount of compensation of our executive officers to a binding say-on-pay vote by our shareholders.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Equity Incentive Plans</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At or prior to the closing of this offering, we intend to cease issuing new grants under our existing equity plans and adopt a new equity incentive plan under which we would have the discretion to grant a broad range of equity-based awards to eligible participants. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Prior Plans</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Historically, we have granted equity compensation through (i) the ADC Therapeutics Ltd 2013 Share Purchase Plan (the &#147;2013 Share Purchase Plan&#148;), (ii) the ADC Therapeutics Ltd 2016 Share Purchase Plan (the &#147;2016 Share Purchase Plan&#148;) and (iii) the ADC Therapeutics Incentive Plan dated May 1, 2014 and Amended and Restated as of October 1, 2015 (the &#147;2014 Incentive Plan&#148;). Each of these plans is described in more detail below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>2013 Share Purchase Plan</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In September 2013, our board of directors established the 2013 Share Purchase Plan as a one-off plan pursuant to which select eligible participants directly or indirectly purchased Class A common shares at a purchase price determined by the board of directors. Participants paid the par value of the Class A common shares in cash and settled the balance between the purchase price and the par value in the form of a promissory note. The terms of the plan and the promissory notes are described in more detail below.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Plan Administration. </i>The 2013 Share Purchase Plan is administered by the board of directors.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Promissory Notes. </i>The promissory notes with respect to the 2013 Share Purchase Plan (the &#147;2013 Promissory Notes&#148;) are full recourse, repayable within ten years (subject to certain early repayment events) and bear interest at the minimum interest rate pursuant to the guidelines for related party transactions as published by the Swiss Federal Tax Authority. Certain of our executive officers and directors previously purchased our shares with such promissory notes. The current amount outstanding under these notes (which is also the largest aggregate amount outstanding since the first issuance of the promissory notes) is $2.3 million.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Repayment of the Promissory Notes. </i>Under the terms of the 2013 Promissory Notes, the relevant plan participant may repay outstanding amounts under the promissory note at any time in cash or repay the principal amount in whole or in part by delivering such number of shares as required to cover the amount to be repaid. In connection with this offering, each of our executive officers and directors and their respective related parties who held 2013 Promissory Notes entered into loan settlement agreements with us (the &#147;Loan Settlement Agreements&#148;) dated as of August 31, 2019 (the &#147;Settlement Date&#148;) pursuant to which they repaid all amounts outstanding under the 2013 Promissory Notes by delivering such number of Class A common shares necessary to cover the entire amounts outstanding under the 2013 Promissory Notes. After consideration of all relevant factors, our board of directors determined the value of such surrendered shares as of the Settlement Date to be $420,000 per Class A common share ($26.88 per common share after giving effect to the Share Capital Reorganization), resulting in the surrender of an aggregate of 23.368 Class A common shares (365,125 common </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">177</p>

			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">shares after giving effect to the Share Capital Reorganization) for the settlement of the 2013 Promissory Notes and the 2016 Promissory Notes. In the Loan Settlement Agreements, we acknowledged and agreed that all of the obligations under the 2013 Promissory Notes were satisfied and the loans were extinguished. If our board of directors terminates this offering, or if the first day of trading of our common shares offered hereby has not occurred by March 31, 2020, and provided that we have withdrawn the registration statement of which this prospectus forms a part, (i) we will assign to our executive officers and directors the Class A common shares they delivered under the Loan Settlement Agreements, (ii) the outstanding amounts under the 2013 Promissory Notes, including accrued interest, will be reinstated as if the Loan Settlement Agreements were never effected and (iii) each of our executive officers and directors who held the 2013 Promissory Notes will return the 2013 Promissory Notes to us in due course after the date of such board decision or after March 31, 2020, as applicable. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Company Call Right.</i> Under the terms of the 2013 Share Purchase Plan, upon a termination for a reason other than death or serious ill health, and unless the board of directors has determined otherwise, we had the right, but not the obligation, to repurchase the common shares at the purchase price until December 31, 2015.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>2016 Share Purchase Plan</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On November 18, 2016, we implemented the 2016 Share Purchase Plan where the board of directors permitted select eligible participants to directly or indirectly purchase Class A common shares. The purchase price of the Class A common shares is determined by the board of directors in accordance with the Swiss tax authorities. Participants pay the par value of the Class A common shares in cash and the balance between the purchase price and the par value is paid in the form of a promissory note. The terms of the plan and the promissory notes are described in more detail below.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Plan Administration. </i>The 2016 Share Purchase Plan is administered by the board of directors (which may appoint a person or entity to administer the plans).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Promissory Notes. </i>The promissory notes with respect to the 2016 Share Purchase Plan (the &#147;2016 Promissory Notes&#148;) bear interest and have a term of ten years, and we have the right of recourse. The 2016 Promissory Notes are repayable within ten years (subject to certain early repayment events) and bear interest at the minimum interest rate pursuant to the guidelines for related party transactions as published by the Swiss Federal Tax Authority. Certain of our executive officers and directors previously purchased our shares with such promissory notes. The current amount outstanding under these notes (which is also the largest aggregate amount outstanding since the first issuance of the promissory notes) is $7.5 million. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Repayment of the Promissory Notes. </i>As with the 2013 Promissory Notes, the 2016 Promissory Notes provide that the relevant plan participant may repay outstanding amounts under the promissory note at any time in cash or repay the principal amount in whole or in part by delivering such number of shares as required to cover the amount to be repaid. In connection with this offering, the 2016 Promissory Notes were treated in the same manner as the 2013 Promissory Notes, as described above.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Eligibility</i>. Our and our subsidiaries&#146; select employees, members of the board of directors and independent contractors are eligible to participate in the 2016 Share Purchase Plan, and the board of directors, in its sole discretion, determines the eligible persons to whom participation in the plan will actually be offered. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Company Call Right.</i> Under the terms of the 2016 Share Purchase Plan, upon a termination for any reason, we have the call right, over 100%, 75%, 50% or 25% if the date of the termination occurs after the first, second, third or fourth anniversary of the award, respectively. As such, the respective shares vest 25% annually from the date of grant over a four-year period. We have the right to repurchase the shares over a four-year call period. However, we have waived this call right subject to and for the period after completion of this offering.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Amendment</i>. Under the 2016 Share Purchase Plan, the board of directors has the authority to terminate, suspend or amend the plan at any time, with regard to all or some future or past purchases of Class A common shares. Any adverse economic effects of such termination, suspension or amendment on purchases already made are to be fairly compensated in cash, by replacement of other benefits, or otherwise.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">178</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since the beginning of the last fiscal year ended December 31, 2018, we have issued and sold to current and future members of our board of directors and to our executive officers, in the aggregate, 42 Class A common shares (656,250 common shares after giving effect to the Share Capital Reorganization) at a price of $31,281.00 per Class A common share ($2.00 per common share after giving effect to the Share Capital Reorganization) under the 2016 Share Purchase Plan.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>2014 Incentive Plan</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the 2014 Incentive Plan, we may grant options to plan participants with respect to Class A common shares. The terms of the plan are described in more detail below. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Plan Administration.</i> The 2014 Incentive Plan is administered by the employer of the respective participant.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Eligibility</i>. Our and our subsidiaries&#146; employees, service providers and consultants are eligible to participate in the 2014 Incentive Plan. Participants are selected by the applicable plan administrator.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Vesting</i>. The awards for senior employees vest 25% annually from the date of grant over a four-year period. We have granted junior employees share option awards effective January 1, 2017 and 2018, which vest 100% upon the occurrence of a Liquidity Event. In connection with a Liquidity Event, such as this offering, all unvested awards will vest in full and be cashed out within thirty days less any strike price applicable to the award, provided that in the case of an initial public offering, such as this offering, the applicable administrator may instead deliver Class A common shares instead of cash or to allow the awards to remain outstanding on such terms and conditions as it reasonably determines and in a manner consistent with applicable law.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Amendment</i>. The applicable administrator may from time to time amend the 2014 Incentive Plan, provided that no amendment may detrimentally and materially affect any award and written notice of any material alternation must be provided to all affected participants. The applicable administrator also has the authority at any time to terminate the plan with respect to any future awards, but existing awards would remain outstanding under the terms of the plan.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We will be required to settle the awards under the 2014 Incentive Plan upon the occurrence of a Liquidity Event, such as this offering. Upon completion of this offering, we have determined that the awards outstanding under the 2014 Incentive Plan will be settled in common shares rather than in cash.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since the beginning of the last fiscal year ended December 31, 2018, we have granted our executive officers, in the aggregate, options with the right to acquire 6.63 Class A common shares (103,593.75 common shares after giving effect to the Share Capital Reorganization) at a price of $324,292.00 per Class A common share ($20.75 per common share after giving effect to the Share Capital Reorganization) under the 2014 Incentive Plan. The expiration dates of these awards are December 31, 2027, June 5, 2028 and December 31, 2028.</p>

				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>2019 Equity Incentive Plan</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In connection with this offering, on September 6, 2019, we adopted an equity incentive plan (the &#147;2019 Equity Incentive Plan&#148;). The purpose of the 2019 Equity Incentive Plan is to motivate and reward performance of our employees, directors, consultants and advisors and further the best interests of the Company and our shareholders. Immediately following this offering, the 2019 Equity Incentive Plan will be the sole means for the Company to grant new equity awards. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Plan Administration</i>. The 2019 Equity Incentive Plan is to be administered by the compensation committee of our board of directors, subject to the board of directors&#146; discretion to administer or appoint another committee to administer it. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Eligible Participants</i>. The administrator will be able offer equity awards at its discretion under the 2019 Equity Incentive Plan to: (1) any employees of us or any of our subsidiaries; (2) any non-employee directors serving on our board of directors; (3) any consultants or other advisors to us or any of our subsidiaries. </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Awards</i>. The maximum number of common shares in respect of which awards may be granted under the 2019 Equity Incentive Plan is 9,104,000 common shares, subject to adjustment in the event of certain corporate transactions or events if necessary to prevent dilution or enlargement of the benefits made available under the plan. Equity incentive awards under the 2019 Equity Incentive Plan may be granted in the form of options, share </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">179</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">appreciation rights, restricted shares, restricted share units, performance awards or other share based awards but not &#147;incentive stock options&#148; for purposes of U.S. tax laws. Options and share appreciation rights will have an exercise price determined by the administrator but will not be less than fair market value of the underlying common shares on the date of grant. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Vesting</i>. The vesting conditions for grants under the equity incentive awards under the 2019 Equity Incentive Plan will be set forth in the applicable award documentation. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Termination of Service and Change in Control</i>. In the event of a participant&#146;s termination of employment, the compensation committee may, in its discretion, determine the extent to which an equity incentive award may be exercised, settled, vested, paid or forfeited. In the event of our termination of a participant&#146;s employment without cause or a participant&#146;s resignation for good reason (as defined in the 2019 Equity Incentive Plan) upon or within 18 months following a change in control of the company (as defined in the 2019 Equity Incentive Plan), any awards outstanding to the participant (unless otherwise provided in the award agreement) will immediately vest and settle, and options and share appreciation rights will become fully exercisable. In the event of a change in control that involves a merger, acquisition or other corporate transaction, any outstanding award not assumed, substituted, replaced or continued in connection with the transaction will immediately vest and settle, and options and share appreciation rights will become fully exercisable. In connection with a change of control of the Company, the compensation committee may, in its discretion, take any one or more of the following actions with respect to outstanding awards: (i) terminate, cancel, repurchase or cause an affiliate or third party to purchase any such award, in exchange for a cash payment (or without payment of consideration if the committee determines that no amount would have been realized upon the exercise of the award or other realization of the participant&#146;s rights); (ii) require the exercise of any outstanding option; (iii) provide for the assumption, substitution, replacement or continuation of any award by the successor or surviving corporation, along with appropriate adjustments with respect to the number and type of securities (or other consideration) of the successor or surviving corporation, subject to any replacement awards, the terms and conditions of the replacement awards (including performance targets) and the grant, exercise or purchase price per share for the replacement awards; (iv) make any other adjustments in the number and type of securities (or other consideration) subject to such awards and in the terms and conditions of such awards; (v) provide that any such award shall be accelerated and become exercisable, payable and/or fully vested with respect to all shares covered thereby or (vi) provide that any award shall not vest, be exercised or become payable as a result of such event. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Termination and Amendment</i>. Unless terminated earlier, the 2019 Equity Incentive Plan will continue for a term of 10 years. Our board of directors has the authority to amend or terminate the 2019 Equity Incentive Plan subject to shareholder approval with respect to certain amendments. However, no such action may impair the rights of the recipient of any options unless agreed by the recipient. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Employment Agreements</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into employment agreements with certain of our executive officers. Each of these agreements provides for an initial salary and annual bonus opportunity, as well as participation in certain pension and welfare benefit plans. These agreements generally require advance notice of termination, from three to 12 months, and in some cases provide for paid garden leave. Some of our executive officers have agreed to covenants not to compete against us or solicit our employees or customers during employment and for a period of up to one year following termination. We may be required to pay some of our executive officers compensation for their covenant not to compete with us following termination.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">180</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tS"></a><b>PRINCIPAL SHAREHOLDERS</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table presents information relating to the beneficial ownership of our common shares immediately prior to the completion of this offering by:</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding common shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">each of our executive officers and directors; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">all executive officers and directors as a group. </td></tr></table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Immediately prior to the completion of this offering, our outstanding share capital will consist of 65,088,000 common shares. Prior to the completion of this offering, we intend to complete the remaining steps in the Share Capital Reorganization. The Share Capital Reorganization consists of (i) an increase of the par value of each of our Class A common shares and Class B, C, D and E preferred shares from CHF 100 per share to CHF 1,000 per share, against the conversion of distributable reserves into share capital, which was effected on August 28, 2019, (ii) a one-to-15,625 share split of all issued shares and reclassification of our issued Class A common shares into common shares, which was effected on September 19, 2019, and (iii) a conversion on a one-to-one basis of our issued Class B, C, D and E preferred shares into common shares, which will be effected immediately prior to the completion of this offering. See &#147;Description of Share Capital and Articles of Association&#8212;Share Capital.&#148; All holders of our common shares will have the same voting rights upon the completion of this offering. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The number of common shares beneficially owned by each entity, person, executive officer or director is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any common shares over which the individual has sole or shared voting power or investment power as well as any common shares that the individual has the right to acquire within 60 days from September 23, 2019 through the exercise of any option or other right. Except as otherwise indicated, and subject to applicable community property laws, we believe that the persons named in the table have sole voting and investment power with respect to all common shares held by that person based on information provided to us by such person.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The percentage of outstanding common shares beneficially owned before this offering is computed on the basis of 65,088,000 common shares outstanding immediately prior to the completion of this offering. Common shares that a person has the right to acquire within 60 days are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all executive officers and directors as a group. Unless otherwise indicated below, the business address for each beneficial owner is ADC Therapeutics SA, Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The percentage of common shares beneficially owned after this offering is based on 73,252,000 common shares that will be issued and outstanding upon the completion of this offering. The percentages assume no exercise by the underwriters of their option to purchase additional shares and does not give effect to any shares that may be acquired by our shareholders, directors or executive officers pursuant to the directed share program. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">AstraZeneca, Redmile Group, LLC and certain of our other existing shareholders and/or their respective affiliated entities have indicated an interest in purchasing up to approximately $115 million of the common shares being offered in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to any of these potential purchasers, and any of these potential purchasers could determine to purchase more, fewer or no shares in this offering. Accordingly, the table below assumes no purchase of shares by such existing shareholders in this offering. </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">181</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of September 6, 2019, to our knowledge, 53 U.S. record holders held approximately 20% of our common shares.</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.07px; padding-right: 2.07px; "><b>Shares Beneficially Owned Before This Offering</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.07px; padding-right: 0px; "><b>Shares Beneficially Owned After This Offering</b></div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; "><b>Principal Shareholders</b></div></td>
	<td colspan="3" width="21%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2.07px; padding-right: 2.07px; "><b>Number</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2.07px; padding-right: 2.07px; "><b>Percent</b></div></td>
	<td colspan="3" width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2.07px; padding-right: 2.07px; "><b>Number</b></div></td>
	<td colspan="3" width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2.07px; padding-right: 0px; "><b>Percent</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; "><b>5% Shareholders<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Entities affiliated with Auven Therapeutics GP Ltd.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 27,538,099 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 42.9 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 27,538,099 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 37.6 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">AstraZeneca UK Limited<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 4,593,750 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 7.2 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 4,593,750 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 6.3 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">HPWH TH AG<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 7,500,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 11.7 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 7,500,000 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10.2 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; "><b>Executive Officers and </b><b>Directors<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Peter B. Corr<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 27,538,024 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 42.9 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 27,538,024 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 37.6 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Stephen Evans-Freke<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 27,538,024 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 42.9 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 27,538,024 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 37.6 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Jay Feingold</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Michael Forer<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,007,570 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1.6 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,007,570 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1.4 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Dominique Graz</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Peter Greaney</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">St&#233;phane Henchoz </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Peter Hug</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Christopher Martin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,304,042 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.0 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,304,042 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1.8 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Richard Onyett</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Thomas Pfisterer</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Thomas M. Rinderknecht</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Tyrell J. Rivers<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Susan Romanus</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Jacques Theurillat</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Patrick van Berkel</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">Barrie Ward</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">*</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> * </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="27%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.07px; ">All current executive officers and directors as a group (17 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="18%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 32,279,029 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 49.6 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="17%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 32,279,029 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="13%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 44.1 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">*</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Less than 1% of our total outstanding common shares.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Consists of (i) 21,253,906.3 common shares held of record by A.T. Holdings II S&#224;rl (&#147;A.T. Holdings&#148;), a Swiss limited liability company (<i>soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</i>) and (ii) 6,284,117.8 common shares held of record by ADC Products Switzerland S&#224;rl (&#147;ADC Products&#148;), a Swiss limited liability company (<i>soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</i>). A.T. Holdings is a wholly-owned subsidiary of C.T. Phinco S&#224;rl, a Swiss limited liability company (<i>soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</i>). C.T. Phinco S&#224;rl is a wholly-owned subsidiary of Auven Therapeutics Holdings L.P. (&#147;Auven Therapeutics&#148;). Auven Therapeutics GP Ltd. is the general partner of Auven Therapeutics General L.P. Auven Therapeutics General L.P. is the general partner of Auven Therapeutics. Auven Therapeutics holds a 73.8% ownership interest in ADC Products. As the sole shareholders of Auven Therapeutics GP Ltd., Mr. Corr and Mr. Evans-Freke may be deemed to have shared voting and investment power with respect to the common shares of ADCT. Although the managing directors of A.T. Holdings and ADC Products have voting rights with respect to the common shares held of record, the managing directors disclaim beneficial ownership over 27,538,024 of the common shares of ADCT. The number of common shares above includes 75 common shares held of record by A.T. Holdings as nominee on behalf of investors, for which A.T. Holdings does not take into account the wishes of investors when exercising voting rights. The number of common shares above does not reflect 6 common shares held of record by A.T. Holdings as nominee on behalf of equity incentive plan participants, for which A.T. Holdings takes into account the wishes of the equity incentive plan participants when exercising voting rights. 27,534,117 common shares of ADCT held of record by A.T. Holdings and ADC Products have been pledged pursuant to lending arrangements. The business address for Auven Therapeutics GP Ltd. is 171 Main Street, Road Town, Tortola, British Virgin Islands VG1110.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Consists of 4,593,750 common shares held of record by AstraZeneca UK Limited (&#8220;AstraZeneca&#8221;), a private limited company organized in the United Kingdom. AstraZeneca is a wholly-owned subsidiary of AstraZeneca PLC, a public limited company organized under the laws of the United Kingdom, which may be deemed to have sole voting and investment power. The registered office address of AstraZeneca is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(3)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Consists of 7,500,000 common shares held of record by HPWH TH AG (&#147;HPWH&#148;), a Swiss stock corporation. Dr. Hans-Peter Wild and Mr. Pfisterer are members of HPWH board of directors, and may be deemed to have shared voting and investment power with respect to such shares held of record by HPWH through a shareholders agreement. Mr. Pfisterer disclaims beneficial ownership over 7,109,375 common shares held of record by HPWH. The business address of HPWH is Neugasse 22, 6300 Zug, Switzerland.
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">182</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(4)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Consists of (i) 21,253,906.3 common shares held of record by A.T. Holdings, a company controlled by Auven Therapeutics and (ii) 6,284,117.8 common shares held of record by ADC Products. Auven Therapeutics holds a 73.8% ownership interest in ADC Products. As described in footnote (1), the sole shareholders of Auven Therapeutics GP Ltd., Mr. Evans-Freke and Mr. Corr may be deemed to have shared voting and investment power with respect to the common shares of ADCT.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(5)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Does not include 441,081.3 common shares held by Dune Capital Inc., a company which is wholly owned by a trust whose beneficiaries include Mr. Forer and his family. Mr. Forer does not exercise investment or voting control over the trust, and therefore such shares do not appear in the table above.&nbsp;&nbsp;&nbsp;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(6)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Does not include 636,034.3 common shares held of record by Tuula Martin, spouse of Christopher Martin. Mr. Martin does not exercise investment or voting control over such shares, and therefore such shares do not appear in the table above.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(7)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Mr. Rivers, an executive director within AstraZeneca&#8217;s corporate development group, disclaims beneficial ownership with respect to the 4,593,750 common shares held of record by AstraZeneca. See footnote (2).
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(8)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Includes 2,059,655.5 common shares held by directors and executive officers who beneficially own less than 1.0% of shares and an estimated 369,737.8 common shares (subject to adjustments for final tax and social security deductions) subject to options that are immediately exercisable or exercisable within 60 days of the completion of this offering, which represent the common shares that will be issued to settle outstanding awards under our 2014 Incentive Plan in connection with this offering.
</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">183</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tRPT"></a><b>RELATED PARTY TRANSACTIONS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following is a description of certain related party transactions we have entered into since January 1, 2016 with any of our executive officers, directors or their affiliates and holders of more than 10% of any class of our voting securities in aggregate, which we refer to as related parties, other than compensation arrangements which are described under &#147;Management.&#148; </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Sales of Securities</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Sale of Class D Preferred Shares</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In September 2016, we entered into an investment and subscription agreement pursuant to which we issued and sold an aggregate of 627 Class D preferred shares at a purchase price of $167,442.00 per share (or 9,796,875 common shares at a purchase price of $10.72 per share after giving effect to the Share Capital Reorganization) for an aggregate purchase price of $105.0 million. </p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth the number of our Class D preferred shares (and the number of our common shares after giving effect to the Share Capital Reorganization) purchased by our related parties:</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; "><b>Name of Shareholders</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 11.57px; padding-right: 0px; ">
<b>Number of Class D Preferred<br> </b><b>Shares </b><b>(Number of Common Shares<br> </b><b>After Giving Effect to the Share<br> </b><b>Capital Reorganization) </b><b>Purchased</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></b>
</div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">HPWH TH AG<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">214.0000</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (3,343,750.0000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">ADC Products Switzerland S&#224;rl</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">72.1800</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1,127,812.5000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Thomas Rinderknecht</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">18.0000</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (281,250.0000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Jacques Theurillat</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0000</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (46,875.0000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Includes shares and fractional shares held by nominees on behalf of the shareholders set out in the table.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">The shares were originally acquired by HP Wild Holding AG and later transferred to HPWH TH AG. Thomas Pfisterer, a member of our board of directors, is a director of both HP Wild Holding AG and HPWH TH AG.</td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Sale of Class E Preferred Shares</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In October 2017, we entered into an investment and subscription agreement pursuant to which we issued and sold an aggregate of 617 Class E preferred shares at a purchase price of $324,292.00 per share (or 9,640,625 common shares at a purchase price of $20.75 per share after giving effect to the Share Capital Reorganization) for an aggregate purchase price of $200.1 million.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth the number of our Class E preferred shares (and the number of our common shares after giving effect to the Share Capital Reorganization) purchased by our related parties:</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; "><b>Name of Shareholders</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 11.57px; padding-right: 0px; ">
<b>Number of Class E Preferred<br> </b><b>Shares </b><b>(Number of Common Shares<br></b><b> </b><b>After Giving Effect to the Share<br></b><b> </b><b>Capital Reorganization)</b><b> </b><b>Purchased</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></b>
</div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">A.T. Holdings II S&#224;rl</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">105.0000</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1,640,625.0000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">ADC Products Switzerland S&#224;rl</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">56.0000</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (875,000.0000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Michael Forer</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.7709</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (12,045.3125 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Tuula Martin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.5418</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (24,090.6250 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Thomas Rinderknecht</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.3421</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (52,220.3125 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Jacques Theurillat</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.5815</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (24,710.9375 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Barrie Ward</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.4667</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="21%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (7,292.1875 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Includes shares and fractional shares held by nominees on behalf of the shareholders set out in the table.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Tuula Martin is the spouse of Christopher Martin who is a member of our board of directors and CEO.</td></tr></table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In May 2019, we entered into an investment and subscription agreement pursuant to which we issued and sold an aggregate of 218 Class E preferred shares at a purchase price of $350,000.00 per share (or 3,406,250 common shares at a purchase price of $22.40 per share after giving effect to the Share Capital Reorganization) for an aggregate purchase price of $76.3 million.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">184</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth the number of our Class E preferred shares (and the number of our common shares after giving effect to the Share Capital Reorganization) purchased by our related parties:</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; "><b>Name of Shareholders</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 11.57px; padding-right: 0px; ">
<b>Number of Class E Preferred Shares<br></b><b> </b><b>(Number of Common Shares<br></b><b> </b><b>After Giving Effect to the Share<br></b><b> </b><b>Capital Reorganization)</b><b> Purchased</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></b>
</div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">A.T. Holdings II S&#224;rl<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">62.0000</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (968,750.0000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Michael Forer</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.4286</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (6,696.8750 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Dominique Graz</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.5700</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (8,906.2500 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">St&#233;phane Henchoz</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.1000</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1,562.5000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Thomas Rinderknecht</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.0000</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (15,625.0000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Jacques Theurillat</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.1800</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2,812.5000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Tuula Martin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.4300</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (6,718.7500 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 11.57px; ">Barrie Ward</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.0200</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="20%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (312.5000 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Includes shares and fractional shares held by nominees on behalf of the shareholders set out in the table.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(2)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Includes 29.0000 Class E preferred shares (or 453,125.0000 common shares after the Share Capital Reorganization) originally acquired by ADC Products Switzerland S&#224;rl and later transferred to A.T. Holdings II S&#224;rl.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(3)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Tuula Martin is the spouse of Christopher Martin who is a member of our board of directors and CEO.
</td></tr></table><div style="clear: both"></div>

<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Issuance of Class A Common Shares</b><b> </b></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In September 2019, we issued 140 Class A common shares (2,187,500 common shares after giving effect to the Share Capital Reorganization) to A.T. Holdings II S&#224;rl at CHF 1,000 per Class A common share (CHF 0.064 per common share after giving effect to the Share Capital Reorganization), equal to the par value of such shares, and repurchased such shares from A.T. Holdings II S&#224;rl immediately upon their issuance and at the same price. These shares are reserved to settle share grants and equity-linked instruments for directors, officers, employees and consultants, including to settle the outstanding awards under our 2014 Incentive Plan. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Shareholders&#146; Agreement</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In October 2017, we and our then-existing equity investors entered into a shareholders&#146; agreement (the &#147;Shareholders&#146; Agreement&#148;), which replaced our prior shareholders&#146; agreements. This agreement provided our shareholders with certain rights, including information rights, nomination rights, pre-emptive subscription rights, tag-along right, drag-along right, and contains certain provisions governing our board of directors. The Shareholders&#146; Agreement will terminate at or prior to the closing of the offering.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Director and Executive Officer Promissory Notes</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table sets forth the material terms of the promissory notes issued in connection with the share purchase plans between us and our directors and executive officers:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; border-bottom: 1pt solid #000000; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; "><b>Name of Director or Executive Officer</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.53px; padding-right: 3.53px; "><b>Interest Rate<br></b><b> </b><b>as of </b><b>June 30</b><b>, 2019</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 3.53px; padding-right: 0px; "><b>Largest Amount<br> </b><b>Outstanding<br></b><b> </b><b>as of </b><b>June 30</b><b>, 2019</b><br><b> </b><b>(in USD thousands)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Michael Forer</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,945</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Dominique Graz</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">79</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">St&#233;phane Henchoz</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">270</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Peter Hug</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">189</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Christopher Martin</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,621</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Thomas Pfisterer</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">300</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Thomas M. Rinderknecht</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">428</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Jacques Theurillat</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">428</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Patrick van Berkel</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">463</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.53px; ">Barrie Ward</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3.0</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">377</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All promissory notes were made pursuant to our 2013 Share Purchase Plan and 2016 Share Purchase Plan. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">185</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">All amounts outstanding under the promissory notes were repaid prior to the public filing of this registration statement. For further information, see &#147;Management&#8212;Equity Plans&#8212;Prior Plans&#8212;2013 Share Purchase Plan&#8212;Repayment of the Promissory Notes&#148; and &#147;Management&#8212;Equity Plans&#8212;Prior Plans&#8212;2016 Share Purchase Plan&#8212;Repayment of the Promissory Notes.&#148;</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Related Person Transaction Policy</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In connection with this offering, we have adopted a new related person transaction policy. Our related person transaction policy states that any related person transaction must be approved or ratified by our audit committee or board of directors. In determining whether to approve or ratify a transaction with a related person, our audit committee or board of directors will consider all relevant facts and circumstances, including without limitation the commercial reasonableness of the terms of the transaction, the benefit and perceived benefit, or lack thereof, to us, the opportunity costs of an alternative transaction, the materiality and character of the related person&#146;s direct or indirect interest and the actual or apparent conflict of interest of the related person. Our audit committee or board of directors will not approve or ratify a related person transaction unless it has determined that, upon consideration of all relevant information, such transaction is in, or not inconsistent with, our best interests and the best interests of our shareholders. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Indemnification Agreements</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into indemnification agreements with our executive officers and directors. The indemnification agreements and our amended and restated articles of association require us to indemnify our executive officers and directors to the fullest extent permitted by law. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Directed Share Program</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At our request, the underwriters have reserved 5% of the common shares offered by this prospectus, for sale, at the initial public offering price, to our employees and to friends, professional contacts and family members of our employees and directors. We do not currently know the extent to which these related persons will participate in the directed share program, if at all.</p>


<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Participation in the Offering</b><b> </b></p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">AstraZeneca, Redmile Group, LLC and certain of our other existing shareholders and/or their respective affiliated entities have indicated an interest in purchasing up to approximately $115 million of the common shares being offered in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to any of these potential purchasers, and any of these potential purchasers could determine to purchase more, fewer or no shares in this offering. </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">186</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 109-description -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tDSC"></a><b>DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION </b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>The Company</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are a Swiss stock corporation (<i>soci&#233;t&#233; anonyme</i>) organized under the laws of Switzerland. We were incorporated as a Swiss limited liability company (<i>soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</i>) on June 6, 2011 with our registered office and domicile in Epalinges, Canton of Vaud, Switzerland. We converted to a Swiss stock corporation under the laws of Switzerland on October 13, 2015. Our domicile is in Epalinges, Canton of Vaud, Switzerland. Our registered office and head office is currently located at Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Share Capital</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Immediately prior to the completion of this offering, our outstanding share capital will consist of 65,088,000 common shares. Prior to the completion of this offering, we intend to complete the remaining steps of the Share Capital Reorganization. The Share Capital Reorganization consists of (i) an increase of the par value of each of our Class A common shares and Class B, C, D and E preferred shares from CHF 100 per share to CHF 1,000 per share, against the conversion of distributable reserves into share capital (<i>augmentation du capital-actions au </i><i>moyen de fonds propres</i>), which was effected on August 28, 2019, (ii) a one-to-15,625 share split of all issued shares and reclassification of our issued Class A common shares into common shares, which was effected on September 19, 2019, and (iii) a conversion on a one-to-one basis of our issued Class B, C, D and E preferred shares into common shares, which will be effected immediately prior to the completion of this offering. In the Par Value Increase, the contributions were made out of our distributable reserves, which resulted in a reclassification of the respective part of the distributable reserves to share capital. As a result, this portion of the distributable reserves can no longer be distributed to the shareholders, see &#147;Description of Share Capital and Articles of Association&#8212;Articles of Association&#8212;Dividends and Other Distributions.&#148;</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the closing of this offering, after giving effect to the issuance of the common shares to be sold in this offering, our issued fully paid-in share capital will consist of 73,252,000 common shares, each with a par value of CHF 0.064 per share.</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Changes in Our Share Capital During the Last Three Fiscal Years</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Immediately prior to the completion of this offering, our share capital as registered with the commercial register of the Canton of Vaud, Switzerland (the &#147;Commercial Register&#148;) will amount to 66,671,875 common shares, 65,088,000 of which will be outstanding, each with a par value of CHF 0.064 per share. Since January 1, 2016, our share capital has changed as follows, which does not give effect to the Share Capital Reorganization:</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On October 6, 2016, our share capital as registered with the Commercial Register on October 18, 2016, was increased by issuing 586 Class D preferred shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On October 12, 2016, our share capital as registered with the Commercial Register on October 18, 2016, was increased by issuing 7 Class D preferred shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On October 31, 2016, our share capital as registered with the Commercial Register on November 4, 2016, was increased by issuing 33 Class D preferred shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On November 3, 2016, our share capital as registered with the Commercial Register on November 10, 2016, was increased by issuing 1 Class D preferred shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On December 12, 2016, our share capital as registered with the Commercial Register on December 15, 2016, was increased by issuing 185 Class A common shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On October 11, 2017, our share capital as registered with the Commercial Register on October 12, 2017, was increased by issuing 588 Class E preferred shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On October 24, 2017, our share capital as registered with the Commercial Register on October 30, 2017, was increased by issuing 22 Class E preferred shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On November 10, 2017, our share capital as registered with the Commercial Register on November 16, 2017, was increased by issuing 7 Class E preferred shares;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">187</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On June 19, 2018, our share capital as registered with the Commercial Register on June 29, 2018, was increased by issuing 3 Class A common shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On December 10, 2018, our share capital as registered with the Commercial Register on December 14, 2018, was increased by issuing 33 Class A common shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On January 30, 2019, our share capital as registered with the Commercial Register on February 6, 2019, was increased by issuing 6 Class A common shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On June 4, 2019, our share capital as registered with the Commercial Register on June 7, 2019, was increased by issuing 216 Class E preferred shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On June 7, 2019, our share capital as registered with the Commercial Register on June 14, 2019, was increased by issuing 2 Class E preferred shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">On June 28, 2019, our share capital as registered with the Commercial Register on July 5, 2019, was increased by issuing 77 Class E preferred shares; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
On August 22, 2019, our share capital as registered with the Commercial Register on August 28, 2019, was increased by an aggregate amount of CHF 3,714,300 through an increase of the par value of each of our Class A common shares and Class B, C, D and E preferred shares from CHF 100 to CHF 1,000;
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
On September 19, 2019, our share capital as registered with the Commercial Register on September 19, 2019, was increased by issuing 140 Class A common shares; and
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">
&#8226;
</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
In the Share Split effected on September 19, 2019, each of our issued shares was split into 15,625 shares of the same class with a par value of CHF 0.064 per share.
</td></tr></table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Articles of Association</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior to the closing of this offering, we intend to adopt amended and restated articles of association which will become effective upon the closing of this offering and the registration of the amended and restated articles of association with the Commercial Register. When we refer to our articles of association in this section, we refer to our amended and restated articles of association as they will be in force upon the closing of this offering.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Ordinary Capital Increase, Authorized and Conditional Share Capital</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Swiss law, we may increase our share capital (<i>capital-actions</i>) with a resolution of the general meeting of shareholders (ordinary capital increase) that must be carried out by the board of directors within three months of the respective general meeting in order to become effective. Under our articles of association and Swiss law, in the case of subscription and increase against payment of contributions in cash, a resolution passed by an absolute majority of the shares represented at the general meeting of shareholders is required. In the case of subscription and increase against contributions in kind or to fund acquisitions in kind, when shareholders&#146; statutory pre-emptive subscription rights or advance subscription rights are limited or withdrawn or where transformation of freely disposable equity into share capital is involved, a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented is required.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, under the Swiss Code of Obligations (the &#147;CO&#148;), our shareholders, by a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented, may empower our board of directors to issue shares of a specific aggregate par value up to a maximum of 50% of the share capital in the form of: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">conditional share capital (<i>capital-actions conditionnel</i>) for the purpose of issuing shares in connection with, among other things, (i) option and conversion rights granted in connection with warrants and convertible bonds of the Company or one of our subsidiaries or (ii) grants of rights to employees, members of our board of directors or consultants or to our subsidiaries or other persons providing services to the Company or a subsidiary to subscribe for new shares (conversion or option rights); or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">authorized share capital (<i>capital-actions autoris&#233;</i>) to be utilized by the board of directors within a period determined by the shareholders but not exceeding two years from the date of the shareholder approval.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">188</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Pre-Emptive and Advance Subscription Rights</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the CO, shareholders have pre-emptive subscription rights (<i>droits de souscription</i>) to subscribe for new issuances of shares. With respect to conditional capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders have advance subscription rights (<i>droit de </i><i>souscrire pr&#233;alablement</i>) for the subscription of such conversion rights, convertible bonds or similar debt instruments. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A resolution passed at a general meeting of shareholders by two-thirds of the shares represented and the absolute majority of the par value of the shares represented may authorize our board of directors to withdraw or limit pre-emptive subscription rights or advance subscription rights in certain circumstances.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If pre-emptive subscription rights are granted, but not exercised, the board of directors may allocate the unexercised pre-emptive subscription rights at its discretion.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our Authorized Share Capital</b></i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under our articles of association, our board of directors is authorized at any time, including to prevent takeovers and changes in control, until September 19, 2021 to increase our nominal share capital by a maximum aggregate amount of CHF 2,304,000 through the issuance of not more than 36,000,000 shares, which would have to be fully paid-in, each with a par value of CHF 0.064 per share.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Increases in partial amounts are permitted. The board of directors has the power to determine the type of contributions, the issue price and the date on which the dividend entitlement starts.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">With respect to our authorized share capital, the board of directors is authorized by our articles of association to withdraw or to limit the pre-emptive subscription rights of shareholders, and to allocate them to third parties or to us, in the event that the newly issued shares are issued under the following circumstances:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">if the issue price of the new registered shares is determined by reference to the market price;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for raising of capital (including private placements) in a fast and flexible manner, which would not be possible, or might only be possible with great difficulty or delays or at significantly less favorable conditions, without the exclusion of the statutory pre-emptive subscription rights of the existing shareholders; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for the acquisition of an enterprise, parts of an enterprise or participations, for the acquisition of products, intellectual property or licenses by or for investment projects of the Company or any of its group companies, or for the financing or refinancing of any of such transactions through a placement of shares; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for purposes of broadening the shareholder constituency of the Company in certain geographic, financial or investor markets, for purposes of the participation of strategic partners, or in connection with the listing of new shares on domestic or foreign stock exchanges; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for purposes of granting an over-allotment option or an option to purchase additional shares in a placement or sale of shares to the respective initial purchaser(s) or underwriter(s);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for the participation of members of the board of directors, members of the executive committee, employees, contractors, consultants or other persons performing services for the benefit of the Company or any of its group companies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 20% of our share capital registered in the Commercial Register without having submitted to all other shareholders a takeover offer recommended by the board of directors;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for the defense of an actual, threatened or potential takeover bid, that the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders or not to be in the Company&#8217;s interest; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for other valid grounds in the sense of Article 652b para. 2 of the CO.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">189</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This authorization is exclusively linked to the particular available authorized share capital set out in the respective article. If the period to increase our share capital out of authorized share capital lapses without having been used by the board of directors, the authorization to withdraw or to limit the pre-emptive subscription rights lapses simultaneously with such capital.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the underwriters exercise the option to purchase up to 1,224,600 additional common shares at the public offering price, such additional common shares may be issued out of the above-described authorized share capital. Accordingly, upon the consummation of this offering, and assuming that such option will be exercised in full and such shares will be issued out of the above-described authorized share capital, we expect our authorized but unissued share capital to be CHF 2,225,625.60, authorizing the issuance of up to 34,775,400 common shares.</p>

				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Our Conditional Share Capital</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Conditional Share Capital for Warrants and Convertible Bonds</i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our nominal share capital may be increased, including to prevent takeovers and changes in control, by a maximum aggregate amount of CHF 1,430,400 through the issuance of not more than 22,350,000 common shares, which would have to be fully paid-in, each with a par value of CHF 0.064 per share, by the exercise of option and conversion rights granted in connection with warrants, convertible bonds or similar instruments of the Company or one of our subsidiaries. Shareholders will not have pre-emptive subscription rights in such circumstances, but will have advance subscription rights to subscribe for such warrants, convertible bonds or similar instruments. The holders of warrants, convertible bonds or similar instruments are entitled to the new shares upon the occurrence of the applicable conversion feature. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">When issuing convertible bonds, warrants or similar instruments, the board of directors is authorized to withdraw or to limit the advance subscription right of shareholders:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for the purpose of financing or refinancing, or the payment for, the acquisition of enterprises, parts of enterprises, participations, intellectual property rights, licenses or investments;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">if the issuance occurs in domestic or international capital markets, including private placements;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 20% of the share capital registered in the Commercial Register without having submitted to all other shareholders a takeover offer recommended by the board of directors; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for the defense of an actual, threatened or potential takeover bid that the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders to accept on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders or not to be in the Company&#8217;s interest.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To the extent that the advance subscription rights are withdrawn or limited, (i) the convertible bonds, warrants or similar instruments are to be issued at market conditions; and (ii) the term to exercise the option or conversion rights may not exceed ten years from the date of issue of the respective instrument.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Conditional Share Capital for Equity Incentive Plans</i></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our nominal share capital may, to the exclusion of the pre-emptive subscription rights and advance subscription rights of shareholders, be increased by a maximum aggregate amount of CHF 873,600 through the (direct or indirect) issuance of not more than 13,650,000 common shares, which would have to be fully paid-in, each with a par value of CHF 0.064 per share, by the exercise of options, other rights to receive shares or conversion rights that have been granted to employees, members of the board of directors, contractors or consultants of the Company or of one of our subsidiaries or other persons providing services to the Company or to a subsidiary through one or more equity incentive plans created by the board of directors.</p>

				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Uncertificated Securities</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our shares are in the form of uncertificated securities (<i>droits-valeurs</i>, within the meaning of Article 973c of the CO). In accordance with Article 973c of the CO, we will maintain a non-public register of uncertificated securities (<i>registre des droits-valeurs</i>). We may at any time convert uncertificated securities into share certificates (including global certificates), one kind of certificate into another, or share certificates (including global </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">190</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">certificates) into uncertificated securities. Following entry in the share register, a shareholder may at any time request from us a written confirmation in respect of his or her shares. Shareholders are not entitled, however, to request the conversion and/or printing and delivery of share certificates. We may print and deliver certificates for shares at any time.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>General Meeting of Shareholders</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Ordinary/Extraordinary Meetings, Powers</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The general meeting of shareholders is our supreme corporate body. Under Swiss law, an annual general meeting of shareholders must be held annually within six months after the end of a corporation&#146;s financial year. In our case, this generally means on or before June 30. In addition, extraordinary general meetings of shareholders may be held.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following powers are vested exclusively in the general meeting of shareholders:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">adopting and amending the articles of association, including the change of a company&#8217;s purpose or domicile;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee, the auditors and the independent proxy;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">approving the business report, the annual statutory and consolidated financial statements, and deciding on the allocation of profits as shown on the balance sheet, in particular with regard to dividends;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">approving the aggregate amount of compensation of members of the board of directors and the executive committee;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">discharging the members of the board of directors and the executive committee from liability with respect to their conduct of business;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">dissolving a company with or without liquidation; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">deciding matters reserved to the general meeting of shareholders by law or the articles of association or submitted to it by the board of directors.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An extraordinary general meeting of shareholders may be called by a resolution of the board of directors or the general meeting of shareholders or, under certain circumstances, by a company&#146;s auditor, liquidator or the representatives of bondholders, if any. In addition, the board of directors is required to convene an extraordinary general meeting of shareholders if shareholders representing at least 10% of our share capital request such general meeting of shareholders in writing. Such request must set forth the items to be discussed and the proposals to be acted upon. The board of directors must convene an extraordinary general meeting of shareholders and propose financial restructuring measures if, based on our stand-alone annual statutory balance sheet, half of our share capital and statutory reserves are not covered by our assets.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Voting and Quorum Requirements </i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Shareholder resolutions and elections (including elections of members of the board of directors) require the affirmative vote of the absolute majority of shares represented at the general meeting of shareholders, unless otherwise stipulated by law or our articles of association.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Swiss law and our articles of association, a resolution of the general meeting of the shareholders passed by two-thirds of the shares represented at the meeting, and the absolute majority of the par value of the shares represented is required for:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">amending the Company&#8217;s corporate purpose;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">creating shares with preference rights;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">cancelling or amending the transfer restrictions of shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">creating authorized or conditional share capital;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">increasing share capital out of equity, against contributions in-kind or for the purpose of acquiring specific assets and granting specific benefits;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">191</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">limiting or withdrawing shareholder&#8217;s pre-emptive subscription rights;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">changing a company&#8217;s domicile;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">amending or repealing the voting and recording restrictions, the provision setting a maximum board size or the indemnification provision for the board of directors and the executive committee set forth in our articles of association;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">converting registered shares into bearer shares; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">removing the chairman or any member of the board of directors before the end of his or her term of office; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">dissolving or liquidating the Company.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The same voting requirements apply to resolutions regarding transactions among corporations based on Switzerland&#146;s Federal Act on Mergers, Demergers, Transformations and the Transfer of Assets of 2003, as amended (the &#147;Swiss Merger Act&#148;). See &#147;&#8212;Articles of Association&#8212;Compulsory Acquisitions; Appraisal Rights.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In accordance with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from NYSE listing standards, which require an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Notice</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">General meetings of shareholders must be convened by the board of directors at least 20 days before the date of the meeting. The general meeting of shareholders is convened by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette of Commerce. Registered shareholders may also be informed by ordinary mail or e-mail. The notice of a general meeting of shareholders must state the items on the agenda, the motions to the shareholders and, in case of elections, the names of the nominated candidates. A resolution on a matter which is not on the agenda may not be passed at a general meeting of shareholders, except for motions to convene an extraordinary general meeting of shareholders or to initiate a special investigation, on which the general meeting of shareholders may vote at any time. No previous notification is required for motions concerning items included in the agenda or for debates that do not result in a vote.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All of the owners or representatives of our shares may, if no objection is raised, hold a general meeting of shareholders without complying with the formal requirements for convening general meetings of shareholders (a universal meeting). This universal meeting of shareholders may discuss and pass binding resolutions on all matters within the purview of the general meeting of shareholders, provided that the owners or representatives of all the shares are present at the meeting.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Agenda Requests</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to Swiss law and our articles of association, one or more shareholders, whose combined shareholdings represent the lower of (i) one tenth of our share capital and (ii) an aggregate par value of at least CHF 1,000,000 may request that an item be included in the agenda for a general meeting of shareholders. To be timely, the shareholder&#146;s request must be received by us generally at least 45 calendar days in advance of the meeting. The request must be made in writing and contain, for each of the agenda items, the following information: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a brief description of the business desired to be brought before the general meeting of shareholders and the reasons for conducting such business at the general meeting of shareholders;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the motions regarding the agenda item; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the name and address, as they appear in the share register, of the shareholder proposing such business;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the number of shares which are beneficially owned by such shareholder (including documentary support of such beneficial ownership);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the dates upon which the shareholder acquired such shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any material interest of the proposing shareholder in the proposed business;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">192</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a statement in support of the matter; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">all other information required under the applicable laws and stock exchange rules.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, if the shareholder intends to solicit proxies from the shareholders of a company, such shareholder shall notify the company of this intent in accordance with SEC Rule 14a-4 and/or Rule 14a-8.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our business report, the compensation report and the auditor&#146;s report must be made available for inspection by the shareholders at our registered office no later than 20 days prior to the general meeting of shareholders. Shareholders of record may be notified of this in writing.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Voting Rights</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Each of our common shares entitles a holder to one vote. The common shares are not divisible. The right to vote and the other rights of share ownership may only be exercised by shareholders (including any nominees) or usufructuaries who are entered in the share register at a cut-off date determined by the board of directors. Those entitled to vote in the general meeting of shareholders may be represented by the independent proxy holder (annually elected by the general meeting of shareholders), by its legal representative or by another registered shareholder with written authorization to act as proxy. The chairman has the power to decide whether to recognize a power of attorney.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our articles of association contain provisions that prevent investors from acquiring voting rights exceeding 15% of our issued share capital. Specifically, if an individual or legal entity acquires common shares and, as a result, directly or indirectly, has voting rights with respect to more than 15% of the registered share capital recorded in the Commercial Register, the registered shares exceeding the limit of 15% shall be entered in the share register as shares without voting rights (<i>limitation &#224; l&#146;inscription</i>). This restriction applies equally to parties acting in concert and to shares held or acquired via a nominee, including via Cede &amp; Co., New York (or any successor), as the nominee of The Depository Trust Company (&#147;DTC&#148;), New York, acting in its capacity as clearing nominee. Specifically, if shares are being held by a nominee for third party beneficiaries, which control (alone or together with third parties) voting rights with respect to more than 15% of the share capital recorded in the Commercial Register, our articles of association provide that the board of directors may cancel the registration of the shares with voting rights held by such nominee in excess of the limit of 15%. Furthermore, our articles of association contain provisions that allow the board of directors to make the registration with voting rights of shares held by a nominee subject to conditions, limitations and reporting requirements or to impose or adjust such conditions, limitations and requirements once registered. However, any shareholders holding more than 15% prior to the filing and effectiveness of our amended and restated articles of association will remain registered with voting rights for such shares. Furthermore, the board of directors may in special cases approve exceptions to these restrictions. </p>

				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Dividends and Other Distributions</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our board of directors may propose to shareholders that a dividend or other distribution be paid but cannot itself authorize the distribution. Dividend payments require a resolution passed by an absolute majority of the shares represented at a general meeting of shareholders. In addition, our auditors must confirm that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles of association.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Swiss law, we may pay dividends only if we have sufficient distributable profits from the previous business year (<i>b&#233;n&#233;fice de l&#146;exercice</i>) or brought forward from the previous business years (<i>report des b&#233;n&#233;fices</i>), or if we have distributable reserves (<i>r&#233;serves &#224; libre disposition</i>), each as evidenced by the Company&#146;s audited stand-alone statutory balance sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and by the articles of association have been deducted. We are not permitted to pay interim dividends out of profit of the current business year.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Distributable reserves are generally booked either as &#147;free reserves&#148; (<i>r&#233;serves libres</i>) or as &#147;reserve from capital contributions&#148; (<i>apports de capital</i>). Under the CO, if our general reserves (<i>r&#233;serve g&#233;n&#233;rale</i>) amount to less than 20% of our share capital recorded in the Commercial Register (i.e., 20% of the aggregate par value of our issued capital), then at least 5% of our annual profit must be retained as general reserves. In addition, if our general reserves amount to less than 50% of our share capital recorded in the Commercial Register, 10% of the amounts distributed beyond payment of a dividend of 5% must be retained as general reserves. The CO permits us to accrue additional general reserves. Further, a purchase of our own shares (whether by us or a subsidiary) </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">193</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">reduces the distributable reserves in an amount corresponding to the purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which are not distributable.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Distributions out of issued share capital (i.e., the aggregate par value of our issued shares) are not allowed and may be made only by way of a share capital reduction. Such a capital reduction requires a resolution passed by an absolute majority of the shares represented at a general meeting of shareholders. The resolution of the shareholders must be recorded in a public deed and a special audit report must confirm that claims of our creditors remain fully covered despite the reduction in our share capital recorded in the Commercial Register. Our share capital may be reduced below CHF 100,000 only if and to the extent that at the same time the statutory minimum share capital of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval by the general meeting of shareholders of the capital reduction, the board of directors must give public notice of the capital reduction resolution in the Swiss Official Gazette of Commerce three times and notify creditors that they may request, within two months of the third publication, satisfaction of or security for their claims. The reduction of our share capital may be implemented only after expiration of this time limit.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our board of directors determines the date on which the dividend entitlement starts. Dividends are usually due and payable shortly after the shareholders have passed the resolution approving the payment, but shareholders may also resolve at the annual general meeting of shareholders to pay dividends in quarterly or other installments.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For a discussion of the taxation of dividends, see &#147;Taxation&#8212;Swiss Tax Considerations&#8212;Swiss Federal, Cantonal and Communal Individual Income Tax and Corporate Income Tax.&#148;</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Transfer of Shares</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Shares in uncertificated form (<i>droits-valeurs</i>) may only be transferred by way of assignment. Shares or the beneficial interest in shares, as applicable, credited in a securities account may only be transferred when a credit of the relevant intermediated securities to the acquirer&#146;s securities account is made in accordance with applicable rules. Our articles of association provide that in the case of securities held with an intermediary such as a registrar, transfer agent, trust corporation, bank or similar entity, any transfer, grant of a security interest or usufructuary right in such intermediated securities and the appurtenant rights associated therewith requires the cooperation of the intermediary in order for such transfer, grant of a security interest or usufructuary right to be valid against us.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Voting rights may be exercised only after a shareholder has been entered in the share register (<i>registre des </i><i>actions</i>) with his or her name and address (in the case of legal entities, the registered office) as a shareholder with voting rights. For a discussion of the restrictions applicable to the control and exercise of voting rights, see &#147;Description of Share Capital and Articles of Association&#8212;Articles of Association&#8212;Voting Rights.&#148;</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Inspection of Books and Records </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the CO, a shareholder has a right to inspect the share register with respect to his or her own shares and otherwise to the extent necessary to exercise his or her shareholder rights. No other person has a right to inspect the share register. Our books and correspondence may be inspected with the express authorization of the general meeting of shareholders or by resolution of the board of directors and subject to the safeguarding of our business secrets and other legitimate interests. See &#147;Comparison of Swiss Law and Delaware Law&#8212;Inspection of books and records.&#148;</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Special Investigation</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If the shareholders&#146; inspection rights as outlined above prove to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting of shareholders that specific facts be examined by a special examiner in a special investigation. If the general meeting of shareholders approves the proposal, we or any shareholder may, within 30 calendar days after the general meeting of shareholders, request a court at our registered office (currently Epalinges, Canton of Vaud, Switzerland), to appoint a special examiner. If the general meeting of shareholders rejects the request, one or more shareholders representing at least 10% of our share capital or holders of shares in an aggregate par value of at least CHF 2,000,000 may request that the court appoint a special examiner. The court will issue such an order if the petitioners can demonstrate that the board of directors, any member of the board of directors or our executive committee infringed the law or our articles of association and thereby caused damages to the Company or the shareholders. The costs of the investigation would generally be allocated to us and only in exceptional cases to the petitioners. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">194</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Compulsory Acquisitions; Appraisal Rights</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Business combinations and other transactions that are governed by the Swiss Merger Act (i.e., mergers, demergers, transformations and certain asset transfers) are binding on all shareholders. A statutory merger or demerger requires approval of two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If a transaction under the Swiss Merger Act receives all of the necessary consents, all shareholders are compelled to participate in such transaction.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Swiss corporations may be acquired by an acquirer through the direct acquisition of the shares of the Swiss corporation. The Swiss Merger Act provides for the possibility of a so-called &#147;cash-out&#148; or &#147;squeeze-out&#148; merger with the approval of holders of 90% of the issued shares. In these limited circumstances, minority shareholders of the corporation being acquired may be compensated in a form other than through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of the acquiring corporation or of another corporation). For business combinations effected in the form of a statutory merger or demerger and subject to Swiss law, the Swiss Merger Act provides that if equity rights have not been adequately preserved or compensation payments in the transaction are unreasonable, a shareholder may request the competent court to determine a reasonable amount of compensation.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, under Swiss law, the sale of &#147;all or substantially all of our assets&#148; by us may require the approval of two-thirds of the number of shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented. Whether a shareholder resolution is required depends on the particular transaction, including whether the following test is satisfied:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a core part of our business is sold without which it is economically impracticable or unreasonable to continue to operate the remaining business;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our assets, after the divestment, are not invested in accordance with our corporate purpose as set forth in the articles of association; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the proceeds of the divestment are not earmarked for reinvestment in accordance with our corporate purpose but, instead, are intended for distribution to our shareholders or for financial investments unrelated to our corporate purpose.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A shareholder of a Swiss corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights. As a result, such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that the shareholder receives the fair value of the shares held by the shareholder. Following a statutory merger or demerger, pursuant to the Swiss Merger Act, shareholders can file an appraisal action against the surviving company. If the consideration is deemed inadequate, the court will determine an adequate compensation payment.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Board of Directors</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our articles of association provide that the board of directors shall consist of at least three and not more than 10 members.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The members of the board of directors and the chairman are elected annually by the general meeting of shareholders for a period until the completion of the subsequent annual general meeting of shareholders and are eligible for re-election. Each member of the board of directors must be elected individually.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Powers</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The board of directors has the following non-delegable and inalienable powers and duties:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the ultimate direction of the business of the Company and issuing of the relevant directives;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">laying down the organization of the Company;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">formulating accounting procedures, financial controls and financial planning;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">nominating and removing persons entrusted with the management and representation of the Company and regulating the power to sign for the Company;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">195</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to law, our articles of association, and regulations and directives of the Company;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">issuing the business report and the compensation report, and preparing for the general meeting of shareholders and carrying out its resolutions; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">informing the court in case of over-indebtedness.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The board of directors may, while retaining such non-delegable and inalienable powers and duties, delegate some of its powers, in particular direct management, to a single or to several of its members, committees or to third parties (such as executive officers) who need be neither members of the board of directors nor shareholders. Pursuant to Swiss law and our articles of association, details of the delegation and other procedural rules such as quorum requirements have been set in the organizational rules established by the board of directors. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Indemnification of Executive </i><i>Officers</i><i> and Directors</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to Swiss law, our articles of association provide for indemnification of the existing and former members of the board of directors and the executive committee and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and permits us to advance the expenses of defending any act, suit or proceeding to our directors and executive officers to the extent not included in insurance coverage or advanced by third parties.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of his or her duties under the employment agreement with the employer. See &#147;Comparison of Swiss Law and Delaware Law&#8212;Indemnification of directors and executive officers and limitation of liability.&#148;</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into indemnification agreements with each of the members of our board of directors and executive officers. See &#147;Related Party Transactions&#8212;Indemnification Agreements.&#148;</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Conflict of Interest, Management Transactions </i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Swiss law does not have a general provision regarding conflicts of interest. However, the CO contains a provision that requires our directors and executive officers to safeguard the Company&#146;s interests and imposes a duty of loyalty and duty of care on our directors and executive officers. This rule is generally understood to disqualify directors and executive officers from participation in decisions that directly affect them. Our directors and executive officers are personally liable to us for breaches of these obligations. In addition, Swiss law contains provisions under which directors and all persons engaged in the Company&#146;s management are liable to the Company, each shareholder and the Company&#146;s creditors for damages caused by an intentional or negligent violation of their duties. Furthermore, Swiss law contains a provision under which payments made to any of the Company&#146;s shareholders or directors or any person related to any such shareholder or director, other than payments made at arm&#146;s length, must be repaid to the Company if such shareholder or director acted in bad faith.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon the closing of this offering, our board of directors will adopt a Code of Business Conduct and Ethics and other policies that will cover a broad range of matters, including the handling of conflicts of interest.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Principles of the Compensation of the Board of Directors and the Executive </i><i>Committee</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to Swiss law, beginning at our first annual meeting as a public company in 2020, our shareholders must annually approve the aggregate amount of compensation of the board of directors and the persons whom the board of directors has, fully or partially, entrusted with the management (which we refer to as our &#147;executive committee&#148;) of the Company. All of our executive officers named in &#8220;Management&#8221; are deemed to be members of our executive committee.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The board of directors must issue, on an annual basis, a written compensation report that must be reviewed by our auditors. The compensation report must disclose all compensation granted by the Company, directly or indirectly, to current members of the board of directors and the executive committee and, to the extent related to their former role within the Company or not on customary market terms, to former members of the board of directors and former executive officers.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">196</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The disclosure concerning compensation, loans and other forms of indebtedness must include the aggregate amount for the board of directors and the executive committee, respectively, as well as the particular amount for each member of the board of directors and for the highest paid executive officer, specifying the name and function of each of these persons.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are prohibited from granting certain forms of compensation to members of our board of directors and executive committee, such as:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">severance payments (compensation due until the termination of a contractual relationship does not qualify as severance payment);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">advance compensation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">incentive fees for the acquisition or transfer of companies, or parts thereof, by the Company or by companies being, directly or indirectly, controlled by us;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation not provided for in the articles of association; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">equity-based compensation not provided for in the articles of association.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Compensation to members of the board of directors and the executive committee for activities in entities that are, directly or indirectly, controlled by the Company is prohibited if (i) the compensation would be prohibited if it were paid directly by the Company, (ii) the articles of association do not provide for it, or (iii) the compensation has not been approved by the general meeting of shareholders. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Beginning in 2020, the general meeting of shareholders will annually vote on the proposals of the board of directors with respect to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the maximum aggregate amount of compensation of the board of directors for the term of office until the next annual general meeting of shareholders; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the maximum aggregate amount of fixed compensation of the executive committee for the following financial year; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the maximum aggregate amount of variable compensation of the executive committee for the current financial year.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The board of directors may submit for approval at the general meeting of shareholders deviating or additional proposals relating to the same or different periods.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the event that, at the general meeting of shareholders, the shareholders do not approve a compensation proposal of the board of directors, the board of directors must prepare a new proposal, taking into account all relevant factors, and submit the new proposal for approval by the same general meeting of shareholders, at a subsequent extraordinary general meeting of shareholders or the next annual general meeting of shareholders.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition to fixed compensation, members of the board of directors and the executive committee may be paid variable compensation, depending on the achievement of certain performance criteria. The performance criteria may include individual targets, targets of the Company or parts thereof and targets in relation to the market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient of the variable compensation. The board of directors or, where delegated to it, the compensation committee shall determine the relative weight of the performance criteria and the respective target values.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Compensation may be paid or granted in the form of cash, shares, financial instruments, in kind, or in the form of other types of benefits. The board of directors or, where delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Borrowing Powers</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Neither Swiss law nor our articles of association restrict in any way our power to borrow and raise funds. The decision to borrow funds is made by or under the direction of our board of directors, and no approval by the shareholders is required in relation to any such borrowing.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">197</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Repurchases of Shares and Purchases of Own Shares</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The CO limits our ability to repurchase and hold our own shares. We and our subsidiaries may repurchase shares only to the extent that (i) we have freely distributable reserves in the amount of the purchase price; and (ii) the aggregate par value of all shares held by us does not exceed 10% of our share capital. Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out in the articles of association, the foregoing upper limit is 20%. If we own shares that exceed the threshold of 10% of our share capital, the excess must be sold or cancelled by means of a capital reduction within two years.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Shares held by us or our subsidiaries are not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable to the shares generally, including dividends and pre-emptive subscription rights in the case of share capital increases.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, selective share repurchases are only permitted under certain circumstances. Within these limitations, as is customary for Swiss corporations, we may, subject to applicable law, purchase and sell our own shares from time to time in order to meet imbalances of supply and demand, to provide liquidity and to even out variances in the market price of shares.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Notification and Disclosure of Substantial Share Interests </b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The disclosure obligations generally applicable to shareholders of Swiss corporations under the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading, or the Financial Market Infrastructure Act (the &#147;FMIA&#148;), do not apply to us since our shares are not listed on a Swiss exchange.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to Article 663c of the CO, Swiss corporations whose shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in the notes to their statutory annual financial statements, to the extent this information is known or ought to be known. Significant shareholders are defined as shareholders and groups of shareholders linked through voting rights who hold more than 5% of all voting rights.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Mandatory Bid Rules</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The obligation of any person or group of persons that acquires more than one third of a company&#146;s voting rights to submit a cash offer for all the outstanding listed equity securities of the relevant company at a minimum price pursuant to the FMIA does not apply to us since our shares are not listed on a Swiss exchange.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Stock Exchange Listing</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our common shares have been approved for listing on the NYSE under the symbol &#147;ADCT.&#148;</p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>The Depository Trust Company</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Initial settlement of the common shares issued in this offering will take place on the consummation date of this offering through DTC, in accordance with its customary settlement procedures for equity securities. Each person owning a beneficial interest in common shares held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the shares.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Transfer Agent and Registrar of Shares</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our share register will initially be kept by Computershare Trust Company, N.A., which acts as transfer agent and registrar. The share register reflects only record owners of our shares. Swiss law does not recognize fractional share interests.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">198</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 110-comparision -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tCOSL"></a><b>COMPARISON OF SWISS LAW AND DELAWARE LAW</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Swiss laws applicable to Swiss corporations and their shareholders differ from laws applicable to U.S. corporations and their shareholders. The following table summarizes significant differences in shareholder rights between the provisions of the Swiss Code of Obligations (<i>Code des obligations</i>) and the Swiss Ordinance against excessive compensation in listed stock corporations applicable to our Company and the Delaware General Corporation Law applicable to companies incorporated in Delaware and their shareholders. Please note that this is only a general summary of certain provisions applicable to companies in Delaware. Certain Delaware companies may be permitted to exclude certain of the provisions summarized below in their charter documents.</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>DELAWARE CORPORATE LAW</b></div>
							</td>
							<td width="51%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>SWISS CORPORATE LAW</b></div>
							</td>
						</tr>


						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; "><i><b>Mergers and similar arrangements</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock without a vote by the shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Under Swiss law, with certain exceptions, a merger or a demerger of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the absolute majority of the par value of shares represented at such general meeting of shareholders. A shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant to the Swiss Merger Act (<i>Loi sur la fusion</i>) can file a lawsuit against the surviving company. If the consideration is deemed &#147;inadequate,&#148; such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that if the merger agreement provides only for a compensation payment, at least 90.0% of all members in the transferring legal entity, who are entitled to vote, shall approve the merger agreement.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; "><i><b>Shareholders&#8217; suits</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party to recover attorneys&#8217; fees incurred in connection with such action.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may have a similar effect. A shareholder is entitled to bring suit against directors for breach of their duties and claim the payment of the company&#8217;s losses or damages to the corporation and, in some cases, to the individual shareholder. Likewise, an appraisal lawsuit won by a shareholder may indirectly compensate all shareholders. In addition, to the extent that U.S. laws and regulations provide a basis for liability and U.S. courts have jurisdiction, a class action may be available.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Under Swiss law, the winning party is generally entitled to recover a limited amount of attorneys&#8217; fees incurred in connection with such action. The court has discretion to permit the shareholder who lost the lawsuit to recover attorneys&#8217; fees incurred to the extent he acted in good faith.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">199</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>DELAWARE CORPORATE LAW</b></div>
							</td>
							<td width="51%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>SWISS CORPORATE LAW</b></div>
							</td>
						</tr>


						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; "><i><b>Shareholder vote on board and management compensation</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Pursuant to the Swiss Ordinance against excessive compensation in listed stock corporations (<i>Ordonnance </i><i>contre les r&#233;mun&#233;rations abusives dans les soci&#233;t&#233;s </i><i>anonymes cot&#233;es en bourse</i>), the general meeting of shareholders has the non-transferable right, amongst others, to vote separately and bindingly on the aggregate amount of compensation of the members of the board of directors, of the executive committee and of the advisory boards.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; "><i><b>Annual vote on board renewal</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Unless directors are elected by written consent in lieu of an annual meeting, directors are elected in an annual meeting of shareholders on a date and at a time designated by or in the manner provided in the bylaws. Re-election is possible.<br>&nbsp;&nbsp;&nbsp;<br>Classified boards are permitted.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">The general meeting of shareholders elects the members of the board of directors, the chairperson of the board of directors and the members of the compensation committee individually and annually for a term of office until the end of the following general meeting of shareholders. Re-election is possible.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; "><i><b>Indemnification of directors and executive </b></i><i><b>officers</b></i><i><b> and limitation of liability</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">The Delaware General Corporation Law provides that a certificate of incorporation may contain a provision eliminating or limiting the personal liability of directors (but not other controlling persons) of the corporation for monetary damages for breach of a fiduciary duty as a director, except no provision in the certificate of incorporation may eliminate or limit the liability of a director for:<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;any breach of a director&#8217;s duty of loyalty to the<br> &nbsp;&nbsp;&#8201;&#8201;&nbsp;corporation or its shareholders;<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;acts or omissions not in good faith or which<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;involve intentional misconduct or a knowing<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;violation of law;<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;statutory liability for unlawful payment of<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;dividends or unlawful share purchase or<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;redemption; or<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;any transaction from which the director derived an<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;improper personal benefit.<br>&nbsp;&nbsp;&nbsp;<br>A Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any proceeding, other than an action by or on behalf of the corporation, because the person is or was a director or officer, against liability incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably </div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Under Swiss corporate law, an indemnification by the corporation of a director or member of the executive committee in relation to potential personal liability is not effective to the extent the director or member of the executive committee intentionally or negligently violated his or her corporate duties towards the corporation (certain views advocate that at least a grossly negligent violation is required to exclude the indemnification). Furthermore, the general meeting of shareholders may discharge (release) the directors and members of the executive committee from liability for their conduct to the extent the respective facts are known to shareholders. Such discharge is effective only with respect to claims of the company and of those shareholders who approved the discharge or who have since acquired their shares in full knowledge of the discharge. Most violations of corporate law are regarded as violations of duties towards the corporation rather than towards the shareholders. In addition, indemnification of other controlling persons is not permitted under Swiss corporate law, including shareholders of the corporation.<br>&nbsp;&nbsp;&nbsp;<br>The articles of association of a Swiss corporation may also set forth that the corporation shall indemnify and hold harmless, to the extent permitted by the law, the directors and executive managers out of assets of the corporation against threatened, pending or completed actions.<br>&nbsp;&nbsp;&nbsp;<br></div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">200</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>DELAWARE CORPORATE LAW</b></div>
							</td>
							<td width="51%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>SWISS CORPORATE LAW</b></div>
							</td>
						</tr>


						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">believed to be in, or not opposed to, the best interests of the corporation; and the director or officer, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.<br>&nbsp;&nbsp;&nbsp;<br> Unless ordered by a court, any foregoing indemnification is subject to a determination that the director or officer has met the applicable standard of conduct:<br>&nbsp;&nbsp;&nbsp;<br> &#8226; &nbsp;&#8201;&#8201;by a majority vote of the directors who are not<br> &nbsp;&nbsp;&#8201;&#8201;&#8201;parties to the proceeding, even though less than a<br> &nbsp;&nbsp;&#8201;&#8201;&#8201;quorum;<br> &nbsp;&nbsp;&nbsp;<br> &#8226;&nbsp;&nbsp;&#8201;by a committee of directors designated by a<br> &nbsp;&nbsp;&#8201;&#8201;&#8201;majority vote of the eligible directors, even though<br> &nbsp;&nbsp;&#8201;&#8201;&#8201;less than a quorum;<br> &nbsp;&nbsp;&nbsp;<br> &#8226;&nbsp;&nbsp;&#8201;&#8201;by independent legal counsel in a written opinion<br> &nbsp;&nbsp;&#8201;&#8201;&#8201;&#8201;if there are no eligible directors, or if the eligible<br> &nbsp;&nbsp;&#8201;&#8201;&#8201;&#8201;directors so direct; or<br> &nbsp;&nbsp;&nbsp;<br> &#8226;&nbsp;&nbsp;&#8201;&#8201;by the shareholders.<br> &nbsp;&nbsp;&nbsp;<br>Moreover, a Delaware corporation may not indemnify a director or officer in connection with any proceeding in which the director or officer has been adjudged to be liable to the corporation unless and only to the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances of the case, the director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper. </div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Also, a corporation may enter into and pay for directors&#146; and officers&#146; liability insurance which may cover negligent acts as well. </div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; "><i><b>Directors&#8217; fiduciary duties</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">A director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components:<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;the duty of care; and<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;the duty of loyalty.<br>&nbsp;&nbsp;&nbsp;<br>The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction.<br>&nbsp;&nbsp;&nbsp;<br>The duty of loyalty requires that a director act in a</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">The board of directors of a Swiss corporation manages the business of the corporation, unless responsibility for such management has been duly delegated to the executive committee based on organizational rules. However, there are several non-transferable duties of the board of directors:<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;the overall management of the corporation and the<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;issuing of all necessary directives;<br>&nbsp;&nbsp;&nbsp;<br> &#8226;&nbsp;&nbsp;&#8201;&#8201;determination of the corporation&#8217;s organization;<br>&nbsp;&nbsp;&nbsp;<br> &#8226;&nbsp;&nbsp;&#8201;&#8201;the organization of the accounting, financial<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;control and financial planning systems as required<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;for management of the corporation;<br>&nbsp;&nbsp;&nbsp;<br> </div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">201</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>DELAWARE CORPORATE LAW</b></div>
							</td>
							<td width="51%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>SWISS CORPORATE LAW</b></div>
							</td>
						</tr>


						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties.<br>&nbsp;&nbsp;&nbsp;<br>Should such evidence be presented concerning a transaction by a director, a director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#8226;&nbsp;&nbsp;&#8201;&#8201;the appointment and dismissal of persons<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;entrusted with managing and representing the<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;corporation;<br>&nbsp;&nbsp;&nbsp;<br> &#8226;&nbsp;&nbsp;&#8201;&#8201;overall supervision of the persons entrusted with<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;managing the corporation, in particular with<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;regard to compliance with the law, articles of<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;association, operational regulations and directives;<br>&nbsp;&nbsp;&nbsp;<br> &#8226;&nbsp;&nbsp;&#8201;&#8201;compilation of the annual report, preparation for<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;the general meeting of the shareholders, the<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;compensation report and implementation of its<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;resolutions; and<br>&nbsp;&nbsp;&nbsp;<br> &#8226;&nbsp;&nbsp;&#8201;&#8201;notification of the court in the event that the<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;company is over-indebted.<br> &nbsp;&nbsp;&nbsp;<br>The members of the board of directors must perform their duties with all due diligence and safeguard the interests of the corporation in good faith. They must afford the shareholders equal treatment in equal circumstances.<br>&nbsp;&nbsp;&nbsp;<br>The duty of care requires that a director act in good faith, with the care that an ordinarily prudent director would exercise under like circumstances<br>&nbsp;&nbsp;&nbsp;<br>The duty of loyalty requires that a director safeguard the interests of the corporation and requires that directors act in the interest of the corporation and, if necessarily, put aside their own interests. If there is a risk of a conflict of interest, the board of directors must take appropriate measures to ensure that the interests of the company are duly taken into account.<br>&nbsp;&nbsp;&nbsp;<br>The burden of proof for a violation of these duties is with the corporation or with the shareholder bringing a suit against the director.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Shareholder action by written consent</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent.</div>
							</td>
							<td colspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Shareholders of a Swiss corporation may only exercise their voting rights in a general meeting of shareholders and may not act by written consents. The articles of association must allow for (independent) proxies to be present at a general meeting of shareholders. The instruction of such (independent) proxies may occur in writing or electronically.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Shareholder proposals</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice</div>
							</td>
							<td colspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">At any general meeting of shareholders any shareholder may put proposals to the meeting if the proposal is part of an agenda item. No resolution may be taken on </div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">202</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>DELAWARE CORPORATE LAW</b></div>
							</td>
							<td width="51%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>SWISS CORPORATE LAW</b></div>
							</td>
						</tr>


						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.</div>
							</td>
							<td colspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">proposals relating to the agenda items that were not duly notified. Unless the articles of association provide for a lower threshold or for additional shareholders&#8217; rights:<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;shareholders together representing at least 10% of<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;the share capital may demand that a general meeting<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;of shareholders be called for specific agenda items<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;and specific proposals; and<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;shareholders together representing shares with a par<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;value of at least CHF 1.0 million or 10% of the<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;share capital, whichever is lower, may demand that<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;an agenda item including a specific proposal be put<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;on the agenda for a scheduled general meeting of<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;shareholders, provided such request is made with<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;appropriate lead time.<br>&nbsp;&nbsp;&nbsp;<br>Any shareholder can propose candidates for election as directors or make other proposals within the scope of an agenda item without prior written notice.<br>&nbsp;&nbsp;&nbsp;<br>In addition, any shareholder is entitled, at a general meeting of shareholders and without advance notice, to (i) request information from the board of directors on the affairs of the company (note, however, that the right to obtain such information is limited), (ii) request information from the auditors on the methods and results of their audit, (iii) request that the general meeting of shareholders resolve to convene an extraordinary general meeting, or (iv) request that the general meeting of shareholders resolve appoint an examiner to carry out a special examination (&#147;<i>contr&#244;le sp&#233;cial</i>&#148;).</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Cumulative voting</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#8217;s certificate of incorporation provides for it.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Cumulative voting is not permitted under Swiss corporate law. Pursuant to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate their votes for single candidates. An annual individual election of (i) all members of the board of directors, (ii) the chairperson of the board of directors, (iii) the members of the compensation committee, (iv) the election of the independent proxy for a term of office of one year (i.e., until the following annual general meeting of shareholders), as well as the vote on the aggregate amount of compensation of the members of the board of directors, of the executive committee and of the members of any advisory board, is mandatory for listed companies. Re-election is permitted.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">203</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>DELAWARE CORPORATE LAW</b></div>
							</td>
							<td width="51%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>SWISS CORPORATE LAW</b></div>
							</td>
						</tr>


						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Removal of directors</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by a majority of the shares represented at a general meeting of shareholders. The articles of association may require the approval by a supermajority of the shares represented at a meeting for the removal of a director.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Transactions with interested shareholders</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an &#147;interested shareholder&#148; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation&#8217;s outstanding voting shares within the past three years.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">No such rule applies to a Swiss corporation.</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Dissolution; Winding up</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#8217;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.</div>
							</td>
							<td colspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">A dissolution of a Swiss corporation requires the approval by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the absolute majority of the nominal value of shares represented at such general meeting of shareholders. The articles of association may increase the voting thresholds required for such a resolution.</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Variation of rights of shares</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.</div>
							</td>
							<td colspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">The general meeting of shareholders of a Swiss corporation may resolve that preference shares be issued or that existing shares be converted into preference shares with a resolution passed by a majority of the shares represented at the general meeting of shareholders. Where a company has issued preference shares, further preference shares conferring preferential rights over the existing preference shares may be issued only with the consent of both a special meeting of the adversely affected holders of the existing preference shares and of a general meeting of all shareholders, unless otherwise provided in the articles of association.<br>&nbsp;&nbsp;&nbsp;<br>Shares with preferential voting rights are not regarded as preference shares for these purposes.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">204</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>DELAWARE CORPORATE LAW</b></div>
							</td>
							<td width="51%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 4px; "><b>SWISS CORPORATE LAW</b></div>
							</td>
						</tr>


						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Amendment of governing documents</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">A Delaware corporation&#8217;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</div>
							</td>
							<td colspan="2" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">The articles of association of a Swiss corporation may be amended with a resolution passed by a majority of the shares represented at a general meeting of shareholders, unless otherwise provided in the articles of association.<br>&nbsp;&nbsp;&nbsp;<br>There are a number of resolutions, such as an amendment of the stated purpose of the corporation, the introduction of authorized and conditional capital and the introduction of shares with preferential voting rights that require the approval by two-thirds of the votes and an absolute majority of the nominal value of the shares represented at such general meeting of shareholders. The articles of association may increase these voting thresholds.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Inspection of books and records</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Shareholders of a Swiss corporation may only inspect books and records if the general meeting of shareholders or the board of directors approved such inspection. The information may be refused where providing it would jeopardize the corporation&#8217;s trade secrets or other interests warranting protection. A shareholder is only entitled to receive information to the extent required to exercise his or her rights as a shareholder, subject to the interests of the corporation. A shareholder&#8217;s right to inspect the share register is limited to the right to inspect his or her own entry in the share register.</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><i><b>Payment of dividends</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">The board of directors may approve a dividend without shareholder approval. Subject to any restrictions contained in its certificate of incorporation, the board may declare and pay dividends upon the shares of its capital stock either:<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;out of its surplus, or<br>&nbsp;&nbsp;&nbsp;<br>&#8226;&nbsp;&nbsp;&#8201;&#8201;in case there is no such surplus, out of its net<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;profits for the fiscal year in which the dividend is<br> &nbsp;&nbsp;&nbsp;&#8201;&#8201;declared and/or the preceding fiscal year.<br>&nbsp;&nbsp;&nbsp;<br>Shareholder approval is required to authorize capital stock in excess of that provided in the charter. Directors may issue authorized shares without shareholder approval. </div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Dividend payments are subject to the approval of the general meeting of shareholders. The board of directors may propose to shareholders that a dividend shall be paid but cannot itself authorize the distribution.<br>&nbsp;&nbsp;&nbsp;<br>Payments out of a corporation&#8217;s share capital (in other words, the aggregate nominal value of the corporation&#8217;s registered share capital) in the form of dividends are not allowed and may be made only by way of a share capital reduction. Dividends may be paid only from the profits of the previous business year or brought forward from previous business years or if the corporation has distributable reserves, each as evidenced by the corporation&#8217;s audited stand-alone statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and the articles of association have been deducted</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">205</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>DELAWARE CORPORATE LAW</b></div>
							</td>
							<td width="51%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>SWISS CORPORATE LAW</b></div>
							</td>
						</tr>


						<tr>
							<td colspan="2" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 0px; "><i><b>Creation and issuance of new shares</b></i></div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="49%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company&#8217;s certificate of incorporation.</div>
							</td>
							<td width="51%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">All creation of shares require a shareholders&#8217; resolution. The creation of authorized or contingent share capital requires at least two-thirds of the voting rights represented at the general meeting of shareholders and an absolute majority of the nominal value of shares represented at such meeting. The board of directors may issue shares out of the authorized share capital during a period of up to two years. Shares are created and issued out of contingent share capital through the exercise of options or of conversion rights that the board of director may grant in relation to, e.g., debt instruments or employees.</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">206</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tCSE"></a><b>COMMON SHARES ELIGIBLE FOR FUTURE SALE</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior to this offering, there was no public market for our common shares. Future sales of substantial amounts of our common shares in the public market could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of common shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on resale as described below, there may be sales of substantial amounts of our common shares in the public market after such restrictions lapse. This may adversely affect the prevailing market price and our ability to raise equity capital in the future.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon completion of this offering, we will have 73,252,000 common shares outstanding assuming no exercise of the underwriters&#146; option to purchase additional common shares. Of these shares, 8,164,000 common shares (or 9,388,600 common shares if the underwriters exercise in full their option to purchase additional shares) will be freely transferable without restriction or registration under the Securities Act, except for any common shares purchased by one of our existing &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The remaining 65,088,000 common shares outstanding are &#147;restricted shares&#148; as defined in Rule 144. Restricted shares may be sold in the public market only if registered or if they qualify for an exemption from registration under Rule 144 or 701 of the Securities Act. After the expiration of the contractual 180-day lock-up period described below, to the extent applicable, these common shares may be sold in the public market only if registered or pursuant to an exemption under Rule 144 or 701, each of which is summarized below. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Rule 144 </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In general, a person who has beneficially owned our common shares that are restricted shares for at least six months would be entitled to sell such securities, provided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, the sale and (ii) we are subject to, and in compliance with certain of, the Exchange Act periodic reporting requirements for at least 90 days before the sale. If such person has beneficially owned such common shares for at least one year, then the requirement in clause (ii) will not apply to the sale. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Persons who have beneficially owned our common shares that are restricted shares for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
1% of the number of our common shares then outstanding, which will equal approximately 732,520 common shares immediately after this offering, assuming no exercise of the underwriters&#8217; option to purchase additional common shares; or
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
the average weekly trading volume of our common shares on the NYSE during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale;
</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">provided, in each case, that we are subject to, and in compliance with certain of, the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales must also comply with the manner of sale and notice provisions of Rule 144.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Rule 701</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In general, under Rule 701, any of our employees, directors, officers, consultants or advisors who purchases shares from us in connection with a compensatory share or option plan or other written agreement before the effective date of this offering is entitled to resell such shares 90 days after the effective date of this offering in reliance on Rule 144, without having to comply with the holding period requirements or other restrictions contained in Rule 701. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The SEC has indicated that Rule 701 will apply to typical share options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after the date of this prospectus. Securities issued in reliance on Rule 701 are restricted securities and, subject to the contractual restrictions described below, beginning 90 days after the date of this prospectus, may be sold by persons other than &#147;affiliates,&#148; as defined in Rule 144, subject only to the manner of sale provisions of Rule 144 and by &#147;affiliates&#148; under Rule 144 without compliance with the one-year minimum holding period requirement. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">207</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Equity Incentive Plan</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We intend to file one or more registration statements on Form S-8 under the Securities Act to register all common shares issued or issuable pursuant to the exercise of outstanding options and reserved for issuance under our 2019 Equity Incentive Plan. We expect to file the registration statement or statements, which will become effective immediately upon filing, upon or shortly after the date of this prospectus. Shares covered by these registration statements will then be eligible for sale in the public markets, subject to vesting restrictions and any applicable holding periods, any applicable lock-up agreements described below and Rule 144 limitations applicable to affiliates. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Regulation S</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Regulation S provides generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Lock-up Agreements </b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All of our directors and executive officers and the holders of substantially all of our share capital have agreed, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares or such other securities for a period of 180 days after the date of this prospectus without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. may waive the requirements of these lock-up agreements at any time in their sole discretion. See &#147;Underwriters.&#148;</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">208</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tT"></a><b>TAXATION</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following discussion is based on the tax laws, regulations and regulatory practices of Switzerland and the United States as in effect on the date hereof, which are subject to change (or subject to changes in interpretation), possibly with retroactive effect.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Current and prospective shareholders are advised to consult their own tax advisers in light of their particular circumstances as to the Swiss or U.S. tax laws, regulations and regulatory practices that could be relevant for them in connection with this offering, the acquiring, owning and selling or otherwise disposing of our common shares (such shares for purposes of this &#147;Taxation&#148; section, &#147;common shares&#148;) and receiving dividends and similar cash or in-kind distributions on our common shares (including dividends on liquidation proceeds and share dividends) or distributions on our common shares based upon a capital reduction or reserves paid out of capital contributions and the consequences thereof under the tax laws, regulations and regulatory practices of Switzerland or the United States.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Swiss Tax Considerations</b></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Withholding Tax</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under present Swiss tax law, dividends due and similar cash or in-kind distributions made by the Company to a shareholder of common shares (including liquidation proceeds and bonus shares) are subject to Swiss federal withholding tax (&#147;Withholding Tax&#148;), currently at a rate of 35% (applicable to the gross amount of taxable distribution). However, the repayment of the nominal value of the common shares and any repayment of qualifying additional paid-in capital (capital contribution reserves), within the limits accepted by the legislation in force when such Dividend becomes due and the respective administrative practice, are not subject to the Withholding Tax. The Company is obliged to deduct the Withholding Tax from the gross amount of any taxable distribution and to pay the tax to the Swiss Federal Tax Administration within 30 days of the due date of such distribution.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Swiss resident individuals who hold their common shares as private assets (&#147;Resident Private Shareholders&#148;) are in principle eligible for a full refund or credit against income tax of the Withholding Tax if they duly report the underlying income in their income tax return. In addition, (i) corporate and individual shareholders who are resident in Switzerland for tax purposes, (ii) corporate and individual shareholders who are not resident in Switzerland, and who, in each case, hold their common shares as part of a trade or business carried on in Switzerland through a permanent establishment with fixed place of business situated in Switzerland for tax purposes and (iii) Swiss resident private individuals who, for income tax purposes, are classified as &#147;professional securities dealers&#148; for reasons of, inter alia, frequent dealing, or leveraged investments, in shares and other securities (collectively, &#147;Domestic Commercial Shareholders&#148;) are in principle eligible for a full refund or credit against income tax of the Withholding Tax if they duly report the underlying income in their income statements or income tax return, as the case may be.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Shareholders who are not resident in Switzerland for tax purposes, and who, during the respective taxation year, have not engaged in a trade or business carried on through a permanent establishment with fixed place of business situated in Switzerland for tax purposes, and who are not subject to corporate or individual income taxation in Switzerland for any other reason (collectively, &#147;Non-Resident Shareholders&#148;) may be entitled to a total or partial refund of the Withholding Tax if the country in which such recipient resides for tax purposes maintains a bilateral treaty for the avoidance of double taxation with Switzerland and further conditions of such treaty are met. Non-Resident Shareholders should be aware that the procedures for claiming treaty benefits (and the time required for obtaining a refund) may differ from country to country. Non-Resident Shareholders should consult their own legal, financial or tax advisors regarding receipt, ownership, purchases, sale or other dispositions of common shares and the procedures for claiming a refund of the Withholding Tax.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Swiss Federal Issue Stamp Tax</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company will be subject to the Swiss federal issue stamp tax (<i>droit d&#146;&#233;mission</i>) on the issuance of common shares of 1% of the offering price, net of certain deductions.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Swiss Federal Securities Turnover Tax</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The delivery of common shares against payment of the offering price is not subject to Swiss securities turnover tax (<i>droit de n&#233;gociation</i>). Any subsequent transactions in common shares in the secondary markets are </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">209</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">subject to Swiss securities turnover tax at an aggregate rate of 0.15% of the consideration paid for such common shares, however, only if a bank or other securities dealer in Switzerland, as defined in the Swiss Federal Stamp Tax Act (<i>loi f&#233;d&#233;rale sur les droits de timbre</i>), is a party or an intermediary to the transaction and no exemption applies.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Swiss Federal, Cantonal and Communal Individual Income Tax and Corporate Income Tax</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Non-Resident Shareholders</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Non-Resident Shareholders are not subject to any Swiss federal, cantonal or communal income tax on dividend payments and similar distributions because of the mere holding of common shares. The same applies for capital gains on the sale of common shares except in certain cases if the Company would qualify as real estate company. For Withholding Tax consequences, see &#147;&#8212;Swiss Tax Considerations&#8212;Withholding Tax.&#148;</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Resident Private Shareholders and Domestic Commercial Shareholders</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Resident Private Shareholders who receive dividends and similar cash or in-kind distributions (including liquidation proceeds as well as bonus shares or taxable repurchases of common shares as described above), which are not repayments of the nominal value of common shares or qualifying additional paid-in capital, are required to report such receipts in their individual income tax returns and are subject to Swiss federal, cantonal and communal income tax on any net taxable income for the relevant tax period. A gain or a loss by Resident Private Shareholders realized upon the sale or other disposition of common shares to a third party will generally be a tax-free private capital gain or a not tax-deductible capital loss, as the case may be. Under exceptional circumstances the capital gain may be re-characterized into a taxable dividend, in particular upon taxable repurchase of common shares as described above. Furthermore, the capital gain may also be re-characterized into taxable income in relation with a so-called indirect partial liquidation as defined under Swiss law. When a capital gain is re-characterized as a dividend, the relevant income for tax purposes corresponds to the difference between the repurchase price and the sum of the nominal value of common shares and qualifying additional paid-in capital.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Domestic Commercial Shareholders who receive dividends and similar cash or in-kind distributions (including liquidation proceeds as well as bonus shares) are required to recognize such payments in their income statements for the relevant tax period and are subject to Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings accumulated (including the dividends) for such period. On cantonal and communal level, similar provisions were introduced, but the regulations may vary depending on the canton of residency. Domestic Commercial Shareholders who are corporate taxpayers may qualify for participation relief on dividend distributions (<i>r</i><i>&#233;</i><i>duction pour participations</i>), if common shares held have a market value of at least CHF 1 million. For cantonal and communal income tax purposes the regulations on participation relief are broadly similar, depending on the canton of residency.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Domestic Commercial Shareholders are required to recognize a gain or loss realized upon the disposal of common shares in their income statement for the respective taxation period and are subject to Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings (including the gain or loss realized on the sale or other disposition of common shares) for such taxation period.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Swiss Wealth Tax and Capital Tax</b></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Non-Resident Shareholders</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Non-Resident Shareholders holding common shares are not subject to cantonal and communal wealth or annual capital tax because of the mere holding of common shares.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Resident Private Shareholders</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Resident Private Shareholders are required to report their common shares as part of their private wealth and are subject to cantonal and communal wealth tax.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Domestic Commercial Shareholders</i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Domestic Commercial Shareholders are required to report their common shares as part of their business wealth or taxable capital, as defined, and are subject to cantonal and communal wealth or annual capital tax.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">210</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Automatic Exchange of Information in Tax Matters</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On November 19, 2014, Switzerland signed the Multilateral Competent Authority Agreement. The Multilateral Competent Authority Agreement is based on Article 6 of the OECD/Council of Europe administrative assistance convention and is intended to ensure the uniform implementation of Automatic Exchange of Information (the &#147;AEOI&#148;). The Federal Act on the International Automatic Exchange of Information in Tax Matters (the &#147;AEOI Act&#148;) entered into force on January 1, 2017. The AEOI Act is the legal basis for the implementation of the AEOI standard in Switzerland.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The AEOI is being introduced in Switzerland through bilateral agreements or multilateral agreements. The agreements have been, and will be, concluded on the basis of guaranteed reciprocity, compliance with the principle of speciality (i.e., the information exchanged may only be used to assess and levy taxes (and for criminal tax proceedings)) and adequate data protection.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Based on such multilateral or bilateral agreements and the implementation of Swiss law, Switzerland collects and exchanges data in respect of financial assets, including common shares, held in, and income derived thereon and credited to, accounts or deposits with a paying agent in Switzerland for the benefit of individuals resident in a European Union member state or in a treaty state.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Swiss Facilitation of the Implementation of the U.S. Foreign Account Tax Compliance Act</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Switzerland has concluded an intergovernmental agreement with the United States to facilitate the implementation of U.S. Foreign Account Tax Compliance Act. The agreement ensures that the accounts held by U.S. persons with Swiss financial institutions are disclosed to the U.S. tax authorities either with the consent of the account holder or by means of group requests within the scope of administrative assistance. Information will not be transferred automatically in the absence of consent, and instead will be exchanged only within the scope of administrative assistance on the basis of the double taxation agreement between the United States and Switzerland. On October 8, 2014, the Swiss Federal Council approved a mandate for negotiations with the United States on changing the current direct-notification-based regime to a regime where the relevant information is sent to the Swiss Federal Tax Administration, which in turn provides the information to the U.S. tax authorities. </p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Material U.S. Federal Income Tax Consequences for U.S. Holders</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the opinion of Davis Polk &amp; Wardwell LLP, the following is a description of the material U.S. federal income tax consequences to the U.S. Holders, as defined below, of owning and disposing our common shares. It does not describe all tax considerations that may be relevant to a particular person&#146;s decision to acquire common shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This discussion applies only to a U.S. Holder that holds common shares as capital assets for U.S. federal income tax purposes (generally, property held for investment). In addition, it does not describe any tax consequences other than U.S. federal income tax consequences, including state and local tax consequences and estate tax consequences, and does not describe all of the U.S. federal income tax consequences that may be relevant in light of the U.S. Holder&#146;s particular circumstances, including alternative minimum tax consequences, the potential application of the provisions of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) known as the Medicare contribution tax and tax consequences applicable to U.S. Holders subject to special rules, such as:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">certain banks, insurance companies and other financial institutions;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">brokers, dealers or traders in securities who use a mark-to-market method of tax accounting;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">persons holding common shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated transaction or persons entering into a constructive sale with respect to the common shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">entities or arrangements classified as partnerships or S corporations for U.S. federal income tax purposes;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">tax-exempt entities, including an &#147;individual retirement account&#148; or &#147;Roth IRA&#148; or governmental entities;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">211</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">real estate investment trusts or regulated investment companies;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">former U.S. citizens or long-term residents of the United States;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">persons subject to Section 451(b) of the Code;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">persons that own or are deemed to own ten percent or more of the voting power or value of our shares; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">persons holding common shares in connection with a trade or business conducted outside of the United States or in connection with a permanent establishment or other fixed place of business outside of the United States.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal income tax consequences of owning and disposing of the common shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This discussion is based on the Code, administrative pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between Switzerland and the United States (the &#147;Treaty&#148;) all as of the date hereof, any of which is subject to change or differing interpretations, possibly with retroactive effect.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A &#147;U.S. Holder&#148; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of common shares, who is eligible for the benefits of the Treaty and who is:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a citizen or individual resident of the United States;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing of common shares in their particular circumstances.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The discussion under &#147;Taxation of Distributions&#148; and &#147;Sale or Other Disposition of Common Shares&#148; below describes certain consequences to U.S. Holders in the event that we are not a passive foreign investment company for U.S. federal income tax purposes (a &#147;PFIC&#148;) during any tax year in which a U.S. Holder holds our common shares. However, as discussed below under &#147;Passive Foreign Investment Company Rules&#148; below, we may be a PFIC for 2019 or one or more subsequent taxable years.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Taxation of Distributions</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As discussed above under &#147;Dividend Policy,&#148; we do not currently expect to make distributions on our common shares. In the event that we do make distributions of cash or other property, distributions paid on common shares, other than certain <i>pro rata</i> distributions of common shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. Subject to the discussion under &#147;&#8212;Passive Foreign Investment Company Rules&#148; below, for so long as our common shares are listed on the NYSE or we are eligible for benefits under the Treaty, dividends paid to certain non-corporate U.S. Holders will be eligible for taxation as &#147;qualified dividend income&#148; and therefore, subject to applicable limitations, will be taxable at rates not in excess of the long-term capital gain rate applicable to such U.S. Holder. As discussed in &#147;&#8212;Passive Foreign Investment Company Rules&#148; below, however, if we are a PFIC (or, with respect to a particular U.S. Holder, are treated as a PFIC) for a taxable year in which we pay a dividend or for the prior taxable year, the dividend will not be eligible for taxation as &#147;qualified dividend income.&#148; U.S. Holders should consult their tax advisers regarding the availability of the reduced tax rate on dividends in their particular circumstances. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">212</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amount of a dividend will include any amounts withheld by us in respect of Swiss income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will be included in a U.S. Holder&#146;s income on the date of the U.S. Holder&#146;s receipt of the dividend. The amount of any dividend income paid in Swiss franc will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, Swiss income taxes withheld from dividends on common shares (at a rate not exceeding the rate provided by the Treaty, in the case of a U.S. Holder eligible for a reduced rate under the Treaty) will be creditable against the U.S. Holder&#146;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Swiss income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Sale or Other Disposition of Common Shares</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Gain or loss realized by a U.S. Holder on the sale or other disposition of common shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#146;s holding period for such common shares was more than one year as of the date of the sale or other disposition. The amount of the gain or loss will equal the difference between the U.S. Holder&#146;s tax basis in the common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. Long-term capital gain recognized by a non-corporate U.S. Holder is subject to U.S. federal income tax at rates lower than the rates applicable to ordinary income and short-term capital gains, while short-term capital gains are subject to U.S. federal income tax at the rates applicable to ordinary income. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to various limitations.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Passive Foreign Investment Company Rules</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Code, we will be a PFIC for any taxable year in which, after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of &#147;passive income&#148; or (ii) 50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of, &#147;passive income.&#148; For purposes of the above calculations, we will be treated as if we hold our proportionate share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which we directly or indirectly own at least 25%, by value, of the shares of such corporation. Passive income generally includes interest, dividends, certain non-active rents and royalties, and capital gains. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We may have been a PFIC for our 2018 taxable year and it is possible that we will be a PFIC for one or more subsequent taxable years. Whether we will be a PFIC in 2019 or any future years is uncertain because, among other things, (i) we currently own, and will own after the completion of this offering, a substantial amount of passive assets, including cash, (ii) the timing of our recognition of active income for U.S. federal income tax purposes, which may differ from the timing of the recognition of such income for financial accounting purposes, may result in our recognizing minimal amounts of active income for U.S. federal income tax purposes in certain taxable years, (iii) the license and joint collaboration agreement with MedImmune for the joint clinical development of MEDI3726 has been our sole source of active income, but MedImmune discontinued the joint clinical development of MEDI3726 in the first half of 2019, and there can be no assurance that we will be able to enter into another licensing or collaboration agreement and (iv) the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may be determined in substantial part by our market capitalization, which may vary substantially over time. Moreover, the determination of whether we were a PFIC in 2018 or will be a PFIC for 2019 or any other year in which our common shares is not publicly traded for the entirety of such year depends in substantial part on whether we are </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">213</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">a controlled foreign corporation for U.S. federal income tax purposes (a &#147;CFC&#148;) for either or both of those years, and we believe that, if we were a CFC in 2018 or are a CFC in 2019, it is likely that we would be considered a PFIC in such year. Although we do not believe that we were a CFC in 2018 and do not expect to be a CFC in 2019, the determination of PFIC status depends on the ownership of our common shares after the application of certain attribution rules under the Code, and we do not have all of the information necessary to make a definitive determination that we were not and will not be a CFC. Accordingly, there can be no assurance that we will not be a PFIC for 2019 or any future taxable year. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are a PFIC for any year during which a U.S. Holder holds common shares, we will continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds common shares, even if we cease to meet the threshold requirements for PFIC status, unless the U.S. Holder elects to recognize gain, if any, as if it sold its common shares as of the last day of the last tax year in which we are a PFIC (such election, a &#147;Purging Election&#148;). In addition, the Company may, directly or indirectly, have held or hold equity interests in other PFICs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> </sup>(collectively, &#147;Lower-tier PFICs&#148;). Under attribution rules, if the Company is a PFIC, U.S. Holders will be deemed to own their proportionate shares of the stock of Lower-tier PFICs and will be subject to U.S. federal income tax according to the rules described in the following paragraphs on (i) certain distributions by a Lower-tier PFIC and (ii) a disposition of shares of a Lower-tier PFIC, in each case as if the U.S. Holder held such shares directly, even though holders have not received the proceeds of those distributions or dispositions directly. U.S. Holders should consult their tax advisors about the consequences to them of our investment in one or more Lower-tier PFICs.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are a PFIC for any taxable year during which a U.S. Holder held common shares (assuming such U.S. Holder has not made a timely mark-to-market election, or &#147;qualified electing fund&#148; election (a &#147;QEF Election&#148;), as described below), gain recognized by a U.S. Holder on a sale or other disposition (including certain pledges) of common shares (including any gain recognized as a consequence of a Purging Election) will be allocated ratably over the U.S. Holder&#146;s holding period for the common shares. The amounts allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC will be taxed as ordinary income. The amount allocated to each other taxable year will be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge will be imposed on the resulting tax liability. Further, to the extent that any distribution received by a U.S. Holder on its common shares exceeds 125% of the average of the annual distributions on the common shares received during the preceding three years or the U.S. Holder&#146;s holding period, whichever is shorter, that distribution will be subject to taxation in the same manner as gain, described immediately above.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If we are a PFIC (or, with respect to a particular U.S. Holder, are treated as a PFIC) for a taxable year in which we pay a dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders will not apply. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Mark-to-Market Election</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A U.S. Holder can avoid certain of the adverse rules described above by making a mark-to-market election with respect to its common shares, provided that the common shares are &#147;marketable.&#148; Common shares will be marketable if they are &#147;regularly traded&#148; on a &#147;qualified exchange&#148; or other market within the meaning of applicable Treasury regulations. If a U.S. Holder makes the mark-to-market election with respect to its common shares, it generally will recognize as ordinary income any excess of the fair market value of the common shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the common shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in the common shares will be adjusted to reflect the income or loss amounts recognized. Any gain recognized by the U.S. Holder on the sale or other disposition of common shares in a year in which we are a PFIC will be treated as ordinary income and any such loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election).</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In general, a U.S. Holder makes a mark-to-market election by attaching a properly executed Internal Revenue Service (&#147;IRS&#148;) Form 8621 to its U.S. federal income tax return for the first taxable year to which it wishes the election will apply. A U.S. Holder may make a mark-to-market election only if it holds common shares on the last day of such taxable year.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">214</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A mark-to-market election generally cannot be made for equity interests in any Lower-tier PFIC unless shares of such Lower-tier PFIC are themselves &#147;marketable.&#148; As a result, if a U.S. Holder makes a mark-to-market election with respect to our common shares, the U.S. Holder will nevertheless be subject to the PFIC rules described above with respect to its indirect interest in any Lower-tier PFIC unless the U.S. Holder makes a QEF Election with respect to such Lower-tier PFIC, as discussed below. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>QEF Election</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to avoid the application of the foregoing rules, a U.S. person that owns shares in a PFIC may make a QEF Election with respect to such PFIC if the PFIC provides the information necessary for such election to be made. If we determine that we are a PFIC for any taxable year, we will use our commercially reasonable efforts to, and currently expect to, provide the information necessary for U.S. Holders to make QEF Elections with respect to us.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If a U.S. Holder makes a valid QEF Election with respect to its common shares, the U.S. Holder will be required to report on its U.S. federal income tax return, and thus to take into account in determining its U.S. federal income tax liability, its <i>pro rata</i> share of our ordinary earnings and net capital gain (as ordinary income and long-term capital gain, respectively) for each taxable year in which we are classified as a PFIC, regardless of whether we make any distributions. U.S. Holders will not be entitled to claim deductions for any net losses we incur, and we will not be entitled to carry our net losses for any taxable year back or forward in computing our ordinary earnings and net capital gain for other taxable years. A U.S. Holder will also not be entitled to claim a foreign tax credit for any non-U.S. taxes we bear, but these taxes will reduce the amount of income the U.S. Holder would otherwise be required to include pursuant to the QEF Election.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any distribution (or portion thereof) to a U.S. Holder that we make out of earnings and profits that were previously included in a U.S. person&#146;s income pursuant to a QEF Election will not be subject to U.S. federal income tax, provided that the U.S. Holder can establish that such distribution (or portion thereof) is made out of such previously-taxed earnings and profits. If we are a PFIC (or, with respect to a particular U.S. Holder, are treated as a PFIC) for a taxable year in which we pay a dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders will not apply to the portion of such dividend that the U.S. Holder includes in income after application of the foregoing exclusion. A U.S. Holder&#146;s tax basis in its common shares will be increased by the amounts the U.S. Holder includes in income as a consequence of a QEF Election and decreased by the amount of distributions the U.S. Holder receives from us out of earnings and profits that a U.S. person previously included in income as a consequence of a QEF Election. If a U.S. Investor has made a QEF Election with respect to its common shares, any gain or loss recognized by the U.S. Holder on a sale or other disposition of such common shares will constitute capital gain or loss.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A U.S. Holder that makes a QEF Election with respect to its common shares may also elect to defer the payment of taxes in respect of its share of our undistributed ordinary earnings and net capital gain, subject to the payment of an interest charge on the deferred tax liability. U.S. Holders should consult their tax advisors about this election.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In general, a U.S. taxpayer makes a QEF Election with respect to a PFIC by attaching a properly executed IRS Form 8621 to its U.S. federal income tax return for the first taxable year to which it wishes the election to apply. Subject to the discussion below regarding retroactive QEF Elections, if a U.S. Holder does not make a QEF Election with respect to us for the first taxable year in which it holds common shares, a later QEF Election will not affect the U.S. federal income tax consequences to the U.S. Holder unless the U.S. Holder makes a Purging Election effective as of the first day of the first taxable year to which the QEF Election applies.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under certain circumstances, a U.S. Holder will be permitted to make a retroactive QEF Election, provided that we have notified the holders of common shares that we reasonably believe that we were not a PFIC for each of the relevant prior taxable years. In general, if a U.S. Holder makes a valid retroactive QEF Election, the U.S. Holder will be required to include in income its <i>pro rata</i> share of our ordinary earnings and net capital gains for the relevant prior taxable years as if it had made such election on a timely basis and will be subject to an interest charge on the resulting tax liability. In addition, the U.S. Holder will generally be required to amend its U.S. federal income tax returns for each of the relevant prior taxable years. In the case of a U.S. Holder that at any time has held (directly or under applicable constructive ownership rules) 2% or more of the common shares (and, under certain circumstances, in the case of any U.S. Holder), a U.S. Holder may make a retroactive QEF </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">215</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">Election only if the U.S. Holder has filed with its U.S. federal income tax return for the first taxable year in which it holds common shares a protective statement containing certain required information, as well as an agreement by the U.S. Holder to extend the periods of limitations on the assessment of its PFIC-related taxes for all taxable years to which the protective statement applies. Prospective investors should consult with their tax advisors regarding the requirements for making a retroactive QEF Election.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A QEF Election with respect to us will not apply to any of Lower-tier PFIC. If we determine that any of our current subsidiaries is a Lower-tier PFIC for any taxable year, we currently expect that we will provide the information necessary for U.S. Holders to make a QEF Election with respect to such Lower-tier PFIC, but there can be no assurance that we will be able to provide such information.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Information Returns</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">If a U.S. Holder owns common shares during any year in which we are a PFIC or in which we hold a direct or indirect equity interest in a Lower-tier PFIC, the U.S. Holder generally must file an annual report on IRS Form 8621 with respect to each such PFIC containing such information as the U.S. Treasury may require, generally with the U.S. Holder&#146;s U.S. federal income tax return for the relevant year. A U.S. Holder&#146;s failure to file the annual report will cause the statute of limitations for such U.S. Holder&#146;s U.S. federal income tax return to remain open with respect to the items required to be included in such report until three years after the U.S. Holder files the annual report and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S. Holder&#146;s entire U.S. federal income tax return will remain open during such period. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>PROSPECTIVE U.S. HOLDERS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE </b></i><i><b>CONSEQUENCES OF OUR POTENTIAL PFIC STATUS ON AN INVESTMENT IN COMMON SHARES.</b></i></p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Information Reporting and Backup Withholding</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient or (ii) in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the U.S. Holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Information with Respect to Foreign Financial Assets</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Certain U.S. Holders who are individuals (and, under proposed regulations, certain entities) may be required to report information relating to an interest in our common shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain U.S. financial institutions). U.S. Holders should consult their tax advisers regarding the effect, if any, of this legislation on their ownership and disposition of the common shares.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">216</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 111-under -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tU"></a><b>UNDERWRITERS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for whom Morgan Stanley &amp; Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="82%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4.06px; "><b>Underwriter</b></div></td>
	<td colspan="3" width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.06px; padding-right: 0px; "><b>Number of Common<br> </b><b>Shares </b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.06px; ">Morgan Stanley &amp; Co. LLC </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.06px; ">BofA Securities, Inc.</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.06px; ">Cowen and Company, LLC </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.06px; "><b>Total</b> </div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">&#160;</div></td><td width="15%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 8,164,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the &#147;representatives,&#148; respectively. The underwriters are offering the common shares subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the common shares offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the common shares offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146; option to purchase additional common shares described below.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriters initially propose to offer part of the common shares directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share under the public offering price. After the initial offering of the common shares, the offering price and other selling terms may from time to time be varied by the representatives.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to 1,224,600 additional common shares at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the common shares offered by this prospectus. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional common shares as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of common shares listed next to the names of all underwriters in the preceding table.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">AstraZeneca, Redmile Group, LLC and certain of our other existing shareholders and/or their respective affiliated entities have indicated an interest in purchasing up to approximately $115 million of the common shares being offered in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to any of these potential purchasers, and any of these potential purchasers could determine to purchase more, fewer or no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these persons or entities as they will on any other shares sold to the public in this offering.</p>


<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to 1,224,600 additional common shares.</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.96px; padding-right: 5.96px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 0px; "><b>Total</b></div></td>
</tr>
<tr>
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 5.96px; "><b>Per Share</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 5.96px; "><b>No Exercise</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.96px; padding-right: 0px; "><b>Full Exercise</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">Public offering price</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">Underwriting discounts and commissions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="62%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.96px; ">Proceeds, before expenses, to us</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">217</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $7.7 million. We have agreed to reimburse the underwriters for expense relating to clearance of this offering with the Financial Industry Regulatory Authority (&#147;FINRA&#148;) up to $35,000.</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of common shares offered by them.</p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our common shares have been approved for listing on the NYSE under the symbol &#147;ADCT.&#148;</p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We and all directors and officers and the holders of all of our outstanding shares and options have agreed that, without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc., on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus (the &#147;restricted period&#148;):</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any common shares or any securities convertible into or exercisable or exchangeable for common shares;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">file any registration statement with the SEC relating to the offering of any common shares or any securities convertible into or exercisable or exchangeable for common shares; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common shares,</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">whether any such transaction described above is to be settled by delivery of common shares or such other securities, in cash or otherwise. In addition, we and each such person agree that, without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc., on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any common shares or any security convertible into or exercisable or exchangeable for common shares. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The restrictions described in the immediately preceding paragraph do not apply to our directors, officers and securityholders with respect to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(i)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transactions relating to common shares or any security convertible into common shares acquired in the offering (other than any issuer-directed common shares purchased in the offering by our officers or directors) or in open market transactions after the completion of the offering;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(ii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions as a bona fide gift or for bona fide estate planning purposes or to a charitable organization or educational institution; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(iii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions to any immediate family member of such person, affiliate or any trust or trustee or beneficiary thereof for the direct or indirect benefit of such person or the immediate family of such person (for this purpose, &#147;immediate family&#148; means any relationship by blood, marriage, domestic partnership or adoption, not more remote than first cousin);</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(iv)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions to any corporation, partnership, limited liability company or other entity or affiliate of such person or the immediate family of such person; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(v)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions (a) by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of such person upon the death of such person; (b) by operation of law pursuant to a domestic order or negotiated divorce settlement; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(vi)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions to another corporation, member, partnership, limited liability company, trust or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act), or to an investment fund or other entity that controls or manages, or is under common control with, such person, or distributions to partners, members, shareholders, beneficiaries or other equity holders of such person;</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">218</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(vii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions to us (a) in connection with the repurchase of such securities with respect to the termination of such person&#8217;s employment with us or (b) pursuant to contractual arrangements described in this prospectus; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(viii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions to us in connection with the repayment (including any adjustments) of any loans or promissory notes of such as described in this prospectus;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(ix)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions (including through a &#147;cashless&#148; exercise or on a &#147;net exercise basis&#148;) to us in connection with the conversion of any convertible security into, or the exercise of any option or warrant for, common shares (including to satisfy withholding obligations or the payment of taxes in connection therewith); provided that (a) any such common shares received by such person shall be subject to the lock-up agreement and (b) no filing under Section 16(a) of the Exchange Act (or its foreign equivalent) reporting a reduction in beneficial ownership of common shares shall be required or shall be voluntarily made during the restricted period;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(x)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions prior to the date of the public filing of the registration statement of which this prospectus forms a part and pursuant to our shareholders&#8217; agreement;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(xi)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or distributions to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (x) above, provided that any common shares shall be subject to the terms of the lock-up agreement;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(xii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any pledge or transfer by such person (or any permitted transferee) of common shares or any security convertible into common shares pursuant to agreements governing indebtedness or commitments relating to indebtedness of such person (or any permitted transferee) or its affiliates (other than us and our subsidiaries) in effect on the date thereof (and any refinancing or replacement thereof) and described in this prospectus and any transfer upon foreclosure, provided that any required filing under Section 16(a) of the Exchange Act (or its foreign equivalent) reporting a reduction in beneficial ownership by such person or any party (pledgor or pledgee) shall indicate by footnote disclosure or otherwise the nature of the transfer and if any filing is required to be made under Section 16(a) of the Exchange Act (or its foreign equivalent) during the restricted period, and such person shall provide the representatives prior written notice informing them of such report;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(xiii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act (or its foreign equivalent) for the transfer of common shares, provided that (a) such plan does not provide for the transfer of common shares during the restricted period and (b) to the extent a public announcement or filing under the Exchange Act (or its foreign equivalent), if any, is required of or voluntarily made by or on behalf of such person or us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common shares may be made under such plan during the restricted period;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(xiv)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">transfers or dispositions pursuant to a bona fide tender offer for our capital shares, merger, consolidation or other similar transaction made to all holders of our securities involving a change of control of us (including without limitation, the entering into of any lock-up, voting or similar agreement pursuant to which such person may agree to transfer, sell, tender or otherwise dispose of common shares or any security convertible into common shares in connection with such transaction) that has been approved by our board of directors; provided that, in the event that such change of control transaction is not consummated, this paragraph shall not be applicable and such person&#8217;s shares and other securities shall remain subject to the lock-up agreement (for this purpose, &#147;change of control&#148; means the transfer whether by tender offer, merger, consolidation or other similar transaction), in one transactions or a series of related transactions, to a person or group of affiliated persons (other than the underwriters pursuant to this offering), of our voting securities if, after such transfer, such person or group of affiliated persons would hold greater than 50% of our outstanding voting securities); or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="40px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(xv)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the conversion, exercise or exchange of our preferred shares, options to purchase common shares, warrants or any security convertible into common shares pursuant to any reorganization, conversion or share split, as such terms are described in this prospectus; provided that any such securities shall remain subject to the lock-up agreement.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">219</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>provided</i> that, (1) with respect to paragraphs (ii)-(iv) and (vi) above, the representatives receive a signed lock-up agreement for the balance of the restricted period from each done, trustee, distribute or transferee, as the case may be, and (2) with respect to paragraphs (ii)-(viii) above, no public announcement or filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares, shall be required or voluntarily made during the restricted period (other than, in the case of a transfer or other disposition pursuant to paragraphs (v), (vii) and (viii), any Form 4 or 5 required to be filed under the Exchange Act (or its foreign equivalent) if such person is subject to Section 16 reporting with respect to our shares under the Exchange Act (or its foreign equivalent) shall indicate by footnote the nature of the transfer or disposition. </p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">With respect to (xii) above, certain of our shareholders have granted a security interest in all or a portion of our shares beneficially owned by them pursuant to certain of their debt instruments, each of which may include default provisions. As of the date of this prospectus, 27,534,117 shares of our common shares are subject to a security interest. </p>

				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The restrictions on transfers or other dispositions by us described above do not apply to: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(i)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the common shares to be sold in this offering; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(ii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the issuance by us of shares of common shares upon the exercise of an option or warrant or the conversion of a security outstanding on the date of this prospectus of which the underwriters have been advised in writing; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(iii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the grant of any options to purchase common shares, restricted shares or restricted units under an incentive compensation plan in effect or approved by our board of directors on the date of this prospectus and described in this prospectus; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(iv)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">our filing of any registration statement on Form S-8 or a successor form relating to the common shares granted pursuant to or reserved for issuance under an incentive compensation plan described in this prospectus; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(v)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">offers to acquire, transfers, issuances or repurchases pursuant to loan settlement agreements, including the transfer of common shares to us in connection therewith, as described in this prospectus; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(vi)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
the offer or issuance of common shares in connection with an acquisition, joint venture, commercial or collaborative relationship, or an acquisition or license by us of assets of another person or entity or pursuant to an employee benefit plan assumed by us in connection with any such acquisition, provided that (1) the aggregate number of shares issued does not exceed 5% of the total number of outstanding shares of our common shares immediately following the closing of this offering and (2) the recipient of any such shares during the restricted period enters into a lock-up agreement; or
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(vii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">facilitating the establishment of a trading plan on behalf of one of our shareholders, officers or directors pursuant to Rule 10b5-1 under the Exchange Act for the transfer of common shares, provided that such plan does not provide for the transfer of common shares during the restricted period and, to the extent a public announcement or filing under the Exchange Act is required of or voluntarily made by us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common shares may be made under such plan during the restricted period. </td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Morgan Stanley &amp; Co. LLC and BofA Securities, Inc., in their sole discretion, may release the common shares and other securities subject to the lock-up agreements described above in whole or in part at any time.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to facilitate the offering of the common shares, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common shares. Specifically, the underwriters may sell more common shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the option to purchase additional common shares. The underwriters can close out a covered short sale by exercising the option to purchase additional common shares or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the option to purchase additional common shares. The underwriters may also sell shares in excess of the option to purchase additional common shares, creating a naked short position. The underwriters must close out any naked short </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">220</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common shares in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, common shares in the open market to stabilize the price of the common shares. These activities may raise or maintain the market price of the common shares above independent market levels or prevent or retard a decline in the market price of the common shares. The underwriters are not required to engage in these activities and may end any of these activities at any time.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of common shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Relationships</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The underwriters and their respective affiliates are full-service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own accounts and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Directed Share Program</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Furthermore, at our request, the underwriters have reserved 5% of the common shares offered by this prospectus, for sale, at the initial public offering price, to our employees and to friends, professional contacts and family members of our employees and directors. If purchased by these persons, these shares will not be subject to a lock-up restriction, except in the case of shares purchased by any officer, which will be subject to a 180-day lock-up restriction described above. The sales will be made at our direction by Morgan Stanley &amp; Co. LLC through a directed share program. The number of common shares available for sale to the general public will be reduced by the number of reserved common shares sold to these individuals. Any reserved common shares that are not so purchased will be offered by the underwriters to the general public on the same terms as the other common shares offered by this prospectus. </p>

				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Pricing of the Offering</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior to this offering, there has been no public market for our common shares. The initial public offering price was determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities and certain financial and operating information of companies engaged in activities similar to ours.</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>Selling Restrictions</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">221</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published, in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Australia</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act, and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Any offer in Australia of the common shares may only be made to persons, or to the Exempt Investors, who are &#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the common shares without disclosure to investors under Chapter 6D of the Corporations Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The common shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus contains general information only and does not take into account the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate for their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Canada</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The common shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the common shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>European Economic Area</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In relation to each Member State of the European Economic Area which has implemented the Prospectus Regulation (each, a &#147;Relevant Member State&#148;), an offer to the public of any common shares may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any common shares may be made at any time under the following exemptions under the Prospectus Regulation:</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">222</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to any legal entity which is a qualified investor as defined in the Prospectus Regulation;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(c)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">in any other circumstances falling within Article 1(4) of the Prospectus Regulation,</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">provided that no such offer of common shares shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any of our common shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any of our common shares to be offered so as to enable an investor to decide to purchase any of our common shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Dubai International Financial Centre</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The common shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the common shares offered should conduct their own due diligence on the common shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Hong Kong</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The common shares may not be offered or sold by means of any document other than (1) in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong); (2) to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder; or (3) in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation, or document relating to the common shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to common shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Israel</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728 &#8211; 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section 15 of the Israeli Securities Law, 5728&#8211;1968, including, inter alia, if: (i) the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#147;Addressed Investors&#148;); or (ii) the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 &#8211; 1968, subject to certain conditions (the &#147;Qualified Investors&#148;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 &#8211; 1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968. In particular, we may request, as a condition to be offered </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">223</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i) that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968 regarding Qualified Investors is applicable to it; (iii) that it will abide by all provisions set forth in the Israeli Securities Law, 5728 &#8211; 1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv) that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 &#8211; 1968: (a) for its own account; (b) for investment purposes only; and (c) not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 &#8211; 1968; and (v) that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Japan</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) (the &#147;FIEL&#148;) has been made or will be made with respect to the solicitation of the application for the acquisition of the common shares.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Accordingly, the common shares have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or re-sale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan.</p>
				<p class="h5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><u>For Qualified Institutional Investors (&#147;QII&#148;)</u></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in relation to the common shares constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the common shares. The common shares may only be transferred to QIIs.</p>
				<p class="h5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><u>For Non-QII Investors</u></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in relation to the common shares constitutes either a &#147;small number private placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the common shares. The common shares may only be transferred en bloc without subdivision to a single investor.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Singapore</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of Non-CIS Securities may not be circulated or distributed, nor may the Non-CIS Securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.40px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Where the Non-CIS Securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a corporation (which is not an accredited investor (as defined in Section 4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">224</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the Non-CIS Securities pursuant to an offer made under Section 275 of the SFA except:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">where no consideration is or will be given for the transfer; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(c)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">where the transfer is by operation of law; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(d)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">as specified in Section 276(7) of the SFA; or</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(e)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.</td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Singapore Securities and Futures Act Product Classification: Solely for the purposes of our obligations pursuant to sections 309B(1)(a) and 309B(1)(c) of the SFA, we have determined, and hereby notify all relevant persons (as defined in Section 309A of the SFA), that the common shares are &#147;prescribed capital markets products&#148; (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Switzerland</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This document is not intended to constitute an offer or solicitation to purchase or invest in the common shares described herein. The common shares may not be publicly offered, sold or advertised, directly or indirectly, in, into or from Switzerland and will not be listed on the SIX Swiss Exchange or on any other exchange or regulated trading venue in Switzerland. Neither this document nor any other offering or marketing material relating to the common shares constitutes a prospectus as such term is understood pursuant to article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any other regulated trading venue in Switzerland, and neither this document nor any other offering or marketing material relating to the common shares may be publicly distributed or otherwise made publicly available in Switzerland.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>United Kingdom</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Each underwriter has represented and agreed that:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (&#147;FSMA&#148;) received by it in connection with the issue or sale of our common shares in circumstances in which Section 21(1) of the FSMA does not apply to us; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to our common shares in, from or otherwise involving the United Kingdom.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">225</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tEO"></a><b>EXPENSES OF THE OFFERING</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We expect that our expenses in connection with this offering, other than underwriting discounts and commissions, will be as follows:</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="90%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Expenses</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Amount</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">SEC registration fee</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">$</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 29,586 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">
NYSE listing fees and expenses
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 200,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">FINRA filing fee</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 37,116 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Printing and engraving expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 145,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Legal fees and expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 3,048,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Accounting fees and expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 400,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Miscellaneous costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 3,840,298 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; "><b>Total</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; ">$</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> 7,700,000 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All amounts in the table are estimates except the SEC registration fee, the NYSE listing fee and the FINRA filing fee. The Company will pay all of the expenses of this offering.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">226</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tLM"></a><b>LEGAL MATTERS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The validity of the common shares and certain other matters with respect to Swiss law will be passed upon for us by Homburger AG, Zurich, Switzerland. Certain matters with respect to U.S. federal and New York State law will be passed upon for us by Davis Polk &amp; Wardwell LLP, New York, New York. Certain matters with respect to U.S. federal and New York State law will be passed upon for the underwriters by Cooley LLP, Boston, Massachusetts. Lenz &amp; Staehelin, Geneva, Switzerland is representing the underwriters with respect to certain matters of Swiss law.</p>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tE"></a><b>EXPERTS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The consolidated financial statements as of December 31, 2018 and 2017 and for each of the two years in the period ended December 31, 2018 included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s restatement of its consolidated financial statements as described in Notes 1 and 25 to the consolidated financial statements) of PricewaterhouseCoopers SA, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">227</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tEJ"></a><b>ENFORCEMENT OF JUDGMENTS</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We are organized under the laws of Switzerland and our registered office and domicile is located in Epalinges, Switzerland. Moreover, a number of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the PILA. This statute provides that the application of provisions of non-Swiss law by the courts in Switzerland shall be precluded if the result would be incompatible with Swiss public policy. Also, mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Switzerland and the United States do not have a treaty providing for reciprocal recognition of and enforcement of judgments in civil and commercial matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the PILA. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the non-Swiss court had jurisdiction pursuant to the PILA; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment of such non-Swiss court has become final and non-appealable; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the judgment does not contravene Swiss public policy; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">&#8226;</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in Switzerland.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">228</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tWYC"></a><b>WHERE YOU CAN FIND MORE INFORMATION</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form F-1 under the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the registration statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration statement, we refer you to the copy of the document that has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Upon completion of this offering, we will become subject to the informational requirements of the Exchange Act. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements and other information we have filed electronically with the SEC. As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We maintain a corporate website at www.adctherapeutics.com. The reference to our website is an inactive textual reference only and information contained therein or connected thereto are not incorporated into this prospectus or the registration statement of which it forms a part.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">229</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 200-fintab01 -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 6.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><a name="fFINTOC"></a><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 1.33px; margin-top: 0px; "> </div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b><u>CONTENTS</u></b></p>
				<a name="TOC"></a><table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr style="background-color: #cceeff;">
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; "><a href="#tGI1">Group Information</a></div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; "><a href="#tGI1">F-2</a></div>
							</td>
						</tr>
						<tr>
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; ">Interim Consolidated Financial Statements<br></div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; "><a href="#tICIS">- Interim Consolidated Income Statement</a></div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; "><a href="#tICIS">F-3</a></div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; "><a href="#tICSCI">- Interim Consolidated Statement of Comprehensive Income</a></div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; "><a href="#tICSCI">F-4</a></div>
							</td>
						</tr>
						<tr>
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; "><a href="#tICBS">- Interim Consolidated Balance Sheet</a></div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; "><a href="#tICBS">F-5</a></div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; "><a href="#tICSCE">- Interim Consolidated Statement of Changes in Equity</a></div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; "><a href="#tICSCE">F-6</a></div>
							</td>
						</tr>
						<tr>
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; "><a href="#tICSCF">- Interim Consolidated Statement of Cash Flows</a></div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; "><a href="#tICSCF">F-7</a></div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="87%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 15.37px; "><a href="#tNICFS">- Notes to the Interim Consolidated Financial Statements</a></div>
							</td>
							<td width="13%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 15.37px; padding-right: 0px; "><a href="#tNICFS">F-8</a></div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 6.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 1.33px; margin-top: 0px; "> </div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b><u>CONTENTS</u></b></p>
				<a name="TOC"></a><table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><a href="#fGI">Group Information</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fGI">F-16</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><a href="#IROI">Report of Independent Registered Public Accounting Firm</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#IROI">F-17</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; ">Consolidated Financial Statements<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><a href="#fCIS">- Consolidated Income Statement</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCIS">F-18</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><a href="#fCSCI">- Consolidated Statement of Comprehensive Income</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCSCI">F-19</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><a href="#fCBS">- Consolidated Balance Sheet</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCBS">F-20</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><a href="#fCSCE">- Consolidated Statement of Changes in Equity</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCSCE">F-21</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><a href="#fCSCF">- Consolidated Statement of Cash Flows</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fCSCF">F-22</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="90%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 9.71px; "><a href="#fNCFS">- Notes to the Consolidated Financial Statements</a></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><a href="#fNCFS">F-23</a></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "> </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-1</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 6.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 1.33px; margin-top: 0px; "> </div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><a name="tGI1"></a><b>GROUP INFORMATION</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For the six month period ended June 30, 2019</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>DIRECTORS:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Peter B. Corr, Chairman of the Board</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Stephen Evans-Freke</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Michael Forer</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Peter Hug</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Chris J. Martin</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Thomas Pfisterer</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Thomas Rinderknecht</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Tyrell Rivers</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Jacques Theurillat</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Barrie Ward</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>SECRETARY:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Dominique Graz</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>REGISTERED OFFICE:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Route de la Corniche 3B</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">1066 Epalinges</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Switzerland</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>AUDITORS:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">PricewaterhouseCoopers SA</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-2</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADC Therapeutics SA</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tICIS"></a><b>INTERIM CONSOLIDATED INCOME STATEMENT<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.59px; padding-right: 4.59px; "><b>Notes</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.59px; padding-right: 4.59px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30, 2019 </b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.59px; padding-right: 0px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30, 2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; "><b>Contract revenue</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">8</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>2,340</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>625</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">Research and development expenses</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">6</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(46,572</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(60,133</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">General and administrative expenses</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(6,592</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(3,969</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; "><b>Operating loss</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(50,824</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(63,477</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">Financial income</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,306</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,641</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">Financial expense</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">3</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">Exchange differences</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(68</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; "><b>Loss before taxes<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(49,659</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(61,680</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">Income tax expenses</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(199</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; "><b>Loss for the period</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(49,858</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(61,828</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; "><b>Attributable to:<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">Owners of the parent</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,858</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,828</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; "><b>Loss per share<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.59px; ">Basic and diluted loss per share (in USD)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.59px; padding-right: 4.59px; ">13</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (0.84 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.07 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNICFS1">8</a> to F-<a href="#tNICFS1">15</a> form an integral part of these interim consolidated financial statements (unaudited) </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-3</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADC Therapeutics SA</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tICSCI"></a><b>INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.08px; padding-right: 4.08px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30, 2019</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.08px; padding-right: 0px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30, 2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; "><b>Loss for the period</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(49,858</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(61,828</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; "><b>Other comprehensive loss:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; "><u>Items that will not be reclassified to profit or loss</u><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">Remeasurements of defined benefit plan</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">15</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">Total items that will not be reclassified to profit or loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(7</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">15</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; "><u>Items that may be reclassified subsequently to profit or loss</u><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">Currency translation differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(8</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(37</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">Total items that may be reclassified subsequently to profit or loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(8</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(37</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; "><b>Other comprehensive loss for the period</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(15</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(22</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; "><b>Total comprehensive loss for the period</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(49,873</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(61,850</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; "><b>Attributable to:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.08px; ">Owners of the parent</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,873</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,850</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNICFS1">8</a> to F-<a href="#tNICFS1">15</a> form an integral part of these interim consolidated financial statements (unaudited) </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-4</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADC Therapeutics SA</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tICBS"></a><b>INTERIM CONSOLIDATED BALANCE SHEET<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.58px; padding-right: 5.58px; "><b>Notes</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.58px; padding-right: 5.58px; "><b>June 30,<br> </b><b>2019</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.58px; padding-right: 0px; "><b>December 31,<br> </b><b>2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>ASSETS<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Current assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Cash and cash equivalents</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">10</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">182,156</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">138,807</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Trade accounts receivable</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">192</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Other current assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,237</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,081</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Total current assets</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>185,396</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>142,080</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Non-current assets<br></b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Property, plant and equipment, net</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,420</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,540</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Right-of-use assets, net</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">3</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,340</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Intangible assets, net</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">9</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8,419</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,674</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Other long-term assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">264</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">264</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Total non-current assets</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>15,443</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>8,478</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Total assets</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>200,839</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>150,558</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>LIABILITIES AND EQUITY<br></b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Current liabilities<br></b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Trade accounts payable</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,166</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,750</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Other current liabilities</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">14,566</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13,650</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Contract liability (short-term)</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">8</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,765</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Lease liabilities (short-term)</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">3</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,087</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Current income tax payable</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">186</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">189</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Total current liabilities</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>17,005</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>22,354</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Non-current liabilities<br></b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Contract liability (long-term)</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">8</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">575</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Lease liabilities (long-term)</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">3</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,289</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Defined benefit pension liabilities</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,556</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,386</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Total non-current liabilities</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>5,845</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>1,961</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Total liabilities</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>22,850</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>24,315</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Equity attributable to owners of the parent<br></b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Share capital</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">11</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">424</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">401</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Share premium</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">11</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">527,083</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,268</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Shares to be issued</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">10/14</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">26,641</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Other reserves</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,835</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,702</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Cumulative translation adjustments</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(51</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(43</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">Accumulated losses</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(381,943</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(332,085</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Total equity</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>177,989</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>126,243</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.58px; "><b>Total liabilities and equity</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.58px; padding-right: 5.58px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>200,839</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>150,558</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNICFS1">8</a> to F-<a href="#tNICFS1">15</a> form an integral part of these interim consolidated financial statements (unaudited) </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-5</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADC Therapeutics SA</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tICSCE"></a><b>INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td colspan="21" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.50px; padding-right: 0px; "><b>Attributable to owners of the parent</b></div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.50px; padding-right: 2.50px; "><b>Share<br> </b><b>capital</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.50px; padding-right: 2.50px; "><b>Share<br> </b><b>premium</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.50px; padding-right: 2.50px; "><b>Shares<br> </b><b>to be<br> </b><b>issued</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.50px; padding-right: 2.50px; "><b>Other<br> </b><b>reserves</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.50px; padding-right: 2.50px; "><b>Cumulative<br> </b><b>translation<br> </b><b>adjustments</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.50px; padding-right: 2.50px; "><b>Accumulated<br> </b><b>losses</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.50px; padding-right: 0px; "><b>Total</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">SIX MONTH PERIOD ENDED JUNE 30, 2018<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>January 1, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>397</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>452,296</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>5,426</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>36</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(208,989</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>249,166</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Loss for the period</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,828</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,828</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Translation adjustment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(37</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(37</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Remeasurements of defined benefit pension</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">15</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">15</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>Total other comprehensive income / </b><b>(loss)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>15</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(37</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(22</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>Total comprehensive income / (loss) for </b><b>the period</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>15</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(37</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(61,828</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(61,850</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Issue of share capital</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Transaction costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(13</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Share-based compensation expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">284</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">284</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>Total transactions with owners</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(13</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>284</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>272</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>June 30, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>398</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>452,283</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,725</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(1</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(270,817</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>187,588</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">SIX MONTH PERIOD ENDED JUNE 30, 2019<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>January 1, 2019</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>401</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>452,268</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>5,702</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(43</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(332,085</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>126,243</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Loss for the period</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,858</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,858</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Translation adjustment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(8</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(8</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 26.67px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Remeasurements of defined benefit pension</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>Total other comprehensive loss</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(7</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(8</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(15</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>Total comprehensive loss for the period</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(7</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(8</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(49,858</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(49,873</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Issue of share capital</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">23</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">76,277</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">26,950</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">103,250</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Transaction costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,462</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(309</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,771</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">Share-based compensation expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">140</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">140</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>Total transactions with owners</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>23</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>74,815</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>26,641</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>140</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>101,619</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="40%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.50px; "><b>June 30, 2019</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>424</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>527,083</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>26,641</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,835</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(51</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(381,943</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>177,989</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNICFS1">8</a> to F-<a href="#tNICFS1">15</a> form an integral part of these interim consolidated financial statements (unaudited) </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-6</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADC Therapeutics SA</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tICSCF"></a><b>INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.19px; padding-right: 4.19px; "><b>Notes</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.19px; padding-right: 4.19px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30, 2019</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.19px; padding-right: 0px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30, 2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; "><b>Cash flows from operating activities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Loss for the period</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,858</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,828</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Adjustments for non-monetary items:<br></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Share-based compensation expenses</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">140</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">285</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Depreciation of property, plant and equipment</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">269</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">224</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Depreciation of right-of-use assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">3</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">513</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Amortization and impairment of intangible assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">239</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Change in defined benefit pension liabilities</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">158</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">124</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Change in fair value measurement</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">454</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">697</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Financial income</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,306</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,641</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Exchange differences</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Income taxes</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">199</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">148</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Operating loss before working capital changes</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(49,420</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,749</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Decrease in trade accounts receivable</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">182</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,038</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Increase in other current assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(277</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,762</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Decrease in contract liability (short and long term)</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">8</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,340</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(626</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Decrease in trade accounts payable</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(5,579</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,631</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">(Decrease) / increase in other liabilities (short and long term)</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">906</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2,743</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Cash used in operating activities</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(56,528</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(61,987</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Interest received</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">970</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">574</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Interest expense on lease obligations</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">3</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">73</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Tax paid</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(203</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(81</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; "><b>Net cash used in operating activities</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(55,688</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(61,494</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; "><b>Cash used in investing activities<br></b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Payment for purchases of property, plant and equipment</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(150</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(494</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Payment for purchases of intangible assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">9</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,757</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(34</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Payment for rent deposits</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(3</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; "><b>Net cash used in investing activities</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(1,907</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(531</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; "><b>Cash (used in) / from financing activities<br></b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Proceeds from capital contributions, net of transaction costs</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">11</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">74,838</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(13</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Proceeds from shares to be issued, net of transaction costs</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">10/14</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">26,641</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Principal payments of lease obligations</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">3</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(548</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; "><b>Net cash (used in) / from financing activities</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>100,931</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(13</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; "><b>Net increase / (decrease) in cash and cash equivalents</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>43,336</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(62,038</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Exchange gains / (losses) on cash and cash equivalents</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(10</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; ">Cash and cash equivalents at beginning of period</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">138,807</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.19px; "><b>Cash and cash equivalents at end of period</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.19px; padding-right: 4.19px; ">10</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>182,156</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>200,704</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNICFS1">8</a> to F-<a href="#tNICFS1">15</a> form an integral part of these interim consolidated financial statements (unaudited) </p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-7</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 201-finnotes01 -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 5.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tNICFS"></a><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 1.33px; margin-top: 0px; "> </div><b>NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b><p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><a name="tNICFS1"></a><b>1.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Corporate information</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADC Therapeutics SA (the &#147;Company&#148; or &#147;ADCT&#148;) was incorporated on June 6, 2011 under the laws of Switzerland. The registered office of the Company is located at Route de la Corniche 3B, 1066 Epalinges, Switzerland. The Company controls two wholly-owned subsidiaries: ADC Therapeutics America, Inc. (&#147;ADCT America&#148;), which was incorporated in Delaware, USA on December 10, 2014, and ADC Therapeutics (UK) Ltd (&#147;ADCT UK&#148;), which was incorporated in England on December 12, 2014. The Company and its two subsidiaries form the ADCT Group (the &#147;Group&#148;).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group is focused on the development of antibody drug conjugates, including research, development, human clinical trials, regulatory approval and commercialization. Antibody Drug Conjugates (&#147;ADCs&#148;) are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill any cancer cell to which the ADC attaches. ADCs have extensive potential therapeutic applications in cancer.</p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These unaudited interim consolidated financial statements were authorized for issue by the Board of Directors on August 13, 2019 except for the effects of the share split presented in note 14 &#147;Events after reporting date &#8211; share split&#148; to the unaudited interim consolidated financial statements, as to which the date is September 19, 2019.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Going concern basis</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADC Therapeutics SA is an early stage company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. The Group&#146;s success may also depend on its ability to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">establish and maintain a strong patent position and protection;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">enter into collaborations with partners in the pharmaceutical industry;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">acquire and retain key personnel; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">acquire additional funding to support its operations.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Since its incorporation, the Group has primarily funded its growth through capital increases and additional funds provided by research collaborations. The Group never had recourse to bank loans. As a result, the Group is not exposed to liquidity risk through requests for early repayment of loans.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As at June 30, 2019, the Group&#146;s cash and cash equivalents amounted to KUSD 182,156 (December 31, 2018: KUSD 138,807).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Board of Directors believes that the Group has sufficient financial resources to cover its operating costs for at least the next twelve months from the date of issuance and, as a result, is presenting the unaudited interim consolidated financial statements of the Group on a going concern basis.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Basis of preparation</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These unaudited interim consolidated financial statements for the six month period ended June 30, 2019 have been prepared in accordance with IAS 34 &#8216;Interim Financial Reporting&#146;. The interim consolidated financial information should be read in conjunction with the consolidated financial statements as at December 31, 2018, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).</p>

<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Share split</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As explained in note 14 &#147;Events after the reporting date &#8211; share split&#148;, on September 19, 2019, the Company effected a one to 15,625 share split of its outstanding shares. Accordingly, all share and per share amounts for all periods presented in these interim consolidated financial statements and notes thereto have </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-8</p>

			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><b>NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&nbsp;</b><b>(continued)</b>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">been adjusted retroactively, where applicable, to reflect this share split. These interim consolidated financial statements have not been adjusted to give retroactive effect to any other subsequent events as set out in note 14 &#147;Events after the reporting date&#148;.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Foreign currency translation</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following exchange rates have been used for the translation of the financial statements of ADCT UK, the functional currency of which is the British pound:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 5.93px; "><b>USD / GBP</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.93px; padding-right: 5.93px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.93px; padding-right: 5.93px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30,<br> </b><b>2019</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.93px; padding-right: 0px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30,<br> </b><b>2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.93px; ">Closing rate, GBP 1</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">USD</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.26898</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.31515</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.93px; ">Weighted average exchange rate, GBP 1</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">USD</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.29507</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.39128</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>3.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Accounting policies</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Except as described below, the accounting policies applied are consistent with those of the annual financial statements for the year ended December 31, 2018, as described in those annual financial statements.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual profit or loss.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>New and amended standards adopted by the group</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">IFRS 16 &#147;Leases&#148; has been adopted by the Group from January 1, 2019. Under IAS17, lessees were required to make a distinction between a finance lease (on balance sheet) and an operating lease (off balance sheet). IFRS 16 now requires lessees to recognize an asset, being the right to use the leased item, and a financial liability, reflecting future lease payments, for virtually all lease contracts, though there is an optional exemption for certain short-term leases and leases of low-value assets.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group has applied the modified retrospective approach, which requires the recognition of the cumulative effect of initially applying IFRS 16 as of January 1, 2019 to accumulated losses and not to restate prior years. Since the Group recognized the right-of-use assets at an amount equal to the lease liabilities, there was no impact on accumulated losses. The new accounting policy for leases is set out directly below.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group has elected to apply the following practical expedients in adopting IFRS 16: (i) not to recognize right-of-use assets and lease liabilities for leases of low value (i.e. approximate fair value of KUSD 5 when new), (ii) to apply hindsight in determining the lease term for contracts which contain certain options to extend or terminate the lease, (iii) to account for each lease component and any non-lease components as a single lease component and (iv) to rely on its assessment of whether leases were onerous by applying IAS37 Provisions, Contingent Liabilities and Contingent Assets immediately before the date of application. The Group&#146;s weighted average incremental borrowing rate calculated as of January 1, 2019 was 2.66%.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following table reconciles the Group&#146;s operating lease obligations at December 31, 2018, as previously disclosed in the Group&#146;s consolidated financial statements in Note 2 &#147;Significant accounting policies&#148;, with the lease obligations recognized on initial application of IFRS 16 at January 1, 2019.</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 7.17px; padding-right: 0px; ">&#160;</div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">Operating lease commitments at December 31, 2018</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,378</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">Discounted at the incremental borrowing rate as at January 1, 2019</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,976</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">Short-term leases recognized on a straight-line basis as expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(15</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">Low-value leases recognized on a straight-line basis as expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">Extension options reasonably certain to be exercised</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,462</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; "><b>Lease obligations recognized at January 1, 2019</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,423</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-9</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><b>NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&nbsp;</b><b>(continued)</b><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 10.67px; text-align: left; margin-top: 12px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; "><b><font style="font-size: 10.67px;">(in KUSD)</font></b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 7.17px; padding-right: 0px; ">&#160;</div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">&nbsp;&nbsp;&nbsp;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">Of which are:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">Lease liabilities (short-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">924</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="82%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.17px; ">Lease liabilities (long-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,499</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The recognized right-of-use assets relate to the following types of assets:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.30px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.30px; padding-right: 4.30px; "><b>June 30,<br> </b><b>2019</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.30px; padding-right: 0px; "><b>January 1,<br> </b><b>2019</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.30px; ">Properties (offices)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,325</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,399</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.30px; ">Vehicles</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">15</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">24</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.30px; "><b>Total right-of-use assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,340</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,423</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In accordance with the adoption of IFRS 16 Leases as of January 1, 2019, the Group recorded at initial recognition a non-cash KUSD 5,423 right-of-use asset and corresponding lease liability. Comparative information has not been restated. The Group&#146;s income statement for the six month period ended June 30, 2019 was impacted by an increase for depreciation of right-of-use of leased assets KUSD 513. The impact for interest expense was KUSD 73. During the same periods, the Group&#146;s cash flow statement was impacted by a shift from the cash generated from operations of KUSD 547 to the net cash used in financing activities. Overall, IFRS 16 was cash flow neutral for the Group.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are other new standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, and hence are not listed here.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Accounting Policy for Leases</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">From January 1, 2019, leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset&#146;s useful life and the lease term on a straight-line basis.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee&#146;s incremental borrowing rate is used, being the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Right-of-use assets are measured at cost comprising the following:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">the amount of the initial measurement of lease liability;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any lease payments made at or before the commencement date less any lease incentives received;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">any initial direct costs, and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">restoration costs.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For deferred tax purposes, the Group considered the net effect of temporary differences arising from the right-of-use assets and the lease liabilities.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>4.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Estimates</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-10</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><b>NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&nbsp;</b><b>(continued)</b><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">In preparing these interim consolidated financial statements, the significant judgements made by management in applying the Group&#8217;s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements for the year ended December 31, 2018.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>5.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Financial risk management</b></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>5.1</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Financial risk factors</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group&#146;s activities are exposed to a variety of financial risks: market risk (including currency risk and interest rate risk), credit risk and liquidity risk.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The interim consolidated financial statements do not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group&#146;s consolidated financial statements as at December 31, 2018.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There have been no changes in financial risk management since year-end.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>5.2</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Fair value estimation</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At June 30, 2019, the carrying amount is a reasonable approximation of fair value for the following financial assets and liabilities:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Cash and cash equivalents</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Trade accounts receivable</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Trade accounts payable</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the six months ended June 30, 2019, there were no significant changes in the business or economic circumstances that affected the fair value of the Group&#146;s financial assets and financial liabilities.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>6.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Seasonality of operations</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group&#146;s business operations are not seasonal or cyclical. However, research and development (&#147;R&amp;D&#148;) expenses decreased from KUSD 60,133 (six month period ended June 30, 2018) to KUSD 46,572 (six month period ended June 30, 2019). This decrease of KUSD 13,561 was primarily due to a decrease in CMC costs as the clinical trials advance.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>7.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Segment information</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Management considers that the Group has only a single segment: R&amp;D. This is consistent with the way that information is reported internally within the Group for the purpose of allocating resources and assessing performance.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>8.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Contract Revenue and Contract Liability</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Contract revenue represents the amortization of upfront payments received under license and collaboration contracts in order to finance the research and development that is the subject of those contracts and associated milestone payments.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The movement in contract liability is shown below:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.28px; padding-right: 7.28px; "><b>2019</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.28px; padding-right: 0px; "><b>2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; ">January 1</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,340</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,480</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; ">Recognized as contract revenue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(2,340</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(626</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; "><b>June 30</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>2,854</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-11</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><b>NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&nbsp;</b><b>(continued)</b><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 10.67px; text-align: left; margin-top: 12px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; "><b><font style="font-size: 10.67px;">(in KUSD)</font></b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.28px; padding-right: 7.28px; "><b>2019</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.28px; padding-right: 0px; "><b>2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; "><u>of which:</u><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; ">Contract liability (short-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,854</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; ">Contract liability (long-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.28px; "><b>Contract liability (total)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>2,854</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As a result of the discontinued development of a product candidate, the entire non-refundable upfront payment (consisting of deferred revenue and presented as a contract liability) received under the related license and collaboration agreement has been recognized in the first half of 2019 as contract revenue.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>9.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Intangible Assets</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Licenses are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Group has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Group did not recognize any amortization expense of licenses.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During the six month period ended June 30, 2019, the Company capitalized the following license payments:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 1,000 relating to a license agreement with a third party to acquire an antibody to be used in research, development, manufacturing and commercialization was capitalized as intangible assets.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 500 relating to a license agreement with a third party to use their technology to generate antibody-drug conjugates for up to five antibodies was capitalized as intangible assets.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 231 relating to a license agreement with a third party to use their technology for the production of antibodies was capitalized as intangible assets.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>10.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Shares to be issued</b></td></tr></table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Share data have been revised to give effect to the share split as explained in note 14 &#147;Events after reporting date &#8211; share split&#148;.</p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to an investment agreement, consideration of KUSD 26,950 (nominal value and share premium) was received by the Company on June 28, 2019 in anticipation of an issuance of 1,203,125 Class E Shares, and was held in a restricted account at that date. As at June 30, 2019, cash and cash equivalents includes this amount which is not freely available because the issuance of shares was entered in the Commercial Register only on July 5, 2019. As at June 30, 2019, this amount, net of estimated transaction costs of KUSD 309, has been recognized in these interim consolidated financial statements as shares to be issued (see note 14 &#147;Events after the reporting date&#148;).</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>11.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Share Capital</b></td></tr></table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Share data have been revised to give effect to the share split as explained in note 14 &#147;Events after reporting date &#8211; share split&#148;.</p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to an investment agreement, on June 7, 2019, the Company increased its share capital by CHF 21,600 (USD 21,761) through the issuance of 3,375,000 Class E Shares at a par value of CHF 0.0064 for a total consideration (nominal value and share premium) of KUSD 75,600.</p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to an investment agreement, on June 14, 2019, the Company increased its share capital by CHF 200 (USD 202) through the issuance of 31,250 Class E Shares at a par value of CHF 0.0064 for a total consideration (nominal value and share premium) of KUSD 700.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-12</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><b>NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&nbsp;</b><b>(continued)</b><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">The total consideration of the June 7 and 14, 2019 capital increases was reduced by an amount of KUSD 1,445 relating to transaction costs.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the Company&#146;s Share Purchase Plan 2016, the Company increased its share capital as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(i)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
on February 6, 2019, by CHF 600 (USD 603) through the issuance of 93,750 Class A Shares
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(ii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
on December 14, 2018, by CHF 3&#8217;300 (USD 3&#8217;338) through the issuance of 515,625 Class A shares
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(iii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
on June 29, 2018, by CHF 300 (USD 301) through the issuance of 46,875 Class A Shares.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>12.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Related parties</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A.T. Holdings II S&#224;rl (&#147;AT Holdings II&#148;) is a shareholder in the Company. AT Holdings II is in turn ultimately wholly owned by Auven Therapeutics Holdings, L.P. (&#147;ATH&#148;), a limited partnership registered in the British Virgin Islands. ATH&#146;s General Partner is Auven Therapeutics General L.P., which itself is a limited partnership whose General Partner is Auven Therapeutics GP Ltd. The manager of ATH is Auven Therapeutics Management L.L.L.P. (&#147;ATM&#148;).</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Services provided by the Company</u></i></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The Company provides registered office and simple administrative services to four subsidiaries of ATH. The amounts invoiced for the six month period ended June 30, 2019, recognized as general and administrative (&#147;G&amp;A&#148;) expenses, amounted to KUSD 2 (six month period ended June 30, 2018: KUSD 4).</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Services provided to the Company</u></i></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Auven affiliated companies incurred expenses on behalf of the Company, relating to a telecommunication contract with a third- party vendor, and recharged these at cost. The costs incurred for the six month period ended June 30, 2019, recognized as G&amp;A expenses, amounted to KUSD 0 (six month period ended June 30, 2018: KUSD 22).</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Key management compensation:</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The compensation to key management is shown below:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.23px; padding-right: 4.23px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30,<br> </b><b>2019</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.23px; padding-right: 0px; "><b>Six month<br> </b><b>period ended<br> </b><b>June 30,<br> </b><b>2018</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; ">Salaries and other short-term employee benefits</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,477</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,826</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; ">Pension costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">183</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">136</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; ">Share-based compensation expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">107</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">208</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; ">Other compensation</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">121</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.23px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>2,767</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>2,291</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-13</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><b>NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&nbsp;</b><b>(continued)</b><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: italic; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><i><u>Related party balances at the end of the period:</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Trade accounts receivable at June 30, 2019 include amounts receivable from Auven companies amounting to KUSD 3 (June 30, 2018: KUSD 6).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Trade accounts payable at June 30, 2019 include amounts payable to Auven companies amounting to KUSD 0 (June 30, 2018: KUSD 0,5).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All amounts due to Auven companies have no defined payment terms and are non-interest bearing.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>13.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Loss per share</b></td></tr></table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Share data have been revised to give effect to the share split as explained in note 14 &#147;Events after reporting date &#8211; share split&#148;.</p>

				<table align="20" width="94%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Six month period ended June 30, 2019</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class A<br> </b><b>Common<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class B<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class C<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class D<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Class E<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Net loss attributable to shareholders in KUSD</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(9,539</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(15,034</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(8,512</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(8,261</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(8,512</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Weighted average number of shares in issue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 11,312,500 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 17,828,125 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,093,750 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,796,875 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,091,074 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Basic and diluted loss per share in USD</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (0.84 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (0.84 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (0.84 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (0.84 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (0.84 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table align="20" width="93%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Six month period ended June 30, 2018</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class A<br> </b><b>Common<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class B<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class C<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class D<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Class E<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Net loss attributable to shareholders in KUSD</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(11,316</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(19,015</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(10,766</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(10,449</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(10,282</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Weighted average number of shares in issue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,609,375 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 17,828,125 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,093,750 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,796,875 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,640,625 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="42%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Basic and diluted loss per share in USD</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.07 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.07 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.07 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.07 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.07 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><a name="tNICFSE"></a><b>1</b><b>4</b><b>.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Events after the reporting date</b></td></tr></table><div style="clear: both"></div>

<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Share capital issued</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As explained in note 10 &#147;Shares to be issued&#148;, the Company received on June 28, 2019 consideration of KUSD 26,950 for an issuance of 1,203,125 Class E shares (77 Class E shares before share split), pursuant to an investment agreement. The issuance of shares was formally confirmed through their registration with the Commercial Register on July 5, 2019.</p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Increase in par value of share capital</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On August 22, 2019, the par value of each of the shares was increased from CHF 0.0064 to CHF 0.064 (CHF 100 to CHF 1,000 before share split) by transferring an amount of KCHF 3,714 (KUSD 3,789) from share premium to share capital.</p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Redemption of promissory notes</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the 2013 and 2016 Promissory Notes issued in connection with the share purchase plans, the relevant plan participant may repay outstanding amounts under the promissory note at any time in cash or repay the principal amount in whole or in part by delivering such number of shares as required to cover the amount to be repaid. In connection with this offering, each of the executive officers and directors and their respective related parties who held Promissory Notes entered into loan settlement agreements with the Company dated as of August 31, 2019 pursuant to which they repaid all amounts outstanding under the Promissory Notes, including accrued interest, by delivering such number of shares necessary to cover the entire amounts outstanding under the Promissory Notes. After consideration of all relevant factors, the board of directors determined the value of such surrendered shares as of the Settlement Date to be USD 26.88 per share (KUSD 420 before share split), resulting in the surrender of an aggregate of 365,125 Class A shares (23.368 Class A shares before share split) for the settlement of the Promissory Notes. The shares surrendered to the Company are held as treasury shares.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-14</p>

			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><b>NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&nbsp;</b><b>(continued)</b>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: italic; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><i>Treasury shares available for issuance on the exercise of share options</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to have available treasury shares to meet the demand for shares when share options are exercised, the Company, on September 2, 2019, increased its share capital by KCHF 140 (KUSD 141) through the issuance to a related party of 2,187,500 Class A shares (140 Class A shares before share split) at par value of CHF 0.064 per share (CHF 1,000 per share before share split) and repurchased these shares from the same related party at the same price on September 19, 2019. These shares are reserved for issuance on the exercise of share options.</p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tNICFS15"></a><i>Share split</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On September 19, 2019, the Company effected a one to 15,625 share split of its outstanding common and preferred shares. Accordingly, all share and per share amounts for all periods presented in these interim consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this share split.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-15</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 202-fintab02 -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 6.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 1.33px; margin-top: 0px; "> </div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><a name="fGI"></a><b>GROUP INFORMATION</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For the year ended December 31, 2018</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>DIRECTORS:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Peter B. Corr, Chairman of the Board</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Stephen Evans-Freke</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Michael Forer</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Chris J. Martin</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Thomas Pfisterer</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Thomas Rinderknecht</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Tyrell Rivers</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Jacques Theurillat</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Barrie Ward</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>SECRETARY:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Dominique Graz</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>REGISTERED OFFICE:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Route de la Corniche 3B</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">1066 Epalinges</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Switzerland</p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>AUDITORS:</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">PricewaterhouseCoopers SA</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-16</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="IROI"></a><b>Report of Independent Registered Public Accounting Firm</b></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To the Board of Directors and Shareholders of ADC Therapeutics SA</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Opinion on the Financial Statements</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have audited the accompanying consolidated balance sheets of ADC Therapeutics SA and its subsidiaries (the &#147;Company&#148;) as of December 31, 2018 and 2017, and the related consolidated income statements, the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Restatement of Previously Issued Financial Statements</i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As discussed in Notes 1 and 25 to the consolidated financial statements, the Company has restated its 2018 and 2017 financial statements to correct errors.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Basis for Opinion</b></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">/s/ PricewaterhouseCoopers SA</p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Lausanne, Switzerland<br>June 27, 2019, except for the effects of the share split discussed in Note 24 to the consolidated financial statements, as to which the date is September 19, 2019.</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have served as the Company&#146;s auditor since 2015.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-17</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCIS"></a><b>ADC Therapeutics SA, Epalinges</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>CONSOLIDATED INCOME STATEMENT<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><i><b>Restated </b></i></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 0px; "><i><b>Restated</b></i></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><b>Notes</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018 </b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Contract revenue</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">5</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1,140</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1,803</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Research and development expenses</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">6/8</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(118,313</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(85,530</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">General and administrative expenses</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">8</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(8,768</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(7,943</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Operating loss</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(125,941</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(91,670</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Financial income</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,856</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,031</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Exchange differences</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">213</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">825</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Loss before taxes</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(122,872</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,814</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Income tax expenses</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">9</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(224</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(48</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Loss for the year</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(123,096</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(89,862</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Attributable to:<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Owners of the parent</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Loss per share<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Basic and diluted loss per share (in USD)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">23</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNTTCFS1">23</a> to F-<a href="#ftFINNOTE">64</a> form an integral part of these consolidated financial statements<br></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-18</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCSCI"></a><b>CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><i><b>Restated</b></i></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 0px; "><i><b>Restated</b></i></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><b>Notes</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Loss for the year</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(123,096</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,862</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Other comprehensive loss:<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><u>Items that will not be reclassified to profit or loss</u><br></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Remeasurements of defined benefit plan</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">17</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Total items that will not be reclassified to profit or loss</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><u>Items that may be reclassified subsequently to profit or loss</u><br></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Currency translation differences</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(79</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">62</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Total items that may be reclassified subsequently to profit or loss</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(79</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">62</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Other comprehensive loss for the year</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(272</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(86</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Total comprehensive loss for the year</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(123,368</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(89,948</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Attributable to:<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Owners of the parent</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(123,368</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,948</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNTTCFS1">23</a> to F-<a href="#ftFINNOTE">64</a> form an integral part of these consolidated financial statements<br></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-19</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCBS"></a><b>ADC Therapeutics SA, Epalinges</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>CONSOLIDATED BALANCE SHEET<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.09px; padding-right: 3.09px; "><i><b>Restated</b></i></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.09px; padding-right: 3.09px; "><i><b>Restated</b></i></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.09px; padding-right: 0px; "><i><b>Restated</b></i></div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.09px; padding-right: 3.09px; "><b>Notes</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.09px; padding-right: 3.09px; "><b>December 31,<br> </b><b>2018 </b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.09px; padding-right: 3.09px; "><b>December 31,<br> </b><b>2017 </b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.09px; padding-right: 0px; "><b>January 1,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>ASSETS<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Current assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Cash and cash equivalents</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">14</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">138,807</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">143,669</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Trade accounts receivable</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">10/14/22</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">192</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,087</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,908</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Other current assets</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">11</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,081</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,335</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,676</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Total current assets</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>142,080</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>265,174</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>151,253</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Non-current assets<br></b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Property, plant and equipment, net</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">12</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,540</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,142</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">777</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Intangible assets, net</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">13</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,674</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,401</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,914</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Other long-term assets</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">264</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">232</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">133</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Total non-current assets</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>8,478</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>6,775</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>3,824</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Total assets</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>150,558</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>271,949</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>155,077</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>LIABILITIES AND EQUITY<br></b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Current liabilities<br></b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Trade accounts payable</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">14a/22</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,750</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7,619</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,145</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Other current liabilities</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">16</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13,650</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10,452</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,415</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Contract liability (short-term)</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">5</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,765</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,320</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,843</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Current income tax payable</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">189</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">265</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Total current liabilities</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>22,354</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>20,547</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>9,668</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Non-current liabilities<br></b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Contract liability (long-term)</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">5</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">575</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,160</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,440</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Defined benefit pension liabilities</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">17</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,386</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,076</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">783</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Other long-term liabilities</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">292</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Total non-current liabilities</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>1,961</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>2,236</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>4,515</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Total liabilities</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>24,315</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>22,783</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>14,183</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Equity attributable to owners of the parent<br></b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Share capital</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">19</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">401</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">397</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">334</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Share premium</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">19</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,268</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,296</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">255,120</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Other reserves</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">17/18</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,702</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,426</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,593</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Cumulative translation adjustments</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(43</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">36</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(26</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">Accumulated losses</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(332,085</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(208,989</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(119,127</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Total equity</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>126,243</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>249,166</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>140,894</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.09px; "><b>Total liabilities and equity</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.09px; padding-right: 3.09px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>150,558</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>271,949</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>155,077</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNTTCFS1">23</a> to F-<a href="#ftFINNOTE">64</a> form an integral part of these consolidated financial statements<br></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-20</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCSCE"></a><b>ADC Therapeutics SA, Epalinges</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>CONSOLIDATED STATEMENT OF CHANGES IN EQUITY<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="18" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.11px; padding-right: 0px; "><b>Attributable to owners of the parent</b></div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.11px; padding-right: 2.11px; "><b>Notes</b></div></td>
	<td colspan="3" width="6%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.11px; padding-right: 2.11px; "><b>Share<br> </b><b>capital</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.11px; padding-right: 2.11px; "><b>Share<br> </b><b>premium</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.11px; padding-right: 2.11px; "><b>Other<br> </b><b>reserves</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.11px; padding-right: 2.11px; "><b>Cumulative<br> </b><b>translation<br> </b><b>adjustment</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.11px; padding-right: 2.11px; "><b>Accumulated<br> </b><b>losses</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.11px; padding-right: 0px; "><b>Total</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>January 1, 2017 restated</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>334</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>255,120</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>4,593</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(26</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(119,127</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>140,894</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Loss for the year</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Translation adjustment</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">62</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">62</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Remeasurements of defined benefit pension</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">17</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>Total other comprehensive income / (loss)</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(148</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>62</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(86</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>Total comprehensive income / (loss) for the </b><b>year</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(148</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>62</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,862</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,948</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Issue of share capital / capital contributions</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">19</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">63</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">200,025</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">200,088</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Transaction costs</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">19</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,849</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,849</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Share-based compensation expense</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">18</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">980</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">980</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>Total transactions with owners</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>63</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>197,176</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>980</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>198,219</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>December 31, 2017 restated</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>397</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>452,296</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,426</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>36</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(208,989</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>249,166</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Loss for the year</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Translation adjustment</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(79</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(79</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Remeasurements of defined benefit pension</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">17</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>Total other comprehensive loss</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(193</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(79</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(272</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>Total comprehensive loss for the year</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(193</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(79</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(123,096</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(123,368</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Issue of share capital</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">19</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Transaction costs</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">19</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(28</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(28</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">Share-based compensation expense</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">18</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">469</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">469</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>Total transactions with owners</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>4</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(28</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>469</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>445</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; ">&#160;</div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="43%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.11px; "><b>December 31, 2018 restated</b></div></td>
	<td colspan="1" width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.11px; padding-right: 2.11px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="3%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>401</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>452,268</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,702</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(43</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(332,085</b></div></td><td width="1%" valign="bottom" align="right" col="7" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>126,243</b></div></td><td width="1%" valign="bottom" align="right" col="8" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: justify; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNTTCFS1">23</a> to F-<a href="#ftFINNOTE">64</a> form an integral part of these consolidated financial statements<br></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-21</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges</b></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-full" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 2.67px; margin-top: 12px; "> </div></div>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 15.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="fCSCF"></a><b>CONSOLIDATED STATEMENT OF CASH FLOWS<br></b><b>(in KUSD)</b></p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><i><b>Restated</b></i></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 0px; "><i><b>Restated</b></i></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><b>Notes</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 4.73px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.73px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Cash used in operating activities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Loss for the year</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Adjustments for non-monetary items:<br></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Share-based compensation expense</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">18</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">469</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">980</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Depreciation of property, plant and equipment</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">12</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">488</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">328</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Amortization and impairment of intangible assets</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">13</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">252</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Change in defined benefit pension liabilities</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">17</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">119</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">140</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Change in fair value measurement</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,009</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">240</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Accrued withholding tax</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">711</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Financial income</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,856</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,031</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Exchange differences</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(29</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">61</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Income taxes</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">9</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">224</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">48</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Operating loss before working capital changes</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,709</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,083</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Decrease in trade accounts receivable</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">895</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,822</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">(Increase) / decrease in other current assets</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,678</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">379</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">(Decrease) in contract liability (short and long term)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,140</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,803</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">(Decrease) / increase in trade accounts payable</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(858</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,468</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Increase in other liabilities</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,262</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">4,646</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Cash used in operating activities</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,228</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(75,571</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Interest received</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,051</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">771</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Tax paid</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(185</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(145</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Net cash used in operating activities</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(121,362</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(74,945</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Cash used in investing activities<br></b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Payment for purchases of property, plant and equipment</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">12</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(944</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(656</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Payment for purchases of intangible assets</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">13</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,526</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,500</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Payment for rent deposits</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(36</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(92</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Net cash used in investing activities</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(2,506</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(3,248</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Cash used in financing activities<br></b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Proceeds from capital contributions, net of transaction costs</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">19</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(24</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">197,239</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Net cash (used in) / from financing activities</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(24</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>197,239</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Net (decrease) / increase in cash and cash equivalents</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(123,892</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>119,046</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Exchange (losses) / gains on cash and cash equivalents</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(53</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">37</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; ">Cash and cash equivalents at beginning of year</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">143,669</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.73px; "><b>Cash and cash equivalents at end of year</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.73px; padding-right: 4.73px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>138,807</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>262,752</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 18.93px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">The notes on pages F-<a href="#tNTTCFS1">23</a> to F-<a href="#ftFINNOTE">64</a> form an integral part of these consolidated financial statements<br></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-22</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 203-finnotes02 -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><a name="fNCFS"></a><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></div><p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><a name="tNTTCFS1"></a><b>1.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Corporate information</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADC Therapeutics SA (the &#147;Company&#148; or &#147;ADCT&#148;) was incorporated on June 6, 2011 under the laws of Switzerland. The registered office of the Company is located at Route de la Corniche 3B, 1066 Epalinges, Switzerland. The Company controls two wholly-owned subsidiaries: ADC Therapeutics America, Inc. (&#147;ADCT America&#148;), which was incorporated in Delaware, USA on December 10, 2014, and ADC Therapeutics (UK) Ltd (&#147;ADCT UK&#148;), which was incorporated in England on December 12, 2014. The Company and its two subsidiaries form the ADCT Group (the &#147;Group&#148;).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group is focused on the development of antibody drug conjugates, including research, development, human clinical trials, regulatory approval and commercialization. Antibody drug conjugates (&#147;ADCs&#148;) are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill cancer cells to which the ADC attaches. ADCs have extensive potential therapeutic applications in cancer.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group&#146;s core technology platform is based on the development and commercial exploitation of chemistry acquired under license from Spirogen Ltd in 2011. The license agreement, as subsequently amended in 2013, gives the Company the right to develop up to eleven specific ADCs as well as ten non-ADCs using Spirogen&#146;s intellectual property and technology in warhead and linker chemistry.</p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These 2018 Group consolidated financial statements restate and replace the statements which were initially presented to the Board of Directors on March 21, 2019 and which have subsequently been withdrawn. They were re-presented by management and re-approved by the Board of Directors on June 27, 2019, except for the effects of the share split presented in note 24 &#147;Events after the reporting date &#8211; share split&#148; to the consolidated financial statements, as to which the date is September 19, 2019. Further explanations on the restatement are set out in note 25 &#147;Restatements&#148;.</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Significant accounting policies</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.1</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Basis of preparation </b></td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><u>(i) Compliance with International Financial Reporting Standards</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The ADCT Group consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). As of December 31, 2018, the financial statements are presented in thousand dollars (KUSD).</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>(ii) Historical Cost Convention</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The consolidated financial statements have been prepared under the historical cost convention, except for the assets included in the calculation of the net defined benefit pension plan liability, which are measured at fair value.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>(iii) Going concern basis</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADC Therapeutics SA is an early stage company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. The Group&#146;s success may also depend on its ability to:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">establish and maintain a strong patent position and protection; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">enter into collaborations with partners in the pharmaceutical industry; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">acquire and retain key personnel; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">acquire additional funding to support its operations. </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-23</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">Since its incorporation, the Company has primarily funded its growth through capital increases and additional funds provided by research collaborations. The Company never had recourse to bank loans. As a result, the Company is not exposed to liquidity risk through requests for early repayment of loans.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Significant R&amp;D expenses have been incurred from the start of the Company&#146;s activities, generating negative cash flows from operating activities since formation. Cash flows related to operating activities amounted to a negative KUSD 121,362 and negative KUSD 74,945 for the financial years ended December 31, 2018 and 2017, respectively. As at December 31, 2018, the Company&#146;s cash and cash equivalents amounted to KUSD 138,807 (December 31, 2017: KUSD 262,752).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Board of Directors believes that the Company has sufficient financial resources to cover its planned cash outflows for the next twelve months from the date of issuance of these financial statements. To continue the development of current product candidates beyond that period, the Company will be required to raise additional capital within the next twelve months. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to (i) significantly delay, scale back or discontinue the development of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to product candidates that the Company would otherwise seek to develop itself, on unfavorable terms. As the Company has concluded that there is no substantial doubt about its ability to continue as a going concern within one year of the re-issuance of these financial statements without additional capital becoming available, the Company has prepared these financial statements under the going concern assumption.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>(iv) Accounting policy for revenue and impact of adoption of IFRS 15 &#147;Revenue from Contracts with </u></i><i><u>Customers&#148;</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group has adopted IFRS 15 &#147;Revenue from Contracts with Customers&#148; from January 1, 2018. This standard applies to all contracts with customers except those that are financial instruments, leases or insurance contracts.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The approach to revenue recognition that is mandated in this standard is explained in the relevant accounting policy set out in note 2.11 &#147;Revenue recognition&#148;.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This standard requires an entity to disaggregate revenue from contracts with customers into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. Accordingly, further disclosures have been added to the note about revenue recognized in the period (see note 5 &#147;Contract Revenue&#148;).</p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company has reviewed its revenue contract to evaluate the effect of the new standard. The Company previously presented contract liability related to contracts with customers in the deferred revenue account. Contract balance is now presented in contract liability account. No restatement of the amounts recognized in the consolidated financial statements was necessary. There was therefore no impact on the retained earnings.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>(v) Accounting policy for financial instruments and impact of adoption of IFRS 9 &#147;Financial Instruments&#148;</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group has adopted IFRS 9 &#8216;Financial Instruments&#146; from January 1, 2018. This standard includes requirements on the classification and measurement of financial assets and liabilities. It defines three classification categories for debt instruments: amortized cost, fair value through other comprehensive income (&#8216;FVOCI&#146;) and fair value through profit or loss (&#8216;FVPL&#146;). Classification for investments in debt instruments is driven by the entity&#146;s business model for managing financial assets and their contractual cash flows. Investments in equity instruments are always measured at fair value. However, management can make an irrevocable election to present changes in fair value in other comprehensive income, provided the instrument is not held for trading. The standard does not introduce any changes for the classification and measurement of financial liabilities, except for the recognition of changes in own credit risk in other comprehensive income for liabilities designated at fair value through profit or loss.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">IFRS 9 also contains a new impairment model which will result in earlier recognition of losses. The expected credit losses (ECL) model is a &#8216;three-stage&#146; model for impairment based on changes in credit quality since initial recognition.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-24</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">In addition, the new standard contains amendments to general hedge accounting that will enable entities to better reflect their risk management activities in their financial statements.</p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group is potentially affected by only one section of this standard: IFRS 9 contains a new impairment model which may result in earlier recognition of credit losses. The expected credit losses (ECL) model is a &#8216;three-stage&#146; model for impairment based on changes in credit quality since initial recognition. As at January 1, 2018, none of the amounts due to the Group was overdue, all receivables were due from one existing collaboration partner with no defaults in the past and, based on Management&#146;s forward-looking analysis, there is no material expected credit default risk. The Group has not incurred defaults on any receivables in the past and does not expect any credit losses to arise on receivables of this nature in the future. In these circumstances, an expected credit loss model based on statistical analysis or previous experience would be inappropriate. The Group will continue to evaluate the recoverability of amounts due on the basis of the facts relevant to this individual case.</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On this basis, the Group has completed its assessment and has concluded that the adoption of this standard has no impact on its consolidated financial statements.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>(vi) New and amended standards adopted by the Group</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group has applied all new standards, amendments to standards and interpretations that are mandatory for the financial year beginning on January 1, 2018, to the extent that they are relevant to the Group. None of these has had any significant impact on the Group&#146;s financial statements. The new and amended standards adopted by the Group are:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">IFRS15 &#147;Revenue from Contracts with Customers&#148;, and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">IFRS 9 &#147;Financial Instruments&#148;. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The significance of these two standards is explained in notes (iv) and (v) above.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>(vii) New standards and interpretations not yet adopted</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">IFRS 16 &#8216;Leases&#146; (effective for annual periods beginning on or after January 1, 2019) will become effective for future financial reporting periods and has not yet been adopted by the Group.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under IAS 17, lessees were required to make a distinction between a finance lease (on balance sheet) and an operating lease (off balance sheet). IFRS 16 now requires lessees to recognize a lease liability reflecting future lease payments and a right-of-use asset for virtually all lease contracts. The IASB has included an optional exemption for certain short-term leases and leases of low-value assets, although this exemption can only be applied by lessees. IFRS 16 is likely to have a significant impact on the financial statements of a number of lessees, as it will result in almost all leases being recognized on the balance sheet (as the distinction between operating and finance leases is removed), while for lessors the accounting stays almost the same. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognized.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group will apply IFRS 16 from January 1, 2019. It will affect primarily the accounting for the Group&#146;s operating leases. The Group intends to apply the simplified transition approach and will not restate comparative amounts for the year prior to adoption. Right-of-use assets will be measured at the amount of the lease liability on adoption (adjusted for any prepaid or accrued lease expenses).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group has reviewed all of the Group&#146;s leasing arrangements in light of the new lease accounting rules in IFRS 16.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">As at the reporting date, the Group has non-cancellable operating lease commitments of KUSD 4,378, see note 20 &#147;Commitments&#148;. Of these commitments, none relate to low value leases and approximately KUSD 12 to short-term leases, which will be recognized on a straight-line basis as expense in the income statement.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">For the remaining lease commitments the Group expects to recognize right-of-use assets of </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-25</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 80px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">approximately KUSD 5,423 on January 1, 2019 and lease liabilities of KUSD 5,423 (after adjustments for prepayments and accrued lease payments recognized as at 31 December 2018). No deferred tax assets are expected to arise. Overall net assets will be unchanged, and net current assets will be KUSD 924 lower due to the presentation of a portion of the liability as a current liability.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The Group expects that, as a consequence of adopting the new rules, the result before taxes will be negatively impacted by approximately KUSD 57 for 2019. The operating result is expected to be positively impacted by approximately KUSD 73, as the charge against the operating result will include the amortization of the right-of-use assets but not the interest on the lease liability, whereas previously the entire lease payments were charged against the operating result.</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">There are other new standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, and hence are not listed here.</p>

<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>(viii) Share split</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As explained in note 24 &#147;Events after the reporting date &#8211; share split&#148;, on September 19, 2019, the Company effected a one to 15,625 share split of its outstanding shares. Accordingly, all share and per share amounts for all periods presented in these consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this share split. These consolidated financial statements have not been adjusted to give retroactive effect to any other subsequent events as set out in note 24 &#147;Events after the reporting date&#148;.</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.2</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Consolidation </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The annual closing date of the individual financial statements is December 31. Subsidiaries are all entities over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Company controls another entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.3</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Foreign currency translation </b></td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><u>Functional and presentation currency</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Items included in the financial statements of each of the Group entities are measured using the currency of the primary economic environment in which the entity operates (&#147;the functional currency&#148;). The consolidated financial statements are presented in US dollars (&#147;USD&#148; or &#147;Dollars&#148;), which is the Group&#146;s functional and the Group&#146;s presentation currency. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Transactions and balances</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All foreign exchange gains and losses are presented in the income statement within &#147;Exchange differences&#148;. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Group companies</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The results and financial position of all the Group entities that have a functional currency different from the presentation currency are translated into the presentation currency as follows: </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-26</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 12px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(i)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(ii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">income and expenses for each income statement are translated at monthly average exchange rates; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(iii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">all resulting exchange differences are recognized in other comprehensive income, under &#147;Cumulative translation adjustments&#148;. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following exchange rates have been used for the translation of the financial statements of ADCT UK, the functional currency of which is the British pound:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 5.52px; "><b>USD / GBP</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.52px; padding-right: 5.52px; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.52px; padding-right: 5.52px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.52px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.52px; ">Closing rate, GBP 1</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">USD</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.26902</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.34912</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.52px; ">Weighted average exchange rate, GBP 1</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">USD</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.35009</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.29295</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.4</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Cash and cash equivalents </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Cash and cash equivalents includes cash on hand, deposits held at call with external financial institutions and other short-term highly liquid investments with original maturities to the Company of three months or less. They are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Any bank overdrafts are not netted against cash and cash equivalents but are shown as part of current liabilities on the consolidated balance sheet. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.5</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Property, plant and equipment </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Depreciation is calculated using the straight-line method to reduce the cost of each asset to its residual value over its estimated useful life, as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">

						<tr style="background-color: #cceeff;">
							<td width="77%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Leasehold improvements</div>
							</td>
							<td width="15%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">3 to 10 years</div>
							</td>
						</tr>
						<tr>
							<td width="77%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Laboratory equipment</div>
							</td>
							<td width="15%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">5 years</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="77%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Office equipment</div>
							</td>
							<td width="15%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">5 years</div>
							</td>
						</tr>
						<tr>
							<td width="77%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Hardware</div>
							</td>
							<td width="15%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">3 years</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.6</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Intangible assets </b></td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><u>Licenses</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Licenses acquired are capitalized as intangible assets at historical cost and amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received. These licenses are tested for impairment at the last quarter of each financial period. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Amortization and impairment of licenses</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Amortization of capitalized licenses will be charged to research and development expenses. Impairment of capitalized licenses has been charged to research and development expenses. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.7</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Impairment of non-financial assets </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment. </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-27</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">Assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows, adjusted for the risks specific to each asset, are discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the general risks affecting the pharmaceutical industry. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash flows of other assets (&#147;cash-generating units&#148;). Impairment losses are recognized in the income statement.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Prior impairments of non-financial assets are reviewed for possible reversal of the impairment at each reporting date.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.8</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Employee benefits </b></td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><u>Pension obligations</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Group companies operate defined benefit and defined contribution pension schemes in accordance with the local conditions and practices in the countries in which they operate. The schemes are generally funded through payments to insurance companies or trustee-administered funds, determined by periodic actuarial calculations. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity (a fund) and has no legal or constructive obligations to pay further contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. A defined benefit plan is a pension plan that is not a defined contribution plan. Typically, defined benefit plans define an amount of pension benefit that an employee will receive on retirement, usually dependent on one or more factors such as age, years of service and compensation. However, as is the case with many Swiss pension plans, although the amount of ultimate pension benefit is not defined, certain legal obligations of the plan nevertheless create constructive obligations on the employer to pay further contributions to fund an eventual deficit. This results in the plan being accounted for as a defined benefit plan. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The liability recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity that approximate to the terms of the related pension obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The current service cost of the defined benefit plan, recognized in the income statement in employee benefit expense, except where included in the cost of an asset, reflects the increase in the defined benefit obligation resulting from employee service in the current year. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Past service costs, resulting from a plan amendment or curtailment, are recognized immediately in the income statement. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The net interest cost is calculated by applying the discount rate to the net balance of the present value of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expenses in the income statement. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are charged or credited to equity in other comprehensive income in the period in which they arise. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For defined contribution plans, the company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. Once the contributions have been paid, the </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-28</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">company has no further payment obligations. The contributions are recognized as employee benefit expenses when they are due and are included in staff costs. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Share-based compensation expense</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The fair value of shares or options granted, respectively, under share purchase or share option plans is recognized as an employee share-based compensation expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the shares or options granted:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">including any market performance conditions (e.g. the entity&#8217;s share price); </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">excluding the impact of any service and non-market performance vesting conditions (e.g. employee performance targets or remaining an employee of the entity over a specified time period); and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">including the impact of any non-vesting conditions (e.g. the requirement for employees to save or hold shares for a specific period of time). </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimate of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimate, if any, in profit or loss, with a corresponding adjustment to equity.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The proceeds received net of any directly attributable transaction costs are credited directly to equity.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.9</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Share capital and share premium </b></td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><u>Share capital</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company has issued five different classes of shares, all of which are classified as equity (see note 19 &#147;Share Capital&#148;). </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Share premium</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Amounts of contribution in excess of par value are accounted for as share premium. Share premium also arises from additional capital contributions from shareholders. Incremental costs directly attributable to equity transactions such as the issue of new capital shares are shown in equity as a deduction, net of tax, from the proceeds within share premium. Transaction costs that relate to equity and non-equity transactions are allocated to those transactions using a basis of allocation that is rational and consistent with similar transactions. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.10</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Leases </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the income statement on a straight-line basis over the period of the lease. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.11</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Revenue recognition </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Revenue is measured at the fair value of the consideration received or receivable for the sale of services in the ordinary course of the Group&#146;s activities. Revenue is shown net of value-added tax, rebates and discounts and after eliminating sales within the Group. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-29</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">(iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><i><u>Performance obligation satisfied to the state of completion - deferred contract revenue amortization</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue is recognized according to the stage of completion of the transaction at the end of the period using the cost input method. Under this method, revenue is recognized in the accounting periods in which the services are rendered. The recognition of revenue on this basis provides full information on the extent of service activity and performance during a period.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">To be able to estimate the outcome of a transaction reliably, the entity must be able to make a reliable estimate of total transaction revenue, the stage of completion and the costs to complete the transaction. The stage of completion is determined as the proportion of the transaction costs incurred for services rendered to date compared to the estimated total transaction costs.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.12</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Research and development expenses </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Research expenditure is recognized in expense in the year in which it is incurred. Internal development expenditure is capitalized only if it meets the recognition criteria of IAS 38 &#147;Intangible Assets&#148;. Where regulatory and other uncertainties are such that the criteria are not met, which is almost invariably the case prior to approval of the drug by the relevant regulatory authority, the expenditure is recognized in the income statement. Where, however, recognition criteria are met, internal development expenditure is capitalized and amortized on a straight-line basis over its useful economic life. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.13</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Current, deferred income tax and tax credit </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The tax expense for the period comprises current and deferred tax. Tax is recognized in the income statement, except to the extent that it relates to items recognized in other comprehensive income or directly in equity; in this case the related tax is recognized in other comprehensive income or directly in equity, respectively. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Taxes on income are accrued in the same periods as the revenues and expenses to which they relate. Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. The deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences or the unused tax losses can be utilized.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-30</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">Deferred income tax assets from tax credit carryforwards are recognized to the extent that the national tax authority confirms the eligibility of such a claim and that the realization of the related tax benefit through future taxable profits is probable.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income taxes assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.14</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Segment reporting </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one reportable segment. Revenue is attributable to the Company&#146;s country of domicile, Switzerland. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>2.15</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Loss per share </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Basic loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of ordinary shares in issue during the year. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares (share option plans, see note 18, &#147;Share-based compensation expense&#148;). </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>3.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Financial risk management</b></td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>3.1</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Financial risk factors </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Board of Directors regularly reviews the Group cash forecast and related foreign exchange risk. It also performs the risk assessment, defines any necessary measures and ensures the monitoring of the internal control system. The Group does not use derivative financial instruments to hedge these exposures. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Foreign exchange risk</u></i><i> </i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to British pounds, Euros and Swiss francs. Transaction exposure arises because the amount of local currency paid or received in transactions denominated in foreign currencies may vary due to changes in exchange rates. Foreign exchange risk arises from: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">forecast costs denominated in a currency other than the entity&#8217;s functional currency; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">recognized assets and liabilities denominated in a currency other than the entity&#8217;s functional currency; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">net investments in foreign operations. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Management believes that foreign exchange risk is minimal, as the Company receives its revenues in USD, pays invoices mainly in USD and holds cash principally in USD.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-31</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">The Group&#8217;s cash and cash equivalents are denominated in the following foreign currencies:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4.36px; "><b>December 31</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.36px; padding-right: 4.36px; "><b>2018<br> </b><b>in KL/C</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.36px; padding-right: 4.35px; "><b>2018<br> </b><b>in KUSD</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.35px; padding-right: 4.35px; "><b>2017<br> </b><b>in KL/C</b><b><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4.35px; padding-right: 0px; "><b>2017 in KUSD</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.36px; ">In USD</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">135,451</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">135,451</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">240,614</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">240,614</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.36px; ">In CHF</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,143</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,160</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10,439</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10,691</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.36px; ">In GBP</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">929</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,179</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,896</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">9,304</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.36px; ">In EUR</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">889</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,017</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,789</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2,143</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="49%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.36px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>138,807</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>262,752</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<div class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 4px; margin-bottom: 0px; "><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0%; margin-bottom: 1.33px; margin-top: 12px; "> </div></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">(1)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Thousands Local Currencies</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group has certain investments in foreign operations whose net assets are exposed to foreign currency translation risk. Currency exposure arising from these net assets of the Group&#146;s foreign operations is managed primarily through purchasing goods and services denominated in the relevant foreign currencies.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At December 31, 2018, if the USD had weakened / strengthened by 10% against the CHF with all other variables held constant, the pre-tax loss for the year would have been KUSD 20 lower / higher, as a result of foreign exchange gains / losses on translation of CHF-denominated net monetary assets (2017: KUSD 873).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At December 31, 2018, if the USD had weakened / strengthened by 10% against the EUR with all other variables held constant, the pre-tax loss for the year would have been KUSD 158 higher / lower, mainly as a result of foreign exchange gains / losses on translation of EUR-denominated net monetary assets (2017: KUSD 56 lower / higher).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At December 31, 2018, if the USD had weakened / strengthened by 10% against the GBP with all other variables held constant, the pre-tax loss for the year would have been KUSD 100 higher / lower, mainly as a result of foreign exchange gains / losses on translation of GBP-denominated net monetary assets (2017: KUSD 868 lower / higher), and the gain on currency translation differences credited directly to equity and arising on the translation of the net assets of ADCT UK would have been KUSD 125 higher / lower (2017: KUSD 97).</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Interest rate risk</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Interest rate risk arises from movements in interest rates which could have adverse effects on the Group&#146;s net income or financial position. Changes in interest rates cause variations in interest income and expenses on interest-bearing assets and liabilities, and on the value of the net defined benefit pension obligation.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Credit risk</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities and from its financing activities including deposits with banks and other financial institutions (see note 14b, &#147;Credit quality of financial assets&#148;). The Group&#146;s cash and cash equivalents accounts are maintained with well established, highly rated financial institutions. The Company&#146;s wholly-owned subsidiaries are solvent, are managed on a cost-plus service provider basis, and are supported by the Company as the parent.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Liquidity risk</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Liquidity risk is the risk that the Group may not be able to generate sufficient cash resources to settle its obligations in full as they fall due or can do so only on terms that are materially disadvantageous. Prudent liquidity risk management implies maintaining sufficient cash to cover working capital requirements. Cash is monitored by the Group management.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-32</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">Funding and liquidity risks are reviewed regularly by the Board and management. The Board reviews the Group&#8217;s ongoing liquidity risks quarterly as part of the financial review process and on an ad hoc basis. The Company funds its capital requirements through capital raises or partnering of its programs.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The table below analyses the Group&#146;s financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months approximate their carrying balances as the impact of discounting is not significant.</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.15px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.15px; padding-right: 5.15px; "><b>Less than<br> </b><b>3 months</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.15px; padding-right: 5.15px; "><b>Between<br> </b><b>3 months and<br> </b><b>1 year</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.15px; padding-right: 0px; "><b>More than<br> </b><b>1 year</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.15px; ">Trade accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">6,597</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">153</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.15px; "><b>At December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>6,597</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>153</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.15px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.15px; ">Trade accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">7,619</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.15px; "><b>At December 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>7,619</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>3.2</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Capital management </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group considers equity as equivalent to the IFRS equity on the balance sheet (including share capital, share premium and all other equity reserves attributable to the owners of the Company). The Group has no interest-bearing debt. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The primary objective of the Group&#146;s capital management is to maximize shareholder value. The Board regularly reviews its shareholders&#146; return strategy. For the foreseeable future, the Board will maintain a capital structure that supports the Group&#146;s strategic objectives through managing funding and liquidity risks and optimizing shareholder return. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company is an early stage biotechnology company with product candidates still at pre-clinical and clinical stages of development. As such, it does not expect to have significant revenues in the near future. It intends to continue to explore financing opportunities through cooperation and collaboration with pharmaceutical and biotechnology partners &#8211; potentially along the value chain from research alliances through co-development to commercialization &#8211; and through equity fund raising. It does not plan to issue any debt. As explained in note 2.1 (iii) &#147;Going concern basis&#148;, the Board of Directors believes that the Company has sufficient financial resources to meet all of its obligations for at least the next twelve months, from January to December 2019. </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>3.3</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Fair value estimation </b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At December 31, 2018, the carrying amount is a reasonable approximation of fair value for the following financial assets and liabilities: </p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Cash and cash equivalents</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Trade accounts receivable</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Trade accounts payable</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2018, there were no significant changes in the business or economic circumstances that affect the fair value of the Group&#146;s financial assets and financial liabilities.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>4.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Critical accounting estimates and judgements</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-33</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">estimates, assumptions and judgements that have significantly affected reported results or that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Revenue recognition</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company is party to a long-term license and joint collaboration agreement with MedImmune for the joint clinical development of a product candidate, MEDI3726. The license and joint collaboration agreement includes both upfront and milestone payments receivable by the Company in return for the satisfaction of certain performance obligations.</p>
				<p class="h5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><u>Upfront payments for two programs</u></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company received an upfront payment in 2013 under the license and joint collaboration agreement. This related to two separate product candidate programs. In each case, MedImmune received, in addition to the license, a commitment from the Company to perform development work on a product candidate to be chosen by MedImmune from a specified list; in return, MedImmune agreed, inter alia, to make an upfront payment of KUSD 10,000 and to bear part of the development work costs.</p>
				<p class="h5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><u>First program upfront payment</u></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The product candidate for the first program of work was immediately selected by MedImmune and the Company currently recognizes the upfront payment of KUSD 10,000 over the period of the related development work, based on the ratio of the costs of the work done to the total estimated costs to completion. This method requires that the entity be able to make a reliable estimate of total transaction revenue, the state of completion and the costs to complete the transaction, which involves some judgement. The related revenue recognized in 2018 amounted to KUSD 1,140 (2017: KUSD 1,803). Please see also note 5, &#147;Contract revenue&#148;.</p>
				<p class="h5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><u>Second program upfront payment</u></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">MedImmune deferred selection of a second program and finally decided definitively not to proceed with selection of a second program in 2015, when the upfront payment of KUSD 10,000 was entirely recognized in revenue, as there was no remaining performance obligation.</p>
				<p class="h5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><u>Milestone payment</u></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the first program, the Company was also entitled to receive a milestone payment of KUSD 10,000 upon a successful IND filing. The performance obligation was deemed to be the development work to be performed in order to achieve this filing. This amount was not recognized over the period in which the work was performed, as there could be no confidence in advance a successful outcome would be achieved. Accordingly, the entire milestone payment was recognized in revenue in 2016 upon a successful IND filing.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Licenses</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company enters into collaboration, license and sublicense agreements with third parties, which grant the Company the right to use their antibodies with the Company&#146;s licensed warhead and linker technology to develop new ADCs for anti-cancer treatments. The license fees (upfront fees, signature fees, milestone payments) paid by the Company under the agreements are capitalized as intangible assets. The Company considers that those licenses have a finite life. However, they are not amortized until the commercialization phase. They are tested annually for impairment. An impairment loss is recognized for the amount by which the asset&#146;s carrying amount exceeds its recoverable amount (higher of an asset&#146;s fair value less costs of disposal and value in use). Impairment losses are recognized in the income statement. Testing for impairment inevitably involves the application of judgement. The license costs capitalized in 2018 amounted to KUSD 1,481 (2017: KUSD 2,494). The Company has performed a review of its licenses for impairment </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-34</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">and, in relation to the termination of one of the Company&#8217;s programs, an impairment charge of KUSD 227 (corresponding to the entire carrying amount of the capitalized license) was recognized and charged to research and development expenses in the income statement in 2018. No impairment was recognized in 2017. Please refer to note 13, &#147;Intangible assets&#148;.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Share-based compensation expense</u></i></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Incentive Plan 2014</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The details of this plan are explained in note 18, &#147;Share-based compensation expense&#148;. The fair value of the grant, which led to the recognition of expense and equity of KUSD 108 in 2018 (2017: KUSD 251), was based on the application of an adjusted form of the Black-Scholes option pricing model. Significant judgement was required in estimating a number of the variables in that model, as explained in that note.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Share Purchase Plan 2016</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The details of this plan are explained in note 18, &#147;Share-based compensation expense&#148;. Significant judgement was required in estimating the fair value of the grant, as explained in that note. The fair value of the grant, which led to the recognition of expense and equity of KUSD 361 in 2018 (2017: KUSD 729), was based on the application of an adjusted form of the Black-Scholes option pricing model. Significant judgement was required in estimating a number of the variables in that model, as explained in that note.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>5.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Contract revenue</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Contract revenue represents the amortization of upfront payments received under the license and collaboration agreement with MedImmune for the joint clinical development of MEDI3726 in order to finance the research and development that is the subject of those contracts and a milestone payment related to the same agreement. Unamortized amounts are carried forward as a contract liability. No other upfront or milestone payment has been received or will become receivable under the terms of this or any other existing license and collaboration agreement.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The movement in contract liability is as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.31px; padding-right: 6.31px; "><b>2018</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.31px; padding-right: 0px; "><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; ">January 1</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,480</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5 ,283</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; ">Recognized as contract revenue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,140</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1, 803</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; "><b>December 31</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>2,340</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>3 ,480</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; "><u>of which:</u><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; ">Contract liability (short term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,765</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2 ,320</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; ">Contract liability (long term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">575</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1 ,160</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.31px; "><b>Contract liability (total)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>2,340</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>3 ,480</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amounts of deferred contract revenue arise entirely from an upfront payment received in 2013 under a license and joint collaboration agreement. The basis on which contract revenue has been recognized under this agreement is explained in note 4, &#147;Critical accounting estimates and judgements&#148; under &#147;Revenue recognition&#148;.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As explained in the accounting policy set out in note 2.11, the recognition of revenue depends on estimates of total transaction revenue, the stage of completion and the costs to complete the transaction. These estimates are reviewed at each period end and any necessary adjustments are made. Historically, such adjustments, which have related not to the transaction revenue but to the costs to complete and to the period over which the costs will be incurred, have not been significant.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-35</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 12px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>6.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Research and development expenses</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Throughout the period, the Company was ultimately responsible for paying all development costs and developing and maintaining the intellectual property of the Company. The Group&#8217;s business operations are not seasonal or cyclical. However, research and development (&#147;R&amp;D&#148;) expenses increased from KUSD 85,530 in 2017 to KUSD 118,313 in 2018. This increase of KUSD 32,783 is principally due to increased clinical trial costs.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>7.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Employee expenses</b></td></tr></table><div style="clear: both"></div>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.62px; padding-right: 5.62px; "><b>Notes</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.62px; padding-right: 5.62px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.62px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Wages, salaries and other costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">19,245</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13,030</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Social security costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,452</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,966</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Share-based compensation expense</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">18</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">469</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">980</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Defined benefit plan - pension costs</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">17</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">535</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">466</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Defined contribution plan - pension costs</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">481</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">269</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; "><b>Employee expenses</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>24,182</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>16,711</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>8.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Expenses by nature</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">This note provides an analysis of expenses by nature.</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.62px; padding-right: 5.62px; "><b>Notes</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.62px; padding-right: 5.62px; "><b>Year ended<br></b><b>December 31,<br></b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.62px; padding-right: 0px; "><b>Year ended<br></b><b>December 31,<br></b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; "><b><u>R&amp;D</u></b><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">External R&amp;D costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">93,185</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">69,347</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Employee expenses</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">7</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">19,246</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">11,951</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Administrative and general costs</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,953</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,742</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Depreciation of property, plant and equipment</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">12</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">330</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">191</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Amortization of intangible assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">13</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">17</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Impairment of intangible assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">13</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">227</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Facility expenses</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">832</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">550</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Travel expenses</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,563</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">981</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Laboratory supplies</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">960</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">755</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; "><b>Research and development expenses</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>118,313</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>85,530</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">&#160;</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; "><b><u>G&amp;A</u></b><br></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Employee expenses</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">7</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,936</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,760</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Administrative and general costs</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,131</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,630</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">General and administrative costs charged by related parties</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">22</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">38</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">41</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Depreciation of property, plant and equipment</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">12</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">158</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">137</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Amortization of intangible assets</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">13</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Facility expenses</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">224</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">202</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; ">Travel expenses</div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">273</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">173</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; "><b>General and administrative expenses</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>8,768</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>7,943</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="56%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.62px; "><b>Total expenses by nature</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.62px; padding-right: 5.62px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>127,081</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>93,473</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-36</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 12px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>9.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Income tax expenses </b></td></tr></table><div style="clear: both"></div>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b><font style="font-size: 10.67px;">(in KUSD)</font></b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>Year ended<br></b><b>December 31,<br></b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>Year ended<br></b><b>December 31,<br></b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Current income taxes for the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">218</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">154</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Current income taxes related to prior years</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">6</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(106</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>Income tax expenses</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>224</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>48</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group&#146;s expected tax expense for each year is based on the applicable tax rate in each individual jurisdiction, which in 2018 ranged between 11% and 27% (2017: between 11% and 34%) in the tax jurisdictions in which the Group operates. The weighted average tax rate applicable to the profits of the consolidated entities was 11.3% (2017: 11.5%). This decrease is due to changes in the mix of the taxable results of the individual group companies. The tax on the Group&#146;s profit/loss before tax differs from the theoretical amount that would arise using the weighted average applicable tax rate as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.61px; padding-right: 3.61px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.61px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">Loss before taxes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,872</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,814</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">Tax calculated at tax domestic rates applicable to profits in the respective countries</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(13,321</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(9,577</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">Tax effects of:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">- Tax losses for which no deferred income tax asset was recognized</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13,766</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10,085</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">- Utilization of R&amp;D tax credit (US)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(310</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(299</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">- Income not subject to tax / (expenses not deductible for tax purposes)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">83</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(55</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">- Tax relating to prior years</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">6</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(106</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; "><b>Income tax expenses</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>224</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>48</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>10.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Trade accounts receivable</b></td></tr></table><div style="clear: both"></div>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.61px; padding-right: 3.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">Trade accounts receivable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">192</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,087</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">Less: Allowance for doubtful accounts</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; "><b>Trade accounts receivable, net</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>192</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,087</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As at December 31, 2018 and 2017, there were no trade accounts receivable past due and no provision for impairment. The credit status of receivables is considered in note 14b, &#147;Credit quality of financial assets&#148;.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The carrying amounts of the Group&#146;s trade accounts receivables are denominated in USD.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The maximum exposure to credit risk at the reporting date is the carrying value of the receivables mentioned above.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>11.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Other current assets</b></td></tr></table><div style="clear: both"></div>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.61px; padding-right: 3.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">VAT receivable, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">549</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">444</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">Withholding tax receivable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">968</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">396</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">Prepaid expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,384</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">394</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">Other</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">180</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">101</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="67%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>3,081</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,335</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-37</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">Other current assets increased from KUSD 1,335 in 2017 to KUSD 3,081 in 2018. This increase of KUSD 1,746 is due to increased prepaid research and development expenses and withholding tax receivable on interest income.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>12.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Property, plant and equipment</b></td></tr></table><div style="clear: both"></div>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.57px; padding-right: 2.57px; "><b>Leasehold<br> </b><b>improvements</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.57px; padding-right: 2.57px; "><b>Laboratory<br> </b><b>equipment</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.57px; padding-right: 2.57px; "><b>Office<br> </b><b>equipment</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.57px; padding-right: 2.57px; "><b>Hardware</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.57px; padding-right: 0px; "><b>Total</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>Cost<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">January 1, 2017</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">332</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">274</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">201</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">266</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,073</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Additions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">46</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">355</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">137</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">118</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">656</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Disposals and scrapping</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(92</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(92</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Exchange difference</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">42</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">4</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">53</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>December 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>291</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>671</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>340</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>388</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1,690</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Additions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">226</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">327</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">277</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">114</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">944</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Disposals and scrapping</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(7</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(7</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Exchange difference</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(3</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(59</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(13</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(5</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(80</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>514</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>939</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>597</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>497</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>2,547</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>Accumulated depreciation<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">January 1, 2017</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(86</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(75</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(59</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(76</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(296</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Depreciation charge</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(73</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(82</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(76</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(97</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(328</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Disposals and scrapping</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">92</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">92</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Exchange difference</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(3</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(11</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(16</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>December 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(70</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(168</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(136</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(174</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(548</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Depreciation charge</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(57</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(159</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(118</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(154</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(488</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Disposals and scrapping</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">Exchange difference</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">17</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">22</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(126</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(310</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(245</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(326</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(1,007</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>Net book amount<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>January 1, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>221</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>503</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>204</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>214</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,142</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.57px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>388</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>629</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>352</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>171</b></div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,540</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2018, the investments in tangible fixed assets relate principally to the UK laboratory and offices, as well as to the offices in Switzerland. The 2017 &#147;Additions&#148; related mainly to investments in the UK laboratory equipment, as well as investments in the US office improvements and office/IT equipment. The 2017 &#147;Disposals and scrapping&#148; concerned UK leasehold improvements, 100% depreciated, which had been scrapped due to a move and reorganization of offices.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Depreciation has been recorded to the following categories in the income statement:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">330</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">191</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">158</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">137</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>488</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>328</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-38</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 12px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>13.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Intangible assets</b></td></tr></table><div style="clear: both"></div>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b><font style="font-size: 10.67px;">(in KUSD)</font></b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.12px; padding-right: 5.12px; "><b>Licenses</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.12px; padding-right: 5.12px; "><b>Software</b></div></td>
	<td colspan="3" width="8%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.12px; padding-right: 0px; "><b>Total</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>Cost<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">January 1, 2017</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,515</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">36</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,551</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Additions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,494</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,500</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Exchange difference</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">2</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>December 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>6,009</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>44</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>6,053</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Additions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,481</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">45</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,526</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Exchange difference</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(2</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(2</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>7,490</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>87</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>7,577</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>Accumulated amortization<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">January 1, 2017</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(626</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(12</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(638</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Amortization charge</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(13</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Exchange difference</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>December 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(626</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(26</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(652</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Amortization charge</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(25</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(25</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Impairment loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(227</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(227</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">Exchange difference</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(853</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(50</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(903</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>Net book amount<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>January 1, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,383</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>18</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,401</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.12px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>6,637</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>37</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="5%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>6,674</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Amortization has been recorded to the following categories in the income statement:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">17</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">8</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>25</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>13</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Licenses</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Licenses are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Company has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Company did not recognize any amortization expense of licenses.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company has capitalized certain payments for licenses, in accordance with its accounting policy note 2.6, &#147;Intangible assets&#148;. These licenses were acquired from six distinct third parties. The largest amount paid to any one party was KUSD 2,500 paid to Spirogen Ltd. in 2011 under a license and collaboration agreement, pursuant to which Spirogen Ltd. granted the Company access to its next-generation PBD-based warhead and linker technology. As a result of changes to the ownership of Spirogen Ltd. and of the applicable intellectual property rights, the agreement was subsequently amended and restated (with retroactive effect to September 2011) with MedImmune replacing Spirogen Ltd. as the licensor thereunder.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the agreement, MedImmune has granted the Company an exclusive, worldwide license under certain patent rights and related know-how to make, have made, use, sell, offer for sale and import </p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-39</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">product candidates in the field of human therapeutics and diagnostics that consist of (i) PBD-based molecules directly conjugated to an antibody (i.e., ADCs with a PBD-based warhead) that specifically bind to up to 11 approved targets (&#147;ADC Targets&#148;), and (ii) PBD-based molecules conjugated to a non-antibody (i.e., targeting-moiety conjugates with a PBD-based warhead) that specifically bind to up to ten approved targets (&#147;XDC Targets&#148;). As of December 31, 2018, there are 11 approved ADC Targets subject to the license, including CD19 (the target of ADCT-402) and CD25 (the target of ADCT-301), and ten approved XDC Targets subject to the license. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the agreement, the Company has the right to grant sublicenses to affiliates and, subject to MedImmune&#146;s approval (not to be unreasonably withheld), third parties. In addition, with respect to each licensed target, the Company has agreed to use commercially reasonable efforts to develop and commercialize at least one product and submit an IND application with the FDA (or its equivalent in another jurisdiction) for one product within 48 months after formal designation of the target as an approved replacement target, which the Company has done with respect to CD19 and CD25 upon submitting the IND applications for ADCT-402 and ADCT-301, respectively. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company is required to make no further payments to Spirogen or Medimmune, beyond the upfront licensing fee of $2.5 million paid in 2011, in consideration for the rights granted under the agreement. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2018, the Company capitalized the following license payments:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 231 relating to a license agreement with a third party to use their technology for the production of antibodies, was capitalized as intangible assets.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 750 relating to a license agreement with a third party to use their technology to generate antibody-drug conjugates for up to five antibodies, was capitalized as intangible assets.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 250 relating to a license agreement with a third party to use their technology to generate antibody-drug conjugates for up to five antibodies, was capitalized as intangible assets. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 250 relating to a license agreement with a third party to acquire an antibody to be used in research, development, manufacturing and commercialization, was capitalized as intangible assets. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On April 25, 2018, the Company announced the termination of one of its programs. Consequently, one license was terminated and an impairment charge of KUSD 227 (corresponding to the entire carrying amount of the capitalized license) was recognized and charged to research and development expenses in the income statement.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2018, the Company also performed an assessment of its other licenses in the context of its annual impairment test. Given the success of its development activities, the Company concluded that no additional impairment was required under the provisions of IAS 36.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2017, the Company capitalized the following license payments:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The Company entered into an asset purchase agreement with a third party to acquire an antibody to be used in research, development, manufacturing and commercialization, and an amount of KUSD 1,000 was capitalized as intangible assets.</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The Company entered into a license agreement with a third party to use an antibody in research, development, manufacturing and commercialization, and an amount of KUSD 500 was capitalized as intangible assets. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 550 relating to a license agreement with a third party to use their technology to generate antibody-drug conjugates for up to five antibodies, was capitalized as intangible assets. </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">An amount of KUSD 444 relating to a license agreement with a third party to use their technology for the production of antibodies was capitalized as intangible assets. </td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-40</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 12px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>14a.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Financial instruments by class and by category</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The accounting policies for financial instruments have been applied as indicated below:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; "><b>(in KUSD)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.29px; padding-right: 4.29px; "><b>Notes</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.29px; padding-right: 4.29px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.29px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; "><b>Financial assets - financial assets at amortized cost<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; ">Cash and cash equivalents</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">138,807</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; ">Trade accounts receivable</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">10</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">192</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,087</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; "><b>Total financial assets</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>138,999</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>263,839</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; "><b>Financial liabilities - financial liabilities at amortized cost<br></b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; ">Trade accounts payable</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">6,750</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">7,619</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; "><b>Total financial liabilities</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>6,750</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>7,619</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.29px; "><b>Net financial position</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.29px; padding-right: 4.29px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>132,249</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>256,220</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>14b.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Credit quality of financial assets</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The credit quality of financial assets that are neither past due nor impaired is assessed below by reference to S&amp;P&#146;s credit ratings (where available) or to historical information about counterparty default rates:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>Cash and cash equivalents<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">A+ UBS</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">71,493</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">120,323</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">A Credit Suisse</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">66,066</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">141,614</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">A- JP Morgan Chase</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,248</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">815</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>138,807</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>262,752</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>Trade accounts receivable (without external credit rating)<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Group 2</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">192</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,087</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>192</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,087</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 6.67px; margin-bottom: 0px; ">Group 1: new customers / counterparties (less than 12 months)</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 6.67px; margin-bottom: 0px; ">Group 2: existing customers / counterparties (more than 12 months) with no material default risk</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 6.67px; margin-bottom: 0px; ">Group 3: existing customers / counterparties (more than 12 months) with some default risk. All defaults were fully recovered.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>15.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Deferred income taxes and tax credit</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Unrecognized temporary differences, unused tax losses and unused tax credits</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Taxes losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">329,254</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">205,861</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Unused tax credit</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,009</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,622</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Deductible temporary differences related to the retirement benefit plan</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,386</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,076</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Offset of recognized temporary differences related to intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(2,364</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(2,364</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>Total</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>334,285</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>207,195</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-41</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: italic; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><i><u>Tax loss carryforwards</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Potential deferred income tax assets from tax loss carryforwards exceed deferred tax liabilities. Deferred income tax assets from tax loss carryforwards are initially recognized to the extent of suitable deferred income tax liabilities, then to the extent that the realization of the related tax benefit through future taxable profits is probable. On this basis, the Company has decided not to recognize any deferred income tax assets at December 31, 2018 or 2017. The amounts of deferred income tax assets that arise from sources other than tax loss carryforwards and the amounts of deferred income tax liabilities are insignificant in comparison to the unrecognized tax loss carryforwards.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>Tax losses not recognized and to be carried forward (in KUSD):</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 5.61px; "><b>Years of expiry</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.61px; padding-right: 5.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">2018</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,727</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">2019</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,209</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,168</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">2020</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">14,966</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">14,867</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">2021</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">20,200</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">20,068</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">2022</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">31,615</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">31,407</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Beyond 2023</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">256,264</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">131,624</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>329,254</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>205,861</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All of these carryforwards relate to the Company. In 2018, unused tax losses of KUSD 1,727 have expired (2017: nil).</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Tax credit</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">ADCT UK has made a claim for an R&amp;D investment tax credit for 2016 which has not yet been paid. The tax credit will be recognized upon confirmation from the UK tax authority that the claim is eligible for payment.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Deferred income tax assets from USA R&amp;D tax credit carryforwards are recognized to the extent that the realization of the related tax benefit through future taxable profits is probable. On this basis, the Group has not recognized deferred tax assets related to the following tax credits carried forward:</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>R&amp;D tax credits carried forward (in KUSD):</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 5.61px; "><b>Years of expiry</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.61px; padding-right: 5.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">2036</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">783</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">783</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">2037</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,839</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,839</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">2038</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,387</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>6,009</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>2,622</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">An amount of KUSD 310 was utilized in 2018 (KUSD 299 in 2017), as per note 9 &#147;Income tax expenses&#148;.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These R&amp;D tax credits, which may be carried forward for up to 20 years, relate entirely to ADCT America.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-42</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 12px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>16.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Other current liabilities</b></td></tr></table><div style="clear: both"></div>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b><font style="font-size: 10.67px;">(in KUSD)</font></b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Payroll and social charges</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,939</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,391</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Research and development costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">8,124</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,240</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Legal, audit and consulting fees</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">414</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">626</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Tax consulting fees</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">158</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">149</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Various taxes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">15</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">46</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>13,650</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>10,452</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Other current liabilities increased from KUSD 10,452 in 2017 to KUSD 13,650 in 2018. This increase of KUSD 3,198 is due to increased research and development expenses.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>17.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Pension obligations</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Swiss pension plan is classified as a defined benefit plan under IFRS. Certain employees of the UK subsidiary are covered by local defined contribution plans. Pension costs for these plans are charged to the income statement when incurred.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Swiss pension plan</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company contracted with the Swiss Life Collective BVG Foundation based in Zurich for the provision of occupational benefits. All benefits in accordance with the regulations are reinsured in their entirety with Swiss Life SA within the framework of the corresponding contract. This pension solution fully reinsures the risks of disability, death and longevity with Swiss Life. Swiss Life invests the vested pension capital and provides a 100% capital and interest guarantee. The pension plan is entitled to an annual bonus from Swiss Life comprising the effective savings, risk and cost results.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Although, as is the case with many Swiss pension plans, the amount of ultimate pension benefit is not defined, certain legal obligations of the plan create constructive obligations on the employer to pay further contributions to fund an eventual deficit; this results in the plan nevertheless being accounted for as a defined benefit plan.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In 2018, the guaranteed interest to be credited to employees&#146; savings was 1% for mandatory retirement savings (2017: 1%) and 0.25% for supplementary retirement savings (2017: 0.25%). While the rate for converting mandatory savings to an annuity remains fixed by statute at 6.8%, the rate for converting supplementary savings to an annuity at age 65 for male and 64 for female employees was reduced for the period 2016 - 2020 from 5.8350% to 5.0980% for male and from 5.7186% to 5.0995% for female employees.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Swiss defined benefit plan scheme is valued by independent actuaries every year using the projected unit credit method. The latest actuarial valuation was carried out as at December 31, 2018.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The net amount recognized on the balance sheet comprises:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Present value of defined benefit obligation for funded plan</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,372</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,070</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Fair value of plan assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(2,986</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(1,994</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>Deficit of funded plan: liability on the balance sheet</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,386</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,076</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-43</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">The movement in the net defined benefit obligation over the year is as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.04px; padding-right: 4.04px; "><b>Present value<br> </b><b>of obligation</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.04px; padding-right: 4.04px; "><b>Fair value<br> </b><b>of plan assets</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.04px; padding-right: 0px; "><b>Total</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">January 1, 2017</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,957</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,174</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">783</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Defined benefit plan - pension costs:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Current service cost</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">461</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">461</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Interest cost / (income)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">12</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; "><b>Defined benefit plan - pension costs</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>473</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(7</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>466</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Employee contributions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">163</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(163</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Employer contributions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(326</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(326</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Transfers from joiners&#8217; previous plans</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">260</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(260</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>423</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(749</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(326</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">18</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(12</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Remeasurements:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Change in financial assumptions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(108</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(108</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Other actuarial losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">229</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">229</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Plan asset gains</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(6</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(6</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">78</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(46</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">32</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; "><b>Remeasurements</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>199</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(52</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>147</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; "><b>December 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>3,070</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(1,994</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,076</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Defined benefit plan - pension costs:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Current service cost</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">527</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">527</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Interest cost / (income)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">23</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(15</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">8</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; "><b>Defined benefit plan - pension costs</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>550</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(15</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>535</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Employee contributions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">208</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(208</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Employer contributions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(416</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(416</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Transfers from joiners&#8217; previous plans</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">382</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(382</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>590</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(1,006</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(416</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(12</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Remeasurements:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Change in financial assumptions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(99</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(99</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Other actuarial losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">295</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">295</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Plan asset losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(22</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">14</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(8</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; "><b>Remeasurements</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>174</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>19</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>193</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.04px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>4,372</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(2,986</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="4%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,386</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The present value of the defined benefit obligation related to 19 active employees based in Switzerland (2017: 13 active employees).</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-44</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">The principal actuarial assumptions used for accounting purposes are as follows for all periods presented:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.50px; padding-right: 7.50px; "><b>2018</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.50px; padding-right: 0px; "><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">Discount rate</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.85</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.75</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">Interest credited on savings accounts</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.00</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.00</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">Future salary increases</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.50</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1.50</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.50px; ">Future pension increases</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.00</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0.00</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">%</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Assumptions regarding future mortality experience are set based on actuarial advice provided in accordance with published statistics and experience in each territory.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Mortality assumptions for Switzerland are based on the LPP 2015 mortality generational table. The average life expectancy in years after retirement of a pensioner retiring at age 65 (male) and 64 (female) on the balance sheet date is as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.83px; padding-right: 5.83px; "><b>2018</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.83px; padding-right: 0px; "><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; ">Male</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">22.50</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">22.38</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; ">Female</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">25.53</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">25.42</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The sensitivity of the defined benefit obligations and of the service cost to changes in the weighted principal assumption is:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.18px; padding-right: 2.18px; "><b>Change in<br> </b><b>assumption</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.18px; padding-right: 2.18px; "><b>Increase in<br> </b><b>assumption</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.18px; padding-right: 0px; "><b>Decrease in<br> </b><b>assumption</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Sensitivity of the defined benefit obligations in 2018:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Discount rate</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">0.25%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">Decrease by 5.4%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 0px; ">Increase by 5.9%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Future salary increases</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">0.50%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">Increase by 1.0%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 0px; ">Decrease by 1.0%</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Interest credited on savings accounts</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">0.50%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">Increase by 3.2%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 0px; ">Decrease by 3.1%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Future pension increases</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">0.50%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">Increase by 6.2%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 0px; ">Decrease by 5.6%</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">&#160;</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.18px; padding-right: 2.18px; "><b>Change in<br> </b><b>assumption</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.18px; padding-right: 2.18px; "><b>Increase in<br> </b><b>assumption</b></div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.18px; padding-right: 0px; "><b>Decrease in<br> </b><b>assumption</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Sensitivity of the defined benefit obligations in 2017:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="14%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Discount rate</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">0.25%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">Decrease by 5.5%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 0px; ">Increase by 6.0%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Future salary increases</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">0.50%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">Increase by 1.1%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 0px; ">Decrease by 1.0%</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Interest credited on savings accounts</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">0.50%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">Increase by 3.2%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 0px; ">Decrease by 3.1%</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.18px; ">Future pension increases</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">0.50%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 2.18px; ">Increase by 6.3%</div></td>
	<td colspan="3" width="17%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.18px; padding-right: 0px; ">Decrease by 5.7%</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The above sensitivity analyses are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligations to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting period) has been applied as when calculating the pension liability recognized within the statement of financial position.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The methods and types of assumptions used in preparing the sensitivity analysis did not change compared to the prior period.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Expected employer contributions to the defined benefit plan for the year ending December 31, 2019 amount to KUSD 485.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The weighted average duration of the defined benefit obligation is 22.7 years (2017: 23.1 years).</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-45</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: italic; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><i><u>Asset-liability strategy</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Swiss Life Collective BVG Foundation, to which the pension plan is affiliated, manages its funds in the interests of all members, with due attention to the priorities of liquidity, security and return. The Company&#146;s pension plan benefits from the economies of scale and diversification of risk available through this affiliation.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Investments by asset class</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Investments by asset class in KUSD are as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Cash</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">65</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">54</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Bonds</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,919</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,300</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Shares</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">147</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">94</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Real estates and mortgages</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">720</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">450</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Alternative investments</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">135</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">96</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>2,986</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>1,994</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Defined benefit plan reserves</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The movement in the defined benefit plan reserves (included in &#147;Other reserves&#148;) is as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.97px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.97px; padding-right: 7.97px; "><b>2018</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.97px; padding-right: 0px; "><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.97px; ">January 1</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(850</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(703</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.97px; ">Remeasurements of defined benefit pension plan</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(147</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="72%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 7.97px; "><b>December 31</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(1,043</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(850</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>18.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Share-based compensation expense</b></td></tr></table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Share data have been revised to give effect to the share split as explained in note 24 &#147;Events after reporting date &#8211; share split&#148;.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Share Purchase Plan 2013</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Board of Directors approved the &#147;Share Purchase Plan 2013&#148; in October 2012. The purpose of the plan was to allow participants the opportunity to buy shares from the Company.</p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Participants acquired 1,562,500 Class A shares in accordance with share purchase agreements executed on September 19, 2013, and there is no contractual obligation on the part of the Company to buy back the shares issued. In consideration of the shares granted, employees at grant date paid the nominal value of the shares and issued promissory notes to the Company for the balance, representing the amount of share premium. These promissory notes bear interest and give the Company the right of recourse. In accordance with IFRS, the Company has accounted for these share purchases as if they were non-recourse and therefore, in substance, share options. To effect this, the Company has deemed the strike price to be equal to the purchase price plus accumulated interest up to the expected date of exercise and the life of the options to be equivalent to the period remaining until a likely Liquidity Event (see Incentive Plan 2014 below) and has offset the amount of outstanding promissory notes against share premium. The Company had the right for a period of time to repurchase the shares but, as it had not in the past demonstrated any practice of doing so and as those rights were cancelled as of December 31, 2015, the plan has been accounted for since inception as equity settled under IFRS 2.</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amount of promissory notes offset against share premium at December 31, 2018 in respect of this plan is KUSD 2,150 (2017: KUSD 2,150). This amount excludes accumulated interest, as this expense has been recognized within the strike price in calculating the compensation expense.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-46</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: italic; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><i><u>Incentive Plan 2014</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the Incentive Plan dated May 1, 2014, the Company, at its discretion, may grant awards to plan participants (certain employees and service providers working for the benefit of the Company at the time) entitling them to receive, at the election of the Company and upon the occurrence of a Liquidity Event, a defined number of Class A shares at a defined strike price or an equivalent cash amount. A Liquidity Event is the first to occur of four possible events: the sale of the Company to a third party buyer, a merger of the Company with another entity, the sale of substantially all the Company&#146;s assets to a third party buyer or an initial public offering of the Company&#146;s shares. The strike price was set by the Company at the fair market value of the underlying Class A shares on the date of grant, as determined by the Company. The awards for Senior employees vest 25% annually from date of grant, over a four-year period. In the event that a Liquidity Event takes place before the end of a plan participant&#146;s vesting period, all of the awards granted to that plan participant vest as of the date of the Liquidity Event. In addition, for junior employees, the Company has granted share option awards effective January 1, 2017 and 2018 wherein there is 100% vesting but only on the occurrence of a Liquidity Event. Fair value of the awards is measured at each reporting date using an adjusted form of the Black-Scholes option pricing model, taking into account the terms and conditions upon which the awards were granted.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company will have to settle the awards under the Incentive Plan 2014 only upon the occurrence of a Liquidity Event. The Company has made a significant investment in preparing itself for an IPO, including legal, accounting and organizational matters. In the event of an IPO, the plan will be settled in shares rather than in cash. Therefore, the plan has been accounted for as equity settled under IFRS 2.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company has used an independent valuation firm to calculate the fair value of the award grants per participant. For awards vested 25% per annum from the date of grant over a four-year period, the Company annually takes a charge for the vested portion of award grants and for partially-earned but non-vested portions of award grants. This results in a front-loaded charge to the income statement. For non-vested awards, the Company annually takes a pro rata charge to the income statement based on the expected IPO date. In all cases, the charge to the income statement results in a corresponding credit being booked to &#147;Other reserves&#148; within equity.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The contractual term of each award granted is ten years. The cumulative amount credited to &#147;Other reserves&#148; at December 31, 2018 in respect of the Incentive Plan 2014 is KUSD 1,871 (2017: KUSD 1,763). The expense recognized for services received during the year is KUSD 108 (2017: KUSD 251).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Movements in the number of awards outstanding and their related weighted average strike prices are as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 6.57px; "><b>2018</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 0px; "><b>2017</b></div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 6.57px; "><b>Average<br> </b><b>strike<br> </b><b>price<br> </b><b>in USD<br> </b><b>per share</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 6.57px; "><b>Number of<br> </b><b>awards</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 6.57px; "><b>Average<br> </b><b>strike<br> </b><b>price<br> </b><b>in USD<br> </b><b>per share</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 0px; "><b>Number of<br> </b><b>awards</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">At the beginning of the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9.4 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2,352,656 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 7.7 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,138,125 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">Granted</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 20.8 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 125,313 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 11.1 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,214,531 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">Forfeited</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; "><b>At the end of the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>10.0</b> </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>2,477,969</b> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>9.4</b> </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>2,352,656</b> </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Out of the total outstanding awards of 2,477,969 class A shares as at December 31, 2018 (2017: 2,352,656 awards), no awards are exercisable as there has been no Liquidity Event. No awards have expired.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-47</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">Awards outstanding at the end of the year have the following expiry date and strike prices:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 5.44px; "><b>Grant date</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.44px; padding-right: 5.44px; "><b>Expiry<br> </b><b>date</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.44px; padding-right: 5.44px; "><b>Strike price<br> </b><b>in USD</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.44px; padding-right: 5.44px; "><b>Awards<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.44px; padding-right: 0px; "><b>Awards<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Feb - Sep 2014</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2024</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 7.4 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 752,969 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 752,969 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Mar - Jul 2015</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2025</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 7.4 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 181,094 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 181,094 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Oct - Nov 2015</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2025</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 8.9 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 14,844 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 14,844 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Jan - Jul 2016</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2026</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 8.9 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 189,219 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 189,219 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Jan - Oct 2017</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2027</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10.7 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,172,813 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,172,813 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Nov - Dec 2017</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2027</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 20.8 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 41,717 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 41,717 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Jan - Dec 2018</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2028</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 20.8 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 125,313 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> &#8212; </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; "><b>Total</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>2,477,969</b> </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>2,352,656</b> </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Weighted average remaining contractual life of awards outstanding at end of period</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.44px; padding-right: 5.44px; ">7.17 years</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.44px; padding-right: 0px; ">8.07 years</div></td>
</tr>


				</table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The average assessed fair value at grant date of awards granted during the year ended December 31, 2018 was USD 0.25 per award (2017: USD 0.09). The fair value at grant date is independently determined using an adjusted form of the Black-Scholes option pricing model that takes into account the strike price, the term of the award, the impact of dilution (where material), the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk free interest rate for the term of the award and the correlations and volatilities of the shares of peer group companies.</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The model inputs for awards granted during the following years included:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">

						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.99px; ">&#160;</div>
							</td>
							<td width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">&#160;</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.99px; padding-right: 4.99px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.99px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.99px; ">a) weighted average share price</div>
							</td>
							<td width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">in USD</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">
0.6 to 1.5
</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 0px; ">
0.1 to 0.9
</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.99px; ">b) strike price</div>
							</td>
							<td width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">in USD</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">
20.8
</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 0px; ">
10.7 / 20.8
</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.99px; ">c) expected volatility</div>
							</td>
							<td width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">in %</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">146.40 to 201.90</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 0px; ">130.40 to 235.20</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.99px; ">d) award life</div>
							</td>
							<td width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">in # of years</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">1.02 to 1.75</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 0px; ">0.91 to 2.16</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.99px; ">e) expected dividends</div>
							</td>
							<td width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">in %</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">0.00</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 0px; ">0.00</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4.99px; ">f) risk-free interest rate</div>
							</td>
							<td width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">in %</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 4.99px; ">1.84 to 2.57</div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4.99px; padding-right: 0px; ">0.82 to 1.66</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The expected volatility was based on historical volatility and selected volatility determined by median values observed among comparable public companies.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Share Purchase Plan 2016</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On March 17, 2016, the Board of Directors of the Company approved the Share Purchase Plan 2016 subject to certain conditions. The purpose of the plan was to allow participants, primarily Swiss residents, the opportunity to buy shares from the Company in accordance with plan rules, which specified the purchase price. Subsequently, all conditions were met, including shareholder approval at the Annual General Meeting held on May 19, 2016, and the receipt of a tax ruling from the Swiss tax authorities on November 18, 2016, and the plan was implemented.</p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Until December 31, 2018, participants had acquired 3,453,125 Class A shares (2017: 2,890,625) in accordance with share purchase agreements. There is no contractual obligation on the part of the Company to buy back the shares issued. In consideration of the shares purchased, employees at grant date paid the nominal value of the shares and issued promissory notes to the Company for the balance, representing the amount of share premium. These promissory notes bear interest and the Company has the right of recourse. In accordance with IFRS, the Company has accounted for these share purchases as if they were non-recourse and therefore, in substance, share options. To effect this, the Company has deemed the strike price to be equal to the purchase price plus accumulated interest up to the expected date of exercise and the life of the options to be equivalent to the period remaining until a likely Liquidity Event (see Incentive Plan </p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-48</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">2014 above) and has offset the amount of outstanding promissory notes against share premium. In line with common practice in share-based incentive plans, the Company has the right to repurchase the shares over a four-year call period, but it has not in the past demonstrated any practice of doing so. The plan is therefore considered as equity settled under IFRS 2.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company has used an independent valuation firm to calculate the fair value of the award grants per participant.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The terms also include leaver provisions, under which the Company has a call right over 100, 75, 50 or 25% (as applicable) of the shares, depending on the date of termination. As the Company&#146;s call rights expire 25% per annum from the date of grant over a four-year period, the Company annually takes a charge for the entire portion of the award grants that expire in the year and for a portion of the partially-earned award grants for which the call rights have not yet expired, on a pro rata basis. This results in a front-loaded charge to the income statement. In all cases, the charge to the income statement results in a corresponding credit being booked to &#147;Other reserves&#148; within equity.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The contractual term of each award granted is ten years. The cumulative amount credited to &#147;Other reserves&#148; at December 31, 2018 in respect of the Share Purchase Plan 2016 is KUSD 3,483 (2017: KUSD 3,122). The expense recognized for services received during the year is KUSD 361 (2017: KUSD 729).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Movements in the number of awards outstanding and their related weighted average strike prices are as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">&#160;</div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 6.57px; "><b>2018</b></div></td>
	<td colspan="6" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 0px; "><b>2017</b></div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 6.57px; "><b>Average<br> </b><b>strike<br> </b><b>price<br> </b><b>in USD<br> </b><b>per share</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 6.57px; "><b>Number of<br> </b><b>awards</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 6.57px; "><b>Average<br> </b><b>strike<br> </b><b>price<br> </b><b>in USD<br> </b><b>per share</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 6.57px; padding-right: 0px; "><b>Number of<br> </b><b>awards</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">At the beginning of the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.1 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2,890,625 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.1 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2,890,625 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">Granted</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.0 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 562,500 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; ">Forfeited</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 6.57px; "><b>At the end of the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>2.1</b> </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>3,453,125</b> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>2.1</b> </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>2,890,625</b> </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Out of the total outstanding awards of 3,453,125 class A shares as at December 31, 2018 (2017: 2,890,625 awards), no awards are exercisable as there has been no Liquidity Event. No awards have expired.</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Awards outstanding at the end of the year have the following expiry date and strike prices:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 5.44px; "><b>Grant date</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.44px; padding-right: 5.44px; "><b>Expiry<br> </b><b>date</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.44px; padding-right: 5.44px; "><b>Strike price<br> </b><b>in USD</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.44px; padding-right: 5.44px; "><b>Awards<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 5.44px; padding-right: 0px; "><b>Awards<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">May 2014</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2024</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.2 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 79,688 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 79,688 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Sep 2014</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2024</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.2 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 128,125 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 128,125 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">May 2015</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2025</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.2 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,309,219 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,309,219 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Sep 2015</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2025</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.1 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 200,625 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 200,625 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">May 2016</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2026</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.1 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 126,406 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 126,406 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">May 2016</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2026</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.1 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 200,625 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 200,625 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Oct 2016</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2026</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.1 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 140,625 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 140,625 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Dec 2016</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2026</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.1 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 705,312 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 705,312 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Jun 2018</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2028</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.1 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 46,875 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Dec 2018</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2028</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 2.0 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 515,625 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; "><b>Total</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>3,453,125</b> </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>2,890,625</b> </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.44px; ">Weighted average remaining contractual life of awards outstanding at end of period</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="5%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.44px; padding-right: 5.44px; ">7.37 years</div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 5.44px; padding-right: 0px; ">7.88 years</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-49</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p>
<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">The average assessed fair value at grant date of awards granted during the year ended December 31, 2018 was USD 0.22 per award (2017: NIL). The fair value at grant date is independently determined using an adjusted form of the Black-Scholes option pricing model that takes into account the strike price, the term of the award, the impact of dilution (where material), the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk free interest rate for the term of the award and the correlations and volatilities of the shares of peer group companies.</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The model inputs for awards granted during the following years included:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">

						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 7.47px; ">&#160;</div>
							</td>
							<td width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">&#160;</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.47px; padding-right: 7.47px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 7.47px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div>
							</td>
						</tr>


						<tr style="background-color: #cceeff;">
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 7.47px; ">a) weighted average share price</div>
							</td>
							<td width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">in USD</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">
0.4 to 1.0
</div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 0px; ">NIL</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 7.47px; ">b) strike price</div>
							</td>
							<td width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">in USD</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">
2.06 to 2.1
</div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 0px; ">NIL</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 7.47px; ">c) expected volatility</div>
							</td>
							<td width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">in %</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">170.00 to 233.10</div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 0px; ">NIL</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 7.47px; ">d) award life</div>
							</td>
							<td width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">in # of years</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">0.83 to 1.33</div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 0px; ">NIL</div>
							</td>
						</tr>
						<tr style="background-color: #cceeff;">
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 7.47px; ">e) expected dividends</div>
							</td>
							<td width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">in %</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">0.00</div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 0px; ">NIL</div>
							</td>
						</tr>
						<tr>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 7.47px; ">f) risk-free interest rate</div>
							</td>
							<td width="16%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">in %</div>
							</td>
							<td width="20%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 7.47px; ">2.32 to 2.60</div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 7.47px; padding-right: 0px; ">NIL</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The expected volatility was based on historical volatility and selected volatility determined by median values observed among comparable public companies.</p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The amount of promissory notes offset against share premium at December 31, 2018 in respect of this plan is KUSD 6,891 (2017: KUSD 5,768). This amount excludes accumulated interest, as this expense has been recognized within the strike price in calculating the compensation expense.</p>

				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Share-based Compensation Reserves</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The movement in the Share-based Compensation Reserves (included in &#147;Other reserves&#148;) is as follows:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.83px; padding-right: 5.83px; "><b>2018</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.83px; padding-right: 0px; "><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; ">January 1</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,276</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,296</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; ">Share Plan 2013</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; ">Share Plan 2014</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">108</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">251</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; ">Share Plan 2016</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">361</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">729</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="74%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.83px; "><b>December 31</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>6,745</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="6%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>6,276</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>19.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Share capital</b></td></tr></table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Share data have been revised to give effect to the share split as explained in note 24 &#147;Events after reporting date &#8211; share split&#148;.</p>

				<table align="20" width="94%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>Number of<br> </b><b>shares<br> </b><b>issued<br> </b><b>Class A</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>Number of<br> </b><b>shares<br> </b><b>issued<br> </b><b>Class B</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>Number of<br> </b><b>shares<br> </b><b>issued<br> </b><b>Class C</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 2px; "><b>Number of<br> </b><b>shares<br> </b><b>issued<br> </b><b>Class D</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2px; padding-right: 0px; "><b>Number of<br> </b><b>shares<br> </b><b>issued<br> </b><b>Class E</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; "><b>January 1, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>11,859,375</b> </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>17,828,125</b> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>10,093,750</b> </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>9,796,875</b> </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Issuance of share capital / capital contributions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 9,640,625 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; "><b>December 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>11,859,375</b> </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>17,828,125</b> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>10,093,750</b> </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>9,796,875</b> </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> <b>9,640,625</b> </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Issuance of share capital / capital contributions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "> 562,500 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>12,421,875</b> </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>17,828,125</b> </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>10,093,750</b> </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>9,796,875</b> </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "> <b>9,640,625</b> </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-50</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 10.67px; text-align: left; margin-top: 12px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.60px; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.60px; padding-right: 4.60px; "><b>Share<br> </b><b>capital<br> </b><b>(in KUSD)</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.60px; padding-right: 4.59px; "><b>Share<br> </b><b>premium<br> </b><b>(in KUSD)</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.59px; padding-right: 0px; "><b>Total<br> </b><b>(in KUSD)</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.60px; "><b>January 1, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>334</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>255,120</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>255,454</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.60px; ">Issuance of share capital / capital contributions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">63</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">197,176</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">197,239</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.60px; "><b>December 31, 2017</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>397</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>452,296</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>452,693</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.60px; ">Issuance of share capital / capital contributions</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">4</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(28</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(24</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="59%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.60px; "><b>December 31, 2018</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>401</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>452,268</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>452,669</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All issuances of share capital or capital contributions are shown net of transaction costs. Par value of all classes of shares is CHF 0.0064 per share and each registered share carries one voting right.</p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At December 31, 2018, the share capital of the Company amounts to CHF 382,600, consisting of 59,781,250 issued and fully paid-in registered shares with a nominal value of CHF 0.0064 each.</p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to an investment agreement, on November 16, 2017, the Company, by way of its most recent private placement, increased its share capital by CHF 61,700 (USD 63,299) through the issuance of 9,640,625 Class E Shares at a par value of CHF 0.0064 for a total consideration (nominal value and share premium) of USD 200,088,235 (2018: nil). This total was reduced by an amount of USD 2,848,657 relating to transaction costs (2018: nil).</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the Company&#146;s Share Purchase Plan 2016, in 2018 the Company increased its share capital as follows:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(i)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
on June 29, 2018, by CHF 300 (USD 301) through the issuance of 46,875 Class A shares; and,
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(ii)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">
on December 14, 2018, by CHF 3,300 (USD 3,338) through the issuance of 515,625 Class A shares
</td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the Articles of Incorporation, in the event of certain defined liquidation events, the liquidation proceeds will be distributed to the holders of shares in the following order of priority:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">1.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">First, to the Class E shareholders, an amount equal to the total price paid for the Class E shares, plus an 8% per annum return; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">2.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Second, to the Class D shareholders, an amount equal to the total price paid for the Class D shares, plus an 8% per annum return; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">3.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Third, to the Class C shareholders, an amount equal to the total price paid for the Class C shares; </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">4.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Fourth, pari passu, to the Class B shareholders, an amount equal to the total price paid for the Class B shares, plus an 8% per annum return, and, to the Class C shareholders, an 8% per annum return on the total price paid for the Class C shares; and </td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">5.</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Thereafter, to all shareholders, the remaining proceeds in proportion to the nominal value of their shares. </td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All references above to total price paid for shares include any share premium paid.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the Company&#146;s shareholder agreement, the above liquidation preferences may not apply to a change of control or initial public offering event.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Authorized Capital</u></i></p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">As of October 24, 2017, the Board of Directors was authorized, subject to compliance with Shareholder Agreement, to increase the share capital at any time until October 10, 2019, by a maximum amount of CHF 158,600, by issuing a maximum of 10,437,500 Class A Shares and 14,343,750 Class E Shares, fully paid up, with a par value of CHF 0.0064 each. An increase of the share capital in partial amounts is permissible. As at December 31, 2018, the remaining maximum amount is CHF 155,000, which may be raised by issuing a maximum of 9,875,000 Class A Shares and 14,343,750 Class E Shares.</p>

			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-51</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: italic; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><i><u>Dividend</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">At the next ordinary Annual General Meeting, the Board of Directors will not propose any dividend in respect of fiscal year 2018 (2017: nil).</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>20.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Commitments</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company has contractual obligations as follows:</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>a) Collaborations and co-operations with development partners</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company has entered into various collaborations with development partners, including in-licensing and manufacturing agreements. These agreements provide for the Company to make milestone payments that are conditional on success, and that are spread over various stages of development and commercialization, including achieving preclinical proof of concept, filing an investigational new drug (&#147;IND&#148;) application, commencing or completing multiple clinical development stages, obtaining regulatory approval in multiple countries, and achieving various levels of commercial sales. As of December 31, 2018, the aggregate amount of such potential milestone payments, under all such collaboration agreements, was KUSD 331,130 (2017: KUSD 299,640). These milestone payments relate entirely to product candidates in the preclinical or early phase 1 (phase 1a) stages of development. </p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company has two product candidates in phase 1b or phase 2 clinical trials: ADCT-301 and ADCT-402. Product candidate ADCT-301 is the subject of a collaboration and license agreement with Genmab A/S, under which there are no upfront or future milestone payments payable and no revenue receivable. Product candidate ADCT-402 is not linked to any collaboration agreement. </p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>b) Future minimum lease payments under non-cancellable operating leases</u></i></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Not later than 1 year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,084</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,006</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Later than 1 year and not later than 5 years</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,163</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,146</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">More than 5 years</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">131</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>4,378</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>3,152</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">These operating leases consist primarily of office and vehicle leases. Lease payments incurred during 2018 are recorded in the income statement in an amount of KUSD 869 (2017: KUSD 732).</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>21.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Contingent liabilities</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Group has no contingent liabilities in respect of legal claims arising in the ordinary course of business. There are no material legal proceedings to which the Company is a party. In the opinion of the Board of Directors, the disposition of such legal proceedings should not have a material impact on the Company&#146;s results of operations, financial position and cash flows.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>22.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Related parties</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">A.T. Holdings II S&#224;rl (&#147;AT Holdings II&#148;) is a shareholder in the Company. AT Holdings II is in turn ultimately entirely owned by Auven Therapeutics Holdings, L.P. (&#147;ATH&#148;), a limited partnership registered in the British Virgin Islands. ATH&#146;s General Partner is Auven Therapeutics General L.P., which itself is a limited partnership whose General Partner is Auven Therapeutics GP Ltd. The manager of ATH is Auven Therapeutics Management L.L.L.P. (&#147;ATM&#148;).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The related party transactions listed below were based on the arm&#146;s length principle.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-52</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: italic; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><i><u>Services provided by the Company</u></i></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">The Company provides registered office and simple administrative services to eight subsidiaries of ATH. The amounts invoiced in 2018, recognized as general and administrative (&#147;G&amp;A&#148;) expenses, amounted to KUSD 7 (2017: KUSD 8).</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Services provided to the Company</u></i></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">-</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">Auven affiliated companies incurred expenses on behalf of the Company, relating to a telecommunication contract with a third-party vendor, and recharged these at cost. The costs incurred in 2018, recognized as G&amp;A expenses, amounted to KUSD 38 (2017: KUSD 41).</td></tr></table><div style="clear: both"></div>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Related party balances at year-end</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Trade accounts receivable at December 31, 2018, include amounts receivable from Auven companies amounting to KUSD 2 (2017: KUSD 2).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Trade accounts payable at December 31, 2018, include amounts payable to Auven companies amounting to KUSD 10 (2017: KUSD 10).</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All amounts due to affiliates have no defined payment terms and are non-interest bearing.</p>
				<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><u>Key management compensation</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Key management compensation was:</p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; "><b>(in KUSD)</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 5.61px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="14%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 5.61px; padding-right: 0px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Salaries and other short-term employee benefits</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,512</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,953</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Pension costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">299</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">261</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Share-based compensation expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">341</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">696</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">Other compensation</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">183</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">81</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="64%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 5.61px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>5,335</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="11%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>4,991</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>23.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Loss per share</b></td></tr></table><div style="clear: both"></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Share data have been revised to give effect to the share split as explained in note 24 &#147;Events after reporting date &#8211; share split&#148;.</p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The restated tables shown below are related to the correction of errors presented in note 25 &#147;Restatements&#148;.</p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company&#146;s shares comprise 5 classes of common and preferred shares. The net loss is allocated to each class pro rata to its weighted average number of shares in issue during the period. The basic loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of shares in issue during the period as follows:</p>
				<table align="20" width="94%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Year Ended December 31, 2018 restated</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class A<br> </b><b>Common<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class B<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class C<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class D<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Class E<br></b><b>Preferred<br></b><b>Shares</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Net loss attributable to shareholders (in KUSD)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(23,014</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(37,675</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(21,330</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(20,703</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(20,373</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Weighted average number of shares in issue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,890,625 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 17,828,125 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,093,750 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,796,875 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,640,625 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Basic and diluted loss per share (in USD)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<table align="20" width="94%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; ">
<b>Year Ended December 31, 2018</b>
</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; ">
<b>Class A<br> </b><b>Common<br> </b><b>Shares</b>
</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; ">
<b>Class B<br> </b><b>Preferred<br> </b><b>Shares</b>
</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; ">
<b>Class C<br> </b><b>Preferred<br> </b><b>Shares</b>
</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; ">
<b>Class D<br> </b><b>Preferred<br> </b><b>Shares</b>
</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; ">
<b>Class E<br> </b><b>Preferred<br> </b><b>Shares</b>
</div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">
Net loss attributable to shareholders (in KUSD)
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(22,873</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(37,443</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(21,199</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(20,576</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(20,248</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Weighted average number of shares in issue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,890,625 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 17,828,125 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,093,750 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,796,875 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,640,625 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Basic and diluted loss per share (in USD)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.10 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.10 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.10 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.10 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.10 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-53</p>

			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<table align="20" width="94%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 10.67px; text-align: left; margin-top: 12px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b><font style="font-size: 10.67px;">Year Ended December 31, 2017 restated</font></b>
</div></td></tr></table>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; ">
<b>Class A<br> </b><b>Common<br> </b><b>Shares</b>
</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; ">
<b>Class B<br> </b><b>Preferred<br> </b><b>Shares</b>
</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; ">
<b>Class C<br> </b><b>Preferred<br> </b><b>Shares</b>
</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; ">
<b>Class D<br> </b><b>Preferred<br> </b><b>Shares</b>
</div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; ">
<b>Class E<br> </b><b>Preferred<br> </b><b>Shares</b>
</div></td>


					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">
Net loss attributable to shareholders (in KUSD)
</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(18,431</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(32,706</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(18,517</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(17,972</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,236</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Weighted average number of shares in issue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,055,650 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 17,828,125 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,093,750 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,796,875 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,214,983 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Basic and diluted loss per share (in USD)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				<div style="clear: both"></div>
				<table align="20" width="94%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 2px; "><b>Year Ended December 31, 2017</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class A<br> </b><b>Common<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class B<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class C<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 2px; "><b>Class D<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
	<td colspan="3" width="10%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 2px; padding-right: 0px; "><b>Class E<br> </b><b>Preferred<br> </b><b>Shares</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Net loss attributable to shareholders (in KUSD)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(18,350</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(32,561</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(18,435</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(17,893</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,226</div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>
<tr>
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Weighted average number of shares in issue</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,055,650 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 17,828,125 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 10,093,750 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 9,796,875 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> 1,214,983 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="44%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2px; ">Basic and diluted loss per share (in USD)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="7%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="6" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">For the years ended December 31, 2018 and 2017, the potential impact, on the calculation of earnings per share, of the existing potential class A common shares related to the Incentive Plan 2014 (see note 18, &#147;Share-based compensation expenses&#148;) is not presented, as the impact would be to dilute a loss, which causes them to be deemed &#147;not dilutive&#148; for the purposes of the required disclosure.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>24.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Events after the reporting date</b></td></tr></table><div style="clear: both"></div>

<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Discontinuation of license and joint collaboration agreement</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During May 2019, the counterparty to the license and joint collaboration agreement referred to in notes 4 and 5 notified the Company that it intended to discontinue the development of the product candidate associated with that agreement. As a result, the company recognized contract revenue comprising the entire non-refundable upfront payment of KUSD 2,340 (consisting of deferred revenue and presented as a contract liability in its consolidated balance sheet) during the period ending June 30, 2019.</p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Share capital issued</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On June 4, 2019, the Company&#146;s share capital was increased by issuing 3,375,000 Class E shares (216 Class E shares before share split) at a price of USD 22.4 per share (KUSD 350 per share before split). Subsequently, on June 7, 2019, the share capital was further increased by issuing 31,250 Class E shares (2 Class E shares before share split) at a price of USD 22.4 per share (KUSD 350 before share split).</p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The Company received on June 28, 2019 consideration of KUSD 26,950 for an issuance of 1,203,125 Class E shares (77 Class E shares before share split), pursuant to an investment agreement. The issuance of shares was formally confirmed through their registration with the Commercial Register on July 5, 2019.</p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Increase in par value of share capital</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On August 22, 2019, the par value of each of the shares was increased from CHF 0.0064 to CHF 0.064 (CHF 100 to CHF 1,000 before share split) by transferring an amount of KCHF 3,714 (KUSD 3,789) from share premium to share capital.</p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Redemption of promissory notes</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under the terms of the 2013 and 2016 Promissory Notes issued in connection with the share purchase plans, the relevant plan participant may repay outstanding amounts under the promissory note at any time in cash or repay the principal amount in whole or in part by delivering such number of shares as required to cover the amount to be repaid. In connection with this offering, each of the executive officers and directors and their respective related parties who held Promissory Notes entered into loan settlement agreements with the Company dated as of August 31, 2019 pursuant to which they repaid all amounts outstanding under the Promissory Notes, including accrued interest, by delivering such number of shares necessary to cover the entire amounts outstanding under the Promissory Notes. After consideration of all relevant factors, the board </p>

			<div style="clear: both;"></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">

<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-54</p>

			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>

<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p>

<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; ">of directors determined the value of such surrendered shares as of the Settlement Date to be USD 26.88 per share (KUSD 420 before share split), resulting in the surrender of an aggregate of 365,125 Class A shares (23.368 Class A shares before share split) for the settlement of the Promissory Notes. The shares surrendered to the Company are held as treasury shares.</p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Treasury shares available for issuance on the exercise of share options</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In order to have available treasury shares to meet the demand for shares when share options are exercised, the Company, on September 2, 2019, increased its share capital by KCHF 140 (KUSD 141) through the issuance to a related party of 2,187,500 Class A shares (140 Class A shares before share split) at par value of CHF 0.064 per share (CHF 1,000 per share before share split) and repurchased these shares from the same related party at the same price on September 19, 2019. These shares are reserved for issuance on the exercise of share options.</p>


<p class="h4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i>Share split</i></p>


<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">On September 19, 2019, the Company effected a one to 15,625 share split of its outstanding common and preferred shares. Accordingly, all share and per share amounts for all periods presented in these interim consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this share split.</p>

				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>25.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Restatements</b></td></tr></table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The consolidated financial statements for the years 2017 and 2018 have been restated as a result of the correction of material errors explained below.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><u>1. General and administrative expenses, other reserves and accumulated losses &#8211; share purchase plans</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In calculating the compensation expense related to two share purchase plans, the Company recognized the intrinsic value of the awards but did not account for the time value of these awards. This has now been corrected by way of restatement. The effect of the correction for 2017 is to increase the opening accumulated losses and other reserves by KUSD 2,979 and to increase general and administrative expenses for the year by KUSD 729, leading to increases in closing accumulated losses and in other reserves of KUSD 3,708. The effect of the correction for 2018 is to increase the opening accumulated losses and other reserves by KUSD 3,708 and to increase general and administrative expenses for the year by KUSD 361, leading to increases in closing accumulated losses and in other reserves of KUSD 4,069.</p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><u>2. General and administrative expenses and accumulated losses &#8211; Recoverable expense</u></i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Recoverable expense incurred in 2016 and 2017 was not recognized as an asset in the appropriate periods. This error was discovered in 2018 and corrected in the income statement 2018. The purpose of the restatement is to allocate this correction to the appropriate periods. The effect of the correction for 2017 is to reduce the opening accumulated losses by KUSD 64, to reduce general and administrative expenses for the year by KUSD 332 and to increase other current assets and reduce closing accumulated losses by KUSD 396. The effect of the correction for 2018 is to reduce the opening accumulated losses by KUSD 396 and to increase general and administrative expenses for the year by KUSD 396.</p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-55</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED BALANCE SHEETS<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.71px; padding-right: 4.71px; "><b>January 1,<br> </b><b>2017</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.71px; padding-right: 4.71px; "><b>Restatements</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.71px; padding-right: 4.71px; "><b>Restated<br> </b><b>January 1,<br> </b><b>2017</b></div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.71px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>ASSETS<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Current assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">143,669</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">143,669</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">14</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Trade accounts receivable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,908</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,908</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">10/14/22</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Other current assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,612</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">64</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,676</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">11</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Total current assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>151,189</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>64</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>151,253</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Non-current assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Property, plant and equipment, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">777</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">777</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">12</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Intangible assets, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,914</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,914</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">13</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Other long-term assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">133</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">133</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Total non-current assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>3,824</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>3,824</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Total assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>155,013</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>64</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>155,077</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>LIABILITIES AND </b><b>EQUITY</b><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Current liabilities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Trade accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,145</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,145</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">14a/22</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Other current liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,415</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,415</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">16</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Contract liability (short-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,843</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,843</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">5</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Current income tax payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">265</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">265</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Total current liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>9,668</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>9,668</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Non-current liabilities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Contract liability (long-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,440</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,440</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">5</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Defined benefit pension liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">783</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">783</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">17</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Other long-term liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">292</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">292</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Total non-current liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>4,515</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>4,515</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Total liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>14,183</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>14,183</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Equity attributable to owners of the parent<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Share capital</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">334</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">334</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">19</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Share premium</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">255,120</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">255,120</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">19</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Other reserves</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,614</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,979</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,593</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">17/18</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Cumulative translation adjustments</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(26</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(26</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; ">Accumulated losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(116,212</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(2,915</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(119,127</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Total equity</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>140,830</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>64</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>140,894</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.71px; "><b>Total liabilities and equity</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>155,013</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>64</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="8%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>155,077</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="11%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.71px; padding-right: 0px; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-56</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED INCOME STATEMENTS<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Restatements</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Restated<br> </b><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Contract revenue</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1,803</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1,803</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; "><b>5</b></div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(85,530</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(85,530</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">6,8</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7,546</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(397</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(7,943</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">8</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Operating loss</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(91,273</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(397</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(91,670</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Financial income</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,031</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,031</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">825</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">825</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Loss before taxes</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,417</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(397</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,814</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Income tax expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(48</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(48</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">9</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Loss for the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(89,465</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(397</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(89,862</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Attributable to:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Owners of the parent</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,465</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(397</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Loss per share<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Basic and diluted loss per share (in USD)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> &#8212; </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (1.83 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">23</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-57</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Restatements</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Restated<br> </b><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Loss for the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,465</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(397</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,862</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Other comprehensive loss:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><u>Items that will not be reclassified to profit or loss</u><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Remeasurements of defined benefit plan</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">17</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Total items that will not be reclassified to profit or loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">0</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(148</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><u>Items that may be reclassified subsequently to profit </u><u>or loss</u><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Currency translation differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">62</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">62</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Total items that may be reclassified subsequently to profit or loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">62</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">62</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Other comprehensive loss for the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(86</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(86</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Total comprehensive loss for the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(89,551</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(397</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(89,948</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Attributable to:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Owners of the parent</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,551</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(397</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,948</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-58</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED BALANCE SHEETS<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.78px; padding-right: 2.78px; "><b>December 31,<br> </b><b>2017</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.78px; padding-right: 2.78px; "><b>Restatements</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.78px; padding-right: 2.78px; "><b>Restated<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.78px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>ASSETS<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Current assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">14</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Trade accounts receivable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,087</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,087</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">10/14/22</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Other current assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">939</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">396</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,335</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">11</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total current assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>264,778</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>396</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>265,174</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Non-current assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Property, plant and equipment, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,142</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,142</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">12</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Intangible assets, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,401</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,401</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">13</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Other long-term assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">232</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">232</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total non-current assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>6,775</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>6,775</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>271,553</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>396</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>271,949</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>LIABILITIES AND </b><b>EQUITY</b><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Current liabilities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Trade accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7,619</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">7,619</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">14a/22</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Other current liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10,452</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">10,452</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">16</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Contract liability (short-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,320</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,320</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">5</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Current income tax payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">156</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total current liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>20,547</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>20,547</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Non-current liabilities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Contract liability (long-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,160</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,160</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">5</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Defined benefit pension liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,076</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,076</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">17</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total non-current liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>2,236</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>2,236</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>22,783</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>22,783</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Equity attributable to owners of the parent<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Share capital</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">397</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">397</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">19</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Share premium</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,296</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,296</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">19</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Other reserves</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,718</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">3,708</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,426</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">17/18</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Cumulative translation adjustments</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">36</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">36</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Accumulated losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(205,677</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(3,312</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(208,989</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total equity</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>248,770</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>396</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>249,166</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total liabilities and equity</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>271,553</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>396</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>271,949</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-59</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED STATEMENT OF CASH FLOWS<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.82px; padding-right: 3.82px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.82px; padding-right: 3.82px; "><b>Restatements</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.82px; padding-right: 3.82px; "><b>Restated<br> </b><b>Year ended<br> </b><b>December 31,<br> </b><b>2017</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.82px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash used in operating activities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Loss for the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,465</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(397</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(89,862</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Adjustments for non-monetary items:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Share-based compensation expense</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">251</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">729</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">980</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">18</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Depreciation of property, plant and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">328</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">328</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">12</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Amortization and impairment of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">13</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Change in defined benefit pension liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">140</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">140</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">17</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Change in fair value measurement</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">240</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">240</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Financial income</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,031</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,031</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">61</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">61</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Income taxes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">48</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">48</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">9</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Operating loss before working</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,415</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>332</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(89,083</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Decrease in trade accounts receivable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,822</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,822</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">(Increase) / decrease in other current assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">711</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(332</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">379</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">(Decrease) in contract liability (short and long term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,803</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,803</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">(Decrease) / increase in trade accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,468</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,468</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Increase in other liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">4,646</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">4,646</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash used in operating activities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(75,571</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(75,571</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Interest received</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">771</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">771</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Tax paid</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(145</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(145</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Net cash used in operating</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(74,945</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(74,945</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash used in investing activities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Payment for purchases of property, plant and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(656</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(656</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">12</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Payment for purchases of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,500</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,500</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">13</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Payment for rent deposits</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(92</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(92</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Net cash used in investing</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(3,248</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(3,248</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash used in financing activities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Proceeds from capital contributions, net of transaction costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">197,239</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">197,239</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">19</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Net cash (used in) / from financing</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>197,239</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>197,239</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Net (decrease) / increase in cash</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>119,046</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>119,046</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Exchange (losses) / gains on cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">37</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">37</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Cash and cash equivalents at beginning of year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">143,669</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">143,669</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash and cash equivalents at end of year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>262,752</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>262,752</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-60</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED INCOME STATEMENTS<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Restatements</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Restated<br> </b><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Contract revenue</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1,140</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>1,140</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; "><b>5</b></div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Research and development expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(118,313</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(118,313</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">6,8</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">General and administrative expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(8,011</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(757</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(8,768</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">8</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Operating loss</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(125,184</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(757</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(125,941</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Financial income</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,856</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">2,856</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">213</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">213</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Loss before taxes</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(122,115</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(757</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(122,872</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Income tax expenses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(224</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(224</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">9</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Loss for the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(122,339</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(757</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(123,096</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Attributable to:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Owners of the parent</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,339</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(757</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Loss per share<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Basic and diluted loss per share (in USD)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.10 </div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (0.01 </div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "> (2.11 </div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="1" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">23</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-61</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Restatements</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 4.41px; "><b>Restated<br> </b><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4.41px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Loss for the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(122,339</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(757</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(123,096</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Other comprehensive loss:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><u>Items that will not be reclassified to profit or loss</u><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Remeasurements of defined benefit plan</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">17</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Total items that will not be reclassified to profit or loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(193</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><u>Items that may be reclassified subsequently to profit </u><u>or loss</u><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Currency translation differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(79</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(79</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Total items that may be reclassified subsequently to profit or loss</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(79</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(79</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Other comprehensive loss for the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(272</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>(272</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Total comprehensive loss for the year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(122,611</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(757</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>(123,368</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; "><b>Attributable to:<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="46%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 4.41px; ">Owners of the parent</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,611</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(757</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(123,368</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 4.41px; padding-right: 0px; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-62</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED BALANCE SHEETS<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">&#160;</div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.78px; padding-right: 2.78px; "><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.78px; padding-right: 2.78px; "><b>Restatements</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.78px; padding-right: 2.78px; "><b>Restated<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 2.78px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>ASSETS<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Current assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="6%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">138,807</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">138,807</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">14</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Trade accounts receivable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">192</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">192</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">10/14/22</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Other current assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,081</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,081</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">11</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total current assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>142,080</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>142,080</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Non-current assets<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Property, plant and equipment, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,540</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,540</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">12</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Intangible assets, net</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,674</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,674</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">13</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Other long-term assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">264</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">264</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total non-current assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>8,478</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>8,478</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total assets</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>150,558</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>150,558</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>LIABILITIES AND </b><b>EQUITY</b><br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Current liabilities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Trade accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,750</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">6,750</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">14a/22</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Other current liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13,650</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">13,650</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">16</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Contract liability (short-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,765</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,765</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">5</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Current income tax payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">189</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">189</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total current liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>22,354</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>22,354</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Non-current liabilities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Contract liability (long-term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">575</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">575</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">5</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Defined benefit pension liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,386</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">1,386</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">17</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total non-current liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>1,961</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>1,961</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total liabilities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>24,315</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>24,315</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Equity attributable to owners of the parent<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Share capital</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">401</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">401</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">19</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Share premium</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,268</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">452,268</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">19</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Other reserves</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,633</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">4,069</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">5,702</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">17/18</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Cumulative translation adjustments</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(43</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#8212;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(43</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; ">Accumulated losses</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(328,016</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(4,069</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(332,085</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total equity</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>126,243</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; "><b>126,243</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="47%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 2.78px; "><b>Total liabilities and equity</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>150,558</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>150,558</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 2.78px; padding-right: 0px; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-63</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 4.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><b>ADC Therapeutics SA, Epalinges<br></b></p><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 9px; "> </div><br><div class="group-p" style=" font-size: 13.33px; "><div class="group-p" style=" font-size: 13.33px; "><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</b><b>(continued)</b></div></div><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: -4px; margin-bottom: 0px; "></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><b>&nbsp;&nbsp;&nbsp;</b></p><p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p>
				<p class="h2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: normal; font-size: 13.33px; line-height: 15.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; "><b>CONSOLIDATED STATEMENT OF CASH FLOWS<br></b><b>(in KUSD)</b></p>
				<table align="20" width="90%" style="margin-top: 4px; margin-left: 4%; border-collapse: collapse; ">
									<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.82px; padding-right: 3.82px; "><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="12%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.82px; padding-right: 3.82px; "><b>Restatements</b></div></td>
	<td colspan="3" width="13%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.82px; padding-right: 3.82px; "><b>Restated<br> </b><b>Year ended<br> </b><b>December 31,<br> </b><b>2018</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: -2.67px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 6.67px; padding-right: 6.67px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 3.82px; padding-right: 0px; "><b>Notes</b></div></td>
</tr>

					<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash used in operating activities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Loss for the year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(122,339</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(757</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(123,096</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Adjustments for non-monetary items:<br></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="4%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="5" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Share-based compensation expense</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">108</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">361</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">469</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">18</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Depreciation of property, plant and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">488</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">488</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">12</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Amortization and impairment of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">252</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">252</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">13</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Change in defined benefit pension liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">119</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">119</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">17</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Change in fair value measurement</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,009</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,009</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Accrued withholding tax</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">711</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">711</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Financial income</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,856</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,856</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Exchange differences</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(29</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(29</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Income taxes</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">224</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">224</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">9</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Operating loss before working</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(122,313</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(396</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(122,709</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Decrease in trade accounts receivable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">895</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">895</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">(Increase) / decrease in other current assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(2,074</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">396</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,678</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">(Decrease) in contract liability (short and long term)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,140</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,140</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">(Decrease) / increase in trade accounts payable</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(858</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(858</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Increase in other liabilities</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,262</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">3,262</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash used in operating activities</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(122,228</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(122,228</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Interest received</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,051</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">1,051</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Tax paid</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(185</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(185</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Net cash used in operating</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(121,362</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(121,362</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash used in investing activities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Payment for purchases of property, plant and equipment</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(944</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(944</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">12</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Payment for purchases of intangible assets</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,526</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(1,526</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">13</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Payment for rent deposits</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(36</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(36</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Net cash used in investing</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(2,506</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(2,506</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash used in financing activities<br></b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Proceeds from capital contributions, net of transaction costs</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(24</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">(24</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">19</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Net cash (used in) / from financing</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(24</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(24</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Net (decrease) / increase in cash</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(123,892</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>(123,892</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; "><b>)</b></div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-indent: -13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; padding-left: 13.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Exchange (losses) / gains on cash and cash equivalents</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(53</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">(53</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style=" whitespace: nowrap; ">)</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr style="background-color: #cceeff;">
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; ">Cash and cash equivalents at beginning of year</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">&#160;</div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 1pt solid black; ; whitespace: nowrap; ">262,752</div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 1.33px; ; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>
<tr>
	<td colspan="1" width="48%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 0px; padding-right: 3.82px; "><b>Cash and cash equivalents at end of year</b></div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>138,807</b></div></td><td width="1%" valign="bottom" align="right" col="2" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="9%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#8212;</b></div></td><td width="1%" valign="bottom" align="right" col="3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td width="2%" valign="bottom" align="right" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 5.33px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>&#160;</b></div></td><td width="10%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: right; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="border-bottom: 3pt double black; whitespace: nowrap; "><b>138,807</b></div></td><td width="1%" valign="bottom" align="right" col="4" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-bottom: 4px; whitespace: nowrap; ">&#160;</div></td>
	<td colspan="3" width="7%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 4px; text-indent: 0px; padding-left: 0px; padding-right: 0px; margin-right: 0px;"><div class="group-p" style="padding-left: 3.82px; padding-right: 0px; ">&#160;</div></td>
</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><a name="ftFINNOTE"></a></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">F-64</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 300-bcv -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-frill" style="width: 100%; margin-left: 0%; ">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>

<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 32px; margin-bottom: 0px; "><i>8,164,000</i><i> Shares</i></p>

				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 24px; margin-bottom: 0px; "><img src="logo_adc.jpg" alt="" style="height: 83.60px; width: 170.13px; scale: ">&#8201;<br></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 18.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i>Common Shares</i></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 72px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 2.67px; margin-bottom: 0px; "><i>Prospectus</i></p>
				<div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><div class="hr-centered" style="height: 2.67px; border-bottom: 1pt solid #000000; width: 19%; margin: auto; margin-bottom: 12px; margin-top: 12px; "> </div></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 21.33px; line-height: 22px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 200px; margin-bottom: 0px; "><i>MORGAN STANLEY<br></i><i>&nbsp;&nbsp;&nbsp;<br></i><i>BofA MERRILL LYNCH</i><br><i>&nbsp;&nbsp;&nbsp;<br></i><i>COWEN</i></p>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 240px; margin-bottom: 0px; "><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</i></p>
			<div style="clear: both;"></div></div>



<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 17.37px; line-height: 5.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "><div class="hr-full" style="height: 0px; border-bottom: 1pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 0px; "> </div><div class="hr-full" style="height: 0px; border-bottom: 2pt solid #000000; width: 100%; margin-left: auto; margin-right: auto; margin-bottom: 0px; margin-top: 4px; "> </div></div>
			</div>



<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 301-part2 -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 14.67px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>PART II<br></b><b>INFORMATION NOT REQUIRED IN THE PROSPECTUS</b></p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>Item 6.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Indemnification of Directors and Officers</b></td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Under Swiss law, a corporation may indemnify its directors or officers against losses and expenses (except for such losses and expenses arising from willful misconduct or negligence, although legal scholars advocate that at least gross negligence be required), including attorney&#146;s fees, judgments, fines and settlement amounts actually and reasonably incurred in a civil or criminal action, suit or proceeding by reason of having been the representative of, or serving at the request of, the corporation. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Subject to Swiss law, our amended and restated articles of association will provide for indemnification of the existing and former members of our board of directors and our executive committee as well as their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and our amended and restated articles of association will require us to advance the expenses of defending any action, suit or proceeding to existing and former members of our board of directors and our executive committee to the extent not included in insurance coverage or advanced by third parties.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of their duties under the employment agreement with the company.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">We have entered into indemnification agreements with each of the members of our board of directors and executive officers, the form of which has been filed as an exhibit to this Registration Statement.</p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">In the underwriting agreement that we enter into in connection with the sale of the common shares being registered hereby, a form of which has been filed as Exhibit 1.1 to this Registration Statement, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), against certain liabilities. </p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the U.S. Securities and Exchange Commission (the &#147;SEC&#148;), such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>Item 7.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Recent Sales of Unregistered Securities</b></td></tr></table><div style="clear: both"></div>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">During the past three years, we have issued and sold the securities described below without registering the securities under the Securities Act. The table below does not give effect to the Share Capital Reorganization.</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.34px; "><b>Name or Class of Purchasers</b></div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.34px; padding-right: 1.34px; "><b>Date of Issuance</b></div>
							</td>
							<td width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.34px; padding-right: 1.34px; "><b>Title of Securities</b></div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.34px; padding-right: 1.34px; "><b>Number of<br> </b><b>Securities</b></div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.34px; padding-right: 0px; "><b>Consideration<br></b><b>(in USD thousands)</b></div>
							</td>
						</tr>


						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">
A.T. Holdings II S&#224;rl (for the creation of treasury shares to settle share grants and equity-linked instruments for directors, officers employees and consultants)
</div>
							</td>
							<td width="18%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">
September 19, 2019
</div>
							</td>
							<td width="22%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">
Class A common shares
</div>
							</td>
							<td width="9%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">
140
</div>
							</td>
							<td width="15%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 0px; ">
141
</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">&#160;</div>
							</td>
							<td width="18%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">&#160;</div>
							</td>
							<td width="22%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">&#160;</div>
							</td>
							<td width="9%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">&#160;</div>
							</td>
							<td width="15%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">Various private equity investment funds, institutional investors and other persons</div>
							</td>
							<td width="18%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">June 7, 2019<br> June 14, 2019<br>July 5, 2019</div>
							</td>
							<td width="22%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">Class E preferred shares</div>
							</td>
							<td width="9%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">295</div>
							</td>
							<td width="15%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 0px; ">103,250</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">Directors and officers</div>
							</td>
							<td width="18%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">June 29, 2018<br> December 14, 2018<br> February 6, 2019</div>
							</td>
							<td width="22%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">Class A common shares</div>
							</td>
							<td width="9%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">42</div>
							</td>
							<td width="15%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 0px; ">1,314</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">Various private equity investment funds, institutional investors and other persons</div>
							</td>
							<td width="18%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">October 12, 2017<br> October 30, 2017<br> November 16, 2017</div>
							</td>
							<td width="22%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">Class E preferred shares</div>
							</td>
							<td width="9%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">617</div>
							</td>
							<td width="15%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 0px; ">200,088</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">II-1</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="35%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 1.34px; "><b>Name or Class of Purchasers</b></div>
							</td>
							<td width="18%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.34px; padding-right: 1.34px; "><b>Date of Issuance</b></div>
							</td>
							<td width="22%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.34px; padding-right: 1.34px; "><b>Title of Securities</b></div>
							</td>
							<td width="9%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.34px; padding-right: 1.34px; "><b>Number of<br> </b><b>Securities</b></div>
							</td>
							<td width="15%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 1.34px; padding-right: 0px; "><b>Consideration<br></b><b>(in USD thousands)</b></div>
							</td>
						</tr>


						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">Directors and officers</div>
							</td>
							<td width="18%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">December 15, 2016</div>
							</td>
							<td width="22%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">Class A common shares</div>
							</td>
							<td width="9%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">185</div>
							</td>
							<td width="15%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 0px; ">5,787</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="35%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 1.34px; ">Various private equity investment funds, institutional investors and other persons</div>
							</td>
							<td width="18%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">October 18, 2016<br> November 4, 2016<br> November 10, 2016</div>
							</td>
							<td width="22%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">Class D preferred shares</div>
							</td>
							<td width="9%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 1.34px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 1.34px; ">627</div>
							</td>
							<td width="15%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 1.34px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 1.34px; padding-right: 0px; ">104,986</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The offers, sales and issuances of the securities described in the preceding table were exempt from registration either (i) under Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder in that the transactions were between an issuer and sophisticated investors or members of its senior executive management and did not involve any public offering within the meaning of Section 4(a)(2), (ii) under Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States, (iii) under Rule 144A under the Securities Act in that the shares were offered and sold by the initial purchasers to qualified institutional buyers or (iv) under Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans and contracts relating to compensation.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>Item 8.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Exhibits and Financial Statement Schedules</b></td></tr></table><div style="clear: both"></div>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; "><i><b>Exhibits</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The exhibit index attached hereto is incorporated herein by reference.</p>
				<p class="h3" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><i><b>Financial Statements Schedules</b></i></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">All schedules have been omitted because they are not required or are not applicable, or the information is otherwise set forth in the consolidated financial statements and related notes thereto.</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="53.33px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; "><b>Item 9.</b></td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; "><b>Undertakings</b></td></tr></table><div style="clear: both"></div>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The undersigned hereby undertakes:</p>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(a)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(b)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(c)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless, in the opinion of its counsel, the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue; and</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top;"><td class="group-filler" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; vertical-align: top; text-align: left; ">(d)</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; ">to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; ">II-2</p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 302-exindx -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><b>EXHIBIT INDEX</b></p>
				<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 26.67px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">The following documents are filed as part of this registration statement:</p>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><a href="nt10002526x6_ex1-1.htm">1.1</a></div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Form of Underwriting Agreement</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex3-1.htm">3.1</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Form of Amended and Restated Articles of Association of ADC Therapeutics SA, to be in effect immediately prior to the consummation of this offering</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex5-1.htm">5.1</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Opinion of Homburger AG, Swiss counsel of ADC Therapeutics SA, as to the validity of the common shares</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-1.htm">10.1</a>*#
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Second Amended and Restated License Agreement among ADC Products (UK) Limited, ADC Therapeutics SA and MedImmune Limited, dated May 9, 2016</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-2.htm">10.2</a>*#
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Amendment #1 to the Second Amended and Restated License Agreement among ADC Products (UK) Limited, ADC Therapeutics SA and MedImmune Limited, dated September 19, 2018</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-3.htm">10.3</a>*#
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/S, dated June 14, 2013</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-4.htm">10.4</a>*#
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Amendment to the Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/S, dated November 20, 2013</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-5.htm">10.5</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Lease Relating to Suite 5, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated September 14, 2017</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-6.htm">10.6</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Lease Relating to Lab 11b, Suite 11 Write Up Space and Suite 12, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated December 20, 2017</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-7.htm">10.7</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Counterpart Lease Relating to Suite 8, First Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated July 9, 2018 </div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-8.htm">10.8</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Deed of Variation Relating to Lease of Suite 5, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated July 1, 2019 </div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-9.htm">10.9</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Deed of Variation Relating to Lease of Lab 11b, Suite 11 Write Up Space and Suite 12, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated July 1, 2019 </div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-10.htm">10.10</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Deed of Variation Relating to Lease of Suite 8, First Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated July 1, 2019 </div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-11.htm">10.11</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Form of Indemnity Agreement with directors and officers entered into in connection with this offering</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-12.htm">10.12</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Form of Purchase and Shareholders Agreement relating to the 2013 Share Purchase Plan (including form of promissory note included in Schedule A thereto)</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-13.htm">10.13</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">ADC Therapeutics Incentive Plan, between ADC Therapeutics SA and the parties named therein, dated May 1, 2014 as amended and restated as of October 1, 2015</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-14.htm">10.14</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">2016 Share Purchase Plan, between ADC Therapeutics Ltd and the parties named therein, dated November 18, 2016 (including form of promissory note including in Annex 3A thereto) </div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex10-15.htm">10.15</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Form of 2019 Equity Incentive Plan </div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex21-1.htm">21.1</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">List of subsidiaries</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; "><a href="nt10002526x6_ex23-1.htm">23.1</a></div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Consent of PricewaterhouseCoopers SA</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_ex5-1.htm">23.2</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Consent of Homburger AG, Swiss counsel of ADC Therapeutics SA (included in Exhibit 5.1)</div>
							</td>
						</tr>
						<tr>
							<td width="8%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
<a href="http://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_f1.htm#tSIGN">24.1</a>*
</div>
							</td>
							<td width="92%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Powers of attorney (included on signature page to the registration statement)</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: pt; text-indent: 0px; text-align: ; margin-right: pt; margin-top: pt; margin-bottom: 0px; "></p><p class="foots" style="color: #000000; font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 12px; margin-bottom: 0px; " div="yes"></p><div class="hr-partial" style="height: 1.33px; border-bottom: 1pt solid #000000; width: 15%; margin-left: 0px; margin-bottom: 1.33px; margin-top: 0px; "> </div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">*</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">
Previously filed.
</td></tr></table><div style="clear: both"></div>
				<table class="group-list" cellpadding="0" cellspacing="0" width="100%" style="margin-top: 8px; padding-top: 0px; padding-bottom: 0px; "><tr style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top;"><td class="group-filler" width="0px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; "> </td><td class="group-list" width="26.67px" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; vertical-align: top; text-align: left; ">#</td><td class="group-item" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: left; ">Portions of this exhibit have been omitted because they are both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.</td></tr></table><div style="clear: both"></div>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->
<!-- 303-sig -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">
				<p class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: center; margin-right: 0px; margin-top: 16px; margin-bottom: 0px; "><a name="tSIGN"></a><b>SIGNATURES</b></p>

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the requirements of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Epalinges, Switzerland on September 23, 2019.</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td colspan="3" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">ADC THERAPEUTICS SA</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="8%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">By:</div>
							</td>
							<td colspan="2" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4px; padding-right: 0px; ">/s/ Christopher Martin </div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="8%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Name:</div>
							</td>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Christopher Martin</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="8%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">Title:</div>
							</td>
							<td width="41%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Chief Executive Officer</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>

<div class="block-pagebreak" style="page-break-after: always; width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>
	</div>
<!-- page end -->

<!-- page start -->
<div class="page" style="width: 708px; margin: auto; ">

			<p style="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10.67px; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
<div class="block-main" style="width: 100%; margin-left: 0%; ">

<p class="para" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; line-height: 16.67px; padding-left: 0px; text-indent: 26.67px; text-align: left; margin-right: 0px; margin-top: 8px; margin-bottom: 0px; ">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons on September 23, 2019 in the capacities indicated:</p>

				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="46%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 6.67px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; "><b>Name</b></div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10.67px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 4px; padding-right: 0px; "><b>Title</b></div>
							</td>
						</tr>


						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">/s/ Christopher Martin </div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Chief Executive Officer and Director<br>(principal executive officer)</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Christopher Martin</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">/s/ Michael Forer </div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Chief Financial Officer and Director<br> (principal financial officer and principal accounting officer)</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Michael Forer</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&nbsp;&nbsp;&nbsp;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
*
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Chairman</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Peter B. Corr</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
*
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Director</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Stephen Evans-Freke</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
*
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Director</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Peter Hug</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
*
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Director</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Thomas Pfisterer</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
*
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Director</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Thomas M. Rinderknecht</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
*
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Director</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Tyrell J. Rivers</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
*
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Director</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Jacques Theurillat</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
*
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Director</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Barrie Ward</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid #000000; padding-left: 0px; padding-right: 4px; ">
/s/ Jay Feingold
</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="49%" rowspan="2" valign="middle" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">Authorized Representative in the United States</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">Jay Feingold</div>
							</td>
						</tr>
						<tr>
							<td width="46%" valign="top" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">ADC Therapeutics America, Inc.</div>
							</td>
							<td width="5%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<table align="center" width="100%" style="margin-top: 4px; margin-left: 0px; border-collapse: collapse; ">

						<tr>
							<td width="3%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">
*By:
</div>
							</td>
							<td width="44%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="border-bottom: 1pt solid black; ; padding-left: 4px; padding-right: 4px; ">
/s/ Christopher Martin
</div>
							</td>
							<td width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: 1.33px; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>
						<tr>
							<td width="3%" valign="top" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 0px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 0px; padding-right: 4px; ">&#160;</div>
							</td>
							<td width="44%" valign="bottom" align="center" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: center; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 4px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 4px; ">
Christopher Martin<br>Attorney-in-Fact
</div>
							</td>
							<td width="54%" valign="bottom" align="left" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; text-align: left; margin-top: 0px; margin-bottom: 0px; padding-bottom: pt; text-indent: 0px; padding-left: 4px; padding-right: 0px; margin-right: 0px;">
								<div class="group-p" style="padding-left: 4px; padding-right: 0px; ">&#160;</div>
							</td>
						</tr>


				</table><div style="clear: both"></div>
				<p class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			<div style="clear: both;"></div></div>




<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>


<div class="block-frill" style="width: 100%; margin-left: 0%; margin-top: 16px;">
				<p class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 13.33px; padding-left: 0px; text-indent: 0px; text-align: left; margin-right: 0px; margin-top: 0px; margin-bottom: 0px; "></p>
			</div>

<div class="block-pagebreak" style="width: 100%; margin-top: 33.33px; margin-bottom: 53.33px; margin-left: auto; margin-right: auto; border-bottom: 5px solid #000000;"> </div>


</div>
<!-- page end -->

</div></div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>nt10002526x6_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 6.3.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div>
      <div style="text-align: right;">
        <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;">Exhibit 1.1</font><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div>
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[&#9679;] Shares</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ADC THERAPEUTICS SA</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">COMMON SHARES, NOMINAL VALUE CHF 0.064 PER SHARE</div>
    <div>
      <div><br>
      </div>
      <br>
      <br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">UNDERWRITING AGREEMENT</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;">[&#9679;]</font>, 2019</div>
    <div><br>
    </div>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;">[&#9679;]</font>, 2019</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC</div>
    <div style="font-family: 'Times New Roman', Times, serif;">BofA Securities, Inc.</div>
    <div style="font-family: 'Times New Roman', Times, serif;">Cowen and Company, LLC</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">As Representatives of the several Underwriters named in Schedule I hereto</div>
    <div><br>
    </div>
    <div style="text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif;">c/o Morgan Stanley &amp; Co. LLC</div>
    <div style="margin: 0px 0px 0px 15pt; font-family: 'Times New Roman', Times, serif;">1585 Broadway</div>
    <div style="margin: 0px 0px 0px 15pt; font-family: 'Times New Roman', Times, serif;">New York, New York 10036</div>
    <div><br>
    </div>
    <div style="text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif;">c/o BofA Securities, Inc.</div>
    <div style="margin: 0px 0px 0px 15pt; font-family: 'Times New Roman', Times, serif;">One Bryant Park</div>
    <div style="margin: 0px 0px 0px 15pt; font-family: 'Times New Roman', Times, serif;">New York, New York 10036</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">c/o Cowen and Company, LLC</div>
    <div style="margin: 0px 0px 0px 15pt; font-family: 'Times New Roman', Times, serif;">599 Lexington Avenue</div>
    <div style="margin: 0px 0px 0px 15pt; font-family: 'Times New Roman', Times, serif;">New York, New York 10022</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">ADC Therapeutics SA, a <font style="font-style: italic;">soci&#233;t&#233; anonyme</font> domiciled in Epalinges, Switzerland, and organized under the laws of Switzerland (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the &#8220;<font style="font-weight: bold;">Underwriters</font>&#8221;), for whom you are acting as representatives (the &#8220;<font style="font-weight: bold;">Representatives</font>&#8221;), an aggregate of [&#9679;] common shares, nominal value CHF 0.064 per share (&#8220;<font style="font-weight: bold;">Firm Shares</font>&#8221;), of the Company. The Company also proposes to issue and sell to the
      several Underwriters not more than an additional [&#9679;] common shares, nominal value CHF 0.064 per share (the &#8220;<font style="font-weight: bold;">Additional Shares</font>&#8221;) if and to the extent that the Representatives, as managers of the offering, shall
      have determined to exercise, on behalf of the Underwriters, the right to purchase such common shares granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the &#8220;<font style="font-weight: bold;">Shares</font>.&#8221; The common shares, nominal value CHF 0.064 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &#8220;<font style="font-weight: bold;">Common Shares</font>.&#8221;</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The Company has filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">Commission</font>&#8221;) a registration statement, including a prospectus,
      relating to the Shares.&#160; The registration statement as amended at the time it becomes effective, including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A under the
      Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;), is hereinafter referred to as the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;; the prospectus in the form first used to confirm
      sales of Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the &#8220;<font style="font-weight: bold;">Prospectus</font>.&#8221;&#160;
      If the Company has filed an abbreviated registration statement to register additional Common Shares, pursuant to Rule 462(b) under the Securities Act (the &#8220;<font style="font-weight: bold;">Rule 462 Registration Statement</font>&#8221;), then any reference
      herein to the term &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221; shall be deemed to include such Rule 462 Registration Statement.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">For purposes of this Underwriting Agreement (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;), &#8220;<font style="font-weight: bold;">free writing prospectus</font>&#8221; has
      the meaning set forth in Rule 405 under the Securities Act, &#8220;<font style="font-weight: bold;">Time of Sale Prospectus</font>&#8221; means the preliminary prospectus contained in the Registration Statement at the time of its effectiveness together with the
      documents and pricing information set forth in Schedule II hereto, and &#8220;<font style="font-weight: bold;">broadly available road show</font>&#8221; means a &#8220;<font style="font-weight: bold;">bona fide electronic road show</font>&#8221; as defined in Rule 433(h)(5)
      under the Securities Act that has been made available without restriction to any person.&#160; As used herein, the terms &#8220;<font style="font-weight: bold;">Registration Statement</font>,&#8221; &#8220;<font style="font-weight: bold;">preliminary prospectus</font>,&#8221; &#8220;<font style="font-weight: bold;">Time of Sale Prospectus</font>&#8221; and &#8220;<font style="font-weight: bold;">Prospectus</font>&#8221; shall include the documents, if any, incorporated by reference therein as of the date hereof.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC (&#8220;<font style="font-weight: bold;">Morgan Stanley</font>&#8221;) has agreed to reserve a portion of the Shares to be purchased by it under this
      Agreement for sale to the Company&#8217;s directors, officers, employees and business associates and other parties related to the Company (collectively, &#8220;<font style="font-weight: bold;">Participants</font>&#8221;), as set forth in the Prospectus under the
      heading &#8220;Underwriters&#8221; (the &#8220;<font style="font-weight: bold;">Directed Share Program</font>&#8221;).&#160; The Shares to be sold by Morgan Stanley and its affiliates pursuant to the Directed Share Program, at the direction of the Company, are referred to
      hereinafter as the &#8220;<font style="font-weight: bold;">Directed Shares</font>.&#8221;&#160; Any Directed Shares not orally confirmed for purchase by any Participant by the end of the business day on which this Agreement is executed will be offered to the public
      by the Underwriters as set forth in the Prospectus.</div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Representations and Warranties</font>.&#160; The
        Company represents and warrants to and agrees with each of the Underwriters that:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Registration Statement has become effective; no stop
        order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are pending before or to the Company&#8217;s knowledge, threatened by the Commission.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">(i) The Registration Statement, when it became effective, did
        not contain and, as amended or supplemented, if applicable, will not contain, as of the date of such amendment or supplement, any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
        make the statements therein not misleading, b) the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will, as of the date of such amendment or supplement, comply in all material respects with the
        Securities Act and the applicable rules and regulations of the Commission thereunder, c) the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to
        prospective purchasers and at the Closing Date (as defined in Section 4), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a
        material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, d) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not
        contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and e) the Prospectus, as of its date, does not
        contain and, as amended or supplemented, if applicable, will not contain, as of the date of such amendment or supplement, or as of the Closing Date and each Option Closing Date (as defined in Section 2), any untrue statement of a material fact or
        omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to
        statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly
        for use therein.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company is not an &#8220;ineligible issuer&#8221; in connection with
        the offering pursuant to Rules 164, 405 and 433 under the Securities Act.&#160; Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in
        accordance with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder.&#160; Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the
        Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies, or if filed after the effective date of this Agreement, will comply when filed, in all material respects with the requirements of the Securities
        Act and the applicable rules and regulations of the Commission thereunder.&#160; Except for the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, each furnished to the Representatives before first
        use, the Company has not prepared, used or referred to, and will not, without the Representatives&#8217; prior consent, prepare, use or refer to, any free writing prospectus.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company has been duly incorporated and is validly
        existing as a <font style="font-style: italic;">soci&#233;t&#233; anonyme</font> in good standing (to the extent this concept applies) under the laws of Switzerland, has the corporate power and authority to own its property and to conduct its business as
        described in the Time of Sale Prospectus, is not in liquidation or receivership or the subject of any insolvency or bankruptcy proceedings and is duly qualified to transact business (and, if applicable, is in good standing) in each jurisdiction in
        which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing (to the extent this concept applies) would not have a material
        adverse effect on the Company and its subsidiaries, taken as a whole.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Each subsidiary of the Company has been duly incorporated, is
        validly existing as a corporation (and, if applicable, in good standing) under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale
        Prospectus, is not in liquidation or receivership or the subject of any insolvency or bankruptcy proceedings and is duly qualified to transact business (and, if applicable, is in good standing) in each jurisdiction in which the conduct of its
        business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing (to the extent this concept applies) would not have a material adverse effect on the
        Company and its subsidiaries, taken as a whole. All of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and such shares are owned directly by
        the Company, free and clear of all liens, encumbrances, equities or claims. Other than ADC Therapeutics (UK) Limited and ADC Therapeutics America Inc., the Company, directly or indirectly, owns no share capital or other equity or ownership or
        proprietary interest in any corporation, partnership, association, trust or other entity.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">This Agreement has been duly authorized, executed and
        delivered by the Company.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The common shares outstanding prior to the issuance of the
        Shares have been duly authorized and are validly issued, fully paid and non-assessable.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">(i) The issued and outstanding share capital of the Company
        and the authorized and conditional share capital of the Company conform as to legal matters to the description thereof contained in each of the Time of Sale Prospectus and the Prospectus, as of its date, (ii) except as otherwise described in each
        of the Prospectus, as of its date, the Registration Statement and the Time of Sale Prospectus, there are no outstanding rights (including, without limitation, subscription rights), warrants or options to acquire, or instruments, securities or
        rights convertible into or exchangeable for, any Common Shares or other equity interest in the Company to which the Company or any of its subsidiaries is a party, or any contract, commitment, or arrangement of any kind to which the Company or any
        of its subsidiaries is a party under which the Company or any of its subsidiaries have committed to issue any Common Shares or grant any such convertible or exchangeable securities or any such rights, warrants or options, (iii) except as otherwise
        described in each of the Prospectus, as of its date, the Registration Statement and the Time of Sale Prospectus, there are no outstanding rights (including, without limitation, subscription rights), warrants or options to acquire, or instruments,
        securities or rights convertible into or exchangeable for, any shares of any of the Company&#8217;s subsidiaries to which the Company or any of its subsidiaries is a party, or any contract, commitment, or arrangement of any kind to which the Company or
        any of its subsidiaries is a party under which the Company or any of its subsidiaries have committed to issue any shares, rights, warrants or options or instruments convertible into or exchangeable for, any shares of any subsidiary of the Company
        and (iv) there are no legal restrictions on the subsequent transfer of the Shares except as otherwise described in each of the Prospectus, the Registration Statement and the Time of Sale Prospectus.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">(i) The issuance and sale of the Shares will have been duly
        authorized on the Closing Date or the Option Closing Date, as applicable, and the Shares, when delivered and paid for in the manner contemplated by this Agreement, will, at all times, be validly issued, fully paid and non-assessable; and (ii) the
        Shares, when delivered and paid for in the manner contemplated by this Agreement, will be subject only to any restrictions applicable under the Company&#8217;s articles of association or applicable laws, freely transferable except as otherwise described
        in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, and will not be subject to any third party rights (including without limitation any security interest under articles 24 and 25 of the Swiss Federal Act on
        Intermediated Securities) granted by the Company or any of its subsidiaries other than as contemplated by this Agreement.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Immediately after the registration of the Firm Capital
        Increase (as defined in Section 5(a)(ii)) or any Over-Allotment Capital Increase (as defined in Section 6(b)(i)) pursuant to Section 5 or Section 6, as applicable, but in no event later than 3:00 p.m. (Swiss time) on the respective capital increase
        date, the Shares will be registered in the Company&#8217;s uncertificated securities book (<font style="font-style: italic;">Wertrechtebuch</font>) according to article 973c of the Swiss Code of Obligations (the &#8220;<font style="font-weight: bold;">CO</font>&#8221;)
        in the name of Morgan Stanley &amp; Co. LLC, acting on behalf of the Underwriters, and on the Closing Date will be credited to a securities account of Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The execution and delivery by the Company of, and the
        performance by the Company of its obligations under, this Agreement does not contravene any provision of (i) applicable law, (ii) the articles of association (<font style="font-style: italic;">Statuten</font>) or the organizational regulations (<font style="font-style: italic;">Organisationsreglement</font>) of the Company (iii) or any agreement, or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or
        any judgment, order or decree of any governmental body, agency, or court having jurisdiction over the Company or any subsidiary, except that in the case of clauses (i) and (iii) as would not, individually, or in the aggregate, have a material
        adverse effect on the Company or on the power and ability of the Company to perform its obligations under this Agreement; and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for
        the performance by the Company of its obligations under this Agreement, except (1) such as have been obtained or waived or as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the
        Shares; (B) the entry of the Shares in the Commercial Register of the Canton of Vaud; (C) the creation of intermediated securities (<font style="font-style: italic;">Bucheffekten</font>) by way of entry of the Shares into the Depository Trust
        Company (&#8220;<font style="font-weight: bold;">DTC</font>&#8221;) and the subsequent crediting in one or several securities account(s); and (D) the listing of the Shares on New York Stock Exchange (&#8220;<font style="font-weight: bold;">NYSE</font>&#8221;), subject to
        all of (A) to (D) being obtained or done on or prior to the Closing Date.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(l)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Except as otherwise described in each of the Registration
        Statement, the Time of Sale Prospectus and the Prospectus, all dividends, if any, and other distributions declared and payable on the Shares may under the current laws and regulations of Switzerland be paid in freely convertible CHF and, except for
        certain restrictions with respect to national and international sanctions relating to certain countries, may be freely transferred out of Switzerland without there being required any authorization by any governmental body or agency.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">There has not occurred any material adverse effect on the
        Company and its subsidiaries, taken as a whole, or any development involving a prospective material adverse effect on the Company and its subsidiaries, taken as a whole, in the condition, financial or otherwise, or in the earnings, business or
        operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(n)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">There are no legal or governmental proceedings pending or, to
        the knowledge of the Company, threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject f) other than proceedings accurately described in all
        material respects in the Time of Sale Prospectus and proceedings that would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or a material adverse effect on the power or ability of
        the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Time of Sale Prospectus or g) that are required to be described in the Registration Statement or the Prospectus and are not so
        described in all material respects; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement that
        are not described in all material respects or filed as required.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(o)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Each preliminary prospectus filed as part of the registration
        statement as originally filed or as part of any amendment thereto, or filed pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable rules and regulations of the
        Commission thereunder.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(p)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company is not, and after giving effect to the offering
        and sale of the Shares and the application of the proceeds thereof as described in the Prospectus will not be, required to register as an &#8220;investment company&#8221; as such term is defined in the Investment Company Act of 1940, as amended.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(q)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company and its subsidiaries h) are in compliance with
        any and all applicable foreign, federal, state, cantonal and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#8220;<font style="font-weight: bold;">Environmental Laws</font>&#8221;), i) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and j) are in compliance with all terms
        and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits,
        licenses or approvals would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(r)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">There are no costs or liabilities associated with
        Environmental Laws (including, without limitation, any capital or operating expenditures required for clean&#8209;up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating
        activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(s)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Except as otherwise have been validly waived or complied with
        in connection with the issuance and sale of the Shares contemplated hereby or as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, there are no contracts, agreements or understandings between the
        Company and any person granting such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the
        Shares registered pursuant to the Registration Statement.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(t)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">(i) None of the Company or its subsidiaries or controlled
        affiliates, or any director or officer, or, to the Company&#8217;s knowledge, any employee, agent or representative of the Company or of any of its subsidiaries or controlled affiliates, has taken or will take any action in furtherance of an unlawful
        offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a
        government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for
        political office) in order to influence official action, or to any person in violation of any applicable anti-corruption laws; i) the Company and its subsidiaries and controlled affiliates have conducted their businesses in compliance with
        applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained
        herein; and ii) neither the Company nor its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of
        value, to any person in violation of any applicable anti-corruption laws.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(u)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The operations of the Company and its subsidiaries are and
        have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including, to the extent applicable, those of the Bank Secrecy Act, as amended by Title III of the Uniting and
        Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct
        business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;<font style="font-weight: bold;">Anti-Money Laundering Laws</font>&#8221;),
        and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of
        the Company, threatened.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">(i) Neither the Company nor any of its subsidiaries, nor any
        director or officer thereof, nor, to the Company&#8217;s knowledge, any employee, agent, controlled affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&#8220;<font style="font-weight: bold;">Person</font>&#8221;) that
        is, or is owned or controlled by a Person that is:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 64.8pt; margin-left: 115.2pt;"><font style="font-family: 'Times New Roman', Times, serif;">(A)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">the subject of any sanctions administered or enforced by
        the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control (&#8220;<font style="font-weight: bold;">OFAC</font>&#8221;), the United Nations Security Council (&#8220;<font style="font-weight: bold;">UNSC</font>&#8221;), the European Union (&#8220;<font style="font-weight: bold;">EU</font>&#8221;), Her Majesty&#8217;s Treasury (&#8220;<font style="font-weight: bold;">HMT</font>&#8221;), the Swiss State Secretariat of Economic Affairs (&#8220;<font style="font-weight: bold;">SECO</font>&#8221;), the Swiss Directorate of
        International Law (&#8220;<font style="font-weight: bold;">DIL</font>&#8221;) or other relevant sanctions authority (collectively, &#8220;<font style="font-weight: bold;">Sanctions</font>&#8221;), or</font></div>
    <div><br>
    </div>
    <div style="text-indent: 64.8pt; margin-left: 115.2pt;"><font style="font-family: 'Times New Roman', Times, serif;">(B)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">located, organized or resident in a country or territory
        that is the subject of Sanctions (including, without limitation, Crimea, Cuba, Iran, North Korea and Syria).</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company will not, directly or indirectly, use
        the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 64.8pt; margin-left: 115.2pt;"><font style="font-family: 'Times New Roman', Times, serif;">(A)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">to fund or facilitate any activities or business of or
        with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 64.8pt; margin-left: 115.2pt;"><font style="font-family: 'Times New Roman', Times, serif;">(B)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">in any other manner that will result in a violation of
        Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">For the past five (5) years, the Company and its
        subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was
        the subject of Sanctions.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(w)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Subsequent to the respective dates as of which information is
        given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, m) the Company and its subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material
        transaction; n) the Company has not purchased any of its outstanding share capital other than from its employees or other service-providers in connection with the termination of their service pursuant to the terms of the equity compensation plans
        or agreements relating to any repayment of promissory notes (or any adjustment thereto), or relating to any repayment of promissory notes (or any adjustment thereto), in each case, as described in each of the Registration Statement, the Time of
        Sale Prospectus and the Prospectus, nor declared, paid or otherwise made any dividend or distribution of any kind on its share capital; and o) there has not been any material change in the share capital (other than the exercise or settlement or
        equity awards or grants or forfeiture of equity awards outstanding as of such respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, in each case granted pursuant to
        the equity compensation plans described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus), short-term debt or long-term debt of the Company and its subsidiaries, except in each case as described in each of the
        Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(x)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company and its subsidiaries have good and marketable
        title to all real property and good and marketable title to all personal property (other than intellectual property, which is addressed exclusively in Section 1(z)) owned by them which is material to the business of the Company and its
        subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale Prospectus or such as do not materially affect the value of such property and do not materially interfere with the use
        made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such
        exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, in each case except as described in the Time of Sale Prospectus.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(y)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Except as described in each of the Prospectus, the
        Registration Statement or the Time of Sale Prospectus and except as would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, (i) the Company and its subsidiaries own or have a valid license to all patents,
        inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade names (collectively, &#8220;<font style="font-weight: bold;">Intellectual Property Rights</font>&#8221;) used in or reasonably necessary to the conduct of their businesses as now operated by them, and as proposed to be operated in the future (including upon the commercialization of the Company&#8217;s and its
        subsidiaries&#8217; products or services), in each case as described in the Registration Statement, Prospectus or the Time of Sale Prospectus (the &#8220;<font style="font-weight: bold;">Company Intellectual Property</font>&#8221;); (ii) to the Company&#8217;s knowledge,
        there are no third parties who have rights to any Company Intellectual Property, except for customary reversionary rights of third-party licensors; (iii) the Company Intellectual Property owned by the Company and its subsidiaries and, to the
        Company&#8217;s knowledge, the Company Intellectual Property licensed to the Company and its subsidiaries, are subsisting and, to the Company&#8217;s knowledge, valid and enforceable; (iv) there is no pending or, to the Company&#8217;s knowledge, threatened action,
        suit, proceeding or claim by others challenging the validity, scope or enforceability of any Company Intellectual Property, and, to the Company&#8217;s knowledge, the Company is unaware of any facts which would form a reasonable basis for any such
        action, suit, proceeding or claim; (v) there is no pending or, to the Company&#8217;s knowledge, threatened in writing action, suit, proceeding or claim by others challenging the Company&#8217;s rights in or to any Company Intellectual Property, and the
        Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (vi) neither the Company nor any of its subsidiaries has received any written notice alleging any infringement, misappropriation or
        other violation of Intellectual Property Rights; (vii) to the Company&#8217;s knowledge, no third party is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Company Intellectual Property
        owned by the Company; (viii) to the Company&#8217;s knowledge, (A) neither the Company nor any of its subsidiaries infringes, misappropriates or otherwise violates, or has infringed, misappropriated or otherwise violated, any third-party Intellectual
        Property Rights, and (B) the commercialization of the products or services described in the Prospectus, the Registration Statement or the Time of Sale Prospectus as under development by the Company will not infringe, misappropriate, or otherwise
        violate any third-party Intellectual Property Rights; (ix) to the Company&#8217;s knowledge, the Company and its subsidiaries have complied with the terms of each agreement to which they are a party and pursuant to which Intellectual Property Rights have
        been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect; (x) to the Company&#8217;s knowledge, during the prosecution of the patents and patent applications included in the Company Intellectual Property, the
        Company and its subsidiaries have complied with the duty of candor and good faith with respect to such patents and patent applications as required by the United States Patent and Trademark Office and all foreign offices having similar requirements;
        (xi) all employees or contractors engaged in the development of Company Intellectual Property on behalf of the Company or any subsidiary of the Company have executed an invention assignment agreement whereby such employees or contractors presently
        assign all of their right, title and interest in and to such Company Intellectual Property to the Company or the applicable subsidiary, and no such agreement has been breached or violated; (xii) to the Company&#8217;s knowledge, none of the Company
        Intellectual Property has been obtained, or is being used, by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or
        otherwise in violation of the rights of any persons; and (xii) the Company and its subsidiaries use, and have used, commercially reasonable efforts to appropriately maintain all information intended to be maintained as a trade secret.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(z)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">No labor dispute with the employees of the Company or any of
        its subsidiaries exists, except as described in the Time of Sale Prospectus, or, to the knowledge of the Company, is imminent, in either case, that could have a material adverse effect on the Company and its subsidiaries, taken as a whole; and the
        Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could have a material adverse effect on the Company and its subsidiaries, taken as
        a whole.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(aa)</font>&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company and each of its subsidiaries are insured by
        insurers of recognized financial responsibility against such losses and risks and in such amounts as the Company reasonably believes are prudent and customary in the businesses in which they are engaged, except where the failure to be so insured
        would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for three years
        preceding the date of this Agreement; and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
        from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Time of Sale
        Prospectus.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(bb)</font>&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company and its subsidiaries, taken as a whole, possess
        all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to obtain such certificates, authorization and
        permits would not, individually or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole, and neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the
        revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and its subsidiaries,
        taken as a whole, except as described in the Time of Sale Prospectus.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(cc)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company and its subsidiaries on a consolidated basis
        maintain a system of internal accounting controls sufficient to provide reasonable assurance that:&#160; </font><font style="font-family: 'Times New Roman', Times, serif;">(i)
        transactions are executed in accordance with management&#8217;s general or specific authorizations; </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) transactions
        are recorded as necessary to permit preparation of financial statements in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#8220;<font style="font-weight: bold;">IFRS</font>&#8221;) and to
        maintain asset accountability; </font><font style="font-family: 'Times New Roman', Times, serif;">(iii) access to assets is permitted only in accordance with management&#8217;s general
        or specific authorization; and </font><font style="font-family: 'Times New Roman', Times, serif;">(iv) the recorded accountability for assets is compared with the existing assets
        at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in each of the Registration Statement, the Prospectus and the Time of Sale Prospectus, since&#160;the end of the Company&#8217;s most recent audited
        fiscal year, there has been (i) no material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (ii) no change in the Company&#8217;s internal control over financial reporting that has materially and
        adversely affected, or is reasonably likely to materially and adversely affect, the Company&#8217;s internal control over financial reporting.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(dd)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Except as described in each of the Registration Statement,
        the Prospectus and the Time of Sale Prospectus, the Company has not sold, issued or distributed any Common Shares, during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S of, the
        Securities Act, other than shares issued pursuant to employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ee)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Registration Statement, the Prospectus, the Time of Sale
        Prospectus and any preliminary prospectus comply, and any amendments or supplements thereto will comply, with any applicable laws or regulations of foreign jurisdictions in which the Prospectus, the Time of Sale Prospectus or any preliminary
        prospectus, as amended or supplemented, if applicable, are distributed in connection with the Directed Share Program.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ff)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">No consent, approval, authorization or order of, or
        qualification with, any governmental body or agency, other than those obtained, is required in connection with the offering of the Directed Shares in any jurisdiction where the Directed Shares are being offered.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(gg)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company has not offered, or caused Morgan Stanley or any
        Morgan Stanley Entity as defined in Section 11 to offer, Shares to any person pursuant to the Directed Share Program with the specific intent to unlawfully influence </font><font style="font-family: 'Times New Roman', Times, serif;">(i) a customer or supplier of the Company to alter the customer&#8217;s or supplier&#8217;s level or type of business with the Company or </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) a trade journalist or publication to write or publish favorable information about the Company or its products.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(hh)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company and each of its subsidiaries have filed all
        federal, state, local and foreign tax returns required to be filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not, individually or in the aggregate, have a material adverse effect
        on the Company and its subsidiaries, taken as a whole) and have paid all taxes required to be paid thereon (except for cases in which the failure to file or pay would not have a material adverse effect on the Company and its subsidiaries, taken as
        a whole, or, except as currently being contested in good faith and for which reserves required by IFRS have been created in the financial statements of the Company), and no tax deficiency has been determined adversely to the Company or any of its
        subsidiaries which has had (nor does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely to the Company or its subsidiaries and which could
        reasonably be expected to have) a material adverse effect on the Company and its subsidiaries, taken as a whole.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The consolidated financial statements included in the Time
        of Sale Prospectus, together with the related schedules and notes thereto, present fairly in all material respects the consolidated financial position of the Company as of the dates shown and its results of operations and cash flows for the periods
        shown, and, except as otherwise disclosed in the Time of Sale Prospectus, such financial statements have been prepared in conformity with IFRS applied on a consistent basis throughout the periods covered thereby except for any normal year-end
        adjustments in the Company&#8217;s quarterly financial statements and except as otherwise noted therein.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(jj)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">PricewaterhouseCoopers SA, who has audited certain financial
        statements of the Company, is </font><font style="font-family: 'Times New Roman', Times, serif;">(i) an independent registered public accounting firm with respect to the Company
        within the meaning of the Securities Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company Accounting Oversight Board (United States) and </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) an independent statutory auditor with respect to the Company and a state regulated audit firm (<font style="font-style: italic;">staatlich beaufsichtigtes
          Revisionsunternehmen</font>) under the applicable provisions of the CO, and the Swiss Audit Oversight Act (<font style="font-style: italic;">Revisionsaufsichtsgesetz</font>) and any ordinances promulgated thereunder, respectively.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(kk)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">From the time of initial confidential submission of the
        Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communication) through the date hereof, the Company has
        been and is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act (an &#8220;<font style="font-weight: bold;">Emerging Growth Company</font>&#8221;).&#160; &#8220;<font style="font-weight: bold;">Testing-the-Waters Communication</font>&#8221; means any
        oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ll)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company </font><font style="font-family: 'Times New Roman', Times, serif;">(i) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Representatives with
        entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications.&#160; The Company reconfirms that the
        Representatives have been authorized to act on its behalf in undertaking Testing-the-Waters Communications.&#160; The Company has not distributed any Written Testing-the-Waters Communications other than those listed on Schedule III hereto.&#160; &#8220;<font style="font-weight: bold;">Written Testing-the-Waters Communication</font>&#8221; means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(mm)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">As of the time of each sale of the Shares in connection with
        the offering when the Prospectus is not yet available to prospective purchasers, none of (A) the Time of Sale Prospectus, (B) any free writing prospectus, when considered together with the Time of Sale Prospectus, and (C) any individual Written
        Testing-the-Waters Communication, when considered together with the Time of Sale Prospectus, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to
        make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(nn)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Except as described in each of the Registration Statement,
        the Time of Sale Prospectus and the Prospectus, no stamp, documentary, issuance, registration, transfer, withholding or other taxes or duties are payable by or on behalf of the Underwriters, the Company or any of its subsidiaries in Switzerland or
        to any taxing authority thereof or therein in connection with </font><font style="font-family: 'Times New Roman', Times, serif;">(i) the execution, delivery or consummation of this
        Agreement, </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) the creation, allotment and issuance of the Shares, </font><font style="font-family: 'Times New Roman', Times, serif;">(iii) the sale and delivery of the Shares to the Underwriters or purchasers procured by the Underwriters or </font><font style="font-family: 'Times New Roman', Times, serif;">(iv) the resale and delivery of the Shares by the Underwriters in the manner contemplated herein.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(oo)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">It is not necessary under the laws of Switzerland </font><font style="font-family: 'Times New Roman', Times, serif;">(i) to enable the Underwriters to enforce their rights under this Agreement, to enable any holder of Shares to enforce their
        respective rights thereunder, provided that they are not otherwise engaged in business in Switzerland or </font><font style="font-family: 'Times New Roman', Times, serif;">(ii)
        solely by reason of the execution, delivery or consummation of this Agreement for any of the Underwriters or any holder of&#160; Shares of the Company to be qualified or entitled to carry out business in Switzerland.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(pp)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">This Agreement is in proper form under the laws of
        Switzerland for the enforcement thereof against the Company, and to ensure the legality, validity, enforceability or admissibility into evidence in Switzerland of this Agreement.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(qq)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule
        405 of the Securities Act.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(rr)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The courts of Switzerland would recognize as a valid
        judgment any final monetary judgment obtained against the Company in the courts of the State of New York.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ss)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Neither the Company nor any of its subsidiaries has any
        immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise) under the laws of Switzerland.&#160; The irrevocable and unconditional
        waiver and agreement of the Company contained in Section 20 not to plead or claim any such immunity in any legal action, suit or proceeding based on this Agreement is valid and binding under the laws of Switzerland.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(tt)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The choice of law of the State of New York as the governing
        law of this Agreement is a valid choice of law under the laws of Switzerland and will be honored by the courts of Switzerland.&#160; The Company has the power to submit, and pursuant to Section 20 has, to the extent permitted by law, legally, validly,
        effectively and irrevocably submitted, to the jurisdiction of the Specified Courts (as defined in Section 20), and has the power to designate, appoint and empower, and pursuant to Section 21, has legally, validly and effectively designated,
        appointed and empowered an agent for service of process in any suit or proceeding based on or arising under this Agreement in any of the Specified Courts.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(uu)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Neither the Company nor any of its subsidiaries or affiliates
        has any securities rated by any &#8220;nationally recognized statistical rating organization,&#8221; as such term is defined in Section 3(a)(62) of the Exchange Act.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(vv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Nothing has come to the attention of the Company that has
        caused the Company to believe that the statistical and market-related data included in the Registration Statement, the Time of Sale Prospectus and the Prospectus is not based on or derived from sources that are reliable and accurate.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ww)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Except as described in each of the Registration Statement, the
        Prospectus or the Time of Sale Prospectus, and except as would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, </font><font style="font-family: 'Times New Roman', Times, serif;">(i) the pre-clinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company or its subsidiaries or in which the Company or its subsidiaries
        have participated, that are described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus, as
        applicable, were, and if still pending are, being conducted in accordance with the protocols submitted to the U.S. Food and Drug Administration (the &#8220;<font style="font-weight: bold;">FDA</font>&#8221;), the Swiss Agency for Therapeutic Products (&#8220;<font style="font-weight: bold;">swissmedic</font>&#8221;), and other applicable regulatory authorities (including, without limitation, any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed
        by the FDA, FOPH, swissethics and swissmedic) (collectively, the &#8220;<font style="font-weight: bold;">Regulatory Authorities</font>&#8221;), the applicable rules and regulations of the Regulatory Authorities, and current Good Clinical Practices and Good
        Laboratory Practices; </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) the descriptions in the Registration Statement, the Time of Sale Prospectus and the
        Prospectus of the results of such studies and trials are accurate and fairly present the data derived therefrom; </font><font style="font-family: 'Times New Roman', Times, serif;">(iii)
        the Company has no knowledge of any other studies or trials not described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the results of which call into question the results described or referred to in the
        Registration Statement, the Time of Sale Prospectus and the Prospectus; </font><font style="font-family: 'Times New Roman', Times, serif;">(iv) the Company and its subsidiaries
        have operated at all times and are currently in material compliance with all applicable statutes, rules and regulations of the Regulatory Authorities; and </font><font style="font-family: 'Times New Roman', Times, serif;">(v) neither the Company nor any of its subsidiaries have received any written notices, correspondence or other communications from the Regulatory Authorities or any other governmental agency requiring or
        threatening the termination, modification or suspension of any pre-clinical studies or clinical trials that are described in the Registration Statement, the Time of Sale Prospectus and the Prospectus or the results of which are referred to in the
        Registration Statement, the Time of Sale Prospectus and the Prospectus, other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to the Company&#8217;s best
        knowledge, there are no reasonable grounds for the same.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(xx)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Except as described in each of the Registration Statement,
        the Prospectus or the Time of Sale Prospectus and except as would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, the Company has not failed to file with the Regulatory Authorities any required filing,
        declaration, listing, registration, report or submission&#160; that is a responsibility with the Company with respect to the Company&#8217;s product candidates that are described or referred to in the Registration Statement, the Time of Sale Prospectus and
        the Prospectus; all such filings, declarations, listings, registrations, reports or submissions were to the Company&#8217;s knowledge in compliance with applicable laws when filed; and to the Company&#8217;s knowledge no deficiencies regarding compliance with
        applicable law have been asserted by any applicable Regulatory Authority with respect to any such filings, declarations, listings, registrations, reports or submissions.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(yy)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Except as described in each of the Registration Statement,
        the Prospectus or the Time of Sale Prospectus and except as would be reasonably expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, the Company and its subsidiaries are, and at all times have been, in
        compliance with all applicable Health Care Laws.&#160; For purposes of this Agreement, &#8220;<font style="font-weight: bold;">Health Care Laws</font>&#8221; means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service
        Act (42 U.S.C. &#167;&#167; 201 et seq.)]; (ii) all applicable federal, state, local and all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the U.S. False
        Statements Law (42 U.S.C. &#167; 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. &#167;1320a-7a),&#160; the U.S. Civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), all criminal laws relating to health care fraud and abuse, including but not limited to
        18 U.S.C. &#167;&#167; 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#8220;<font style="font-weight: bold;">HIPAA</font>&#8221;) (42 U.S.C. &#167;&#167; 1320d et seq.), the Physician
        Payments Sunshine Act (42 U.S.C. &#167; 1320a-7h), the exclusion law (42 U.S.C. &#167;1320a-7); (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.); (iv) regulations promulgated
        pursuant to such statutes; and (v) any and all other applicable federal, state, or foreign health care laws and regulation applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
        advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company.&#160; Neither the Company nor its subsidiaries has received written notice of any claim, action, suit,
        proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that it is in violation of any Health Care Laws, and, to the Company&#8217;s
        knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened.&#160; Neither the Company nor its subsidiaries, nor their respective officers, directors, employees, contractors or
        agents, is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority.&#160; Additionally, neither the Company nor any of
        its employees, officers, directors, contractors or agents, nor its subsidiaries or any of the subsidiary&#8217;s employees, officers, directors, contractors or agents, has been excluded, suspended or debarred from participation in any U.S. federal health
        care program (as defined in 42 U.S.C. &#167; 1320a-7b(f)) or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to
        result in such debarment, suspension, or exclusion. The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or
        amendments as required by the Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were timely, complete, accurate and not misleading on the date filed in all
        material respects (or were corrected or supplemented by a subsequent submission).</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(zz)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company has provided to the Representatives a properly
        completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of any required identifying documentation, and the Company hereby undertakes to provide such additional supporting documentation as the
        Representative may reasonably request in connection with the verification of the foregoing certification.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(aaa)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Except as described in each of the Registration Statement, the
        Prospectus or the Time of Sale Prospectus and except as would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, (i) there has been no security breach or incident, unauthorized access or disclosure, or other
        compromise of the Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, technology, data and databases, including Personal Data (defined below), the data
        and information of their respective customers and employees, and any sensitive, confidential or regulated data maintained, processed or stored by the Company and its subsidiaries&#160; (collectively, &#8220;<font style="font-weight: bold;">IT Systems and Data</font>&#8221;);
        (ii) the IT Systems and Data are adequate for, and operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted; (iii) the Company and its subsidiaries have used
        commercially reasonable efforts to implement and maintain, and have implemented and maintained, commercially reasonable information technology, information security, cyber security and data protection controls, policies and procedures, including
        oversight, access controls, encryption, physical, technological and administrative safeguards and controls, and business continuity/disaster recovery and security plans that are designed to protect against and prevent security breaches,
        unauthorized use or access, disablement, misappropriation, modification, or other compromise or misuse of the IT Systems and Data, and maintain and protect their material confidential information and the integrity, continuous operation, redundancy
        and security of all IT Systems and Data used in connection with the operation of the Company&#8217;s and its subsidiaries&#8217; businesses, which are reasonably consistent with industry standards. &#8220;<font style="font-weight: bold;">Personal Data</font>&#8221; means
        (i) a natural person&#8217;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&#8217;s license number, passport number, credit card number, bank information, or customer or account
        number; (ii) &#8220;personal data&#8221; as defined by GDPR (defined below); (iii) any information which would qualify as &#8220;protected health information&#8221; under HIPAA; and (iv) any other piece of information that (A) is regulated by an applicable privacy law,
        regulation or contract and (B) allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#8217;s health or sexual orientation.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(bbb)</font>&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Except as described in each of the Prospectus, the Registration
        Statement or the Time of Sale Prospectus and except as would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, (i) the Company and each of its subsidiaries have complied, and are presently in compliance, with
        all applicable internal and external privacy policies, contractual obligations, applicable state, federal and international data privacy and security laws and regulations, including without limitation, HIPAA, the European Union General Data
        Protection Regulation (&#8220;<font style="font-weight: bold;">GDPR</font>&#8221;) (EU 2016/679), and other statutes, judgments, orders, rules and regulations of any applicable court or arbitrator or other governmental or regulatory authority (collectively,
        the &#8220;<font style="font-weight: bold;">Data Security Obligations</font>&#8221;); (ii) the Company has not received from any applicable governmental authority any written notification of or written complaint alleging non-compliance by the Company or its
        subsidiaries with any Data Security Obligation; (iii) there is no action, suit or proceeding by or before any applicable court or governmental agency, authority or body pending or threatened in writing alleging non-compliance by the Company or its
        subsidiaries; (iv) to ensure compliance with the Data Security Obligations, the Company and its subsidiaries have at all times had in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects
        with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data that is subject to the Data Security Obligations (the &#8220;<font style="font-weight: bold;">Policies</font>&#8221;);

        and (v) the Company and its subsidiaries have made all disclosures of its then-current Policies to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy
        have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Agreements to Sell and Purchase.&#160; </font>The
        Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase
        from the Company the respective numbers of Firm Shares set forth in Schedule I hereto opposite its name at $[&#9679;] per share (the &#8220;<font style="font-weight: bold;">Purchase Price</font>&#8221;).</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Underwriters the
      Additional Shares, and the Underwriters shall have the right to purchase, severally and not jointly, up to [&#9679;] Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional Shares shall be
      reduced by an amount per share equal to any dividends declared by the Company and payable on the Firm Shares but not payable on such Additional Shares.&#160; The Representatives may exercise this right on behalf of the Underwriters in whole or from time
      to time in part by giving written notice not later than 30 days after the date of this Agreement.&#160; Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be
      purchased.&#160; Each purchase date must be at least two, or in the case of an exercise of the option granted to the Representatives under this Section 2 of this Agreement on a date that is less than two business days prior to the Closing Date, three
      business days after the written notice is given and may not be earlier than the Closing Date nor later than ten business days after the date of such notice.&#160; Additional Shares may be purchased as provided in Section 4 hereof solely for the purpose of
      covering over-allotments made in connection with the offering of the Firm Shares.&#160; On each day, if any, that Additional Shares are to be purchased (an &#8220;<font style="font-weight: bold;">Option Closing Date</font>&#8221;), each Underwriter agrees, severally
      and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Additional Shares to be purchased on
      such Option Closing Date as the number of Firm Shares set forth in Schedule I hereto opposite the name of such Underwriter bears to the total number of Firm Shares.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">18</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">For the avoidance of doubt, the several Underwriters will in each case deduct the Firm Capital Increase Amount (as defined in Section 5(b)(ii)) or the applicable
      Over-Allotment Capital Increase Amount (as defined in Section 6(a)(ii)), as the case may be, translated into $ at the exchange rate applicable on the payment date of the Firm Capital Increase Amount or the Over-Allotment Capital Increase Amount, as
      applicable, as documented by Morgan Stanley &amp; Co. LLC, from the aggregate Purchase Price for the Firm Shares or the Additional Shares, as the case may be, payable by the several Underwriters to the Company.</div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Terms of Public Offering</font>.&#160; The Company
        is advised by the Representatives that the Underwriters propose to make a public offering of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in the Representatives&#8217;
        judgment is advisable.&#160; The Company is further advised by the Representatives that the Shares are to be offered to the public initially at $[&#9679;] per share (the &#8220;<font style="font-weight: bold;">Public Offering Price</font>&#8221;) and to certain dealers
        selected by the Representatives at a price that represents a concession not in excess of $[&#9679;] per share under the Public Offering Price, and that any Underwriter may allow, and such dealers may reallow, a concession, not in excess of $[&#9679;] per
        share, to any Underwriter or to certain other dealers.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Payment and Delivery.&#160; </font>Payment for
        the Firm Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on [&#9679;],
        2019 or at such other time on the same or such other date, not later than [&#9679;], 2019 as shall be designated in writing by the Representatives.&#160; The time and date of such payment are hereinafter referred to as the &#8220;<font style="font-weight: bold;">Closing
          Date</font>.&#8221;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Payment for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of such Additional Shares for
      the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section 2 or at such other time on the same or on such other date, in any event not later than [&#9679;],
      2019 as shall be designated in writing by the Representatives in the same manner as set forth in the preceding paragraphs of this Section 4.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">19</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The Firm Shares and Additional Shares shall be registered in such names and in such denominations as the Representatives shall request in writing not later than one full
      business day prior to the Closing Date or the applicable Option Closing Date, as the case may be.&#160; The Company shall cause the Firm Shares and Additional Shares to be delivered to the Representatives on the Closing Date or an Option Closing Date, as
      the case may be, for the respective accounts of the several Underwriters, with any transfer taxes payable in connection with the transfer of the Shares to the Underwriters duly paid, against payment of the Purchase Price therefor (minus the Firm
      Capital Increase Amount (as defined in Section 5(b)(ii)) or the applicable Over-Allotment Capital Increase Amount (as defined in Section 6(a)(ii)), as the case may be).</div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Capital Increase and Initial Subscription</font>.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company confirms that:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font> &#160; &#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Pursuant to its articles of association, the Board
        of Directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) may effect an increase of the Company&#8217;s share capital in a maximum amount of CHF 1,647,000 by issuing up to 25,734,375 Common Shares with a nominal value of CHF 0.064
        each out of the Company&#8217;s authorized share capital, such authorization having been granted by resolution of the shareholders meeting of September 19, 2019; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">On [&#9679;], the Board resolved on an increase in the
        share capital of the Company (<font style="font-style: italic;">Durchf&#252;hrungsbeschluss</font>) from CHF [&#9679;] to a maximum amount of CHF 4,267,000 by issuing up to [&#9679;] new Common Shares from the authorized share capital for the purpose of the
        offering (&#8220;<font style="font-weight: bold;">Firm Capital Increase</font>&#8221;), whereby all statutory pre-emptive rights to which the shareholders of the Company are entitled under Swiss law have been validly excluded.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC, acting on behalf of the several
        Underwriters, agrees, on the basis of the representations, warranties and agreements herein contained, to:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">subscribe (through Morgan Stanley &amp; Co. LLC) on
        or by 6:00 a.m. (New York City time) on the business day prior to the Closing Date, or such other time and date as agreed between the Company and the Representatives, for all the Firm Shares at the issue price (<font style="font-style: italic;">Ausgabebetrag</font>)
        of CHF 0.064 per Firm Share corresponding to the nominal value for each Firm Share and to deliver the corresponding subscription form (<font style="font-style: italic;">Zeichnungsschein</font>) to the Company in the form of Exhibit C hereto no
        later than at 6:00 a.m. (New York City time) on the business day prior to the Closing Date; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">deposit or cause to be deposited, same-day funds
        for value not later than 6:00 a.m. (New York time) on the business day prior to the Closing Date, or such other time and date as agreed between the Company and Representatives, in the amount of CHF [&#9679;] (corresponding to the aggregate nominal value
        of the Firm Shares) (the &#8220;<font style="font-weight: bold;">Firm Capital Increase Amount</font>&#8221;) with Credit Suisse (Suisse) SA, a Swiss banking institution (the &#8220;<font style="font-weight: bold;">Capital Increase Bank</font>&#8221;), in a blocked account
        for such capital increase (<font style="font-style: italic;">Kapitaleinzahlungskonto</font>) with the IBAN [&#9679;], made out to the Company&#8217;s name (the &#8220;<font style="font-weight: bold;">Firm Capital Increase Account</font>&#8221;), allowing the Capital
        Increase Bank to issue and deliver a written confirmation of payment of the Firm Capital Increase Amount (<font style="font-style: italic;">Kapitaleinzahlungsbest&#228;tigung</font>) to the Company no later than 9:00 a.m. (New York time) on the business
        day prior to the Closing Date (or such other time and date as agreed between the Company and the Representatives).</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">20</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Upon receipt of the documents referred to in Section 5(b) and
        before 3:00 a.m. (New York time) on the Closing Date, or such other time and date as agreed between the Company and the Representatives, the Board will:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">adopt a report on the Firm Capital Increase (<font style="font-style: italic;">Kapitalerh&#246;hungsbericht</font>) in accordance with Swiss law (article 652e CO);</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">procure that a licensed auditor verifies the report
        on the Firm Capital Increase in accordance with article 652f CO and confirms in writing that it is complete and accurate (<font style="font-style: italic;">Pr&#252;fungsbest&#228;tigung</font>), in accordance with Swiss law;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160; &#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">resolve in the form of a duly notarized deed on the
        Firm Capital Increase as set forth in article 652g CO and make all amendments to the articles of association of the Company necessary in connection with the Firm Capital Increase (<font style="font-style: italic;">Feststellungs- und
          Statuten&#228;nderungsbeschluss</font>); and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">promptly thereafter, but no later than 4:00 a.m.
        (New York time) on the Closing Date, file the documents necessary for the registration of the Firm Capital Increase with the Commercial Register of the Canton of Vaud;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">provided, however</font>, that if this Agreement is terminated pursuant to Section 12 prior to the Company filing the relevant resolutions
      with the Commercial Register of the Canton of Vaud, (A) the Company undertakes not to resolve on the Firm Capital Increase (if it has not already done so) or to file the relevant resolutions with the Commercial Register of the Canton of Vaud, and (B)
      the Company shall immediately cause the Capital Increase Bank to release the Firm Capital Increase Amount in full to Morgan Stanley &amp; Co. LLC, acting for the accounts of the several Underwriters, as soon as practicable; and the Underwriters
      understand that the Capital Increase Bank may require confirmation, including from the Underwriters, to release the Firm Capital Increase Amount and the Underwriters agree to deliver such confirmation.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">21</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Immediately after the registration of the Firm Capital
        Increase in the Commercial Register of the Canton of Vaud pursuant to Section 5(c), but in no event later than 9:15 a.m. (New York time) on the Closing Date, the Company will:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160; &#160; &#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">deliver by way of email to each of the
        Representatives, the Capital Increase Bank, the share registrar of the Company, Homburger AG and Lenz &amp; Staehelin pdf-copies of, </font><font style="font-family: 'Times New Roman', Times, serif;">(A) the certified excerpt of the journal entry (<font style="font-style: italic;">Tagebuch</font>) or the certified excerpt from the Commercial Register of the Canton of Vaud evidencing the Firm Capital Increase, (B)&#160; the
        certified updated articles of association of the Company evidencing the Firm Capital Increase, (C)&#160; the Company&#8217;s book of uncertificated securities (<font style="font-style: italic;">Wertrechtebuch</font>) duly signed by the Company&#8217;s share
        registrar and evidencing Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters in proportion of their respective holdings set out in Schedule I hereto, as first holder of the Firm Shares and (D) a copy of the share register (<font style="font-style: italic;">Aktienbuch</font>) of the Company evidencing the Underwriters as shareholders with respect to the Firm Shares;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160; &#160; &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">take all steps necessary to ensure that the Firm
        Shares will be (A) issued to Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters, (B) duly recorded as intermediated securities (<font style="font-style: italic;">Bucheffekten</font>) in DTC, (C) duly recorded in an account
        of Morgan Stanley &amp; Co. LLC, all in accordance with the provisions of the Swiss Federal Act on Intermediated Securities, and (D) freely transferable (subject to any applicable restrictions set forth in the articles of association of the
        Company) on the Closing Date; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">take all steps necessary to ensure that the Firm
        Shares will be (A) duly recorded in an account of Morgan Stanley &amp; Co. LLC at the DTC on the Closing Date and (B) freely transferable (subject to any applicable restrictions set forth in the articles of association of the Company) on the
        Closing Date in accordance with the instructions of the Representative.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The funds deposited in the Firm Capital Increase Account
        shall, upon registration of the Firm Capital Increase pursuant to Section 5(c) and upon request by the Representatives, be transferred to a separate account of the Company with [&#9679;] and shall, in such case, remain so deposited, without interest, for
        the account of the Company until the earlier of:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">the issuance of the Firm Shares to the Underwriters
        as set forth in Section 5(d) on the Closing Date; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">the date of receipt by the Representatives on behalf
        of the several Underwriters of the proceeds of (A) the sale of the Firm Shares as set forth in Sections 13(b), 13(c) or 13(e) or (B) the Capital Reduction as set forth in Section 13(d), as the case may be.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">22</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Any fees payable to the Capital Increase Bank for any transfer of the funds deposited in the Firm Capital Increase Account pursuant to this Section 5(e) shall be payable
      directly to the Capital Increase Bank by the Company.</div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Subscription and Issuance of Additional
          Shares</font>.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">If the Representatives exercise the option granted to them
        under Section 2 of this Agreement, Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters, agrees, on the basis of the representations, warranties and agreements herein contained, to:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">subscribe (through Morgan Stanley &amp; Co. LLC)
        for the number of Additional Shares for which the option to purchase has been exercised pursuant to Section 2 (the &#8220;<font style="font-weight: bold;">Applicable Additional Shares</font>&#8221;) at the issue price (<font style="font-style: italic;">Ausgabebetrag</font>)
        of CHF 0.064 for each Applicable Additional Share corresponding to the nominal value of each Applicable Additional Share, and to deliver the corresponding subscription form (<font style="font-style: italic;">Zeichnungsschein</font>) in the form of&#160;
        Exhibit C hereto to the Company by not later than 6:00 a.m. (New York time) on the business day prior to the Option Closing Date (or such other date set forth in the relevant option exercise notice delivered by the Representatives pursuant to
        Section 2); and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">deposit or cause to be deposited, same-day funds
        for value&#160; not later than 6:00 a.m. (New York time) on the business day prior to the Option Closing Date (or such other date set forth in the relevant option exercise notice delivered by the Representatives pursuant to Section 2), in the amount of
        CHF 0.064 multiplied by the number of Applicable Additional Shares (the &#8220;<font style="font-weight: bold;">Over-Allotment Capital Increase Amount</font>&#8221;) with the Capital Increase Bank, in a blocked account for the Over-Allotment Capital Increase (<font style="font-style: italic;">Kapitaleinzahlungskonto</font>), with the IBAN [&#9679;], made out to the Company&#8217;s name (the &#8220;<font style="font-weight: bold;">Over-Allotment Capital Increase Account</font>&#8221;), allowing the Capital Increase Bank to issue
        and deliver a written confirmation of payment of the Over-Allotment Capital Increase Amount (<font style="font-style: italic;">Kapitaleinzahlungsbest&#228;tigung</font>) to the Company no later than 9:00 a.m. (New York time) on the business day prior to
        the Option Closing Date (or at a later date, as set forth in the option exercise notice delivered by the Representatives pursuant to Section 2).</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">23</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Upon receipt of the documents referred to under Section 6(a)
        in relation to any Applicable Additional Shares and before 3:00 a.m. (New York time) on the Option Closing Date (or at a later date, as set forth in the relevant option exercise notice delivered by the Representatives pursuant to Section 2, the
        Board will:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">unless passed already prior to such time, pass a
        capital increase resolution (<font style="font-style: italic;">Erh&#246;hungsbeschluss</font>) regarding the issuance of the Applicable Additional Shares subscribed for pursuant to Section 6(a)(i) (the &#8220;<font style="font-weight: bold;">Over-Allotment
          Capital Increase</font>&#8221;);</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">adopt a report on the Over-Allotment Capital
        Increase (<font style="font-style: italic;">Kapitalerh&#246;hungsbericht</font>) in accordance with Swiss law (article 652e CO);</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160;&#160; &#160; &#160; &#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">procure that a licensed auditor verifies the report
        on the Over-Allotment Capital Increase in accordance with article 652f CO and confirms in writing that it is complete and accurate (<font style="font-style: italic;">Pr&#252;fungsbest&#228;tigung</font>), in accordance with Swiss law;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iv)</font>&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">resolve in the form of a duly notarized deed on the
        Over-Allotment Capital Increase as set forth in article 652g CO and make all amendments to the articles of association of the Company necessary in connection with the Over-Allotment Capital Increase (<font style="font-style: italic;">Feststellungs-und
          Statuten&#228;nderungsbeschluss</font>); and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">promptly thereafter, but no later than 4:00 a.m.
        (New York time) on Option Closing Date (or at a later date, as set forth in the relevant option exercise notice delivered by the Representatives pursuant to Section 2) file the documents necessary for the registration of the Over-Allotment Capital
        Increase with the Commercial Register of the Canton of Vaud;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">provided</font>,<font style="font-style: italic;"> however</font>, that if this Agreement is terminated pursuant to Section 12 prior to the
      Company filing the relevant resolutions with the Commercial Register of the Canton of Vaud, (A) the Company undertakes not to resolve on the Over-Allotment Capital Increase (if it has not already done so) and to not file the relevant resolutions with
      the Commercial Register of the Canton of Vaud, and (B) the Company shall immediately cause the Capital Increase Bank to release the Over-Allotment Capital Increase Amount in full to Morgan Stanley &amp; Co. LLC, acting for the accounts of the several
      Underwriters, as soon as practicable; and the Underwriters understand that the Capital Increase Bank may require confirmation, including from the Underwriters, to release the Over-Allotment Capital Increase Amount and the Underwriters agree to
      deliver such confirmation.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">24</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Immediately after the registration of the Over-Allotment
        Capital Increase in the Commercial Register of the Canton of Vaud pursuant to Section 6(b) in relation to any Applicable Additional Shares, but in no event later than 9:15 a.m. (New York time) on the Option Closing Date (or such other date set
        forth in the relevant option exercise notice delivered by the Representatives pursuant to Section 2), the Company will:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">deliver by way of email to each of the
        Representatives, the Capital Increase Bank, the share registrar of the Company, Homburger AG and Lenz &amp; Staehelin, pdf-copies of (A)&#160; the certified excerpt of the journal entry (<font style="font-style: italic;">Tagebuch</font>) or the
        certified excerpt from the Commercial Register of the Canton of Vaud evidencing the Over-Allotment Capital Increase, (B) the certified updated articles of association of the Company evidencing the Over-Allotment Capital Increase, (C)&#160; the Company&#8217;s
        book of uncertificated securities (<font style="font-style: italic;">Wertrechtebuch</font>) duly signed by the Company&#8217;s share registrar and evidencing Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters in proportion of
        their respective holdings set out in Schedule I hereto, as first holder of the Applicable Additional Shares and, if the Shares of the Company are not already listed, (D) a copy of the share register (<font style="font-style: italic;">Aktienbuch</font>)
        of the Company evidencing the Underwriters as shareholders with respect to the Applicable Additional Shares;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160; &#160; &#160;&#160; &#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">take all steps necessary to ensure that the
        Applicable Additional Shares will be (A) issued to Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters, (B) duly recorded as intermediated securities (<font style="font-style: italic;">Bucheffekten</font>) in DTC, (C) duly
        recorded in an account of Morgan Stanley &amp; Co. LLC, all in accordance with the provisions of the Swiss Federal Act on Intermediated Securities, and (D) freely transferable (subject to any applicable restrictions set forth in the articles of
        association of the Company) on the Closing Date; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">take all steps necessary to ensure that the
        Applicable Additional Shares will be (A) duly recorded in an account of Morgan Stanley &amp; Co. LLC at DTC on the relevant Option Closing Date, and (B) freely transferable (subject to any applicable restrictions set forth in the articles of
        association of the Company) on the relevant Option Closing Date in accordance with the instructions of the Representative.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The funds deposited in the Over-Allotment Capital Increase
        Account shall, upon registration of the Over-Allotment Capital Increase pursuant to Section 6(b) and upon request by the Representatives, be transferred to a separate account of the Company with the [&#9679;] and shall, in such case, remain so deposited,
        for the account of the Company until the earlier of:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">the issuance of the Applicable Additional Shares to
        the Underwriters as set forth in Section 6(c) on the relevant Option Closing Date; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">the date of receipt by the Representatives on
        behalf of the several Underwriters of the proceeds of (A) the sale of the Applicable Additional Shares as set forth in Sections 13(b), 13(c) or 13(e) hereof or (B) the Capital Reduction as set forth in Section 13(d) hereof, as the case may be.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">25</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Any fees payable to the Capital Increase Bank for any transfer of the funds deposited in the Over-Allotment Capital Increase Account pursuant to this Section 6(d) shall be
      payable directly to the Capital Increase Bank by the Company.</div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Conditions to the Underwriters&#8217; Obligations</font>.&#160;
        The obligations of the Company to sell the Shares to the Underwriters and the several obligations of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the condition that the Registration Statement shall have
        become effective not later than [&#9679;] (New York City time) on the date hereof, no stop order suspending the effectiveness of the Registration Statement or any part thereof has been issued and no proceedings for that purpose have been instituted or
        are pending or contemplated under the Securities Act.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The several obligations of the Underwriters are subject to the following further conditions:</div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Subsequent to the execution and delivery of this Agreement
        and prior to the Closing Date there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries,
        taken as a whole, from that set forth in the Time of Sale Prospectus that, in the Representatives&#8217; judgment, is material and adverse and that makes it, in the Representatives&#8217; judgment, impracticable to market the Shares on the terms and in the
        manner contemplated in the Time of Sale Prospectus.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received on the Closing Date a
        certificate, dated the Closing Date and signed by an executive officer of the Company, to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company
        has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. The officer signing and delivering such certificate may rely upon the best of his or her
        knowledge as to proceedings threatened.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Each of the Representatives, the Capital Increase Bank, the
        share registrar of the Company, Homburger AG and Lenz &amp; Staehelin shall have received pdf-copies of, (A) the certified excerpt of the journal entry (<font style="font-style: italic;">Tagebuch</font>) or the certified excerpt from the Commercial
        Register of the Canton of Vaud evidencing the Firm Capital Increase, (B)&#160; the certified updated articles of association of the Company evidencing the Firm Capital Increase, (C)&#160; the Company&#8217;s book of uncertificated securities (<font style="font-style: italic;">Wertrechtebuch</font>) duly signed by the Company&#8217;s share registrar and evidencing Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters in proportion of their respective holdings set out in
        Schedule I hereto, as first holder of the Firm Shares and (D) a copy of the share register (<font style="font-style: italic;">Aktienbuch</font>) of the Company evidencing the Underwriters as shareholders with respect to the Firm Shares.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">26</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received on the Closing Date an
        opinion and negative assurance letter of Davis Polk &amp; Wardwell LLP, outside counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received on the Closing Date an
        opinion of Homburger AG, Swiss counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received on the Closing Date an
        opinion of Hyman, Phelps &amp; McNamara P.C., outside regulatory counsel to the Company, dated the Closing Date, in form and substance reasonably satisfactory to the underwriters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received on the Closing Date an
        opinion of Foley &amp; Lardner LLP, outside intellectual property counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received on the Closing Date an
        opinion of Mewburn Ellis LLP, outside intellectual property counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received on the Closing Date an
        opinion of Cooley LLP, counsel for the Underwriters, dated the Closing Date, in form and substance satisfactory to the Underwriters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">With respect to Section 7(e) and 7(i) above, Davis Polk &amp; Wardwell LLP and Cooley LLP, respectively, may state that their opinions and beliefs are based upon their
      participation in the preparation of the Registration Statement, the Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto and review and discussion of the contents thereof, but are without independent check or
      verification, except as specified.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The opinions of Davis Polk &amp; Wardwell LLP, Homburger AG,&#160; Hyman, Phelps &amp; McNamara P.C., Foley &amp; Lardner LLP and Mewburn Ellis LLP described in Section 7(d),
      7(e), 7(f), 7(g) and 7(h) above shall be rendered to the Underwriters at the request of the Company and shall so state therein.</div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received, on each of the date
        hereof and the Closing Date, a letter dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Underwriters, from PricewaterhouseCoopers SA, independent public accountants, containing statements and
        information of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and the
        Prospectus; <font style="font-style: italic;">provided</font> that the letter delivered on the Closing Date shall use a &#8220;cut&#8209;off date&#8221; not earlier than two business days prior to the date thereof.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">27</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The &#8220;lock-up&#8221; agreements, each substantially in the form of
        Exhibit A hereto, among Morgan Stanley &amp; Co. LLC, BofA Securities, Inc. and certain shareholders, officers and directors of the Company relating to sales and certain other dispositions of Common Shares or certain other securities, delivered to
        the Representatives on or before the date hereof, shall be in full force and effect on the Closing Date.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Underwriters shall have received certificates from the
        Chief Financial Officer of the Company, dated the date hereof, the Closing Date and the Option Closing Date, in form and substance reasonably satisfactory to the Representatives, on such matters as indicated and substantially in the form and
        substance set forth in Exhibit D hereto.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The several obligations of the Underwriters to purchase
        Additional Shares hereunder are subject to the delivery to the Representatives on the applicable Option Closing Date of the following:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160; &#160; &#160; &#160; &#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">a certificate, dated the Option Closing Date and
        signed by an executive officer of the Company, confirming that the certificate delivered on the Closing Date pursuant to Section 7(b) hereof remains true and correct as of such Option Closing Date;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">an opinion of Davis Polk &amp; Wardwell LLP,
        outside counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 7(d) hereof;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">an opinion of Homburger AG, Swiss counsel for the
        Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 7(e) hereof;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">an opinion of Hyman, Phelps &amp; McNamara P.C.,
        outside regulatory counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 7(f) hereof;</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">28</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-family: 'Times New Roman', Times, serif;">an opinion of Foley &amp; Lardner LLP, outside
        intellectual property counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 7(g) hereof;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(vi)</font>&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">an opinion of Mewburn Ellis LLP, outside
        intellectual property counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 7(h) hereof;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(vii)</font>&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">an opinion of Cooley LLP, counsel for the
        Underwriters, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 7(i) hereof;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(viii)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">a letter dated the Option Closing Date, in form and
        substance satisfactory to the Underwriters, from PricewaterhouseCoopers SA, independent public accountants, substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section 7(j) hereof; provided that the
        letter delivered on the Option Closing Date shall use a &#8220;cut-off date&#8221; not earlier than two business days prior to such Option Closing Date;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ix)</font>&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">each of the Representatives, the Capital Increase
        Bank, the share registrar of the Company, Homburger AG and Lenz &amp; Staehelin shall have received pdf-copies of, (A) the certified excerpt of the journal entry (<font style="font-style: italic;">Tagebuch</font>) or the certified excerpt from the
        Commercial Register of the Canton of Vaud evidencing the Over-Allotment Capital Increase, (B)&#160; the certified updated articles of association of the Company evidencing the Over-Allotment Capital Increase and (C)&#160; the Company&#8217;s book of uncertificated
        securities (<font style="font-style: italic;">Wertrechtebuch</font>) duly signed by the Company&#8217;s share registrar and evidencing Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters in proportion of their respective holdings
        set out in Schedule I hereto, as first holder of the Applicable Additional Shares and, if the Shares of the Company are not already listed, (D) a copy of the share register (<font style="font-style: italic;">Aktienbuch</font>) of the Company
        evidencing the Underwriters as shareholders with respect to the Applicable Additional Shares; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(x)</font>&#160;&#160; &#160; &#160;&#160; &#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">such other documents as the Representatives may
        reasonably request with respect to the good standing (to the extent this concept applies) of the Company, the due authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance
        of such Additional Shares.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">29</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Covenants of the Company</font>.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160; </sup>The Company covenants with each Underwriter as follows:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">To take all steps reasonably required to implement the Firm
        Capital Increase and any Over-Allotment Capital Increase.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company undertakes to keep an uncertificated securities
        book (<font style="font-style: italic;">Wertrechtebuch</font>) in accordance with article 973c paragraph 2 CO.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">To furnish to the Representatives, without charge, four
        signed copies of the Registration Statement (including exhibits thereto) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto) and to furnish to the Representatives in New York City,
        without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section 8(i) or 8(j) below, as many copies of the Time of Sale Prospectus, the Prospectus and
        any supplements and amendments thereto or to the Registration Statement as the Representatives may reasonably request.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">All sums payable by the Company under this Agreement shall be
        paid free and clear of and without deductions or withholdings of any present or future taxes or duties, unless the deduction or withholding is required by law, in which case the Company shall pay such additional amount as will result in the receipt
        by each Underwriter of the full amount that would have been received had no deduction or withholding been made.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">All sums payable to an Underwriter shall be considered
        exclusive of any value added or similar taxes.&#160; Where the Company is obliged to pay value added or similar tax on any amount payable hereunder to an Underwriter, the Company shall in addition to the sum payable hereunder pay an amount equal to any
        applicable value added or similar tax.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Before amending or supplementing the Registration Statement,
        the Time of Sale Prospectus or the Prospectus, to furnish to the Representatives a copy of each such proposed amendment or supplement and not to file or publish any such proposed amendment or supplement to which the Representatives reasonably
        object, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">To furnish to the Representatives a copy of each proposed
        free writing prospectus to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which the Representatives reasonably object.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Not to take any action that would result in an Underwriter or
        the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file
        thereunder.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">30</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">If the Time of Sale Prospectus is being used to solicit
        offers to buy the Shares at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to
        make the statements therein, in the light of the circumstances under which they were made, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in
        the Registration Statement then on file, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and
        furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the
        light of the circumstances when the Time of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or so
        that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">If, during such period after the first date of the public
        offering of the Shares as in the opinion of counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with sales by an Underwriter
        or dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the
        notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law,
        forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses the Representatives will furnish to the Company) to which Shares may have been sold by the
        Representatives on behalf of the Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the
        circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">To endeavor to qualify the Shares for offer and sale under
        the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request; <font style="font-style: italic;">provided</font>, however, that nothing contained herein shall require the Company to qualify to do business in
        any jurisdiction, to execute or file a general consent to serve of process in any jurisdiction or to subject itself to taxation in any jurisdiction in which it is not otherwise subject.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">31</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">To make generally available to the Company&#8217;s shareholders and
        to the Representatives as soon as practicable an earning statement covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of
        Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">To comply with all applicable securities and other laws,
        rules and regulations in each jurisdiction in which the Directed Shares are offered in connection with the Directed Share Program.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(n)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Whether or not the transactions contemplated in this
        Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company&#8217;s counsel and
        the Company&#8217;s accountants in connection with the registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary
        prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated
        therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) all costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes payable thereon, </font><font style="font-family: 'Times New Roman', Times, serif;">(iii) the reasonable, documented cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares under state securities
        laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities laws as provided in Section 8(k) hereof, including filing fees and the reasonable, documented fees and disbursements of counsel for
        the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, </font><font style="font-family: 'Times New Roman', Times, serif;">(iv) all filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering of the Shares by the Financial Industry Regulatory Authority
        (provided that the amount payable by the Company with respect to fees and disbursements of counsel for the Underwriters pursuant to subsections (iii) and (iv) shall not exceed $35,000), </font><font style="font-family: 'Times New Roman', Times, serif;">(v) all fees and expenses in connection with the preparation and filing of the registration statement on Form 8&#8209;A relating to the Shares and all costs and expenses incident
        to listing the Shares on NYSE and other national securities exchanges and foreign stock exchanges, </font><font style="font-family: 'Times New Roman', Times, serif;">(vi) the cost
        of printing certificates representing the Shares, </font><font style="font-family: 'Times New Roman', Times, serif;">(vii) the costs and charges of any transfer agent, registrar or
        depositary, </font><font style="font-family: 'Times New Roman', Times, serif;">(viii) the costs and expenses of the Company relating to investor presentations on any &#8220;<font style="font-weight: bold;">road show</font>&#8221; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses
        associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives
        and officers of the Company and any such consultants, fifty percent (50%) of the cost of any aircraft chartered in connection with the road show to be used by both the Company and Underwriters (the remaining fifty percent (50%) of the cost of such
        aircraft to be paid by the Underwriters), </font><font style="font-family: 'Times New Roman', Times, serif;">(ix) the document production charges and expenses associated with
        printing this Agreement , </font><font style="font-family: 'Times New Roman', Times, serif;">(x) all fees and disbursements of counsel incurred by the Underwriters in connection
        with the Directed Share Program and stamp duties, similar taxes or duties or other taxes, if any, incurred by the Underwriters in connection with the Directed Share Program and </font><font style="font-family: 'Times New Roman', Times, serif;">(xi) all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section.&#160; It is understood,
        however, that except as provided in this Section, Section 10 entitled &#8220;Indemnity and Contribution&#8221; , Section 11 entitled &#8220;Directed Share Program Indemnification&#8221; and the last paragraph of Section 14 below, the Underwriters will pay all of their
        costs and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any offers they may make and all travel and other expenses of the
        Underwriters or any of their employees incurred by them in connection with participation in investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the offering of the shares, other than the cost of aircraft
        chartered in connection with the road show, for which the Underwriters agree to pay for the other fifty percent (50%) not paid for by the Company, as described above.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">32</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(o)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company will promptly notify the Representatives if the
        Company ceases to be an Emerging Growth Company at any time prior to the later of (a) completion of the distribution of the Shares within the meaning of the Securities Act and (b) completion of the Restricted Period (as defined in this Section 8).</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(p)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">If at any time following the distribution of any Written
        Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state
        a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at
        its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">33</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(q)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company will deliver to each Underwriter (or its agent),
        on the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company undertakes to provide such
        additional supporting documentation as each Underwriter may reasonably request in connection with the verification of the foregoing Certification.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The Company shall pay, and shall indemnify and hold the Underwriters harmless against, any stamp, issue, registration, documentary, sales, transfer or other similar taxes or
      duties imposed under the laws of Switzerland or any political sub-division or taxing authority thereof or therein that is payable in connection with (i) the execution, delivery, consummation or enforcement of this Agreement, (ii) the creation,
      allotment and issuance of the Shares or (iii) the sale and delivery of the Shares to the Underwriters or purchasers procured by the Underwriters.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The Company also covenants with each Underwriter that, without the prior written consent of the Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. on behalf of the
      Underwriters, it will not, during the period ending 180 days after the date of the Prospectus (the &#8220;<font style="font-weight: bold;">Restricted Period</font>&#8221;), (1) issue, offer, pledge, sell, contract to sell, sell any option or contract to
      purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, grant any instruction rights pursuant to article 25 of the Swiss Federal Act on Intermediated Securities (<font style="font-style: italic;">Weisungsrechte</font>)
      or otherwise transfer or dispose of (or publically announce any such issuance, offer, sale or disposal), directly or indirectly, any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares or (2) enter into
      any swap, hedge or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Shares, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of
      Common Shares or such other securities, in cash or otherwise, (3) file any registration statement with the Commission relating to the offering of any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares or
      (4) announce its intention to do any of the foregoing.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The restrictions contained in the preceding paragraph shall not apply to (a) the Shares to be sold hereunder, (b) the issuance by the Company of Common Shares upon the
      exercise of an option or warrant or the conversion of a security outstanding on the date hereof of which the Underwriters have been advised in writing, (c) grants or settlement of options, restricted shares or restricted share units to officers,
      directors, employees and consultants of the Company or its subsidiaries in accordance with the terms of any incentive compensation plan in effect or approved by the Board of Directors of the Company on the date hereof and described in the Time of
      Sale Prospectus or the issuance by the Company of Common Shares upon the exercise of options outstanding on the date hereof or the filing by the Company of a registration statement with the Commission on Form S-8 in connection therewith; (d) offers
      to acquire, transfers, issuances or repurchase under or pursuant to the loan settlement agreements, including the transfer of Common Shares to the Company in connection therewith, as described in each of the Registration Statement, the Prospectus or
      the Time of Sale Prospectus (e) the offer or issuance by the Company of Common Shares in connection with an acquisition, joint venture, commercial or collaborative relationship or the acquisition or license by the Company of the securities, business,
      property or other assets of another person or entity or pursuant to any employee benefit plan as assumed by the Company in connection with any such acquisition (provided that the aggregate number of Common Shares that the Company may offer or issue
      pursuant to this clause (e) shall not exceed 5% of the total number of Common Shares issued and outstanding immediately following the completion of the transactions contemplated by this Agreement), or (f) the establishment of a trading plan pursuant
      to Rule 10b5-1 under the Exchange Act for the transfer of Common Shares or other securities; <font style="font-style: italic;">provided</font> that in the case of any transfer, distribution, offer or issuance pursuant to clause (e), any recipient of
      Common Shares pursuant to clause (e)<font style="font-weight: bold;">&#160;</font>shall enter into a written agreement substantially in the form of Exhibit A hereto, and in the case of clause (f), (i) such plan does not provide for the transfer of Common
      Shares or other securities during the Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such
      announcement or filing shall include a statement to the effect that no transfer of Common Shares or other securities may be made under such plan during the Restricted Period. If the Representatives agree to release or waive the restrictions set forth
      in a lock-up letter described in Section 7(k) hereof for an officer or director of the Company and provides the Company with notice of the impending release or waiver at least three business days before the effective date of the release or waiver,
      the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit B hereto through a major news service at least two business days before the effective date of the release or waiver.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">34</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Covenants of the Underwriters</font>.&#160; Each
        Underwriter severally covenants with the Company not to take any action that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that
        otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Indemnity and Contribution</font>.&#160; (a) The
        Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act and each affiliate of any Underwriter
        within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or
        investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any
        amendment or supplement thereto, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act,
        any road show as defined in Rule 433(h) under the Securities Act (a &#8220;<font style="font-weight: bold;">road show</font>&#8221;), or the Prospectus or any amendment or supplement thereto, or any Written Testing-the-Waters Communication caused by any
        omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue
        statement or omission or alleged untrue statement or omission based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">35</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Each Underwriter agrees, severally and not jointly, to
        indemnify and hold harmless the Company, its directors, its officers who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange
        Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives
        expressly for use in the Registration Statement, or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus, road show or the Prospectus or any
        amendment or supplement thereto, or any Written Testing-the-Waters Communication.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">In case any proceeding (including any governmental
        investigation) shall be instituted involving any person in respect of which indemnity may be sought pursuant to Section 10(a) or 10(b), such person (the &#8220;<font style="font-weight: bold;">indemnified party</font>&#8221;) shall promptly notify the person
        against whom such indemnity may be sought (the &#8220;<font style="font-weight: bold;">indemnifying party</font>&#8221;) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the
        indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred, documented fees and disbursements of such counsel related to such proceeding.&#160; In any
        such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall
        have mutually agreed in writing to the retention of such counsel or </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) the named parties to any such proceeding
        (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them or (iii) the
        indemnified party shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party.&#160; It is understood that the indemnifying party shall not, in
        respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all
        such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred.&#160; Such firm shall be designated in writing by Morgan Stanley, in the case of parties indemnified pursuant to Section 10(a), and by the Company, in
        the case of parties indemnified pursuant to Section 10(b).&#160; The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for
        the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment.&#160; Notwithstanding the foregoing sentence, if at any time an indemnified party shall have
        requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any
        proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified
        party in accordance with such request prior to the date of such settlement.&#160; No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which
        any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are
        the subject matter of such proceeding and does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">36</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">To the extent the indemnification provided for in Section
        10(a) or 10(b) is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party
        thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities </font><font style="font-family: 'Times New Roman', Times, serif;">(i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) if the allocation provided by clause 10(d)(i) above is not permitted by applicable law, in such proportion as is
        appropriate to reflect not only the relative benefits referred to in clause 10(d)(i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection with the statements or omissions that
        resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.&#160; The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering
        of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the
        Underwriters, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the Shares.&#160; The relative fault of the Company on the one hand and the Underwriters on the other hand shall be
        determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and
        the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.&#160; The Underwriters&#8217; respective obligations to contribute pursuant to this Section 10 are several in proportion to the
        respective number of Shares they have purchased hereunder, and not joint.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">37</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company and the Underwriters agree that it would not be
        just or equitable if contribution pursuant to this Section 10 were determined by <font style="font-style: italic;">pro rata</font> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of
        allocation that does not take account of the equitable considerations referred to in Section 10(d).&#160; The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 10(d) shall be
        deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.&#160; Notwithstanding the provisions of this
        Section 10, no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages
        that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.&#160; No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
        Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.&#160; The remedies provided for in this Section 10 are not exclusive and shall not limit any rights or remedies which may otherwise be
        available to any indemnified party at law or in equity.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The indemnity and contribution provisions contained in this
        Section 10 and the representations, warranties and other statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of </font><font style="font-family: 'Times New Roman', Times, serif;">(i) any termination of this Agreement, </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) any
        investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and </font><font style="font-family: 'Times New Roman', Times, serif;">(iii) acceptance of and payment for any of the Shares.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Directed Share Program Indemnification.</font>&#160;
        (a) The Company agrees to indemnify and hold harmless Morgan Stanley, each person, if any, who controls Morgan Stanley within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act and each affiliate of Morgan
        Stanley within the meaning of Rule 405 of the Securities Act (&#8220;<font style="font-weight: bold;">Morgan Stanley Entities</font>&#8221;) from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other
        expenses reasonably incurred in connection with defending or investigating any such action or claim)&#160; </font><font style="font-family: 'Times New Roman', Times, serif;">(i) caused
        by any untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for distribution to Participants in connection with the Directed Share Program or caused by any omission
        or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii) caused by the failure of any Participant to pay for and accept delivery of Directed Shares that the
        Participant agreed to purchase; or iii) related to, arising out of, or in connection with the Directed Share Program, other than losses, claims, damages or liabilities (or expenses relating thereto) that are finally judicially determined to have
        resulted from the bad faith or gross negligence of Morgan Stanley Entities.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">38</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">In case any proceeding (including any governmental
        investigation) shall be instituted involving any Morgan Stanley Entity in respect of which indemnity may be sought pursuant to Section 11(a), the Morgan Stanley Entity seeking indemnity, shall promptly notify the Company in writing and the Company,
        upon request of the Morgan Stanley Entity, shall retain counsel reasonably satisfactory to the Morgan Stanley Entity to represent the Morgan Stanley Entity and any others the Company may designate in such proceeding and shall pay the fees and
        disbursements of such counsel related to such proceeding.&#160; In any such proceeding, any Morgan Stanley Entity shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Morgan Stanley
        Entity unless (i) the Company shall have agreed to the retention of such counsel or </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) the named parties to any
        such proceeding (including any impleaded parties) include both the Company and the Morgan Stanley Entity and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them.&#160; The
        Company shall not, in respect of the legal expenses of the Morgan Stanley Entities in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to
        any local counsel) for all Morgan Stanley Entities.&#160; Any such separate firm for the Morgan Stanley Entities shall be designated in writing by Morgan Stanley.&#160; The Company shall not be liable for any settlement of any proceeding effected without its
        written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the Company agrees to indemnify the Morgan Stanley Entities from and against any loss or liability by reason of such settlement or judgment.&#160;
        Notwithstanding the foregoing sentence, if at any time a Morgan Stanley Entity shall have requested the Company to reimburse it for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the Company agrees
        that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Company of the aforesaid request and (ii) the Company shall not have
        reimbursed the Morgan Stanley Entity in accordance with such request prior to the date of such settlement.&#160; The Company shall not, without the prior written consent of Morgan Stanley, effect any settlement of any pending or threatened proceeding in
        respect of which any Morgan Stanley Entity is or could have been a party and indemnity could have been sought hereunder by such Morgan Stanley Entity, unless such settlement includes an unconditional release of the Morgan Stanley Entities from all
        liability on claims that are the subject matter of such proceeding.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">39</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">To the extent the indemnification provided for in Section
        11(a) is unavailable to a Morgan Stanley Entity or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then the Company in lieu of indemnifying the Morgan Stanley Entity thereunder, shall contribute to the
        amount paid or payable by the Morgan Stanley Entity as a result of such losses, claims, damages or liabilities </font><font style="font-family: 'Times New Roman', Times, serif;">(i)
        in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Morgan Stanley Entities on the other hand from the offering of the Directed Shares or </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) if the allocation provided by clause 11(c)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
        relative benefits referred to in clause 11(c)(i) above but also the relative fault of the Company on the one hand and of the Morgan Stanley Entities on the other hand in connection with any statements or omissions that resulted in such losses,
        claims, damages or liabilities, as well as any other relevant equitable considerations.&#160; The relative benefits received by the Company on the one hand and the Morgan Stanley Entities on the other hand in connection with the offering of the Directed
        Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Directed Shares (before deducting expenses) and the total underwriting discounts and commissions received by the Morgan Stanley Entities
        for the Directed Shares, bear to the aggregate Public Offering Price of the Directed Shares.&#160; If the loss, claim, damage or liability is caused by an untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
        a material fact, the relative fault of the Company on the one hand and the Morgan Stanley Entities on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement or the omission or alleged
        omission relates to information supplied by the Company or by the Morgan Stanley Entities and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">40</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company and the Morgan Stanley Entities agree that it
        would not be just or equitable if contribution pursuant to this Section 11 were determined by <font style="font-style: italic;">pro rata</font> allocation (even if the Morgan Stanley Entities were treated as one entity for such purpose) or by any
        other method of allocation that does not take account of the equitable considerations referred to in Section 11(c).&#160; The amount paid or payable by the Morgan Stanley Entities as a result of the losses, claims, damages and liabilities referred to in
        the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by the Morgan Stanley Entities in connection with investigating or defending any such action
        or claim.&#160; Notwithstanding the provisions of this Section 11, no Morgan Stanley Entity shall be required to contribute any amount in excess of the amount by which the total price at which the Directed Shares distributed to the public were offered
        to the public exceeds the amount of any damages that such Morgan Stanley Entity has otherwise been required to pay.&#160; The remedies provided for in this Section 11 are not exclusive and shall not limit any rights or remedies which may otherwise be
        available to any indemnified party at law or in equity.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The indemnity and contribution provisions contained in this
        Section 11 shall remain operative and in full force and effect regardless of </font><font style="font-family: 'Times New Roman', Times, serif;">(i) any termination of this
        Agreement, </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) any investigation made by or on behalf of any Morgan Stanley Entity or the Company, its officers
        or directors or any person controlling the Company and </font><font style="font-family: 'Times New Roman', Times, serif;">(iii) acceptance of and payment for any of the Directed
        Shares.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">41</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Termination</font>.&#160; The Underwriters may
        terminate this Agreement by notice given by the Representatives to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on, or by, as
        the case may be, the SIX Swiss Exchange, NYSE, the NYSE MKT, or the Nasdaq Global Market (ii) trading of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption in
        securities settlement, payment or clearance services in the United States or Switzerland shall have occurred, (iv) any moratorium on commercial banking activities shall have been declared by Federal, New York State, in Switzerland or relevant
        foreign country authorities or (v) there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any calamity or crisis that, in the Representatives&#8217; judgment, is material and adverse and which, singly
        or together with any other event specified in this clause (v), makes it, in the Representatives&#8217; judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated in the
        Time of Sale Prospectus or the Prospectus.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Effects of Termination on Shares</font>.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 90pt;"><font style="font-family: 'Times New Roman', Times, serif;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">If, after application and registration of the Firm Capital Increase or any
        Over-Allotment Capital Increase with the Commercial Register of the Canton of Vaud pursuant to Section 5(c) or Section 6(b), prior to the Closing Date or the relevant Option Closing Date, as the case may be, this Agreement is terminated pursuant to
        Section 12, or if the delivery of the Firm Shares or Applicable Additional Shares to Morgan Stanley &amp; Co. LLC acting on behalf and for the account of the several Underwriters is not completed on the Closing Date or the relevant Option Closing
        Date, as the case may be (each, an<font style="font-weight: bold;"> &#8220;Event of Non-Completion</font>&#8221;), and unless the Company and the Representatives, acting on behalf of the several Underwriters, otherwise agree within ten calendar days after the
        Event of Non-Completion, then:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">the Company shall have a call option pursuant to
        Section 13(b);</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">if the call option is not exercised, the
        Representatives acting on behalf of the several Underwriters shall have a put option against the Company pursuant to Section 13(c);</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">if the put option is not possible for legal reasons
        or insufficient to dispose of the Firm Shares or Applicable Additional Shares, as applicable, or if such put option is not exercised within the deadline set forth in Section 13(c), the Company shall effect a capital reduction pursuant to Section
        13(d); and</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">42</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">if the capital reduction is not effected in
        accordance with Section 13(d), the Underwriters may sell the Firm Shares or Applicable Additional Shares, as applicable, in the market as provided in Section 13(e).</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Call Option.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company, acting on its own behalf or on behalf
        of third parties, shall have the right (the &#8220;<font style="font-weight: bold;">Call Option</font>&#8221;) to request in writing that Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters, delivers the Firm Shares or Applicable
        Additional Shares, as applicable, to an account specified by the Company against payment of an amount representing the aggregate nominal value of the respective Firm Shares or Applicable Additional Shares, as applicable, plus expenses of the
        Representatives as set out in Section 13(f).&#160; The Call Option shall expire on the tenth calendar day after the Event of Non-Completion.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">An acquisition of the Firm Shares or Applicable
        Additional Shares, as applicable, by the Company for its own account shall only be permitted if the Company has delivered evidence to the Representatives reasonably satisfactory to the Representatives that the Company has sufficient freely
        available reserves to acquire the Firm Shares or Applicable Additional Shares, as applicable, under this Section 13(b) or, alternatively, that the Company has entered into arrangements with a third party other than any of the Company&#8217;s subsidiaries
        ensuring for the immediate on-sale of the Firm Shares or Applicable Additional Shares, as applicable, to such third party, at no less than their nominal value, on the date of acquisition of the Firm Shares or Applicable Additional Shares, as
        applicable, by the Company.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Put Option.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Following the expiry of the Call Option pursuant to
        Section 13(b), the Representatives, acting on behalf of the several Underwriters, shall have an option (the &#8220;<font style="font-weight: bold;">Put Option</font>&#8221;) to require the Company, subject to article 659 CO, to purchase all Firm Shares or
        Applicable Additional Shares, as applicable, entered in the Commercial Register of the Canton of Vaud at their nominal value, plus expenses of the Representatives as set out in Section 13(f), within ten (10) calendar days after receipt of a notice
        in writing addressed to the Company from the Representatives, stating that the Representatives exercises the Put Option.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The notice in which the Representatives exercise
        the Put Option shall specify the date on which the Representatives will deliver the Firm Shares or Applicable Additional Shares, as applicable, to the Company against direct payment therefor, and shall contain detailed instructions regarding
        payment and delivery of the Firm Shares or Applicable Additional Shares, as applicable, and amount payable (including satisfactory details regarding the costs claimed according to Section 13(f) subject to an agreement to the contrary by the
        Representatives with the Company).</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">43</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Capital Reduction.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">If the Put Option is not exercised within the
        deadline set forth in Section 13(c) or exercise or settlement of the Put Option is not possible for legal reasons or insufficient to dispose of the Firm Shares or Applicable Additional Shares, as applicable, the Company shall immediately call a
        shareholders&#8217; meeting and table the reduction of the share capital.&#160; Such shareholders&#8217; meeting shall take place no later than sixty (60) calendar days after the Event of Non-Completion . The Representatives acting on behalf of the several
        Underwriters, will vote in favor of a reduction of the issued and outstanding share capital of the Company (the &#8220;<font style="font-weight: bold;">Capital Reduction</font>&#8221;) by cancellation of the Firm Shares or Applicable Additional Shares, as
        applicable, entered in the Commercial Register of the Canton of Vaud against repayment of the aggregate nominal value of such securities to Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters.&#160; Prior to such shareholders&#8217;
        meeting, the Company shall use its best efforts to cause its auditors to confirm in writing, pursuant to article 732 para. 2 CO, that the claims of the Company&#8217;s creditors are fully covered notwithstanding the Capital Reduction, provided that if
        such confirmation is not made by the auditors prior to such meeting, the meeting shall be cancelled.&#160; The Company shall use its best efforts to cause its shareholders to vote in favor of the Capital Reduction.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">At the earliest possible date, and subject to
        statutory law, the Capital Reduction shall be consummated by registration in the Commercial Register of the Canton of Vaud.&#160; The proceeds of the Capital Reduction, being an amount representing the aggregate nominal value of the Firm Shares or
        Applicable Additional Shares, as applicable, shall be paid (for value on the date of the entry in the Commercial Register of the Canton of Vaud) in cash to Morgan Stanley &amp; Co. LLC, acting on behalf of the several Underwriters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">Upon consummation of the Capital Reduction, the
        Company shall deregister the Firm Shares or Applicable Additional Shares, as applicable, in its book of uncertificated securities (<font style="font-style: italic;">Wertrechtebuch</font>) to reflect the number of Common Shares registered with the
        Commercial Register of the Canton of Vaud.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Sale of Firm Shares or Applicable Additional Shares.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">44</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 90pt; font-family: 'Times New Roman', Times, serif;">In addition, if an Event of Non-Completion occurs and,</div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">the Company fails to acquire or cause a third party
        to acquire the Firm Shares or Applicable Additional Shares, as applicable, in accordance with Section 13(b) within ten (10) calendar days after the Event of Non-Completion; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">in the event and to the extent the Put Option has
        not been exercised within the deadline set forth in Section 13(c) and settled or the exercise or settlement of the Put Option is not possible for legal reasons or insufficient to dispose of the Firm Shares or Applicable Additional Shares, as
        applicable; and</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">the Capital Reduction has not been resolved by the
        shareholders&#8217; meeting of the Company within sixty (60) days after the Event of Non-Completion, or such longer period as may be agreed between the Company and the Representative;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">then</font> the Representatives, acting on behalf of the several Underwriters, are entitled to sell any or all Firm
      Shares or Applicable Additional Shares on the open market on terms which the Representatives deem fit under the circumstances.&#160; The difference between the proceeds of such sale and the nominal value of such Firm Shares or Applicable Additional
      Shares, as applicable, sold, less the costs and expenses pursuant to Section 13(f) reasonably incurred by the Representatives in connection with the sale, if any, shall be transferred to the Company.</div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Costs; Indemnity.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company shall bear (A) all costs directly
        incidental to the Capital Reduction, including but not limited to notarization costs, costs of the Commercial Register and costs of publication of the Capital Reduction and (B) the costs of the Representatives reasonably incurred in connection with
        the Call Option, the Put Option or the Capital Reduction, as applicable (including but not limited to (x) taxes, (y) interest at a rate of the higher of zero or the 3-month CHF LIBOR, calculated on a 30/360 basis, accruing from the Event of
        Non-Completion until the payment of proceeds to the Representatives, acting on behalf of the several Underwriters, and (z) reasonable out of pocket expenses of the Representatives and their counsel).</font></div>
    <div><br>
    </div>
    <div style="text-indent: 57.6pt; margin-left: 75.6pt;"><font style="font-family: 'Times New Roman', Times, serif;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">The Company further undertakes to indemnify the
        Representatives and their affiliates for, and to hold the Representatives and their affiliates harmless from, any reasonable costs, expenses, third party claims and liabilities, actual or contingent, that may be incurred by or made against the
        Representatives and their affiliates in connection with the Capital Reduction.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">45</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Effectiveness; Defaulting Underwriters</font>.&#160;
        This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase Shares that it has or they have
      agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is not more than one&#8209;tenth of the aggregate number of the Shares to be purchased
      on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite their respective names in Schedule I bears to the aggregate number of Firm Shares set forth opposite the names of
      all such non&#8209;defaulting Underwriters, or in such other proportions as the Representatives may specify, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; <font style="font-style: italic;">provided</font> that in no event shall the number of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 14 by an amount in excess of one-ninth of such
      number of Shares without the written consent of such Underwriter.&#160; If, on the Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs
      is more than one&#8209;tenth of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Firm Shares are not made within 36 hours after such default,
      this Agreement shall terminate without liability on the part of any non&#8209;defaulting Underwriter or the Company.&#160; In any such case either the Representatives or the Company shall have the right to postpone the Closing Date, but in no event for longer
      than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected.&#160; If, on an Option Closing Date, any Underwriter
      or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs is more than one&#8209;tenth of the aggregate number of Additional Shares to be purchased on such
      Option Closing Date, the non-defaulting Underwriters shall have the option to (i) terminate their obligation hereunder to purchase the Additional Shares to be sold on such Option Closing Date or (ii) purchase not less than the number of Additional
      Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence of such default.&#160; Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such
      Underwriter under this Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill
      any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with
      respect to themselves, severally, for all documented out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder; <font style="font-style: italic;">provided</font> that, the Company shall not be required to reimburse the Underwriters in the event any such termination is effected pursuant to Section 12(i), (iii), (iv) or (v). In the event any such termination is
      effected after the Closing Date but prior to any settlement date for the Additional Shares, the Company will only reimburse the Underwriters for all documented out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably
      incurred by such Underwriters after the Closing Date in connection with the proposed purchase of such Additional Shares.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">46</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Entire Agreement</font>.&#160; (a) This
        Agreement, together with any contemporaneous written agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and the
        Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the Shares.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Company acknowledges that in connection with the offering
        of the Shares: </font><font style="font-family: 'Times New Roman', Times, serif;">(i) the Underwriters have acted at arm&#8217;s length, are not agents of, and owe no fiduciary duties
        to, the Company or any other person, </font><font style="font-family: 'Times New Roman', Times, serif;">(ii) the Underwriters owe the Company only those duties and obligations set
        forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement), if any, and </font><font style="font-family: 'Times New Roman', Times, serif;">(iii)
        the Underwriters may have interests that differ from those of the Company.&#160; The Company waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in
        connection with the offering of the Shares.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">16.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Counterparts</font>.&#160; This Agreement may be
        signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">17.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Applicable Law</font>.&#160; This Agreement shall
        be governed by and construed in accordance with the internal laws of the State of New York.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">18.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Headings</font>.&#160; The headings of the
        sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of this Agreement.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">19.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Notices.&#160; </font>All communications
        hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed or sent to the Representatives to Morgan Stanley &amp; Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate
        Desk, with a copy to the Legal Department; BofA Securities, Inc., One Bryant Park, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; Cowen and Company, LLC, 599 Lexington Avenue, New York, New York
        10022, Attention: General Counsel; and if to the Company shall be delivered, mailed or sent to ADC Therapeutics SA, Route de la Corniche 3B, 1066 Epalinges, Switzerland, Attention: Dominique Graz.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">47</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">20.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Submission to Jurisdiction</font>.&#160; The
        Company irrevocably submits to the non-exclusive jurisdiction of any New York State or United States Federal court sitting in The City of New York (the &#8220;<font style="font-weight: bold;">Specified Courts</font>&#8221;) over any suit, action or proceeding
        arising out of or relating to this Agreement, the Prospectus, the Registration Statement or the offering of the Shares (each, a &#8220;<font style="font-weight: bold;">Related Proceeding</font>&#8221;).&#160; The Company irrevocably waives, to the fullest extent
        permitted by law, any objection which it may now or hereafter have to the laying of venue of any Related Proceeding brought in such a court and any claim that any such Related Proceeding brought in such a court has been brought in an inconvenient
        forum.&#160; To the extent that the Company has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with respect to itself or its property, the Company
        irrevocably waives, to the fullest extent permitted by law, such immunity in respect of any such suit, action or proceeding.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">21.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Appointment of Agents for Service.&#160; </font>The
        Company hereby irrevocably appoints ADC Therapeutics America, Inc., with offices at 430 Mountain Avenue, 4th Floor, Murray Hill, New Jersey, 07974 as its agent for service of process in any Related Proceeding and agrees that service of process in
        any such Related Proceeding may be made upon it at the office of such agent.&#160; The Company waives, to the fullest extent permitted by law, any other requirements of or objections to personal jurisdiction with respect thereto.&#160; The Company represents
        and warrants that such agent has agreed to act as the Company&#8217;s agent for service of process, and the Company agrees to take any and all action, including the filing of any and all documents and instruments, that may be necessary to continue such
        appointment in full force and effect.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">22.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Judgment Currency</font>.&#160; If for the
        purposes of obtaining judgment in any court it is necessary to convert a sum due hereunder into any currency other than United States dollars, the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be
        the rate at which in accordance with normal banking procedures the Underwriters could purchase United States dollars with such other currency in The City of New York on the business day preceding that on which final judgment is given.&#160; The
        obligation of the Company with respect to any sum due from it to any Underwriter or any person controlling any Underwriter shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first
        business day following receipt by such Underwriter or controlling person of any sum in such other currency, and only to the extent that such Underwriter or controlling person may in accordance with normal banking procedures purchase United States
        dollars with such other currency.&#160; If the United States dollars so purchased are less than the sum originally due to such Underwriter or controlling person hereunder, the Company agrees as a separate obligation and notwithstanding any such
        judgment, to indemnify such Underwriter or controlling person against such loss.&#160; If the United States dollars so purchased are greater than the sum originally due to such Underwriter or controlling person hereunder, such Underwriter or controlling
        person agrees to pay to the Company an amount equal to the excess of the dollars so purchased over the sum originally due to such Underwriter or controlling person hereunder.</font></div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">48</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">23.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Taxes.&#160; </font>If any sum payable by the
        Company to the Underwriter under this Agreement is subject to deduction or withholding, under Swiss law, the sum payable to the Underwriter under this Agreement shall be increased to such sum as will ensure that the Underwriter shall be left with
        the sum it would have had in the absence of such deduction or withholding, provided that no such additional amounts shall be payable as a result of any taxes imposed on the Underwriter by virtue of the Underwriter having or being deemed to have a
        permanent establishment in, or other connection with, Switzerland other than solely by reason of execution and delivery of this Agreement, the performance by the Underwriter of its obligations hereunder, the consummation of the transactions
        contemplated hereby and the enforcement of the rights with respect to the foregoing.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 46.8pt;"><font style="font-family: 'Times New Roman', Times, serif;">24.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Recognition of the U.S. Special Resolution
          Regimes</font>.&#160; (a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or
        under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a
        state of the United States.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 54pt; margin-left: 36pt;"><font style="font-family: 'Times New Roman', Times, serif;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">In the event that any Underwriter that is a Covered Entity or
        a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent
        than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">For purposes of this Section: (i) a &#8220;<font style="font-weight: bold;">BHC Act Affiliate</font>&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted
      in accordance with, 12 U.S.C. &#167; 1841(k); (ii) &#8220;<font style="font-weight: bold;">Covered Entity</font>&#8221; means any of the following: (A) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (B) a
      &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (C) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); (iii) &#8220;<font style="font-weight: bold;">Default
        Right</font>&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (iv) &#8220;<font style="font-weight: bold;">U.S. Special Resolution Regime</font>&#8221; means each of
      (A) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (B) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[Signature Pages Follow]</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">49</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z6a7d2a8abd954a0b84c598ca8484f573" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="3" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="3" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">ADC Therapeutics SA</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">50</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Accepted as of the date hereof</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC</div>
    <div style="font-family: 'Times New Roman', Times, serif;">BofA Securities, Inc.</div>
    <div style="font-family: 'Times New Roman', Times, serif;">Cowen and Company, LLC</div>
    <div><br>
    </div>
    <div style="text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif;">Acting severally on behalf of themselves and the several<br>
      Underwriters named in Schedule I hereto</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z545c2e0f29534efc886c5a0709232094" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">BofA Securities, Inc.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Cowen and Company, LLC</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">51</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%I-%%-->
    <div><br>
    </div>
    <div style="text-align: right; margin-left: 346.3pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SCHEDULE I</div>
    <div style="text-align: right; margin-left: 346.3pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
    </div>
    <table id="z8be2853663484c5a82bfec604620d5f7" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 86%;">
            <div style="font-family: &#38;amp; font-weight: bold;">Underwriter</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 2%;">&#160;</td>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; width: 12%;">
            <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Number of Firm Shares<br>
              To Be Purchased</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 86%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255);">
            <div style="font-family: &#38;amp;">[&#9679;]</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 86%; background-color: rgb(255, 255, 255);">
            <div style="font-family: 'Times New Roman', Times, serif;">BofA Securities, Inc.</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 2%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(255, 255, 255);">
            <div style="font-family: &#38;amp;">[&#9679;]</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 86%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman', Times, serif;">Cowen and Company, LLC.</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255);">
            <div style="font-family: &#38;amp;">[&#9679;]</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; padding-bottom: 2px; width: 86%; background-color: rgb(255, 255, 255);">
            <div style="font-family: 'Times New Roman', Times, serif;">[&#9679;]</div>
          </td>
          <td colspan="1" style="vertical-align: top; padding-bottom: 2px; width: 2%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); width: 12%; background-color: rgb(255, 255, 255);">
            <div style="font-family: &#38;amp;">[&#9679;]</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 86%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
            <div style="font-family: 'Times New Roman',Times,serif; margin-left: 27pt;">Total:</div>
          </td>
          <td colspan="1" style="vertical-align: top; width: 2%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; width: 12%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
            <div style="font-family: &#38;amp;">[&#9679;]</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">I-1</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%II-%%-->
    <div><br>
    </div>
    <div style="text-align: right; margin-left: 346.3pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SCHEDULE II</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Time of Sale Prospectus</div>
    <div><br>
    </div>
    <div>
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1a2f24c53314fd8af78d3c43d13faae" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">1.</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Preliminary Prospectus issued [&#9679;]</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcce2094f1d4d4e3da3b8a45417d10124" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">2.</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Price per share to the public: $[&#9679;]</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Number of shares offered: [&#9679;]</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Underwriters&#8217; option to purchase additional shares: [&#9679;]</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">II-1</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%III-%%-->
    <div><br>
    </div>
    <div style="text-align: right; margin-left: 346.3pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SCHEDULE III</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Written Testing-the-Waters Communications</div>
    <div><br>
    </div>
    <div>
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5069653614604eafab1b53008c901cd4" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">1.</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-family: 'Times New Roman', Times, serif;">Testing-the-Waters presentation dated [&#9679;]</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">III-1</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%A-%%-->
    <div><br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-weight: bold;">EXHIBIT A</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">FORM OF LOCK-UP LETTER</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">A-1</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%B-%%-->
    <div><br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-weight: bold;">EXHIBIT B</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">FORM OF WAIVER OF LOCK-UP</div>
    <div><br>
    </div>
    <div style="margin-left: 216pt; font-family: 'Times New Roman', Times, serif;">_____________, 20__</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">[Name and Address of</div>
    <div style="font-family: 'Times New Roman', Times, serif;">Officer or Director</div>
    <div style="font-family: 'Times New Roman', Times, serif;">Requesting Waiver]</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Dear Mr./Ms. [Name]:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">This letter is being delivered to you in connection with the offering by ADC Therapeutics SA (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) of _____ common shares,&#160;
      nominal value CHF [&#9679;] per&#160; share&#160; (the &#8220;<font style="font-weight: bold;">Common Shares</font>&#8221;), of the Company and the lock-up letter dated ____, 2019 (the &#8220;<font style="font-weight: bold;">Lock-up Letter</font>&#8221;), executed by you in connection with
      such offering, and your request for a [waiver] [release] dated ____, 2019, with respect to ____ Common Shares (the &#8220;<font style="font-weight: bold;">Shares</font>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. hereby agree to [waive] [release] the transfer restrictions set forth in the Lock-up Letter, but only with respect to
      the Shares, effective _____, 2019; provided, however, that such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release] by press release through a major news service at least two business days before effectiveness
      of such [waiver] [release].&#160; This letter will serve as notice to the Company of the impending [waiver] [release].</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Except as expressly [waived] [released] hereby, the Lock-up Letter shall remain in full force and effect.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[<font style="font-style: italic;">Signature Page Follows</font>]</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">B-1</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC</div>
    <div style="font-family: 'Times New Roman', Times, serif;">BofA Securities, Inc.</div>
    <div><br>
    </div>
    <div style="text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif;">Acting severally on behalf of themselves and the<br>
      several Underwriters named in Schedule I hereto</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z90a3930781b7405d85c85d3ebbcfbb2e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">BofA Securities, Inc.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">cc:&#160; Company</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">B-2</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">FORM OF PRESS RELEASE</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">ADC Therapeutics SA</div>
    <div style="font-family: 'Times New Roman', Times, serif;">[Date]</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">ADC Therapeutics SA (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) announced today that Morgan Stanley &amp; Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC, the lead
      book-running managers in the Company&#8217;s recent public sale of _____ common shares are [waiving][releasing] a lock-up restriction with respect to ____ shares of the Company&#8217;s common shares held by [certain officers or directors] [an officer or
      director] of the Company.&#160; The [waiver][release] will take effect on ____, 2019, and the shares may be sold on or after such date.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be
      offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">B-3</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%C-%%-->
    <div><br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-weight: bold;">EXHIBIT C</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">[Form of Subscription Form]</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">Referring to the articles of association of ADC Therapeutics SA, with registered office in Epalinges, Canton of Vaud, Switzerland (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;),
      which are known to the undersigned (the &#8220;<font style="font-weight: bold;">Subscriber</font>&#8221;) and which authorize the board of directors of the Company to effect an increase of the Company&#8217;s share capital in a maximum amount of CHF 1,647,000 by
      issuing up to 25,734,375 registered shares with a nominal value of CHF 0.064 each out of the Company&#8217;s authorized share capital, such authorization having been granted by resolution of the shareholders meeting of September 19, 2019, the resolution of
      the board of directors of the Company based on such authorization of [&#9679;], regarding the increase of the Company&#8217;s share capital in the amount of CHF [&#9679;] from CHF 4,267,000 to CHF [&#9679;], as well as the prospectus of the Company dated [&#9679;], the Subscriber
      herewith subscribes&#160; <font style="font-weight: bold;">[&#9679;] registered shares with a nominal value of CHF </font>0.064 <font style="font-weight: bold;">each </font>for a total issue price of CHF [&#9679;] (issue price of CHF 0.064 per share) and herewith
      unconditionally undertakes to make a full contribution in the amount of the total issue price.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">The contribution is made in cash, for [&#9679;] registered shares with a nominal value of CHF 0.064 each and a total issue price of CHF [&#9679;], by depositing the amount of CHF [&#9679;]
      with Credit Suisse (Suisse) SA, in Zug, an institution subjected to the Swiss Federal Act on Banks and Savings Banks.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">This Subscription Form shall be governed by and construed in accordance with the laws of Switzerland (excluding Swiss Private International Law and international treaties, in
      particular the Vienna Convention on the International Sale of Goods dated 11 April 1980). Any dispute arising out of or in connection with this Subscription Form shall be submitted to the exclusive jurisdiction of the courts of the Canton of Vaud,
      Switzerland, subject to an appeal to the Swiss Federal Supreme Court when provided by Swiss law.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">This subscription form is valid until [&#9679;].</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[<font style="font-style: italic;">Signature Page Follows</font>]</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">C-1</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Accepted as of the date hereof</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC</div>
    <div style="font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div><br>
    </div>
    <div style="text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif;">Acting severally on behalf of themselves and the several Underwriters named in Schedule I hereto</div>
    <div style="text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z131bf93f16c54e4db86343b20bb5f9d7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Morgan Stanley &amp; Co. LLC</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 41%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">C-2</font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>nt10002526x6_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 6.3.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: right; font-weight: bold;">Exhibit 23.1</div>
    <div><br>
    </div>
    <div style="text-align: center;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
    <div><br>
    </div>
    <div>We hereby consent to the use in this Registration Statement on Form F-1 of
      ADC Therapeutics SA of our report dated June 27, 2019, except for the effects of the share split discussed in Note 24 to the consolidated financial statements, as to which
        the date is September 19, 2019 relating to the consolidated financial statements of ADC Therapeutics SA, which appears in this Registration Statement. We also
        consent to the reference to us under the heading &#8220;Experts&#8221;<sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>in such Registration Statement.</div>
    <div><br>
    </div>
    <div>/s/ PricewaterhouseCoopers SA</div>
    <div>Lausanne, Switzerland</div>
    <div>September 23, 2019</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo_adc.jpg
<TEXT>
begin 644 logo_adc.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( )@!-@,!(@ "$0$#$0'_Q  ?   " @$% 0$
M    "@@)!P$"! 8+ P7_Q !G$  ! @4!!0(%"@P/#08'   ! @, ! 4&$0<(
M"1(A,1-!%")187$5%B,R-X&1H;'1"A@U0E9R=9*5LK3P%R8S-#A2<Y.EL[7!
MT]3A&20E)S9$4U1B=H*4\2E#155ETCE&5W2#ML+_Q  > 0 " @(# 0$
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MP1\?CILX\DDCRG\:%N]\UJYJ)9.HFF],M6X/4J3F$U/MFO!FW>+A:01XRAD
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MTD6>[.P'Z#=@<O\ P&1_)&8S=%8>4YN\R8<E?BCXPS*QQW+*HHLD!569@J@
M   #8 >@VV]!J[[ ^'SDS8PN)GFY><.22RXVA)+(U0EGD>M"SNQ+DDL26)))
M+>IU2F=RALY<*@)EX$@@$JFC@]QQVO<?FC%UX;C*PYJ1F'+,U <I$^A"U,!4
MBN8"E\RA!*W"!W#)'PQ?[!'PK<Z^:%6194XOR<A4@]-AX[$9VV[-',CJ0=MB
M-NX[:[5WPT<D+T+0R<O<)$&4KUU%L5)5W"C=9:\T;J1M]$@]NWQ.Z.>T_L,Z
MV[+<T9F[*1,5>TG7%B5NB6;XFUH2H)"G)=@+[($D)\<CO,0SCT%M3=-K7U5L
MVM67=U*EJM2*O)/RZFIA"5*;=4VH,.(<4DJ24.E*O%YG !A'?:QT*GMG37.\
MM-)A*S3I&=,Q1WU)(2ZQ.%4SP(/,'LD+2G.3G APN2/.27F%':PV<C@@XBQ\
M L"6NOEP9*H&6-YEAW/ESPLR><BGH8.'15V8:KK\37ATAY03T>(N&9[-K@_+
MV33,-MO.M8;(LAECKO8V!GJ6(UD->20>:C1M'(SDHS1QZY!Z'R_$>_F#S'?%
M[NZ4VTEV*FOZ)Z@5?]+\M3YJ<M":GG\(E5RTN].S#?&X<J#CB4H2%'R 11%'
M(E9R;D70_)3+TJ^ I(=8<6TX$J!2H<2%)5A0)!&>8,2KQQP=CN.>';G#^1 5
M9^B6M9Z \E.W$P:*Q&.QZ@-T<!EZXV9"=CJ"N6/,3,\KN,,;Q;AF9Y*GF0W*
M7F&.'(T)UZ9Z<WJI5OHR(S*WERQHX&XU)[;'U]K6T3KO=UY3\XX]1I6H.R=N
MRI62S*MRRERKRVTYX<.AOBY) /E.8BS&I)42HDDJ)42>9))R23WDDY)[S&D;
MW$8NIA,90Q-")8:>/JPU*\:@ ".% @)V W9R"[GU9V8GUUY7/YO(<29O*Y_*
MSO9R.8O6;]N:1BS--8D:0@%B2$0$1QKZ*BJH   T $E*0%*4M24(0A)6M:UJ
M"4)2E.5**E$  #OBU;9*W5>K.T-3I"\+QF7]/[)G\.R3TQ+)F'Z@T/;'L3P/
M-<L8)'/.<GE&/=V?LU2NT/K_ $]VX9%4[9MDOMS=::4DEE]UQ';2?$?]EY Y
M'D<<\B',Z73)*DR$G3J=+,RDE(R[4K*R\NVEEIMIA"6DX;;"4\TH'=SZG)A<
M.>O.K(\&6X^%N%FBCS#UTLY#(R(DQH1S#J@@KQ.&C]ID3:5Y)%81QL@52S$J
MY/A:\-6(YDT9N.>.4GFX<BMO3Q&'AD>L,K-6*BU:MSQE9?8XI"8$BA9#-*LA
M9PB /31;6Y3V=:6R$5Z9>KLQP86]F98XE\/M^%#G+GDX_LQC[43<>Z8U.1?=
MT\N]VV9]"7%,H5*NS:7%X)0@EUW P<#..GHB^F"%7AYT<SH+(MKQ?E'DWW*3
M2+-7/R->16AZ2.Q4(!I[+/ALY)VJ)H/R^P4<14J):\4M>VNX'TEN12+9ZAMN
M&,A/8;^ITC+M-;$NM>RY/%=Y46:J-KNN+3)W/+-=HTXV@X2IQF7"NR!)2/'(
MZ^G$08]!G4C3:T=4[2JUFWE296KT6K2KLN\S,-)6IM2TJ#;C;A!6@MK/'XI!
M. .8A+W;IV4*KLIZP3]OM-..V17IIV8M.H%!2TI&"_,M9)) ;*@V"LC..6(;
M_DOSL7CYGP&?2"IQ)!$TT$D($=?*P1@&5HXR3Y5J(?2DB7Z#H&>,+TLHKQ\2
M7AG?E.L?%7"LUK(<&6K"5[,-DF:Y@K4W:%)9@H\^A._['#8<>9%*5AE+%D=H
M4@D%"DJ4A;:TN-N()2MMUM7&VM*T^,DI6 KD>>//#*6Z.VX9^ZV&MGG4FK>$
M5JFH2W:-0FW0'*@T IUYOB6?^X:"4)"EG/( =T+6X]'PCYX[KIS?=;TQOJV+
M\M^<<DZG0*I*.(<:<*%&6=F&A-)/"1G+(4.><#R1)7,G@:AQ_P +WL-9CC]L
M6-[&)M$#KJ9"--X65O413':&=1V:-]_ME4B%^37-#*\I^.,7Q'1FD..::*KQ
M!05B(LAB99%%A'3?I,U=3[16D(W25 /M78'T(0<C/Y^GW^L:QA/9YU6I>M.D
M5F:A4A:'):LTN72XI*^/^^95E#,P5')P5/)62#Y8S9%5]RI/0MV:5J-HK-2>
M6M/$PV:.6%S'(C#W%64@ZO<QF0JY;'TLG1F6Q3OU:]RK.AW66O9B2:&13\'1
MP=$$$$=;7>T0000:-$$$$&C1!! 3CF8-&OD^\W+M./.K#;32%NN+40$H;;25
MK62>0"4@F%<-[3MNN:C7+,: :=U4BU:"ZIN[9^2>/!4W58=8;"DX([%U*D$(
M)SW^2++]Y]ML2VSUIQ,V':,\VK4B\I=Z4D^Q=27J:R!PS!<0,A)<86>$KX3W
MCG"BDW-S50FYNH3TPY-3L],/3<U,NK4MQUV8<4\KB4HJ4>%2R!DG'=#?^'#E
M9[5,G'^=K?M>O(5X>K3*")["=GR11AWC@.Z5B>S3=4@^Y#>N[QE<]32@EY3\
M+7/VW;C1^+[E=^]:HX5XL*CJ=Q+;!$MT#NM?HA;[LZCCCD .X?-U])[SWF,G
MZ-Z3W1K=J/;>FUI2;TU4Z].MMN+:05)EI5M:%32G%8*4\3!61Q%.<<HQFVVZ
M\XTRRVMY]]YJ789;25+<>?6&FDI2G*CXZAG Y=\-<[J/8I:T<L)K5N^Z6@:@
MW>RU,2S,PV.VHTN@$-EM1R/[Y86DGVO+/6&/YJ<P:G+SA>SDV9'RMH/4PU1B
M"TUQD.TS+N"8*H(FF/H?H1[[R#2;\BN4M_F]QS2P<:2Q8.BT=_B.^BD+6QL<
M@WKI)MTBU>8>SUU[D;O*1TQ'4^- MGZU]G#0AK3RW)9I"I&V:@Y49M+00]-3
MC\@XZ]VJN:E=FZ5A.5$ 'D!"2^M?NQ:B_=Z<_*WX?RN(8M^N#_T6J_D3T(&Z
MU^[%J+]WIS\K?A?/"Y?MY3.\>9&].]FY=AQ]FS/(>IY9I;D[NS$_$D_(#L.V
MFW\<V)H8+A;E5A\75BI8[&V,K3I585"Q05Z]&G%%&H'_ %54;GWG<ZQG%P^Y
M;_9$5W]R:_)U13Q%P^Y;_9$5W]R:_)U0P?.'[V?&'\DO_:Q:4?P\??LY<_\
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M<JN6V(X>M*GV9L]>6SSIL1]E;P1I8%8;]2TXEBJ*P)#>26'KH@@@B,]3=HB
M^\#VFI_9VT<J;]LTZHU.][DE'Y.WY60DYB94 L%B:6I3+3@;+:'"M/$!DCES
MB?$?C52WJ'6U-*K%)I]3['/9"?E&)I*,]>%+[:PG/FQ&VP5VACLO0OY3'G*T
M:EB.>?'>?[.+8B/4L+R^7*5C=@!)LA+)NH()W'G>+,9E\SP[EL5@\N,#D[].
M6I6R_LQN-0:<!'L1U_-A#S1QES"3( DG2Y#!=CY_-9H.I%Q5>I5ZM6W<T]5J
MO-OSL[-O4JI+=<+[JGDI)5+D^Q<? .>.7+$?F^LB]1S]:-QX )/^!ZAW<_\
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M:[;#I,N8/KV)Z@E(;CU[ @_'Y=ROX =^CVGF4WK],0<.@;CW=+29([$_,;?
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MSMZ?#U]1\OP>X=_?IN+3.^*3J-I]9][T6>9J$A<MOT:IHF6%I6VI^:D9=]]
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M"<DZ*6/"J/5%2C3W&PDN>#\14EL*2K&.8S#<"&4A*1D@ 82$$H2E(]JE*4X
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M#V&@.UY,-N3K<M,-2\K2G[=I962W)I]L79MTD\*!@^7E&4MOJS;JK6^;W?\
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K;0DQ3M3=I.>I=5]:W;,S!H,A3'7#(-F;EE!M_CDUMC. 1CF((((-<-?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>nt10002526x6_barchart1.jpg
<TEXT>
begin 644 nt10002526x6_barchart1.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( SX'D ,!(@ "$0$#$0'_Q  ?  $  0,% 0$
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M]!KH!ZD7+_WN*3]!KH!X9MSKYMW;[&3+/5;+T0>+WNM4?K;>JOE$L9OK=?\
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MY1+&;ZW7_5I&)?ZX#FO[N*E^C*_-!ZX#FO[N*E^C*_-#+0]2+E_[W%)^@UT
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M1+&;ZW7_ %:1B7^N YK^[BI?HROS0>N YK^[BI?HROS0RT/4BY?^]Q2?H-=
M/4BY?^]Q2?H-= /#-N=?-N[?8R99ZK9>B#Q>]UJC];;U5\HEC-];K_JTC$O]
M<!S7]W-2_1E?FA[3#O/CFEJE[T*GSKUJ+L204CC4';2FR5LHW:KXK=H9?+\P
MRG/4BY?^]Q2?H-= <F'E0P&@RFID7#RE,R&=>+=)MK:1KSZ=9V1X6^['N>-6
M#9DC<Z=F:VC)HS0O>9-\A2D8*54.I'Y)P.C)1B*'F=MP#=78O#NU:;K#TT9L
MFS)HT9FWE@]\0A;-2D0-[AY9%"F/G':*CP !\RC[,
M
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MS^)<'D+_  U?6(2LM!])"=  !XQ0     ;341&2=#W\QZ;OG&X
M        !M-1%NW:_">FG_7:&X         '!J?XMG_$Y/V*Q"& _P"(ZE\=
ME?Q#@F^I_BV?\3D_8K$(8#_B.I?'9?\ $.#1>:K_ +>D2LM!])"?0 !D4
M   ;35H>F[Z1%^HP ;@&S:TUU+FY]#VC^8AJ:M-#W;^V>G_7[P ;@
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M_*1<%Z!@G2SLNDUOT055*337W44^2W'M]"]5Q$J2R>P1FK52#,SU/74Q5GG
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MQOL4"$,>/Q'3?CL3^(;$WTS\6P/B<;[% T?F)^LKH0)6>@NDQS@ !D4
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MH9& 0,L9&7()0   0
M
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MVNW+/QS*TY=RV_?,2ZJW!AT)ZE[4IIMBFQIR8:C4EE#*B)*2T3J>JC/2Y/\
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M;.BVA:<!&B(C2C>??49[:ER)*TD\^HUF:B-Q2CZX]XJ* 94>$9GE   !
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MRA")%"!8R/\ #H%R\N8M.;0:@ #
M
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MHW]1S]ZAQ,7O8'6/^'^V2.7AA["J-_4<_>H;]&7US_E(8+SST=0D$  8&P
M          &FA:Z]D:@ !S[C&FR1:[N?GWF-0 !X;$3#FS,4[2JMD7Y0(-R6
MQ66>(J-)GL-/L2&SU+0TO(61&6IFE1%JD]Y:"U_&X#'@UHES(NUC ?8J;<TJ
M@F+Z8:H=*3))WCB65)-SD6SQG7;)-[.OP"[R "D9EB,RT#RUFV;;5A6W3+3M
M*D1*';](81'I],A--L1XS2$DDDI0TE"=3));1[.IGO/4QZC0B+3L#4 $&A$1
M<PT))),S+7?\)C<  -AH29Z[_P Q&9%\PW\VX@
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M;1[.[=_UH+@'E1ST]885BM0J!  &!H
M   ''E2XL)E4B9)CQ&$:;3\IYN.RG7FVG75)0G7L:GO"-*C364R(DF/*87KL
MO1GFY#*M-Q[+K2E(5IV=#W  Y #IYEPT&GNFQ/K='A/)_"9F5.'%=3KOWMO/
M(66[0]Y$/I"K5)J1F5.JE,J!)_"Y#/C2S2?8U)AQ>FH .T <65,BP6E/S),>
M(PC>M^4^W'907;4XZI*"^<=7!NBVJHZ;%+N*@U)\C,E,0:O3Y;Q'VN+CR'%D
M9=DC2 #O@'2R[CM^ ^<6=7:+#DITVH\NJ0HSY:EJ6K+SR7"U+>6J=Y#YM73;
M+SR([5Q4%U]S<AEJL4]QY9]I#27S6KY", '? !&1D1D>I'O(RWD9'S&1CX29
M4>&TI^5(8C,(_#>DNH891KS;3KAI0G7L;1EKV  ?<!Q6YL1Z.4MF5&>BF1F4
MEJ0TN.9%SF3Z5&V9%V3VAPXE>HM0>4Q K%)G/H,R6S#J,24\@RYR4TRZM9&7
M9(TZ_FW@ [8!UL^KTNEDE52J5.IR%?@JGSHT,E\WX)ON-D>G9Y^P/O#GPJ@T
M3\&9$FLG^"]#DLR6E?F<94M)_. #E@    .O75:6W,;ISE1@HJ#VO%0ERF$R
MW="U/BXYK)U>A;SV4'H6\QV   #8XXVTA3CJT-H21FI;BB0A)$6IFI2C(B(B
MWF9GH1#H3NVU=3+TS6]JDS)1'6J<1I,MQD?^4'H9'J1D>F@ /0@.K@UNC5-2
MD4VKTNH+1IMH@SXDM2->;:2PZX:=>QJ1#L]2/F,@ :@ :D7.>@   &H  #Y.
M/M-&DG'6FS7^"3CB$&?]4E&1J^0?%,^"J2J&F9$5+01&J*F2R<E)&6I&I@E\
M8DC+>6J=Y;P <L!IJ7;+YQKKIS@      .CJ-S6]2%&FK5RCTU1:$3<ZI0XK
MIZ__ &;[K:M_YASX51@5)@I-/FPYT91:ID0Y3,IE1=G1UE:T;NSO !S0'1/7
M1;49U;$FX:%'>;W+9>J\!IU!GS$MMQ]*TZ_"0[.)-B3FB?ARHLMA7X+T20U)
M:5^9QI2DGIV=#YP <H!\'Y+$9!N2'F6&TF1*=?=0RVDU'HDC6X9)(S/0B+7>
M9[@=DL,LG(=?9;9(MHWG'4(9(CYE&ZI1((NT9J(C[!@ ^X#K(59I-16I%/JE
M-GJ1N<3"GQ92D'VEI8<6:=^[?H.S              '&E_Z+)/\ W9_[-7^(
MY(X\O_19/Q=[[-0 (!P1_&%W_&D?:."H84\X(_C&[_C3?VBQ4,-M/./0G^4A
ME/FE>L  !@:                                &A_\ ,OWD*=:A_KPI
M']1[^&,5%'S?*7[R%.M0_P!>%(_J/?PQC:,:OJ*Z!#Q<I=)"HL  8%
M                              'F;O+_ .#E6^&*]]FK_GJ(PP!+6RD\
MW^ES/XEP2A=_L<JOQ1[[-0C# #V%(^.3/XEP>0O\-7UB$/SBL(_P(3H  /&*
M                                    .#4_Q=/^)R?L5B#\!OQ%4=?=
MLK^(<$X5/\6S_B<G[%8A# ?\1U+X[+_B'!HO-5R=(E9:#Z2$^@ #(H
M                                  "&L=/8),^,P_XA F40UCI[!9GQ
MF'_$(&D>>GZR>DA#Q'H/H'O[0+_X.4GF_P!%:/F_^S3S?*/3#S5H>QRE?%&?
MLTCTHR(G%HAT$?X@   T                                --"Y]"U&
MH      " <>?Q%3M/=L7^(;$X4S\70/B<;[% A#'C\1TWX[$_B&Q-],_%L#X
MG&^Q0-'YB?K*Z$"5\A;8]0YP  R*
M                    (SQ>]@=8_P"'^U2.7AA["J-_47_[1CB8O>P.L?\
M#_;)'+PP]A5&_J.?O4-^C+ZY_P I#!>>>CJ$@@ # V
M
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MD?U'OX8Q44?-\I?O(4ZU#_7A2/ZCW\,8VC&KZBN@0\7*720J+  &!0
M                             !YJ[_8Y5?BCWV:A&& 'L*1\<F?Q+@D^
M[_8Y5?BCWV:A&& 'L*1\<F?Q+@\A?X:OK$)66@^DA.@  \8H
M                        X-3_ !;/^)R?L5B$,!_Q'4OCLO\ B'!-]3_%
ML_XG)^Q6(0P'_$=2^.R_XAP:+S5<G2)66@^DA/H  R*
M                        AK'3V"S/C,/^(0)E$-8Z>P69\9A_Q"!I'GI^
MLGI(0\1Z#Z!(%H>QRE?%&?LTCTH\U:'L<I7Q1G[-(]*,B)Q:OY2   !H
M                                    0%CQ^(Z;\=B?Q#8F^F?BV!\3
MC?8H$(8\?B.F_'8G\0V)OIGXM@?$XWV*!H_,3]970@2L]!=)CG  #(H
M                                               C/%[V!UC_ (?[
M9(Y>&'L*HW]1S]ZAQ,7O8'6/^'^V2.7AA["J-_4<_>H;]&7US_E(8+SST=0D
M$  8&P
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M@6GAU0X]O6?1(=%I<8C)MB.TV3JB,]=7GR23CQZ\QN&HR^<>S
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M]X\A?X:OK$)66@^DA.P#9ME^2OZ)AME^2OZ)CQBC> V;9?DK^B8;9?DK^B8
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M2C_,DS_<0T)U)GIHKY4*(OGT !] &AJ(C(M^I_ >GSC4      !H9D6\QJ
M #0E$9F6_=S[MWS@ U$-8Z>P69\9A_Q"!,HAK'3V"S/C,/\ B$#2//3]9/20
MAXCT'T"0+0]CE*^*,_9I'I1YJT/8Y2OBC/V:1Z49$3BU?RD   #0
M                                @+'C\1TWX[$_B&Q-],_%L#XG&^Q0
M(0QX_$=-^.Q/XAL3?3/Q; ^)QOL4#1^8GZRNA E9Z"Z3'.  &10
M                                          !&>+WL#K'_  _VR1R\
M,/851OZCG[U#B8O>P.L?\/\ ;)'+PP]A5&_J.?O4-^C+ZY_RD,%YYZ.H2"
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M9*+4OA+YA^-^<7B3VYN[RDDM-[9-2-*DK0MFV9I:LUH6DS2I*D*(R,CL.!E
M?K<GYWE!@3P[*4:,-HS,EI4A:&C)9LVB%H41*2I*B,H&1'6-0 !^,?L
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MD/QWFGV7"U0ZPXEUI9=M+B#-*B^$C'7U>NT>@QE2ZS4H5-C)(S-V9)9CD?\
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M7"M:V850)7HA#MRB19YJ/:/ED>G1VI)&>_57')69GJ>H 98CRU'T\N@>D
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MZ8[*=SQND3DD5JTE)_<.XW??7I"2<UH2EKOK1]0N*L*)E H5'EPC\-L[^:_
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M.*U,C;.C<I44AHHG-X2DG=Y=GMLM;DW-."LD1-=^8 +X?A_?N_4 ^61]WD
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M@<E,R8H>4+)L\$]$^*0MZ[LWT^Z3;+1Y"E&TB<4>3"$(8AN  ''!R(
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M]\-'B$3S@?<W>:7OAH\0B><&9#ZJ7+]WU+9^MX/]X LTF7[OJ6S]<0?[P'A
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M"0+0]CE*^*,_9I'I1YJT/8Y2OBC/V:1Z49$3BU?RD   #0
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M1OZCG[U#B8O>P.L?\/\ ;)'+PP]A5&_J.?O4-^C+ZY_RD,%YYZ.H2"  ,#8
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M+?%K49FJ/FGY-0W  #T0]X
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M'I'KMN^0V;3UX78MI7X2#N*K:'IS?^E=@=?Z*UGNCNG](JK_ 'H=3REKM/\
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M]E%)[Z<G$R1#"PC9$\X10WLSHPM[CADG-PJ17H  .DAW(
M                          AK'3V"S/C,/^(0)E$-8Z>P69\9A_Q"!I'G
MI^LGI(0\1Z#Z!(%H>QRE?%&?LTCTH\U:'L<I7Q1G[-(]*,B)Q:OY2   !H
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MB4.I)@NQE(1&CS%3&4)DFIE@MDSU/> JDPC1"%9'')ITBZ+FKX5?#G!#%-O
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MOZCG[U#B8O>P.L?\/]LD<O##V%4;^HY^]0WZ,OKG_*0P7GGHZA((  P-@
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M1Q*<.%[Z-TK>WY\6DF:5-I18K8/1J)FF*6C-:UJ+ \U,5'%)$=A<KF_@^];
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M1G[-(]*,B)Q:OY2   !H
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MU'/WJ'$Q>]@=8_X?[9(Y>&'L*HW]1S]ZAOT9?7/^4A@O//1U"00 !@;
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M;;JE4PWO6:E^'6Z?$?FE&6P1\<3K49MUQ&TZHTEMZ$?.7PVB>,_W&M?4T_S
M^L9L]P%(4F^]V]=S]RL<+>\&._;VG?=]P:=]WR.%A^5$?+DY3?CEN4?? VN_
M]U-8;X:H;UA?!;U&C>M[P<"%$.4;>)+W=6OKB;YT.)+W=6OKB;YT;N,_W&M?
M4T_S <9_N-:^II_F![Z)9;W,M8]'"\3O5>)C;Q)>[JU]<3?.AQ)>[JU]<3?.
MC=QG^XUKZFG^8#C/]QK7U-/\P$2RWN9:PA>)WJO$QMXDO=U:^N)OG0XDO=U:
M^N)OG1NXS_<:U]33_,!QG^XUKZFG^8")9;W,M80O$[U7B8V\27NZM?7$WSH<
M27NZM?7$WSHW<9_N-:^II_F XS_<:U]33_,!$LM[F6L(7B=ZKQ,;>)+W=6OK
MB;YT.)+W=6OKB;YT;N,_W&M?4T_S <9_N-:^II_F B66]S+6$+Q.]5XF-O$E
M[NK7UQ-\Z'$E[NK7UQ-\Z-W&?[C6OJ:?Y@.,_P!QK7U-/\P$2RWN9:PA>)WJ
MO$QMXDO=U:^N)OG0XDO=U:^N)OG1NXS_ '&M?4T_S <9_N-:^II_F B66]S+
M6$+Q.]5XF-O$E[NK7UQ-\Z'$E[NK7UQ-\Z-W&?[C6OJ:?Y@.,_W&M?4T_P P
M$2RWN9:PA>)WJO$QMXDO=U:^N)OG0XDO=U:^N)OG1NXS_<:U]33_ # <9_N-
M:^II_F B66]S+6$+Q.]5XF-O$E[NK7UQ-\Z'$E[LJ_YSJLTU?2XW7R#=QG^X
MUKZFG^8&G&_[E6/S'29VU]'B=?F CR'>@^H+XQIQ)>[JU]<3?.AQ)>[JU]<3
M?.C=QG^XUKZFG^8#C/\ <:U]33_,!$LM[F6L(7B=ZKQ,;>)+W=6OKB;YT.)+
MW=6OKB;YT;N,_P!QK7U-/\P'&?[C6OJ:?Y@(EEO<RUA"\3O5>)C;Q)>[JU]<
M3?.AQ)>[JU]<3?.C=QG^XUKZFG^8#C/]QK7U-/\ ,!$LM[F6L(7B=ZKQ,;>)
M+W=6OKB;YT.)+W=6OKB;YT;N,_W&M?4T_P P'&?[C6OJ:?Y@(EEO<RUA"\3O
M5>)C;Q)>[JU]<3?.AQ)>[JU]<3?.C=QG^XUKZFG^8#C/]QK7U-/\P$2RWN9:
MPA>)WJO$QMXDO=U:^N)OG0XDO=U:^N)OG1NXS_<:U]33_,!QG^XUKZFG^8")
M9;W,M80O$[U7B8V\27NZM?7$WSH<27NZM?7$WSHW<9_N-:^II_F XS_<:U]3
M3_,!$LM[F6L(7B=ZKQ,;>)+W=6OKB;YT.)+W=6OKB;YT;N,_W&M?4T_S <9_
MN-:^II_F B66]S+6$+Q.]5XF-O$E[NK7UQ-\Z'$E[NK7UQ-\Z-W&?[C6OJ:?
MY@.,_P!QK7U-/\P$2RWN9:PA>)WJO$QMXDO=U:^N)OG0XDO=U:^N)OG1NXS_
M '&M?4T_S <9_N-:^II_F B66]S+6$+Q.]5XF-O$E[NK)_GJ\TR^4N-WAQ)>
M[:N7P(JLQ!?,3NG_ %\(W&Y_N-:^6CSR+Y^(#C/]RK!_"FDSEE\Y,Z?-J$;;
MGUT"47/1V1VC;Q)>[JU]<3?.AQ)>[JU]<3?.C=QG^XUKZFG^8#C/]QK7U-/\
MP$2RWN9:Q87B=ZKQ,;>)+W=6OKB;YT.)+W=6OKB;YT;N,_W&M?4T_P P'&?[
MC6OJ:?Y@(EEO<RUA"\3O5>)C;Q)>[JU]<3?.AQ)>[JU]<3?.C=QG^XUKZFG^
M8#C/]QK7U-/\P$2RWN9:PA>)WJO$QMXDO=U:^N)OG0XDO=U:^N)OG1NXS_<:
MU]33_,!QG^XUKZFG^8")9;W,M80O$[U7B8V\27NZM?7$WSH<27NZM?7$WSHW
M<9_N-:^II_F XS_<:U]33_,!$LM[F6L(7B=ZKQ,>OLB_KXPSN"F7=85V7#0J
M]1);$Z)*35Y[S1<G<2ZMM<=3Y-.$ZE&QUZ3(M=1^CGP3^;6N9NLHUB8@W<YQ
MMX,17(-<=ZTN..&YR1ATR01))2T-[1Z:GO+7?O/\X"U+1NR_J[3K5LJV*_7*
M_6)3,&'";H]0;2HY+B6E+6\<<T-D@E[6JM",B/M#]'#@C\I]P93LH%AV1><=
M42\9L5R?6HJM#..F8[RN.@S29D:B;<(CW$9'N/?N+JG=5*3_ 'K<S7O7OCW4
M6\8.#OYL#0K?<+XQLHX$#.C"Q#L_<Q-^]\WHF>^]P=S&;>.%O)-B6C>H1\G?
M<'#Q4FF)G4+HX  Z%'>(            X-3_ !;/^)R?L5B$,!_Q'4OCLO\
MB'!-]3_%L_XG)^Q6(0P'_$=2^.R_XAP:+S5<G2)66@^DA/H  R*
M                                AK'3V"S/C,/^(0)E$-8Z>P69\9A_
MQ"!I'GI^LGI(0\1Z#Z!(%H>QRE?%&?LTCTH\U:'L<I7Q1G[-(]*,B)Q:OY2
M  !H                                        0%CQ^(Z;\=B?Q#8F
M^F?BV!\3C?8H$(8\?B.F_'8G\0V)OIGXM@?$XWV*!H_,3]970@2L]!=)CG
M#(H        ",\7L6;)P2P]N7$O$"KLT2UK8A.RZA/?U)"5);4IEE/94X^M)
M-(2G4S4K<0DL^8_S&+!'\H3N2NP,F3%N1Y$F%;-RWM93%R36%+;2VPFZ:<A#
M;KC9I,D.DM2%$:ME23,CU+<84J3(K1Y^TN$RSUYGF*G?.4_)N_<N#<*7-:H%
MZ5"ZXU&=NI$%YQA]2*;4VFI$=/&,F2#V>O2LE),R,C%362'A2(>8+%*X\M^.
M^';V N9*UUM-2,/ITMRHHJG&-K>XV!4^+;C2B3'03SA,+<V-K0]#T(7#LO\
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M2.7AA["J-_4<_>H;]&7US_E(8+SST=0D$  8&P            TUYP
M     -"+F+0-"Y]-_;       -"[0                           *4<Z
MM*MRL9:<5H-TU-^DT5R@2ERIL9A^0\A3<=U;3:&8Y&ZOC%D2#V2YC&+ED'X5
M/(OEOP.;PDQ$PI-ZX+;KUPH7<,RQ9M0?KZ9%8D.-K6I5+<4WQ:.8U+/4CY^P
M,O'%NL610</+JK&(11U6E3:9)E5A$I&VRZPPPX[Q2DF1[1K))I(M-QF,3&L<
M+)D-8N671[<R:0[BHRJC4XT"NII[R/19V#(=1,=B-'35'(V7$*-7$FLDZZZ[
MQSV:C%3[)[^XJDJ4I18=TL'@U.3XR<T,6B&;1)82VB#PU*2:O)B<$IC C*(X
M+.EJERE!Q?DRG)TGMNYV[N27QU:/:FR%M&2CP4,U%@)0I*?*@1F:H81E0+W>
M0+A!<K6;VY+PH> ]H-V]4;<*&=6>;M1^@&]RE"E-:NNPHO':$DRW*5L]G3>+
MKB3(RU+MG\_9%B7@I\Z.#F:&^L3*5@]ENBX10;5]#DU.MI(H\NHG)2KBR>AN
M1(SS1-J(TI-1=<1D9'H+[*3U+733GW#CLX'5+E*;9W2Z/#D24,C[G>GEF]-T
M83-*BPVK,B2>$1Q(H$:2,DG21CD,@/)ODF,6ZGI@^&I34NZ'9@MV8KP5FGR&
M32*BA"!GB4=)#< "B3-+G1M;*W?&$MK791GI=,Q-ES8CE::4ZI-&7%6AMHW6
M&D*XQ+RUD6JC222+4ST'I,8]SB%;8"F/$W,I1</[APJHK%/16X^**'W8$^/*
M+BXS;333I*^][:7-2=(E)VB-)D9'H9&)=J&)MDTFJ0*-4[BID*ISVVUM1')3
M!*2;B$K)#QFX7$J5M$22<TVCYMX!?\1[\-.S_P S_=S#R->OJT[:CG(K5>IL
M!!;!Z.RV"<4ES394ALW"6M)D9&:DD9$6\ST';TFNTFN4]BITB?&J,&06K4F*
MZV\TO?H?7-*4DM#W&6NI<P .VT+77L_+^[F&W83KKO\ S:GI\PIH=S'TQG'=
M."3U+0U*4G:357926TJ_R?C]$M*T(S_F[C&ZIYCJ53\=;?P5136Y,FNHE+*J
MM3$+3'*+'Y0K;:1J1:ENU49:?(+ \E4>3* J7T+?\//SC4BTW$/!,8F61(K[
MEM-7)2W*RVK8Y&F9'/57Y*7"<,E*+LI+>1[O@'18F8PVEAG1ZC4:M5:=RR#&
M6^FFJFL(><V4&LB<(W-MHED76&M);6N[40!+.A:Z]DPT+?\ #SBGS"[,+:U_
MX54+%&JNQ+8@5R1.8CQI,MI:U<CE+C&IK;4A3Q*-)+4:"/8(]^[>.NQLS(6]
MA+8\:]H;46Z84B= A;$&:TKBSG2VXJ5N*8-S8V3<)6BB+70]0LK 5)I02=Y:
M_*9F-#;29F?7;^T9B+;EQ+:IMLOU6@QX5;K3$6D2G*(=18C*:15$-.D4AY2]
M&#0V[JDG"0:S+0M3,<MW%"V*51XE0NBK4NA2GDM<?"7/C.N1UN[))09<82C(
MU*(B5H1:;^8 'SO/"##Z_)\&IW-;L>H3H*]MB2G1EPU:EIQZFR)3Z2TW$[M$
M1;B$A0*?"ID1B# BLPXD9"4,QX[:&6FTD6FA(;)*=?RCTZX]3/G'QC56%.IR
M:G DL3HBXZY#4B,ZAUEU*$&OK7&U*1O+GT,]#/3?H8@7![,#"Q9O+$>T8U'5
M3G,/GX3#\DW^,Y8<PEZ&2=")&SL]L]=0 5%Z%S]OX3+_ )AH6_X>?>?[]1UB
M*U2G)S]-34(ISXR24]$X]KCVTF6UJIK:XPBV=^IITTW]L=%-O^S:>U)>EW'2
M641=SVU.BDI)D9D9$DW=5&1EUQ$1F79T !['F&SBTD>O7?2,1PK%S#M,:G2U
M7;1RCU1Q34-TIL4TN+0LD*0K[[][5M&1)VM-KL$8[>N8@6=;K:7*M<%-A[1-
MJ0A<I@W5I=T-"DM<9MFDR,CU(M"(]0 ;8.']I4^Z*C>,:C1T7%5";Y95%I2X
M^YQ2=A&PI1&IOK=Q[!EJ7./:$1%J?;YQ2]C5F<MW!]-E278\6L4R\7G&F:DU
M/:1%CDVM"#4;J#4TK\/>6V1D9::"<+9ONV+K@JG4>LTZ8TS&9DRN*EL*.*3S
M9.:/$E9FV1$9Z&LDZZ:]H 'L="TT[':_..GA4"D4Z;/J$*"Q&FU,VSG264(0
M[*XLM$&ZM)$I>SO(MHSTUW#SU&Q(LJOU671J1<=-FU&&>CT5N4P:STU-7$Z.
M'QVP1'M\7KL]DRT&DS$NQH-3C4B5=%'9GRC<)IA<^*6]K4UI<4;NC1EH>Y>F
MI[B ![K0MWP<P&DCU^'GWF/'4:_[0K\^H4RDW!3)LZF$E4R,W+CFMI*TFHE:
M$X9J3LEKJ1:$6\SYS' A8I6'4*^Y;42YJ8]5VU;!QDRF-%JTU-+3O&;#IIYE
M$@S,CW'O ![]*23S:_*9C70MWP<V\QKKJ6I;R/FT[1]D1E7+YJE)O>W[:11H
MKM(JJ92IU:=J++"X!,-<8DTQ%J)QXEGN4:2T06\ST( $F:$>OP\_.-I-I+MG
M^<S,AX>/B58\JMMV_&N:DOU5U2TM16YL9?&FC7:2VM+ADM2=#VB3J9'N,B,>
MU>D,1V5OOO--,MI-:W77$H;2DBUVE+49)(M-^IF #>AM#>I(0A!&>I[""3K^
M?3G/X1NT+?\ #S[S'BZ'B'9UQS9E/H]PTR=+@GI(91+CDM.FNNP7&'QI)T/;
M-!&2-.NT'PAXE61/KKUN1+DI;]78/1<1$N.9F>FIDVLG#)TTE^$2-32>Y6A@
M ]WH6[X.;G RU(R/LCP]7Q(LBB3&*?4[FI,.6^K92R[-C$I)ZD7WTC=(VM=2
MV>,V=KL:CXEB79S\NK4R!7J9.JU*I\BH.4YB9'6ZZAF,N41,[+AF[M(0>IH(
M]G7> #WI((B,MYZ\^IF8)02=Y:_*9F*5<#,UEE8R4M4IQZ#;M1*I3J>FFR9[
M)K4J%+<BF:EN*1L&LT;24F1&>NA:B5X>(DI5Y7+0:K3H%,H5#1$7'K[M5C:2
MRDM\89NQU.$<<DGN2:]-LMZ==0 2IH6FG8^4-/S_ #GY1XRAX@V=<52FTFCW
M%3)T^!IRF,U+CFXDC(U$:4I<,W"))&:C3N26\QPCQ1L0KB3:YW-2_1E:C2F+
MRIC8-22U4GC^,)O:+?UNNNUUNFH /?D@B/4M?G/3YAKH7P_.?E%.+>8ZU:C?
M&(F'-!.-4;NL!%.7)IRI*6$RN7M<:C[^M1-H)*-^NNBBTT[ ]O"Q6HT.U:=<
M-Z2*?:[\YQULX*I\>4:30[Q:>+4E>KI'N-1H(]CLZ  E?3\_SGY1M)M)'KUW
MRJ,><.\;833&:PJNTM-,D-FXS.5-C)8=2DM5;#AN<6:BYC22C,CW'OW#Y6Q>
MUKW@V\Y;M:A54HZC0^F,^TMQHR,T]>VA:EI(S+K341$HM#+< #U.R6IGOW_"
M8*02MYZ_(9D.N.LTLICD!4^*F:TDUN1E/MD\E))-9J-LU;6A)(S,]-Q;SW$8
MZYZZZ$FDRJQ'JM-DPX[;YE(1-CG&4^T2B2R;Z7#;2:G$\6>JM4GN/?J #T>A
M;O@Y@T(M3[?.*4ZAFBH%K1K2]/D.';M1O&146J/$:J#4Y#J8#IH)?',J-">-
M3LJT49:;1%O'QP^S967>=YWW:-2<A6ZY9BJ6E,F5/9_[0]$TDILR0XI'%[.J
M=.?77X-Z!WU *LC(C,C[7,&A;_AY]Y_]%\@^3$AF0RW(9=;=9=03C;C:TK0I
M"DDHE$M)F1ELF1ZD8IYQRS'V;@O:%;N.1-I]6J%&E4Z*[143V&W5+J$A$=.J
MB6:DFG;VM#(C,RTT !44:2/3GW<V\_\ K\W:&NA::=CY1X6R;[IMX6]2:TER
M-$?J<-$PZ><EM3[#:VDNZN(-1.$DDJUU4DM4[R'93;UM6GT\ZI+K]+8@$:R*
M4N;%2T9H5LJ)*E.DE1I5UID1F9'N/> #U(VFA)EIO+\QF/-V_>%MW/"<J%#K
M,&I162,WG8\AE9,I+7>Z2%JXLMQZ&O37L;AUM;Q'LJ@4I%8J=Q4UB XLVVGD
MRF'3=6E6PLFT(<-3FPK<LT:[._730 'M]DM"+?H7PF-%))7/KN[1Z"F'&#,U
M;N&- MNX:?&9NBGW'+:BL/0Y220WQDAMC:4IO;(C2;A&:3W[CUT,3_!N:CS(
MA2?1"&@VX<*7,1RED^1E-90\VE\]O[WN61%M[.NA@ [_ &2TV=^GYS[ UV2W
M[N?3LGV.8>1K%^6A0H*:A4[AID2*X9$TXN9'U=ZXDGQ2#<)3FR9]=L$>SSF.
ML5BE8*7:2R=UT;;K)K*GZ3XII?-&FTDU$[LMJWD1$9ZJ,]Q  D'0MWP<PT-"
M3+3>7YC,>%N;$JRK1>BQZ_<-/@/3#23+2I#*G.OTV#<02]II*B,C2:B(E%O(
M]"U$/8LYF;;PKO7"RUYK469 Q,]$SCUQ,YM,6$BG-I<-9*2HVWB<VM-"66R9
M:<^X Q"IPB)):%^L]1\)?^BR?B[WV:ATUMW30KK@HJ%"J<.I1U$1FJ,^TXI&
MO8<0A:E-[]Q;1%KV!W4HM8TA)<YL/$7RMJ+_ )@ I,LO#^SL2(=\6[>UO4NX
MJ3*>0AR+4(<>09)XQ9GQ3CS:U-G_ %#3\(\<K@Y\G2U+6K!BAFI:E+4>PCG4
M>IZ=9N+4^84)9JN%3P9R >F&E5I+=WXDU9Y1P+*8?6PLU-K4?WZ6T2TM$:%$
MOKR3KS%J+4TO^4\WNJ2\J+E\),8U'Q)>F%O78YT\[>O,9:Z]D<SDF;4[']W)
MYDM@](=&L#0LG@G9#6!)2:D)6T9FM,8P61&DX'3"(XA*DXIK.3SW/*35V:/3
M.A2>YS>5LZ8X*U)0LD&4?-,R,HP.$1DB^MS9.>\O0_H)Z(>MS9.>\O0_H)Z(
MQLONG>_O]GTOTA:\V'W3O?W^SZ7Z0M>;'M>\R?W!>?XDSL^GORF/6=]DQZ/\
MO5^SEYOT5FRFL9)OK<V3GO+T/Z">B'K<V3GO+T/Z">B,;+[IWO[_ &?2_2%K
MS8?=.]_?[/I?I"UYL.\R?W!>?XDSL^GORF'?9,>C_+U?LY>;]%9LIK&2;ZW-
MDY[R]#^@GHAZW-DY[R]#^@GHC&R^Z=[^_P!GTOTA:\V'W3O?W^SZ7Z0M>;#O
M,G]P7G^),[/I[\IAWV3'H_R]7[.7F_16;*:QDF^MS9.>\O0_H)Z(>MS9.>\O
M0_H)Z(QLONG>_O\ 9]+](6O-A]T[W]_L^E^D+7FP[S)_<%Y_B3.SZ>_*8=]D
MQZ/\O5^SEYOT5FRFL9)OK<V3GO+T/Z">B'K<V3GO+T/Z">B,;+[IWO[_ &?2
M_2%KS8?=.]_?[/I?I"UYL.\R?W!>?XDSL^GORF'?9,>C_+U?LY>;]%9LIK&2
M;ZW-DY[R]#^@GHAZW-DY[R]#^@GHC&R^Z=[^_P!GTOTA:\V'W3O?W^SZ7Z0M
M>;#O,G]P7G^),[/I[\IAWV3'H_R]7[.7F_16;*:QDF^MS9.>\O0_H)Z(>MS9
M.>\O0_H)Z(QLONG>_O\ 9]+](6O-A]T[W]_L^E^D+7FP[S)_<%Y_B3.SZ>_*
M8=]DQZ/\O5^SEYOT5FRFL9)OK<V3GO+T/Z">B'K<V3GO+T/Z">B,;+[IWO[_
M &?2_2%KS8?=.]_?[/I?I"UYL.\R?W!>?XDSL^GORF'?9,>C_+U?LY>;]%9L
MIK&2;ZW-DY[R]#^@GHAZW-DY[R]#^@GHC&R^Z=[^_P!GTOTA:\V'W3O?W^SZ
M7Z0M>;#O,G]P7G^),[/I[\IAWV3'H_R]7[.7F_16;*:QDF^MRY.=W_Q+T,MY
M?S$_KZSF[8A:=D"RC-XM4RBE@Y1SBNI=-6B4\7N9VMZ>+W[_ (2T_?8;^Z>+
M^_V?4_+<+7-X,>&D?RD.^G[PBW86!"4'&)9%#]'6SVMI&QO7Q?RC29FS]+&3
MP5!E_P"TD4G11_CG&-,(T41/&,G.R8]%#O5^S5'DRL=5=&4S&4,?!RY.2,RZ
MB]#W?T$]$/6YLG/>7H?T$]$8V7W3Q?W^SZ7Z0M>;#[IWO[_9]+](6O-C/>9/
M[@O/\29V?3WY3&N^R8_J]7[.7F_0V;-(R3?6YLG/>7H?T$]$/6YLG/>7H?T$
M]$8V7W3O?W^SZ7Z0M>;#[IWO[_9]+](6O-AWF3^X+S_$F=GT]^4P[[)CT?Y>
MK]G+S?HK-E-8R3?6YLG/>7H?T$]$/6YLG/>7H?T$]$8V7W3O?W^SZ7Z0M>;#
M[IWO[_9]+](6O-AWF3^X+S_$F=GT]^4P[[)CT?Y>K]G+S?HK-E-8R3?6YLG/
M>7H?T$]$/6YLG/>7H?T$]$8V7W3O?W^SZ7Z0M>;#[IWO[_9]+](6O-AWF3^X
M+S_$F=GT]^4P[[)CT?Y>K]G+S?HK-E-8R3?6YLG/>7H?T$]$/6YLG/>7H?T$
M]$8V7W3O?W^SZ7Z0M>;#[IWO[_9]+](6O-AWF3^X+S_$F=GT]^4P[[)CT?Y>
MK]G+S?HK-E-8R3?6YLG/>7H?T$]$/6YLG/>7H?T$]$8V7W3O?W^SZ7Z0M>;#
M[IWO[_9]+](6O-AWF3^X+S_$F=GT]^4P[[)CT?Y>K]G+S?HK-E-8R3?6YLG/
M>7H?T$]$/6YLG/>7H?T$]$8V7W3O?W^SZ7Z0M>;#[IWO[_9]+](6O-AWF3^X
M+S_$F=GT]^4P[[)CT?Y>K]G+S?HK-E-8R3?6YLG/>7H?T$]$/6YLG/>7H?T$
M]$8V7W3O?W^SZ7Z0M>;#[IWO[_9]+](6O-AWF3^X+S_$F=GT]^4P[[)CT?Y>
MK]G+S?HK-E-8R3?6YLG/>7H?T$]$/6YLG/>7H?T$]$8V7W3O?W^SZ7Z0M>;#
M[IWO[_9]+](6O-AWF3^X+S_$F=GT]^4P[[)CT?Y>K]G+S?HK-E-8R3?6YLG/
M>7H?T$]$/6YLG/>7H?T$]$8V7W3O?W^SZ7Z0M>;#[IWO[_9]+](6O-AWF3^X
M+S_$F=GT]^4P[[)CT?Y>K]G+S?HK-E-8R,[BX.S)Y%H=3D-X,T4EM1W%D1)2
M1ZDA1EL_>SYM/A'@,'.#]RAURU.62\&Z.;G*9*3VR2I1DE]22T/BR[!:%N^'
MX1C^5/\ E-5^U&!*@G@ EOE+:F^,],#1[!*29:Z<5OY]=/@'G;)_E)=^6=2/
M0M.!"9FCCKA.^CS;>]QPUZ&GB^QKH9C13.G[@FF#SA&9&1>^:,10C1O\-9TP
MTC/?9,>)%!V_AJLVO>>JVL9/WK<N3GO+T/Z">B'K<V3GO+T/Z">B,;+[IWO[
M_9]+](6O-A]T[W]_L^E^D+7FQGO,G]P7G^),[/I[\IC7?9,?U>K]G+S?H;-F
MD9)OK<V3GO+T/Z">B'K<V3GO+T/Z">B,;+[IWO[_ &?2_2%KS8?=.]_?[/I?
MI"UYL.\R?W!>?XDSL^GORF'?9,>C_+U?LY>;]%9LIK&2;ZW-DY[R]#^@GHAZ
MW-DY[R]#^@GHC&R^Z=[^_P!GTOTA:\V'W3O?W^SZ7Z0M>;#O,G]P7G^),[/I
M[\IAWV3'H_R]7[.7F_16;*:QDF^MS9.>\O0_H)Z(>MS9.>\O0_H)Z(QLONG>
M_O\ 9]+](6O-A]T[W]_L^E^D+7FP[S)_<%Y_B3.SZ>_*8=]DQZ/\O5^SEYOT
M5FRFL9)OK<V3GO+T/Z">B'K<V3GO+T/Z">B,;+[IWO[_ &?2_2%KS8?=.]_?
M[/I?I"UYL.\R?W!>?XDSL^GORF)WV3']7J_9R\WZ&S9I&4OAGD[RY835<ZY8
MF%MOTBJ:D92EPHTE;9D6A*;XYE6P9%S&DR/4M>?050I224DDB(B21$1)(DD1
M%N(B(MQ$1;B(NP0Q1L ?Y2Y9UT7C2+;QIPJ58M$JTQJ&JY4U54XH;C[B6VS5
M&9;U42UJ))F9D1%OYM1E%6'?5M8D6I1KSM&IL5>WZ[#9F4^H1UI6T\VZVES3
M5)F1*3M$E1&>NI#BLN2/+DE-6?OTQ;I4T(R9-FC3?T+),(I2V2I:3,J(IPHX
MCA"!CDTB2O(LILVA2.U8FED9&T8LV>\J1$B@:F1I0J!U*A \H]@  /0CWH
M          X-3_%L_P")R?L5B$,!_P 1U+X[+_B'!-]3_%L_XG)^Q6(0P'_$
M=2^.R_XAP:+S5<G2)66@^DA/H  R*
M          AK'3V"S/C,/^(0)E$-8Z>P69\9A_Q"!I'GI^LGI(0\1Z#Z!(%H
M>QRE?%&?LTCTH\U:'L<I7Q1G[-(]*,B)Q:OY2   !H
M                      0%CQ^(Z;\=B?Q#8F^F?BV!\3C?8H$(8\?B.F_'
M8G\0V)OIGXM@?$XWV*!H_,3]970@2L]!=)CG  #(H        "D;.[E3MG.3
MEVO? RYWDQ&+@1%G4VH\5QCD"K4AXIU+=1HI*NMFMM*,B41'IO%7(<^XP 8I
MD[$SA6\N&!-0RF5K .H8DSZ>\4##_'Z+<$.&N1"BRC736W**REQ2"BQT1X_W
MQS16R9GSF(!RP6/GP3GGP+QCX4.Q:A56+?*N'@O565-RV*-RF%Q+[,F-2D.-
MD<G[PV2Y9)-)F:R/LC,F>A1Y!I-YB._L;T'(9;>-!_T3<2HT_)H/E)ID"8MA
MR7!@RUQM>3KE0V'UQ]=/\PIQ"C:YM^P:=P#6%C\E-,2C#HR#$3S>VIPAV+N?
M.?B%B%E J&-F6O#-^%)P@P_1>S-"ITQ,J*A3TB831DF227TM2$M3&UDC\!)%
MJ9"\QDIS1YP\3;U58F,.2MG+Y8%)CLQJ36(ESPJE&3':CZ-M(@Q&T)2:-A#:
MCT(U'UW.+KIQVE'J;;1[B(M6D'H1;B(M2/<1;B+L#<AEM!ZI0VD^VEM"3^=)
M$8"&<2(H%1IZ\9UBE[.5<V--I9=,1:UE_M=5WXL)IBXEJ4%,EN*I^1,2N.IY
M+SI<6DXZ5<?UQ;S21$9'H8Q>\E:>$*RNN71B-?O!UO8QYB[XJ4J9<V*59O\
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MP]A5&_J.?O4-^C+ZY_RD,%YYZ.H2"  ,#8
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MN?7$/I!ZS5PB7>-<^N(?2#O@D/C>3?OC#\]I:P]XY:XIE+[FW_)>&B-K\!=
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M!ZS5PB7>-<^N(?2#UFKA$N\:Y]<0^D'?!(?&\F_?&'Y[2UA[QRUQ3*7W-O\
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M'I1YJT/8Y2OBC/V:1Z49$3BU?RD   #0
M            @+'C\1TWX[$_B&Q-],_%L#XG&^Q0(0QX_$=-^.Q/XAL3?3/Q
M; ^)QOL4#1^8GZRNA E9Z"Z3'.  &10
M                      !&>+WL#K'_  _VR1R\,/851OZCG[U#B8O>P.L?
M\/\ ;)'+PP]A5&_J.?O4-^C+ZY_RD,%YYZ.H2"  ,#8
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M>-\AM1H7:\LE%SEJZ?[FQ/7)8_M$?P"/(-.1Q#YXL8S[?$-=$(HX'M'9VZ[
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M.W78$%9=G;>.B$!]7-WN8E_VOFPZN;O<Q+_M?-B?.1P_<D;P#71#D</W)&\
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MX1Q1'S?C&52:-5'*(DC@5-&2!5'?^XI_ZMO_ (3?^@OS0=6W_P )O_07YH5
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M3<89<,ILK>MI"N:0YH6JDF>A=CX!HE(P5>1P?C'3RU=MA"&1Q+RJLD*RC?\
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M5U )4 >7NV\K9L>CR:[=5:I]#I45!K?F3Y+,9"4EK^!QRT;9]K9,Q#N'6:G
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MH84\X(_C&[_C3?VBQ4,-M/./0G^4AE'FER])@  ,#0
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M['*5\49^S2/2C(B<6K^4@   :
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MDB=&R'MA%JY/KN3-+0R)FMGA+(Q?H /\?U;@'S&/M\J:0
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M(\E$>0A(F4(G0<<1:(6]/XBIC";A+V;GP[QGQ)Q$LKTCTK"R12J5'BO3N/\
M1>J5&2JGH:;7LI-)*FD2361*2G:U/0B(=6YG>QTL=NAXHXH8>TFDX3W#4(D9
M]N-=-+G2Z''J,AN-2W^31UKER#G<<TZ:-C[WKHK30Q08U@S=N)_![T'$IRVG
MZL]<]US:E?ELQ'#CR)=-C70IV.X:F$DXYR.*2G$FA)F9ITYS(2K3[ RTXRWK
MAO8>#&&EVWQ#6W37KYF5:J7%2H%K5"C,QWF4%&J9ICS2.4RI)<66A;&NF\@@
MG)69'9"%9F4*8WH%(S/9RXHY3HU4P/*/=X_XHXV8B<(3A':UJ45^1A_8,!ZM
MN\14$LM5")5Z.U437,;0I.SR=!F:>.(S5IN[0E56;6Q*%5,S6.,?#QQ$["A5
MIP$5XZJ^XQ<LNHZ0'&&H^]J.<9XC;,T$>V>_34>0PXKT6A9U\TJ;EH-4B5&/
M9](IV'"3B3'XLE42UW8LAJ/+2T;"#;V$(UV^O/=S\]-S.']Z3,G]K6BY;50]
M,^.>($^5<\=49[CH\2V[O5(AG)4;>NRY'+5/&:$I/-J0N0C*$"25%$2/RC,^
M3;L$=)Z3JR0*B&/9TBJ^YL_&8>W;'LO'.H8)'3,**K4HD*I&[6F.4&BIS68,
M1\F%)3*TVWDN;D[R^#>*A\9\X5VG?%NX-8!V=Z=\1:G3(-3N-29:8C5J(FP6
MJC&;?<>3Q+G*67#21J4G9T,Q$V=VT+AN%O+/@C;E#=7;]>1"57"BL**)"] 6
MZ?(2J0EM'%I-3C2CU7IJK41M2+[7E/SCXT7-?=J2)UJ8FV]:[=G7+ 2Y53:>
MM>@I:E-.,PT/K@)<=03)F[Q>T1F>ID1F,P(RB15&<(VD15Q.O%"(8H$9UPCR
M1[*](G+ S.WBA>F8^1ELO["Y5M7%;#:5735DU)N8TDY,3E,0RXI/%*)9%H1H
M49%J0JUS88QO8%X$WOB/&CG(ETR.U3X2"5L[,NJN<@C/%N/4VGGD.::;S3IJ
M+=?!W7=,S"9CLRV/M<H)4=F9+H4:VV=SAMLQ$.Q'7$O$E)JXQ#9*-![T&>SH
M*^,Z>$E?QKRZ7U8-KJ)-;FI@U.GD>R?'.TB4BHDQUYDDC>-GBR,^;:+3X(9%
MA$4(>;&G+"-]H)Q8XY#LOCMB*.LG>3&S[QP^8QCQYA3;VQ5Q#<F3:S/F3Y34
M=J"X\X=/98A<:<9KBX3B&S4TA)J,MH]^\2I8^5^!E-K^.&(MHWI(IF%UR6_)
M>CV%(4_+:I,MBERB2;$R4ZXMM3TM7&$2"3IN3OT%/N"7"'4'#G"*+A_BM:EP
M4#&2U&)-';M-BCU.:Q/DLFN+35HJ4>*J*A,@FVG#/:-*27OW#R.(UZ9I:CD[
MQWQ8Q2@3H\V]95$38^',9GE$N@4A%0XF6Z4B*@W7^60E)?-"D$:-=D]^HT9*
M,Z3@1F10H+&9>:60J*:A2,J*X8ZZJ^J$8U44.#WRAX6XRX0U7&;%2WIMQ5W$
M&X;@;4^_5YS:CC0JS*C,FVVETB;+B="(R(M=.?LES< :467O//BIE\PWG38^
M'%XTYE$"BR)<FI)M23Z$..\H0[*<=<+C)+A.I21HYMD==EUSTV!@YE]M+#>U
M+/N.LWK36)G)[?51JM$;<JL]Q3I$<IR)Q*?\J<,S4H].SS:CWV UDXD8;Q\;
M\\>.UK/IQ'O6%'DT"QVE<I?M]N"P['@DT['2OC3F-&RI22;3L:Z*WD!Q\J.(
MZ"(])0@5E%)"$14%"DB*F&+%$N7(.EQ9RS8$Y>L'\2+KQ[N69B#B'>4IU3%3
M;FSH]4ESW);I4-F!2XKRGF4PW7([;BH[9)4E.TYNWB#L5KFQ?L3@X,-L+JY0
M*_5\0+^K#IM18ZYJIR*"S<"'X,=Z8P2G&>.ICC2#-Q25$1[^;0>#P;S&X=XD
M7Z6.&:RDW55;Z377(ECV"]0JV=-M%!S3A$Z]Q$8X-0*6T33R3>:/B3YM--1<
MVS#YA+KPBO?!J[5VB5:R_5R-*<N^HII#<Q^UV>3M^AIM02BNRC-QQ1$9--I-
M.F\#B1D1TG&.0C,BQ%U_W$*F,**(0A33"DZ;ZR%*V6BL8#6[C'86%F(&!E5P
MFQ#F4]AZQJA-N6IU5FX928#;]3=4:SXAI2%&:]EQ1Z*7LEO(7S6TH2A*4:$E
M*4I3H>O6I+1'_ET%F9^KR<ZV;G"6\L/;8E1<),$O1%Z;>;\)ZF/UE59B))IM
M$64RQ)049Y/%;*=4Z%KN(S%Y=ELFFT(+F0A#9:\^C:221G^?34955EA26.']
M\<*AHJ[QH+&/J  ,B@        ./+_T63\7>^S4.0./+_P!%D_%WOLU  @'!
M'\8W?\:;^T6*AA3S@C^,;O\ C3?VBQ4,-M/./0G^4AE'FER])@  ,#0
M                           T/F^4OWD*=:A_KPI']1[^&,5%'S?*7[R%
M.M0_UX4C^H]_#&-HQJ^HKH$/%RETD*BP !@4
M            >:N_V.57XH]]FH1A@!["D?')G\2X)/N_V.57XH]]FH1A@!["
MD?')G\2X/(7^&KZQ"5EH/I(3H  /&*
M      .#4_Q;/^)R?L5B$,!_Q'4OCLO^(<$WU/\ %L_XG)^Q6(0P'_$=2^.R
M_P"(<&B\U7)TB5EH/I(3Z  ,B@
M      (:QT]@LSXS#_B$"91#6.GL%F?&8?\ $(&D>>GZR>DA#Q'H/H$@6A['
M*5\49^S2/2CS5H>QRE?%&?LTCTHR(G%J_E(   &@
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M3Y)D;<RF4R8N\@2/W.N66Q-F:&CZ],UH:=SM,1K,EQ>7HS_Q&ZTIQ,H#X<W
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M!J7;+YR !J TU+ME\Y!J7;+YR !J TU+ME\Y!J7;+YR !J TU+ME\Y#4
M B66]S+6   !$LM[F6L   ")9;W,M8    \U=_L<JOQ1[[-0C# #V%(^.3/X
MEP2?=_L<JOQ1[[-0C#  _P#X%)^.3#_:7!Y"_P -7UB$K+0?20G0  >,4
M                                 <&I_BV?\3D_8K$(8#_B.I?'9?\
M$.";ZG^+9_Q.3]BL0A@/^(ZE\=E_Q#@T7FJY.D2LM!])"?0 !D4
M                               !#6.GL%F?&8?\0@3*(:QT]@LSXS#_
M (A TCST_63TD(>(]!] D"T/8Y2OBC/V:1Z4>:M#V.4KXHS]FD>E&1$XM7\I
M    T                                        ("QX_$=-^.Q/XAL
M3?3/Q; ^)QOL4"$,>/Q'3?CL3^(;$WTS\6P/B<;[% T?F)^LKH0)6>@NDQS@
M !D4      :'N(S^  #F[>\_S_\ N(;%MI<(R425)/35*TDM)Z<W6JU+7X1:
M&X1/-UBWEYQ]RD6'A]-1%H.+%6K\6[&UML+XYJ <?DY;3I&:--M7X!EV><70
MZU7I4*Q*W7&74%/A65.K;)DI!F4MBB/3D+-)GS$\E*M3+9TTUW $,1Y<0]NE
M*4EN+FW$1)T(OS)(MWR$-=DCWGO[6I;R^4]__7:&,/@IPFF9B],@F9G'JLU5
MMR^\-+H53+:DE'B$EJ*5RRJ:1&A*>*5_DK2"Z\C/LZZ[Q>4X.C'"]\P^4G#'
M%C$-],JZ[G34CJ;Q(;02N3RG&F^M:(D%HE)%N(@%-)EKALB*X.)1M&O922SY
MUDE).'IS:K(MH]/A,?733F^?M_G&H\)B'B396%UO2KGOJXZ;;E&B)VG9<^4P
MRHRUTT9:=6A3RM="T;VC[8"#W?\ US +%^;SA(:E0\8LI5 R[7K3JW:.*M5N
M"+>"&BC'+4U3W66XW&1GM9+.IFO9-*")2=#(S(R,73L0\R.$>#]-I$C$N^*5
M0)51I\.0F&;[+]04XY';<=-4%M9R$%JHSU4V1&G>6X@%@=%N(5!#0C(]=.QN
MYC(0#;>9+"2]["N"_P"R;SI5PT2@TJ?4)KL>2R<B,J+'==;1(BI6;[!NJ:-*
M>,0C4SU+<+<G!Q\)U3LYF)>.%H5%R+2_215&H=M13?;7RIIEZ0W,=-PB(D$A
M+1.*XP]"3KOW )#&>3&+S0^2V4+,C4E"MG\';0E9I_JFHC,OD%*EU9U<M=FW
M,Y:=>Q3HL:LM/MQGFH[[,J(T^XHDI;<FL+7'0>T9)/:<3H>X]#U%35%K=*N*
MEQ:Q0ZC#JE,FM)>B3X,AJ3&?;4DE$I#S*UMGIJ6T1*/9/<8 .TV2+MG\YZ?F
MT+=_UH/F;*#63FR@UES+-"3<+MZ+TVB^<4,9O[EQDH->PJ:PNQ&IMC0YM1=1
M<D:<W3W%5E@GF20TR<U:%)-*#6G5G4]5%KV!-U<S%X160_)HMY8A4.F5ZBTR
MGO5B%)F16I27'HK;JG6XZGDN.<=O61-H,B)1:  GTTD9:?G_ %\_S]D?-#+:
M#,T)0C:_"V$)1M?UC21:_*(=PFQ_PEQKCRY&&UZTJY2@KV)C#$AA,R.K:-)<
M9$V^/21FD]#4@B,MY":  !MT/L'H7:T&X  :%KV3U^30:@      (SQ>]@=8
M_P"'^V2.7AA["J-_4<_>H<3%[V!UC_A_MDCEX8>PJC?U'/WJ&_1E]<_Y2&"\
M\]'4)!  &!L      ?-QQMM)J<6A"2_G+62$_249$ :,8H9SYYLJ%E<P@J]8
MY;'5>-8B/1+;I:G4)>?6Z1L/.D6IFDV2<)PMI/.6X8D^#^&6(N</'N)1$N2Z
MO7+KK/+[@JQ[3R(4)#_*B:<69J;;UC&;9:J3S:#*[S+Y",*\TMV1+EQ!JJY7
M(4J*G4]$QU++!K02'#)#;Q(7KIK^ 9$>_G'L\K&1S!W*FY6IMATQI53K?$G*
MJ#IJ==1Q.I))I3IJ4V1I/0]A1:ES]L?24P-TR9NYO,65"D9D^/D_I68J);RV
M=$(<W99G@.[%#8VIK4Q=$FIX4G (F[>"3@DDP^+=UG<3W1]V;=2D,YQ-Y/DW
M<ID%X0;)S=Y06TE!]0DDM'QX:.R6)()ZE!:$NB%FT/N1UPE)BM2L*4,(LNF'
MN%6'EM6)3*%%Y+1(+2%KV$;3LEQM!R5+4>JE:O$H]ZCTW;.X;\6K$M6#AM>D
MF+2([#S5#J+C3J4I)2%IAO&E25$1:;)D1\^I:;OAGQ;S3224MQM"3[*W$H+Z
M2C(CW_"//7)2J==5O5:B2WV#A52&_#DK2\@TI;?:4TK525:$>BMV\AT*F67]
MM*27Y\?7IJMH^I>GIHILM2FBE-R:ME'%5*E'A':9CZM:S:DMWD5<E29)CBP9
ML9-:.#DR2P9,T,4)=C8.Z$F2(I2@B21&43*$1@@VK?%Z.XMTJ&[=,M<5=\NQ
MU,JE.;)L^C>QQ9D;FAD2.M(M-/@(9 ?"XT&D4G*?:C\"&Q&=<I-'6XZDDI4X
MI;4-2U*5NU-9J,S/74M>;G$I4K@=LN\*YH]S19ANS(U856")MYYPBD*E\KTZ
MUU1%U_8/=V-!71F+RKV!F-P_IN'=Z;Z33HL6(P1+<0K8BH:0C3BU$KF:2?/V
MA].SPW8IF2I/'<YEJ2C?DN$W'ILVE@DN27=:TJ-V-&]LTM")NKX-IYQE#+2/
MB#<Y]SINDR%N=;L4VIP%)C25IXN+H[S>6<IJ?$,E,^ZM^WQLT9F;LDR:LS\F
M.$9&4/)(SQ$<EN:5C*5B6_B"_;J+I;E,M). F<F(:=(YMD?&%M:\^NFG8TW[
MC%UN=P[JUPY#<#!YM$I:5$PHZZGK5JUT/>G0]#,MQGOWB?Y_ H9>52B>1650
MXY[!(CN*=YDZ$9$I;Y:Z_F/L#T">!<RR$VDU)6HDI2:G>.D$A6G.>UQNSO\
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M"?\ RD0^HV-N)<22D*2I)\RDJ)23_,I.I'\AC>/DD?T#(B(B(JKWR8@   4
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MHU+,S;-'A!FEJML9FT4J.-4!J  /1CW0
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M0<1:_4J!*.NVO$H#M3IY3GE-\=5HK9L,I26K23)2R29I21F>\Q,$]<-L/Q.
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MR&_H)\@:D?.VWX-/D#P<S4_T+7[TWLSK-IAX0)T?ZYG]U8V9MAZQFG(_E-6
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MT>085N73;.&"N4$Y8/#.G%E8G7>F I;I4XBQI<%8O.8+H@9'4UL[1^@IZ_\
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M'*5\49^S2/2CS5H>QRE?%&?LTCTHR(G%J_E(   &@
M                    ! 6/'XCIOQV)_$-B;Z9^+8'Q.-]B@0ACQ^(Z;\=B
M?Q#8F^F?BV!\3C?8H&C\Q/UE="!*ST%TF.<  ,B@    -#YC_,?[AJ![R,NV
M #&9X>NUKSO?&')):N'=W'8-ZU6M7.FBWBF(F>='6AR*IQSD:]$/;1::)48D
M*X<@7">HL^O5%[A)G9%.:L"<^\P>&\!OE,1%O/+7!T)76\8T1L$X7-J:M17!
MGJR37?F<QJRQXCV[<94:!@O4JW,J\0XZ'CJ*:D;'%I):C(V]CBSWI+>+BU7H
M#T^S*M;R'=B1/M.904/::[+TBD.P$N[/-UJUDO3Y/S!J-!%DC&B-=I#"1R?P
M*G2>!US?4JMU ZS6H-V-L5*L&WQ/HC);N^8V[)XDMS?&N$:]DN;:T[ R5^!V
MU];^P/W*_P W63YC/0N7/<_9+G[(HKPAX)?$NPLE&8G+A4+X3*K^+%;DU:D5
M?D+22@&NN3*HR1LDK9<V2?0G>9<VO9,0=@9DIX8O+SAA0L)+ S(QXULVR[4"
MI:56M1%J)B7(4\A"E.&:U;!&6FT9[R^$P&C,CC RQD=,<A%TC*&<49)(R[*D
MEVC+4R(8VF?6DHS5\)_EBRLXES:BC!B$=R2ZW;$.H2J4FZW&J:B?&)4B(ZRX
MODLA!&9??"/\$]"W"]=E)H&8"WL&Z%2\REV(O+$]HY!U>MHAQH)/ZO&IC1B+
M]Z3LMZ)ZW7X=11EPAF06^L>+WPOS'Y>;ZZFV8/!==1?MRJ-0$3?1E%3)#<N,
M^AY:6"VXZ%,DIPCV25JG0RT,,E0>LB/(>46F>$*R88-Y=<^F02\\(:;.MU-8
MJESQJQ0'JK-FQYR(#<=F,XTS)>4VQQ2"XQQ3;9;9ZFH^R/59IZOE%IF>"_JG
M<5&N3,YC2]2K5CIPLI,ZOTZD8<&_1V&>*>F0#>I;QU-I6I&XE'%J+L*$L57@
M\<^.9+,;ESS%9B,5RB1<$UUIE.':*7!6V^BJLIB29'+XRM-J223DD1D9MFO0
MCU(>FNK@^LW&7;-EBSCSE1N&G5FW<?D6VU=-#K-)I=0D6RN@1$1428T^L$\\
MHEN&MXT,&G\$D\P#4<185)$=.(L98ST%5CRTB@K@]($F-P@>;'#$L-JM@OAS
M=]KL/S<*IESS;B:(D6S+DMK;D/NFJ%MK5QQI0A!GKHK70>QX)_!'!FQ7,]5Y
MKJ1X<+MV;*:1>3TI^4BBQ*@]4FIJDL+=2EUQYE2T-EKMDHR-._05^Y8>#.S#
MX89TKUS48K8P(O\ E8L4E4.ZHB*+&IC=+--&=I[#32&3V#)KCMDS:21*-&O9
M$;63P2^-UN7_ )HL.ZMB,Y4LO681QB8TS'B-0WZ%,@E)E1C)]MQ,M]*ISJ-I
M.T232G95JDP$,R/"IJ3E.,,<(TZ^C%;9M]C*;6<&;_LW!++E=^9E4LKKG5#&
M.;=5RVPFHU)AV=+.9'*>>C**7+)2DI9?V'";(BZT7I. &N:YJ_P?%BMW)4)<
MQ^G5V[XL=J;)<G2(##5?E--05375N.2"BMH2P2U+/7B]2Y]]+N"V0;A$,/L+
MZCE*A8D4>V\*X[-PPZ=B6Q;%"7.DP*N<I;;#C#:.6FI#;R8YN+<-2OPC[(N4
M<%GDXOS(]EUC8&7I='IN<I-5K%0B5LXZ(IREU>IR)[SAM)-6SJIWF,]WP<P
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M>/PJR<>E+*E-PAK=(HTR\)M2KLUVJ.TR"N0LYU4?F15&X;2CU0APBUVR/=V
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MIZ:,V\ALU<F:6:5FK3?QJCW$6@J><O/%S+_BW@!A[6\0W;PH-PVO=M;N9UR
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M,VI&K"4[I,F9E'R33@EB&H  XZ.0@
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MVB3*VT[RU+12$&1[M.8AP?4!9TN\/5?&%^:'Z=RDVTLS4LK86H^=2BIJC/\
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M[4C/%7 \F0\9B>"QUA1*[Q&U@QA&"<<%QQQQ92L,?E6^IYQ_[TMR_5E0+_\
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M-7&H+3<66\W.2TMPGE/N\7L1#2A&NCQI,SW%KH L#R8L=[T"\6 %O(C[8 (
M            T,M2[7^!ZC4  60N%=X/;'?-12$7-@3BW.M"? BR?1RRFVC7
M'NQ*V]AE"Y3KR&891T),S5IH9*,SYA9XP X)[-U1<.*+1JAGDI&"=43)J1+P
MW34:14"I9G(6:W%RRJ:4ZRM#>-*B(TFHTGS&,I3.Q>MT6!EHQ5NBSW7F*] H
M4A$1^.V;CK*7V76G74)21GJVVHUZEO+34835"RA4J[[+RY8\WOCS<TRFXZW-
M?$7$&K-UVK1H]KR859<A4PI*6J@2&$\<YLIVN)(]G0=I33?7]XD=;LN4'5R=
M&#TED[F<DL7]X:-28-G@V:L."<'>T*P%+PFBC@S0HBH'6,ZG-P82LS;H<7E[
M>FSN;5N12HV<6#-GO[NP2M.!A*CAK3AI1@LTE%:R,Z2R-N#$X/2T\K6+&(V(
M%S9BH./.,%VE3_1J5$<:VJ><5I2&S<3&E2&U<8T>XSTTTW<XONI(B+0M_.>O
MYQC!\$3A9AYEASJ9D\"J=?E0Q5J;$.T)U'O%=8EU*(MFH4SERD)2<J9'0;;;
MA-*/C-3,MY$>X9/;>FSN[9Z_GU'$9U[\<K*6V?&C]OCLZ-&3RMW0Z$MBMW9J
M9$AW10R9I29)2F!&4*2'*YK;R4E)2Q=6;GO;R],VCNAX4]&AJALI+0UO"_*:
M+4HL)2HF43*!F-X  XV.1@
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MM,N.UI%$F19LR.U2W95904YHXC+J&'R?U4A6V@]GM!@%337#%7&%Z0PNO'5
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M<0]=>X0+O]S/JR-Y1U#G"A9[7:JW6EXXRSJ;6O%R?0YCK2,M#ZW79YMV_F%
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MW)ELML\(=,3;]MO4Q+-"AX<PX49=/IRV2Y&E+#J&T&ZPR32W"1M*-1K49GO
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MH2D[&IL$C7?SBNBB4Q-&H](I*7.-32J53Z8ES39XQ,"*U&)S3L;9-[6G8UT
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M$3H>5(?71VP)&9);NCVDWN6#42%)4;)+1U9&A251:)/"5$R(R24*2%US@:;
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M/[UVXMLD1G9>UKV"FM?X_K'&].N+7<0?CS?D%P#RIYR;+;;T185A\I:"_&]
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M])"<]"^'YS\H:?G^<_*-0'C%
M'!J?XNG_ !.3]BL0A@-^(ZCOYILK?_Q#@F^I_BV?\3D_8K$(8#_B.I?'9?\
M$.#1>:KDZ1*RT'TD)]  &10
M   $-8Z>P69\9A_Q"!,HAK'3V"S/C,/^(0-(\]/UD])"'B/0?0) M#7TN4GX
MJSKX-/\ S'I1YJT/8Y2OBC/V:1Z49$3BT0Z"/\0   :            #0CYR
MU&FA=HOF(:@ #30NT7S$&A=HOF(:@ #30NT7S$&A=HOF(:@ #30NT7S$&A=H
MOF(:@ #30NT7S$&A=HOF(:@ #30NT7S$&A=HOF(:@ #30NT7S$&A=HOF&H
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M,H\TN7I,  !@:                                &A\WRE^\A3K4/\
M7A2/ZCW\,8J*/F^4OWD*=:A_KPI']1[^&,;1C5]170(>+E+I(5%@ # H
M                                \U=_L<JOQ1[[-0C# #V%(^.3/XEP
M2?=_L<JOQ1[[-0C# #V%(^.3/XEP>0O\-7UB$K+0?20G0  >,4
M                          <&I_BV?\3D_8K$(8#_ (CJ7QV7_$.";ZG^
M+9_Q.3]BL0A@/^(ZE\=E_P 0X-%YJN3I$K+0?20GT  9%
M                          0UCI[!9GQF'_$($RB&L=/8+,^,P_XA TCS
MT_63TD(>(]!] D"T/8Y2OBC/V:1Z4>:M#V.4KXHS]FD>E&1$XM7\I    T
M                                      ("QX_$=-^.Q/XAL3?3/Q;
M^)QOL4"$,>/Q'3?CL3^(;$WTS\6P/B<;[% T?F)^LKH0)6>@NDQS@ !D4
M  &AF1<XTVT]O]1^0 &X!IJ6FO8^?]PU               !H1D?-V  :@
M  --2/4NUSC4                 $9XO>P.L?\ #_;)'+PP]A5&_J.?O4.)
MB][ ZQ_P_P!LD<O##V%4;^HY^]0WZ,OKG_*0P7GGHZA((  P-@
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MG3;.347H=OVS3Y#S)H;0^J.E1.Q5(6[RG90O0T];M:&-UAY!LV6)5NHNVV[
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M)G\2X)/N_P!CE5^*/?9J$88 >PI'QR9_$N#R%_AJ^L0E9:#Z2$Z  #QB@
M                                #@U/\6S_ (G)^Q6(0P'_ !'4OCLO
M^(<$WU/\6S_B<G[%8A# ?\1U+X[+_B'!HO-5R=(E9:#Z2$^@ #(H
M                                "&L=/8+,^,P_XA F40UCI[!9GQF'
M_$(&D>>GZR>DA#Q'H/H$@6A['*5\49^S2/2CS5H>QRE?%&?LTCTHR(G%J_E(
M   &@                                       ! 6/'XCIOQV)_$-B
M;Z9^+8'Q.-]B@0ACQ^(Z;\=B?Q#8F^F?BV!\3C?8H&C\Q/UE="!*ST%TF.<
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MDHXFS-HS2LT&>5)JP3M(  !XQYP
M                                            !Q9LMJ!%E3'S)+,2
M,_+>49Z$EJ.TIU9Z_ E!_, #DDHC,R[)? ?_ $8U%K'!_/97[^S-5?#VJ6ZJ
MGX7U^6[#PXNMQ[2/6'J8A:*LE)&E.QQ,E!HZ]1Z]@5LXE9CL)L)9\.F7M<AP
M9\Y:4,Q(<-^HO(VC223D(BH<4PE6T1DITDD9;RU(A3(R.%9E&_XB1(Q.H"*Z
M7C/AS6:A1J93KCCRIM>COR:6P@M52&8S7'/JW?@FVWO4E6AES&*?\=<ZF&^$
M-O,UF/*57#75(E,>;C-.KY.[)FMP_OAM)5LZ+7_.W'H)CH(45J *=[QS080X
M?1K>=NZXG(4BXX<27#B0X$FH2&RDL-/?Y4S&;<<BI(G4]<\E!::GS$)@H-VT
M2Z[?:N.W)[-4IDJ*](BRF%)-*^+0:ME1),]A1'UII/KB/4C(C( 'I]2/4NUS
MC44BY?L=Z_BCB%B]:M6IY0XEB2J<S3WB<0OE!2^,VCT(M4[)I+G_ #">V\3;
M+=NRH64FLM%<E+:)Z93EEL+0V;1O&I"E[/&$39&M6QKH7/H #WX"G&M9K\#*
M F2JHWHTDXJG$+0Q&=DN+6RHTNI8;92M3YMFD]OBR5LZ;]!Y5>>#+@W3*96%
M7VHX%7DE#BN)I<Q1M/F\F.E$Q"6C5"VW5$E!R";)7.6HL#/$1@*N!H9Z?^XS
M_<(#OK,Q@YAW(@1;GNM,:54HR)4*-$BNSGGV'&DO)<2U&2M9D3:B6K=UI:ZZ
M:"G?'O.A0[ M?#V_K0EHK-E71+DM3ZJ@MER,AB0AE6W$,C>)6T:DDDTDHS(B
M+4P(C.K& N"@(#PQS(83XJTJK5.U[G0^BWH,657D36':<Y X]CC.N:F$TX>U
MHK9T3HO=IKV>@MO-G@M>]:FVM:=U*F7"U$J;D6+)@2(3$M^!'=<6B-*D(0R_
MLJ;T,VC47P[]!('DQ8PB67'BM%31'K_[C+]XUUWZ"VQ@OG\L>X)UQT'$JHN6
M[6Z96/0UAKD;\F.6W,7'9XV8RCB&N,(D&GC%IUVM"WB4*=F7F*S 7IA_466H
M]FVU"I\YNM<:A3;C$N 4O:))=<9F1[DD9GJ>G.8ID98RO<Q",C%:X"FJQ,VN
M!N(US':%L76\_7M91(ASJ9+IQ/\ (R6J0<=V6VVA]+:4*4:FE*(DEKN(R&C6
M;7 Z1>"K%C78Y)N$CD))MFGR7(*EQDJ4X@JBEM40U)V33H3GX6[GW"0/(+'J
M%2P"@"F9S*%?U5QEM.VI2Z+4<,Y= 8*J26%DT]Z*ND2BU?0EI)&G<77;]>M$
MUW#F8PNPUIEO(O\ NOB:G5VD;"8,-VHN*69)U4^W#2Z<9)FLE$;A)3IO+<6I
M('?6%_P%2@T(R/>0\= O.CW#9[]W6U,14Z:NDSY\*2WN2Z<6,XZ23_(5M)))
MD>\CW'O(01E1QKKF-UB2[EKL H$IBJU*$EHEI<U1$G/14*U21%HI+9'VRWD
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M5Z0YNSTI+PT_PD-F2V.^'")I0:J#5FQB=48"]( T(]>8:CB(Y6
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MFK0]CE*^*,_9I'I1D1.+5_*0   -
M        " L>/Q'3?CL3^(;$WTS\6P/B<;[% A#'C\1TWX[$_B&Q-],_%L#X
MG&^Q0-'YB?K*Z$"5GH+I,<X  9% :'S'^8QJ  +&?#$92<;\S<O+PK"&UDW(
MU9=S)GW$2I#+*(L4JE"?-9I>W.?>VUJT(M=PO-VC;[-)MVW8KE.@QID*W:+"
MD<7$CI<1)BTYAAY'&H02CV7$&G7733F'L#+7M?*6HU 6-!%DCM%H3A>,M6+N
M9/!&V;3PBMX[AK<"Z[<J,F-RAI@VXL&O0IDAS:=/0]AAI:M"W[M!ZCA-\O6*
M>/7!_2,&\,Z$=;O]2L*C12"?;9VO2[.I3U5+CG.L^\MQGNSUVSNYQ=2,M>U\
MI:C4]_\ CO (XK#CT=0QD<[^3K,C3\5,FN8VW<+)6/EI8+VX_!O? _T;11(#
M$N11HE/:Y0\I2F9NQ);4\6TRHDF78U$>XR8$YW\SF8#*?C93,K='P>PNP>FU
MCT1LFG2Z*N5*;JW%,H>>J$=EF4?(E)X[1>IKV=G=J,JQQI#B32I*5)/G2M)+
M0?:U2K4C^8:)90A))0E*4ES)2E)(+\R"T(OAT 4E0A01PCCMLQ7L&/=CC6<^
M>$>.6),>[<M]!S=9?+ZHU"AV&S-30*/,L%YBE(9J$9,IR,_.E')E+XHG%*3L
M;&T6[F@O+/P4&).(6#^="/BC:DC ^!F:7:]8LO"ERJ^C\&R9]I/.3HZ8[J7.
M(4BJR4LK6E+:$HVR)1&1&190CK#;Q:.-MN$6\DNMI<21_ 2B/3Y!]"21%L]C
MM%N(B+F(B+<7R )'(1%BRU<L-@Q<;+N7A$\(\&8F6")D9MFZ<3;?>DT6V\9W
M9%J\3)I;TE33%3535T]:4KAT_BW#0X\9N;!E^$8OPY+,.<5L+\O=F6MC;6H-
MP8F-E-F7'4J?2X5'C)7.D')9@IA0$(C)Y"A9QMMM.CAHVSYQ50<=HW"=XMOC
M"UT<-M!NEKVG#+:+L]D?<BT #.-191U=7CNR:?4&64[3CU-G,-EKIJX]'6A"
M?E49$+//!L97\9<#,P^<2]<2;<.C6[B;5K=DV?+Y0T[Z(M03D<I5L-GJWL;:
M?PN?47FAIIS\WS?O[8"9;?[CHKEHK=Q6[7K?>5LLURB5.CO*TU)*:A">AFO3
M4C/8)XS(BYS(8V.!UGY]N#9K>*6 5A8!2,?L&+MEUB5A;<\>X85!30Y5<<F2
MYZGHBDNNNI1+F%N<-.T39:&1;ADV#XK8;6:5*0VHT_@FM"5FG^H:B,T]CF\@
M"D<+8Y1BCY9^#QSRUW+]GRH6+$:5AMBKC[*MRJVK48DUAUYZ/2IK\U=)0Y$<
M03?&QE(AJ<-:3Z[:/4Q\,$K"SHVQE=KN4>U\C-+M+$!J!6J;,QAJ];HM>E.G
M)-\T3314([KJU3T*,TDE_5DW3[*2TRPR3N,NP?S_ #]GX/FYA\2CMDM3A(;2
MM6FTXAM*'%:?E+21*/X-3,!<(\A8R/E(H#%X:R$YKYW KTW*^_96F/-EWF5T
ML6YRR*15TF[S3<"V42->(CI6PWLD1?@DLB(BTT'2YJL <Z&-J<F&:"NY>)E:
M5@+2ZC1[\RS)NIJ/#J6Q#BTB!*DU-"B8DZ\GY>E"F5[.UL;MQC*G))$6F[7?
MOT+]?;_YC8IE"D&@T(-)\Z30DT'S\Z--D_F ,([,9GKQW[1B?9C\"<\>;>\<
MM-_VIE0H^"N'F$56XRK6G!FT5Z77&)4J,2U.U!EAF4WR'BU.:F9FYII\(RJK
M;C/Q*#0V)+?$R&*'28[[.NIM/L0F6W6]?YVPLC3KV=!VR&4-I)"$H0DN9"$)
M2V7;T01$7[A]@$,XP+%#\0   0    1GB][ ZQ_P_P!LD<O##V%4;^HY^]0X
MF+WL#K'_  _VR1R\,/851OZCG[U#?HR^N?\ *0P7GGHZA((  P-@     #RM
MZW3%LRVZG<<QEQ^/3&3><::0MQQ9$6NRE*$J4HSTYB+4 % '"1WOCC!PM.P<
M"+2EUZXKQ:=CS:K%D<0JCL-JT6G0RT7RADUIW&6G/O%BO)_P;F,V(>--%7C'
M9TJWK)I=054ZY(DO%)54)"EE,;)6IDX9<H+0R(S+0]3W<U[*@<*'@===]O8<
MPZ/4W[NI\A3-1I[U%J!JA)U5LN+=<BF6BD%MD>I%IV16YAOCAAOB,Y=#5J3&
MG9%HQFI5?;1$-A41+C*GRVCV2VS)#:^;?JD=O34W7Y5F7-24)M2#)4G.KQ*:
M6W=4N?#G*1M&R39I:)5OF])-W8F:'<M[@S49M(89F9_/$_?<\2#ND3\DF><Z
MY=EA_=)%4[=Q38(G9$C)8NZT-E,5IWO?U)>GA.^/2C:839!$R,\!*2*5+>M^
MF6Q1:;0:1%:ATZEQ&(D6.P@FVT(8;2V2B2G0M5;&IGVS'VK32W:156VDFMQV
MEU!IM&I]<M<9Q*4Z[SWJ,B^44AWUGJP+LK#UO$)^M/S:;+FOP*<Q&@RG7YDJ
M++.'(0AII"W/O;Y&DS))Z\XZVP,\F'5Y42[K@E4ZJ4.EVDQ#>G/SJ?/:)Q,]
M&U&2WQ[+>V;FI),D:Z&9:]H=2[ZM37?EJ-;0VF^*4HS,UJ-6$9J/&9J.DSM'
MT"3NS0P)W9I)DR2S)DA*")*6:"22$I0G$E*4D1)3B(B(AB_XVY/\R58QBO6K
M4[#";)I\VYF)+$E+J=%LIJ!N<81;/,2=%=G<6G/N/('Q$PXOB1P;DJPV* \]
M=Y4*&R5%2K5TW$OI-2=HB/F+7L'^83;:V=K"2N/P':W2G+?IM8E*C4VK3*0\
M;$APG>)0;BW(R4M\8LTDDUK+77=J)AQCS*X2X(R+-I5^55N"=]N$U0FDPER6
MI&IM$DW$-I4VRE7&HV3<(B/7=S#NB<^[9*TZ&4TV+S)#@[IFF_N;^[FQ:-S-
MZ6YH8(2AMAK/!2I+!,31 Z3,H#YIF/[F.;TQFT_FSE."5GI4_9(E"27WNADZ
MEW&SE!HW:+:N^ DL);-3=6"33R3K*$"+"_B95\S4%?'P<,JS%DMOOFW)8?>8
M>;VG#_ <;2E1:EVC+GW]H>TIV6#.O5FENQ+2O!;:2V5;=?J#9Z'N(M%.EKJ1
M:;MPR]<:<P6'&"Y6?'JM+C5"J7TTM^W*?%I:7%S6FVVWG%D;+"]DDMN)7O(M
M1YJ@YO<$9E"N^JU-V/07[&CQW[BILBDJ:?8Y6@U1DLI6TA4@W-.9I*C3J6H[
M ;>ZIEQJ43FE("EE B6V4\M3),2,R\I9&5D#@1TTXAU*[^X0FRP.!;H$ZF;$
MZ38NS)R81501&9DE1'"&,R,X4810HQ=<-N#3S<8G5QJ/4;.GT&&\\A,ZNU*I
M)GNQVE*T6M*92S<5UIGJ1'V.UH,FK)%DGL[*)9*J=!4S5[OK#+*KAN!3!(>?
M>1JM"$)6:C:XK:-LS0KKM-X\SA?P@N%N)=PT^C6]0:JS!JB:DY'JAT>H1XRF
M*6EQR0XI9Q4((B0VI1;2B(^P*LK+QNP_ORQY>(5MU7EELPCFD_,XI:-@X"W&
MY);"NN/BUM+(].T.M)_[MD[I_N924^=R27(^$A;23I-0T0S>%,X&CNEJU:-&
MK5*%%A(9X269*@K B1&7=>Y-[F;<_P!R:43EV3^[Y<G%O:V3&5Y9:,FK5S0U
M+!:DY,6+)DQ8+:I\EHUP5MC2:DDT)*E$< YR<DV'>;:T%TZMLL4F[J>TXJ@W
M.VR1OQ'E=<HG$M[*GMLTI07&*/9+X!C/XO\ !?YJ\(YLJ91[?FW51XSJRB5F
MF3TT]];1*T;4;49?'?@DGGW_ *QD48D\)!@CAW0*=>,[T0F6;4),F(W7H].G
MN,)D1GSC*;433*B)1OEQ9:F6_F'K;%ST8-WO0H=:G\HI--JSK+='.HTZ493S
M?<2V@TMR&DF77+3J>FA$9&/','=IGA,!W*3G)J[RE(V&:RDR4D+:LF.'_B=R
MM6:T-F!+QJ0E1L\(S5O9F9Q\NZO[FC<\W6'PY:E)B^2).$V:69RW(K1#!N\[
MV4&7=S%HS:L'HV94):*0AN22).^X*2(L2UG*AFNN:;&@O8>W-49#JR;91/JT
MQYDCU)/7)DFIO<>G/V2Y^<7L^#HX+VX\.;LIN,N.D9N/7Z87&T&UW4MO(A&Z
MC96I3S9FE9F6RK12=2/FYA</QAST8 8/7<JQWR]&KLALQYE5I])H#\KT*BR6
M$RFWGWX<5Q"-J.HW2)2B,]-.?4B]75,\^7^FX)1,=4W2;UGSU''A)Y'(;GO2
MT2"B.1TT[9*61HD_>]>*+7GYM1R>>'NBYV3GD=XD-T<9.D%T?&2F#VT<2:K>
M6K!90:,4-&JU)8LVI12TWM!+4F*261&9#@^YW[CJ84R)Q.<YY1E65YUO\G-F
M;S)["5.YV;DP>F1I4R>FK%BSPGELQ6DEL2:M=Z0HB4;-1D4*RD(2VE*$D1)0
MDD)(MQ$E):)21=HBW#<*-LON=C"/,!<-4LVWI-0IUX4A$=V91:C39T/5F4V;
MT9QA^6RTA\ELZ.&39GL\Q[Q601D>\CU'SV/KXB(B@5!$-0
M
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M/C3_ .V>;/HK3U#Q]XLZ>*S^\,/SC$X 98_W+_6?]H@_T>__ )@?<O\ 6?\
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MS4(PP ]A2/CDS^)<'D+_  U?6(2LM!])"=  !XQ0
M               !P:G^+9_Q.3]BL0A@/^(ZE\=E_P 0X)OJ?XMG_$Y/V*Q"
M& _XCJ7QV7_$.#1>:KDZ1*RT'TD)]  &10
M              $-8Z>P69\9A_Q"!,HAK'3V"S/C,/\ B$#2//3]9/20AXCT
M'T"0+0]CE*^*,_9I'I1YJT/8Y2OBC/V:1Z49$3BU?RD   #0
M                            @+'C\1TWX[$_B&Q-],_%L#XG&^Q0(0QX
M_$=-^.Q/XAL3?3/Q; ^)QOL4#1^8GZRNA E9Z"Z3'.  &10
M                                      !&>+WL#K'_  _VR1R\,/85
M1OZCG[U#B8O>P.L?\/\ ;)'+PP]A5&_J.?O4-^C+ZY_RD,%YYZ.H2"  ,#8
M   #CRFFWFC;=;;=;4I.TVZA+C:BUYE(61I47P&0Y   M)X>4.C)S]9A=*'
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M#NU/0R94-@WYL^8_59B=C793'DSE//1TD1FDR:6DC3HD]PJ"
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M./\ 2#R,JN:7YM-RI>5FZSZM-RI]%Z?[3]^&?U>0/3_:?OPS^KR#SO46P_\
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MH98A<\.3SE_Z9([?]<0[-PYMEO%.G6XW&>*ER$N&XT<ETUF:6=LM'35MEO\
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M(,^$KFE9;IOC>5FZSZM-RIFYNMTATS)%1AF9=CE#73'V]$Z;[OA^,L],0:G
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M]QN'KV_^001PC+_ML*W+'4+3DR?A';'5KG4  9%
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M@FY^$"P<MS*7$S9\K3(LVI,MHIL7[XEV74G'TQ#@H+0W#-,U1,FO9Y]XI8P
MX6V)B1BS9^&&+.$<O"!>(JI)V#5I]0=FLU]B,WQINHVF6TL[3:FU$E2M>OT+
M707!49&<,48V0QZHTA$J*<>(7G0%$&<_/1A-DVP]?NZ[JC$J===Y/Z"VJP_M
M3*EQZT(U43.TXPE)+)9&XDM2/=NWB6<K..[693!*T,86**=OLW6U)>:I9O\
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MC^H]_#&*BCYOE+]Y"G6H?Z\*1_4>_AC&T8U?45T"'BY2Z2%18  P*
M                             /-7?['*K\4>^S4(PP!]A2?CDS^)<$GW
M?['*K\4>^S4(PP ]A2/CDS^)<'D+_#5]8A*RT'^ G0  >,4
M                       <&I_BV?\ $Y/V*Q"& _XCJ7QV7_$.";ZG^+9_
MQ.3]BL0A@/\ B.I?'9?\0X-%YJN3I$K+0?20GT  9%
M                       0UCI[!9GQF'_$($RB&L=/8+,^,P_XA TCST_6
M3TD(>(]!] D"T/8Y2OBC/V:1Z4>:M#V.4KXHS]FD>E&1$XM7\I    T
M                                   ("QX_$=-^.Q/XAL3?3/Q; ^)Q
MOL4"$,>/Q'3?CL3^(;$WTS\6P/B<;[% T?F)^LKH0)6>@NDQS@ !D4
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MO!A>7_%2?A@_,.;,I!421,>V=G1V<RS(-O34R+BU+-!_FYMXR9L,O_FP(?\
M^+<_[1P=\;LLWYF(D"8$J3=D.2'1VEB<TFP;NDGL793W)[PR):4-<%"5*9-$
MFE1H7&,2,Z1\K^YOG5NC+G3NM2'.Z=$X7]^F],B6"-VE"5GE\3)\K.CREFT:
ML,-JM#-X8KBDFK*&"<22<!8C]<^SF\9*(L2W5;%0GLMI13(ZE&AJ4XA"4(26
MTK921%NU,^<^V-GKGV='F]/]8[?L;7O_ +']9"G'+72:?7<?[#HU5C)F4Z?<
MU2;E15Z;#R3G*W*U(R,BU[7^.9W3LH>7Q^# ><PXI*W%T^"M:R;:(C4J,@S/
M>CG,]YZ]DS,AR'=,EW<RW,WR3'-]W-I'E-4I.C1Z2T=W&3F*69,VI,C2I+1W
M6:C.&%$H0C BK+A^XI-/=LW:Y.EN4I+W99P2*B1G]@XM&3[*DLO*FRF[$FQ+
M0IB]H)*4I\F!D9F=,1C.65PO>;&W)L55P51VY8,=Q)R($J#'IKC[9&6VDENM
M)61[)&>[FU%_[)7P@F'N;"B/Q]EBVKXI,=*ZO;KKY+6G1!J4XV\O82Z1H0IP
M^+UV=>R0@_.YP;F"UZ867'<U@6NS;-\T*&[-A38AK-+J64FZ\DV4[+1F;2#+
M73LZ\XQ;L.,2[WP8O!ZYK+JCU%N&G.U2DO.-F>PZ@^-@/&XUJ2%FI&WLFLC-
M.N[?S<<=9H[FF[A->47R:$B,9J3CDQ:69(0A+!FALT3ALDO+-W,V#9U>4H6D
MFR62&S):3,TX)05S)\W0=VKW,,^9&DW="G*WG[,^662FV&U:M'MJT=F*DLFZ
MW%L^$EY=7]S6MFM3NT;+8-F:R+"\HE)R/,[W"UPL)KBJF&."T!NX;GIRC9J=
M=0\E#5,=YTDE#B3:?UZY)[)GH9"TZYPL><?T5>J+=Z2-AT]4PF*.S);921;D
M[;;2D[B/\_RGNH7MRC5S%3$:ET4GW)->O.L-D_*69N/+Y1*2<EPS,S,R)+BS
M(C/<7,,O[ C@V<M^'>'M!I=6LR+<=??IL=^KUB0XX2Y+LIE#JD\6XI24<6:U
M(ZS3734C(M!^Z<,F[D6XE(DCN$LS68SFE>461FT6W8,'EY>#9)03R\J6]&;)
MV=]]/ 8,V+,E*IQF2UCU4T99]T'[IJ<LX94FY/EXF7-Z17A&],W9Z>7)R=$M
MU+-R<63%Q(F[\][P6^/#9NT-*3.-!*0@K0F"/#68K6]4XD;%ZWO332'7D(F5
M/C6H+L5I2ME3IQFVR</8(]K30M=GYLBW ?'_  [S"V13KXP]K,>I4^:RE;S*
M%$E^&YN);;K*OOJ=ES:21J26NFI;C%DSA$."]M*CVA4,5LO]!73ZG22-VKVQ
M'XR3Z)$XHDD;9K->QQ2=I6B$GKS:<QBAS@V,2<:,ON/%%I4ZUKF9L&[Y*HE?
MA.Q)_)8[K"3:84@ELFAI)/*,S-!$1[M3,APV<DR-S;='F6^3RW/6;*0)8DU#
M5H]R(MJS=R;FP9[ZU=C=%-5(9MC8Q:.K9U,F+6& I&$<4=CS+W3=V?<:W2I-
MW.-U]N\3LF]+*W=E)\Y63%L]J=DO34F#N^H?DL&;1J[);P8OSL^EW0PB31"S
M018>8, X\5\I,=B0E)I2^PR^E)\Y$\@G-#W$>I;6A_N(<@?(IT4'C(?T*(R,
MB,J8D1ZR(^@P   4                 &U:TMI4M9DE*$J6I1\Q)06JC/X"
M+>*%,1.$ P0L7$*+AN52=JU?7)3%E\FC2%Q8CJU$24KEM(6P9F9Z$1K+?N[8
M]E)LD2G+#5HQDMQ>7YHR9*;-4N[-33>V2"BIHT,B@A)0QJ,HG043'I9;G%(D
MW&#%YEN4W.3&+PW0[,%O;9#+?F[0R)#)DDSPFC14?-01P*)G B%=H"!K S$X
M<8B7I7[ HE42=SVZQ ?J%/=0MIPDSV2?9XLUDGC?O9ZGL:Z=D3R/RO3H].30
MF+VP:N[53-FU)#9"D*-DU031DLB41&:5H42DJ*A1&1D9D/VN$HN,IL3>)/>V
M#XP2U:L%-7=JEJA+9@LV;=D:DF<&C)H1H:)."DJ(R,@  'YQ^T
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M(K,H-KQXD2BQ;;@SW%L);XIU4B S+FOO.H+1>TM;BUFM1\YZBBW,WB3A!:&
MN/N)N%#E/<N*HKHU$NRHTU"6T2GITDZ8RC;:+BEFCC5(5LF:MK77>(GHF6W/
MS;=$/!NFX[&JR4I=IT:\ET2$J0Q17MI"H7$*4;ZM(A\D)S:U+3;+0QZS%/@[
MJJO*6O+OA3>+U'JE2J,2LW!<TEE4UZK5&-5$54W5MRG%&E)R25HC;T22MDBT
M("@1E%6,RU1QGU8XA3#%5M@59XZZ14=D.LM.%^56PJ+46VXJ$,5>MS5/(2VD
MF:D^[4EK=-9$6AH=,]5\Y=G04=Y2EP;\STYQ;SMCB6\.746W%E2(Z4,TNI;$
M!V/+)I2"1'5Q:^,)XV]>8S5H.\@Y9<^5PV]$P]K68I%O6DBGQ:5,>CVU 4X[
M3F&$1G6$J9-+J#?82;9K29&1JVNP*E(64,\*,LEP8-8$UI5KW;68KK;UYJ:.
M7.E2ICJW)\AXY"C<63JG'30E:SXO:T3N(A*/*II5DQ%21QQ=%(9*#(BRZ**[
M>F-.*FG'+%AB[DSLGV4&UV9M3FS%,WM=42,VBD6<Q*D<HE&2W62AU5R:TM]!
MFAU2F%;MRB'78QY$:]<F%N"&73#W$^+:L&T'YM3N?C&H\E^?/ER&ZDLTP77N
M,43<GC#3L),DEH>XM"'D\#,G&=; :DTZV[3Q?C)AIJKDVM5-^@TZ14:JU)F\
MI>0Y->VI1$25+0G5P]"/0B(B%5N8[*[B;=%XX=XWX1WI*H.)]D1'452%H;T*
MYGID9N.ZMV,ZX4-DF2):B2;9D9GNWD+B,B(R@5,81IAC.)?VKI"V%-!0R$<*
M*L5S*JGVV*KCQE>S;8/X07-BB6)UB8N1)D1-/]#8T)VVBMZG((M32:WE%)61
M&7-H1=DMPO*)/4B/MD1_(?,7R"W-@)E-OU.+1Y@\P-W'=M^1DZ6K23BHC-6G
MMLG'F<2IE1LO<K1OW)+9[',+C1;OU_K/4156@J2*%\G)D%*O36<;.T:@ #(H
M        #CR_]%D_%WOLU#D#CR_]%D_%WOLU  @'!'\8W?\ &F_M%BH84\X(
M_C&[_C3?VBQ4,-M/./0G^4AE'FER])@  ,#0
M        T/F^4OWD*=:A_KPI']1[^&,5%'S?*7[R%.M0_P!>%(_J/?PQC:,:
MOJ*Z!#Q<I=)"HL  8%                                    'FKO\
M8Y5?BCWV:A&& 'L*1\<F?Q+@D^[_ &.57XH]]FH1A@!["D?')G\2X/(7^&KZ
MQ"5EH/I(3H  /&*                                    .#4_Q;/\
MB<G[%8A# ?\ $=2^.R_XAP3?4_Q;/^)R?L5B$,!_Q'4OCLO^(<&B\U7)TB5E
MH/I(3Z  ,B@                                        (:QT]@LSX
MS#_B$"91#6.GL%F?&8?\0@:1YZ?K)Z2$/$>@^@2!:'L<I7Q1G[-(]*/-6A['
M*5\49^S2/2C(B<6K^4@   :
M   $!8\?B.F_'8G\0V)OIGXM@?$XWV*!"&/'XCIOQV)_$-B;Z9^+8'Q.-]B@
M:/S$_65T($K/0728YP  R*
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M=4BW;>:6EQN@T=#B#VDK12H25I,]^J5ICD9'KOU(]=1R:G46:93JA47E)0S
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MKLP>G=:D*9FIB\,TM62C0LDK09H6D\%1$HHP,B,  !X!^L
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MCW\,8J*/F^4OWD*=:A_KPI']1[^&,;1C5]170(>+E+I(5%@ # H
M                           \U=_L<JOQ1[[-0C# #V%(^.3/XEP2?=_L
M<JOQ1[[-0C#  _\ X%)^.3#_ &EP>0O\-7UB$K+0?X"=  !XQ0
M                         !P:G^+9_P 3D_8K$(8#_B.I?'9?\0X)OJ?X
MMG_$Y/V*Q"& _P"(ZE\=E_Q#@T7FJY.D2LM!])"?0 !D4
M                         !#6.GL%F?&8?\0@3*(:QT]@LSXS#_B$#2//
M3]9/20AXCT'T"0+0]CE*^*,_9I'I1YJT/8Y2OBC/V:1Z49$3BU?RD   #0
M                                      @+'C\1TWX[$_B&Q-],_%L#
MXG&^Q0(0QX_$=-^.Q/XAL3?3/Q; ^)QOL4#1^8GZRNA E9Z"Z3'.  &10
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MEQZYL>L([0J2*1<>(-L4VI*=XM41=8IYN,J-6B4R"Y01L:ZEN=)(!"'+2)B
MCUWD*4\T>:&V,N^7J[,>$2:1<%)H,1EZ%R>K1.25%4A7%H)F6TZMM1H49;1(
M4K0R,C(AY+(]FUI&:K+9;..,U^D4-=5=JGHK#758JVJ2U$EN,L*E2#<2ALG6
MTDI'&&G:WD6I\X(41JQ"MD!#-&S 8.UZNG;M*Q%M>55S6;2(A5BG)XYQ)Z*2
MPHY.CJB,M#)O:/7=V2$RI,E$2DF1DHB,C2>I&1EJ1D9;C(RWD9<Y;P :@
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M9F9F9F9F9GC']"&#%F[L6;!BA+-DQ9H9,V:2)*4,V:20A"4E024I21$51$
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MKRQG ZN[F^&MIO2&1,F#LT:,TNK!V9L79@>%A+2QPUEA*,  !PT=D
M
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M;%@/=VD_13Y W=I/T4^0/ U,'BY[^_M[+=-\3QC=U3CIRJ_9+IFYNG5;3?\
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M\6S_ (G)^Q6(0P'_ !'4OCLO^(<&B\U7)TB5EH/I(3Z  ,B@
M                            (:QT]@LSXS#_ (A F40UCI[!9GQF'_$(
M&D>>GZR>DA#Q'H/H$@6A['*5\49^S2/2CS5H>QRE?%&?LTCTHR(G%J_E(
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M.*L<UV)EQWE!PPP8IF)IVO>3=%8N*[JG%:)QPFH$%BLQD.MM+22.5,M;'/\
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M1DSBU)LT>WQ6\+A!FG?8$9*\DL9@ !Q$=A
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MBL0A@/\ B.I?'9?\0X-%YJN3I$K+0?20GT  9%
M                   0UCI[!9GQF'_$($RB&L=/8+,^,P_XA TCST_63TD(
M>(]!] D"T/8Y2OBC/V:1Z4>:M#V.4KXHS]FD>E&1$XM7\I    T
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MF,I43+!2.YO+1"V<GJ?D+:LVBT+WQLI*%J0R-MO:#P2(  !P@=G@
M
M                                            ./+_ -%D_%WOLU#D
M#CR_]%D_%WOLU  @'!'\8W?\:;^T6*AA3S@C^,;O^--_:+%0PVT\X]"?Y2&4
M>:7+TF   P-                                #0^;Y2_>0IUJ'^O"D
M?U'OX8Q44?-\I?O(4ZU#_7A2/ZCW\,8VC&KZBN@0\7*720J+  &!0
M                            !YJ[_8Y5?BCWV:A&& 'L*1\<F?Q+@D^[
M_8Y5?BCWV:A&& 'L*1\<F?Q+@\A?X:OK$)66@^DA.@  \8H
M                       X-3_%L_XG)^Q6(0P'_$=2^.R_XAP3?4_Q;/\
MB<G[%8A# ?\ $=2^.R_XAP:+S5<G2)66@^DA/H  R*
M                       AK'3V"S/C,/\ B$"91#6.GL%F?&8?\0@:1YZ?
MK)Z2$/$>@^@2!:'L<I7Q1G[-(]*/-6A['*5\49^S2/2C(B<6K^4@   :
M                                    $!8\?B.F_'8G\0V)OIGXM@?$
MXWV*!"&/'XCIOQV)_$-B;Z9^+8'Q.-]B@:/S$_65T($K/0728YP  R*
M                                               (SQ>]@=8_X?[9
M(Y>&'L*HW]1S]ZAQ,7O8'6/^'^V2.7AA["J-_4<_>H;]&7US_E(8+SST=0D$
M  8&P       !25G>L&X\2<L&+]J6JXXW6YML5&5&XI6RXMN%#?D/-HT,C,W
M&VU)V2WF9Z:&+;' .8KVC7\@EOX74^JPJ)B/8-8OZGU^WYBV8M1I4^37J@B#
M+=AR%-O+XUQ)/%JUHI)%O,C%]9]AJ2RZP\E*VGVG&74*(C2XTZDT.(41[C2I
M*C(R/MBR3CIP/,*K8P5G'/*?C%-RS8B74Z3]URJ?!?K-+J[S:30RXFD*>1!C
M&G52E&TSJM2C4HS,!HC*!D=%9:;>P4=Y^\0.$DR;6JO&9[-[0KHM==]6W 8P
M\5;-O-S7:56KDBP#C-*-:I+IM19&AN):,RV=H]-13)FOOK'N].%EPA5;>'C6
M+,VU[0I%7M*RJU6(M'HTJ=7[1AS*DXAJH&4"=LON&X2#:<V#W$1:BY#:7 K5
MV^<0[=O;.GF/JV96+:\YFHTBW3ILFV8#4J.XAYAQUF+(XF1Q;S;;J>-:41&G
M<0JYSH<&Q;&96O8=XE8=W@[@WC=A3&*)8V(<",[,<@1R89B<7*@H<;;G$45E
M#*>4DLB(M2(!8D60Z#B<(0C#09UY*#%HB5A#G,O?/KEPQFO'"FW<N=2M*%>_
MHW%I%RT!\[VBR*4XRTAR@T];!.%!829)4<=S<>V1EKJ/><%5@)AE=^?SA!\3
M+HMV#<%?3+LZ+%*J)3.B0S?A28\XVX,@G(R5/]<9'Q?6F9&78%<V!_!<WO2,
MP%!S*9GLQ%9Q[Q-LR!/@6.^B)*MRG4-NI4]5.EJ>ID224*<;K)I,N/:,TF6X
M]3,5/Y4,CE$ROXIX\XG4ZYUUV9CA-I4N?$5%4P5-]"^-)""4:S)S:)S34B3S
M (9_RD5>4CK%FS+#:=!P[SB\+_:5H1"H]LIM*W%-4-AT^015RK:J#CJHT8C)
MB+M.*-9\4V@C/G' X*[+#A-3N".Q'N>=;-.K59ON5BL_69]2::G/FY3ZU651
M%Q'Y*'7(:V3V3(XZFS,R+7F(7?[0X/JWK4QKS88QLW8X_-S1TJETNJT[DBDE
M1$4VFO4]"TN;>CVVEXUZ)).FF@]1EPR/T++WE'?RJTVY5U:DOG=Q^CBHRFEE
MZ:I<N4[]X-1F?$'*-)==UVSNT (U1.'DXK"I%F?@QLMF#[W \W?4:G:L6MS[
MF<Q.=J4^KK*ISC72*Q5E4_DTV8EY^(4<TH)!,.H(B01;B(B%,&%>(F7>TN#"
MRF6YC-9,_&;$:M7UB.S@WABY<50I+=Q2:9>;Q*:E5)#AL*;A*0RI*)>TC92:
M"+3<,C?+AD?H67O*,]E4IURKJU)>]-O_ &Z<932B]-4N7*=^\&I1GQ!RC277
M==L[M!11=7 M6/4\M.#^#MO8AKH6)&!5>NBO8:XI*IRY)T:5=%975YQ'2E+-
MM\C-1-??#,M"U+X N$43B9^='D@?+ILQ"SIPI%V9E[MP^P/J>+662V<N= I5
MSV<W09%$N*@NU=4!RM4MMA*'*6EB>\:F";2[O4>AF2^SK5!CEAOAYBAPQF2B
M#B0Q$J,.FV2U(I<"=*)EF<^5DT]U*G6UK24I1.DE6BR49F?;/?5MBIP,V(F9
M:D6T6:+-+.Q0NJR*E1)UF59F@KHL2C-T>9&D*:<IT1Y$>7RAJ*VUM/(,T;U%
MJ8EG-5P1D/,/C?A+F!HN+TRP<2,'**U2[4JT2 Z\3+K=*8IG'N,H>;;=)11T
M+-#A*+3< L2@11A0HJ(P*,(8Z121PEUGV=A#PBN02_,(X<.U\1:Y/NV%5HEN
M;+)56%'BQXS?HA2X)H:6344SV%OLG^66_4SR"V,-[*K*556JVQ2I53K,.E2J
MI+D08RY3\EIEIU*S><:-U*D.:F9$LNU\!6S<N_!>UFT<PD',]F>QG?S%8NVT
M2V[%JTNE'1HEKQW(_)'DLTY"UPW5.QB0A2S;29FG74S,7@B(BYBT[&[<1$7,
M1%S%H6X!DSQ%CA7?(/'U:PK2KDV%4*M0*=4Y5.94Q"<FQ6)/)VE(XM26DOMK
M).J"(NMTYB'=T2ATNW:<S2J-"9@0&%+4U%80E#39N*-:]E*"));2C,]Q%SCM
M@ 9                    '1W-RD[<KQ0E\7+]!ZF<=1Z;GBAO<6>I[BT5I
MO/FYQ8&R_97,(,9JC?=:QRO9:[WC5F64VG/W"_$3#:5.?3&XLTRT-N$IG8/K
M"ZWLZ&,@6K0DU&F5" MSBD3(<B,MWVM+S2VU+YR_!2HSYQ8RO3)3EFH]W5?T
M=QU53*[/FO2)<>-+DH-"WG%.;#G$RT_@;>A&KFT'9^Y[*+)U=I<<RE64I&>G
MPG)3!\DF36C^]DAW:-#:LS-FI*F3%1++#@I)J43,XP29'T=NO2,V?GZ:THG(
M4C3B<9.5*:'J3I>EIA)3@IH]LW=+!J1-TJ2W>69LU;W%*DI0;1)I(U)4FM/+
MSE'RZ81W\W=>'5>:GW"@EDEA-P.U!1DILT']X5*=(]"/G-'8_.+A0M(94L!\
M <-,8(LZR<7Y5WW*M+ALT@Y$V0T9<09*U4Y)=:(R2>T>I<Y&+MY>7]XX_/53
M5<KI4UE:4Y:4;JQ@^2LZ-7)Y-/E09DQ;+6LV:*20O"P54P*@<MW,F;!E-Y;-
MA($B3<2F4'DE2=($HL)3<B7@LXM5/#NAF@FZRAOC,RPD0*)P,@$0W7BK&MBL
M.TIRDR92FB3]];0XI)ZIUW&E!E\QF)>'P7%C.*-;D9AQ1\ZELMK4?YS4DS'$
M2A642TP'89QJ.')$0)U=H7O#,\&[YL?->/=.;TXRAS$Z\WWE\_W-B?.0PO<<
M7Q=KH#:JG4]>FW!AJTYM8S)__F#6$C@>T=EFG78) ^%L*^6^. O5 4GWFF^+
MR/-!ZH"D^\TWQ>1YH3UZ%4SWOA>*L] /0JF>]\+Q5GH!%' /G_\ $(*X6PA
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M$6?!5SBLLTWQ(*REJT=M\45]7FSORI?BDGS8=7FSORI?BDGS8E3TN43WMB>
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M1_?&'XPUTP]':/[XP_&&NF(SZB-F>U3/'9'3'R>P-LYQ!I0B8@^WRV3_ ,G
M@CA*YO\ RO#1&^59K/J$H^CM']\8?C#73#T=H_OC#\8:Z8B'J"VG^7,\<D^<
M#J"VG^7,\<D^<"#/A*YI66Z;XYY62]$:].K7+WH[1_?&'XPUTP]':/[XP_&&
MNF(AZ@MI_ES/')/G Z@MI_ES/')/G @SX2N:5ENF^-Y62]$:].K7+WH[1_?&
M'XPUTP]':/[XP_&&NF(AZ@MI_ES/')/G Z@MI_ES/')/G @SX2N:5ENF^-Y6
M2]$:].K7+WH[1_?&'XPUTP]':/[XP_&&NF(AZ@MI_ES/')/G Z@MI_ES/')/
MG @SX2N:5ENF^-Y62]$:].K7+WH[1_?&'XPUTP]':/[XP_&&NF(AZ@MI_ES/
M')/G Z@MI_ES/')/G @SX2N:5ENF^-Y62]$:].K7+WH[1_?&'XPUTP]':/[X
MP_&&NF(AZ@MI_ES/')/G Z@MI_ES/')/G @SX2N:5ENF^-Y62]$:].K7+WH[
M1_?&'XPUTP]':/[XP_&&NF(AZ@MI_ES/')/G Z@MI_ES/')/G @SX2N:5ENF
M^-Y62]$:].K7+WH[1_?&'XPUTP]':/[XP_&&NF(AZ@MI_ES/')/G Z@MI_ES
M/')/G @SX2N:5ENF^-Y62]$:].K7+WH[1_?&'XPUTP]':/[XP_&&NF(AZ@MI
M_ES/')/G Z@MI_ES/')/G @SX2N:5ENF^-Y62]$:].K7,**S2G%;**C#,^UR
MEGIC[^B-/]W0_&6>F(:3@3:Z#U0[,2?;Y7)/][@^G4/MWW3-\:D^=$@CA*YO
M_*\-$459-O9>&B,P^B-/]W0_&6>F'HC3_=T/QEGIB'NH?;ONF;XU)\Z-#P/M
MW0]),TCT/?RJ3N_M @CA*YO_ "O#1&Q5D+7V#N<6YL-RQ*PAN7&<4?)]$H?:
M6H_OJ>8DK,QRL,YL)NS*.ER9%0HD.:I7(:2HMY]@UD9?*(<OW"&F4"UZC5&)
M\IUR.;1I0MYY2#):R29*)2S(S+4M^@Y%F8.TJM6W3JB]4)33DA*U*2EY\DEH
M9D6A$O9+Y"&X)P"\HX81TX-<"B6/;T#)1PSQ8LN+%8*FO1&G^[H?C+/3#T1I
M_NZ'XRSTQ!O4'HOOI,\8>Z8=0>B^^DSQA[IC$$</V>W3<Z-1/)MT=NJT3EZ(
MT_W=#\99Z8>B-/\ =T/QEGIB#>H/1??29XP]TPZ@]%]])GC#W3"".'[/;IN=
M")Y-NCMU6B<O1&G^[H?C+/3#T1I_NZ'XRSTQ!O4'HOOI,\8>Z8=0>B^^DSQA
M[IA!'#]GMTW.A$\FW1VZK1.7HC3_ '=#\99Z8T]$*>?_ *=#\98Z8@[J#T7W
MTF>,/=,.H/1??29XP]TP@CA^SVZ;G0B>3;H[=5HG'T0I_NZ'^?E+.OS[>HU]
M$*>?/.AG_P 2QTQ!O4'HOOI,\8>Z8=0>B^^DSQA[IA!'#]GMTW.A$\FW1VZK
M1./HA3R_].A_GY2SK\^WJ-?1&G^[H?C+/3$&]0>B^^DSQA[IAU!Z+[Z3/&'N
MF$$</V>W3<Z$3R;=';JM$Y>B-/\ =T/QEGIAZ(T_W=#\99Z8@WJ#T7WTF>,/
M=,.H/1??29XP]TP@CA^SVZ;G0B>3;H[=5HG+T1I_NZ'XRSTP]$*>?/.A^,L=
M,0;U!Z+[Z3/&'NF'4'HWOI,\8?\ .!!'#]GMTW.A$\FW1VZK1.?+8//RN)^?
ME#/[]L:\M@GSRXI__MV>F(3+!*G$1$58EZ%S??GO.#7J)T_WXE^%>\X$$\+V
M>T^D2*N#M(37RV#S\KBZ_&&>F'+H7NR+XPUTQ"G43I_OQ+\*]YP.HG3_ 'XE
M^%>\X$$\+8815P=I";.6P_=<;P[73#ED/W7&\.UTA SF!K*EF;=PRVT]A.VZ
M>GRFX-G4+1W22_I.^<%@CA^R=G;JM%IR7H[=0GSED/W7&\.UT@Y9#]UQO#M=
M(0'U"T=TDOZ3OG ZA:.Z27])WS@8*.'[)V=NJT3RLEZ(UZ=6N?.60_=<;P[7
M2#ED/W7&\.UTA ?4+1W22_I.^<#J%H[I)?TG?.!@HX?LG9VZK0\K)>B->G5K
MGSED/W7&\.UT@Y9#]UQO#M=(0'U"T=TDOZ3OG ZA:.Z27])WS@8*.'[)V=NJ
MT/*R7HC7IU:Y\Y9#]UQO#M=(.60S/0I48S[7'M:_-M" ^H6CNDE_2=\X.3$P
M21&DM/\ IBEN&WKUAJ=WZE_]X?-^;_F$$\/V3L[=5H15DO OQCL$^  # T/.
MW<Y*:M:XW86O*FZ'55L;/X1.)@OJ2:?Z1&1&79UYMXQC6,);$O/#&[L6Z].K
M-1OJW[L./>D)<NI,N18<RNKBQU;'&$24\E,U=:DBV2U^$9/U?D.0Z)6);,<I
M;L6ESWT1E*V2D&U&<<XDU'N+C-G9W]L6S,K%0P@QMI6,,>Y;+I%FU2XIYP;M
MI$FL1R*:420^Q#?;2M;:6E&22=U:21ZGOWCLV8<MO4@R=+;^P9/9LV3Y(JGE
MNY-6*&Q,#;MD-75HS4HFRF+PR4T,ELRP4-V3'#\XC+H[=6FRXSJEJ;$E/3RX
M$V>).G,AS=)38O"W=3T3LZM&#ZQ:(2;NEY=&[-B@T-C)31T;/!LHF@R.FK*_
M;N#.'.;N@4O"60_7Z;==,:>6\<V5*10)+-*2[*0M;KCI*XYXUI(E&G9/4B+<
M0OO%N_7^L]11M@#E$P$P*N*I7!8+$-ZN5%TW4OG5_1!]C:VC4EE*WW5(3LJT
MZS0M--VF@K)'I9\RTZ2Y*S!X<VTHO2'>3W9U6^2H24O;VT981FU6A*UI01)4
MEF4%'A8&&?E*,<HW+IM2A->0'MTE%WDAQ:O<KOC^RDZ0U*:2>X,6Y,B)@R:J
M9LE-#4M"VQF:"P-])FGR4D   X8.R0                 !H9Z$?8^$ '%F
MSX--CKEU&9%@16].,DS)#49A&NXMIUY:&TZGN+51:]@(4^#4HZ)=.F19\5S7
MBY,.0U)87IN/8=96MM6A[CT4>@L3\,UC%=]3I6'F4W"BLR8]^XRKGD:J8\M$
MV%Z#FB2G:-HTN(XQ!GIUQ:EVQS.!UQ=O.W8E_90\8*O)?Q P<*F+;.J.K7,J
M"*VE<P]A3IJ6YQ;9E_.5H7:&\ \##CR5PC".L2-,+QR:J1>WGW9:U+D*B5.Y
M*#3I2--N//J\"(\G4M2VFY$AM:=2YM2(?>G7%0*NHTTBN4>J&G\(J=4X4Y2?
MSIBO.F7_ %VABMYF,*).9/A?*E@I7;PN"CVG4V(ZG8M.JE0C-)XBC$_HAJ+)
M:(C4LNP1:Z[QV6/N%M_\$_CM@I?F&.)U:N+#:_ZVJEW-:%4>E2DI)4AB$PHI
M$Y]\RT6^;GWOL[C^&[V5!87E*21D4**:81CCY!,+&<*".&/;B&4]/J,"F,+E
M5";$@1FTFIR1-DLQ6$$1<ZG7UH07TAYNBW_95PR'(E#NRWJM*:/97&@U>GR'
MR5KIH33,A:U?#HD8^V>3%'%3-9FUP>R2V-=<JR;.N6EQZK?U0@K,GY;$FDQJ
MPTT3C2VGF>M<6WM-K+GU/L:>IO7@C;\P;NFP;_RA8IW#:]RT.=%=NIB=/G5=
MBM-DZP4K5JI2W66MMLGCT).XU_ )@D4,)4#,HE1$B(X0B=M-$-)D$3J*,#@=
M-\0OXS[MM6ER%1*G<UOTZ6C3;BSJS3HDE.N\MIA^2VZ6I;RU1S;Q\&+VLR2\
MB/'NVV7Y#IZ-L-5VEN/N'VD-)E&XL_ZJ3%D_A \@M&O6S[TS%UR]+BIU_P!*
MMJ [+8@52IQ8GHA"IJ6GG"8BRFXY<:ZVI9DEO9W\_:I6X*O(;;^,N%F'F9:Z
M+]NB1=$"M5Q')7:Q5UQUIIU3=BM$Z@Y?$J(VVB/KD&1:[PP4X.%A60P:STF0
M1.,(<L<G)TC)_(R,B,C(R,B,C(]2,CYC(^R1]@^R.FJ-QV]1W$-5:NT6EN.'
MHVW4:I"A.+/=N0B2\TI1[_YNO8[8ZV=68%&I$Y3<^ XY2*))>)KEL<WUG3H2
MW$ZM\8:]_%:F9D6G9WC$'K&-.%^:O'+'FZ<U6,ET69;]K5%FGX6T2WX=<DHI
MDIM;T-Z3(.B+3JA#[;;YE)3L:)/L:B)3A1J(LA1.DX% A3.$,IY<5M(S&43H
M;D4IK<R(Y$-.T4I$EI44T]E1/I4;6S\.T9?".N@W-;E4?.+3+@H=1DI,R7&@
MU:#+?29<Y&U'?<<(RT/4C21_F&.GC7B[>.7#@NHD>P\<W,6JG=M5A4FU,0$1
M.12X=,GUYJ&]&<:-QQW;:AOE',W5$O5)GH2MPI>O/#N^.#_N7*%C99=_5Z?-
MQ1><D8ATV?.FRX]375%1"8-+<N0ZTSQ1RUGHV@BTT+3M:)$?C4F9DDH'3#HQ
MPQ8Q(XJ,D:<IPY1EPR)4:(TM^4^S&9;+5QZ0ZAEE!=M;KAI0DOA,R&R%/@U*
M.B73ID6=%<-1(DPWVI+"S2>BB0ZRI;:MD]QZ*/0]QBQ)PIV)N<&KX852AX/6
MZ_;&&T>WJ/4KQQ'9G,<:::A!9F(;9B*V7RVE+4R9LJU+G/L"K/@AZG4:OD4P
MIG52?*J<YQ^X$2)DQ]R0^\\W4EI<4IUU:W#U7KH1GHDMQ;AG!\G"B6.$,E$:
M18TPARZNL7,P ?-W\$OZR?WC(HZ=ZY*$Q5H]#=JT%NKRB5R>G+DLIEO;!;2C
M;8-9.JV2WGLI/0M#YAW@L?8KSIZ.%HP B(GS40W(]R\9"1*?3$<THNI&Y')9
M-+T/>6T@]#U,MXO@BF4(6E$,MG]Q\W76F&U.O.(::0DU+<<4E"$)(M3-2E&1
M$1%O,S,>4ZH%C:J([PMDC09DHCKE-(R,CT,C_P IYR,M#+GU':W!0X-QT>H4
M6HDM4*HQW(TDFW%M+4TZA3:B2MLR6D]E1Z&D]2/>,>O-=DSP9HF9C+;@YAPB
MY:<YB)4+FF7DA%U5MXY*8FDQ!*)4K[R1[2R(DZ%H9:;MPJ2(S@9PMA'\2$.C
M9M,B&0C2[HMRMN.-4>N4FJ.-:<8BGU"++4C7FVTQW7#3KV-HB'>BVY4;!P"X
M/ZW:G?-F6[7Y%Q7"W3XD:C/5BLU=-4G-DB-IQDA4A$0E/+(U+,DEHK7L#XVE
MGJN^!BC8>'..>#S6%75-*2Y9-29N!FO>B;4=HGE+=9B$HXQ["VS-+NR9&K0]
MY!@F>*GIH*)T6!'+CH(X4X\6B-HN4@+;N)&?PJ!C3>. V'6',C$/$"T?0EV1
M 8F+A1UQ*BRB2[(=F*;5'8*/%-3NRM1&K9V=W8X51SZ716KAJ%LX38.NXAU:
MT8K<K$9+-6Y)&M=*H_'J2U)4A3-04A*'B43"E:&WH>\R$P3R8RCC+%1UD$2O
M:+EX"V]A!PC^%F)5FXK7U58;EJ6WA8J#$J<V4ITSDU2<XJ,B&VVXA"STFI./
MMIVB/7:YMXZ&!G_NJG.T&Z,0L'FK.P<N*<F'3K_7<+$IPTOR$QH;JZ2C20@I
M3CC9))1)TVNR00/)?)ILQA$LM[UBYP])CQS03[[+.V>B>-=;:VOZI+,MH]^F
MA=D<?T4IG*R@>B$+ERMY0RE,'*,M-=>()?&\V_\ !YM_,+*6;;,3C!7,Y6 V
M#>&UI2I]K_Y34ZNMFIE';N*#)A,5!E]PRV3BIA,F;A)4HS<YNR)J;QSP;@XL
M8ZXE2J3,17\!:=;::_/]%9API+]7@$UQ*(NWR4U,J2IK5"#-2BU/?O%P3@5I
M1@6/'"G2$2OHCL%U(!:.J'"9U=BQ:%B]2\%)DW!Z?5FZ95[S>J:XJJ4N14$4
MZ.X5/=:)]\GGUEILEH1;^85&XS9SZ38DRQ;4P]MI6).)&($%$Z@VA&D+AF3?
M)6I;I2Y?%J1%-#+FTGC]G;V>M,,$\F7)5CZ2")7MQ7Y!7( MNX49_4WQCM2,
MNUU8=2+.Q)=0\NX:8J6Y+:HA)C\ICD4DFR9D<>WJ?6JZWF/>+C,F4Q$COR7W
M":8C,NR'W#YFV8Z#<=49\Q;*4J,]>P1B&1ECT\@I'$<>=5Z52U,IJ53I]/5(
M5LL)FS(\53RM2+992^X@W#U,B,D:F0^LRH0:?&.;.EQXD1.R9R9#S;+!$O38
M,W7%);+:U+9U46O8U&-SG*Q!OG,]?E\W[9EPU"G84Y9KAMI%+ETYYUB/=;E:
MGLLU!!K86C:Y$^TI*MHW"W'KH0O7SZ!2\QV6IBAO/OMM7):D9,>1$D.LO)J5
M/@H.(LGF5H<)7*T-FO16_>2B/704TPA$\>.S$>N!X@*F^._:*G&)4>2RF1'?
M9D,++:0\PZAYI9%V4N-FI*B+LF1[AUR;AH2WY,9-8IBGX6R<UM,Z,I4/;UV.
M5$3FL?:TZWC=C7L:C'RP_P [6*.!%CW#DYG4N3=V:*@5!^EV?&Y1MOU.GU>:
MX29CKQ$XTR=*ICB'R2\K5S8V=QF)(Q3PBNK*CDSQ.O\ O"]JC<&.N+%2M;TP
MUA<A]HTG-JS+;4&'$2ZIF-R%B3R=Q4<D&YQ9*/>>ZX&*)XS(DVEET4\M0SA5
MPQ8[#R8J?PK%]6++BS64R8<AB5'7KL/QW4/-+T/0]EQM2D*T/<>AGH8Y IVR
MKV;4;%P*P_H%2D2),U-+;J,AZ2ZXZ\M52;3,ZY;BE+/_ #N[51D*B1@QH
M             !QY?^BR?B[WV:AR!QY?^BR?B[WV:@ 0#@C^,;O^--_:+%0P
MIYP1_&-W_&F_M%BH8;:><>A/\I#*/-+EZ3   8&@
M           !H?-\I?O(4ZU#_7A2/ZCW\,8J*/F^4OWD*=:A_KPI']1[^&,;
M1C5]170(>+E+I(5%@ # H                                    \U=
M_L<JOQ1[[-0C# #V%(^.3/XEP2?=_L<JOQ1[[-0C# #V%(^.3/XEP>0O\-7U
MB$K+0?20G0  >,4                                    <&I_BV?\
M$Y/V*Q"& _XCJ7QV7_$.";ZG^+9_Q.3]BL0A@/\ B.I?'9?\0X-%YJN3I$K+
M0?20GT  9%                                         0UCI[!9GQ
MF'_$($RB&L=/8+,^,P_XA TCST_63TD(>(]!] D"T/8Y2OBC/V:1Z4>:M#V.
M4KXHS]FD>E&1$XM7\I    T
M   ("QX_$=-^.Q/XAL3?3/Q; ^)QOL4"$,>/Q'3?CL3^(;$WTS\6P/B<;[%
MT?F)^LKH0)6>@NDQS@ !D4
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MW$*1(2M!;1:'H1I,R,7S:E2J?5X3U.J4./-A/D278LEI#S*R3S$:'$J3UO\
M-W=:?,/$5C";#VO4ZGTJK6K2Y\"E\:<"-(C,.(AF\>KG$$MM1-[9\^QL]H7"
MB9&98LE%%5$*JK*+0ADKRE&G+RECUBF7#+/;EFNNH6GA_;=Y5*77I=,@T^!#
M7;E6CM.+APVFE)-]V.EM&A)_G*(NT*WT+2XE*T'JE24K(]-.M61*2?RD8B:C
M8&86T&IQJO2K-I,*H1#,X\IJ,P3C1JW'LJ)LC+=NW'^L2V1$DB(BT(B(B_,6
MXB^08.%6T4HU[!J                ./+_T63\7>^S4.0./+_T63\7>^S4
M" <$?QC=_P :;^T6*AA3S@C^,;O^--_:+%0PVT\X]"?Y2&4>:7+TF   P-
M                              #0^;Y2_>0IUJ'^O"D?U'OX8Q44?-\I
M?O(4ZU#_ %X4C^H]_#&-HQJ^HKH$/%RETD*BP !@4
M                 >:N_P!CE5^*/?9J$88 >PI'QR9_$N"3[O\ 8Y5?BCWV
M:A&& 'L*1\<F?Q+@\A?X:OK$)66@^DA.@  \8H
M              X-3_%L_P")R?L5B$,!_P 1U+X[+_B'!-]3_%L_XG)^Q6(0
MP'_$=2^.R_XAP:+S5<G2)66@^DA/H  R*
M              AK'3V"S/C,/^(0)E$-8Z>P69\9A_Q"!I'GI^LGI(0\1Z#Z
M!(%H>QRE?%&?LTCTH\U:'L<I7Q1G[-(]*,B)Q:OY2   !H
M                          0%CQ^(Z;\=B?Q#8F^F?BV!\3C?8H$(8\?B
M.F_'8G\0V)OIGXM@?$XWV*!H_,3]970@2L]!=)CG  #(H  T/<1G\  !GH6N
MAG^8M3_4-NV7Y*_HF+0?#)YO,8,GV6,\0,%G4L7E.KE#H\-]2&'$M*JU8BT[
MC#0^1H5L%(VM--^F@I4EVSPRJ\-X-_T3&N/5),FV85U-T,[>HC''L.TUNJKA
M'(41;'&-*XHEZ$9:D9 *11*,2*JF]HR*"41EM$1_FT/7YAN&,_:7"\8Q7AD!
MQUQ#GVQZ5,R67VX+6H-YTWE,>8U_VS<*:8F5QA(*,7'1DJ>,D&9()6G8U%W#
M+_G,PXNK#+#*;B)B%;=-OB[J:R](B.5.GD@Y2VFEFVZZ4A+3*E*7LI2K12E'
MH1:[@ R,L=\76*\ 'EJ]>EJVS1%W%7;@I%*HJ&2?.I3)\5B*II2=I*FGGG4-
MN;1<VRH]>8M3$46)F=P.Q&K2[?M+$6A5.L(6;:8"IL9AY]1:ZE&0X\2W]-#W
MM)679Y@$%0 "*L1\:<,\*8[$B^[OI-OIDZ\G:D2V.5/$G\(T1^,)U24ZD9FE
M)D1;S/0=O8.)UB8F4@JW9%TT>XZ?H9K<I\Z-(>8(CT_REAEU;D?LZ<:E.XOF
M /? (!NW,W@=9-R,6K<F(UOT^MONI9*'R^(Z3+BC(DHE.(>-,<U&9$7&FC4]
MPG"G5&#5H;%0ILR+/A26TNL2X;[4F,\VLMHE-O,J6VK<9:[*CT !SAH1D?-_
MUY1 &8_,GAAE<PUJ^*&*E4E4VWJ6R>QR*GRZG)ES'?O<.*W&A-N/GQ\DT-&H
MD&E!+VU;BT%I/@O.$EQ=SQYGLT= NFVW[*PVL!ZW/2!;TQ)<KY'4&5J<E.&X
MTU*;Y4@FWTH>3UNWH7, L#@9U$+]@#1)ZD1_G_>(:Q$Q^PEPLGP:9?%[T2B5
M*H&I$:GO3HRI9KW$7'L$\3K!:F1D;B$D9;^;>803*1ZF9:'N[9'H?YC[(U%H
MG*-G2OS''/-FZP6GU"%4<,\)6[/=LN=#>B/QW&JS .3+5Q\<SUV5?A\8L]G0
M]=-!77=N:G 6R:Z=N7'B7;T*K$ZAER.W4(C[;#BS)*4OO-O&VR>ID1DXI)D>
MNO,>@6'X;?[BHLSTWF'.+>^?W/#;647*Y7,>:-*I5T2$2*.U;\.+48ZF*JU4
M)S,:0ZQ*:4MI7)6W#<61*,R,MD]#YI1RN9FK8QPR^6MC/.KM)@PJG3SFU:7)
MG16(D S(E<6Y(=<0R1D9F@B-1&HRT(M3 2VH5;@*=;4S48"WG<2;6M[$JWYE
M;6XMIJ&Y/BQRD+1J2TQW'7DI>TT_[O:UW::BHE)DHB4DR,E$1D:3U(R,M2,C
M+<9&6\C+G+> #4       $9XO>P.L?\ #_;)'+PP]A5&_J.?O4.)B][ ZQ_P
M_P!LD<O##V%4;^HY^]0WZ,OKG_*0P7GGHZA((  P-@         "-\6,3+:P
MCL2OWU==09IU)HD%Y];KRDIXQ\FU'';21F1F:WB2GK>V/,[N[9[;L79W9+;-
MV[1#%BR9I-;1HT:*)"$(2F)J4I1D1$6,S'YGQ\=I/=7A^?&[)V='1BT>'ENV
M6EFR8L&*36U:M%J@24(01J49XB(4A<(-F^I&5S"2H/1);#E]7'$D0[<IJ7$&
M^9J+B9+ID6T;?%(<-9&M):Z=:?9&-1DSR[7;G)QXJ-=NPYDZVX:JC5KTK;Q+
M<0OC6GI<!A*E:F9(7]Z^]J/3L[MQ>'Q_QCQ SN9ASD1U2'FZS6O0ZU*0;AJ8
MI\-N0465(TW-D3K&CO7$6FF[?H994^3[+Q8V5_!&)9=/ETQZZ9M!D2KAJ:7F
M$O3'WXBI"&5'MZ_>36;>FT>IES<P^Q&Z&&X)N=(<F!):;H<\F1=T-F98323'
M8TD30R4432S<DK-#,R.#5]6IH44LBA_.=T:O7NKMV-<I/1K9;D.YVW/N1V:J
MP&,M/B583(E(4<&C64ULM^:T&;"34(8F:6C<XXA./=!I-KYAKFMNAQRBTBC7
M)08D*.6NB":FM-J61GOU<-&T9=LQDSYOO_FSJA_^ :!^]D8[69&QKRFYE[XG
MPK=FR8;MV4EQN2VTXII3:*@E2E)4E!I-))(S/?S;]=PR$LWU7IWK;L^F<L9Y
M>5#H:%1"6DW26@V=LE((S41I/774NQ\._E.Z6W)[;;A2DM2>&I2Q)*WA25[Z
MT):F4DFM38R-2B4:B4:C729Q,ZQP?<7=C<'3W4K-;OW&Q5-N76;JA3+>&2D)
M;RVEFS=R,DH4E*,!*4LXD10(A8RX+U"',X^&:5H;<2;E4U2XA+B#^\*YTJ(R
M/YAFEE381D1\B@D1I3_Z&P9_@EK_ #"^$86W!=?_ "R<,O\ [RJ_8+&:PC\!
M/]5/[B'4WNIE**?LF0,R_1QTQ&?^J?!WS[A-*5;ELN81$?Z8/F,H_LN3#%N?
MA),!K.Q2RWWE+E4."5QV[%1+H]2CQFVGH^BR=>WM(2I>TE/\Y6A;^WNPRH<V
M=".1R27(BK*1)B/&PZMHW"CNK9T7L*3M%HDRT,ST^<AGGYGIE/@8'XAR*FE*
MHB*)*2M*M"(U*C.D@]3[2C+YA@6R%(7,JBVBT:56JN:$]HCG/&7ZNR.TO<K2
M@]O<V9QR>\K:-G1RE1U:.Q-CWQF@WI@O?F3,E&>"46*%FDJ,)6%"*CCT?[NV
M27!PGM,Z5W-#%V?Y3D)]9/JF"=Z;-B<GEDEW;M302<-6 \-&25F9JP48$8$1
M"JW(]A+3L:\S6'=CUEDGJ,_,?EU!@^9U45*9+>U^=:-5:\^\9O5"LZWK?I,"
MCTRBTF+"@1(\9IE%/C$6C+2&^NT;+4U;.\^?\XPMN#AO*/9&;[#&HS'T1HTI
MZ:PXZYH2=IR/Q:"U4>A&9J(B_/VQFW1WDOLLO)/5+K+3R3[:74$LC_,9&6@Z
MZ]U2]2CWW2&[*:M2DU$AH:NK,E&3+NA;TW2\M"+S3:&2&)&JE1)2F)CN#W"#
MC(YS G.^H8,%2RTG0IW?FQI0;;N1G)[JMR9X5*R8X31NI)4)-9K/'$6EN$7X
M/6#F+MUJ[<,*/!IN)U,,S:.(TU&14N-4E*N,(N+8(T-D?X6NOZQ2/P?^2'-M
ME?QOI]QUVGJ38U6VTW1$1-C<6YQ;!HCKXM#A\RSVNM3SZF?PY$__ %VA\>-;
M+_O&_E=+_F.J)/W6YV.,SWN8ZS<I1D1Z8MV&#*+!;R\.[%O@P9N[8VJ39I8M
M")JPH5O30XI@1$1=^2Q[GZ8,I[H;ANFLDRG(\Y7)Y=GO#D=Y9.CH]O+L9$;9
M\=R8*)JIY9?^G>H*3O[&A7E&9G]$ZF1&:=DS(C,M==#/>9:_ ?9[(W!KKO+>
M0#J\=Z8@                &AEJ6G_7.-0 !09F9R,VMF/NRD795;BE46=2
M"=)E47CD._?4$@]EUEQ"D[B[!]OMF0IL]:2L13_*_3]53E]B6;DTY1=C=(.1
MQI=K\+F%W.M37:;2*I466>4.P*?,F-L$>R;JHT=QXFR/L&HT:?**5,L.:.-C
MU2KA>JU+AVG5+>J$B$_!E5%GC%I;E.L-.&3JD*+;2V2^8_PM-=-!S^2)USZ=
M9':G)4IO+.2I')@[M$,S8?\ IT/31H;)!(4DVBD+6E<322DD?G0,R'4<X)A[
MES[.1@F7)#<VLNSB-Z?&;1KW81O:W!FP2\-#:(:$Q0U9LU,X$HTJ6F)H(X&(
MSR]9":!@'?S5\P+TJU:D-DLN1S),UQH]ILV_P7I#B-Q'KO(Q<*_Q_7O'"8J,
M"2LFV)L)]?Y#$IEU?R)0HS/YAS1Q65Y8E.7'LGR5GEH]/1,D,M]:)2E6]HC@
M)@A*2@4<@Y[-R;DAS8D\Y.D!R9.+BILMX-BQ6T:(WYH2=\5%HMHHC/!*B,"R
M   /5#WX
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M=W2?"M=,/5*8+]W=)\*UTP]YY6XM?ONK?\EMX&'?'(/',E_?W6SZ2T]0G@!
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MP ]A2/CDS^)<$GW?['*K\4>^S4(PP ]A2/CDS^)<'D+_  U?6(2LM!])"=
M!XQ0                                   !P:G^+9_Q.3]BL0A@/^(Z
ME\=E_P 0X)OJ?XMG_$Y/V*Q"& _XCJ7QV7_$.#1>:KDZ1*RT'TD)]  &10
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M-(T21:FE)&9[S,9!JT[23+^BHOSZEH+7>6G)K?6$>>;-GF.K=8*7:^-QVF=
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M99(E)AO6_+=)0>UM&K9U:LU,ELR4:39F9LU()25   .##M(
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MXY,_B7!)]W^QRJ_%'OLU",, /84CXY,_B7!Y"_PU?6(2LM!])"=  !XQ0
M                                !P:G^+9_Q.3]BL0A@/\ B.I?'9?\
M0X)OJ?XMG_$Y/V*Q"& _XCJ7QV7_ !#@T7FJY.D2LM!])"?0 !D4
M                                !#6.GL%F?&8?\0@3*(:QT]@LSXS#
M_B$#2//3]9/20AXCT'T"0+0]CE*^*,_9I'I1YJT/8Y2OBC/V:1Z49$3BU?RD
M   #0                                        @+'C\1TWX[$_B&Q
M-],_%L#XG&^Q0(0QX_$=-^.Q/XAL3?3/Q; ^)QOL4#1^8GZRNA E9Z"Z3'.
M &10   !HI)*+0]?D/0:@  -#(E%H>OR'H&A&6G8_/\ \QJ  -AH29$G?NYC
MU/7?\(T)M)%IUWRJ,S^<?0  ;%()6FNUN[2C+Y]#WC5*226A:_*9F?SF-P
M^9M),]>N+\RC(OF(QO(M"(B[ U   :$1$9GOW_">GS#4  !L4VE1ZGM%^91E
M^X;P !M2@DZZ:GKVSU&WBDZZZJ^D>GS<P^@  VD@B(RW[^?>>OSC3BT[.SJK
M3G_"/7Y]=1O  'S)M)$9==O[:C,_DU,?3F           1GB][ ZQ_P_VR1R
M\,/851OZCG[U#B8O>P.L?\/]LD<O##V%4;^HY^]0WZ,OKG_*0P7GGHZA((
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MV52)-,HQG3:8I,5"5))\DFXI>I:GO%[=&FAZ%IURM2Y]^N\9'D&\
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M>O=Q$GQA70#JSU[N(D^,*Z 8"LFTNNV\##"*Y'U6EK%0H"GKJSU[N(D^,*Z
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M,!63HZ[2%PBRD*A@%//5RD]RDSYW?-AU<I/<I,^=WS88"\E[F6L(EE+60J&
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M9?E'J>KE)[E)GSN^;#JY2>Y29\[OFP[X9Q\<RI]_>;/I=&O1!WFS1_VW(/\
M"G&SZ&R\"'EO43Y;N]U"\,ORAZB?+=WNH7AE^4>C5CWL*-*K9F$9<Y:/'^YL
MR&WJ_%W-3/HO^:#O@G'QQ*E7R]YL^ET7*AWFS0_VW(-7[*<LWZ&SD_[1Y[U$
M^6[O=0O#+\H>HGRW=[J%X9?E'H>K\7<U,^B_YH.K\7<U,^B_YH.^"<?'$J??
MWFSZ71<J'>;-#_;<@U?LIRS?H;.3_M'GO43Y;N]U"\,ORAZB?+=WNH7AE^4>
MD1CXVI1)<MR8E)\ZMA\]/DXL<KJ[0/>.;X!_S8=\,XZ/^L2I5\O>;/I=&C5!
MWFS0*'Z-R#_"7*SZ&C%> \CZB?+=WNH7AE^4/43Y;N]U"\,ORCUW5V@>\<WP
M#_FPZNT#WCF^ ?\ -AWPSCXYE2KY>\9OTNC790[SIH?[;D'^$N5GT%EX$/('
MDGRW%_\ 5U"YR_[Y?;_.(5FY2\ F\6*90TV'$*"ZETW&N.7L*V6=HNT?ET^
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MR#D  #C\EC^T1_ (\@<EC^T1_ (\@Y   X_)8_M$?P"/(')8_M$?P"/(.0
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MDFA#ZHKIM/$E*M_6K+37L\X@#VW)(ON:/X%OHAR2+[FC^!;Z(Y T,R+>9Z
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M-0 *>\%&&%U"[B6RRO24@BVVT*(OOB^8C+=\@J#Y'#]R1O -=$0%@C^,;O\
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M9[)Z?D"GFH1HY8VTALH[!-FA[5!-(V#_ ,G/G3L[)\W:%2!\WRE^\A3K4/\
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M,+W'%\7:Z <AA>XXOB[70'*  @62]R+4.+R&%[CB^+M= .0PO<<7Q=KH#E
M0+)>Y%J'%Y#"]QQ?%VN@'(87N.+XNUT!R@ (%DO<BU#B\AA>XXOB[70#D,+W
M'%\7:Z Y0 $"R7N1:APU4^ LME4*(HC[!QF3_P#S!\O0BE>]T+Q9GH#L0 !U
MWH12O>Z%XLST ]"*5[W0O%F>@.Q  '7>A%*][H7BS/0#T(I7O="\69Z [$
M=#4J33"IT\RI\,CY'(/=':+31E>G,D0M@7"AOT*H\?%CNGRR26KC+:S(BD+T
M(C4DS+3FW=C<)YJ?XMG_ !.3]BL0A@/^(ZE\=E_Q#@T1^2KD/:)66@_P(39Z
M$4KWNA>+,] /0BE>]T+Q9GH#L0&11UWH12O>Z%XLST ]"*5[W0O%F>@.Q  '
M7>A%*][H7BS/0#T(I7O="\69Z [$  ==Z$4KWNA>+,] /0BE>]T+Q9GH#L0
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MRE^\A3K4/]>%(_J/?PQC:,:OJ*Z!#Q<I=)"HL  8%
M                 'FKO]CE5^*/?9J$88 >PI'QR9_$N"3[O]CE5^*/?9J$
M88 >PI'QR9_$N#R%_AJ^L0E9:#Z2$Z  #QB@
M           #@U/\6S_B<G[%8A# ?\1U+X[+_B'!-]3_ !;/^)R?L5B$,!_Q
M'4OCLO\ B'!HO-5R=(E9:#Z2$^@ #(H
M           "&L=/8+,^,P_XA F40UCI[!9GQF'_ !"!I'GI^LGI(0\1Z#Z!
M(%H>QRE?%&?LTCTH\U:'L<I7Q1G[-(]*,B)Q:OY2   !H
M                         0%CQ^(Z;\=B?Q#8F^F?BV!\3C?8H$(8\?B.
MF_'8G\0V)OIGXM@?$XWV*!H_,3]970@2L]!=)CG  #(H //U*ZK=I%3IU&J5
M;IL&J58W"IM/E3([$N<;>AN%&8=<2X]L%^%Q:5:%SZ#X>G*UO1\K8*X:/Z83
M+4J(=0B%4E%L[>J8?&\I5UO7;FSZW?S  ]. ZVJU>F42"]4JM/BTZ"QLD]+E
MOM1X[1J/1.VZZI#:=3W%JHM3/0AYZJXA631*,U<%6NJAT^BOZFS5)=2A,PG2
M(]D^+D./(97OW=:L]^[GW  ]F AN+C_@U,D-QF<3+.XYU1);2Y7Z4T2U'N21
M*7+(NN,R(NR>HEJ',C3X[<J')CRXSJ24U)B/-R([J3WDIMYM2D++3LI,R !R
M@ ::EVR^< &H -#,B+4S(B(C/?VBWF?R$ #4!T5-N6@U>?4:93*O3Y]0I1ME
M48<64P_(@F[_ )LI+33BG&=O^;QB4Z]C4=[KKS   --2[9?.0:EVR^< &H#H
M:W<]O6XAARNUJFTA$E9(CKJ$R-$2\LU$DDMG(<02U&HR(B29GJ9%IV!W:'$.
M(0XA:5(<2E:%$9&E2%D2DJ29'H:5$9&1EN,N8 &\ U(^8]1IJ7;+YR !J Z&
MK7/;U#E0(57K5-IDNIJ6FGQILR-&>FJ1IME&;><0MXTZEM$VE1EJ.\)23(C)
M23(R(R,C+0R,M2,NV1EO(^T #< :D?,>HTU+ME\X -0       1GB][ ZQ_P
M_P!LD<O##V%4;^HY^]0XF+WL#K'_  _VR1R\,/851OZCG[U#?HR^N?\ *0P7
MGGHZA((  P-@         #Y//-QVG'G5I0VTA3CBU'HE+;9;2U&9[B)*2,]_
M: J:"QF(9D1&9T$0\9B)?UN89VA6[RNJH,4VCT6$])???424FM#:ELMEO(S-
MQ9$@M.R8PQ<S..6(.>C,8U$H3,R9395:]#;-H+2ENM1XR7RC3I!I+K32MLN/
M+C$EIIN/F%<W"VYW#Q!N)W ##NIJ*W:*]R>ZYT%Y1HJ<ATTKB,I-!D>J'RXL
MR0HR/^<*A^"&R4KMFGM9B,0Z8VW5JJE*[0BRTH-4!"2-E]TD+WF;Z#)9&I)&
M1Z&1F8^N]SZ1G#<?F*];ILY'=*IR2L[J=YL28W@35DAX1%DLD&6$AH\)^';J
MA%DYI)$24V,A_/3=<G'*ONB=U)PW$YF/31$S9OOJ'R>\M.AF;!LT=&B2>4&T
M3Y*V+FJ+JZH4>"VE%9K.*&!&5CG-5@;ZG;$H\-G9'*ZC#@0951<-.SLN3(3<
MGBS3O(C;4HT[NT>X9(60#_YN\O\ \ 7'^Z6++?"WG_\ IDWJ9(?66Q +:;8<
M<1IR%.XE(2HMW-IV-Y:"]%D!6DN#P(C/85Z 7%UKGWM?X,HSU0O11<^XC+>.
M5[JTI/<L[CFY[*K^T-L^RC*D@/CTU,H8;9N[MFC0X%01$HS(B*@DD5HX'N"R
M/)\W?=$;KLA26Q[FDV2)!G;)SBQB:M[=G1\=&3))J5$U*-*8J49F:E&9UC%_
MLEAJ3C31HSZ$NL/WY);=:41&E:%5S9-*B/4C(R,RT,M!G+6_@;A2];] =78U
M 4M=$I2EJ.G0]5*."P9J5JR>JC,]5'V3,8-UA?Z\*!__ ' >_P#RZ0SZ[:]C
MEO\ _P"!*5_ ,#CWNI7MZ=6DQNYGANPPY/E$U;RU:,\(R6YP,\!28F6(HQ@.
M6>X2D]Q?F&Z=W8YNKUO<J2+O9O+NR;8$63^:B3OB%0B>.%=(H2S5Y#L%<9L-
M+ECQK0IU&NB%39,RD5B$VF.J.[%9<D*+BHZ6T.<9Q9(T41F6OR##JIM:NO"*
M_P"9-H%1>I-SVM/JE-8FLJ-*T,FZ]$/:21EM;;2="U,S+M[A^@/722JC5=*_
MP%4FI$O^J<59'^HS&!-F-C08F/>)\>G+2N&BL.J;4DB).VI]TUD1;_YVI'^;
MX=1^WW+TORC*S*=4W95>6THR<R=G5Y8,'Q2GEDR)NT6[/3$M]-1$S;H4C"9>
M89I,\&E0]?[N.:<CS?;S$G?(+F[2/+#=]?G)[>I.0S<FS=3LR8/;D\&3 D&;
M=U:):8#P7PB26E)J@21X&.FN8C7Q";DR79MP795X4>3+<-2W72>DMMNK/:,_
MP4K4>AJYAF599,AF!^$6&EMP)-FTZL7#+I<:55ZK+23SDAR6PV_LFEXEI1L<
M8:=$Z;R/X2/#SP:J4>CXN8>U27LE&BUZ$ATU:;)<=,92DU&>XM#,M-1GXVO(
M:E6W0)+"TK:>HE*6A2#)2=%0F5%O(S+=KH9=@R'F]U)+DKR4RFI)$FO;=PDU
MX9/K=LS=%K8);-'93NQ8L5FR-,6;!D<4,S\DL.)%00_/[A>:\W9=>)^3@EEP
M=)5EIR;R8ZNK1_8LGM;LQ?4O#=Y>&9-TM(-GILF#1M##43,RPO*5&SOG[X-#
M#R_L/ZK?.#UN-4#$2C-JDIBPB,T5@C/KD&WJ339H;(R+1&AZ[MY;[.N3"DYF
M\NF.]LW-$L&NQ:#(J9T^Y(9<>464WQA1$/*;XLVR)&JG"T3H>O/V1F7+0E:3
M2M*5I/<:5I)23_.1[C'5>@]'2K7T+I9*(]K4J;'VB/777:)OGUWZ\_9'2LV]
MV^6Y)FM*,T9:<&,Z),?F39@S.5'AL;=U8-V> MDS:>4I:4+)+5CAF>\K+R(%
M B^E9X^YBFQ+L^Y'W0)M2F\3'EF3&[L]-DR&Y.Z75^>G5LEHS>&K$C9I9M&B
M,)@\X!8+RS-.^$9DK"Y-,D+F4^#+6DT+E0HLA:#YT./,H<<0?PI4HR/X2'.&
MA:$1$DM"(B(B(M"(BYB(NP7:^ :CI)1D9F9% C,X%D*HK88HUCZ=01I0DC5A
M&22BJ$,(X%$X51.F%40  $&@            &U?X)_)^\AN&AEJ6A@(>+4>H
MXBQQG<8Q.DYN\*FL'7D1[^--4]"'3)E2DF41/'&27NL_ UU,_E'?'0N%-4K7
MT>;WZ?\ =THMVFG;+]V[M"XU<^7&U[FQKM'&F7(4BO6GRKD31$O17*F287S'
ML[D]LM-=/SBH_33_ -YCLUK/MW=9,D!P=9&D.4U.$E)=WEO*TEI>&Z'CNIX:
MFR9-5-"BP)FM!I(BH6I1XQT@PW*WI^ER=LJO\XYS2*B59?4^.+O($NK<G9JZ
M=PN3(FS=@AF9)>3:LFB%&9F>]I12+:V6FEYZ(F(K3F.M53*LG97QC1(@%JKB
MCV=[![?^<T^?X#%RHOA^']^[]0 .$2S*QRR]D]FXR=)YDR0RWB3'9+H[^1'R
M]Z29EAJCY2HTP(=H3:D!$W)..3T2I*\KD;=HW[JEI]4_O9;X22WHFZDI/>48
M/D(A!,3R@  /4CD                 #0R(R,C(C(R,C(RU(R/G(R[)'V2[
M(U  '&CQ6(Q*)EB.SMGJHF&6VB5\*MA*=HS^$:R(K$E*4O,,/$D]22^RVZDN
MSJ1+2HB/7M#D  #KW:;">5M.0H+AZ::NQ&%JT+=IJI"CTT[&H^T>(Q&(TL,,
M,)/^;'90RD_SDV2=?E'*  'S=:0\@T.(0XA1:*0XDEH47:4A6J3+\Y&.'%ID
M&&HU184&*:MZCBQ&(ZE'_24TA)G^\=@  -BT(<2:%I2M)\Z5I):3_.E6I'\H
MV,,ML-DVTTTT@M3)#+:6D%KVDH(B_/N'V   <?DS''\HXECC=/\ .\2CCO"[
M.WI\HY   T41*(TF6I&6AD>\OE+L_F' CTR#%<6['A08[CF]QR/$98<6?;6X
MVA*E=O>9CL  !\W&T.H4VM"%I5SI<0E:#_.E1&1_*0T99;8;)MIMMI"==$--
MI;06I]A"2))?#H1#Z@  -JD[1:<V\C^8;@ !13=.3NE7-FLL+,\Y<BV*C9#=
M2;:H11C4B5Z(0^2&9O[6B-@NNYMXK6 !3,SA&HH%H !\4,-H<<=2TTE;FFTM
M#:4N+T_+61;2M.QJ9_(/L @#BRX<::WQ<J-&DMZZFW*8:D-]LNL=2I.I'S;A
MHS!BL$CBXT5HD$9))J.TV22,C(R3LI+9(RYR+37FYARP !T=9M^GUNBU.AR6
MDHAU2')B/)8_R<R3(96T:TFSLFE1;9J)1'KJ6O.+7_K=5X^A,O#I>.\I[!";
M5O1-^PI-&Y1.49SN7J8],+KJJAL&^>FSQFA(ZW39W"ZX I&98A#(CQWQ=0\=
M9-C6[85J4BSK<@-0J)2(K<:-$(B6WUJ"2XM25:DHW5$:U:ZZFH]1Z*)384(U
MG%A0HAN'JLXD5F.:SY]5FTA!J/7?J>HYX""CB*@Q5OE(5%BJ>(M">7':4\6I
M:'HZ:=O0RW'UWP#=R2-L(1R>/LH,S0GB&ME)F>IFE.SHDS/>9D6IGO')  'P
M=C,O&DW&FEFDE)2:VTJ4E*BT42%&6J-2W'LF6X6[\0<D][SL3;QQ!PBQJE8;
MHOYMAB[J/+I/IBC38[3)Q^+B%.=6B :FU+(U1DH/:5J>\BTN+@!'"\0%.V7#
M+I:&76R4VM;I<KG2G79-:K:R43]5E/O*?6ZX2U*4E).+4:4&9DDCT3NW"H&1
M&9DHXMYEAY'Y#[*'4?162B_5VAR #'28#K&:33V'"<9I].967,XS"CMN%^92
M&R,OG'->8:?:-IUMIY!\Z'FTNH/\Z%D:3^4A]@ !U'H'2M=?0JE:ZZZ^AT77
M4N8]>*YR'8(C,(7QB&6$JTTVD,H2HBTT+11%M?K'W  'R>9;?1Q;K;3J=2/8
M=;2X@S+FU2LC+4N<CTW&"V6G&^*6VVIO=UBFTJ;W;RZQ1&G=V-VX?4  ;4)2
MA))2E*4EN(DI)*2_,DMQ?(-P               ./+_T63\7>^S4.0./+_T6
M3\7>^S4 " <$?QC=_P :;^T6*AA3S@C^,;O^--_:+%0PVT\X]"?Y2&4F1)*)
MPQ](  # U&.(                                :'S?*7[R%.M0_P!>
M%(_J/?PQBHH^;Y2_>0IUJ'^O"D?U'OX8QM&-7U%= AXN4NDA46  ,"@
M                              #S5W^QRJ_%'OLU",, /84CXY,_B7!)
M]W^QRJ_%'OLU",, /84CXY,_B7!Y"_PU?6(2LM!])"=  !XQ0
M                        !P:G^+9_Q.3]BL0A@/\ B.I?'9?\0X)OJ?XM
MG_$Y/V*Q"& _XCJ7QV7_ !#@T7FJY.D2LM!])"?0 !D4
M                        !#6.GL%F?&8?\0@3*(:QT]@LSXS#_B$#2//3
M]9/20AXCT'T"0+0]CE*^*,_9I'I1YJT/8Y2OBC/V:1Z49$3BU?RD   #0
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M5?ALL?J34&6Y4&I4&WH$Z*ZDE-/Q9=K*8>;6E1&E6TTXI)&9'LZZEOY@\A'
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MH[R:Y,90?#(B-Z?6;LS2]-S(B2DM];$M?DI)--!0   >O'MP
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M3DR<&,IN+!3,F#RZ,&2$)[G.)HPX*PFB6D%J3@F   X..T
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MOJ*Z!#Q<I=)"HL  8%                                    'FKO\
M8Y5?BCWV:A&& 'L*1\<F?Q+@D^[_ &.57XH]]FH1A@!["D?')G\2X/(7^&KZ
MQ"5EH/I(3H  /&*                                    .#4_Q;/\
MB<G[%8A# ?\ $=2^.R_XAP3?4_Q;/^)R?L5B$,!_Q'4OCLO^(<&B\U7)TB5E
MH/I(3Z  ,B@                                        (:QT]@LSX
MS#_B$"91#6.GL%F?&8?\0@:1YZ?K)Z2$/$>@^@2!:'L<I7Q1G[-(]*/-6A['
M*5\49^S2/2C(B<6K^4@   :
M   $!8\?B.F_'8G\0V)OIGXM@?$XWV*!"&/'XCIOQV)_$-B;Z9^+8'Q.-]B@
M:/S$_65T($K/0728YP&6NXP 9%%,>*N4;!/&3%S"W&V^K:]%,0,'UU%RQJMR
MEYKT,55$)1,/B4'Q;O&(21=?S#ZTC*9@M1,=Z[F,I]M\5BE<;41FJUSE3I\>
MW"B\D8+D^O%IV&=$[BWBI<  0+F*RV809IL,ZIA-C1:D2[++JTB'*E09!)0Z
MAZ#)3*CK8DDDWF-E]*5&32BVM-#[ @?&#@X<K..&!EN9>,0;)<J>&5J-I:HE
M(;J,J,Y#0AQ#J.+E,J)[5*VT*(R41D:2TW::5Y  1/+;RY19DIG 0\'O EQ)
M#M@W;.9AK84W"D7_ '2[&648TFRA;*YRFU-HV$EQ9D:33JD]VX76<,<+K&P@
ML^E6+A[;T*V[8HS7$4^FPVFT);1NU-Q:4I-U:M-5+7JHSWF9GO$A  1,\9Q$
M>8I86V1C+8];P[Q#HD>X;3N!CB*G2Y!%L/I+7841Z&:%MJ/:0M/7)5O+>+8%
ME\"CDOM"Z(E83;E?JU&I%0]$Z);%1NJO2Z5!E&_RK:<B2);D9]*7R);:'&ME
MLB(D$1$+P0 +$RQ&8H@S6<']EPS>T*UJ5BM:*GI=CQ^2VA6*3/E4>?0V-E#:
MFV)5.6R_HIIM+9Z+_!+G,MP\%@OP7.4[!*Z[%OZUK-EO7W8#=0;HESU.L5&I
M3T(J+7$R"4[-===7JV9IWKYA<<  B>*)P%KC%W@B\GF+5]7QBE4[/J5,Q*OT
MX?H[=5+KU4I[\A,1'%I2M$-]K75HU(+0]VNO8$YX 9",N67'#NY,.<.+05"I
M=Y0W(=U3YDZ5/JM:;=0XA92*E+6Y,5HEU9)-3A[)'H6XM!6H !$\43@*=,+,
MK>#V#V"KF -BV[Z%X:N^C6W1>4NNZ^C[SS]2^_+/C-7G'W#/M&?P!A;E;P?P
M?P4<P!L:WO0S#5TJT2Z+REUTC]'WGGZE]^6?&%QSC[A[CZTSW<PJ+ !!0BO@
MYLK+F$ED8*+L?7#_  _K,ZO6U2N7R2Y%4JC5/1>4]QVUMKVYI<9HH]W,.CS0
M<&GEES2U"WKDOFV9<*\[4ALT^AW11JK/I$UF*U';B$W)<ISK#DLRC-):2;ZU
M&DBU(R%PH %B>4Q1!EGR 9<LKE*NB)A]:*GZE?$/D-W5FMSY5;FU>.;2V-DW
MZHN0\UHRXM'6++<?.0I3J' D9*9EW3:S'MFX*=;U5J1U:IVC!NNOQJ7)FG(.
M6:T1F9:8S2%234XMM+6RO4TJ+347BP (GE/6*/KGR,9<+KZD*:C8T=MG _E7
M4\CQGW(S5'.;Q?*%;#6REYQTVTJ6I9;1JU4HS,S'ALT7!R9:LU51I%RW_:TB
M->E 8*-2+JHM3FT>>RSQ2&%IE.TYQAV7JP@FT\<XK8+>6@KZ  B>4Q0_EDX/
M[+EE7IMS,8;6FXFL7I =IUT7%5JA+J]5J49YAR,I")E16_)8(V75MGQ3I$:3
MT/<)5P&RM8/9<+/JUC856]Z!6[6WZG(GQ.4.O\:[5GGWYJMMP]HN-<D.GH6X
MM=PJ+ !(BF_ O*I@WEVJ5Z57"^W?029?LMN9<CG*79'+)#3CCB5Z.&9(T4ZH
M]"[8J0       1GB][ ZQ_P_VR1R\,/851OZCG[U#B8O>P.L?\/]LD<O##V%
M4;^HY^]0WZ,OKG_*0P7GGHZA((  P-@    -#,B(S,R(B(S,S/0B(MYF9GN(
MB+G,:CYO-(?9=8<+5MYM;3A$9D9H<2:%D1EH9&:3,B,MY'O !"6*]CX*XPT@
MK8Q(EV_5Z:A>ATY^X(<75>T1D3C12DJ4HE$6A*29Z]@>!P[RAY9L/;FA778U
ME42)<%/(SB2V9;4Q3.VC9-1-FI9=<GF/3X?A%N',/E'PCEYW,N]O\5<,>@WS
M(N6?=%*8NBLLM5)^FL<JB&6S*3Q26WBU-+9:&6XRTW#KJAC)B'@+G7Q!L'#F
MPJCB%:L*%26X5']&7VDT-#=+(S2;CZG5.\>9$>JM#UW\X]H[RY++JYM).=I5
ME!W<&N&35S8O;=FZM-]*#3#8(63-6^$1$O"2>$5!Q(>A>YK3:?Y192P^R#)#
MW*K#>C8RD\2>ZMGUD; \)B;-Y:,E-D&R52SP5E@G25(OGN5.FQTOJ=GP&41-
MDI!N2V&DQB5N23YJ61,:\R=O9U[ XT>X:!,<)F+7*/*=41F34>I0GW#)):J,
MD-O*49$1&9Z%N(M3W#&NO;'/$J^L.,_5S7)2*G9LVGUG"QN):J*H^Z]3F7JD
MVU*9CR6UH4V<UO:(S;)/X6F\5=Y9YE@51^'(HV"ESV?78]EU"25T3[FK,Z,E
MPJ"XY(DJC2E&PKCS)2T\^R9EL[R(>K'OA<!OC+EEAQ&N:=<]W42U:Q<=1-"9
M<IVL0B>>4@MA*323VNT1=:1<^N[=S"6;:PQPUP[LA5G42F4ZA6>XRXPN&Y*;
M9B&W*VB6GCW%)1]\VS).BMYF6FIC'EAXE9=J7EMEWQ/I]VR\16;RF057.W4K
MA5%1+<N5<2,?%I6<8T-J-)&6NQH6_<0JRS&8FIN*QL#\O]S8G28%4O>BU&O5
MVM4IAY^4PW0H;=9I##Q0%FX@UH;;95JHC5KU^IZCV;:697>'9BYMY3?VSH[F
MS-@[-7MNM@Q-D6"S-DR4LT(-F5",$BP2Q0'HW:;,W7-^>92=)#DEVE!\)LE[
M?6$GNK)Z>2;J)38F[=#(FK4FJBPFA+4K#52J)BMV9D+R@MI>J,[#VBQV9+JY
M+LN14DL1UN/K-Q2^.6XEOKUKU+16AZD.%%R)Y,YJ^+A6/;DQQ);:FXU::?<2
M2>NVC0V\I1)TWF>XM-Y[A;UO7,/;F(^2"W*Y6KGG5"';-;:H=XHCKE0JFN/'
MKB*=3U.H96F8@WFVB/70C/:WZCVM!HE+FXHV55LM='N*@46GV17Y6)-5J<^J
MR([RG;;<<IZD,U11((S7M:&SS&>O./9%/*=I0A.67"(H%#WT?84?_6O4/3>#
M?<_.DYE37,SI,SD.38F=9G_Z>NL7#[5RVY6+.G1Y-!MRRXTV*K1K;J%,DJ2X
M1D6AH<<5JLC+30TZD?P[Q5# .F--G%IRX"&8R$ER>$IA+;"-.M-33)[+9&G0
MR,R(C+F&/KDNH=LWO95%J-T817-<U>E7-=12+X]-U8:8><B5F232RAI=-DDL
MFDB)!=:9%IS"MO*K<%4?QOS<4*36'WXEO4R@%38#[ZUJI2%4J0>A)<6I2=-$
MZKT3M;.IF8].^RE*$HK)H_OSV^K24$K>GAJW419"-JI1ER#D,FR)(\C,U,I)
MDN3Y-9*@:F;BZ.[HA1D1$1J2P9H(X0HB1PJ%RJ17*)'29R:Q2XZ=Y;3U0BM)
MW;CU-;J2_.1F(QO*P<&<48#T*Z*=9]?866R^XAVE*=Z_0M%R6C-S4]VFJ]>P
M0M3X.6E2,9L-L=95]3ZC7%6ZJI+HLF-5YD9,-:7IAD2'8SY)<V30G=M;M-#(
MC$;6W85)LK@Z9&*%O3*K&ON==L2/)N!ZLU&4XN.S>"8262;>D*;2GDI<4>A$
M9ZZF?8'@=WANZM4-W9LU=VS,R4AJQ:*9M$F5)&E:#2HCT&/U/;DYO[!H[/KJ
MP>V#4C2T8/+%FW9+2>,E(:I4A1&5!D:3H%QJI9&LFM$2B?5;%M^G,J63C;TZ
MK-QFG%;1*U;-YU*'"UYR29D1<XJ9P\M3#"R* B/A_$MFGT.,WH4FF/4]:$H+
MLO36%=CMK=^<6@:5:R\WV9^9A7BI7IC6&V#]OV^Y3[29J,FER+D<K]#8?D.)
MF17F9+IL/:NF9&YH1Z;B'H[[RP5S"/#?,9AO@'C3MN5]RVE6KAY/J)')LN,P
M_P =5(+E;J$LW376FMMIM3JT*0:RV-3W'[%^E^7)39I8RC+$I/S))X263V^O
M#=F2LI(:-%)C; >GDN:,UI#;J>9&F](LEO"DX*F[A)KFZ-5)QX)M&#%"C3$H
MPCCLH%XRFW9;-9?5%I-PT2I24&9+CPJK"E/$9<^C3#SBSTWZ];N'H1C=Y<:7
MAYAUCQ@] K$6X<MF)S"ZFW4:)5*U5[OIF)<EUHB=D(F2W50(*$F:GDI09I/C
M-DN8AD?,+);3:B<)S::;7MD1$2R4@CVR(MVB]=K=N+4>H'(A]@
M     !H9Z%V_\3T&HT/73=S_ .( =[WTD*/<5<?<0K)Q>MFPJ'AU)KUO5F)5
M'YMPMOJ0U"7"B*?9;4V2%$KCW"XLM_.?9YA;HO[-3?5S5V>U<F3I-P*ARW6F
M:BI]MI;Z6WE)0X:BB*4>T225O4?ZM!6/FNN[-K;]X45O JR(]PT1:7N7S5J@
MH<9/BRV-%2$&X1&>I=:>_L\XI4+$3A(W-5GA)2$D9_A/NT-LS,^?>MLMH_\
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M13O;0D>69JIH   </'8H
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M'OX8Q44?-\I?O(4ZU#_7A2/ZCW\,8VC&KZBN@0\7*720J+  &!0
M                          !YJ[_8Y5?BCWV:A&& 'L*1\<F?Q+@D^[_8
MY5?BCWV:A&& /L*3\<F?Q+@\A?X:OK$)66@_P$Z  #QB@
M                    #@U/\6S_ (G)^Q6(0P'_ !'4OCLO^(<$WU/\6S_B
M<G[%8A# ?\1U+X[+_B'!HO-5R=(E9:#Z2$^@ #(H
M                    "&L=/8+,^,P_XA F40UCI[!9GQF'_$(&D>>GZR>D
MA#Q'H/H$@6A['*5\49^S2/2CS5H>QRE?%&?LTCTHR(G%J_E(   &@
M                                ! 6/'XCIOQV)_$-B;Z9^+8'Q.-]B
M@0ACQ^(Z;\=B?Q#8F^F?BV!\3C?8H&C\Q/UE="!*ST%TF.<  ,B@
M                                           ",\7O8'6/^'^V2.7A
MA["J-_4<_>H<3%[V!UC_ (?[9(Y>&'L*HW]1?[S&_1E]<_Y2&"\\]'4)!  &
M!L        4]WO@#2+TQJPOQEE3U,5/#-%71!AD@S*5Z+,<0YJLC(D[!;]Y'
MJ.MM_+A0*%CI>N-R9C<FJWBB B1!=CDLF"@QN3IV5KU+KD[S(B+7<1BI8  4
M"8C9%K<OJ/CXEBX4TF7CC+M6;,?1");=*?M9]+\11,$HD/$XM"3,M"+GUU'K
M;!R_8UVX<>FW1CA#N:UD4631'Z,S9\"FN/178*H+)<L8)+I<4V9&9ZZKTWF8
MK.  %%M%R86+2LNTG+\XJ#*I,BI3*GZ*N4]DWRD2ZFNIDHU*2;IJ;>5HD]O4
MM-QCR&#N0>Q<.KVJ=\7-4E7U5'8Z(M#Y<AQ*:+&X@XS[327%.)-+S)[!Z$G0
MOD%P$  6UZEP<>'[M9Q"<HM8]![6OVIT2J/6N4=3T2$_1Y29?WM*E;'W]])K
M5LI+37?J*^RM"EMV[)M^-%AQ6I- 50E/QXC++G%'3S@$XI32$*5HE1J(C5VB
MU'K0 !;IPGR?8TX,T6':-C9@V:?9L"LSZG&HR[1AR'$-U*H+G2XQRW-73XSC
M%-[1GN(]2YB''Q$R2W[(Q4O#%7!+&56%E<Q*IT6GXC->@R:JU<*(T'D*%H;>
M5Q416PIQ6K22,E++>1D0N/  "CW+]E'MK S!&=A1&JJJS/K:*HJX+G=2XEZI
MR*FZ\\XXII2U;"6U/JT21[BW%N'%7D^MM>6DLN/HPKT%*K)JI5+B5$KC45HJ
MP2>+VMK<Z6SKM?JW"LP  6Y<8LBU3N:]+)Q2P:Q+<PEQ2M:GG3YMS-4\ZFU7
M6RAH@L')I[CA,*-AA&B-M*C(SU+?O/QE/X-R/4[&Q7B8BXHU6[<4L6GZ)+N'
M$-@YM,XN90'R?ICD:G1WTM,):4E!.(9V4O$G19&1Z"Z:&@ +3]O\'EB37\1<
M-[KQ]QY:Q4M[#$WTV[06;8CT*7Q2VT(CH=JD79DNJ92TUJIQ2C7LGKSGK=:C
MQVHS+3#*=EMAEIAM.IGLM,H)"$ZGO/1*2+4]YC[
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M7M3/@DAQ#7M3/@DAA)_=ESE=805PMA" .JW>?< _XU_@'5;O/N ?\:_P$_\
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M[@'_ !K_  $_\0U[4SX)(<0U[4SX)(82?W9<Y76$%<+80@#JMWGW /\ C7^
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ME=$13+Q J+F(\"X#MYU,A@G"*G\8HW'-IK8W*V=>M+?S'\@K3.+']HC\Y?\
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M9=G;>.B$%=7:F^\\SQ>1YL.KM3?>>9XO(\V)UY!!]Q1/%F>@'((/N*)XLST
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MLJ,9N/LL[\<H/4@LVB"<VK=;PE+=J1JWU+%HV(FBV1),XE   !P(=L
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MJ ! ."/XQN_XTW]HL5#"GG!'\8W?\:;^T6*AAMIYQZ$_RD,H\TN7I,  !@:
M                               &A\WRE^\A3K4/]>%(_J/?PQBHH^;Y
M2_>0IUJ'^O"D?U'OX8QM&-7U%= AXN4NDA46  ,"@
M                #S5W^QRJ_%'OLU",, /84CXY,_B7!)]W^QRJ_%'OLU",
M, /84CXY,_B7!Y"_PU?6(2LM!])"=  !XQ0
M          !P:G^+9_Q.3]BL0A@/^(ZE\=E_Q#@F^I_BV?\ $Y/V*Q"& _XC
MJ7QV7_$.#1>:KDZ1*RT'TD)]  &10
M         $-8Z>P69\9A_P 0@3*(:QT]@LSXS#_B$#2//3]9/20AXCT'T"0+
M0]CE*^*,_9I'I1YJT/8Y2OBC/V:1Z49$3BU?RD   #0
M                       @+'C\1TWX[$_B&Q-],_%L#XG&^Q0(0QX_$=-^
M.Q/XAL3?3/Q; ^)QOL4#1^8GZRNA E9Z"Z3'.  &10
M                                 !&>+WL#K'_#_;)'+PP]A5&_J.?O
M4.)B][ ZQ_P_VR1R\,/851OZCG[U#?HR^N?\I#!>>>CJ$@@ # V
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M>9[_ #AFLQDZ9LZ9.2U6N36K=U<DO;5FS-KW.MAOC-@U2\I(R=WIW9LUDU+
M:IA$B[*FU.3=VW!=T*2YI3Y>)7W19C2PI@S9RRP=WV4EN+!JU2P[L9/1LFKT
MP:.2X&]N+TT:LU,3PV*HF2CS& '"IK[DJ!!DNHXMR3#C/N-G_P!VZ\REQQ';
MZU:C+Y!S1\@F1D9D>,C,CA325&.L?T.0HEI)1$9$HB,HY#(C+'3B.NDCH
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MOX8Q44?-\I?O(4ZU#_7A2/ZCW\,8VC&KZBN@0\7*720J+  &!0
M                         !YJ[_8Y5?BCWV:A&& 'L*1\<F?Q+@D^[_8Y
M5?BCWV:A&& 'L*1\<F?Q+@\A?X:OK$)66@^DA.@  \8H
M                    X-3_ !;/^)R?L5B$,!_Q'4OCLO\ B'!-]3_%L_XG
M)^Q6(0P'_$=2^.R_XAP:+S5<G2)66@^DA/H  R*
M                    AK'3V"S/C,/^(0)E$-8Z>P69\9A_Q"!I'GI^LGI(
M0\1Z#Z!(%H>QRE?%&?LTCTH\U:'L<I7Q1G[-(]*,B)Q:OY2   !H
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MLB6S4;-:3-"B)23.!D   _(/8@
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M"7$*(R,RT-*B/G,?<=3&4*#H,J#(ZAWX1DHB,CB1D1D=ATEK*DLI4D   "@
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M7Q1G[-(]*,B)Q:OY2   !H
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M$F'MLV.O#JCVI2H]F.<L-=O.Q([]/4<YQ;DE1QW&U-&IQ:U+VC09DH]2T/>
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M_>H<3%[V!UC_ (?[9(Y>&'L*HW]1S]ZAOT9?7/\ E(8+SST=0D$  8&P
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MQUO_ %\/8^+U6I45$A3U2I\=N$2>5&[,CM(B$?X'*#4X1,$9%UI.;.NFX=/
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M   /&/.
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MLVE,4\V9"B5M%(-1*5Q1$6FY6I"\J-JD)66BDI47:46TGY4GN,7"/%1#)H*
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M_#&*BCYOE+]Y"G6H?Z\*1_4>_AC&T8U?45T"'BY2Z2%18  P*
M                         /-7?['*K\4>^S4(PP ]A2/CDS^)<$GW?['*
MK\4>^S4(PP ]A2/CDS^)<'D+_#5]8A*RT'TD)T  'C%
M                   '!J?XMG_$Y/V*Q"& _P"(ZE\=E_Q#@F^I_BV?\3D_
M8K$(8#_B.I?'9?\ $.#1>:KDZ1*RT'TD)]  &10
M                   $-8Z>P69\9A_Q"!,HAK'3V"S/C,/^(0-(\]/UD])"
M'B/0?0) M#V.4KXHS]FD>E'FK0]CE*^*,_9I'I1D1.+5_*0   -
M                               " L>/Q'3?CL3^(;$WTS\6P/B<;[%
MA#'C\1TWX[$_B&Q-],_%L#XG&^Q0-'YB?K*Z$"5GH+I,<X  9%
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<S(*4MWA@Q4HFS[%*6C1F@S+RX1(CB4:RR&/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>nt10002526x6_barchart2.jpg
<TEXT>
begin 644 nt10002526x6_barchart2.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( = 'D ,!(@ "$0$#$0'_Q  ?  $  00" P$
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M36GHAV77&/XVEY-:>B)#78ML&G%D7E)WSH=BVP:<61>4G?.B;[VU]J[ERK/
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MDUIZ(=EUQC^-I>36GHB0UV+;!IQ9%Y2=\Z'8ML&G%D7E)WSH;[VU]J[ERK/
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M(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@
M0A" !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A"
M!"$( $(0@ 0A" !"$( $==W_ )*Y^3K?PS1V(Z[O_)7/R=;^&: "PME/QC5O
MRHG\0\9!1C[93\8U;\J)_$/&04 "$(0 (1^0, B(9" AWPRC]0 (0A  A"$
M"$(0 (0A  A"$ "$(0 (0A !X'@^</VA&/#_ /SVRG_"M_+QD./!\X?M",>'
M_P#GME/^%;^7@ R(A"$ "$(0 (1^3& NT0'Y@SC]0 (0A  A"$ "$(0 (0A
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M<9E"E'(0-\Q1']D ')".,%2B.61OG(8 ^G*/T8X%RSSV]X!& #]0A" !"$(
M$(0@ 0A" !"/P90I1R'2'XBB/[(\E,!@S#/YP$!_7 !^H0A  A"$ "+.7R]H
MKSY2R_FDXO'%G+Y>T5Y\I9?S2< %?TC[797\E2_<+%213=(^UV5_)4OW"Q4D
M "$(0 43<>:OI)0%<3F6JZA_*:5GTQ9+99ZIRSE3IP@?(=@Z"J939#PY;=D0
M3\'6)_=N]T&K2^;>Q6(OJ+)[653,)<JB>GY,J&I4FCQNQ1TG.B.8$1*7/;L#
M/+NQ.?N[_FLN3WO4/4^?Q=1'N<?.EW)F:;IW+J^Q5]C[D*$YERE</_5J+AS*
MD"HJ]6ICU/$H3+/2'2TMB>T0#:$!R(Q*_9L_:Q8QMFP;;I[NBF'#=$:6P*;H
M%,B5@6O!?)2.IB$ER M3-6!G0'!NP VF"@F)GF.P/@C*6PVZ-WW/NQN)G#]=
M:Z3!GA]MTWI][)97,B,6*#!"8R4SU02NE#)J+9GR-EF)L]G"(19#!%N3N.Z[
M>/:5X[]T=G*))_0B;Q6FJ522EYB.3.9>=J;^D2P^@GJ0*0P")0TLN",(*4PN
M4EB[^Z$<1=#7(-,%K=R\\B3J61RZ8.Y8K.4"2,PLTCOF*J2R8) 3+,##I< Y
M\$!9),SQ?L5R*HE3(IEYCY\0FHV5Q9V!O\[F,OM7<N1U9,)8NH@[8MG38KLA
MR*'(($;ZX5E  2B.D4HY@&?!';O7BGL/A](V-=BY$@I-1UI:AFX?-3OS:.6D
M)F0*[X* 9@.8I\&W@B%[)+/TE@+^Z(+5VKPWISFE;=U>9YU5I->>3.:L%M5(
MBJ:2A7[A0@AK#F4,(E':.8B$92;IU*]SUG.Z S5_=IY5&(>]Q6C4B.'ZGYC4
MTM8RA9>5D(!%9C*%5&)=<006TE"%R$._G 8X-92F<R(Y6WW%;6?G$JBRN)NR
M&(!J[=VGN'(ZN39 47231XVWR@!\Q*)FP*BL 9 (CF0,@VC%N[KX[,+=EZF-
M25P[M2*23\ARD5EZ;A!V9N8P ( N**A@1'(0SUFCEW0X8A0[DF6;49NQ5S+?
M6WH.H+)T34U/31)*V$RJF8S]"1.5:7=]353N'RPA^%7437#2(70SVCF$8^UM
M1-9X0,3N(F98]<(%7XF:7K^>.E))7T@KV<*)R"6Z]T)%B2Z0'=@EJ4%4^U_!
MC^"R[@P%P*Y3L29%5,YRJQD567$/HNVVNM;Z[5-MZKMY5LFJJ1.2"<CV5OVC
MO0*'#O@C=504/_Q0+P#WMEC+E8XL+UIZM3HBNKO4W)JE56(@,N!^T7%%500
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MOL#( 2$N6P. (#,TUJE*HD6998LE9B9:MBXP[-J8&KG%VJ23D(+J-]_&G,M
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M=\:KMO4MZ,*TEHV6.:MH"G*F>R9VY!Q3LM!118DI5ZH+"9SIK9"B8>'N0&6
M7S:S^=9*N92JJ,\<ZI^<A,>MAB,LK>!15&WEQZ9J5RCD!V36;,#/MN>6@T*N
M*Y]FWM4QV14=R+PVUM-+!F]PJSD5*L=FB>:3%FU64[8 S21<+)J'R'AT"CEW
M8A [F7=#<S)SCEM[5MJ9C7N%VZ)BN"-[.U8[K29,:D=HL0371!U/CHLP%,P"
M8HZLV8F#+;%LMT&O_1V(?=F*BM7BW=U?,<,MI2,19V]IAU/4U9BG-9.14RIA
MIXP/#@98"K%S3,  .S(("8%<JY$4SJKL*JNL3R[;WBMI=F6!-K>UI(:J9?VC
MRN9,W2R>8Y *J*"RBA-(<\M,I<\MD7*44(D0RAS 4I"&4,/>(0HF,;X@ !&(
M&F 6M&UD-UOHV58)Z;K]I@_N>+E"I*9J1Q4BJ<G-+I9JT#@:H0,X(*CPPJ=H
M4NWAS (GA&33>MSIJ$$$W+42'+F.8$<IB!R9AEMT3"&89=_+. Q,I2O(CO\
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M+_C+^V/G\;K?<FYMH=W7MY<*SU#J7(N)(=::046F[*R-.#+25(JY0<G Q$M
MFW,Q1@,V9$:CF4ZC.6C7FYAE5=7=B-USP&5%1=7XUL,ZDNM//IFR9O'R<]EB
MR:*+URBV!8YF")C%U8K ?1$0TLLMHYQL/W33=@*\L593"->7#TQ+,Y+?V8L$
MIB!CHI@U27?RYLZ)FY)M!#?*@"8,LP#/@VQI]QIS3=>-US;4/AQJ3"&K9:@E
M9M*5ZBGSB>2V<"5FS>MG8K$$R2:B?X-(3"!#@(Y@&??K3[H P_S##?@ZP%V,
MD,U%S/:5?-Y0E--6!!2F#^8RM)P<J8F$!%LL<<N !$G:]P1#.29HF22,SK(C
MFF4JC.L_77CM$S^BKNT9.*9HM>:UK2+6HI]3<CF;F5*5')P>%=3"6-G:J8MQ
M=@L!M8L)0+H (CL (N@^FLMEC07\QF,OE[$I=,SUZ\;M6A2"&8'%PNHFEHB&
MT!TLA^&(#VZA[GK4F#W!3:W&?)KU5>M?F5I4+,)U-DYK.464U0F#F5$:M2RP
M'N\4"MFIP1'12R. 9B$;8,3$^G.*C<JK"5C=3%NKAHE,\DK'U<3A"6FF,UJI
MJQ4:%U#--NNB] YTR'1,9KI'S4 1V[(#CP2J,CJ,Y8K:K/.0DJ2NZ%N)V\ZG
MR>OZ-FC[2T09LJDD[AP80'(0(BB\.H<P9<!2C%0SJI*?IQL#R?SV3R-F(:0.
MIM,F<O1,'YBCM9%,P?"!AX8^9IBLJ7#MANN-ALK/<_KN70?5"G54G8UM451$
MK9FPGPN)I+VKI=-I4*H-#D< 9<P:D#D*"@99;(W$[O\ 5QB$]4N#FI*GEM93
M;".^I=D\N<SI%69H.G^NDTM5.HNK(\IB41=F5. ESX>Z&4!31+!KG.ZLL5GG
MZA,LD%P:&JDX)4W6=+3Y81$-1*I]*WR^S/\ T+1TLI])>#;'MIW4M/TVAOJH
M)[)Y"U#_ +S.)DTER0_X3NU4B&V[!R-LB#!N<D\P%3[&;;"KL*6+FM;*OB!H
M3FR%:RVK)@C4SH6A$E4"S.J5R)HB176&#0*.D)L@#9'3W6C%:K??=4I5A(OO
M=ZI[9X5[;I-SU.>EF4U?/IZG,I4D]14!*0"68@4Z^9@T-+(#^Y" A)F<B.R>
M+7V"=)(JNI>IR"K3E2R&H$2^R4DTV83$"#W-/>:ZVCGM ,\N"/;OWJ<O9NWB
MV>J9M'+Q40 3""35(RRF0!M$=$@Y &T>YMB _@TQ!R#";NIEJK<8.+C7)NGA
M3NR=TUJ61U'(:K;I2-67R\"HJF>U 15<N^'AS*9 8H=S@B>\BHF^9D,=+\$[
M9IG,D8,_P;I(!,D8!#(<P/HB&7S0!2<&5I'65A^<K#(1,KV;KYCUQ%XI+H6!
MW/.Q<SGLFLP80JBKYDL24MG^:"J^B@2<-TTSZ(H*$S1.8.[LC,?<?]UQKS&%
M75S\->)"A!MWB M$X:LYPS%X1]U45=BJ8# *!"H) FDF)@T1'2SX>"+U;H7C
M>PD;EE;^KJL:4[)#7PN6S<2^F:,D+)-2>5/-7)#LT3N#2]$SE'4*N$U/PY!
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MHF>73^6N'39TP?LC"Y:&*=HJBKHF<%(!@T\LL@'9G&90 !0R#]8YP'+(<^"
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M_?,6C*KZ!F\NE3AI-"2V6)2ID)U9T"K8AM205!$J8YB.T<]L2JA* B!LQV<
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ME-W2W)3"CB=K-J[F=XFJ<EE:51J/W.6]'4QEDK7*HTTQ;G,=F(I@<Q1, CI
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MY&;MW2!Y:YFM.X;\0$MF0)I3&9/7$L:^I*FQ!$@J.E3)E$Z^B41S+F;OQ66
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M/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@
MR$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SX
MO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$
M)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<
M^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+
MS8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"
M4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/
MK[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&
M/?7/K[Q"4\^+S8=<^OO$)3SXO-@ R$A&/?7/K[Q"4\^+S8=<^OO$)3SXO-@
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MV4_X5OY>.3KGU]P>H)0=H?\ ?2C^PN?HX8M<\K&I3W'8SDU+G3F:0'!.5;X
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M18IBET0 /9" !M'+/XH ,E:9;HNJ8E[=<@*(N&&]UB#P'160T%"&^ Q1$!^
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M1Q.[A$JXLG,4J :H9TI-3-Q'5&, A_3$QR,(9QN7ZY]7^(:WG?\ NCP%SJO
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MU1U:Q!,".F@LB.1A#(#9#P1+1"YU7AG_ -05 S[SKA#X=D N=5P?^X*@?$Z
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M?DP],<D( ./5D]PGY,/3#5D]PGY,/3')" #CU9/<)^3#TPU9/<)^3#TQR0@
MX]63W"?DP],-63W"?DP],?E==)ND9595)%,N6DHNH5),N??.<0*'P9B$$%TG
M"95454EDS9Y*(J%53'+O'((E'YA& #]:LGN$_)AZ8:LGN$_)AZ8Z+F:R]JH*
M3B82]N<O"1P];HJ!W=I%%"F#9WPCE:OVCP!%LZ:NBAPF:N$G  /YVJ,?+X(
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M)^3#TPU9/<)^3#TQPF>LRN"M#.VI7)\]!N9PD#@^09CHHB;6&R[N0#D&V.U
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M5 N@<R1]0@:HI1GVAS!H"(FX=$<P&";3R$9^SKD"BG*J=9>NOJR"\]+4#1&
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M*_DJ7[A8J2*;I'VNROY*E^X6*D@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A"
M!"$( $(0@ 0A" !"$( +"WV_$4N^6-_YA&+V2S\6L/D;;^"2+)WV_$4N^6-_
MYA&+V2S\6L/D;;^"2 #O0A" !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0
M@ 0A" !"$( $(0@ 0A" !"$( +:7=]H<X^)#^*$?NTIS*4+)S'',=%8,_@!0
M0"/Q=WVASCXD?X@0M%[0Y/\ $M_$& "Y<(0@ 0A" !"$( $(0@ 0A" !"$(
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MJ]7:E,40,&;514R)B@)0[42"$9CRF3RN2,&\LE+!I+F#5,J;=HS02;H)$*
M  FB4A,\@#,=':.8CF(YQ[.$)A+V"W*5J*%0KAQ<5.1HA5[H"%6FXCI*B!$]
M44"@.>CVG:]KEG%-WDP^VJOS*FTGN93*<\:M!,+55-=5D];"80,;4/6XD<I
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ML'A&H:H=T?N!+Y-.:[E]D#N[?4DYEC*I)QU:(0R3J<+$:LR%0,36'R<GU8Z
M#EEF.01=ZB,:%=+7*8T7<FU1J/859(GD]H>9=52/!FJ,OE1YFY3%),N: Z %
M(&GD(B.R+(];L8DR]5F7%J8V-QPIN4%3J))KHJ*)9 HFFJ10Z>?!K"%$3$S[
MFD 9QJTD>/6XTPI257;G-FE))9R8SR82)U4QIP54[ [>9GE**XM ("Q@7<
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MLKN+NUJE)C]<Z8G.*HG*3/HX>N=,3G%43E)GT<1G.W_._7#M_P []<-[ZA_
M;KZ3:[C+NL\H;X=,>&WGT65W%W:U2DL/ONFG$T^9N&A[6$(5<@IZ?5-H.B!@
MR$<M7\/_ #F,>EI;[I0Q+4Q+>IZ-L4W!=8H<#A,6A0 5#B<0RU8]_+/A[OQQ
MP>W_ #OUP[?\[]<-[ZAW 3KIFVG95_N6RKRAOATQX<>I9),I6%XN[*),?KG3
M$YQ5$Y29]'#USIB<XJB<I,^CB,YV_P"=^N';_G?KAO?4/X#=?2;7<9=UGE#?
M#ICPV\^BRNXN[6J4F/USIB<XJB<I,^CAZYTQ.<51.4F?1Q&<[?\ ._7#M_SO
MUPWOJ'\!NOI-KN,NZSRAOATQX;>?197<7=K5*3'ZYTQ.<51.4F?1P]<Z8G.*
MHG*3/HXC.=O^=^N';_G?KAO?4/X#=?2;7<9=UGE#?#ICPV\^BRNXN[6J4F/U
MSIB<XJB<I,^CAZYTQ.<51.4F?1Q&<[?\[]<.W_._7#>^H?P&Z^DVNXR[K/*&
M^'3'AMY]%E=Q=VM4I,?KG3$YQ5$Y29]'#USIB<XJB<I,^CB,YV_YWZX=O^=^
MN&]]0_@-U])M=QEW6>4-\.F/#;SZ+*[B[M:I28_7.F)SBJ)RDSZ.'KG3$YQ5
M$Y29]'$9SM_SOUP[?\[]<-[ZA_ ;KZ3:[C+NL\H;X=,>&WGT65W%W:U2DQ^N
M=,3G%43E)GT</7.F)SBJ)RDSZ.(SG;_G?KAV_P"=^N&]]0_@-U])M=QEW6>4
M-\.F/#;SZ+*[B[M:I28_7.F)SBJ)RDSZ.'KG3$YQ5$Y29]'$9SM_SOUP[?\
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MB!QE2ZKYDQN#BIKN54?1*CPQU4J9EDIJX],/EFK5P<42[Z8JZS,I"".P0$1
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MF;-DO.C.T"G*0II:FJ.6^BB)A+VH ,;/K\X[<3DGN+2F'FPMB%ZMN*23,3W
MJ!]-DI-*Z4<*2U!RV(F\?D)+YAKQ$Z9A26$""&W; 7!.J\IXRJUUQ#=*X=H-
M&SEVX/JT&B"SE<Y@'M$4$Q55./P%(41'XHM7:N^5L;SMYJYMS4S>HD9*Y.TF
M1T $-[+D5.B9,WQ*$,7YHTVX>]TEO+4=]:XP>8H;6,Z'K]]2-2GI&>2VI&,]
M3G@(4\]>.]826BHDT!N0 +VYBB8=I1BE]P>* 4G?SMUS?]<YF&2ZZBPAE/9B
M':BH8P@&S@#++O0#!J.Z7GF)"\6)OQB0L]AMI<M87AJYO2,@,8"D>K)F5TS"
M<$P*4A $QA$Y@*   B(CW8OI_8_\O^R(U/W1\26'L':OJXHJE)?5C(^J1B.%
M&Y-[!4$NUNL,F8N9=7I9@8<LLP[L!"*9D0V3#NN.!0#(%/=UVB#A1%-)9:G)
MLD@)ES%*D8RRC8J92&$P#IB(%RVYY1EI/L3=DZ<MBQN_-*ZE9+>S%5DBTJ-N
MLFY:J*OUTV[9,3(G.4ISKJD3$HCF!AR$ $!C45<!#<I5L/:PU@I2JJ:=L6 .
M0ERZJCP)D-,DWOH%9&%R+H7F66K#:I\<:&)8O5U-;BM?.>S M0C9]A<RF7=F
M6TU6F",R6;H7#!11N51V8)@5-?123)K.U!,P" :,!E@E>59%7?DO_*L3S)=,
MF<T8,9FQ6!=E,6J#QHN7V*K=PD59%3X .F<I@^ 8[HB !F,1BG.Z;XYK&V/M
MQB"JS">HUPXL)71DCFLP4JMH9RT:/DY?)FK\[4"[]."AS@OEH]W*-D&*S=!*
MMMO;VRCVP5JGEVZ]OW+ >4E*$7)Y<R8&2;MUIAOV9JI"T; U*L82BY43UFAD
M7:.4!C@GSWE*HIG7<-JA3@;8&?S@(0,8"\.?S!G$>5ANF>*^P%][36VQ967E
M<EHV\KA5"554PJZ4S1:2K)%3S04ETM,HL<166*CFH4.#/XJ_OONE%])_BHK[
M"WA>MG*Z@G=IY;)YI6$\F]3RV0ZXD_E99I*T&;>:G2!T98@@D.]A.)!, FR'
M@!(]3*63'B&]P! 0S"/R)R@.6WXP 1#Z8U)88MT/KB>6HO/56*ZU"MD9W8YL
MD>>BM,@FS&=*/ 7ZG T>H)E;'WR*:91%%0X)ZP<\M';AK*MTSQS7*HV88C[9
M8<)*ZL@Q?N^I3!>X$B;/)])I:[4;S*9:EPH5ZWWLW1.[!(29J!D4O# ,$]3*
MWUB1U%N[GW4H2SU)S"M;AU&QIJG9:0%'3YXLF0P (Y%!%(YBG7.([ *F!C9[
M,ASBS^#[%)16+^QE+WIHA1$)=/=]M'C%-8%AE\REJYF4Q:F.&1C:EVFJF!\L
MCZ B79MBQ6.G 4SQKSJTR-4UV_DEN:#?NG]540SWRD6M#F6178$7>-E$S($9
MK) 80',#@(@(9# +:ZLHK>S.Z)83K]5@6A;<W,*^J8YSD0ETWEKN1[[,F B;
M>BDR3;E<@  (YHZ8#F40V"$9P@(" " @(" " @.8" \ @/= >X/=B*MNN% 6
M0HVXV%RV>'24DE^*A&=LFU&MJ1=+%<,I9+G; )T:?$EQM2 K2M-02#,@ 3YB
M),S",2A:/(\2I6F$IEGU23IN1DF F',V_"2UL5UI?G:\%,QVY_M 92(CRV'J
M6,5+"$(""W=U$@6HB<$'8&BE^HX#_P _LC@M'[1)/\&^ ^A40CMW.]IDX_PI
M_O%CJ6C]HDH^-S_&- !<N$(0 (0A  A"$ "$(<$ '$LLF@DHLJ8")I$.HH<P
MY%*FF F.81X  I0$1S[T1C]U:QZS.I*G4L7:6>JR^5R)04ZIG4M<'S=JFR40
M(0Z9@,75'*)!U9QSR[8.]L?W3;&JRP[6T=492KTAKD5BV7:2XB*Q!5EZ(%T7
M1E2;=$3H',)=(2CW0VQH$P7X3I[B:FU=W'J[?*M'4JRF4UFTR<@H89J[<MG+
MA(I%#CIFU#D!+VAC '> (]0["5"(7"8>\;*E-6:6<'AIX$"=7A!*^'/JUDQ2
M\I8K^:V)+51,71!D9-&YJ:&6"QF/"^V:V3XY'XNZ;!6QJV6VI#&$FUI2^NK5
M3/L9#F;+X2IR6\,CPG>;%*GF(-",E,W4D,9FIXP1CW:*Z5S%[J4$@M7,^504
MG;$BB9Y@],50N^D2FTB&<"&0AGF @("&S*)%NZYU)4$APN4V^D<X>RMXI+)2
M*CEFX505.)DF8F$3I'(81$1$1S&(T]M$TT;YTPW1+H(M:S4:(ESSR2:S8J*?
MTD(48D?;L3_\E&E__LN3_P %G'<6R8ZN9;*.PZEFZ.S-FW?7DVC-+NQ2E9*:
MNAR:)2@DKE.7SB,L<JAYXV$XA$MXK;&+:Q!\;-G2'0]+%LT>GAHMDI#)[(S9
M+6T-2)F7>F4RE,1R:;JJ_58/"RZE*DJB?3 B:>DT;3"8&4 !( [0(J<<\LQX
M-O<BNAIO&"4!,+&N@ F9A'?4UV:/".0&S'++@[L9N;C2U;.\1\S3=-F[I/>Z
M':.$4URADS-P%4*8 VY=R)9)9!)! ?\ H63^R-L"6-.^(;?P7TCE'XME+9F9
M['E*5T>84/@L19H<G1Z^$MB2Q69O*,,T&AFP-,D2D1S,SF8^CL&;6]MLNT&9
M4N>MD2DD&;-(F_.'P-VPWEDE+FMFDFFZ-'M"YKPIF4JK+#*#[;W&%BLL+4B"
MC>LIZT78+D,\D<W:+@+I(A@$Z15'W#I$ P9E <L_BB2;8/=+K<7(PZU%=FJ%
MF\DJ"AI>F%32-5P!EA>+%,DT%+@,KOE4FE^"*;5@;;P18'=B<,]'3.SKB]$E
MDS.5U/2ID]\.&+<B!7172Q$OPA$BD3[4F?L@^/;F,1@VDWFC5D[8,W[EJQF0
M)=4&:2JA$'8I^QUJ93%(;0-F(:11R[D<KG1BA&S[19PI$PA+"C<6=(FAW?UN
M+)DEI_@-&+1\<VBV2&27AF\.S0E.[=HSW1@T44\))+(_RQ"F^R=M3:=Q2B+S
M'WFF4!?X*T>X4RB;=NMC-[9MF</B+%FW:/"G1LZ/C(TOCLR:[B\LDJ+YJE(6
MC/3$GNC6(&_M33$\IJ9]2=%E=+MY/(&)-8L9$%#)@8JR&@N<50 IP <Q#/+A
MC'YB]Q4 T)4S!:O#,D1WR1^8)T.0%'3T][FSTB]KGP9 &7<C)+<Q+$T_?'$C
M+$*K9EF%.4HIOEXQ.'X-PJ='6H:?<[50@#D("!MOQQ,:;4;2C>7)RQ"FY&1B
MDW!F1OU+8Z.H(GJ=$?P'") R$1#,1VCWX_-3_9+HKL/OSA0^ T)A;\3%R8-W
MS#2Q8(9LVLB9H4OX.V:O+PU9I-JU:ME2^>52IF0_=L3;"M/-L/#(ILB4JV2X
MY##;Q-Y=8>;,WAZ:O#=W-!MFJ61/;N[N;DP:K)BQ8,$$?^&J1H))3B08;MU6
MQ V<G\NE]QYBZKBC4G"+5_+GJ!9>Z8HB<$C'.)R"X-JP$3CLS-HB'=SB539&
M]-$WXH&35_0LT0F,IFK8BABIF %&JP% %DE4Q'6%T%=(@"< TM$1C2-NB^YA
MSNKZB97%PY4LDK-)FHN:II"@=)NBL8V1$CD$^2:>6D8^290[W#%;;E?8K%?A
MQJFI*4N;23B6V^G@-CLU%9@BY3EQT"&.<$D@.82ZQ4V7: 'PYYQUILDN>QA3
M:AC.F]%GB$4=I(Q231]H\3PZNK=[231+-X9? DFA)O#(U;LP;L6:2>64R4DU
MF6#W7L,Q+9PV,=DAKL84Z<Z04PH8\M-PAE+C='Y^=7!:F)M7-X3$FB6JDN;<
MB)W>G5Y;+4Y/!IP%DC"P]\4(!\/P_MV?JA'E@>[R"$(0 (0A  A"$ "$(0 (
M0A !CCBNM+,KVV#N1;:4/3L)G44C=D8+I^R%TBW4.BB&1@V+* 5,<Q .VSV\
M$0C'U]\3F%F667P]5YA+FKN>8=:EJYRUJ27$4.%8I5!-E'C0RJS)F<B($2!,
M!TU#9@<<]F<3D,1=WVEB[-5Y<YX@+@M,R9VNV1 VCK'QVZI60".0Y +G0 =F
M67#$5^^.Z>8I1P4VXJ<U,TY*[]XD*HGLHM?,7,DD4U>LD)-49F&L$%6J@J:3
M0Z0_A> -N<=E4%6^[DMW*'.D0<7B(,62">7MJYJ9/BW5Y2MJAHR)2E,6;INR
MG@E(424241$K'UE3QDX[JAY.)/4/?G>'M%K4[.S)[)JYI>W5;-B;%JI)$T:O
MB6*6*TF7SII49$H9C[DO:R_-Z<3U\,=UY;;J6:EEQ6E,MZ2HX#)GUZ<G8#+7
M!U11(CM,!06'6IYYCW1S&))!"Z(9?"(_3$>+<D<6F*I6[MS,(F,APUFMQ*(E
M].323S=BTE[!)9"H& 375F:2TA4$]6W4*3(=N8=\,AD.E-I!G\(A]$:[3 GD
MHTT2\(=4(0[NB'-+DT6U=?@"7=F3H;%JT_Q&B398,UM)*4K",R(;'0[X*<&0
MIV6]+6MZ?%OBGUFEB]?#E-U&][JQ1\QDHFLY,T'@I3@XQ^H0A&KC:@A"$ "$
M(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A !UW*8K(+)EX
M5$5DP^,Z8E#]8QIRI:W.+JP5_K]UA0-K$:ZIJZ*LI-*WYIPQE^\3,4CE%75*
MB)CZ)S:60@'!EGD(QN5CQE\?TCZ8I'(0RG+*0T].L&UXJMMO>2M*Q>)N[R7A
MG5'/EI3JVY2R%K3<R15%(JQ!U"NDT+H@)=HZ.?#%Z*;PWW#EE>7MG[A, 95Q
M3%,RR3=NGVSJ624K-SGD.8?A@$.VR#+@V1L<   !#/X\QV[>^/#'ZA.S6SV$
M$BTZ=;_8-/I\.-_K=2##55M(TX6JJLLR]KLTSI<7;9IU02JERJ#=0'9Q$B>]
MTC@KD7,3991^I'AUQ#J2O$+6<[D+52H[HJTXLVHU<[)<CI*7J9NFH/# 9-(P
M)"8A5-@@.1@',(V_Y?'](^F&7Q_2/IA,]=,_6!$1>;V$7J+K,:.:0P(W(KIC
M<B5S:0/;-494R,N6-13F<GJ;JL]EI14**;PZIC-"K.B H!2Z)2 <"[ +'N;4
M83KDEK&W4GGUG3TE)J.=/NJ=9N*B+-DYJB"FDQ40EAS&!F.B0ND"10$1-MC=
M;E\?TCZ89?'](^F$SRA(LFLYC$_&/:RK;JX=:HH&A4 =U*N>1+RQ 3D3!<TI
M>-W DTU,BETP1RS'++.+!6VJ?&FZEDOH"I+.)4E+ D3J5&J\)ZQ?;Q408&;M
M%=Y%VJ:XY2;,NUS^>-EW#'C(/A^D?3"=Q!*\\@C\3_!CB!J:A/4G-K;.G5?H
M54WFKZYZE1%%I.F:<\*_3*G3XJ;U;;W:E!(1(7,XAI#MC.:F,.U12ZIL24^K
ML!EU,W'I.D6C)PD!55$'%-R0K==310'6G JZ8FT1V#P!F$;(<OC^D?3'$N@D
MY1507("B*Z9TE4S;2G34*)#E$!V;2B(<'=B:Z\P$1%K[*A&]K2NKER:R]O;1
M2%%.>TBE5;UNE4R": O9ZW5GQ=80\H*4SIAO$HBGIF(450#3SX(R&J'![7-&
MUS7=04K:5U<^5W/D]+;T>$J0TC"F3MY<B5VHN@*H;_TU#F'5J@.AH:( '<V>
M4_A>LM3-8#6\II J4_,L=?7+NUG+)-501$YTF*QCM4Q,(B8=!,N9ASX=L9"
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M6Q5R[=(4:!5J^I4AM].AR5J.5E. "Y.(#D9V _" ]T!X,MD-]JF./<'&5O\
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M,TJSNM4Z38\\J91KO<[<Z)1T4D$M,Y$]$IQ3$4\M( S&-RYR=J %#^T4?H,
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M3@(*_I'VNROY*E^X6*DBFZ1]KLK^2I?N%BI( $(0@ 0A" !"$( $(0@ 0A"
M!"$( $(0@ 0A" !"$( $(0@ 0A" "PM]OQ%+OEC?^81B]DL_%K#Y&V_@DBR=
M]OQ%+OEC?^81B]DL_%K#Y&V_@D@ [T<9_P#]4_!_ACDA !$0MYA%L9BTW:+'
M5);XTA.*CE]-C0HR<47TVDC=+?$H,9;1>,C(E=9F*&P%#Z'!LX(D V1W.C"/
MAYJ!K55L;6HR^?,U/Z+,IR_<3Y5L(CH&% 9F=<4A$O=)HCGD(B(A&3<ALS;B
MFJ]J6Y<FIADQK2K=[=7YZF0@.9CO5/5M]:8"@8=63M0S$<@BZ/:\ Y=\ ^?/
M/Z8"F9Y:I2D(W3IHF\W<1PT7;/#-G4K79KFWJN#0[=S31D52;X FI[9,PERT
MO@^"-;V,=U7^#3$UB"PAV\D,[-(<:]1T>-KG;!!V+.2-I,\3=U9D*!#()[Z3
M<+:S2.0#"(Y9Q,7ZSMNAN#USPIIGZM]'+J\!2[YRU>JRTM'2]AVO#P1UZPLE
M;"O*OI:NJKI"5SBJ*.,X-3LW=-D%'$M,Z "KBF<Z9C9G  #V0?! 7"Q58B(N
M8YS$;/=&</:F$^TN!.N)%3+N<VFP^+N'MP46;55V5L[K!=@JHY4ER*:RCC0>
M*JJ&-JAT!()A$ #.+J[J[C7L!>O 6E:6U4]6KFX]WEK?-Z,I67R=XNMK)=,I
M::8BMHHG%@9B7,PZXI ,)!T1#+;(KJ>D:;K&0O*:J:3,)U)'[<6SJ6OVR+EN
MJCH: %U:Q#D*)2CVI@+F4<A*("&<8HVQP X5;15D:O**M<R8U(9=1R1U,7!Y
MJV;*J"8QS-6CT5D&^8F$0!$A-$<LN ( 1E5.<RK*^VL:!<7,O##1<?<@#W7?
M3!A+Z49562H9RFS<OTY8O.63#>35T=$J@(F$ZQ$ !0Q=$<P'(0'+NXBL2MQ,
M0./JM,/DUOC][=9*D973;NF:A+2";Q2Z32829%\[U<\*D@X:FE_L0#?)S")M
M#(,L@DJ7FP^VDOY)F,CNE1[&J&$L72<2\BH%369*HJD63,U6*&L0 %$R"()F
M* @4 'N1:VZ^!G#/>=G3#*O[;MIH6D4RI21RT<J2]^@F4J92E6?-12<N2@5,
MA0!94V10R  #9 "462N1EHKF1D64JZA%3P[)6PDNZY2B16UJNHKA(I477B<Q
MK&:2N<)-9FJ2CGN9VJS\ID@R. AD@J(&$0^"-JVX0@8*4OZ!D':(^K6:['39
M5L(_]/3':0%2E$P#WPS#+(0'*-P]+85;#49,:7FU.V]E$MFE(M7S*23)))+?
MS=O,$!;.R+NM %W.M1,)!%8YQ !'*+AV]M-0%KTIDE1%.-) E-ES.7Y&Q"E!
MPL=0RICGT2EVB<YC?&, -4YU8R(N8YY!<C^Q_P"7_9$:S[H[D[&H["6KIV:L
MWKZ53BL)&S?MV2#A511NO4,N24#3;%,HEF0Y@$X99 .>>S.)*O[(M=<RSENK
MN,F,ON!3+.I&DM<).F:+LA3E0715*NFH72*;(2J$*;,.Z'# 0CD9'D&MJU^X
MZX!Y?2]%SY&T4P5F#FFJ8F"^^JKGKE!1T,K9.!.HV<NCI;51$QDQ)H]S1"+"
M;N/0]+43N>JE&TK3R4KIR7UG;U!K)I1+])(B9:KEH  MFB61AV:2AQ)GPB88
MWU-6Z+-LW:-R DW:H)-T$R\":*"94DB!EW"$*4H? $4/<:V5$W5D!J9KR1-:
M@DIW#9T+!T4IDA7:+$704R, AFDJ0IPV;!" 3K(S,SD8U ;J6R;,=R.?M&K(
MY42R&SH U:LS*'+I/)-I"#9(FEF&TQNTS*.8F[L:\L4N(V[MO*-W/[#]2=9'
MLM;R\$CGB55WK6I=.HCR DM8M54$M4JW,K+M]G,+?,JR(CGI;<HE'5A;6BZZ
MHP] U3(FTWI0Z;%(TG7*4R IR\R9FA1*("'X 4R"79LT0RBVMSL+5C[NT$QM
MQ7E"L)U2DM3!*7,>U1<2\@"4=%F]3*#AL Z(:6I4)F   P CQ3OZR(NH0V<7
M5/VAH'$?@_EU/WKJ.^E;&G[A6?5-U%G02B7*KN6BB!S".OEZ8.M+@*8H%'9E
MLC.S%A0&"R_V,6M*3J6J)]ADQ,TC3%'NFUUVP3U26UJ92GVSA-55)N=M+5NI
MS<H%U1U%<Q[3(!'*) %+X%<,-(4VTI:36NEQ96P72<M#/3B_F""R*Q5TS)S!
MT"KLNBH0HY%5RR#1'9LCV=\,%N'/$*K*G%TK=LYX\DR*:#&8,U32R8@BDF1)
M--=ZSU3EP!"$*0 55, %#( RS" RPL4YU3K+'99BLQ",!;F98I\1>'W=!,(Z
M5P76(:C+<-Z*7M[=U.F"4FM-V*!E'TY3(0J1%IB+1)$6^D9981$N8 &<6FPS
MT/A66PD$J:N\353T*]HI*>RFK[=*22H"N$7!W#A@+-%B"B:C@'ZA3$UB+<V0
M* ;;PQ,HM+8RU]DZ6"CK;TFPIZ1:LR*K<J9%EG:9@$#%>.3EUSH,C"'X<ZFP
M1",>*KW.G"-6=>FN//;3,5JG.Y3=J*-7"C.6+.$S 8JBTJ0$C)4=(-(=-$VD
M(B(\(P E>;1+0=U?K&.VXV4#:NC\'M-/[.4[,Z=H6>S&=KRMO-#OR.71BS18
MR[P6LR CEN#I0PK@!B% 0/LV!%/;KGNF$EP#VXIZ22M!\]NQ=4RLKH9%FS<.
MBL0!4C5],5CI)*(DW@DMOH"+B76:H2@(B.S;S))%**=E;.2R.6L93*V")$&C
M"7MD6C5!-,H$*!$4")I@(@ :0@4-(=HYCMBQ%ZL*EBL0#R5O[L4&QJ]W)M:$
ML6>" F9ZX *IJ=(!T!. !F)<A@,2,L*9E,IS,LHCXX *ZP'6HN(-Z[Y8@75Z
M<7=S5F3F95?-:7FR"4J6>Y RE<M8'*LQ9"T0<$8J*M@3UHIZ9^V&)23-P@\:
M-7C8VFW=MT7*!]'1TT5TRJI&T>$-(ARCEW,\HP1E6YK8.I--&,XE]HFB$PES
M@CEHXWZL8R2R:A5"&#,PYZ)B@(!W@RC/%LW2:-V[5 N@@V12;HD]PDBF5-,O
M_E(4 ^: '*R=\Y=4AS0A" @M_<[VF3C_  I_O%CJ6C]HDH^-S_&-';N=[3)Q
M_A3_ 'BQU+1^T24?&Y_C&@ N7"$( $(0@ 0A" !%BL1%\J7P_6OJ.X=3O$6[
M>5LE-Z(G5*55R[5*8C<J1,](^2VAGH@.0#F.01>>9S!K*F#R8O5TFS1BV7=.
M%UCE(1-)!,RIQ$QQ  [4H\(_%M$(A^[IOC.>XC+G+T+2DP64MQ1ST[%J1L8X
M)SEVN<$3 8A,A/JG)-$N8& 1[P1VCL3;';ULATG8.."MG!W$V;W&GLB.3)U2
MLI,$*E@_"'HRW-DDSF18;0R-+-0Z*V?]F!QV(*$O,32IFVI%$TM'&C</4HC-
ML_*16]M43PO@K@E1-VQRDI6YLIDIHF>-L\G5SL=V)8IUE%W<YK"="FT244_H
M\IE35;1.8-(01)K6(:0^PS^$>"6%0EBJ*P[86YG;BEC,14:TH_,_<)G1!P[>
MKL%5%BJ:)A.?06$Q2@.8\&7<"-0F ?!3<BFZ%97:+3QR3^J$]9+5E3%1<,44
MQ$O:D. ')KDA#;D7,-H=P8S]GMKKRR:2S2;3=)X$KE[99P_$[P3EWN0ACJYD
MTQTPT"F#++: 9<&<=V;+<;A<?B$)HK X]#8=1RBS9@P90UBMG@O;\ZK2R[QJ
MDC0P(B8,2,C/#-JTK-8\S;7^C$<HI"(_3RE-%HS&:8T[=7EZ;1IY9M,)PA3Z
MS-O,C:,5F31Z4OX4\J)1%N26+(B)*#(1=+=R.>)WTD"IY/,"(EKMV8RIFC@"
M$)U;$=(3BF!0+H[<]A<LAX(D/[L*[:K84Z7(BX15-U+D_:I*IJ& 029@("!3
M"(9#GGF&P0$.&,16.*?#P[GR$E:"P"<K3(TO1T984JF_]];W$ 4!',!U_P#:
MT@',.'NQ46Z+T56=.8>VLTJ1%<DNF"+1PP,JY%8NI6.FHGD03#H!H'(( (!L
M[F7#O4>?'JD&R%L8/<3<6E'FD,?5(='9[,U+BF&MW-9L#63(RW+!02I)7^V6
M*WJVB</A]$MB'9OAT"BK"ESO&X8R:1%^AY$EG S8I;DS0]DA3<O\?#42#6MG
M6S5*98K#;C#_ /*2F?R9#^3-$MDO /\ B/\ OFB)%N,BA$L2,U,H=-,HH(B
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M66.<$Q,"0&,(@03 (YAWHT)X<]TKQBW6O;0E!.ZI%VQG\R< Z;)2YII&9D4
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MJ $ ND;X0BRJ*5_44SM$G;HMRRNU\]6YDM54X=QO-.>2A5WD<2MTYBT.J82
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M:E[,U@6832OZN!R,GDLN8/W:S@&B)5ULMYHK>Q3',=GTY1L7HP?^I='\ ?\
M5:F__P!&-8B@[HU=YG8S=E\,E>OJ,+7B+%"J0&0@U*[.MK9(5/,I!0<;29Z6
M>K-EEG 1)3GHF-J=NMVOPMU-<>0VUK+J[;Z<U0XWK(G,YD4Y;2]TN @44U'[
MIHBU0$3F*0NL4#3,.0!G&S2]%_[66#MG,KLW.JEE3U%RYD@]/,%# HHX2=D
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M[-/HU)0E0-9Y+%<Q$R9BIND=N63IH8=>W$1 =$%2$S[D7%CSB/9A%(I!"$(
M$(0@ 0A" !"$( $(0@ PYQI5V^D=@+K,J&J^GY5<!.GW9&#1W/)6S?HD5:+
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M%4Z0*)--'4%!0@@<NKT2Y" @.89\,5['Y,8I"B8YBD* 9B8Q@*4/C,.P ^&
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MM>^^,LCQGT?RY+/M4/OC+(\9]'\N2S[5#XQTPX5C?2'N[.UF>2H5&J&U?Z1
M[/W+KF7:-3JU0^M\=SDXK%.6)ESX>M\=SDXK%.6)ESXVO??&61XSZ/Y<EGVJ
M'WQED>,^C^7)9]JA\8Z8<*QOI#W=G:S/)4*C5#:O](@=G[EUS+M&IU:BY[]S
M^[G2PD\P=H6M.59! YTS]5YB(D,!!'@UFW@S_P"=M%6JW!;<]:GIKJA,[:&=
M.->X3UG5:8$R*18Q  2@IEL* !F$;BJGQ#625D$U(6YM(B)FRG!/)8(YB0W
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MKU^<!$"Y%(&P=D>W)9_$Y/K+,<)\SMHG+:=1J [U[<SJ@S4(9FC.1F;;0EA
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MY"_-NL:\XJ(]UY'6ULST?6ULD9.NK3I9CU0ZI)3P@K2XX.DB"FF"B(IG-PZ
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MK=:R_(4YV"XUNL<%1U#<:WM(UU:D]$2"ZH/S4)41IJ#TTT++4M8Z,=J0FFW
MN90_"@7//9G&1^(;$%(+#TNWFCIH,YJ&;JIMZ<IY,QDU9NN=4B0E(H!1U8$%
M0HF$2Y  CGP1C14V'JXLPK;"?.&<L3%A:YM/4ZK.51 F\S/6Z::&@7,!-I&*
M.>K^>*ZQD6,K.Y,LHRMK?%"85C;AP+J6R%35@E-BN%$A<IF.MFD02IIB &,
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M;G^">+)V)_$4Q^6./YA: "_4(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A"
M!"$( $(0@ 0A" !%G+Y>T5Y\I9?S2<7CBSE\O:*\^4LOYI. "OZ1]KLK^2I?
MN%BI(IND?:[*_DJ7[A8J2 !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@
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M-9H\8 J)  "@NFV53*L4   T5 ,&6S@B]-,4S)*0DK*GZ>8)2V4R\FK:LT0
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M$&#DBQ3-M),Y4S"*Y!,EEF<,Q$^6P>]%Z99.Y9-VQ'4OF#%VB9NBX,9J[0<
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MO5.8-5'.8<(:@BAE-G=[79W8 /:0$,X]6O.Y.U5U+F;2MNJ.P$EY@U15$?\
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MQ9.T'0$$> #ZDYP+\^4 '>CQD [1#/X]OT=Z. 738%11%PW!4H")DA63!4H
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M1++".$4W0/DT2)[41#(V>6W.-Q5;8?[5W"KRCKE513+=]65";\]3<Y*.I6:
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M@ZO2[^<;0);@6P_RNJ$ZE;4TY$S=VH_;2Q2:/5)<BZ65%953>)U1;&TE1%0
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M\^_&,%7X#<.];SB:S2?4LY43GKUF_FLN;S9ZU9.73!8J[54&R*A4""5<@*&
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MCZ_N^33SU/FP[%YCZ_N^33SU/FP[.P7A>&]-=KN,O(.P,;X)B'0WBV7%YQ#
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MR<?X4_WBQU+1^T24?&Y_C&CMW.]I<X_P$'Z!#T1T+/*%5H*4&+P:3D/G!8T
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MT?XNEY,_X:+]=3);[P9^;(\R'4R6^\&?FR/,A,\I\YA@)^J6LO80L+UXZ/\
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MR/,@ LGU]I%X.>>;N.AAU]I%X.>>;N.AB]G4R6^\&?FR/,AU,EOO!GYLCS(
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MR/,@ LGU]I%X.>>;N.AAU]I%X.>>;N.AB]G4R6^\&?FR/,AU,EOO!GYLCS(
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MQT,>!OQ("AF:7O"E#A'>[CHHO;U,EOO!GYLCS(_)I3+#E$II>S$!_P##(\R
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M?DO@UGY!+FP]3\E\&L_()<V #'&L;SR&>4Y,98W;.B*N"% @F;KE*&7?$R8
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M$( $(0@ 0A" !"$( $(0@ 0A" !%G+Y>T5Y\I9?S2<7CBSE\O:*\^4LOYI.
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MR)JZ(DS#6$ ILA'9F 9][;=93%<[NKA=^^$5IGJ8L+!^\"1[Y!7:S%0-#7@
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MF:2BH:!#99@ ;0SB7IN?^(Y;%;A7MM>IRQ2EKZHF[QI,VB($*FG,92OO)\8
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M 5G*CA-F453@)C"!0[81', $8ZE)X\*ZE=U+?VWOW9E"U1+H[Y/1$S;U&A4
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MYKNF522JEJ4NF:QKHMEJAF+>7O*Y6FQD5)>H\>),6INI9TP<*%5<JE* Z(@
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M '1F?XM?_(W/\$\63L3^(IC\L<?S"T7LF?XM?_(W/\$\63L3^(IC\L<?S"T
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M>=)F,Q%)?,I0!0-;GD #LC:EN%4OF+"EK]D?RY^P,>M)H9,KYFX:"H49[,1
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MMSBYMS5UF*\INEZ36MU?*G'54"G7)UJ?;+NUGC>0E12*:6E*0I4G2QQ./:E
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MYJ@"/2LJ=DLOF3^;LY8T;S*9:O?SY-!(KEUJPR)KE2D!0^@&P-,PY!P1[J$
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M9W&+)+CUHK2K^47%HRL";TIU282>3I.*!061.@\.19VFHN]UP*&, :0"70
M[D;:8_ D PYCG\PB$ D,/L&V%YOAJMR>3S%^E.JSGSA=_5$\1:D9%>++N#N4
MD0;)Y)D!KK12 2;# 7,-F49A"4IBB00 Q1*)1*8-(HE$,A 0'8("&P0'A#8,
M?H RV!"&.LP%G9K8:T\YJ-*J)A0TD7G*1]8#HK%JFF<_NE42I FH;9GF<IAS
MVYYC%P)G2=.SB3#3\QDTO=282E(,K.U0WCHDRT0WL)!1[7+,!T.$ 'ABHH0
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M\4JQ?*66HMS)UY0YEE&T\P<2-!9O+'365L4'#9%PF*2Q-\)($4-K2=H?,_;
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MJ*XI"J;/M]Z$,1,  1X "/B4#V:8 UHPF@FR="VL8@B$H8.;\R1N[9BP0?\
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M@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A" #\F,!0$QA*4
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ML_%K#Y&V_@DBR=]OQ%+OEC?^81B]DL_%K#Y&V_@D@ [T(0@ _!^ O^,O[8C
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MQR*W+_;*-\29A,41'N&,'T"(1^XXT@$"B AEVY_WACD@, A"$ %&U[[59O\
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ML-(!X @ IN47IOFO9Q6]K[$I*TCI5 [9C0AI/+"G,DA.#LDVF_!.!M)0A0(
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M#(=D4O1.$R\;*86FK"=4V1.:/9S.IC5TF,=N9"G$%'N^&.AD.J5,ND;,13*
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MU2QSU#A$M9(9!:^6#/;Z78>IR:VDF*<J9U%1=(M)@^ 3E,F/4])<'0D.&1]
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MAK&3I%TF @(@("=$YR@(#LR$>',.& #N@&7?'XX\QZM].);+1*#Z8RUCI["
M^?-V8G'\T%U"";O;(M=>N[C6T-J:LN=O)*=MZ9EZC_>J#DNJ=@FF8^@1PF)B
M[='+,HCPA !>,2@/"&?? > ?C#@'+N0T0R$ V />_P!G_/ZHQ"P:XL9-BQL!
M1M[PES&CO5>^G;-"0.YHB99,9-,5F!Q2,L8BBYE!2!31*41*!@"*EQ.8J[6X
M5J#<5S<R:.):P%JX79&39.72*RJ)!$B2RR!3%;@H?1*4YQ !SS#8 P"ZT9,
M0H#F   ]W(,L_P#$/",?J-9>%;=1L/\ B7M-.;CL9BYECNEA>'JB4M9>^F!)
M6W265(S6*Z22,FXWTBF"HE3$=5I"!\LHHC#ANO>'#$+>NLK.269J(/I0\;LZ
M4=)-'CE6HU1T@>@JB1,>IXM3%T0UXEU@;0X("R.NK%CUURC;7"/PF<JA"G(.
M93E*<,PR[4X 8NSXA^:/W 0(0A  A"$ "$(0 (\" B&P<MH?J&/,( -#.[ 8
M*<7F(*G5)[AHNT\D4OWHX+5=NT6J>C4I-7H($"8*JEWIJPS$3$#;F.>64:;<
M,&YP[J)2UGI')Y+BTD]E6K9S,P);IS-*?F;B5G6=*"LH=TO,"JF%V816T3%#
M0TM$-@1+$QN7$J:UF&6ZM;4B8Z<_E4B<%9*IIZTR.^4543K 3(<]44VGM#9E
MGG$'.6X5KAW!D6&Z^M:XJJC38XD*DKIM54Q0>OVK"B%Y5-E6<L3<)MY@5 -<
MJH4@ <$O8CLV#';]#GU_>X&T=&CU"G-R8/B4,&C>#HB+PW;H=GAX4S4@L%)R
M8LUX#1H2FAG)F@Z\$^H*9.SDY1UD^,72)/SZV<S4W8L8I\ =V+!H].[!+8EK
M0LY[LI!+0DR21*PS*1&92/\ <L=SCJS#5>&Y5[+T8A6%YKMU[U.%^FR=-#BQ
M%DB9(NL29/'"8::0YES*'P#WM_Y2Z(9 .>T1_7$6?<<K4R7#!C7Q-V&J2[DQ
MO#54O:T@\DE5*3)X]9ND)E+=_:"2(NG+9 4D% 3-D("80S$,QB4NGEH[.^.?
MQY[8TJF.[G&VBF[X3]ANKFT8O*70G%DMW:.S-;$F+L7^VS0@R0DC(C^:9F1&
M9D-TH:IB<%03-T-Q4AZ?&39V4]F_-&;=F\+0UW1Y/_<6I981X,TD1I))FF1C
M]PA"-5&UA"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@
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M %*1$<CKD96XO;CZA<3'+CQN#6%83/!1@,E[6K;X3LYI37-;RY5HE*+8R]\
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M#6$]VGY0/1#6$]VGY0/1&/\ UL*^\?5/,2\Z'6PK[Q]4\Q+SH ,@-83W:?E
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MJ4J0WNT*!<\D]!/9VO#%C9K@6L\HO3KV1,5)%,*=-,M[O$7"XJ*IS72!X01
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M"&][R^_$_)H0WSZ:\+?]JZV2XG-(-ZVA7!1]+>[N.NUKG$T]:KU!_>1#N?\
MNT3I8M!4OW,I<)C6;.E))?LCI)R!A,]&0(D$FBGIY:LRF8YCWN_$R@S>\H!F
M#L@CW@(AM^/X(M$Z"XG7$8ZP?^L/X3>^U/0RU?;9AGH9:(=T/UQ4;*--$F1]
ME$JE8IT=#+$13_V2.=648JV*Z%**78Q:<5:7Q[(ZM+8ZLMM]IQ2O6M=X./\
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M%",?>O#4WB*X\X-S8=>&IO$5QYP;FP 9 :)>]_S\7!#0#/2V@(=X<@^B,?\
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MRC*23"&!$RAC L)L6YPC"-Q(R:*29,S41'A$HC)H1E,ESQ#S"$(U\; $(0@
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MDJO\,P>F+8V#]IA?ECSYOZ0I%SJN]KLT^2J_N&BV-@_:87Y8\_F#P 7RA"$
M"$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ '1F?XM?_(W/\$\63L3
M^(IC\L<_S"L7LF?XM?\ R-S_  3Q9.Q/XBF/RQQ_,+0 7ZA"$ "$(0 (0A
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MBI"(Z1<LLQRCVE0[J;+7%X:DL*G:*I"/.ID[8)5$5M,0: <)>X J@*;SU&B
MY#L4^ !#.--& ZVV)>YE=8Q5K17=:6I<TVOU=GBC^3,)P\GZ20OI@V9J ]_#
M(% B8HF,.8:)MNR!%C,["+'.W%BUF!GB(CMLE84[:AOXD^Z3T"?!M,L5]3T\
M]I=&3&%C,J4F*3INY2FPO1EJ+1,SA)-18%7I=6"A""7(0-[';&+5E]V J>?7
M0MS2-];%KVEI2\#EXE;RK'$W%^E,T6@A^%,B5,NIUH'2$H*B&TX $:ML16):
ML\1.YI%"MI<U9U!0=?RJ4UJ_EC9LS83D$*U19-W)V[%--J03E1%4P!F.9LC;
M=L9![ID$A1MON?2E,E:D=Z,L&7&9%2!P)A/*M]:H4@!0?[6GHC\<613D98S,
MJCQ%+WVV6"3/'.HI62G,Z\=5EF7&1#9+BDW3.HK8WP;X=;#V9F-Y;F[RZHS-
MH5PXD[-@T%D68I'"8+(BT6UK7MLBJ"(#LBZ. [=");B^>5S1E0T<:W-T[<+-
MF]5T@JZ,].T5<F.5( <Z!2'S @F[79E\$4MBXQ&6&PA4/([CS"G)//K]UG2$
MHE5'R5(B75J=/EI.VEY3J+$*==N" K$.(J  '* [0"+/[DWA9N)1#JZ&)J^+
M)K*KHWU=-)FM3J*[<YI&P;**'EY3BU,"9S+,U4A[8@"7: AF$2K!Q2R'/&<Z
MZLFM8M<\<RKJEBR%/^_YC=F Y[0C\F-HAGEGM /I&/(  !D$?A7V(?XB_MC$
M9#7K6F,.>4SC9MGAB1IK7RBMTILHXGV^BEWH,O8"[*&]Q#2/IF[78(9<,;#H
MT47;_P#G>L//R:J/_P!"QO7BF4I7D1C$CG/_ -1EZAZ&I7LVE\CF3N1R[JK-
M4&JJC%AK01WTX*0PII:PVPFF<"DTAV!GGW(TNW6W0+&-9RJJ2I&K,+)49O7\
MPF#2DVI*L9JG?),5M 5<DP,*8BF8B@E/D( .V-WQQ$ V<(B ?2,:9[W3'KM;
MI;8*D,M]2RT99^O.6^6D1(TUEH+MA4 ,P*(F ,A'O@,"E:4R\_Y93D*<[+O6
M7Y#,?#M=C$I5[Z<+7XLZVM5(6Z#5>5S1:HF+]%X1PGK#Z8D,4J IYE 0./#W
M C+&5U934Y7.UE502:8N4QR.@RF3-RL7X-6BLH<<OBS#NQKYW0RO:;E=*TQ;
M1_7[NF7M9+&(VIJ5,W#N85&@P53,HV359"+EF!4P$FF ; /G&LZFAEE%8OL,
MTAL?2<]M<YG[:HW=9DF51S*>!4*4M8 X%PLTF*Q@9Z1"J* 02!EIY9=K"4[L
M9EDJQUF<_6).1RQXNO07KE.P20GT_D<L$_5&<RICJA*50'<P:MS)F..1 .55
M4HE$XY 4!R$V>S..LZJNFF.IW[/Y,TWS_D^^9FR1%?@_J@46+I\/"7.-&-&V
MV<XM<5&)^M:YJ2;N[-42RE#J34BR>O&2$TF4IEJRJPIO&BR9D"I/VNF<I0$!
MST1 0V1V<+UEY)BMIRXEY;POIF\IB2)3EE;2G$)\]9%I$*?!VS.X<.6K@@O=
M8+1-4-\AF AD.>8YI7Y+,I3*W3S>86=V7JM]4M.2L;UF\TEKPJAFDP8N@1*!
ME1;.T%P2*(9@944SF!,!#: GR 0X!CU;:KJ8>/CRUK4$E<3 @Z)F:,T9*.,]
MN8%2*L*AC!W0 N89;<N[&"HF[MW[#8:KWUA3E63"J9]<>I)?(J$F:ZBAB-Y9
M+YZ>63)LVUQE":168ZD3E$#B8-(.VBJ)U*IK2T@HV?6?MM4DLOJG,9 \/5DQ
MJF9BWF))J\:+3@Q)8_5!HH0C=9<  I3  9:/<A*^V63).>3&)A8JCQ3Z_97U
M#>7=W%125KKOVKLR?>,QJJYRLQ(S;B_21.P++DRJ*&7*)NT$Y!$2 IHZ6S+,
M>"JY9<>X3N[4]I=[2#%G;^5),U$*PZMLSBN9PW!0Y5V0'UC4"*YD**HE X=L
M$:>E[+4S>G=%JEK2I&CYX]L]2$JFT^ LQ=E0;S)S2I70G3!-0$T/Z4F(F!/1
M ^60YA%K)I<ZX*N'?%?>%G4C])Y<2IJ0IN@RE75,+5*63WJ*Z%EV_"0@%%02
M  FR'2&+@WV%CRGBZM/L85=UDCQU%5BKG/6V1T:JJ:(X1:*5#(BNW B"#89L
MQ!940X0(GK],P_ 4![T=R93J42=$'$UF<OER!LM%9\\0:IFSX- RYR%,&T-H
M&'AB/)B.PYL;-8>K15.[J:>S'$7,9E3KZ5U.6;S%,JJ+^8,%W[<965P+9319
M+"B;2*.0=MD CE&0[>0SW&1BJJ6U5Q9JZ1M986FZ14F5-M'JTO5J1U4$@;+G
M66=,U47*)F[D!5'2$VEMS'+9$E;.KV2Q<Y2Q7R">0LDM!^JW4QN39SV2S 4R
ML9O*WAE@$4BM9@U<'5 .$2%25,8V7=T0'+NQRS29LI/+GTUF+A)JQES5P\=N
M%3E(1)%LD990PB80#80AA ,]HAD&T8T;88K73*FMT.NO3-(U9,9C:NU9)663
MTZ=^Y?-Y/U6EPBL15THNKO@QE1V:P1T3!\$9P;I1.YM3V$&Y$QD[U=@\.[D+
M0SIMIZTC5]-4&[HOX,0-HF04.4PY@ %$1&$JR+++K%GC,RQ3\Y"P[C'!?J]\
M^J)KA0LJI6]#TX[.U&O'$W1E:,T704.DNBW:/2%$VBNF='23,8/[0;,HO=AD
MQES>Z,YN#;2ZU".K;7<MBPWY45/*JJOFRR0M5G:2B$Q(D#53302U@@F<='2T
M1VA%S,%E(TI0F&^WTKI06O4GJ<K,5G;;5B"SAUDZ>*+KDSTC%5.<3"H<='+(
M> <K:W@O59&3TE?FN*'=RQ_7=(RE.4U;,FJ*8"FM.VJS!FF9Z0NK<FR4T #6
M&$A@RV;0A4>(O7/SV5^L"G(C,\=?/[!C126//%3>B=5BZL9AL+6%$4T_69,J
M@/5#1B69G:KJH."D17 # )5$C%V".W@SC)W"[C83O3.*]M_<6CS6QNO;1J#J
MJJ/6="_,FB*"CDJC=V!"INA%ND942HZ0AGD.W9%,;E_2"=&81J2>S!(&DSG4
MVJ:;3-RL()"9%Q.'3M,RAS99%*D81S,8,PC&*UNHN7NG%X:II$R"E)4(V8(5
M7-FPD"6S(KZ4&0T5'!,D7!4A Y3]N?1VYY#P6JNK%B.O*199"5U5X[,?-<6,
M]%XN?,MT O!5KJKJJLE8=W6MJJ&=F1>U.ZFG4=29HMU3I3%5-B\3(N ,126'
MM $#@78&647GG^/^A)?AIIV_LID[J<N:M74EM/4NU2<J*NYN@]"6NVPKI)'U
M)6SP1(910  0*(AD&8Q8V^-[GE:/IKA0P<4V@\G;YR9M7M;2]NDC*J-;/%15
M<Z)CHE9S4[] ZZ8BFJ)D3".>1HR.IVW%EL'F&FG9-<=U+G5/T"FZF>^GK8BZ
MKB=3=??;A-LQ$%5%#*S$XE#5%,)<P'9W%5562JNO^]DKPKKKOKQ$=UV.?FMF
M+34?C>NO3%S;=T+B)L\6VTNNL#E6DIX$]0FH"F@B5<H*MVQ1,D8Y5$BB531.
M43;0SC:$DJFL0BB9M(BB9%2&]T10H&(8.[M*(#\\:<K<43<G''>ZC[]W D*E
M%V-MBN\&V\@<%*+BK$G)=[JN##H)/&)$5$DU2@J0-840*78$;C$44T$TTDRZ
M)$DR(D+GGHII% A ^8H!P[8ARL\^3S6Z;Q2G[)XS\VN@<L(0B"A"$( $(0@
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M(0 (0A  A"$ "$(0 =&9_BU_\C<_P3Q9.Q/XBF/RQQ_,+1>R9_BU_P#(W/\
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M0[7OQ&JP78=JLQEW^>3JK#O'M.,W+N;5I.URJ*D4%4JKIBW QAV@4P:G,AA
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M#PI7+M4YQ.4@% I@X2AG$GY1)-5,Z2A"J)J%,0Y#@!BG*<! Q3 ;,# 8!$!
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MM\VM;46T;I-F-,M*8829)NDB@"28 =H4NT!*4QC:/;"&8C&>7^__ '?JCP
M'_Q$8\Q!0A"$ "$(0 (0A  BVEW/:)-_C;?QBQ<N+8W@.5.@IN8PY!I-@S^-
M8L '>MC[3)/_ (5/WC1<"+?VR]IDF_P*#](F&+@0 (0A  A"$ "$(0 (0A
MA"$ "$(0 (0A  A"$ "$(0 >!X/G#]H1CP__ ,]LI_PK?R\9#CP?.'[0C'A_
M_GME/^%;^7@ R(A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$
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M_9 !JYW2O=&'. 6FJ$F4IMB:Z$_K]^,MD\B":#*])SOE%L0NOR$  QUB[3"
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M(#+!*<B/)E/)7D$I;&+B\M[@YM$XNQ7RS<\N)-)-+&[(SDJ:KI6<3!&7I&2
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M*D %XX0A  A"$ "$(0 (MO=BYE,VBH2?UW5DP1ETIDC%9<ZJIBAIK:LV]TR
M(@)A.L!2[,^';%PG#A%J@JX74*BB@F=950X@!2))%$ZAA$=G:D 1B*?NL>-8
MUV:S7LC0,T,-%4RL9&?O&:Q@2G+D^1TD^U$!_ KE%/(!'2SRRVQV)L8T!?MD
M*D[K"&!-&3@Q-+S%GU*?FNKBS6G=)*,L'=FW^TP0=9M%$<L%*C+IS9PV689L
M0T(?J0/*F3>+-R4Y0"&+5);]$VB#-E-)?.^"NQ?X[TT*1)9HP9X2TD>#F(2\
M]>8U,0AWJ9W2R$VG02ZEI4!C&0E[(C@&KEP 9ZLH*(%UO;%#X(E.X.;(VTPO
M6:EU'2]]+3U0]DYW-1336)%6>.%T!732..8B HB<4]'/N#LX(TW;FW@9JZJ*
M7->Z92\S)5]D%-)N4B@<"$,**YR@< $ND7(P&R 1X0[\;65L+MP44EUU9FZ*
M1%!=P<=\&]B@F902A^$X! -$ [@; "._-F&.T:?F;CL?0:/.\(@5&#0[/#F[
MIW1+R_.Y)9I2T4DR):76:L(C-6&\K:-%'AI(>4-KK12F<+:1/9=I%19[I#2F
MFQ-'QSB+ZHV:W*&/:MU6U8I6E1LUO_S, RP=R<V;%B@L!2B$<+&+:ZX-0XF[
MCSF2TRY?RMY/)0JW>)9BFJ1)P45#$R*("!0#,=O?[F8QO+NE.9<TW,E]3CER
MFE/$9$S15EXF_#$4!8IC (;,L@S^'9& ]P<;%$6[KB=T+-J<;NYG(WZ+!PY4
M*4ZBJBZNI*<3&3,(B [=HC\&49/WLH2;SK!_4MW$5SI2*:2YNX38Z?:)$.;1
M+D3,.$3!_9X=F81L%)VL0B#ML7.<=="@[E#(O!3@[YA;IV56R9N;-DG!PCW/
M=624-+)8<IU#4J$L(1"7O9PB%%GY5(8C'*/4D*D4/P#9=@F3PU?F[=IAX);K
MN+=:V4K<'"Q'(:2L#VS%1:8!X0FDQ_>B=++?\B:?(F?\ L06,$BR*6*:U*RR
MJ:"(369"958Y4DB )\^W4.($+PAPB$3C&%34V1DT$U12(H R:Z0#-F "&2!-
MHYKAE\$:=MK&;1=**.FE"E2@BYX*5'(_ASQ541RQVCL3:%M63.@],B:-&;.=
M)F!EAK2BHH8Z&9_.,IXK!35Y9FRE%L:W?/R%.V2I^9@<IO8B*C)8I<_G_P!V
MW;$ RH'"3NH:C=H$!-!:?S@R90X +U07[O!MX8E?[IGC:H&VUI*@MO2T[:3J
MO:J0WHW08."+E:)@(%7TU43*)=LD8V69@V9_!$<?!_8)]B1OG(+=E154E;\\
MT=3YV4IM6U5534=(ZTX9 724$0VF#/YHW+:XPYK1&AU+*7QYDU<(<\&R;LEM
MDJ0IJYPQ@W6V>&;->":DK:-B9,CD6Z-$FE,ZAUQMR(R[[(.R/0'8]HHV81>,
MN?PAT;LW5:&J643C;RZ,G=T:MF>&2%,V3 VS=$SW%FHEKE6/&#.L&U"8GK5U
M$\4*FU0F"R"BAQ "E,ZT42 (CP9F, !P1.LE:Y74O8NB"!B.6+-P0P" @)5D
M"' 0RV99" @(;-L02,3EC:EPRWOG-$/$'+-.2OF#VG)F)#D2>"B8CH2I+;"#
MD)"E'(X\,24]SXW0B@+PV]D%#UW4#>1W'D35)BY0F"Q4R/")%!) 075%-$,D
M2%'V6W/OQ\S;&T:>*50NC.R!1UFN)0TH<3!Z6[)4U4S<VY_"W1Z4AF2C)F2F
MK9DV.7^$T)*52F/M[3BFCK0..4TV):8-F4$C"HQ\*<&3ZT2P0VB+HE+C$'%*
MVN DVRDL6#=V*9&W9X1H(Y#;F.0@.?!W=N7Z^Y'K#3.6IGT#/F)3@.6B=^@4
MP#WA(*F>?P"$8]X@,3%L[+6WJ&K9Q5<G,9*6.2RY!H_;.5E72R"B;<2IMU3G
M'15,0=@1#\/BQQ+5[<I(\KN+-=.H*M1!A+D2'$=XC-0 I2@4PCHBW$,^UX.$
M(Z1V.=AV.;(+I%(@S>F4&<(82"^%O[%ON3RT-*UM$,32F1[@A&$U49D2,))'
MCJ].[,>V+HML21"!0ELXMZ1Q6-&M7P&%/3KNKDQ);!DQ:/)*4=;RT:&A@S*M
MH3)H98B$YDIBG*!BF*8HAF!BB!BC\0AL$/AC]1;RU32=,[>TBC4"YG$VZBL%
M7JI]ACJJM$CB)@V[<S#F&><7#CJ1NS)BW;,26EH3)HMF31/[*R0HTX:9UX*I
M3*=<C'H%S;J>G5W>%,EL%-V#%LIBTEALC:LTM#9KE5A(PL%4JID$(0CB'Z0A
M"$ "$(0 (0A  A"$ 'C(!X0"&0=X/H"/,( &0!P!E"$( $(0@ 0A" !"$( $
M(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A" !"$( $(0@ 0A'7<N4FB"[A8V
MBDW06<*F[A4D""H<P_ !2B, '8SX0[W#"-<%I\?#*Y6):H[)^I-27TR"^]Z)
MK51P86U3K-DS#,R(IB4")F:*D%,0TQS'(,LQVYGUY>"W]N%6;>KJB:RM=^H"
M3= @@X7$PG @:U-,1.B Z11S4*4,MO $)'S_ )A,LHNA"*/;5Y23QU+V;6?2
M]PYF:!G#))%PBH+A,B8*G,70.;V!!S. >QX!RR&+%7NQ6V[LM(FD\F3]&8I.
MY@VEX)H'U@IK.':;0-9J=(2"50X>RRS$! /@ ,I819VJKY6YHMC3[RIZ@2EP
M5&U:N6"29#.5S Z224*"J2(&41* *E[90I0X1SR"+ELYTPF<J)-Y6Y1?,EFI
MW*#A!0BB:I2)ZS+2(8P .669<\P'8(!E ![>$8N6.Q"+7;KJZ5(*2/J86WCA
M@@1UK];O_?@'VZ(!^#T=';M[L7]3J^GE9V]IXDU;#-V! 4=,14("R11)K-+1
M$VD( 0!,.0; X8 *FA%I9M>^V,F1>+3"KI<D1D(@N!54E%,RB(&!,A#B94Q!
M 0-H .B(;<HIQ7$M9A&726:GKAAO*>K'0EZH"4PBJ14$A(Y*!A,VTE! I-<!
M-//M<X +^PBUM6WEMS12:2E0U.S9"X33502(8J[A9-4I3D.DBF85#ET3 )A*
M40*7:;( $8L!?+%Y3UJI70=02I)K4-.5@NNFI-DW1$TF9$52)F,8 $P"8-(>
MT$0',,N$<H!B&:,(M905XJ!N)*W$SINH&;Q)@T0<S(IU"('9:U(%,EBJ"4Q0
M]ED8P !LLPS <X]+);_6QJ6:3F14[4[693N4M7JYF0Y)%74:(*+&3:JG$"N,
MA()3"B)]$?9!W8!/KQ"]L(P4LOC=H>XKR<RJICMZ5F\NF:DN1:JK@LFH8KH[
M<HJK#HD0T]$!("@AF(Y%SX(KB58EDGU^ZLM"XE2+264TU9NQJ)1X0J"R+IEO
ML#:)LBE "Y@';9FV99[(2/(),LN/^XRSA%EJ-O\ VKKN>O*<IRJ4'<W9G4(J
MT63,U$XI:6L%N=;1*N5,"B)Q2$P% ,QR"/VA?NUKFL%Z'0JELI4*)53&; ']
M%'4IBHH4CW/>YS%*40$"G$V>9<LX"S+*+S0C"V5XNI!6LSNS3-$MTW<^MBZD
MR#DKA<K1)SU45T!$5E]%(F@4!$O;=OL !X(O-.;X411DHD+JNIZTDKZ<E(";
M5(Y'B@*&T0R."!C"0ND;V1@ !#;P! ->87LA%/C43!S3KBHI4X0F3$DK=S)N
MNV5(JBN5LV.N! .F8Q0$VB!1#/,HY@.T(L7AGORK?RC'55+27J(9O,I@QWMK
MP7T@9/56@'TL@]GJ]+O!G !DI"+6U_>.WUM5F+>KJA1EJ\P4U;9!(@NEM+2
MOX9)'2.B7,P;5  ,MN>0140UY2922549XQU<_*)Y4<%TA!Z!0*)M4('',Q=(
M ,4,Q*(Y" # !6$(QUOQ?N5VDM_5]5RQ-O4$VI)S)D'TC(Y(DNF$W<IHI'.(
M"8Q0T3Z89@ CELBL*)NU(*GE--+NW35A.:@8B\+*2KD64;E(B58X+F*.:(%(
M(B!E  #9#D, %VH19Z47UMC.ZN<45+JH;.)^V$2J-A+H-C&*43&!%V(ZA42
M Z0)G,(#L'(1C\5)?JU5*S=&2SRKV#*8K* GJ-,AP1.(@!0<F*80;@81[05M
M#2#@S@ O)"+/2Z^%N)Y/YI24CJAB^J5@R.Z++P4(0JX[U,X2!NL)M6L E !.
M*0FT,^VRCTD@O/*Y?;HM;7$>LJ?3WT]1$J+I%\<Y&[HZ)!0*@8QEA$I0TBI@
M82".0Y# !?R+4WI_S?3;_6-?XH1[:WUSJ*N;*S3:C9VC-VB8Y*Z(:MP@.8@
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M:"A1]T'Q@,<@" \$0?Y7]U,732?MU)EA]*JR*<!<)^J%$-(F8:6T""(;,_\
MG*) 6YM[KU9+=!6[R22M!*BKF2LB/5&BW#DZZHG5 1 6[A0I"N.U*)QU0&T>
M 8^3%Z!TH@CJI]?H<HG5G(VC9BU9-TLB,R(C:$R6I24S,OG&6#64S(?6@]/J
M+QQZ2Y.$1)3TT_VV+9BV8&TE*9(-JA*5*K_9(YG8-OT(\ (#P1YC3QN00A"
M!"$( $(0@ INKO:[-/DJO[AHMC8/VF%^6//Y@\7.J[VNS3Y*K^X:+8V#]IA?
MECS^8/ !?*$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 =&9_
MBU_\C<_P3Q9.Q/XBF/RQQ_,+1>R9_BU_\C<_P3Q9.Q/XBF/RQQ_,+0 7ZA"$
M "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (LY?+VBO/E++
M^:3B\<6<OE[17GREE_-)P 5_2/M=E?R5+]PL5)%-TC[797\E2_<+%20 (0A
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MF@T;-VY 33#4IE3.IHE -J@DTA^$1'AVQ[:;)F/+I@4@"8QY>^(4,\\S&;G
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MQI*F]&((N)\@^D)FZZ*;D@G1U"2R":CDQBAF((E,)> 0CL!KMI8HW42V]#(
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MHMC8/VF%^6//Y@\ %\H0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0
M(0A !T9G^+7_ ,C<_P $\63L3^(IC\L<?S"T7LF?XM?_ "-S_!/%D[$_B*8_
M+''\PM !?J$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A
M BSE\O:*\^4LOYI.+QQ9R^7M%>?*67\TG !7](^UV5_)4OW"Q4D4W2/M=E?R
M5+]PL5)  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0
M6%OM^(I=\L;_ ,PC%[)9^+6'R-M_!)%D[[?B*7?+&_\ ,(Q>R6?BUA\C;?P2
M0 =Z$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "$(0 (0A  A"$ "
M$(0 (0A !3=7>UV:?)5?W#10%C?:*S^4O?YI2*_J[VNS3Y*K^X:* L;[16?R
ME[_-*0 7CA"$ "$(0 (Z[E))9(4UDDUDS&*!DU2%43,&? 8AP$I@^,([$>!
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M\,N6;R>W]6D3Y.K\D\,RCE)ITL.K\D\,RCE)ITL0&^O_ 'NXR)WY=?I8=?\
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MT^[O7R@D#J[G48L\,N6;R>W]6D3Y.K\D\,RCE)ITL.K\D\,RCE)ITL0&^O\
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M<HD,.8E*NOM$1S'/\+MV[8=J+%JO_&,-LJ['O->*W=:K9SQW5RI?]06!2_\
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ME'*33I8@-]?^]W&1._+K]+#K_P![N,B=^77Z6':BQ;RPAO0'F[C=/N[U\H)
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M\,N6;R>W]6D3Y.K\D\,RCE)ITL.K\D\,RCE)ITL0&^O_ 'NXR)WY=?I8=?\
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+,ZU3E;,RF59C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>nt10002526x6_barchart3.jpg
<TEXT>
begin 644 nt10002526x6_barchart3.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( ;H'C@,!(@ "$0$#$0'_Q  ?  $  00" P$
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M":.$T:,GU=S?$-X)%\K,=W$[\UZ<'=H*]C,5/(%Q>HI_V =C,5/(%Q>HI_V
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MPFCA-&C)]7<WQ#>"1?*S'=Q._->G!W:"O8S%3R!<7J*?]@'8S%3R!<7J*?\
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MN:E4B I7PCXS4P>?$._]H-D\D[=]34_[N&^R8Y/X31GI-'-]7<WQ#>"19?\
M5J-ZJ"<EU?\ -?Q&@KV,Q4\@7%ZBG_8!V,Q4\@7%ZBG_ & WZNT&R>2=N^IJ
M?]W#M!LGDG;OJ:G_ '<-]DQR?PFCA-&C)]7<WQ#>"1?*S'=Q._->G!W:"O8S
M%3R!<7J*?]@'8S%3R!<7J*?]@-^KM!LGDG;OJ:G_ '<.T&R>2=N^IJ?]W#?9
M,<G\)HX31HR?5W-\0W@D7RLQW<3OS7IP=V@KV,Q4\@7%ZBG_ & =C,5/(%Q>
MHI_V WZNT&R>2=N^IJ?]W#M!LGDG;OJ:G_=PWV3')_":.$T:,GU=S?$-X)%\
MK,=W$[\UZ<'=H*]C,5/(%Q>HI_V =C,5/(%Q>HI_V WZNT&R>2=N^IJ?]W#M
M!LGDG;OJ:G_=PWV3')_":.$T:,GU=S?$-X)%\K,=W$[\UZ<'=H*]C,5/(%Q>
MHI_V =C,5/(%Q>HI_P!@-^KM!LGDG;OJ:G_=P[0;)Y)V[ZFI_P!W#?9,<G\)
MHX31HR?5W-\0W@D7RLQW<3OS7IP=V@KV,Q4\@7%ZBG_8!V,Q4\@7%ZBG_8#?
MJ[0;)Y)V[ZFI_P!W#M!LGDG;OJ:G_=PWV3')_":.$T:,GU=S?$-X)%\K,=W$
M[\UZ<'=H*]C,5/(%Q>HI_P!@'8S%3R!<7J*?]@-^KM!LGDG;OJ:G_=P[0;)Y
M)V[ZFI_W<-]DQR?PFCA-&C)]7<WQ#>"1?*S'=Q._->G!W:"O8S%3R!<7J*?]
M@'8S%3R!<7J*?]@-^KM!LGDG;OJ:G_=P[0;)Y)V[ZFI_W<-]DQR?PFCA-&C)
M]7<WQ#>"1?*S'=Q._->G!W:"O8S%3R!<7J*?]@'8S%3R!<7J*?\ 8#?J[0;)
MY)V[ZFI_W<.T&R>2=N^IJ?\ =PWV3')_":.$T:,GU=S?$-X)%\K,=W$[\UZ<
M'=H*]C,5/(%Q?MH<\O[]X#L9BIY!KZN=%%G++I)C8-]VHV+935/G.)M*WM9$
M20I)E1Z>62B:49'LCY[#R%IL&+7M>J4*4].MF@2'$2I*24ND0#/52^LDEM8[
MQ%EW^N;[)B9>C^%T<*(E=+U=LU?@+O XN4_.U&]'Z#<TR];2[<UXT>^QF*GD
M"XO44_[ .QF*GD"XO44_[ ;]7:#9/).W?4U.^[AV@V3R3MWU-3_NXN^R8Y/X
M31PFC1D^KN;XB;P2+Y68[N)WYKTX.[05[&8J>0+B]13_ + .QF*GD"XO44_[
M ;]7:#9/).W?4U/^[AV@V3R3MWU-3_NX;[)CD_A-'":-&3ZNYOB&\$B^5F.[
MB=^:].#NT%>QF*GD"XO44_[ .QF*GD"XO44_[ ;]7:#9/).W?4U/^[AV@V3R
M3MWU-3_NX;[)CD_A-'":-&3ZNYOB&\$B^5F.[B=^:].#NT%>QF*GD"XO44_[
M .QF*GD"XO44_P"P&_5V@V3R3MWU-3_NX=H-D\D[=]34_P"[AOLF.3^$T<)H
MT9/J[F^(;P2+Y68[N)WYKTX.[05[&8J>0+B]13_L [&8J>0+B]13_L!OU=H-
MD\D[=]34_P"[AV@V3R3MWU-3_NX;[)CD_A-'":-&3ZNYOB&\$B^5F.[B=^:]
M.#NT%>QF*GD"XO44_P"P#L9BIY N+U%/^P&_5V@V3R3MWU-3_NX=H-D\D[=]
M34_[N&^R8Y/X31PFC1D^KN;XAO!(OE9CNXG?FO3@[M!7L9BIY N+U%/^P#L9
MBIY N+U%/^P&_5V@V3R3MWU-3_NX=H-D\D[=]34_[N&^R8Y/X31PFC1D^KN;
MXAO!(OE9CNXG?FO3@[M!7L9BIY N+U%/^P#L9BIY N+U%/\ L!OU=H-D\D[=
M]34_[N':#9/).W?4U/\ NX;[)CD_A-'":-&3ZNYOB&\$B^5F.[B=^:].#NT%
M>QF*GD"XO44_[ .QF*GD"XO44_[ ;]7:#9/).W?4U/\ NX=H-D\D[=]34_[N
M&^R8Y/X31PFC1D^KN;XAO!(OE9CNXG?FO3@[M!7L9BIY N+U%/\ L [&8J>0
M+B]13_L!OU=H-D\D[=]34_[N!V#9/)*W3_\ W-3ONX;[)CD_A-'":-&3ZNYO
MB&\$B^5F-[B<^:].,V@KV,Q4\@U\N95&FI4?AR2;&9Y%M#L9BIY N+U%/^P&
M[S>ULVQ$Q%LR%'MJ@-Q9*IG"&BI$#5=U4%JY_@.\?%GG_P 1>]-A629)_P"Z
M5N_!2>?8:GY<7ZO_ -= A;K)GD_A='"B-$O5YZMF?8*>X#BR_P"K4:<[_P#W
M&Y=F]:^']QH+]C,5/(%Q>HI_V =C,5/(%Q>HI_V WZNT&R>2=N^IJ?\ =P[0
M;)Y)V[ZFI_W<7?9,<G\)HX31HR?5W-\1-X)%\K,=W$[\UZ<'=H*]C,5/(%Q>
MHI_V =C,5/(%Q>HI_P!@-^KM!LGDG;OJ:G_=P[0;)Y)V[ZFI_P!W#?9,<G\)
MHX31HR?5W-\0W@D7RLQW<3OS7IP=V@KV,Q4\@7%ZBG_8!V,Q4\@7%ZBG_8#?
MJ[0;)Y)V[ZFI_P!W#M!LGDG;OJ:G_=PWV3')_":.$T:,GU=S?$-X)%\K,=W$
M[\UZ<'=H*]C,5/(%Q>HI_P!@'8S%3R!<7J*?]@-^KM!LGDG;OJ:G_=P[0;)Y
M)V[ZFI_W<-]DQR?PFCA-&C)]7<WQ#>"1?*S'=Q._->G!W:"O8S%3R!<7J*?]
M@'8S%3R!<7J*?]@-^KM!LGDG;OJ:G_=P[0;)Y)V[ZFI_W<-]DQR?PFCA-&C)
M]7<WQ#>"1?*S'=Q._->G!W:"O8S%3R!<7J*?]@'8S%3R!<7J*?\ 8#?J[0;)
MY)V[ZFI_W<.T&R>2=N^IJ?\ =PWV3')_":.$T:,GU=S?$-X)%\K,=W$[\UZ<
M'=H*]C,5/(%Q>HI_V =C,5/(%Q>HI_V WZNT&R>2=N^IJ?\ =P[0;)Y)V[ZF
MI_W<-]DQR?PFCA-&C)]7<WQ#>"1?*S'=Q._->G!W:"O8S%3R!<7J*?\ 8!V,
MQ4\@7%ZBG_8#?J[0;)Y)V[ZFI_W<.T&R>2=N^IJ?]W#?9,<G\)HX31HR?5W-
M\0W@D7RLQW<3OS7IP=V@KV,Q4\@7%ZBG_8!V,Q4\@7%ZBG_8#?J[0;)Y)V[Z
MFI_W<.T&R>2=N^IJ?]W#?9,<G\)HX31HR?5W-\0W@D7RLQW<3OS7IP=V@KV,
MQ4\@7%ZBG_8!V,Q4\@7%ZBG_ & WZNT&R>2=N^IJ?]W [!LDO_T2MT^;L-3O
MN_\ U_>&^R8Y/X31PFC1D^KN;XAO!(OE9C>XG/FO3C-H*]C,5/(->+F.C324
M?R)-C,\OH#L9BIY N+U%/^P&[Q==LVQ&Q/M" S;5 1$DG+W]@J1 )+FJWFG/
M\!WL]@OB5@V3D7_=*W>(O_0U.\'ZOGTB%NLF>3Z%T<*(OE+U<>KQV"GN XO/
MYVHV_P!1N[/6WATC06[&8J>0+B]13_L [&8J>0+B]13_ + ;]7:#9/).W?4U
M/^[AV@V3R3MWU-3_ +N+OLF.3^$T<)HT9/J[F^(F\$B^5F.[B=^:].#NT%>Q
MF*GD"XO44_[ .QF*GD"XO44_[ ;]7:#9/).W?4U/^[AV@V3R3MWU-3_NX;[)
MCD_A-'":-&3ZNYOB&\$B^5F.[B=^:].#NT%>QF*GD"XO44_[ .QF*GD"XO44
M_P"P&_5V@V3R3MWU-3_NX=H-D\D[=]34_P"[AOLF.3^$T<)HT9/J[F^(;P2+
MY68[N)WYKTX.[05[&8J>0+B]13_L [&8J>0+B]13_L!OU=H-D\D[=]34_P"[
MAV@V3R3MWU-3_NX;[)CD_A-'":-&3ZNYOB&\$B^5F.[B=^:].#NT%>QF*GD"
MXO44_P"P#L9BIY N+U%/^P&_5V@V3R3MWU-3_NX=H-D\D[=]34_[N&^R8Y/X
M31PFC1D^KN;XAO!(OE9CNXG?FO3@[M!7L9BIY N+U%/^P#L9BIY N+U%/^P&
M_5V@V3R3MWU-3_NX=H-D\D[=]34_[N&^R8Y/X31PFC1D^KN;XAO!(OE9CNXG
M?FO3@[M!7L9BIY N+U%/^P#L9BIY N+U%/\ L!OU=H-D\D[=]34_[N':#9/)
M.W?4U/\ NX;[)CD_A-'":-&3ZNYOB&\$B^5F.[B=^:].#NT%>QF*GD"XO44_
M[ .QF*GD"XO44_[ ;]7:#9/).W?4U/\ NX=H-D\D[=]34_[N&^R8Y/X31PFC
M1D^KN;XAO!(OE9CNXG?FO3@[M!7L9BIY N+U%/\ L [&8J>0+B]13_L!OU=H
M-D\D[=]34_[N':#9/).W?4U/^[AOLF.3^$T<)HT9/J[F^(;P2+Y68[N)WYKT
MX.[05[&8J>0+B]13_L [&8J>0+B]13_L!OU=H-D\D[=]34_[N':#9/).W?4U
M/^[AOLF.3^$T<)HT9/J[F^(;P2+Y68[N)WYKTX.[05[&8J>0+B]13_L [&8J
M>0+B]13_ + ;]7:#9/).W?4U/^[AV@V3R3MWU-3_ +N&^R8Y/X31PFC1D^KN
M;XAO!(OE9CNXG?FO3@[M!7L9BIY N+]M#GE__('BFGXH+_%T2O.9<>]T6:O+
MY=5@\OVC?DF6'928<LRM.W<RBR,O^QJ?XI?_ .KBR."MGVC*8KV_VO07=66X
M2=>DP%9$3R\B+6C[,O\ HC#?9,<GT)T_I-&C)S_\NYNC^H%N XL[_.U&]'Z#
M<V3X5T8TC2+[&8J>0+B]13_L [&8J>0+B]13_L!OU=H-D\D[=]34[[N':#9/
M).W?4U/^[AOLF.3^$T<)HT9/J[F^(;P2+Y68[N)WYKTX.[05[&8J>0+B]13_
M + .QF*GD"XO44_[ ;]7:#9/).W?4U/^[AV@V3R3MWU-3_NX;[)CD_A-'":-
M&3ZNYOB&\$B^5F.[B=^:].#NT%>QF*GD"XO44_[ .QF*GD"XO44_[ ;Y,^GX
M.TI]46J-8>4V4C+7C3SMV&^C/:6LS(-MQ.?>S268]<*'@Y4WTQJ8WAS49"_@
MQX+EN2GU?HLQ]\6K]A!OLF.3^$T<)HT9/J[F^(;P.+Y68WN-S9ZUVXOEH==C
M,5/(%Q>HI_V =C,5/(%Q>HI_V WUIUN884M3"*I2;*IKDH\HS<^+1(:Y!YY9
M,)D(;4Z>>S)LE&.2*P['41&FU+;42B)23*CTXR4DRS(R,H^1D9;2,MAEM#?9
M,<G\)HX31HR?5W-\0W@D7RLQO<;FSUKT]/X:"_8S%3R!<7J*?]@'8S%3R!<7
MJ*?]@-^KM!LCDG;OJ:G_ '<4[0K(/BM.W/4].^[AOLF.3^$T<)HT9/J[F^(;
MP2+Y68[N)WYKTX.[06[&8J>0+B]13_L [&8J>0+B]13_ + ;]7:#9!<=IV[Z
MGIWW<.T*R#XK3MT__P!ST[[N&^R8Y/X31PFC1D^KN;XAO!(OE9CNXG?FO3@[
MM!7L9BIY N+U%/\ L [&8J>0+B]13_L!OU=H-D%QVG;OJ>G?=P[0;(Y)V[ZF
MIWW<-]DQR?PFCA-&C)]7<WQ#>"1?*S'=Q._->G!W:"O8S%3R!<7J*?\ 8!V,
MQ4\@7%ZBG_8#?J[0;)Y)V[ZFIWW<=;J$'!VD22AU9K#JERSR),2H+MR')49\
M1$Q)WIS;WLDF9^ -]DQR?PFCA-&C)]7<WQ MP)%G_P!68WN-POQI7I\-=VAS
MV,Q4\@7%ZBG_ & =C,5/(%Q>HI_V WXHUEV#,91(BVS:\AAPLVWH],I;[+B?
M"AUIA2%%\AF/>=A606T[3MPB(C,S.CTXLB+C/^;\1=\-]DQR?PFCA-&C)]7<
MWQ#>"1?*S&]QN'J]:].,V@MV,Q4\@7%ZBG_8!V,Q4\@7%ZBG_8#?/@T7"FIS
MYE+IU,LJ?4:<:"GPH<2C29,(U_ *4RRVMQC6_JDXE)GWLQS?:#9/).W?4U/^
M[AOLF.3^$T<)HT9/J[F^(;P2++_JS&]5!N'JU4KTXS:"O8S%3R!<7J*?]@'8
MS%3R!<7J*?\ 8#?J[0;)Y)V[ZFI_W<.T&R>2=N^IJ?\ =PWV3')_":.$T:,G
MU=S?$-X)%\K,=W$[\UZ<'=H*]C,5/(%Q>HI_V \54_%%M)J<H=P-I+C4NB3D
MI+Y3-C(AOV=H-D\D[=]34_[N+>8IV/9K%DU9;=J6^A1;SDI-(@)5^,(N-,?8
M6WBZ? &^R8N]'\)WFC1D^KN;C.!;@2+/_JS&]=!N$7_[7\+_ ,M%9-/Q1<22
MFZ%<"TGQ*11)RDG\ADP9&/+L9BIY N+U%/\ L!O588V/9CUETA;EJ6^M2B=S
M4JD0%*^&?&:F#SXNH7 [0;)Y)V[ZFI_W<-]DQR?PFC/2:.;ZNYOB&\$BR_ZM
M1O503DNK_FOXC05[&8J>0+B]13_L [&8J>0+B]13_L!OU=H-D\D[=]34_P"[
MAV@V3R3MWU-3_NX;[)CD_A-'":-&3ZNYOB&\$B^5F.[B=^:].#NT%>QF*GD"
MXO44_P"P#L9BIY N+U%/^P&_5V@V3R3MWU-3_NX=H-D\D[=]34_[N&^R8Y/X
M31PFC1D^KN;XAO!(OE9CNXG?FO3@[M!7L9BIY N+U%/^P#L9BIY N+U%/^P&
M_5V@V3R3MWU-3_NX^299V'\!HWI=N6G%:+8;LNGTJ,T1F>1$;CK*4YGQ$6?&
M&^R8Y/X31PFC1D^KN;XAO!(OE9C>XW/FO3X:[M"#L9BIY N+U%/^P#L9BIY
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M%\K,=W$[\UZ<'=H*]C,5/(%Q>HI_V =C,5/(%Q>HI_V WZNT&R>2=N^IJ?\
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M*DBB78)4&I@DP[+'D20J)B37_P"RRLO*3GEDW3   :K&^@
M
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M<'ZV[]<X "0(       -"/3]POQ TM-WNJ6BV6-U?PRLRZ&&%KDQJI.CPH/
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M/O"_ #$
M
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M1]RCT\H5;N!;L-]<1^PV*'6F:YV$9J-5FNUZ'%>ITE_52TEU;1ZII21(V;"
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MZZE&1J/:>8D< ^8
M
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M+ML:/^C;;&C>B4BY+9H%"FT!Y^0QJ)G1)S"X[Q*:6:]7\&M1%M/+C+:1"4P
M)L&K]??\'&I,2_[YKNC;I*7!@-8>(D]4RZK$I4.H38TM+SKCLMMI],QHHW"%
MNO9J:0G+7S[PRTZ)^YJX#:+>C94]'.DQ)UTT"YH$R)>$ZMU&?4EUUZ;OJG7S
M147I"F#)UYQQ*4'L,]G>RR,9  IF9YSG(:I-U?P8^UBN"[*?A/I*W'AG@Q>=
M4[(5["V#&J3\-YMR4N3(C-3"FMG'2\MQPE&VDBR5EED1#(]?&XT8#5?<_'M
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MN]F,N   QG/JN''U;_)E0_4Y'U2A9? GXNS?UR5]>X+T5;_)E0_4Y'U2A9?
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M66TC\&?]XJ #$8>X^Y)V)'W2I[=%^W-U5VNY9VOP1S4+*G\ +^4[YJ9:O=?
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M-NI6DU)=U2U=N0QZ6*4BW/X-14*Y@O&I3.(\VD:EP3;:*&JXEP^S#K4LISD
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M(MA$DB+F'N  #+O=X   %,B+B(@R+P%T"H
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M,8.6!>ALAVJ8P<L"]#9 !(3,O"7209EX2Z2$>^U3&#E@7H;(=JF,'+ O0V0
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M1'X4JVI/]I#R'E<>\".9$99C%,BY^D^L,BY^D^L5 !13(N?I/K#(N?I/K%0
M!3(N?I/K#(N?I/K%0 !3+Y>DS^D5
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M@ >W"SXDTGY'OK#%PQ;S"SXDTGY'OK#%PP
M           <?5O\F5#]3D?5*%E\"?B[-_7)7U[@O15O\F5#]3D?5*%E\"?B
M[-_7)7U[@ +\                                        CW?W])]B
M_I3?W2$@D? 3^BGZ"$?;^_I/L7]*;^Z0D$CX"?T4_00 /(
M                         $>KR_I:LGY9OU9"0A<1?(7T"/=Y?TM63\LW
MZLA(0N(OD+Z  5                                           !\L
M[^93/U61]4L6(P-_$7!^MN_7."^\[^93/U61]4L6(P-_$7!^MN_7.  D"
M                                         +<8L?$:L?(Q]:D7'%N,
M6/B-6/D8^M2 #SPK^)%(_1=_?,7$%N\*_B12/T7?WS%Q
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MCVC83#S40RT^PM+C+S:'6EHO0MMQ)+0I)Z4J2HC(])&   P'V
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M5Q,D5?I=J->. 8I,X=33\-$E Q+[\,S$G#Q+;3J6UOPSS9S3-"D2623,I]I
M '7QW(                             RSXP          #(
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M  '@IQ"#(E*2G//+64E)[/ 1GF?/EQ AQ#B=="T+2>9:R%DM.P\C[HMFSO\
M. #SR[_? >"5I4I24J29IRS(E$9EGX2(\R_;QCY79\5IPVERHC:RXT.26D++
MY4*62B_:0 /M ?*Q+CR#434B,\:>,F7VW3+/BS)"E&7[1]0  "F9<699BN>?
M$   IF1\1D*@ "V^+/Q&JW^P^L(7(S%M\6?B-5O]A]80 /;A9\2:3\CWUABX
M8MWA8?\ W*I'.3W[YF+B &,=H  !,M>,&7:$\2/&G$C   )EKQ@R[0GB1XTX
MD8  !,M>,&7:$\2/&G$C   )EKQ@R[0GB1XTXD8  !,M>,&7:$\2/&G$C
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MEF_5D)"%Q%\A?0 "H
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M1F+Q@ #0X]<@
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M7]+5D_+-^K(2$+B+Y"^@ %0
M      ?+._F4S]5D?5+%B,#?Q%P?K;OUS@OO._F4S]5D?5+%B,#?Q%P?K;OU
MS@ ) @                                           "W&+'Q&K'R,
M?6I%QQ;C%CXC5CY&/K4@ \\*_B12/T7?WS%Q!;O"OXD4C]%W]\Q<0
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MIM25%DM!<1D.G6]HL8>V[H[EHXP65E8Z:;*II-:[FMO$HUFYW9JWS^N>6WY
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MHHD6Y4UN!B'*FP.#D^<-AQ+%.*+()3J4$UDK6V99$,WA<7[3/^\ %0
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MNNLQ5(1CZXRD(IU))B'$H(LDTY)W3  &G1Z8
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M69= J  *&699;,LLLC+9T>#F'@AIMM.JA"$IS,\D(2@MNT]B2(LS[Y]\>P
M>.J61%DG9M^"67["[P:I9F>1;>^19'SYGQCR  'J0RVVI2D-MH-?PC0VE!J_
M2,BS5^W,>>J1$99)V\>S8?REWQY  #TM,-,Y[VVVWF>9[VVEO,SX];4(B/P[
M1;[%@S*QZOELV,E^PW"S+]HN.+;XL_$:K?[#ZP@ 8]<4=SVP[TAJ)2KNI\M%
MHW:\EY4VI-,J>3,4G)"#4RE24)-)%QY'M/,Q%Q[<>K@WU9-8I?@R/N3[%)VE
M\[_KI&;+"SXE4GY'OWS%PLOEZ3ZQLBA;6J^T! L4;1]..%!0R";AV8EB'B_(
MMI_9;;<B&G'"0DKDHRLE)7)(BN&D:S[G>R2MU+1--TO55@Z2C7#>C(B"BXVC
M_I+RI9;KS4&^RRIU9EEK<R"6M9S49G>, WO/5R?VI?[I3[0>\]7)_:E_NE/M
M#/SD7/TGUAD7/TGUCEO/I:3^^F>[:/\ ]OTX*_KN]0L2XKQ'?5+[/O>S%TL
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MA?0(]WE_2U9/RS?JR$A"XB^0OH !4
M            'RSOYE,_59'U2Q8C W\1<'ZV[]<X+[SOYE,_59'U2Q8C W\1
M<'ZV[]<X "0(                                            MQBQ
M\1JQ\C'UJ1<<6XQ8^(U8^1CZU( //"OXD4C]%W]\Q<06[PK^)%(_1=_?,7$
M                 R+BRV> 4R+P%T"H  9$?&6899<0  "F1> N@5
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MK4-$PT,1.PZ%)E$-.NW.E^S.8N2  -2CT6
M                                        *9ES]!]0 *@*9ES]!]09
MES]!]0 *@*9ES]!]09ES]!]0 *@*9ES]!]09ES]!]0 *@*9ES]!]09ES]!]0
M *@*9ES]!]09ES]!]0 *@*9ES]!]09ES]!]0 *@*9ES]!]09ES]!]0 *@*9E
MS]!]09ES]!]0 *@*9ES]!]09ES]!]0 *@*9ES]!]09ES]!]0 *@*9ES]!]09
MES]!]0 *BV^+/Q&JW^P^L(7'S+GZ#ZA;C%@\[&J_^PYO\X0 /;A9\2:3\CWU
MABX8MWA:>5DTCCVD]WO],SXN,7#S+GZ#Z@ 5 4S+GZ#Z@S+GZ#Z@ 5 4S+GZ
M#Z@S+GZ#Z@ 5 4S+GZ#Z@S+GZ#Z@ 5 4S+GZ#Z@S+GZ#Z@ 5 4S+GZ#Z@S+G
MZ#Z@ 5 4S+GZ#Z@S+GZ#Z@ 5 4S+GZ#Z@S+GZ#Z@ 5 4S+GZ#ZA7_KBR^D
M   ''U;_ "94/U.1]4H67P)^+LW]<E?7N"]%6_R94/U.1]4HQ9? GXNS?UR5
M_P#4.  OP                                       "/=_?TGV+^E-
M_=(2"1\!/Z*?H(1]O[^D^Q?TIO[I"02/@I_13]  /(
M                     $>KR_I:LGY9OU9"0A<1?(7T"/=Y?TM63\LWZLA(
M0N(OD+Z  5                                           !\L[^93
M/U61]4L6(P-_$7!^MN_7."^\[^93/U61]4L6(P-_$7!^MN_7.  D"
M                                     +<8L?$:L?(Q]:D7'%N,6/B-
M6/D8^M2 #SPK^)%(_1=_?,7$%N\*_B12/T7?WS%Q
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MX1T#":VG8\JE6\J4F'):BHC+..\\;C3+ID6NX;"-5LE.*49ZN??$AP 8ST:
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MWS&[Q*?G,!OF-WB4_.8$B@S(N,\@ 1UWS&[Q*?G,!OF-WB4_.8$BA3,O"72
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MS:DYG^#XBSS,6UPWQ&=MQNJ(10WYO"9"G#-!K(D9N*5D>25%W_[N(3 G1(O
MI?\ )H_\UD?YEOQ2_P#1%C,$&67&*]KLLKU9;F6NTA663SGA+, 'G[MTKDK*
M^>Y]F'NW2N2LKY[GV8OUP2+^;1_,M^R'!(OYM'\RW[( +"^[=*Y*ROGN?9A[
MMTKDK*^>Y]F+]<$B_FT?S+?LAP2+^;1_,M^R "PONW2N2LKY[GV8>[=*Y*RO
MGN?9B_7!(OYM'\RW[(<$B_FT?S+?L@ L+[MTKDK*^>Y]F'NW2N2LKY[GV8OU
MP2+^;1_,M^R'!(OYM'\RW[( +"^[=*Y*ROGN?9A[MTKDK*^>Y]F+]<$B_FT?
MS+?LAP2+^;1_,M^R "PONW2N2LKY[GV8>[=*Y*ROGN?9B_7!(OYM'\RW[(<$
MB_FT?S+?L@ L.C&R0I1$Y:\I">^K-Q67[-['U>[.UY E?-<^S%[N"1?S:/YE
MOV13@</\UC>8:]D %DCQH:+;V E;/]%S[,?/[N<+R%,S+C_ O?\ %LA?7@</
M\UC>8:]D4X#"_,XOH[7L  L7[N4+R',\T[[ >[E"\AS/-.^P+Z<!A?F<7T=K
MV X#"_,XOH[7L  L7[N4+R',\T[[ >[E"\AS/-.^P+Z<!A?F<7T=KV X#"_,
MXOH[7L  L7[N4+R',\T[[ >[E"\AS/-.^P+Z<!A?F<7T=KV X#"_,XOH[7L
M L7[N4+R',\T[[ ZE?&+D2N6U/IJ*1*8-_>LG%MO)26JK6//-!%Q%QF9?M$H
M> POS.+Z.U[ MUBM$BMV15E(BQT*+>.Z2PVDR_"%M(R21EX,^< %I;*Q>B42
MW(%-72)3RHY.$;B&GE)/65GLR;,NC8.U^[E"\AS/-.^P.Y871(KEE4E2XT=:
MC2[F:F6U'\/PFDS%PN POS.+Z.U[  +%^[E"\AS/-.^P'NY0O(<SS3OL"^G
M87YG%]':]@. POS.+Z.U[  +%^[E"\AS/-.^P'NY0O(<SS3OL"^G 87YG%]'
M:]@. POS.+Z.U[  +%^[E"\AS/-.^P'NY0O(<SS3OL"^G 87YG%]':]@. PO
MS.+Z.U[  +%^[E"\AS/-.^P'NY0O(<SS+W_!LQ?3@,+\SB^CM>P' 87YG%]'
M:]@ %ETXV4<R(U4R81]\N#2-G_RAY>[91O)TST:1]D+S<!A?F<7T=KV X#"_
M,XOH[7L  LS[ME&\G3/1I'V0]*L=+?0>JN#,)1<9<%D;/_ED+V<!A?F<7T=K
MV!ZU4NFK/65 AF?AX.U[  +*^[M;OYE,]%?^S#W=K=_,IGHK_P!F+T=B:9Y/
MA^CM>R'8FF>3X?H[7L@ LO[NUN_F4ST5_P"S#W=K=_,IGHK_ -F+T=B:9Y/A
M^CM>R'8FF>3X?H[7L@ LO[NUN_F4ST5_[,/=VMW\RF>BO_9B]'8FF>3X?H[7
MLAV)IGD^'Z.U[( ++^[M;OYE,]%?^S#W=K=_,IGHK_V8O1V)IGD^'Z.U[(=B
M:9Y/A^CM>R "R_N[6[^93/17_LP]W:W?S*9Z*_\ 9B]'8FF>3X?H[7LAV)IG
MD^'Z.U[( ++^[M;OYE,]%?\ LP]W:W?S*9Z*_P#9B]'8FF>3X?H[7LAV)IGD
M^'Z.U[( ++^[M;OYE,]%?^S#W=K=_,IGHK_V8O1V)IGD^'Z.U[(=B:9Y/A^C
MM>R "R_N[6[^93/17_LQUR[,9*%5Z!/I[,26ER0V24FJ.^E/?XS-&6SY?^(D
M7V)IGD^'Z.U[(Z5B%3:>W:564W!BH4EHLE(8;)7AV&22,N/O& "S&'V+E$MZ
MU8%*DQI2WHZGS4:([RT'KN&HLE)09&>WP_*._L8XVPXG-;,QL_!P21]F.1PA
MI\!^PZ2X["C.+4N49J<9;6L_PRB+-1I,SV>$Q<SL33/)\/T=KV0 6I]VVU?R
M9GHDG[,/=MM7\F9Z))^S%UNQ-,\GP_1VO9#L33/)\/T=KV0 6I]VVU?R9GHD
MG[,>"L<;11EKG,3GQ?R.3M_^6+L]B:9Y/A^CM>R/2[0Z0]EKTZ&>7%_)VO8
M!:KW=;._+E^AR?8#W=;._+E^AR?8%T.URB>38GF&O8#M<HGDV)YAKV  6O\
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MY3-*0A4A93&^0HMAV5G\%2$/&H(XA*"5'N132&BAUR/R3:3RS<(U2R4F8O*
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MS-*#R+/:>PN\(_T:OX28#8%V]B=<=*HUJ4.E6=;<BLU>F4./PM).TN(DEJ3
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M+/B32?D>^L,7#%O,+/B32?D>^L,7#
M      !Q]6_R94/U.1]4H67P)^+LW]<E?7N"]%6_R94/U.1]4H67P)^+LW]<
ME?7N  OP                                       "/=_?TGV+^E-_
M=(2"1\!/Z*?H(1]O[^D^Q?TIO[I"02/@)_13]!  \@
M                     1ZO+^EJR?EF_5D)"%Q%\A?0(]WE_2U9/RS?JR$A
M"XB^0OH !4                                           'RSOYE,
M_59'U2Q8C W\1<'ZV[]<X+[SOYE,_59'U2Q8C W\1<'ZV[]<X "0(
M                                     MQBQ\1JQ\C'UJ1<<6XQ8^(U
M8^1CZU( //"OXD4C]%W]\Q<06[PK^)%(_1=_?,7$
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M&MG7XT6Q%2YIW32)$%B7PM"5-DPI.^)6M)LGFO-!9YD69ED0[U9P48JM4*W
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M:(&+.DQB!HWU_#>,E^!AO7)TVXC4XRC>V'Y,5QLRWU1&KN6E9ZF9C+\&6?\
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MUS-<;8G(B2?=9<>P2>R^7I/K%<LO_P 3/Z0,YZ"Z>J0$4M)]>,:0  $%
M         6WQ9^(U6_V'UA"Y MOBS\1JM_L/K" ![<+/B32?D>^L,7#%O,+/
MB32?D>^L,7#                                     !Q]6_P F5#]3
MD?5*%E\"?B[-_7)7U[@O15O\F5#]3D?5*%E\"?B[-_7)7U[@ +\
M                               CW?W])]B_I3?W2$@D? 3^BGZ"$?;^
M_I/L7]*;^Z0D$CX"?T4_00 /(
M    $>KR_I:LGY9OU9"0A<1?(7T"/=Y?TM63\LWZLA(0N(OD+Z  5
M                                    !\L[^93/U61]4L6(P-_$7!^M
MN_7."^\[^93/U61]4L6(P-_$7!^MN_7.  D"
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MJ/>3$0,?"L1D&^DE$EV&B&DNL.))1$HB6VM*B)1$9$=Y   /S#]H
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MH;L
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M2KW N4C5.G(&FH5ESR+ZX1R:V'93)#["R2\RI17H)Q"<M-Z9D/<  ."';0
M         !'N_OZ3[%_2F_ND)!(^ G]%/T$(^W]_2?8OZ4W]TA()'P$_HI^@
M@ >0                                       (]7E_2U9/RS?JR$A"
MXB^0OH$>[R_I:LGY9OU9"0A<1?(7T  J
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M,(ZU N9%'L.3)G)NV*;33BGVLT(8,B4>^]SFHSWM.0[75)FGZ2I%-#4%2<1
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M'>
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MWQR1EGL/:1[#(^^(!;;^J0QRZ$EE79;N$N(%+KU&>ID^>Y<R(<9TSUGCE.U
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M0C[?W])]B_I3?W2$@D? 3^BGZ" !Y
M         CU>7]+5D_+-^K(2$+B+Y"^@1[O+^EJR?EF_5D)"%Q%\A?0 "H
M                                         /EG?S*9^JR/JEBQ&!OX
MBX/UMWZYP7WG?S*9^JR/JEBQ&!OXBX/UMWZYP $@0
M                        !;C%CXC5CY&/K4BXXMQBQ\1JQ\C'UJ0 >>%?
MQ(I'Z+O[YBX@MWA7\2*1^B[^^8N(
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MQ\K/\&SUAVM8Q\K/\&SUAE*UXP6)F&0G&,3Z)2 WAKQ3/FDAO#7BF?-)$?\
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M>%'^'Z@ 2) 1VRQN\*/\/U!EC=X4?X?J !(D!';+&[PH_P /U!EC=X4?X?J
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M(CZ%=0L'OV,OYJGSK ;]C+^:I\ZP "_FSP'T*[W$*YES]!]0L%OV,OYJGSK
M]"YN-:%:J:8EPBXE;['+, $@=1.>?=?)W67T"JDI5QZVSP:Q?00CUP_&WR2G
MST<.'XV^24^>C@ D,1D6PB/H/J#9EED>7R*ZA'GA^-ODE/GHX</QM\DI\]'
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MU:#5ZM&*).JM,AU!Z,2R7O'#(S<A+9J+C-).:N?-MVF$C[11VD
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M;OUS@ ) 9%S])]89%S])]8J  *9%S])]89%S])]8J  *9%S])]89%S])]8J
M *9%S])]89%S])]8J  *9%S])]89%S])]8J  *9%S])]89%S])]8J  *9%S]
M)]89%S])]8J  *9%S])]89%S])]8J  *9%S])]89%S])]8J  *9%S])]89%S
M])]8J  *9%S])]89%S])]8J  *9?+TGUBW&+!?\ <:L?[ __ )J1<@6XQ8^(
MU8^1CZU( //"O;9%(_1=/_QGQBX@MWA7\2*1^B[^^8N(
M                                      .C8B_%"L?ZHN_S9CO(Z-B+
M\4*Q_JB^@ '$8._$&D?I2OKU"Z M?@[\0:1^E*^N4+H
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M2.TJM!'&#1-7%JUSE)JEKR'%<%N: O@N\K;4DDK<1%5KM]V:<M8RS[W/*/1
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MA9\2:3\CWUABX8MYA9\2:3\CWUABX8
M       ./JW^3*A^IR/JE"R^!/Q=F_KDKZ]P7HJW^3*A^IR/JE"R^!/Q=F_K
MDKZ]P %^                                        1[O[^D^Q?TIO
M[I"02/@)_13]!"/M_?TGV+^E-_=(2"1\!/Z*?H( 'D
M                     "/5Y?TM63\LWZLA(0N(OD+Z!'N\OZ6K)^6;]60D
M(7$7R%]  *@                                           ^6=_,I
MGZK(^J6+$8&_B+@_6W?KG!?>=_,IGZK(^J6+$8&_B+@_6W?KG  2!
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MDE$9&1EF1D9*(R/B,C+89&6TC(>0  Z-B+\4*Q_JB^@=Y'1L1?BA6/\ 5%]
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MW$/-MNMJ)3;J$N(47$I"TDI*BYC29&/,=-&R2.=Y7D=Y&6D
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MU.')MUPR\DDUI3^V8^D  = &XP                             RSV&
M                      ];K:'FG&74DMMUM;;B#VDI#B32M)EWR4DS(^8Q
MUFU[+MBSF9$>VZ-#I#,IQ3K[<1EMI+KBU&M2U$VE)&HU*,S,R[X[4
M    Z]<EJV]=U.=I5Q4B!5X+J=5<>;&9D)R_T#=0O4,N/-.1YCL(  Z+9F'%
ME6%%.+:EN4VC-J4:EJCQ6$OK,U&KNGTH)T\C,\B-1D19$0[T       #YI<.
M)/CNQ)L9B7%?2:'H\EIM]EQ)ED9+;=2I"MGA28^D,^]WP 6NMO!O#6TZM*K5
M!L^CT^I2E[XY*1"BJ4E>TS-C\$6\YYGGO1IV\8NB19;"V$6PB+O        #
MQ-:2-*34DC5Q),\E'\B3VF/+_KP?2       !F1<9Y   &?>[X
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M8E1*+,C(R\)'F1_(?$?[!#(RSD9=76,DK2K,9'T&1Z"/1TBH  @R
M    ''U;_)E0_4Y'U2A9? GXNS?UR5]>X+T5;_)E0_4Y'U2A9? GXNS?UR5]
M>X "_                                        (]W]_2?8OZ4W]TA
M()'P$_HI^@A'V_OZ3[%_2F_ND)!(^ G]%/T$ #R
M                  !'J\OZ6K)^6;]60D(7$7R%] CW>7]+5D_+-^K(2$+B
M+Y"^@ %0                                           ?+._F4S]5
MD?5+%B,#?Q%P?K;OUS@OO._F4S]5D?5+%B,#?Q%P?K;OUS@ ) @
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M1?0.\CHV(OQ0K'^J+Z $'$8._$&D?I2OKE"Z M?@[\0:1^E*^N4+H
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M.B&B'6XB+>-QA"B<2B40^ZDI.?:FDB/;(5  '51L$
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M"JA5&P'67:/<]8E3H4G)YI,656S?CR%-N(-L]]9,GM4T]SGD+T:2&C]B7?\
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MN2OKW!>BK?Y,J'ZG(^J4++X$_%V;^N2OKW  7X
M                 !'N_OZ3[%_2F_ND)!(^ G]%/T$(^W]_2?8OZ4W]TA()
M'P$_HI^@@ >0                                       (]7E_2U9/
MRS?JR$A"XB^0OH$>[R_I:LGY9OU9"0A<1?(7T  J
M                       #Y9W\RF?JLCZI8L1@;^(N#];=^N<%]YW\RF?J
MLCZI8L1@;^(N#];=^N< !($
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M7XH5C_5%] [R.C8B_%"L?ZHOH !Q&#OQ!I'Z4KZY0N@+7X._$&D?I2OKE"Z
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MAG>'H\=YG86]/,-NLF1<1;VM*D;.]LV=[(>7"XOYS'\\W[0<+B_G,?SS?M
M\&H45IC@S<:*VQGF3+<=I#)&1YEDTE)(Y_@[#VCV<'9S<,F62WPB2O\ !(S6
M1%D1+/+NRRV$2LR+Y!3A<7\YC^>;]H.%Q?SF/YYOV@ ?/'ID&*O?&(,%A6T]
M:/$897F?&>LVA)[<SSV[1R!EGL/:1[#(^^/GX7%_.8_GF_:#A<7\YC^>;]H
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MT<)8\<QYY <)8\<QYY Z:-FCW@/1PECQS'GD!PECQS'GD  ]X#T<)8\<QYY
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M9*R[V9'^P<B*9EX2Z2#,O"720 *@*9EX2Z2#,O"720 *@*9EX2Z2#,O"720
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MOS>1_P!X]J5$M)*2:5$?$:3)1?L,MA@ C][A[_*B7T.^V'N'O\J)?0[[8D&
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MVP]QJO<MI7FE^V)!  ".;F#%T&HS;OJ0E/>(XYG]*C,>'N+W7R[?]&/VA(\
M 0BN7#^MTV\+<I$BYG94JHG()B<;1I5&WM/=9)S//6V%WA<TL&+J,B/M[?VD
M1_S<_!^D/LO[^D^Q?TIO[I"02/@I_13]  (Y>XO=?+M_T8_:#W%[KY=O^C'[
M0D>  (X>XO=?+M_T8_:#W%[KY=O^C'[0D>  (X>XO=?+M_T8_:#W%[KY=O\
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M?KL=Q3CZ+U(>P7CE,Q&*RK8.WV''&DDX[V+B;X1JD?@R(D?E#%%7;=TFL2<
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ML( 'MPL^)-)^1[ZPQ<,6\PL^)-)^1[ZPQ<,
M            ''U;_)E0_4Y'U2A9? GXNS?UR5]>X+T5;_)E0_4Y'U2A9? G
MXNS?UR5]>X "_                                        (]W]_2?
M8OZ4W]TA()'P$_HI^@A'V_OZ3[%_2F_ND)!(^ G]%/T$ #R
M                          !'J\OZ6K)^6;]60D(7$7R%] CW>7]+5D_+
M-^K(2$+B+Y"^@ %0                                           ?
M+._F4S]5D?5+%B,#?Q%P?K;OUS@OO._F4S]5D?5+%B,#?Q%P?K;OUS@ ) @
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MP=^(-(_2E?7*%T!:_!WX@TC]*5]<H70               !0SR+,^K_KGY@
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MTW1!P+KB#*/HUTB-;T(RDHR'.1IRU21EH  'EH>["VYP
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MJWT]!K3$Q=84P[2U&9(2XJ'.)B4I??6M><DW=Q  &G!Z8
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MJW^P^L( 'MPL^)-)^1[ZPQ<,6\PL^)-)^1[ZPQ<,
M                 ''U;_)E0_4Y'U2A9? GXNS?UR5]>X+T5;_)E0_4Y'U2
MA9? GXNS?UR5]>X "_                                        (]
MW]_2?8OZ4W]TA()'P$_HI^@A'V_OZ3[%_2F_ND)!(^ G]%/T$ #R
M                               !'J\OZ6K)^6;]60D(7$7R%] CW>7]
M+5D_+-^K(2$+B+Y"^@ %0
M    ?+._F4S]5D?5+%B,#?Q%P?K;OUS@OO._F4S]5D?5+%B,#?Q%P?K;OUS@
M ) @                                           "W&+'Q&K'R,?6
MI%QQ;C%CXC5CY&/K4@ \\*_B12/T7?WS%Q!;O"OXD4C]%W]\Q<0     $.-/
M''>Y=&_1AQ'Q?M*&4ZNVHU"7"C&M""<X0^EM6:ED:2R(SXR&+S&'=-\9[(W)
M"FZ;=#M@I^)DB>VE5OI?82;L9NN(A2$I=-!MFHXVMJDE!F9["VB:6Z\9_P 0
MG&_+CX/2N+];0,&>*JE)W 7"U1%K$=\T%MQ"B)27&7+\A)>;4DR,C2XC-!D9
M'L,P&:2*XS*?VR+JU#/7N:NGK;&GEH^6YB1'910;\:A).]K*?4I-1H$G\6TI
M]MU*'33*-)N(5J)29'F6PR,6PP:TV,0[\TPM.' NITE+-MZ.]LT^L6O+)QI1
MSGI-ORZHXG521+1DZP2<UF?'F,;F+]EW!N;&,V#>G?A)3)C&COBC;=H0=):U
M*:E? H#RJ+3:3;\UF.TE9-D<N0N2^<1A!'D:G<RS,=RT+;QMO$/3_P!T_OJS
M:HQ6K5NC"^W:E2JE&<0XTX<FQ)LAY@S0I9$N,IS>ED9YDI)YD1ED DKC,LTN
MPYE=C0+;Z+FF/NJ6FA:%R8G854B-3+6BW+<5'I,53]'<4\W1ZQ+IJ#-3R4K1
MK\'2?=%GDK,Q*#1FW2G2,P[TE+8T2-/7"\\/KJQ"=E-X9W\NIQY4*ZS@LG(G
MD;<1O@T0V$J0V1.+(UF>:=HZ]_!W/_)+NG7W[+M_OG5RWS5^-]4^#EL\'$.A
M;NZAAS%K0E30,DXDKNF?VLKC%_VIP=-0@]DM34_#FC@VL2]N66L RNGDR+8>
MDKIZ[QLMMNH=0E:%$I*TI<29&1DI"RUD*(R,R,C29'F+?7/BSAQ9TQBGW+>M
MN4><^K43$F5>GM/I5F66^LN2$.-9YEEOB4D9;2V;1]M%;J#ECTA#:S;J:K*@
M()Q>6:*@NC-I0M>L9;4O[59[.//(:8N+=)B8-:5>/]3W1G!V^L1;)ON0TC#W
M%:U[HN)<2A,--/)7+11+86\A/ B6TI25$C7-K;M 8$4\?V+Q&Z9(O&U8U%*X
MGKBHR*$K>B36"J4-=.,WE$ELN&)>.-K+49)26^YFH\B+/8/MFW!1:?2CK<VJ
M0HE))+:SJ+\EEN(2'<M[5OZUDUDO,B2>OD>99#4UQ/J6%-*W%S$J/H]8^UO%
M>S8=\6([2ZE+;JE%N"UVIE[QEKITLIKQ50B1KG$(WS1OB$9D1D8R8:;<^HQ]
MR1ES&*A-BSRM:P#X<W+>8E$:G*?K*X4E:7<UD>U6MW6>TSS 65Y;3EFZ+_$7
M:TQ=-NZ<#])W0\PMM!-.J%E8[.W=VQ5U50AM08C-"92XRKA+BMZ5K9G\%PMI
M9> 9$;1Q6P^O.2NGV[>-OU>J,-L\(@0ZM >DI<6@C42&6GE..9'GGJ(,B[XT
M\M)_#&IX^4G<A<-7KIG45-SO8BG4ZWO[ZYRXT1R.Z\P4DG2D?RAHE-:R7,RU
MM8C/(2MW0G16M'<\)VC]I1:+55K=CW);M;HE+O"DR+@JU7C7JFNS:=2W'W(]
M3F.L,J9)YYW)#9D1K+(BV &25U^>?@?3T9IC9VJ>(%D4:3/B5:[;?IDJF(2N
M;%G5:GQ9$=*TZR36S(?;<+63M+N=O>,<3$Q<PUGT)RY(E]6L_1&343U036Z:
M;3)H6:#)9E)-*.Z(R+7-.?>&JW=& Z]+C=EZY0,0;CN%6&#%I6?4KLL^!6:E
M3HU:=K%GQ9FJE<*2T4;>WW%'FVC(\\\LAU_#C0<L)_=3<8M%.G7'=$'1=IC-
M&=GX4'<=<>5.7+I)S,VJXN8<R.29>;JM119YFGB ,DM?^'*S?U&U=6\08ER8
M?7%7<+*_0[DJD:G2UTY=/JM/?:1,0RYO)2'&WW$1R-TDEF\:2[XMOHM7QB15
M<!Z+=.D#)HM$O0Y]<*L/)J]+?IK,.//=13S[(1WN J4J*E.LE+FLE7<J[K8-
M>;!"P8FBUIJ:>NCCA55J["P=?LN#(I-KSZQ4JJN@NIM6;,6<:?.D.R"4[([O
M-!I,C(BS\%IJ996DSBKN)N&#&"[]7N^;!O\ OQ^\[;.ONP*S<M(A7Y)=<CLU
M9V04Y!,P6W4D3*U=SW)$199 EMNNO,M93&VE;&+.'%XRWH%MWM;=7FL*U%0X
MM7I[DE2B/(][9;D*=<RR//40K+OY;!]5V8FV%9"VFKJNZ@4-Y\\FH\^J08\A
M?%F9,O/MN9%F1YZO$>?$-0'1GO'0*KND!@1)M^JX@:'V.UI:\*J6I<3MY7#1
M+ZJYL,QYJ7*E55-TEC)Y#AH,U*2HW,D'GD.UZ=%$K.&NG3BGBCI@8.W;C1HT
M7K3* C"6X[3NNLQ$V0PS1VV*S/>HUN../R.'.*)]"7VB,LNX,]@!DWR_(L\\
MV>7B-HC&2_KAD8.W)<N"-5H-PW(RW'51GXU9IBH*S4X1.[[,-Y45DR3GD3BR
MS/9Q[!YX 7=?$W!BWKEQG?I-)NE13%UY\ZI 73F$-O+)@^'LN%#/-LB/N5\>
MP]NP:U^$<W1XC: ^EW)T6,<;GN^U'.UEYBP*S'KU+K^&#CLY:WF%2ZPZ54D%
M+=-62C)!:J2U<TF0Z+<UVXG7]HV[G%H@TJ_:I;=KZ2=5O\[]KW"GUU&1$M:J
M)F,Q3F&\4PM_02V-9#I&DEF?, N3^.DI:)Z\:Y#;&MK%S#:[YTBFVY>]M5:H
M1E;VN'%K%.<D*7F9&33*)*G'LLCSWM*B+OCFZA?5F4F7*A56Z[?IDN$@G),6
MH5>G0WVTFG7(]ZDR&W#S3M^"8UE]TMT%,-M W 6T-+S1<K%PX>8BX37!9,&=
MOMPURL1[J3<E9IU,J+C\:H37(R5+:<?61&V9)WPM0BR%CKWPD=TS]U=PQA7E
M<UR0\.*I9]#G7K:L&KU.GM5V1(M"')-6<22QP?\ E"EK[E)$K6X\MH"$DCOG
M=(SS7W2V[=8VT[5Q!LF]4..6I== N#>E*0\W2ZK!F/,J2HTY.-1GW%HS,CRU
MB+/+,AW,:N5B8&6_H1;K_@[AC@)6:]0\,L8V*^N[;-J-:JM;CJ<HM&-^*MMZ
MIR'C:,WE&X>]$1&9[1M%I+(CR\)_28"&4I;2GFD/(=&Q%^*%8_U1?0.\CHV(
MOQ0K'^J+Z $'$8._$&D?I2OKE"Z M?@[\0:1^E*^N4+H              "&
M^FKI2VUHOX05RZ9\IE=R3(;T:W*2:R)^6^\2HZG$$6TMX4HG.(RV<8D]>MWT
M2Q;9J]TW#,:@4FCPWI<J0^HD-EO32G$-ZQF1:SAIU2[^9D-+'3BTI;CTM<:I
M4R J6[:=-JITFS:*RI;B%NN/<"><)M)&;A+=23A&I!DG//,B&Y+&+-7:_P!8
MTN1J%-U<H=2(JEX@YI2[DF2VH%"SD67$Y)^4,C_5L$XNXR21^;]TG;2Q9-4Y
M;-&N(=KA6)+L#5^%*2UL91$A^E7&RF?DX,ED323+]=%*:;(C++ET'#.VKHTM
M=(%N9>E3E.)K]9[(7/6726ZF%"8?.1&CZN9DDG(Y;R>H9;-IEGL&W+8=_8$X
M887L8<6;,:@4VFV]*I\5EJ,LB<FO05M.FH]4CS=D&9YGGEK""6@[N=4JR\(:
M5<5QSBI%YW5&;EU1E<<G'H[1Y.12)P^+796G,DF1]X^/;,"M:(Q4FC5:J%<Q
MN*IM-FSDM\'RWTXD9Q_5S)1Y:YHR[V68V':S76J%;Z7A:&8I:(AZ%JXX4#1T
M% MJ3!.Q#2DM*B2DRI"DI)*68<R5D)93-/[2C/4%@-FEH-G=7HVLK]7H6,K+
M7%G])TM25*/-KI%B#?0<0B#,U1*'$.*-Q43%I4GRBXA62J?DDRUJ[JT.\8ZG
MBW5+KB4[7I$B[&:JT[OC1&<1%4*4I61GK%^"VY99Y][C(99-T9Q*MRXM"]%I
M4Y[?*M3J91(LEK541(=C''0Z69ED?=(,LR&.*H:?MP0KQDVL5GZR(]PE1.$\
M,26:>R/ =]U<N\7=ZO>XA.O3ZPL[6]#]R_#J7"%UB%2Y9PR:U=Z.2XTX:-\S
M/6U=\RS[YEQ>'9=/_I9ZM%EA5N;8A%PU+0Z*O%!FDRB5?\"2RB<A3LI(0S^U
MY.\U2U%I2J2JNLU%MU\WK\52+<90$4Y6]5(I4@X-!_I VS@R<0Q,E.+B2,D$
M]]E*3U&>/#<E_P#RS;$YFYI=$$R_X#<O&E#N9]\VMASI66;=-Y59JB4**W,4
M_/?VMMFY$422/Y5&1<7AV'Q'M4KTWM&=!+6K$ZF:J4J4>19Y$DC,\O#L+9EM
M&M-TO0E,4C7Z#?@*+CXUDJOP+9NPL(^^WY1,1%S1EM(4G+(E$9I,YD1EK(;K
MW%%9ZN4-9124-2U.T11L0JMM).I8C:1A(5XVC@J.2EPFWWD+-!FE1$LB-)Y)
MWS(?!IXU]%L:+N)]77J&3=.::R7JZN;Y[T7PMF?=&9#1I0K6X0O)1F[/G/9)
M2:CR=D+6622+/+NB^3F&>+=0-T0M3%VWG<$\&JL=4MZ6K_O166TK:;=WE:76
M$I2ZDC/)1*+N3//9WA%3<T=$8])&_P"OU2XZ4X_8MN0'V7GG$*2Q*ES8;K<5
M;2\LE&W*-*CU,]I'M+/;M"QF!=LKLQIRLU;8=RCBBXM-(%"/$;46<,VVW#PC
M2FG)&B(B7EN&VTHB4:#2I1$6;1VZ/I-FW:VVK-2K/XIFF%4?1YT.J.AU>7H\
MHYUYR,CWTOM91.0L%#H:)Y]!F@EI4A)G(A;_ '-/$>'AKI<8?SZF\ABG5=V7
M'DN.*)*"6IC>6B-1F61J4K9F?&-UR.^B0RT\V9&AYEI]!EQ*0\@EI,O"1D9;
M1H?:0^"][Z+>-]6M:HLRZ;(HM914;8K!-K0S)9*1PQMMMXB)LB0@D-J[K;Q&
M69#84T+]U=POO*S:3:.-E73:M[T>(Q".:\E;S522RA+;2]9M!-MZK22XS/6+
M,QU3="5)CJWMT%:%5.'<IJ!?HIF'C$P"3?>*'RC>@XM+39*4MO(>6R]DD:F5
M-I)9%,Y=\W(MIM%V=O5HLDK]%M5:I*'IV(BZ/52KB86'.+R&X6/H]<0\:6VG
MLN';B(8EJ2F(0XO(,U$4\U[SS4=I;S[B&FFTFI;CBB0A"2+,S4I1D1$1=\S'
M26\3+!=?3';N^@K?4X;26DU6 :U.$K5-!))[,U:W<Y%MSV#%5IO;I-@K;6$M
MPVWAM=B+CO>O1%18+$,G6C82ZDVW%[^1$E)DVLU%W1'LV;1KK:+5$Q"Q6TA<
M/[9I5:N.H2)]??J<QM-6J"FVD%**<M#I&^:$I).L1:V1&6PAK"I5A5)5AJW3
M%9:P1T15:$HUMYV'3&T>HUQ;4-#N/OO9+ST.III)I2TE9I-*U*5DF>08WA:7
MNIZ&JC7*KM2ZI47!UZI"F'H:'BW*-I=)-T?$1L8S#0L/E0\/%(??6E:GEMI6
MA3:4HROV[M[A*DK2E23)25$2DJ(\R-)EF1D??(R/,C%1QM'8<BTJEQ7,]>-3
M8#"\SS/?&8S;:\SXS/-.T^^.2&A%$25*(CF1*,B/61'(CZ\X]8MJ-:$J4G)4
M:4FI.I1D1F74<RZ@  &(S                 4RVY_\3^CB%0 )!E_UF8
M!^8
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M&>8S*T_2"LFIXLR\)(4N/*N"(E!K5%>3(;+69-XLUM:S:>YV;5"TND5I>1,
M*LU$J5EU"LTXTK5)J<<I!MQTH1K9F332R/P<9'LZ(7Z/>&-I87:<-STVTKF[
M/1)U/I+CL%4A<Y=+65)2M3IRUNO*5PI1FX1&HM7/5[PR.Z2L:,>#EZ25Q(3K
MS4)>HY(AL/K3K)61Y*<0H\^?9Q!I[-@N?9XZ.K7C19G1STUZ-I"UAMBAVC,I
M=#?-Q,>NRC?;CN*:(R=3^':;0G56DT?"VF)RG,BD39G)C$3NMO9F^V1.:O'O
M9Y]WEW]7B[XQ26',D43<]BKE%WFG59J145-SX4-MN0WG6G$J,C90E?P=AJUB
M(D\9Y"U54Q3N)5N:*S,>\B=J-98O553;CR$O.S514J-DI"&W34@VLLRUR[Q@
M>>[-V^(A'<4]1'VR(O[^\9I7*U267=X=JM+:>5\!ERH1D.JR+;DVIPEG^PA[
M&*K3)3RX\:HT^0^UM=98FQWGFR,LR-;3:U+1F6WNB+9M&NE>]NW/<N&N,V,D
MB_ZM'O&TJ]:D.UY+3TM#-%9J=5;AU!"HZ'4LR>$,J-)&M)ZO&0NAB!#N31PO
M?"B[["NJJU2MXDVW.<NR*ZY*D-U!QJCHWJ2U'>6XAC@N^*>,F4%K:NWPA+&V
MZ?XAE;/'7*7;/\<XSM-UFE.R."-U.FN2]I<%1/C+D;./\"EPW-GZ(\UU6FMR
M"BN5&GHDJSU8RYC")"LMIY,J63AY%M/))Y<?$,"\F@MV3H^V[I-6YB;*GXQG
M7W4RC*6Z\[66YE:**Y%313D+2R4*.M3*E$QD9$2N\>7<,,[6N#%O&+'W$.XK
M[J5*JUE6];;EJ125(*-1)=8HV4HW&4NI9>X6ZHCS=1DT9YEQ&$KIXT>_^@L_
MQVZIZL^PY?@,VS-8I4B1P5BJ4UZ269''9GQG9!&7_J4.&YL+/,C2.DXL_$:K
M?[#ZPA@SP%K%7PNQAPZ<Q:1+H%>KE6K:(][Q;@=N!F]6]_6EDG*+$?>:I?!F
MU(;+60G6,\SXC&9C2(NE-L8*W=<;1;[P6E-OLF99&:GFLV7<CXCS-*M4^(]@
M^\+#/1D3#PD.G+?B7FV&4SD2G'5DV@IGF(U*(C,\P_)'1T-1T%%TA%K\G"P,
M,]%Q*Y&9MLL-J==5+.>2A*CVRD.&IN,V&V&%E41-ZW53J.XXE\R94\VZ]L49
MGK-(4:T[#S+,AP!Z;VC66?\ ^46'L/+^;N=7]XU1;RO6Y+^K<^MW'6*A-?=F
MRB9;X7(:98:0\M*$I:2LFR[DB+8DO">T=0WE'Y<GTI[VAZZHO<TT3]"8.EZ?
MCU1ZFT*B$P+#"(9MPR(U-MF]EK62#/)RSR<J4R24Q_.>G=W!6(Z3BBJ[5"B$
MT2AU:8-=*1,4[&O,I41(>>*'-III3A%EFTC+R,J669E,;='\=_1J_M%B>CN=
M0?QW]&K^T6)Z.YU#47WE'Y<GTI_V@WE'Y<GTI_VAR&]JJM^_::_RX/X,3Z)<
M/OWZ_<5*KZ/\=(\W^/LQ(I[='\=_1J_M%B>CN=0?QW]&K^T6)Z.YU#47WE'Y
M<GTI_P!H-Y1^7)]*?]H-[55;]^TU_EP?P8GT2;]^OW%2J^C_ !TCS?X^S$BG
MMT?QW]&K^T6)Z.YU!_'?T:O[18GH[G4-1?>4?ER?2G_:#>4?ER?2G_:#>U56
M_?M-?Y<'\&)]$F_?K]Q4JOH_QTCS?X^S$BGMT?QW]&K^T6)Z.YU!_'?T:O[1
M8GH[G4-1?>4?ER?2G_:#>4?ER?2G_:#>U56_?M-?Y<'\&)]$F_?K]Q4JOH_Q
MTCS?X^S$BGM[4_3.T=*G(1%B8A05O.*2A)*;-M.LH\B(U+R(A(^AU^CW' 9J
M=$J$6HPGTDMM^,\VZDR/BSWM2M7Y#R&CV39%M2]+0?Y2);Z5%SD:5D>9>',9
M9=R]Q_NVB8IL8152JRJA;=QDKL<S)<<?5!.,RIU6JXX:UJ):S+/;L+,=+KUN
M?X:@: CZ;H*EXF+51C*HJ)@XYELE.0S<C>6R\R9$2FD3<R%(/*2E4E$<B/9M
ME.Z_CJV5NHFK%:ZN0%'MTY%-P$%2-%1#ZDLQK_V(9N)AXC+FT\YDM>5;=(VU
M*29I-,S+8W 4+B_ZXN]_<*CS"/=X            X^K?Y,J'ZG(^J4++X$_%
MV;^N2OKW!>BK?Y,J'ZG(^J4++X$_%V;^N2OKW  7X
M                    !'N_OZ3[%_2F_ND)!(^ G]%/T$(^W]_2?8OZ4W]T
MA()'P$_HI^@@ >0                                       (]7E_2
MU9/RS?JR$A"XB^0OH$>[R_I:LGY9OU9"0A<1?(7T  J
M                          #Y9W\RF?JLCZI8L1@;^(N#];=^N<%]YW\R
MF?JLCZI8L1@;^(N#];=^N< !($
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M+:;O256K1P@?,YFWP+4,K_OQFE5XUCS<3V ]^,TJO&L>;B>P,4 !YI+-.)=
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M7Q;,3,"W0%M-WI*K5HX0/F<S;X%J&5_WXS2J\:QYN)[ >_&:57C6/-Q/8&*
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M+XMF)F!;H"VF[TE5JT<('S.9M\"U#*_[\9I5>-8\W$]@/?C-*KQK'FXGL#%
M >:2S3B70/LA?%LQ,P+= 6TW>DJM6CA ^9S-O@6H97_?C-*KQK'FXGL![\9I
M5>-8\W$]@8H #S26:<2Z!]D+XMF)F!;H"VF[TE5JT<('S.9M\"U#*_[\9I5>
M-8\W$]@/?C-*KQK'FXGL#%  >:2S3B70/LA?%LQ,P+= 6TW>DJM6CA ^9S-O
M@6H97_?C-*KQK'FXGL![\9I5>-8\W$]@8H #S26:<2Z!]D+XMF)F!;H"VF[T
ME5JT<('S.9M\"U#*_P"_&:57C6/-Q/8#WXS2J\:QYN)[ Q0 'FDLTXET#[(7
MQ;,3,"W0%M-WI*K5HX0/F<S;X%J&5_WXS2J\:QYN)[ >_&:57C6/-Q/8&*
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MV!B@ /-)9IQ+H'V0OBV8F8%N@+:;O256K1P@?,YFWP+4,K_OQFE5XUCS<3V
M]^,TJO&L>;B>P,4 !YI+-.)= ^R%\6S$S MT!;3=Z2JU:.$#YG,V^!:AE?\
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M?9"^+9B9@6Z MIN])5:M'"!\SF;? M0RO^_&:57C6/-Q/8#WXS2J\:QYN)[
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MS.]/)U59-Q,^++\@8KP$.R.S0[CJ50)EJ^B%?T_: MT!;5,C*TNM1&4C(RI
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>D1"P\12+YO.-,' 0KAMI,Y$2<M:CD1$4SGGO'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>nt10002526x6_barchart4.jpg
<TEXT>
begin 644 nt10002526x6_barchart4.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( > %"@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
M    "08'" $"! 4* PO_Q !D$   !0," @0$#P@/!P,# 0D  0(#! 4&!P@1
M$B$)$Q0Q(D%18146&#(S-515<I&2D[+1TA<C<7.!@I2Q&31"1E-66(.5H;/"
MT]3P"B0V-U)BP25#X29$8W2D\1HHA*(XM,/_Q  = 0$!  (# 0$!
M     0(&! 4'" ,)_\0 7A$  @ "!08&# @+!@4"!04   $"$0,$(3%A!1)!
M47'P!A6!D;'1!Q,74E-BDI.4H<'3%!8B0E15TN$R-#9$5F-R@I6R\3-D<W2T
MPB,D0V:SHJ,E)C5%=3>$I,3B_]H # ,!  (1 Q$ /P#W\
M                                     QBU8:M,.Z-L35C,N;:\5OV1
M1":.=/ZAV2I'7.$TCA99(W%^&9%X)#)P^X_P'^H>9;_:>:LTK1'#L];II<O*
MO42E-,%OPO*DUR%&V,^[EUWC_J L*FTG<VE9BR;#1_K7P-K<QJUE/ MTMW-:
MKBC2<A+#L=ULR<-K[XP]LZC=9<N));^+?O%BM6G2OZ.=&62;2Q5F[("*#>=X
M3F:?2:8W"DS%G(?<:;:0ZJ.2B9XU/(X3<)/?YAYS>@2OJJZ)]4><M%U[H7#I
M]2LRV;KLV/)<-#2&V;9.XYZHR5;)/<C,U\!EW\^_81*=)5/J^K;+VI_6]):?
MDV1BK)&-:38D@R4N&VX5R1J-4^SK,NK1LZSLK;R>,#-0)Q2G\FRVRW.E+GGH
MF?I8V_<%,N:ATFX:2\<BF5J!%J,%XDF76QIC")#*^$^9;MN)/8^9;CMNM3Y%
M>(N:3+]9")JY<Y:DK7T)8JN_3!BMG+.1:G9UOM1*6[6X=$8BI*!":<><FS-H
MR2::,W-EF6_#MYQ$=/Z8?7!HTSCB:T]=&)J!$QQE^J%385PTB]*#6'*#)4\S
M'0Q(AT5QY[?M+Z&MW23N:=_*!BH7%=*>J:F]FLF-UM]*#C/1;F_ V$[RH+E4
MK.<Y\Z#1)2774%$7!6TE9FE"%I5OUI>N,OBW$GU.J#51I\">V1DW.@PYS:>_
M9$MA#Z$_D2LAXX>GTJ;-6UY=&/6F$MJB5JH5*JQ%F25[LU%JFRF=E&1['P/)
M\_(2O](7TIDW2=-PSIRP79L;*>I;+MOP(]L6JJK,T9NF=CID1QZ1*FRB[*C@
MCN]<2'C22N#A3ON!<VR"5\2>%S:)S$K2KNW+\*3+]8WCRYXBZ6;5YIQU)XMP
M7TA.,:5;%O9R??395^PKGI-4;B.L-H=7%=ATE2R2:7'FXQ*>X>(RW(N\>H&%
M,9GQ8LR.KCCS(K$R.X7<MB2VEYI1?A0M)@8M-7Z;GH>PY8  $
M
M
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MGVQ5-G0+U@=>AI#G'V64P243&%*,B,S:?XD;GMOL1D,GP,0
M
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ME)?D(B P;G+4L$N@^@  $
M
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MQ*4FBVM;[!1Z534N*=*,T7[DEKW4K\)GN*\ _,
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MMZ2R_&J%!F(=6PIB2Q)0V^1&ZVM*%*0DEDGB3R,MPD[Y6&8H  $
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MQXLIB;'CRXSB78\J.S*CNIYI<8D()QEQ)^,EH4E1>8QR (
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MTB9'Q55RFQ.-V/5::ZT['G4B;'=5'D1Y,:0E$ALD/H6A*EMI)9)-2=R&58$
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MAN3!,#'\Q%0MZG9%R:]>5'FM4ZC6G48KE-=:B&M*)!5.#$(C0TX9MFX7%S(
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M:MH4UE#,2W:%2Z4@D<B6Y"@L1G7=C,^;BVC6?=L9\N0K,#
M                                                  T/D1GYAJ
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MT2)Y)*)WJS;X4[;\BY[[]WD_KJ[&%<*Y;=9KJ62CIGFI9,D?%P;*/EQ>/O\
M/^$=/5LOY)KF5:[D2KUJ&DRGD^C@I:W5E!2)T4%)F.")QQ0*"*?;(;(8F[;4
M?DJQ1QTL5 HYTE&IQ0VS2<I2LD[U<["Y(  [@_4
M  -JE)0E2E*)*4I-2E*,B)*4ENI1F?(B(N9F?(B%E:KJ'PQ1JRY0JAD6VF*F
MRX3+T;T5@*ZAQ1[$E]12-FE;GM]\X3Y>8 7L =?3*K3:S#9J%*J$&IP7TDMF
M93Y3$R,ZD_&AZ.MQM6VY;[*/8^7F'/W(^XR &H#3<O*7QC7?;O   W(^X]QI
MN7E+XP!J ^3KS;)$IQQMLC,B(W'$MD>Y^(U&1'OXO/L/J1[\RYD?,C+Q@
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MNZM<<U372>0\,=Y%C_V,V_\ QZDZD?G517#/XS?W''7T8-\+7UJM2E;)S_\
M'3Y3:/D)DD1$?C+;8_'WB_'JGKY]RH^4U]D/5/7S[E1\IK[(O=IX%^$RCZ#'
M]H<<U372:/F3U='LQ+%.]&-?3Z22YJ2JB$ER_P!VI#T8U$7<;G5/HZP_.K?R
MC:UT85\,*-;>I.L+,^],BEOOM'MW<33LA2#V\Y"^_JGKY]RH^4U]D/5/7S[E
M1\IK[(=VG@9X3*/H,?VAQS5-=)Y&Q\OW8F-MS]%'7[NH=4H%R:BJU,HM5:X*
MA";A2XR'4)(]DI)J275IVW)1)+GOL8Z/'W1*2[(M"F6I96H*KT>V*2[)73:=
M'@RTHCN/O&X^K]L$:C<<,U*,R/F?CW&5BM3E\J2I)Q4;*2:3YM=QEL?[D<>'
MJ3O6"PF.U&0:$J4HN;1<U&:CY&GSAW:>!?A,H^@Q_:''55L^5277=K_9]:T;
M"RCG1CWV\CJUZDJHE'+<V:0\RZO;N-QUM]*W#+_N,_R#YM]&!>S2R6C4I6E*
M3W$[3I3K9_";7)-*OSB/R^(7Y]4]?/N5'RFOLAZIZ^?<J/E-?9#NT\#/"91]
M!C^T..:IKI/(UR^^S"R\L0[T8=\/F2G-2=80:>Y,>F2&&BW[]FFY"4%OYD\S
MY]XU9Z,6^HY&3>I*JK2K;<I-)?D[? ZV0K@/SIV/_P 7V]4]?/N5'RFOLAZI
MZ^?<J/E-?9#NT\#/"91]!C^T%EFJ:Z3R-D_OURQ+"GT7][*4:U:E:\:E=YE!
ME[?D+M1$1>0MMB(:?L7MZ?RE:]^@R_\ -"_?JGKY]RH^4U]D/5/7S[E1\IK[
M(G=IX&>$RAZ#']K;NK7'-4UTFCYCLNWY,2PG[%[>G\I6O?H,O_-!^Q>WI_*5
MKWZ#+_S0OWZIZ^?<J/E-?9#U3U\^Y4?*:^R'=IX&>$RAZ#']K;NK7'-4UTGD
M/#'1_MV%A/V+V]/Y2M>_09?^:#]B]O3^4K7OT&7_ )H7[]4]?/N5'RFOLAZI
MZ^?<J/E-?9#NT\#/"90]!C^UMW5KCFJ:Z3R'ACH_V["PG[%[>G\I6O?H,O\
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MW"I@        !2?[XO\ 7D%6"D_WQ?Z\@$=W*NE%6   4
M           -CGL;GP%?1,;QL<]C<^ KZ)@"F;=]DF_#_O"J12UN^R3?A_WA
M5(                              *9JWMS1/A/\ T14PIFK>W-$^$_\
M1%3 17O;[$   *           6.U%XA>SIBBX<:,W'(M4K@[*AZL1"<[0U'9
M>)QYILVEMN)Z]OB;-25$9;[D/-'TD&CBUNCOM'%6HS2[?%S6YF*BW71H,VER
MZ]6*V=^HK5;A0*@IJFSYCS3:8\=YU:N!E? 2M_!VW'INSMF['VGC&%S9:R=6
MFJ%9]K0ERI\UQ*EDITTJ*-'2A!*4I4ATB:+8O!-7$?(AYT\-7U0^DNU%4'55
MJ"O&B6AIQQC5Y+6#,:5*HP3]-+S[IPIDN<@GF)"5(EM-2F"F,F?A$3>W(#*&
M=_S5?CAC/U'I-LRX)LK'-JW)7VNR3Y%ETBN5A"E$HVW3HL>;-4HR(B+=1NJ-
M/)2?6GS(QY<,^:PK>UAZD,I6ADK.]:Q7I,P_-APY%$MJAU"M3,CKE$IN4E<N
MB_\ J-(*F2VE<2^+99&?<DAZ*LK9_P /61,MK#=1NAB#?&7+0N6!C2ALM+?.
MKH@41Y)-LN-<1-$VA;7":N2B,N?C'G[Z'ZSL!8SOW5CC#.%+I%(S/3*E4IUU
MIO-Q"(T^DU-ZHS8JJ<JJ\$-YQ-.<(R**:E)5L7)?"0"&YO2I2Y[7:G=K)C=,
M..-*64M)R<;X&NB=<F(ZO'=CN2EUFHJK:%&XHGSE+D25U2&M3IK-).J0>W)/
M(A"9TG>A/2UI+P.ZUC^7>SV<\B5ZF0\9TQN]+H=DON2JPRS5Y#+)SUDXB(W(
M-U230:>%.W(A>KH<T0J/K"Z0.KXL<J$?3#'FV[+L\Y7:CI2'8;4MZO+I)2O
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M?D/E#_,5'_541UF5_P 2C_;H_P"9&+H  ^-S4@
M                                                           R
M>TM?\95'X+7T%#&$9/:6_P#C*H_!:_LU#=.QU^6_!W_/+_QQ_><S)_X[5_\
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M    4G^^+_7D%6"D_P!\7^O(!'=RKI15@  %
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ME*2)*4I(B))$6Q$1%R(B+D1%R(AJ "<[P       "D_WQ?Z\@JP4G^^+_7D
MCNY5THJP  "@                         !L<]C<^ KZ)C>-CGL;GP%?1
M, 4S;OLDWX?]X52*6MWV2;\/^\*I     8/ZW=1&8\!8]75<)X>>R_>,NF52
M;&H[=412T1&Z;'6^\\Y)<0;>R&D&YLHRWX3+GXK/=%1K$R)K/TYQ<G9/MM-I
MW;Z*5>#4:.4EJ64-<&IOP^JZYHB0OJR:,MR[]O+N)"LDLM+Q_?2UM-K6BR[I
M)"E(2I:>*ASMR2HR,T[^,B[Q"ET!V_J4J[OON5]7OWGOW734N[S>0"V9KLMF
MK;<>30<?I+^DHU.Z4+M:@XWP"Y6L:4FX;;I5PY-<K<>.TENNU")#2IJGO-\3
MG"I]2#ZLU'N6_+<31ED*E4?%M/R1=$MFE4Q-G4^YJK(?<2E$<GZ.S4GD$I1I
M)2C-2T((CW4K8DD9F0APZ?!IM&CA+C;;:'%WU8?&XA"4N+VNNF[<2TD2E;<]
MMS/;Q#NNE_NRZ+3Z)^I3;2D2(58FV_B*EMS8ZEH<CMU#T'BN*4I.Q\!I<\,C
M,B4DC(^1@64Y:)N71UE+V]KUU;ZN[TB3-*6)F*7@:%77*>G*D^N06)-S-0IQ
MQ:D;- J1-S$)CN-NMI4VD^-)DM)F7,3KTLY?H93CGGO.[#$.:>Q%O*ZAOM![
M%R]EX^[EY!Y9*EH^U+X7T(6CG/'.I?T#NRPZ+ NJG4RGT2&U3G8\PV9U2A/.
M-/)BO.R&>L94MQ"E$M1GOQ[[S5='KJGJVI[1ECS/EUQ$TZL5.GUYBJ1W7$)7
M+DVJX]#?>;(R22CF.15.$E!'P]9W& :TJ4IRG;ZY^PK?6WJ^L_1WA6Y<DU]*
M*C6H].DKMFVFUJ.?79I-K2VF*RT2GUI:>-LW%(;42$F1JV+F,6>B2USY'UQX
M,J>1LGVH=G7#%J4ULJ*<AN2IF'Z(/LP5J6VE);N1DMK,C\).^RN9"(>Z-5F.
M]2^L[)>1-4C]VVKC+3]1KCIV$K+=M&NU2FW#-J]%FP:B](7&B$PXEF8A#[:Y
M2%I1OQ(,BV,4QT5NOO'V&-,NI.JT*G5RY;RHE5JAT"WH5%J;92>W5.HIIRVW
MFXKC22BH<9<4T1$9\/ 9D!<VR=L[-%ENC:2>]+3TL$O1+2:'9^'[:1D7*]5K
M5)@56F1975(MF-+J$9I;M0>X'&&3=C.K6V3YM\7#PIW,9,9SZ0:D:?-%]NZC
M+GI**M=MS4JAMT2SDR#;?J=<K9QHI,MNH09<,:7)22E$6QD7,B(>7'+V8<.S
M]#&?<Q97KERUC5SG.[[5FUZ)5[0K;#5KTVW+G0J"Q#G2(O8HYJI9)0KLZFC>
M-/A;J,91ZK,MV;F;3OT?=P4.7.D8\H\UJ->7HA F4^.B8F?3F(77(F(;)S>6
MC[VK;;?8R,!FVI2=]KY%LLG-(SCE=(9K=TOW)C+)&K/&)Q<&9=F1DRI+=0A+
M+',>INL-T+KCAH4[-.IG+8V)>QM;^$7,2>Y\ONNE5[:J%OU9R)3:U2XE4C=7
MS2Y'J$)J6R>Y&7[AU._CW/RF8P?Z<]5+5T:1,LKBE47JGB#T#(^K.2I!5FB[
M'%(_OBB)!H,^J\7?R%\[C;J+.-,&-5=2EU-%DT0Y*E^O-)T2%U1*WYELDR_4
M/+>S!34]7X&4]-5Z>FJ]+#7Z@E24-)'11RBI9-9\$4,23E:IVG5Y6;52BBA;
MA>? ODMIWJW7@[3A'D.^=S_^HW_DG]8T^Z'?7\8W_DF*. ?)/&^5OK7*7IM9
M]YO/9+5.W4OA:3RHNO#>;*N5?MZ+6AQ=P/FXWOU:N$_!W[]N?C\8W_=#OK^,
M;_R3%' '&^5OK7*7IM9]YO/9)VZE\+2>7%UE8_=#OK^,;_R3#[H=]?QC?^28
MHX XWRM]:Y2]-K/O-Y[).W4OA:3RHNO#>;*Q^Z'?7\8W_DF'W0[Z_C&_\DQ1
MP!QOE;ZUREZ;6?>;SV2=NI?"TGE1=>&\V5C]T.^OXQO_ "3#[H=]?QC?^28H
MX XWRM]:Y2]-K/O-Y[).W4OA:3RHNO#>;*Q^Z'?7\8W_ ))A]T.^OXQO_),4
M< <;Y6^M<I>FUGWF\]DG;J7PM)Y477AO-E8_=#OK^,;_ ,DP^Z'?7\8W_DF*
M. .-\K?6N4O3:S[S>>R3MU+X6D\J+KPWFRL?NAWU_&-_Y)A]T.^OXQO_ "3%
M' '&^5OK7*7IM9]YO/9)VZE\+2>5%UX;S96/W0[Z_C&_\DP^Z'?7\8W_ ))B
MC@#C?*WUKE+TVL^\WGLD[=2^%I/*BZ\-YLK'[H=]?QC?^28?=#OK^,;_ ,DQ
M1P!QOE;ZUREZ;6?>;SV2=NI?"TGE1=>&\V5B>0[YV_XB?/PB+N,N1GS+O_KV
M_+XA(Y@V5(FV%3)<MTWI+I.&ZZKO6?'XRW/;XQ%B?=^4OUD)1\!_\NZ1\%?T
MA[9V#J]7:UE[+-'6JY6JS!!DN"*&&GK%+30J)UJB6<H:2*))R;4TD[6IR<CN
M,C1QQ4]+G1Q1+M=T43:_"6O39>7J  'TX;(    %BM1V:6< 8=O3*[]).MM6
MC!.8JFD\;!RB))JX>M+FCN[Q?48&])+_ /X:YLY;_P#H:O%O^X4!5>MJ*XT-
MZIXNLS3C9NH"';IVK'NV56HR**<DY9QCH]2=IYJZ\R(U=:;7'L9<M]AEF<AH
MGDLFZR3BM]FS=03I[%SX6]^(]O'L1B'_ *"P]NC5PN9;%_ZM>I%L6W[Y9>_=
MYMQ:[*><<L4OI>\"XEI]W/1\<UV-<:JO;1-)-J8<:B]<P:G.+=/ [X9<N>P%
ME;%+1-\B)T5R&4.MLJ>92XYOPMK=0EQ>W?P-F?$K;Q[$8^$BHPXR75ORX;"&
M=NL6_*9:0UOW=<I:DDWOXN(RW\6X@9U@YXR[:72UZ$L46W>+],QY?*KZ*[+<
M2P2FJOV&F(<B<3I[&GJ5^$6V_P#4,<:LUJPU8=)SK TU4;-DZR<$64Q9Q2J=
M%@(?=)51I1R$*8>2XW(:X9'A> HN+EN8$2Q24I^N6^L].T.=%GM$_$E19;*C
MV2]#D-265?@=:4I&_P"7S#CS*Q38+K;,NHTV(XZ>S34R='C.N&1['U;;KB5+
M_ DC/XQYO]#65LZZ4]8.IO1[DC(,W+&.["MTJ_8%9G1RB2:8IJ@2Z[+:6DUO
M/O&\ZTEK=Q9DDMS(]MA;C2[8FH_I1Z?D#5A<V<JK85J0ZO<4'$UG0(9N-4!Z
MV9LVG27'GX[S)3$RWH:'32^E7!N:=N\"YN-EENVZR\]2;,EE]2TM/,.&@DF:
M6GD.*22NXU$@SV(_$9[;^(;I$AF,TIY]YEAI'-3C[J&6DEY5.+-*2_*9#S[]
M#%E+4-=68M86/<_9%>R'4L;5*V*?19[L-N$3$1WM"$$3+:E))2F6V]S[SY[[
MGN)/==9T,L"7$=S9@1AJA%V8ZC<R8W;99,]>7$S%AH<1(?6ZG=G9@E*2:B/;
MQ 1JV6SUF7T"KTVI&LH%1IL[@/9?89T>7P'W;+)A:^'GRY[#[/U")&)Y3\J(
MREDB-Q3TEII+1'XWC6HB;(_%Q;;^+<>0/"NJ*G8"Z033;CS3WG>[,LXHS<_7
MH]_6S<5LUJAHC/4J(11I$2=6T<3R7I"U/EV<S2G<B/=.PR$R!5]5^IGI3=0^
MF*T\RS;#P?2(-K+K$&/ ;E.LE/HI2T$RX3B'D&;QGN;:DD?>9^,"N''1.VS"
MZ_K/3Q"J$.H-==#EQ)C1[[.PY+4IGER,NL94M.Y?A\PXE2K=.IA&4RH4^&M3
M3RFD3)T:,XZIM!F1-MO.H4OF6Q\)'L/-AH\R+GK1SKMR[I!O?(<[*^+/0"7<
M-D2Z@R4610SI- E5VH(4I:WI#W:GF^#PG#)&_@\A1>FBWM0O2N7?E;4)7LSU
M7'N,[:K-5I.*;-@15.MT^12)<RF3GGI+#S*I"79$1+O"\2B3N1$1@,W&RQSP
M=UA)9I UV7SGO6[JZTY5R@(@6S@ERU4V_5D26GBJ::Y%6^\9(;+B1P&1%NHS
MWY&7E%W.DOU8W9H\TW3\NV=1BKE7BW';%)3"-Y#!&S6:Y%IKR^-:33][;?->
MVW/;8N9B&'H4[2ONP^D7Z0VT,D76N]KKHLBQ&95S+C)AJJ$<XCI1$JCH/9!L
M,$E!GSXC+??<9O\ ^T$KJ+?1[W>Y1D\=8.ZK(:IJ=R+AENW/"0P]N?@_>730
MO8_7;; )?*2_9]<B8VPKXAW+:%G5>;.ID:JW!;M'JK]/<J$5,I#U0IT>6XA+
M!N$ZOA4\9<D]VQBOG)#37#QNM(XR,R)QQ#9F1%N9I)1EOMXS+D1#S 7[H@UC
MTO2U;^IND:E:M3\Y6G:- N*'!13$E ]"85/BR7("F.T%"5UE,:ZCC-H]M^,M
MU$+/ZD>D(U/Y1T4Z-LR8JKSEG9'R76;DLRO(:0S(*4]2*TU;DNHJXN%LS+A=
MDDC;O/8C\8#-G*33]FD];,>H0Y/6]1+B2#9]D*/(:>ZO;OZSJUJZO;Q\6W]0
MXL:MTN7(5%C52ER9"#V7'C5"*_(2?D4PVXIPC\I&D>:/4G?F>NCTT^67C>@Y
M<GY!U#ZI5T5NC7Y+A%%*W26_$<K!,T]UQV.Z3<6<XT2MVS/@W(N>PIS5!I<U
M3Z'<%T_6-C#4W6+BR!:SUJU2^[=FTPRBW9'N67#*8PGM,AV-!*%'D/I2;:"Z
MPB(]B,!FW6JVZ^VX]1SDEEI24K=909D9\*W4(69$6YF25&1F22YJ/;D7?W#B
MPJM3Z@MQN'4*=,4T>SJ8<V/*6T?B)Q#*UF@_,K8>8O6)JAU,YFR]T;](T[Y!
M>QRQJ.I%VLWEP16IR4O46FQTSU<+II)1NN*?-)I]9Q>".'=UO:BNC6UN:8&(
M6::IDW&NHB;6V;_M&?$..B/,I\=KJG&9+[SRDH.2^MPDM<.VVVVVP!0STVNY
M;.C ]1$J7'AM*>DOQX[2/7O27FV&4_"<<4E)?E,8;:W=2-1T]:9<@9ELI%/N
M.JVJ[26X\6%4(K[:^W36XR^)UM3B$&25&9$KF>Q[=PB8U%9BU#ZWM>5SZ',1
M7[)P_C;$$*C3,K5J)';J$BX&[EI2*I364%Q-/Q38,U-<3+FZM]SV%0:L-)U4
MTJ='KJ8ILS)=1R+%KY6P=+:GMOH52ID:>GPR=DNNJ<Z^0M*S(O!21&G< DK)
MN]JS!XDM.D7/<K.6!,>Y+NCT/HM<NUF2X]3)-0C-O$IE9I)+*5K0IX^[<D(/
M8N_O&53LAIE!...LMI5MLIUU#:3W[ME+,B/?Q;'SY;#R"61I7U45?HX;)U'T
MG4/4[5R%8")M;M2A1J6@XE.IT>I&N1$=4V^EB4<R&SU>[K1]62N(CW%\,_:X
M\]7OT8& <^T>YW+2OVXKOIMNUZ:RTVZJ8FE79!HDITTIX4I[8VAPSV];QGN9
M[ '#C9G2V'J,>?:8;ZUQUEM'+PW74-M\^[PU&1<]RVY\]R'QE3XD-CM,F5$C
M,%L:GY4EIAA)'W;O.*2CGXCWV,0F=,GFO*>'^CKI^0<:78]:]YNOXD2NMLLD
MZLTU:H45NI> >Q?[PV^Z1^,N(8A]);GS+]#M?1)1:]>U?L#3GD"U5.YRR=0Z
M/-K4AF6JDP7*4Z["IR%S64NSG%)4M"DDE)FI1\) 1*<L9^JT]-\*?#J#770Y
M<.8T9\G8<EJ4T?\ .,J6G^L<P1Z='1;%DT+"D*3CO-'W9+3J;:'Z=674K:FQ
MB-9K<*5'?>=DLK4:N'@?X3+;;8^8D+ C        ([]4J25=T#??_P!SN_%I
M$B CQU1_\70/YS^S2/+^S!^0^4/\Q4?]71'697_$H_VZ/^9&+FQ>?XS^L-B\
M_P 9_6-0'QO):M]TN8U(TV+S_&?UAL7G^,_K&H!):M]TN8&FQ>?XS^L-B\_Q
MG]8U )+5ONES TV+S_&?UAL7G^,_K&H!):M]TN8&FQ>?XS^L-B\_QG]8U )+
M5ONES TV+S_&?UAL7G^,_K&H!):M]TN8&FQ>?XS^L-B\_P 9_6-0"2U;[I<P
M--B\_P 9_6&Q>?XS^L:@$EJWW2Y@:;%Y_C/ZQKM_K<P 22U( B+F7/F1^,_)
MY]QG_I1Y6E,V\2R_J6H8 EW_ )#_ %&,_P#2C_PG,_&%],QZKV&TOCO5;/S&
MO?R0'9Y)_'(?V(O]I0FN?6K3-&]A1[E])E3OVY:G'FR:);4!J62)B8"#<E&_
M-89=;BDVV1J(WC3Q%W#E]'[K%:UQ:<;9SVBT3L<Z])JL9VWE2SG*A*I<QR(O
M>09$:C4;:CVV(R/ER%]=0=*IM1P_DER=3J?.=C63<JHRYL*/+4PHZ-,,S9-]
MMPVC/O,T;<Q%QT"I;:!K9+8B(KTR&DB(B))%Z:Z@1$1;;$6W(BV[A]B&W69N
M,^F?4?+6ATP](TIYIH^*:5B*I7S'<K-,I%S7*X_+I4*B+JLAB-%6TMQ@F9G&
MI[F33A[&6QB8.7>M.IUC(OBHH<9@G;L6ONM-H6^M*)-/3.)E*6R4M9EQ=61D
M1[B"7IYJ53F,-8XG1Z=3V9C][6SU\QJ%&1+>VN.F\/62$MD\O;N+B6>VXG6L
MEII_'UEM/-H=:7:5KDMMU"5H41TB'NE2%D:5%Y2,C( Y24E*]/&4B(/3CTP$
M+/VL%[3!&P[/MNE2),Z/0KUJ$R0R[5CIS+KDE14N0RTXT23;))&HME$?$7+8
M37K6LD.*0CB4A+AI3OMQ*01\);^+B/E^7<>;^YH$*G=.)C9B!!AP6.S5=1-0
MXC,5OB50>(U&EAMM)FH]S,]MS,]SYF8](2.Y7PU_K L22E+2DR)C,FLS778^
M2[GM7'NAAR_[.HR2=I=Y>GJ)3D52.AI3LETXCA;L$PE)[\1EO^0=3T?O2:WK
MK'R+G3'-YX)<Q54<%M07+@F-5XJY$DG,8=>4B.^TGJ'5-=4I!I96I7%R,M^0
MO5TF>JV-I/TPWE=]-4S(OFX6XUKVC1D)2<^>_<3Z:.X]&025.+[)VLG5*21\
M.R3W+O%(]%3I.D::-,]$=O2(E_+&1E2[GONNO;'+J;%:E+JU*8D'X2C3%C3$
MM$E2E;I+8TEML LS9RMN5_+I+!1^F/I=0UI8_P!*])P[5%V]D"=6(%-R-/?E
MTY*G:,VHY/54Z2PVITB=2;>Y&HNY1<C$A&L75WC_ $>8<J65KZ6E]+2X,6C4
M-!K.76*A4GVXL2*PAI*W><EUM"UI09()6ZN6XBEZ1BETVF=)QT:_H=3:? )V
M3D53IP84>*;JNQ(/B>4PV@W#W\:^(]S,4[TS[2*WJ%T#V?7))M637:[7G;@8
M=W5"?>@K@O4\I#9_>EFE\D\'&1['S( DFX=">,[I],B\UG=+#E"T<I8MM75M
MIR>P-8N;EOJQO>Z[@36V)D=M"%QW9;$=O_<CE$\P2$R5(5NYLGB,C(3CQ);$
MV/'EQED['E1V94=PO6N,2&TNM.)\RT*2HOPCS[=//2:9'T66/5J?%CKK] N#
M&S-MR$=6U+C,KK=&:<*&X1$ZTE;*22I+1I(T\CY"<[$STU_%^.7I[?53'+'M
M94A._$9+.AP3W4K<^:M]SWY[F8$<I)RE>N:767#   A\9'L#WXM?ZC'26O[4
M,_C7_P"T,=W(]@>_%K_48Z2U_:AG\:__ &A@32MCZ45"  !0
M             .MJW[0?^"./;_M5'_/^D8Y%6_:#_P $<>W_ &JC_G_2,#'Y
M_P"[[3N@  ,@               I/]\7^O(*L%)_OB_UY ([N5=**L   H
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MH*]F,D'NEGQ[$7EV$KI))/=YB[BWY>?Q^;R#51<1;?K+<"3MGL]5W0>:B_\
M)72=W)@B#HT@Z9I4:\ZA1*);$S-!713SB1J2VQ'C3W?0GJR;4I,#K&]NMYD7
M=Q#YYIZ,?,5B8,T585Q33CO9C$=;J]=O:HDMJ&3$RX*K'J\XNK<4?'U;ZGT[
MI/A,T;D6VV_I4[,UUO6]6UUG\+U:.N^<VXOZQ]]B\WY>?X0+G2N26DAWZ4'0
MK?&J3"N.+@Q;+[#FW"C%%J5FLFEM12WF#@NU:!UCJTM([0W$4QQJ(^'CXDEN
M1#"#.%=Z137AB&E:2*AIC=PE3YC]LP<B9,<N2#5T1(ELR8BDO-P#2@W?19F*
MO<FE'U76^8AZ9S(C[_\ 7^OB/QCXHCM-K6M#;2%+V-2FVT(6O;NXU)(C5MXM
MSY 1.4M,K5.=GK()LE:&\FV_JPZ.*?CBVSJ&*M.U+NZ/>E<[2VWV*96:4PR;
MILK/K5]IF(<49)WVXO,+B=)/ICS1F[4+HXO7&=MG6:#C&KU^3=\PI#;)4UF8
M<;J%&A9DISC)M7K>[;SB9LR(S(^7+S%O\?B RWV[N7E+?XO( 3E)ZOOZSSJZ
MC=,^K/2MK?E:Z],=B+S32,ETJCQLPXR;J,6B.J50Z.U3*<I-1D<2E=4KC=^\
MH,CX2(R,A>3+EQ:KM=>C#.=G5[36]B6YIK]LJLND.W#'JB[@-FH(=J9&X2&R
M8.(2.]1%Q^+D)PUMI<2:5)2HC[TK22DG\)*MR,;6F6V4=6VVTVG_ *6VTH1W
M_P#2DB+^KO 3NL4U*W9RD5U@Z?,J4CHVT8/J%!-K(Y6S4H'H-U[9F4E]3IM(
MZ[?@Y[D>^_+?81[U[HXM0-X]$%9^ VZ4="S[8-U5"ZJ51#>CNIDH9O ZZB*;
MYJ)E*I49E!$H]]B<,^].Q^E[;EMR^+E\0TX?!X?-MRY%\1?J[@$WZY\IY,]7
M%$Z2W7_I%HN!G],+F,IUI5:QH=Q2G+DI]0*X8ELU:GEVYMHTHZG>/!-]24;G
MNO8^?,2C:B;WSOAG"N*<7T;2/ U T&;8[5O76N=5H,<Z'-:HK$%KJFY++RB4
MN3OLMG8TF1*(^0F!1';;XN!#:.(]SX&T()7/]T22+B/\/<8U>8;?227&VG"+
MF276T.)^)1&1;>+8!.ZQ24[-N-^@@]Z&S2%F;3C S1>>3J!,Q[2,KU*%4K5Q
M+)JIUEFR6F9$AV0AB<:U)6F9UR7.$D()LO!(MBV$Y!#:E))+8MB(N6Q%L7+N
MV(N1;%RY#< ;FY@  "    !'CJC)9W= X6GG/9/8VEN$7WM)<^$CV$APM\[0
MJ35[BJ)U&$S*4T31(-U"5</$CF9;I/;N^/F-3X:<'*3A5D"LY'HJS!5(Z>DJ
M](J:DHW20PJAIH*1K-ABA?RE#).=DYG%KM7=:H'0J+-<44+44IRS7.Z:G8M9
M$GU;ON:7^BN_9#JW?<\O]%=^H3 >D:UO>>)\TW]D/2-:WO/$^:1]D>)]P:O_
M %_5?0Z7WN_(SI^(X_#P^0^O;O?#_P!6[[GE_HKOU!U;ON>7^BN_4)@/2-:W
MO/$^:1]D/2-:WO/$^:1]D.X-7_K^J^A4OO<=Y,<1Q^'A\A]>W=6P_P#5N^YY
M?Z*[]0=6[[GE_HKOU"8#TC6M[SQ/FD?9#TC6M[SQ/FD?9#N#5_Z_JOH5+[W'
M>3'$<?AX?(?7MW5L/_5N^YY?Z*[]0=6[[GE_HKOU"8#TC6M[SQ/FD?9#TC6M
M[SQ/FD?9#N#5_P"OZKZ%2^]QWDQQ''X>'R'U[=U;#_U;ON>7^BN_4'5N^YY?
MZ*[]0F ](UK>\\3YI'V0](UK>\\3YI'V0[@U?^OZKZ%2^]QWDQQ''X>'R'U[
M=U;#_P!6[[GE_HKOU!U;ON>7^BN_4)@/2-:WO/$^:1]D/2-:WO/$^:1]D.X-
M7_K^J^A4OO<=Y,<1Q^'A\A]>W=6P_P#5N^YY?Z*[]0=6[[GE_HKOU"8#TC6M
M[SQ/FD?9#TC6M[SQ/FD?9#N#5_Z_JOH5+[W'>3'$<?AX?(?7MW5L/_5N^YY?
MZ*[]0=6[[GE_HKOU"8#TC6M[SQ/FD?9#TC6M[SQ/FD?9#N#5_P"OZKZ%2^]Q
MWDQQ''X>'R'U[=U;#_U;ON>7^BN_4'5N^YY7Z,[_ %EMR_*)@/2-:WO/$^:1
M]D4Y3++ME=8J[:J1%X6^IX"ZI&Q;ESV\'Q_5S#N"U_\ 2"J\M2I</UVK>R1.
M(X_I$'D/KV[JV*,FW>?^[2_6J_\ MG?(?_;^H9^Z4DJ3:<OB;<0?&1[.-J;/
MFM7<2R(QD%Z1K5]YXGS2/LCNZ;2*=2&C9IT5J*V?>AI))+XDD0VW@3V*JUP4
MR]0Y8I<K4%;@HZO6*%T$%6I*.)NFAA2BSXJ2)+-E=*WD.74\EQ56G5*Z6&)*
M%J2A:<W+3/ I'*5OS[IQW>]N4PMZA7+9K-+A%N1;R9M-DQF>:N1??'$ES&"/
M15Z9LC:4]*=%Q/DYM+5T0KEN^INI2MI9=FK%>ESXGA,F:.;#J.6_(27#0BV\
MI_A'M9W&&^GK(G>E5TF92U68RLNV,8,I=J5%N:C5.82G&4;1H59A37C^^J))
M_>F5=QF?X1)]:U-DTJU+9I,DO]ZIE H=/DEN7)^#3X\=\N_;V1M7=^05(9;^
M7\A[#4 0Y7)HXRW4>D]LO5"PRG[FU%9G-3'>L9XB5(I)1&_ WZWV7R%L7C/8
M=EJSU(YVCZWM+NG/!%5ETN@7/(N1[+TWT,*1%CQXD=$NG(7*>;ZMLG$<22-#
MA'S,N\A+UL7^C/\ 5W"D/2':AW.5X*HD)5Q$6R*LMEI4ILN#@/JW5(-Q&Z?!
M/A46Y 6>O5)$2.HK1MF75+KGPI=^2&"<TVX1.;)325.,*C7=4)T%H^NDLH5U
MB%0ZBT3B#=0OGZWD0F4BPV8<6/#C-DU'BQV8D=M/K6X\="6F4)+Q$EM"2(O,
M.3L6^_/Q^,]N?F[AJ G.6!$SK,TE93S/K9T79MM!I*[-PL]>"[P6:V4F@JQ&
M0U$V)9DM6ZB/V,C\6XJKI,M$56U>8?I)V'4_2_F/'4J%5L?UTFTO+8?CRH\N
M="2A:DMD4],?LQK69$CCXNX2=[<]^?Q\@,B46Q_U'L F[,+CS;5/2[KRUV7I
MA*S]5]AHP_AO#SS:;ECM52GUHLF+IO9SI,YQ,127("F7X;<C;PC4:R2H^0]'
M%(IK5'IE-I4?E&I=.A4V.GR,P8[<9K_^QM/_ )'8<);D>Y\O.8W &YZ$M@
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MCIZ.C<XE-Q+-B=EBN=YV63*[3UJECAI7 U#!-2ADYMI:WH1>H  >ZG=@
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M7>3.Q   @               4S2_;NM?S'T$BIA3-+]NZU_,?02 *F
M                       ?&1[ ]^+7^HQTEK^U#/XU_P#M#'=R/8'OQ:_U
M&.DM?VH9_&O_ -H8$TK8^E%0@  4                         #K:M^T'
M_@CCV_[51_S_ *1CD5;]H/\ P1Q[?]JH_P"?](P,?G_N^T[H  #(
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MCBT(L\L1T2:VS!M:0MV@H54D]C635-?4AU*=B>0M1K[MU&8[_I;*'9EDZO\
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M1[ ]^+7^HQTEK^U#/XU_^T,=W(]@>_%K_48Z2U_:AG\:_P#VA@32MCZ45"
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M=OV.'[DC?,-?9#L</W)&^8:^R.2*?G73;E,?5&J-Q6_3Y"?71YU8@Q'T[_\
M4R^^A:=_.D,R#O(?)75@N826K?=+F.#58L4JS12*-&(E&_N74-\_!^#_ .!4
MO8X?N2-\PU]D4I(J4"IU&B2Z=.A5"-O(,I$"4S,CF24\S)YA2V]B\9\1[>/N
M':MW1;SLST.:N"@NU'?8Z>W5X*YQ&7>794OF_OMS,C06P9D'>0^2NHB2ML5_
ML3.V['#]R1OF&OLAV.'[DC?,-?9"5+CPV%29+[$9A!<2WY+R&&$)[^);KBDH
M06WC4HAP*;7Z+6#<]":Q2*L31[.^AE1B3S:/NV<*,Z[P<^7A;=P9D'>0^2NK
M!<Q9+5ONES'*<8@-[$IF"@S_ (1ME._X"-);C9U=._@Z=\ECZAA[J@N6OT.H
M6\BD5-R"A[M/6DW^[X2+;?8RWV_*8Q5^Z'>_\8Y/R1X[PD[+63>#F6J[D:ER
M-6JQ25.*CABIJ..K0P1]LH:.E3AAC6<I*-*W4=36,JT=7IHZ%T,43@E:G#)S
M2=D[ON6HELZNG?P=.^2Q]0=73OX.G?)8^H1)_=#O?^,<GY(?=#O?^,<GY(Z/
MNZY)^H*]YVJ=6"YC\..Z+P$?/#AU=&JV6SJZ=_!T[Y+'U!U=._@Z=\ECZA$G
M]T.]_P",<GY(?=#O?^,<GY(=W7)/U!7O.U3JP7,..Z+P$?/#AU=&JV6SJZ=_
M!T[Y+'U!U=._@Z=\ECZA$G]T.]_XQR?DA]T.]_XQR?DAW=<D_4%>\[5.K!<P
MX[HO 1\\.'5T:K9;.KIW\'3ODL?4'5T[^#IWR6/J$2?W0[W_ (QR?DA]T.]_
MXQR?DAW=<D_4%>\[5.K!<PX[HO 1\\.'5T:K9;.KIW\'3ODL?4'5T[^#IWR6
M/J$2?W0[W_C')^2'W0[W_C')^2'=UR3]05[SM4ZL%S#CNB\!'SPX=71JMELZ
MNG?P=.^2Q]0=73OX.G?)8^H1)_=#O?\ C')^2'W0[W_C')^2'=UR3]05[SM4
MZL%S#CNB\!'SPX=71JMEI6BF\"]T4[UBNY,??UI^8=/:Y()$K@X.'K#VZO;A
M]<?=MR^(16GD.^-N5Q2#\(BYEMR,RW+O[O\ 6_B$C>#94B=85,ERW3?E/$X;
MKRM]UGQ]Y\S&Z\".R+4>&5>KE2JN3*>HQU2JPUF*DIHZ&)1P.EAHLU*BM33B
M3MLDCEU/*$%;I(H(:.*!PP9TW*3M2E9SK"S;>,  >EG9        #?;O&QQQ
M#2%N.*2A#:%.+4HR2E"$%Q+6I1\DI2DC,S/8B(A%+J"Z6W3CAZ]ZEBVVY%1R
M7D:CJ)-5H=OTNI3H,-1EQDE=6@,289JX=_!ZSDHC3W\@"3=Q*[OOW ,(-&NM
M6TM7E-N9VA6[6+9JMIG%*KTVJ0)\4F^UFHFNI=F,,D_W<^JXMO&,W.,N$U;'
ML7F/?X@!O 8(:V];UOZ-*#9U=KMN+N!J[:O$I+#:)*F#87+G1X25F:4*XN%3
MY*,N7<,V:+56ZQ1Z15D(-":M2Z?4T-EX1H1/BMR4H/Q^"3A%N??L Q.V ;>(
MM^'8]_P'L?X# U$1D6RN?F/;XP!N#;Q^,:$>YF7/EYCV_(?C SV+?G^0MS^(
M@!J&Q%W%L-IJ(MMR/GYCY?A\@&HD]Y'^0C, :[%Y"^(:C3?GMS\W+O&AJV/;
M8S/EOL1[%OY3_K_  -=B[MBV#8O(7Q"-Z!TAUL3M=-6T3IM5Q-?I33+J[A[4
MHT+)ZG]N+_=^#A+9/@^O/O(Q) E1*(S\AF7E[CV 2ERVF[8C[RW#;?O&TE$>
M^V_+S'S_  >4.,MN+96Q?]I[@#=L1=Q; -IJ(BW_ %<S^(#41$9GR(DFH]RV
MV(N9[_Z_\ #< M_;.3K(NZYKFM&WJ_$J=P6B<<KAIL=:%NTPY1;QR?)*C-'6
MEZWB(MQ7^^^_?R\WZO* -0&A'N9EL?+RD>Q_@/QC0E$9F6RN7?X)@#< V$LC
M[B5\1_\ [QN(R46Y;_E+8 :@          "WSM>I-(N*H)J,UF*ITFC03JDI
MXN%!;D6YEY1<$1XZHS65WP#2ZZW[)[&ZMO?9!'SX%%OW^,:GPUX1TO!7(%9R
MS0U:"MQT%)5Z-4-)2.BAB[=304;;CAAB:S<Z:LMD<2NUAU6@=,H<]PQ0K-G*
M><Y7R>LSA]/-K>_$3YUO[0>GFU??>)\ZW]H0_P#6.^Z)?Z4[]H.L=]T2_P!*
M=^L>(]WK*'Z/57TZEP_4[VZ[>GX\C^CP><?V27[T[VKOOZ,1=_QK?X/^H;O3
MS:WOQ$^=1]H0_P#6.^Z)?Z4[]8=8[[HE_I3OUAW>LH?H]5?3J7#]3O)Z[7'E
M)]'@\X_LDP'IYM;WXB?.H^T'IYM;WXB?.H^T(?\ K'?=$O\ 2G?K#K'?=$O]
M*=^L.[UE#]'JKZ=2X?J=Y/7:X\I/H\'G']DF ]/-K>_$3YU'V@]/-K>_$3YU
M'VA#_P!8[[HE_I3OUAUCONB7^E._6'=ZRA^CU5].I</U.\GKM<>4GT>#SC^R
M3 >GFUO?B)\ZC[0>GFUO?B)\ZC[0A_ZQWW1+_2G?K#K'?=$O]*=^L.[UE#]'
MJKZ=2X?J=Y/7:X\I/H\'G']DF ]/-K>_$3YU'VAVE,N"CUA3B*;.9E*:VZPF
MEI4:=^[?8S[Q#7UCONB7^E._:&7>DU:U5:X]W7EE_NO)QU;GB/N)2CV[QL?!
M/LOUSA'P@R=D:ER-5ZK!7:2D@BIH*W24D4"@H8Z2:@=%"G; DYQ*4V[=/)JN
M5HZQ3T="Z&&%1S4U&W*2GJ4YRY,3/(-R/N/<6%U!:D<2Z9;&FY R[<S5NT&(
MG[V26ES*A.=4? VU"IT?BERC-PTI5U+2^$E$:MB&.6DG773=5\V\9-KV#6*+
M:=OL]HI5P5-B;"776NK<<)3<.;'9=:W)"2+D?KB[^0]W1W4G?H)!MR\I?&-=
MR/N/<0L9$Z6A^Q;YN>S_ +@EQ5)-N..DY4VRJ!,2&F26IUY*BAF@DH;0:SV4
M9;>/89"Z >D:QMKS1D-NQJ-*HT[&[\*-7H[Z)/5I>F+<0E#;[S3:'30IM1*Z
MLU;&7A;'R LG*<K"2(4S2O;NM?S'T2%K-0NHW&&F7'=6R9E2JS*7;=*C.ONN
M0J;+J<APTI5P(1&AMNO'Q+(DFI*?!(]S[AC'H'U\XGUV4B]KRQ9'DL4V@RVH
MTCM3,F.^Z1O.,M+6Q*0VZWQ=69[&@N_R 23OT:217<B[SV 1F:L^DJQGITOF
M%B*WJ-*R9F"6T])<LFEHE<<&+%9*5(<F3([+S48RBDIYM+W";IIX4;F8NGH]
MUW8;U?V-7KGLNH+IU9LMIUR^[8G,2(LVUS8ZWC[2B4AMTT;,N*)9H22B21ER
M,C LG*<K#-_<O*7QC40D9)Z:G"UIW?7V[5M2K7OC&R:G&I=]9)@1*EV*AORI
M)1&S99:BN)GI3)XVW3869-$DS7MSVEMQ)EBR,V6!;V2<>5EFO6I<D5,BG5%C
M?@</A+K6E%WI6RL^K61\R46Q\P$FM&]Y<H  "                  !\9'L
M#WXM?ZC'26O[4,_C7_[0QW<CV![\6O\ 48Z2U_:AG\:__:&!-*V/I14(  %
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M,I*5*1_NBY*V=T[\1I,^6X$>FZUV;+;<+]MY(*7<7X"&H !B
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MQM18S3#2N+?BXD-I2E7%OX6Y<^>^XY@T,R(C,S(B(C,S,]B(B[S,_$1>,_$
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M1%N8[H_8VI:0E:EI0A*E>N-*$I4KR<2BYJV\^_F%L\JX=Q_FFW/2GD:AIK]
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M6O[4,_C7_P"T,=W(]@>_%K_48Z2U_:AG\:__ &A@32MCZ45"  !0
M                 .MJW[0?^"./;_M5'_/^D8Y%6_:#_P $<>W_ &JC_G_2
M,#'Y_P"[[3N@  ,@               I/]\7^O(*L%)_OB_UY ([N5=**L
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M3\E/U  26K?=+F!H>VW<GUR3]:7E_ )1\!_\NZ1\%?TA%P?=^4OUD)1\!_\
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M:_U&.DM?VH9_&O\ ]H8[N1[ ]^+7^HQTEK^U#/XU_P#M# FE;'THJ$  "@
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MWO?.<JY:=2+GIE<MN[I5*6<FGPJ;<35<8IJFU.+>>2AAEN$A:U\DIXN7<)I
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M!Z%50M__ $V=W'_]J\7B^!_K\(F.]!J3[VP?T5G[ >@U)][8/Z*S]@7N"?\
M<;_AZP_O.]N XC7TA^1__HQETK1I$>U9J9##T=1N(,DNMJ;,]EJ/N41;_4,:
M]3.BW4EE#*C^2,'ZKIF%DS6NIG40K;17&'D=GZCP3>=X&SX>)6Z4%S,2<,18
MT9/#&8982?[EEM#:3_(@B(<@>X<&LC/@_D/)V1W3_"?@% J'M^9VOMDFXL[,
MSHLV^4LYW7G<U:B^#T-'1)YV9"H9R2G+"V1&+HGZ-^V-*]W7YEVZKO=RKG?)
M/9EW9D>='=BNR78:%MQE1H*W'&HA-MKX#)CA)1%S(6UU!=&GD[4WDRK3,O:E
MZO5<#U"9$E-8>IM-D4A3:(JTNFPNN0)#,A:'7$[K3X25$9I41D9D)A-B+N+8
M-B/O+<=Z?O-SGI(9ND#T_P!Y6]H\MS2GI+M.10(M9K-MH1,H\I<9^CP*5684
MJI+6\E2''%S6$.FXLW"4K?F9GR%/ZQNB7JVL*S=/]LNYPJ]@T3$-&B.O4,H<
MBHMUBKO1(KCSL]1R"*23$]I3B4R"<+Q;%N8FT<8:=-)N-MK-'-)N-H6:?@FH
MCX?R#Z;%MS(MB_!L0";Z7SD0^GSH_M3.'\DVG=%RZOW+TLFVXKD!VPVK*BTJ
M#.A*C%$:8XF7.K;X6B(EJ)O=9[J/<S%.Y=Z+&[CSA>&==*&?'].=T9):;9R+
M&CT,ZY"N%IN,J*GJXKKA1H2NJ6Z9K9;29J5Q'X1;B9K8B[B(:[>/Q@)O#F71
M(CATI]'#B?3GC7(EJ55TK_N_,$5YG*=Z5!"R>NIU:7R9>5'>4YV?LIOK-HD+
M\'EP[;;#!0^A/NEBD3L-4_4U4H>DF=<":\[@XJ,^I9.>BGHNM@KAZ_MA-KF[
MJ-!*X> ^KVX>0]!(TV+R%\0%SGKO*"QGC>U<461;U@V936:3;MN0&(5/A,$2
M6T$TTAM;A[=ZGE)ZQ9GS-1F9\QW%+]NZU_,?02*F%,TOV[K7\Q]!(&)4P
M                         #XR/8'OQ:_U&.DM?VH9_&O_ -H8[N1[ ]^+
M7^HQTEK^U#/XU_\ M# FE;'THJ$  "@                         =;5O
MV@_\$<>W_:J/^?\ 2,<BK?M!_P""./;_ +51_P _Z1@8_/\ W?:=T  !D
M            %)_OB_UY!5@I/]\7^O(!'=RKI15@  %
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M_P"T,=W(]@>_%K_48Z2U_:AG\:__ &A@32MCZ45"  !0
M         .MJW[0?^"./;_M5'_/^D8Y%6_:#_P $<>W_ &JC_G_2,#'Y_P"[
M[3N@  ,@               I/]\7^O(*L%)_OB_UY ([N5=**L   H
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MJ%-VI6*_5VF2:M3T%-2.EHW!"Z.QMJUS5EC>ASV%T0 !]"G?@
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M[4,_C7_[0QW<CV![\6O]1CI+7]J&?QK_ /:&!-*V/I14(  %
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M<5+H-2I\MR"^TZIQ+:S2J0TX25\)$HBW+<N9XU)(MEGQO<WGO_><+_W%>?\
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MQ-D1ES+<:5VXJ';-/>JM?JU/H]/82:G9E0EQXC""+?O<D.-H/NV(M]S/D7,
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M2.N^\\1))6QF),R/<MP)=8S44S2_;NM?S'T$BIA3-+]NZU_,?02 *F
M                       ?&1[ ]^+7^HQTEK^U#/XU_P#M#'=R/8'OQ:_U
M&.DM?VH9_&O_ -H8$TK8^E%0@  4                         #K:M^T'
M_@CCV_[51_S_ *1CD5;]H/\ P1Q[?]JH_P"?](P,?G_N^T[H  #(
M       *3_?%_KR"K!2?[XO]>0".[E72BK   *
M    &QSV-SX"OHF-XV.>QN? 5]$P!3-N^R3?A_WA5(I:W?9)OP_[PJD
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MC29DHD[EMXK0I,MEEP/<GGO_ &7#_P#<5YOU_P#[OE[L\/\ ^-9$_P#QU/\
MZA&L9=<Z>B?B/_::@'YKWS#GV0_->^8<^R/")K7ONUSG1S6O?=KG !^:]\PY
M]D/S7OF'/LA-:]]VN<36O?=KG !^:]\PY]D/S7OF'/LA-:]]VN<36O?=KG-#
M[ORE^LA*/@/_ )=TCX*_I"+@S(B+=+WKDE["X7>HO*G^OQ"4? ?_ "ZI!_\
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M;:.DZJ^E[*=?91"AU\DQG%08;KG53D):DFE!F_$6XV2R42D&>Y<]Q]:=@_\
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M:5Q*:PXNDT_T/HDM,^8OA24%2NU$AI/A\'"H]S MDLV:NOT3;3U:D6<PHF?
MZ=+4JU0&>JI<Z-:QW+V0R0T:T4 SC]I;:V3OQ]QN%ON9GWCTCM>M/X:_I&(D
M^CIT/9&PU>66-3.HFX$W-G[.C]/D7&TXPV@[=:I1N-P8C3C"E1W.&*M+)K;+
MF2#,]S,2X$1$6Q 8N_D7J2-13-+]NZU_,?02*F%,TOV[K7\Q]!($*F
M                       ?&1[ ]^+7^HQTEK^U#/XU_P#M#'=R/8'OQ:_U
M&.DM?VH9_&O_ -H8$TK8^E%0@  4                         #K:M^T'
M_@CCV_[51_S_ *1CD5;]H/\ P1Q[?]JH_P"?](P,?G_N^T[H  #(
M       *3_?%_KR"K!2?[XO]>0".[E72BK   *
M    &QSV-SX"OHF-XV.>QN? 5]$P!3-N^R3?A_WA5(I:W?9)OP_[PJD
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M@#[$DB,S+?GYSV&JDDHMCW_(>PUW_J[P #;EL/GU22/?=7RE;?%OL/IOOW
M-O"1J)7/<O.>WQ#4R(S(^?+SGM\0U  ?,VTF>^ZM_,HR+XNX;B01$9<^??S/
M?XQN  ;>$C(DGW%L?Y2/<8[GI6PJ>;RU#G:Q?=5)' 5P]J=WX>H[-MV?V/V'
MP.X9%  /FAM+>_#OS,SYF9\S,S/O_"-5(2KOW+\!F7Q[#>  VI022,BWY^4S
M,_C[QJ1$1;%O^4SW^,:@ -J4DGNWY^4]PX2W,^>Y^<_]?ZY#<  ^9-)(]_"/
M\*C,OBW'T       6NJ5FV[<]QSEUJG(F*C]7U2EGR3Q)+BV+;Q_K/O+N.Z(
MPNSIDVZ[$NMEJWI79T2R/KRZM*R5P(+A]=OMMW\B\@UOA7E?).0\C4^4<M56
M*MU"BI*&&DH(:"CK+BBI*6&"C:HJ5PP19L<2<V[)35J./6J6BH*)TE-"XH%%
M#8DHIMN2L=AD-]R&P/>%CY1A]R&P/>%CY1C!'U1V3_?5'S#7U!ZH[)_OJCYA
MGZAY/W4>QI^C]+H_^T5'Q?UF.\V=7QGD[P$7FH,,</5BS.[[D-@>\+'RC#[D
M-@>\+'RC&"/JCLG^^J/F&?J#U1V3_?5'S#/U!W4>QI9_\OTFC_[14?%_68[S
M8XSR=X"+S4&&.'JQ9('1L=VC;\U%1I5):BRT;\+J3,S+<N$_C+D*T4DE%L>_
MY#,OU",CU1V3_?5'S#/U!ZH[)_OJCYAGZASZKV9> U3H^U53)^4*K1.+/='0
M5"KT4#BB4"<3A@IX4XFI3<IN1^D.5ZE LV&"DA6J&CA2T3L42^^SDDTZE/E7
M\M7UC>I)*+8S/;S&9?UD(R/5'9/]]4?,,_4'JCLG^^J/F&?J'([N/!#Z/E?1
M^:T.G-_O'C>HRXYJG>TWD+[6W=V29/QF9##L9YLG&7D*;=;5S)Q"B-*DJ(^1
MDHC,C(^1D9[ES'742@TBW:>W2Z)3HM+@-J<6B)#9:CLI6ZLUN*)#*4)XEJ,U
M*/;<S,]Q&]ZH[)_OJCYAGZ@]4=D_WT1\PS]0=W'@C]'ROZ+0^+_>,?4..:IW
MM-Y"^UMW=DG!$22V+^L]P,B46Q_U'L,:M/&1+FOV+6W+BDE)7"-@F#)"4\/&
M9\7K>_\ +W>(9&3)D:!'<E3)$>+':2:G9$IYMAAI)%N:G'7%)0@MM^:C(>FY
M RW5.$62:IEBHPTT%6KD,<5%#3PPP4J4%)%1O.AABC2^5 Y2B=AV-!30UBBA
MI8)J&.<LY2=CEH;U'()!$>_,S\YF?F\8&DC/?F1^8S+]0LW;&?<3WC>4^Q+9
MO.F5RY*:9)F0J:^U+::4I)JV[1'6XT9D1'N1*W(^1\^0J2^\IX_QM3SJ5[W=
M0K;B]:TRDZE4H<9]QUYPFVT-L/OMNK-2U$6R4F9>/O'<'ZEP$I));%_6>Y_&
M8W#K:35J?6Z?%JE+E-S(,UI+T:2RI*FWFUI):5H4DS(TFDR,C(^XR'&N&XJ+
M:U*EUNX*I"I%+@M*>E3I\EF*PTA"34>[CZT(-1D1DE/%NH^1;F .[%,TOV[K
M7\Q]!(LQB[59@C,%<GV[860:76*S3W#9>I[CC<1]Q9&9&41#ZT+E$7"9FI@E
MEP\S/8R'99"S/C?"R:S<>1KKIUN4U?4$UUK[2YC^VR#ZF$2RD.\)[<75MJ(B
MYGR(!JLOZM^<OV M?B[,>.<Q4%NX\>753KDI:R/B7&?:[2QLHR_WF*2S?8XC
M];UJ$;D6Y"C<CZG\'8KK]-MF^,A4:BUJJ/$S'@G)8>6VX9D24S#0X?8^,U%P
MG)ZOB[T\@!D$ X%,J=/K,&-4J7-BU&!+:0]&F0GVI,=YM:24E2'F5+;5R,M^
M%1['W^0<\                       ?&1[ ]^+7^HQTEK^U#/XU_\ M#'=
MR/8'OQ:_U&.DM?VH9_&O_P!H8$TK8^E%0@  4
M  #K:M^T'_@CCV_[51_S_I&.15OV@_\ !''M_P!JH_Y_TC Q^?\ N^T[H  #
M(               *3_?%_KR"K!2?[XO]>0".[E72BK   *
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M+U/5ZS/6O=*=DJZZI>U:TT:<TYHQ'C^4MJX,@'=#-")4>(XXW4GXT"21.O\
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M-N)2Z@I,9QMU).)29<1EXA/(7<7X" QB_">^WUFH  &(
M  ?&1[ ]^+7^HQTEK^U#/XU_^T,=W(]@>_%K_48Z2U_:AG\:_P#VA@32MCZ4
M5"  !0                         .MJW[0?\ @CCV_P"U4?\ /^D8Y%6_
M:#_P1Q[?]JH_Y_TC Q^?^[[3N@  ,@               I/]\7^O(*L%)_OB
M_P!>0".[E72BK   *                          &QSV-SX"OHF-XV.>Q
MN? 5]$P!3-N^R3?A_P!X52*6MWV2;\/^\*I
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M=W(]@>_%K_48Z2U_:AG\:_\ VA@32MCZ45"  !0
M    .MJW[0?^"./;_M5'_/\ I&.15OV@_P#!''M_VJC_ )_TC Q^?^[[3N@
M ,@               I/]\7^O(*L%)_OB_UY ([N5=**L   H
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M*?J !\;RWWV(U(<O(GY*?J'>6V1>F&C'LG?MC/B+NZTOJ'1CO+;_ .(*-_\
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M_/UFVWF&0 & %,TOV[K7\Q]!(J84S2_;NM?S'T$@"I@
M           'QD>P/?BU_J,=):_M0S^-?_M#'=R/8'OQ:_U&.DM?VH9_&O\
M]H8$TK8^E%0@  4                         #K:M^T'_ ((X]O\ M5'_
M #_I&.15OV@_\$<>W_:J/^?](P,?G_N^T[H  #(               *3_?%_
MKR"K!2?[XO\ 7D CNY5THJP  "@                         !L<]C<^
MKZ)C>-CGL;GP%?1, 4S;OLDWX?\ >%4BEK=]DF_#_O"J0
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MR.DDPEWC'J<AQ3V_5J2Y#2ZLTEWD?#S'J6)ALEJ<)#9*5WK)M).*^$O;B/\
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MH2X@]N[P5$9<O%R[QO2VE.VQ%L1<BX2+A^#MR(O,0$G9+"4\+T:-I-*3(_\
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MC'26O[4,_C7_ .T,=W(]@>_%K_48Z2U_:AG\:_\ VA@32MCZ45"  !0
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M]'1N<2FXEFQ.RQ7.\[+)E=IZU2QPTK@:A@FI0R<VTM;T(O4  /=3NP
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MH8[N1[ ]^+7^HQTEK^U#/XU_^T,":5L?2BH0  *
M    !UM6_:#_ ,$<>W_:J/\ G_2,<BK?M!_X(X]O^U4?\_Z1@8_/_=]IW0
M&0               4G^^+_7D%6"D_WQ?Z\@$=W*NE%6   4
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MA=-0TE$FU6J*Q..&%-RMDK=:.YR+#%#3TN=#$EVN]PM+\+$O*  /IXV0
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M ]^+7^HQTEK^U#/XU_\ M# FE;'THJ$  "@
M=;5OV@_\$<>W_:J/^?\ 2,<BK?M!_P""./;_ +51_P _Z1@8_/\ W?:=T  !
MD               %)_OB_UY!5@I/]\7^O(!'=RKI15@  %
M             #8Y[&Y\!7T3&\;'/8W/@*^B8 IFW?9)OP_[PJD4M;OLDWX?
M]X52                              "F:M[<T3X3_P!$5,*9JWMS1/A/
M_1%3 17O;[$   *    &T^'<C,]C+SGX_-XQJ9[?&1?&>PACZ1_I3;FT3/\
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M0%+67<J+OM*VKH1'.*FX:+3*NF,:N(V"J,-F631&?-7 3W#OYO**I Q ;%Y
M&AGM_P"3[B+\H U&FQ>0OB&TUD6YGR(MMS4?"GGY%'R\8Z2XZ_%MNWZW<$Q+
MBHM$IDVIR$-MK<<6W#C.25H;0@C4M2DMF2221F9F1$6Y@#ON1^<OC#8O)W=P
MQ6TG:I[2U7XX7D:T*95*73$U.ITSLU4@S8$@W:9.=@.J)F:RR[PK<9-25<'"
MI)DI.Y<QS-7>HV-I8P)>V;I-#],;%G)A*72$R#CJDE,?0R1&ZDC4V:>+BYES
MV 8:3)S8N_8MQJ,8='^HZ/JLP%96<(M"]+;-W]MX*0<@Y)Q>QR%L']^,B-7%
MP<7=R&3P                       "UM2O*W;8N.<FM5%N&J1U?5$M._'P
MHY\R\G_Q^"Z0COU2)WN^ ?$LO9"\%:D_N$^0:APXX15G@MP>K.6*K04-9IJ"
MEJ\"HJ=QPT<2IJ:"CB;<'RII1-J6E(X=>K$56H'30PJ)PQ0J44Y?*<G=M,Q/
MNNV![_L_)_\ @/NNV![_ +/R?_@1-[?]SWS[GV@_.>^?<^T/">[MEWZFR;YZ
MM88[=[NFX[I_ T?E188;><ED^Z[8'O\ L_)_^ ^Z[8'O^S\G_P"!$W^<]\^Y
M]H/SGOGW/M!W=LN_4V3?/5K#';O=..Z?P-'Y46$]&WGYI9?NNV![_,'^:?\
MX#[KU@>_S'R3$37YSWS[GV@V(]RXWNX__></Q'Y5"]W?+OU-DSSM9P^_>YQW
M3^!H_*BPV8\Y,C0+GHMSQURJ+,1,909$I:",B(S\7/\  .^4HDEN>_Y"W&)F
ME'P;3G&7$9]8CUZE*_\ <5XS/R'YN?Y!9K5UGK6!9%Q4VT--FG963D2VY#U0
MNA5PQ:4W3#CM=<TT4>26SO:3+JM]_!WW'T'P4RQ39?X/Y+RO6**CH*:O5=4U
M)143B=' W%%#*%Q?*:DD[3OZK2NL4%%2M)..%-I.SD;)%^2ME<^7G,OC(.)/
ME_J/ZA$KH&Z16[=3-X9EP1F#%BL3Z@L(LPRN.T%51-63+>J;#KU.),UEOLZ#
MD(0VOUVQ$O8^XMZ!O_55TGULUN[G*3HHCS[.H#50G0[@>OZD142Z= ;>?7(4
MT[LIO=AKB)*CW,S(AL)R).<M.U$U)&1]P&9%WB*+HNM?V0]=MFWS<]\8D<QD
MU:E0.F0G?1(JG'K$F/*?AS29?0A+9]0\RI)FA2B,Q7^N775)TQUK&^*L?63]
MTK.>8CJ+6/K)[<5,[>NF$E4YTYKB39;[,TKKMEGX1%MY@$G.6DD=2HE=WQ'R
M,:F9%WF(5L =(GG2GZEK&TM:M<*EB^[\IIFO8[JZ*XQ545LH$4YD]KJHB30Q
MV1"DMF;AEQ]Y<Q\^D8Z5NY]%E;.C6A@N?DJ-3JS0:7=-?5/=I4*A(KLV-%C/
M)<<:-F5Q$^9FE"SV-.Q@7-<Y<MZNVSD37#;Q%OMO]7QBR#>;K=IF#HN:[M=9
MH5$]*3%S3^N<(T1C>IJ9Q1>/EQ*6L^H09%X1F7+F(/ZETO6IB39;^J*U]*TF
MKZ1Z?7ETAZ]2N-IJ7+C-57T(D5!%(4UV_JX[Q&\KA;X321'OL9;B)-GHQ%,T
MOV[K7\Q]!(HK!^9K*S[C&U,JV!4$5*VKJ@MR8LA!&1-R"0GM<4]^?%&D&MD]
M]MS09[%W"M:7[=UK^8^@D"%3                             /C(]@>_
M%K_48Z2U_:AG\:__ &ACNY'L#WXM?ZC'26O[4,_C7_[0P)I6Q]**A   H
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M^"OZ0[[L#?E!EO')-'_JZ(_;(G]O2_X:Z2]0  ^IC9@
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M%<E-9JA52F/[FY&?<F.+4DS,BW\+?8]MC(2.@8.][6   (
M     1XZH_\ BZ!_.?V:1(<([]4JMKO@%PK/V0_!0I7_ +:?(0\O[,'Y#Y0_
MS%1_U=$=9E?\2C_;H_YD8O@&_P#VO?,.?9#\U[YAS[(^-YK7ONUSFI3WWVH
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MOF*==,M^7%M^"[E+]NZU_,?02!':V\2I@  (
M !\9'L#WXM?ZC'26O[4,_C7_ .T,=W(]@>_%K_48Z2U_:AG\:_\ VA@32MCZ
M45"  !0                         .MJW[0?^"./;_M5'_/\ I&.15OV@
M_P#!''M_VJC_ )_TC Q^?^[[3N@  ,@               I/]\7^O(*L%)_O
MB_UY ([N5=**L   H                          ;'/8W/@*^B8WC8Y[&
MY\!7T3 %,V[[)-^'_>%4BEK=]DF_#_O"J0
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MB42C4+5)21I+.2=BG9>6AJE7J\4Z&C4#<,FU-V+-LM;U=)5   V4Y(
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M1[>7N&\  %,TOV[K7\Q]!(J84S2_;NM?S'T$@"I@
M        'QD>P/?BU_J,=):_M0S^-?\ [0QW<CV![\6O]1CI+7]J&?QK_P#:
M&!-*V/I14(  %                          ZVK?M!_X(X]O^U4?\_P"D
D8Y%6_:#_ ,$<>W_:J/\ G_2,#'Y_[OM.Z   R       #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>nt10002526x6_diagram1.jpg
<TEXT>
begin 644 nt10002526x6_diagram1.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( BH">@,!(@ "$0$#$0'_Q  ?  $   4% 0
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MNM%06B(4W%.J/Z@%0UN:Z?OS_76N@;?^(3Z*.YSUVZ+Q)P!)"PCV[+/0@J)
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M!&HU.I'*L6Q!LFQSAQI4Q.4=<S*H%US-/6F=:0.)6&;N(3?\RD <XRK#NUW
MF)7$R\E6FI>;4?5EJBA4BZO2]FR_9MQ7LI63RC+>!04-1]>1J-6B/1G?BE,B
M.(>79LJN*NWC)3,YY;<*-=)[KTJ+>Y2B$K4HI8;8B *T_J(2=VO=K5V)A'&F
M&,=62#B+"5\MN(;+<6&Y$.XVJ6Q-8=:<2%I4I<9;B4':H:A1!!Y=M:W4DI)2
MH%*@;%*@00>X@Z@^,;*2I*P%)4%)(!2000H'4$$;QSCE5:,AAJ2TIEYIEYM6
MFYM]M#K:M#J-4+!2=.T:@Z&M;MYBE4CE&FTTVRA+;:&VTI&@2VA*$)_Y4I
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M\-*^G:-  V$)2 $I:2&D@ : ;4 )[/ "I]WG]--WG]-<0TV%*6$-A:\H6L)
M6H)ME"E  J N<H)(%Q'(K6I*4*6M2$7*$%2BA!.I*4DY4D\2 ">,2[4_Y?\
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MQ6]:Z$DGU6F\J$WM8[S W&./\28WG%S%7G5_90LF6IC"E-R,JB_JA#(-G%@
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M)4@V)+$LH!YXD&Z;)2@\5B,&Q=MGP7A9MQM$\BM5$!03(TM:'_6 T#\T#V#
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MI)L01R((CTR;6%H2M)N%)2H$&]PH @WXW!!\XFI2E<8YPI2E(1I.K"$$E02
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M,H @GEXZ_M^OPJQ)X<_QA\!,B+ASB7X?)^%U(4RS+Q.FYOO('9USYC,1="
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MKANXN_G')5O2Z"6TRY:I,AK8DG3;X"K_ (Z-SI=N$WI6\LG,/LJLD+,1=K3
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MNO1;97=)5P]WC!=\MT2#FCA^!+EY>8P0P#,MTU*52'(Z]@2I[\XMMM@%UPA
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MTU04+.[4'5/]/:.ZN9:D$@J[/+_I4PI.>EJC+M3<C,,3<J\E*VGY=UMUI:5
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M'H:PU1X'[^--4>!^_C4=WG]--WG]-+K[OB.7U]_*&O0^OCT-8:H\#]_&FJ/
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MVVN.2Z\I]?L( 2UN45;E)(!!Y\J]J_P_O0FXSXI\Q[7QP<8.&Y;66MMF)NF
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M'X>3C\L?'9P+VW .*+@B?F=E?97\+9A0'W4J>,&>EVV0DE"OZA^224G:%::
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M!!["#R-11JU1>J]3GZG,$EZ?FWYIRYN0IYQ3A%^Y.:PY"):4BG,4BF2%,E@
MQ(2DO*-6%KH8:2VDVX$Y2H\S&I2E*M\7&%#SY4I2$>!/XC/A:7Q)=&[FPBR0
M53<98,C0KG8DMM=8\AMJ6F1,+9T*A_*:U5H.8%8ZKACQ_!7E4N'B*ZLPY&#I
M$J!/+[B$K:5'DK84G:I0*B"TH:#4ZUEAN.G/+(S(+AES6QQG_>+?:L IPK=H
M$Q$XI6N;)N%ODQ(;<>-KUKQ,AQ"=6DJV$ZD 5B\NC]Z)?,'I'\Z\UL:86N4K
M*G@]LN*[M?\ %>/;FLQ;:FQKN<N>D1Q-<C&1^9:2MM(862@J '=6>;/<<S&
MJR]5F943J7Y&8E')53I:;<*\JV5*4 HV;=0E1L+D7 (O>, VB8&E<?45JD/S
M)DE,STM-MS:&@ZMH-DH>2D$CUG65J0!>U\I4"!:. 0.(_*&XWT8?C8F29I=Z
MI+I8<#*W"=NT.G^7_5RU"OB:[R0M#B$.-O;T.)2M"TZE*DJ&J2""1S'ZU]G2
MJ0>BBP#AK!O#?T?^$7L99OX8F)M^,,UHDJ[I2_<XLAH27.HD!;*DJ=:>3JEP
MIT/A7"L#PKE;<'8>@W995<8\)H2=VA5J6D;03SUTT.I)_>I9;(=I-<QZY6$U
M:FR[#4B&7)::DVW4,GM7"DRJ^T6L+=2E(6E25?A!S)&EXD;8=F= P S17*/4
M9J8=GU/-S,G.NM./@--H4)M'9H;*6E*.125)L%$!!(N(Y7R]\_(TY>^?D::J
M\1\TTU5XCYIK=]T]W=_3S\/=[]&=;SRZ_N8<O?/R-?+-F1[="EW&6\&HT.,\
M\MQ?()4AM2D [O$@"OKU6=-""2= !IK5(G$KCNZ3%6/)W!)>GXNQM<H5G5$@
M(6_*0J9*:CH4&V0M1T2\"K0: <U=]8SB_$TEA+#\_6YM0"95H]@R2 J9FU@)
MEI=-SJ5N6S:$I0E:M+7C)\'88G,7XAIU#DDJ)FGDF9> )3+2:"%3$PL[@$-@
MY;_B<*4[U1ZM_AT^$J?QJ=(Y=N(3$$%RYY>Y&SDKEH?;/Y1YVX1W&(:D*5[!
M4EYI)]D<B-.6@KW3_%S\5@RVX8\N^%NPSBF;G2\N),@Q7"'&H]BE1E,)6E&I
M +8Y Z<M*]1>A"X!L-]&QP+VF9C"+'MV86)L-.XNS*O,@H96_&CQUWF"A]1.
MB5(C*V@;MQ5W;@*L5^E<XP9O26=)9B&[X9EKN.3&5=W=MV%P=RX\9]ALQ+D4
M%0_\R3'4=>8)^%>=,JQ/XNQ*RRD+?J%<J:<]KJ47)M[,ZLWN0E 4I2B=$I22
M=!'H]-3%.PCAIY]11+R%"I=TC1 #,JPE+2 ; 9G"E* !;,I>@OI'3F3&$VL%
MY;8;LJ4]4\F*'9(V\RIY*'/:Y;CS4>TBNTN7OGY&H!*6PVVR4AMMIMI(Y#0-
MI"-=/AX?MWU'57B/FFO2RDR#%*ILA3&$@,T^4EY1H 6&5AM#8/\ \E JX[SW
MQYDU2H/5:IU"J3"BI^H3DQ..DF_K3#JG+>"00!?@.<.7OGY&G+WS\C357B/F
MFFJO$?--7'U=-.[^FW'P]WOZ-NKGKAU<PY>^?D:<O?/R--5>(^:::J\1\TT]
M733N_IMQ\/=[UNKGKAU<PY>^?D:<O?/R--5>(^:::J\1\TT]733N_IMQ\/=[
MUNKGKAU<PY>^?D:<O?/R--5>(^:::J\1\TT]733N_IMQ\/=[UNKGKAU<PY>^
M?D:B" 5**O90TZLDCL"$*5W^&FO_ ,5#57B/FG_I7 LSL9P\"X'ON()KZ6RS
M#=;C@]JUNMK;&W0\SJ0/H171J,]+TZ1FY^86EIB2EW9IYQ9LE+;+><E1/( #
MC>WGVZ?(3%4GI.G2J%.3,],LRK*$W*E+>6EL #SN>X7)TO%77X?/+Z5FMTS-
MCQVPRJ39<"+G?G9"$^PT7[4ZAL*(UVDK1H-3S/URCC>W3V?Z1[ _9'L_]*L9
M/P@G"+B2WV#.?BZQK =1!S$F03@:5(C[5.MPWY$>86EJ2%)2D$))[_U'9?.(
M2$I '?J?GSKS!K,\:G5JE45?BGIZ:FCXOO+<TXVLH;X]2J-("ETFFTU/X9&1
ME91.X:2[#;7#CZNL3TI2K;%SA2E*0A2E*0A2E*0A2E*0A2E*0A2E*0A2E*0A
M2E*0A2E*0A2E*0A2E*0A2E*0A2E*0B1:=P[!X<QKJD]J2.\$<M#5A#^*CZ-K
M$N%<8X>Z0O)'"[KHA/%W-Z1:V3UC;:2S#MJUL-)*E!20HK*&R -=U7\-=6YR
MY28)SORYQ3EEF#9HM]PMBNV2K=<($QI+K14^PXTR^$J!]J.M8=3IH=4]O=7T
M9><EW6GV5J;=9<0ZTXDD*0XVH*0I)&H*5 $$1\GF6GVG&7D)<:>;4TZVH9DK
M;<!2M"@="E220;\"8Q-&4N9%KS2PC OT-:/SK;"&KC%W#K6'6AU1"DG1045I
M.J=.6A[*[-T\GJK[^E+Z.#.3HAN)ZYW[#MLNM]X;L<7>7/L-WBQGG(33+SJG
MY33Z6TN_E4QG7RV@O% 6$^SR[. X+QKA_'EBBWZP36I,:0VE;C*%CK&7- %I
M4C4KUW$_X>XCE4^]E&TN3QK2FI2<=0SB*192B=EE*0E4XEL)2)Z62;9DKT+Z
M!ZS:]?PD&//S:SLRG,#U9V<DV5NX;GW5.2<PD%0D7'#F^P3*@+)4@DAA9LEQ
ML ?C!$<OV^3U4V^3U5)[)[SI^H_[_P#2HZ)][Z&MO7'+AW#]/+JWA;3\3;?)
MZJ;?)ZJET3[WT--$^]]#2XY<.*?9Y<OAX61-M\GJIM\GJJ71/O?0TT3[WT-+
MCEPXI]GER^'A9$VWR>JFWR>JI=$^]]#31/O?0TN.7#BGV>7+X>%D3;?)ZJT)
M,9F5'D19#(<CRF7&'6U$$*#B"C4@\CIKW_#F:U=$^]]#31/O?0UQ4$K24J"2
ME0LI)RD%) "@1;<1<'O\"!%4J4DA224J20I*DFQ2H&X(/ @Z@\#''^CKXT<;
M]$AQP6+&4:1)=R.S*O<6'C:R)4M$*:E]:8T9YQ?M=4F([(+IT&A .I'8,B-Q
MP\)60'2]<%CML9=M%]&)L*HO67N*XBFI+UINBH:;@J(TXTHK0IR7LC+U6.8Y
M]G/''9JY;6;-#"TNQ3V4_G4-+7;)BA_,C/H_F I4.>JEZ $'EVZ]M>J70&=-
M!>>!/'AX,^+:YSGLJ+[<HUMP-BFZ2'G$836Z_JE()WKD(F/.--ZK<"6D\]=!
M4"=L&SM[!];=J,BPHT"JO+=E5H!4B3?42IV3<4-$V)*V+_C:-@2I"HG]L;VC
M,8RH;5.GGDC$%*90S-H44A<XP@!#4\VG>K, $3%KE+HS&P6(\3[MA7-?@,SY
MQ;PK\1MDN%A>LMW?B66=-2Y^55!6^XN"['E;>I?ZV.6E*"'%%&NBM#54K+S+
M[3;[*FWF'DI<:=;<"T+0L;DD*22.PCO_ $[:OM>EKZ)#(GI6<CDXBPNNR0\W
MV+0W=\N<R;,8TE;YE,(EH9D+AKZMY3S?51_]X=66BKN4DUCN,V<NN)SHV\TK
MGD9Q18'OC-IMTQ<:VXA4P_)@.1$J)9D"9':6SHXUL7M+IV[MO:FLRV1;9449
MJ7PSBEY7\.04M4ZJ+NLR220$R\UO4J6!_P"FL7+-['[O\.%[7]B[E;>?Q/A1
ME'\34DN5*EH"6Q/J2!>8EKD)3-D?C;)"7_Q Y_Q5,;?)ZJ;?)ZJX;A''^#L;
MP&;AAZ^PI"'DA75+>;96V3K[&U:TJ)!Y=G_6N37";!M<*5<9TZ*Q"B-J=>=_
M,-*("05 !(4==>S4=G/L[:EQ+U.GS4LF<EIV5?E%-]J)EE]IQCL@ HN=HDY0
MD)%R;Z6UMI:(#].J$K-&1F9*:8G Z&3*NL.(?[4D)#?9J2%9RHV %[Z6O&W8
MEC6"39+@,41XKMF9CO*D?F@C0 -J.B%.:\SV>S\ :H_X0N(/B.X7,]K[Q*<'
M5LQ.Q@#+:\VXX_3;$3)=E7:9DD,2VY,4H7&=0Y&#Z?Z"$ZDBNT,I<I>(GI,\
M[+1P^\->%[I+L:KHS%Q#B!A"VX,> '4JDO.2W$I8 2PEU02703H$I.M9(O@0
MZ'+AWX/.#JY<.;N%+/B6^8^PL_"S)Q)-AMN/W>[28;GY4Z/H=4R;?*?4$J:7
MHLH!U(-0FVU[0*1BVH,4RBRTN]*TMQP.5GLD=O.NVR]G+NY0X)-O6US9U?K!
M( 253AV(;/*QA&GS%3K<S,M354;;R4;MEF7DFA927)AJY;,\YH#8 LMC(223
M:UCZ0K+K!_&5D1E7TS/1\14X5S@RZ5;[IGI8,,J4W.DRXC\6)(,F$R6EL=<J
M/+6LAD:A2B=:NTNA[Z0W#?2$<)F#<Q4/,Q<?V*W,V?'EB#J7)-NFV[;;DN/Z
M *"Y+C#CAU2""2.9JTDX+6[KT172=YU]'UG;UDCAIXH9-SM]INUWU58VESX4
MQV&W#BO[V/Y4JX-MZLZ'<D$UR_H_\78CZ&OID\;\(U_N+[/#UQ!7EN\6*[R%
M*:MQ1/CN7>(F(VLE '736T?RB/UK1,;ZT']_ ?Z>,9!2E?#"E,R8K$AA76LR
M8[4ME8[%LR$!UI7[%"DGXU\K]\M<9WJ'[I:6'M= T_<8K3NOAU:W K7X4BL;
MQ7P7*:S;X4N9(<2S'AQ9$V2ZH@);CQ6E//+43W);0HGLY=]?2V^VZA+B%H<0
MKFEQI27&U?LM)*3\Z\5>G6X\D\#O!%CS$&'IR6LS,;0QA_!$$.!#\M=S=_AD
MP,[NU2&Y([!R)^-(1;1=)KG9FCTV/2.X8X#LC+G.C</64-[<>S%Q+;72JUW"
M#&"+A/:N(0I* &Q$D-)+CAT).FG970O2S<9=PPSA2T=%-T6N&I</ N6=D,/.
M2[X+;<<DXCDM043):I5SC-]>WU$EF7N29"M=2GLY5V1PPRQT2?129E\8.+70
MKBPXT1*3@^VW!O6\LF;<WX3_ .4DO!;@WQKDD^P$\M-.ZO7#\-CT9PRLR&QA
MQ59\6)J^9I\2ZI]RE1,111+G6:#,D2NM2AV8'%:2X<PA! 3M3_3W:(I;C_KP
MTU^ ^6[6+%3A*1@*3;KE&<M:6LP[;,?:O1N:BN>J<B0XE_?^;U<*PX%ZG7MT
M[ZK='/\ P#4<CH=.SE\O"O4SIVN@ES#X9\Q+_P :W!7AZ7,RYERW;QCC!EH0
MI:L/J6HJ<=0V-[LI,MU3SI#31#0//D!IX?9*YTVO-*V.QIB19L4VO_=KK:IA
M+#R9#2BVM*TO!"DJ"D*)&T:>%3/V';1://4R5PE--2M,J\FC)*AIMMAFJMI%
MRX"  9T)'WJ5$J=U6FZB0(4[=-G%:D:I-XOEGIRJTF<6%S0=<6^]27%6!0 ;
MG[ I1^Z4FR6+AM8 RD][;?)ZJ:>3U:_Z5\CTN'%;4]*G0F&4 E:URF!M">T\
MUC7EW:?]:IFS,XF</X:<7AW S$K%^+Y:TPX4.U1WI;@DO$-( 1'0YNU4L<]-
M!V]U;OK^**%AB3<GJU4)>290DJ2EQ:3,/$ ')+RXNXZXJUDA*2+[R !;1V'L
M+5[%,ZW(T.FS,Z\M20I:$$2["20"Y,3"K-,H3>Y*UCV0381V)G!FW9,JK Y+
M?6B3?YB%L6NVLJZQYQ]S^6D;$;E%6Y2=$E))KW=_#B]#OB7.;'S?2!<5F%7T
MV&/)3.RILM[:7I<]5*9D/+BO)2II,90;=0IYK0@!22!SKK#H9_P_^;W%-F!A
M'BUXXK/,M64\>2W><.X#N84ES$6U0<CEU*2A^(F,\EIS1UH!P:I/+4U=0=*3
MTG_#QT2O#I%L5J;L:\>7##\NQY89;V5^.VXVZU%_(AYY$+41EL!3<@"0VDNJ
M3WDDU!/:;M+G<?5%*6DKE*))+5_#Y(JNM:CH9N9(L%3#@W#<TDY$_F)GELPV
M9R.S^FK4M3<W6Y]"#49\(]5(%B)26!]9$L@[SHIY8SKTR@>=7XE'I8H7"[DD
MWPEY'7N.[G+FA$-DG.6E]"W\)V^.&VD,+::)3ME07"USV;4CO[!9?\.V5;V7
M^%GKI>$]=B?%#KESNSSG-X/RG525K4HDG5Q3JE'GR[/TKB=CD9H<5N=>*^*G
MB$N,Z^W[%%U?N%KCW!;BD-12\Z(K++"E%MD1V"VC5"4[]H-58 )T !VI "4I
MT.@0D )&G=H !\.=;LV"[.7:>W_QE66.SF9ELMT67=!2MJ6<'WDZI)%TJ?22
MVQQ#94O\PC2&W[:0U4%_\%49]+DM+N)<KDPTH*0[,-D*:D$+!(4AE7KS%M"Z
M$HWH5$P3I_@^NFM1V^3U5+HGWOH::)][Z&I/@C3=PXI]G]OAX6BY$VWR>JFW
MR>JI=$^]]#31/O?0TN.7#BGV>7+X>%D3;?)ZJ;?)ZJET3[WT--$^]]#2XY<.
M*?9Y<OAX61-M\GJIM\GJJ71/O?0TT3[WT-+CEPXI]GER^'A9$VWR>JFWR>JI
M=$^]]/\ O4!M).JPA(!*EN>PA*1S)*B=!I^I /C5+@=V@OO3PR\;6'T\+.7?
MU_:)CM3J5 (2E)6M:E )2A W*)43H.0/;5,%ARTS#X^N*/+KA2R7M\J[IF8@
MB?QU^*A;D5,"+)9E3Q)>TZIH?ET/!/6+!5V)U)K;,VLSL18SOL#(_).#-Q-F
M!B>:Q:DIM+#LEQIR4\AD'^0AT)2 [S)T&@U.G;5_;^']Z&2W< V4K.<>;MN9
MG<1>9<.)=+LN:REV5AI"@78Z&725I2J1%> 6&]NG8KGKI$S;GM/9F6W<&4&8
M#K94!6IYA8+2^S((I[2D_BRK ,RH&UTI:%P%1+G83LM>E76<:8@EBT[V950Y
M%]LAU"7  :BZE7X"I!*99)&8 EW2Z(]O.#7AGP=PD\.N6F1>![>Q;K/@^PPV
MWFF6TIW7*1':=N)6H>THF7UAU43^E535*E.U('S_ '[ZFJ*T2OA2E*0A2E*0
MA2E*0A2E*0A2E*0A2E*0A2E*0A2E*0A2E*0A2E*0A2E*0A2E*0A2E*0A2E*0
MA3MY&E*0BF_B>X6\H>+7*C$V3^<N%;=B7"V(X#T4F5':5*@/J0OJ),:24%]D
MLO*2Z0TM&_;M.G.L:/TGO0U\3?1.9B77-3*"+>,S>'"?<)$PR[=$6XJSQ'G2
MH1EP&3(DE+1<ZK?L[$%9Y<ZRI';R-<0QC@7">/K!/PQC"PVW$5AN<=V--MMT
MAL367674*0M*42$.)02E2M"D @\P=:[M/J,[2IR7J%.F7I.<E7$NL3#"RAQ"
MTD$6(.H)'K)-TJ&B@0;1TJA3I&JR;\A495F<DYEM33\N^@.-N(4+$%)W*M^%
M0LI)L4D$1B(\JL],)YG1&T-/ILU_0 F79INK#[;O8I*A(V*22=204 CL[>5=
MX'5/(K'[IT4#^RD\C\":N3.E'_"RX.S-O&*<]^"2]?\ AOCC^;<QEU";<7&O
M$O13BD-2GWDL1P5[E!(3I[6T=@UM$<PK9Q?\%.(W,O.*3*'$<1%KDO157AN)
M)EPPRTLI2^J7#CK9T4V KF[W_J:EA@;T@9&90S3\9M?8YD!*/XQ+(*Y9\Z)"
MIJ60,S"C^9;(6V1=10WJ8B1COT>)R7<>J&"G?M4NI6<T6;<")AD'5292960A
M] _(VZ4N"X3G6;15%S]\?(4Y^^/D*ZFP1G;EMC^*T]9[]';E+3[<)]74K0OW
M#UI2=0=0>0\*[72H+3O0&G4GFE33B' 0>SFC=]^%2.IU4IE6ED3=,G)6?EW$
MA2795]#R+&U@<BE%*M]PL)(.EM-8UU*DU.D3*Y.J2$W(3*%%*FIIAUE5QORY
MT@+'$%)((UO;6)N?OCY"G/WQ\A4.?^7H?UY?ZBH]O8@?--=_3]/=^KE^YZWV
M[K?X<O'HZ.?OCY"G/WQ\A3G[@^8IS]P?,56WL_\ ER^O6^NO1^GCT='/WQ\A
M3G[X^0IS]P?,4Y^X/F*6]G_RY?7K>UZ/T\>CH\#O&H[.S^]=)9Q9,6/-:U K
M4(&(X7\ZV79@%M]M]LAQ!"T;5:A:4@*W:Z\Z[M_38-?W34#J>000>XC_ .*M
ME8I%.KU.F:55)5N;DIMO(ZRX";Z#*M"OQ-N(/K-K00I) L>^Z4:M5/#]1EJK
M29I<G/2C@<9>;4=^ET+3^%QMP70M"@4J2;$=U6?11]/?GMT;^)+=P]<54>[8
M^R/7,8@VC$,Z4Z7<)P^L2%.]<$O2):5[DD)+FB$IV]@J^+ND'HZ>F#R/C/3E
MX&S5PIB*V M/+D0+;B&#(?:&J3J4W0JCO*TT]D*".1T-8X?'^%,$8JLDJ)CA
MBW"&IM03+?<9;>8T!]L$D.*(/,<^6GZ<Z#L)YYYO<'V:,"Z\(F=.+3?$3D*C
M6BSM72[1FG2X VR+<EQ^.H*)V?\ !([Q4&]IVRI>!W53LE4I2;I3KGW3+TRR
MS4Y?,=&ERRE!<P$_E>938@'.E-HG;LOVKMX[91)3M,G).K,M??NLRSSM+F"A
M(S.MS24%$LHF]V'E@@D!"E7B\,XE_P 'N@8ANV,N%OB"FX0MTAYV3;L$?PM^
M0W'"U*4EE,U^3M6G4\CIII5#C'X57I [W<(]AQ#FR\WAI^8RW.EAB*HF$'DA
MU10F3O.K6XZ:DU=,= 9Q4<>?%-D-?L2\;.#9]E=@Q;4,$XHGMM0I6*&E^S)<
M7;FVF78A80$<G4ZKUUJX!#2>1U7K_P ZO[UJ=JH3S#*V&9R::9<!2MIM]U#:
MTD6*5(2L)*3;4$:\8VV[3I%]U#[TG*NO-D*0ZY+M+<0H$$*2M22I)%M"#'E]
MT771?Y-=&KD79<NL$VVW77',F*A>,\>+AI3<+U+)ZP %T+<C]0I:T:-. +',
MZC33U#*$E.W34=O;S)'ZU/2NG'<BT2_%6<(5SQ=D5EMQGX$AJB8IX:K]#O-R
MDVQC2X7!F7=H:P'GF0'5!MMA0))(".X#6O)?I0[Q)XU.CEX+^E:RW4+5C;(Y
MV"QF2]!T<GK;MMSMUH:$PMZ/(U:AN?UC7YU?><7N3=FSYX<\V\L+]$:GP<08
M0O3B8K[:7&URH=MDOQO94""KKTM[>7]79SJR6Z G#>$LZ\O..'HO>)%HPK!:
M\4I?MUJG+42;7$O=PNSRHT<E*FTIC-ZGJP-12*<?'Y6_>WO\XK/RYZ;GC!X^
MLN< 9*]'IE#<%XT3AVU6;'>=EQ6B#:L&KAP(\<S$LWB.U!N!6&W2OJWCL4GG
MH37S8CZ-[C6Q'?8-]SJZ:C#F$,R;DL2!AQBRX?<:@35:*_)N+BW5+/\ *60U
MJL ';V<]*X5C+.Z5>\>L=$?T.>'K=@.VX;D/6C-//:V18KDZP-2B9#Y<_.-(
MD2%.@26D[96J--1I5?.5?X97A48P-)_^H3'&.\X,WKM'5)NF/SC#%-EZJ[24
MJ===:MT6Z%E"6)"U );(!"!R I%>NO+]XZ!7GATO?1?(:Q?F+B"'T@/#!8G(
MJ;UBS##]CMLNP6N0M*%33'LRILZ84I4IWJ^9_EE)'.O(OI N,6Q].]Q]\(/#
M3DE-ND? .';Q(O.)K?*A2X:HR[=^3NUQB3X\IMEU*8SL9]H+>2D+"2I(T->C
M>9O#7QZ=!E+N&;.3F+;EQ6\$4J2EO,C*#$C;3ZL-V-]SJ$J-PO+EPF2PRVZX
M_P#RTZZ-=M5,\*V6/1R7N-F-TP?#V;1A^ZKP;?'\1X9C-+99P_?WK'+MSD9!
M6&VXZ_XB7$;FFD!:AJ-:0W]>XQY#](/;U](CTN/##T:^7<<HRGX8TV<3I-M!
M<M1D1K5;KA+3)0T SJN3"<!#BM-Q/?K5_P#8$PI;\$80PSA*UQ(\*!ARPVFT
M,,1FT-,I5 @L15J2A "05EK<H@<U$GO%63_X77+*]9[\1G&'QNY@VY3LB^XN
M*,$726GKW3&9N-PA._EI2P5;>I"=0E6FF@J^-0-$]NNI*OF=:0\=\;3?;%:L
M0VJX66]6Z)=;3=(K\.X6Z:PU)C28\EM3+J%M/(6V=4+5H2@D$ZC0C6K(3I+_
M ,+7BC,#/R^9W<%.,$X$M6,9*YMRP-$C(ZBV22"75HD/.MI6)+RUN[4I 1KI
MSY5?*5(I"5=NH_91'^E?1IUQEQ#K+BVG&U!2'&U*0M*AJ"E22% CO!!CYNM-
MOMK:>;0ZVXDI6VM(6A23O2I*@4J!MN((C'+8 _"7<9V8%R;@YJ\04G!]G+B>
MO?;MS,PJ;UU4-K$@*[ 1^YUJXEX OPZO!#P#)B8]S&59LU,R+6D2T8XQ6ZBV
MPV'&1O==,&Y.N1%Z 'D0!J/VJXFQ*[<8.';_ #+,PJ7=XEENDFU12YI^9N+$
M)YV&SN4=$]9)2VWJ?>K%@],'TF72TX@S:Q?E#GU+QADKEPW>Y]OM]CMEO?7$
M-I$IQ##_ /'K<TRDA^,$/:==JG=M/,:5]7YJ:G7 J9F'IA9LD*?>6X1P_$XH
MV'>;VCXL2DI)-E$K+,RZ-5%+#*&P;:_A:2FYTT&\\(NRNE;_ !%G#;P/8;N.
M4'#NJUYHYSLPY%HC63#JD1+;AJ0IKJ([C3L-MV#(ZL%+FB-.:-._6K$R\R\]
M.-G-RX\1O%1B2Z7R==Y[EPMMFGO.F-'94M1888BA?4L=0V6T$H:3UFW<0:XG
MD-EKE))+.*Y.+1CO%<L_F'I%YF.N2425>TO<J<\ZM1"E$::D\NRJUDH"$)2E
MII+:0$MI8V]4$CL"0C5'9IV?45*397L5E'3*8CQ),R51; 0_*4N2?:G)8*T6
MVY//,J4VO+H?LR21<6<)%T&*^U?;=.L&:PWAF5GJ<Z>T8G*M/2STI,9+Y7&Y
M!AY*%HS;OM2@" ?NDW]<:<>/&B1V8L-M$:-'0EMEEM(2E"$#:- -.9 &O+GW
MUK\_?'R%0U'9L'QT'^HJ/_H'S%2L0E*4I0E*0E( 2E(("4@   )  2!H !8#
M0;A>)2E*6I2UDJ4HE2E*45*42;E2B;DDDDDDW)WG71S]\?(4Y^^/D*<_<'S%
M.?N#YBN5O9_\N7UZWTUZ/T\>CHY^^/D*<_?'R%.?N#YBG/W!\Q2WL]WZN7[G
MK>UZ/T\>CHY^^/D*<_?'R%/_ $#YC^U0YGL;_P"@^)TY533](_S<OWZTO3W>
M_P +\.M._2.OG'R!_P!*AKY_36SW:_V2PLJ?O5RA6]I*5**ER&2K1(U/L;PK
ME5,>*N*6VN7+_9C*S#USQ[B9YP1X[=IA3)*@\L[$:B.T\.T\B>6G?6-8@QAA
MK"\NM^MU24DRD&TN7>TFW2 #E:EFRIY2N64 #>H:F,HPY@S$V*YA,O0Z1-3>
M8C-,%!9DV@?S.S3H0RD;_P Q)W 7-HJAO%YME@@O7*\W&/;X;"%....K;2H!
M()T#:B%'7L[/I5*47%N=/%EF%:L@N%?!=YQ/?<2SDVX76!%D?E V7 A]]R86
M_P LP&FRI7M.IW;= 2>0]..!KH&..[I'<26[%V>BKGDGDK+=9DIFRF4NO2X6
MH6IHP=S,E&](#>I1J-VO=RO[.CZZ*WA<Z/3+ZU86RHP1:)&*&XZ$7G&LR(B5
M<;E(0!J\VJ6EUV+JHJ)#2T\B=21RJ*.T+;O4:^V]2L+MO4FF.)6T_.K*14)Q
MLC*0C+<2;2A>Z4*+I!U6D7!EML[V"TW#SK%6Q.MFKU9LH=9DT@FFR3B2%)44
MJL9MY)W*<2&DD7"%&Q'EMT(G0!Y?<"EFMN>.?,:)C_B)O<:-/"[I%;>;PD^Z
MC<XTA+AD,25J;64A12.K4D$<Q5S\AM*  E*4A*0E*4@)2E*1HE*4C0!*0
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M^.^ ="IAYMY((.FA+:E >&A.NNM?12$*4I2$*4I2$*4I2$*4I2$*4I2$*@2
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MVVDK6M2B E*4I!)))   CYNNMLMK==6AMMM)6M:U)0A"$BZE*4H@ )%R238
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MP"O:DJ*P/:W$Z<S'3$F$,0X3FOLM=IDQ)*)/9.J3GEGT\%,S"+M. [[ YAQ
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M@/:-:4BMSWG3=% .2O1Q<-^1^8,O-7"F'I2\P;S;_P"'XBO\ZY3IKMX8_)&
M4NHE..  QU+3H2>2C71MRZ''A1?S9NF8]JM=YL4'$BY3F)\*6Z_WB+:KHY*0
MXE:DQ6)*(L<*6XMQ?5M#>5'4UZX4T[^^D+G?<WBFCAJX3\G.%'"TO!F35@_V
M=PW*>6^J )#L@)=<=6\XO>Z2K<MU:EGQ)U.NM5+TI2*0I2E(0I2E(0I2E(0I
M2E(0/,$>-6X_XFSAL.=?1P8_QC:HB9>+<KEVVZ63:R'9" JXM/2%-*T*D:):
M!5M/8>9%7'%4W\6F6%OS?X=\W< W**B;'O.#+ZX(S@!2X]%M<IYC1)U!(=2G
M3O)TJA (((!!X'<>1Y=\(M>^@ISZ?SMX!<OX=WD![$F 1.MMV;*]SC.R8J*R
ME: =4^RUI^OTKV4', ^-6D/X;S&EQP'FSQ:<.>)WEQ9MMQA)19[4^5(+;2+M
M<7OY3:B-$]4 >0_6KMT$'73N4I/_ +21_P!*_*#Z;V /_IUZ3>U*CLL]C(5&
MM)Q-3PE.5K[-B-ANJ+2R/_;:FWYED=Q;*=X($RMGE2_B>$Z2\I:5NML?9W;;
MPJ646/6MH5*" N_$*$1I2E1.C-H'F"/&O&#IX,D+GG!P$8TG8?B/3<18&=ML
M^V1XL=4F4IS^(MR-64-I4X2DM@G:#R_:O9^N%XTQ'E]:;>NVX\OF&X,6X(4H
M6R_3[<RF6&1N.^+-=2%!': I!^NM;0V+8LJ^!-JV \94.0F*I4L-8DIE6:IL
MLE:GIYN5F6S,2@R-N%"9F7+K*W2A26TN%1&D6>O4]FJTF=IS[B&D3C#DN'7+
M96U.I*$KU(!RD@CPX;XL<N%O*?I(>.;)_ V$<Q\R<6999%Y<-RH%F(_,VV1)
M8<7U+R5M-NQ9:@E36B=X.@.H.E=JXOZ)W_8]IZ=A7/W&36)X[:WFIG\3OH+T
MML%:2=T[3FX!W]_ZU[><8/'9PRY"X;N'5XOPZ\_";>%LPOAQN&E,A]0(2@?P
ML[5:N%)_I/;\1XX\.?']=.*#'>+L.7BPJP]$ANA6'VW7=7GF2%J*RA24.#<@
M)4-X';I7ZDME6-=H^T:6:Q35J:K#-(F0TN5HX:/W+:PDA"IF99;?G'1F^^="
M&V]"&T)&D8!0\$[+Y"=IV&JF\W6:Y526T*#[N8.9"K7[.[V4HDV(:"R7%*M>
M\5H=#%TK&?G"KQ)6;@?XL<03<58)Q3,-OP;BB[/:+LX9U6!UBE+=E?FUEM/M
MN';K5^]'N$=Z(S,2Z@1Y$9F6R\M00V6'VDNMK4M6B4C8H$DG]>RL5?QZJEX2
MQYE%G)9"8UXPOBJ!)?F,C8ZB*U=(OYA2EIT44AA"CH2=>8KV3X__ ,1-CO%F
M6&6^0'!8^\[C&[83MMIQMCV.D%5J=9M<5E0$9]O:I2OYK94A8T(UU\))]@\E
M;;64K<<2WD2D$J65@6 2-;DZ "]XTECW!SF&,93N&I%#\T"ZPJG("%./OLSJ
M4KEVTH0"I;@4LM>J#G*+@:Z7OMWSGRIL,LP;MF+@V#+"MJH[V(K0AQ"NS1:5
M3 I)\0H#Z5R^QXJPYB2.)>'[]9[[&(!ZZTW&)/2->S=^5>="?TUTK$E2,K<\
M\?R9.*\R\[,8OXJNKBY<M35YNS+:7GEEWV6F)@;1H5=@3IH/#2JF^$GI$^,'
MHP<T;%>AC6]YB9*W"Z0XM_PW=);CX<B.OMQU.B9+<?=:#'6*<.W3=MTJ\S>&
M*[(28GYJGNMRQ2E2EW0I305:Q=0E16V!<7*DV3I<@Z1<:[L>VBX;H@Q#6,-S
M4K2PAMQ]T.,NNRB'-4+G)=IQ3TLC4 J<2$H) 64DB,IV"#V4JGCA;X@\(<4&
M1V!<[<$2$2,/8SM;,IKJE%?4RTMH_.,DGGJU(*T'7370&NV[]CG!^%VW'<1X
MIP_8TMZ;DW*\6^&Z-?%J3(:5]-?&K#&LHY92N'6#'V"\4H2K#F+<-WS=V(MM
MYMTM[X-1Y#B_37+PH*&H^O+2D(F[.9JG#BAXILGN$;*7$^<6<^*[;AG"V&X+
MLD_F9#0ESGPA?Y>-&B%Q,AXNO)2V2TA>S>"H<JCQ2<3V5/"3DYBW.C-[$<'#
M^%L+6YZ63)>;2].E!M?Y6-&8WAYWKGTH:):2K9OU4-*Q=/2+=(MGUTQ>?TIQ
M<J[8/X=<)W69'PYAN-,>_)+AI<4VI]]32FC+$LM)>"7@OJ]^@/*KE2*14*Y4
M):ETN6<FIR;<2VTTV+FY.JUG<AM ]9QQ5DH2"28ME8J]/H5/F:I5)EN4DI1M
M3KSSIL D#1*1O6XLV2VVFZEJ(2D$QVOTG?3$\3?2SYDW7++*J;>,MN&R!<'H
MC<*W2G&C=X;+I1^8<G,B/)VNEKK=I7H K;V52EE=DOA7*RVLQ[?$;N%X*09E
MXDCKGGG3[2E$N[U;MQ/M;N9YZ]]<QP9@NP8#LD2P6"(U&CQFPEUU"!UCR] 5
M**]-_->O?7*]$^]]#4Y]FFR2DX,EVYZ?0U4<0.)"G)Q:0MF2*@F[,DE0(&4Z
M&8L'5ZV*4$"('[2]K]7QM,.R%/6]3,-H44MRK:RA^?"20'YY22+I6 "F6![-
M&A5F6+B;3GJ4>K0? =W]M*;?)ZJET3[WT--$^]]#6XP?:'#@/9Y]:]PC3/E\
MOWZMX7FV^3U4TTYA'CWZ\CVC3]?C^U2Z)][Z&FB?>^AI>^A(([B!RWZ^_P X
MK?D?A^_5O"_![KEI@.]W-%WNF%X<JX-JWB1M0C57<2D(T/=V^%<TCQV8K+;$
M>.AAAH!+338"$H2- !HD =P[OF.=:FB?>^AIHGWOH:Z<O(2$JZ\_*RDI+/3*
M@J9=8EF6G'U:>L\M "EG7>HG6YCMS%1J$VTPQ-SLY,L2R<DNS,3+KS3"3;U6
M6UK4EL<D <>4<3Q+@7"6+]AQ'A^+<G&CJAU24I7V_P")01N4>7>3R^-;Y:;1
M;+'";MUHMS4"$R $,M!*1I^J@ 5::=_96X:)][Z&FB?>^AHW3Y!J97.MR<HW
M..C*[-(EF43#H]71UY(#BQ>Q.91U![H.5"?=EFY)V=G')-DYFI1R8=7+-*TU
M;84LMH(UU2D6UMO$3;?)ZJ;?)ZJET3[WT--$^]]#7<S>U\!RY\_GW".IY?+]
M^K>%YN8.J4#7P4K5)'ZI.J3^Q%=,YHY%X.S/@N?F8K=IOB4J5%O$0%EYIX#5
M"DEC8L**M-"% CMUY:UW)HGWOH::)][Z&K95:13*W).T^JR<M/2;Z2EQF8;"
MAJ$^L@WS-K3O2M!2I)!(,7.D5JJ4&>9J-(G9B0G&5 H>EW"@D7%T+%\KC:MR
MT+"D*%P0=+\XZ.+I@.+'HC\?6[ ^/YMWS5X=9<YEB59[A*6Z8,!3@27VY[QD
MRD!CK"[L2L:A&P<B*R3W!=QO9%\<>3^'<W\E<6VR]VF]PVWI5M:D-BX6R3M2
ME^,]#6O\T.K?*VPI;20L(W D$&L8/BC"UBQ?9Y=DO\)F;"E-[-5H&]HG4!25
MD%?(G7D>RN!<)G%EQ&=$3GY;,ULJ;O=L09.7&Y1_]JL'+E/FW28"G$M.*;;=
M4\W$_+(6XO\ E-)+A3SY\ZA7M1V.S>$E/5FAAV>P\I14XV;N35+"E&R7LH)=
MEDWL)BP*= X-RC-S95MEDL8):HU<[&0Q&E*4MD$-RM5RI *V,Q :F3:ZI:Y"
MM2V;>J,OZ""-1S!I5 '1[](-DGT@>1^'<V<J+_ DR)4!A6(</HDI5.LT[:EM
MYMUE9#Y"I 6 2V 1SJO[4::Z\JT5&^8C2MAO&)L/X?:,B^WRSV5@ DNW6XQ(
M T':4_F76M=*X]8\T,O,2.+:L..,*79Y"MBF8E^M;SNXG0 -MRE+42=>P&D(
MY_6WW"Z6ZUQUR[C/A6^*V"I<F?*8B1T@:\RZ^XVCN[=VE?'?[[;L/6.Z7VZR
M&XENM%OEW*;(<6E#2(\..N2X0M1 .Y#9TT//XUCK^EBZ8OB(XS\]\6\//#!B
MR=@[(["]P>M5PO5K<]N_+;46I.DA);?C_EY#;@U2Y[7<.ROJPP],O-R\NVMU
MYU00VV@%2E*.@  Z U.D=ZF4R?K,_*TNERCT]/SKR6)65ET%;KSJS9*4I'F5
M*)"4I!4HA()&04:SQR@?F_PYO,S!*I>[9U7^TEFUWZZ;?_OG;KR_?E7946XP
MYT=N3!E19T=[3J9,.0U)CN ]Z7F5+;(&H.H416(I&1>:+2!/B9UXU3B%!$E+
MW\=O1'YK7>.V=M/\SN[.T'D:]@NC5Z<KB2X*,<VK(_BTO$[&F2TF+-C6S%DW
M_B8?4B,LQ2I:0[(E%Y\MC52_9(_6KM4\.UFD-(>GY);+2[?> I<0DG<EQ3:E
MA"C[5@>$9OB[91CS \HS/XCH$Q)R3Y2@33:V9IAMQ0!#<PY+..IEUF]DI=*<
MQ! )MK[+_B#>EVQWPZNV?A&X9+FIG.7'0<@8@O,+:[(PTTYU:F]62% F3'=6
M =4E!&NO+E;1X'Z.K'F<T5C%6>.>^,7\57HFX2F/XI> F.[,/7G:EB=M ]O7
M: $CL[N7'L79LQ>+[I.LW,])%P5?\//2K?(PW*?!6R&?R:D@-MN;@WM2$@Z)
M&NFM51<2?%7<>&K!=GOMC@BZWJY.[8\/K V>JC.I2ZE.X$$EK70 'N'>-,9J
MLM/&FEV3<++SBE(96,OXDV%R5 @6.\;C&P]FN \+KP94\>8P:,S(,.NLR[*B
MX&T-2ZFFW7NS94A;KJWG.R0F]M#I'#Y'"OQU<!SK6=G"/G/BG&ELL$.8Y<\/
M/R94H".ZPM"DI8GR7]_\LK("6]>W3PKE/00X<S3XH./#.SB\SSL-TAXQL+\%
MN1*O-OD1E.R'HK\)PL*D--A0"@3JV2.\'32JQ."+I*<D<Y+=$@8LO,3 V+D)
M9:GV&])!9DJ<T2H$3>K:*5)U5_3MT/ARKW7RIQWP_P!N0RQA7$. K1><0)2H
ML6J78XCUU6-"DK1&<;6I0*B1J%$D_K7F'Z:NV7:5A?8YCW #N&)NI3&*) TA
MG$,HV^V_3Z;,NM&HJ>EV)=;,XA<FEU@/-.,]DAU2G,V6+W*X"P8_5J;BG#56
M933&W$OFGI=#@[8@):#:G'!,2Y;=(*VGDK4%#0@;ZDN94LGO<61^Q4=/I_\
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MZU%O:VG>JFJDI2&BX&Y4=75EPJ!']/+36FW V";'@##T3#UC9;:8CM(#KJ4
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MOUZL-A'Y3_:M40AT.(+:F6(RHK+*G%(0@]<=4G4FO*#A<_$-.Y.90S\K>+[
M]]O&?^7@79D1W(EP8F7UZ(XN*ELL1XO\LLH9"0LI/6#16IU KPS],O\ ].2M
MM8@5C[T>:$JI4ZNSX36\!2:FF5T>=FUV_B%##JFF12''#>:E%NI,@M?:,YI8
ME#,@,"[4F4RHIV)'\BY9L=A/K!5V[:<H[-[?]ZE/X5;E@6/K6S7<X2M1T2A9
M_7:K;\5::#^W.MJO%ZLN'XKLV_WRR6:&RA2W7I]U@Q2A"02H['WD*.@',:5:
M#W'IA^E!XT)TO#O!5PW8FPG'DN*9MURG1EI:<2K4(6ERZ0FTZ<M?ZN^N8X)Z
M&#IP>.QUB7Q:9MWG**P71U*W?R;\1U2(RU@N)4Q;I32Q[!T[-? 5K'9S_P"E
M)MKQ%]DFL?8BPU@&2=RF9E&G7,0UMI)RDI$O)AJG!RQMK45A*A8@[HN]4VRT
M26SHILM,5!P*.193V#"@!H<[GW@U_P#Q:C<=Y&K^(;XQ,J,S,O\ */AWRGS
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MFQ9CX)L.*[?)1L<3<+;#>D[?!,EUE;J?@H?O7:B&TIYA(!T   T"0.02D=@
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M5HS(XO;O/R=RRDN-S8]G6A$QZ\0U:*6PIIAYEV.2G1)*T:@JJ^[X%>C/X6N
M/+Z+@K)++VRPIG4,HNF(YD5N?<9\AL E]$B8AV1'*G-RM&EC3=IKI46L>;>*
MO7T/TW#;;E%IC@4TN:*P:E--D $%Q.DJA0O=#1*R-"Y;02LP#L#H^'EL5/$C
MC5<JK90XW+Y"*9*.)-[I:6,TVL'<MX! .J6]RH\,^AF_#?Y?<)SEAXB.*1,;
M,C/62RQ<[9:;I'2['PC)?;"W4+2I3\2:I:5C3>G5LI[CI5V*Q:H4:"BWLQ8K
M4-#(CHAMQVD1$L!'5]2(R4AG;U?L$;-".1%;BE(2 !W#3X#N'@/ 5-4?B2HE
M2B5*)))))))WDDZDGB3$A$I2A(2D!*4@      6  &@ &@ T T&D6K736?AY
M\M^-"'><_>'*-%RZXAK;'?N4MBUQT-,XPD,-E338;;4Q%B+0VWH2E'\Q2B2=
M>1L2W\79S<*V/+ED5Q5X-O.%KU8)R[<W=KA%DIBK0AQ2&WFI8:##X=0E*_9=
M5MUT/A6966A*QHH?I\#V@^(/>.^O,;I#.BHX7.D1R^F88S9P3:8^*68[R,/X
MT@Q$1)]LDNZGKGE0TM.R_:"2 \M6@'=63X5Q?7,'5%-1HLTIE1LE^77=<K--
M@@]G,,W"5BX%E"RT;T*!C%\5X-H6,Z<JFUN42\V"5,/H^[FI1RUNUEWP"I*O
MU)-T+&BDF,<9:[M:;Y"9N-EGL7&$\A*VW67$*5HH:Z%"25#3LY@Z]M;AJD]@
M5KW]WZ^%=L\=G0B\='1BXIN.*,I(EVSER.#TB2B[0FM7HD%O<I+7\/09$D]6
ME0;UV:D)UKS]R_XI<.7Q_P#@F.K?-P-B1IQ4=^+=XDF,XIY"BA8*9#;6GM \
MP!V_*9&"=MV&,2H8E*HZFA5=>5*F9IS+(NN>J+L3ALE(6;6;?R*23E"E6O$+
M\;;"\5896_-4EM>(*0BZTNRK9^WLM]S\FFZEY-;NL9T%(N4I)L*J>7@?F/[4
MY>!^8_M7PVZ[VVZLA^V7.%-9*0I*FGV2HA7,<@LGL[OVK<B2.U>A_P"6MT-.
M-.H2MIQ+B% %*VUI6@CU=0M*BD@VT(/=W"-)N-.,K4V\VXRXDV4VZE3;B2+"
MRD+LH&^FH^>NGR\#\Q_:G+P/S']JGW>?TTW>?TU]<H[^[C_+SZN.X1PT[_CX
M<_#W\XDY>!^8_M3V?U^8_M]^%3[AS)=2D $E2]$I ',DD\ARKH7-'/\ PEEW
M$<8BO_Q_$3NK4.TP4J?>4^K5"$H# <*R%D: #MY: U:*S6Z3A^1>J-6GF9*5
M83F4Z\L)S'2R&D:K><5896VTJ4;C3=%WHE!JV(IYFG4:1F)Z:>4$I0PA2DHO
M;UW7-&VFQO4MQ24@7).NNY9VYK6W*W"4N2XZER^7)I46TPDJ!?==>U9 2A.J
MMQ4M.T%.I)T%70GX5+HS<085M.)>.O._#KS>(\=.-R,L#=8Y;EVYE"W8\]:$
M/IZU(>:6D@J2G5)"D\N=>2W0T="OG-TCV;UMXD>*6RW;"&1.%+G"NUAL-WBO
M,'%G5O)<9 CN=3(C-QGFFS[3>CH/,;:R7F!\&V# &%;%A##%KAV>Q8>ML2V6
MZWPF&H[#+,1AN.E26V4H1N6EM*E'34DZGGSJ!>U/:(]CRLH4PE;-%IN=JFL*
MT4YF([2;>2-.V?RIL-<C82D'?>?NRG9RU@"BJ0^IN8K51[-ZIS"+Y$%(NW*,
M$_\ 98S*NK_N.%2CI8#E2$[4Z=^I/S.NGP[JGI2M6QM6%*4I")5?X?\ F%>$
MN0^HZ7WBP.U1'Y?!@W!!.FMD[R =.?C^M>[9&NGZ$'Y5X(<0/!AQN6'C)S(X
MD.&',1FQVS,EFU(NUI<MEODE)M4$162'I:MPU5J?9 Y4BHXZVN./B(J=Z7O'
MF,,ON#3$.(\#7A5AOS.,L"1V[@8R7]K,O$\%B2WU;B=IZUE2D:\MNNM41\9;
M6=.8W&7P'9/8&S4G8#PSFI@FY.YC&+&,@71,7"L20D);#C?4J<*W0"V04E0U
M/+6NX\8\)W&[Q+<,F8.4?$-CYF3B.Z8CP9=L-7%%NM[8C-6.^1[E.06HQ"%=
M:TSL!6?9[1J>55.XWX-\6XDXL>$S/6/?PS9<B,-S[/>K;U"#_$G95ACVI+G6
M:[F]KC16 D:<P.SL14$#CNOPY"V_GU:/*W+/"^8W WTEF#.''"F9UVQ7E+GY
M9,8/77#ET,B0JS2;-A^1++J)4UY]Q0E2W%.[$*"4<D]@J@C"_%1BK"F>F??"
M'E??I>7N.,X\76V-<\W'(CCELPC$@71QUR,XM\(@K5=(RUQ4$R$%*E:HU4-#
M<09Q<#F,\P./O)?BF@8C$7#675KQ=!N%E_+-K,M=_LKEN86'M=Z.J<5OT Y]
MA-4]PNB,9Q=@GB9PEF+?&5R\V;I:KY@_$D6"W'N^'+E9)SESA*9GQRB8I"Y0
M8#B0\E*DI*5 CE2*YA[P/>#O/?W\]T4T\?N<V)N%^+PC\&ELS O+.%<T(=ZE
M9C8RA0YEQN5U_*LLW%9BML%V9ME*4ZG6*X0V%@CD!76W#1FU>\N^,[+_  'P
MUS<;W?(?,7"^,G,TXU^M]^2SAZ=:,.R'K?)3-O396?SD\+>"65IV:@<Q596,
M^CLXF\Q,H,C<3W[,^(GBJX:EWJ+@/,"=8K?<&KO:)[P8;A2+6_OA*4+2RU$Z
MV0%J!._DJJB.&3!7'%+Q5<6L^;;ANRX8%CN=IWP+%AUF3<GI=L?A)EH?M[")
M$?<\L/E 4.2MIY"D+Z'CO\R3OW:\-YORCSNZ.7)_.;B3SMQOF/FCG)=YN!,H
M\57'_8'"B$.M-[)URDMRD2'VGTJ>2E38V]<E>@T"15SHPT&6FFP20VTTV"=>
M8;0$@G7M)TUU[:\Z> /A#Q7PM6_,:)B>^_QI6+KU(N,0]2AK\NV[/DR@CV20
M=$NI2"?#6O1P<@!X4BBC<Z;N$*4I2.,*4I2$*4I2$*4I2$*4I2$*4I2$*4I2
M$*4I2$*4I2$*4I2$*4I2$*4I2$*4I2$*4I2$*4I2$*4I2$*4I2$*4I2$*4I2
M$*4I2$*^:7*8AL/29#J&68[+C[SKB@AMIEI)6XXI2B$@)2"3J0.7.M=2@D:G
M[-6J/XCOIA)?!ME8UPZY$8A:&?>:,>5:I#\%:7IF%XR@&W0ZR-P"ID5]003M
M*>1'.J@%1"4@E2B  !<DDV  XDG0"**(2"HFP )).X :DGN XDZ#C'7'3-?B
M1<)\,%SN'#IPB*8S%SKDIDVR^7VWNI6QA"4M)0RI*2EV-,4L*4%;5?RRCGH:
MLI,<8<XBN,W%TG-;BRS$N=_N=RDNS6($LK+,=I]94&6&&W2VP$MJ"%%#:=VG
M.OKR+R4=M3DG,G,1Q_$.8&)9+UVES+FZY*D,R9KJY*U*4^IPJW%T[4ZZ)'(
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MI!C-\!X[JV :O_$Z<$S#+K9:G:>\M:9><;_+GRWR.M*LIIT J3ZR?PJ,4U9
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M<0P84*)W1($.)R[ 8S"&B!_[>[LK'T_A&.&U_,G/+/CBOQ/#T.&)D!K"DUU
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MW V166%EAVNU89M4=%PD,,I2_<+D\TVY/<D/:=:[_O?6E <6H)!T3IV56)4
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MPJ'+W1_[Q_>N7K?J'#B.7L]7'F\_E^W5_"T=5>^GYC^U-5>^GYC^U0Y>Z/\
MW_\ >FGD/S)_TI<_J'#B.-O9Z\M7G\OVZOX6CJKWT_,?VIJKWD_Z_0#6M)YQ
MIAM;TAQF.RV-RUO/(;VC3771:AR^'PJFK,/B9P9A-UVR8<3)Q9B92NIBP;6Q
M(EN]>H[4I"(J'2H[B.[_ $JQ5S$M%PW*JG*U4I:08 .4O+2''5  Y660"Z\H
MWLD(0=2+D1?*#AJNXFFDR=#ILU4'RI*5]BV>R9"B!G??(#+*!>Y+BT\@=([]
MQ%B6T83M<B\XAGL0+?'0I:W'"D+5H#H$H)W'<1IR!\>RNB<GLL>)7I,,W[?D
M+PO84NLRP3IS4:[XA::<8@1X06E4B0J8\A+(#;0=5M+PW:;1S(JO/H^NA XV
M>D^Q38<>YS,73*?AXERD2DW&>QH]-@(6%+8-N68\M/7)3U6XHU&[=V=N1$X$
MNCLX;NC^RT@Y=Y&X+MUH<1%8:N^(.J2]<;I);3JY(_-/)5(:WN[U[4N#DK0Z
MZ#2'NTK;;4,3AZCX>[>FT-5T/OD]G/5%&XI6I!/V>67_ .R@E2Q_U%6)3$R=
MF6PZGX64S6<1%JJ5Q(2XPT/O)"G+]504TE:07YE)_P"^H!"#_P!-%P%12'T1
M?0U9&]&?EE;U6^T0<1YW7V%'>QMCR2R%RG9H0%AF.V]UHC?E]ZV"N.M/6;03
MK7M@VVAL:)&GC]]W[5,E(2-!V?.IJT#$@@+"WTX0I2E(K"E*4A"E*4A"E*4A
M"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A
M"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A
M"E*4A"E*4A"E*4A"MGO%AL]_AO6Z]VNW7>!(:<9>AW.''G,+;<24*3U<EMU
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2A2E*0A2E*0A2E*0A2E*0C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>nt10002526x6_diagram2.jpg
<TEXT>
begin 644 nt10002526x6_diagram2.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( J@%#@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
M    " <)"@$"! 4& PO_Q !O$  ! @4" P0$" @'!Q ' 1$! @, ! 4&$0<A
M"!(Q"1-!410B87$5,E6!D:&Q\!88(Y25P='3"A<S0G+2X20W4E16L_$E-#@Y
M1U-B=(*#A9*RM+7$&28U0W.3HD1%5V/"U#989'67&B<HHT9EP__$ !X! 0
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M"?DT./R4RY*3"4(? *@A]M:.8$@XS&%]VEW:/]I1IOPE7!HSQI:$.V4SQ$_
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M7!HQIU3;'ITE9]8EG7I"4$[47G9JFS<NQB8#2IM9[QP#XRNONBX=:=IV_9-
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M< YC@<M< 5^4C/5;X$G9FDW11+FMZL,]]*SU-F;>JO*PX>9MYM+RY9*%@'F
M4G(. 1X1)+ARUYTWG+4KG!UKI;UQ5W1S4!]E-B7O+V[5W9G2JJMO&:#C+<I*
MKFYI%2J*F^\'>(0A"3S^K'Z(VI/!_P .FJ\VN=O?2JVJK-.'+C[--DI-:S_A
M*4PPA1)QODD[^TQYNV.#SA3T?9G*_2]+K0H<M(RSTQ-5&JRM/>8E66FE+<<[
MR=:4A"DH!4CUDGF Y3MMT/:7I0J-J;1%;[A9J:.MIIHZFDN5+53Q24]1&!\]
M'%NNP7ZAS.LW>&,$ K0]G.C:FV8NLM?;[O524E1#)3U-NJJ>&5E1 \@]5)*"
MW.Z=6OZO>X@Y#B#BK]GQP^73P4:B:@:A2LI)ZXU-M5&FF*U4)"5I[U(HKJ0J
M5[J3FD.J:6BGJ2E?*E"R49.5=+PW$%QCTCB<L6:TMMK2J3OFC5&CSK%W2LX\
MPANEOHE%EM;:IAE6#+O<RTAO!RCPVBSOQ\=HUH[I+K/?=+X2:NB_*M69EF2N
MNGRS"Y:G2"93+3K,O,NI5*O)*.\2.ZV3@8Q@"(2:>=IRW;.H= IHH;NGEE76
MZJ4ORN)"ZF9-<T UWP:Y.<I+CKA/=J 'B2!'!K[0=.ER@VZO5MM=EN/7R6F7
M86Z7"&[F.4.B@;>W[3/C80YU/()I*%](X,F;N1R%N"Y=(H:_86WR6>SNN#*-
MT#)X[A;H:FB8^(!SG4C*")SPX;^6ME9(W>!+B,Z 4MOS@RKG#-;DYQ+WG+5.
M^=/6*A55:?:>4RF3,X53<S-NL/+?F))#ZT)IDRI+K:9A 2L,X2,=((.7PU6*
MK5KJNIZX9BZKA6@U3-M5-"VY5@E-/E4L"6'*9:7[MG*4CFY<G<F/T@>">S>'
MVY.'2W9>R+AMK5^V:U+NSLY4)N6D9MQ;LXYW[K;E,F3,.R*FG75(RIM!605
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M.Q]%[FM:X<"TN!6H;>7>IL>RMUKZ-VY5-CC@@E'&*2IF9#UK>.',:YSF'DX
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MXOE3SD)& , 1V.5'Q6?=S*^D[_7'JS9[H9V;HJ.)U[9+=;BYC73DS2PTL3W
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M4@DE*DSA=2H*WYH_-64A#S4TVZA*VUR<US(*1RX#*@DA." 4 Y! R#O&8?\
MP;*YZ[/\*-=M><JLS/T2VIYSX&8F%+<]$]*GWUO)0XLJ4I)5L!G"0,"-4Z=+
M/,QMCO+JR29@#K6ZGDW6M$@9UYJHVMQATVX[K@!@$1[N&Z#9NA2[0N_;=G;2
M,A?OMN39H]XET;BR 4\CG9);"".I).2"_>R=5DHPC0=![A&L>=UWQ(0A!$A"
M$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$
M(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(
M0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$
MA"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$
M2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$7YGG
M!;VA.H.G5D(L?B8IZN(?AIOEY$K=5KUE24S]L2[;W(F:DJJ\F8J.0M9F%B64
M@GN^16Q$7E[4[(WLZN,ZE'47@^XB*;IC3JDRU-.4*INJ>F*;-O("WY7N:O.,
MNJ2R^I;8(;QA((V(C'2K.G%1T9O6[](*S(KD*A929/OY":;/JBH-]Z.9#@PK
M*>FVQWV,=73I*8H<ZY4;8K=?MF>?(4\NF5JHRDLI0&Q$K+3#3*0#Y)W]O4^D
M(.C5]RM-EVBV*O$EDJZNW4DE5"V>HCIYINJ:))&20N,D3^L:X/C<U\>]DC=R
M0?/]1TCQVZZWJP;8VEEXI:2XU3*6?J())XHC(711OBF 9*P1N!9(US) W1V]
M@$9%\U_!Q[Y0]-"E<9-M34J$_P!RJ3(4@] < GTPGUB ,G??KMO;1XN>S#XL
M>#&E3=\7(PC5C2.06E-1OBC+E%&E-N*#;+BY"GJ?=6EQ9PI1P$@9.PB)=/UI
MXBJ.P9:CZ[7)),G *')F>?/*.@RY,$[>S'MBZKV4_%_KM>G$O1N$?72^U:L:
M-ZXTVL4UVDUB1:6*3Z+3'@'4NOAYU:B\OO$D*"@4CE/C%E<*;I;V-IGWVKOT
M5RM] 875,#ZKTICX72-8=^*6&-Q;EP!>UPD:""#H<7=OJ>BK;"H98Z6R/M]=
M6LD%/,RD%*]DK6%_J312O:'AK2YK7M+'8((R59EEWV9IAJ;EG$O2[V%-N)P1
MS#!4A0&>52#ZJ@<'(.<&/;Z5ZKZU:#W56[NT0U-FM.ZE<J&45],O*^DMU 2[
M9;8*FR0@=V"<$@Y,7<.T4[$C4#@RLJ\]>]&[TG;ZTMIU474W=.Y2D*5-TABK
MSRG'N[F4][-/H;+JG.5*<)2C VQ%DJGUJEU8#T)]Y#H2D.R]1EW*:^V\  ZT
M&IH-N*Y%\R<\N^,QU"R;0[*])=J=3U%-'/U,E.^JME< QS:AK ]LD+1('30M
M>7-:\=F' +FEXL.T_1U<VU--421">.H92W.BRYIIR\-,<Y,9;!,YNXYS'<\%
MKCA34LWM&>T'T^J[M<MWB5G)J:?<#KTK,467=0\4G/=CO5*0@*SC(3]47].S
M?[>V<OZ]:%H9Q@TUFU;HK+J92W=1'IALR=P/X]?OF)="9>1(44(3WJQS%6P,
M8I73V$1U]5IC58DE2SJW67Y=;<](3K#BV9N5G))8F9934RV0\@%]M&0A8"AL
M01G.,VDZ(MF;I0RBTT<=GN3&%U--3.D%.^0#(CGA<YS>K>="]@:]FC@3@@Y+
M9WI6VCMM9#^UJM]WMSG-%1%.V/KV1DC>DIYFM:X/8/6W'ES'C(."0X?JR2$]
M*U*4EYV3?:F96:9:F)=]E:7&GF7D)<;<0M!*2%(4D['QCF187[!3C,K/$APP
MITYONJ*JVINCB42%PSTPY_=4U)3;ZD4H+05$D-2;:$E0SG8F+\^=L^S,>1ZJ
MFFHJJHHZEACJ*6:2GGC/%DL3BQ[?<1H>8U7JBFJ(:NG@JJ=XD@J88YX9!P?%
M*P/8[NRUPR.1T6U:TMI4M1"4I2I:E*("4I2"5*43L$@ DDQ8'[2+MQ-+^$VO
M3NCNCU,9U:UJ8;<8J-,DIP2TG;[ZT<S*USX2Y*/GE5SE'>#!24D9SB3/; \:
M[O!GPG7?<=LSZ&=3+HE?@BS)+*0_,)G7/0:@ZR%?SI=E\N @9!&1ON/S\Y-%
M2>?J%>N">?K-UW+-OU:NUJ><7,34RN>>7-H:2X\IQQH,=Z6@$+ Y1CIB.A='
M&P1VSK9Y:N62GM%!N>DR1X$M1,_!92PN.0TEN72OP2QA& 2X+0^D#;ANQ]%
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M'=.CO85^R%+4U%;-'-=;@V-LPA),--!'ZS8&.('6/<_UI'XW<M:UN0,GE#8
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MG9(4F._]$O2'2VR$;,WR=M/2[[G6RME<&PP.>=Y]+.\^PQ[R7PR'#6N<YKR
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M(G)'JDYW'3,43K?!7V8':P:>U^\^%VK4NS]6)66?GI>I2)?E)V5J2@XXVS\
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M9\.2E!&<Y6!G_@K5M]1C\U+@#NR8L7CXX8[@E %/&H5AA2><)4H/M)9.,[[
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MC-L3#;@!24.H*L'IE()(/L($=C$$:<^W3I[_ % JLW9]72K>DS*'YIAU8/Q
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M/]$7*I3]4Z0AV2LEJN.O3UN)FF9*8:E^^*7)B;[PS0!5RY&,YBV1VLB4:_\
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MU+N!27Y=R5GGI=0>;5A;8YD'EY@ 1TSU/ZNL_(RM2DYJ0G643$I.RS\G-,.
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MXYQTA=$%3<KE::R>D-EJ*Y_I%QGE#^NK* QQMC?$P%S#4-+!&-_JRQK\O&0
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M(3[>L:V[P1<-MK:^UKB:HVG\O+ZSW &15+P7-/.S+X88,LV$M+)0V$LGN\(
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MP!\*QC QF)H6I:-O61;]*M:UZ:S1Z%1)5F2IM.E$AIB6EV&TM-H2AL)2<(0
M21OU.YCTL()E11GN"?AQJ'$+)\4DU8$NO6V1!$O>29IY$PD*E_12%,I/(L=S
MZ@"@0!TB5V/O[H0@B0A"")"$((D(0@B0A"")"$((D(0@B0A"")"$((D(0@B0
MA"")"$((D(0@B1\G66WD*;<0EQ"@0I#B0MM0/@M"@4J'L(,?6$$4.==^ SA8
MXD4J1JSI/0ZXXXE87-2;+=*?)6,%2GI)MIU2O:I1/7?>+>U4_@^'9U3\],33
M6FLY+-NDE+"*_5BE'L&'<8]WAC$7SX16BJ:F#/45%1 #[0AFDB!\=QS<\%3D
M@@F(,T$,Q&@ZV)DF!W;[3CW?BK0VFO8@]GKIHIJ:INCB*C/M*Y@_/U>?FD$Y
MSNR^M2%#&Q"DD'V1);6'A,L='#I=>E.D5ITVU6YAF5FI*0ILNPPAU=.=]+2V
MH-(0E14I&Q5DY/F8G M:6TJ4HA*4I*E*40E*4I&5*4H[)2 "23M%A;M*.VWT
MLX1*C,Z3:2R<MJQK<IMYB9HLA-AF4H3RFR6G'J@D.RCI"25J;*P/5Y#DF*T$
M-=<ZJ*F@94U]7.X,BB;UE1-*X\@/6<[3B> &IP J,TM';Z:6>=]/14D#=Z65
MQ9!#$P<R?5:WN'/@ 53"V]<)/3^UW[5U,D5VW==O-3M-$C.%;?IQ4%R\J6E+
M"$*"DI03R\P2#OB/+NZ:75,: 3>KJUT7T1^JM3BK=17*<N85*IJ@4'3*)?[W
M(:'><O=9\(QCM<^,KBEXF[W:OS52^VY)V5>F':1;<E392633&YC_ -V],R:6
MQ.%*>4!3G-\7((S%)V-6-=9*:5-R.L5:ER5(/HBU3+LER(.>[]#6\9;"D^K_
M "8WWZQKW1K\A2W='ESVZVEV=IG4%7TBLG;=K;<+P9&4-)4/FFGH[>R&G(IF
MS3U,LHZV::2(EL8>UC,+7;_\HNSW-MLMM7-4U<-F<T4]924&(YI&=6P2R&65
MKY-UC&@EL36N&\0TYRLOF\M=+;KEE2U!LIN=KUT7%+R-+EJ5*R4RIIAP);E9
MCO'DM*;1R<RL%6,XB\-PFZ/NZ<</]KV/==.EIJ;>9F9NIR,^RU-2ZDU!PS26
MW&'DN-*Y4NX]9)W\CF,'[A-[6'5SA5O61K=V:>R>J]F+<9360^Y)2CL@TGE0
MN;:YF7'5*2"I_E;&>9..I$9K/!?QTZ%\;>G4A?6DERR,T\IA'PK;KC@EZC29
M@>HN7,H]R3"TH<"D!0:"5)3S="(TOHT^3+:_DS6^\6&VTUW<[:&ZNNE7<[M-
M#4FJ,;#'24M/-3,93&&BA>YC0!USW.?)-ZS@!NE3TE4_268;A3UE),VAIQ!Z
M-3M?#)3[Y#GOF@F/6M=*X#76,!H#3A>,U:[+K@DUNK+U=U T5I$[4GBLN/T]
MU=(;*EC"E=U(!E&3G/Q>I)B@%.["?LW:?/IGF]%ENJ0LK0TY<-34@$G.X[W<
M9\#M%X>$=/945$;=R.>:-GU(Y9&-/BUK@#P'$*S?##([?DABD>,8<^-CG#',
M$@D'O44]%>"OAKX?P$Z6Z64"@K2$A$S,2C%0F4<HV*)B:;<>0=^J5CI$J4-I
M; "0$@  )2.5*4CH$I&R0!@ #RC?"*/$DG4G4DZDE5.0'(: #0 =PY)"$((D
M(0@B0A"")"$((D=7.SJ6DE*3OOF/K.3264['?!\8\%4ZC@JRKF)S@>WQ)]T8
MZLK!"T@8SC3MSV^ [_T1;:C4<%7K;^ S]OE[CCVXCPU0J>"HE63OX[#^S_3'
MSJ51(YCS94>N^ !X_?ZH\%4JE\;UO/QC0;G=2-[#\Y/;QY\^ \$\?/9Y_P!5
MR9^J$DA*LDG&,^?B?(#.3G V]QBR+V@?:UZ2<,-\26BLO:].U1N5;S8O.6=6
MVN5MAI7=NL+65MOR[JG&B5)3E*@I.!O%W*H5-?)4 VYRNNTJJ2\NOKRS3TFZ
MW+D#S#JD'/F/?C"]N?LSN+O6GB_U(DKSH+U%L:YKEDJA7-3IJ;8GC,4V3FC-
M2K#,DM9<;2I@>C*[I6P.5#PC#6ZFZ/;]#M)#TH7P6?8ZGV<NDMW+:LT-1602
M4[H'4M-5 YIY'!^\9@6E@USVVE54W^E?1/V9HF5MY=<*..E9*T/A@)F:75,T
M>0Z9L36G$+,ND>YK<8RIH=HC3]>>,/A_T4UOX7:15*CI:IBK/7!0Z%.N4%Q"
MD+0CE2W+EA]T,O!?*4H]8(R-C$'>SUU)XXM-N)2RK5H-,NVHZ?U>8?E[ZH5<
M]-6Q3VV$!+2A/U(*YN4E2\MJ 40!OM&5;IG9UNZ/:<6GIE:#,NU;UI4]N5EF
ME-)<8>F%-($Z\IAP%*N^>2MPA0(]8XVCN79B72E^:;IU'E3@EQ^6I$E*O>))
M[YIE#@/B3S#;V1Q2#I@V/Z#>AB/8C9_9.U;2;)2W"&W[,54Y96[0];M#<B:>
M>*\[[&SEIF=,TES86M:8V-:" MA?8+IMIMD^Z5ESK+?<8:6>2X0"22"U.AH*
M?UFU-N+'X<-UHWF;DI=@O<<+T<[5DH6D)7A*F&'%^/*^XT%/-^9"'"I.<8.(
M\[,58G.#CR)./OMCW_/%';DU>L2W75M52XV&'D9YFD8=*2/#U"=^O4#Z>M%*
MYQ7:92'.&)]506G( #3J,_/@X\HN*.S[67O<%HV=O=PZP-+?1K;52M.=W3?:
MS<.#IG>PM>J[E;;>"ZMN%#2-;Q=4U4$ X^U\Z]NAXC0::'OEJ]5NOY0D^0'W
M_LV,=<Y5B I*DMNI/5,TVE](/7*0Z%!!VSE(\,Q;_K/&?3$\Z:1;JI@[X49E
M2?#K@I^CV]8]EH[K9<&ISU7FI^F?!U,D.[[G\HEP+[P$'H =B-Q%[M#T<=(V
MS=AGVFV@V=J[+9Z=\,3JBX200/?+.YK(HHH#(9WR//!H;H 23@%8BW;8;+W>
MX.M=IOMON5>R*2=]-0SBH='%'N!TCW1;S&M!<T:R9R1C)R%,)=6P<!7ELG!V
MZ;)&< #H/+;:(O<0VN5^:<4\_@I;CTVTXE0<K:%!7HW@%&6*5$C?'3;&>D1\
MX[^*RX.%_19V\[0IPJ=UU):$41LN);2TI,PEIT'G"D*Y@1\;&_A'AN!?C&F>
M+K3ZXJ1J-1)>0ORUVI?\)J<XIIXS3=1R98H4E(0DI:.26_GC&;,T5TMUJIND
MJY[,LVAV(MU\AM-QCFJ7Q12U+FLDZB3J7ME:',T:]V8B\ACFD+)UDT<[I;7!
M<!17*HHI9J=S&L?40Q!PA]+CBE#XWB&5[06NRWAO#!5!Z_Q*:R5QYPS%V3#*
M5+5^32VE'+OL#RXZ=/,8\HZ>G<1^LE!>[^4O"87RG/(M 6%8_IJ/AGP\XJQQ
M#:$BTYIVZK684Y0)A:G)J6;!5Z$HG??=1"E$]!X'J!$-9GQVQU__ !MOFCZL
M=%M%T)]*&Q])>=FMD=FWT,C1#6V^6VTQJ[=5M8.LI:KU3(U[>+7[P$C"'@G.
M5X:VZO'2QL/M%)1W3:R\R-?F:WU\-0YE'6T^='QQ;HB8]GLS0%F8G#&K"USK
MA.G':#W;27)>4ON0^%I,J2AV;YT-*0GH5<K:23C/AY8BY5I?KW8FJ4DB:M>L
MRZYGE2IZGN+#3C:B!ZJ2XH*60<]$GV@1C:+_ ),?/]N/UQV5KWC<5DU>7K-N
M5.8I\Y+N)<'=N+Y%X.Z2V%!&" 0<C&\:CTB?)%V2VBI:FNV%D.RU[:QTD-'O
M/ELU4\9(B?&XF2D+R-T21.+&Z9;CAMFQORA[S1304>U\#+K0O+&.N--&R&X0
M#U07R1LQ#5-&-YWJ1R$9PYQT.5-+5<@X*BD^(.?]&-NO3KTCT<K5=P>;YP?O
MY?LBU[PV\8U)U':EK8O!]NFW0VE#+4PZL<L\H#'_  4(PD#QWS$^)6J#U2'!
MN H84%(4%#((4"001N<'YH^=6TUDVCV#OM3L]M1;JBV7.E?@QS-/5S1 @,GI
MI1ZL]/(-62,)&NN'97KBTW:W7R@@N=JJX:VAJ6AT4\#@YO+>:YOM1R,/JOC<
M&N:[0@8UKC)U7 3ZV>F^>AW^SRCULC5LX];Z^F?/[>L4(DJKN,JP=M\[=?[8
M]?(U//+ZV#Y9ZXV/LB:AN^,>MD:<^'#&>W&G-9'&N.>GWJO<A5?BD*\M\[GP
M\QT]OS1[>GU3)'K>6V=M]AC..N/IB@%.JAR/6\AC.WECY_9B/<T^I[CU\C;;
MRQ[_ +1&\VV['0M?V9!YZ9T[#H?P&B@J_4ZIXY1S>J#U\1\WOV/3SQ'OZ;4O
MB^ML<1'^G5,^KZV>GC]_OX^,5 IE2&4^MUQG?YHZ#;+IO;OK>.OARX:?!%6Q
MIU+J0I)]XCZ1Y"F5 )Y1S93[_ ^7]O7?WQZQ"PM(4/&-VIJ@3-';C/CH/U1;
MX0A%TB0A"")"$((D(0@B0A"")'R??9EFG'WW$---I*UK6H)2E*1DDDD#H(W.
M.(:0MQQ00A"5+4I1P E(R22=ND1@O.Z9[46JS-LT";5(6S2U<UP5H'E0I"05
MAM&2G/,4J;]11.>HSB*T,1E=QW6-U>\\&C\R> ',D!75+2NJ7D9W(V#>EE()
M#&9 X#VG.)PQ@U<XX"Y%V7I5K]GIJW+3?]!M^4)%:N%1"&TMC<H;[S 5S<JT
M?DU$YQ\WDJ-(35P%5I:>-+DZ&TONZW<ZTE3LZ<Y7R=Z.] Y^=/J+(P?&.30Z
M,Y?CC=M6PVY2["I2^6=G4Y#E7<"LK)6>5W =2K^<H8..F<RFH="IMO4]BFTN
M61+R["0D!(',H[<RE*^,HD[[D]8O))&0,$;6^L-6L/T3I\Y+]:0_19G=9S!(
M65GGBH8VPQ,'6##FQ.PX,.F)JKD^<\61>Q$,9!*Z.S;'HUFT]$K3V$J>4 7Y
MMS\H\\X=U**UY6/6R<9VSCPCVD(1CW.<\ESB7./$G4K!OD?*\OD<7O<<N<XY
M)*0A")5(D(0@B0A"")"$((D(0@B0A"")"$><JEVVU19Z5IU5K=-ITY.%0EI>
M<G)>7<?Y>H0'G$$X\< Q*][(V[SW-8T8RYQ#0,G U.!Q1>CCJYJN4:2>$O.U
M:FRCYZ,S,[+,.?\ 4=<2KZH)K=&6 45:EK2<$$5"5(/B,8<,1EU8X7[(UBK_
M .$E0J\XS4@!W2Y"J3*&T81R_P E+/H0K('B(Q-VJ[C#2]99:.EN=7UC!Z--
M7>AL,7%[FS-BG]8:!K2P;V?: U4[ TGUW%K>T-SKIRTY+Y<7"%US1>OKMBY9
M23K%.<D9V6>E*BP7%(EYA#SJ?R;^3S(0H8WV)CW?#7>T[J#H[:5RU!SO)Q]A
MZ4F%YR5+D5F5))\22C._OB'E]<#,I2[9K\W(:BU:6EV)%^85+/JFWVU^CL+<
M""7'E#UN7&<$;Y\(K#P#NO\ \0-%E7>92)*?J\NVX3D.AF?>;*_85<N2,YW]
MQCGMIK[Z_I#9^U;3^R&W'9J=G41W)E?3U$EMKH'1S@,CCZI[&UCV$N8USPYH
MUW57<V/T?U7;^[(-2TM(WFZCOX=OY*;4==5*5(UB3>D:A+MS,N\DH4A:0=CX
M@D93CKD;QV,(ZV"000<$<"K8$M(<TD$$$$'!!' @J(-W6'/6)Z2Y+2JZW9$V
MHF;I^Y=IP*MG&G3S/$!2BK",;#'E&RT+UG;&]'<1-.5JQ9U>&9@Y[VDDJPIM
MQOUGU#O#R@K &!GIO$O'F6IAI;+[:'6G$E"T+2%)4E0(((((Z&(P7OI].V?-
MS=P6W+^G4"<R:U03A2>17J]XTI?,6^3F4X0VD;CKX1D(IVS Q3 %SN9.!)H
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MJ5G;]FWC]QXQ06ES^0G)/AT\/U;Q4>E3Q4$CFW'U]-]SCZ/?'3;3< 0WUL#
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M,GW;GBGO9E#:3R_-'.+=2=&%;,UE+45^SUR>QH92RW*\V&J!=N[HBAGJ(8I
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M5O/GNC[U]80A!2)"$((HX<6.K+FB?#YJKJ4R%>DVU:M7>DU)!);FUT^8$LZ
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MRLNIP8YTXP>ABVO\UIIK:*BZT5+<>IFC?04=33PU4D]QT%*RECE8_P#XASR
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M3,=TFH,S$YR!@@@*8;4DCQ&1&M7;8[;&S-I;M'?]G[U2V7,[?1+7Z#6NI&L
MEI8I*:NGIG1RLT$?58+PPM#2 MSHMIJ"Y8'434E1H6![BYKCEN\UV\QKAD:Y
M/,:G(P;S;+J'FVW6U<[;B$.MK'1;;B>="A["D@Q]8C7PDZKHUGT%L.^4K2IR
M:IPITSA04>_I24R3A5@D@E;).^YS$E(WFFGCJJ>"IB.8YXHYF'M9(T.:?@5L
M(.0".!2$(1744A"$$2$(01=?5:>Q5)":D)EM+K4RRXA25;CF*"E)P<]"<CRQ
M$&*E3IZW9V>HA*TU.UYQ$S17=PIYB9>[Z9"#XA+.QZ[>43WB.FMM#5*+IMXR
MC(YJ>5LS_*!^53-D,)*_/D"SO%[12;KS&>#_ &<\-\</M#+#W'NTR]HJ-R8P
M./JS>P#P$S?9'A(W>B=W/SR58[.N!BY;?I]58((>:#;@!R0XR.[<SX[K!^F/
M41&71FL(I=8JEK..YE'4LOTH$G"E/([Z8",GP4HY_LB344)X^KD<T>R?6;_*
M[4?#.%9UL'H]0]@]@XDC)SK&\;S<YY@'#N\%(0A%%6B0A"")"$((D(0@B0A"
M")"$((D(0@B0A"")&F0.I$:*4$C)\P/I.(LU<>';-</W SJK0=(+RI=5N2\Z
MXW,+;IE&I]2J,TT)=@/GF9ITM,N>L@Y&4C;W00 G@KRV1YB-8LXZ$]KYIAKQ
MP^:Q:]VQ8=RR-*TBEI.9JE*JU)K%+F9U$TMQ/Y!$])LO+Y V5*[I"L#!)B:G
M!!Q8VSQJ</-JZ_VG2GJ+1;GFZO*,4]\N%QERDSSDB[DNH0OUG&R=TC QX04<
M$<>W'O4NH1H2!UC3G3Y_4?V04%N(!!!&0=B#N"#U!$=9+TJE24P]-RU,ITK,
MOX+TS+2,NQ,/$=.^>:;2MPCPYU$QT-]7G3K$M:KW34PHR5(EUOO )5ZV$J*4
MC /QB,9]L6I*WV@FJEY!QW3C37T.C%^88E:R[4627^X=4TI?</)24@%.?OF)
MFL<_V03^2@7 <5>([Q)V(.#YI./OX1T3EJVV].&HN6Y;[E1.?]4'*-3USN#L
M<S*I<O[IV/K[C8Q9FE^+OBCIKZ9Q^EM5E@*YU4[OI.7]4')1WF,G(VR(ECH9
MQY6Q?M=8LG4>C_Q?7A,E+4A+3#QF96?< ]?^[.5,NT<8P%+W)P(F=$]HRYI
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M!8YM-<)3<:1Y'JOCJ?6D#3P^;FWV.&<@XSQ&=(0A'0%HB0A&H!) ']@'B2?
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MI1GOB>&-L=?OX;?1OTJI1G<E&_3'^CZ//H1[HZ18Y_69K]73/>WW>[W<%/\
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M"-_GS]N!CVQU"[V5G^7Q[<]?+R$1EF[OP5?EM_Z73/N]GL]_MZA5X#/\I_\
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MO\:FM>N=U)O/7_7F;E*A>TX91N5-/7(NNKE9=(946'.[:=[GF1U"<D9.U[X
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M  8 &!P&">SU/T4W5EYV3AKHZ6EHVR5U:PPT;7LA!B=&W> DDE=O.^EZV.&
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MBTCS\NWJ\W>9SC;K]6P[]1].FSLD#'5MMN=-48&_'$V"HCS@9W).LC);GZS
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M)/TQT[_1/O/V1]18>#?$?@%\Y6^S_A'XA=4[\<_?Q,=7,^/S_P#XT=JXE2G
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MPMSIO KUAL?TD[&[="H9LU>8:V>C#344DC)*:KCC) $WH\[6/="3H)&;S0<
MD$@'6XIA<O<=KN).$H,P3OCP'C[QO%0S<J=LN>"1O[!Y8_LBA=T7/3ZC6*8*
M8[WR) NA][!2!S] //.?#Z?+XKN $[.9&WB1]6?],?6KY"&R=SMG0':F7BV5
MEMJ:B]W>H;!74\E+,^GDG889Q',UK]R5NH)&O9V>+_E1[00Q;?T%)35,,II-
MGZ5DS896O=#-)55$ABFW'$,D#"U^X<.W7-T];*KXBY$9^/U\<D#K]'S=/HCL
M6+B'7O/9C/M(V^YZQ'9%PC( 7OXG/7?P'A'9L5_./7Q\^=_OY9R?/$>QY+*,
M>QW<CG4#S\>2\XQ;0N#@#(0-.)YZ=_'E\3XU"U#K*9U5N2RCS%3CN/'^>/V
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MHH2&YE +,P% **BV5 #KY1%GBDX792\Y"<O6QI)N6NF5;6]49%G"14 D$D@
M!#9;0"< 95[XW_8/;^W7B@MM7%<8+E9[O24];:;Q!)UD,])5L;+33=9H7T\L
M;@YDA&\ 0'=W.-N^CJHHJFLEI*-]%<*"62*XVHM#<21'$O4L&0V9NI?$T[KA
MES-< V=W?CG[^)CJ)CJ?<?L$=_/RLS(SDQ)3C#DM.2KBFIAAU*D+0M"BD[*
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M$$7%G$\S*O'&?O\ M]D4QK"=E9Z)SGZ.OW]D53>',VH>R*<5AHX<\/HVQO\
M0<[#V?/&%NS<LSCW_#L[C^FN$5'*RG'/@;;[_9]FWT122LHV4/?[CU^W)BM%
M8;^-D?/U'W/V^V*3UEGXX\B=NGC^W_3B.0WR,YD]QY=W;YXHJ,U=O96W3/[<
MCW9^N(E<0VG3^H5G3$K3\"L4L*>I^P*E85WCH"C@#*4X^?'MB8M7:/KCY^GW
M^^1%+:NUZR\#PSGP]V-P?=Y>$<P=7UMDN='=[?)U-=;JJ*KII"#ZLL3FN;EO
M-I]EPSJTD:*C4TT%;35%'51MFIJJ&2GGB< 6R0RM+)&.SR<TD?A@JR$M#\O,
M/2,ZRN4GY-19F)=T%L@H44!22H#FYPGFVSX;QI%Q;5/1>UKX4N>6RBEUH!1;
MJ#*3@K\.9EOE2K.P/-F()WK8]PZ?S:6*TTN8I[BB):J(3ZJ@-AS-HSR>"?6W
M/S1[FZ,_E [*[;FDM%RE;8]I9&-C]$JG!M+73AH#C0U!PQSGD%P@?NR#. '8
M!/B/I!Z"KWLXZKNNSN]>;&PR3.@8#^T;? ,N(DB Q511#0RPDOW1O/CXE>5Y
M>=,TT3@3-/G90'R5,,+:3]:HM3<)5QM:,<3&M6A]ZN)I<[=<_*35JS<T RU4
MQ^5G'TMO+Y4$MI6E..91S@==C=9V."#D$!0(/GN-Q]D0^XJ^%N3UVILA<]JS
MIM?5JTN>;MBY)8$/./)(=6RZE!0ESO4H2R"Z2$@^77M-UIZAYI*ZC:):FWRN
ME$!.!40R,+)X0<C$CF8,1)QO@ Z.RN;;'7*V0B];/WN5U):MIJ.&DDN#6%YM
ME=25#:FW5SV ;SZ>.=I95-;ZPAD<]NK,&7;X*04J&""?<1D$$'Q!&^1]D=;,
M?%^G[(M?V+QVW)I('=/.+.U)^@7'0VE2\G=J6GYJ6K;4L@I:6L2;988*FT(!
M*E]59W(Q$FM"^,#1OB%:F&+5K4K(UN76MOX%><Y5N *4E"T+>*.8J0.?"1MG
M '41>6V^VNJDAA;5,BJY-YOH<_S-2Q[2-]CXGX(>TG0 D.P=TE4[QT?[5V>*
M>MFM4U7::;<=^VK?BMM4\,V>IJ(:J$N:Z&0#)) ,1(;,&.4BW>OSJ^V.NF?'
M[_X,=B[U^<_JCKIGQ^_^#&Y0<&^?HK2Q[9\/T73O_&/]'Q]T<!AE=5FVJ=3>
M2>GGUI:;EY=Q+J^99P,ALJ*<9WR/?B.;-2<Y4$.R%/;6]/SB%,2S;:5*6M3B
M2D)& <9*NOAU\,Q+/A1X<9JPZG;=RW'9#E'K,J9YZL529J1GTU037,J4(E7%
M*0P6TJ&P W]V8PU_VIJ[!<MF*"GV<N=Y@OU;5TM;<Z)T H]G(Z:A?515UV$K
MVRFEJIF-HH33MD>*B1F\T1[SF[UL1L/'M?3W^I??:.TOLD-%/#25,4KY[L:F
MH;#+!0N9AC9X(\SN$IW2P=JK+H!H!)V1*M73=$LF<N5]DS#,LM <]!2$%6 G
MUDK4MO Z#!B:FFM\64JV[^N"\GFJ;:5IB5=JCLQ^3F)9X*495MIE7*\OTAY"
M48;'0],1TM.<<;J$NXVI*'"[RI4I(*$H4H ^J=B GP/NB-'$;8\E=6H=#L*D
MWNQ+LWO4J8]=DE+<C#+;=->8?:0^EMQ*.5:0H;@>.<G,<%Z=-M=J-EK?:+_;
M)8)*!]S%NO%--&#NMN+/1[750S'!IVT5PZHRAKP)(Y7[P.[E>J^C+9FR1];;
M&TQ!AIQ)3$/#>OE8,U GR?GC/&3D%AW,#<<W12@L7C]T3N:;G*#7K*GK:EJJ
MX&J!7WI:>+=?^#E>H$<S*4MA1;0G/-A7/G>/<7'>^CW$;4[?LC5O35^RY:IN
M*8LV[$S4TRXIMHI#ZTJ92TML3"0D'*QD*)WBG7%5:S5[LV3HOH71Z7.5G3:B
MMU%=1ITK*90J6D6I^8YYAMLI<+W<*!"EDYVW,<.4UFH.OO"&;AJLY3+9U;T?
M+]-GZ>Z9:3GVID3:I.76VR>Y=<+G<A64)5UWCRE=ML]K[E)M# ^[T5QM-CIW
MNDHY[7324&U!AB@FOUMD=,7L='24[FPQ1QM^<>/7WA&0N^T5'2T,E/B)L52_
M#HYH\Q20%I/5EKP<]87O<[>R'8/'5;-9-3],N&>XV]#>'_35W46^*3+%ZJ^C
MS;RC3Y5^7$TI^9F%)=2^5RZEK2'%$@[#?$4FM#7*@ZB*IDM0;=F)"JK<FD7'
M*S'?I,D^%%);4AY "AS!: < 8WQC85ZX**'2M-M-M4.)O5&J4RL7M?$NS*H,
M\9:8FVTR?>R,HAIEQ2UH#B"A)*$#(QU$0<D=0ZM0^(5ARY:*U0:1J3-SRZ6Z
MEIMMAY$JE92I'(A"4<P4D^9)\XWC9SI#VE%YV'M5JO,-NL]^JJ":HHHK;2RT
M]AV6CGCBH6;S&AM.ZXO?%0,:_P";C=4/=$QIA!6J;362WRT5RNE92F:M#*AT
M;3(YLD]6\9,CWY)>]C6]<\ZE[8PS."0O"<6O"XU=LK,Z@6%((:N"50IZKTYA
M(3Z<D ;I PA!;0DJ]5/K&+/L\R]+3#\M,M+8F&%K:>8<!2MMQ!*5 I("ANDX
M.,$#:,H<C!4" 0H*R% *2MMW/4'((4@^W'A%L3C#X5A.-S>INGE/S-@*=KU)
M83LX ,)6@>&!S+/(DGS,?278[:GJI([7<9,1DAE)42._LSD!L$KCP9RC>?9]
MDZ87BW;?8\2-FO-KB^= +ZVE8/[09!=40M'TQC,K /6'KC4$&TXOK\WZS'7+
M^,?F^P1V3J5(6I"TJ0MM2FW$+!2M"T**5)4DX(PH$?-'6K^,?F^P1V6#G[_R
M7*6^U_A'X!;80CDR<H_/S3$G*MJ=F)EU#+2$@DJ6XH)& /(G,5)98X(I)IGM
MCBB8Z261Y#61QL!<][G' #6M!<XG@ 2J\<<DTD<,3'22RO;''&P%SWR/<&L8
MUHU+G.(  YE>PT[L.M:C733;:HLNX\_.3#8<6A!*6V@I)<*CCE'J9ZGP^:,D
M;0[3>G:7V/1K6D&TI<8ETJG'4I +KC@2X0<=>59(!SUV]L13X1= I#3:V)2X
M:K*H5<]6:0\I;B 5RR2,IQS<V.="ATQ],7"*0SCDSD\N"?ON>N_ACV;1\7_E
M2]/KNEK:X;-[/S.&Q>RU9-%2O:?5O%S8>IGN+L:.@9@Q4@.?4S)H7A>]>B7H
M\9L19?2*QC7W^ZQQ2U[\?^5BP'0T$9U/S1?OS.TWILC5K&X]_2$;C'F![L8&
MWO\  152C(]8>(]7^T_;%.Z,ULC(SX_Z/OTWVBJ=%9W3[3]_'W?9YQP^R1:L
MTT&.[/L]_P!WY!=9/GSY^"]TU49&BT]ZJ5%WT>1E$I+[Q&>0'IMU/ET\_&.+
M3.(K2=@)+E<?.%<I*)"96"4GE."$D'W9V\Q'FM3&\::7$=QD2PV..KF,?..N
M/UQZ#0S3FQZKIW;LY4;=8FYE_P!)+SQ(RYAT]<CZ/GCONS-#0"V?M"L%6]_I
MS:.-E.Z)C0T0-EWG=8QV<G08\-.*S5)36YMN=75S:N0^F"E8RF?%'@=5UA<X
MR,=GLTQIWJI--XI-%V"GO*_-)Z?_ ',G#X>QO[[GW^B'%KHA_E)-_HF<_J1Z
M:FZ.::OI'_JI* CQR#GI_P 'P\3^P1W/\2NFO^2\G]"8Z11BW")I8RK P!AT
MD1/+L9C0=@_1-_9_]S=/?/3]VFD/C\5X#\;;1#_*2;_1,Y_4C:KBST14E0%Q
MS>2A0'^I,[XC^A%0?XE=-?\ )>3_ .JF-B]%M-0%'\%Y39"O 8Z'V$??ITB[
MS0_4J?\ W(^[^#Q^'QAO;/\ [FZ?^]3_ /\ Q49*7=E)O"5U0N2VIAR9I<R]
M2@T\MI;2E?E.50+:P%#RZ=/=$M]-4J19M'"A@\BSC;QR?#SZQ%95*I]".J5*
MHLFF1D&GJ06Y5OXH(<YMMA_.WZ?-F)5Z;N+=L^CK7\;NU#IC89 ^B*]9CJAN
M#U#(S&>..HBQO< 2-1^"KW7JS!F(.;$9H=P/(+PWT.#=#BT $XXX &>"]W&A
M&?+YQF-81C/\ONU6O*WCI_OQK:N9*OB4;;F.-I+(VSX8Z=,1P]=9Q^8XN]!9
M$(44,KKFX.?C2R3T'3[^V.;I_P#[-;5S^A1_^XF.#J3/MO\ &SH])<@YI85@
ME>.;//)9Z8VQ]GCUC@\ASL]/'O[G7=*;8\XSG_ZHC?N^\-/9P]ROF_V@YXI
M?_ZQVJ>%W#EM.X=FU\M#G_5>;#J/]8N]4+R#TZ8ZQ9BTZX']-^)'19RX)9+E
MFZI4ZL5R8HEZTIQV7<:G&ZH^MH.RLLMA#J5*0A&%D@ GPB\M?LT)2SKH?*0K
MDHT^,*/*G>4>&ZC@?7%FG3'CCTUX=-$4T9D/7AJ=4ZS7&:/8]*:>F'79E=4>
M0V'IJ6;?2QZRDJRX$C Z]2-HVI=:_P#>^P1W9T)I!8MH'2-FSC/7VEK"P#UN
MNW@1%U7SN\!N:JU.YZ-+OXQUD?'M];ASSX:KU'#OQ<:A\/=\37#EQ@3IEYRG
M(6W9VH<WR-LW%(RK:G5'NFAW;:I>62VV0IQ2EJ\S'*U.[1N]=3;IGM,N#JP*
MAJ#5$=ZW-7BXEVF2-.+2%*4\CTQD2TP  H^JX1ZH\XC;>O!KQ0<>]*J>JNN=
M05IXU2)5ZJ:=60RS+N3K;7=K>6PY4Y4M/J,TE#:>5X@IY^7&Q$29[-S5ZTY?
M3JZ]!KCMFFV3K#IA)UB5K4K-(814JLVM$T9*8;FUMH=?*Y=M+BN5:\<^#$*6
MNO+I8;3)555LM=1UTELN%7$/VI5T\(:[T/>D);3RAN\Z*2=AGDA .X'M)5H-
M\D,R6M=[+L9<=1@<\<^1)"AI:.C'$)Q2W?=R>(/5Z>DY&V'I7TZW9&74PA7I
M)/\ <XF9%UL?D\<A4.N,[;1XFO<).C-M:R2=K2]+J-2IK+:S-EZLSZR^ON.;
MG/>/+*<KR??X1<4X8I=4Y2M2+F<"E+K%6>2%K.2OT2??;ZG)P,;;^[:(]U\"
M?XA[C=",B0;:3S<WQ>>6QTW\HO\ 9NS4=TV<Z,KA<(37W3:/I#MD=35UI=4S
M3VQE7<JMM,[K=]HIW45)$R6-K6LD&2_B5SG:>KGI*C:5L$LD<-%L_6OC#"&[
MM2Z.")LN\W==U@EE<6.R7-)TU4)M9N&_2BG2Q>H5,G*/-*<Y6WD5*<64GGY0
MKE[P9Q^SQB+MQV!?^GR1-6M<;U:IR$)<<ICJ3GDQDH[UU2B=L^1]\7$-;=Q)
MMXSWCZ^IQ\5P1'B[4$%*1G'(WL=Q@ =0?/QCTOLGL%L[=^E#I-%/Z;LVW9W9
M_8V2VUFS%7-9IK;<*BBNE?5U<<5,&T<[IF-@Z^.HAFCE9&QKV<UY?VQVNO%L
MV.V/$@I+S^UKK?XZVDOE-%<H:RECJ*"F@IWOES41-8Y\G5202121N>YS7*&*
M[R;N%IUJ995(U5GU9J37D$*R02DJ"0>A(P/[/#S1*GED^?C["1%1M9J VF>9
MK5*;$M4)4<SP;3RA].!GF2D >JDGSS[S%*)6>34)=$R" KHX"<$%/JGK[0?;
MGS\?1'R=^E6^;7V.TVG;BD91[0W"PMVEL%R86"#:G9HU+Z05P8T-9#=:-S(A
M=:6,!@$T53&T1R8'GSIGZ/;1L[<[E=MDZEU19:.[FQWFWNWC+L]?>H94>B%[
MBYTMNJFOD=;JAYWCU4D#W.>P$\F-,Y\/I\O9C(CJGZD ^B3DVO3)QU7(VTC/
MQB< 9 (/OWZ^'2-L_3;FEGS+SR?@]S"26O47RA8RG<=3@CK]4;K>.G+9"CVC
M=L;L[3WC;S:YD<\TMCV1I8JXT\=,^*.H?5W*HGIK93MIY)HHZC_B7N@?(UDC
M6N< M7MG1+M+4V1NT][GM>R&S;WQ1QW7:6I?2=>^=KWP-IJ"&&>OF,[(Y'0G
MT=C9&L<YCBT97<8)&<IQ\V?^U"/M4K&JM.H5-K;E9)54><I8[H#EY%8Z^.1Y
M=!XB.$RA;;2$+5WBNBE],Y\<#;I\WCX1?=&/2A/TELN=5%L7?=GK9;JZY6H7
M*ZU=JF@J[G:*]]NN5##'0U4TPEI:F.1KY',]'?U;NKF?HK3;O8&#88T$#MJ[
M/?*ZMI:*O=0VZFN,4M/0W&D96T55))64\43HYX9&%K&NZYN\-^-NN/'ZC7M3
M-.[(N*\JL\AB6I<DZVT5J YYJ:;<9E$IW!*B^4X !!R.OC]^ CLH;:XP-&JA
MQ"\1->KE,K>HD],NVM*IFZC+^@2LC/.M!0:EGFTJ2]+AM0RD;;Y.V8@\8M0E
MJK=&BVG%V33U#TONFXY;\,+B2AQQB7]%J4LY)-/I;P4I>=_)$J4  22,",R[
M2N@VA;.F=B4&PE23EF4^W:4**](K;7*O<\A+E]U*FB4<RUY6L9R%'!W$?'W_
M &O?RG-MNCV78?HWV N=ZV:KIYY+Q7[06\2TOJ4\<;C2051;U;Y)3-"U[!O$
M0-ER-V1?3/\ V>_1!9*C96][>WJ"AN51?)G4-)32MAJ?1J"BE+,/8X/ZMTT[
M99'M<&NP(OJY5E2O]@=H:_1I]JUM4ZY3*XS3YQZF3!?JSP$XS+K<EF^5<R$_
ME'@A&_@8M0\/E5O+334#43A6U=>F%WMIY/&7I<Y/ H76)";<==:6WS[*Y90(
M)"2K;8[QFC@ J0$XSWB.F.F<G/L Z^&(Q0.U5F[3KG:/Z5R.CR&D:CT<SQU0
MGY @MEIR00J03-A'Y$GN 4@*).=NL>5_]F;\K?IKNORA*#8K;"_[3=(-FVFM
M\T,C:V4UDEGZE\>]4YPP-@F$C8SO[V[.V#<P'/SWGY7'0ML/>.A[:&MIZ.T;
M.UUC@==J"X1P04@94T4;Y6,=+&QKRV5K7Q/;G!:_."YK5732N1IU#N)IV1I:
M93TGO4OO-2X3WBBE0)4L(&<E1W).Y\NM<S0J-4IV:DJS(,STK+)5,@+"4+;0
MA)><Y72DJ2",D@'UAZOG%.;+N]Y,Q3Z.J096A*&T+F &^?O>4=Z3@<WQP3U(
M^J/4ZAKN'X$N-JTY5<W7YH2C$DA"N4I;?/=S*N8C Y&E$X.QQCQR/MS!7;0P
M_*1O\=[V.IMFZ6Y]$]486T-VI;S#M'1[-[4M9:[I+3T]+3F@JW0W&> 4DPDD
M ?NB1X;K\KWQV^OZ(;%+0[6UE^K:3I#HXY*JY4M703V2HO5B'IU"VKJJJ<U=
M+$^BCF](C>Q@:W(8W>PJ_P"@FHUA7BFJT>Q5LI:M5YMBHRS3'<%IQQ10-RE)
M>/,D[@''7:+AMBO'#0_H#P\.H^H_<XBS-P[Z/7_I%?\ ;-4:F%5F@W-Z4_=Z
M0VB7^#W0WSRZ5_SGORJR,C..7,7D[&'\ECH% @^Q6^/HQ[?&,[<YJF>D?Z;3
M>BU4;W,?$&AD8;ZKXC& YS2T1N:QQ#B ]K@<'0;19J>BI;A&+96>G44L<<D4
M[WF20OR8IA*2UC@[KHWO;O-&8WL<-[.3-*QW".YR3L$^?7^W[<Q,VQG26VQY
M)'U#I\X^R(66./Y #KZGL.V/O],3.L4>JWY\OT^K_;'GK:P#$G>1^('X9[UZ
M\Z/G.S#QQAO/CH,^[\>_157A"$<X78TA"$$2$(01?"8W9> ZEA[_ +$0 K%0
M9I]P5=J9<"%LS\NHM$=$]^%$^/1._P!F\7 )@D,ND=0RZ1[PF+?M=I\O5KEJ
MSTPV2Z]/RZ"O)'J]\$$8&VZ<_-],9&WXWI=[ANMX<?:_3/>L]8]W>J-_.[NL
MX8SG?';[\\PI?2NJ%E)EI8*K*$K$NRE0[M6R@VG(^*>AR(^_\:-D_+2/_EJ_
MJQUDKI!8:Y:74JCGF5+LJ4?2'=U*;!)^,>IS'W_B>L'Y'/YP[^V*&*3MF^#>
M[O\ 'X_"R/[+R=:SCV1?KX^>',_C1LGY:1_\M7]6'\:-D_+2/_EJ_JQP_P")
MZP?D<_G#O[8?Q/6#\CG\X=_;#%)VS?!O=GGX_'X0_P#"_P#]SX1?KX^3IS/X
MT;)^6D?_ "U?U8?QHV3\M(_^6K^K'#_B>L'Y'/YP[^V'\3U@_(Y_.'?VPQ2=
MLWP;W9Y^/Q^#_P +_P#W/A%^OCY.G,_C1LGY:1_\M7]6'\:-D_+2/_EJ_JQP
M_P")ZP?D<_G#O[8?Q/6#\CG\X=_;#%)VS?!O=GGX_'X/_"__ -SX1?KX^3IS
M/XT;)^6D?_+5_5CK*QJ99;]+GVD5E*EN2KZ4CNU;J+2@!\7Q./MC[_Q/6#\C
MG\X=_;#^)ZP?D<_/,._M@/1 0<S9!!X-Y;OZ'XJ9IM8(.:W((/"+B,'M73Z&
M+#EDRRTYY5S,ZI)*2G*53*BDX/F-XK/'54>BTZ@R3=.I<NF6E&L]VTDDA.3D
M[G?<^<=K%&5XDD>\9PYQ(SQP>&<*TJI6SU$TS00V21S@#Q )YX2$(135!(0A
M!$A"$$2$(01(0A!$A"$$2$(01(TR/,?3&BCC'M4D?28LTW]Q]UC1OBNUXTUN
M]-1K-M4BDR#UHRDC3YB8%)F%TE<PZMQ<HRZ3WCX2K#N!MM! ">"N4\0U HMQ
MZ17C3*]-^@TUV2+[LT&C,=TY+ NM*[I()4>= VWWQ%AW0RN7!K%>M(L>YI.G
MWY8&G%1GO@&L3[<I3)RE=Z\I>95N82)LY6A(/(<X3OL3$\^$'B%N[B,X=+XO
M>Z&G+D4^]5&J52'V_1'%-LS<RRTTM*DA:,H2A/KHW\?*+0]=U8L#AQOR[-8M
M?$S>E5%H<T^]3+;8$W-&K.*+B&VF$2@2J8+R^3(0A?)S]/",K;F!CX)GD-CZ
M\![G>HP,;NDETC@6!N''0X+M1D<5@KO(Z2*LIH@7S-I7=6U@ZR0R/R UD3'-
MD<XX&HT;D./ *[/Q"51Q.DU_%I3H6*&N1;=:*P6&_1'9=*@M.Z>Y3@@YWY<C
MS&-).W_>NCO#'1-+KNNUVM6[J/=SZ[ N%B?])J5+4S<??3[,RTP\Y.)"EK[I
M*9DI'*,)VVBI%^<=W'9V@::G8G!YHE4-.-*JP33I_4^JOMA<Q($J:$TBDU=E
ME\<[94H!/4$$$C>([WIV.'%[I[9-#O2Q]=)C5.^:!,N5ZIZ?3E/9E99^:])$
M\MB5FIIU<O+GG"QEA(YLYP=HT3;3Y5G0-L)M%;MF+UT@6:FO%6]UNDCIYW5<
M-O,VX'&ZRTC98:&,X+-ZIDC+'EATU(P-AZ'=NKS;:FO=:BRG;/%710S@"><P
M1R=682[V'B4@XP\/CWV.&3I=VHVF=,I;%/K->GWJ_4)BCTQT>D%U+:4KDFB"
MME:E-JRDC/,#O'57+\#JD52TU+2:*5(I<F W,=TW)RJ6\N+<)<PTCXI7X$G&
M.L6\-,>TTDI6KITCXMK+J.AFJ%&E1(./3;4W4*;4T4V7Y.=,\VRB1;RPR%)2
M'-RKE&3%!KMU6UT[1[4N:X?>$INHVYI%)S2)?4/6-+#B&')%9YBW*LS*&BOO
MD)=ER99XE/-D^$>IZCI:Z(NC_H\JND.KVEL<>RL-*ZN-=%60S,K"Z-K])"^1
M\SY?5:W!>7DL9$'N+6GR_6]&?2QMSMQ'LM56RXP7",LB?5543H[?;Z%LFXV2
M!T+6PN8/6ZJ*##G.R7AOK.%:KD[0GAJEM2)O3!Z\714Y)Y,HY5I>FSDQ2TNX
MY0UZ<TE4GA"AW9(>"01OCQJZ_=%,K4FW4*+5)&JR,P@.,S$E-L3"E(4,I*FV
MG%J1D$>J1MX^,>JU1['33FG\-]#TKT8E&5W91Y=V8N.K3 [VI7I4'UB9F#\(
M39,Q)%+W>!/*]@!>$X $6HK=X&N+W3:<O)S11=8M6N6!+KGZ_IE47%U25J<H
MPRY,.+8KD^I4N@&6:<>(9/J\P1X8CS;T,?[3[H?VRJKB=HA#8+53W::EIZJ2
M>..LI+>:IE-15]PH)2UXIJLO8YDL)E9#OL;4R0R$,71.DCY!]\@M]/)L=>YJ
MF[LHF/J*&ZL!I+A5-CWI12U=.TFE>7-<&Q2L>W&H. 7*>\\I^KIFY)KF")B5
MF9=;F2GD4\RX@'/L*AX[G$0?D']1],*3<.G<K9R:\AQZ931*R)II"7T5%UQ4
MRMQOE(/<)=/+WA.>7;PCVW#WQ"5G6C3ERJU*B?@[<%+FINF5R5#H>)FY&9<D
MWCSI &[K2SZIQY15-3JUY*B%<VY*DA2M_)1R1[,1].-F_P!J;7]3M0RK@M=@
MJ*.5NS;*)L=37UE!6;G67"NFG:Z&)M7''&ZGIHXM^GW6O?(79:?"FU++#T?,
MGV-=0SW[:BGKJ>7:R6X22TEIM]SH XPVRUPTTC*BH=1/FE;55SYA%5B1[(XM
MW=>/+:5:<5.T].:;)//^DS[+DU-3[*>4=RJ;>4_R!*3@\A7CU>H \8]+N#A2
M%I(.#E)&#TQ](_7'75F\S8-"JESK45R\@E*%RY)(>=F,MLIWSRY<(]F^^T49
ME+GUGJ*)"[E4M$W0JJU.S#]%*Y=HR+4NE2F7._P%.=XD!>!DXVC+6ZJNM@N-
M59*YHN=HBIH*FS3V^G>ZNH*'K12FDN=.S(DCA<W,-;$3+,W?WX<QDK#W:ALN
MU5HH]I+;)^Q[]-65-'M#2W6K8RUW.Y]3Z:*VS5;\OBDJ&/W9[?,UL-._JNKJ
M,2L::[Y]_P!!^SK&L1=E>(ZW_P "J[5ZE/N2USTR::EV:6F66XE2W)DLE/?I
M!;]4#<Q(.U*H_7K8I%<F$H0]46U.+;"TE24]4G WZ'.XVSB-CMU^M=VD$5!4
MLGD-(VM<UA:3'"^9T#1*&N)CEZQKAU3\/ &<86H7?9B]V*$SW2BDI8A7.MS7
MR->ULU0RGCJ2ZG+F-$T'52-(F82PD[N<KOX0A&86 2.6Q-+:(&24^7[8XD=!
M6KHMVW>Z^'*HB0[TGND!/>N*(VW;0>=(R1N1@C?&(IRRQ0L,DTD<48QO/E>V
M.,9X9>\AHR>&3Q56"&>HE;%30RSS.]B*"-\LCL:G=9&USG8&IP#IQT55*?42
ME2<$G/4??S\/V;14FC54CD(7ZI_^D[?<@9$1N:NZWI=$A,+K,JEBIDBGN%QL
M>E%) 4!E>Q23@CSR(J!)W-2I&?D:;-5!IF?J.3)22EI[V92D<RE(3GF("2#Z
MHQ],8ZL;32QES9H3CJQELK#K*&F)KB':&4.:8LG+P1NAVBOH(ZN"1O\ PU2U
MKNL=NF"4'$!Q,]HW<D0D.$Q;I$6D/W=TJ55$JGQ#S;^6?OL<>SQW/C66@U0D
M(/-TQ[/#Q\O ;Q%NBU!0[O*AZP&0E0*@/^$ 21X$9&^^(K)0*CN@<WEC?J>N
MWGX^0C1KM0:.]7'=V^[N[??Q6[V2XEI;Z_#&N>(]77P\>Y2LMZJ9[L<WB,[^
M[[^\>R*]6S4"M21S8*&EO*WZ-LMEQS'GZHSY[XB)-OU#XF%=<=3[OL.#[L^)
MBO=LU%2%((.ZT%M6_5MQ)0XG/_"02GKY8CE=XH\%VG+/#N'Q\XYKM^SMP)ZO
MUARY]N[^&N?U7B*!JKQ!ZVWUJ#2M$*\FS[5TQ:0^J<5*RT^JXUAA;SLN6Y@<
M\KRN,EKG/7FYN@B:G!IK]6=;;'J+UVTX4B_+/FW9&ZY-+J7DY3-+EI282XV.
M[_+I1WO(C(058V\(&4O2'6O3F^[ZNK0F[F9"WM2&6V:U17V98-T=*6%LN/)F
M)I0[SO.\6Z C!S@8Z1*/@THEH:62-;T[E[I1<VHDS,F<O2K%HRQJ+TR^N:8;
M:03R*]&"RWS,E0P,F.&76GJ63EM02S??(!OO!9+ZV6-@;G.=P:8' '?&]@+U
M%8:RFDI=^E$4C(HZ-T?41N](@&XUM2ZM?NXP93C+G$$EO5X;E7BK%JGI$J99
M:LE !2"1XY.T5"B/5CU,L34OZWJDX5O_ ,G!\\>6=_JBOK\RU+L.3#JTMM-,
MKF'7%D)0VRV@N..*4=@E" 5')Q@$QR^[0=15OP,"3UAXZ \^W7WKN5AJO2:!
M@/M1X;_AP"WX X]R^RE!/4'Y@3&[KN(Q5^.[ML=>Z-Q2NZ+\"NF3FLU(T8?4
M[K=.T^>:9DURLRR)AE+,TZTXVM;#3;X*9997SIPH9V%T/L_>UQX<..:B,4:F
MUIJQM8J4!*79IQ</>4V;I]1:)9<;EWZBF6]-"G$.*!80H8*?,1KT-TMM36UE
MLI[A13W&WM@?7T$-3#)643*EN_3OJJ9CS- R=OK1.D8T/&K20MA?33QQ1SOA
MD9#,7"*5S'".0L.'!CB-UVZ=" <@\5=EA&B5!0"DD*! (*2""#T((V(/@?&-
M8OE12$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$A"$$
M2$(01;5#F21YB/$5ED K&#DY_L^G_1M'N8\[6&,I4H ;@[@=/?\ 5_HBQKV;
MT1^_W$8/QXHJ)5=GXV!Y_7YC]7N]L4JK#'Q_:/9[OK_TB*W5>7W6,==QMG[/
M#[^ZE=9E\\Y WSY=-M_'S]GL\HY9>X.)\==>[0GA^**A]89P5$C'QL[??[['
MPBEM78P5;="K/7IX[??/LBMM8ECZVWF?OC[CSWQ%+ZO+9YMOM]WO^C)]L<AO
M-+J\=OY8'<.?)3-XC3.=/P5%:M+?'VW'L'3QV_9]8BCUW4&0KM/FJ74I=+\K
M,MJ3A:1S(7OR%*L93A6^W7$5_JDL<*R.A(\//VCYL^[K%,ZO*8YO'&Z?;]G0
M_JCEUQCFIY6SPO?%-"]DL4T3G,DCE86NCD8]N',>UP!#@<@C7AA" 1K@MX$$
M9!& -1KG(QEO\PT5KZY+>F;2K\]0)DEQMEPJDG2,=XVO\H0,_P" D@>.>OG'
M3_2/I!_;$A.(BF,R\W;U42D)?69A+B\8Y]@!G'7 /U>41\/7Z#](S'U0Z"ML
M:W;?HUL5WN;G27*%L]LKIG<:B>WO$/I![3+&8WN)P=\GBOGMTU;-4FS.W=;#
M01LAH[G3PW:&!@W64[JDO;/&QHP SKXWO:T !H?NC0*F^I^EMC:M6U/6S?%
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MOW]W?W?>5C]U'B8[5(\P<X(6DYSG_P!>*4=O9MUCPM0XD.U#<SWG!8VGK_\
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M2QC+YJNIIZ.  ?6E>6CD?I ]RN8-NMJ+K,RDM-JCGJ)!I%24M363<1J&-<<
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MQGL\5ITVPA#O['X-([.PZ_Z'QARU8^^>Z_\ IP=O;C[/I&(]!)62<C\CN/\
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M":,EL4;3KU;29'XP ,Y79.CSH6O^UM4RLO$-38["PL=)43Q&.LK6Y!,5%!*
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M0H%(V]9((',#G! \ATBEFBG:Y:27/<DA0+HHB:$W.S"9=NH+F''$M<RPE!*
MD C) R=L'?I%M#M9$B7UDE98J5S<H]0J44_R",>J3CKY1:A0ZMIQ#K*U-.-E
M*D.()2I"A@Y!&^0=\YSM'+WT\UV;4S&KD@_XB>&&.-D9B:V%^XUT@<TND+BW
M).^W&< # *^MO03\E78G;'HIM.T]PKKM3W^]0U,L$\3XQ243XI7PQ#T<L)GC
M+F;S\O82,AIR,G])+2:MVS<5(E;DH-:IM2ILZPT_*/M3DOS<KB$J(4@.**"
M<;[Y&=ND09U@H=8U\XN;/L.YGY1C3JRGG9IB18G9>93<#CC"9E)=9:7S(5+/
M(! 6D],;>&'SIIQH<1>D].52;-O^IR<@M'==RZXM]*4X(PCOG#R[';&_L$74
M>Q[U;U&U=XP6ZY?]PSM<FTI?4VIYUP-H*I-?/^3*R@YV\_".>7G9RYTK:JX5
M+Z<PQ;NZZ.1Q<[><UC=UA:""0279Q@YXE-H>@3:O8*QW"Z7"HL\MIM;HAZ1!
M5/,]8:BHC@BZNF=$US'$R N$C@&M:0"[3.8%)RC$E*R\G+MI;8E6&I9EM"0D
M(;80&D 8QC"4CH!TCEP'M]OV[?5"-07)4B/7$+Q%6=P^VRW5[A49JJU#*:'1
M4!?>U-U*PA24*0E10$E0RK&V?")"Q:([1T)5J=H*% + -=/=K]9HGD3CF;.4
MJ(.X)2<=1$S '.:T\"<*#C@$^'XK?+=I!?$K,JGZ_HJY)VXXXT?3$5@.N,2J
MU#+_ '"$%Q6$'GY2"=L=8N':2Z[:=ZQVY+7%:->DWV76TEZ5F'42DS+NCU7&
ME,/E#OJN!2<E(!QGH8LP*5G(4AM25("2A;:%(*2D CD4"G<9'2/#_@4W3ZFN
MMVC69VTJJZ<OO2K[ZY9U6^")1"T,HVST3OX^R[?2CZ!QW'7*IAYYZCW+(+KE
M_P!H6\[*L5>X*9*/SJPW+,^F2ZWG5$@<J6POGSDC& ?LCU[;B'4(<0>9#B$N
M((\4+',D_.-XQE+EMZ?:O?3ZOURZ*I<-755F0F9,U-L-)Q-,HWE@Z6U C;XI
M'L&8R6:)O1Z2=\FE4_J2>LJV?G/MZQ;21F,@'B>Q3M=O97:PA"*:F2$(01(0
MA!$A"$$2$(01(0A!$A"$$2$(01(0A!$C8OHG^FG[8WQL7T3_ $T_;!%9QT+_
M -M#XJ?^+6?_ .$B+QZ/BCY_M,6<-"_]M#XJ?^+6?_X2(O'H^*/G^TP43Q]P
M_ +="$(*"0A"")"$((D<*9DVWTGU1F.;")'L:\8< 47AYZE8YARY3[,^7G]&
M(\?.4DD*PG(&3CZ1UZGW161QM#@(4 <^8S'33=*0L$I'MV^K[[#V>>&JK6V3
M)#0>X#3E\//B"H5-TG(/J^SIX[^/SGV>PQYB;H_QO5W]WO\ U?..D5UG*1UR
MC?Z_9OX_/^N/-S5(W.$\WL(P>I\??]F8U2LLH).68_'ESQY[2BH5-4?KZN.O
MZ_'Z?K\-CY*N6=2:Y+JE:S29.HRQ!!0]+M*60<YPXI!5Y_SOIB04Q2!D@HQO
MY=#C^TQTLQ1]SA'L\O'Z-OF^S.MU%E<QV\P8(.6G):1J-01@Y[\@CD<\"A%6
MN%;1.LS"IF<L>7[TDD]V\ML*)Z[) 2/;CW1YMSA T)_R';_.7-OOY>^)U/48
M$GU/JP?#ICKY'^V.O<HPS\3KX>[WY^O$2.??(FAD=UNT;6CU6LKJIH;[.C6B
M4 <@-!W:!6KJ&B>XN?1TCW'4N=30N<>'%Q82>'/EHH-'A"T*Z?@.W^<N']1C
MGTSA6T3H\RF;DK'8[X'JXX7 "-NBAC[XB9BJ+C^;[MAC]?VQ\S1CXI_^D']<
M6;Y[](US'WF[.8[1S'5]86N'J^J6F7!TY>'N-H:)A#F45(UP.0YM/"UP.G A
M@([=#\2J*4NS*10V1+46E2=.EQMR,RS*%X'3\HE"5>7[8[ANC'(]0D^>YSY[
M[_K,54%&/3E^8 #]L?=-%\.4[^SRZ;;]/=&*_8I>XN>'/>2"YSMYSG'U<EQ/
MK'':3KQ[5=?Z*FC5% 'Q-_'V9]_S^&?LCLV:-G!Y3X>'E]\^SQR(J*U1@-N3
M[^>WU>/MCLV:/C&$?2,??S\<9R?.+Z"QZC$8Y8R,9]GCH>..[LY!%X*7HW3"
M/I'W\?OUCOY6C#;U/$;GV_<_LP3'M9>D8P>0>[&?'_2/I\]^^E:2=O4VVW(]
MWOZ[_P"B,Y2V0C'J@ 8Y8^KW=_8B\C*4CIZGU??/3.-O+V1Y'5W5G2WAYT^K
M>J>K]TR5HV7;\NJ9G:E-K1SN !10W+RZEI=?4XL<F&@H@J ,5[8I6.3U,Y6A
M.,8&"0"?/.^?KR8PX.WQNZ]>*?C[X7.SQHM6G:78E7K4R]=DC)/NLIJDI+>B
M5(M/EE;:E)Y M/K%0P< >!VRVV-I(WF;K 1O8&O#0#."<@=FF,J9C=XXSCF>
M?#BI:5W^$[<(=*KTZBW-+[JN6R*=/IE'[X9H]QHD.Z#W<N30*9)3/(D@KV<*
M2!G.#&0+PA\5&B'&9I-1-8]$;EE+@MBL,\ZVF#B8I[J#R.,S,NLF8;4EWF0.
M]0G/+D;"/!V'V>/"9:/#O+Z!R6D-I,V?-VC*TNHJF:;(/3KDU,4Q#<Q-JJ+K
M'I27!,+6^#WN<[#.T14X:N "E=ECH%K@]PJ):OBX+H])J5"MJIUUJF4J6FUO
M34RA+,[4YE4E*AA;P4 .1*@C$;7%0T\;6;K-W=[<9Y<3@:Z=XYCM426GV01X
MD=W'LYZ_%7HVTI0 $IP,=>AP/^#UCZ]8P8N)+C'[73AST;G^+*_^*:UZ7/4V
MYF67.'6F,VI6EMTV8K8D42XK4A,.J452A"^8-Y!VZB+EG&=VM^KNFO9#V)Q8
MV>H6AK;J"Q2VJ-+NMLS3AG$U&5DII*&G4=VLS9</\S">?(B] #1@<%#<.G [
MQP,'GI^JR;RK<@ [=2=A\Q.QC3(2.;UM_ Y)^81A :W<8W;1TG@(HO'95=2&
M]+*!;XI,U4;2>IE&FG[JEJG.L,-?E%!#TMSMJYAA!SSX\(GOJ1VWMYZ*=EQH
M'Q!7+;IKO$CKTW,4:S+6#S;#L_4V:@S2E3@*&RV.1;Z)@I4D)(VB*CN'3@<N
MW=-=?AW\EE$\QSTR/9UW]G6!4!CJ<]  28PV)^_/X0?I;0[!XEZK6'=1[8NJ
M>I=0K>B<O3J+*+I5#K$U+&53\)LI4XYW<C,ATJ" H\F_6)4=I/VQ.L^F$SP^
M\,W#Y;\K1.*+7*20S7_A&HR3+.G<TS+RKLT_,NU (DWPIMYUQ*7%(QW9 .8*
M&Z<@ @Y[#H/$K)_"L^'T'/TXZ1NC#)=X^NT,[._BPX=+.XJM>*!Q&:5Z_P V
MMF931OP?85;#ZD2_++._ [\R\KEF9H-<RN3/)G<14#M%^USXSM.>T?T[X5.%
M*15=**O2$3,_9K#<ISSSE:H3,]3WW9QYM9EQ(+F$OD*P' C!\X*.X=.&HR#R
M.%EZ@[D;9'AG)^<>$:Q:Y[-.TN/:DVU>5T<<E\HN&X+I5*3=LVRW(R$LBU9<
MK4ZJ6](D3R3)+2T(4I:0H<L71H*0Z=_@D(0@B12K5&R/PHI29RGCN:Y2LOR$
MPG 7@'G>0=QS<Z1RY4?'Z:JP(SL=P=B#XQ.Q[HWA[3@M/Q[0>XC0]RJPS/@E
M9+&<.8<CL/:UPYM(T(X$*$-+N.=I%21>5/96U,RKB):[Z0GU20D]Q+NA/560
M"X2A/M)B8]#K4A7Z;+5.G/)>EYE 4%)ZI7@%:5#J"E1(.<10G5"RYJE3RKWM
MR6#B\$5NFI2"W.LJ')SD'*$EILJ7LDG.X,>%LR[!9$Y+S\HZN8LBM.<KC9*B
M:-,!7*XE:3EPAQ]1&X P-MNE_(QE3$V2/VQH&\] "8CWC4QG0.;ZO$+.5$,=
MPIV30:2M;NM;S. ":=QYO9J8'?3C&Y[35,>$<64FV)V79FI=Q+K+Z$K;<00I
M)"AS8R,]!U^O>.5&-6O$8T.A&A!Y)"$((D(0@B0A"")"$((D(0@B0A"")"$(
M(D=#<U;E;<H%9KDX\AB7I-,GI]Q;A"4 RTLX\A)*MLJ*, >>([Z+<7::ZMO:
M>\.U6H-$?4U=E\S=.H]%0VOE>4W,SS4I-*; PI7*T\20,;9WBQN=:RW4%76R
M>S3P/D ^LYK3N,'>]V&CO*@X[H)[!E1DX&[2?XCM>M6.+2_F6IND3L^:78$K
M/EMR489D2_2Z@64._DTAT(R2$#!(B0NKO#_<>E%TO:S<.]0EY.H-.*G;BLX3
M[(E:JPDE3Q;#SQ99[MKO5<K;>5'I@Q3S0+@FURL?2>T+6IFM2K>I2I4U9RG-
M4=EQ3+E6"9]Q"GDJ"EJYWM\YQY'$5A<X+]2)TO&KZ\5"<#Z>1:13%MI*",+3
M@/#(4"1\\<;J:"\7.U0TDNP]W-QCG?<(;VRZVFBK::Y3.ZUU922^DR2L&\0P
M12-W7P@1RQD9"N:9K86@F=GK#,C-UY:XG!+7  > (X8T.A4DN'W7VWM<K3;J
M<FMF3N"GCT>OT8/)<=DIII1:7@Y]<..(4H8& (D'%GFX=&J]P2W/;^JUIUB<
MK]JSTZEB_)9+2VVE&8=1+RKI;YEA("W5+)2!L/6QC)NTVU7Z?<]#IE=I<PW,
MR52E&)EIQI04GF=:2XM&1G=!5RD9V(,;ML3?[I70SV;::G;1[36AD'IT37L?
M'64T[?\ A;C3NC]1S9MU[)Q'ZL=2R1NC=W,)HVM(?&<Q/SNG!T(]IISS!X=R
M[V$(1OBH)"$:$@ D^ )/AL.IS[((MKCB&4+<<4$(0E2U*4< )2,DDG;I$,=6
M;]%TSZZ9(+4:#374MNJ03_J@^X0&DI2-R&G0.G,#MG;,>SU@U)YB[:M"FN5>
M,5:>;(Q+IZI;&#A1>'J$I.QVCS6DVGJ[BG9:OU*64Q0Z<M2Z=+.@DSCBS^5<
M7S>M@.>ND+!'3&(R-/$V!AJ)AC3YMIT.O C^)WT?JC+CR6P4%,RCA_:%6,8P
M86'1PSP(!UZQ_!GU6YD.F[FIFCEA*HTC^$-6;'PO44I*4*3O*MIV;Y? <[?+
MG&#Y^VN\;4(2VE*$ )2E(2E(& $I&  /8-HW192R.E>Y[N).@Y #0 =P"PU3
M4/J9GS2'5QT')K1HUH[FC '@D(0BFJ"0A"")"$((D(0@B0A"")"$((D(0@B0
MA"")"$((A('6+>_$]VH7!AP@W1+V9KCJHB@W1-*"$T2F4J=KLZSLE7--,TU+
MSDJGE4%%3X0.7)Z Q<&4D*'S$?2,1C]=H;P>Z":#'7SC8IW#C-\1VME^4%<D
MBWYBMSC<O(XIS],5/2DN]Z3*RYDV7?2N5EILK4V!DG$%$8)USW8[5=6H7&UP
MWW)H'-\2]!U EJOI#(2YFIRX9&7<F7I5H**3W]/:YIIM04"DI6@$$'(&(J'P
M]\0VE?%#I?1=8=&K@_":PJ^].L4RK^C.RG?N4]]4M-)+#P#B"V\DHW&^(Q>>
MPIT0HFHG 'KMIU1+U=JMX7Y5I\7'II4DN*=TX1/5N>6B4(G%J[Q(:?*$%+38
M(;!2,$1D;\#?"U3.#KASL_0FE3PJ4M;LU5Y]<VELM!;M8GG)]Q ;)/*&EN=W
MMUQF"B0!G77/W84O81&_7GB8L/0!5%1>29]1K??^B>A2$Y.?R&.?G,JTYR=0
M!S8SX1';_P!)1H9_O=?_ $%5_P#\FB.#QP5)D=H^*N"UL_ZD54>/P74/^ZN1
MCO6T$BLWP0 ":M,Y(\?[K>_9%P^H]I%H;,4^H,);KP6_3YUE)-#JWQG)=Q*<
MYEL<N3@D]//&8MKZ<5V3N=FX[AI_,)&K5"8=EPXE2'$I,RX?RC:P%MYYM@L#
M]47-,"'G(^CIGMR.7@2J;R#C7X*HT:CJ/?&D:CK\Q^PQ?*12?[/9+9U-UN7R
MI*Q\!^MMD?DS\_3]7OB[1[HL <+G$M8N@&INL+=Z-5%Q5<51C).24C.SH3Z.
M@]YS^BM.!/4?&P? #QB<W_I*-#/][K_Z"J__ .31C)<F1QP=3V=P55A&.("N
M,QT];IJ*E).,D#G R@GP/E\_3]L6_O\ TE&AG^]U_P#057__ ":'_I*-"_%N
MO_H*K_\ Y-$K'/C<U[,AS2"#@\1JH2-CEC?&_!:]I:X9' J$G:-R9D[]TQ;4
M %<U4!3MG'(,;=<8]D0,/4^\_;$C.,_7^R=>-3]/ZA9:9Y"*6*CZ=Z9)34ES
M=ZT.[Y$S3;?/TWY,X\ND1S/4^\_;'S\^59.:CI-@D(P7;-VO.>.6OJ6G[^"M
MJ&E%)3MA!R&.D(/:'OW@>7):1T-88;FJM;4LYT<F"0-]REQ.^WE@?3Y1WT>8
MKU0EZ36[5J4TE:Y:4?<4ZE"5+5CG2=DI!)^8'S/2.?=!8C/3!T>.E<&QQ[34
M$SW'4-;"YTI)[O5P?'M5*\1R2VJYQ1!SI9+?611M;[3GR4[VL#>\N( ':5*"
MN44 ( 1L)9CP\.[3C[>GCX':*35BB@\WJ#Q]FWGG]?T^RH53UJL69*.[EYW
M892<R4V,E*$@X_)CQ'C^R/!5'4VT9C(0Q- DD[RLQ]?JC?[XS'Z#+?MWL_&&
MA]YHFXX9FQCPQV_Z+YY77HLVOESU>S=S?G0;M/G7XC_/ES*I75:*?6RC8[^
M_P!$4RKE*#"I=WE&$OM>'_X5/G]?G%;)Z]+<?^*U,>S,L^/?U2/9%-[IJU+G
M)=I$JAQ+BGVB"IIQ*?Y0=5*2 -O,^7A$=N=O=G*O8+;*DAO=#)45.S%[AAA9
M-E\DLEOF:UK0![3CH._FL=L=T5;:6_;K92X5&S%UBI:/:&V5,]0^GW8X88JF
M-[Y)';VC6-R2<9 [559O^1E\;?W.S_FTQNC:W_(L?\79Z?\ PTQNC\STG]H_
M^=W]17TP77UG_P!CU __ (!8_P#H,0E52U.K=7R9YGWB-NI"U#IMG]>(FK7U
MENAU!2>H:/U@B(Z2$DRY*(6L$%;CI/J$CXY\<;^7V;1]6_\ 9D[06G9R?I2K
M+O7TM!#4QV&F@DJ7[G62QF:5[&'!.=W!\/!>4OE7[*;1;6;-[*4FSMJKKK-2
MWRKGJ8J&+K71QOH>K9)(W(]7?]4'M)5.$TA6?Y,^[']A_4(Y[-'65#U,#P\?
M#!SX_P!NT5&$E*CP/_4.#[ML_?QCFM,2:-RA>V-N10\O+K[?OGZS.Z4MB\:;
M26D\/_N"<<. W3PYKPXWH8Z2R1O;&W_&A_\ )@9.F/ICM'W+P*Z,6Y53I'Q'
M&C[<%:?]'Z]XE7;G_L"F_P#P@/H $47J"Y%%.>2E"^;O&<$MJQ\<=3C[^R*W
MT4 4>0 QCN\[=.@_;'R4_P!IAM-:]HG]&#[77T]PCA%[;++3O#VQOQ 6L=@#
M#G!Q<!V!>YODK;)7[9+9S:BEOUIK+3/5WJCJ((JR/JWRQ,HFL=(S4Y:':$YX
M\AE=C&US^1F/^+O?YM4;HV.D)8F"=AZ.]_FU1\J8QF2,?^HSA_,-/>O57^7W
M:KG:,TIR8HCSRD'"YA[E.^^'E[?,-^GLB4E#HP]3U=_5^;/G]/S^[,1:THU*
MM:W[>3)5%J94^T^_S*:EIAQ)R\HX"D(()QC?]45]IFOVGTMR]Y+3WAG$C.*Z
M>YHD_L^?/Z)=E-J[-2[$[*43[I3,FIMG;/#)&Y^'QO90P;S'-QH6G(([>.J\
M/[0; ;35NV&T5Q98JY\-7>JV:*1D),<L;ICNR-=O9+7-&\.''/A)*WZ/CNQR
M^(_T;]-Q_;@17"WJ2 6AR[<R/IR.I_MS[/6B(M)XH=+Y4I#DI4L#P%.GO9M@
M-?1CZ(J52>,;2&44UWLG52$J22!2Z@<X.=OR'T_3[\5=-IK;*'=770O[VOSG
M48QX_P"O!;E8]A[U3[G6VJJCP6^U'@<@>9/W\E8U[7UGN-?95!&/4'U2[?[?
M?GYHM(1=%[4S4:WM4=9I2Y[90^BFN)P$3##TNXDI8;2<MOI0OJ/$ GK%KJ);
M'(V:WLE:<B2:H<#VYF?Y'<OMU\FR%U/T-;'P/:6OBIZMCFD8(+:VH!!':MR>
MN//(^J+Z78/R[+O$A57G$Y<EFT]RK/Q.>4="O?G]<6+$['/L/V&+QG8_:L6S
MHKJM6KSNE$TNGD-@JE)68FW$_DEM_P G+-N+&<YZ?5%AM>?_  &J[WP 8U_Y
MS?T5U\H*1L?1?>M[Z=5:F#N)KX7?@TK-Z2<C;S/VF-8MRCM*-"]\-5[J3M0Z
MOXG/^+=?.-?_ $E&AG^]U_\ 057_ /R:.+8/8?@5\Z,CM'Q"N,Q:6[0]A#^I
M>AI7C+7P[R[[C+:?#]OB??%4/_24:%^+=?\ T%5__P FB"'$9Q(6;Q :S:6?
M@=Z<EBABK^EIGI*:D@OOV/4Y!--M\V/$(SC._6*D0/6,T/M#DI7$;IU'+GWK
M4]?J^C:-(U/4^\_;&D9-4EYJI2[,U>^F;$P@.-*J1*D$X)*9AL@CQV/E\\9#
M5(P*=3TC9*:;(A(\@)=O'U1C=:@7-)V;<>G-SU(.JIM)G7G)Q##;CKBDEY!&
M&V@5KQUV!QCVQ<UDNTCT-8E)-E;5>YVI.5;5BAU;JAA"2-I;H",?K,6-2"7C
M SHJC" #DXU5R.$6YO\ TE&A8!);KX !/_L*K^&_^+1+_1O5^VM:;0E;QM83
M0IDTIQ+?I4L_*NY;64*RU,(0X/6!QD=(ML$<0I\@\"%5J$(1!12$(01(0A!$
MA"$$2$(01(0A!$A"$$2$(01(V+Z)_II^V-\;%]$_TT_;!%9QT+_VT/BI_P"+
M6?\ ^$B+QZ/BCY_M,6<-"_\ ;0^*G_BUG_\ A(B\>CXH^?[3!1/'W#\ MT(0
M@H)"$((D(0@B0A"")"$((ODXRVX,*2(ZM^E-K!Y0#T^_GX#^V.YA%)\,<GM-
M&J+Q<Q1R<^I]_G\S^L1TKU&&3E&"??\ /UR/$Q4T@'J,Q\5RS2^J1]$8Z6V1
MNX ?Z8QG3X_'M14C=H^,[>[;;&_OZ^WZ(X#E&/B@'VX_5T^;[(K"NG,K/0>S
MZ(XBZ0@@X ^_W]GLBQ?9@3[/QQW<,'\NY%2!5%/BW[<CH/IVCYFC#_>S\P'Z
MAB*N*HR<=!\^?[8V? GL3]!^X^:+7]B_P C(Y?RD_@?SY)[_ #[QY^"I/\##
M_>_J3^R/LFBD8PV/#W_Z8JD*(D#<#/NVQ\^8^J*.D$>J!]GW_P!$1;9M1EGW
M'^'LXXQIX=R*FC=&.WJXQ[,X\O#]AZQV+5&!QZN?#&,#WG[]8J*FEM@^MO\
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M23WTK+-.;DG^=C!CO+EM&V;PD5TRZ+?H]P2"P0J5J].E*@UO_@HFV7DIWWV
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MB0A"")"$((D(0@B0A"")"$((D;%]$_TT_;&^-B^B?Z:?M@BLXZ%_[:'Q4_\
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M\[<&HFHCTTVAQAYU)IJ9:61,\[B$-K00II>?6*>G3H8LS\"_'QQ7</W:6R/
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M\VN=TVU6<4$4ZT;ADI^0?J"@DN.!MVI,RHRA SLE1/3;K%H_^##:94?5&O\
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M_:UOA1J%3;20#A+([\DC_P"%S'KM^J*,7#KVCE>:MNG"9&X$XMP-%'4!7=+
M*O/&_E[8II1M*+TJJD.FGNTQ+N"9MZ9])V/\[NW%16.@:#TF7<;F+BFOA=X8
M44(099(/M#9 .#MN.OT14$='!J]_6N'T00=?!NG?J_W<56]'M-( 9IC4R#Z+
M#D$Z$8:P[OVI?%JCY,U:\=0ISNG%3E765$)E$)<DVVLD_P#O4\J% >_?'NBK
MEJ:%S4TAEVZICNY9)"A2T !0\0DS"#S'VY\//K$DJ70Z51V$2]/DF9=M P,(
M25XZ?'QS'/7<F.WBG)7/(W(6B%@X8QO>[  ;PY GO5&>\2%O54L;::,>S@ O
M'+(TW6GO WOXBNGHU!I5 E&Y.ERC4NRV,#"07#_2<^,=]]R8[B$(LB222223
MJ2=2?$K#N<YQ+G$N<>))))]Y2$(1!02$(01(0A!$A"$$2$(01(0A!$A"$$2$
M(01(0A!$A"$$2$(01(0A!$A"$$2$(01(0A!$.^T6FNU#[+^F=I#1]+*54=0E
M6&--:_+5QIU-.5/F?5+U"5GPR0DCN\F6",_\+/A%V6$%$$@Y'%>5LZW$VC:%
ML6OZ4J;3;M#I5%$S@H,P*;(L2272G.W.&0O!SC.(L&_P@3B@X9[9X3KUX<=3
M$U:K:F:FM2LC8-NTVW*M47)NHMS">5;=2D)9Y,IW3KC:R5*2#CKM&0Y%(+\T
M)TGU*KE&N*^+&H=S5>@N*<I<Y5)"4FU2BU8RI(F&7/(8/48V\8(#@@]FJLL_
MP=K@NJ7"OP/V]<%YTR9IFI>I[DY/W&W/I6JH)IS,\Z[1$S#SWY97+(N-\J5G
M* ,8&!&0*-@!Y1QI.3E9"69E).78E9:7;0TS+R[2&66D(2$I2VVV$H2 D >J
M!L(Y,$)R23S2$(04$BE>M&C=AZ]Z;71I7J319>OVA=<@])U*G3(RVHK;6EIX
M'JE;*U!Q)'128JI""+%!G?X.EK';0K6F^C7&]<&G_#I<<_,OSFF;-%FYTR<C
M-3+DQ,R#%37.!]#;W>K;RT0$I.",1?<X"N!'2+@%T2I.CNE<JI3$OWKU9K3K
MC[DS6IU]Y4P],O%];BTE3ZUK YCCF.\3@Y4^7W]W2-T%$DGC^ 'X<4C:M"%@
MA:4J!VW /VQNA!07EJA:E.G02E :6=^8#(SYXZ?5L.GE'@JGI^^"I3 #R?8
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M ,6L_P#\)$7CT?%'S_:8LX:%_P"VA\5/_%K/_P#"1%X]'Q1\_P!I@HGC[A^
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M4F)>0>>?]5M*9B5;2Z"2,="-LP3!QGDKDT(B?^.OPS_A_P#Q;?QKT'\*>_\
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M<L]19I35"2I+%=J\S4 2'"I:@WWP/*HG.#TR8FKPE=FCKS<7$71>,3CQU/\
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M1JDNJ;*60DKFZB[,MGE!+6R%CQCV'#]PAZA:;=G>WPRUJ<2Y>R:9=$KZ5RM
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MF:]*+,G+'O@)>;,OE+JL+Y=P02"0D9.NF6D]XP,\N(5J6F:>Z?5?AKDK$I7
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MM?6'^$9WKJCPV2\NWI5IE2:L_?U<MR53)VY,O,VI,!GF1*(13U=W,,K *2H
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M]#%N"TOX,]PF4BS[ML2Y+JN6Y;6K$[Z70*(Y6JZQ2[>!FES2VTR(G3+/A2E
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M5.(#0+@XF;IX>J'-U+T&KOW5+4^9N2ETF8=8J<^W)3329QE,HVPY,)2$$N)
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MP'004"XD8[P?@,#S@??IZ.$(04JB_J/_ '^M'_\ IC_,1*"(OZC_ -_K1_\
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M#C>O;ASGY^X.,)>J3FE3-&KEN6NQ9,K2GUR%KNLSSK$O.M$.,<DO(!)"2DK
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MW-V/7 C==X35[U#2N>E*K49[X1J$K2KHK-+I4W-)=+X6JE24PS) %TE:TI9
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M/,DI4#XI4%#;VC:-2<9Z8 R23C'O\O?!%K"/BAY#@RE2%C?UD+"T#&<\RDY
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MIM01T.[A3TVWC[]LS:5UW%:W"TW;MOS]97)5.A&=1)RS[YEDMS-)*BZ&D+Y
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M@#;>.Y70:*]+L2LQ1Z4_+RQ!EY=RG2BY>7P<CN&5M*;:(P#EM*=P/*/A^$U
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041'&TY:QH(YAH!^/N7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>nt10002526x6_diagram3.jpg
<TEXT>
begin 644 nt10002526x6_diagram3.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( K $\@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
M    " <)"@$"! 4& PO_Q !F$   !0(#! $+#P0.!P<$ 04  0(#! 4&!P@1
M"1(3(3$4%B)!45=AD971U!47&3(X5%9Q<G.!EJ*QM H8(U,:)#,W0E)5=92A
ML]/5\#0VDI.RM<$E0UEB@M+A)B@U\60G.D5C=/_$ !T! 0 " P$! 0$
M       %!P$" P0&" G_Q !>$0 ! P("! 8)#0P&"00# 0   0(#!!$%!A(3
M(6$'%#%!<9$B45.2DZ'1TO 6-#925%5B=7:!E;&U"!47(S(S-U9RE+2V0D-&
M8W/!)E=E@K*SU.'Q)&1FTR5$PJ+_V@ , P$  A$#$0 _ ,_@
M
M
M
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M(RZ2YCM0-0
M
M
M
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M+HJ+]1R?')&NC(Q\;K7T7M<Q;=NSD1;   9-
M
M
M   -#,DD:C,B(B,S,ST(B(M3,S/D1$7,S[1"C52S 8-TFZVK+J.)-IQ+E>7P
MD4IVN4Q+Q.::DA9*E$:%GJ1$E1$9JY$6O(>#SCWI?-@9;<6KJP[CO2KMI5L5
M-=*;81Q'4J5"?)QUM&ZK532=5EH6NJ2TYC\@"]<;\8[HQ.N#$FZ<0KV+$/KX
MJ#RI1U:LQ7H\J)7'BA,)I:9"=$[R$-$1-DE:2+D9&!T9&K[[;6MX_3R7/VF&
MY;#S:'6G$NMN));;C)DZVM*BU2I"T:I4E1&1D9&9&1CZ\5/<5_LF,(O*CM$-
MN3/R_8=R;2RD5'$NW/4_J>D7Q-N.G4J57(D9*&FENT^4UQV=QM*2(W.:]=XM
M1,:D[2#;;18++-3V=C\R:G7BR.ORE()?/EV!-<M.@#&@[X/?)NW[TWF5=Q4]
MQ7^R8<5/<5_LF,6+V2C;3_\ AQ/_ %^I7]V'LE&VG_\ #B?^OU*_NP,:*[N^
M;NW[T,IWBI[BO]DPXJ>XK_9,8L7LE&VG_P##B?\ K]2O[L/9*-M/_P"'$_\
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M)9=<3NI,E.H)*SU+74^9F?,2R Y
M       !9@R.Y0<)\6<MEC7S?";BJMRU;U0.?/.XZNUQB:DJ;;_1HD[I&E)=
M)%SZ1+?V/C+U_)MP?6BL^DC@[-'W'^&?R:I^,4)[#Y#+^"81-@6#S2X=222R
MX;1222/A8Y[WNIXW.<YRI=SG+M55VJNWE+]X4^$K/V'\)>?Z&AS=CU)1T><<
MPTU+2T^(U$4%/3PXI4,BAAB8]K(XHV-1D<;$1K&)HM1$(+^Q\9>OY-N#ZT5G
MTD/8^,O7\FW!]:*SZ2)T )?U/X)[UT7[O'N^#N]-EO@OPK<)'Z[9D^E:K=_>
M;O&O;(+^Q\9>OY-N#ZT5GTD/8^,O7\FW!]:*SZ2)T 'J?P3WKHOW>/=\'=Z;
M+/PK<)'Z[9D^E:K=_>;O&O;(+^Q\9>OY-N#ZT5GTD/8^,O7\FW!]:*SZ2)T
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M+/PK<)'Z[9D^E:K=_>;O&O;(+^Q\9>OY-N#ZT5GTD/8^,O7\FW!]:*SZ2)T
M'J?P3WKHOW>/=\'=Z;+/PK<)'Z[9D^E:K=_>;O&O;(+^Q\9>OY-N#ZT5GTD/
M8^,O7\FW!]:*SZ2)T 'J?P3WKHOW>/=\'=Z;+/PK<)'Z[9D^E:K=_>;O&O;(
M+^Q\9>OY-N#ZT5GTD/8^,O7\FW!]:*SZ2)T 'J?P3WKHOW>/=\'=Z;+/PK<)
M'Z[9D^E:K=_>;O&O;(+^Q\9>OY-N#ZT5GTD/8^,O7\FW!]:*SZ2)T 'J?P3W
MKHOW>/=\'=Z;+/PK<)'Z[9D^E:K=_>;O&O;(+^Q\9>OY-N#ZT5GTD/8^,O7\
MFW!]:*SZ2)T 'J?P3WKHOW>/=\'=Z;+/PK<)'Z[9D^E:K=_>;O&O;(+^Q\9>
MOY-N#ZT5GTD/8^,O7\FW!]:*SZ2)T 'J?P3WKHOW>/=\'=Z;+/PK<)'Z[9D^
ME:K=_>;O&O;+1]V8$69@!FJRW>MR[6:<S<J[E36HLNLU&>Q,ZECD;)FW)?6@
MMS4].7AY"[<DS,BU_BI/Z3UU%OO,O[JG*C\]=OX8A<#1T)^0C[C'FP2"&EJ<
M<IZ>-D,$>(Q:$4:(UC-+#Z-SM%J;&Z3E5RV1+JJJ2W"1BF(XU@W!IBF+5E1B
M.(U.4:Y*BMJY%FJI]3FS,,46NF?=\BQQ,;&Q7JJM8UK4[%$0W@ #Z$JD
M
M
M                      #B3X,2IPI=/G1VY,.='>BRH[J$K;>8?;4TZVM*
MB,C)2%J3S+MBS'=VP0V<%YXPN8QUG!>,JOR:FBL3(K-0ELPWY[;I/I=ZE;,H
MZ?T^CBD[ADHST,7IP RBJG(JIT'D;4LBVK)M^E6M:]'@4F@T6*U#IM/8C,I:
MC,,MI:0DB2A);VZ@MX]-3/F>ICT74;/ZB+_1V_\ VCF !@X?4;/ZB+_1V_\
MVAU&S^HB_P!';_\ :.8  X?4;/ZB+_1V_P#VAU&S^HB_T=O_ -HY@ #A]1L_
MJ(O]';_]H=1L_J(O]';_ /:.8  X?4;/ZB+_ $=O_P!H=1L_J(O]';_]HY@
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M   FRN@
M         M\YE_=4Y4?GKM_#$+@:.A/R$?<8M^9E_=4Y4?GKM_#$+@:.A/R$
M?<8A,+]?X_\ &,'V;1%CYT]B_!;\DL2_G#,1O  $V5P
M
M
M
M                   $"=FC[C_#/Y-4_&*$]A G9H^X_P ,_DU3\8H3V$)E
MKV/8)\54'\-&6+PO_I6X2/EOF7[6J@  )LKH
M                                      +?.9?W5.5'YZ[?PQ"X&CH3
M\A'W&+?F9?W5.5'YZ[?PQ"X&CH3\A'W&(3"_7^/_ !C!]FT18^=/8OP6_)+$
MOYPS$;P !-E<
M
M
M                                                ! G9H^X_PS^3
M5/QBA/80)V:/N/\ #/Y-4_&*$]A"9:]CV"?%5!_#1EB\+_Z5N$CY;YE^UJH
M ";*Z
M       "WSF7]U3E1^>NW\,0N!HZ$_(1]QBWYF7]U3E1^>NW\,0N!HZ$_(1]
MQB$POU_C_P 8P?9M$6/G3V+\%OR2Q+^<,Q&\  397
M
M
M
M                  0)V:/N/\,_DU3\8H3V$"=FC[C_  S^35/QBA/80F6O
M8]@GQ50?PT98O"_^E;A(^6^9?M:J   FRN@
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M
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MMMQ)ZZ*:6EQ!Z'S[))F7+X^D?4
M                             $"=FC[C_#/Y-4_&*$]A G9H^X_PS^35
M/QBA/80F6O8]@GQ50?PT98O"_P#I6X2/EOF7[6J@  )LKH
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MCQB"!N)22US<0K65=/+524LC9K-A8C&HEWE)ZEJ-PV(Z/I_Z$-XMD_!H
M
M            !C0[<U"7,RVS\;6AM:%7-<FJ7$)6@]'X72E1&1^(9#]%MJA5
M"VJ1%FT:D28DJVJ5'D,/4V&XEUIZFM-.(7O,GO$:#,N>NA<AC>?E 5W47#K&
M;(O?UTE4F+6MRX;C?K%1I]+FU/J-M3\/=4ZW#:=4DE:'TZ:EJ)DUO;N;/>R;
M1BI8Q'N:KW%%MJ"U3J/$L*YG.K:FW3D)CQ.(B"O<-R22&C49:),S/H(#>RJU
MMD[?UENW+JN!E3VXV9_#S#F.JDX<W[1HER5JW(2C138)T"V)%7=X3"=&(QR'
M4K49H;1J9ZGO"HF$&)>>+:QXE8MW?A1CB_EHR[6#6)%'LIIBBQ;@.[YD25)I
MTQSC*X3\8HD^/O:+,R7J9%R(B#9D8(8Q9ILQ.;?:)XM67.LFG8T6[*HV"]OS
MT_ME$9NAU"@JDF3J6WXR93;C+VXZT1EODG3I,J>;*G-=8.ST]>3)YFV<J>&5
MU6C=U9K= JKM$J50B7)#KM:G5I2F9D6,N-O1X[S>J>*HS,]WDKL0,]OG<B-W
M]/SIL1?G6_;D;D[S79JL)LVU_;.G-9>:L0[DJU,DM8,8PG$C4TZJ\FE/S77U
M4J,1[GJ>I3)&3J]%[FNNAF0HG3-J]C1L_;[S$8!9[*K+NBYJ9(2SERNHH:(R
M<0959ZH6S%CLPVG$-)I3CT-A1J4?%W25J7,<'""_HV=#:T5+-_A?3JF[EURS
MTFIRZA?LRF3:8W<**A;[S4CJ6)/89?<ZE>86V1M$LU'IITB'^8'![&G;A8]X
MBX_8;-R+)PFRFU+U1P3J%2HJ$/8B2X"W%U^,MN8Q'?(VI5.-EM3Z7"5O;S1$
M7(PLE]J(B:*:6Y?\K\_(A<OLJZMIE6=F[BQF/NJ^9E*QWN:;&N2P[3.E15O6
MC:5,K"Y<A)K26Y**I4 D\W$;S>I\]2YR[P2VD%/N39B.YP[JG,^K=)H=9HM5
MWUI0XU=<-QZBQ5NMD1;BG:HA*T(-)$H^Q\ [W9C9Q(N=?+?7+%O*AR;6Q=P^
MI%3L+$JSYM,=CLP6B9D4&ERFW'6&8TA,V.SU0? 29)WR(S[8Q?,4[6Q>L3,C
M?&QNMV-.*P,7;\HUS428P:SCM1J?6DW94VVR3R0ETE.(41+21D?;Z ,(EU5%
M2UEO\W/R=I.?YR?N(V?3/=AALH;:S1U2^7W<;,2+U?IM#ISU-C,.4^ER[R33
M*8?9))"TJILAE234DC/34S/42GHMM;1C+]EOQ5S<8T9I'+GF7':EM5RV<-CM
MF%&3:BI5/;<<,J@R9ID]4*>0YV1%IIH7;'7[='#ZFX<Y%L'K$MRBR&8%M5W#
M>GIA4J"])-+T>N41J4\IJ,VLR-QY"W'%;NA<S/3MW.\Z%DW+?NSJKMLVE3':
MG7)&$]IR6*>@C2\ZB%;T*3(223+>):6T*[#3>U+=TU (J;-B;7+?9R)LV;>3
MYCI]G'CQB;C;L]K?QFQ&KAUG$"=0<0IK]7X#;)J>HZJEZG'PD=A^@)ELM-.R
MW>8L]85YI<9LT.R[S9W+C5<W7-6*+6*Q3Z4^<5F/N-PK@J4.#')+1$1_HV6F
M]3+PF6O,=ILZ-ISEBP7V<$?""\JY78.,%KTC$NC5&P56Q7?5!%0F/U1B*@E]
M1FEQMU2R42D$>J3U(]-#$5LACE4K.R"S5U:90ZM2IU1KU6K#5(D4Z8B7P5W/
M49D1*67&D.K-]HT'NI09EO<RY 91+*NRW9);KYOF[1[C9O98-HYC!D)M._K3
MS1.X)4RUG+SJ^'=B-VQ!JO&;@5&7(?CNS#6A2O5#@)2E3J3-'$Y= DI8NU$S
M"7CLY,Q%5N%UF@9ILN-4H]%NFJOQH<YJ2W/KJX$.:Y 4V<5)RX;).DG0]WB:
M>V+4<79E[6#*_AML_J!:N+M;KEAXA6A#O6GRK5DVK6W'9,N7(FLTIN,:8:>,
M<M9MEJT1DGB$:E::ZPFL#"[$21L[<_\ FLNFU:I0(&9&X[3D6O1%Q'U3E4^@
MW&ZRU)3!X924E(CJ:>,C9+=)9%X0'*JW1/RDMLMRKX]G27 \5]I_CQAWD"RX
M3;;0S<.9O,A)G4JV*JPS$@LP^I*HS#FSDPR;**9Q8SYO&DR+>X>A%J>\/KB%
METVM^7JR;1S"8?9FI.8&\5R[>J%VX.G;=.HJ*O K\F(<F,BIK4M#'J/$D.ZK
M0C]*;1]L0/QXPZQ A9#=GOF@H=J52O6SEYJU>?O:F,Q)!3V(=<K,=HI!PTM*
MEJX#1./&E#1ZD@Q=?QVVV& -$P(M=[+:]5\7,;;F3:-)M7#MFW:Q 6^_QH4*
MMIE29,,T0_4]*W5&<A)$OAF:3T 6[2(MU5%V73EV7[2<Y]\1<W^8FC[3#([@
M9(G1+<LO%F@7+(Q(LQRGP9DINI4VW&)2$-U93?5#?#FJ<,^"LB41:'R$1Z_C
MAM",TFTLS2Y-\(,:5X6X56"Y;:3O%%%A55VVTSX"I1);B.&EZ0<I23;Y*(DF
M>IF.\Q0J=W7%MBMFY<=Y6[/HET5>@WQ/KU-;CO2H=(7+M=E]IE^>TV<9"M7#
M21*4GF1IZ>0J#D/COIVT.T?=<ASVFENX><.2]"D-1'M*6YKP)*VR9>T_A<-2
MMWMZ 8V(G-^0ENG23QVOZ;#I\J>,N=3*GM&*/DGS!XO/8_8?XDM2GK+O&12(
MM!=IATRF*J$\CBLFMQWBNF2.R7V.G+7I&3"6O/7NGI\6HQW\>V7O9M<I;J8<
MU374UZ;\E$-]<1'_ & 6G%E)1P6]>@M]?,^1<RT&1 71])_>8&'<V]J*:@
M:@
M0)V:/N/\,_DU3\8H3V$"=FC[C_#/Y-4_&*$]A"9:]CV"?%5!_#1EB\+_ .E;
MA(^6^9?M:J   FRN@
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MNJ=+4QI#4/?-*KYHDT%2.9RNO)&FKCLQ]V]BW9L2SH  '0\8
M
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M(F$BGE':.&W&3$1&4A*FBC(;)E+)MF6X:":(D;NFF[RZ!RM2[I>,@U+NEXR
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MRT<N(3[?#=)MTT\1)+1V)Z*+4>Y
M                                0)V:/N/\,_DU3\8H3V$"=FC[C_#/
MY-4_&*$]A"9:]CV"?%5!_#1EB\+_ .E;A(^6^9?M:J   FRN@
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MLT8'0POE=#$Z5\:N5JV1[MP  ^N/SP
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M2.X''BQ68<=B+'1PV(T=F,P@NAMEAM+;2"\"4)(OH'( X@
M                                                   $"=FC[C_#
M/Y-4_&*$]A G9H^X_P ,_DU3\8H3V$)EKV/8)\54'\-&6+PO_I6X2/EOF7[6
MJ@  )LKH
M          +?.9?W5.5'YZ[?PQ"X&CH3\A'W&+?F9?W5.5'YZ[?PQ"X&CH3\
MA'W&(3"_7^/_ !C!]FT18^=/8OP6_)+$OYPS$;P !-E<           &A)(N
M@AJ                     T(B+H(:@
M                                                           T
MW2UUT&H                    #0DD700U
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MYPS$;P !-E<
M
M
M                                               ! G9H^X_PS^35
M/QBA/80)V:/N/\,_DU3\8H3V$)EKV/8)\54'\-&6+PO_ *5N$CY;YE^UJH
M";*Z                  ",6<']X&^/FHG]LD=;DI]SM8_QU+\4X.RS@_O
MWQ\U$_MDCK<E/N=K'^.I?BG!Z$]:K_C+_P +#E_7?[COKC)7@ #SG4
M                              "WSF7]U3E1^>NW\,0N!HZ$_(1]QBWY
MF7]U3E1^>NW\,0N!HZ$_(1]QB$POU_C_ ,8P?9M$6/G3V+\%OR2Q+^<,Q&\
M 397
M
M
M                                         0)V:/N/\,_DU3\8H3V$
M"=FC[C_#/Y-4_&*$]A"9:]CV"?%5!_#1EB\+_P"E;A(^6^9?M:J   FRN@
M                C%G!_>!OCYJ)_;)'6Y*?<[6/\=2_%.#LLX/[P-\?-1/[
M9(ZW)3[G:Q_CJ7XIP>A/6J_XR_\ "PY?UW^X[ZXR5X  \YU
M                        M\YE_=4Y4?GKM_#$+@:.A/R$?<8M^9E_=4Y4
M?GKM_#$+@:.A/R$?<8A,+]?X_P#&,'V;1%CYT]B_!;\DL2_G#,1O  $V5P
M
M
M
M                                  $"=FC[C_#/Y-4_&*$]A G9H^X_
MPS^35/QBA/80F6O8]@GQ50?PT98O"_\ I6X2/EOF7[6J@  )LKH
M         (Q9P?W@;X^:B?VR1UN2GW.UC_'4OQ3@[+.#^\#?'S43^V2.MR4^
MYVL?XZE^*<'H3UJO^,O_  L.7]=_N.^N,E>  /.=0
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M5:F5+QRI#4QQR+'(FUCT:K7;;*M@  /40H
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M5FE?>!MZ,7?;^NCJR97$FQ%;QM[LN"]I)C&:R,B)Y"3/0] %E[2]1(X  #
M
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MOWMC+ 2Q)A-M%%:MI3##S,=MDHSG!66ZZ@E&V2=[=YZEH(S8)8!YW,M%MU3
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MN0Y   ^D*=
M         #I:]_\ B:M_,]3_  C@[H=?4XJYD*;'0>BI$&9&3\I]A;:3\:B
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M]>S(M.UJ!E5NKMNRR6ZT_P"Y=23[4O\ /;&X:$6A:?YZ1J!H
M                                                  $"=FC[C_#/
MY-4_&*$]A G9H^X_PS^35/QBA/80F6O8]@GQ50?PT98O"_\ I6X2/EOF7[6J
M@  )LKH                  (Q9P?W@;X^:B?VR1UN2GW.UC_'4OQ3@[+.#
M^\#?'S43^V2.MR4^YVL?XZE^*<'H3UJO^,O_  L.7]=_N.^N,E>  /.=0
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M.8:<]>WT?Y_S_6-0'8C30R(S(^?+PC4
M                                       'S-I)F9ZKY_\ G47_ %&J
M6TI/4MX_C49_>-X #0R)1:'_ %'H/D9((]#-9_2HR+7PCH;MNFE69;5<NFM2
M$QJ70*7-JDUY9]BAF%&<DK+ESU4EHR+PZ#"EQT_*S'[5QVJMNX8X(=<^%EM5
M]='DW!ZME&54T1Y9Q)KZ8[C1.HZE6VXK=+V^G<,#9K5=L:ES-\));N[ST^/G
MXQMX9'TFH_\ U&+:.6?:HY4<Q&#5HXL,8FVS;!W'$XDJA5&JPV)=.DM$E+[+
MC<E]IXMUW>(C4C0R+45[_/CRK=^NS/+=-]* Q9>TO5Z=M"6IH(R)//0O">O_
M ,C4RU+3Z.GGXQ$G\^+*MWZ[,\MTWTH/SXLJW?KLSRW3?2@,67M>GHJ=9+7=
M+=W>U_7\>O=&WAERYJT(]=-X]!$S\^+*MWZ[,\MTWTH/SXLJW?KLSRW3?2@%
ME[7IZ*G62U-)*+0_ZCT&ID1EH>OT&>OC$2?SXLJW?KLSRW3?2@_/BRK=^NS/
M+=-]* 67M>GHJ=9+8R(R,N>A\ND]?'TB!V>O)'1\Z]ATNQ:U>E6L^GP7]Z2]
M2Y$UAV;'6\A;\=Q<-]A>ZZVE31[RC+170/=_GQ95N_79GENF^E!^?%E6/IQK
MLSRU3?2@,[?3YO*G6>PRP9:L-<J.$%M8-X64ENF6S;K3A-F:E/29<A]7$DR)
M$EW5]U3KYJ<_2K4:34>AB0:C0H]T]?C+4B\9?>(.7_M$LI6']DW+>]1QEM*3
M!MNG2)CD6/5H#S\AUIAQUB.VTU)4ZHWG$$WJA)[N]T<ABDR_RN&H-8VJ99P$
M-S!M-R)HB:KZND2EQ53^H"GDQPB?T_[\D]LN70!E&N=>R*O;^<SFR01'KJHS
M\)F?WC7=(C,^?/IYG_5W!1K +&VT,PN$UFXNV-)3+MN\:8Q/ANIWM$.+:0I]
MC57,^"ZI3>I].[J*S :FU*23R+7Z3U&I$1&9\^?A/3Q#4
M                                                    ! G9H^X_
MPS^35/QBA/80)V:/N/\ #/Y-4_&*$]A"9:]CV"?%5!_#1EB\+_Z5N$CY;YE^
MUJH  ";*Z                  ",6<']X&^/FHG]LD=;DI]SM8_QU+\4X.R
MS@_O WQ\U$_MDCK<E/N=K'^.I?BG!Z$]:K_C+_PL.7]=_N.^N,E>  /.=0
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MXCAE9-1X?2-<J:,%)3,<J10Q-1&L;=7632<YSU5Q8S]@5R;?J;I^MMQ^G![
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MOF;&IFSXIC5=/B%;(QB1QK/4/5[DCC;L9&W8UC4Y&M1   /40(
M
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MFC*IEJPPP.14CJJ[,H[34J8I!H-<N0VAV2C=,ST)MXUHY&9<N7(2M#H #F
M
M       ! G9H^X_PS^35/QBA/80)V:/N/\,_DU3\8H3V$)EKV/8)\54'\-&6
M+PO_ *5N$CY;YE^UJH  ";*Z               #JJU685 IDNK5!:D0X+2G
MI*T(4XI#:$FI2MQ)&H]$D9\B':CBS8K4Z))AOI2IF5'>C.I4DE$:'T&VK4CY
M'R48)OY.>P+9F9/.)@%>N$%XVO0+Q*57)*FX[,%4-]M:W6']'4ZJ+0MTTGKK
MIKVAPLK>;_ :P\%[/M6Y+P3#KT5Z4T_ *&^XM#DF6K@%JDC(]_?+3=UT[>@M
M=9TL$%X,8S5=J''<;MRXY"I5'=W5):-9EQI.G\']T69&1F1=P?')E@BYC1C-
M1HTN.XNW;?D)E5EW=4IHEI(GHVNG8\UH(N1_'TB7XO!Q:^F_5_G;W2_(B:/)
M;F1.D\.MDUUM%-+\C;?G5-OSV13)^H=:@W#2X=8IRU.0IS27HZUH4VI;:TDI
M*C0LB4G5)D?,=N.+!B,P(<6%'2E#$2.S&:0E))(D,-DTG0BY%R20Y0B#W)R)
M?EYP                                    +?.9?W5.5'YZ[?PQ"X&C
MH3\A'W&+?F9?W5.5'YZ[?PQ"X&CH3\A'W&(3"_7^/_&,'V;1%CYT]B_!;\DL
M2_G#,1O  $V5P
M
M
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M[:Y^IU/]'2TK\_1T7VFFK;IZ?/:W_<W@ #B;@
M             6^<R_NJ<J/SUV_AB%P-'0GY"/N,6_,R_NJ<J/SUV_AB%P-'
M0GY"/N,0F%^O\?\ C&#[-HBQ\Z>Q?@M^26)?SAF(W@ ";*X
M
M
M
M                       "!.S1]Q_AG\FJ?C%">P@3LT?<?X9_)JGXQ0GL
M(3+7L>P3XJH/X:,L7A?_ $K<)'RWS+]K50  $V5T             ::EW2\9
M #4!IJ7=+QC4  &FI=TO&0:EW2\8 U !IJ7=+Q@#4!IJ7=+QC4
M                        6^<R_NJ<J/SUV_AB%P-'0GY"/N,6_,R_NJ<J
M/SUV_AB%P-'0GY"/N,0F%^O\?^,8/LVB+'SI[%^"WY)8E_.&8C>  )LK@
M
M
M
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M4^)NACI,1P^NBB@>BI)/&CF2)9S4E308Z-KI,B\!M3S27^>CD-PM,_#H
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M8-6,K*&N7&:2:K;24,SJBKP](:R>CU&(PHQ.+U$JPZ^*-%?I4\L3[HK]%.Z
M='2KDM^MFHJ17:1531R6F!4(DIQ!ZZ:*0PZX9?21#D5.M4FC-\:K52GTMGM.
MU"9'B(5\A3[C9*T[>FOQ#NCV*W31[5;[9')H]=[$6M/4)+J%@F2>Z)J5B>DM
MUY$U:MT[KS)8[0!TM)N&B5Q"G*/6*954)]NJ!.C2S1W-],=UPTZ]!:D0[H9:
MYKD1S51R+R*U45%Z%38:21R1/6.6-\4C=CF2-<Q[>EKD14^=   ,F@
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M)[9'T#O*95Z768R)M)J5/JD-TM6Y=-F1YT99?^5^,XZV>G0>BNGD .R
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M8<NR25&7,-AP[5.H<%PRO<UB5KFRP1*^2-%;V,SGZ"RL8VH9<B+M>#N:\QJ
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M6I?$BK)ER:":I6*F>J8=4L1SM!R,[&V?C'B5F)O?9U8>W9;TBH51U^0J#?\
M-IR5>J#M)IE5;B&I!1]9.JH;3IGP>R/F?27*DMET7)OB8_AY^;CC3<F#V,=&
M?@.5=RX$7$\S49_$855(ZT5QYN(7%6E]I!D6B=\MW7D)14*'FEPNR-8;2\*+
M9;FW+;U2K3UU61,9B.G5*<_5U+42CF(4223$-Q:2)"N?1J(@9A*E;V;*VZ+:
M&&.6VH6UCI,J=%7(K]-?ET1NWY,";'<J;YJ:8C1Y27B;=4:35H1:D72/!B>D
MU*6HF:^MK'8'A&C08G25VNJ)8F:=L$Q&E=K*:M=+V-2UT:NUB,>]49=5^JR8
ML%2N-X/ADT&7\N1<)>?D=FG)6/Y92APBCJZIL#9.$K)^.0<4QS+=/1-UN$3P
MUC(>*+4P0-?4(C";&=*NW!2,V61ZEPKAE=33&:VU5E1'W&XU9<8A1T\=QMI9
M-+):R4Z1*)1)WBT$>[_P^N;'O:27UAA4KUJU+PZ9AT-5?H$63):34DG2$.H2
MTXR\VJ-V1&:C;TWM2,^9"MF8#"#$YG&S(2R=,E7*=C0JTS=U=+>(H2W8,5#2
M'B+>U-*DFC>-79&6O;,QZ:P<.[ZB;3'$N])-NR&;2FP:$F+6C,S9>6U1B;=2
M1;I%V+G8GSZ?$)6MI:BMQ*:*>GJTIY\VX,Z6'\=H<7^\#%EC<YO8K DOXN:R
MZMSM)KKJY;_"Y:QO"LM9-P^MPK%<"?B^$\ ?"%#08@B8?K_OLG"K4LH:N"&=
M%DBQ*2A<VKP]',2K@@6*6!&M8UR4C]95S)QGOP)M_"BXJQ&P^Q537E7%;50J
M$VIH5ZCP=Y"DO3GG31O.&I9DC3GJ7/0A1_,+F"PZQ9SJ7MAQF$OVX*#@GA:<
M$J?;E$@59]=>54HF^\3TJC$4B/P'RU(W.2N@A<%S265>%9SGY3+FHU">J%!H
M"KM17*B@S)N"B7%)MO?T(_W351%S_K$3<:,.KPRKYN[UQV]:5G$["'%DJ<JN
M$M#+Z[:.EQ"92I#)LOOO=4.J,SW$EIH1=LAPQ:AJ:&.NI:.)8,&@S73R5,,E
M/55-%'0R83#(NE3021O?0I7N:^:.-Z1L>JN>W021"4R%F;"<S566<;S%6,Q;
MA%Q+@*Q6CP;$*7%\$P?,=7F6BSY7TJ:O&,4I:VFILSKE2*6##JJL@=6S0HV*
MGD2HDIGE"+8Q\PEP*S587GE.NV\KAPRO^3)B7W9E1I%Q.,4XX[:68"_5&JMK
M-)+=4;I[AI/I(].@\ER#)ZKBQ9))-!28L>223_@\=I#NZ>O/4M_0]>@66<+<
M0,0\?\>;*5A)@E3L/<': Y(<O"YY=+A$_45.MDJ*34>7#;DLFT\DVS4SIKR,
MRYEI>M90;;:&S,CW&VT:D1$1[B2(S(BZ"U[7:'UF2HI&18H]D[9:*6N1U(R"
MBGHJ&/\ $1:[B#*F>:5U.^2[E<FA%K5DU:*W:43]TE64M17Y(IYL+EH<QT>6
M'0X[4XEF7#,RYFK$7$:IV&^JJIP?#,.HXL7IJ+1A1DFOKG4"4:UDB2)9/J
M/MS\S@                  %/<5$EZV&)?-7.P[N_A'R_\ I^H'RY\N?C%0
MAX?$N))FX=8@PXC1ORIEE71&BLIZ7I#]"G-,M%V]5N*2@O"?( 8W_P"3<I=5
MEXQK)AWA2%7K=Y,.J/4FG^N.K\)P]>1$AS=6>O+0N?(4QQEPKRLP,R^*-V;2
MS,]7<0)-7D,HP]L"S?5N.W9<9+:FWT2'+1DN)?6^T;:BZH;)1*3H7/HD%L',
M$<8<,LM>/5N7U:<RR[CKM8OM- ;D*,UJ?J%2K94Z2@U$G^&\PZ7:\)<Q;2RG
M059*,;,=J'G0RYW#B9C!<-T*EVE>U1DU.MPKF;>J,B13F&8R&)D*F(C,.QV%
M<T$HN:BY<ATY7.5%7FY+77D^KG*W[(;%2UJ;M"\SF7G+KB'<]T94YD2E1K:H
M]SL5AN=36YU)?7.)IROJ.HI4;[BMQ9;ID1$:3(AT.:#,#C?L/\QN(Z&GYF)&
M!F:B2JFX2T2I5C]/95:=0Y$??;=E/2)+F_5)Z'B)6ZE/#W2[$>PR6V]F9@;5
MO%7,1?\ E[/"+"V_J*BH6U2J<N,[%X% MQTV&SZB8;2VY,W&RT6@E)6OF1GT
M]Q#R.8O[8+'K&?&_-K;E2LC"##]^2SELL>2XXX;=6B-R8[E0)Y"F7DI548T:
M7H\GMD1$H@&S255Y-%M]M[[$V73GV7Y.8J=AQ2<=MGALWL;\Z&+-X5&[,Q6+
MZJ7)E=42^/!HD6YZHN-;J(B"?>A)5%A3V-XF6D;QM=F>\.9E8V2=H9C,KB\:
MLRUY7==^8;$NGU:YH]Y1+DK=)CT1]KC5"BI:I4"<B&XF,VMAM24H)*R1V1'J
M9%U^#&%&9S,QDUS';-?,O2:A2+ZPQD0'\.\1I*#?:O:)!J#]5H,)#;9<&/U%
M&CPXI*6ZK4SWN6HZ?+UM'LPN4W QK+!C=EKN2?C;9$:L6U;+D63*D1+F1+4]
M#I,DI42(Y#B)1'ZG<42W#U(]#W3(S ;=MK7OS6Y+):V[_L4IRWXWXSUK)SG[
MRDXPW4_?%4RP,TN%2;LDMI;D5"F5V1+<AL.(U4O6+$0TUO+6HUFG>]L>HO ;
M"\]=FY@J9])5&]-3^*X9FIBVIEUR5YC[1R>9T<<\5[6>IV->:IFGS7L/D.M/
MOTJ'29$KU,1U4R1DZ;L-UI1Z)(TGTD1D+JNQGL2\L-=GYA%:5^T%ZV[GI\^[
M53J1(,U.QTR:[*=94HS))_I&U$LN70?< PY4LMO;?_SM7K_\J<K:_8XO8&9)
M<2*Y1Z@4:YJ_)H5MT:,VK23)37ZFS291-)+LE)2W)5OZ:]/<%3-F=@2[EVR<
MX3X=2(Z6)G4DNY)G8D3CCES/>K)J=/I49G*UYF?]9B 6U-PXO_,IFOR:Y?:%
M09\W#6?5Z[5L1ZHDG"I\-='5'J5*ZI+<)H]YU@MW56I*U/7M"_'0Z:FCTBDT
MEO0FJ72J=36R+H)$&*U&3IIRTT:+^KM: :\R;[K_ ))_F=BZDE;AGKR6CH49
M?PB[AC%&<_\ [C1G_P#X5<NU_JQW!E>++4D^!23_ *QC+.8(XN'M\6<6"LB9
MZVI0U).[-X^IB5UN\'=W=W37B]A[;S 9;;LK^U6W3="0>UAPV9OF]L+Y>-.9
M->$^5NB/5)W$.Q*6A:ZW>I+W%0VX[E.D-5EGJ:26IG'2K4E<^Q%AO,3B5DZP
M!S&Y7;NV;V)>(-*NN=<!T^\X%<3>,FE5MAV3$B$HW+A5U G5I3JM&R7H:O;&
M8GIM2<'\3K,VC6$^93&+#BX,9LJ=+.HEZATVHSF8=LN+@-Q]^33*?Q55'JB8
M9+(G6%;G27(Q&G/I-Q:S4LY?JSE6RD]:V#N&%U4MVL7:TRS#J<N).K$)2E+B
M/0F:B?4VZM.IZF:2UY$!LW9;;=+;=J(B7YE3;?;T%QW:HVAC+EAN7"O:<X+W
M!/7&P\H5.J&-=C/U%2*;>**K38D=A26Y#_4L;@D;KFC+!J49\]>1G3K9Q5K%
MS:39@+CVF&(E9J%M8%6;279.".&4.I*=BG,A4IZ+<YS3C/MFI*IL93C?5;*B
M(C_1),N8];GHM3,?M L<<',C-KVY5K2RR4FW:'Z_E\.+-4>MEZAP)<*&B.IM
MIU!-26W8QFRM:B,S-1GT#X9;L$,9=F'G&>RSVA:M0KV2#':E+I-K3&E+=CX9
M2(E(4U59)MD3K\@ZQ4'UN&2C1PS,TD9IUU!/R;?TK;/V>U\_*G:0I;EOPUJ>
MUYS<YAK\S#W97G\O^$-4B4?#K#6CU.?1T:O$_ J*WJC3)$=]?[88)U)O)7_%
M+0N8[6AV+=VS+VF&$.72P[WK55RPYN8USP#L2JS9E0>M9JBTE9*)FJSWWYCJ
MI#SYKU;6DTF1<^1#A8?2L;-COFFQ]=JN$U6Q.RQ8XSZ?6+1O&F+=)RW7&$N3
M)C:Z9$9?E/=4RY/#U<26Y[8N@>^P>MW,!M*-H;@]FTO+"Z?AIE\RYJK)V0Y4
M9'$D7B=PP>IGU''=;9EPNHY"$JT6@]_77H+0!V_:6]+)V[\Z_61,R>Y+,'Z1
MME\YD*6W6I=-P?10[JH#)5VJMK=>J=&D5F2F4Z4C?DI)PM$)?-:4)/=01$*.
MSLWN6'-EG@Q]D9\\5;XH>"V$DRGT7"S"VUZ9=+K+R#97 J:Y-8MHB5V+C*'B
M.49GKJ2=3,3EJ<K&+*CME<>KKK6#U5NG"K-)&H5$HU\0W'N#1F*;0SIKZG6&
M&G-[F_N_I%)UW3,CZ=*2,8>7?LOLW..U>O[+8SC?EFS /4>M6[>BX;$N5:CS
M+!S9K10$Q)<YTY$R0;)F>[N[IF8&;WO?ET6HW;M7D1>7GY5V[>T>,R5YJL-,
M&]I3:N!&3O$2_P"]<JF.E-N%55H-PVW=),6$Y0Z&^_&_[:KS*W73FRU:DKB-
MFDR'RRW9-:YM"<^>>*R,8L5KH5@_A9<5E3:)9\"J52#OJE.KEZ-S(4QIUM)/
M-I4:=229=B?+D)^9-\0L?LRN:PK^L/+I1L&,JUITJKMIJ;U)I**G=RY]*>:9
M)CC08]4IYQI>A'PS(W->?(C'O-DOA)B=8.<_:&7/>]H2K>H-X5JRW+6J3ZC4
MW5VHI2"?4UJDM";U3J1&?2!A55+]O11.5%7E3EV<O^72A:HSG8^X1)SV47(]
MCCBC>-A92LO,6+&J]&H,.X*S5+W:J%-:?CMR:A1C55(AQ7VR[);A\0C,]=-1
M3FY<UN6+*?FOP)OG9PW]B=7+-N^K^H^*^&%5MV]I\6:A:X]/IKYU*NMR$Q";
M4XN2KA;N]S)?(M2G[GEP!Q5RB[0R;GIMS!*-CW@UBD3*,4J(ZU%6=LMTR F#
M"=:8=CR7Y/&<4ITTL-D9;O,=E8^.F+>;7,1A5;^5'*Q1\,L(J/,?DXJXBU.@
M4Q+B#42'XK+,&JTUF1JEY+C!+CGJ1D2S[1@.:_*EMNU$2^_?OZ#)\MZH.5:A
M46J.-J:54Z/3*BMM1&2FW)L-F2MLR/0R-)N&1D9%H?<'<CA4YIYB%#8>4E3C
M$.,RX:4DDE/-,H0ZHDI(B2DUI/1):)(M"(M!S0.8              %O?:;9
M8V\U>47$K#B/':]7(L>+<]$EF22D1W[8?]6B3'<U)23=5$).B3(U'H0M]Y:M
MH?"H.R9N+&7$"=K>^&-*K]@5VGR%FB9"F*E2K6M]:B]OJZIII3>J2/DDR[HR
M )\-F?$E0Y"=]B;&?A/H[2F)32F72/P&A9D?QC#'S;9(<R<?.=<^4K#"R9\G
M*KF6NFW;AKM:8>X=/MM=I3&:ZX2F/X75TLEI7NFGF9ZZETC9MN1>9;^5.KF)
MP[+S *OX8[-_&K,'=:I,+%W'BDWM7;@G/)<14$08CM4?H2S?5HYV,1UKA;IE
MHDNUR%O"L8EXIH_)Y(-UTR^ZU&OR3BK4J5'NI4V6Y/9;EXG+@%J\I\W5I:96
M222;FFZ6Z7(986+&'?6[E0NG#BT:.WO4O#)VATZFQ4DVEZ4S;RXADDDE[9Y]
M!:GIS4HS[>@Q?9F6['I6P4H>$Z<-J@>)+6,#E1<M/?44E$$\4BG]4&K<UW>H
MRZHZ/:\@,HMUOVW-_P _FZ_G*QXR;)>UXF1!O,/,Q'O*?F>AVQ;5U,XDMW!7
MHT;?:9BSDL^HB)Y0C_0I*.K5LTJ+51ZGR%/LYN(>(^8#8(6'<%W5I=1Q"KMS
MT:V7*TM"2<45-O*'2(\E22/=WFVT)<U,R49ETZ\Q?XQFLVZ:EL]W;0@49Z3<
M_K8T*$5(29\8Y;-&CMNL:Z:[R7"-/1TD+%N->7_,#,V%=DX:6IA[.DXP4N^7
M:O&M4EFF011;Z144$I:DZ))YA!*WE$1)(]3 (M[;=NFG+Z<GB*V538MVO"R1
MTF_X>(-VQ<T=OV13+TA8H-U^M)B-^IU,9K*(?J"4XH&Z<9E,0]4;NFIB(N97
M,A>>:781VY?V(M255+[H6)%NVS<,U2";.4BW\1(E&BO=AHC5QJ*2CTU/4^9Z
MD).5[:8YK*IES@97866&X8^9VJ6I2K,<IG5CQT^/#DT]FF2)JJD<3J S;@+5
M(-!O%T;G3H/)9D\A6+^!VQ<M3+O0K9>N_%%Z_P"W+KNB'%,DNJ.JWW#N"6R?
M#WT?M!MUU!F7MB1SYF!G;LORZ2*G/L\A+W/CAY/Q R[956+FS$^L9E]IUFTA
MW&&DQFR=J]YQ_4JG+I[$(X[[-4:-E9&A9PB4>B^RY=-BK.E>^13 :=@GB#L[
ML3L1:/C'2;LH%-J3E4Z]I=)KK<^L0(-1<>77%%36R<86^I)&:R(UD25&8GYM
M/,$<78&+N1+'.]<.:_BQECPPM-MC$3#RE5*;3FZ1(?H%.B,*EL0#4]4N'.0M
MTDK97N[ID1$7,1XVAM:Q!S:X&VE0,FF4'U&P]LNZK+E7%=? 1 JK49NO4^0M
M*&)D%FH.\%+3C:E(,S-*349\^8,_H[=G4B7V;>=5]$N2CVN][WK QNR@5;,@
MS=LG(Q4;5CSL4)%HIJ_5+\N30*>^T[).W"]4DZU)Q2]>X?3NCW&17#C)Y>6:
MZU<4<@^:JLT+#94.7#Q#P'NANN*EW0W*IYQ(Z(LFZ)13([D4U+=,XS6^:O#T
MUMS?X[9O,#*KEVO6-@Y$QLRHS+,IM-Q8LV;3:<_(MQR'0(,%I2.J(LF>\M<L
MEN'P4$9;A:\N8MNV]@ZG.-G[R\8O9.,OM>P%MK#FH52=BM?[50J-/IU0ZO;;
M5'CKMV0W#8=2VI+D=*D-K).N]R )M;VDM95NBI\[>WO3;M0["R\EN#E2V\F)
MMM28M:.B4>72*U&BHKU40\<MZEE45FN2F1Q%H.01F3:S-))U21;O(IG8.7?=
MJ=LCGMM9=R51VV+=L:DLT:AN3)*X<!$:R)9(-EI3IM)69MH4:TH)2EEO&>]S
M%,<>(^-^4;;$P,?W\):I?V&&+*:'1UW-3WG4E1W:?2(]*?DN-,,O*/C/K4O1
M>A%H?20KA@_A#BHWM;<[&*$NRID6Q;XL&CNVW7EFKA5%^38\DE1DI-):*:D/
M)9/GKO=KM 86ZI>]^Q3Q*ERW_LN\EWY_]S9C:CF4Q&NRZ\/+:NJJQ+,LZ)6Z
MQ2E4E<BJ5!E;BI\*:TZ\E#J$.DE6NA))!:$8F'LSTWODZS5[07+*Y?%4N7"'
M!2WZ96,/8=6?D3I%$<E4.=5N%U5+=>DO;SZ&T&:UZ$1=LM2%<]A+A#B=A73,
MPB,1[0E6JNL7G-DTQ,E2CZKCKK=0=2ZC5*="4VI*^6O(R'>8+8'X@3]IOM#*
ME7[3D0[!Q.MJWJ/0;A<4?4]2><MB5 6MLM"+]KOO)U(E'J9<P"KM<E]EDV?.
MG)VOF+%N73,[DGS;7ABSC?M(<7\1*I<M5N*M42R+%MVD7I&IMGLTFH3*2E],
M^VB3#GFZTTU(W5>U-.Z9D?3/+8[9NX] SI8M91\*[RO3%3+(\Y!D825^Y+=K
MU+*@-+C.SZE'.9663D2M7C)DE//'IN\A2#+J[=.RTK^).7?,CE4C8EX<+N"K
M5G#/$Y%.8J;U;.L5*757HRX\2!+D1^$[(:BDMY>AEV1:$+JNS-JN8W&C&7$W
M&F\,$J+@-@$^JGIPFMMJF4A51GL):6S4'ES&8C%08WEDE[=>T/11I(#+N?M*
MB6VI;FM9+=?SWVE]M!F9'KTDI2?$>@WC:DC(N?3J9^,_ -P',
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M!U,2MXHW4;'4Q*WM[>X&YP][7LM=W7>Y]/,<[>[A&9=WH\7=&I*(^CQ'R/Q
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M,>)&CQ64%HAB(PW&807<0TTE*$EX"20Y0
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MS/S"\JG>AH/^X:_NP_,+RJ=Z&@_[AK^[#4YP]W8'^Y57_4^E^BS[X_<Z;/\
M1?A0YO[38!\'_8?3U=-X9^SG9#/AK<'U2K_H@>SG9#=2_P#K6X.9D1GUI5_D
M1F6I_P"B=HM3$S/S"\JG>AH/^X:_NP_,+RJ=Z&@ZES+] STE\;1_<&ISA[NP
M/]RJO^I]+]%GWQ^YTV?Z+\*'-_:; /@_[#Z>KIOCV[0+;QU&7*H]L9,*O*8B
M*)[U:N^93G(KS9F25LDFGU-I#G(]4=B6O;[@[G97[9;%7$C&*'@EF7JBJZY=
M1K*V+C;BH0II49I3L@EQH:#5V1Z((U]!:Z>&6.T&V)%D9@"I%UX"/Q,,KII)
M/%-@1(3;S-8XA$EO>U-MEKA)+EJ7/7I[8X&S3V+3>5V_RQCQ@N)J\+R@F?6[
M 7#0PFD&MM3,DR6A1MN<9!DKHU+3XS'R+://B9IAEDGTJ%)8UD?$_0PU:71;
MK&)3+(LB/LBM1'7?I[=+1/T-+F+[DU> BOH:+"$AS0Z@JHJ.FKH%GSLW'%D<
MM)._&HJ2.E=2H[0>]S-73<41T/%TE6RW<$9T< SJ.*U,.Y9W56#2*4Y?9>HT
M_=IR*T@W*>;*N$29?%06JN!O;G\(AQ_SW<O10L+JAUT3^I<87JHQ8J_42H:U
M%RCN<*<3R>%K$)M1Z)-_=)9>U%6O6/PQ-Z[I"K3@&_?"897.LFT$=63!+2*E
MXR26]P4\DZZ\N7+D/CZP^%9LVG'.SZ?PK*7+<MI!MMZ4I<U6_)-CL=$FZ?-6
MFFO;YBQ='%-OXVBY[7BEV?\ J+MY)?<O8K_?=FG8]B?C1)<A[+T69>2.]L0P
M_E3"%;+:] OY6.6F9?\ )PV\"Z50NO2G9YR,"4UC%2B'<4[U0P;CTF5?37J/
M/TI[-99X\!3"C:W99N-=DHF#6:>A7,=(WGHR[N4C#"MHN>H'3L7I-5B6.[ZA
MU'>GO49XX\Y+Z.%O1";<Y)-_=)?27@K:>#&&QS;MJ!VK!ZKO5N(U<KW";WJJ
MW!;X<5#W8]D32.2=[7QC@-X#X5-Q+6@HLZGIBV:Y+=MQGA-[E+<FKXDE3!;N
MB3=5S,R))GVS/I!6XK?9+16[+EAE7_\ 816?UJ7_ /37:[D_'6<EF]B&39$L
MFG09D5UH-+1Q&@1%5,(<RHM>@6VEC:LGBO?1PY'0.TIU29/ )SB8%*KN*-N(
MN*:=6P?BTN;?+'J//)-/8K#'5$!3#O"W)9N,]DHF#5N'R/IU'GOSZ\NO6_AK
M<_7/4/4?%>94X-EOE0ZB:YTBD2.I)J7FB:WXI-NGNI-\DDLN:=>0K>C!C#9N
MHW;5$6M!*=>S41FYI'#;WZLW";X49+Q[NIDTCL4ZZZ%T:'H.O3@+A2FG6S2B
MLVG=06D_*?M^/PFS1379;O&D+9(TZ)-USLE:$6O;[H*W%-MI:)/R[7AEV?CV
MJS^MV_\ IM)KNW+9R(UJ:*HYLB)H:R@S*OK;3T<0H$O;"GLJT;>@6VEC6A-!
M?2T,/1T#].=4F3P",XN!2[EQ-M4KBG%6,)(5+GWLSZCS]R!&J\7JN"MEPVR1
M*-QGF:634:#Y*T,><//=ES*V\-KK*Z*@=%Q6G5*G69(]0ZCOSI5*E=13$/,D
MT:XI-OGNI-\DDLN:=2%=#P:PW.H755.M6!U=>3$2/<<@FF]^J,PFN#&0\K=U
M433?8)U,^7T#JDX!83II=LT=-FTXJ=:3\F1;\;A-[E->EO$](<9+<T2;KG9*
M,B+M@YN*[=&:B_IVO#+W=JQWM+S4^DUUN654<EF]B9CFR'^+UM!F5?6NL1F(
MX>E[84]M9HJM MM/&5CF@NCM##T? _2G5LR>)5F^P/;N_$>QUW#-3<.%E/IE
M3O"-ZD3C;A1*K#ZNA+9>X?"DFN/V2DLJ4I!\E%KR'F&<]F7)VT</;V3=50*W
M\3ZA4:7:$GU"J6_.F4N9U#,0ZR;1.121([$E/$DEEV2=2%=%8.8<JK-RUX[7
M@G5;LCQHM?F&VWQ*DQ$9X$=MX]W526VNP+4ST+M#J48!83MT>W*$BS:<FEVK
M)DRJ%$)ILD4Y^6]U0^XR6YHDW'2WU&1%SZ=>0*W%.RT9:/\ K-&\,O/,Q8E6
MTO\ 1I]-K[6TI=%Z6:F@NL<V1+1:VAS+=$H]=H8A0(BVPR5M>D:+0KHZS%]3
M+3:6EJZ%)87ZR9S96^.+-M@D=Z8A6"FX)IW-AC3:?5;OA^I,WAPH53A=7PW&
MG^'PI)N1NS-+)J-!]BK0QXQ6?++@BQ[#Q"5=%1*U\1ZG/I-JS/4.HFY,FTV=
MZGRT.L<'BQTMRNQ);I))2>R3JGF*]HP>P[17KDN1-L0BK-UQHT.O3MQ'$J,>
M*QU-';=,TZFEMGL"(S/0M.0ZCU@L)O4&@VWUF4WU&MN5(F46";3?"@29,CJE
MYUHMS1)N/_I%;I%SZ0<W%+.T9:._XW1O#*MKS-6%5M*E[4^FV1-FE*J.2S4T
M5139%18==0YD<B<1U^AB% U76PV9N(ZN] Y&J_%5@EI%=I:NA;+%)IS.;*WQ
M;6;G!%V^KYPZ3<$TKIP[I<"L73$.DSN%#@U&!ZHQ7&Y'#X+ZE1.S-#2E*2KL
M%%O<AY#\_++>FP+)Q*5=513:>(%5G4:V9GJ%43=ESZ=4/4V4VY'-HG8Z42^Q
M);J22HNR(]!7M.#^'B*Y<%Q)MB"58N:)'A5J=PV^+/C16.IF&G%;N\:6V?T9
M:F>A=H=&YE^PD<MVAVLJRZ<="MV6_-H]/X:.%"DR)'53SK2=W0E./_I%&1%V
M72"MQ2SM&6CO^-T+PRVVRL6&]I=NC#IMDM;2D5KFZ+4T5139$O!KZ',BHG$.
M,:O$*!%<C</G;B>JTJ!4:LN)K32TFEI)#1MFBD625[9&^/1FZP17?]XX:%<$
MWKLL6DPZU<,/U)F\*/ G4_U3C.-R>'P7E*B=F:&U&HC[$RU'BTY^,MIX>VEB
M:5U5'K2O:K3*+;\SU"J1NRI\&H'3)+:X_!XS*42RW"6XDDF79$>[S%?TX.X=
M)N"LW.FV(15NNPV8%5J'#;XLR*Q'ZE::</=U-*&/T9:F?+I+I'2%E]PC3;M&
MM8K*IOJ%09C\ZET[A-\*)*DR>JWG6T[FA*7(_2&9$1[W3VAAS<5[+1EH_P"M
MT+PR\\L>HO:5+Z,.L23DTGJU6Z*(J+F*;(:+!KJ#,KD3[W\8T,1H&Z2-HJAN
M*:J]"Y&ZW$%I9*/2TM32LGBEUDCV2-\E'S;8*2<1KIPL;K\P[QL^D1JY787J
M3.X,>GRJ<=58=1)X7!=4J&1N&A"C4D^Q41'H0\,>?O+46'5N8HE==1.S[JK$
MFAT:=Z@U(G7ZC#J7J6^TN-PN*TE,WL"6M)(,BWM=!(-G"##QBY:O=K5LPDU^
MMPVX%3J7#;XTJ(S%ZD;96>[J:4Q_T9<SY<CY&8Z LO>$2;8IMHE95.ZWZ5->
MJ$"F\)KA1I;\DY;CZ"W-"4J1^DY$79<QES<5L[1EHT7\=H7AE7E?'J-*TNVT
M>L26UM)ZM5NBB*BHILAHZ#74&9G-3[V\82/$</:KM&EJ$Q;5*Z@=H:VM6D=1
M:6GJJ=D[)5E>]CV^8CYLL%I.(=R87M5Z8=WVI1X]<K,+U*F\)BG2:=ZJLNHD
M\/A.J5#,W-Q"C41]AIO<AX-.?C+6K#.B8L]=E2395P5B30Z9/]0:GQG:A$J1
MTI]M47@\=M*9A&V2U)))EV6N[S$A6L(\/F;BJ=U-VU"37:M";I]0J'#1QI,1
MJ-U(VRM6F\:$Q_T9$:C(B\ \\O+[A(JUH%G]9=-ZW:;.<J$.F$TUP6)3LKJM
MQY*=S3>7(_2'RUWN9@YN*=EHRT?]=H7BE7^G'J-+\:G)'K$EM;2<K5;HHBH8
MBFR+I0:^AS*K4=AG&=7B% BN:VGJ$Q?5:5"Y&K+5+2/H=+2U,#)V2ZU[V/;C
M:[5_:_XV80XT+P4R]33MMNAQ8,VK7(;+4A<UJIPVIT(RBR4$MOL%D1I+GV7,
MN7*5FQJVFN)&;MZ[\-<:".9>=J)A=2U]*6TE5"E)4XLUL,I)#/#01%V1D1_U
M'TVTQV,$S-5B4WC)A/=:+6NB6TQ&KE-*$A]$UF+'1%AZ+=7PVRCM(+D1<]"$
ME]EILO:?D5I%Q7%<]?1=N(MX)BG4)QQCBG *)JE*4)2LVU;Z%;IZ<N6I\S'P
MU'2YQ3.$LT\LGWGULJV65G$UI59:%D4*.5S9471OV*.TD57*J+M_5&8L<^YN
M?]SC08=A-!0)PDI0T$::%#4-S#'CK:B)V(U-9B*QI%)A[XDG5C-<Z)8W1,BB
M8]O8R&S+^ZIRH_/7;^%(7 T="?D(^XQ;\S+^ZIRH_/7;^%(7 T="?D(^XQ]?
MA?K_ !_XQ@^S:(_-V=/8OP6_)+$OYPS$;P !-E<%!\R>-$+ #!B^<5:A%.8Q
M:U-=>1'29D;DAQM:8^ID1F1<;<[7QC"M3MW<Z2\357<FLIZQTW XT=E]3PMW
MU*:FFTHRFFC>UZF2:].G7ETC-WQFPIMW&G#>ZL-KI:)ZC7/3WHDA*C/1MQ3:
MDLN]CH9\-Q25Z=O=T[8Q1$?DYF(7KLG%5BDGUK3KJZFIWU,;W^I%RSF*AZ<3
MC&DR/@[Q'_YA7F=:?-<U1ARX ^9(&Z22MIY6Q.2=7L5KI])6Z46BEK75J=EI
M(MS]B_<Q8QP 89@^<F<+E+A<N+2ZEV'28S03U\+\,;!*D\&&)#'+J,169473
M1(I7(L>JD31>A=3LK;N9*JI:- J%T7)6J1<<B$SZLTMFVZW,;B2TM()TD2F8
MIMNDIW>/L3,BY\^C7T_LYV0SX:W!]4J_Z()161LYLJEG6E0K7+"VBU!-'A,Q
MU37F6U.RGTMH2\^M2VS69N.)4OF?+>T(>J_,+RJ=Z&@_[AK^[$O'#G+5LTZ[
M!=)&-TKT=2JZ6BFE=4J$15O>ZHB76ZHB):U<U>)?<WK55+H,L<)NH=43.AT,
MR8(QB1++>-&LEP:61C=!4T6ODD>U.Q<]RHY5AG[.=D,^&MP?5*O^B![.=D,^
M&MP?5*O^B"9GYA>53O0T'_<-?W8?F%Y5.]#0?]PU_=CIJ<X>[L#_ '*J_P"I
M]+]%O-]\?N=-G^B_"AS?VFP#X/\ L/IZNF\,_9SLAGPUN#ZI5_T0/9SLAGPU
MN#ZI5_T03,_,+RJ=Z&@_[AK^[#\PO*IWH:#_ +AK^[#4YP]W8'^Y57_4^E^B
MS[X_<Z;/]%^%#F_M-@'P?]A]/5TWAG[.=D,^&MP?5*O^B![.=D,^&MP?5*O^
MB"9GYA>53O0T'_<-?W8?F%Y5.]#0?]PU_=AJ<X>[L#_<JK_J?2_19]\?N=-G
M^B_"AS?VFP#X/^P^GJZ;PS]G.R&?#6X/JE7_ $0/9SLAGPUN#ZI5_P!$$S/S
M"\JG>AH/^X:_NP_,+RJ=Z&@_[AK^[#4YP]W8'^Y57_4^E^BS[X_<Z;/]%^%#
MF_M-@'P?]A]/5TWMJ8\;>;*Q0<+[DJ.#]9JUR8AHC\.@4B70:M2V77W2-!N+
MF2XR6&^">CA$LRWM-.@60,)-NKG)I>+=$K%^UU-PV-5J_'A3[9ZFAQRC19TQ
M$:.E,E"#49M(=2K5/MMW_P PRB\==E]E@Q=PQN2Q*?85)M:H5:-NP:[%CH-^
M!(;U6TX@FT-J,N)NZIWM#TY]P6,<(_R=N^:9C%39N(.)I3L.:%6FZDTT5,:0
MJHM1I)28K)\-PG&N$;:$:G[;IY#Y''J3/\E=0+35+'QHK=N'*M- QZ/17<;C
MFE<Z1JMWN9:Z(U'+M_0O!+F'[D6DRIFR+'<%J:6ODCD<R/.38\;Q:HIUIM&*
M/ :O#J*GAIIDGOV*,BJ$E5DCIG1I9F6+8=V1;VM"V[JAZDQ7J1 J!)41D:')
M,5I]:.9$9DE3AI(^CEKJ/8#H;9MZGVK0*/;U,;2U!HM.B4^,@BY$B*PVP2N?
M/51-D?@U'?"U&:2,8C[:2-;I6Y-*R7MNO>Q^"ZE8%J)UID<VF6:58&OVO;"K
MW:I'+[9&:*+O   V.                                 !PYTM$*-)E
M.?N<6+(EN=W<C-*=41?&23_Z# (VK'Y0WF\LO-A?N#>66L]85FX;38[#\\X\
M2>NO+6C5;:VI#9.1R2ZVI!J[9*U+D,_R1':E-.L/)WVGV76'4_QFGD&AQ/TI
M,R&&EM/?R:.Y\Q.8VY,>LO.(J;79Q"E,.7);/J:W)3#X24M\4I$APB5O;RW=
M$%TEIS Z1JU'=FFSF[5[IRGN-G?^4Y8(U[!A$#.Y5ZG:V+%%2E#DVF4*I5MN
MO[[IIXJRI$9;$/<:(E$2N:C/3I$^_P!DF[,?OD7/]1;G]"&FSKV#67'*=@PS
M:V+5 I.+V(560A=Q7+48+;*U.)6;K:&VG$NI;X9*X>K9]ENZ\Q<%]C*R3=X>
MV/Z+&_N@,+J[K9'6OLLJ)]:+T\W:Z+??[)-V8_?(N?ZBW/Z$'[)-V8_?(N?Z
MBW/Z$+@GL962;O#6Q_18W]T'L962;O#6Q_18W]T!CL.T[OD\WI]%V6^_V2;L
MQ^^1<_U%N?T(/V2;LQ^^1<_U%N?T(7!/8RLDW>&MC^BQO[H/8RLDW>&MC^BQ
MO[H!V':=WR>;T^B[+??[)-V8_?(N?ZBW/Z$'[)-V8_?(N?ZBW/Z$+@GL962;
MO#6Q_18W]T'L962;O#6Q_18W]T [#M.[Y/-Z?1=EOO\ 9)NS'[Y%S_46Y_0@
M_9)NS'[Y%S_46Y_0A<$]C*R3=X:V/Z+&_N@]C*R3=X:V/Z+&_N@'8=IW?)YO
M3Z+LM\._E)VS)2Q)<1B/<REM19#K2#L6YR)Q]MI2V&C5U%HDG722@U'R3KJ?
M0,7?-I^4SYT+SQUK=8RV5\[$P@H\XE4&E*AQ9;E;@LG^GXJY+9/Q^,ALST<+
M>2:^CD,XF3LQ<E#\>3'3@3;*.J8TB*:BBQNP3(:4T:R_0Z[R25J6AD9&7+F,
M6;-Q^2I7;=>.]8NK+YBDW:^&=UU%M]RW$TEIY%OQUKUE(;=><);I/;Z_:%V.
MG@T,=&+%?:B_[VWZD\>PR(-C5M#ZCM#<J5 Q.NFF'2K[@-KCW2P2R=0X^A]<
M=MY*T(0V?%X:G#)&N[J2>0N^%SYBWALU=G_8>SQRX6S@E:LLJU4X;"G+AN/A
MK875I;SG5"M6%&KADTXM:="/GKX[AX');76R63F3_P @  #
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MRRU5:?+A&^F*P2V%R([C*'T&AM*B4RI9.%HKI+H SV':=WR>:GIT[,$G%?\
M*9-H%7<9*C>&'EQ)MS#*'7/^R;*.' DIDT=N4:%FJ:XC?2J1%3Q-U79(->[T
MEH,]39KYO"SO91,,<P3\ Z34KJ@O(JM.WC<X4V"LHSSA.;J4J)YU*G.PY),S
M+330QB0XO?DFN(TW'*8>&N,Y4_!ZL5TZB37J,TM5(A.2NJ7H:>(]QG26E2F"
M,O:Z$9:C,DR595K3R9Y<[!R_6:\4FCV9"4WU7PS;.5*DFEV6Z:3,U)WW]Y6F
MIZ:\NX0VDU=FZ'+S\M_G)7   <@
M                             @3LT?<?X9_)JGXQ0GL($[-'W'^&?R:I
M^,4)["$RU['L$^*J#^&C+%X7_P!*W"1\M\R_:U4:&1&6AC1*"3S+7Z3U&X!-
ME=                  !M4DE=/]1Z E))Z-?I/4;@
M                    ;5))73K]!Z#4B)):%_6>HU  6^<R_NJ<J/SUV_AB
M%P-'0GY"/N,6_,R_NJ<J/SUV_AB%P-'0GY"/N,0F%^O\?^,8/LVB+'SI[%^"
MWY)8E_.&8C>  )LK@#9PTZZ\_BU/3Q#>                     V$A)'KS
M[NFIZ>(;P                                          &Q2$JZ=2^
M(S+QZ#>  T(B(M"&H                 #8IM*CU/>+XE&1>(AO  .CD0
M                              -BFTJ/4]XOB49%XB&_HY$
M            V&VDU;W9:]S>/3Q= W@
M                                       @3LT?<?X9_)JGXQ0GL($[
M-'W'^&?R:I^,4)["$RU['L$^*J#^&C+%X7_TK<)'RWS+]K50  $V5T
M                                                        %OG,
MO[JG*C\]=OX8A<#1T)^0C[C%OS,O[JG*C\]=OX8A<#1T)^0C[C$)A?K_ !_X
MQ@^S:(L?.GL7X+?DEB7\X9B-X  FRN
M
M
M
M       @3LT?<?X9_)JGXQ0GL($[-'W'^&?R:I^,4)["$RU['L$^*J#^&C+%
MX7_TK<)'RWS+]K50  $V5T
M                        %OG,O[JG*C\]=OX8A<#1T)^0C[C%OS,O[JG*
MC\]=OX8A<#1T)^0C[C$)A?K_ !_XQ@^S:(L?.GL7X+?DEB7\X9B-X  FRN
M
M
M
M                                   @3LT?<?X9_)JGXQ0GL($[-'W'
M^&?R:I^,4)["$RU['L$^*J#^&C+%X7_TK<)'RWS+]K50  $V5T     -=>@
M                                          #4NZ             M
M\YE_=4Y4?GKM_#$+@:.A/R$?<8M^9ER_^ZG*C\]=GX8B_P"HN!(/D7R$=OP?
M_/\ G40F%^O\?^,8/LVB+'SI[%^"WY)8E_.&8CZ  ";*X
M         &NO0                                           !J7=
M                                               UUZ
M                                  -2[H
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M=:O_ ,P?$RQ#3)-^].?\ZU?_ )@^)EC:3\MW2<J7\Q'^RGU(  !H>@
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M&\/]5J__ #3/_#.")V27][>=_.]5_P"8/CLW\S)^TP\TGKB']B3_ (HR:H
MXGI                                     T/H^DOO(6\LQ_NB<%?GJ
MI_9-BX:?1])?>0MY9C_=$X*_/53^R;'2+\I?V7?4>.M_--_Q(_\ F,+@T;]Q
M:^99_LR'(''C?N+7S+/]F0Y YGK3D3H3Z@  !D
M           #R%^?ZGW)_-4W\,L>O'D+\_U/N3^:IOX98RG*G2GUFK_R5^;Z
MT(C9%_WN*G_/%2_Y@^)T""^1?][BI_SQ4O\ F#XG0.D_YU_3_DAQI?S$?[*?
M4@  '(]                                  &A]'TE]Y#4:'T?27WD
M(&Y@_="8(?.U;^S2)VL?N37S+7_"()9@_="8(?.U;^S2)VL?N37S+7_".C_R
M8_V?\SSP_G:G_$;_ ,MI]@ !S/0
M   !YJ\?]5;@_FBH?A71%+)+^]G+_G:J?CGQ*V\?]5;@_FBH?A71%+)+^]G+
M_G:J?CGQU;^:DZ6_6AY7^N8OV9/KB)I  #D>H       ($[-'W'^&?R:I^,4
M)["!.S1]Q_AG\FJ?C%">PA,M>Q[!/BJ@_AHRQ>%_]*W"1\M\R_:U4  !-E=
M>2OG_5&X_P":IWX58]:/)7S_ *HW'_-4[\*L93E3I3ZS23\AW01AR3?O3G_.
MM7_Y@^)EB&F2;]Z<_P"=:O\ \P?$RQM)^6[I.5+^8C_93ZD   T/0
M                          !H?1])?>0U&A]'TE]Y "!V8;]__!#YZK?\
M"1.QC]R:^9:_X1!/,-^__@A\]5O^!(G8Q^Y-?,M?\(ZR?DQ?L+_Q*>:+\]4?
MMI_RXS[  #D>D       +?.9?W5.5'YZ[?PQ"X&CH3\A'W&+?F9?W5.5'YZ[
M?PQ"X&CH3\A'W&(3"_7^/_&,'V;1%CYT]B_!;\DL2_G#,1O  $V5P
M               >;O#_ %6K_P#-,_\ #.")V27][>=_.]5_Y@^)8WA_JM7_
M .:9_P"&<$3LDO[V\[^=ZK_S!\=F_F9/VF'FD]<0_L2?\49-4  <3T@
M                               :'T?27WD+>68_W1."OSU4_LFQ<-/H
M^DOO(6\LQ_NB<%?GJI_9-CI%^4O[+OJ/'6_FF_XD?_,87!HW[BU\RS_9D.0.
M/&_<6OF6?[,AR!S/6G(G0GU   #(
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M$%W$))!>(N0WC+ETG*O)=;V-(F:MC6(M]%$2_0E@  ,'0
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M:66B,M#X+1&7<,D$1E]!D/N #4ZIL1$[0
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M?P[O2XJ8Y2JU<-KT:H5*&X9FM$F13HSSKBM2+3B+<4YIH1%O:> 5B U
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M+Z"Y+?-Q>A%V]"Y 95MN>Z<ET[=D54\9(L  #4
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MZWZ/5]POX"JC3X\Q:=="/L3>W3\):@95+6VW1;[4W<IZ0  #4
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M3R SH[+^G:Y>3YC)9 ;4F9ES+0^?_P"QN U
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MOR:DQ3X>^EPS4:E1B)G]K&K>,U<'<-6O,Q)8B(BT+D1=!=P#5SM*VZ_CL
M-0                         /A(0XMITFU;JS9=2@^XM2#)*OH/08G&>C
M8EQ,5,4\S.<G,=B75[^H+%"<GX<8;N.S8M+MQV+2I*'U))F3U.\;CJ&W>S9Y
M&DBYZC+.$/L]>A95,;#[MHU;74]?_P#'2>C7HZ0-FJJ*EME]GS7,7+\D,T;M
MC-NA.I-1+FAPV$?Q(T*JS66$%\EI"4]WES$*<]%38Q=_*0[$M&XFE3:%;E6C
M*AT^7J]':7ZF,KWDM.:H(]]!*/=3T](FO^2%FA=NYO\ =42BZ]$D9:D?37*A
MR_Z<Q#/:]Q7\H.W-PES1W=2I=/PWNJL,H.N%&>7!;)N'&B/+=?0@T-DA:_X:
MTD>FFI](';^M?S+H\F]4;?\ SMVU)!_E9-NT.UF\E=V4.F1*=78U6@$W/AL-
M1GC*--IB&R4ME"%*T0@D\U=SN"\;?.#V=_-SD]RFUG*YF.?P&K-.MR,B\Y94
M.-7UUYDHL)$8E%)4G@\%I"BU2?,8^7Y0UFNPHSUXEY+\%,O-:1B%6V*G2G*E
MZB-N2NI>._2Y#I+X!.DDD%Q"/>TTW3UZ-1G#Y4L-%X59>\*+%?2:'Z+:5&X[
M>NAMNOTZ*XXA1<^R2LS(R/F1ZZZ'R(<UV,9=-MW+9>UL].0P_,[-J7?AMF_R
MDX6[4R\JOBMEFHD&[RK5_0;?GPT51]ZFI<;-]5O-KEP^',T2DC=+?^(2BV'M
M28:SW9M:3E%@U9G(DERUSLYVJTV=&-1]1NG+-F55VD3I&DT]-=]9IUZ=!E)X
MLX&868VT,K>Q-LRDW93"/]&W/B1W7V>R)9\&0XVIUHE&79<-2=2Y'J.9A7@W
MAO@O;S5L8:VE2;4HS1&11J?$CLN.$:C5^G?:;0X]HKFGB*5IKR UTMEK<UMW
M*BW1.WS%3F][=[+NGI\6O+^H;P #4                          +.>UA
MV;%\;1Z#A18%,Q>JF&&'M#G3'[_BTQ,G?N*&M]EYB(X[%>9=;3NMK;,T[VI+
M/4N0O&#:9=D1]PC[?Q%T?2!E%5%14Y4/S>X^6##?)SM_,&< ,*(:X5I6>M+3
M9K>>><ERGZ*PY,DN+?-3IF])WW=%*/0U::\A?[_*D,1*K:FSQ<MBGR'F&+L]
M1F)7"6I!*;8F1"T6:3+D9*TY]T6E,URD%^4[V:G>(CZN;['EK_\ A6SZ-?\
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MM=3UU Y7V+OMR;.3<G0GUGNDD1%R[?/N\SYC<  8
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MLMH:;2DM$H;;22$(27024I(B(BT+D/J  8
M   #0TDHM#[I'])'J0MMX][*_*5F,S VIF4Q,LM=6Q0LV24JB5<JA+93'>)*
M$DHV&EDTKDVCDLC+EKV]1<E !>W(=0Y0Z8_1CH,F(S)I:Z:FE.Q'T)=:=@IC
M]2\%:'"4E1&SV/9%X18JQG_)V-G1C'B=.Q-JN&[])J56GE4*Q IE:JD&#/?X
MG%4;D2(\U',EK-2CU0HC-1B_8--"/I(@,HJIR*J="V*&Y>\N>$>5_#>C858,
MVE"M*SJ&SPHD&,E)N*WN:UO2-TG7C4O51&X9F6O+NBN8 !@
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M;E)QWS(VWFFQ LI53Q9M60F32:T50ELI8=2VVV2CCMJ)E78-D79%VB^,7)P
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M4(0VE*$))*$)2A*2+1*4H+=2DB+D1$7(B(B(;M"+H+0 ,JJKM555=^T   8
M                                +;EY;++*7?.;6!G/K]E*DXX4YU+L
M:X>KY2"2LHY1R/J9)\ _T1$7,OZS%P&OVK0;HH$^V*_38U5H=3@JITZG3&FW
MX\B*MDXZD*;=2I&I-F>ZK34CYD/1  N8_MY?DW^S;N_$Z5B(_AK*A%-J9569
M0HU=JS-.?E\;JA2EQ&7D132IXU+W#:W2UTT%[3"#![#[ NP:%AIAE;L.V;/M
MV,F-3*5$;2E#*"21*-2DD1K4HRU,U<]=14W0NG0M1J!E55>557I4   8
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M5OU#S']'S;MV_P!-E[DP"VS[)O@+^IN;ZM5WT,/9-\!?U-S?5JN^AAZI\O\
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MJJ"J;JZFGU^:\P31:Z)5THUDB>V1B.1%<QS7)L5%-P  ^B*E
M
M
M
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M1WKEJ_OG[)!URU?WS]D@&FF_Q>4K$ H[URU?WS]D@ZY:O[Y^R0#33?XO*5B
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MZAQP.0
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M#4 Y]M*DGW%)-)_'H?\ GM]
M
M        .>707Q%]P 707Q%]P #X2_\ 27/H^]0XXY$O_27/H^]0XX
M
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M27Z+334ND2NRU9O<7L^VQ@Q1N>\\1GL/,3L/:74J=6L16HZ7W:EZES)4-+?
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M+4YIIV!:NZZ]',99Y=*^X3BR+M<B4>@'&1$1RHFQ+-6W[347_,U   T
M
M                                  .>707Q%]P 707Q%]P #X2_])<^
MC[U#CCD2_P#27/H^]0XX
M
M"!.T^ONNX=Y$,?:Q;%,G5BXI=$;@4N!3FGWI;QS2<BN$VW'0MP]"</7=+XQ/
M8<>5$ASF51I\*'4(R]-^+.C,RXR].9;[#Z%MJT/HWDF!E%LJ+RV5%MV[&'9L
MN,-<0LL&QES/XM3[1K$#$7$UNJ;E'5"E)K,CJRJ5!I.C!,]4GV$@C]H?8\^1
M"8/Y.IA!<F7_ "#8RXOWI;50HUXWU'O&IN09L9]FI/N-R:J[%(VW&TR%*5OH
MW=4:F9ER,9)A4JD%$.GIHU'333Z:8BF0D4U7/7LH*62C'SY\V^GF/HS!I\:.
M<.)3J?#A&1D<&'"C181D?21Q66T,&2OX1;FAZGJ7,#HZ57(J*GY2HJ[>6UMG
M)U+O,0W\G_P=O^^,\>;S-EB;:-7H+KMR(9MV168LEAQ]A$B="-<<Y33:E)-L
MB/L-2T,CYD,OH_\ O#_C+<67_J4:B[0XL.FTNFDM-+I-*I273WG2IE.B0"=5
MW7NI6FN*>IZZKU/4<P#5[M-U[6V(B)VK(B&,7^4[8(WC?N7;"/$S#VW9]P77
MAW+G26DTJ*]*F,//S6396E$=MQS5)H)1<N@N0H9^3NY&\2+@N^Y\^N:&ESWK
M^F,4>-8L>XH[A2X[$%CU,E;C4LB6SNL(3IJA)GIRZ!EO2H4"H-&Q4J=3ZG'/
MICU*%'G,=W]QDMN-]//VO2-T:+$A-)CP84*GQD<D1J?$8A1D:].ZQ'0VV6O2
M>B>D#9)%2/0MM6Z:7/HK;9T;/2YA\[07#[$7-=MV\ [,3:59DX:8:U1R8]6U
MPI1TEGC0(THBXZFBC=BZV9%HOD9<A2K;Y/XA65M&LK>(=TX;5^[L%<-Y-/C1
M54R).GQI2CB4^,DU(A,/&R3+[9:[Q$1Z#-4*E4@I?J@5&H_JB?34_4R&=2Z-
M.4[@]4EH7+]TZ.1:$.)6+;MFXT--W';="N!MA1*8*K4F!/6THC)1*0Y+8=4G
M0R(RT,NT!E)K:/8[&MT>7IV].TPVMLK=U_9Y<1]GI8MEX=7 W8M9E1G:Q$3
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M N3,-<M0GTHIC:VY*H-.K<TF'"WR)>XY%<0I)F1<C(RUY#),+P]/2?QGS/\
MK'F++LRVL.[0MRPK.ID>CVO:M,B4RE4Z,VEMMM,:,U'<>T0E.JGU-<16I&>I
M\S/I/TX'-[M)RN[?)T)L0   :@
M
M    '/+H+XB^X +H+XB^X !\)?\ I+GT?>H<<<B7_I+GT?>H<<
M
M
M                  U,N9&9'W2,R/QES&IFI1ZJ6M7<)2C,B^(C/0:
M UWCTTU/3N:GIXN@:              ?Y\'TEVP       :[RM-W4R+N$>A'
M\>FFOTZC0
M                                                         <\N
..@OB+[@ N@OB+[@ '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>nt10002526x6_diagram4.jpg
<TEXT>
begin 644 nt10002526x6_diagram4.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( R(#D ,!(@ "$0$#$0'_Q  ?  $   8# 0$
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MW_ 5[=V&B,\KUFJ1;X.U='\-]LHJ#N5US4._1XKHOUB<_P#:6X"WQ_G*P?\
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M%.[ L?\ ^W_0W\%O+9,._O<K?J\D@6_U//L5=DP\_K)7L'DD#VL/H5$Z1K$
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MU/T>=*_]?L_A\7/'QU&== GPD.5,^]_,?Z#]$IOA'\J;L_K?Q]N[;(?1K?\
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MUGKHG?J!Y;_,L#^08MSVU]Q&Y_XWWA^1V<N<;M_]I72%_L_NC\NGED@B*!(
MN5IA=&D@"I0D 7*M8L;H'AZ]O7ZN]0BQMNP^''IZ>C<K-SNDJXAP]IYYVGL"
MM8D7/GNX\>0<[I)5M$B7V#\GO/J4L2+?=L Z>./;:/?X>OCZSV736UX#G)63
MW[^P*9S^H]YX]:M7Q!UV'7UA<=5JQ2Z+)QJC6:G3Z33I>&Z+&FJA-R\HQC&
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M/GFF?C.76>FB>;9!9;G_ *E@?R#%N>V<="-S_P ;[P_([.7.-W#3U2FD,_\
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MF2Q<&F)Y2[G)F-J Z]@XWU;=)6F51!MU$'>"+@^9>#>"[-B7GDHDA;=GP)Z
M\'5,1@$:"["D27C@=)!B-I5KF.&.=1@O:L.\-L7=G(<[9$]'E(S""0Q[NBB#
M/4BPJZD1AVM<"-N!H5^E9H\Z1V5>DW@"G9BY38AE*U2IN7AQ)R2AO#)NFQB
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M71Z[ P?..=!C2KB3S>KJ@DVV[2!?QW^Y97=2=,&<=)N=]CF6DL!. C,%12N
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M9IU8W?$A&&V*RG"&X@C7M(P]Q(%_R;5R?HXE)=NFN].JQM)=UONEZ8!I?.P
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M-18<RPN%NEK[[?#H7GK_ #0%EI,4+/K!.9$*6<*?B^'--?,M;\0F2EF0OC.
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MZ-B28GWZFO#A7HTQ%A%YVM&UMQTKU7\CRX/KVD*1NA5F6EP+=$"=CPQX:JP
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M69B11+S\1\#6:YS3":X16ZS=FP7V[=R]B%(PIA'#;!#P]A7#]+:W=S=(D-<
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M1FZ<B-;6L(:,6')VNN+FB++ROV9P8^H0G&^LV&2Z$#WC9M7WFASRB47%V?\
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M0S]"E4"0!<JB22;E1<ZY[ I55:-ISV#<-W/I1$1%,J3G5PV#QHI7&W>=RB2
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MAYO9M4U&MS\?H15">DGQ4NLT=/M]2AJ#I-U'4;U>D^]-=O%$UV]?H*QKTO'
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M^I8:FVS4Q6Y&HLDJ=$J42'$FY:#Y'+:L%K8?VV(#<_LKVZ";RM.D9C#-#-[
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M)S,*$3UEC2?&5S5%HV8CL&38T4-Z@]P 51AZ/#ZOR^;>JBMU6:;CMZ>.U1(
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ML_I&8V?7V^&NCD;_ --](/Y[@_C"86820_0JTFG?%NI_>;UKVV#73MH2.?\
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MW6V;5#G.H>G\GK6-.BEI)X0TILHJ#F5A>8@^6QI.'#Q#3&O#HU/FX36P'OB
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MJV@=,P&M=!BNH,71()+"<:]&*K=VC&V(D:3F[)BO)]:.;'E@2#2#$.K$8!3
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MH\4"),OAPV@3D,-#B\M-]FS:M06>/)<Z46#YW'N9-6E,,G#,+&,S5W1I?%=
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M?'CCH4K#0T.WR\^9%,TW':%,J+38CMX'I590<-4X=859IJ/*IV';;K556ZN
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M%<'Q)>!$>*4>^##>\4((HYS2X4IA0X8T463$Q#:6,CQF,-:M9%B-::TK5K7
M&H !J,1@<%R4[6:S4I>6E*C59Z?E)+6,G+34S'CP90O-WF!#BO<R$7G:[4:+
MD;56C8AQ#,4QE%F*Y4IFBPK\S2IF<F(\I!N;GFH,2(Z%#N=IU&M7#HINA@T:
M.BA48XO8.C91CS4E[13P7$DDN%":G'%2=+%JX])$JYH8XZ[JN8* -<:XM  &
MJ<* "BY7[.US[&?83[,5#["_M3Y5'\AWW_X-K\Q\KXWR-_:N*1%.UC&:VHQK
M-9Q<[5:&ZSCFYU *N.TG$J#G.=36<YU &C6<31HR:*DT V 8*(WWZMI[AM*]
M!?(+991JAF'F-FG,R[A*T%L@R1C.8=1QF(+X,34>=E[[['O"\_DI*3,_-2DA
M)0HD><J$W+2,O A,+XCWS49D %K6AQ.J7@FPV6VKW$\F]HZLT<M&3"5&G8#8
M>)\2R@GZ\XPPR/J17B9E!$V7-H<0#L V[EJ?3);<*S;I1K/#P)JV8L.4A,'M
MN@8]D69B4_!#6MADY5B 9Y9]HXLQ\[>"%-D'H+.8Z.\T%#$(U(+<?=:QUQP:
M<5G[;:\_LGO=YG.)]2D;\5Q;U[N.-RG;N'<I7C<1T<>OUKCQIH:';AW8#T+I
M!5V'HZ]W'&Y3D7!"H [B.]7"/%"#O\H16ZKM-P"J;QMOU^Q18=X\X]JF=BT'
MM]//!3L.--_E^A5%58=A'5[524S#8]_''>I!BUPW8^GGBJJK(B*#30A1&T;Q
M\_CI15F[6CCC8IE38=X\_O\ 8JB.%"56;B!U*H[:&'J>QQ_[+@3ZEY9.7RRN
MF:9F7EUFK+R[C(XAASS)V8:PAC'2T&'!9KNW7)V"^\[KKU.-VM([QX\%:]>4
MUT<G:1VBWBNE4N5$QBO"LMY?02U@?'$-C_*9S4V7_L<,W]JS71W;;+ O?9$]
M&<&2SXSI*9>30,@S@$$O/!D0PWFN0:3L6+7ULI]L7;M&5A NCLAB:@-&)=$E
MSTFH/?/AA[!O+@%X73OOU[1W':%!7$U+3,E,S4E.0HD";D)J9D9B#$8YCV/E
M(SX#B6N <+N83M'3L5NNZ6D$ M((H*$8BA (H=HH1BN2B""010@T(.PC,(B(
MHJ"(B(B(B(B(-I ZT4=PN1?6(AL VDQ8GQ8;0-Y+G$ 6Z41;/^24RCF,S-*:
M6JQEC%I>"J-78\[%+"Z'",Q1YA\'6-K EP%K[-U^M>I3D<7:]8T@C^PK,O '
M^+"GH[&^  LL&N19T7IS*K1LQ_G3B>GNE,09F4.;=2F3$+5F)>%(2\S")&N
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MYR]S>]]J*>K0[6&L<:[, 1B.-#OP*TWLQEBJ#RG<'#D&MNAX?@9+0X\&FM:
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MZ9_ 52RD.#OSCRL:J3=%&&VQ8.K%C2\E"FY1M3\H9!9$+&PWV M8W)6Z2/H
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MGDX]"'$VE[G%2/*J?,2V5^%IZ6GL3UN)"?Y-$,)[9B4APRX-$0/C0N;=S;G
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M/K&3H:'&UK.SH*_KD[_%P51VFO1\6MI:5H5RI]0[7X?$^>.2VEJHS>5JP_1
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M2Y0BX(5#=L*@(CQATC]X\-V7?OP^G&4083F_XJ'4>\;F.SFJLOL92OVJIG\
ME?HECII6TZGP<A<<OA4VGPGB#+EL6%)RT.(WXY'Q7,AAP\Q'3M63"QTTL/U
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MO^DU)(Z;TV3/_H]GN5XJD/I\WM4KXL35/V1_]-W#BJX@PJ"L*%7#]39N&X<
MK3[$T?\ ::D?Q9)?0I]B:/\ M-2/XLDOH5?HJ1B1*^W?D/=.W#BH]#!_<H7_
M  V<.' =RL?L51Q_Q-2/XLD_#^PJLVE4?5']1J.?_P#6R?7_ ))7"K,^2//Z
MRH=)$_='_P!-WI4\.#!!_P 5"R_<V;QPX!4H=)H]F_U%H^_]K)/K_P DKG[%
M4?\ :6C_ ,62?T2K0OUOG]JN%(^(_5_QC^'A.].ZJN&081/^*A8#]S9P][SV
ME?.XCI5(_.KB0BC4AI%%J1#FTV3#A_2<8W!YF^\;^Q81<C8 *GG_ &  %:@6
M %@/Z>C[ !L Z-G1L6=N)-F%<2?,=2],G'*P3Y&S],](#YZ@?SZ,LD:\NT5Z
M2PYSB1%NK2I)_9-V_+S]BP2.QC-.NA74:U@,O?CVK6MP^H[:9 >-;UD1%S6N
MRQD.H>1$1$441";+XO&68.#, TF<K6+\24F@T^1AF+'BST]*P(C6 $DB#%BL
MB.V;;!M]BGAPXD9[8<)CXD1Y#6,8TN<YQ- &M:"222   J<2+#A,=$BQ&0V,
M%7/>X-:T4K5SB0&BF-20%]I>V]%IGSRY</0DRD?-4VGXX9BZO2;GPXDA*RLT
MV&8C"06B98QS#M!VW'@M?N(?S3'EU(3?-8=R6BUF5UG#REU:BR]V@["&<TTC
MM&W;U+8ME:(M(]LP6QY&Z=J&$_%CYF$V2#FX4<WUV^#K UP(SV+7]J:6-'MC
MQ'0IV]%F](UQ:YLL^).EKA[EWK2'& <-H)!"]327!W&Z\K=&_--&!)J:YNM9
M'1:;*DMO,-KL2+JB_P 9Q9S+B;#;;@YRY)<O%H69G34K3<1XH_.15)MS&0Y>
M9EIR8AB(_8&NC&&U@L3;6.SI52T]#NDJR8+H\Y=*T^C:-9SI9D.=U0*$DB4B
M1B *XU"IV9I<T=VM$;"E+TV<'N(:!,NB20+G4H 9ID)M37#PNJJW?HNM<O<W
M,NLT:1*UK N+J-B&1FV")!,K/RKI@L< 6WEVQ716DWW.:/-T]D@W%QZ5K>+!
MC2\1T*/"B08K"6OAQ6.AO:X8$.:X @C<0MAP8T&8AMBP(L.-"> YD2$]KV.!
MQ!:YI((.P@T441%355$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1:>
M>6*^Y^IWSM3_ ,8P%VSH_?J'9<_-3?Y-BZFY8K[GZG?.U/\ QC 7;6C]LR.R
MYZC26?R3"5T=(_<<NE^-UO?(I)<=VC_VBK]_[/[K?+II=J*E$&[M%N/%5CO/
M>?6J43H\_L6.LR(YQ^A9Q$V=OF5FK=7!V$A6T5[80?$>0UC;DGS$]BJ$@ DF
M@&))P  S)*H/!<6@ DDT  J232@ &))V (2&@N<0&MVDDC8%\M4\3RTL7094
M"/%%_C7( \=FZ_H[U\_6J_%G'N@2SC#EVDBX_7[2-AN".G@KYGCK]:P>UKT/
M:]T"S3JAI+731%22,#T33D*^[(QV"F*V18%R6&&R;M@$EP#X<D#0-!Q!F'#$
MDC]3:13W1)P7+3=;J$V27QBUO0VPV><+BW/>[:Y[R>DZSMOI4J+#8LS,1W%T
M:/%BN)K5[W'NQH,L@MA2\G*2C!#EI># 8!0-APVMP[!4]I*7(W.=^^=[U6AS
M$>$08<5S;=I(\+_E5%%3:YS#5CG-(R+7$$=H-56=#AO!:]C'M.!#FAP(W$$$
M+Z&3Q'.RY BGGV;C^M-NWK^I?7255E9\7AO#8G3#.STD_E[+KK!3PXCX3VQ(
M;BUS2""">A9#9MYI^2<UL9[IN7P!9%-8C1OAQ#X0(V-<2T\,UB=L7-LNTF/?
M+PVR,V02V+!;2$YVSI8(\$@X N8&N QQR7;JMUPM&K(G0($<ZL<"S2;6?8>
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MOOM>#ZO35X)K[+-3LO:D-LO,&8,M!@6Q C2T;UJQ\36:V&R.[H"'$:S6Z^N
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M( !\6UK;-BR3V]#XC>L->YH/> 0"HHE<*(HM%W- Z7-_U@H*_IDL9J=@L N
M;N[-QV\=2JP(+IB/!@,%718C(;0-[G #NS5O-1V2LM'F8A#60(42*XG*C&EW
MFHNQ)=AART%O4WPOT*JJSFC5 '0!;O %_:J*WFQH;!8P?J36L'4UH;YJ]BYE
MCO,6-$B'.*]\0_Z3G%Q\M.)**D\6-^M55*X7':-RF::'Q*@J*D>+B_5ZN/:I
MT3VKNKR(1445 &QNJZH.%C95&.Z#YN.Q3/%0'#D*W(H:*1XL>PJB?BNOT'?Q
MZ1X*[(N+*@1O!46G6%#CZ$14WCI\?8HM-CJGS>OZU.I,6.YQ'/C4"*CSJW4K
MFZP[>A5'-MNW'T*53D:P#FY[/1S@J;3JFA^A6_8BJN;?:-_K5)3 U'':.*@Y
MM,1EY%3<SI'A[O=^14U<*4M![#UJ*HN9N[N?H5%%$@C>H(J: D;E.'GI%_0I
M$4" <PH@D9%5-<=(]ON6.&EP6_![Q]86/D\MX\X;;!Z/.LBUCCI;_<^X\_R,
MI_*.7MW9:!>.P2*C\V;-\<Y YYHL:OH\^Q"] SK8%K#(;9&,OA= HM&CM0+[
MQ,3_ //'^^UUF9K@;A[%AAH%[='B@#_I,]_.XBS+5Y?5H-[[RUJ?S9G]IIC'
M)IGZ.I6.CAQ%P+G 4^UVS,:"O^3,]&U3EYZ!;TJ4DG>H(L8  R"S,DG,HB*(
M!.Y14%!3M;?:=WK4S66VG:?0IT51K-I[O3Z/H1$55K+;3M/JXXOO4"0 JS6U
MQV>5&MMM._CCT*=%%HN?:I1^$[/R#GFM5,XU(:,O%] 4S&W-^@>E54W; I7&
MVP;RI#5YP[.'/S*<"@HI?E.MT#T\>]5FBY[.GCM4C186\>]5VBP[>E3DZHH.
MSSE14RHN-SV#<JCC8=IW>U40+FR@P>Z/9YSSQ15&#I\%44 +"RBI3X3NOR<X
MJN!0446BY 5=2,%A?K]7'L4Z..-!D,%%%,P7/=M]RE55@L+]:B,&D[3@.>_N
M4[1B.&/;L]([5.IV#;?J]JD55OQ6W\_N4BJH-KR>K9QZ5.I6[N_;QYE,B(B(
MBK,%&]>*J,&\]>Y5% "PLHJD3@3^$?$/G4R(BBT7(4B#'!5@+ !7,(?)\?:/
M8J %R KN'TGCC<BN%45W!&SOM;S[;>D*T&W8N0A#Y/C[O8K6([!QYYHKJ$,0
M-M/'EYUQ>)Q;"F)1?=1:D;GK,G&'L].U8#<C=^FND#U_9N#_ #^/]:S]Q/;\
MZ>)K[_L)4[?P*,L N1N_332!^>X/\_CK)I;[E>DS^4NI_>;Z^-8%/BFG70I_
MJ]^/%8T+/R+>JI'W N.L7[KJ=%SFNPA[4=07AG_-$65,WA/2BPSF.^7>R3Q]
M#F&B8U26N-.E(<+?NV&_5T+4/H>954C.W2;RIRRKSVLHM?JIF9\.O:+#ISX<
MT(1V@VB:I9W.Z=Q]EG+U:+$YGEHNQ,PJ#(&?Q5E6U\Q(08,/6F'P)Z.SRMPL
M"2&06.<[?8&Z\0.4^9->R?S)PCF9ALNAUS!U5AQ(;=C7.$"88V>@$N^3KMA1
M(9)&S6)M;8OHSH8MV/>;1$R0LV9$.VK)D;0L1KB\ P)@0WFSHN\-Z.+"U7D4
M#H;P/:KY\Z7[$@7;TK/GK1ES$L>TYR3M@M#"1&@1(D/U\RN#2[IH<:K=:NJY
MM11PKOYTR^4IS9T1-+&/D-D]A_#=+R9RLI]$DYK!T3#]&FIC$<&H4R!Y6UTW
M,2CIH.B.URUUWN!>;$;%R_)H9K80TC-.3/G,ZDY82F7U.K^!ZI&CX3G9:',0
MH$W PE/"/,0H<S+L;"\HCAT<:D,6N".@CY#%.DMR6>DCF#1M*/.^3?0,VI.0
MD#BC 8959J#B6H4J2A2TGK3<%HEX.M$@!YLTCXUG;EU9H^\HID+@_3)SESPG
M,+P,NLN<689FL/X0H,F'S$.!J8>F:- B7@0FNO,Q'0XAUV M+C<[UBPN^^+=
M"TK-LVX-N6=>2#=)DA;%K1(3X#;2M43LFZ-"AL;&<+8C3$1D::;/AKNB@C5#
MP7EBR@V[#A7ILZT;1OS8\_=^->83ME65#B-B?4ZS3 F!"B/<Z$TV;"@PGP(#
MI$EFN\UZ,MA->?H*YE7B>M<F[7*Z[&DA+X.K6:E0I!PHVA2GED!D]C^+(%S:
MP&"9LPQ.<#6OM8!@ &U=E3/)':)>$\X<'Y!XKSU=$S+S.PC#KF#:,VBS=Y.:
MAX?AU>/!B1H;S#^,Z(T!T8@'> L8AIQ9-#03&C^8SOS]#,@XG+=2/JFG?GV^
MSVMK:O-W\AVZM[D[+77V^,^4#R/KO*,Y-Z3,M-Q8V76!\)PZ/5XCF3-X4TW"
MTO2;,AN;S@_IJ&X$L;8]=C=7WK'2)"=;$&SOJS9$#UW?>TH?K"2EH9GIB6EK
M)==]KWNEWEXFHPF&->"(LP&Q&:YIAYD"<N!$%E1;3-E6G$$G="0?Z\G9IPDH
M<Q$M1MM.8QD9H;ZWA^MB]F,."7,<UH.?/:.^C=CW*K)O3ZRYA8UDZ? RYF,+
M251DYBA2<_&KS*I-1H=-YF;C-?%D2T:ES"(UK_&W+K7!O)]Z+V665&6N+-+W
M.3\XF+<[GX@B81IGV)FIL4M].COM$=%E7!D03 B0X@;$ U?DC8ONX/*$Y%-;
MISO\LB0SGS'P9-8#A\S,'RB+AV(Z+&:]Q:=2SPT?;; WZ57I^E/H+:4N3N3M
M,TLZC'PMC/(IM>\DI,*%4)H8LAU*(72T)L>2 9)ZL*'#%[[2ZYVJL]]_($6=
MFX\K>"0E+2M.RHUL3-@69 =;#W"ZDJ&^MX;X,3I(0MD.@S;BU_1AHA.>R%K4
ME@LN1%A2DK"FK$G9FS[+M2%9,O;-HQV64UQO/-@>N(C(S.C>ZR2V+ :'MZ36
MZ1K7QM0'%_)C0^T8:UFYF;AK'>=4Y6\'8,F:2S"<Q(X9J$2%BZ'6";AT:3#F
MR'D.LT$Q'?'L5G'3] '#&B-IJZ'V-L'5Z#B?+W-N)B2-3Z=-R0,.G-I\LR[8
ML.9YQT?G'1-SV_%(W"R^ R"TT="G#DKGS@^A4N!D))8LBT X"QC.2TQB^- A
M49Y?.ZL"9AQ(C?LBUFH-9PYHQ=AV;/O,XN4CT<\69@:&N(J/B")5J?D'%Q6S
M%DSY'-2XGA5M2'+QVPG-O#$34+PR&#JWM8A4[5FM(T_:\>39*WG^I4S8L_(3
MLK.RLNZ#';%NR]\O';ZRE1*0)F-:GV-XA3<>(V.7PW"%",-IFLB!<*0LF#-N
MF;N_5*7M:1G92/)S,P(D![+Q0X4Q!<)N8,S&@P[,K$ANBRL&&8(;$!B10\C7
M;RM$O+2VG]G3 E)>7E9=LOAO4@2D&'+P&:U+A$\W!A-;#9??L;OW[;KNKD.L
MJ8F9&G/A*IQI9T:CX0AS[ZB_F]>'#$Y)'F@X[@76-KG:5A]I\YV8.TA]*[,G
M.' ;G/PIB>7HS*:\M>TF+)2#)>*W5B 1-L5IM<;2=@(*].?YG4T6I_ ^56+-
M('$U*="FLR/)1AZ),0]2-!ATV+$@1BP/ >!$;T[ 0;C8O9OW;3[H:"X$&=#I
M6TYJ[-EV#"EHQU)@3DU)P8$Q#(.(B0((F'OW%E#G0^1<FQF7LTU18LGJS5G2
MUXY^VWS$+PH!E)::='@/P'A0X\3HF,V'I <UZ<$1%\YE]"41$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1%IYY8K[GZG?.U/_&,!=TZ/3;9&9;7Z:5#O^!A+
MI;EBON?J=\[4_P#&,!=WZ/K?ZQ.6QMOI,/;_ -U#]E_-YET3+']!JZ8V&]MO
M^*2DJ>-<A30KZHR_G^S^ZO5_ETW2O.:[5B#8.G@CZ_!<=%%G<=X]:Y5XWBUK
M[N@>CT]G>N/C-V7XV;?>L6@G,<XXT[,5GD5NW=EXJ\]BLW-#FN:1<.:6D'J(
MLNE\0TQ].GXE@>9C$NANMLZSMW=/CUKNI<+6:7!JDL^"\ 1 +PG]+2 ?6=GI
M[[.VK,^J<EJLH)B#5\ G::#6AD[ \4%=CJ')>K=VV/J/:&M$)]:3%(<P!CJB
MO@Q0-\,U)&UI(W+I%%=3DG'D8[X$=A:YKB ;&SA?80;6W6Z=JM5JU['PWN9$
M:YCV$M<UP(<TC,$');IAQ(<9C8L)[8D-[0YCVD%KFD5!!&\(B(I5.B(B(B(B
M(G'CL7W.'*>8,(S<1MGQ+:@(W6V'>-FSQ7"T6D1)V*(T1I;+PR"2[9K[1T';
ML/F78NJT0PU@LUH :!U#9]:SFZECN,06G,,+6,!$JQPQ>XX&-CB&M%0PTQ)J
M,EK2_-X&-A.L:4B!T2(09U[34,8"'"!4>Z<0#$'N6@ XE4U1<+'L.[VJLI7"
MX[1N6P6FAX' \\X+5#A489YA441% BAHJ1W[_+M'HX45%PL>P[O:I5<%NL.C
MQ'O5ONV%3>V;7:,.OGG-0YY[U*X7':-RH[MH5PJ3VV-^@^A18?<GL]'/G4CV
M[1V\\%4!N+J5S;[1O]:D:[5/9TJLI2"PX=GH*I*U<+C9O&Y&NOL.\<?E59S;
M;1NZ1QP.[=1<WI&\>GCZE4-'C#LX<_.BFW["J+FV[E4:Z_>IM^PJF"6FA[1S
MR5*YNMYBK=2EH/?UJJYMMHW>I2*>FMX330\X'GO4@<6X'Z%;D%N_QX_+V(KC
M?L*IEG5X*(=L=@?$HEH.+3V<Y<Y*FI"P=&STJ?<BF5,MWCG@?0J):1V]RE5P
MEK[T4A8-AIXU;K''2W^Y]QY_D93^4<LE=4=06-VEPT#1\QY_D)8^$0KV[L_;
M'8/\\V9\L@^=8O?1A]B%Z#AA8%JD_P!2C+K[0+^YXH'^<SO\[B+,M8<:!+0=
M'>@;/[O/G_37#VK,T-:.CQVJ\OK]M]Y?YYGO^<58Z-V$W N:<*&[MF>*68J*
MF#7'H\=BK6 W"R+&%FH9O/<I P=.WCCJ4X &Y$]:*H&[@B $[!Q[%.UAZ?KX
M[U4  W!2EVP8GAEV\]RJ!H&+CV<^10:P-V]/''N4R*9K2[NZU"E/"<:D=PYY
MQ4"XNP:,.>X* !)58  6"  "P0D *0DN-!V#GD*=K:8[?(H.-AV]"-'2=Y]'
M'U*#02=8^;CU>*JM;??N'I50 -%3V^@*93,;TGS*INVE%2<Z^P;O6J>+W<X!
M%*3<W4[!;:=YW"VWP[>-ZIW8UL2)%B0H,&"QT2-&CQ&P8,*&QI<]SXL0MAML
MT$B[MMK"^Y:GM,3E:<E]')\]A/ 9E\Q\PH#8D)\K*QS!@4R8 (:?*6Z\"-8W
M<?C;VV-B5[%DV):MO3;+/LB2C3DPZFLV&WP(3#AKQHKJ0X4/>Y[@,*8G!6<_
M:EGV1+NG+1FH<M!;4 O-7O.UL*&*OB.X-!VUHMM+M6'#,6-'E92$T$O?.S,&
M4: -YO&>P;!M/LZ>LL19UY.81+_SS9C4"FN@WYUC)^3F"VV\6AQR2!8A>+?/
M;E,=*[/6;FV5#',UAJA1G/YFC24.&QT*"XG5A^4RY8\ZK2-I-]FP+!:IXCQ)
M6IB+-5G$E?GX\5Q=$>^L5#5<XFY.J9@C?NMZENFR- UH18;8EL6S DWN )@2
M4$S3FU -#&B&$RHR.JQS=H)6L[0TN2<)Y99MF1)EH)'33,7H0:;6PF-<2-HU
MG##->_/X8FBT/_G#2=^K\E@VWMTQ>M=BX;SLR<Q>(?YV<QJ!4G1K<TR)/R<N
MYYV6 $2.#MOU7]GYV&O%_P#KJKU_IG._3+F*9B7$M$F(4U1L25^0CPG!T-[*
MO/ZK7 W!U?*+';UCT+UX^@*2<PB7O%-MB4PZ>2@NAG!M 1#B,<-F-3D<*XKS
M8>EZ8#ATUCP'LJ*B''B,=3"M"X.%<Z84/!?I"L B-$2#&EIJ$ZQ:^3F84VW5
M.[; <\;05<<6W>A>&/(;E.M*[(B=E&2>-IK%- @EC8U%G60GNC06D?:_*9C7
M<VX!V@W]2]&.AQRM>2FDB^GX3QP^7RXS&F R$R2FHYCR]1F-E_Z9=S<O"N=H
M^,+ZUEK*\^BN]%W83YH08=J6?"!<Z:L_7>^&P>[CRS@(K&@"I<SI&C:0,5GU
MW](-@6V]DOTCK/FWD!L"<+0Q[L!2'':=1Q)(#0X,))H!7!;; +D!5';2&^/'
M'0I83H;X;(T.)"C08S&Q(4>!$9&@1(;QK,<R+#)8ZX() )MNZ%.W;=W7Z %K
M)9XID1$40*D!%,T7(4JJL&R_7QQW*5V7$X#M5=3HB*F[.F[#T^-$52'TGCC<
MJ:K-%@%*IF"IZN>>I56#;?J]JNV_)'&_:J$-N[MW\=VY7*E<: JX:*D*>&+N
M'&_8N1ABW=L';QQT*S@CIXZO>N08#8#K\_;T>SQ5G%.0KGY-I[JJ\A-KVGO&
MWS]RXG$[?]RV)0.BB5,G^!1C[@M?_(W?IMI!?/4#^?S"V#8D;?"N)R?VDJ>S
M_P #&L.WZNU:^>1N_3;2"^>H'\_F%E,J:Z*])HW1;J^.TWK K1%-.NA/_5K\
MUZ_J/!S6]9$1<Z+KX9#J'D7SF+,-4O%^'JQANLRT*;IE:ITW3IN!'8(D,LFH
M$2!KEA!!+-<N&RX(!&W?^=GRI.@OB/0NT@*Y+R]-F7Y78SJ,U4,'UED%YE&N
MB.=,ST.(X B"&QHVHWG7,UOUFS8OT;UB)ID:(.7&F)E)7,M,>4Z6?$FY6)]A
MJRZ"'35*FVZT2$Z%$;:* Z-J:P#P"!MON6W-#VDN-HYO$(\QKQK"M/4EK7EF
M5):P.^Q3L)M:&-*DEU/U2$Z)#S<TMU3I;T<P=(-WS"E^CA6W9VO'LJ8?@'.(
M!B2<5V8A3(:T5KX$1K'9:P/YB9#;W,.$3UF&TW[;VVILOM:P]A:T@=P(V>99
MP::^@;G-H49@U##6-J)4*E@V+-1SAW&<O*Q(LM/2NLYS&1FP&Q&2W,,,.$3%
M<W6M?NP?MU$._P 4W\;;CU@KZ563:UFVY9\M:EDS<&>D9N$V+ F(#@YCFD#
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MUQ1%B0J;QLOU>U7$5MCQYO=YE2.W8O0AG9L.(YZEYT0>+-?/56E2M3AF'&:
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M$@W!((Z02#Z%[$E>BTY5S>EB>NH6%6QL7TP]K$%' T&%:C?M6/6E<>Q)YCC
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M]X?,6?,#IY"8I2O22[SJM<0 .DA&'% P#PL'OAH[NK?> (=N6;#B1V,+8$_
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MA&-3ZA!'Q)F&/US!MO[=Z^M:X.W>!V%$4R*4N:.G=V'W)K"VMMMW&_@B*9%
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MJ.[9UKW+L!AO'8.7Z<6;M^-P5C%]J>PZ]5?X/6O3K]8QEU]H!N<-'.@AH_\
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M*YGQ +8OE;RWV?.6>>^663NGKHOS.05,SKC%N L5Q,1PZQ BC4AQ&PWP96$
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M@PO>L;.6*^Y^IOSQ3/QG+K)?1S;_ %A,LCU4IA\84+CS+?Y^XQ='&GY[[?\
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M$=[_ $=J]R[ <+QV#G3ZL6;D?CD'958S?4?G.O7^+ML?(8R^ Y/]H.CE0/\
M.)_^=O/K-UFGJCJ'@L+>3_-M'*@'_I$_O_SM_M6::N[[!QO?>6F7U:G]OP[O
M.O.T9C]#NY7XN69\EAHB(L7U'=7/!9NB*(:3T*8,/2;>E1U0,W#J'/F12(JH
M8.]3VMN2K1D*\3]'F14@P].Q5 T#<%%% N)]"(B(H $Y(B;]@4P83V!50 -R
MF\%O%WB!YY"J!I/ ;=Y] Y-<U*UEMIV]G&]=?9KY780SGP!B'+?'-.@5'#^(
M9.) BMC,:YTO'#'>31H3K%["R,6O(9;6M8]"[$40"=RFA1HL&+#CP8CX4:"]
ML2%$8XM?#B,(<Q[",6N:X @C&H1\*'%AO@Q&-?"BL<R)#> YKV/%'-<#4$$&
MAJO!QIPZ%./M#[,RI4:I4Z<G\OJI.1YC"V)8,![Y>+ >]T9\*+S8>(/,Z[80
MYUS0;7;LVK!XBW:.@C:#YU^BUG!DOEQGK@FI8"S,P]*5ZAU& ^"TQF-;,2;R
M"6184R&F,W4>0\ACVZP;8KRG:9W([9N9+3E3QCDM C8_R^=$C30D(#6R\:D0
M"7/U UQ?'F+7(V-_6]JZNN!I:L^V(,O9=X8\.0M=C6PF3<5P9*6@0 UKM<T;
M F74\.&XM8]Q)AFI+1SQ?'1S.V;&C3]C0GSEG/<7NEV#6F)2IJYI:,8D$5\%
M[15HJ'#"ITJHN1JU)JU!G(].KM)J=)J$O$=#CR\Y(34!L-[39S><C0F-(!!V
M@^C:K  $7UX?[]OO6ZVN:YH<UP<UP!:YI#FN!R((J"#L(P6K"US7:KFEK@:%
MK@00=Q!H1VJ5%'9^S9^^"B0 +Z\/]^WWJ92J51 OV#I)V >=<C2*/5\03L"F
MT&D5.KU"8B-AP8$G(34=KWO(#08D&&\ $D;3U'H6Z'0LY'/-C.>>I.-,[H$;
M .7@B09HTZ,UL>/5X(<UXAN:PLCR^M:URT';V;?"MZ\MC7;E'SEKST&58UI+
M(1<'3$=PQ#($ 'I(CG9"@H,"31>Q8]A6I;LRR6LZ4BQW.< ^(&D0832<7Q8I
M\!C1O)[%A]H*Z#N/],/,NE4Z4I\W3,MZ9.0)C$V)XTN]L 0H3Q&9!A"*&<\(
MQANA$PG.M?;T!>XC+#+7"64. \/9=8(IL"F8>P[)PY:7A06!IC1A#:V9C1'
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MW(Z"JBHN%1QV*W13.;;N4J*CE@52C084Q"="BM#V/%B#Q^5=<U?#L>3<Z-+
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MO(;ZX' [/-3ANW9;EY\1F=,>&\;]OS]=58D A6SV'SCTA79!!L5*0"%=-=7
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MV-:@M21AQR&]*W['';NB- J1[UXHX==-BY_O%8IL6THLL"XP'_9I5Y]U!<<
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M1$1$11 )R1$3?L"*J&@<3O13M;?:=W5UJ9K;;3O]2G4A=6M,!M=Z.?,IDW;
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M=CU!:\TARK7R$G.4\.!,&"7;=2,VH'8]@IUE<QJ.ZO2/>L9],1I&CGF"2/\
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MZSW <_.O3A0J>GG;R,,XM;?8-WJ5=K>@*#6VV#?ZU=PX=MIX^KU]RLWNKC7
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MMP%<,AD[A8;./K/FNK9[R<SAUX=I&'8-^=0KN'!KU;N<SS54F,\Y]7'6KR%
MN;GCCKW]V]5H<$-W^''Y>Y7;&$]%AW<>*MW/W=^7=NYZU?0H/8.>:>3;38RV
MQH\_''>KMD.VT^XGW>U3M8&\<>*K-;?:=WK5L^(!M[=IZO3]*OF0J4P\6)]
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M%49#ZMG:>/<KID-K=^\]'&_U;]ZMG/)R[]JKM9U ;AW^=4V0KV+N/?W[E<
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MW]B_JGOXR;@_V3F>'QGFO4M??Z,QDM^YBJ_P*H?^V4?T9C);IPS5OX#4#_\
MXX6P/X'NCQ][6D?@H/N3X'NCQ][6D?@H/N3ZN:#/X%WN_+\O_P!-U\G![%_5
M/?QD7!_LG-</C/->I:^7<LMDJ?\ DO5C_P"#J/T'M5,\LEDD=IPK5OX)4OH5
ML*^![H\?>UI'X*#[E#X'FCO][6D_@X2F%OZ#1]YE[_[0P!NW2W6H&ZWJG#^V
M/<"OXI3/#XP>'>.%->AY9#) [\*58_\ A*C]"I#RQN1W[DJK_!:D/2(*V'?
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M3"^VAD?>=>W^T$+WOP' GK4IT;^J-=2ND2X6S*ZDQ[WX;;YQO6J8\JWDF?\
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MO+O)O+'*N29(X P-AW"\%@MKTVDR,M,N&^SIF! 9&=U;7GT(A>,"!B  ,<*
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,$1$1$1$1$1$1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nt10002526x6_diagram5.jpg
<TEXT>
begin 644 nt10002526x6_diagram5.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( Y (. ,!(@ "$0$#$0'_Q  ?  $  00# 0$!
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M][[ M#LYE2U93\.SFKF.2#GW%OJG*>5),BJLG=XAOF;G41:$KJ+J 9V@
M
M
M  / JUST"B2Z?!JM6A0)=44M,"/)D,LNS%-Z;Y,(<6E3AIUY[A'IKSTY#WCZ
MC]@_B&D;:8N55.9[(^4%^K-L*JUT]+1!7+3'<+=C;G2RCGPS+^2;NOK -W)*
M)1$I)D9&1*(R[I'S(_8,NH<CS*3KY7T_777RN@ZZ]>O1V]=?7'I@
M
M
M                                                           \
MNLRW85,J4EKDY&ID^4V?_P 2/&<<1_\ W)(8,Y*LP%[XVJQ(*[WDN^9JK*B4
M\DH;3NM%+?:T/<Z^U01=L8SHJS++].J#3[O":=ITUEUS37ALN1W$NN:?\B#-
M6G=T&%V3[#7#:P%8@^8&]6[L\M:HIZK$B,;'0'CE/+-H]5*WNW4I.OK:@,XB
MYD1^L.0+J(
M
M %H<<KII]G88W5<53HR*_"ID-3K]*<63:9B22KZ6:]#W2T+KT% Y1<1*)BC@
M7:5YT"U6[.IE3E5=J/0&GB?1#5%G/,N+2X24DKC*0;GH2T,_=%P,;[*?O_#*
MZ;3C3&H+U8AJ91*>4A#;)FE1:J4XI*"YG_&,B%!92L)YF"^!]J8?3:I&K$BC
M2JL\Y/BN-.,O%-FO2$DE;"EMF:"7NGNJ/JY]T!DR
M
M                                              .#ZC]@:W,Y6/\
M9N$^-.6NT;BPQCWM4L0)];8HU<>EICKMA4/@<1QMLT*-WC[_ %$9:;HV1GS(
MR]8:Y<XF5RJXXXRY;[Z@7+3Z-'PMG5J1+@RWHK;U3*>3.ZF.E]U#B]S</7A)
M5IRUZP&PZ \EZ+%<0V3:78D9U*"/T"7&DJ2C_ND9)U]8=T=. P<>+%9-1*-F
M)&9U+J4;324&9'WCW=2]8QW
M
M
M                               >'<25*HU92DC4I5%JJ4D1:F:E0W22
M1:=TSY$0UA[-JBURDKQC\N($^%QZZI4?IJ'T<1/3I)ZMF\1:IT,CU3[(VB5B
M4N'3:E)01*5&ID^4DC(CU4Q&<<2D]>6AFDM>YWQ@_DNQ\N+&I6(Y5R##A^9N
MJJB1>BL1F>(@I3[.J^ A&\>ZV1ZJ,^>NO? 9YEU%[!?$.1P7,B/UAR
M
M                                             QRS4NRFL"L0'(CD
MAJ0FG*X:XQN$\D]U7H#;,ED?WHM'LZY%0DY4\/'JF_-DS%S[BXCL]3RY2B*J
M2=WB*D&;ID1:$G>ZB(B+D1#(_&VZ*5:&&ET7#6:.FNTZFQ#=E4MQ?#3+025&
M:#5H>A:%I[HH3*=B#;F)N"-J7A:UKMVA1:G*JS<6A-N\9$-4::ZRZLG-U.]Q
MEI-P^7=\ 9*@
M
M                 #@^H_8/XAI-VEDZO1LS>2-JE3JQ&BOU:Z2GM4]V8B.\
M22C;G3"CJ)M9%KHGC$9=>@W9'U'[ UUYP,>L/\*\8\N5J79AK'O.KW[.K3-O
M5IZ43"[97#)GC.-MFE7%X^\7\8M- &P*DF9T^G[QF9G3H1GKKJ9]';U,]>[W
M]>8],=."\AZ+%<0CAI=BQG4H+F2$.-)4E'_<(R3[!#N
M
M
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M[\U5O_7^W_?F!\\'FJM_Z_V_[\P/GA $\ZHVR7JQ*W^+M>.AYU1MDO5B5O\
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M1]TC[A]T!2MAR7IEC69,D+-Q^7:ENR7W#ZW'GZ1#=<6?KJ6I2C]D!BV356
M                                                   L]CM9LR^\
M+KLM: ^U&E5>&;+3SRVVFT&:3+52W#2A):GUF9> 6^R?X6U3![ >T;#J\R-.
MG4B76'7I,5YEYEPIDYY]!(<84MLS2E>A[JCT/KYZCU,U3TEC G$!V*\^R^FF
MJX;D=2TO)/=5Z!39DLC]@R%HMG3*G2\J6'C]1DRY4I<^XB<?FN/.R5D54D;I
M+6^9N&1%H2=X^HBTY ,ZP
M
M                          !P?,C+UAK3SH99KEQIQLRS7M1:O3H$+#*?
M7'ZG'ERHC#TM,\F=PHZ)#B''33N'KP25IW1LL/J/V#^(:2]I=4JW#S.9(F:;
M4:K$C2:M=)368#\MJ/())1MSI:6%I;<)/\4G2,B[@#=1 85'B1&E&1FS#C,G
MIS(S:90@SU]E([H\RDF9T^GZF9F=.A&>IF9F9QV]3/7N]\^L>F
M
M
M                                                         #RZ
MQ*7#IM2DH(E*C4R?*21D1ZJ8C..)2>O+0S26O<[XP?R7X^5[&E6(Y5JFPH'F
M;JBHD;HD>,SQ4%*?:U<Z.A&\K1LO1Z\QG#5XZ)5.J,=QTF4/TV='6X?/AH>C
MK;4[I_\ #)1J]P82Y-L&+7PG5B+YG;_8O7R^JBI,SA1B8\K5]*?<X2M%*W^V
M6:=3TYEU ,["YD1^L.0+D1%W@           :$?)+/I0>8W\(L_Y<0,/MBHD
M_.S,NA\1TM6*WR2ZM)<YFO41^N8S!\DL^E!YC?PBS_EQ Q V*GI9>73^8K7Y
MX0W/F3Z0U7Q2?:VVH\\O1^G^-?NY;2]U7_%>_M7/U@W5?\5[^U<_6'Z =-<U
M?G=5_P 5[^U<_6#=5_Q7O[5S]8?H 'YW5?\ %>_M7/U@W5?\5[^U<_6'Z !^
M=U7_ !7O[5S]8-U7_%>_M7/UA^@ ?G=5_P 5[^U<_6#=5_Q7O[5S]8?H 'YW
M5?\ %>_M7/U@W5?\5[^U<_6'Z !^=U7_ !7O[5S]8-U7_%>_M7/UA^@ ?G=5
M_P 5[^U<_6#=5_Q7O[5S]8?H 'YW5?\ %>_M7/U@W5?\5[^U<_6'Z !^=U7_
M !7O[5S]8-U7_%>_M7/UA^@ ?G=5_P 5[^U<_6#=5_Q7O[5S]8?H 'YW5?\
M%>_M7/UA%3\D:D?T<=GMJMQ7_7MWT:U*_P#;=-ZMXST_\"$JX14O)&OU<-GM
M[>WOERFC <Y_0FL[K7MJ&=YM^F='WW/95I[6''U/+#]IEK_(<$ PX^IY8?M,
MM?Y#@@./.MJS
M     6@QSN&C6QAA==;KU&*O4J!#-R92E.\$I:"2KM#<(CW2T+3W10&42]K6
MQ P+M*Z+.M5%G4&H2JNW#H"'SDIAKCSG6WEDZ9%O<9Q)N=7+705OC[:%2OC"
MF[[8I*FDSZM"4S'-YQMELE&E1=LXZI*$EJ9<S,A;K)GAC7L(\ +.L6XU1UU:
MDRZR[)5&?9D,FF9/>?;W76%*:5VBRUW3/33GS 96
M
M                                              #@^H_8&MO.7C-A
MEASC3EKMN]L,FKUKEZ3JVU;%;7..*JV'(I,\=Q+1)43_ !]XNLRTW1LD/F1E
MZPU@9WLMU\8R8Y97;SMAR"FEX;5"NOUPI4V'&=4F<3/"*.U(<2X^?:'J3)*,
MN6O6 V:0'6W8D5;;?#2Y$C.(1U[J%M)4A&O_ "$>[[@[@Z-/87'AQ&EZ;S4.
M*RK0]>V:90A6AEUEJ77W1W@
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MZW(=!\SE45$3T5N.DY1%*?:WU\%M&I]IKVVO-0#.PNHO8+XAR!<R(^^
M      #0CY)9]*#S&_A%G_+B!B!L5/2R\NG\Q6OSPAE_Y)9]*#S&_A%G_+B!
MB!L5/2R\NG\Q6OSPAN?,GTAJOBD^UMM1YY>CM/\ &OW<MIH  Z:YJ
M                           BI>2-?JX;/;V]O?+E-$JT14O)&OU<-GM[
M>WOERFC <Y_0FL[K7MJ&=YM^F='WW/95I[6''U/+#]IEK_(<$ PX^IY8?M,M
M?Y#@@./.MJS
M    8ZYIIDN#@9?\J&^[&DM4Y1M/,J6EU![JN:%(,E$9>L8M'L[ZG4JOE6P^
MG569)G379]PD[)EK<<?<)%4D)02E.FI9DDB(BU/J+D,A\<ZQ;M#PPNNJ7122
MK5#B0S7/IIN&R4IO=/5'$3S3RU+\O,4!E$N>Q[NP+M*NX>VV5JVM+E5=%/HJ
M9"I)17&9KS<A?&66\OBNDI?/JUT 9/
M
M                                    #@^H_8/XAI6VDUR7#1LS&2B%
M2*M4($.I56Z$U"/$>?;9EI;*-N%(2TI*5DG7M261Z:\M!NI/J/V#&MK.9B1@
MQ9N-.6JBXCX>)NZY;DG5MNRZP<YV*=NNL$STI9-H+=?XVJ2[?33=Y -B=)4I
M4" :C,S.G0E*U[JCCMZF?KF8],=* MI<2*II&XA<2,MM/7NMJ90:$:_\J3(O
M7T'=
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M#S&_A%G_ "X@8@;%3TLO+I_,5K\\(;GS)](:KXI/M;;4>>7H[3_&OW<MIH
MZ:YJ                                  BI>2-?JX;/;V]O?+E-$JT1
M4O)&OU<-GM[>WOERFC <Y_0FL[K7MJ&=YM^F='WW/95I[6''U/+#]IEK_(<$
M PX^IY8?M,M?Y#@@./.MJS
M               68Q]L^IWSA3=]L4?A^6%6A*:C\5Q#2-XTGZ);AD@N9ES,
MR%NLF>&%P818 6=8MS<'RXI$NLNR> \R^UNRY[S[>ZXRI39]HLM229F1ZD?,
M5/FAJ4ZE8(7[.ITEV++CTY2F7V=XG&SW5<T[NAZ_H%I]GS7:O<65RP*M7)K]
M0J,B=<"7I4@UJ=<2W4Y"&R4;AFOM4D1%J?5R]8!FZ
M
M                                               .#ZC]@QK SNY;
M+\QEQRRO7I:W0_*K#6H5Z17NDRXL=W<G$SP>"V^XEQ[T!Z\(E::<QL_/J/V#
M&F7:.7M=EM9D\E],H-9G4Z!6ZK<R:M&C+>2U-2R4?AD^3:DI5NZ]KOD?6 W&
MT]A<>'$:7IO-0XK*M#(^V:90A75RTU(^?=[@[P\VE*4N! 4HS-2J?"4HS[JC
M8;,S/US,SU'I
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M;C3K3K;EU4U2'&7$.MN).34#)2%H,TJ(R,C(TF9>N)T[7H3^^5\8#Z
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M<PXKF))XC4V=6*E6*;*.FIIW05U6HR*C(:-&IJ<T5(W",_Y/N#8@")XSW@
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M&"7$F2F(J#_Z*D%R4\XA)][KZ^0G+-7A;))/6Y;9]&OJKU-/^,?>D?D[@"K
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MX(!AQ]3RP_:9:_R'! <>=;5F
M                 M!CG6+=H>&%UU2Z*25:H<2&:Y]--PV2E-[IZHXB>:>6
MI?EYB@,HESV/=V!=I5W#VVRM6UI<JKHI]%3(5)**XS->;D+XRRWE\5TE+Y]6
MN@K+,':58O;"2\;:H;;;M4JL%341MUUME"EF2BT4XX9(3U_QCT%M\E.&ESX3
M9>K+LB[F&8]=I4NM.S&H\AF2TE,N>^\R:7F%*;5JVM)GNGR/D>A\@&6@
M
M
M  X/J/V#&MK.9B3@Q9N-.6JBXCX>INZY;DGUMNRZP<YV*=NNL$STI9-H+=?X
MVJ2[?33=Y#9*?4?L&-6.>C+IB3C!CQE5O&S84.31<.:C7W[E<D3XD5QA$TF.
M ;+4AQ#D@SW%:DT2MW0M>L!M"@+:7$BJ:1N(7$C+;3U[K:F4&A&O_*DR+U]!
MW1T:<RMB'#:<(B6U"BLK(CU[=ME"5:>L1D?/NCO
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M5'_TG[VC^+4>>7H_3_&OW<MIH  Z:YJ
M     BI>2-?JX;/;V]O?+E-$JT14O)&OU<-GM[>WOERFC <Y_0FL[K7MJ&=Y
MM^F='WW/95I[6''U/+#]IEK_ "'! ,./J>6'[3+7^0X(#CSK:LP
M                                           &/6:&ISJ1@A?E0I\E
MR),C4]2F'VC4E;:MU7-)I,E$?KD>HM/L^:_5[ERN6!5ZW/?J-1DSK@2_+D+4
MMUQ+=3D)02E+-2C)*2(BU/N#(#'"?:M.PQNJ9>5.\M;<8AFJIP.(IGI#6Z>J
M.(CMD]WF0H'*16,.J[@;:=2PMH7F=LQ^55TTNE<=R1T=QN<\F4HW7>W5Q'B4
MOGU:Z>R&38
M
M                X/J/V#&F3:.WW==KYD\E]+H5<F4R!7:I<R*M%CN.(:G)
M9*/PR>2A:4JW-3TWB,;FSZCUZM!K@SCW=E]M_&?+=3L6;)\TMW5>=6DX>U/I
MC\;RD?;)GIB^$T6X]Q=4?OFFFG+K,!L.I2U+@0%*,S-5/A*49]U2F&S,_=,S
M,>D.G 4RJ)%4RG<;5$C*;3S/=:4TDVTZG_)3H7?,=P
M                                          !K7VLW\!+'#\!@?YZ1
M;S8D>ES8'?A-T?+$L7#VLW\!+'#\!@?YZ1;S8D>ES8'?A-T?+$L!MK
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MMC,A_03/^(87^1>_2I\*?Z;O/_\ 2&4,T-MGZ6QF0_H)G_$,+_(O?I4^%/\
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M57I7E<'RR5+5HGI\H_I)23]#IIZ#EIIS ;9"Y$1=X!P747L%\0Y
M  :$?)+/I0>8W\(L_P"7$#$#8J>EEY=/YBM?GA#+_P DL^E!YC?PBS_EQ Q
MV*GI9>73^8K7YX0W/F3Z0U7Q2?:VVH\\O1VG^-?NY;30 !TUS4
M                       !%2\D:_5PV>WM[>^7*:)5HBI>2-?JX;/;V]O?
M+E-& YS^A-9W6O;4,[S;],Z/ON>RK3VL./J>6'[3+7^0X(!AQ]3RP_:9:_R'
M! <>=;5F
M L=F(M2N7GA#>=MV]&1+J]4@J:AL..H92XLTJ+0W'#)*>ONF7LBVN2'#>[L*
MLNME65>T%NG7%2YE;=FQ6I#4IMM$JH/O,FEYE2FU;S:DGR/EU'S%=YFJW4K?
MP5OJK4J4N'/AT]2X\A&N\VHDJT,M-#[G7ZPM9D%NNO7GECL.X+CJ+M4JTR=7
MT29CVN^ZEFI2&VR/4SY)0DB+GU> !FF
M
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MAR]P0_\ L1"E^K<Q(_&KB_:X=B(4OU;F)'XU<7[7 3 ?HTX0?;5P\^&%O?M
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MEY=/YBM?GA#<^9/I#5?%)]K;:CSR]':?XU^[EM-  '37-0
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M]N0EM$NH/O,F3K1FA6\VLCY&>G4?,!ET
M
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M:%WB\!#D '&A=XO 0:%WB\!#D '&A=XO 0:%WB\!#D '&A=XO 0:%WB\!#D
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M67ET_F*U^>$-SYD^D-5\4GVMMJ//+T=I_C7[N6TT  =-<U
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M<>[<]]\EJY]6NA=X!DR
M
M                         .#ZC]@QJ&V@V,N(>'.8?*!;=H7&Y1Z/>=3N
M-FXH2$)4FHMQNC\$E&:B-.YO'U$?,QMY/J/7JT&N3.+4\ML+&;+>QC+;YU:]
M)4ZM%AK+*1):*GR$I:Z:HT,%N.;^J/WSJ,N0#893'%NP8*UJWE.0(;BC[ZUL
M(4H_=,S,>@.G!-DXL4V"W6CB1C:+GR9-I)ME[B-TN^.X
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MZ7-@=^$W1\L2Q</:S?P$L</P&!_GI%O-B1Z7-@=^$W1\L2P&VL
M
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MP_:9:_R'! ,./J>6'[3+7^0X(#CSK:LP
M                        %BLQMLUJ[L';UM^@12FU6HP%-PXYK2V3BS2K
MEOKT2GKZSY?E%LLC-@77AIEOLBT+SIR:5<%-FUQR9"2\V^EI$FHOO,F3C9FA
M6^VHE<NKJ]87(S)W#5K8P:O>MT67T*I0("G(LG0E<)9)5H9$?(^9:]??%K\A
M][7)B!EJL:Z+KJ1U6MU";7D2YIH2CBICU*0TT6Z7(MQ"23R[WN ,R@
M
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M]ZW\)7O% ^VG)O\ :&A_6]/_ -3QCNR]V:3WSI_[ZW_-V^,2G?[Z>_\ D/\
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M3DW^T-#^MZ?_ *GC'=E[LTGOG3_WUO\ F[?&)3O]]/?_ "'^@-]/?_(?Z!!
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M>Z6G/0]2&XH .#RZ)2H]"HU)HL0B3$H],@TN,DB(B)B!%:BM?_ZVD_E[X]0
M :U]K-_ 2QP_ 8'^>D6\V)'I<V!WX3='RQ+%P]K-_ 2QP_ 8'^>D6\V)'I<V
M!WX3='RQ+ ;:P
M
M               'EU=]J/3:B\\SQFF:;.>=;UTXK34=Q;C6O<XB2-.O<UU&
M$N37%&P,158BE95@MV4='JBF*D:)9R?+)WI3R#=,C27#[="E:%W].X,VJQ%7
M,IM2C(,DJDTR?%29F1:*?C.-I4>O+0C46O<[XP?R78!W%@JK$<ZY.AS/-)55
M2XO17XSW#0<I][1? 6O=/=<(M%$7/77O ,\RZB]@<C@N1$7K#D
M!H1\DL^E!YC?PBS_ )<0,0-BIZ67ET_F*U^>$,O_ "2SZ4'F-_"+/^7$#$#8
MJ>EEY=/YBM?GA#<^9/I#5?%)]K;:CSR]':?XU^[EM-  '37-0
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MOH[4]YM1'R 9A
M
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M\!+'#\!@?YZ1;S8D>ES8'?A-T?+$L!MK
M
M                                   >'<2E)HU94DS2I-%JJDF1Z&2D
MPW329:=TCYD8UA[-JM5RK+QC\N)\^;P*ZI,?IJWU\-/3I):-D\9Z)T(BT3[
MVC59YEBG5!U]KBM-4Z:\ZWKIQ&6X[BG6]?\ G01IU[FHPNR?8E8;7^K$'S V
M4W:?E55#9JIHDF_T]XI3R#=/5*=WMTJ5IU<] &<1=1>P7Q#D"ZB
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MGM8<?4\L/VF6O\AP0##CZGEA^TRU_D." X\ZVK,
M                               !8K,;<]:M'!V];@H$LH-5IL!3L.3N
MDOA+)*N>ZKD?5W>7Y1;+(QB!=>)F6^R+OO.I^6UP5*97&YD[A(:XR(U1?:9+
M<1VI;K:2+D+V8THLQ>&]SIOYW@VH<0_+APB6K=8W3U/1OMSY:]6I_D%"Y5&L
M*6<%;71@U(.58!2:J='>-+J34\<QWIO:O?3"TD;Y=MX- &2
M
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M:8C']/7#CZGEA^TRU_D."*S%%8<J(L/;#(]>=F6OW.7^Q(/=%9[Z>_\ D/\
M0/N!WA^@'YWT]_\ (?Z WT]_\A_H ?H!^=]/?_(?Z WT]_\ (?Z &MG:S?P$
ML</P&!_GI%O-B1Z7-@=^$W1\L2Q<':RJ(\B6./K08'^>D6^V)'I<V!WX3='R
MQ+ ;:P
M
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M6'[3+7^0X(!AQ]3RP_:9:_R'! <>=;5F
M                         L+F3MZK7/@S>]$HL3IM2GP%-Q8Q*)/%6:5%
MND9\BZ].9=_06NR'61<F'V6FQ;6NNFG2JW3YM>7*A&M*S:3(J4AUH]Y/(]]"
MB5R[XNMF-N:M6C@[>MP4"44*JTZ IR'(-"7";625<]Q>J5=74?+\HMED9O\
MNO$O+?9%WWG44U6X*E-KC<R:EEMA+J(U1?99(FVR)"=QM))Y=?7ZX#,(
M
M
M  <'U'[!_$(PVW_QTOC 7%+)1=&&6'YXGWX56N@J#9J9R*<JK.[T1*VRF.$I
M+6FI:F9=TA)Y/J/V#^(1FMMTDEYQMFRE24J2=Q7EJE:26D^V@]:3Y'[H"A//
M9-L*PB(W'V4,I#)4ZG\(DXH4]1*:.*WPW=[A?^M3HO3N:Z'S(<^>U;8S[E%,
M_O.IWS8D[V_"C*H]'/HT0]:)2?11VE'_ *DR7,S3J?5X![7E?%_]TA?BK/Z@
M"+=Y[5MC/N44S^\ZG?-AY[5MC/N44S^\ZG?-B4CY7Q?_ '2%^*L_J!Y7Q?\
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MN9Z)+7KY&>NFIBAMB3Z7-@=^$W1\L2P&VL
M
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M[6''U/+#]IEK_(<$ PX^IY8?M,M?Y#@@./.MJS
M                               6CQO8L]_#*ZFKYE=#MA<,_+6225N<
M)G=/4]U';*Y:\BT/\@H+*5$PPAX'6G'PBJ)U2Q42JL=)F&TZT;KJIKQRR-M[
MMRW'S6GGUZ:EWQ[.9FB5*X,%;ZI-*BJF3YE/4B/'1S4ZHTJ+0M->^7<[HM7D
M$M2O69EBL.W[CIKE*JT.=7UR(3I'OM)?J<AQLSU(N2D*(R/0@&:@
M
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MWFQ(]+FP._";H^6)8#;6
M
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MM/:PX^IY8?M,M?Y#@@&''U/+#]IEK_(<$!QYUM68
M                                "QV8BZZY9F$-YW);TE$2KTN"IV&^
MXTAY+:R2H]3;<(TJZNZ1^P+:Y(<2+NQ5RZV5>M[3FZC<54F5MJ;*:CM16W$1
M:@^RR2664I;3NMI27(N?6?,7>QP@6K4<,;JAWE4?*JW'X9IJ<_AJ>Z.UNGJO
MAH[97=Y$*!RCT;#FA8&6G3<+:[YHK,8E5=5+JO <C](<<G/*E)-IW5:>&\:D
M<^O37V R;
M
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M6
M
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MV_3.C[[GLJT]K#CZGEA^TRU_D." 8<?4\L/VF6O\AP0''G6U9@
M                                          ,?\S5%J5?P4OJE4J(N
M9/ET]2(\=O7><4:5<BTY]T6KR"6K7;-RQ6'0+CISM+JT.=7UR(;Q'Q&DO5*0
MXV:M2(^V0HC+EU>$7HS!7=6;(PEO&YJ"ZAFJTJ";L1Q;:'4)61&>JFW"-"NK
MJ,A;C)7B9=.+67NS+XO&2U+KU6F5IJ8^PPU';6B)/?89(FF4I;3HA!$>A%KU
M@,LP
M
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M>UF_@)8X?@,#_/2+>;$CTN; [\)NCY8E@-M8
M
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MY[*M/:PX^IY8?M,M?Y#@@&''U/+#]IEK_(<$!QYUM68
M                                   "T6.$"U:CAC=4.\JCY56X_#--
M3G\-3W1VMT]5\-';*[O(A0.4>C8<T+ RTZ;A;7?-%9C$JKJI=5X#D?I#CDYY
M4I)M.ZK3PWC4CGUZ:^QZV:&F3JO@A?E/I\9R7,DT]26&&B4I;BMU7)))(U&?
MK$6HM/L^:!5[:RN6!2*W ?IU1C3K@4_$D(4AUM+E3D*0:DK)*B)23(RU+N@,
MW0
M                                                        'Y4L
MD]>ON$9@/T/RI1)Z]/=,B+PGR'!K(DD>OHM"+OZF>G5W_6&C;:)9P)CV,5FY
M1\*<RJ<MN(]>5)35+ZFVXFKP(#I-(DPFUJF$B&7'29-$9O%HI1]X"(RWE)62
MM=#2>G>42OBZA\3DLI<)HW&B</J;-U!.GIWFS/?/P#6%@$SC5E,R]XBXDYG<
MR<+,&4"B.5&D71#I<&F0D.-1WG8B6S@N.L.=*<X*3T49H,]#T,8(V-C9FFQ<
MRCUK/Q2[WD4^>BM3W;9P^3#:6W&H5%KCL&H+5)Y)<3*@,FXDUMF:=X]W4R!.
M/KB,[^,^/&Y(O<<0R@UK4AM)?QEJ)M!:_P I2C(B]WF9C](6EQ)*2:5)/J-)
MDI)^PHN1^X8C[7/M KKS.5/)59V%M:<LRAYC*3B1YK:L2$OI@5:P(*U%NK62
M-XG9S"]4I<(DZF1ZD,@MGOFYNZY;>QVM3&6N(J:L!9.ZY>+_  H[%89D.R5,
M-HW?I>^26D,)22U&:E:<C Q.,]7\<?7#<(IU&\;>\DE:'VIJ(E'R[B>LQ&@V
MW'\,C9L>V*\_\4$;4,J5Z8MX]WY>6.%:DR:/@]-E%$PWMQYLM]Y,%3D*HOK6
M9(?2EQU'%2;J-#U[3EU:K]MQ_#(V;'MBO/\ Q000DCVY_L6C?T)2OS-H>Z/"
MMS_8M&_H2E?F;0]T
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M!WX3='RQ+%P]K-_ 2QP_ 8'^>D6\V)'I<V!WX3='RQ+ ;:P
M
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MV_3.C[[GLJT]K#CZGEA^TRU_D." 8<?4\L/VF6O\AP0''G6U9@
M                                          +)Y@[MK%DX27C<M#<;
M:JE*@J=B..M-O(2LB4>JFW"-"NK^,6@MODIQ+N?%G+U9=[W<^S(KM5EUIJ8[
M'CLQFE)B3WV622RPE+:=&T)(]TN9\SU/F+JXYT>W:YAA==+NBK%1:'+AFB?4
MC;-XHK>Z>J^&GFKEJ?Y.0H#*);%CVC@7:5"P]N0KJM:)*JZZ?6DQU1BE./37
MG)"."L]Y'"=-2.?7IJ R>
M
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M2E?F;0]T>%;G^Q:-_0E*_,VA[H(
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MIM2]I$RSDSZF2WI;%-O"3,=I/EA/D$I!2F6$PB-;AZ)61$1@8W<=^[CNC?\
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M^$W1\L2P0VU@
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M %_M_P!^8'SP@[><@;9KU:]?][V?' \Y VS7JUZ_[WL^. )Q/FJM_P"O]O\
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M'[3+7^0X(!AQ]3RP_:9:_P AP0''G6U9@
M                         ,=<TT.7.P,O^+#8=DR7:<HFF64K4ZL]U7)"
M4$:C,_6(6CV=],J5(RK8?0:K#DP9K4^X3=C2T.-OMDNJ2%(-2722LB41D9:E
MU'R%_P#'V[ZE8^%-W7/24M*GTF$;T<GFVW6S425>B0Z1H46I%R41BW63/$ZO
M8N8 6=?5QICHJU6EUEJ249AF.SNPY[S#>ZTPE+2>T06II(M3Z^>H#*P
M
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MCPK<_P!BT;^A*5^9M#W0
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M!#;6
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M_F*U^>$-SYD^D-5\4GVMMJ//+T=I_C7[N6TT/#[AF7Q  Z:YJ!X?">G@ZB
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M''U/+#]IEK_(<$ PX^IY8?M,M?Y#@@./.MJS
M                             6EQNH-!N/#.Z:-<E531J/.AFB;45(-Q
M,5&Z?;F@C(U=WN^L*"RF6=9UBX(6I;=BW&BZ;;@R:LY!K2&383*6_-=<?23:
MC,T\)Q1HZ^>FH[N::)+FX&W_ !H3#TB4[3E$TTP2S=6>ZKD@FR-9F?K$+2[/
M&G5*E95L/H56BRH<YJ?<)NQYB74R$$JJ2#1ODZ1+T-)EIJ75U=X!G(
M
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MK?YZA_(#PFYL^A/[]?\ B,0C,CG_ &DO-;_/4/Y >$W-GT)_?K_Q& ^H
M  X/J/V#^(1G-MQ_#(V;'MBO/_%!$F,^H_8/XA&<VW'\,C9L>V*\_P#%! 21
M[<_V+1OZ$I7YFT/='A6Y_L6C?T)2OS-H>Z
M                  '_ )ZM?B'YWBUTYZ^N1D7?ZS%B\>G\6'K2.CX1)*#<
M]46AMJX#)ITJ,DG$DMXXSW:O[R#,]T^K3087/5O/I@545+J-+3F4H3S:%N2F
MUT^UW("UH)1M$TDC6[NK4:#/3GNZZ\P/'CH];)/.IF9MK*?E]O;%^Z'9+,&D
MQVH3+L.'(GR&'ZHHX3,U,:*VXZX41UPGS22>>YH?(QIRR$6+C-F*OZ@X]T;:
M,MXEV4F;,J-:P@=L^/1ZBQ%ENJ7$A/<1Y,UOHR#).^IE.\2-3ZQMWL^EUK'B
MPZO^Z2LBE4*E7%PT0;!K$Z%(9ADTLTN).2YHF0ISDM.J#-)Z;O,:<,<LEEM9
M.<^>77&W*<50M-K$&378V*.'\*I2IM-N-LHR8L!Y$13RXL!,-+JGBX,=).<]
M=3T!5&,3'"9SOW8QQW]7R,C;PQ^Q'S2Y^;RRA6977K>PZP-AQ$8BRH9)<57)
ME9I72:.ZIQM27(W1)226I*%F3FFZK7J%EX>??%C O]VAEYN6HO7)?V7-RT(U
MD5<F2X]=AW>I2W%H90E>GE;%6DS4HU;R4[VO,=#(0V=@[8/:"4*Y%J8FWC%P
MUG4)4Q!H.8M-#Z3.1$<=TXI1S4:5\(S))>BTT%/X/V&SC'MF<ZT.72VZU8,*
M%9L.X'2(G(3ZGJ"IEOZ:1&VXIITSW32HS2HBZC X=']&F>_?'\9A4N"^/V,>
M'./.21$N_7[OI.:==]OW[2TMH-$,[?:-R"VHR4YP."I>G:D@CW#WN1#85C=B
MG?N-F.U#RYX,UIZETNWI+4O%RZXC:9#-$09(G4N,@_0R.EDE3"N"YJA1]N,?
M\8,#L'<I:;7JEG4]R[\:^EU6!@50./(6];K=P/G&N20SOJ<07#CR#>(G4$6C
M>B#(6N=O.Z,LN+N".5JPZPIG%_'.DWE=6).*$F,3\F,Y1*<Y<-/II19)*XQ)
M29P=]M>B"[8R(BT!&Z>_YNN<_)'1XG?Q3F%18,.*ITWU18L>,MY1:&\XPTAM
M;QD?,N(I)JTU[H[HUT;/;-U6\S5D71#NZ#P+QL"JRZ56YA.)6W4.'.D16)!$
MVGAH-Q#!.&E!GIO:&0V+ES(C[X(X-:^UF_@)8X?@,#_/2+>;$CTN; [\)NCY
M8EBXFUE(SR)8X:=R!!,_8)].IBU.Q0J],C[.C Y#M2IC2RE722D/3XS1EI69
M7+13A'KS+4M.6I -OH#P_-#2/KM1_?2'\\'FAI/UVH_OI#^> >X \/S0TGZ[
M4?WTA_/!YH:3]=J/[Z0_G@'N /#\T-)^NU']](?SP>:&D_7:C^^D/YX![@#P
M_-#2?KM1_?2'\\'FAI/UVH_OI#^> >X \/S0TGZ[4?WTA_/!YH:3]=J/[Z0_
MG@'N /#\T-)^NU']](?SP>:&D_7:C^^D/YX![@#P_-#2?KM1_?2'\\'FAI/U
MVH_OI#^> >X \/S0TGZ[4?WTA_/!YH:3]=J/[Z0_G@'N /#\T-)^NU']](?S
MP>:&D_7:C^^D/YX![@#P_-#2?KM1_?2'\\'FAI/UVH_OI#^> >X \/S0TGZ[
M4?WTA_/!YH:3]=J/[Z0_G@'N /#\T-)^NU']](?SP>:&D_7:C^^D/YX![@#P
M_-#2?KM1_?2'\\'FAI/UVH_OI#^> >X \/S0TGZ[4?WTA_/!YH:3]=J/[Z0_
MG@'N /#\T-)^NU']](?SP>:&D_7:C^^D/YX![@#P_-#2?KM1_?2'\\'FAI/U
MVH_OI#^> >X \/S0TGZ[4?WTA_/!YH:3]=J/[Z0_G@'N /#\T-)^NU']](?S
MP>:&D_7:C^^D/YX![@#P_-#2?KM1_?2'\\'FAI/UVH_OI#^> >X \/S0TGZ[
M4?WTA_/!YH:3]=J/[Z0_G@'N /#\T-)^NU']](?SP>:&D_7:C^^D/YX![@#P
M_-#2/KM1_?2'\\+=XLXKTS#C#B\;Z:D4FI.6M1*A6$P$U6(GI90(CTHV=\G3
M-)N<+=(].[U<@%VW#(TEH?\ &3\8A2[>STUG9U^V&X/BAC8UD0\DG9+<VE9E
M8?8B5F/@KBHBXJC085LU!QZ7%G.P*D]!0[Y:.I:BMI>2T3A&:]WM]"/D-9VW
M4KU&N#:F[.2HT.K4RKP)%;KC[,JF3XLYI3;J(*T*-<9UQ*=Y*B/0SU 35+5_
MW?H'M?HWY@R*B%.VK_N_0/:_1OS!D5$     US[5&GG4LDV+R&ILRG28T> ]
M%G09+\63'<1(2I*D.L+;<(M=#,M[GH6O+D-C Q-SI8&W-F,P"O'!ZUJV5LU"
M[FX[1UXV$2N@DPX2ST869$O?+EZV@)CC'?"/3@UA_0<!MF[:&?B-4KDK./-J
MR9U-CU^36ZH_$=BUJM'05\:FO2'(BC9C.:;ZVCW"(UZI,M3OC=^4O&#,SETP
MIQ"P=K4JP,6(U5@W UBZQ<A5"&_&DU2--J<5ZFJEE#7Q8QNPR2M1FV:M"21E
MH-DV7_(<W:>25W)OC%5V[XHAP:K&76SC)A&\]47G9,=\F6CWD]"D.)<26NIF
MGEH9C!;+5LOL[& 508P8+.',K.5.E5J34Z99;ELLE-;BR9QU H**RMXZ@26G
M32T1\0B-*2+J(%68SG/"J>.>'CHW<5=9P(U2@YZ]EO#KLDJG6X5)O&'5YZ"+
M=J$V+1HS,B21(,TEQGDN.JW==-X^8Z.-M@6Q7<T>8F0_==1QQN6K6B<BB834
MZ;,H<?"=ZGVY(<.2_5(KW ?.6:"E$E[AGO(W"U/JR-S(9'<5\6,RV6W&FT,2
M#MJ@9=&JK'@6ZNG-35UUJN1&HL]2I3JC<9,MU:]5;QD:NU[XME&V=&.=CYO,
M;<<,+L;EV_9&8J@QJ7?5N2J,U4EP'8%$=IK2X<N4I3L<GGG5.*3%W->I6N@(
MSVXW>O:SU-51UZ^KAV$]YU.OW55T7A9^(1PJ+66JC+3/I3,B_P!R,<54IIXG
M9),LD3!&MP]4H[VH_>;K*-'LW9V899WK$OJYZ)F.PVD6?,.[4UBK/1:W%JM9
MIT65%?I*YG0]Y<,UQR-32M=_>UWN0O+F9R8W]D@V6&92P;SQ9;OZA5F[K9J5
MJ,.4QJFG17ZC=I37UDHE&J1O/R"5HH]"W3[FHR>P7RMXPYJ<EN"N#U^WTR6%
MTA%.JESR68<9TK@;I<J+4J9'/A*);!1UM);Y*T6?,P59QOB=VWGOX3ZO6Q.S
M&YC,?;2+ _,[?N&=:Q3RZ7+:)0;]ATJIR(<[#PBHD>G.U5V! )<^H=.?4[-(
MB:(V]W4CT+4>U<V:+#NQLH^!=+RM7O/N+#;'"X9QR*Y4Y$R)+HKT>NMJFTN:
M[4W.E1=Y]UR$VI]36_H6YKU#:9=&5/&ZU<39M7P\NR#5L(*I;3%LRL*JA1H,
MF EENC%2.DH=FI<0A:5:RM4-DHU<M=1CW6-C'A]=&3^\\O4JXUT.Z;HJR;CI
M5V1&74>9>JLU=5;C% B,N-I:24K<2M+'#2M*-%$:3!3F-V?5PQOQGKF.OICK
M>%6\GN,5+S+8'9CL'ZO*PCLRS[1K=<Q-H3];\OX>(BUVX4F$I#<J0IN/PW4J
M<(F6UZFYS+04?DFN>%GQNC-AB1BM+DU1%$AS:-;%MLU&5"5:JHL*HT^4^;<-
MYHU'-4P3R"=01$1\B/K%^\GF2'.78]9I$/-3FA?QBL2RH4BCVU;A6^S152J2
M]&5";8DRX;O$=X,9+234\:C41'WS%#T_9F8T9>LRN*&*F53%SS)898ZL&S?6
M'+E(9G,P7&83T:._'ES%&:%J=?<?4;"4*,^2C S&)B9WXC9G$[M_#AGNX]2B
MMA?;]-LFW\?+)IDI4F+0KIDF@W75O/H3)JTYQ*7''%*<5NEVI;QGU<O7SVVB
M]_R:7A%#PRMQUY-ZXF56EQ:(U'-7&<B1*C&.J$E*>9D<92][33M3/D+>;.;9
M_7KDQK6+E<NO%([_ %8I3XU17$52TP"IKC3[KZT$I)F2]5.F6J=.H9)XBY>*
M]B+F/PJQ8JU<;7:V&!554&W5Q$*:DKJ<;A*4XO\ C&VX1+(UI/J+0RY 3,;6
M>,?Y?QXKX8,6#2<-<-K2M"CL='BTZDQ'UMD6[I+F,-OS#,N^J0MQ1^SS+7JN
MJ/RA.ZDDEIH7))$1%HDN24\N\0_0*0   'CUO_9U1_HNH_FKH]@>/6_]G5'^
MBZC^:N@(,.S'_P"T+9I?Z0@_),@3L6?0G]^O_$8@C;,Z5'B^2%<T:I$AB.DZ
MA![9]YME/^RI!:$;BDD?AZ^0G/-7!2"2K_I:C_OBR_VI#_E'_P#&T_* J !X
M?FAI/UVH_OI#^>#S0TGZ[4?WTA_/ /I79#T6DU5]A6XZQ2:E(:5IKNNLQ7%M
MJ_[JB(_<&O+(+C!B#BBK%7S;UPJQY1UE4>F?26V>CL],D-DGM.1]HA):GWM1
MGU4Z];ZZ?4"F5:D'&.FSND[E3B*5T?HSG'(DD]J?TO>ZB,8:90:OEU;/$,\'
M:E3D'Y9GYH>)4$)(Y727M><ATB+Z::_0GIU=8#/4NHO8(<CP_-!2"T_Z6H_O
MI#^=#S0TGZ[4?WTA_/ /< >'YH:3]=J/[Z0_G@\T-)^NU']](?SP#W 'A^:&
MD_7:C^^D/YX/-#2?KM1_?2'\\ ]P<:D769#Q/-#2.6M6H_,R+_:D/NF1?\7U
MQH0S0>2 ,NN3O.Q-RKX^4UJU[68<@M,8ELRUU!KBS(J'DDN!%0LTD3KA-&9J
M(BYGW 'N^26?2@\QGX19_P N(&(&Q4]++RZ?S%:_/"%T-O7F,P9S$[%/'B^<
M(+_M^\+?JZK/?AN0ZE#Z>ILZTRHM^GD\<IM1$HM26V1Z<^KF+7[%3TLO+I_,
M5K\\(;GS)](:KXI/M;;4>>7H_3Q_]5^[G^#::  .FN:@  !U_P#Z]/RGR'U)
ME9\]YC3OF^V1>P1Z]?<T[_(=9Y@Y3+D4G#9.0DVB>(M3:-9&DED7=-.]K[@T
M2VM<>8S$7:,8R978>/<BA6'9[,!^@J*BMR%-R)]+<F)29Z\0R3(W"[8]-.\6
MHL]9K(TD6<VKEV;UWR5%-O9SM[-5<;IF,YBF>&9SB,;UYI-).JB_,7:+4:>S
M-^N:XJGS(JIHG&S3._-<;IQN;WC(R,R,C+3NZ'NG]ZKJ47KD T\Y.\V^-J,X
MV+61S'JH-WG6+(<B':M^LICQT2XK\=R<YQXT75#'#CI2CZ>LM=#,^9#:'4,6
M\+J56RMRIWI B5HW5,)84MLX7%)1I)"ZAO\ 1DJ,]"W5+UWC).AF)TVML:FU
M-VFK8V;E=FNFYBFJB[;JV*Z)WXF8JZIF)S&)E&IT5[378M51%R:K5N_15:S7
M379NT[5%R,1F(F)WQ5$3$YB5Q20:M=%-(T[KSJ&D_P!99D6O<(NZ8)2:]2)Q
MA&G\9Y]MI!_>K6:4K];=/4QKCVH%QXAV3EK7?6&E\G:%4I-P6PTZ]%:1,15(
ME2K41E:4/)4:$DIA9IU29^BZN1B[.*UM2\1\'<)63QE8PDJBJ=09TJKO--ON
M5]\VX4EYE+2WFE:OJWFCW=XR-SOD%>JBFY>M1;JJJLVK=W\:BFFY%VJJF(IF
MJ8Q,33.=K$3NPFG21-G3WINTTT7[MVU^+7551-JFBJ9FF(S,3MQC9STYX,P?
M_/+J]SOEWC[H"B3OZPZ9.IEJ3[MA-W*BGP8[=->6VW+J"VXK:>DLLJ63CA2"
M+CF3:5;I+Z].8]&JWG:-"FM4VM5UFGU%]!NL0UI(WG6THXBEH1J2C2EOME<C
M(B+4]--1<Q73B?.IW;I\Z-TST3OXK78KS$;-6_?'FSOCKC=P5* I2W[ZLF[%
M246K<L*O*A;QS2A.-O=%)&N\3W"6O<-.Z>I+,NHR/F*)OC&>U+<MVI3K=GL7
M-<##K4.'16%I2M<J0YP$F:T&K3@N&2C)1:'H9")N413MS73LXF<Q,3G''&_?
M/9&951:N5511%%6UF(Q-,QB:N&<\.^<1C>O&2#46O$CM>M(D-,*]Q+BDJ/\
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MO\AP0##CZGEA^TRU_D." X\ZVK,
M                   !9W':\IMAX779=5/9;?ETB&IYEIU"'&UJ)*N2DN$:
M#+4NHR,6_P G^*=6QBP'M&_:U%CPZC6)=8:?8C--,LH*'.>80:&V$H;(S2@M
M=U):GU]T7#QSMZC7/AA==$KU9*@TJ?#-N955-<8HB#2KMS;(RWBT/7W!0&42
MR;6P_P "[2M>SKJ1>-!I\JKN0Z^A@XR9BY$YUQY!-&9[O!<4;?7STU 9/
M                                                           _
M#CB&DJ6L]$H0IQ1]Y*"WE'[A$8#]@-/V.FW2V;^73%:Z,%L4L8*I3,0K.7';
MN"C4NSJ[6U0%24<1DG7:<RZ@M]/,M>X+3]D=;*3[=%V_W8W?XF WL@-$W9'6
MRD^W1=O]V-X>)AV1ULI/MT7;_=C>'B8#>R/RI24)-2U)2DBU-2C)*2(NZ9GR
M(O7&BCLCK92?;HNW^[&\/$Q1F(GDB_9<U"P;TAT/&F["K4BV:TS1_P#T:W<T
M?EFNG24P%$XJ%NMZ23:,U+41)+F9D1 ) "93+[*7676WVU+T2Y'<0\T9DK0R
M)Q!J3J1\C+7D?6(5FWL]-9V=?MAN#XH0TCY,/)3&:O+/B1<%!Q@=>QVP95>%
M4.A0I:V:-*I-%E5>0MITWMQ4IXT15MK)I:B46[N:=8RISN[27 +:/;0O9Y8A
M8*5&8])HU7JSET4F3 FQD4B1**$E+#4J4TVB81.$I!J9U(MW7N@/Z)EJ_P"[
M] ]K]&_,&140IVU>=O6^?_X?HOY@P*B     87Y_I<.%E.QA?GF@HQ4"02B<
M:)]*C4RZ1$31D9+/7J+0^9<BU&: H3$3#FT<4;9FVE>M+\N*#/229=/-U;2'
MDD>I$HT&1F6O</K[H$;IB>I'0RLV57,1-AFQ PNIK2[QCRKOJ4;@P6HM51&I
MUT2YL]"-YM$IE3T)M:4F6AN(/1.\0HS*3F/V>&8?)_:N%V,\&I2;OM^MOT^Z
M<+JA#KC4XZY!K7"ANIXK)*W5S&4R"<90:=#U/ES$D'"O!##7!NW'[3P\MMFW
M[??)U+E*2M3T0TO&HW2)E9FV1.;ZM\B3HK7MM>8L7$R!Y5(.+"L:86%%,AW^
MI_I*ZE%7P(2W^KBJIC24PU*U/>WE->B[;K!5F-_'CF,<<M4.?*?:%G9D]F72
MXD!ZV*,AR[6J33-7Y_E?#4S&3"3)?/53/$9-O<)_</\ BD7(>]>>9>V+NSRY
MAL"V]S"V3A_8455:N55*Z7(Q515K/>D1T1)!LI<9.GI,FEE'=<WM[11=P;C<
M1<L."^*5R4*[+WLYJMUVVEI<H<UR0X@Z:I&YIT9"3(F2/<3J39)(]-#Y#RKM
MRD8"WGB+1\5*_8D:7?%$BKAPZVR\N,ZN.N,40VYJ6MPII$P1-IZ1Q-TN9: 9
MC&.R8]>?'^2)+:-VV74MD7FMLZB.OO3+=Q%H;TV'.IC\;@-O7XX\IW=E-I(R
M>01KZN>I<S&?>;3Z'.(.QAM.U:'#I58NBYI%BL6I#@4YAZL'/@W#3NDO1NCL
MJE1TL*+><41HWB+4]4ERRVVH^6FUK/R38S65EZPO;?OS%2K6H_(HU,2;?EHU
M2JRT_+6:D(X;'#C\19]J1K,^LQ?+(-E?PMCX 80UNX,/GJ=>5NP#X]+JDJ5,
MCT^<:6R=4<.7O1EF;B34DR;[4RWBT/0$S,;I^%G'R1_!JTQ RJ'?)X6L88X^
M2\"L\6!MC>6SM=F4]ZJ1KFC2K?9FLTMYB6XBFJ,Z<T4(B7Q#0:^K>Y#&7&G,
M-F Q'R3X98X8T6/4N!E\N^13,8D46&J,BZV)5SHIT.KMP:5'02B0VRN<O@-N
M;I*/>/NB5'?65# [$6[D7O=-H'*N9+:6_+2).D0'%-I:)E+:^C+;WD$T1()*
MC,MWM=-!7</!;#.%A_(PR:M&E+LJ4R\Q*H<F*Q(8E(>-1K-_BMJ)YS51J2XX
M2EI5S(R/F"-KANSCK_9^SJ^;&GNR\0]GMFFN#"B\<-F).(>+T&QJJQAZ_P .
MKQ'[8JSMNDQ.;>=?;(VG"?(D$3YH+5&B=1BCLJ\;:-AMBWG2P'QQ=D6WC%#9
MEO+?K;,DO-#3WXE3DPV8<U]!-2>C0C:1N-N+(S(B/0]"/>M@7DGRX9<ZW5K@
MPDP[BVQ5*R\I^9)X[DLDN*4I2CBH>WBBI4:U:I8W",N1CM8EY,\O&+%\T_$>
M\[ CS+RII/$S6Z?(=I<AXGD<):9JH1M*F$;?:D4@W"(NKUQF-\;\3B,SOF,-
M1.PYOZAW77<TM$H4=]IFB70@TK=@O0&7^D5.:9J80XTVE1;QZFIO4CUWC[XS
MCV@M:K%[3<)\L5#4M,[&&K%+D.--FOA,VQ+CSUH=6DC)LG$-J+12TZEU$8S2
MPIP PHP7=JKV'%HP[:=K7".IKBD1*EFSKN*=,B(U*(S,]3UU,^8JRIX:6;6+
MQH=^5&D-R;HMTI!4>IK69KA%);X;Y-)/4D\1'(]"($3.9SP_R>Y:M%8MVWJ)
M1(S#<=FF4FGP^$TA*$$['BM,NJ(DD1:J6@S5WS,S[HJ$ !    #I3OWB1^"2
M?\I0[HZ4[_5Y/X))_P I0"$ID<_[27FM_GJ'\@/";FSZ$_OU_P"(Q_/DL/.;
M@%DS\D+9J,0<?;GGVO:[S]$2W.@4*IUUS4J*XT>L6F,OO^C,B]!Z_5J)(;?D
MCG92$DR/&>[2[=?_ .[&[SZU'ISZ&767/3N -[H#1-V1ULI/MT7;_=C>'B8=
MD=;*3[=%V_W8WAXF WL@-$W9'6RD^W1=O]V-X>)AV1ULI/MT7;_=C>'B8#>P
M?4?L'\0C.;;C^&1LV/;%>?\ B@C(H_)'6RDT/_TT7;_=C=_B8T_9\=I;E(SY
MYW=GO1<M=\U:[JA;-?NMRL,5.UJU;O1DR3BFSNN56,PAXU$VK7A&K3EKIS(@
MF?6Y_L6C?T)2OS-H>Z/#MXC*CT=)]::+2DGZQE#:U'N
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MRE-K-1LDSOJ224JTTT[A$,K  S+$:D98(TG,+7,=[WKAW/)9X'F!HKS)H9M
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MM/:PX^IY8?M,M?Y#@@&''U/+#]IEK_(<$!QYUM68
M                                #''-4S)?P)Q :BLOO/JIJN&W'2M3
MRCW5>@2V1K,_8(Q:+9TQ9T3*EAXQ48TN+*1/N(W&)K;S4E!'5)&Z:T/D3A$9
M:&G>+J,M.0R*QVO*98F%UV73 8:DRJ1#-YIEYMMUM9DDST4AQ*D&7+J41][N
MBWV3_%*J8PX#VC?E7AQH,ZKRZNT]&BM,LLME#G/,(-#;"4-$:DH(SW4EJ9\^
MZ RB
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M=$*;;V>FL[.OVPW!\4,!,]M7_=^@>U^B_F#(J(4[:O\ N_0/:_1OS!D5$
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M)(MT]:-1S/K.BTHS]DX;0]P>%;G^Q:-_0E*_,VA[H
M
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MM"+0MU1'[!@-F9=1:=7< <%U%[!#D          !H1\DL^E!YC?PBS_EQ Q
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M/J>6'[3+7^0X(!AQ]3RP_:9:_P AP0''G6U9@
M                             +0XY6M3[QPQNJW:G644"%4X:FGZJX@G
M$PTFE7TPT:EO%H?5J*!RBX=T3"[ NTK,H%U-WC3*9*J[L>OM,DPB8J5.>><0
MELE*)/!4LV_1'J9>X._FI:E.X%8@-Q&Y#LA5.5PT1B<-]1[JO0$V1K,^]NBT
M>SKCU"-E3P]9J;$V/,3/N(W&J@EY,I)'59.Z;B9!$Z1&6AI-761ZER,!G2
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M^A*5^9M#W0
M
M                           ?-WT)??)^,0GMOI)C1-JIL[GY<F/$8:N"
MX5./RGVX[#9$F&>JW75(0@N7\91";&I.\6FNG,C\!B/7M?=A:6U)Q#PPQ!C8
M]2L'ZCAMY9'%.'1WJ@_(7/0A)+;?:=;4R;1HUY&1GKU@-X5KXB8?IM^@[U^6
M81^4%&+<.Z*(2TF4!C7>2<TC+W14/T1\//L\LSX44/QX0TB\B;XS)T).TEQ
M224DA))IE;(DH26B4D15331)$1$.>Q.,9_NDV(/O;7/VH F6?1'P\^SRS/A1
M0_'@^B/AY]GEF?"BA^/"&GV)QC/]TFQ!][:Y^U [$XQG^Z38@^]M<_:@"99]
M$?#S[/+,^%%#\>#Z(V'GV>69\**)X\(:?8G&,_W2;$'WMKG[4#L3C&?[I-B#
M[VUS]J )EGT1L//L\LSX44/QX<%B+AV1Z^;RS/A10^7L?Z<(:G8G&,_W2;$'
MWMKG[4#L3C&?[I-B#[VUS]J )E?T1L//L\LWX4T0OBGA]$;#S[/+-^%-$^+I
M^@AJ=B<8S_=)L0?>VN?M0.Q.,9_NDV(/O;7/VH F5GB-AX>G_7RS>7>NBB>/
M!]$;#S[/+,Y__BBB>/"&IV)QC/\ =)L0?>VN?M0.Q.,9_NDV(/O;7/VH F5?
M1%P[UU\WEF?"BAZ?GP_7T1L//L\LSX443QX0T^Q.,9_NDV(/O;7/VH'8G&,_
MW2;$'WMKG[4 3*SQ%P\/KORS/A10_'AS]$;#PO\ ]O+,^%%$\>$-/L3C&?[I
M-B#[VUS]J!V)QC/]TFQ!][:Y^U $Q2NW5A7<='J5"JUZV;)IM6B/PIK'FKHJ
M.+'DM+9>02TSMY)J;6HB47,M=2,6#R_8'Y1\L$6L0\&Y=D6VU7ICLZIN/7I3
M*E)>D//.2'%)D2Z@MULE.N*/=0LBYZ::$(L_8G&,_P!TFQ!][:Y^U [$XQG^
MZ38@^]M<_:@"99]$?#S[/+,^%%#\>#Z(^'GV>69\**'X\(:?8G&,_P!TFQ!]
M[:Y^U [$XQG^Z38@^]M<_:@"99]$?#S[/+,^%%#\>#Z(^'GV>69\**'X\(:?
M8G&,_P!TFQ!][:Y^U [$XQG^Z38@^]M<_:@"99]$?#S[/+,^%%#\>'DUK$3#
MY5-J6[?EEF?E74")/FHHF\9G%=TT(IVI^OH(=/8G&,_W2;$'WMKG[4''8G&,
MY]>TEQ ,C(TF1TVMF1I/DI)_]*=1EJ7N@+0[+V7%G>2#\T4J#+BSHKM0@FW)
MAR&I,=PO*J27TMYE:VW-.KM%&6O6)W+/H3^_7_B,1H]EAY'M<V<68>KX_P!3
MS'S<7JM5DH)Z+.H;\.2:DQEQS4Y,?>=<<,][7ME'I[N@DOH3N$9:Z]LH_">H
M#]   /(KDEZ)2JI(85NNQZ549#2C(CW76(KCC:M#U(]%)(]#&O[(CC;B-BZK
M%(K[K#=4*@5A4:E<.*Q&X+)2Y#1)4;22W]$(26JO7,;!JJB*NGU!,M>Y'53I
MJ)"M-23&5'63Z]"Z]UO>/3UO#AOE%H6!5&.__H.7!Y=G)J1KN(N ^ST:5TE\
MS1].UWM73<+M="Y>Z S9+J+V"'(%U%IU=P           &A'R2SZ4'F-_"+/
M^7$#$#8J>EEY=/YBM?GA#+_R2SZ4'F-_"+/^7$#$#8J>EEY=/YBM?GA#<^9/
MI#5?%)]K;:CSR]':?XU^[EM- =:9,B4Z)(GSY#42#%0;DF4\M+;32"(U:J6L
MR3O&1'NI,]5'R(C%FZ7F-P5K%PP;6A7@Z=>JBI*:7#?ILB.U4.AD9RS8D.I2
MTXEDDF9F@U:\M/7Z55<MT3$5UTTS5NIBJJ(F<S$1C,[]\Q#G%-NY7$S1175%
M,9JFFF9B(XYG$;MV_NWKV@+#5'-!E]I3USQYF(S)/V;P/-/'CPURI-+Z1J;)
MJCLFIU:5:'J:4Z)(M3Y<QT9&;/+A&L6)B4YB:P[94YU3,>J1(3DJ1Q$/='44
MF"QOR(Q$[VNKR$EIVW40H]T6-_X:SNB9G\)1NBF<53._=$3NF>$3QWJXTVHG
M&+%[SIBF/P=>^:HVHB-W&8WQUQOC<R' 6[+%O#%5B1\32O*G>8&6E*HMP\5H
MDR-Y1)2AMDW-Y3AN&2#0DS42CW3+7D/&L+'C"+$VMS;7LZ[>GW#';-#](EPW
M:?)W)#9[CC#<DFW'BW#XI*;29;NA]T5>5M9II\I;VJ\31&W3FN)X33&?.ST8
MSGH1Y&[BJKR=S9HF8KG8JQ1C&=K=NQF,YX=*[>\WO\(I,)QWEJTQ,8>=;UZN
M,VVM2VN7/59%R#>;WE(3)AOK3Z-,64S)4WKU<4F5K-LS[A+TUZNL:G\JI7)%
MV@&<6QJE=LVMV[!I]&51X3QN\*D+E4>0Z[P4K6HM=]6]VI%Z$NZ/IL\)ESM8
M]9S+7KUT3+EI]NU2WE47I2G=(*9;KSCJ&DN+5NE_%/=T+D0L[>OBY58H\E53
M-Z_J;&^J)V*M/M[YQ&^*XHG&)W;LKRYR?Y.C45^6IJ\AI]+J(C8JC;IU/DXB
M(WSB:)N8G/'&8;7@'BU^XZ%:='EW!<U112:+ ;XDVH+3O(CHTUWC3J7>/V.O
MN"PM0SAY8Z73*'69V*3#=)N.2[#HU2:@NO1),EEXH[C;TALU,QMU\R1J\M)>
M Q>5W;5N<5W+=$XSBNNFF<9B,[YC=F8C/7,+*BS=N_\ =VKE>_'F455;\9QN
MB=^-^..-_!DH L37LSN7^V+GHEG5W$:+"N"XTMKHS*8ZGJ=+)U"'&B.IH/H;
M:EI6CM5.:[RMW347$O+$.R</J>Q5+PKK-+BRVB?A):3TN5,:-.^2X\1HS>=+
M<,E?2TJT(^?<"+MJ8KF+E$Q;W5S%=,[.8S&UB=V>W!Y&]$T1-JY$W,S1FBJ-
MN(W3-.8\Z(GC,9QTJR\'NGH7NGW"[Y]P?G>;WE(3)AOK3Z-,64S)-OO<4F5K
M-LS[A+TUZNL6XP_Q7PSQ@BUMBPKK9K#L*GS45&*ZT<*H0%NQW$LK.$\:9)]M
MVQ?2RY%J1Z#73L\)ESM8\YR[8KUU2KDIUN5"WG:0J8MPFZ>W(6\Z^EOBN*))
M$1:'H:=22/&O54TW--13$7*=35<IIN4UQ,4S;MS<X1G,3$3&Z=TO>C2556M5
M<KF;=>EIMU3:JHJBJJ+ERFWQG&,;43OXQP;7P%C*[F6P*MFX8]K5^^TTVJR'
MBCM.+@NG3#D*42":55.4))FM1(+>=U-7(N8N'=V(%E6)26:Y==?CT^F264OP
MW8^[-?FLK22B<C1V#4Z\6Z9*/A)5H1\Q[1=M3M3%RB8H_'F*Z<4YX;4YW?*\
M)LW8FB)MW(FY^)$T51M_^7=OXQG'!6 "RM%S%X(7!;M8NJD7XQ)HMOFV5><7
M'4U-I/%6:&3DP5**2T3BB/0W$)U(M2U+F/1J&.F$-+LN!B+.O5AFQ*HZ;-/N
M9+)N1'GB>Z/PU*2HT-GQS)KME%SY=81>LS&8NVYC9VLQ73C9SC:X_BQ.[/7N
MXI\A>B8B;5R)FK8QY.K.W,9BG&,[4QOB.,QOA==2FT)WW),..DN7^E2V(QJ,
M^XV3RT;Y^LG4]>X/U\7</N&7?+OD?</J,N9<AJ9VH-9J98<X*XBX?WK)ID1^
MX8&ZN"IQ+59BR:O#;,E*;622(FE]1[Q<SY<CTV:W#>UK6+:]#KEW59-,@JMB
M@O*4AM4B4^M=,C*=<:B-ZO.F:U*4KAH,RU'C1JJ:[VHM3$4Q8IM5>4VZ9HJI
MNQ5.>C9V=G$YG>]:]+-%C378JVZM15>H\G%,Q5159JHIF)ZYG;SNC=TJQ 6N
MP\QIPKQ5C52585WQJN5#2:ZS&EI*G3:<C12B4]$E*1(3O)2:DDI!;Q%J1GUB
MGRS)8(G7(5NKO1QNJU)]R-3$KITA$2?(95N.MLS#24=?#7VIFE:N?<(>OE[.
M*:O*V]FO=35MTXJGAB)SB=^[OW<7EY"]FJGR5S:HWU4[%6:8XYF,9C=O[M_!
M?$14O)&OU<-GM[>WOERFB5<9&6[KRWD(<3ZZ'$DI"B]923(R$5'R1K]7#9[>
MWM[Y<IHPO.?T)K.ZU[:AF.;?IG1]]SV5:>UAQ]3RP_:9:_R'! ,./J>6'[3+
M7^0X(#CSK:LP
M    %H\;[U?L##*Z;LC0VISU'AJ>1%>2A;;QDE1Z*2XE2#YE_&(R%!92L6)F
M-&!]J8@S:7&H\BLRJLRY BMM-LLE"FO1TFE#"4-D:R1O'NI+KY]T7 QLL^'?
M.&ET6Q.K"*%%JT-3+M4<22T1"-*BWS29I(RT/7F9"@\IV&-,PBP1M6Q:1<[-
MWP:3*JSK-=8;2VW+.7-=?6DD(4HBX*EFV?/N>$,E0
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M_97V2W[$[I]X[B\0#LK[);]B=T^\=Q>(#=AYUGD8]3_:WXNQ\R'G6>1CU/\
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M&_H2E?F;0]T
M
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M'[3+7^0X(!AQ]3RP_:9:_P AP0''G6U9@
M                         ,<<U92#P)Q Z*F2I\Z:KAIBDX;YGN+TX9-?
M3#/O;O\ \A:'9SIG)RHX>%4$3D2O+"XN(FH$^F41>6LG=XA2?II%IZ'7EIU<
MAD=CE>*[%PPNNZ&X+507289O%$=)"FW]$F>ZHED:>YIS(^\* RBXH/8OX%VE
M?;U(CT-RKRJNTJG1D-(98Z'.>8(T)92ALC7N;QZ)+F?/GJ R=
M                                                 '0J'^JR_P "
ME?Y*QWQT*A_JLO\  I7^2L!%NV2OIQFU=_#,,?DYP2GD>A+W?C,18=DKZ<9M
M7?PS#'Y.<$IY'H2]WXS ?H
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ML6C?T)2OS-H>Z
M
M
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MK3VL./J>6'[3+7^0X(!AQ]3RP_:9:_R'! <>=;5F
M                                 M%CC:+-[X8W5;+]4;HS55AJ:747
M22:(W:J[91*-)&7/J,_=% 91L,XN$N!EIV/#N)FZ&*5*J[J*S'2A+4DY<UY]
M22)"E)^E&O</0SYEW.H=[-9TCZ!.('1ND<;RM5P^C<3C^A5^]\/M_8W1:'9S
M]+_<H8>=.Z9TGRPN+B=/X_2?]J2=W?Z1]-TTTW=[N=7(!G8
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M<$IY'H2]WXS ?H
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M7YFT/='A6Y_L6C?T)2OS-H>Z
M
M
M                               #R:W)=B4NJ2&3(G(]*J,AO4B,B<8C
M..(,R/D9$I):D?6,!LC&.%]XOKQ.*\I<:3YGJNJ+3NCPXT7<:*6^UHO@(3OG
MNH26JS,9^5=IAZG5%N0[P67*;.;><T,^&RY'<2ZYRZ]Q!FK3K/3D,),FEB85
MV:K$0\.+V3=WEE5#=K)%$7&\KWSE/JX1[YGO]NI2-2Y<M0&=I=1>P0Y NH@
M          :$?)+/I0>8W\(L_P"7$#$#8J>EEY=/YBM?GA#+_P DL^E!YC?P
MBS_EQ Q V*GI9>73^8K7YX0W/F3Z0U7Q2?:VVH\\O1VG^-?NY;30 !TUS4
M                               !%2\D:_5PV>WM[>^7*:)5HBI>2-?J
MX;/;V]O?+E-& YS^A-9W6O;4,[S;],Z/ON>RK3VL./J>6'[3+7^0X(!AQ]3R
MP_:9:_R'! <>=;5F
M         M%CC=S-D88W5<S]+;K+5*AJ=73G322)/:J[51J)1$7+K,O<% 91
ML3(N+6!EIWQ#MUFUV*K*J[2*-'4A348XDUYA2B-"4I^FFC?/0BYGW>L5]CE9
MR[ZPPNNUVYS5/75H9LE+=-"6V-4F6\HUF2>[KS,N^* RBX7O808%VE8CU7CU
MQRD2JNZJHQEM+9?Z9.>?(D*94MLS1O[IZ*/F7/GJ R=
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M%@V2GIQ>U=_#<,OS!T2GT>A+W?C,%+]
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M+1ZRRG<9JU+I]3:3U[K<^(S*0G7UDND7N#U!6J
M
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M/I0>8W\(L_Y<0,0-BIZ67ET_F*U^>$-SYD^D-5\4GVMMJ//+T=I_C7[N6TT
M =-<U                                  14O)&OU<-GM[>WOERFB5:
M(J7DC7ZN&SV]O;WRY31@.<_H36=UKVU#.\V_3.C[[GLJT]K#CZGEA^TRU_D.
M" 8<?4\L/VF6O\AP0''G6U9@
M                ,<<U9R"P)Q Z*J2E\J:KAJBFX3Y'N+TX9M?3"/O;O_S%
MH=G.J<K*CAX=07.7*\L+BXBJ@;ZI1EY:R=WB')^FF6GH=>6G5R&2>-EX0[&P
MTNBYYU'178M)AJ>=I;BB0B61)4>X:C)1$6A:<R,4'E.Q.IF+N"-JWU2+89M"
M#5I56:9H3#B7&XAQ)KK"U$M"4D?&4@W#Y=WP!DJ
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MC\G."4\CT)>[\9@/T
M   .E4*A$I<&549[Z(\2&PY(D/+,B2VTT@UK/GUF22,R3UF?(B,8BT//?EJN
M.YBM*GWM,:JW2G(A'.H=1@P%OM+-M:4SY++<91$HM-XG--!E5<=NTRZ:3*HE
M7:4] FDDI#2'%M&LD'J2=]!D9$?=+J,NLC%F;PRP8*WO:D>SZ]9<-VCQB<X)
M0C*!.0IU6^M73HJ6Y*C-7;:FYKWP._QX\2]N];WH]P4RI67:-UP"N^Y:+48E
M#?I[C-03%=D074(D.J86XVV;?$2ZDG32:C21%H(QDVOY[-E-<T:]\P=MT3,W
MEMN&[S9N:])=O4*-4[*:K=9)BE;VL274II$]*0A*MXN&EO4]$C?K'P3PRR:V
M/>N(V%UDU2OU:%'1)72Y59GU"0^VT1FLHSDM;ZVC0@E'HV6JR(B[Q#"R]<Q$
M?:%8"/846-AK5&J[=E:BIN2FUF)*89MQ-#JR'#=)=2C-M2C=0TM:%(,MWK29
MZD"J.[,;LYC_ #W?.Q8SSW_#QRVCNS.L&,HDX:W5!NNN'":U33J@9T>+4X[+
ML=!$PLX3JDH22T'N*3R(M"TJO:G/+PTSX[/6XK1DE0ZK6*;B5;$SHB";34FI
M5$32HRI2$;J7SCMO%PS=)1IT[4R%P<[63.][%N+)GF%PHI[M<G94RJC5<IC6
MG2:A&N5$:+-<2LS6YNP&B=4E*25O$DB(BUT'VQ!PQN'/UG>RQ8KTRBRV<'LM
M\:J/U>JS&'HAU:I5ZFM$ZRB-*0T\DXD]"VM])*)6Z2BY=1,8W=41.8SW_7F.
M'[&*MPY/,?8.!6+^4^GV<JJR;_NNT;SH^(#C[+;B($&OM7/55J4LC4A+,8W$
M:+=3J1:$,U+VN^C8XW%;EBW15CI.6W+Q2K<A8F5YUY2(=Z59$&(W"99=-:#-
M4"JQ5,FB.MS?,M#+GH>8V<C$"^:;!M?!+""ER%8B8G).F4^ML1]4T6E0.&U4
MN+(4T;:>D4\W$IWG4&7\7GH0P?V@N4F]+3R)V_ASA!'F5$K=N2V:[>4.&:FZ
ME6EKN*%5*HZ_+;4J4\W%,I*R;4I9&CM"+0RU(SGCT]..O$3/J^O@VPX*8XX0
MXI1)=#PSK<>1YE8L.)(I!QCI\F''X1-Q%]%=)MQ276D$HEDWHHCWM3(]1H8V
MW'\,C9L>V*\_\4$7JR@VO=]\Y_;_ ,6['I]2IV$T*U;'IM4FO,R:?#JT^%;,
M>!*;;@/H:22HTYMQ"UH0?$41K,SZQ93;;ZEG'V;&O,_-%>?^*"")_AZXRDD6
MY_L6C?T)2OS-H>Z/"MS_ &+1OZ$I7YFT/=!       -"ODE-1IV0^8PRZ^):
MI<RU+0ZPDCY&(K.SMP]P^J^3K">H5:RZ'49\A%4Z1+D4V&Z\Z923TWEN,*4K
M0N^HS]SD)4GDE7TH;,;_ #EJ_+"1&*V;O\"_"+[RJ?YYC@'^T/>O6>:W(U5F
M]=LU3RY$35:N5VZICW)>W3-%5,S'9,X<[^R177;Y(T4T5U43[OQFBJJF<39J
MZ:9C,=G!E+]"O"O[7UN^]4#Q8/H5X5_:^MWWJ@>+"O 'R![NU_O[6_K5_L^'
MV>-V.,^Z-1^?O?WMS^;L\9E0?T*\*_M?6[[U0/%@^A7A7]KZW?>J!XL*\ /=
MVO\ ?VM_6K_9\/L\;L/=&H_/WO[VY_-V>,RH/Z%>%?VOK=]ZH'BP?0KPK^U]
M;OO5 \6%> 'N[7^_M;^M7^SX?9XW8>Z-1^?O?WMS^;L\9E0?T*\*_M?6[[U0
M/%@^A7A7]KZW?>J!XL*\ /=VO]_:W]:O]GP^SQNP]T:C\_>_O;G\W9XS*@_H
M5X5_:^MWWJ@>+!]"O"O[7UN^]4#Q85X >[M?[^UOZU?[/A]GC=A[HU'Y^]_>
MW/YNSQF5!_0KPK^U];OO5 \6#Z%>%?VOK=]ZH'BPKP ]W:_W]K?UJ_V?#[/&
M[#W1J/S][^]N?S=GC,J#^A7A7]KZW?>J!XL'T*\*_M?6[[U0/%A7@![NU_O[
M6_K5_L^'V>-V'NC4?G[W][<_F[/&94']"O"O[7UN^]4#Q8/H5X5_:^MWWJ@>
M+"O #W=K_?VM_6K_ &?#[/&[#W1J/S][^]N?S=GC,J#^A7A7]KZW?>J!XL'T
M*\*_M?6[[U0/%A7@![NU_O[6_K5_L^'V>-V'NC4?G[W][<_F[/&94']"O"O[
M7UN^]4#Q8/H5X5_:^MWWJ@>+"O #W=K_ ']K?UJ_V?#[/&[#W1J/S][^]N?S
M=GC,J#^A7A7]KZW?>J!XL'T*\*_M?6[[U0/%A7@![NU_O[6_K5_L^'V>-V'N
MC4?G[W][<_F[/&94']"O"O[7UN^]4#XNC#3OM+K7M:V,?\EGF:MVF4(Y5]Q^
MD] B1XYODFMT\D\3@M-[QIYZ:Z^P-X@TK[4K^$!DE]O4?Y;IXZ;]AW5ZNY]D
M7F];NZK4W:*JM9%5%S47:Z)QHKV,TU5S3/#IC=T-HYF7KU7.3DZFJ[=JIF;V
M8JN5U1/X&KHFJ8?T]<.?J>V'[3+7^1((K,49AQ]3RP_:9:_R'!%9C[Q?00
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M2VA*UZ:;RTI(EJT[F\KGIW!]00
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M%*J1I4=KT0]#Z([S(C@GVW>[I'H8R5'CUO\ V=4?Z+J/YJZ @E[*RB4FW?)
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M"+/^7$#$#8J>EEY=/YBM?GA#<^9/I#5?%)]K;:CSR]':?XU^[EM-  '37-0
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MZY_ZH=D#;*?U3=)]ZY_ZH#=( TM]D#;*?U3=)]ZY_P"J'9 VRG]4W2?>N?\
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M3G!*>1Z$O=^,P'Z
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M9'KW1#2V]GIK.SK]L-P?%# 3/;5_W?H'M?HWY@R*B%.VK_N_0/:_1OS!D5$
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MS%:_/"&Y\R?2&J^*3[6VU'GEZ.T_QK]W+::  .FN:@
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M4\CT)>[\9@/T
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MJ,KZ\%;_ &8'9)%4]1E?7@K?[,$GSZ']D?859OP9I'BH?0_LC["K-^#-(\5
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M:XII2DBWG-Y1GSZS,!-DM7G;UOGW[?HOY@P*B%.VK_N_0/:_1OS!D5$
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M:D;:(;0GI+M:J+-GU>RY%M19U;J4J+25U-#SLOH\=]];*2>4HS,DI21:=0D
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MM.0R,QSN&C6QAA==;KU&*O4J!#-R92E.\$I:"2KM#<(CW2T+3W10&42]K6Q
MP+M*Z+.M5%G4&H2JNW#H"'SDIAKCSG6WEDZ9%O<9Q)N=7+70!D\       IV
MZO\ =^O^U^L_F#P]UQYMHTDM;:35Z$EN)0:OO24>JC]8M1X%T*)5OU_3['ZS
MU\O_ *@_X?< 0Q-@GZ:SM%/;#;_Q3!-;:]"?WROC$*38)^FL[13VPV_\4P36
MVO0G]\KXP'T       !3URW11;3IKM6KTU-/I[)$;LEPNT;(^6JCZDD769F9
M$1%J9BU<;,?@O+D-L1<0J%(XBMPGVYL5R&E>N[NN2DNFPVHE=J9+6DR/D?=
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M=_#,,?DYP2GD>A+W?C,!^@
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MD."*S'WR^AP
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M/4AM7TQ!&1]N1)U(:_['PWN[$S%W:-X&6SAS6K2C8QT^Q:KAY.D'+=:E)MJ
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M@W8%+PTPZMBT*2P<>- I[,IULS/E.G-IDSM=>[TEQP]=?<%T@4    /'K?\
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M:12>.Y)Z*E^$ZMW1YSMU;RN?/4R(]-1+D1Z$O=^,P'Z
M                                          !P?,C+UAK2SHY9;IQJ
MQLRS7O0ZG A0,,I]<?JK,J3$9=DIGDSN$PA]Q#CN[N'O<$E::\RYC9:?4?L'
M\0TK[26X+CI.9C)1$H]3J<*'4*K=":BQ"<DH8E)04?AE*)E1(4E.I[O%UTYZ
M -SD!A4>)$:49&;,.,R9EU&;3*$&9>ZGEZP[H\RDJ4J! -1F9G3H2E:]U1QV
M]3/US,>F       #0GY)5]*&S&_SEJ_+"1&)V;I__0OPBY*/M*IU%K_]8,A*
MI\D,6#=N)>RMS 6?9-#F7#<=1\SJX5*@M./29'1ZHEU9(;:0M:M$\S(DF((N
M73,IG1P!P;M/"6+DUNVNLVMTQ"*H9SX_22?>->O!.$9ITZAQ_P"S-S3Y<YW\
M@<F:'D'2TZO4Z;E6-5=MU7[-B*;/N>Y;VHJO5T4SY]5,8B<[\XPTSGOR1K^6
M>3M+I^3[,7KMO5^5KIJN46XBCR=5.<UU4Q^-B,1F>G$M^?/O*_JJ_0'/O*_J
MJ_0-/'[O?.SZAZZ_QB?XD'[O?.SZAZZ_QB?XD/F[[R7V1_[%L]']8Z'X/Z?M
M^KM<P^X7G-[RM_K-CL_2=_J;A^?>5_55^@.?>5_55^@:>/W>^=GU#UU_C$_Q
M(/W>^=GU#UU_C$_Q(/O)?9'_ +%L]']8Z'X/Z?M^KM/N%YS>\K?ZS8[/TG?Z
MFX?GWE?U5?H#GWE?U5?H&GC]WOG9]0]=?XQ/\2#]WOG9]0]=?XQ/\2#[R7V1
M_P"Q;/1_6.A^#^G[?J[3[A><WO*W^LV.S])W^IN'Y]Y7]57Z Y]Y7]57Z!IX
M_=[YV?4/77^,3_$@_=[YV?4/77^,3_$@^\E]D?\ L6ST?UCH?@_I^WZNT^X7
MG-[RM_K-CL_2=_J;A^?>5_55^@.?>5_55^@:>/W>^=GU#UU_C$_Q(/W>^=GU
M#UU_C$_Q(/O)?9'_ +%L]']8Z'X/Z?M^KM/N%YS>\K?ZS8[/TG?ZFX?GWE?U
M5?H#GWE?U5?H&GC]WOG9]0]=?XQ/\2#]WOG9]0]=?XQ/\2#[R7V1_P"Q;/1_
M6.A^#^G[?J[3[A><WO*W^LV.S])W^IN'Y]Y7]57Z Y]Y7]57Z!IX_=[YV?4/
M77^,3_$@_=[YV?4/77^,3_$@^\E]D?\ L6ST?UCH?@_I^WZNT^X7G-[RM_K-
MCL_2=_J;A^?>5_55^@.?>5_55^@:>/W>^=GU#UU_C$_Q(/W>^=GU#UU_C$_Q
M(/O)?9'_ +%L]']8Z'X/Z?M^KM/N%YS>\K?ZS8[/TG?ZFX?GWE?U5?H#GWE?
MU5?H&GC]WOG9]0]=?XQ/\2#]WOG9]0]=?XQ/\2#[R7V1_P"Q;/1_6.A^#^G[
M?J[3[A><WO*W^LV.S])W^IN'Y]Y7]57Z Y]Y7]57Z!IX_=[YV?4/77^,3_$@
M_=[YV?4/77^,3_$@^\E]D?\ L6ST?UCH?@_I^WZNT^X7G-[RM_K-CL_2=_J;
MA^?>5_55^@.?>5_55^@:>/W>^=GU#UU_C$_Q(/W>^=GU#UU_C$_Q(/O)?9'_
M +%L]']8Z'X/Z?M^KM/N%YS>\K?ZS8[/TG?ZFX?F7\57>]"?Z!I7VI7\(#)*
M?/3S=1^X9?\ MNG=\5#^[WSL^H>NO\8G^)#&S%6JYO,XV/.6N37\KMUV+$L&
M]*=(<D+9G2VWFGZO"<<<6KH:":2TE!F9F?/3P;U]C7[%O/7F]STY&Y8Y6Y+M
MZ?0:2K4S?NTZW279I\II;ENC%NW=JKJS57$;HW9S/3C/\V.:?+O)W+>BUFLT
ME-NQ9FYY2NF_9KQM6JJ8\VFN:IS5.-T3CI?U9\./J>6'[3+7^0X(K,4E8##D
M:Q+*C/(-MZ/:5N,.MJY&AQJCPVUH,CYD:5),CU[I"K1];NQ@
M
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M7].)*5&24N;Q)+D1$0RT !P1$DB(NHB(B]@NH<@        -46VJ]+?S(?T
MS\:AKB\BM^ENV]_3ER_+\H;'=M5Z6_F0_H!GXU#7%Y%;]+=M_P#IRY/E^4 D
M\EU%[!?$.1P747L%\0Y     ="H?ZK+_  *5_DK'?'0J'^JR_P "E?Y*P$6[
M9*^G&;5W\,PQ^3G!*>1Z$O=^,Q%AV2OIQFU=_#,,?DYP2GD>A+W?C,!^@
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M\':9XN'F'M#[$K3^#M,\7%6  I/S#VA]B5I_!VF>+AYA[0^Q*T_@[3/%Q5@
M*3\P]H?8E:?P=IGBX>8>T/L2M/X.TSQ<58 "D_,/:'V)6G\':9XN'F'M#[$K
M3^#M,\7%6  I/S#VA]B5I_!VF>+C](LJTFUI=;M2U4.(,C0XBWZ8A:3+F1I6
MF/O),CYD9'J*J !P1$DB2DB2E)$24D1$1$1:$1$7(B(N1$7(B'(
M
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M&G%TW2W>KD6H+LH393_;6K?P,N'Q4.RA-E/]M:M_ RX?%0,MQ"LF.7A6"\3
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MF?5H']#[#CZGEA^TRU_D."*S%&X<D:</;$2?65FVP1Z\CU*B02/4N0K(
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MR<X)3R/0E[OQF _0
M               .#ZC]@_B&E;:37)<-&S,9*(5(JU1@0ZE5;G*H1XCS[;,M
M+91MPI"6E)2LDZ\B61Z=P;J3ZC]@QK:SF8DX,6;C3EJHN(^'J;NN2Y)]:;LN
ML'.=BG;KK!,])632"T?XVJ2[?JW>0#8G25*5 @&HS,SIT)2M>ZHX[>IGZYF/
M3'2@+:7$BJ:1N(7$C+;3U[K:F4&A&O\ RI,B]?0=T
M
M
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M6B4D1%J?5X &;@      #XOQVI+3K#R-]I]EQAU)ZZ*:=0:'$G]\E1E[H^P
M-9-\[(39_P"(]VUN][PP#I%8N2X'BD56HO2'#5)=(S/>W3,R3S4?5WQ27G)F
MS8]3?0O[90VQ@ U.><F;-CU-]"_ME!YR9LV/4WT+^V4-L8 -3GG)FS8]3?0O
M[90><F;-CU-]"_ME#;& #4YYR9LV/4WT+^V4'G)FS8]3?0O[90VQ@ U.><F;
M-CU-]"_ME!YR9LV/4WT+^V4-L8 -3GG)FS8]3?0O[90><F;-CU-]"_ME#;&
M#4YYR9LV/4WT+^V4'G)FS8]3?0O[90VQ@ U.><F;-CU-]"_ME!YR9LV/4WT+
M^V4-L8 -3GG)FS8]3?0O[90><F;-CU-]"_ME#;& #4YYR9LV/4WT+^V4'G)F
MS8]3?0O[90VQ@ U.><F;-CU-]"_ME!YR9LV/4WT+^V4-L8 -3GG)FS8]3?0O
M[90><F;-CU-]"_ME#;& #4Z6Q-V;):Z9<*&6I&7)Y1<C+0^9#.[ '+C@_EFL
MB+AY@Q:,>SK2B&M4>DQW%.-MFXX;B]%*/7FLS/W1?0        !T*A_JLO\
M I7^2L=\="H?ZK+_  *5_DK 1;MDKZ<9M7?PS#'Y.<$IY'H2]WXS$6'9*^G&
M;5W\,PQ^3G!*>1Z$O=^,P'Z
M                      !P?4?L&-6.>C+IB3C!CQE5O&S84.31<.:C7W[E
M<D3XD5QA$TF. ;+4AQ#D@SW%:DT2MW0M>L;3CZC]@QIFVCE\7;;.9+)A2Z!6
MIU.I]<JES(J\:,MY+4U#)1^&3Y-J2D]W7M=XCZP&XRG,K8APVG"(EM0HK*R(
M]>W;90E6GK$9'S[H[P\VE+4N! 4HS,U4^$I1GW5*8;,S]TS,QZ0
M
M
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M0VG$'ZZ5I4D_8 541$1$1$1$1$1$1:$1%R(B+N$7<+N ,2RKD
M                                         !:7&VJ6Q1\-+IJ-W4XJ
MI;\:&:JE!-:FRD-;IZIWD\RY:\R(4)E.N&P+HP1M2LX:4(K=M"3*JR:;2DO+
M?*.XU-=1)5Q%Z*5Q'B6OGU:Z"J<P5HUF]\);QMF@M(>JM5@FU$;6XAI"EF1E
MHIQPR0GKZS,6XR5X9W3A+E[LRQ[PC-1:]2IE:=F,,O-2&T(EU!]]DR=94IM6
MK:TF>A\NH!EF
M            .A4/]5E_@4K_ "5COCH5#_59?X%*_P E8"+=LE?3C-J[^&88
M_)S@E/(]"7N_&8BP[)7TXS:N_AF&/R<X)3R/0E[OQF _0
M                                            .#ZCUZM!KKS@7]@3
M:F,>7.DXI66FY;JK\VM(L.IG*>8.B/,DSTM1-MENN\75)=OH1:=T;%#ZC]@Q
MJRSS9<L3,8L=\JUY653XTNB8<5"OOW.\],C1EQVYQ,\ VFGUI6\9[BM2;(]W
M3F VA05LKBQ5,IW&U1(RFT\SW6E-)-M.I_R4Z$.X.C3F5L0X;3A$2VH45E9$
M>O;MLH2K3UB,CY]T=X
M
M
M                         'A7'O>4M:W=[7RDJNF[KO;W0W=-W3GO:]6G
M/7J&KC9HJJBEXS^6*ZJO2O*X/EBJ6>B>GROW@I)^A^\Y::$-J-7DE$IU1D&V
M3I1Z;.DFV?4X3$=;AM^MO[N[KWC,849.,<J?C"K$0H5F1K4\SU45%<Z.MM73
MU%*>;XBR;0C0]4&KGKS/K 9TEU%[!?$.0+F1'WP
M
M                              8_YFJU4J!@I?55I4I<.?$IZEQY#>N^
MVHDJT,M.?<%J\@EU5V\LL5AU^XZB[5*M,G5]$B8\9\1U+-2D-MDK4S/M4)(B
MY]7@%]\<)]JT[#&ZIEY4[RUMQB&:JG XBF>D-;IZHXB.V3W>9"@<H]9PYKN!
MEIU+"VA>9VS'Y5732Z5QW)'1W&YSR92C==T6KB/$I?/JUT]D,FP
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M_)S@E/(]"7N_&8BP[)7TXS:N_AF&/R<X)3R/0E[OQF _0
M                                            .#ZC]@QITVB.)U[6
M3F-R;T.VJ_*I5,N>J7*BMQ&=[<J"(Y,<(G=U1%VF\>FI'UC<6?4>O5H-<&<>
M[LOMOXSY;J=BS9/FENZKSJTG#VI],?C>4C[9,],7PFBW'N+JC]\TTTY=9@-A
M]+<6Y!@K6>JEP(:U'WU*80:C]TS,QZ(Z<!3*HD53*=QM42,IM/,]UI323;3J
M?\E.A=\QW
M
M
M                 >95XIS*;48Q+)!R:;/C;YZ:(-^.MLEGKRT2:M3UT+0N
M8PER:X#2,&58B&_<D.O>:.J'*3T5R.LXA=*?=W%\%Q>Z?;Z=MIS(9H7'KY2U
MK=-1'Y25;3=UWM>ANZ&G3GO$?5ISUZAJWV:#M2<7C/T]ZIO:5Y?"\L%R5[I=
M/E_O)2%'HGN=KRTT ;92Y$1=X!P747L%\0Y
M
M                          6.S$6I7+SPAO.V[>C(EU>J05-0V''4,I<6
M:5%H;CADE/7W3+V1;7)#AO=V%676RK*O:"W3KBI<RMNS8K4AJ4VVB54'WF32
M\RI3:MYM23Y'RZCYBN\S-;J5OX*WU5J5*5#GPZ>I<>0CDII1)4>I::=XN[W!
M:O()==>O/+%8=P7'4G*K5IDZOHD373/?=2Q4Y#;9'J9\DH21$6I@,U
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MOS!T2GT>A+W?C,%+]
M                 X/J/V#&J3/CEYQ5Q<Q\RGW?8E%C5*@X>5&X7[JDO3XL
M5<)N:3'1S::?4EQ\U;IZ\(CTTYC:V?4?L&-.VT0Q1O>Q\QN3BA6S<#])I=TU
M2Y6JY$:,R34$1RC\)*]%%Z#>/K(^L!M[IK+C$*$VX6BVH,1I9:D>BVV4)67+
MO&1EKW>X.^/.I;BW(,%:SU4N!#6H^^I3"#4?NF9F/1
M
M
M                                                 !YE7D(BTZHR
M'&B>0Q39TA;9\N(AF.MQ36O_ ,0DFGW1A+DVQGM?%A6(OF=L!BRO*&J*C3.%
M))_RR7TI]OBJT2G<[9!JT/7F?6,V:Q%7,IM2C(,DJDTR?%29F1:*?C.-I4>O
M+0C46O<[XP?R7X!U[!96(YUJI0I_FDJBI<;HDB,]PD'*?=T<Z.M>ZK1PO1Z<
MP&>A<R(^^ X+D1%ZPY
M
M         6CQO?L]C#*ZG;YB],MA$,_+6,2EM\5G=/4MY';)Y:\RU/\ (*"R
ME2\,)F!UIR,(J<=+L5<JK%289NNNFTZF:\4LS<>[<]]\EJY]6NA=X5)F-MFM
M7=@[>MOT"*4VJU& IN''-:6R<6:5<M]>B4]?6?+\HMED9L"Z\-,M]D6A>=.3
M2K@ILVN.3(27FWTM(DU%]YDR<;,T*WVU$KEU=7K ,P@
M                                !PHB41I,B,C(R,CYD9'UD9=TC[I=
MTN0Y !XC-N4)B0J6S1J4S+6>\N0U3XJ7#/O[Y-$HCZN>NNH]"7!ASV#C38L:
M7&46BF)4=J2RHNX1MO)6@].YJ7+N#M@ Z$&ETZF-FU3H,."T?_JX<9F,CO\
M-+*$)/GS+4N7<'Q\I*2=1\MCI\151+JFKCM*DHY:?2WC2;B.7(]U1:ER'J@
MZ-1ID"K17(51B1IL5TM'(\IAJ0TON\VW4J0>A\]=-=>9#QH]!H]OTR7$HU-A
M4V/T.69MPXS,?>,VUGVYLI3OZ'Z$E:[O<T%3CH5#_59?X%*_R5@(MVR5].,V
MKOX9AC\G."4\CT)>[\9B+#LE?3C-J[^&88_)S@E/(]"7N_&8#]
M                                                  X/J/7JT&N3
M.+4\ML+&;+>QC)0#JUZ2IU:+#664B2T5/?231SC-#!;CF_VG[YU:<N8V-GU'
M[!C4OGZP)Q0Q1S Y2;ILBWVZM0K#J5Q/71,5+98.GMRR8Z.:6W3)3N_N'Z C
M,M &UV";)Q8IL%NM'$C&T7/DR;23;+W$;I=\=P>?3&ELPH3;B=U3<&(TLNO1
M:&$)47N&1D/0
M
M
M                   !X5Q&HJ+632:B45$JII-.N\2BANZ&G3GO$?5ISUZA
MJ]V:DRL2EXS>6DNIR=RO*)CRP<E.;B>G2N3)2#,B+33DCEU=S0;3:M(;BT^H
M/NM$\VQ3ITAQLSTXC;,=:UM:]SB)(TZ^OX<,,H&,5EXIJQ!*T[#9LSRCJ:H\
M_A2"?\L7"DO-FZK1"=WMD&O3U^7? 9P%U%[!?$.1P747L#D
M
M                                     !87,G<-6MC!F]ZW19?0JE @
M*<BR222N$LDJ/>(CY'U:\S[^@M=D.O>Y,0<M-BW3==2.JUNH3:\B5--"4&ZF
M/4I#31;J>1;B$DGEWA?7&E=F(PWN=5_-<:U"B'Y<-D:T[S&Z>I:M]N7+7JT/
M\@H7*H[A2]@K:Z\&HYQ; .352H[)J=4:7BF.]-[9[Z8>LC?/MO#H R0
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M\+K_ .3=]?\ *.X
M
M
M                      #RZQ%7,IM2C(,DJDTR?%29F1:*?C.-I4>O+0C4
M6O<[XP?R7X!U[!96(YUJI09_FDJJI<;HDB,]PDG*?=T<Z.M>Z>CA>CTYC->X
MC45%K)I,R45$JII-)F1DHH;NAD9<R,CZC+F1]0U=[-.=59B\9O+*;49?#KRB
M9Z>[(=-M/3I7)HI"CT3IIR1R[@#; 7(B+UAR."ZB]@OB'(
M
M                                    "Q68VV*U=V#MZV_0(A3:K4H"
MFXD8UI;)Q9I5RWUZ)+K+F?(6RR,8?W7AIEOLBT+RIJ:57Z9,KCDR$EYM]+2)
M-1?=9,G&S-![S:DJY=7Y!<C,G<-6MC!J]ZW19?0JE @*<BR="5PEDE6AD1\C
MYEKU]\6OR'WM<F(&6JQKHNNI'5:W4)M>1+FFA*.*F/4I#31;I<BW$))/+O>X
M S*
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MH7>+P$.0 <:%WB\!!H7>+P$.0 <:%WB\!!H7>+P$.0 <:%WB\!!H7>+P$.0
M<:%WB\!!H7>+P$.0 <:%WB\!#I32+@2.1?ZI)[G_ ,)0[PZ4[]XD?@DG_*4
MA*9'/^TEYK?YZA_(#PFYL^A/[]?^(Q",R.?]I+S6_P ]0_D!X3<V?0G]^O\
MQ& ^H      X/J/V#&I;/U@1BABEF"RD759%OMU:A6'4KB>NB8J4PP=/;EDQ
MT<R;=,EN[^ZK7<ZNZ-M)]1^P8U$;03&7$3#K,/E!MNT+@52*->53N-JXX:6D
M+*H-Q2C\%)FKFG<U5U=_N -M%,:6S"A-N)W5-P8C2RZ]%H80E1>X9&0] >?3
M'5NPH+BSU4Y AN*/OK6PA2C]TS,QZ
M
M
M                                     /+J[[4>FU%YYGC-,TV<\ZWK
MIQ6FH[BW&M>YQ$D:=>YKJ,)<FN*5@8C*Q$\Q5@MV4=(JBF:D:):I7ED[TIY!
MNJ(TEN=NA2]"UUWM!FS68KDNF5..WIOR*74(R-3(BWWXSC:3,S,M"WE%J?47
M=T&".2+ J[<&U8EG<RXBO-%5E2H719<:29-G+?<[?HZU[A[JR]'H>H#8$747
ML#D<%R(B]8<@
M
M  +2XW>8_P"AG=/FZU\R_0S\MMW?UX.Z>O[WV_5KKIS_ ""@LI?T+_H'VI]"
M#_<3I56\J->-KQ>FO=+_ '[Z9^_[WHNYU<A[N9.WJM<^#5[T2BQ.FU*? 4W%
MC:DGBK-*M"(SY%S/3J[XM?D/LFY,/\M5C6O==-.E5NGS:\N7"-:5\),BI2'6
MCWBY'OH42N7?]T!F4
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M&VHN\M#"$J+W#(QZ
M
M
M                        /#N)2DT:LJ29I4FBU523(]#)28;II,M.Z1\R
M,:PMFS7:U65XR>6]2FSRCUY2(_2W7G2:3T^41);)U2C(M"(M$Z<B]@;1JNZP
MS3JBY(:XS+=-G./-ZF7$9;CN*=;Y=6^@C3KUEKR&$F32^\++R5B)]#BR4VCY
M750VJP:9:Y/E@^4I]/%/?(MSMTJ5H7+GH SM+J+V"^(<@740
M
M                                       +%9C;FK5HX.WK<% E%"JM
M.@*<AR#0EPFUDE7/<7JE75U'R_*+99&;_NO$O+?9%WWG44U6X*E-KC<R:EEM
MA+J(U1?99(FVR)"=QM))Y=?7ZXO-C>Q9[^&5U-7S*Z';"X9^6LDDK<X3.Z>I
M[J.V5RUY%H?Y!064J)AA#P.M./A%43JEBHE58Z3,-IUHW7537CED;;W;EN/F
MM//KTU+O@,F0
M           !^%MH<2I*RU)25(5ZZ5D9*+W2,?L &JO&W8O[/3,'B3<&+6*&
M"JZS?ETK9<KE;B7%5Z8Y/5'3N-&ZB$\T@]Q/(B,6H['WV6_VAJG\-[E\<&ZL
M &E3L??9;_:&J?PWN7QP.Q]]EO\ :&J?PWN7QP;JP :5.Q]]EO\ :&J?PWN7
MQP4=B'Y'_P!F7%L*\WZ)@-5#K35LUQ5(2F]KC4I54*F23@$252U)/63PBT41
MESYEH8WN#A2241I41*(RT,E$1D>O?(^1EZP#^8CDP\BJYG,Q6)%P7-CLM>!6
M$*;PJJZ&V\AJMR*S0V*Q()IC=0ZF0QOQ4H;)Q:=[M][74AD?GKV<.7?9T;0_
M9XX?8$4*335U>KU9%SU)^H3)15>1%*$:7VX\IQQ,3><-:S2UH7;<^H?T5>CM
M,M)0VA#2"46B&4);;3J>IF2$D22,^Z>G,^?7S$*O;V>FL[.OVPW!\4,!,]M7
ME;UOE_\ A^B_F# J(4[:O^[] ]K]&_,&140          #YN::%KU;Z=?"(V
MUT8N0</]M:BU\;)OE=:]YL):PDE5PS;M]*H]#TK"3D2=(#6\M1$9.J+4^KGR
M$DT899M<AV7/.?3J+%QLLXZO.MMQQR@UNFSI5'JU.-Y:5/$W4*<IF7HYND1E
MQ=-.75J0)B>.>F,=S"/-IAQEYB8+9R96!M(@O8DW;!MV7B5)HZRFT^I(B)6[
M3W(Q1]^ DF6=XUG%(^?,SUY#5CB_<]IGY'\H,!=7ISTQJ_*(T45,AAZ='<8Q
M 9)TELDLY$;=/0NV2C>(O6Y24,%,GN". ^'55PSL:W7TVY7J>Y3:RFJU&55Y
M=1C.-+9W7ID]QU\S2A:B2HU&:?XO4,5XFQ_R8L6==N'SMDU&39-VU2/6)= >
MK]4<AQYK,XZCQ&&EO&VUORC-PR:01:^QJ"8F-W'=5$]^-WR=G'J:D,^;=L5Z
MY]E%TI5/FQW:54$FM3K"M_<@4TC0XO4]2U[7<7U^AT[@R&VKMZ43 K%[(U<E
M5X5DX*.%/BX@5FC4A*:7'EOM0V:&NJ1Z>RVR\E<IQO=<D$9%Z(SZS&S.\-FA
ME8O8\-BKMH2GV\(C-6'J3K$\CH2E\(WMQ9N[SQ.&TC4E'H1%IIH+_P".>5_!
MS,=A3(P;QBM6/=ME2(<>&J(\M3,IEN&E*8JH\Q'^D,+;W$*WVEI,S3S,#,>;
MNSC.?E8"4S /*U=.:7 S,=*ONEWMC'!ICS]C2[8?2VP46;2V6W4U6-1WE134
M4124H34$[R5$>[HK4;?T\R)7\HB,_ ,"<INSARS9-Y,Z=@];55B3YJM52JS<
M%5KIQTD:MQN*FJ/O]&2E)[NC.Z6A$0SX(M.1 IGY^_Q(          .E._>)
M'X))_P I0[HZ4[]XD?@DG_*4 A*9'/\ M)>:W^>H?R \)N;/H3^_7_B,0C,C
MG_:2\UO\]0_D!X3<V?0G]^O_ !& ^H      X/J/V#&I?/UCMBAA=F!RDVM9
M%P-TFA7Y4KB9NB&J(R^=0;B$QT<DN.D:FMS?/T!D9ZC;0?4>O5H-<F<6F9;I
MN,V6]_&2OG2;TBSJT>&L0H\EXJA(4373B-;![C>YHC7B:ZZ\@&PRF.K>A0G'
M%;RG(,1U9]6JUL(4H_=,S,>@.G!)DHL4F#WFBB1B:/GS9)I)-G[J-T^^.X
M
M
M
M     #RJU%<ETRIQVM-^12ZA&1J9$7$?C.-HU,SY%O&6I]1=T8)9(\"+PP:7
MB6=T]%_ZQ5=4J#T>3&D'PSEON]OP%JW#W5IY+(CUY>L,Y[A<6W1JPM"C2I%&
MJCB3+K2M$-TTJ+UR/F0UF[..Z[CN5>,'E]5)=1Z%7%-Q>E*<5P4=.DI(D$M1
MF1:$7).G4 VF%R(B]8<C@NHO8(<@
M
M                  +"YD[>JUSX,WQ1*+#.=4I\!3<6*D]#>6:5%ND?/OD7
M4+6Y#K)N3#[+38MKW73%TFMP)M>7*@K/>4RF14I#K1F9$1=NA1*]T7<S#W97
M++PBO*Y+=E)AU>EP5.PI"FT.I;625'O&VOM5=74?+UA;7)%B3=V*V76RKVO>
MH(J5Q5696VILMMAN.EQ$2H/LLD331$A.ZV@BY$6O6?,!ET
M                                                           ^
M;OH2^^3\8A2;>STUG9U^V&X/BAB:V[Z$OOD_&(4FWL]-9V=?MAN#XH8"9[:O
M^[] ]K]&_,&140IVU?\ =^@>U^B_F#(J(
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M6XRA2ST+OJ49CO@
M
M
M                      \VK.1VJ?4')+?$8;ITYQ]&NF_'1'6IY&I?RT$:
M?=U&&&3^\L(+K5B#]"ZU$VT<"J&W7-)+C_39!27DFX?$(MWZ8E:M"Y<].H9E
MUJ,[+I=3CLD1N2*54(S9&9$1NOQG&VR,SZB-2BY]P8#9&,#[[P@7B<=Y1(T;
MS0U=4JG='F1I6^T<M]W5? 6K</=6D]%D0#8>740#@NHO8(<@
M
M                                      +48TP[/G8;71%OF;T"V'8B
MBJLO<6YP6329&K=1VQ\M>H4+E3IF&-(P4M:#A'53K-C,RJJ=)G\)QGC.KFO*
MEIX;NKA;CYK3SZ]-2Y<QZ.9JB5*X,%;ZI-*BKF3YE/4B/'1KO.*-*M"+34^[
MU>N+69!;4KUF98[#M^XZ<[2ZM#G5]<F&]KOM)>J4AQLSU(N2D*(RY=7A 9I@
M
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MI]\AVQYU+;6W!@H66BD0(:%%WE)802B]PR,AZ(
M
M
M                                             /$N!Q;5'K"T*-*F
MZ-5'$&76E:(;II47KD?,AK-V<EWW'="\8?+ZK2JGT&N*;B](<6LF$%.E))*-
MY2C(M"(N6G(ALZJZXS=.J*Y3?$8139RY"-=-^.F.X;R-2ZM]!&G7N:ZC"C)Q
M<N"]?/$/Z$UI^9HXE4-%>/I;TCIDGI3Y&Y]-(MSZ82U:%RYZ ,Z2ZB]@AR."
MZBTZM!R
M                                                          L=
MF(NNN69A#>=R6])1$J]+@J=AON-(>2VLDJ/4VW"-*NKND?L"VN2'$B[L5<NM
ME7K>TYNHW%5)E;:FRFH[45MQ$6H/LLDEEE*6T[K:4ER+GUGS%WL<(%JU'#&Z
MH=Y5'RJMQ^&::G/X:GNCM;IZKX:.V5W>1"@<I%'PZH6!MITW"VN^:*S&)575
M2ZKP'(_2'')SRI23:=[=/#>-2.?7IK[ 9-@
M
M                                        #@^H_8,:I,^.8;%7"/'S
M*?:%B5J-3:#B'4;A8NJ,] BRES6X1,=')IU]*G&#3O'KPC+77F-K9]1Z]6@U
MP9Q[1R^W!C/ENJ.+-[>9J[J1.K2L/:9T-^3Y=ON$STQ'%:/<9X6B/WS777EU
M& V(TUYQ^%"<</5;L&(ZL]"+5;C*%+/EWS,ST[G<'?'3@)93$BI95OMIB1DM
MJYEO-):23:M#_E)T/OD.X
M
M
M                            #R*Y&>E4JJ1V$[SLBDU&.T1F1$;KT5QM
MM)F>A%JI1%J?(AK\R'X)XBX2*Q2.^J2Q3?+^L*DTO@S(\HGF3F2'"4K@J5N=
MHM)Z*(CZRT&P"ONN,TBKNM*-"VJ/4W4*+^*XW$=4A7LI41'[@UM;/#$&[KW7
MBZ5SUE^J^5E;4U"XVOTALILE&ZGF9Z;J2+EIR(!L^+J+V"'(X+J+V"'(
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M@#D U(NL] U[O<
M                  &/6:&F3JO@A?E/I\9R7,DT]26&&B4I;BMU7)))(U&?
MK$6HM/L^:!5[:RN6!2*W ?IU1C3K@4_$D(4AUM+E3D*0:DK)*B)23(RU+NB^
M.8.[:Q9.$EXW+0W&VJI2H)NQ%N--O(2LB,]5-N$:%=74HM!;?)5B5<^+&7JR
M[WNZ0S(KM5F5IJ6['CLQFE(B5!]ADDLL)2VG1M"2/1):GS/4^8#+0
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MM.W<90I6GK&9GR[@[P
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MS]P47@_C7AMCM:;5[87W&Q<]M//R8S5382:6UO1'EQY""U[K;J%(/NZD NP
M!J  .-2[Y>$ASJ7?ZNL  -2+K/0<:EU:EJ Y <:EU:EJ.=>YW0
M
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MUR$_3ZC'G7 IZ+():76TN5.0MLU$X1+[9)D9:EU<_7 9N@
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M25$?<4F.V1D?KD9#T@
M                             4M>=X4.Q+:JUU7#+3#I-&BN2I<A1&I*
M$H0I1$9)Y]L:=->YKJ8JD6.S$S+)A8/WNO$&*[,M%^EOPZRRUQ=\F)C2V#=3
MP2-W5DEFYHGKW>L!AM$VA[4^3859AX;/5'#C$"IU&FT2]*7455)K?ITOH;RY
M$6(VZJ.7&T+Z<:-.?<(75Q4SA^9RM7+;.%]GQ\3+CL>EQZS>E,*KLTPZ%3WX
M7E@3AK=U2\LHA+<-">VU2:--[41]+.CXQY KKPEO7+MB@6/^33%:MW)%1@W*
MH;)5"Q9D^<N.MUJIS2DU1PBJ<HY!FE*"(F_Y/,5E@5F#P6P&SU9M<(LX$RM6
MI5\2:;:,^PJ_(BU1VGUZ%-I!SJG ;D,I*(ST*-(Z(I)N:K,C(BUU(BK9XXW_
M ,<QF)CBW0X6;3#+WB?EWGX_P*VF%3*34%46JT1UMY,R/6O+%5)1#;;<2AY]
M*YZ>%Q6TFDB[?J,C'GT#:&TR!CYAW@+BOAW4\/K@Q<9FR\-IR"EU:%7(4&*4
MU^1)DQHYQZ<DHRT+(I+B==XR+J,:1\^]!PGPQP&L3'S*A8U63@%9MVPYF(S<
M)JI.)KOEA<+'^G'35-F\:8KQNR%&VTLM"-6NG,;FK(S;Y6<PC>%/T-G8=\8B
MU>P*C LN6FBNMR[=J*K<Z/+:5+>C<2$XAY7#T<6WJI':F9<B$QB,[\;X[L8X
M]O[.I=.]L[$?S;7]86#5E_19K^%D5F=B W$GE"9H<1Z.J4AQ#YH<;EJZ.A:C
M0SVQ*3NF6HMS2=J+@97LL=Z9CJ,MR;!PZFLP+WMHFY*:A093L]5/)#[)M]),
MC>0O=5PR)9)U+D8UO;)&ZY.%&87.S@GCH\Y2<2(\QB>J36T.-MUZF26Y\Y+,
M:<^DF)/ A+2CA-NK+J29$?(8M6I8SMI6YM5\8"@/P\%\1JGAZFQV'(;G09+U
M*FO,U9<& I&Z7^D[REJ::[<]%&9ZZ@G$9QQX;^O./X[OVMKEQ[8K#VW;:POQ
M0DV!4%8+X@3RILG$$U3$M4.4]+:@1&W(1L<5?'F/):YF6[UGR&?>-F:^P\(X
M%AQM_P N[SQ.BQIM@VHR:TR:ZR\RQ)4HE()2F":9?0M1K3IIKWC&@7'JL66K
M8>655T,Q^BJOBU5QS12TJG$E%\PC=-N.EHY*"27-1D@BW2U/D6H]#,EBY&P;
MVB&STQDQ#\L%X"5RT'8-'N9$63,IE"EG:L"$12V&D.-LJ=FK)"3D;FZK4R/4
MN0Q'#'#:CMG'#K\?,J-%ZO7EMJ\'CK]CS[$N^#"K+M5CKJ3\V)442: 2HQI,
MMV,9MM&1F22,TJ,R/0Q)I-Y!$>BV]>,9?OB>ZO0RTZ_9$;O&W&&PJCMC,K$>
MW:B4IRX*1=Q%7X%.<?BPW)MN%Y727IK+9M.F@W6W";<=Y:;AEKJ,W:#DRSU4
M[%B->M3SU.5>PD5=Z<Y8IV-%92_ ?DFZS#Z=O;Z>$THF]_NZ:]T$3T;_ .C'
M'/;X_P F,E9H-,INVEMRL1&I#4^LQ9?E@LI+RF7^CT+1O2/O<))D7>3J9\]=
M1E[A1F#R\77G5S 650K+<@XS8=PH<N\[A6]*(Z@RBF/28B4,.()KM8S)H^E&
MH^HST/D,-KBN.E1]M%A[09$YYVJG F-*TBN$PX\W;Z2=6J01&TA3B]5;IJUU
M/=+F/AAC<UNQ]L!FXI'&)J?(MVE*428AH9?-%K/J<UED@FGU%SWDFM1DKD?,
M$SO^2B/KAD)3]KM9UY4'%J5A;AK4[UKV#\TF;GH*%2XBFHR9+S<F5QEL&DR9
M89=D:)(]XD[I&,L\*,^V#.*N5RF9HJ=4VX%G5!]VG<"2:VGFZPQ.\K5P"0\2
M'5:3R-CB$G0M-[JZ]5.S'J]H5.]MHHEAJ(HX=.E]-.136V&E$=-K&O#-UI*9
M&JB(C)&]O+TZS,AK;<K]1:V4%$OBRX-4K=KX58K5Z3B+;=.C2X\I5/FXBNFB
M04-A'2%ICLI=?+AM&1I3Z^H&S&<1UQOGMCIZM_=QWI#RMI+;]EXX8=8-XVV4
MG#:1B^<M6&5914BK#%PM1&DON..E&;-$'Z6MLR*0HC4:M$\R&PF_[DJ=OV'<
M]SV]3O+JH4JW:C5X%/2ZEGI9L4]Z6R9.*(R3KN)/PC2?8^*VS;S6N8'71;$2
M9B;B%3*93&K*IKC-8@2[?J,>)$:K*7'74&N.;3S:]2=-LG-S0M2,;M+G:;18
M=Q,LLJ;2FR*NTVQS6I"$T5Y*&>^I22W4=6JC]<%,QC''/3GU8:-\E.;7%G.U
M@;F-^C!A^_1Z0S1[T@_[22LH2*6Q58["TJ9))J-S@I/M3+=,84;-;/%3LFF0
M"C595A5.[;*H.(EWP+MK)RY?_5UJHWK+BPW.:'')J5;Y*,D*/<).A\M1D+LM
ML4+)AY><TMDRI[\*Z*/'Q \L:=*I[T5YCI*ZVMCFZA!KXJ#(TZ=>I;O60QKR
MDR;<>V)N*,B5&;6EF]KD=D(DTW669%>T]:5G'=;XZN1;R%;NFG-)Z&"KA,QC
M=M4QC,]O^J177LX^$\'"BS<3:356*JUB##9=L^E*6J,[6)2TM)>BH-?;)Z.\
MZ3:U&6A::F+ V!M(;3GX[5#+EBG::L.<59%)F5JT:&B8JKM7-"@4QVK2EHF,
M(Z.P;<-!+-)J-6\K=Z]2&A'&C$VGX;Y>]FYF,J]*K5;P!P\J5\Q,350(]04Y
M".JU)N#3'9,&*VN2:&I"M])FWHE*=2Y%RV\8;7CL_L<<7+)Q2PH@N7CBI2K'
MN1^BW6:*FT5KIF6T[TEF6;Z":>4ZR9LDV\KM33NES!&,1F<],;NB8GQ\[R[7
MVS]B8A52OTG#K#*K71*M*N+H]U)9Z<WY4$B<J&J0O_1C):2)M;NA<C)/(Q=N
M\=J1:\%O$JL6+A_.NZTL(D6VO$.X)#DFD-T?S0);X9,-26$G-..M2T+X!JYM
MGKIJ,%MB[,MF7>V=^>5+B5-=.JRI;C4FDM-=)**[4WG&V2=8[<G#039J;UYF
M1GJ>@LI7,S-GYBL+\Y[+<7Z%=O6J_ BU'#QFBK?J-9<C2)+3;YOHCMS'D;[7
M2$ZI6E"5%NZ$"9B,XQNC&=_7CH^?QB&V7&S:PY?\',*L'L7IJI%5M+&)R1%H
M$QEB7VDV+(:B2(ZTH:4HMR4YPR4O3>TU+K%N;;VPV&:<R=L8 8DV54,.RQ$C
MMOX;794"F' NA1PD2W&S6XPAB&:3=;:3Q7"WC5RUZAHDQ@O&T*ULTLFL]A?%
MIE$O^HL2W)U/<:7')R]8K31$B0WO%O:$2M"]GD-D.URP^IF,E.R6V1AK3X<W
M$RI)MRH6[.H,=E4R#"IZ*-,G$_-A(-<-*XK:RW'G$;Q:I(C Q&8[=J.[$_PX
M_.V8V9M$;/N3.%6,GM0M=VBWW2T1Y#<IYYTV)\65"Z>R_#<4VEB4DXQI6K@+
M<X9*T5H8OW1LS$*NYB;CP&IMN.OR;61&56*ZEU?"C'+C=(:);9)W>V]#Z+77
MK&J/:BX6W=@3'P)S^85T5N1B#E[H5/I-UTV&VE$RZ55^G0:(@YKI$I3RX7;F
M1K2YR(NHSU/.79WTRL7M8U1S+W?$73[RQM8A2ZK3I+7^DT\Z:GAMI-Q225HL
ME<M"27+JT!$Q&(F.[Y?\_'4V1?\ C^3D  "D
M                                          'C5Y]R/2*L\TK<<9I%
M3>;5_)<:B.K0KW%$1^X-<NSZQ2O?$9>+/FOKKE8\IZTIBG[Z224=KILE&X6A
MGJ6ZDB]@AL@JZHJ:=43F)WXQ4V<<E.IEO1BCK-].I<RWF]XM2Y\_!A9D[GX$
MS58A_0;HITDVZH:;BU??>X\KI+Y&KZ?Z'Z:3AZ)Y?_,,Y2ZB]@AR!=1:=7<
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M)CJC%*<>FO.2$<%9[R.$Z:D<^O34%+)X
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M'/#*K46G7_6*$JR*D4^=$;K+-.<?*7O]&-DD)2G=+1[>2HCT))D?+<)F0O\
MN_*!@6=4R\8")Q/ETMUF/$LNGU%JCKWY<I+*GUR^$KB*;WC>4:B,U:>BYC-)
MJ#!B*-YJ) 85_P 1F*PRK4^LS<0A)]_4]>?4+88VXTX:8%6+*O\ Q3JOE5:4
M27 AR)J:<[5=)-0DHBQ$%%8;=6K??<0G>)!DC74S($YS/#JW>KH8KY,L.;_J
M]2N[,?C+:<6SL1<5F::\]:2DQI4JV40&N&VRJI-((Y)N-&DN9ENZ&7KEL('B
MV]6J5<-%IM;HSO%I=5B,38+O"4QQ(\AI#K2N$HDFWO-K2>Z9$9:D7<'M CB
M.-2Z]2T'"UI06\HR(N7,S(BY^N?(O= ?H (R,M2/4CZC+F0IJ[;LHME4.5<-
M?DKBTJ&II$B0VTM]39O+)M!FVV2E&G>/MCZDES/0!4H#QJ#7Z3<M,C5>BSF*
MC3I:=^/*CN(<0LNZ6J#425)ZC29ZD?(R(Q[(
M          X/J/V#&L#.[F3OS!K'+*]9=K=#\JL2JA7H]>Z3$BR'=R"3/!X+
MC[:G&?1GKPC3KKS&S\^H_8,:VLYF&^#%Y8TY:JUB/B&FT;EMN=6W++HYP791
MW$Z^3/2D$X@]UC@Z)/M]==[D V,4]]<B'$=7IO.PXKRM"(NV=90M75RTU,^7
M<[@[PZ4!#2(D5+2]]"(D9#:NK>;2R@D+T_YDD1^MJ.Z
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M-@WM]&^71G'=TI&B>:N#O[O4K05\1D9:EU .0
M                                       'CUV.])I-5883O.OTFI,-
M)UTWG7HKB&TZ]S51D6HUY9!L'\0<+E8JG>]%12?+RL*D4S=D,O\ 2&3F2'"6
M9-F>[JA:3[8N^7,;#*\^['I-6>95N.,TBI/-J_DN-1'%H5Z^BB(]/6&N?9]X
MHWOB*K%@KOK:JN5(K2F:?O-I03#?39+>[VNNO:H27L$ V8%U%[!#D<%U%[!#
MD                 '!GH1F-+NT[SL8U99\2\OV'^'5C.5FDXHU68Q5*\W/
M::Z*F$^QNHZ.:349.$HT<N>AZC=$?4?L'\0T [92XJ39V)V4*ZKBZ2Q0*9<%
M41/GMPGIC454B3$;:)[A-K)LG%F24FLTZ]_D"JF,S$3XW+#[2JJ0:9G:V9F+
MMP4*91KGG0;SDU"GL3'WN/)72XQ1VW&F>T<XZU)(C-)\/>UZR&SG+?M';0Q7
MQSO7+I>UJ2,.,1;0@0I,&#*=?EIK<$X!S5R6WS;0RA+<-'&4E.IEKHK0RT&N
MC:+WI:=SYXMEK+I\ORP@.Q;I<WTPW'8[:7*=$4WTG5)HCFHC(DD[NZGR3J.[
MB/5;?B[6RFT.$A+%P5W#VZ&::<6'PFGY)V+(3'0[+:036IN+0EOB+/MCT3SZ
MB>-,1CA$SGY6Q'&3:)TK#^AW7?EH60W?V&5BS(T6[[NC59,=5,)Z1T=Q;4$D
MK>E<%Q+A+)DCTW.V(A1N-FUSR]84818.XU0U2;EL;&-4R+;]39CRV]RH07FX
MDF(MM+2EI-$Q? )2]"/34AJ(V>N8O*31L,L5,K&;I%6MK%JS[KN;S6T6JQ:P
MXW<<6N5VH2:.AAXVC8E:Q7&R1P>)P]\N9"H-IC3<$[-RK94+>PGM=RU<.SO9
M3UNVX]$D5"0P4FZ8;LB09R&CD,HDK4;VBDI225=X#9C,1,3Q[HF,=_B.UL^B
M[6.S(-%N2H7GAS7+:G,.4)NR*=T>I2CO%5;6TA'#=1%TBI9XS2E*7RT49GR(
M7DPAV@]M7KC5=& -^VJO#_$VBT5FNTZAG+54CJL%ZEJJY*XS:";944,DJ-)]
MMO&:=-2&*NT8S(6?E^LW+);SEA0'YV)5/M^-3;_;I;,B-9W1(M+(W9+*(RF7
M2E$X26^,M.X9&:3U&#E O&SJ-M:[.=FW/*N.O719TY;]9;H\EF'-WK/,VFD.
MH0<<TLDX39I2HR(NYU@C$8SC^C/3G?&/$L[9NV>P[K,7&*-ACAQ5K\N7!J6T
MS<E!CIG1UI8X[J'Y'%Z,HOI+++CQ)(NWTT(Q6],VOV#%SY0YF;:SZ))K]JVS
M-CTZ^Z(@I354M2;)J14IMJ1"4STUQ*I1++?X)))*-\SW>8PBV5-0LF-F@VD]
M*K::*W):\J)$F--CPVTN1%PJ@XXELGTDEPUMGVR$ZJ4?7S'9V5N6R#>U<S]S
M*E;27,%,:I46GV53)\13-+.;3_+&-)E0X#B$--*9J"D/H6ALB4I*3[8CU,G$
M1G.=V.GKQF.CY.'2W!_NSK0>RJT_-%"II3+<J28'1*<U(-9N+GRVXC3:74D:
MC6EQPB4DD[Q&1D9%H9#)S#6\'[\LNAW7(I2Z,NL1D2DT]Q9K4RVX@EMF:C(C
M/?09*YD76(Q&46FXQ0<8YVRYOFE3',/L&[DE5M^[G$F[$J,2M3W+AIK'#(C3
MNQ$<-A'TQ1:%R(M1*CI<%FFP(4".24L08<:$TE"20DD16D,D9)+D6I((_P#]
M0*9C$^N.[H>@  "                 68L[ 7"VQ;CD75;%KLTNO2R24JHH
M=4IZ02$[J..H^V=W4GHG?-6Z75H/5Q*P<P[Q:B,0<0+9B7-"C[W#ASB2[&U5
MS,U,.$MI9D9;R34@S29$:>8ND "/#M?\MMXW/AW@?A/E_P *UW/0*#<<>56:
M5'D]'9I4)-8B2W5DM:32HN$AQ:4HTT)))(B,;@<$L%<,K3M^V;QI%I)@W$BV
M*0U*=FN.39$*7!I;#,EJ(J43BHQ\1"T&IG<)?>&2CT5AXR4MB.XHNZZRVX?N
M&HC,A]D(0A)(2E*4ERW4I)*?ZI<B!.=T1U9]:-_A9E]O:]-K!F*Q6Q*PEFL8
M37_YGXUGW<52=94X5*IBHLTS;CDAY!+=223U,DF2N1&0WTQL$\-8MD/X?Q[7
MAMVM)WBDP$(2AR62EFL^E2"2EV1J9F>CJE]9D+GIA1D.$XF/%2HNI28[25EK
MUZ*).I=WJ/V1VP)G/S1'S1^WBMEAOA%A_A13Y5*L*W8MNTZ6K5Z%%(DQE'J9
MJ-+"22VG>-1FO1);YF>NHH&XLK&!]SW<Y>U5L:&JX7G6W9,J&LX,>6XUIPU2
MXL;AL2=W0OWY*^>HR+ $+773@]AW>)6\BOVS"FM6P9'16$MH9C0CU2>J6$))
MLSU2DS/=YF6O69CR+ZP!PGQ%JM&K=X6= K-5M\VSHU0>0CI5/-HD;O1GMWB,
M\FT$?#4G>TT,M!>@ %IW<%<-7K^I6);EKQ%WI1F.CTZNFE/28S1L%&-*5&6]
MS922#Y]0N-5J13JY39E)JD1J; GL.QY49Y*5MO-.H4A:%$HC+FE1EU<M=2'I
M  QRPQRJX'815*75+#L:)1Y4Q]R2[Q%G*CI><6IQ:V8[V\TR:UJ-1\-*>?/N
M"^%PVW1+II,JAUZFQ:G2YC?#?A2F6W6EIT,DZ)<2I*%(UU0I*=4F1&DR,A[H
M +28>8*8<X6HF>8NVH]-=F&I;S[ZNERE&>\K<;DO[SS2-5&G=2LDDD]TBT(A
MCA;.4:TDYGZGF-D6TS;UR,'I$E1G$[]7XL949:I7"-._PT'JDG=\TZ\M!G4&
M@"R=VY?L*;UN6+==Q6G%FUR*YQ2EMGT=$A9:;ASFFB)$SAZ%N]()S=[@NSY3
MTSRM\J.@0_*WH_1N@]':Z+P=S<W.!N\/T/+7=UUYCTP 63L_+[A18U?EW+;=
MI1(-6E.FZI]P^D-,+49FM4)ATE-Q-\S/>X!-[QF1F*MQ PSLS$VCG0[RH<:L
M0-4F@EI)N4QHHE?Z-+27'CD9D6^32T;Q%H>I"OP 458U@6GAW1VZ):5&C4B
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M/KTU$E%HC))Z_P I9^X:CT!$XW8ZHSWX?0  $
M       .#ZC]@_B&E;:36W<-9S,9*)M(I-0GPZ;5;H54)$1E]QF(EPHVX<A3
M25)02M.U-9EKIRU&ZD^1&?K#6!G>S(WQ@WCEE=LRV&X*J7B34*ZQ7#E0H<EU
M*8),\(X[LAM3C!]N>ILFDSY:]0#9;24J3 @$HC(RIT)*M>XHH[>I'ZY&/3'1
MI[ZY$.(ZO3>=AQ7E:%IVSK*%JT(NHM3ZNX.\
M                                         _*M=.769D7L:GUC]#\F
M9%H9GH75[IZ: -'V*6--6S"[2NU<K\-U].'^#AN2\2J8PZM**N[4Z>F?1N.M
M!DIK@/((R+4]XNL9CX\9T:)@SBM8>7^QK*F7OB/=D"JN4^BMID4ZG0HU!@G*
M43U5-GH39KCHU2;CI&9Z$6IC6!@:[*L?;BYHF*[%6VQB>S:B[6E2$FA,@J90
MC7+3%-22)SAF>B]PST[I%J+FYOLW<6DY[\.\NM7HJL/Z74Z?7R>Q*\I3J;E:
M05)5(..Q**/Q(1I(^C_2WTFO>+D?495C/"/Z,3ZN/;OG]C(ZP=J+9MX838Z7
MO.LY=,N_+^J(5_68S,<E]#*8\ZW'4W.;;-#V\AI3GTK>T+D9D,5[DVY$.FX.
M65F)H6 56KV"-:J[]*NZ]&9LE)6H;=332VWC@E%-Z8E3^]OFCDVE)FHR(A@1
MEKO##V%5-J%8UO\ EB:Y],MMZG(J-&G,M3N%"F/R7^D2V2;42M%.%JH]-=$F
M?(7URJ7UA;,V'KM+GHIU3D.3;RHZJ05,1(F+JD^YIL6$IN&3*W'30\XC1U"5
M&C0C/=(M2)Q'5QF(Q/1F(GU=[8UF!VM6#6"ML8#7S3Z:N\+-QZ8>\R];AK?)
M*9C"64.Q%--MK42FY3Q1U&O=T,M>YH*&LS:\TEK-#;>7#&W"6;A"[B)'.1A;
M=,R:[-A7<E$%,Q\M28;9A&VE;:")U>JC7VI:C2#B_AY6LN^339RVGBM%7"GT
MB]KPGRRGLG*>C0ZY=+,NEI-+A*6A)QWFR(BTW"Y=1&-CFTYL./F'QHR(6%A9
M&:J-ZP&F*J[5*5%)*Z/ CPZ9.=3)J#+9)CD[&;67#6\DC(S26O,#9C=V[6_N
MX3ZO6R4OS:]E0<;,8<O]EX)3[TQ'PHE6TT]2&*BZP54C7#N.HE$_P%-MI9C+
MX^FI[Q<M1DF6?E=P5FE6!AWAXJ[,7VZ:N=>=B(J)QUVBLXA3(\>3.4CA+5);
M)1(WMTS-/(M>0UC94IM!D;9O-S1WF2=E*MW#:FL29%*-<21,@6HW&DJ8F.LF
MR^MM]"C7N+7HHB(SYCZY8+EG99MKYFYM[&AN1!I>.AVP]A9<<J&Z=+ELT&E+
M=JA-220<: 325$C0W$FZ?(B,^0(F.SA3$]_#_-LXR][0:W\>D8O6=3K251\<
M\%XYR+SPKDS#1*8)QIY^*3$UU*$R3D,,FX7 2HRUYZBQ.$VUSL_$^Q,8*HSA
M[*I.(V$E;I=%J6&TB4\FJ5!ZJU,Z>RY&2ZTEYU!$7'4MEI:4H/51Z<QBO@G8
MTNI[5K-!FGM]QZGX/6[ HKE=JC,=V/ N,V:&XP9(;-*$R3:>0M.J4N&9GJ9<
M]#Q8S/PJKAUC=1-K]A;:S\K!BAW 5+OZR(D0T-76T].1;K50D4MMDE+.FN;\
MO>Z&HU&1JUU[8#$3\T3'?/\ 1^7H_P!4J_#RXJW==GT.X;AM]5L52JQ&ICU&
M4^4A4-#Z$NM$ITB+4U(41F1D1I,]#YBLW$J4A9(5N+-"TI5IKNJ,M$JT[NZ?
M,852L_.6ZA8(6%CS<%W2J;8=_,TQBD2V:)47W$U&8N-%5!7#0QQV.#-D%&WG
M$)1H6\1Z#,J#48M2IT*J1'-^'4(4>H17%)-!KBRF$26G#2KFG5EQ*C2K0RUT
M/F"E@!BED)P$OQ[%2^L7J3YLJO=E!J#LZ?-GR8T>GE"I\@F%162=)J,XA.FB
MF=PU*21GJ8T/95[DQ/R/9"\YE[6U6:L_A!2*RQ1<%CJ+TF2Y 17:W,IM:2Q(
MFK<D+2EQ_=0I2NU22=S0B(;.\Y6T2P!5B7.RK3,0:M:<J(XU]$:OQK>JDMFE
MQM"DLQFG6&N'(*8TE;"S8<[7>/4NX*1Q!GY>,\^2+&[*YE(ERJE%LVGTNJ2.
M)2)U,:>F0WO+=]UM=09:Z0Y+DQU'H@U&1KW>9Z KB9Z8G$S&^>$1GYE@+3P8
M0]L9GKF=<==Q'G+D7H[=CDEXJNM]NOKJ[+935.<9#:4[K>XESFGM>KD-J.RZ
MQJNW,%DIPDQ)O.0J1<$XJK29;RC2:EM4*>Y3&#,T\C/@QT\^L^LSYZC4_0<8
M'%;'=W#63 FEBU&D/6:[9:8TI-42I5PJI;3Y-DT2^$;.CV\2=-WGZ'MAFCE:
MQ/PGV8>3K+OA/F5N>3:%<N>147:0A-,E5%#LBNU$I;;$EV(E;<4]9K:-7E),
MS/4] )X8Z=J>'=OPQJN.^JWF)VT+.$EQRW9ECY<H_$9H*W%E EJN>AD^KI;"
M5$W()#A;R2>2K0_0Z'H/ 7BG<V6K:JXP6!;DU=-PYQ2LNLU-RD(<-R'3I=MV
M?+G1518RE**/O2D)4?"2C4R[8Q[%?LRKY?\ ; TK,)58[GT+<SE+C3(]SH0I
MV#"CT2WD%'<DK:2LF>D$XC=2Z:5:JT21F/.H^#5>S.[4+'#%V@4Y^9AOA[9U
M2I,&M+)UF)6IEQ6E,I[*8AO)02N'*4E)\/7U].8'U;'[?XOOLI[09S+Y3,Q6
M/F*:WKDN'%^5?;4B;*><-R,JR)U;C45R"I2E'#-GHS!KX'#XA)T5W#&M.5G*
MQ5E;-:CX$RZ[.1=57Q5>HC-P)E+.<NCQ<0^C]#Z0E9/$CH!<'3B]760V1[,&
M[UY3\JN8C+MBY#ET"Y<*I5[K;AN,.K<J*[[FUE^CMP=U'^D[W2V"6;'$W"5J
MO0]1KWF9%,5J5LT;:QA\STY5^T;%&3<:K7-M:YR*+-Q Z:4K=W3<-/E<KC_O
M?(NZ"8QF<_E1C'9P]6/G;%MJ=0',K^6?+7C=A"A5O7'A4]9L>/(C/FVY,5>,
MJC1:NY.5O).:;W2'E)Z1Q.'O=KIIJ-_UJ7([,PQMR[7TG(DR;%I->DM:Z<5Y
M5#8G2"UTZUN*47L&6G>$?;::U8\X> F67 ?"*/+N"OXB/6E)D(9:>;\JW;-D
M4B556IVJ=Q@T'&?2CCFC?))&GGR$@6A4=R@X:T2@NH)#M'P_A4MY&NI$]"H#
M41Y)]9'],:/7N&"CHCOG]G^;3BSMD_->G&RE818$U+$"\<$9#2;BMQJH/PU'
M%4Z[QY)25QS3]*C,N/DE.N]N[I=9"\^%FUQP(Q-RAU_-)%B3XY6E485$NVQF
M(<^55J)6ZA52H\2&ZPW'.4I#D[M#>X)()/;GVO;# #9;7?8M$S3;26D5Y^F1
MIK*:0\\Q)BLI0\R4&H*<:;6:#2ZIU/+<_C'R/GH0Q"PWO.X<H6#N>/-13L/9
M%=PSQ@O6RJ=9E+<I*EPX!P[D.FU.I,T9V*M/^CNN*E[W 3O[F^E7=(JQ'1$_
MT<;^.<;OKG=^QOAMO:)SF,>,(L#<5<+DV!5\<84^H8;2TUA-375H\&"F>?'8
M:(S@J<9<:+=D;AD:]--2/3&:Q,ZN9VZ-I;BQE_F88+\PEBKI*::15B-N&Q/@
M&\M\S(M>VTXA$>ID?+UA@ABYBEA+1<Z&SAQ.?OBL7I)J$>X7J_=#5N5-N) D
M56G12BTY+*&EL1TQ5NE$-39H(^'J9%U%E)8V*-IX?[8_&B+=C]0IAXAP;2<M
M.0JE3'(E32B@H6XI,I#)M-[A.)W^V,RUT,BTY$8W</Z/KB<3\WC=N9Q80YGL
M(;PSM8Z84-8;MT#$S#N'2)5UW@IU:W*@T]352D:I4VE.[%CMK3JE9ZD1F/CB
M]M("LJV+PQ%P[PW:Q'PQL::Q&N.Z&*TW#=8;5).-)=9I^BGI!Q5(=-:6TJUW
M.YJ,',/KLHDS:R9S;7IKC_E]7[*BQZ0XFG/-QI<MRS9:&DMSS:)EU2G%I3Z,
MU)4?/0QAQD"S0Y3,,;.Q.RF9T*-7K8Q<LZZ[B54H<Z!<$V-=C%P5N?*I;3+K
M$=<1W_1W64D:362-_F:= ,=F<;,S$=4Q&9^?ZVWW$_:[X,V3A9@-C';U&F73
M8V.,F?3Z54B;F17*?4Z?);@R(CD=3)NGNSG. 2UDDCTWBY'J/;M':62G\T=H
M9;<2L(I5@2\3Z<]4<)[@<J*YC5XIC4TJE(032&B3"-LEMMZNJY[YF7,:U=H'
M.P?LO W)_ L>TGK,L:3=LUZWK9139-35&3)N"*X<E>\P;L<I2ED_VZ$[I*[Q
M"_F=>\+3H6T#V8+LQ2FE(H=?)R5$IKCR(Q2:%"X"94IELTQS62DI2EY:-/0]
MS0#$=N^*L9[.$[E88(YV\RUX[0S,?@U=.%KD&P\+VZ1(CH.LQW"I4!VFNRWY
M9[B2-WC--F]N&6I'VO(9'W#M&WY-"NJ]<*L-&L2;&M*L4VCU6I0:TANILOS9
MZ:<^;E&22YR"BO\ $+4VB):4[W4>HPSPAQ5L>Q=KEG7H%Y+J$1Z][=M1Z@-G
M2IKD6MP8=L..U%MB8EHV?WA1I/<4:M5:=8P;Q7PYJ6$\/$//1L\,79EM1F+S
MI$;%'+;4:(]5475TBO)IIKC*K!+3%X9J?E&J+&[I&9]T$XCJZ*<<<;\9X=?\
M6W;:?52K6[EMM_-_A^_(H.(&&<BVY\!MHE-*=A7#/A,U:/,+5!/*9BN.MEQT
M*-.AFDR,;&,N6+])QRP:L/$RCN$[%N.BPS=61[VL^/&:;G'KH7+I).>QWS&L
MS:.WY/OC937==URT0[8J]PT>S4RZ09$I3%2ES(;1DE"4HT-Y]9K2A*2W2,BZ
MBU&1VRMLVNV%D?P7MRXH[\>J,1)\IQJ1O$ZEF;(5(CJ,EZ*T4TXDTZ]P]01_
M1[<X^3'CYVQ<  %(
M               #S*OT7RNJ'3/]6\KIW2>O7HW1U\?_ /U[W5SUT&%V3WZ
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M@UI;?96DSU;4:5I6@E&IM25$9:*T/4M--0 5,
M                              M!CG;U&N?#"ZZ)7JR5!I4^&;<RJJ:X
MQ1$&E7;FV1EO%H>ON"@,HEDVMA_@7:5KV==2+QH-/E5=R'7T,'&3,7(G.N/(
M)HS/=X+BC;Z^>FH]#-4S)?P)Q :BLOO/JIJN&W'2M3RCW5>@2V1K,_8(Q:+9
MTQ9T3*EAXQ48TN+*1/N(W&)K;S4E!'5)&Z:T/D3A$9:&G>+J,M.0#.L
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MIJF*V+$IB5>=8<0DGG&H+CATUC4C41='CK)H]PRWMTC/49M!U
M                        .#ZC]@:V\Y>#.&6(V-.6NY+VQ-:LJN67.K;M
ML41R"<H[G<E$SQVTNDI),<#=+F9'KO#9(?4?L'\0TE[2ZFUN9F<R1/4VG567
M&C5:Z3FO0&);L>.2BC;G2U,(4VV2OXINF1'W &ZF TVU$BH;<XB6XD9M"^K>
M0AI*4+T_YR+>]T=P>922,J?3]2,C*G0B/4C(R,H[>I'KW>^76/3
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M+J]W4QZ>A:ZZ<^^7=]GO^Z.0
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M(TEY>KZ%FE1-$2B3J7(]3PNV7UY6'2LUVTGIM;?ID24TBC+=8DQ64)>9;@5
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ME59R+76VN"B8J3-=>=03>\K=X*U&V?/N>$,E0
M
M                                          !P?(C/UAK3SH9F;EP6
MQLRS631:13Y\+$V?7&*G(EQ8C[T1, F=PXZY#2W&M[?/7@FD^^8V6'U'[ UU
MYP,!</L5,8\N5UW;B5'LRKV%.K3UO45V*3Z[F7,)GC-MN&I/"X&Z7</7> ;"
M(#ZI$2(ZHB(WH<9X].1$;K*%F6GLJ'='3@LH9BQ6T+XB6HL9I*RY$M#;24I7
M_P!\B)7L&.X
M
M
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M[U%C4LEL0VXZT[R$\2,:"7PR3J7HN8#.LB(NH '(
M                                #'+-2U*=P*Q ;B-R'9"J<KAHC$X;
MRCW5>@)LC69_>BT>SKCU"-E3P\9J;$V-+3/N(W&J@EY$I)'5).YQ$R")TB,M
M#3O%S(]2Y#(C':\IEB8779=,!AJ3*I$,WFF7FVW6UF23/12'$J09<NI1'WNZ
M+?9/\4JIC#@/:-^5>'&@SJO+J[3T:*TRRRV4.<\P@T-L)0T1J2@C/=26IGS[
MH#*(
M
M          <'U'[!_$-)NTL@5Z5F;R1NTJ#6),6/5KH.>[3VIBX[!**-N=,.
M.DVT$?\ $-XR+O#=D?(C/UAK3SH9FKEP5QLRS611:13I\+$V?7&*G(EQ8C[T
M1, F=PX[DAI;C1JWSUX2D:\M>H!L:I)&5/I^\1D94Z$1ZZZD?1V]2/7N]_7F
M/3'2@/JD1(CJB(C>AQGCTY$1NLH69:>RH=T
M
M
M                                          'F5=,55.J)3%;D8Z;.
M*2K0SW8QQUD^K0N9[K>\>A<^7APLR=T_ F$K$/Z#=9.JFY4S.XB-A]G@2NDO
MGN_3O1%Q3<+5/+_Y9F7 TX]1ZNTVDUK=H]3:0DOXRW(CJ4)_[RC(O=&MG9WX
M>W98ZL7?--17J253K:G87&(R*0@YLE>\GD1Z;JB/EKR/K ;0"ZBTZNX X+J+
MV"'(
M                                                      "T..5K
M4^\<,;JMVIUE% A5.&II^JN()Q,-)I5],-&I;Q:'U:B@<HN'=$PNP+M*S*!=
M3=XTRF2JN['K[3),(F*E3GGG$);)2B3P5+-OT1ZF7N#M9KUJ1@-B$I"EH45-
M7HI"E(47:+ZE),C+W#(6?V<#KCV4S#I;KCCJSJ%QZK=<4ZL]*K)ZUK,U'[IF
M SR
M
M         '!]1^P-;F<K "S<6,:<M=W7%B='LFI8?SZV_1J&]$3(7<ZIG!XC
M;;AJ2;7 W"YD1ZZC9&?4?L'\0T>[3>2^SFBR-MM2)#27:O=6^EE]QI#A$48B
M)Q*%I2X1=PE$>G< ;MH#*68L5M#A.):B1FDK(O1I;:2E*_\ O$1*T]<=T>72
M/]GT_P#HV#^;MCU
M
M
M                       >17)+T6E520PK==CTFHR&C,B,B=9BN.-J,CU(
M]%)(]#Y&-?N1#&S$7%Q6*17U56*EY05A4:E\&&Q%X+)3)#>BN"E._P!HA):J
MU/NZ]T;#9\-$Z)+B+/1,J))B*/O(DM*:4?N$K48ZY?\ +?0,!3NPZ)/.;YJ9
MIS)6J#3PUF\X]IS4K7FX9 ,E2ZB]@AR!<N0
;                                 __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nt10002526x6_diagram6.jpg
<TEXT>
begin 644 nt10002526x6_diagram6.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( XX(,@,!(@ "$0$#$0'_Q  ?  $  00# 0$!
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M(T)35&)C<I/#X?$5,U64TP@D)39%5J2T-#=#9'-U=H*5HD2#H[+_V@ , P$
M A$#$0 _ )_
M    #JJY56*'1JI69/./2X$N>]_BHC"WW/\ ]E!CR[0/6>W=?=-:5J7:R331
MZK-JL)@CXL]92ISL%_[(B5^VM*[2%]7W3I=7LRZJ7 ;ZV;4+?JT.(V:B23DB
M3!?990:CY)XG%I+)\BSD^0Q7Z/W2V]=&]LMIV'J!36Z3<].K5V2I<)M]J2AM
MBHUV5+B*)UDS;5UD=Q"C(CR6<& S4
M
M                                   %#[#]PQJZZ2"\KAM*FZ7+H4_N
M)4RO1VI!]63G6(.H1DF7/L[TSYD-HQ]AY[/",*-WU=T+HT.R3UFH!UMF15&D
M4)/7OL]SR^ZV"0OZSS5AXVU=]RY8 9=6XXMVBT5QP\K<HE*<6>,96N&TI1_C
M,^P=Z.LI"XJZ=3E0T<$95-@KC)SGABJCH..C)\SX6^$LGXOA[,
M
M
M                                                      !0^1&?
MM"H'[?8 UV[^M:=0=(*!8LNQ*LFER*M6XD6<HVFW>M8<GQV5H+K.19;6HO'S
MSVD,^+?E/3*/1Y+ZN-V31Z9)=5C'$\_$:<<5_P"):C/\8Q$WA4+0VM4>TD:T
M5_SCA,U6,JCN=0\]U\PIC)M(PSS3E\FTY/ES+.2&8-'1$13*:F$OK(J:9 1%
M7@RXXJ8S91UX/F7$UPG@_'\ =H
M
M                   M#4";)IUCW;/AN&S*AV[6),=TNUMYFGR'&UE_@K22
MB]LAB/T<U_75J7M7M"[;SJRJU7IM=O"/(J"TDE3K4*ORXT9!D1F7UME"4<C\
M S%NXZ6FU[@.MIXJ.5'J1U-//G [D>[J+O>?-CC+)<R\ Q]V<.Z.O:$6\YH3
M'.+IP=5N(J6R:GEFF856D%5#R_\ 7.^F]:?/EXN0#*0
M
M                                                 4/L/W#&NC?O
MHKJ)J] TZ9L.DL5-RBUIB542?EQXO4LHG1W5*(WU)XSZM"E83SY8&Q<^P_<,
M:Q>D6U!NVQ:=IBY;%:>I"JA78[,LVCQU[:JA&0:#YE_!49>'D?8 V1T&,]$I
M%)COIX78](IL9U)&1DEYB(TVXDC+MPM)EGPCN!T=NO./T6C.NJ-:W:+2G5J_
MC..0VE+5_P")1F?XQW@
M
M
M                       "A]A^X8J*'R(S]H!K(Z1VP;LOFV]/F+7HS]7=
MA5Z$])0SQ9:;14HJU+5PD?(D$9_B&QNVV7&*'1&74FAQJATEEQ)]J7&X32%I
M/VTJ(R/W!@3O[UJU#T>H%BS+"JK%,DU:M1(LY;\./*)UARH1F5I(GTF2#-M:
MBRG!\\C/FWY3TRCT>2^KB>DT>F27E$1$2GGXC3CJB(N196HSP79V .Z
M
M                                                6C?T"55+)NRG
M0F^NF3K>K$6,T9DGK'WX#[32.(^1<2U)+)]F1B?T>.F]X:4;7K1LN^Z6FCW'
M KEW294%#S<A+;,^O2Y45?6M=X?6,.)5@NS.#&5^H$V33K'NV?#<ZJ5#MVL2
M8[N"/JWF*?(<:7@^1\*TDKGXAB3T=-_77J9M8M"[;TJAUBOS:Y=\>3.-"6S<
M9A5^7'C(X4<BZME"4>W@!G*
M
M                             !]AY[/",'-Y,[0J%"L<]9Z0JJL.55I-
M"23S[74R^ZV"0O+/,_KW ??<N7XAG$?8?N&-;W2 Z17_ *I4_3=JQZ,FK+I%
M;8DU!*Y#3'4LHGQG3476'WV$)4>"Y\@&PZCJBJIE-.&G@C'3("HR>?>Q3C-G
M'3SY]ZWPESY_^?:#IJ!&>BT>D,/IX'6*/3([J<YX768C3;B<^'A61EGVAW(
M
M
M
M    ?M]@"A]A^X8#!S>C;.C5Q46SV]7+L]#$2/5HRZ2[W*])[IE)FL+;;PU]
MCQ/)0G)Y+GDQF=16XK=+I:(CG6QD4NGHC.8,NLC(BMI8<P?,N-LDJQX,X&L[
MI*K3N&Z+:TZ:H-*E5-<:X(+CZ8[;BS:0FIQ5FI1(2HR(DI,_!R+M&RBV6UM4
M*AMN)-*VZ%2&UI/D:5HA,I4DR[2,C+!@._             !3)>,OA(8=;]M
MW%&V-[7]0]RE?H1W)2[!9@NR*.F0<4Y7=LDHZ4D\25&G!GGLYB++%\V&V)/8
M*53]HUY5"(M;B&I<!RLS(KO5J-)FW(CTQQI?9SX5'@Q,1,]T3/JC=$S$=\Q'
MKG9-?R7C+X2#)>,OA(0I_5@-H>PYOW^:K_T2'JP&T/8<W[_-5_Z)$\%_S;?J
MS]R.*OYU?;'OXQ[4UC)>,OA(,EXR^$A"G]6 VA[#F_?YJO\ T2'JP&T/8<W[
M_-5_Z)#@O^;;]6?N.*OYU?;'OXQ[4UC)>,OA(,EXR^$A"G]6 VA[#F_?YJO_
M $2'JP&T/8<W[_-5_P"B0X+_ )MOU9^XXJ_G5]L>_C'M36,EXR^$@R7C+X2$
M*?U8#:'L.;]_FJ_]$AZL!M#V'-^_S5?^B0X+_FV_5G[CBK^=7VQ[^,>U-8R7
MC+X2#)>,OA(0I_5@-H>PYOW^:K_T2'JP&T/8<W[_ #5?^B0X+_FV_5G[CBK^
M=7VQ[^,>U-8R7C+X2#)>,OA(0I_5@-H>PYOW^:K_ -$AZL!M#V'-^_S5?^B0
MX+_FV_5G[CBK^=7VQ[^,>U-8R7C+X2#)>,OA(0I_5@-H>PYOW^:K_P!$AZL!
MM#V'-^_S5?\ HD."_P";;]6?N.*OYU?;'OXQ[4UC)>,OA(,EXR^$A"G]6 VA
M[#F_?YJO_1(>K ;0]AS?O\U7_HD."_YMOU9^XXJ_G5]L>_C'M36,EXR^$@R7
MC+X2$*?U8#:'L.;]_FJ_]$AZL!M#V'-^_P U7_HD."_YMOU9^XXJ_G5]L>_C
M'M36,EXR^$@R7C+X2$*?U8#:'L.;]_FJ_P#1(>K ;0]AS?O\U7_HD."_YMOU
M9^XXJ_G5]L>_C'M36,EXR^$@R7C+X2$*?U8#:'L.;]_FJ_\ 1(>K ;0]AS?O
M\U7_ *)#@O\ FV_5G[CBK^=7VQ[^,>U-8R7C+X2#)>,OA$*?U8#:'L.;]_FJ
M_P#1(N6QO-=.G5UW]9MD5+:]<ELKN^MT^C1IM8F5* E#DZ8Q$)QI,R R3W I
M[B,D&?9SP$UM'.:VB/3,3!Q5[N*N_HWA,T =30*JBNT*BUMM'5MUBDTZJH;S
MGJT5"&S+2C/AX2>).?#@!2J=L
M                  MR\/.ST*W%Y]<J3YRU+SRQG_F/<;W=79S_ &GC[.8Q
MVV7%I(6@5N%HBHUZ>^>UR>=JE$\1]V>>\CSS_;_KG*9UG;R\7(>^:@0Y%1L>
M[8$1OK94RW:Q&CM$>.L>>I\AMM&3Y%Q+42?QC$?HYK$NG3?:O9]J7E2SH]>A
MUV\'Y$%2B6;;4RX)<B.OB3@CZQI:5_C 9T
M
M                                        "A]A^X8UI](5JG>^FU.T
MU<LZMG1UU2N,,35$VASKVE3X[:D]]V=XI1<O&-EI]AY[/",*=WKVW]J'97IX
MQE2&#JC7H?(E2$\,SNM@D&?4=OU_JS/BY?B 9>6^^[)HU'?>7QN/T:EON*_C
M.NQ&EN*_\2C,\=G,=T.LI'<GG;3NX2Q%\[8/<O,S_N7N=ON?MY\FN'MYCLP
M
M
M
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MJFU VG6#=EKK$E521U;WUPNKF&ZCGR/&2Y ,K@
M
M                                           !0^P_<,:W.D"TAO\
MU2I^FS5CT/SX72*VQ(J"3>;:ZAE,^,Z:N_[>\0H^7BQ[0V1GV'[AC7!O_P!8
M=0M*:?IN[8M;*CKK%;8C5%2F&GNO95.CM&@NLY),T+4G)<^>?  V#4".]%H]
M(8?1P.L4>F1W4]O"ZS$:0XG/AX5$99]H=T.FH$EZ51Z1(?5QNOT>F2'58QQ/
M/1&G'%?^):C/\8[D
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M_5/\''J+^6U[Z( 370$*+U6?JG^#CU%_+:]]$!ZK/U3_  <>HOY;7OH@!-=
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MEG1^O)]E=/.TX^UY8?O,M?YC@@&G'VO+#]YEK_,<$!QN.Z/5'U.MKS  $@
M                                               "S]0(<BH6/=L&
M(V;TJ9;M8C1VB[7'GJ?(;;07^$M1)_&,1>CCL.Z--MJUGVG>%*71:[#KMX/R
M*>X?$IMJ9<$R1'69X+/6,K2LN7A&7]]5&71[,NFJP'":FTZ@5:;%<-)*)$B-
M!?>94:5<E$EQ"3P?(\8/D,6-@&JMZZS[9K4OW4"HMU6YZC6KKB2YC4=J,A;%
M.KLJ)$23+!$VGJX[:$F9%E1ED^9@,T@
M
M                                     /L//9X1@]O'1H0J%8_ITN*0
MQYZM><."D'F7W6QP9ZC_ .W<'V7+PYP,X#[#]PQK0Z0S3&]=1:=IHW:%$76%
MTRN1WYJ4K)/4M)GQG#7S(\]X@S_$ V.4?N7SLIO<7_-?.V!W+V_\U[F;ZCM_
M^U</;SSD=H.DM]AV/1Z.P\DT.,T:ELN)_BN-1&D+3G^]41E^(=V
M
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MOY9T?KR?973SM./M>6'[S+7^8X(!IQ]KRP_>9:_S'! <;CNCU1]3K:\P !(
M                                                 MN\$4URU;B1
M6'>II2Z+4DU%W!JZN$<-XI*\)YGP,FM6"YGC!#'799 TGIN@-MQ-%*N=<T_1
M5KD.FU!3+S!NRUUB2JI(ZM_ZX753#<1E7;C)<A[YJ)&?FV)>$2,V;LB3;=:8
M9:3S-QUVGR$-H+VU*422]LQA[T:]H7!8VTZS;=N>F.T>KQ:]>3S\%XC2XVW*
MN&8\PHR41'AQM25ER[# 9Z
M
M                            "A]A^X8UP;_M8=0M*8&F[MBUENDN5BM,
M1JBIR,S(ZYE4Z,T:2ZTCX3X%*+)=F<]HV0'V'GL\(P;WDTO0RHPK&+6:NJHK
M+55:50E$Q(>Z^64M@THPSS3E[JTY5X_"0#,N@27I5'I$A]7&Z_1Z9(=5@BXG
MGHC3CBL%V<2U&>/;'<CJZ.F*FF4TH:^.,FF0$QE8,N**49LHZ\'S+B;X3P?,
ML_!V@
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MX^UY8?O,M?YC@@&G'VO+#]YEK_,<$!QN.Z/5'U.MKS  $@
M                                   "U+ZJ,ND69=-4@K)N93Z!5ID5
M:DDLD2(T%]YI1I5R427$)/!\CP,5^C_U3O/67;-:E^7]/9J5RU&M79%ERV(S
M,1M;-.KLN)$23,=*6TFAAM"3,BRHRR?,QE?>+,"3:EQQZJ_W+37J+4VI\CA-
M?41%PWDR'>$N9]6T:UX+MQ@8X[)[?TTMC;];=(TCN/T5V0Q5KE<I]9[G<B]?
M)?K$EV>WU+N5IZB4IQK)_9<.0&60
M
M                                  H?8?N&-8/2-6%=5[4W3!%M49^K
M*@5V.]+2RE2NH;34(RS6K"3Y$E)GSQR+Q#9\?8?N&-=N_/6W4/1^!IV]8E3C
MTYRMUEB+43?AQI76LKG1VE)23Z%$CO%J+*2(R,\^X&>]NM.,T6C-.I-#C5%I
M33B3_@N-PVDK2?MI,C(=X.GH4IZ92:3)?42G9-(ILETR(B(WGXK;CBB(NPC6
MHS(O!V#N
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M4J6Y5:9+;F2(DABKMF_$<C5)3"(CW$R:5J2RXK@SPJP9<QM/O[%H])5H#?\
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MR?973SM./M>6'[S+7^8X(!IQ]KRP_>9:_P QP0'&X[H]4?4ZVO,  2
M                                            ++U'9=DV#>4=A"G'
MGK9K;33:2,U+<73I"4)21<\J49$6.8PUZ,JWZQ;&T:RZ17:?(I=29N"]7'8<
MI"VWD(>N.:XTI27$I61+09*+)%DCY#-2^*E)H]G71589I*53J#59L<U))22>
MC07WFS-*LI41+0DS(^1]A\AB]L)U5NK6C;9:M_7F['>K]2K-U19#D6,Q$9-J
MG5N5#C$3,=*&DF3+:249)(U'S5S 9E@
M
M                                     ?8>>SPC"7>!;NB%>AV2G6&X
MO.%F/5&5T174//=T2BELJ0@NJ,C3EXD)R>>T9LGV'[AC6#TC-B75>E.TP1;5
M'D554&NQWI26"5EELJA&6:E<)'RX",^9> !LLI"(K=-IR(:^LC(IL%$9>,<<
M9,=!,+QX.)LDGCV_@[,=';K3C-%HS3J30XU1:4TXD_X+C<-I*TG[:3(R'>
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M2F>Z.[Q]N_\ EL]%  !2   ,(ND-_>>Z[^\ZJ_-\H:@_,N_W.FD^_&^?TKJ
MV^=(;^\]UW]YU5^;Y0U!^9=_N=-)]^-\_I74 $E@NPO<+\PJ*%V%[A?F%0
M               ?DX1$DL%_"3^<0GO-(_W0SHTO?1<'^T0!-B=^Q+_"3^<0
MG?-(_P!T,Z-+WT7!_M$ !,\LK]REK>]>W_FR,+J%JV5^Y2UO>O;_ ,V1A=0
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M\2V]Z94_272:S[,IY*(HU.:JDWB+"SJ=7;1.J'%DU&>);SO:?@["Y#VT%
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M]>3[*Z>=IQ]KRP_>9:_S'! -./M>6'[S+7^8X(#C<=T>J/J=;7F  )
M                                            %N7?&@S+6N&+4W^Y
MJ?)HU28FR#2:B9BNPWD/N\)<SZMM2EX+F>,#'?9A:FG=EZ!VY0-+;C3=5G1J
MM<CL&LI87')^1)K$EZ<UU2S-1=1)4MK)GSX<D/=]1V79%@WDPPA3CSULUMMI
M",FI;BZ=(2A*<<^(U&1%CGGL&&O1E4.LVYM&LJE5Z#)IM29K]Z..Q9:7$/H0
M]<4UQI2DNDE9$MM1*3DL8/D S^
M
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M41&W_P!VV_HY>MDWK5TI=TZ%6S9^MMSZ6/3M";NK[-$<K=.G]VS:3W75&J5
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MT4VS:':2QG;DNZZHEERZ?(9IDAI=(8H:*-*FFJ4XPDH6&F5\N-LG"224FHL
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M:5R2*S<=3DTJ>A:'V%5*N29O 9+2DSX2=P1XY]I )$)=A>X7YA44+L+W"%0
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M>=IQ]KRP_>9:_P QP0#3C[7EA^\RU_F." XW'='JCZG6UY@ "0
M                                       !;%ZU-^C6A<U6C$1R*;0J
MK-9)1$I)NQH3[S9&E64F7&@LD98,N1\AC-L6U;N'6[;G:^H5T(CMUBIUBZ(C
MZ8K#,=GJZ96Y4-@TM1TH:(S:;2:C))&9\SYC)N\HL.=:=QPZA)[C@RJ)4V)<
MHTFKN>.[#>0\]PEV]6VI2\>'&!CALDLVQ;"V^6U;>G-UIO2U8M7N9Z'7TQU1
M2DORJS)?F-=2LS4GN:0I;.<]]PY(!EH
M
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M2FLR%+QCC);<9*^,R[5<7$:CR9Y'[71I#IY=T\ZK7+6I\NI*-!JJ"&&F9CG
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MB(B*T*H1$7+!%3Y&"]PO , ?,XOW*31?WVZG?IA,&?\ TA?[S[73WHU3_8)
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M@ =+!M^C4Y[KX5'H\)WPNPJ9#BN]F/VQEI"_Z>P=T   H?8?N'^85 ^1&?B
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M/.TX^UY8?O,M?YC@@&G'VO+#]YEK_,<$!QN.Z/5'U.MKS  $@
M                                      "R=26W'=/[S;:0I;KEL5Q+
M:$$9K4M5-DDE*2+F:C/!$1<\]G,87=&!3:E2=H%DPJM#EP)J+AO=3D::VZU(
M2ERY)JVU*0\E+A)4DR4G)<TF6!G!>M2>HUH7-5HY)4_3J%59K*5$E23<C0GW
MD$I*B-)D:D%DC(R,N1\AC-L6U:KVMNW.U]0KE9C1ZM4ZQ=$1YJ)'8C,$W3:U
M*ALFEF.A#23-MI)J,DY,^9F9@,P
M
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MNGO1JG^P2!@!YG%^Y2:+^^W4[],)@#>R
M
M                                !\R,O& H?8?N'^8!@WO1T-8UGHMG
MPGKMBVOYSU>++2[))HRE&W-8>)M/6N(+ON#@+&3R9>$9GT6(4*ETR*3A.E%I
M=/BDX6,.%'BMM$X6#QA?#Q$1<L&6#&KGI/?/3T+Z;>=GGIQ>B*#UGG9W4:N'
MSTB9ZWN7ON'&<\7+&<\AL[M?B\X*#Q<7%YP4?BXL\7%W"SQ<6>?%GMSSSV@+
MA             :,_-'/W([<Q_D]L_/+0P Z#'[F)M_]VX?G%8S_ /-'/W([
M<Q_D]L_/+0P Z#'[F)M_]VX?G%8W/J3\H:K]$G[7&U'KE\G:?]*_NY;:P !T
MUS4                                 !%>\T=_;:Z/?W_\ ^_Z6)4(B
MO>:._MM='O[_ /\ W_2Q@NLOR)KOZF/[;&SO5OY9T?KR?973SM./M>6'[S+7
M^8X(!IQ]KRP_>9:_S'! <;CNCU1]3K:\P !(
M                          MJ\8,:IVI<=.F2B@Q9U%J<61,-/$49E^&\
MTX^:<EQ$TA1K,L\R2,<MDVG5JZ6;?;:LVS+P;ON@P:M<LF/<;<?N5$IV=6),
MF0R3.3X>Y75J9,\]]PY'OFI*''-/[S;92I;J[8KB6THSQJ6JFR22E/#SXC/!
M%CGGLYC"_HP(%4INT"R8E8BS8<Y%PWLIQBH)>1)2E=R35-FM+Y$Z25(,C1Q%
M]CC'(!L&
M
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MBGU:^US[]=D_']*\K 97 ,4OJU]KGW[+(^/Z7Y6*?5K[7/OUV3\?TKRL!E<
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MGVNGO1JG^P2!@!YG%^Y2:+^^W4[],)@#>R
M
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MX^UY8?O,M?YC@@&G'VO+#]YEK_,<$!QN.Z/5'U.MKS  $@
M                                   "VKRJCE$M.XZNRA+CM,HE3G-M
MK(C2M<6&\^E*B5E)I4I!$9*(R,C,C+ QPV2:P5377;Y;6HU8I\:ESZI5KEAN
M0XC3++"$4NLR83:DML(0V1K0T2E83DS/F9F,DKNIS%7M:X:7)E%"CU"C5*&]
M+47$49J3$>96\99+)-)6:S+Q)&/.S/2VWM&]!;<L2U[N9OBCTZJW'*8N)ADF
M&Y3E1J\F6^REM*E$7<KCBF3,E'DT^#L 94
M
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M]&J?[!(& 'F<7[E)HO[[=3OTPF -[(
M
M                              H?8?N'^85 ^1&?B :I.D]<JJ+7TV\[
M'JHTH[B@]:=,5*2HT^>D3).=S&1\.,YXN6!LZM<U'0*#Q&HU><%'-1JSQ&HX
M+/$:L\^(S^RSSSVC#K>EK71M':+9TRKV/&O-%6JT:*TR^\AHH:W)K#)/)-:5
M9-*E\9$7/*1FA192)E*I<I#),IDTNGR4M$>2:2_&;<2T1^$FR5PD?M .V
M          :,_-'/W([<Q_D]L_/+0P Z#'[F)M_]VX?G%8S_ /-'/W([<Q_D
M]L_/+0P Z#'[F)M_]VX?G%8W/J3\H:K]$G[7&U'KE\G:?]*_NY;:P !TUS4
M>=:I:L6!HM9\Z_-2ZX=O6M3U,HE5(HSDHFUON$TT2FVB-1<3ADDL]N1V]AWS
M;>I=GT:_;/F^>5L7 EU=)GDE2.Z4-'A2N!7?)]P__(Q3QTXYQ\=>TBO'--XX
MHK,[<4U[^'?EOMMNK[._!&7@MV<VX(R<,\$WB-^&+=W%MSVWWVYKN  R7C[.
MT5*  %,EVY+ "H    ZRM5FEVY2*A7JU*[CI-*CNRY\E*3>6PPRVIU:S901K
MP2$*/L["S[8\ST8UXTOW!6]4+JTGN KDM^F2'(DF>4=R-A]EY<=U'5N<^\>0
MI'+ERR*9O2+UQS>L7M$S6DS'%:*[<4Q7OF(WC>>Z-U<8\DTMDBEIQTF*VO%9
MX*S;\F)MMM$SX1,[R]?  %2@ ,Y[   %,EXRY]@KG^GL      \)%XS(B]TS
MP7](L=W46U&K_C:9'4"7>,E"EE34)4KJDH:Z[+KB<H;XF\F7&:<^#(B;5KMQ
M3$;S%8WG;>T]T1YSX0F*VMOPQ,[1-IVC?:L=\SY1XRO@17O-'?VVNCW]_P#_
M +_I8E0^$R_BJ-)^ZD\&(KWFCO[;71[^_P#_ -_TL8/K+\B:[^IC^VQLYU;^
M6='Z\GV5T\[3C[7EA^\RU_F." :<?:\L/WF6O\QP0'&X[H]4?4ZVO,  2
M                                               +(U*)P]/KT)HE
MJ<.UZX2$MDHUFOSMD\)()/?<1GV<///9S&%71<M5%K9Y9"*HS/CS"N*]S<:J
M:9")9).Y9O :TR2)XDFG!HXBQPXX>]P,Y[RJ:Z+:=R5=MM+SE-HE3G(:61&A
MQ46&\\E"B5E)I4:"(R,C(R,\D,;MD>KL_7';W;.H=3ID6CRZG5KEAK@PVF66
M&TTRLR82%I1'0AHC<2T2U&2<FHS,^8#+8
M
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MR
M
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M.--2)],HD^B6=P<92?KO":<<'%RX<<)X ;#0
M
M                                          /D1GXAKKW];JJ?MAH5
MC5JJ(HZ85;JC45^15^XB9CMJF,,J6E4Q)I3PI<XC-)D98Y8&Q,^P_</\PBW>
M:/K0H^I$#:SIS<Y2WK6NNZ'X=:AQ)DB"Y)CG4H"#04B,M#J,I6HLI41EGES
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MF?,!O<
M
M       ^7, /F1EXP&#.]+5VS-*Z+9\J[M/VKZ9J=6C1HC#LKN8H+KDUAE+Y
M*X5<1I6M+F/[WD?,9H462U+I=+D,LDPW(I=/D-M$>>J;?C-N(9SX>K2HD9\.
M,^Y@_OAT)N76NAV7"MV5#BNT:L19<@Y<J-&2IMJ='?4252'$$H^%!EA.3SV9
M/ S?H<1<&DTJ*X9&N+2:=$69&1D:X\5MI1D99(R-23P?8?@R [<
M   !HS\T<_<CMS'^3VS\\M# #H,?N8FW_P!VX?G%8S_\T<_<CMS'^3VS\\M#
M #H,?N8FW_W;A^<5C<^I/RAJOT2?M<;4>N7R=I_TK^[EMK%C7UIEIUJ=!9IN
MHEH4VZH4=1+CIE1V.ZF%$HEY;EJ;4\DC419(ED1D7"?(S%\@.F6K6T36U8M6
M>4UM$3$^N)Y2YO6UJ3%JVM6T=UJS,3'JF-IA8SNF.G#]MQ;.>M"GKM*$G@C4
M-#33;!)R1D3Y)029&%$2BZU*N$RR0^*3I!I5,I$6WY=DPI% A'Q1*.X2%PXZ
MC5Q\2&%(-HCXR)1&2",CYD9CT8!3V>/^+IW;?D5[H[H[N[R[D]KDCNR7CGQ?
MEV_*GOGO[_/O6#7]*],KKMEFS;FLNF5NU8Z2*-29C##ZHQ$9*Q'D.MK6SS(N
M39IY%CL'ZTC3#3BW[6.R*%:,&F6@HC2Y18Z&VR>3DU<+KJ$)4Z6?L2<R1%DB
MY'@7R =GCWXN"G%P\._#7?A_-WVWX?+N.TR;</:7X>+BX>*VW%^=MOMQ>?>\
MX9T?THC4=ZWX]D0F:!),CD4=' F$\KB-?$J.2":,^,^(S-!Y/F9Y%7=']*'J
M*U;CUD0G;=8/B8HSG J&TKBX\ICJ2;6>/"L\'(^9<QZ, =EB_B\>VVVW!7;;
MT;;=WEW)[7+_ !F3OXOR[=_I[^_S[UC5+3'3FLVVU9]6M*#-M>.6(M,<0V;L
M0N(E8BRC0;L?OB(S)DT9P61]]IV-9MB0UP+-H+-%BND1.Y44B4Z2?L27+<+K
MU)+L)*E&6.1<N0NH!,4I$Q:*5BT1M%HK&\1Z(G;?;R4S>\UX9O::S.\UFT\,
MSZ=M]M_/O6(>ENFJJK5*YZ#J>W6:VE*:S4&&V6'*@E"30DG.K;29]X9I/)GD
MC/.1\L+2'2JFTV=1Z;94.#2*F?%4J<QP-L35<1KRZVA)(4?$9GWR3R9G[H]%
M 1&/'$[QCIOSY\%?'O\ #Q\?3XI[7)W=I?;ERXK;?%_)Y;[?%\/1X+*@:;:=
MTNWYEJ4ZSZ6S:]02:)M!>C1WX+R59XN!AQLVFU&9FKB2C)JY\S[.LLG1W2?3
M>+48=@6-3;8CU?B\\TQ6VNMD\6342'DMI6TDS4KO4J(L'C&#Y>D '9X]ZSV=
M-Z1,5GAKO6)[XK.W*)\8C:$SER3$Q.2\Q:8FT<5MK3'=-HWVF8],\UB6]I?I
MO:52>K-JVE%HE7D*4N3/C\*7)*U&9J4^:$)-[.3QUAGC)\N9X_"1I+I;*N>3
M>DBQZ6Y=LQM34NL$PPGNIM;9LJ)]@F^!W+1FG*^+&<\AZ$ =GCVB.SIM$\41
MP5VBWYT1MM%O/O1VN3>9[2^\QPS/';>:^B9WYQY=S49TG>AM;NO0BW=*] M)
M(U5?E7%2ZC5(-/6Q":0Q&K4:=+6OA;2A1K:0XOQD9GC!C8'HSIS8%(M>T;A@
M6&U;=RLV]3HDI$M[SP5!G0Z<S'?)@GR,F>L>0HE&T22YYYX'N:7%(^Q2T?MK
M:;</\1K(S(<3,U'DR21GX$))"?Q)21$7XA;TT>.FIRZJ)WMDICI%)K7AQQBF
MTUFG+>)F;3OSV[MES?6Y+Z;%IN<1CR9<DWB]^+).7AXN.)MPS$<%=N7I[VM[
M4*J;M]:=6+CT(FZ5(M/09,ZFR7=4%U.'-*K-15IF$WYU'AU!=8CJ"Y\B/B\
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M[3C[7EA^\RU_F." :<?:\L/WF6O\QP0'&X[H]4?4ZVO,  2
M                                     +;O&I%1K4N.JFRF25.HM3FG
M'5CA>*-#>>ZH\D987P<)Y(RP8QQV3ZLHULV_6UJ"BWX]L)J56N2(5'B]7U+'
MG;6),/K$]4E",O\ 5=8K"<\1GD9'7C32K-J7'2C>3&*HT6IPCD*QPLE)AO,]
M:>3(L(X^(\F18(8X[)])DZ)[?K;T^1<$>YTTRK7)+*KQ>K-E_P \JQ)F=6GJ
ME+1ECK>K5A1\TGD!ED
M
M                        *'V'[A_F$9CI_P#]UNS7WY/_ #I3A)G/L/W#
M_,(S'3__ +K=FOOR?^=*< D>61^Y*U/>K;WS7&%V"T[(_<E:GO5M[YKC"[
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M_36T4^T_I5_H^M'YA@#U$>7:*?:?TJ_T?6E\P0!ZB/OZ.Z/5'U/HD  $@
MPEZ0O]Y_KI[T:I_L$@8 >9Q?N4FB_OMU._3"8,_^D+_>?:Z>]&J?[!(& 'F<
M7[E)HO[[=3OTPF -[(
M
M                  H?8?N&*@?+F U5])M4JS3K8TW52)M1AK<N&"EU5/<D
M(4M)U2*1DX;"DF9&1\^(\&6<\ALTMA2E4&A*6:C6J@T=2S5GB-1P634:L\^(
MS[<\\]HQ!WE:J6#IG1K1E7Q9#5Y,5*K1H\)ER0;!0WES6&D.D9)5Q&E:R<Q_
M>C,FC2&9-,IC[#),,OTRGR&FB//5-/1FUMM9\)-H,DY\.,@.U
M  :,_-'/W([<Q_D]L_/+0P Z#'[F)M_]VX?G%8S_ /-'/W([<Q_D]L_/+0P
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M>9:_S'! -./M>6'[S+7^8X(#C<=T>J/J=;7F  )
M                             %D:E\?I?7KU?'UGH7KG!U?%UG%YVR>'
M@X>^X\XX>'GG&.8PJZ+GSP^H\LCSS.H'+]$5\<?GIW1W9P^B6=P<?=7U[AX,
M<&>7#CAY#.F[ZFBBVM<-6<CE+13:-4IRHJL$F0F+$>>-D\D98<)' >>6#&/&
MS'5V%KCH);FHE/M:/9L6IU6XX:*#&4VMJ.JF5>1"6Z2FTH09R5-&\K">U7/(
M#*H
M
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MZ83!G_TA?[S[73WHU3_8) P \SB_<I-%_?;J=^F$P!O9
M
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MGT2SN#C.29O<))QP<7+AQCD V&@
M
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M_E;7/[8/4OW1%?>)G_*VN?VPD/@'SS[9\O/R@WGT^_O$>Q'@]2_=$5]XF?\
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M[[=3OTPF -[(
M
M            'V& H?,C+V@&"^]74/3:PJ+9TC4*QD7G'G5>,S3V%RU1>XWU
M36$(>(TD?%PN*2O!\N]P,TZ(\Q(I=+>CL]0P]2J>\RT1YZIEV*VMIK/AZM!I
M1GPXR,$-]VA]Z:S4*R(5GM17'Z/6HDN64F9&BD334^.^HT'(6@E'P-JP2<F9
M\NT9V4&(["I%)BO$1.1:138KF#(RZR/$::<(C+D9<23P9<C[0'<@
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M=/.TX^UY8?O,M?YC@@&G'VO+#]YEK_,<$!QN.Z/5'U.MKS  $@
M                                       "V[QJ+5(M2XZH]&*8U3Z+
M4YCD0S))241H;SRF3,R,B)TD&@SQRXACCLGU2I&L>WZVK\H=I,V33ZC5KEBM
M6\PZEYN,NG5B3$==):$I(SDK;-XRX2P:O#VC(V\J8NM6G<E(:<2TY4J)4X*'
M%F1);7*AO,)6HU&22)*ED9FHR(B+F8QNV1:15'0[;W;.G=4J<6K3*95KEF.3
M8;K+S#B:G69,U"4N1UN-&;:720HDJ,R,CSS 9;
M
M                                 +8N6\;:M!AN3<=9@TEEU1):5+DL
MLJ<,U</>(=6DU$1F6321X\("YQYGJ)JY8>EL:+)O.MHIA3>+N2.VTJ5,E<!D
M2NHB,\3[G!G*N!M6"[<"[X-Q42K1^Z:96:7.C\*7.NB5")(2E&.+*S:=42.7
M/GC T'=*IJ'J+MGU_P!M6\YJCN:D;=M-Y%?9U.I,.4A2*,S54MP8DI,!HI#E
M6ZITU/J2VPZ3?!WQ$0)B-YV]/=Z_"/G[F[33K6S3G5-^HQK-N!$^72^J[N@R
M&EPIL?KBRWF+()#Y\9<_L>SGSR0\YUYW@[?]MTND0=7K\CVM+K?6^=['4+EN
MO=3CCXT,\2F\9+'&19\'A&L;9=6*7NTW/7GO-T3N%M.C$ZE0G:+3F7DL.7'.
M;I2HTB'-HW&V_2U0IR3:)<B,V3QI-9%S&N3>+J!J+ISN1O[5+?MLHJM[[;)]
M8I,.S]2X%W25)LJ,MU,-V5YPTE#C\A$E2D*5Q()+:4FH^19!,5Y[>KEW3SVY
M1OX\TGBD[E]&ZQI.QK5!O".O3N22CCUQ]I3"G^%SJC2S%=)+SBC<[TDH29YQ
M@O .^TIUSTTUIASINGMQ-UI%.-LI["F5Q9D/K#,FSD1'>%]I+N.)M2T))1=\
MDS(QHNWBT&W+LVX;7[TVM0I54VST:H(J%>IE'?E.9C2JA#>)N2E!JDNJB.\9
M.H-)_8F1XR.XVP7RG2W=7O8W!ONRK>T)FVQIC%MQV0P^Q&K%88H#<,HM/ICR
M4&VM-4)++RV&N^49K<\)@;<M_/:/HY>OGW>3>G6M4[(H-Y6_8%1K;+=UW04G
MSGI31=>Z]W*WUCW7=7Q'&PGFGK>'C\ CM^: "Q=VS4O_ -<G_P"FJ4X;%-J-
MK-UN\ZIN=URJ\.GW_J#)<]!MKU&>TTJU*?$4N,PZAM3R$).J0S:=)*FT'WV,
M&?,:Z.G[6E=U;,EH4E:%W@\I*T*):%$JJ4XR4E:3-*B/MR1F0*4C^R/W)6I[
MU;>^:XPNP6G9'[DK4]ZMO?-<878
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M3"8,_P#I"_WGVNGO1JG^P2!@!YG%^Y2:+^^W4[],)@#>R
M
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MVO+#]YEK_,<$!QN.Z/5'U.MKS  $@
M                  "R-2C6G3Z]5-J6EPK7KAH4V:B6E14V3@T&GOB41\R,
MN>>P84]%P_/D[.['=J4B=*EG<-[DMZH+?<E*25RS202UR%*=-*4X)&3P22+'
M(9T7C.C4RU+CJ,R*4Z+!HM3E2(9JX2DLL0WG7&#5@^$G4)-!GCD2ACELFU$M
M75/;[;5Y699S=B4&=5KECQ[<:D=U(BNP:Q)C27B>PGB[J>0I\RQWIJP RR
M
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MI(UD?N2M3WJV]\UQA=@M.R/W)6I[U;>^:XPNP%(
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M[0  (
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MX3,OQ]F!L@MIUQZAT1UU1K<=H=)=<4?:IQR$RI:C]M1F9F [X
M !HS\T<_<CMS'^3VS\\M# #H,?N8FW_W;A^<5C/_ ,T<_<CMS'^3VS\\M# #
MH,?N8FW_ -VX?G%8W/J3\H:K]$G[7&U'KE\G:?\ 2O[N6VL  =-<U  #]KM
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M%[?+:TYK4^-4I]+J]RS')<1UEYA:*I6),UM*7(ZUM&:$.DE1)4>#(R/F/?\
M4E;C=@7FXRI2'46Q7%-K1DEI6FFR32I!I[XE$9$9&7//9S&%_1@U"J5/:#9,
MNL2YLV>NX;V2X_/6\N2I*+DFI;):I!F[PI01$C)X).,<@&P8
M
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MYG%^Y2:+^^W4[],)@(;V0
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MH^IUM>8  D
M6Y=\V+3K6N*?.C%+APZ-4I,J*9\)2&&(;SCK)JP>"<0E2#/P$H8[[+[^LW4O
M0.W+ML*U469;<VJW''BT!M\Y"(ST*KR(\ITG3))J[I?0IXRQR-6,GVC(2]:8
M]6;0N:DQS23]2H55A,FI1)23LF$^R@U*5WI%Q++)GR(N9\AC+L5TFK^B6W.U
M]/KF>C/U:FUBZ);SD20Q)8-NI5J5,9)+L92VC,FW")1$HS2?)7,!F"
M
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MKC"[!:=D?N2M3WJV]\UQA=@
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M2JO<K,.@)DJE%&?BUF2S,=ZY9$I7=,A*WL&7>\7#X &6@
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M/O\ :N:T;\C4V?;C2H,:"E+JE27WD&XA7$1,/.I3E>"5PECM'P[#=,MPFO\
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MCM+_ /$ D?V1^Y*U/>K;WS7&%V"T[(_<E:GO5M[YKC"[
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MO1MV7,4XM]:&;CFMM)4ITU+,D-D24Y/L+ER 9^@
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MM3WJV]\UQA=@
M
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MYSPO,0VFW4Y\/"M)EGV@'=          #CPEG..?]'P#D #1GYHY^Y';F/\
M)[9^>6A@!T&/W,3;_P"[</SBL9_^:.?N1VYC_)[9^>6A@!T&/W,3;_[MP_.*
MQN?4GY0U7Z)/VN-J/7+Y.T_Z5_=RVUBI'CQ'R,C)1$I)D?(R4D^2B,N1D?(R
M% '37-7SHBP6TN);H]";2\9&\A-'@)0\9'DE/(*.27%$?/B7DR/F6!S7'B.&
M1N4VDNF6.$GJ9$=2UC_L$+:,F3_P.$?J )WGTS[7X'%A'S53J6Z?@6_3HCSJ
M,=G5..-*6WCQ(,BY$*28<&:TF/.I]/G,)^P3,A1I*FL&1EU*WFUJ;+)<R1PE
MCD/H -OI[S>>7.>7=Y>IYGJ_84_4C2J[-.Z!6&[/GUV.VFG5F#$0E-.=CY4@
MBCLDVE9.J)*5%V'SXLD->VE>E>__ $]HL/2RJP+0N:UZ<Y/CQ-09-NVMW4J!
M4'%]:MR,[&6^XLF5\)&M1J)1$9<^S:J*=_\ ]J][G6KQ_)SC\6!9:G0X-3DQ
MY<G'%\<36.&VT36>^)K,37GO,<41%HB9C?:5U@UF3!COBBN*]+VB^V3'Q3%X
MC;BK:)K:.7?&\UGQAY%HII-3='K,.VV%0JG,J"W)%=><@LE F2'G3?4A-.4A
M49M+;BUI,D())]N.P>KLQ8,9HV(E+I%/85S6U3J9#@H=,SR?7)C--$[D\_9$
M?:8_<!=TI7'6M*1M6L<-8]$+>][Y+6M>9FUIWF?3/J[GS]R0>9%3*4T1]I,4
MV(RES_')0T1.^/O^(.Y(/_V*HY$?:TFEPBCJ]M3!,]6H_#DTYSS'T *MH]'O
M[Q'L4[SZ9<$-,-I4AN' 0TLN%<5,*.4)9>$E1"1U!ES\*!P8C0XJ#;A4VE4Y
MM1Y4FF4V) XS/M-PXK37%SY\\]IC]@!&\^GO[W%24+(TN-MNH/[)MYM+K2R\
M2VUD:%E[2B,?*Q3J;%>5(B4NEQ)"\<3L:GQ65%CEEOJVD]6?C-&#5S,^T?8
M;)WGNWG:7 VV5.)=7"ISKR,\$IZ#&=F-Y[>KE*;-Y.?:67+D/S>BP9*VW)E)
MHD]UDS-E^H4F#-?:,_"AZ0PXX1EX#)18\'86/W $;SZ7YN,QWC)3T&G2#(L)
M1*@QI#39> FFW6UI;QX"01%V'X!^?<D+EFFTIWGDNOIL1[@Q_P!EUC2NJ\)]
MYC!XQV#Z #;W]_5"=Y],OP[DA>&G4Q9G_P#2.T^*X^G'9U;RVS<;Q_>J+D7B
MY#]R+'(N1%R(B\  "-P17O-'?VVNCW]__P#O^EB5"(KWFCO[;71[^_\ _P!_
MTL8+K+\B:[^IC^VQL[U;^6='Z\GV5T\[3C[7EA^\RU_F." :<?:\L/WF6O\
M,<$!QN.Z/5'U.MKS  $@
M         "W+OD08=K7#*J;'=5.CT:I/38YF:2?BM0WEOM9+F76-$I&?!G(Q
MWV875IU>>@=N5_2RW2M6S9-5N-J#1DO+D$Q(C5B2S.<ZUPB4?7R4K<QV%G!<
MAD#?%-DUBSKHI4))*EU&@U6%&2I1)2;\F"^RT1J5@B(UK21F?(NTQB_L)THN
MW1;;9:M@7O'9BW#3:S=4N2S'D,R6TLU*N2ID8R>84IM1FRXDU$1Y(^1X/D S
M*
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M"L*XJDK1'=-;=Z'4+5?DRIR;:=M:V)$AE;4R4Z\^GKI*NL+A4@R,B[XQEON
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M^=*< D>61^Y*U/>K;WS7&%V"T[(_<E:GO5M[YKC"[
M
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M^UY8?O,M?YC@@.-QW1ZH^IUM>8  D
M                   6;J))?AV)>$N,X;4B-;=:?9<3VH=:I\A:%ECPI4DC
M+VR&'O1KW;<%[;3K-N"YZD]5JO)KUY,OS9'$;JVXUPS&6$GQ&9X;:2E)<^PA
MFA>+U/CVI<3]58[JIC-%J;L^/Q&GKXC<-Y4AKB+F76-$I.2[,Y&.6RBOZ9W+
MM^MNK:1V[Z%;(>JURMT^C=T.2NHE,UB2W4'.N=[]77RDN.\^SBP0#+$
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MA'+C^3J_+@]3^=*+^$<N/Y.K\N 3/?19;GKAMWX[I_\ ;AZ++<]<-N_'=/\
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M3WJV]\UQA=@
M
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MO,M?YC@@&G'VO+#]YEK_ #'! <;CNCU1]3K:\P !(
M                               M.^Z=+J]F732X*"<F5"@5:'%;-1()
M<B3!?992:E=ZDE.+21F?(LY/D,6.C_TLO/1K;-:EAW] 9IMRTZM77*EQ&)+,
MMM#-1KDJ7$43\<U-J-;#B%&1&9I,\'S(90ZARGX5B7?+C.&U(C6W67V'4]K;
MK5/D+;67MI4DE%[9##[HV+PN"^MI]FW'<]3=K%8E5Z\F7YSQF;CC<6X9C+"#
M,S,\-M)2@N9\B(!GF
M                 *'V'[A_F%10^P_</\P"/-YHW_>3P/\ 2%I]^F%+&]O2
MK[5^FOO"L_\ 1RGC1)YHW_>3P/\ 2%I]^F%+&]O2K[5^FOO"L_\ 1RG@+_
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ME:GO5M[YKC"[!:=D?N2M3WJV]\UQA=@
M
M
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M$@EGD^W*N9=HX@ Y&LU$238AI)/8IJ(PV[_.)02^?AYCC_Z_]?\ F78?88
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M7^8X(#C<=T>J/J=;7F  )
M           %MW@NFMVK<2ZRWUU*11:DJHM9,NLA%#>.2C)<RXF>-.2YEGD,
M==E<[2:HZ VW*T3I1T73]=6N1--IYNO/&U+16)*:FOK'_KA]9,)U>#Y%G!<B
M&0-^P)55LJZZ;!;ZV9.MZKQ(K1J))./R(#[32.(^1<3BDISX,C%#H\]-KRTF
MVOVE95^4Q%(N2!7+MDRH*'VY*6V9]>ERHJNM:R@^L8<2HR+F6<& S<
M                                                    SGL#( *'
MV'[A_F%10^P_</\ , CS>:-_WD\#_2%I]^F%+&]O2K[5^FOO"L_]'*>-$GFC
M?]Y/ _TA:??IA2QO;TJ^U?IK[PK/_1RG@+_
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M;>^:XPNP
M
M
M            !0^P_<,5 _;[ &NG?[K1J'I!;]B3+"JS-+D5:MQ(LY;T2/*)
MUARH1F5I(GTJ))FVM19+!\\]HS\M^4],HU'DR%<;TFCTR2\HB(B4\_$:<=41
M%@BXEJ,\%R+L&(F\*B:%5BCVDC6JN^<L%FJQET=PF'WNNEE,9-I!$R>2R_U9
M9/Q\QF#1T1$4VFIA+XXJ:9 3%5@RXHJ8S91UX/F7$UPGSY\_@#M
M    &C/S1S]R.W,?Y/;/SRT, .@Q^YB;?_=N'YQ6,_\ S1S]R.W,?Y/;/SRT
M, .@Q^YB;?\ W;A^<5C<^I/RAJOT2?M<;4>N7R=I_P!*_NY;:P !TUS4
M                             !%>\T=_;:Z/?W__ ._Z6)4(BO>:._MM
M='O[_P#_ '_2Q@NLOR)KOZF/[;&SO5OY9T?KR?973SM./M>6'[S+7^8X(!IQ
M]KRP_>9:_P QP0'&X[H]4?4ZVO,  2
M                    +/U F2*=8]VSXCG52H=NUB3'=(L]6\S3Y#C:\'R/
MA6DE?B&(_1RW[=&I>U>T+LO&JJK-=F5V\(\F>I!(-QJ%<$R/'1PIY%U;*$H+
MM[!F-=ITM-KW JMIXZ05'J)U-//OH)1'NZB[WGS8XRY<^?(8^[.']'I&A%NN
MZ$Q#A:<*JEQ%2XYJ>6:)B:M(*J'Q/_7#XIO6JY\N?+E@!E(
M                                   //=2]4+,TDM>9>%\515,H<#@-
M]YIAR6^?&K@2345DE/.GQ'S)"3,@'H0Z2X[@IMK4.JW#5G%M4VCPI,^8XAM;
MJT,165ONFEMLC6HR0@S(DD>1CUIAO"T#U<G/4^S[TS,9(S7'KD&103Q@SRA5
M32P2N19+A,_Z1Z@_>MJWE2;SI]#J#%6\ZJ%5&JAU1$]$^OP'R2E#R>-A\E$2
MB/@4>.>0'A.U/>MH_N]:O.9I+/?J-/LR<=/J$B1%DQ'#D(?>C+2;,E"%IX76
M5I(\8/M[!QWB;T-,=G%CQ[QU *?-.=GSNI%*@3*C.F<"R0X:(\%IZ09-\63P
MT?C\ UO=#S#BP;[W6Q83#,6.BXX*DLL-H:;2:ITQ2C)""))&K)F?+M/(_+I%
M]L&_BX=:*7N+VWW_ $^LT73>/)J-.T@JM!I$Z%6XYQ25/C*DU5+C*%.(:7P&
M;9JXE=Z6< JVC?;?ER[_ #CU?Y,S]N722:.Z_:87UJTW%JMGV=8[4150GUZF
M5*G&XN:I3<=M#,^.PXI2W2ZOO2/!J+L'=Z,=(#IKJIJ-0=.Y,-ZVZI?#DXM/
M%R"?45UM4U*ESG&.L0A+9,MD2^T^+BY=@UT:;:SUKI1=C.L6C$33Z'HMN(M"
M;0VM0;)IL6+"[CETJJ];'<-V+'ALO>>:8JW$DDE$E#N"+!#H+;TRU/9U6VC:
MM:B6BUI]9FT"FWI'O2IF^PGS[D5J <:D(4E!-K<7(D,I0GAZPR-TO;R-H]4\
M^^8]'+PY[S[\X;L-<]QMG:)JMRF512JA<MV3"BT"@1R6N3.X'D-25_6B6ILF
M$KXSXDD1D1_B]_AR>[(4:5P&V<F(Q)-L^UOKVDN<!^VGBP><=@TN:;:BV57=
M4/JL=Q\QRB,5R5,9T*LN2T[,E4F+3U.0JQ,;A()3SZ9;2$RN)QC#:3XDGRR-
MN>G>HMGZI6K"N^QZQ'K=!J!.%'EL&DN^94;;C:VR,S:4VLC3PJ(C+!E@$3&W
MOX^AH@\T;_O)X'^D+3[],*6-[>E7VK]-?>%9_P"CE/&B3S1O^\G@?Z0M/OTP
MI8WMZ5?:OTU]X5G_ *.4\$+_
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M_P#[K=FOOR?^=*<"$CRR/W)6I[U;>^:XPNP6G9'[DK4]ZMO?-<878
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M +P <4+0XE*VU)6A:24A:%$I*DF624E1&9*29<R,C,C+L'(
M
M             =)5;EMR@J:37+@HE&4]GJ4U6JP*<IW';U13'V3<QX>'./"
M[L!9OIBZ?>ONS?E/1/+@],73[U]V;\IZ)Y< O(!9OIBZ?>ONS?E/1/+@],73
M[U]V;\IZ)Y< O(!9OIBZ?>ONS?E/1/+@],73[U]V;\IZ)Y< O(!9OIBZ?>ON
MS?E/1/+@],73[U]V;\IZ)Y< O(!9OIBZ?>ONS?E/1/+@],73[U]V;\IZ)Y<
MO(!9OIBZ?>ONS?E/1/+@],73[U]V;\IZ)Y< O(!9OIBZ?>ONS?E/1/+@],73
M[U]V;\IZ)Y< O(!9OIBZ?>ONS?E/1/+@],73[U]V;\IZ)Y< O(!9OIBZ?>ON
MS?E/1/+@],73[U]V;\IZ)Y< O(!9OIBZ?>ONS?E/1/+@],73[U]V;\IZ)Y<
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M[</SBL;GU)^4-5^B3]KC:CUR^3M/^E?W<MM8  Z:YJ
M                BO>:._MM='O[_P#_ '_2Q*A$5[S1W]MKH]_?_P#[_I8P
M767Y$UW]3']MC9WJW\LZ/UY/LKIYVG'VO+#]YEK_ #'! -./M>6'[S+7^8X(
M#C<=T>J/J=;7F  )
M      %I7[ E56R;KIL)LG9DZWJO$C-&HDDX_(@/M-(-1\BXEJ2G)\BR,3^C
MRTVO'2;:]:-E7Y2TT>Y(%<NV3*@H?:D);9GUZ7*BK)UDS0?6,.)7@CR6<&,K
MM0)LBG6/=L^(YU,J';M8DQW2(CZMYFGR'&UX/D?"M)*Y^(8C]'-?EU:D[5[0
MNR\ZH=8KTRNWA'DSS2E!N-0K@EQXZ#2GE];:0E'X@&<X
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MTA:??IA2QO;TJ^U?IK[PK/\ T<IX(7^
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M,S-2E&9F9F9GD>FCR[13[3^E7^CZTOF" /41]=QSB)\G9@  2
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M.TX^UY8?O,M?YC@@&G'VO+#]YEK_ #'! <;CNCU1]3K:\P !(
M                                       MR\/.ST*W%Y\_]$^<M2\\
MNW_F7<;W=/V//]IX^SGXN8QVV7'I*>@5N'HB1EI[Y[7'YVD?79[K\]Y'GG^W
M_7/^>=9V\L=G(>^Z@0I-1L>[8$-OK94RW:Q&CM=G6//4^0VVC)\BXEJ)/XQB
M1T=%A75IIM8M"TKSI9T>OPJ[=\B1!-:7#;:FU^7(C+XD\CZQE:5>UG #.8
M  !11DDC4HR(DD9F:CP1$19,S,^1$1<S,^PN8"H"U5WM:3:U-N79:J%H,R6A
M=P4Q"TF1X,E)5(RDR/D9'SR.'HYL_P!=]I?*.E^4@+M 6EZ.;/\ 7?:7RCI?
ME(>CFS_7?:7RCI?E("[0%I>CFS_7?:7RCI?E(>CFS_7?:7RCI?E("[0%I>CF
MS_7?:7RCI?E(>CFS_7?:7RCI?E("[0%I>CFS_7?:7RCI?E(>CFS_ %WVE\HZ
M7Y2 NT!:7HYL_P!=]I?*.E^4AZ.;/]=]I?*.E^4@+M 6EZ.;/]=]I?*.E^4A
MZ.;/]=]I?*.E^4@+M 6EZ.;/]=]I?*.E^4AZ.;/]=]I?*.E^4@+M 6EZ.;/]
M=]I?*.E^4AZ.;/\ 7?:7RCI?E("[0%I>CFS_ %WVE\HZ7Y2'HYL_UWVE\HZ7
MY2 NT!:7HYL_UWVE\HZ7Y2'HYL_UWVE\HZ7Y2 NT!:7HYL_UWVE\HZ7Y2'HY
ML_UWVE\HZ7Y2 NT!:7HYL_UWVE\HZ7Y2'HYL_P!=]I?*.E^4@+M 6EZ.;/\
M7?:7RCI?E(>CFS_7=:7B_=%2_#V?_G("[0'SQ9<::PB3#DQY<=PLH?BO-R&%
M^,T.M*4A1>X9CZ     %#[#]P_S"HH?8?N'^8!'F\T;_ +R>!_I"T^_3"EC>
MWI5]J_37WA6?^CE/&B3S1O\ O)X'^D+3[],*6-[>E7VK]-?>%9_Z.4\!?X
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M1728=XW^/E^-EO$3XX\-9C?P[2L][W-7\/GR,UF7M$9G@O@&EGI@/^D=J?\
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MPD7!-01'W3]?-M#26R;4L\&DB-)X&WLNPL]OA!3/*9CT
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M"_P
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M,S;EQS;97?I;7WK:M\\6B\::+[XL.]_@>WP>;6[/>TX]HVF9WG;XV[#8MG=
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M1Z];-^4U(\J#TP+(]>MF_*:D>5",'ZFWJGLS;Z^&M_28>IMZI[,V^OAK?TF
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MQ+S..F*5UP9,-$Y1IB-EB,<6.XVD^(^)>,GSR-7/FGWGT0FO1_\ W5LLO_\
M(8_ZAL(.Y[)O;5W;,QIZ@I=.H%!DI5)CDM7G+%72&"C19)GS-9-)2T?6F1\1
M&1#7QYI^//1"Z]&1Y+STLHL^/%PQBS^/!@I9$] M]RXVS_YGG_[4H;CAIQZ!
M;[EQMG_S//\ ]J4-QP    "A]A^X?YA44/L/W#_, CS>:-_WD\#_ $A:??IA
M2QO;TJ^U?IK[PK/_ $<IXT2>:-_WD\#_ $A:??IA2QO;TJ^U?IK[PK/_ $<I
MX"_P
M   #[#SV>$8/;QRT(.%8_ITYZCST:\X>3YGW7W6QPYZGG^W=7]ERR,X#[#]P
MQK2Z0K3"]M1J=IHW9]%55UTRN,/S4DM*.H:3/C.*5WQ'GO$J/EVX ;&J04/S
MMIW<9%W+YVP.Y>7_ .:]S-]S]O/]JX>WGVCL\%XB^ ATUOL.QZ-1V7D\#C-&
MI;#B<YX76HC2'$^WPJ(RSV<AW0"F"\1? 08+Q%\!"H *<)>(O@(6R[9MKNUD
M[A<MVB/5P\8J\BF0GZ@C!<)=5+<95(;Y<C-#A9+D+G !JFZ:%))Z./<=C_[
M,]O,N1GC!'R(B\!$(8_17_O,+(_S[=GSU*$SKIH_N<>X[_,#7^L8AB]%A^\P
MLC_/MV?/4H<'_P"4-_U)T/\ ]0:3_P KJW/OPD_(6G_^8XOL\C8B  /B]Q
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M;NX__,3/^L0UQ>96_N;MO_Y\N3Y_E#8[TUGW-W<?_F)G_6(:XO,K?W-VW_\
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M>QOI_P"2VF2_TCY17WR-;L8M.*$HF5'SX"42^>,X(R\7+M'/ZA7I^OPDW_\
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MIL?9FP[0/'BS;M/,!?P
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M"@  D
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MU+=MZ?H4<I-C4E%.-Y$)F<PU'F-*=)Q).]<VUCB<(S(SR7/.?QW#='E+U^W
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M:=QCK6F8K:&W<>#K$D2\>#. ';             -&?FCG[D=N8_R>V?GEH8
M=!C]S$V_^[</SBL9_P#FCG[D=N8_R>V?GEH8 =!C]S$V_P#NW#\XK&Y]2?E#
M5?HD_:XVH]<OD[3_ *5_=RVU@ #IKFH
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MR+I]9[G<C=?*>K$ERH-]2[E:>HEFXUD^2N')<C 97\*2\'_G^<5P7B+X"%0
M>>WGI;8.H$ZB3[RM:DW)(M];KE)\]8<>:S$6[PFM269+;K9F9I29'PY(TD9&
M1BM_PX\#3*^XT1AB+&9L:Z6V8\9I###2$T&<1)0RVE+:"(B(BX4ER'H(LG4O
M[7%_^\FZOF*> AM>9*_MC=(K_I'B?/U8$UL0I/,E?VQND5_TCQ/G^L":V
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MOTU]X5G_ *.4\:)/-&_[R>!_I"T^_3"EC>WI5]J_37WA6?\ HY3P%_@
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M:FT=AS&.-JG0V8;:L<\<2&2/'@%P@ K5
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MQG_MXOY0W_6#NQG_ +>+^4-_U@'V /C[L9_[>+^4-_U@[L9_[>+^4-_U@'V
M/C[L9_[>+^4-_P!8.[&?^WB_E#?]8!]@#X^[&?\ MXOY0W_6#NQG_MXOY0W_
M %@'V /C[L9_[>+^4-_U@[L9_P"WB_E#?]8!]9]A^X?YA#H\UM_:>VR_Z0J/
M^DU*$PLYC.#^OQ>P_P#\X;\7^$(>'FMAU"]'=L?"MM7%J#1S[Q:5%^Z:E%RP
M9YR>?<P9=H"5%MF^T#H[[P;5^8X(]Z'@NV;[0.COO!M7YC@CWH       %EZ
MC,.RK"O*.PA3CS]LUMIIM.34MQ=-DI0A)%SRI1D18\)C#;HR[=K-K;1[+H]?
MITBEU-BX+T<>AR4+;=0A^XICK2E)<)*B)QM1*+)<R/)<AFG?-2DT>SKHJL,T
MIETZ@U:;&-224DGXT%]YHU)41I41+0DS(RP?8?(8N[!]5;KUGVUVK?UZ/QY%
M?J-:NJ))=C1F(C2F:;7)4.,1,1TH:2:66TDHR3E1ED\F S,   !9.I?VN+_]
MY-U?,4\7L+)U+^US?_O)NKYBG@(;7F2O[8W2*_Z1XGS_ %@36Q!H\ROZG:?:
M=ZD](<W?%Y6[:SDS41A<1%;JT&FJDI;KU6X^H*6\T;AIXB,^'LSS/L$QCZI_
M;]]^*POE31/+@'OX#P#ZI_;]]^*POE30_+@^J?V_??BL+Y4T/RX!]&J>W33;
M6&=!J-YPJE)DT]+J8YPZM-@()+R>%PE(C.H2O)?QBY#PZF='7MCHDJHSJ1:M
M6@S:PMIRJ2&KCJJ7)BV#XF3<-+R3/@5S+)F/:?JG]OWWXK"^5-#\N#ZI_;]]
M^*POE30_+@-_#P>IVC9U(L>VX5KV^AYFF4UM:(B)#[LIU!J/*34\\I3B\*P?
M,QK7@]'57H>^*9O/]-I2Y\U;9.V@='22.I;B]QI;[J)7#CJS_B^U[8S5^J?V
M_??BL+Y4T/RX/JG]OWWXK"^5-#\N WV^?DP5O;HUKC?WA77NOTKUI<T]EZE4
MU5-U.MIRC>>Z+D832ETN*4=]]2DT[J6W%F9QR1QY+.<"T-%NB#L73ZP]?])K
M^OE[432_6]UF8=K/0W894*ILO/S$S$2>L6X\93W2DI21D23222,BP-C/U3^W
MW[\5A?*FA^7!]4_M]^_%87RIH?EP)WGZOH[O\VH=70\:MU/;37]HEQ[JY56T
M->K$*I6M07+:(I5%CPZN55;AKJ'6G*E)0I*&T&XX9)(N1$62'M6L_1:5C5BP
MM [$8UI=HD/0QQ"X<KSGZ]=82AZ,Z2%9<RU@H_#Q&9_99Y#8=]4]M][/3BL+
M'OIH?EP?5/[??OQ6%\J:'Y<!O.^_W>+$#<MT=5-UKNS1S6.U+R] .OFC$(H=
MNZA1X*GW)"%16(<KNF"E:&GNOCL]6GKN/@)62Y\Q?NENRM4354]<]:[K+4G4
MR'3G:=;=3<A% ]#Z)4 Z?4'&4-&;9G-9,S41$G!GVF8R"^J?V_??BL+Y4T/R
MX/JG]OWWXK"^5-#\N!#"#2'HX;AT,UBUXU$T]UE>IMK:W15QI=DJHY2$4Q3L
M21&>=3,=<,W#4N0I["4E@RY8'0[>^C"JN@>ANL6C-,U>554:KOS7RK:J.32J
M,<^7*E2$DR:SZ[B[J4DL'RQDAG[]4_M^^_%87RIH?EP?5/[?OOQ6%\J:'Y<"
M=Y]/H^CN:QI_0UV/=.RF!M$OV_GZ^Y:M4G5FPM0&(CU.J%L5&?5U5EUY@H[J
M7UD<K@XDFZ1+)/"9&1F0]-V?='EK%H)5(]6UIW,U+7>1;5-E4O3YMZCN45%L
MQ9,-4(B>2AY2:@;;'5$1OI49]7DCR8SL^J?V^_?BL+Y4T/RX/JG]OOWXK"^5
M-#\N WF??WV8<;4^CSKNV[6_7K5Z7JP=X-[@%,(NVB*HZ89-L1&9$>*VU(XC
M-*FFGC3QMDE7+MYF/#[;Z(RI61>>OOH.USDT?2#7A*%5K3I5(7)D1)#;;ZD.
ME6W'#E*),IXW^!*R+!<!8+D-F_U3^W[[\5A?*FA^7!]4_M]^_%87RIH?EP&\
MQ]'T=R-MTCNTMS9?T7L;0R1J0[>'<^H-N2+?K!P%1W:>JI7M$EY1#XU+>)DW
M4I4K&"X,GCM/:W0]D=Q:\VOH/)UUU01?U@67:]O5)FVDTUN,Q5U'2X$J(3K\
M=1D2H#K;9X<)1F:,<C'N&NJMB^Y&G4ZDZPWOI_=5.I3R9$*([>E+C,MO(=2\
MA:D,SR2LTNH2M/$1\*B(R'J]GZW[7[#MRFVG;6J]B0J'2&$QH$5R[Z/(4RPE
M)(2WUSL\UFE*4D1$9X(N1 ;^W>9]NWW,%-_FLNVC5[3>\-EQ3E73J),>M>E,
MV(S3IB7H\:')C\!HGMM&EI+$5'&9DM)JQCEDQL%VJZ'4+;QH98NE=NH-JFT"
MG(=0A?$IQ"YR$27&EN+RM1M*7P=\>>][.0\"I\'813-8*IKQ$NO38M3ZP;1S
MKA>NZCOFXIEKJ6S3%<G&RV:6^1<!%SY]HR*+<]M]+D6L5@D1<B(KIH9$1>(B
M*;@B]H@/*/>??YWOX#P#ZI_;]]^*POE30_+@^J?V_??BL+Y4T/RX$/?Q'G\T
M_?<A=>?\Z67^D,8;F?JG]OWWXK"^5-$\N&@_S2MKEI%>?1-:W4&UM1K2K]8F
M52S>YJ;2Z]2YLR1P5^.I?!'C2G75<)<S-*#Y9,\ ,X>@6^Y<;9_\SS_]J4-Q
MPTY] PDT]%SMH(^WSGG_ .U*&XP    !0^P_</\ ,*BA]A^X?Y@$>;S1O^\G
M@?Z0M/OTPI8WMZ5?:OTU]X5G_HY3QHD\T;_O)X'^D+3[],*6-[>E7VK]-?>%
M9_Z.4\!?X
M        !]AY[/",)MX% T.K<.R4ZR7#YQ,QZHTNAJZA][NB64M@T(PT9&G+
MQ(3E7(B/GR&;!]A^X8UA=(S8=U7K3M,$6U1Y%55 KT=Z63!*RRV50C+-2N$C
MY<*3/GXB ;*Z0B*BFTY,-?'&338*(RL&7%&3'03"\'S+B;X3P?,L_!V8Z.W6
MG&:+1FG4FAQJBTIIQ)_P7&X;25I/VTF1D.\
M
M
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MEC>WI5]J_37WA6?^CE/ 7^
M                     "A\B,_:&O;?7KE?>C<'3YZRY<>*NN5AB+/Z^+'D
M\;*YK#)DDGTJ)!\#BBRGGDR&PD^P\]F!@QO-M?1NXX5BIU8NWT,,Q:JRNC+[
MD>D]UR>[&%);PU@T9=2A.3\8#-"ARG9E*I4EXR-V32:=)=,B(B-U^*VXX9$7
M81J4>"+L'<#JZ,W&;IE-1$<ZV.BF0$1UXQQQD1FTL+QX.-LDJQX,X':
M
M
M
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M[7/OY6G\94[RD8)>I/-G_K_N_P"/;C\O#U)YL_\ 7_=_Q[<?EX?CQE_D&/\
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M&6O\QP0%PT6FLT6CTFCQSS'I--@4U@_&S BM16C_ )#20&HPVIV0
M                                            "U[VJ;]&M"YJM%X3
MD4VA52:P2B)23=C0GWFR4E1&DRXD%DC+!ER,8R[%-6KCUMVY6OJ#=28Z:S4Z
MQ=$1\HS#,=GJJ96I4-CA:CI0TD^J:3DR21F?,^8R=O*+"FVG<<.HR>XX$FB5
M-B9*-)K[GC.PWD//<)8-75MJ4O'AX<#'#9):%AV+M\MJW=-KJ3>=J1:O<KT.
MOICKBE)D2JS)?F-=2LS4GN:0I;.<X5PY+M 9:
M                                     "A]A^X?YA44/L/W#_, CS>:
M-_WD\#_2%I]^F%+&]O2K[5^FOO"L_P#1RGC1)YHW_>3P/](6GWZ84L;V]*OM
M7Z:^\*S_ -'*> O\
M               %#[#]PQJTZ26U+@N:FZ6IH5*E5,XE>CN2$QFW%FT@JC%4
M:E=6E1D7"1GSP7(;2SY$9^T->N^S7"^-'(.GKUFR(K#E<K+,6<<F'&E$II<Z
M.R9(Z]"N ^%PR(TX,CP>0&=UN(6W1**VM)I6BB4E"TGR-*T0F24DR\!D?(QW
MHZ>A2G9E)I4EXR-R32:;)<P1$1NOQ6W'#(BY$1J4>"+L[!W
M
M
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M%\!"H
M   LG4EMQ[3^\VFD*<=<MBN(;0@C-2UJILDDI21<S49\BQSSV#"_HP:94Z1M
M!LF#5X4N!.;N&]E.1IK;K4A"7+DFK;-2'B2LDJ09&G)8-.#+D,WKUJ;U&M"Y
MJM&))OTVA56:R2DI4DW8T)]YLE)5E)EQ(+)&6#+D?(8S;%-6K@UMVY6OJ#<[
M49FKU.L71$>;BQV(S)-TVMRH;!I9CH0TDS;;2:C))&9\SR?,!F"
M                                             &2/L/(  !G/8&0
M4/L/W#_,*BA]A^X?Y@$>;S1O^\G@?Z0M/OTPI8WMZ5?:OTU]X5G_ *.4\:)/
M-&_[R>!_I"T^_3"EC>WI5]J_37WA6?\ HY3P%_@
M                                      'V&,$]Z%@:8WQ"L5O46^$V
M<W3ZLT]3%JAKE=W/IF,+2UA)EP<3B4HS_?9[!G6?8?N&-6G22VQ<-QTW2U-"
MIDRHJC5YA<@HB75&T@JA&4:E]4D\%PD9\_ 7N@-F]&:88IE-:CN]<RU2X#3+
MA$9=8RW&;2T[@^SK$$2L>#./ .U'16XA;=$HJ%D:5HHE)0M)]I+1"9)1'[9'
MR,=Z
M
M
M         'S(R\8"A]A^X?Y@&#6]+0Z)K/1;.A2KNBVJ5'J\66AZ231E*-J:
MP_U2>M<065&@DE@^T_Q#-"B1"A4JEQ2<)THM+I\4G"QAPH\5MHG"QR+CX>(B
M+E@R&KGI/3J)6QIKYWG4B5Z(H/'YW'))9EYYQ<\?<W/AQV\7+';R&SNU^+S@
MH/%Q<7G!1^+BSQ<7<+.>+//BSVYYY[>8"X0
M
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M_P"\G@?Z0M/OTPI8WMZ5?:OTU]X5G_HY3P0O\
M                                    %#Y$9^T, ][^NUVZ+P;!?MA$
M5:Z[6&(DONF-'D$3:YK#)\!/H423X5JYIY\O&,_3[#&#^\;2_3O4>%8[5]WL
MU:#=+JK4BG+<CF_W:\F6PXEHN%1</$M*49\9@,RJ)+<FTJER7<<<FE4Z4O!$
M1=9(BMN+P1$1$7$H^79XL#MAU='89CTVFLL.D\RS38##3A%CK&FHS:&W<>)Q
M!$KVLX':
M
M
M             !\B,_$ 'S(R\8#!G>EK=2M'*+9TRIV5&O!-7J\6(VQ(=;;3
M$4Y-89)U)N(5DTFLED18^Q[1FC1929E*I<E#1,IDTNGRDM$>2;3(BMN);+'(
M^K)7"1EX"^##C>3H">N=&M""5U0[9\Y*M&F];+-E*9/536'^K1USB,FKJ^$N
M')Y,C&8]&A]P4NF1.L)WN2ET^)UB<8<[FC-M=86.6%\/$6.6#Y& [4
M
M                                              !;5Y5-RBVG<E7:
M;2ZY3:)4YR&UD1H6N+#>>2E1*RDTJ4@B,C(R,CYD,;MD6KU3URV]VUJ)5Z=%
MI4VIU>YH;D.&TRPPA%,K,F$VI+<=#;1&M#1*49)R:C,S,S&2=WTYBK6M<-+E
M2BA1JA1JE#?EF62CM2(;S3CQERR3:5FLR]H8\[,M+[<T>T$MRQ;4NYJ^*+3Z
MK<<IBX6628;DN5"KR);[)-DI1$<5UQ3)GGF:<@,J0
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MWMZ5?:OTU]X5G_HY3P0O\
M                    %#[#]PQJJZ2ZDUNITS2HJ1!J$PV;@CJ>* B0LVTE
M48IFISJ$F9$1%_"P6,C:J?(C/VA@'O?UUNG1B#8#UML0WUUVL,1)7=46-))+
M:YK#)\'=#:R0?"L^:<'X<\N89OVTE2:'1$K(R4FATA*B5G)*3"9)1'GGDC[<
M\\]H[X=31);DVE4N2Z1$N32J=*7@B(B7(BMN+(B+D1$I1X+L+P#M@
M
M
M                                                         %#[
M#]P_S"H'R(S\0#5'TGJJHFV--?.QVJ-*.XH).'3%2DJ-/GI$R3G<ID9IQV\7
M+ V=VOQ><%!XC4:O."C<7%GBXNX6<FK//B,^W///:,.MZ.MM)T<HMG3:I94>
M\4U:K18K3,AUMLH:G)K#!.I-Q"L\)N$O'+['M\>:-%E)F4JER4-$RF32Z?*2
MT1Y)M,B*VXELL<CZLE<)&7@+X [4
M
M                    !9&I1.'I]>A-$M3AVO7"0ELE&LU^=LGA)!)[[B,^
MSAYY[.8PJZ+IFHL;/;(;JC$^/,*XKW-QJI(D(EDD[EFF@UIDDEXDJ3@T<18X
M3+AY8&<]Y5-RBVG<E7:;2ZY3:)4YR&UD1H6N+#>>2E1*RDTJ4@B,C(R,CYD,
M;MD6KM2UQV]VUJ)5J;%I4VIU>YH:X4-IEEAM%,K,F$VI+<=#;1&XELEJ-*>:
MC,S/(#+8
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MLZY/B7_(5^H.N3XE_P A7ZA"3_9"O-$OL09/Q]1O[,/V0KS1+[$&3\?4;^S
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M&RG=?816-78;3ZZ]15284AR ?G:N;&RY';3Q]822/D?+/BP)BJ3SGVE&7P&
MY      "A]A^X,%MY^D]CZG0K%:O&_VK(12:LS(@N.1.Z?/!Y,QAQ+)%Q%P9
M4DD9Y\U9,9TGV'[A_F&J#I-XM3DTS2@J=$J4HTW!'-PJ>U)<-"?/&+DW.YTJ
MP6/XV"QG/+(#:91H[4:F4UAEXGVV*9 8;=(L=:VS&;0VZ1> G$D2L>#.!V@Z
M"V245"H9*)1**A4@E$HC)1**$SDE9Y\1'VD?//:._
M
M
M                                              #YD9>,!0^P_</\
MP#!;>KH//UMHMFP85>AT15&J\68MR6[';)Y+4YA\T)Z]Q!&9DCA[TS/)XYC-
M2B1%0:52XJEDLXM*I\0U%C"CCQFVC46.6%&G)8Y>(:M^D^>J35KZ:G3Y%2CJ
M.XH/&=.<DMJ4GSTB9)SN923-..7?9+!GX!L]M?B\X*#Q&HU><%&XC49FHU=P
MLY-6>?$9]IGSSV@+A
M
M          6W>-.:JUJ7'2WY10F:A1:G#<EJ(C*,B3#>94^9'C)-$LUF7A)(
MQQV3Z74?1S;];5B4*[6;WIU.JURRFKA8:2RW*74:Q)ENLDVE2B(XJW#9,^(\
MFG(][U+X_2^O7JR6:_0O7. F\FLU>=LG!()/?&HS^QX>>>SF,*.BX1-1L[LA
M-0;G-RO1%?'&BI)?1+))W+.X.,I)$]PFG'!Q<N'&#P V'
M                                             "A]A^X?YA44/L/W
M#_, CS>:-_WD\#_2%I]^F%+&]O2K[5^FOO"L_P#1RGC1)YHW_>3P/](6GWZ8
M4L;V]*OM7Z:^\*S_ -'*> O\      <5_8G^+\Y"$EYJDY[L^C$2?,CO6LY(
M^9'_ ,)T[M+L,3;5_8G^+\Y"$EYJC_?:=&'[]:S\Z4X!,QL*!$79%E&<2&?_
M !.MGFJ*RH^5'B%CB-!G@N6"[/\ SN[SMB?]S@_DC/\ 4%O:?_N'LKWG6U\T
M1!>(#K_.V)_W.#^2,_U \[8G_<X/Y(S_ %!V  .O\[8G_<X/Y(S_ % \[8G_
M '.#^2,_U!V  .O\[8G_ '.#^2,_U \[8G_<X/Y(S_4'8  Z_P [8G_<X/Y(
MS_4#SMB?]S@_DC/]0=@ #K_.V)_W.#^2,_U \[8G_<X/Y(S_ %!V  .O\[8G
M_<X/Y(S_ % \[8G_ '.#^2,_U!V  .O\[8G_ '.#^2,_U \[8G_<X/Y(S_4'
M8  Z_P [8G_<X/Y(S_4#SMB?]S@_DC/]0=@ #K_.V)_W.#^2,_U \[8G_<X/
MY(S_ %!V  .O\[8G_<X/Y(S_ % \[8G_ '.#^2,_U!V  .O\[8G_ '.#^2,_
MU *G0R6G,.%C!\BB,$?9X^#/_P"(=@.)_9)_'^8!!CTO;2SYK*U3;0E"$DQ!
MPEM)(06;37V)21$7P<Q.;1V*_P -7YQ!HTT_ZV=JI_D\#]$UB<NCL5_AJ_.
MY@      ?(C/Q#!'>GKU5]$X5B/TJD0JH=>JS,-XI;$9XF4+F,L\2.O;7PGA
MPS[W',BY>+.X^9&7C&"V\[12@:O0K%9K=^1[+31:LS)CK>80]W>M,MATF4\2
MT\.5()'+/V7,!FI1I:IM,IDI24H5*I=/E*2DB(DJD1FW326.6$FHR(BY8[!V
MHZNC1D1*93(S;Q/)CTR!&2X7+K4,1FVTNX\'6$DE?C^'M
M
M
M                                                   ^7, /F1EX
MP&#.]+5^S]**+9\NZ[ 9OEJJ5:-&BL.RNYBA..36&4O$?"KB-*UI<QX33CPC
M-"BR6I=*I<AIDF&Y%+I\AMHCSU3;\9MQ#.?"3:5$C/AP,(=[^A%QZV4.S(5
MF0XCE&K$66^<N5&C$MMJ='?4E!R'$$I1I09$2<GG\0S=H<1<&DTJ*X:37%I-
M.B+-)D9&N/%;:49&1F1I-23P9'@_!D@';@
M
M                          +;O&I><UJ7'5NI3(\[:+4YO4*QPO=RPWGN
MK/)&6%\'">2,L&,<=D^K7IV[?K:U!\X(]M>>56N6)YTQ2:)EGSMK$F'UB290
MA&7NKZQ6$]I\\C(Z\::59M2XZ2;Z8I5&BU.$<E6.%@I,-YDW3S@L-\?$>3(N
M7,8Y;*-)VM%-OUM:?LW%'NENFU:Y)95B-U?4O^>58DS#;3U2EHRP;G5JPH^:
M3R RQ
M     %#[#]P_S"HH?8?N'^8!'F\T;_O)X'^D+3[],*6-[>E7VK]-?>%9_P"C
ME/&B3S1O^\G@?Z0M/O;_ /;"E^(;V-*W$ITNTTR2^=@V=C"%'_[.T_MY<O\
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ME&@FSE4V!+-!8P@Y$9#IH+!8PDU8+'+!<B':
M
M
M                                         *'V'[ABH'RY@-572;U"
ML0+8TW529E2B+<N&"3IT]R0A2TG5(A*)SN=23-)EV\1XQD;-;8-2J#0C6:C4
M=!HYJ-1F:C4<%DU&K//B,^TSYY[1B%O)U7L32^C6A*O:QVKS8J56C1H;#L@V
M"AO.3&6DO$9)/B-*U)<QX>$9D4:0U*IE,D,-$RU(IE/D--D>>J:>C-K;:]QM
M!DG\0#M0
M
M%D:E\?I?7KU?'UGH7KG!U?%UG%YVR>'@X>^X\XX>'GG&.8PIZ+GN_P"H\LCS
MS\\.[/1%?'6>>?='=?#Z)9O!Q]U?7N'@QP9Y<..'D,Z[OJ::+:UPU=<=,M%-
MHU2G*BJ,B3(*+$>?-E62,L.<' >2,L&,=]F.KT37+02W-1(5L1[/CU.JW'#3
M0HJFU,QSIE7D0E.I-I*$9D&UUIX27-7,!E4
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M(B0TTE+:"(O E)$ FC6!^X>RL=GH/MK'Q1$%X"SM/_W#V5[SK:^:(@O$
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M'\/:#H+9XO.*A\7%Q><5(XN+/%Q=Q,YXL\^+/;GGGM'?@
M
M
M                                                 !\R,O& H?8?
MN& P+WOZ$7/K90[+A6Y)B1W:-6(DR0<J1'82IMJ='?423?6@E'PMJ(B3DS["
MSD9O4.(Y!I-*B.&1KBTFG1%F1D9&N/%;:498R6#4D\'X? -97277!7J%;.G*
MZ)49U/6_<,%#RX:WDFX@ZG%2:7#941FDR,R[[E@S&RRV5K70J&M9FI:Z#2%K
M-6<FM4%DU&>>>3/F?AR N
M
M              !;EWTLZW:UPT<GDQSJ=&J4#KUX)+/=4-YCK%&9D1$@U\1F
M9D1$7,QCOLPT=<T(T#MS3ARO1KD72ZK<<PZM$4RMAXJI5Y$TFTFPM;>6>MZM
M6%9R1Y(CY#W34HUEI]>AMFLG/0O7. VS43A*\[9/":#3WQ*S]CP\\]G,85=%
MRNH.;/+(75':@],.XKWXW*FJ0J6:2N2:3?&<HS>X23C@XN7#CAY8 ;#
M
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M_P"'B+'+!D.T
M
M
M                 #[# 4/F1E[0#!;>KJ/ISI_1;.D:@6*F](T^KQF(#"I:
MXO<;ZYK#:'LI(^+@<4ES'][@9J41YB12Z6]'9ZAEZET]YEKB-75,NQ6UM-9\
M/5H-*<^'&1@COMT.O+6:A61"M%$53U'K427+[IF1HI$TU/COJ-*I"TDH^%M7
M)//."[1G708CL*D4F*\1$Y%I%-BN8,C+K(\1IIPB,N1EQ)/!ER/M =R
M
M                                                MN\:BW2+4N.J
M/1BF-4^BU.8Y%49$4A$:&\\IDS/)$3I(-!GX"4,<=D^J=+UDV_6W?E'M1FRX
M-1JURQ6Z!'=0\W&53JQ)B..DXA*4F<E;9O&6.1JP,C;RIBZU:=QTEMQ+2ZE1
M*G!0ZLR)+:I4-YE*U&K"2))K(S,S(L%S&-^R/2*=H=M[MK3RHU2+695,JURS
M%SX;K+K#B:G69,U"$KCK<:,VDNDA1$HS(R//,!EJ
M                                                     XK^Q/\
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M3)*&B93)ID"2ELN?5I?C-N):+LY-DKA+W/@[0
M
M
M                                         !0^P_<,5 ^PP&K+I+[D
MKUO6SIRY1*G+IJW[@@MO*BN.MFXA53BI4E?5J29D:<D><\N0V6VRM;E"H;BU
M&I:Z#2%K49Y-2UP65*4?MF9Y,QAOO3N_2.U*+9SNJ=G>BR+*J\9NELG+=B]R
MR536$-NY;SQ<+QH7@^WA(AFE1'(SM+I;D5KJ8[E+I[D=O.>KCKBMJ9;SX>!L
MTISX<9]T.V
M
M   61J6:TZ?7J;9K2LK7KIH4V:B62BILG!H-/?$HC[#3S(^P84=%P[.?V=V0
MY4I$Z3+5<5[\;U16^Y*4DKDFD@EJD&ITTDG!(XCP2<8Y#.F\9\>EVI<=1EQ2
MG18-%J<N1#-7"4EF/#>=<8-7@)U"#09^ E#'+9/J/:^JVWZV[TL^SF[$H4^K
M7+&CVVU([J1%=@5B3%D/$]PIR<IUM3YECO35@!ED
M                                                     "AEGPF7
MN'@5 !QX?[Y7PAP_WROA'( ''A_OE?"'#_?*^$<@ <>'^^5\(</]\KX1R !Q
MX?[Y7PAP_P!\KX1R !QX?[Y7PAP_WROA'( ''A_OE?"'#_?*^$<@ <>'^^5\
M(</]\KX1R !QX?[Y7PAP_P!\KX1R !QX?[Y7PAP_WROA'( ''A_OE?"'#_?*
M^$<@ <>'^^5\(</]\KX1R !QX?[Y7PAP_P!\KX1R !0BQX3/W3%0
M ^9&7C&#^\;;^]KC#L=AJYH=N^A^JLS%+E+824HD2V7N!!OK01YZOAPG/-1>
MT,WS[#]P_P PU0])L[56J7I1YV/U1@SN"/UITU<I!J3YXQ<D[W,9&:<<N^Y8
MR VET>(<&FTV*:R<[EIL")QIQA?<\9#1K+!XPKAR6.6#Y&.T'06R:CH5#XC4
M:O.*D&HU9XC4<)G)JSSXC/MSSSVCOP
M
M
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M*B5S(C_&6 '(!0S))9/^@LBH
M                                  "VKRI;E;M2XZ0TM+3M3HE3@MN*
M,B2A<J&\PE2C49)(DJ61F:C(B(N9X&..R71ZIZ%;?;:TYK%1C52=2ZM<LQR9
M$=9>86FJ5B3-;2E;"UMF:$.DE1$K)&7?8,>^ZDK<;T_O-;*E(=1;%<4VI&26
ME::;)-*D&GOB41X,C+F1]G,87=&!.J=1V@63+J\J;,G+N&]DN/U!;RY*D(N2
M:ELE*D&;II2@B)&3P2<8Y -@X
M          9X  %,\\8/W<'CX>P5      %#,DED\_B+("H"F>6>?P<_@%0
M       %.(LXYY]HCP7NGX!4
M                      ^1&?B&$>\+6VU='X=D/7+84>]DUNJ,Q8C;SZ62
M@.+EL-$\GB0OB,E+)?@/O>T9N'S(R\8P2WI:"U36R%8C%-K4*D'0:LS+=.6]
M':)]*)C#W"CKW$<1X09$2,GD^0#-JD26Y=-ITEIDF$2:;!DH:(\]4V_'0XAK
M/A)M*B3^+X.S'54:(J%3*9%4HEG%I=/BFHC(R4J/&;:-18Y84:<ECEXAVH
M
M                       .)*)6<9Y>$R,B_$8Y  #B2B5G&>7A,C(OQ&*D
M><E@RQXR,L^YD!4       %#,DED_P"@LBI'DL_GY'\
M
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M==9[H>X5/.NFHG%NGC!E@B+D0S<($>H        %",C[ %0
M    <>(N+AYY]SEX^T<@ !Q)1&9D6>7M'CX>P<@ !P4LDXSGGXB,_P PJ2B,
MN+GCVR,C^ !R <"61^ RSV9(R(_QCD9D7C/VB(S/^@!4!0C(_&7M&1D?](J
M        ?^NS'YP       !;EWS8M-M:XJA-C%,APJ-4I4F*9\)2&&(;SKK)
MJP>"<0DT&>.1*R,=]E^H%GZG:!VY=]BVJW9EN3:K<<>+06WCD(CO0JO(C2GB
M=,DF?=+Z%/&6"QQ8&0EZTQZLVC<M)CFE+]2H=4A,J6I*4I<DPGV4&I2C))))
M2RR9G@BYGR&,^Q?26O:([=+8T]N1^+)JU,K%SRWG8;[$E@VZG6I,UDDNQE+:
M,TMNI)1$K)'R/!@,OP
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M^K<<4@B4?81=G8")C9["  "
M   %#[#]P_S#5!TF\BIL4S2?SNE5**:KAC$X=/=DMFM/GE%(R<[G4DS29<N^
MR6,^ ;7S[#]P8+;SM6[*TNA6*[=^G[5\(J]6:C0FW)?<WG>ZJ6PT3J3X3XS)
M:DKQRSPX\)@,R[9,SH5#-1J,SH5(,S5DU&9PF<FK//B,^W///:._'5T:0U*I
ME-?99ZAM^F0)#;6<]4V]&;6AK/AZM)DG/AQD=H
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M223P]AF781,;?1\^_O/L;&@  0
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MS(A[T!,[_-R@  !     *$9'V"H
M H?,C+VA@-O=T)N?6B#8+-NR8<=="J[,N5W5*C1B4VB:P\9(.0X@E'PH/!)R
M>>7:,^3[#]PQJHZ2^J5JFTS2HZ1.J,,W;@CI>. Y(0:T>>,4C)SJ%$9IP?/B
MR6,Y+D VA42(N%2Z7&<,C7&I=/BKP9'E<>*VVHR,N1D:DG@RY'X.0[8=#;2E
M*H=$4LU&I5#I"E&K/$:CA,FHU9Y\1GVYYY[1WP
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MY8(L;""(B[ 1,^'A'=\X "F2(\>,$*@
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MT^ 3AN%!@Q(7$K)J4J*PAE2S-63,U&C)F9GDS!3ML[$
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MHUEU:NU"14ZB]<%ZMNRY2W''EH9N.:VTE2G5*69(0DDED\$18+D"&?X
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M%78TTHTLRSHMO]9#-U!829I49GDR,\\Q)-06",O[Y7XN?8!,;;><1+F  "
M                             ^PQ@_O&U3T_TVA60[?%D-7@W5*HU'IZ
M'))Q^X7E2V6TNIPD^(R6I*_!G'XQF^?,C+VA@+O>T(NO6F#8+-LNQ6ET*KLR
MY?=,B,P1MHF,/'P'(6@E'PH5R3S\':98#.>COM2:;37V&B9:?IL!]ILCSU;3
MT9M;;6?$V@R3^+([0=31(CD*E4N,[CCC4NGQ5X/)&Y'BMMK,C+D9<23P.V
M
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MJHW?3U//J4XZJ/2Z[)AQD\2C,^%++:4I+."P-KX(GER
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M\^K;;;2WE2NU:UDDC4M65*5DS/)B[ 4]X               H1D?8 J
M &"/M+(  !CP^$
M6W>+\"-:EQR*HQW536*+4W9\?B-/7Q&X;RI#7$7,NL:)2,^#.1CCLGN+3:Z=
MOUM5G2:V_0G93]6N5N!1>Z')7426*S):GN]<[A:NZ)27'<']CQ8+D,B;XILF
ML6=<]*AD2I51H-5A1R4HDI-Z3!?9:(U*Y)(UK21F?(NT^0Q?V%Z477HKMMM6
MP+U89CW!3:S=4N2U'?9DM$U4JY*F1C2\PI;:LLN),R(\D?(^8#,D
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MGM/ [4
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MGS[4F,TA0B(B(B(B(B(B(BP1$781$781> O *@@
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M0".%W0E)DE759[WBSXP-N^/1&_U>_P!*2/UB/XQ /R.,@S,\GS,S^$\@"E]
M                                                    "S=1)+T.
MP[PE1UFT_'MNM/,N)SE#K=.D+0HL>%*B(R]LAAYT:MUU^]-IMF5^Y:D_5JO)
MK]YM/S9!J-UQN-<4QEA)FHS/#;24I+GV%R&:-XOP(UJ7'(JC'=5-9HM3=GQ^
M(T=?$;AO*D-<1<RZQHE(R79G(QQV3W#IK=&WZVJQI+;?H4LE^K7(W HO=#DK
MN>2Q6)+4]SKG>_5U\I+CN#Y%Q8+D RR
M           P7B   ,$786                           #!'VED
M                                                  %#YD9>T->^
M^K0Z]M8X.GK-GLQ75T.L,RIW=,R-%(FD3H[QF@Y"T$L^%LS(DY,^SW=A!]A^
MX8U9=)/=-?MNFZ6*H=4E4TY5?CHD'&<<0;J#J,5)I7U:DY(TF9'GP'^(PV;4
M.*[#I5*C/$1.1J33HSF#(RZUB*VVX1&62,B4D\&7(QW Z&VUJ<HE%6M1J6NA
MTE:E'VJ4N$R:E&?C,^9CO@
M                              P1]I9   ,%X@
M        P7B
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M>1CBE))[,_C/(&\_7]/>U<ZK[*;BMK<K4-UF@LLJ=>5VQ.X-0*"VE*47(AJ
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MT\9F9*P1F9D7BR>< /K $
M              "U+ZITNKV9=-+@H)R94*!5H<5"E$@ER),%]EI)J5R22G%I
M+)\BR,6-@&E=Y:-;9K4L*_8+-.N6G5JZY<J+'DL2VT,5&NRI<11/QU*:4:V'
M$*,B,S29X/F0R@U$DOPK$O"7&<-J1&MNM/LNI[6W6J?(6A98\*5))1>V0P\Z
M-:[J_?&TVS;AN:INU>KR:]>3+TYY1J<<;C7#,9929J,S^MMI2@N?80#/4
M
M
M   #[#&"V\VZ]'K9A6*K5:T"NAJ756FZ.@Y3L;N.2<QA*',MD9JPZ:%8/)<L
M>$9T'V'[AC7;OST2U"U@@:=LV+3(]0<HE98E5$I$R/%)IE$Z.ZI1&^I)+[Q"
MCPG)Y+'NAG]1G(SM,IKD5OJHZZ9 7';(S,FXZXS:F6\GV\#9I3GPXR.U'3T*
M*]#I-)C/I)+L:D4V,Z1&1D3K$5MMQ)&7(R)23+)=O:.X
M
M
M                                                 #[#SV>$!0^P
M_<,!A!O,B:%2J+9Z=:JBJGPDU:,=&43;[G',*8P;2<,\R^O]67?<N?/ED9ET
M4HA4NF%"5Q12I=/**?,LQ2C-]SJY\^;7"?/_ /%K@Z1G3N[[^MS3Z/:M%=J[
ML&O0GI2&_P#Z)I%1C.*4>"/D2$FKL\!#8O;C+L>B45EY!H<9HE)9<2?\%QJ$
MTA:3]M*B,C]P!WH
M
M       "V[P<IK5JW$Y6&NNI2*+4EU%G)EUL),-XY+>2YEQLDM.2YEGD,==E
ME0TGJF@-MS-%*.="T_75KD33:<;SSYM2VZQ)14E]8_\ 7#ZV83B\'R+."Y#W
M74W[7E[>]:N_-DD80=%69JV:6,9X_='?/86/_::< V,
M
M                                                 "A]A^X8UA=(
MS?=UV73M+UVS6)%*5.KT=F4;!JR\VJH1D&E7"9<C29I_&-GP\KU*T7T\U;:I
M3-]T1-8;HLA,FGI4\MKJ7D.(=2KO/LL.(2?/Q +XMUUQZBT9UU1K<=HM*=<4
M?\)QR&TI:C]M1F9CO!^$:,S$89CL)X&H[#4=I.<\+3"";;3_ .%"2+\0_<
M
M
M
M  !0^P_<,5 !KHW_ &LVH>D5OV)+L*KLTJ15JW#BSEO1&)1.L.5",RM)$\E1
M),VUJ+)<^>1G[;\I^91J/)D*XWI-&I<EY1$1$IY^&TXZHB+LXEJ,\>#.!XUK
MIM[M#7B#1(%UI4IJAS&IL7!K+ZZR^W(3]B9?PVR[?Z1[G!A-P(D2(UGJXD2-
M#;_Q<9I+2/\ ]E) /L
0                 !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>nt10002526x6_diagram7.jpg
<TEXT>
begin 644 nt10002526x6_diagram7.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( :X#+@,!(@ "$0$#$0'_Q  ?  $  00" P$
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ML1T'M5TF1L'TV@SGHXEQH[ZF')$B=$6R\XB06D2DHD)(Y5\HK$6%"AVZ.B+
MBLQF&TA*0&T%[8>!6_MWBU>G=9)\?6:V.Z/^@2KOM+!=]J*B:V4<[&2P6Z%,
M5LL3\.:^=ST5M.CTU:W<<]6KE=W*&MG2#[0%'8JRHL^RU-#=:VF>Z&JN$[E6
M@@F8J(^*%K%1U2YBY1[D<R-')A%=J2QZ@]O'VF.?R'UXO?8VD\)Y:U-Q/([9
M>%-MK.Z$=X4A7F @;[C?;TDUT@KM9^U'6Z9"N)1KO2HKV^"MM\?'QVVZ$_\
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M-IIJ=E922N;N2I#(YS4CF:GN]8Q6*BN;AKT]Y$3@;=]&FW'_ *^V:CO+Z/\
M!5451)15D+7*^%:B%K'.D@<J(Y8GMD:J-=ES%RU57B?9TI2J_+!%*4H!2E*
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M0L%B7 >5&G1CW@"CW$E#C7,=@KEW'C0C"\>1W]2E*$"E*4 I2E *4I0"E*4
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M=P!UK ++[%G^EV:2M-M9<'N.FV>15J:5:9B'WH$DI!)5%NJFT1) Y1S;LN*
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M[J%G5P>F*,U9<:L]N2ZY[VM16%*4PSO"4VA992@JV!7N:],#8=22?6=_^>]
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M^&&0-#8]3N4SNOJ->M:L3QVU.=[#BRGI .YD7B=(O#A(]/>3UO*!/B#OOO\
M57TE*L*CV9L%NDZRALULI'Z8=3T4$3T5,:H](]Y.:Z*F-"NJ[:7:*YLZJOOE
MUJXN"QU%=42QKXL?(K?-%XE2DK.XY0EL%92!RH"6QS$A(  &PZ] *V,?<O\
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MWWBZW&ZNIXZ>2OJIJR6&!'=3$^9ZO>C-Y55K-YRXRNF>)=5JNHV_/^8>)/S
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M7OEHN.EN>*D1V4:F6)-[]]56M$5&S5N-NMC#,#O5K4I?^T'G5Y-![19;UEF
M8M>.SNN4/,[(Y MM]FW//)D^!:WK5W$=%T0S*2N(]Y06#+2V@;(W"1L0-MGL
M,-A:U]VWS+&REAM(<5\RE[<RA]9/JKU6K9!9?,AN#!;>))4\W$80\KZW4H"R
M?G*J$[W'1/EE$Y=B]Q#CIKH/JK:^TXU.U;FX<J!IS=;9C;5IO'?(6C_5;$B.
M[&0V!S)3&<'< CHKEWJ9II)2G8C;SE$?43TH&D!9<"$<Q\5<B>8_6O;F/YZ\
ME#C]OIH*4I0"K5(2M*DJ&X4E22/6%#8C\XZ5=2@.H,%T)TRTWS7.]0L0QUNU
M97J4N"YF%S0\XM5U7;4*1#*T*\UONDJ('+XUQ%YX;M(;_J]C>NEWQA,W4K$A
M)3C]^=E.J][1+9[B1W$<DM)+C?0E(!W /C7>U6+W( !V\Y/AZM^OV4!U/J[I
MOICK7BL_2K4Z':\@QZ^O19$O'I=P9:DR78#R94=;3'/W^[+J$N#NT]!UW&]=
M!ZK=GQPM:T6W ;7G^!2+FQIDQ+CX8]&O=QM\RT,S4);D-MS(KJ)"PM"4I',O
MS4C8=*UG>)/BQU<M/ND;0W1.V9I<+?I_&]\4S["'EBWR?*,?;=2'6BL-JV<5
MN-TG8[?76YC'<+B&U$[\[+2]_65(!)'HZ[[T&3#'2;L^^%K1.-E,3 -/5P#F
M,?R6^S[A=IMWN+['=K:+<>X3W'I<8+;<6A?<N(Y@?.WK(31[1G3S0?!;=IQI
MA86\;Q&UR9LR';&G%.=W(N$E<N6XIU7GK4\^M2SS$^.U=I4H,G0T3AJT>@ZP
MW#7>)BS<?4ZZ):3<,A:D.H7,#+'D[7?L)(;=Y&O-3S@[>BN^  D;#UD^VJTH
M!2E* 58M"5@@@$$$$$;@@C8A0]((Z$'H1T/3<5?2@(YN+OLN>$'C-C/O:N:9
M6U_(>1P1,AM95:)++JT_[1TV\,J?((!_"%1\=ZA:O7N7?A[9EW.?;]3+BS9F
MHL^2Q8PQ.6H):9=<::#_ )3S';9*=_'8=!6U]7A=;0M)2I"5I4E2%I('G-K!
M2L'P.Q23Z:[&BN]UMS7LH+E743'HK7MIJJ>%KD7CO-8]&K\T.OK;3:K@YCZ^
MVT-:^/\ (ZJI89WMQKAKI&.5$RG!%0_)_P!1='[;H%Q$ZXZ.V=Z0Y:L)GP8T
M!,E3RG$!TK*E?AB5CG(W]7IZUQM3'=OSPF7WAJXR'N(NW6AY&E>O"TB\38C"
MW(EBDVB,B.UY2IL*[ORJ2L\O>%/C4-H5N4]4J0XE+C:T*"D*0L<R"%)W2>A&
MXWW!-;[=#6T-)>MAK5&R=9*RW-=15S'R+),V9CU5)9%<JNW9D=OM<NBIGLP:
M ]-5AJK)M[=7RP=51W-T==;WLC2.!U.Z-C%BC1B(Q.H>Q8W,1/=]W/%#R4I2
MK9*E/E\UAN3L:?0SOY1#NEHN[.Q\X>]4QF82".HV[G??:I..T&+^J_#)P'<9
M]M_UR%/M^3V+4&6RD.&$NTABQ6L3WD[E/.IH);[PI)\$[^-1W%*5I<;6 4/-
M.L+!&XY'D%M1_,":D:[.W+<)UCTUU?[+_7"[Q[1CFJ\5NXZ!Y-<BGN+)>;*'
M[W,BL.N%*6%7"X!I@%;K845] =]JU[Z;**LM59LIM[;X%D=LY<&QUJ,3+OPL
MTC'(YW/<RCXE75$61%5-==B.@ZLHKO1;7='UPF;"S:2W.DH5>N$_%Q1K$]&Y
MTWVM6.9$XNZMV,JFD<_0A*P00ZA#P((/FO)"TGIZTD5X'WV8[9=?=2TVDCF4
MKT ^H>)/J%>UE&$9YHAJ+E.@^L5JD8]J'A,]V,%34EJ'>;4XXLV>1"FJ2B)(
M2NWI9<(8<<*><!7G5\-G3+"[([(DRQ$;AR8KJ>0]XN:M#R5HA-(2>9SRM:0Q
MS(!Y>\!(JW*;:6ENNS:[0V9\%?$MODK(8UF9"Q\L<6_^&ED?E(7M=EDF\B;B
MIGAA2G:K9BKM6T[-FKVDUOE2X144\K8'SN;%+*V-M5!&F%J&/8Y)(]Q5WT)&
M>R.PQ6KG::\.\>T+5)@8D[?I%V=2T5)C=[!+K7E'_J>;E\WGY>;IMO7Z5D9H
M,M-MCP:9:9'J_!("/^5?GM]E/J_B?#5K5C7$8_I1/T[7ECUOM&I6/W1<I;T?
MG0W:K)<(#LQI*BF;WB9;@AIY0E>SAK>LSKB6T9TSQJTY-FV=6:RVZ\P8MPB!
M$R/+E+1+8;?"1&:<4]YH< _%W^HCIY[;=;42[8;25M\FIOP:S-AA;2I)US86
MT\:1JULF$1R*]'+E$1%RFAZ([![*P;&;,T-@IZEU8VG=-,ZJ=%U+IGU+UE5R
MQY=NX:K6XRN,'RO&EI[+U.X9M7\/A-]Y)N&*760TC;FYO(X$A_H/3_L_KWK\
MM3$)D>R09V,75_R:[VK*LHC/Q7$E*V^6\RT([X$#N>9(\SG YO\ =WZ5^E9Q
M"]H?H5AO#OG>IF'9+;<VE,VURTP,?$E$.X3%WE*[=WK419,AU$4O=ZYRM$<J
M3S; [C\\+BIL>.X_D]U$?3VXP[IJC>7[UEFKC8E^\T/>8J=;XK#00(#:N1WR
M1PL.I)4"5]>E95T/[95.R6TCHZ>B97NOJ4UM;%)4LI61O=4QJV5TKT5J(UJO
MT7&55#%NF#8NEVOV<;)4UTEO;8EJ;HLT5,ZK?(QE,]'0I"QS7+OJC%RW*HB+
MH?&__/VU\[E5S3:;%+F#SG'G8UH9;&Y4X_=G4PF4H ZD\[P&P!^?T5SJ>5EA
M 4ZPEEF*W^'<?;0VIIMH;NA:U!)*D@J W)W.W4[5E=P#\,2.*_5Y_43.>:P\
M*W#\KX1ZE9?=&S#MUYG16U7"Q1H9D]T)9-QB(CDQ%N %0*AMMON5M[MC1[(;
M-5ERJ98VU4D$D-NIU?\ [M36O;NQM8U$RYL:KOO?A$1&9SJ:5]'NQ]=MGM/0
M6REB>ZDCJ(Y[E5;BI%3T44C72.>JIA'RM]R-BKE7.Q_BIV]QD6"5H%V>_ OP
MLRE>3Y7GYS"^9U;  W(:8\O;O5G5.;&RE!;+B5-%P>'XM1\ ^:TG8 -,,L #
M_P#)0&_^5=W\7?$I)XR^)S+];F(RK=IY9?(\8TLL_@S B8]&%CER&&^5(2F:
MF(A[<H3OS#J?&ND/_B?;U-8QT(6"IL^R"5E>QT=??JN:[3H],2;D^ZD"OSJB
MN8BOPO!'ISR9;TY[0TMZVS=0V^1'T.SU%#9XMQ46/K8=:C<QIAC\1*J<5C5.
M""E*5<A3 '0@^JL\>RG[-? ^T8UFUUL6;7Z=9AA";";7,C^5N-1E3F%J=_!L
MNH;.Y1Z2.OAXU'M>KW%L-MDW&9N4#EB164)4M^3,F'R>(VRRD%UPJD+0#R).
MV_6MV[W.=P8Y+H!PX7K6W4"WN6S.M=BQ,EVV6R6Y4*#;9#GO>M14 H=_%6VL
M$I3TW'6M=/:%VD9;K#;+72U<E/=:JOCK(?P\SX:B&GIVO1\JK&YKFM>YZ,;K
MA<KS0V,]G79J:YWZZ7BJHXY[-26]]%+^)@9+!4552^-S84;(US'.C8Q7NT]W
M37*IGX/2KW,3PF8SD4>ZZE9)/U&ML=Y+HM)<N%M0KNU;I2IQJ1N1N!N"-C\^
M^]; &@W#+HKPUXE!PK1S!;1B%CM[8::$:,TN>X !YSMP4CRITDCQ<</B1\U=
M^!( '0;_ //_ .=75IM67&ON+TDKZVJK)$X/JIY9W)X+(YV/E@W0H[?06^/J
MJ"BI:*/]%+3Q0-7Q2)C<_/(  \*4I7QGV"E*4 I2E *4I0"E*4 KC;G>+59V
M?*;K<[;:X_ID7*=&@L#T?[62XVC<GP\ZN06H)3N?3L/;T^:M,#W3SQ#ZP9#J
MIPJ\%NB&87;#)6K%YN5ORVYV>0\B6VVF1$5'>"8RVG@EAMPKV"]U;'?IT &X
M?]T/ _EQAO[36;^=I]T/ _EQAO[36;^=K2\M'N5[B/NUHLUR':89XPJXV>VW
M!QA5IO'-'<F1&GULG:Y'F[M3A1S;^=MO\U<C]ZF<2'Y37.OU3>?ZE0XY=^GZ
MH;F7W0\#^7&&_M-9OYVGW0\#^7&&_M-9OYVM,W[U,XD/RFN=?JF\_P!2I]ZF
M<2'Y37.OU3>?ZE09=^GZH;F7W0\#^7&&_M-9OYVGW0\#^7&&_M-9OYVM,W[U
M,XD/RFN=?JF\_P!2I]ZF<2'Y37.OU3>?ZE09=^GZH;F7W0\#^7&&_M-9OYVG
MW0\#^7&&_M-9OYVM,W[U,XD/RFN=?JF\_P!2I]ZF<2'Y37.OU3>?ZE09=^GZ
MH;F7W0\#^7&&_M-9OYVGW0\#^7&&_M-9OYVM,W[U,XD/RFN=?JF\_P!2I]ZF
M<2'Y37.OU3>?ZE09=^GZH;F7W0\#^7&&_M-9OYVGW0\#^7&&_M-9OYVM,W[U
M,XD/RFN=?JF\_P!2I]ZF<2'Y37.OU3>?ZE09=^GZH;F7W0\#^7&&_M-9OYVG
MW0\#^7&&_M-9OYVM,W[U,XD/RFN=?JF\_P!2I]ZF<2'Y37.OU3>?ZE09=^GZ
MH;F7W0\#^7&&_M-9OYVGW0\#^7&&_M-9OYVM,W[U,XD/RFN=?JF\_P!2I]ZF
M<2'Y37.OU3>?ZE09=^GZH;F7W0\#^7&&_M-9OYVGW0\#^7&&_M-9OYVM,W[U
M,XD/RFN=?JF\_P!2I]ZF<2'Y37.OU3>?ZE09=^GZH2V>Z(.(' \&[+3B ,++
M\<GWB\0[3#M\*VWNW39+Y=G);<[IF-)==7L#ML$'ZJC+]R*Z\8K>.$;/< N>
M1V:U3L,GLONL76ZPX&QNUPDR-T)EOM;CJ.8H!'4;[;UUU)]R1:DY;+MT'5;C
M_P IU PMF0ARZ8Q<K+<U1[@TA:5]VI3TYQ*=RGHKE)!.XVKE;Y[D:FXWF%[N
MG#KQI9%HMA]X8@MJQBU6FY.)#T5E*'G77VIC9=[YX*="5[\G-T^8,N_3\LIY
MFY4-0L#  ^'&&] /_P#)K-_.T^Z'@?RXPW]IK-_.UIF_>IG$A^4USK]4WG^I
M4^]3.)#\IKG7ZIO/]2H,N_3]4-S+[H>!_+C#?VFLW\[3[H>!_+C#?VFLW\[6
MF;]ZF<2'Y37.OU3>?ZE3[U,XD/RFN=?JF\_U*@R[]/U0W,ONAX'\N,-_::S?
MSM/NAX'\N,-_::S?SM:9OWJ9Q(?E-<Z_5-Y_J5/O4SB0_*:YU^J;S_4J#+OT
M_5#<R^Z'@?RXPW]IK-_.T^Z'@?RXPW]IK-_.UIF_>IG$A^4USK]4WG^I4^]3
M.)#\IKG7ZIO/]2H,N_3]4-S+[H>!_+C#?VFLW\[3[H>!_+C#?VFLW\[6F;]Z
MF<2'Y37.OU3>?ZE3[U,XD/RFN=?JF\_U*@R[]/U0W,ONAX'\N,-_::S?SM/N
MAX'\N,-_::S?SM:9OWJ9Q(?E-<Z_5-Y_J5/O4SB0_*:YU^J;S_4J#+OT_5#<
MR^Z'@?RXPW]IK-_.T^Z'@?RXPW]IK-_.UIF_>IG$A^4USK]4WG^I4^]3.)#\
MIKG7ZIO/]2H,N_3]4-S+[H>!_+C#?VFLW\[3[H>!_+C#?VFLW\[6F;]ZF<2'
MY37.OU3>?ZE3[U,XD/RFN=?JF\_U*@R[]/U0W,ONAX'\N,-_::S?SM/NAX'\
MN,-_::S?SM:9OWJ9Q(?E-<Z_5-Y_J5![E.XCP3S=IIG>W(LCEM%X*BH)/*D
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M@CE/C4<D6#!M\?R6!#BLL]VIH;L-+>*%I*%<[ZD]XLD$]5'<GK7R#6'2RF)
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M2E* 4KP.2&6E)0XZTA2OQ0XZALJ_\(405?FWKS@[C<>!H!2E4W \2* K2E*
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M1K ?C$U8U4TWO^EK6F<-Z[RKRJ["=8V]FTW'N$)*.>2I)2SW7577\;PH29\
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M)6CG;;4%!/,.A%=[Y7FN,X5:G[UD]ZM]DMT=OO7'Y\IB.5 =0EE#RT%XJVV
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MFAI)PRZ/:-8O9,4PC%40[98&9<>'Y=(=N4@&:"F<MQ^8IUYSRE2EDA:R %;
M;=*ZZUKX'=!M:<5@XW>L95:%65R3)QR=8YLBT*M-PDNF0903;51^]_UGE=4A
M71>Q!Z;[AK_?TX<>\RVDW:W18*[A(G0H\%#9<7-?E,M0P@#<J\I6L,E.W4$+
MZ^C>M>KM6==#Q!VN)P]\+..OZU:RP''C*QZ"'H5J92A27W#[_J;7;%E+"%KV
M0\22 /&NP+/PJ<1^;9Y>^&S.>*N9>]'L4<BIDXXU8TP+E=;;(3W\>$JZ,/)G
M-&.T SWO>%2P.8GK4M.AO#3I#P]X[&QS33%(MICL(V<G3%*N=VD/*\YYU=RF
M%Z8>\<*E%)>( 5R@=-@&OAY<=/OR(X>RYXE<0QO2'".%[51N1ISK[AXG-9!A
MEU8?;A,.2'ER&T1KT^AJ%+\PE2BPZH [ U,6+M;>Y5(]\(!80DK6^)C!9"4C
M<J[P+*0 .NY/KK'G6[AGT?U9;3DF7XE&?R'&;5>)%EN]L<7:)C$E<1Q27'WX
M'<O2BE:4E(>6L#;8#8]("\4R;B4T^N^!:=Y?/O.3:7:VY!?[7:;P"^TK&K;9
MK@XP['=<;*GU^4M'N4K<6A0Z*!W\0X>OWRNN3.;M#^*?!]2\&R[A:T;M$G5_
M6._2;<M&*P&9#-K1[VR&YCO>7U+3EM!#395L7OQAR^/2OMN!;C"T[M>+8IPZ
M:GQ7=*=9<:95&GXC=6'VK6VMSSVDM7Y]MFW.E38YO,=\3MXFLY]#N&_2#1&T
MH8T^Q*+;G9\>/+F7"<I5UN3[\A >>6F?.[V6CF<6K=(=V .P  VKBN(+A-T7
MXC;"NU:BXLP](CLO.V^\6AURS7.'+0GO&)"YMN+,IX-.I0OD4X4D)*? [4'?
MIG^,^N[]UR*<N]O1 7<53H8@I;4Z9QDM>0]V$E17Y5S]QMR_3J(7C^UJRRZ0
ML0?X;;W&R#,L;>G2IT>!'8G,.0V%I<FMHF;.L)4(S;J=D+YB>GCTJ)SW\XOG
MN,)' %*UWF.\.PF&*Y(%K;1<7;5R>4IMYN 5[XC9&T?O>]W_ -^ME/13A+T4
MT,Q2!BV#8PMJ$Q'W=?N,Z1=9,A^2GGEO*D3U.N[2'5+44%7*D*Y0-A0<>U._
M*9^F3!W@,XM,<U$&7Y-FLM&'R\@-M@Q(%XC>]J!/MF\2X%4N4AA"N]D)4I/.
MK8[[(W],MR+K 7!3<$S8:H2FPX)J93)A%&V_/Y4%]SMMZ>>L8=7N#;0;6'$I
M>)Y3AR68,C=QEVRRWK*]'F!?>L20[;C'6>[D<KI3N>?EY3N":@CU4PCC?Q/4
MZ[\'.EVL\O+,#[L-67'G8+$*>("VC)\E-Y>=\K'<M$(YU/>=R[^)Z!JFF,^&
M/YQ_)*YQ3=IIHKP].R\:L\J+G^I+2VVHF(PY'=1Y#SA 2VFZ-\\;FZCP6>O0
M]:X_AU[3+3K5*Z6W#-5;'*T:U)NOG0L<N:93]LD(([QM8OSK+=O'.R4K\YX=
M5<HW/2L0N%7L>K7#=M^:\2EQDY+.\J,UK!)3SSC]HE-/=XEQ5Y0\IR2'70'0
MDK( '+X5*MK+PGZ#ZM8%\#\YPN*]9K/;'50)%N<5:[G!1 8YV5BYP0U-5W?=
M(/\ M#S ;'H=J$)E=5QCL^_K/8ADW"GQ+C':E0I,>9'>3SM2(CS<B.XD@$%#
MS2EMJZ'T*->Y6OCP'Z_9IB?%)<.&NR9O*S31M$J9&QFWS&E)D8LB$AU;K*ID
ME2Y<X.N(" I:CR@=.E;!;:BI))]"E#V$BAR+Z4I0"E*4 I2E *4I0"E*4 I2
ME *4I0"E*4!\=G]X9Q["LOOK\A,=%IQB^S>]4=@AR/;)+[9W]?,V GPZ^D5^
M5KJ5GUSUAU\UOU>O4A<VXYAE,Z$)3JRXHM66X28;025%6VS;:1L#L!\U?IS<
M7"9ZN'/5T6T.>5G#[X6^[WY]O>N7S;;?1WK\L'3P/"QW$2.;RKX89AWX5OS
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M="?1WJ0%D>CFJ,F7P1:F*E2],X>H#+&AEQO35Z?L_O/&7*0\U/\ ?/D\N/\
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M* H$@> JM*4 J@2!X"JTH!5JT)<0I"TI4E:2E25)"DJ21L0I)Z$$="#TJZE
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M)(Y=7/ZJ1&N<NJ[N555U7[NE*53Y<0I2E *4I0"E*4 I2E *4I0"E*4 I2E
M*4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4
M I2E *4I0"E*4 I2E *4IN/#?KZJ 4KT3<H =?9,Z%WL;D\H;\J9#D;G_$\H
M1S\S//\ [G.$\WHWKW$+0XD+0I*TGJ%(4%)/U$$@_F- 74I3<>&_7U4 I2E
M*53<?] _]'\U5H!2E-_1Z: 4I2@%*;CUTH!2E4W\?F^8T!6E*4 KHG7C0G&M
M<<6%DNZE0+E#4';/>FBYW]K>"TN%;8;4E1YE)3N-^H&QV&]=[;TH"+C+^SK3
M,Q9^ZX3J=<<6UO(:<&J"&I$@R3#(,1EZU*?##B4LH3&W<*NGG;$FHKN*+C6[
M1/0[+]/^$/(<:D)R7/TW*V8SK;"\DD.9JQ#;_"H-CBH7[V%#2A'+BR#NOO-^
MF];2Q V]&P(/S#KU^S?>HF]?[6FZ=H?PI7-4.)<+79V\P$^8M+,N/;%O6[9C
MRA:PXW#4XOHWWBFU*5^("=J$*FFFG!/EGR_DQ5X/>S?UHNULR#)^(C)+E8SE
M"F)[6)R93ER=CR4J4^S,9GI>4Y&YW5(E*:;Y?_5J&PJ6SAXX9K%H=)R2_KNK
MF39GE@BMWW))"7$.2H\#=NWLI9<4M+?D['*T5((YPG=77>LGFN0)/+MRDGEV
M/F\NYY>7KMR['IMTV^:N#RB^PL<L5UO$Z=!ML:!;IDCRNX2H\**E]N.M;"%R
M)+C;*2XX$I2"L%1.PWH2<YW[0<#7>-\Y_P!SG3WG^7^/]GSUY>8>L=?#J*@&
MOFONKZ\3RGB"@ZPN*R"U2Y\:T:4P[2B8F4RF2]":<9G,\Z'4]TE+_,E"@!OU
MZ[U[6F?&+Q<Y+;>'IO)L FV*P9E<KZB]9TJ0V^JX-1I@2PARVA <C=V#W0WV
MWZG;QH"?"E>E <6[%BK6>92XD9Q2B-MUK:2I1^;<DFO=H!2E* 4I2@%*4H!0
M]01ZZ4H" KW1CI=,SKLYM1;Q!C&5*Q678I(0CJXEM=V9+B@D;D@)22=O#T^B
MM$VTRFYUIMTMI7,A45ACQW\^.REIP;^L*20?97ZC?%;HO9]?M =3=++X@.P\
MCQNYJ;;*.\!F1(;[\,<OI49"4 ;>G8U^7*]B%^TNS#/-',IC/0\DT]R2\-S(
MTE!;=$.;<I"[>>16QV5&""-O016SOLVWV"FN-]L,SMU];##7TN5U>^ERR=J)
MS5(W,=X-4U>]IBQ35%JL6T$;5?';IYJ&JPBKN,JT:^)Z\41J/C<U>]S4[#WJ
M4^RE;AIKKVFG I2E *4I1$QH@%*5:=R0D#QV&_JW-0Y4:F5!X8=DFY9J'I7A
MUL"E7&_YC8'HK: 5J4B!>(3SI" #OLA))]7S&OU:=-H M>GV"VW?SX6(8VRO
M<;'G;L\1M>X]'G ]*_.L['?A^E<2O:)Z<*D0'9^%Z+NRYF5/);+D9MVX0N_M
MY6K;DW[YL<NY\1MOZOT@(D=J*PS'9'*U&9:BM)'@&HZ$MH'YDI ]5:$]/%Z@
MNVW<\-.]'QVFC@H'N:N6_B$5TT[>U%8Z1&*FN%:NNJF_G0'99K3L!33SL=')
M=ZRHN+6N;NKU#D9# [754>R/?3X7(J<3VJ4I5+%V"E*4 I2E *4I0"E*4 I2
ME *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E
M*4 I2E *4I0"E*4 I2E *4JAZ@CYJ ^,R'4'$\6O-CL%\N\>WW3(D2W+1'?4
ME E(@MEV20M92E/=(',=R-ZKB.?XIG#<MW&;LS=&X+A:DK9V*6W HH*0I.Z5
M;*21TK$+BJX>LLUHU,T8NEH=>B6'%(N4-7V:Q(+2F%W*$688Y$K2MSG<Z;IW
MV]-8<\/VMV/\'NK3?#/J0U<VYV47&1Y/DK[,UZ(SSN+DL#R@-K96' ZA!/>^
M83UH1P\.WR):]6M6\%T2P:\:B:B7ENQXO9$(5-G*0IY25.JY&4-LHW6XIQ9"
M=D@[;U$5G?;2Z96B1OI_@DS.8YD-LI>2])@O]VMP(+IBK9+J1RDK2".H'3QK
MG.+"Z?Z6W%/ICPLXY+>G:>8PM^XZV^2\RXS;;\=JY8\EXH(20^I   5MNKSO
M569-E[/KA4L>0+RF#IE$-Z=9ALOR52'#'6J"TEEM8B*W925! 4K9/G$^=0:]
MV-/'CK]"$C4'5WB.N5ZUZXJ--XV27+3?,YV M7?!0U,;<L[:'F(97 4XGOEA
M"EJ==\F0.8)\X['K/OPWZM8AFN&V>Q0,C8G93:+5;W[]:I2O)[I#=G1D/):5
M$>4)"R@J4G<(_P!W<UWM:\/QFS6ENR6ZQVN/:VTI3Y#Y#&5'6$ <G>MEOD=*
M2 4E:3L>HZU$_P ='#%<].IUXXP^'._R-/\ 5G&6DR,AAL!R5;,P9" PTPJ
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M4;1? LH:6E:9-GBP%+2  7+8PW#7O\X4T=SZ_KKO:A(I2E *4I0"E*4 I2E
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M0'F-)2?FZ>CH&OKP\/6?!"4K[Z8[._\ [[E7[(Y/_(4^^F.SO_[[E7[(Y/\
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MRL/O;*CIMSDQ"G(Z4RW0&9',E"C^")Y=NNU9K)4%#<'<;D>SI0%:4I0"E*4
MI2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *M"0!MUV^<FKJ4!:$
M@)Y>NQ^<[^VG(-MNO3P.YWZ_/5U* M" #ONHGYR33E&Y/7KX[DFKJ4!X^[&V
MVZ]O5S&K^4$@]>GAU/V^NJTH"@2 2>O7;Q)/A0 #U^GTGTU6E 6\@Y>7KM]9
MW]M"D';J1MX;$BKJ4!:$!)WW5O\ .2:H4 DG=0W\=E$?\*OI0%  D;#?\YWJ
MM*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
M*A#]T,Z43M7^RNXA<8LMMDW6],1[%<84:(AQ;Z_(+DB4]R(:"ED!""=P.FQ_
M/-Y7!Y)CEERRR7+'L@MT>ZV>ZQG8D^!*;0ZS(8>0IM:%(<2I/5"B =MP>HV-
M :/W9$^Z#N"WA'X#-(^'[6VXWZPZAZ>JOEMO%M58[W+Y%"Y.]WNZU%*=^5)\
M%$ ;#;<5)>/=4?9J?*J^?LS?_P"4J12?V+'9PW.=,N4SASL;LR?(>ERG._6
MM]]Q3KJP!L$\RUJ.P  \/"O5_L2^S8_NWV/_ #U_OH1Z]:<^9'K]]1]FI\JK
MY^S-_P#Y2GWU'V:GRJOG[,W_ /E*D*_L2^S8_NWV/_/7^^G]B7V;']V^Q_YZ
M_P!]"?G^W]>L^&(]?OJ/LU/E5?/V9O\ _*4^^H^S4^55\_9F_P#\I4A7]B7V
M;']V^Q_YZ_WT_L2^S8_NWV/_ #U_OH/G^W]>L^&(]?OJ/LU/E5?/V9O_ /*4
M^^H^S4^55\_9F_\ \I4A7]B7V;']V^Q_YZ_WT_L2^S8_NWV/_/7^^@^?[?UZ
MSX8CU^^H^S4^55\_9F__ ,I3[ZC[-3Y57S]F;_\ RE2%?V)?9L?W;['_ )Z_
MWT_L2^S8_NWV/_/7^^@^?[?UZSX8CU^^H^S4^55\_9F__P I3[ZC[-3Y57S]
MF;__ "E2%?V)?9L?W;['_GK_ 'T_L2^S8_NWV/\ SU_OH/G^W]>L^&(]?OJ/
MLU/E5?/V9O\ _*4^^H^S4^55\_9F_P#\I4A7]B7V;']V^Q_YZ_WT_L2^S8_N
MWV/_ #U_OH/G^W]>L^&(]?OJ/LU/E5?/V9O_ /*5:KW5+V:2 %+RR\MMA2 M
MQS&[ZA"$J.Q4I:H@2-AN>IZ[5(9_8E]FQ_=OL?\ GK_?6)7'%V+W -:.%?62
MY8-H%9[1DENQF?<+;.:?6IUAZ'$D/\[?3IMR;G<]>GST(U]?]?/[<.M9_NJ#
MLPVI'=6S/KC=FDI07'HN/WIP-J4D$I4&XR]MB=NIZ^JO4^^H^S4^55\_9F__
M ,I4.WN9/LU>%SB*T?URR[7?2BVYJ]&RB5;K&_,=4A<=F#>9T1QML)&PV2TA
M)*O0#T/A6TD.Q+[-C8?_ %;['X#_ /'7^^@U7N]>'K/@I'M]]1]FI\JKY^S-
M_P#Y2GWU'V:GRJOG[,W_ /E*D*_L2^S8_NWV/_/7^^G]B7V;']V^Q_YZ_P!]
M"?G^W]>L^&(]?OJ/LU/E5?/V9O\ _*4^^H^S4^55\_9F_P#\I4A7]B7V;']V
M^Q_YZ_WT_L2^S8_NWV/_ #U_OH/G^W]>L^&(]?OJ/LU/E5?/V9O_ /*4^^H^
MS4^55\_9F_\ \I4A7]B7V;']V^Q_YZ_WT_L2^S8_NWV/_/7^^@^?[?UZSX8C
MU^^H^S4^55\_9F__ ,I3[ZC[-3Y57S]F;_\ RE2%?V)?9L?W;['_ )Z_WT_L
M2^S8_NWV/_/7^^@^?[?UZSX8CU^^H^S4^55\_9F__P I3[ZC[-3Y57S]F;__
M "E2%?V)?9L?W;['_GK_ 'T_L2^S8_NWV/\ SU_OH/G^W]>L^&(]?OJ/LU/E
M5?/V9O\ _*4^^H^S4^55\_9F_P#\I4A7]B7V;']V^Q_YZ_WT_L2^S8_NWV/_
M #U_OH/G^W]>L^&(]?OJ/LU/E5?/V9O_ /*5QMV]U+=FS/MEVC,99?$/R++=
M8\97P9O_ %DOPGFXZ/\ T38<[JDI)/AO4CG]B7V;']V^Q_YZ_P!]#V)79L$$
M?Z-]CZ]/_2%_OH1KX^/_ %Z_;7:]S02Y_$?QO\=7%1'M-R9Q.]7G'WL>ND^-
M)B(FQW52VDED2&VRZ0@IW YN7P.U;PK:>5.WAU)]I^>L?N'GA<T.X6\7<P[0
M_ [=@UA=(+T6$E)6^0I2QWSW*''.4J/+SJ5MOL*R%H2@I2E *4I0"E*4 I2E
M *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*
M4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4
MI0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"OF,QQ&QYUC%\Q'(X@F
MV3(;=+M=SBE10'HLR.Y&>1S)ZIW;<4-QU!-?3TH##;@ZX%N'[@=PZ\81H'BZ
ML:LE\N4RZ7%E4R3+4]*FS'ISRN>0I2QN^^M0 .P!V%9DTI0"E*4 I2E *4I0
M"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
M *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*
M4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4
MI0"E*4 I2E *4I0"E8B\4O&KH9PDP;(O57(7HEVR8OC'K%;H,JZW*YF,1Y1W
M<2 AV0D-@@DELC8;^ -5X8>,_1OBKMN0RM-I]T,O$VVGLAA7BS7&S^0-R 5,
MN!RXLL=ZE2!S**=^0=3L.M!A>.-.TRYI49&L/:N<*6E&:W'3Q637/*LLLK@3
M>8F/6*ZW>% 'XRM[C;6)$1:DI"B4APD*3R^(-=[Z&<<.@'$%@N2Y]I]D=QDV
M7#HXDY,F=9+E;I5L3LL[>2S&4/.[]VL (2K<CIXB@PO89@4J)N#VR/!J_J!:
ML)FY5>[2U?KD[:K+?KGC%[@VV5.9?\F=:<E28K<9@>4$--E;@#FXY=]Q4@VJ
MNN>F6C.G\K4S4')XUDQ*-;V[GY?_ +9Y^&ZR)#;L6*WN]("FBE7X)*M@=SL*
M$X5.1V]2L;^&GBIT=XL--F-5M&L@5?\ #'W9K35Q>BOP5%4!]QB25LR4I<0E
M"VE]5 #8;^'AB7J_VMO"-I%G=WP*Z93=+O=,7DQXN6R+-8+K=(-D<EJ"8_-,
M@,/1W4J)/>*#@#7*>8C8T(PO82B4K&2X<7N@ELT%3Q)2\YAMZ2+CH>1D:4*7
MWBUN!E,=N,G\,M_OB&E-I27 KQ'C6-&A_:K\*FM^I-MTOLF2W.SY-D;CR<4:
MOEBNEHCWY,=)6\MB5<F&& $H 4D\Q"]QL?"@PO8294JU*DJ *2% @*!!W!"A
MN"".A!'4?-UJZ@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E
M* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*
M4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4
MI2@%*4H!2E* 4I2@%*4H!2E* 5:M/,-OG!]E75:KF \T;G<>S?K0$!/::<./
M$/C7$EH?QR:#8,-<%:-)OSN3:0SI,:/"N<*YQ4Q7'D*F]\QS1(X<DI2ADJ4M
M("=E$&N%D]I'IUJ]P:\2>=Z*XVQI?KYA%OM5DU-PEJU"WW#'W;VIRVE(4J-%
M,T=VM]276VU!*4A:2/&LW>*?67C<TAU(BS]&^'Y.NFF,MMQ-PA^_\"RJMZ^Y
M"6DD/I4Z^EYXG?IL!XUA/PI<!VJNL6LO%)Q%\4.GT;2:+Q!6JW0;=I+"D19$
M.TO6ZVOV^/,>DV_NFI"T.+1,_"-E16/$DDT.6=$SC3&.&<9X*GAZU/+P V73
MOA6[/7'-9(^GT35/,LNF7Z[95<IS*;Q<;LMZZOOK09$IJ8ZVF*'5I[M!VY4\
MO@ $Y3\#'$_PX<6+VO$/3;3N-BN3XRBW#4?'68JX;4A]QIY<!DL&.RTGG+:D
MGNT>=ONH&L&]#,0[1+L\\;RCAWL6A#?%7HK#F7E[3W*'[S;+$Y:FK]*DS%QU
MQ'TOOO)CKD(8!>Z%+>Z=MS78W9[<,_%WHBUQ;Z^9IIY%Q;4W7!VPS\5TT9E6
MY;=M59U/;QS.9"6%&0TI(YE)'*5?70E=<KE..BY[>6.Y/#'@8&]J+K7<-1+-
MBW#OD7#='T4TDE9O9UW77."PP^]CRK;D,63$Y6XD-F4@79]L,K4)  "RI6XK
M8/S[A\T4URT(P^1D\5>8VG"]*I*<:E-W*2U$DEO%@DR)#++G=R5*4TASE?"R
M@G8U$GQ//=H7QJZ0W/A=R/@UAZ:N9)?[.Y?]4QDMHGKM4"T7AF8F0Q#2VVHK
MF1VU=4.<R=]M_7)9E]JUMX6>&;#-+-$M)9.N]W9PZ=C]T2Y?6[*["ESK;Y(M
MSO9!=[U"'G%J W\$;;)!! A>"<$7*\%\->.AB)V-5G6K@[U"L%C;3%<7(U$M
M-H99 ;2P\N9>(D(( V"5)<4WYVP)(W/6H^.#;6+3?A"PGB.X?N+#3&Z'6*ZI
MS-Z/>IN,S<E^%S5P-VEVU0N:8$MJ"(,=YDH6'P1RC8C:L[^RDQCC1T @OZ0:
MQ<-*L8QN[W'(KT[G R>')3"=G2I=SBQ50&@5.\[KR8W-N-OQCTZ5]GQ :N\>
MV873-M*=/^"2P0YEW*[+:]9)=UQZ:ZQ:I_/%G350Y<5QQ:A"<4I*0X%#P'G;
M4)YN3DJYSE$_M.9!'IS9-5M7>RRA3L)L]XR7!],-2I]ZN. MO2 _-M<C/ESE
MJ[P\S[J8<9M3GD_(O9*>ZY0.A[W[0WC&T'UBQ;A6F:&8U<;+J/A]PQNTFZ-X
MS.QAVQ2/*K5!NL;O%080G(<[MUKF4I73=1)W.\XFC.@.I? /P6V[#=,-.86O
M.IL:1,N^161UV)9V+W*O5P7<)4929"5QD)@%]QM.R2E03YH\!6(KO#_Q0\>F
MN&E60:W\/]DX:M$=+YLB=<<;@FR7-[.I3A0_'4N5;X\=^'Y!-:"QOOS^&^U"
M<IG/)%7FG-.SBN?IX(3YX0XZ]A^(O/J*WWL5Q]QY1_&4ZNUQ5.*/SJ6I1)KZ
MJO1MT%JW0H<%@<K,&'%@L)^*Q$92RT/\"!7O4/S%*4H!2E* 4I2@%*4H!2E*
M 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4
MH!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I
M2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@+%H2L;
M* (]2AS#_">GV55*0GP]GH'U#P%74H#QEM)&QV(\=E + Z[] ?#_ *]-7!.V
M_4G?;T^KU#T?FJZE >/NT[E6P!/BI("5'ZU#J?SU>0#Z ?K&]5I0%-O2=M_7
MMM_S-6%M)5S;)!]82 K_ !>->2E 4V&VVPV]1ZC\^_C5J4!.VVP WV"0$I&_
MT1TJ^E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *IOUVZ^SI[:\3Q
M<"%]W^-W3G)\[@2>0>W:M6+1?M-.*Z_=O#J7P*YADK2M%[&(RK/CZH4-MUE+
MMD7/)3*2D2'MW %=5'E\/"@SC]C:CI5@*NNZ?]Y0'7;H"=O:-C5=U?%^T4!=
M2K=U?%^T4W5\7[10%U*MW5\7[13<^E/L(/V4!=2K=U?%^T4W5\7[10%U*MW5
M\7[13=7Q?M% 74JW=7Q?M%?&:BW]W%]/\XR-IT1Y%BQ+(;M%=5L0B5 M$R5&
M5UZ'9YI!V\/70'VN^_\ \B/^-*UI_<^?:1<1?: /<4[FNM\3>X>FF9*L^(N)
MA1XJ6H:;O<892%1T)#NS4=L$J)/3?IO6RQ0"E*4 J@._K_.-J^;S.?+M>(97
M<;>ON[A;\:OL^$O8'DEQ+9*?C+V/0\KS:#L>AVV-:U/8'=I5Q-<;VM'&CI[Q
M#Y&W>&=%\HB6W$6/(HD-<>')N,UD)VCI0IS\"RV-U@GIOOUH#9[I5@*MOQ?M
MV^PU7=7Q?M% 74JW=7Q?M%-U?%^T4!=2K=U?%^T4W5\7[10%U*MW5\7[13=7
MQ?M% 74JW=7Q?M%-U?%^T4!=2K=U?%^T4W5\7[10%U*MW5\7[13=7Q?M% 74
MJW=7Q?M%-U?%^T4!=2K=U?%^T4W5\7[10%U*MW5\7[13=7Q?M% 74JW=7Q?M
M%-U?%^T4!=2K=U?%^T4W5\7[10%U*MW5\7[13=7Q?M% 74JW=7Q?M%-U?%^T
M4!=2K=U?%^T4W5\7[10%U*MW5\7[13=7Q?M% 74JW=7Q?M%-U?%^T4!=2K=U
M?%^T4W5\7[10%U*MW5\7[13=7Q?M% 74JW=7Q?M%-U?%^T4!=2K=U?%^T4W5
M\7[10%U*MW5\7[13=7Q?M% 74JW=7Q?M%-U?%^T4!=2K=U?%^T4W5\7[10%U
M*MW5\7[13=7Q?M% 74JW=7Q?M%-U?%^T4!=2K=U?%^T4W5\7[10%U*MW5\7[
M13=7Q?M% 74JW=7Q?M%-U?%^T4!=2K=U?%^T4W5\7[10%U*MW5\7[13=7Q?M
M% 74JW=7Q?M%-U?%^T4!=2K=U?%^T4W5\7[10%U*MW5\7[13=7Q?M% 74JW=
M7Q?M%-U?%^T4!=2K=U?%^T4W5\7[10%U*MW5\7[13=7Q?M% 750'?UCZZQJX
MM]4KYHYP\ZIZCX^XB/><6QJXSK8\ODY&Y34-]QES\)YBN1Q*%<JO'PVJ)GL
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M3'/\KC77$LM91 O<-+>*1W'(CGX-TI>;4'4<K:U*V0H<VVQ]%;+O8H\"F6<
MO!)@FD6HP"]3 ]=+AF"TEL@S)\]R:!S-*4V2E3J@>7I_PJ7GE^DKVU4#8;=3
M]9W-"43'-5\<?T5I2E"12E* 4I2@%*4H!2E* 4I2@%>M)BL2T=V^Q'?1N#R2
M&4/HW'4'E<!&X/4';<'J*]FE 42D)2$@ !(      Z; #H!Z@.@JM*4 I2E
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M5R_"KQK:!\8EBNMZT5RER]&PJ0W?+9-@2K7<K6MQ:FVQ)@SD-R6^\4E7*5(
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M4IOF'XW+S>FN2I2A I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
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MP?5%[(+3:C<(%U1(8BH5;'69!83;F'&&B%D=Z&]]QN:V/@D $>O]VVP'H'J
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C4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>nt10002526x6_diagram8.jpg
<TEXT>
begin 644 nt10002526x6_diagram8.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( A(#? ,!(@ "$0$#$0'_Q  ?  $  0,% 0$
M    "04("@$"! 8' PO_Q !E$   !0," P(&#P,(!@0(#@,  0(#! 4&$0<(
M$A,A"3$4(D%1DI4*%189&C)56&%Q@9'1T]0C5[$7)#-"4I:ATA@E5G+!\&*"
MU>$H-#4V0T6RPB8G.%-48V1S=':$HK7Q=8.%_\0 '@$!  $$ P$!
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M(OE.G).,EVKAP/H  /&/8
M                                               MYW1[A+;VOZ,7
M-K-=D1Z;0K8>IS<YB.AUQPDSY;<4G"2RE;G"V:^-1DG!)+)G@=IT0UDM'7C3
M.V-4;(EHG6Y=$?G07VS,T\23)+K9YR9*;7E"B/J1I/..X >NY\GE 6*,;[--
M*AN\E;0Z2P]4;[I"$KN!YE#ZFJ.3L/PR,4A:4*92;R.A<2TF1^3(OA1+9<6M
MM#K+BD*,E(;<0MQ/4_C(29J+/TD .3DBP7G[AJ(Z=W>^"7MHUZVSZ.1[/]T#
M6O<VX(CU5\,\']I2HJ&E$KDX,WN;S,&73'02&1)!R8\=XT\//C,/XSG!O-I6
M:?LXL #E!DC[CR.HWU>M!T]M&X+RN6:U HMNTR94ITEY1)0EJ+'<?-!&?>MP
MFS0E)>,:C(B+.!8!L [3C0KM!7M2HNDCZVY>FM3.F5>-+:D17W%^%/QB6RU+
M0VMQ*E,FK+:5%PGGNZ@"2W/^(".#>IOHF;5-3]OVG\:S2N5&M-1J<%V?X9X,
M5)\ 4RDE\O!\[CYN<?00D+A5%$FGPYSG PF3!B2S-Q:4(0<IA#O":U83XIK)
M/?DP&.3[>15 'S;=2ZDE(4E:3[EH42T']2TY(_O'T
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M\)&7G4HR^HSSC[.X;A;TN&
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M>,><9P,8/Q)6=M'2] U)-0OZ6H5:%*HO]25)THU6M[GBG4@I*.<)O/6S)_\
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M_CMD;4F6;VK>N;DXW7(]W%0W:3(<XE(>1'I:5+)A:^ADDCZD@\>06$_X=_\
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MS))&HO%-.>G>)L$I))8+SF?VF>3 X2PWGS\>[/'!N   @
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M8)UYA"HD/P:*;+>7GB4L\]<Y'5$*0I!*2M#J5$2D.,*)U"B5U(^)"E)Z^;^
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M?OP-X #:E!)[L_:9G_$:*0E74^(OJ49?P,;P &U*23W?>9Y/[S&X
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MOKM6+ V',Z44BH2*=*U?JE/IQN19"X\A11JM%2:$*;4ESQB=P9$99(\'DN@
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M^"I]E_\ [ 3_ %]6?U(#CW>7W+P_A"G90?.:I/JB?^ ?"%.R@^<U2?5$_P#
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MUJ6W3K0MRAVQ26^53*!3(5*@-D9GP18,9N*PC)]3PTTDLGU/ ["
M
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M8+S%]Q#4 !I@O,7W!@O,7W#4 !I@O,7W$&"\Q?<0U  :8+S%]Q!@O,7W$-0
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M);,V&ZI:&Y#*TN-K4VHTK(E(,TF:5$9'@^AEUZ@"H@
M
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MM  >9:OW[+TSTTO6_(5)]NY-IT&IUI%+YW(\,]KH3TLVC=,CX.(F3+.#QGN
M'IA&1]2&HB&[);M.:CVEVF5ZZB3M+RTS3:MP5&B-04U7VT1,.GU2735.I>X$
M</$<?C-/DSP]>\2\EU(C\X  !F1$9GT(NIG]!#K+EX6TTFHK76(:4TI3**@H
MWVL1%/JX6B=/B\0W#^+QXSGH .S8(NXL /A&DL3&&Y,9U#S+J24AQ"B4E1'U
M(R,C,C^PQ]P                    QGO
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M9D4^6Q+3RW4DM!N$PXYRE&E192O"DGE)EDC'8@)
M                  ^+[R&6UN.*)"&T+=<6KN0TV1J<69G@L)21G]1 "W;=
M7N/T^VI:(WKK9J35X](MJTJ8^^HWEDE4J<XVM%/8:01DXLW9?+;\0E8XLJ+
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ME%(IE)I3BB\9A5$:>.G22;3PM<2V3+Q.(BR>1*&:25W_ 'ET,:D1%W$!&/\
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M_A6W098S[H;)[L<7_C$/O\O?W?8,G"T__-FVO_RY1?\ ^/8 +K]]2.Q@  2
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MOW[^IW\  "0
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M*=.I"2Y2C."E%I]:::?U1JRK4YT:U6C4BX5*,Y4JD9+#C.F]R47WIIK_
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M<)+/;A+CQ   @
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MQW$2$)P73!>0<X;4*):247<?4C(R,C(^Y23+H:5%U(RZ&7<-PQ%7)&7P
M
M                                 ?-QUMI"G''&VT(+*EN+2A"2\IJ4
MHR))?6 /H X351A/(:6W,AN)>-1-+;E,K0Z:?C$TI*C)PT]RB29\)]^!S0
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MBN&Z= +)K=T///5R8[4SGJ?)27$.)END;2B5U/E'^S(^XR+/E %U
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M";\4DS:#I-_#5-+T_4J:Q"^LK:[2[/CT85,?1RQGN-P  \\]
M
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MJ6VD6%&:[)1MX;R^CRNWMXFH  \$]\
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M@?<:]6VVVWEOBV^;;YM^)L222226$N"2Y)+DEX
M
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M/E"/>V:@ "BRM@
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M]*L;73[6&,4;6C"C!XX9DH).4N'&4FV^M@B(NX  >>>@
M
M                          !M4DE=_D\QX^SH-P
M                     #:I)*[_ / \#<
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MVLTOC,S7QE0X)+SGJ>%$9'D^\AZ0
M
M
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MS26FDE]"4(27V#E@ $@
M               &U1XQ]*DE]YX %'=N.WV*DFCO5VBLU5S^CI;M4A-U)?3)
M\,%;Y25=.OBMGTZBM#!"WV:MWYIA[(^T<=E7E6HMB5"6;/M&NK3(5#RNBL-G
MS&3D(AK\=7%U0>%#.*IEWV^]#@NE7Z#AZG07BXJS )7[6.VOJ7/SY>\^\NH
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M7/?T\PU
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M;;3PH;;0TVDOZK;220A/V)(A]@ "0
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M
M                                'QD1V)3*V)+#,AEPN%QF0TAYEPCZ
M&2VW"4A1&73"B,AQJ=2Z;28Y1:73H%,C)-2DQJ=$8A1TJ49J49,QVVVR-1GE
M1DDC,\F>3'/
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M]H'!\^6.7#Z&H  $
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M6W3+7"W6[HTRNVG732'",U.Q7VCDL84:<28B5F_'R9823R$<6#QD >M
M
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MM,I[Z&FW8$%UMD_V3;L1EQ#7_P!TA2#2V?=\4B'.  <23!AS&TMR8<22VC'
MW)C-/MIX<</"EQ*B3PXZ8+ITQ@:2H$*:TEF7#ARFD</"U*C-/M)-..$TMN)4
ME/#@N'!=,%CN',  <-V!#>=CO.PX;KL4C*.Z[&:6['(RP91W%)-3)&18,D&7
M0<6IT.CUE*&ZO2:75FD=4-52GQ9Z$'YVTR6G4HZ]>A%U%6  4J-1:5$4RJ-2
MJ7&..1E'.-3XS"HY&6#)A3;23:(RZ&2,9+H-M3H-&K/ 57H])JJ$?$34Z;$G
M$@S[S04EITD^?I@5< !2Z;1J52$K12Z73*8VO&6Z; C04'C^TF,VV2OM(50
M
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MUPI1?81C>-B"/!Y+&5*/[#/I_@-X'6
M
M
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M$9A"5RG.)7$9RYJD^$2E9ZD;ZUF6>GESZV #+[0
M                #3/7&#^O'0:@                        #0CSY_M+
M  U !H9X\AG]19 &H
M
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M\N\S^.<GS+]!7X!SD^9?H*_ 8 _OK7L@[YO=7]"F_HP]]:]D'?-[J_H4W]&
MR^SU\/OY=YG\<Y/F7Z"OP#G)\R_05^ P!_?6O9!WS>ZOZ%-_1A[ZU[(.^;W5
M_0IOZ,!E]GKX??R[S/XYR?,OT%?@'.3YE^@K\!@#^^M>R#OF]U?T*;^C#WUK
MV0=\WNK^A3?T8#+[/7P^_EWF?QSD^9?H*_ .<GS+]!7X# ']]:]D'?-[J_H4
MW]&'OK7L@[YO=7]"F_HP&7V>OA]_+O,_CG)\R_05^ <Y/F7Z"OP& /[ZU[(.
M^;W5_0IOZ,/?6O9!WS>ZOZ%-_1@,OL]?#[^7>9_'.3YE^@K\ YR?,OT%?@,
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M&^1Z+ZI@_DA[G*-\CT7U3"_)%>  4'W.4;Y'HOJF%^2'N<HWR/1?5,+\D5X
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MOD>B^J87Y(>YRC?(]%]4POR17@ %!]SE&^1Z+ZIA?DA[G*-\CT7U3"_)%>
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M;Y'HOJF%^2'N<HWR/1?5,+\D5X !0?<Y1OD>B^J87Y(>YRC?(]%]4POR17@
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MO X;$4U8_MFRA'%CR9%0
M
M                         ,]Y>;O   #/7        -JEDG&326?[2B3_
M ! &X!H:B+RC4  &AF1=YC4  &AJ(O+_ ,?X#4  &G$GSE_S]/<-0     !I
MDLX\HU
M
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M0
M
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MVHS9_6EI*2/[2', -YZL)>V   (
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M[(!Q
M
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M2'BX7*50*-3G$].CL*GL1G"Z>8VS+H>.@[   <0
M
M
M
M
M
D                                             /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>nt10002526x6_diagram9.jpg
<TEXT>
begin 644 nt10002526x6_diagram9.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( H@$E@,!(@ "$0$#$0'_Q  ?  $  @(" P$!
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MZ^H?Q20/[]4TU^E*\*4$C9W_ "&S_<*]/53[Z5_^"?\ IK=--?I2OS2XE1T
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M\I+Z/3[7>T_N]X/;]J_*38++,;89E6:SRF8V_EVI-LB/ML;]_00XTI+6_OV
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MI!]-Q)0K2B01HUV8N)2=$*W^221_?K5--?I2O12TIUO9W^"2?^E.\=O=YU_
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MM:7%)>+9*5$)4.T:U]]C==MYXN4ZV\:7MNVV]RY2IK+2$M,E7>A/[BCI/<5
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MM(2V@J]UD [UH>??\ZQ( L0J@DD@  <DD^P U);NL:L[D*J@LS$@  >Y)/
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MP]ZFVT$#VV03JL =3?39(X:O<,6M^3>&+W(<<:4TRZXE2'%]P5ZH[^[87O\
M>TGQO7M5OGPSNG#$\*QP\[YC;6H QJ#(N"YT]':ES3+BP$%X )/T]H[?)/\
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MX7FU GSL>1]JNB'C_'_$[JF?6W,X3-[XM6<'>7*0Q5J]>UDTCBBAO6XU/?)
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M0AN*XAP%,=[0/<![I_\ .I\ZL_\ [?V-N/C+TE*&2E /0$:1%%5HQRGQ0_\
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M\XXM:W''G%.K4I2BI1[EE2O<G[Z%>(\A(>48EP4W(CD*4EJ>6U,GW3W)2X"
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M'LYAI<EC</E;EBQ42F&J]D$\HD1;%@+ZG)(#"+A$C/@ECX'Y_?Q2]2>FV_\
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M5OVQ!<JQ7<7BH8?V7!8B=!8%F(+-5EBY ]3N*R LORN5.L[7W(K3CT15UO\
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M[JY?K^Q?D+I:ZAE\K7O!YL/CCD:2X)WRG?-8MB(*?1:==7';7V^JI7?HE/\
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MT<J]0_)%JA8OTV/8!D,5W'W(W4!;<N#;MHAP?EEOPG[)'6T9X,=HP$J=4H)
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MT4?,*\J!0\1IS_Z*C[Z]ZF+']1<='M6#'U:T-?,1+\,^)LPRHU: #YK%B"<
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M3*1(84ZYH+\@M)<_#S60;5+P_I9XJ=YWY$A(NV57)OLP7&7CV./27%?+EU!
M5W>FI:'/*"/!\CWJN/.>;NJ3D?*_]8*^2U8;?65+>QN W;H\I%F8=V&FU%.F
MWRZR4)/>-I\^*@F]NBV<U8EPPJFO"AK6KEPRE+=Z&3O4P>C\["N7:.6;Z]Q
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MO:E*::4I2FFE*4III2E*::5^,AH/L/,G]UYEUH@^Q#B"@[_D37[5X/M_,?\
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M@:;&_N/)((_ZY ZG.+;[FMG_ %CMUY<:@V-HK?LWID!84GR%*)&BD@D[3O\
MZ"$/#?%$KEK(7;2B0[!@P7>R<^&5K.DDZ2A/N2HI*3V>V_M4O;:PVV+.UKEO
M)2QO*C,]NTBNL^/'R^E''R/F;_J^4,LA?M\C4 [MS^\:>\<?0Q$4J02(BTJ<
MCQM5RAY_?32\,.U #V_,Z/&$[O'(YNYXVY<NED-LOV*75JZ69^2PGT7VFY")
M+3CJ$J 4]WA&@=?Q^U2>ZIN=KG=6./>,>.&(N,S,Q2AO)'XT9CYE*0&5$I<2
MA+B/42M7[BA[^/8U'7@3@"S8U9;(QD%T&.X-9WV77I<A1?D35!U*R1'4KYA
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MVTTAEM"I3 *6VDA"!VE8/@)  UX]J_*VYKBUV5Z<"^6]]9]D_,L@G^ [QO\
ME_.M>:_9AE632W9M]OEPFOO**UE+[S* 5'R E"PGP?'C5<9"O-XMCR)5NNUP
MBOLJ#C:_G)"AW)(4-H+FCLC[^#]ZRI.CO,'[S-CXDCDA*I:(-X^7DRJY'/([
MNT'Z\>VJD3?BH/QI,.TF:AW^\F3[;;Q\CY^P5VB5R.3V%R.?!?ZZV50H* *2
M% ^0000?X$>#7FHV]*^8WO-.)K'<[_*^<N 2ZVY(.N]P-N%".X G6D@>_DG9
M-22J',C2DQM^W0E96DIV):[LG/:S1L5)7D \'CGR =6KP.8@S^&QF:K))'!D
MZ5:[%'+QZB)8B615?MY7N7GM/:2.1R/&E*4KA:[?2E*4TTI2E--*\'V.O)^W
M\?M_C7FE--0JO+3,CE;,Y4I#;D^'\DF(EX)<4R%-:5Z#:]^Z?*NS7@>?:OOD
MMLRH\R/,:;=BNPI0?0^VDMZ]%?OW@I3K[:^]=EYPX?R2^RF<XXXN2K9EUO"U
M.Q VEQ%Y[@$I;67%!MOM0"D$@^^P=U C.;AUC9"Z]@ULX\<LDF5N-(NZ9L=U
M*VU?2IT#0">])*NT'QNH]R6XUVO':K7<+F;CR6+,M,XS'27X,D;4AD1&DA#+
M7FY?T95LA!P@=2R<<8M;S*8..>&SC<C99Y97K_ U'M1W?6<NJ,\?(A?EC&XG
M[0.T,&92 ,0]**E6?K+F6S&5J_0K\R7\TVRH^@3Z3A^L)/9X5O0/C7MK[W[5
M 'H\Z17>%D3,RS20+CG%Z(>>*DCO@+VKO 6"I*^\*.]:U4_JX72? Y3 [;G&
M5K_!6,IEKV63'<CG'P6V5HJS <JK*H[F4'Y">TCGG7#V'BKN+PTHOQ?#37K]
MJ^M/D$U(K+!HX3QX# #N91X4L0?/.NHYU%9F8AE4=^,Q+;7C-]_8R&&Y"%+_
M $;([!Z3B5)6>[6DD'?V\UJZ9%?.4\0Z(<4A81&?Q7'KWF.5L<A7RVX_Z5UM
M['ZT/MV\H]".B?VN)5H*:4$A'GVK:W6A#B%MK2%(<2I"TJ (4A8[5)(/@A0.
MB/8BNFR>/L.EV23CK^.VM=EEJ6J1;E0XQCN*6HK4KTRV4)45DK*@G?=YWOS4
MGZS76HYU"=.=PR7C/B,9AF^1<I89/G0W,3B"'<F',:4[,C*N?S*T%;LE4A:B
M4_,#;.OIUJK0_AF].^$<3]2O5#)QRTW.+Z%IXZ,.3<%SG0M3UH0IX-/2B?5[
M22DA*E=F]>-5<9:>)N/[-:8MEA8Q;Q;8;BG8T9]AF0EA:U^HHM^JA79]7G2=
M:]J[?;L?LUJE3)MNML2'*GI:3,D,,--N24L)[6@ZM"4J6&QX2%$Z'MX]FFN8
M3[#^%>:4III2E*::4I2FFE*4III2E*::4I2FFE*4III2E*::P5S%P%AG,,()
MO49+-T9"OE+DD'U&5*]RH)T5_8#9\#QYJ$=VZ +RU)4FUY@E<8J^G_8D!02?
ML5*/<?'CW_\ &K4:X+)!=?T-/_0SH:N096J*X=$)4E.]D*^DZ/X_]/%95A]Y
M;BPT2U:.09*P;Y(9T2:*/N/DH)%8H.?)"^/<D'4=[CZ3;%WA>%W,8:$WY6C2
M2]!+-2ED (4&=ZS)ZO:.!W2*[=HXYXU0)U$MXCTO7.S8G!6WR+RM=_47%M25
M?))LJV ET.O*)4PL%!#B4N !7;H [J)5WY]ZGX\NZ9+8LI8<N$]D?/XV;?"^
M5E,1VRA,1/<GT6BAL>GZB$ J/U>Y)K@N?,IO;W61R5!SZXMR,@DN0D6F:\IM
MIEY#48A28H[O2;[&P$J]+6_N"=Z_%2@T%NNN(:;;"UN.N.!* A *E'O4>T@I
M!WY_(5)AL6[45.QDY?VA8>"*?U)E!B!E[9.RO&H5(HUX5044.67N9NX#B\'2
M_H9TVZ;[8K4</M/"SR9W%029JY<K?M!\K#<196JR2V^]Y*2CM01?*&92[ ,?
M'=.G[D:U=4S>4X/=K8,0Y(LSK+%ZQ1UTNINCDM:@A;<I00TD*&W--[ [M?;5
M20N7#W''1O8GLERJVL1KZ^VJ2S:N_N#"CM:7%.IVE??W!>E@_A_&LKHXR495
M\1W&[7CC+D[%Y;K[F0NQDJ9CN*@0BMM;LE [3V+22-J.]:\U==\2WC6T<F<<
MKRW&KHB=#8AJ1<EQE^K\FJ(D-(;4A*R1M392? W[^3688O/W9-R8;:V1R%FM
MM_+_  TMWT2XE#2\)'5EG#?PNR2%.]?69>$#G7GW^-/\//3_ *3SY#?'3O;U
M>KN&? IGZ&WK,\<^/PPE?LN38RI.&M*L<H,P@=WKUT<,%X0 5/\ (/719+N'
MI<-AV[3BX6F8K;KL-AIM*B@#TT]K2SV>-E.R?.QNIC\,\PV#DGB6#9.1\>,[
M%[HASY#U'E!ZQ+#FU+;<2GU7.]>E* (]M>1XJ@!RVS6TR%B#*5'B2B''_E74
MH[67B "KL ^H)_&K>.GF_1K_ ,6V)<:&8B(:'$J0H*TX0OL)T4Z]]G53;U2Z
M8[,N;..$LX>+(XJ[8%>['9D]1?2,3-&G:.T(P8 HRJLBL.XMY\^3O2OJEO&W
MN^[>MY)$L?LV0BL]97BN*\T:6%G642?$1,OAUD<K_"8^UD!$U,,Z-9.>?,W#
MBCE5Y-K1MR5#0E;"H3*MD)]);R%+"$[!(2/;>_-=BQ2W\:=-&629KBU<G<C6
M[Z4W.4ZZTU:WEH(4I*72XPY]P='QVUUC@O+KUB6>1DV=YY)O$28P]&0XH-.D
MQEMH^C?:"GN\  ;/^.-\PM\^+?\ (;?<TN,W!UR09*G=EU"9A64'9^HZ2Y]/
MY>VJI)MC\+/3#;^[Y[IH3W*U6*"_AZ5V_8GBJR22LDC^@TG8PKN@]-@O=\Z\
MD,IU;ZYU+DAVMBLG@\3#CL_^TK5._=/JVZ55X((IZTF.K6GE@KSV5D9OW@E,
M!A<Q^X(BEUM=;W*&5YQ%M-MOCD9BV+4I<>*Z@LLA8"@T?24$K\#M^^C]]TX%
MZT;/)?LE@SQGYF0\ZAF9&>)69NUI2#ZNCZ?:/([3_P"%0^ZB>&7>/;DQ>X]R
MDWEG('W5)1Z+JUM*]3>BHE:OWE:&_8?E6;N >G*S*M=HSS)U*?G.A;\2WK0M
ME;!2=I45#1)/TJ\_A5^9L!T_I[&Q\*UD6NL30U):4/P]N6X%;U![=R]LG)+2
M'Y> ROW$$TMBW=U6R74S*WI;TTMZ2>.S?BR5CXRE'1[XO2YY)C?OB[0(T7A@
MQ1HRH[=6@\GWM<J9#<L*/T5B-PCM.VN$P0%)_9(4]W2$]JU J.]+/WUH>0(J
M<O<AM<9X;,R'TD2)8T(;!6$O.+4KL)[OWM@D$D_SJ1-V3WX+C*UG98,AML'R
M0A+@2D G9/T@#\?O4">J+C3)LOM1R&V750M-E0I<BSE 0E06/^VI0^XW]_\
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M<3S^HS32\^G#'%&TDDC\ GA44GP.=6? A0!!!!^X.Q_(CWKS6..)X^11N/\
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ML2O--*Q>221BS,S'DDD^?)UZ94:-3'58*5&O#5JUXTBA@@18XHXT4*JHJ@
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MJ4ZM:PQ^$D*NSS3V@4,A3NCBB< -ZG!&N9=R?('9[US-R6B6ZX5]R4Z0 #M
M],?3H#0/X^_G[YTP+,,+SZX6S$N5K5%3\RKT(F4MH2RXPM6@@+:82E:^]1"-
MK5^/\*KLYJYY@\1NP("+>FZW2:5DL)>["RA!!)5[CZD$D; WK[_;G^,^<\/S
M^#;IC$]JUWL2XSKEM6LA2%,OH60EU92"3K9UX^WG=9;>V?=LX>/(K1GKUG5D
MIY"F.RQ78*465?1_>+$"O_Y%,+]O# ZC[$=0Z>/S\N+?)UK]A9(Y,EA\I_S%
M.]&S(\D,BV.8GF8-SS"RV(F8,C @\6"\PW_C[IA7<K5AEJ_26?2V6_T5>9 <
M]-EN4WY4TT^E3*R67![$Z/CW'C#_ !9TQYSS-'>S_-<EFVAB\N%]"TEU/S@[
MCM):;6GM#6])V""/;Q7*]9DB9D%IX5S9U*7[3)VAV4TVDI2F,J.VKUW6QO1U
MH>HK_P *L3XQFVZX<>XM*M*FW(!A)#8C]I"5I;0E?<A'M]0^X\FO+3<<=SJ1
MU?W=B-Y7LI/1VC6KT(,-+D)DKWV,B^I<>*+T/^7=D27T1R WIGOX &O0K:^&
MVOFLQ9HXG&M@]M5<+BK46"I7)5K9*:]%#8EO66C$4EB-W*,(Y6E]-E0!^U0!
M%6Q\?\E]+5TC9IBV0+R_"FWFFL@LDB,DJ0AY26F'$NO^HY]"E>H0@#]W1J+G
M6K:+YS;>K^JVWEZUM7F)%?@.)05)*FHX<?8;3M(3H[0=:'Y5;!F[\.-B%Z=N
M!2F,I+39;='EQQPE#7:VKRO]H1OM2=??51#Y4P*WW'!,.1:)#2LXM0N3URLR
M5)]9^/)67&3WE7]6.>X  _A]O$\] Q!T^ZAMCL09DP]S#/>@KSM)=AP=Z"[
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M>SXPAZUQKN[#,?%,4CJ;1,N\H)"$H6ML%UG;A0>YT:TK>B!5$W2/U5/9#S)
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M]58$D97B+M(JLC LO@0!OW"?&V27MS(+O84/W!X$/J#BD!PE/;LA.D['\O\
M&L;6SI@Q?'L_M.:6*XF#&@S&EBV!#BMEQ:1KU2=CS[ #[&K"%<#YFZR)-N>@
MW**1W!XSHC2BD^=]A<[O/_LUW+'^FF]1X;>6<B76'B^#PEIDR[@7X\GUPROO
M"&VVW M>U(["4>Q/XBL^L]2JN#QUJQ:W3'5QT522&PL]H&-:X0]\0BFY[&"
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M0XO2(:(S@4HA*R ON&_(\[_.K';WWQTUW1M"?&)F<>%%:.<58)(5BC>1.R2
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MS,5F"?*3M/!%*E6W%R2(P->KV_<;A(=IY^(T*LDV/LXW*X3-TL?6JU$PE@K
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MN' XSWLB&A*T]S;@"]NASRCZ_8>WWJX1IYF4TU(CNMO,NM-E"TK2H[*!W)4
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M@9+CDD.R&UR2YWO_ %!2$KT%DZW6?[0CV:,1<IYC.Q5,CN%),>7FPLEV+ I
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M^6\ A10G:BK9W4X<'P7C+I'X0B8SC$2)8L-PRWN%L;2A+CRT=SCJW5:4HNO
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MVTI2E--*4I332E*4TTI2E--*4KP?_$?]136A/ YUC7DWBW%^4;$_9<A@M/\
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M<E(;TKMUXU^?M4C[EZBV+>W9X;T4=9(%:Q>LQ2%$F@A4L(A%QX#G@,O>P8@
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M90/RED1I.?'OW<CW'G496NBW32Y;%R7:U)9>[O*5WL5J['D'S5@E2#CQY 0
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M8J0XH]Q[A]NPD@>3^59;I2HSM6K%VS-;M2--8L2-+-(WN[N>6/CP//L!P /
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MW  'D^P.=;)V%<WO+<6.Q%4I41"+-B6-IBTL[,(((H%X]21^QVX+*H5"2>2
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M^9I^NV'?VKQS_C5N_P S3379Z5UC]=L._M7CG_&K=_F:?KMAW]J\<_XU;O\
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M::[/2NL?KMAW]J\<_P"-6[_,T_7;#O[5XY_QJW?YFFFNSTKK'Z[8=_:O'/\
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M &4R+_G/(/\ -U.JE.3]_P!?H#^VG:OV_7Z'ZY.H*_T<G2S_ &4R+_G/(/\
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M?M^OT/UR=05_HY.EG^RF1?\ .>0?YNG]')TL_P!E,B_YSR#_ #=3JI3D_?\
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M].7>8TFSIEB02E'RXN+;!=T1H^GW $_C334S]@>YU38/L=U"_J#ZRL'X+S[
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MT]4>/!\_R]N0/]_;6V7U']1. =,G%M^Y8Y%N+$/&L?D6V-.TOU) <N<IN)&
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MXJQ%N:&'G \@]Z2A)&O/M54/^D-O7)[IJP-_&!'E7UW([&_8T2'&4PGW5WF
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MQ[D?')\9./9(QZ]OD2WDQ XCQK7S!02HE0';[[-9,=E,M!M2WHZ X-H+CS:
ML>""@J4 L:^Z=BM*+,NK+EBX9%Q'TS8MD,K!L3Q##_G(&O\ 9F,FN[MB9GQ%
M-RU*92 )Z4=R0M21W]JO%=TS?GWXC')>+?#^X?O')3O#O*')5^SZ+DF31VH-
MX1>K'8KHG]&#TF5!G:K6A*-I45#N[C]5.T^_CVY_I^O]1K7U1]B>/'\SX'^_
M^-;5?4UU(\?=+/#]WYGY(FB-B-FN%GMTN2RE4@"1>I[=OB!(9"E*[GW4C:?;
M[UW!',F%-\=Q.3IMS;C8Q)M,:\AT KE"')CHDMK3$'[97[)8/:$]VOM5._QA
M\:O''/PE<TM617I>97O''\#N$RY/,AA=ZND6\PY2$>F2H(,B2CL2 21W^!XJ
MKWH(ZG>6.HSCCJ4Y+Y"S]S&LEX[PS&8.*\ W*(F.O$(Z+,88EL2'_2_2Z;DP
MRB;I+"PR% ;^]:<<CG\_^W'^NAD(;MX^@(_(_7^?]-;"*_B7=-LCDSB+C6UY
M ]-NO,T+,IN'+<@2XZI36#PWYE[[D.(_9>BVPO7J:*];3[BLW=+O5=QEU78A
M<,SXRFKFVFW7.?:I"U-.M$2;=->@R!IT))T\ROV\5J-<,95=\TZD_AE9)D<I
MB;>I]AZJ$29+<=F.%ICV:ZH;0EII(2GTTCM44@;UY]ZN%^"%<G+1TE\J7>(V
ME;]JO?(URCH;2/K?@W6]2FD@ :*E.-) &O)-:E>/\?G]_P A]M:+(68 ^Q_+
M\EX_R=7[&=&$E,4R8J9"]]D=4AI,E6AOZ6"KU#^)TDZ%09ZA_B!<(]/W+/'_
M  C?+HFZ<E\ARG8UGQN$EY^0T6"@NJD&.E?R^D+[QZP3W >*UE<AZH>K/+.#
M.5/B!QNHU>.Y;@G)MCQO'^%E6V+\]$MDG,DX[+08RG4/O)E04EP+,17:D]P/
M]:LQV#B^X\R_&3XPY8NF6N6V[7S&K'=Y./S89G(C2CB<.3*4RW();CF4X5K/
MIH0-J'OXIV^_/T!/]1Q_WT]3G@ <$E1R>/8GW'_;6U;>^6\ QF\XCCV2Y/:K
M'?<UCE_'[9/F1X[\_L90\\AM+SC:B6TK'V\UD-J7'>[_ $Y$=P(2E1]-]M?:
ME0V%*[2>U)'D$ZV/-:NWQ?N"%YA\1#X>IF\JW#"H&1W'*T?,I?D0[; 7:F(V
MD/*1(9CK$Q0[&TNE.BHI2#XWF7B'J$SC$>K/XD/$^5<N1CCW%&!X0YQHQ='(
M\)+,B3B;KTB1;5RGD&>IU]"'5!DKT3[DFM./'/Y<_P">-;O4X8J1XY !Y^Z@
M^1].-;$!GQ0A*S*AA*N[2C):"3V^_:KNT=??1.OOJO'Z0B$-*^;A]KQ(:5\T
MSIWM.B&CWZ<*?OV[T?>M+_C/GGJ_ZAX_P^.-,:ZB)>&S.9[QU IS+*Q:VIJI
M\7%9TY5I1\N5C098;2VA2#Y!"O%8ERCDSKTQ+C[JRNJ.K*;/'1QF''\;$W/T
M"P@WV/F.0-L79I\ESN0D-=R$^MW@;\ :K7M_,?Y^_'V^^MOJ_P#Z3]/M[\ G
MZ_;G[ZWGI,N/%;]5]^/';\?M)+R&&_/L.]PI3Y/MYHJ6PEM+A?CI2L;2M3S:
M6U#QY0LJTH?F"=?>M3OD;JTZA^K3ECI[X28Y65PIBUSP6^W?*+VY'85'S"YV
M?&1<XC[4MQ<9#)8FM=ZD-/'O*NQ6SXJ&=TZ^>M7+.E')L"M'+<QCD;C[.(&+
M6'E[]&,H:O\ ;[CE(M;JF8I[6'3#A?LRI+B^[6][-.T_Z?TY/ UKZH^Q_+\^
M #_H=;RK3S;R XTXVXD_UFEI<0=>^E))'^-?K4;.DKC[,^,^!>/L8Y"SQ_DG
M,$V*#<[QETB&(#EP?ND9F8I/RJ5K" RIU3:3OZ@-^*DG6W7U'D _?2E*4TTI
M2E--*4I332E*4TTI2E--*\$@#9.@/))^P'N3^0^Y]A]Z\UAKG[*;SAG#?).3
MX_&<E7FS8A?Y5N::!4Y\PW:I3C;B$@$E3:T)6 !]J:'QYUTC->KS@3 N1[+Q
M5D.<-(SB^NJ9@66VQ7KFKU$@$IE.PTO(B^%#7KEON\@>VJDNT\V\VVZVK:'6
MVW4$@C:'$A2#H^VP1X]Q[&M!3I4Y ZEN'N+X/Q+\RE1N1H^6\G7*Q9?AUTN,
M$Y"F,,Q=QZW.1K1)<=N<1,5I8=4J/%0'$([E'MV:WF>.>5<-Y"M4-=EOULDW
M1C'K#>;Y:(\MAV59$W*VL30U,:0M3K':EQ2?VJ$^$[%:D<?G_P!_J-?-'[O?
MP?<#\OIY_P!M8<ZF>N7IIZ0Y^$VSGG/V,/G<A3C;\5CJB.S')\H/-1^Q263W
M,#U7FTA3@ \D_8U[=277#TY=)^%8_GW-6;)QS',JCQY./R68,BXN7)J4AIQ@
ML,10MQ7<E]HZ .NZM03XHG(-KZG.O'GC&KMC5XY"QGIT38KGA4NU?I!R%:IC
MD$39JTJAH<:5VRHW<KO(T4^0*[#U.\UCJ/Z(_AU<BY%+9E+_ %NOEGNK$]Y
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MO:I'=4/Q68W43T5=1EBP&/<N&>?N*<DXQC7C'I'S"YD*-D&1PTL%EUYM@O\
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MZSIU5]%7 G5Q"Q3_ %R6!5QG8'<6[IBMW9N<FURK/)3):E.*;D1G&G.UU;*
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M0VE>@H[^]?#R3\'WHGY+R:XY/>^/G&YV01[-'R?Y:\3HZ;TG'F6F;.7@TX@
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MI4A"DG[+0%#^:5#7]]?#7(U0UT4?#?<?X:YQO')=G=X_R+J.R:'=;SB2WU7
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M5H[(T((EP2A26FW"E9+G>2YO[Y E?#0ZC9/$_7/C;F$6IZ_\PW3C7_5ZM_\
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MBNC;<F&^U)CN:]RV\RM;:P/^ZHUH&(]OY_K_ 'UJ8U;M]_ X'!^GCS_3[_\
MC6MOD?PR>;[#F?PS7<,QZ++LW3];N1CR].2Y#:7%N690D?M5)40N2?G''C^R
M[O;\#NL29_\ #PZRVI/77Q=C_'\2_8'SW(P"7@^9)G6Z(M!L3GS5R:5#)#HT
MX2R>_04!L;!U6U;3_P!^^_\ K3N/C\O^_/\ KIZ:_G_?_P#3V_Z:UHF?AO\
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M)O6!QM<,$M2LYY5S?#+SA:7#:G),J#:,J_2<U8F$%31;B:4.]85]D^17(?\
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MN<&^+?\ 5VY(%K>>GKQGL-T_;.)4I@M=I *U G0[?:MFQ*4H 2D!*0 D >
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MA)/O^?\ GR=:A IY!(^XY^P _P!O.OH%*4K36_2E*4TTI2E--?!<I*H<*;*
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MGZ<+ITR]2'17!Q_E'+LEM75GQIR;-Y5M\J1>76+H]9<,=?MB-2'W40%,N/$
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M1<B8A"R6[X*^](QB7+0%*M;TA25.J;"@=]Q0DD?D*^.S=-_#-BY"S+E*U85
MBYQG=N8M647YMM(?N4"-!5;F6%$#:$HAGT?I/L?/WK=W?WXXY_P/[#D:^)C)
M;D-X+ _GQ]0#^9_I]-:'W#/ $S&>A/+>N;#^2,GQSD7C_FN#:,?L<)F[,1V8
ML_DK]"W .06UMQI DQN[:W&3V]Q5^=3\YCZ@>;L%ZTNJ[+./9-RG9%#X\XD$
M**S;7%N0V;WAL1%\N#+GI*]9;33STE24[6E2=;!\UM,P.CCIVMO&-RX>A\=P
M6>/KK=F[W/Q]*CZ,BY-7']*HDJ5[A29W[;[>?%=@@]+_  ?;<YO'(D?!+><M
MO]KCV>ZW)YM#_P Y;XD$6Z.PXTXE39#4/]DDD; \CR*U[OJ1S_/CVY'C_76T
M0MP."![?<^>#S_?_ &UJQ8!Q3P%9_AW<W<QX;RW?N5.8<Z?87FKMS=NX<BSW
MKFZVN.FQ3GW41OD%.N-I4TPD.!L*'VUACI:XMR'I&Y>^&SR-@O(633E\\7'D
MHY]9GQ<UVZX(@.=D-I4-]U<6$(R72!VLH"R-ZW6U9B/P]^E'!W,P7CG&2+>U
MG,A$K)(9N$IVWS'D.J=2IN&MPQF-.+4K3;:1L_B!645]*W!:E\=.*P6&5<5+
MN#F"G9_^HEW-7=.+/XEX@$[_ ([K0-QSXYY/)_[>VMWIGY?8=O'MS]P>?\??
M5 G^D(0K/D5[Z.[7E&03L1L%WNEU3=LE@0)4UZVM/N0.]($1/K-!\+4V5A2.
MP?5]JKMC9]R!TB<L<[8MT.\AY7RCA-VQO$V\QCNM76>QAC$VRM_-3(TNX+E>
MNIX.O/J;C*2IHI[#HCQN0<S]-W#?/L.SQ.5,-B95'L*'T6I$@E!AID)"'2VH
M>4DI2-*'D$ CSJNK<+='G3SP+;LEMO&G'D"SQ<N:]&__ #I_2CUQ:[%MAMQ^
M:'G0E*5J2D=VDC6M "@8< <>WT^A\@_KWT,9+%N0.>#R/<$ #C^O\O;Z>W&H
M%@-Q/!66](W+O31R]EG(W-W(Z>3)W(6,R$WEYK(KA$0^MN/+B377XUG_ $4M
M:T-!;38D! *![5T[/;RODSC;J$ZG^6.9LPQ?JVQ/+<)_5W$6F[VR<<4[?FHR
MX<:U1W6HMT1<HR4MK6B.M+*5=YT*W#.,.A7IAX@SJ1R)@G&<.U99)>D2/GWW
MG)K,9R45?,*A19!6S$];O5Z@CH;"MZ5L"ORS+H-Z6\ZY,'+.2\70)V:&0S)7
M,;=6Q DO1^WTG)5L:[8;ZFRE*DEUE92H;!!K7N'VY\^YXY/GG@^/U_C6GI'_
M -P^OCSP"0!R/S_G_P"=:OG7+E7+DJ+TO=4'/$Z^99QU9Q9X.<<2VR\2\>N5
MH3._1UOM5Q7^C7FIUP,MPIG+;2RLM@E*]#S7*<<<(=/N1_&+Q3D.YS<FL43+
M;18I^!1YDR^LM3E,XY&=?CK<><0E9C+*6R7=E1'XJK9\Y0Z(>FSF'*;)F/('
M'Z;Y=[ 8QMJ3.DL6QDQ VF/ZEL:6(;P:#2.WO95HI\:W78<YZ7^GS*<RP7D/
M*L.L[.4\>H4QB-X^;9M"K>AQIN.6QZ:F?7VVA" %]Q^WO6G=^7T(_ES^OYGZ
MZU,7Y@^0?/W'N3QQ[\#Q]/IYU4/\:3DKC7U^&NG^]6*_7O-\\L672,.7;+S=
M;#&A*L%M,HR95RAN,QBI*6T.MMR'075 H1LJJ@'"^:^<LV^&[=N-[QR-E,6=
MB_(%HL=IR%*+B9\.W73-$0I,0NI<$B4GY11CAY3A^D=X.JWA^;NE[A#J'C6-
MGE7#(^3C'VUHLTM+RXTV"T^E*7!'G,%$A*'4) 5V. +3X5L$UT*S]!W2W8<4
M<PRV\7P(^.NRHDURW^HM87)@R$2HSJE'94IM]*7-GR2#YH& '''U!_7^FM61
MBQ(( ((_/SV_Z<<_VUKR="MIS/I2^*[(Z><:S_),AXXS[$\6NMSM-V-RF1XT
MPXC'NCKC<N<Z\$%Z6ZI:@A2=$Z/BLW]4>;95;OB8Y5:8=UF,6UK"<D<999A.
M'TGD8?*<;=:EI3M*FW %@)5M2AKQ5_$;IPX:@\IQ>8H^'PV>18\1B%'R#U-2
M41HT5$)EI*/ZP1&0&_'L!YK],AZ=.'<CS>1R->\0AR\MDQ7H;]X=<"'%L2(Z
MHCK>SH?6PHM^_L?%.?R_Z>/Z_?6@C(7CG_KY\>W'C_S]OY>VM%K#^%.03QAT
M9\I1.<<W@Y7S]R#RS:<RF+-[>0];[;E,FW1HZXRI!;CA$1PLH6$I\?4D^ :E
MU,A9OTR6/XH/3ABV?Y7<,1P=GA"3B,R0[=9,JRRLM#$V\/Q);SSDET/R)"UK
M0V[IL:3^Z!K:N:Z6^F&WQ, PE.*6".G IUTN>#V)<YE,NWS+I(,ZY/Q(REA]
MWUG]NKT@@>]=COO2CP1DERS^\7C!(<RX<FILJ,UD+40J\IQ]*46D.CV'RB4)
M"=?A6O?SQS]/^X/^!XUM$1 \$<_ES]N/_/Y^/RUI[QNC_(K)ROT#8JQSOFHA
M=6%@Y/F<K3%+OBTW%6,6ER3:$=BI7_U>8RCV M>F7"/(-='?Y&Y=XPZ6>LS@
M^%G^77K#.G?DGB@XY>O3NJKE;X=]S2.]<]/]RYLIEQL*"]N*2AO8/TBMU9?3
M7PR]=>.+TO#8BKCQ0Q<XV"2"3NQ,WAKT+@AG\?F&_I4?)_ UU=OI Z>&HW)$
M!/'=K7&Y85$5G<=TI<_3BH*E+B+<0L'TU,*65(4D!25>001NM.[[^?;[>X/_
M &\:")ON!SX/OY':!]/'OY_W^^L#RYU--<C_ !">-FN->0[_ '?'X7#D_P#2
MT6(W<F;<U<6^-TZ<4I)##KS<Q)6H>5!U)W]50;QC&^2>$.G[I)ZU[!R]F4KD
M[*.4.0(%W8D&\2(]QBMYJY:XT5Z"\\N,TA$5?I(4MH#M^H;U6Y5@?P^.D_CB
M='N>*<61+?<(S4YAF:]*>E24LW%M;4ILO/*4X4+;<4VE)5I"3I( U7<9_1GT
MY7'!,8XVF<=07<.PZY2+MCUG*CZ5OG3)WZ0??;5[[<E_M3YUNG=^7V'\_?[C
MZ\_T^FM3$3]0#[@CGP?E_P!A_P#&M/SJGSWJ"ZB.KSJ$Q^1%O\;-,(@<37+A
MV6J_R\>@8]*N=LA2[PXRR7HT.\?I!?U+;4' R5:T*V_^BI[F1_INXU7SRZ'N
M346ST+ZZE3"PMID);A$KCDM+)C(0>X'9]SY-<5RMT+],W,^26G+,\X[1/R"S
MIB(A7.W3I-I?4F VTW$$I4!QE4H,MM(2D/J<T$ZUYU4J;#8[9C5I@62TLJCV
M^W,-QH;*G%NJ;::0EM"2XHE2M)2D;423_&A(X  _G_@?YX\ZWHA5B2>?<#^O
M!_[C7,TKP2![_>O-;=?32E*4TTI2E--*4I332E*4TTJ$GQ#X_(,GI(Y99XM$
MLYBNU)^2$)2TR2P.[YSTB@]P)C]^M:._;SJIMU^,B.S*9<CR&FWV74*;<:=0
MEQM:%@I4E2% I(()'D'WKB7ZOQM*W3]5X?BJ\L'JQ_QQ^JA3O7V^9>>1KL\+
MD?V1E\9E37BMC'7ZMWX68<Q6/AIDE]&0>?DD[.UOR.OY'',-KS1G(9+5WBYN
MJ2;I<@OU$WUR5^D#*6!HGN=U\P?H(\#QKQ6XK\'OHAE=2O0?;+1U38K.4CM?
M_4.\7?UV[S%95-4IY3JW.V<X"GL[?64?IT$C5; 5^Z(.F'),D.67CB:P2[V9
M"9)D&(P&R\E7>%^B&O3\J\GZ?/W]ZE%9[+:K#;HMJLUNAVNW0VTLQH4&.S&C
MLMH2$@(:80AL> -D)&SY.SYJ.-O]/33:2+--1OU/2EKB!869+*.1P]A9!P''
M'=PI8A^&#@C5B-__ (@!GJ]5MJ5LO@LHMNO>;(/<19L?- O!AQ\E;M8QN69"
MT@4&+Y&C(8G5+W''P0>F3#\R@Y3?0O)VK<_Z\2VNF2RTA22%("OVB@X 0-A0
M.]5<CBF)X_A5C@X[C5KBVFSVYI+,.%%:0TVTA*0D>$)2"3H$DC>_)V:['H?@
M/[J\UF^'VY@\ LBXC&U:/J_^HT,8#N![*9#R_:#R0O=V@DD#SJ$MT[]WAO5X
M'W1N#(YCX8<0);G9H8B?=DA7MB$C#@-)V=[  %B -*\:'X#^ZO-*[O6(Z\:'
MX#^ZFO;V\?E_T_"O-*::]5(2H=JDI4/P4D$?W'Q7D#6O _D-?PU_+Q7FE-->
MI2D[V$G?OL>^Q]Q]_P"=>&VT-C2$(0/P;0$#^X5[TIIK\_1;[BOTT=Q_K]@[
M_P":_<T#3:5*6EML*5K:@VD*.O\ M*'D^/;?M7Z4IIKT6VA8*5H0M)]PM 4#
M_$'P:]@D)&@ !^ \#^0]A7FE--*4I332E*4TTI2E--*4I332E*4TTI2E--*4
MI332E*4TTI2E--*4I337JI(5X._Y'5>U*4TTI2E--*4I332E*4TTI2E--*4I
M332E*4TTI2E--*4I332E*4TTI2E--*4I332E*4TTI2E--*4I332E*4TTI2E-
M-*4I332E*4TTI2E--*4I332O52 O6RKQ^"B/^E>U*::\)2$C0W_,[/\ >:\T
MI332E*4TTI2E--*4I332E*4TTI2E--*4I332E*4TTI2E--*4I332E*4TTI2E
M--*4I332E*4TTI2E--='Y(RQ>#8-E67-QOG#CEEN%X,;N[/63 B/2U-]W]7N
M#13OS[^U4/\ "'QN[OG_  1ROU)\D<&+XXX?P.]KQ[%LHD7SYE&:W-5V?LC3
M34<H0N,$W%#;2E#N []G0%7J\K8I+S?CO,\3@O\ R\O(<?NMJCO:"O2=FP7X
MR%E)("M*=!U[>/-4M6GX1,K,OAB?_ _R+E*(^1Q<EOF2P,HC0TLJ0\_D[V0P
MF76(Q2'^XEMD*<4HH)[JU''U^X_M]=;'[O\ IY\ GCQY/(X'^O\ ;C71^*?C
M@S75<B6OG;A.9@616*W)NN"VVU7!W)#ET%^,Y-8<#EN9=3$W%]%:@K9'?HZ(
M\\YQ'\83DS..D'FCJ^RC@IC&,/P:Y0H>'6E631I%TR%+ET7;7_FH _VVUD*2
ME2!)925]VT[U7"=+/P\>;>(H&72LAQ6!+S2T6UJT8;DMR5!N8N$-N*N"X%1)
M/JH;]6*E"$^H.Y'=L:U4'.;>@/EWIFZ3^M?F//+Q.BM\M7K!EVKC" RN="LD
MF)>0TF9#CPU.,)2\^XB4XAEA"?=*O8UK\I/''U'W^XYX'TY_,G7RYD !)/CG
MQP.?;Z_?Z#V]SSJ9G%_QO.49N;\2W#G'I;E<3<"\QLWIW'^3Y.2?I$1D6)DJ
MD+=MR&4.@/.Z0D.:]]C8]_SY#^.!R1"R3-,WXKZ9)&>]+G&=ZQ^U9/S$WD@@
MH>1D4UJ U):M2VE/J$5]:@I+7=OM)) K 73=\/;JJZK<$Z=X/4%R.W(X&P>V
M7M1LZ;#"M\J^1KRP#$;2I@-2X!@J*4D_272GZO>N_9+\(OJGQJ!G735Q7R['
M@=,'(MZQZX^D[88#S^-Q;-<&[E)C..O%4R<J>M*FPM2B6=@@^!6OR_KGCW_O
MSQ_3_30&7CZ_EX'// ^G'MS_ '_OK-/,WQHL\M/,+?$G3MT[O<W3[OCD?)+/
M-9R!-G:3&CV9-YO#;OJM*2DPV0ZCZU)*RW]/DUZ97\<J';.B;"^I6U\-SYG(
M&67BY8^_QPQ,DNMV6Z6Z]&R.-R[LAA;;:5O@J]1[L1H$[T-UE3A[X8^2\/\
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MTI2E--*4I332E*4TTI2E--*4I332E*4TTI2E--*4I332E*4TTI2O4+!.AO\
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MD,.Y,26$.3;:ET)EV]U6@II;*R'3I?<-E(]MZ -?R?"1O78C0': $)UH#0\
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MA*2?OY]ON:@C@?)6=8)*4,3N$Q3DY3:5Q#WRR\XH@!([^_MVHGV_B:]I]O\
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M43]S_=K5!^M_7Z;ICF+NU\-BZ63RE64U[-NY)*8:]B-E=TB2%T]0"+M$C,W
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MY\Z&U>]6 Q'X<]JP;1;-Y7(7\ID9,9\;Q3<15X[)4,T:=JN[K&WRN6X/(<\
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M0;!)/CWU5V-L]$LAN39B;DAR*0WK8GEQU!H2T4\-=VC*R6 P].:9T;TP%8*
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M6N;J/N_=6#H)D-RYZYB[6/HM'C[F1MR5UKB*.:O$]=Y2A]+N7CN4D,.=> -
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M0VH-])7%5TS'E2'R#*M[S&/XCW_(2)#:F_GU2FRA92E82H!M0^V]^^JN# T
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MUKL\V<?7WDS&GK=:;\];)#:'W9;:@7%SEM]SBT**U H"2E21_=[5>EU!=>7
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M>/\ &MG+J$Y=X7Z4,+QO#%XU!RW)G&)",=QHJ2A^6ZVD*DJ=DE*U1P3I8+H
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M,MY)Q7D:US+#?V+_ '9Z!$=C.AF8W<9\AYA3,D(#3I4VXA0"%*5LZUNO5_\
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MJ);<44;/_9K^<5?>+K)8L)N4R4A=POC3C<]ZX/K<6\N6'?F%J4XX5*65.]Q
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M>#Y&9YO(M^1P9#&.VV4ZAY]QMQM,A*%K#8 (!T>P>WX^1JI*V1%M&';64>Y
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MCNG?\3FZ][[8Z<-+L&*9\UDLE6QC6JC@6*$<RR.;"GD=G#1=I<>1_#P>XA;
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MW*Q9Z$TL4M.7D.4)B+%8T K%^+3G&21;_P -\<QGY$/%LI_33EX;9<6TF<N
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M\?;852H+&QY!T0?<$'R""/!!'D5+V,RM++U_B:4OJ(&['5E*21N "4D1N"K
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MPU:'<&W'%_!Y5D:[3?MCL*\*NA0/\XKV(N_YAPZ2*$\E"K:XW4?ICM#KSMF
MVRR31)*E.=PW-:82QM+!;KJRL61XBOAU>-CWHQ!^;28^#Q<+?R?U[<?7EBSS
M&DXNU<ER%RH<AL-KD6]?8%EUM(2>X$?5HUN/]2G'#O*G$&58E$!$R3&]6-VC
M9*HFWNT)\;[NW0]]?:N"XNZ1NG[AC*+AFG'?'UNQO(;D4F9/C =RRE)2DI3V
M@-C2B#V@#^ZH6?$=^*/QYT28ZS;+8W'S'DNXR&41,:C2 /0;+R!)7(?0EQMK
MM84I82Z4]VNT;-9'U*R-GKON:2OC<3;D.5Q*8AJ9["XB[)!/*[I^[BC42L6E
M8@ #O;CV'%Z?;&P'0SI?=V]G<I53$+8O33V6>0 I>5(UA3U?WLLS\=L42@MR
M0B=X'<:RL/R&1Q[=+GB6517H#D26\PM,AM;99#;BDH4GO2.[O WX\Z_PR7<>
M2<8A1%OLS/FWE)(9CMMK+CCB@0@!*>Y7E1'VU4], Q#B7KYZ=,;ZAQC4:WY7
MDUMER/\ 8WO*)D8%!:6AGM!45@)V4^3L_:N>Z:^A7 (MBM68<AV%4C)4S99-
MND.N%#"(\E:8JS]78OO;2E9!3H^Q^]>8^Y?PA;E3<EY#;QZUJ^1:G8D>V8YN
M8V=6,U3T7<21B,I*87*,_':P!Y&0X/;^\8L)!-A+V"O8&5JXQE^U*ZWDJ7HW
MLP2BFH[I%CB7R22B.R+W<'@8IZ/^G3.,N:D\JW2\S,.%QD,OP8RFE*,QEAS2
M@ZDJ;*4EL#]Y/L=U+/J5Z)NE_JFC69'+M@QZXWFQ/PWH5S:N,:#)4_%<9<*I
M 86A;WJ*:&T.*5[D:\FHU?%-ZR1TK\+HP'BF[0[+RYF4=4/#F(B6%N6YN*4H
MEJ<CI^ALF.=@N)25:V"3YK35Y!ZP>M&T7Y+F0<T7AR<_,:=CNMMJ0VX\^Z%H
M:[&W.SZ5J"-:TKQ7IGT)Z";GI;&PKX'+_L;'8;U*-'(-'-%8LS$B2U-&:P4B
M!Y9&C4L[#P4\]I.L(WYUHV/L5\=TLSD*[KR-:@V0M4'CH\<7;#6)I)Q*K,\I
MEYF6,]SQ1F,J0/;^CI@N%8O@6,VG&,0ML"U6.U0V(D./ :90WZ3#26TDK92
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MY*\R,W=[  :[3\076+(5MUW]NW,Z<#A<?;%*M6BGDJF].L44DT]F6(B61>7
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M4M[)20EP**2/'MKV)_"O@L?1[RS.<2N^,1\:MB"/FI\F1&#+#(_>*BXI*0
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M]7+U.XH<0LQ@V01W(^H?4DZ\Z/Y?>NM<.=7%EG/6]G.G!;+RV\VVW*.UI?\
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MLMZ)';W =NQ_VJS-7HXA+B%MK'<A:%(4#[%*QVJ!_B/%:AG7DQD!^U@I958
MD$<E6# \>_!!U]89Y:T@FA*"10W:9(XYD!*D?-'*KHP\^S*1K7%QV8Z\N[6^
M>\7+Q;KA+:N"G3V.NJ$EQ*75)601WZ*@/P( KL+[S49EU]Y:4-M-K4HJ('LD
MG6B?.ZE!U4=%V:G+IW)7"Q+KMU47KI8F^Q" IM.@4K<.B2>Y?TI_([/@P43P
MGU,9=<5XX[BDP.H[DN#U4MM@CS_O=!*@=?B=^WN:\KM[=$=XX_=^2A-"W8KW
MLG8G@LUZ<\Z64LS-(&@:!'C9F#_P%D,9Y#  <F%[.;RN$#XVY@<C;O1N\52Q
M3A]2E>4L?0E#QK^Z[E(]2(*"A!X &OTZ?\XNV.]0-OS#&[*]?51GW&WK7'6I
MH/A:"T5K4E) " 2L=PT='^6QSAF02,GQRW7J7;U6I^8V5.05J*E,*'NDJ(&_
M._L*K3Z!N"H6#W7+WLPM2F^0+48@E,RF5+:B>J%!'HNK1Z+OJ-^_IDD'WV:D
MQU)=;73[TGS<0M/+V7P<?FYG+,*S1&D!]TO>JVS^V:8*E1DE;B=*=2D:\C8&
MZ]!NAVP<]MK:=;;UG%V#G+=R6\*4+/:LI6-6%8HWCB:2,2"*'UI/3Y[0_#GN
M!UF&VZC;+VQ8.[8JF'R%C*296Y:LW52*&#(+#\+7?]X:J=W<KJR,6)D5&)8<
M#J/Q"^IQ[I=Z<\MSVT%+F3J9:A6)@J2DJ=F.?*..I*@4[9]0.>=$ZUNM%?J/
MR;*,]M60YSFUU?OV5W^0B1/N$MPJT)+VXS3#2U*0QZ3;B6_V7:5:\[]JWDNM
M7I8QSKYZ?TXE8<T8LQNL>%<L?R>&$7!EM"E-S 2TTLH45I[4*2I7TDG>O(JI
MG$?@!R[D(,?E3FTWZS0I41Z1;$6/Y?YYJ$\VXVVIYIS: 4M@'S['R/M5\.B>
M^.G6Q=MYN3/2O7W/;L30\_ S36/@UCC]*O%(J%8E:8.9 64]P'?X5=54_$CT
MPZO]3M[;*7:A@GV-B16NW86R,-6 WS.6DN2PLX:TZ5^U8%[650>4/+MQ.KX(
M^$7#$N@SC)ZX377S=DW)YN-(2H?+H$U2AX7[A85X\ $?EYJWH)2VD )2D @Z
M2 D>_D@#0W_=_P"%5Z=0G//#OPR>F&!<&K2AS'\2A1X=AQUMU;2I[A+;#RDN
MA)*>YP]YVG^M_"JQN/\ _2-.G_(I*&<WPN5AR%+ #J9$JY?0HCM7VLL[\I(.
MCY'X5#]K;.ZM\WLWNK"X2Y=Q]S*W)1)$D?<#)*91&L7<'=D210Q16'/UU8RG
MNO9_3W';?V?G<_2HY.EAJ,)25Y>PB&%(C(TQ1HXU9U8J)74]OGCMU$/XT7#.
M7X?U6V;F&_2KO<\.S%+J;"Q'BRID:R*AQ$L/_2R'$H]9S[J2@??9\U2QR18H
M%_E82Z\ZP&U919$K4ZM"'"AR[100M"B%CPK1"O(]OX[D%I^)K\.CJCE6? \B
MR:!=+I>=P[7;+M8Y(5ZDKM;6VS)DLCTBHKT"G7G?W'G%'*?P+NG7DS-U9K8[
MX_C=FES;9>[?9&4RG6HY8=:FH4A8=3]+RPE>NT  A)&JL)LOK(FS=JP;,WQM
M[*X:Q6HRP4+YINBV0LG;'W5W2-@T2E 94+]S+RW#'DU%ZC?APFZ@]2DZJ=.M
MXXG,PS9*K-E<1\6DOP\8B'K+!;CED4K8;U#Z$H3L#_+X7C5O_ >.6O%N'N.;
M-9T,MP(V+V=QI+';Z?>];H[CBD]OCRLDGW\FL-=>]BS_ "3I5Y8M'&;DEG+Y
M%F4J"N(5?,>@VE2Y0;*2#M3"5IT//GV.]&2G'^'L8'A]@Q*-)7+CV&WQ[>R^
MON[G&H[*&4$A14K]U ^YKH'-O4-PWP+9$7;EW+K;C-KF;80F:IMUQ\.*#13\
MJ25J22K1^DCM))\54ZG/8.=AMTH),C83(K:A@])Y7M,D_K*KQ(&9N_CYP ?!
M.KW78*J[>GI7IX\96?&&G//ZZ0I522N(&=9B51/3YX1^0.0...=?SP,%CV["
M;-/_ %I1<+7DBKQ=$WIVZPI3<@OMSW@5%^4A*E@J"BE061HC7@U+?H"XXQCJ
M;Z[.(K '7I=CQZ5.FW65%]4);<9CB3&[W6C] +C0 !4 ?;R*V)N=I?PB^H&1
M^A<ZN^,*O>2E*(<NWAVW[D2->FM1BEII)4MQ)/>02?<U('HS^'CTP=%+>5<L
M\:&)<_TY#3<8]\$A4AN/&:86XAMAU;CB>YQM00>U8T3YJW&Z/Q 5WV+D<?9V
M]EMNY&SC'K5C9@9:Q<QA)K,-EA$%6$%G93%SX Y))U0C9?X3QB^JE;>0WGC=
MT8VGE6R-WT[,?J05^XRK5M5E:9G[D5$5O6[ .25^\B.L?AKA_FG@^;PWRS+:
M@6"^QH$&!<76UK5$D6\MHB.A:/K!]9#9([OJ \G5:W^1? JYBF\\X!;8N9P\
MVX-B7!$^X7-M4..N% :4W)BQU1TO*DO>HE*62?M[GR"!.CJ$ZIL]Y]RN=BV,
M=]NQ.+-<8@M-D*4ZN.Z0MWU@$N(TXCO *@"//MH5U_%\DZ@<(D1[M8^0)JWX
MWIK5!=3ZJ'6F@"6?VBU)&VP4[U_/VKS<J?C@H=-IK6W\)9R$N.OS6$OM)\,:
MS.>V%+]&%SZZNO:Q61WB5^U&X9?:R.\L1TXZBY'$Y:;9>6SF0V[8FA_;M<P0
MHL"/&17JJS!K,,@]19DD7O[2/193(3J__B[C7$N)L,L6$X=9(-DM%GMT6&AB
M'';9]1UIE"'7'5(2"XIQ:2K:BK6_>L <V]>G2YT\9.C#N6.2X.-9$YK5M7'=
MDNI^D+'>&=E&TD$=^M_:NE]+74AGW.5S7;KA8$VV/C#2&LAEJD-J5(==1VLN
M):T%#:TE6D^//GQ6IC\6?#861_$@Y/C9#=)$MM"K2N)#$IUM#>K>E2@A"'--
M[^^D@G[_ 'JRG1?;N*ZQ9>J?VO(]'*XE\S!;JR1RSS&1X@$E=_46.13*?61N
M75E,9 ;V[GK+U+'27IU4W?BZ5.]69J2)6!]1*M>6&5Q#)!6=&CL1^BL,D#,C
M0,6,H!0C6V1C7Q.^B_+,@L^,67ER&_=KZYZ-M0]!DQV'G-@!*I+J4LMDD@#N
M(W]JR]U:)?O73UF2[&I$MR3 C2(SC(#Z7&%GU.]LI"@06CW;3[#S7\^CDMJ!
M8,?LT*R(DP[NY?+,W9E1Y+R92'OTC'2"VM"@Z=K[2H ZU6_IT<67*9_2GQK9
MN3E.7&]S<9;9N2I:=N.1GXJ$Q@L'9)2PM(!/U'0^]9+U^Z+8S9.'BHXS-V+1
MSM*]0F6TL:S0RR5RHFA,03F-1( P(Y!*GGSP(\Z =<\OUZP^YX\E@(<$((Y*
M].S4EEDA>&8- IE]0\K+W%B.P]I".!_#R:,>';W$8CS+/(<2S(,ET-A>D]ZT
MNJ]0'R -$:\^WMH>*SPI2$)4I;C:4)25*45HT$@;)WW:]ANLH<Z_#WSNSY+<
M,@XD*KG:)DAR4W:D$,+AK<6I:P'5J"E]ZU$^/ ]A4>L8Z<><LJS6-QQ?7)&/
M3'7 AXK[70&$I"G=+V ?V>]Z/Y"O%+<'0/?DVX+->MA,A+(79I'@JO8K2)'V
MHUF&TA]'TF7M<^HZ,O)[@."=2!@9-V8B X&3:N3R4V-CE:"S14-6DJQMSZLL
MI^18X^\=S]W<%/SJ&4ZDYTCX&_RQGN6W&->)=MLN/O6]>V"ZEJX*WLCN0I"2
M$.)T?)JW;...\7Y%PFXX'F%L8O>/76WFWS8<E <;=062TES2@KZD;[@???G[
M5T/I_P""L=X(PB)C%G[9,TH"KI<BDI<FOD]Y*PK:AV*) VH_B*SL5!(V?\/-
M>A?2K;E_8VQMM[>L3M\9BH6D)C?_ /AYYYVLLD<B<$M$[\=P/\8)4\<'4K8:
M"^,#7Q^9,<S,;<TU7M1X(3?E:::L.5_>(H81L7[@W:2/!XUHW_$,^$AS5PCR
MLS'Z=[%-R;BGD2\H#5LB$I&.MO24?-%:U*4M:5J>6KSK03X^FMJKX>?3#'Z4
M^F'C_C!V*VW>XT'YR]R$I <=?G$3/3<(V265+*!O[@[_  J;LB)%F>F7XT>1
MV':/F([;Q0?N4>HE7:KV\C7G[U]0&@ -  :  T!K\!]A^53_ +GZF;AW9M_$
M8#*R+)%BV+O9#/ZUUD7TZ[6.3V]T,98<@?.S%V^;SK!=H=)-J[*W+G-R86L(
M)\SX%=418:8D99+(@X'<1.Z)_'R8T7TU/9QJK;XBV.M,6RRY.AAQ\(AW1$E+
M3:E%14P4(V4 D>_C['Q^=:C.4VVX,7>[S7K5(A0WIDE3*GV7$)\O+V>Y:1O9
MT1Y\_COV_H 9?A>+YS;E6G)[8W<X)\%EQ) ]]Z"@-@?B!_"H%]17PY>)>8\8
M<M&.P8V+2RMHEYF/WJ4D.I4O1 3K8WYWO^'O4N=&.M.&V33APN;J6S%+,L<F
M11N^*M7$CR*QA7YV*F7@\ G@#@GG@56_$S^%W='4S,7MU[5O8]I8X!/%A9 8
MK-NY\/#"X6Q(?157$"M\S+RQ/V'-$?1'QJJ]XPW+Q2V.W;);XX$2"VTM*6?3
M=*$$N=I0/I/W(_"KNN&NB[+[9>[+EV1WY=FE0%!\6]MH+.E:44%Q"][/WV=?
MC^!D[TP]*6 =-&$PL:QV$Q(N*$#YVZ.-A:WU@]P*4N EO1V/I/\ Z2IUKV_]
M/Y#[?RK$NHO5ZWG\UEC@2T6-LS3(EJU&LEJQ78>FH".&C@B]/E50*7"\<L#X
MUG_1;\,N-VGM[ S;R LYVG!5F;'49Y(<?2MHRS,S2Q,LMNP)1W2.7$7?W*JL
M/FU^3+?I---]W=Z;3;?<?=7II">X_P ?>OUI2H,U;L   #V X'\AI2E*:UTI
M2E--*4I332E*4TTK 745P[B'/W&>0\6Y--B,(O3*51UJ>:$B-+CJ]:,XAL.)
M=^EX(5VC0.M'WKN_*O($#C3"[OE,Y2-0F"&6U+"5+><!0T0/<]JRDG0_\:HQ
MOW,?(5\RZ3FAR"5&N"I2G(B$.J+3#25D-@LI5V':-#Z@->_W-9WLW9N2W$9K
MU:TM"*DZ^C9=&;U+:]KK&@4C@("&D?SV\@=I)XU%&_\ K50Z5Y'#>E!8O9AY
MX[J15)DADHUH91VW&=U9?4,BD01>/4*.690/,4^7.@[J%PU-VP7)L!E\GXA)
M$AFUY5$N8MJ93!"A%0] C*W_ +."VVDN;WV]WWJR'X</#;_1ATTWV^<Z-Q\5
MQMMQ4N/;K@ANX*LC)E.N?LRI*UN*=!2H! !\:&SO7+87ULYY!D6N!E5N9OL0
MO,1GI3P8&DN+0V%]I2H[&]Z_+\_'2?C!<[?J#P/@\]J*J=CV4%I^YP&G%1HS
MR6G6'$M.O('8V I12.[04/'Y5D69Q&[W:MMQ\14NV<M+)+4KXZS!6;,W:4)>
M*K'8LLM6E9ML$A%FRJ1H65GXB5AJ1;WXN,/OOIWN+TEI8^MBS3RNXYWQ=J*P
MKKW)%>GIUVE6<H>][#40TD@C,<87N -CW%74KP!U-V>]6KC7-+=D3;;+L.3;
MWV_D)*5J2ME!1#D^F\M(4-CM;(T-^VJHWZAND[#L8YCR"1D]G7-=E/N.0GU*
M<;9=2\E2CI7^[/IA0^_G7@53WB_.UXX]YQLW4%QA!N6%)1*M(?M4>3*>LTF(
M?08FN)6"(3O['U%KT%$*)^];DEBMO%/6APQA^?QRQ-:N]K9,6[LG3C$UMI#<
M_O"-*5VR0L:6?8#[>:S"G0W!T:& SE^*[B\?N[#UQF,7#?J9"[MG-K'%)>PE
MO(8R0T;MC'RL\+S5F1+ 5V104 U2VWE=K_BJP^<Q6,BH/N?8&9EDQDUVI9J4
M=PX>=W2IE:M7(Q+<K5KZ1K)$L\3FM,%#GMDYUK]<=\'8MQM?[O?K,M*W+@I!
M89[CJ&$@A2=DD+!!/G8_*L_V*PW');E%M5KCJ=>>D-*6ZH=C+3:7 IQ9>4/3
M\([E:[AOV%3/YEZ7<)X:LGZQ7;)ES(JE?L+:(KJ?6TH)"/50H]HT0 3[FHNW
M+D!Y$$V?%8*<?M:TZ<4-//R$G[AXCU6_ST1[ZV16>INN7=2?M&A)/?+@0?'W
M4:&*/T550"K 23&,<?)&O!/\4B\\Z@NWT^3I[9_8^?CJXKTO^:_9&+EBMVIU
ML.7Y#1EH*J2D,/5G?N5./3A<  2EY/P;!<KPBQ8[@U[8NF?X3%6N="0@-*G&
M0@..I2X5=BC'2%#Z23X^WO5?^28[#R&U7'&[RRM,:22Q-CNA;:DJ944J':=*
MT2#[#R/XBNT6?(9V,7:+>+;=&X-T965-N/RD%;O>?VB%H=6._P!0;2._>@:R
MX_*QCEFY1P_Z6+9=,[&UR4CU(]S= 2E!';VL,[\>?915NN)C8;NW JO8GNT5
M=[2W2H^*I6&D,TQ:.)>6J&0F2)HPS0'N5P5X8=CG;>+WR_K04J>(S!CBQ[8I
M9&&/RM*.%*U7TYYV^3)+"JP6$F:.*XH62,I(&1HJX+QKB?',5^-B\$1/FE=T
ME[O65.GN)3LJ\C6R/X>/M4G>#\=?S'-F</82Z$WX.-NRVFENHB>FV3W+*04^
M=^.XIWY K/V'=#N?7F8T;_<D6NUK['$OMAF0'VE *"AZ2O'<G7XZW4;_ (D_
M,6:?#7X]P&1P)C+LJ^YU,,._YYZ'S#=A].2U';?<8=;=0E+B72=%2-@'?X5P
M,GN^KN"X<+BKZY7/Y972"9YB((95C,@GL69 0?16,LL4:R.[(L:KRP!R?:/2
M+.8*.ON'<.(;;FT\'+#-;A:$"U9@>5(GJTZ,+*X-CU?3:Q*88XU=I2_"\ZGN
MOX?EG1;EAC*E"YE#JO7,16BIS9[.SNUXWK9^]5><E?#GR#!>3)N=W&W.Y TX
M\EV,\PT4H^@:"BTUW?@#K1/Y5!7G/XHW7;Q.]AB<2YLC<B.95;G9\MB/8[:P
MFT%N*B265NI2L*([RC:M?N^U7O\ PENK7DOJ^X"7EG+[#$O*+<\MJ1+<CQ^R
M1_M2VOI;0CTP$I3KZ?'Y5AV W=OW$[/K]1*&9K9K:F>:>@DCUK^-N2B*W/3G
M05K^/H7:ZK9JRH \0#H!(BM$ZN91R_3;HGU W(=@UL-<V]NO!1Q9-?3EJWJ\
M8,$<L,LJPY"]7G+12@A@RL'!5G#@KJ.&#\<.1WT9?R*%8O@^/^F_+ERDD+DE
MC1CM-1U!#JNYQ"6R4)4 #L@#Q7&\O]3'%&?7=)L?&ZG/DD)B)O+,M]/S:&$A
ME+Q92@=NTH[M;^^]UWCXCF:76[\DV+CF*H0[-;E$+C14ICMR?F$(62X&@@.=
MA.QW;U[#\L)8SB=JL5MCM(BM+DJ;0IYY2$J[B4@@ $'V!T3[G_KYS_B$_%[O
MC';P-3:MEL!'AF>E%\%V/8GFXC>W)++.CKZ(<I'VB,E^WGPO UW> Z;4:)S.
MS\=\)=I0687S>7RU"&Q/<MQK^XAJUSW)6CK!I!'Z;>IRTCO(>\+K)G$'$W 7
M4T[^J=]O/Z&N25MK_5R6T_VS.U0<4A$AWTT_2D;\;/G7Y5<1QMQ7QOT\8$NU
MXM;H=DL=D@ORI4HA*"IJ,RI]Q1>6 3W!"B/.R3H$U1A=+>;3(A958%&UY#9Y
M+'R,N,?3VMYU"=.(1VI6/9("O8?E5O6!XQGG+G"-^LG)5Z5+_6^P/0K<IIL1
MG(:U1%LMJ+D<I4KN4I*E#8W_ #J0^B'XA]T=:]OW<5N[,RF? 7*CV8%(C2W#
M:Y4714@2.%YH1&P=R%!^7@*21J5-@]/-M;8GR^0IX7;]?<E:I$M?(PI*EW)U
M)6?MAB$WKM56&9 M@12+&0Z,%/D:UD?B$]8W*'5UGV>XWQK<KK_J7P!3T5E%
MG=>C_I)PH<:E+<DQ>QY(8?:61M1! \?3K58& \7R,(LG#O+'%/,]_D\MY)ES
M;$G!X\FXR9$1IB^,1I"7D_,N>J#'*R2IO0&S^-2(Y%QCF_H.Y9Y0X*NHN#%@
MR&5.D0,A38EW1F^1)9D2RA+J6'0R6&W@V3W]RC_$UG[X$'3YBG*74]G_ ";E
M-LGR6.,9C$JPM7B++8MX?NR73*<0S*2F,?VGU^WT^-:KT6RE'<.'VTF4Q65V
M_MWIOM>]A<K@3MQ8,MG.I6+L8.6MG,+ONOE:'I85),_;@FK6<//-9->L [1\
MLFJ?X"Q8W5U2R>%W#!N:]O\ SDERIETS0FQ^W]C&KEVFP]S9D]&UW9'LPE60
M6(KJ1I\4Y'+CM;6TQS;PX[ROTTP;7=?0&6-8C9)J[DMEI,@2&K:Q(D(6L@*[
MU%*DD%6^XD'\*U\HC[^/37(MVMTQ]B)+?C_N/,H7\L\ILE+P2D+!*?J )!V1
MJML27;[-D-KD6I]3$RWOM^@\W%D)4GTDCL2WWLK/8 GP "->U1@Y0Z2^-<JL
M=MA1;9%M-NQ\3)[B$-A;LKR9+B5NZ#A[NU2=D[&_'MNO.7J5TDQ_4.RF3@R,
MF'S8 K";TS)3DJ<RN%D6(K.LRLXBADC;M".W>K<+Q?#,[(I9B2KE(,W:PF>I
M+#!'?,7KT32AAD:0V8T)L/,S]B)Z9[.QW]0-P-470^0KSDGRV-83C3PN,PHB
MLEJ,I"6TN$(<6M\MA'TI/<2I7G7OYV+>^GO(>,NF7CBW8YFF2QV\MF),F\I2
M YVK>5Z[:%NMJ4@% <[?)']X-0CRCDRVX[=;Q9>-,7AXK!C*^13/[69CKJF2
M67G$%QLN-E92I7@['</?50?ZA,WCV3!;Z[+O[L;(IW8N&IQU;CSJPLE?8E2]
MH'GV&@!^0J3_ ,.WX+4V?DCE-PY..7+Y81UJ\.+26<U8;+QO++/8G#2-*WCU
M J<(H8$\ECJG^Y>OW_"#7LCCWBW#D,9!:A^-OQG'XFLD3?O8Z%4-%)//9>)5
M$\IA7M[55&Y.MES'N?>'\Y2JWV[++<ZJ:R[&6P^\B,'&WT%M;84ZM(/<E1 U
M^-5_9Y\'+H_Y"Y!O'(Z\>6Q+R1X2KBU%N4PQY#AV5*;]%T-)[RHJV@ [5O\
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M2FFE*4IIKYI*5J;="-]RF'DHU_VR@A/\]ZK^:3\;ZP9-:/B <J2\@1*+,U^
MJ$Z\EPME B GTR=I_=(WH_A[U_2^(V/_ !JA[XM?PJ+?U@6USDO!H++O(EJC
MNNRK<E"$.7L); 2"^HA+99:02/\ M'Q6!=0,;>N8RO:H5Y+DN.L-/+4BX]::
MN\312F 'P\T88.L?(,@#(OD@&<N@NY\+@-TVZ>=N18RIG: H0Y.<'X:I<2S#
M8K?%N.3%5F,;0R3<%8BZ2. B,1_.H5H#SH[(2 -*V2= :&S[U/\ XF:OL+B^
M%'FVXRK8]WJ(5(##J0%E2?.PX@$^WL/P%90O/0O-XRRN5;,RPF_M7*VRE)7
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MU%GHDZ0XO1GB$K"49O$O5GN+$/\ 1UN>CLP'H4EM(7+2EUQ?JR^]Y2ON>W[
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MJ-E392VX>]*4D]H"@->W^'BIJ<%]0QY,FMXW=;8[$NS#2$&:VM9;D=J/)44
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M\4:J7D;CN4@<'GF=>GFV^E/2W(6]B[4NT\?E[*PVK&'LY)I;KJYDFA*0S,
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MH+E<-QWK'8BXD]-N/FC)*$\-P".=5J6'I#P;BZV2,RY+OD>\?HR*]+1 >(B
MR&FU.-)2>\>IMQ"1H)5^8_&LK.[GF/.^2W&]2)[MBPZ+)=BV"T,/?+,,,1EE
MA1/IJ:#H6$)5M23^9W5Y/4UQ!#Y1P>9W?,FY6F.Z_ 2Q(>:"@D>HZ%H;6D.?
M2GP%A7W ]Q5%-[CRX;<2VR"] ML==RBZ:;674/I4MIDN-HTOZG@#M0T?WO8&
MJ??B^WUNS)G:>+;,VQ7R R=FQ'\,[5A)3$7IQ5J\4J):L^FY*5^Q2!W/RS*
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M?3=TUY7%P6;%B3Y.6WM\072XTB#\\PE*)A3VGL2I(#:@22!6P@ 0G7D_5O\
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MQ-T0<?(RK/GV+C=[BI0LV,M.]TBXA#@2_P!X:[U-!M*@KZT:/G7Y<1T@]37
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M5X9'_B>*&-&;D\GEE4$\GSK#K>9RU^&.O>R5ZY!#QZ45FW//''P.!V)([*O
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MB?'GWG[J1C=E9K839W;L53&6,!2_:&!S&-,,2J(NWFHS0]O?'. 8O3<=RRD
MJ&!!KST>?JO@>ILNV]_9.3<V(W9=.-W-MS*P692&F\1WJZ3AE@:NQ64NA[&B
M'<')[6U;UU@?#5Y<R:=:F\(A,W2)&>?#ER8:CL*4TXL=@6V-*.D@)VKWUO\
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MY3]BL7J,.J+#LSU])6AL>GW)95X3H ^PV?'FLS8/F.,9MCK<NV 3;G:@M3D
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M/:!M2RGN)/G?YUVVIQVI@5VU@<?AQ+Z[U8?W\Q\>K8D)DF?_ /E,C-V\^0O
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;I2E*::4I2FFE*4III2E*::4I2FFE*4IIK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>nt10002526x6_diagram10.jpg
<TEXT>
begin 644 nt10002526x6_diagram10.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( F($A@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
M    "0<("@$" P4&"P3_Q !X$   !0,"! ($!@H,!PD("A,  0(#! 4&$0<(
M"1(A,1-!"A0B415287&1H189&B,R@96QU/ 7&"0S0E-55UB6T=(E<I?!U>'Q
M)C0V5EEB=9*4-3AS=':RM=,G*$-$14948V2"DZ*SM+8I-SEF@SI'2&6$A:/"
MQ/_$ !X! 0 !! ,! 0             ! @8'" ,$!0D*_\0 6!$  0,"! 0#
M!00( @4'!@\  0 " P01!082(0<Q05$3(F$(%'&!\#)2D:$5(S-"L<'1X19B
M)#1C@O$)%QA3<G-T)28U0T2B&39%55=U@Y*3E+*SM,/2_]H # ,!  (1 Q$
M/P#/X  !$  !$  !$ !H:B+O]'G] (M0&U*R5V)7SF6"&IGCZ,Y\OQGY BU
M=++N"C03/UZL4>%COZW4XD?'S^*\C Z&5J5IW!1SS;_LN(19R;UST1OZES4G
MT\\$"+W "F\?5_2F6OPX^IMANKSCE3==!R9^XOW?U'?LWK:$HR*)=EKR3/\
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M]N_,@@\NRS8 &U!Y+N1^9&78TGU2?XR&X>$O:0  $0  $0  $0  $0  $0
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MD1^\OE(S(_J BP6,F?SF9G]8(A=B^8AJ  B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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M"RW(BO-R&'"]Z'6E*0HO\51CYV.];T=W<_LIVTZB;EGN(1?5WNZ:(@5%FVO
MK,8JD:I!9(Y'PBHD$@R+.2ZD9EVR,F3T=/<]=.X_AS::S[XF2:K==LJJM-J-
M9ENK>?GI8J+D5E3AK-:LI0UYJ4>5'D$4^0 74B/W@"(  "(  "(  "(  "(
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M!:C0FV/6X_KYJ)'B8\'Q?%SR=?P/E%>B4DR(R,NI$9=2[&62^D$6X R1]CR
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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MN+%BFLF42(_BJ<4R3*G7)"DQVTDKEP?F/ID;/=W.D.\[1:U]:-'KAB5NWZ_
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M1[DDE?-7-V)3XSF?&\2J7%TL^(U9\Q)+&B4M:SF?*UK0&CDT;!  !<RMU
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M)\?#S*H\"YH%%2VETOO:?#:CI3CWE@^N!]<#;OUT.TF/IA5@VLKIV]JAP3Z
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M4QY^,IAQURH2)#BS4:UJ=/FR>3,AD2D1%V\SS^,QJ-,]<8/Z#Q]((M0  1
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M!X50831M:VFH*:.GCT[7T"Q>18>9YN]W^9Q0  >6O40  $0  $0  $0  $0
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M(VW(>147V(K"4(,R<?/ER@B02CSV+KU]_*V*,P;,.$8G(;1T==3RR?\ =^(
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M )1[M_3P^YF>%3_-5=_^4>[?T\9!H BQ\ON9GA4_S57?_E'NW]/#[F9X5/\
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M)<3<N))/<G<GYG<^JWD    Y  #X 6'Y(  (4H  "(  "(  "(  "(  "(
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MX[<VDU.%-:<21IY)#/B&2NI9;Y^8C^0^OEW'>\ZT]5$9E[L?YRZ?-^I#)/W
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MJ[9/!^_&2&Y.#<:N'L]/!"VK?A0C:UC*>>F>R.%H:!H;X+7QZ>Q'0=UI9C?
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M?888H(V10QLBCC:UC(XVAC&,:  UK6@!K0!L   @  XER(  "(  "(  "(
M"(  "(  "(  "(  "(  "(  "(  "(  "(+5=Y^YJA;1MOEY:W5^*<Z+0/48
M$.(2S0;]3K4A,"G%S$E1I(I;K>>F/?T[75"&SCP].'/J3V_X5Z=]RS_\:8!
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M+LEM)-I+YB3@L>X<H I6G*1>1#4 !$  !$  !$  !$  !$  !$  !$  !$
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M18(:@B   B   B   B   B   B   B   B   B   B   B   B   B   B
M B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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M_/XOLSB6DO9[%DLE@02!>YY:;_[SM+?Q=L%/4#J;V]=(N?P&Y]%=4 \P_=]
MAT.)<-0J46GTV9%8E-/RWVF"-N0VEQ!I)U2>;)++..V1^^C5ZCW!$3-HU1B5
M**OL[$D-/EY_A>$I7)\F<9^<5$$$@BQ;LX=0?7LH#@X-<#<.%P>XM?9=P !G
MR_S'^?L(4H ?KVQ^</U[9_,"(  "(  "(  "(  "(  "(  "(  "(  "(  "
M(  "(  "( ZZIU:FT:*Y-JDZ) BM)-2WY<AJ.VDB_P">\I*3/W%GJ?0==;]U
MV]=#!R*#5X%3:2HTJ]5E,.N(,C,O;:;6I2,F70U$1&6#+(?RY^B<OX?->B
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M#ORMN#UW[;SO@ "54@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M6S]T=2  '35@(  "(  "(  "(  "(  "(  "(  "(  "(-JBR6#Z]2/Z#&X
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MM_0<Z\-?@]2P9F>>GZY'(-"[%\Q#4;VM  VY'<?@%H8.0^ _@@  E2@  (@
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M*W++QI'A*CLJ^]((F\$9-?C''1.L)FMLP/IZLN:[S%Q9B,#26CDTDFY=<.L
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MOLW8MM6Z6DGM<W-KZALYNP*G":;2A."(B(C,DD71*2(^A$78L?(1#D,B/O\
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MI[EZ)-PT)2:\%\8SP/W@ (23N3?X^FP_)   1   1   1   1   1   1
M1   1   1   1   1   1   1?A?IM/E2HTV1#CO2X?-ZK)<9;6_'YRPOP75
M)-;?,70^0RR7<&*93XTN3.CPXS,R;R^MRFV6T/R.3\#QG4I)QSE[)YU'@?N
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MR1S\OD8(I#   1   1   1   1   1   1   1   1   1   1   1   1
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M"AVEX!YGXE   4(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "+12241DHB41^2B(R_&1]QL0TALN5*22GR2DB2@OF07LEWZ]!R "(
M"+8IM*^Y%\QEDC^<CZ'^,:H0EM))0E*$EV2A))3^))="^4;@!$  !$  !$
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M-,:_\'*90\C_ .U60_8"E   1   1   1   1   1   1   1   1   1
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M*BKD!=4SV <#(^^BV^S6ML%H!G//V8L[U8FQBHO31N<^DHH]H*4&P:&#<ZM
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M+!$7D.^!0=R3W0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $5K.[G;TK<9I+4[+IU5*
M@W U)@U*BUA3/K),2*=*;FDR<<S)"_65M):RK\#FYA9)/T?W(ZJ2[4EZ[0$V
M[8^C,"4X]%8.+,7?C<.*1PY1%$+Q8*H9Q&WB0DE*=,R2)@1Q*9;62DK23B5I
M-*DN>VA1&6#)259)1&70R/H9"&C2;[.&MLH:X7:)6:=,@ZZAI:;7+26M):2T
M%0X:K]"6.C+A]HQN^U&>[3=P[C4X @$K'SLOB5:EV_>=V7%$8=U/TBITIFFU
M*DSV$VM4=.HE-6<(UQ8DMMN=7_6B:-9^"TLTD@C/N))J=Q$]K50T@<UC1J$R
MFWF&3]9IQ17E5]F82C95%.B$1U,\R2-I*_5R2I.'"Z'U_%N4V':0ZS)J%XTV
MFM6;J=!@S'Z+=5-2I$",^3"S4N90XYM0IYKP7^^&U8/*NYGF#GA&[1+3N3>#
MO(J&N\A>J-]::U:U6Z+5G%OTRAM-R4R"(F[9865*)1-MH29JCGS*+G/*CR4I
MRL/P^']OZ7-RI+(VH6L'$1MBZ;5@Z7S+"T+JC\6;:&ID^5S2*N]27SE,J709
M2&9;!*E--H+Q$XPO/4AWZ="MS^MZ;2TJUGB-T'3:R93/PA6D+AR57JQ3WFW:
M4KU=@R=@'%]7:R1?OAG[1X+I+'3J9 I41F#3H<6!#8;2AF)"CM18[:$D1$26
MF4H01X(LF22Z]?</W$DB/.3^0C,S(OF(&$QNU-V_6,E(Z>+& (Y+?>986Z&P
MU V".&H6//2YE^H8_P"VP=@ZY/<'<$&Z_)3H;=.@0H#1_>H,.+#;\OO<5E#*
M#_ZJ"'[<Y["V?<1N<L?;]&H4*M&Y4KMNUQUJT[9CM.N2*RZPI*7DI4TE9M$W
MSI,U*3C!GD4%@<0BP*=3[JBW_1W;)O.U'Z,W4+9F&\M*T5MUM,-QF8I"&GOO
M3B7'/#SX?4EX,@O>YN-B;WVN18D#N0'!Q Y#<V"J#2;- N38 #<^8Z6W',!S
MO*TFP)V!)4B0"W"X=RUAT&NZ:4!=0I\R;J6R\]26X<YB4MLF6D.J(TL+<,CP
MLB,E$D\_+T%QC:R<0A9=EH0LOF662%1:X#400-3F7M^\T-+A\M0_%4W%[7WT
MAUO\I) /S+2/D5O  %*E   1   1   1   1   1   1   1   1   1   1
M   1   1   1   1 QCL  B   B#8X>$_.9%])X&\;5=327RY_ZO4$6!AZ5K
MN)J5^ZT:"[2J2^XW2$/U.3=49ITR;D$A+$Z)ZPVDRYN4RP7,1]"(A!%3H;,"
M'#@L-I;9AQF&$)26$EX;;:#/IT\L_6) >/-4#N/C"71!=7XK5JL028(U92T<
MBBM\^.Y%U+ZOIL0;+!*_QE%]!F-T/9UP>*ERY5XLYK3/B%:^(/MN(8 VT=^=
MB7$VY=^ZTH]I/&)JK,F'8*'D4U!0-G++[&>I<27:>5PQK!<[FRY,8P7R%^8
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M=]IN0:T.D32E/-.*2DE*2>?P>N!1:D576/:GKEHK:=>U.?U*M?65F:_5*2Y
M;C/TA^-#;D<[:TJ>=<;<>>4:5$22,D]L9%4;'R$6:0'2.B8XVL^1D;)'#G<
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M:FBYZ$7/Q^"X0T:PZ^_A,CZ;M87:7?\ O:>VW>ZU  '&JT  !$  !$  !$
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MMRLN -(>';?L8X[#NQSR2!R (</G<]5J  .)5H  "(  "(  "(  "(  "(
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MS+3S*D\JF'FD.,*218)*F5D:#3CIC&"+L/TD6.A="+H1%Y *7'4XN-KN).P
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MC\AUD*A4:GR'ID&DTR#+DF1R9,*#&BO23+L;[C+2%NF7D:U*QY#M@!$  !$
M !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
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MXJOR&I)Y+F2MU:3+/EC!^>1=7_21Q80:?T!1^-;=WO,P:3\-)L.P%MO56?\
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M0  $0  $0  $0  $0  $0  $3!'W+(8(NQ8  1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
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M=-+F8N2G4Z4_"ER&4FDF9,=]R.\VK/FAYM:#^85>&/\ <!!M+>A^I9)6^O\
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M>H(L[@!QM?@GY^TK\XY 1   1   1   1   1   1   1   1   1   1
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M#=)N"TGT@L"[J7J!=4>@3K@LRZ8]*9=;4XN4[\"S&^1LDGU4:EI3CY?>(<>
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M"IG5YLGP3>0:',M.NJ0K*3,O:(\>0)<:;"]_X_'^2OI+'E^I>0  *E   1
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ME-62+'490HX)#$:4RY'E,L26'2-+K$AMMYIQ)E@TK;<)2%$9=#)1&0(L)O@
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M"0EYX^8LEXBE8\A74$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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M>\=-[.FTR\;;^QN8ZX2D1BF(F<Q$M1YYT&9%T/) G;Z_G_$!1B7#Q4=1M/\
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M.\*8P16]6:E9[5-EM=8LE<%M]F43*B+PS-+B3)?*9]>XF4+KU!0>?X'\0"@
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M]07-FNS&T.<YJ5B/XIH3E1ECY!<R  B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B#0S))&I1D
M1$1F9F>"(BZF9F?0B(NIF?8:BW/==J:[I%H+J'?+3R6'J91I#3"U+2DR=EL.
M,)-)JQA65D98/)'VP8#?8<RBN$CRXDQ)KB2H\I!&9&N.\V^DC(\&1J:4HB,C
M+!EG)'T'Z!"WP9M6+IU/TAN]VZ9S\^3#K4QYAR5)4^\;<FI2EHR2U*6E))-)
M)Z$6,8Z":05.;I<6]OZ74 W%T  %*E   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
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M,C[D1CFEWM:4*<W2Y-RT!BI.J22(3U7@MR#Y\&G+2WTN)-1&1I(T^UY B]4
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MN*>)#I%TYN12N7S'Z8]PT*53OA=BLTIVEXS\(MU&(N"77'M2TNFPGKTZK[]
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M%?8CQ78\B,3BC;YS994AGE0:"RM9&KY14UI=L+7]3903;Z^ODLFDW"]RR_\
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M@4'G^ _ 60  %"   B   B   B   B   B   B   B   B   B   B   B
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M18,SR?7WF>"^8O(:@"(  "('< !%LY"]ZCQY&HS+Z!O  1   1   1   1
M 1   1   1 ,L]#  1   1   1   1   1:$6/?^,\_G&H "(  "(  "(  "
M(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "
M(-JL8ZGCSS\A=3/\1#<-CB"<0I!]E(6@_F6GE/ZC!%B?<72[[GUZW.T/1.QX
M4NO.V8]ZN_#B(==:-=5:;,O$Y"4@B29F?M%CIU]PO,V+<)>W[*A4N^=;*>S-
MKB?5I]-HAM);;AKREXN?POO:S/V3]I'?H99$L-H[4](;2U1N+5Z);T>5>UQ+
M97,JDK,@T*90:$<B'R6E.$F9$:,&6"R+E4I)!821$1=B(L$7N(B[$1=N@Y#(
M=(8-A87/4G;X6^MU3I%R3O\ P44&^WAEV!N;I7V1VK'AVSJ#2H1(@OLQ&EQY
MQ,,I:::<CI)$?/AH2@E*29D?M=^^/SH'2=3]B&\"U(>H-#F44VJL=/5,-M10
M9K4I11VG">0@HZ?96E7+S'U/'R#-F,B/N+<=P>V'3'<508U*O>B17IL"5'ET
MZKMM$U,B.QWVWR/QFN5U7,ILBZJ,B!LA:-)W;8BW:_;^B%HO?K]?7]57ZD34
M5*ETVHH6E:)\"'+2I*B4DRD1T/=#+H?X8[$>;M*WF[6MZE4!I]4AJE16HC+J
MLFI3++:6FR/F,SZ(2DLF9]OE'I!QJI:&6?,R^8QIR_\ .5](W "(18_U]1;#
MO#VQ6GO"V_7UM_O9\XUMWS'CQZ@\25*-"8[I.H/"#2K\(O(R%SP BC=X<7#@
MTPX<NF%2TRTTGKJ-,J;YOOO+0X@\^.X^18=6LSPI9EW$D!H(RQ_S33^(RP-P
M BQN=ZOHWFU[>GN0O;<A?%P2H%U7JJ&J>W'];0I"H3!,-\KC+[9%[/N(A;*U
MZ)/L^9<9=1?->YV7V7R,YM7/JRM*R+_?O8^7&#&6_@O<7T!@O<7T$"*VW;-M
MLM;;/H%:N@=JRGI=NVM2YU,B27UNNNN-3T+0ZI2WEK</HL^ZC]Q",'1O@9:
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MBGEH)6<_P3/N0(NP <;3J'FTN-K;<0LLI6VM+B%%[TK29I47RD8Y 1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   18O?I*.QZH:N:!4#=;IM3?%U3V]O*DLMP(_[MJM/J\MEJH*=4V7
M,XF-"0XKVB424D1%Y#%4LF[:=?%I4F[(#B/5)$1U,OJ1>!*I;9(J27,X-*DO
M-ND?,1=2Z#Z?U^V=1[^M"Y+.KL./.I-R4:HTB7&DM)=:5Z]$>BI6I"B,C-LW
M>9)XZ&1&/EN;U]O^I>R/=SJYLLM"DU&I,ZA7=3$:./,LNFW(BW'/]9N0XF$K
M)28K,U7-A1DDDEC!=L3\4,ES9EIL.K,.C#L2I:F.EDL/MT53(UKG./44SSXO
MI&9%]#?8(]J+#.!6-9SRUG:M?%DC,&#5F/TFIQ+:7-&!TCYH(8039KL<I6'#
M[  .J6TFUU*7P'=IKN\G?#7-S-TTTIFDVW.0TBR$3&373ZU+J\9<68IGG+E<
M.)*:YCP2\&7\'N/H!L-(9:0VVA*$-H0VVA)8)#3:22V@B+!$24D1$1=!&UPI
M]EE"V.;/-,M(XD..5PG2TUJYZF39)E3IE:Y:HIN2OJM1QW)"VTDI70R,NG8I
M*QD7!<*I\$PJAPJE $-%3QP@]7O O+*[87=+(7/<>Y[+2[B?Q!QKBKQ S7Q!
MS!(Z3$\T8Q58BYCG%S:2E>_10T$5R=,-%2,AIHFMV#8@;7)0=-<3ZXM"J\AN
M4J"MFG3'43$-&^J,I$=Q1/I:(C-PVC+G)!$?-R\OF.Y&U24K2:5I2I*B,E)4
M1*2HC[D9'DC(_,CZ#TU8:Q]7MRM^)NM<(MZ=RI:*X?5O@XM(:B:"1\(^'ZEZ
MP47'+R_>/&SC'M]1(KO=D*F;*[\E/3%5!;]OTYU<]QHXRI:EMMJ.0ME6#:-S
M)K-"B]G)E@7K?8G:YK\0[:MXW.;GY_@6G<_-G/-S>!GFSUSG.>N1YC5/3&V]
M6+!N'3RYHQ.4&X82X4QA!FT1-F@T)Y?#P:>7/0DX]Q ION/2W;T]!^:CHX;-
MY(MS8!I_4*&U N.M4]=S.Q: Q4XJ),UQ-4DGX1$EQ3A*[&?L&:2/.!:OQ&:[
M?>Z#8?JT>H%@S-'G+=N"U(U/;.IKFE4T2[@99-T_#\/DY$D2\*SWP+OML/#-
MLW:_=]!K-F7M5'[=MZ95)=/M9]V:[#0JJ.../I43TA;:R);AF7,@_D(A?!KK
MH?9VO>FE:TPO"*A5NUN539<QIE)LFMVF2VY<<S-GE49DZVGK\_D"7\U^E[_F
MH2([MV;:HW#RTWMZ^G&Z'<L.NKN21),F8]31X$5YA#[K[A(:\+F-)&:L'Y#E
MUNW8ZFZ;ZX;RIMK78FKPK.B:=4^@TV$MF6W1#N6&U%ER_O2G$F1&\;YFHB(N
M4^I8,RD[U^V+:4:\:>6;9M90]3JAIZTTS9M?COR$/T=!>%XQ()E:%K\9+24F
M9K+_ #"G>DG#-T(TTE:H521'DW+6-8*?3H%]3:A+EO?"B:1&.+37$-R'7"CJ
MBI,C(VC(S,B,SSU!3<<S\]O4&_S%PK:-$=,[FT3TB<W)'K,O4*[:A0JU5JY2
MFWD.%5Y,Z*^Y 2U'1*>2P=&6Z1K2TT7-X1\^!8;5Y.K-/V9(WZ)URD2=9ROA
MICU)!MFTY3W;N*E?!Z:>F4;1N-P%>">(V2(N?N)CM N';8VB%<F/LW-4[@MM
MMNK1Z%;4U^:N+2H];;>:J#2_'?<1(YT/J)OG1]Z(BY,"FU&X3.BE,N-N,[4Z
MC,TJC5ERN1--')<XX+4]Z8=16XIY3QI67KQ^.E*D<J<<I%@$!&^_;H-P.G/X
M?@K$=4M1]2(^LMN:R;EJG+M_02NQ[,^PFXHE163EHU&1&@LS2F4B"ZF3)*LU
M!PD)]:;PUSY21D-VX;6;5W7?>+>^AU @R+BTYTTMJBSK7AHK'V.JJDFKV^B;
M3I2'_$8=?Q(\%Y9&IS&32O!=Y-]9>'E9.LU\'4[DN)[[ 9+E$<J%A&TZJ*^=
MNE'.E>KO$YRQ? <CMK4;2"\0R+FR.SUMX?VGFH]XT+4:T:F[I]?U'@1Z:[<$
M3QWSGPHT1J"PU(CI<0A9MQ6B:2I>3+.2(C! 1\.E^W*QY\^=_P"'-<G#CD[D
M4Z!4^E[E:,BG7E2YU3:BOHJ,:H^LTWUYU,!!O15+0:F81-(,U*-1F77KD2#"
ME6C.FC6DUATFS451^M+@>*IZIR#<\24X\LUJ69.*6I)<QG@N8^@JJ"I0  $0
M  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M  $0  $0  $7&[^"7^,G\XQ)>*E3:<]QMN&>;L"$Z<F9?YR3<BL+.0;=.8\,
MWS4V?BFC^ ;G-R_P<  (LL^GD28L1*2(B*%%(B(L$1$R@B(B+H1$70B+L/W@
M (@  (@  (M,%[B^@:@ (@8QV  1,!@N^.OO  1,%[@P1]RR  B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
+  B   B   B__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>nt10002526x6_diagram11.jpg
<TEXT>
begin 644 nt10002526x6_diagram11.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( <X#?@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
M    "0(("@$$!08' PO_Q !E$   !0," @4#$ 8&!P0%"0D  0(#! 4&$0<2
M""$)$S%!410:(@H5%U=866%Q@9&4EJ'1U-46&2,R5I5"57*2L=(D,S128M/P
M&"7!X35D@K+Q*#=#1%-4=).B)B<V.$9)<X6S_\0 '0$!  (" P$!
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MF-\*Y%D@
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MUKK-.::H,<I<ZKQZ52:W&15VVXC*"EO)>A&YO)#1X1VECM!Q[[>VZ7U\)O\
M0D]X3>.713C&T]N34/1RK+JU+MEZK,5%EZ,_#D,O4EV2RXEQF2E#J4N.1EDV
MHT$E23W),R/)[3A8XS[;XFJEJ=3J;1D4 ]-9[4&>_(EEU+YNOO,DM3CI(0V7
M[(SYGWX^ 04\$FOVB^DG'!<FB^AKE2B:=Z^V(E^- J=#J%#APZM0[15)JSD;
MUQ8CH<<?J*G5+4T1'O,_$<]PQ7=9ED:6\:,K4"]2T[HT^ZZ#$_2*.TN3),WZ
MZ\RB,RQ'-+QG,-9,;F^:-^[D <?/GVV_/YF4) JD"II4N#.@34)_>5!F,2TI
M/P6;"UDD_C\!R QP^"#5:Y[.XY*EHY9UQ5)S2FY(<.85#JRY$B0DO6ORU$MM
MV>I4E!2W%=>24X))*V]G9D<-J-23,_\ >47R$HR(##6S/H  !@
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M?EU0ME&#?UZ4M_F^Y9G LMNP<.Z]*-UN+CV6J/W5;.J$II?12;V-0 !^0_4
M                                                ?)UYME"G'7&V
MTIP1J=6EM!&?(LJ49$6>[)\^X:]:V:4K);9H5V+WIV'GLPKL//P #Z -,D>?
M@[^[XR/O+X103K9GMWMY\"<29_, /H H4XE.=QDDB[36>U//X3%62,L]W;DN
M9?(??\@ U ?-+B%&9)4E1EV[%$K;_:QV9[LCZ
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M<W^,I-O^;/3FN"KKA6O%<(P7X0BHK^2   X',
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MR1[91LH.0GEVX=W%DN0&)>WMV\;)/S[I&^   X@
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MVFR(N[DA)%R_^(X^HTNFU9A<:HP8S[+B32K8RTR]A18/:^E/6)Y>"B'89?\
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M"A2ES:+;%!I<MPS-4F%28,9[/BAQAA"TFHS/=A19[R':@
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M5;]I9R?//:+5_'X3,_G/(TKD3H[TW@?'S+J^G)UC*R-0LG*+4[*W+TJ6]_\
M;%R2?^K=>=WNW/K65J?'N1AUV*>/HN'C:?",9;PA;T^M?%)-KJC*:C+Y;;
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MW)ONVWN_<FB$(50C77&,*X1480A%1A",5M&,8Q248Q6R22V20  '$Y
M          R1=IX%*UI01J4HDDE*E&9]R4EE1GX$1%VF(.>+GI_^C]X/=8JO
MH=J1J(X[?UNJ;37J93J54*@5/4\T3K)&]";=;7N3S/;^[C!\P!./DO$OG(,E
MXE\Y#&;\Z?Z,K^-:S]6*]^%#SI_HROXUK/U8KWX4 9,F2\2^<@R7B7SD,9OS
MI_HROXUK/U8KWX4/.G^C*_C6L_5BO?A0!DR9+Q+YR#)>)?.0QF_.G^C*_C6L
M_5BO?A0\Z?Z,K^-:S]6*]^% &3)DO$OG(,EXE\Y#&;\Z?Z,K^-:S]6*]^%#S
MI_HROXUK/U8KWX4 9,F2\2^<@R7B7SD,9OSI_HROXUK/U8KWX4/.G^C*_C6L
M_5BO?A0!DR9+Q+YR#)>)?.0QF_.G^C*_C6L_5BO?A0\Z?Z,K^-:S]6*]^% &
M3)DO$OG(,EXE\Y#&;\Z?Z,K^-:S]6*]^%#SI_HROXUK/U8KWX4 9,F2\2^<@
MR7B7SD,9OSI_HROXUK/U8KWX4/.G^C*_C6L_5BO?A0!DR9+Q+YR#)>)?.0QF
M_.G^C*_C6L_5BO?A0\Z?Z,K^-:S]6*]^% &3)DO$OG(:'A6"(RY*(^WP/(QG
M/.G^C*_C6L_5BO?A10OU4[T9BDO;+XK+:RBR3:7^C%>/+Y,K-E&/)<>FYM3D
M\8SV@""?I&[ZH].]4LZ;E+=:;;H54I[4IPU)Y.3*3&0VE7/D>X\$1]X_0DM]
MU#M)I+J3+8[1Z6XCF7-*X;2DG\QC\=WC-XUYVO?2A7+QQV=2;DF:?Q[QMJ<Q
M5DTFI^3QZ3 ?CLO+4X<?#?6,MJ5A2B,RP7:,[>T?52O1K0K4M>+4KQK354B6
M[1852:.VZZOJID2G1V9"=Q12)6'D++)<^7:8 RALEXE\Y!DO$OG(8S?G3_1E
M?QK6?JQ7OPH>=/\ 1E?QK6?JQ7OPH R9,EXE\Y!DO$OG(8S?G3_1E?QK6?JQ
M7OPH>=/]&5_&M9^K%>_"@#)DR7B7SD&2\2^<AC-^=/\ 1E?QK6?JQ7OPH>=/
M]&5_&M9^K%>_"@#)DR7B7SD&2\2^<AC-^=/]&5_&M9^K%>_"AYT_T97\:UGZ
ML5[\* ,F3)>)?.09+Q+YR&,WYT_T97\:UGZL5[\*'G3_ $97\:UGZL5[\* ,
MF3)>)?.09+Q+YR&,WYT_T97\:UGZL5[\*'G3_1E?QK6?JQ7OPH R9,EXE\Y!
MDO$OG(8S?G3_ $97\:UGZL5[\*'G3_1E?QK6?JQ7OPH R9,EXE\Y!DO$OG(8
MS?G3_1E?QK6?JQ7OPH>=/]&5_&M9^K%>_"@#)DR7B7SD&2\2^<AC-^=/]&5_
M&M9^K%>_"AYT_P!&5_&M9^K%>_"@#)DR7B7SD&2\2^<8S?G3_1E?QK6?JQ7O
MPH]!TM]4R=&;J7?%(LIK4R31)-7)\X\RHT.JQ&2ZA!K5^TE,M-ER+!94 ,B0
M! #?7JEGHH=/KJJEI5O79:ZC2C;*0N';U5EL'UI;D['H[;C:N7;A7+O'4/.C
M>B*]O6;]5:Y_R !D6@,=+SHWHBO;UF_56N?\@/.C>B*]O6;]5:Y_R !D6C0\
M=F?A^8\C'3\Z-Z(KV]9OU5KG_('P?]5$]$:XW))O7B:VYY#--A7Z)UQ6Z24=
M9QV_]26.L=)*,GR3G/( 8]?'#?M'I?JH>S)B'6I!4:H0(TM.XDI2N31([*2-
M?,L[NSXNSM'Z&-$>)^FTYTL8<I=.=+'/DY%;67^/(Q^.OQ6<<,75CI4[@XYK
M.B5RIZ=HO:@3&:\BG3TQ44:$^S'=>6\;6UO+"5K)"E$:OW2R>"&??:/JH7HF
M(MJVNS5-;IT:JL6[1HM3BG:U;7Y/.CTZ.W);ZQ+&U>UY*TY+MP7,P!DH ,=+
MSHWHBO;UF_56N?\ (#SHWHBO;UF_56N?\@ 9%H#'2\Z-Z(KV]9OU5KG_ " \
MZ-Z(KV]9OU5KG_( &1: QX:7ZI\Z)&KU*%3(VN\A#\Y]MAI3]LUEELEN+2A)
MJ<<9)!%E7/)\N\=IU$]4H=%%IK<K]KUW7OKZC'8C/NJ@T"J3&B1*92^V76QV
MUH,]BB(RSR/EV]@$^H#'2\Z-Z(KV]9OU5KG_ " \Z-Z(KV]9OU5KG_( &1:
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MXA?4[' -K).57;?LZ1IW7WUONO2H-3J3C"G73SO3%:>2RDDF>=I%C&2P1#(
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MBN@_##HIPVP:U3='+(A6;#K\I<RJM1#R4N0XZM]3BSP1Y-UQ:OC48N"
M
M           >+Z\Z :5<2NG55TJUDM=F[K&K2XZZE1'W%M-R%172>8,U(,E%
ML<22N7>1#V@ !Y;HUHWIYH'IY0M+=+* U;%D6VVZU1Z,RM3C<1#RS<<(EJ](
M]R^?,>I    &>[O  !H:B3V_X&?^ T4K:63\2+YSP([=>>)G5./JA.TGT/M5
MJO5BUHKE1N^:Y/CQ3@1T13G-(2S)QUW7LH6@S;SLSD 2* +7^%#B'8XBM,8E
MVR:5ZP7!&DS(%=HA.G)3#DPI*XF\I)$2'.O4TI>$_N9P8N@  !P=QW%2+5HM
M2N"N2TP:328KLR?+664QX[#:G77%%WDE"%&9? /(=!^)31SB1H$VY=';PCWA
M1:?+?A2IT=M3:&I,=]R,\WZ7::'FEH/'>0 ]Z   'G&K&E%BZV6)7=-M2*(U
M<-G7&R3%8I#JU-HEM)/))4I.%%@^>2'E_#5PCZ"<)-J2K+T&L=BR+=F/+?D0
M&'W)!..N.J>4HUNF:O\ 6+4K&<<Q<OGN[P                    '&U>DP
M:Y2ZC1ZFP4FGU2'(@36#/!/193*V'VC/N);2U)^4<D  M8X;N#/AVX35W<O0
MC3^+8ZKYFE4;F.,\X]ZY2^N=D=:OK#/:?6NK5@N]0NG
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M:2?(R[AI7'W"V+Q=PUJ&DW5IY$J9WX%KVWIS:8.5$HM^.IKTY>-XR:]]UNG
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MTR,N>1-7@L8QR&W7$8<<;<6TTM;>=CCC:%NMY[>K<41J1GOVF6>_( B&L'@
MOW6VM0-2^-R_ZCJ%4$/IJ%"TYBF[1(-I*-9.^2OOTN0VS5"+T"/KF\>AS+TC
M(7BZU<$N@&MMGTVTKELR+3VZ#%-FW:C0%JH<ZF2$(),:0[*I?DS\LVG$-N*)
MU:NL))DKM,7=DDD]GSGS/YQ4 (2(">)+A^O.S^%&FZXJJ3=VMU9VW+_JE(C,
MG:<.DM*FM05MRU'ZX^4,DB)UJW#V&6\^T;&AV[KYQL5>Y=&+]U>DVM:VDTMB
M/J"S28+;B-38]1<-43J:I <;53"C(;/?Y*XHS->U79@26\0?#-9>O::'4*RI
MVF7-;)244&X(KKK3\%N<6R8@R84A3I/-906Y7H9R0['H5H%9&@ULJH-IQ5&]
M,/K*K4WW7'Y52=WFO>\Z\I3JB2I2MI*49$1X+D .C6#P8</.G>G$G3&A:?P%
MVY/C=14CJ2E5*J2UN)/KGBJLWKIR%+6I2R-+Y&G)$G&"%C5U<%6M_"W5*C?G
M!->]0CVLF04ZK:%U%Q=13<*=YN.M,5ZK/.J@)0HUN)2UC]XD$7(A,F*5))6<
M]_+ER_ZY<OB $*C^N?2!<33B--;)TC=X;^K2<*[=3)-2@7!ZWI-/5N*CTQYM
MOK_*TDXDE-&HVC62L\A[G1^CHHD*Q[>;J%]SIVKM'*:I_5!:)"7Y*ZFO=/+R
M'K=B"6VM;2?2PDCY8P1"3%J*PRI:FVFFS6>5FTVEHUX[#<-!$:S+Q5D;G!=F
M.7@ (LKPZ.V52;.H;FA.J$_3352@'*F'>QL/U7U[DNK-]34J#(=-I1/&1L)-
MPEDWUF4]F!XXQQ0](38K#6C-8X;'KZU#<WT^AZDHN"%!C5ELO075G826SCQ?
M)633(ZI:B-PRV\Q-?@C[AME1&%.H>-IE3J,['5-(4\C/;L=,MZ<]^#( 1*:;
M]'K=&J%P0M4.-2_JAJO<[+Z*A0;29ZZATVU'#43BH;[=.?3%JB6_01N>:,CV
M&9=IBZK7[@>T(U[M^F4ROVM'HE4MZ,35L5RW%KH4FE2$(2F,^^=*.*N;U3B&
MUFE]2M^TR/D9F+RB222Y?.?;\XU $)T&K<3&C]UVMPGQ=;O7&I/QZM(B:H5&
MCQ(ZJ?"IS*Y\.G>1REDF8:XZ405/=:HTF76'S' VM:^N/'A/JFG6I6JDNU[(
MTPG>27[0Z5$2:=1VY#RBAK:K$!UI=/)KJC6M,9Q1GOV*[!)9Q \+=E:[RJ%6
MZFMVCW5;:9+=)K\1QUIUAF<GJIC;B&%(Z[KF=S9&X9[,Y2.ZZ&Z#V/H-::+8
MLZ$;2'%*=GS7G7'Y,]Y;BG5.///&;JOVBE&1*49)(\%R[ .A6UP9\/5L:6/:
M14_3Z NT)<<F9B99^5U>0I63<>]>9!.5%*U.*4LC)_<G)8Y$6+#K@X0N(;A$
MJDV].#.[)]<T_9>.94- :HZ4M54;W&MY+%R5=UUZ,3>7'4H1C/)M)"9P4J0E
M18/O[<<LD98,C\2,NXP!"FYK)Q^\6:X]BV1IO(X7Z.C?#NG4>1-A7&M*,;'V
MV*:ZAI9]=AUHEMYV;]^>19]ZI?1S6S2K4MA4>]:@C52BE,]<-1C.4IZKJJ2C
M.>3L)3QH(G$+=;01J/JR7Z.,$)*V8C#&>J99:(SYDRTADE=^5$@BW'GGD\\^
M\;C!=F"P (K]0.CWK% H-L5?AJU-F:5:EVIY;-<KYQW:NW<LJ2KKGF9,.4[U
M!>4*W,I4XE1-=9N+DD>2)XJ.D'I$3V'97#,[5]2SS3X6HGZ1P6H<U.XVU5DX
MG5G':ZIG_2C84LLGZ&,B:LR(^TAMO)&.M)XV63<3^ZZ;2#?29]NUTRWER\#+
MP $4FE/1W5&\+EBZL\8U\3M9]0VW6Y]'IZ>OH=)MIQ1DXJ$[3X3WD%12TG:S
MN=9,CZK=CTA<?Q <"NAFO%/@.5&W6[:N>@,$5M7);KCE&72WVT$EE]]FEJBI
MF]6I#:C3(W[MO,\'SO5(B(L%_P"?RF"NP_B/_  8[VL?%YQ.]%B]2J#K.A[B
M3TUN5;D.T;L23%!DT1+!DW&B.18Y//RC4M;,=3KIGR3UF>>3]XX?K<XI.-:L
M6SQ!ZH7I(TMTCELS%4/1F,PQ.5.AR6C9-;U:C+;>+*32_A9&9;MA=ACR[IOH
MJY%"T32454A*9U1W)*,<AM)]<QC>G8I*3S^[DLY[!)?P&(4CA=TN2MM;:DPY
M!;'$*;6GTSP6U1$:2QV<NS& !U:]NCWT(OV@6O1Z]1NM>M&:Y.H=19=>9DQW
MWI*93QN.-&EQ[>XDL$XH]O/ \#U4T:XPM =0:IJ]P^7>]J=94B- 14=#)+<:
M"1PZ9&1'W,5Z8M;C9I;0I\R0E)GC:>1+B.NW9,8I]LW!-?<ZIN/1:FI3F#/;
M_H;QD>TNW!D1EXXP (<"U,X\.,]R+:MGVJ?"U9*.LB7'?938-TNU)'^KF1FX
M1DAU@\D[&ZQLR,MQ+SRR+SN'?@,T0T'A3IB*"S>-ZU]I171=5RFNLG5)"TJ)
MUZ-%JIRVZ?UBG'#VQR;QDO#(ZWT?MZQ;NT]K[;%6<JCE/KE32XIR*J*;9*J4
MC:G"B+=R(B(__B)!P!&/=G #;=@ZDGKEP\W5.TAN"' K55NJE,G)JE)N5UB&
M\[%;9IKSI0*<E!I,E&RR1'NW8,R%A>CG2H:JU]BOV-J'33MZ]YM>=H.GE97U
M;D:Z.HJ+D*;+;-*$QV3AH)+IMJ4K<?HE@QD%W4MINV[B6\UUS3=O5EQUO<:3
M=:3 ?-QLE%^[O3E.XN99SW#&<M_5;@TOG3_3VCS; FMZBV3?E<;MVDMHJ:&H
M<F9<RDRI#E<0TEB03JBZXD..F2/W" $IEF='Q;=UZE/:U<1%WU#66['VZ?4K
M98=5*I%,M_KF4..-.TMAXX$])I4E"3=:41;=Q%DQZEQ$<!6B6N\6'45T9-GW
MQ0FD_HQ==NN/4GUJD-I233TB%3'(K4XD&V@]KY+S@_$Q>9;YMJI%(4TCJT*H
M]+-",YV-G$:V(,^TS27+)]HYD^9'W@#'>U@XV.)SHOI=+L[7RGO<1=GW.LX%
MA7ZVJ/0GV>HVM,178$=+KRS2I;$=3CW-1)ZPSYY%QG#U8/%!Q:5^V^(C6J^G
MK%TYF19R[=T2BQV'R:A3XZF=S];BK0X\;K:T/X=2HT&>SD/!^G)C*D?]GM)1
M524IJM2R7DQR4I,I$;!J(D+))^!\N9"6G@X0I'#OILE:'&U)II%M=0I"TEA.
M"-*B)2>787A@ >17OT=FA-\0M.FJI2ML_3:35I= J3#K[#Z7:N\;TDY"FE)7
M),E8V]>:]O<+>-0]*^,;A5NZK:IZ(W-(UITQ3%*34]%Y*(U,738%-C&;SC5<
ME+=?7M:0Y(-*2(SV[,<S$Q(ZO>Q$5FW<>/\ ^F*_\1_]U2CYEV& ,9K6#I(N
M)#B0H-OPM-K7JVD5OW7(J%'I3,)A=>7>LR$\<*JPER6F251_))*5L$\LT$YG
M>DS(A[MP;=&AJ:=TTG576:0JTX?[>3+TXK'5W0NJ)G(5E\ZI)<><C=9O\H)M
M/^K-9(Y8Y7C=%;:EN5#A>MVLS:-3)=48NV]^HER849Y3'_[1S2/J>L;5U9F7
M::-N3P8E.0A*2+;V8(B\"(BP1)+L(B+L(N[EV8 $2NK'1[5"P;@EZP<(6H$W
M1:]T).;7Z>X3M;I-R>3HRF*W G/>04Q+B$J:-331$76;C["'>^"KC5N762Z[
MLT8U=M5NU-3K#5'BORH\]JI1KD4M*MTMM<4CCL&I"">-M*U;#7LY8,7X:KF:
M=.KP-)J2HJ#5#)23-*B,H3^#)18,C+N,CR0QV^BG>=?U_N!UYUQYU=;K1*>>
M<6\^HDR9)$2WG#4XLB+DDE&>U)8+D ,F4C)19+X2^8:CYM?NG_:5_B/H
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M%W$ -0
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MFU6@^4^5G$FT:8NGR'.O)*4K*0ZRMTB+DG.WN %TX
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M5544P5=--===48[=,:H04:XQV]E%)+;VV   ^1]0
M
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M,9&5%?E2*52WII&F6]2Z>]*298-,IV,VM\C^$G5*S\W< .5
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MV;MRJ%=I]UDFW*QX=GI0G-OS)U]'4VVY--OR<F  (T)-
M
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M^+A??3//MBUTRB\V;NA&2_U*MPW[GT  $;DE@
M
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M"SZ7'I-NT"FTR'&;ZMI#42.3J4&6#2IXFR<41ER5E7,LD8 CAZ.77FA2-![
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M&K;EP:Q\.=V3K\T6I$I"IF@]2<W/-.59_JDO(N:INORMK4EXY.Q)D1DDF^1
M";^Z[TMFRJ3+K=SUJGT2F0V'9#\B?*8C'U;2#6LV4/+0IY1)(\);)2C/!$6<
M"*&\>EXTGI5XQXUIVU/N?3:'+<BW-J%*3,I+5)4E9M(5$@RH[:ZDE3I*3F/N
M(B3NR9&0\(X<=,ZYTBM2E7]Q,ZFSZ_0+?<B37-!H"'Z2W:*Y.'8[3]>ICS!U
M)+RDI<PO<6$F@RYB2/6W@1T-U>TQINGA6Y!MU%O1EL6M4H;6Q=+6LBP[*0SL
M.HJW)2K_ $DW#R1\^9@#W31W7W2_72V8%U:<W3"K=-GM[VVU+3&J"5%R<2J
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MWY;D]V]_=GH%"$:X1KA%0A",80C%;1C&*2C%)=DDDDE[(  #B<@
M
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M#,DD9F9$1$9F9F1$6/$SY%\8^3+[;Q&;;C3F#P9M.)<(OCVF># 'V
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MU/AW #')U_X7>)FWKFX@.(73>EU2MZA5V98*;CMA$Y;+%[L,.,1ILB/N7Y/
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M=UVCKG74ZI0:2<-JT[X)B)25U:.9?M$K@L>DT<=!):-3AF:S+=GQ OG
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M5<TF9?" )I"["^(AJ!<B(O
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M//9X9%0   I))$9F6>?PG@5
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MOA'R9?:?;)QIUIU&3+>RXEQ'(\'Z2#,LEWEGD /L    T(L>)_&>1J
M
M
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M  #
M
M
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MO,O0[1RH #@*/:UMV^2BH=!H])WF9K.GTV)$6L\Y])<=IM2O@W&>!SX
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MK*9+52FM5Z<\Q+)9.ME*J:GD;C<],]Q*-1<B+',LY$\
M
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MOLW1VP[<TYL*DM42U;7@LP*33F?W&&FFDMYSRRI>TE*,^9GV]X]#
M
M
M                                           %))).<=_PY%0
M
M
M
M          XZJ'-*!/.GEF:5/FG#3RYS"87Y,7/ES>V%SY #;2K@HL*3Y'+K
M-&B2C,B3%E5.''DJ,^PB8=>2X9GRP6W)Y&_E38L..<J3)C1XY$2CD2'VV(R2
M/L-3[BDMD1]QFKF,4Z@5JW+^XO=6;%XTM2[FTWUF:N2B*TKWM5B-;I1VY1.+
M:\NC.,49?E$9+2-KJS])6WFH7E<3=_ZH\2_%!9W!/IQ?TBRM.;(I+3NK]Q0$
M%*>N2"JE-3J6IIQM:7V,MMJRJ.Z9JW9,P.73X_#=MKM[>/GYV_$G9@W!1:DX
M;5/K-&J"R[40*G$EK+EGFAEU:B[/#X>X4'<=#3+\A56Z*F::MI0E56$4PS\"
MCF]UN?@VY^ 0Q\,6C_#WIYQ"4FFZ2\0%5<K;$>J0:S857*IOKK\LH;D=4B,[
M4I*MODKN^0:6$*+D1'RP8L/Z1&+IWHW<ZY&G6N=T?]KRH7C0?T:A+@UMBB+A
MO5J-ZYQW7WG"HK1)IJUMDITRW'^Z6X!MN]N_M[?U_P"^YE0294>(R;\A]B.R
M6,O2'D,LISV;G7%)06>[*BR?8")4=Q@I+;[#C!IW=<AYM3."[3)TE&C!=YYP
M(A>D:MG76[>"^EU^SM8G--9-!MJVI]X(@P&YZ[DE+C0WOV<QI:3C8=)>XVEX
M5O//(6QW5Q#ZRV%T.= U-MRMU%^^':C3Z%4KK88<FS(M/DW$W3)TCR5)..+Z
MR&IW*B_U1$9\L9(8V[)_-[?@9 \*NT>H.J9@U>DSG49)QJ%48LIUM7@MMEU:
MTGVE@RR-)5>H\*04675Z3$DJ,DHC2ZC$CR%F?826774.&9]Q;<GDL9&+S.O.
MW.%#6;A'O71C5ZHW8QJI0;FJ.I%N/NRY:;FK)4=#\5M927WRIJH4YU7H)0DG
M#+!EW#J[5P)XB8/%5JCK!JY6;*U;L%=$JMD4]13H";.0RMR0EEF"VZPS5DU-
MAEI)F32B:)6XR ST_I\]O??;^O\ +Z]C+$2HE)2I)D:5$2B,CR1D99(R/L,C
M+F1ER,N9"H6"=&9K?=/$-P=Z9:FW?4%U2NU!RM4R3/<:)I4MFB5!VG1WC01%
MM-QEE"_C/F9GS%_8'%]NP
M
M
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M(I'_ -X*(P4C_P#.V;__ -78 W[I_+QY]GO\R%?C']G'2;@AM+0>B6-.UFU
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M]PP\.%@://RTRY%OLRYDMQ#:6B:D59\YST7:D\*\F<=4P:RSO-O=V&+L@[
MX@
M
M
M
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MB.X<--]:*];OZ+U2]J8F?(HGE!2O(]R4J2GKR21+W)41YP +K
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MOI-;_*QFQ>Q=IE[7%B_5&WOP >Q=IE[7%B_5&WOP  PG?.ZM=?>W;^^DUO\
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M;^^DUO\ *P\[JUU][=O[Z36_RL9L7L7:9>UQ8OU1M[\ 'L7:9>UQ8OU1M[\
M ,)WSNK77WMV_OI-;_*P\[JUU][=O[Z36_RL9L7L7:9>UQ8OU1M[\ 'L7:9>
MUQ8OU1M[\  ,)WSNK77WMV_OI-;_ "L/.ZM=?>W;^^DUO\K&;%[%VF7M<6+]
M4;>_ ![%VF7M<6+]4;>_  #"6D>J\];8C#DJ7T<E]QXK!;Y#[LNMI;9;3S6M
M:E4PDI2E)&9F9D6"[1Q$/U996KF?C0+%X(:U==6+>FHT^E5V=+D17$9+:XW&
MB.K(R,E$9&DL8,9GNK.C>EM8TOU$IDC3JR$,R[+N9)J:M2A-K)946:;:R4W
M)6Y"L*(R,E%W'WC!3]2SZ$6K/XX^-N14K7I==A6)>;B("ZK2XLIF"B?4JGE#
M<:8PXVDCS@L)(MI%CL( 7&^=UZZGG'1O7\>#,O\ ::WVE_\ ZL/.ZM=?>W;^
M^DUO\K&:\WI=IGM_^;>Q2RI1\K1M_P 3Y\X'>/I[%VF7M<6+]4;>_  #"=\[
MJUU][=O[Z36_RL/.ZM=?>W;^^DUO\K&;%[%VF7M<6+]4;>_ ![%VF7M<6+]4
M;>_  #"=\[JUU][=O[Z36_RL/.ZM=?>W;^^DUO\ *QFQ>Q=IE[7%B_5&WOP
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M7])MUJ"EQ*O TJ(_A'=DI)*22DB2E)$E*4D1)(B+!$1%R(B+D1%R(N0 U
M                      '7;KM6B7K;E:M6XH:9]$K]/E4RIQ%&:2D1)C#D
M=]O<7-)J:<41*+F1GGM(6R<)/ UPW\$EL5NT>'>QRLRBW#4954JS'EK\U4J9
M+EO37G#<D&:R(Y#[BB+L+.TN1"[T
M
M     ;2="C5&',@2T=;%GQ)$*4WG!.1I32V7D&?=N;6I.?A%GG#+P"<+W"'>
M&IE]:#:?-6=<FKDQB=?,U$QZ4=5DQW''6G-COHLX6XM6&^1[A><  $6.1
M
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M:-;%!H4:FV@U"9H;3CRX[=.=:>AI<=6:WNJ6RI31EUAGDD'R/E@@,/;V_?\
M)':@  ,
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M\-_IOX)5P N9$?B &
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M(>B8(^TL@ W
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MY%M?<94Z6"Y%A98+L&_.##-XGSB1#>))HZXXS1O$DT[=I.;=^W&2-.<;>78
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MM_S^FWR*RY$1>   &
)         __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>nt10002526x6_linechart1.jpg
<TEXT>
begin 644 nt10002526x6_linechart1.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( 8 #!@,!(@ "$0$#$0'_Q  >  $  00# 0$
M    " 4&!PD! P0""O_$ &H0  $# P(# P,.!@P*!0@)!0$" P0 !1$&!Q(3
M(0@Q010B40D5%A<8(S)55F%Q@973=I&2H;74&20V-SA"4G66L;32)28S-'*3
MP='A\#5#1%-B1494@I2BMO$G8V1SI+*SP\1E9H.%H__$ !L! 0 # 0$! 0
M           ! P0"!08'_\0 1A$  @$# @,%! 8(! 4$ P$  0(#  01$B$%
M$S$B05%Q\ 84,F$C)$)2D>$5,T-3@9*AL3148O$'%D3!T25R@M(U9'23_]H
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MLI79K*9,=UR)$Y[3:VHY4EI)0VI!0M+*",X4G(7P=_C5-T_H?2FF)4^;8K%
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MHLQR8-.I%ULKIJJ[/]IO,7<S:_4.JF;K9])VZZ:Q1I2Y!$I8N*I$A]$A4UA
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M%-(X< @*Z'.!U[]BEBVRT5IZ]7F_6NQ6UBX7T1A.<3$CD+$5/"SP@MX1A/\
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M'T_;V6U<6>+B0VE*3Q9\[(.3DGO-?/M;]H<)2V-Q;<&DY(:&G+;RP2<E24!
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M4)P/  8R2,GI@]2>M606K0LAYA94C* 'J<Z,D^.Z%LDG=VP -JU<(X#)PN:
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MO)Y7+R??/>\Y^>OF#OYN])TOJ.\O[&OQKG:7VF[=:#>$*5=4./%M;@=Y8#?
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MD=*I$_L][4W"S1K(]I2V^21"T6 ([04DM*2H94$ G)2,Y/YJH*WG-)62$1Z
M%!1B=>=R<,.['?Y#K7FW$'M>TLIMK[@RPFW00B2RN=8GR2Y;%UTQC!.1W:1N
M3'S7OJ@VQ.C["W=HEVGW.2XN&GR-=HN,8!,E:$J/-6PD9;"R<?QN'IG-9BL/
M:GV>U#"M<R#?IRA=8OE+"39YZ/@-!UY)XV!CEY(Z_"QTS57UIV<]J-<65JR7
MC2UN,9A<5;2FV&FU Q5H6CSFTI)!*$YR>OB*R! V[T=;8\2-$L5O:;A1T1V
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MBMY+9)0?)F>A/>1[WTS\U?2M"Z36256. 2HI)/DS/\7J/^K\#U^FHQ-]Z/\
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M/&\G *@/2/34@]#=H.YZF[1>Z6S\FT"/:M$1[/)@W3G)4J6W<(?E3F6 .)'
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M.$$I^?-9'WCW8UWM]JW3[5JT/'OVG9RW6I<TS8[4E*U!*&E(94"^0%J&2D=
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M\0R/3BN:SUYM00]4@_@I:S_GW2'Z=AU+7;+][_1WX.VC^PL5$KU2#^"EK/\
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MG923HI;DB46TPBNI,1'#1+-)$HU!?I6)88-3OI5 &J-- ?NBL).?C>!X]?\
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MIA]WR5R/Y,@HBA:R C)/I-?HZ]BNF_DYI[[&@?<5R-+:<'4:=T^#Z19X(_\
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ML( XO&MP_L5TY\G=/?8T#[BGL5TY\G-/?8T#[BJF=G8L[%F/5F))/F37:J%
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9*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>nt10002526x6_linechart2.jpg
<TEXT>
begin 644 nt10002526x6_linechart2.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( >H#6 ,!(@ "$0$#$0'_Q  >  $  @$% 0$
M    " D' 0,%!@H"!/_$ &@0   % P$% 0<+#@D)!@4"!P ! @,$!081!P@2
M$R$Q% DB05%58=$5%A@C,G%R@9&3H1<S.%)8DI25E[&RM-/P&20Y0E=T=;72
M)3=35H*6L\'A)C0U0T3Q)S948J(H@T5D<W:$A]3_Q  = 0$  04! 0$
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MN[/N3^&O](P1;H  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M#H/G/J34>WO[ER(  HB   B   B   B   B   B   B   B   B   B   B
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MK/?&A);W7PBW0V6Y$=YAY!+:>)YIQ"BR2FW-Y"TF7B4DS+XQ:X$M<&NVN+2
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MZRZ9:8R;STQG2)5;CN1:C=KDDV2<[&:6$R#B&T6"=).\6#W3(QT:V.XK[,-
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M>33?)&UQT&@U(]B  ")6X@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@Z??=Z4G3^UJO=E;<X=
M,HT=4F6O!JW6TI-1\DY,^1'^^,]P$<-J_P#S":C_ -C/?\%8WL76CN9*A4EW
M"*S<K02;#H[9+*QCMI(.AT)T.AT*B\W;EH8C)W8-O.J8^Y9BWC<WF00ND9N
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M1)F9&9ECOE%\1&9$?QC4>C+RA   1   1   1   1   1   1   1   1
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M%N\5;GN\\\'C!>\+Y6?<G\-?Z1BHBX?Y3*S_ .KS_P"Z!;NS[D_AK_2,$6Z
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MW&_>W"Q\@UX:,D>XC)=.]+)>]XA]@-I0FI]I^E;9MH,\FAL_?01G\HTX3?\
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M@6UR' @\ZP=""#H9GD'K[1U'@OH!IGW_ )#+\XU$*MY   1   1   1   1
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M?:&3]KX&^2\*]US(NHFJO%$,G#N(SMFI88[+=CCCHU6BU.+5UY9%7:=8FO\
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M$IBB+=)YMOW/AW2/SD7+%\C/N3^&O](P1;H  (@  (@  (@  (@  (@  (@
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M%P3BE1NQJ)M*SB]GXW$XF#[_ -LP9=>0X6-LPWRS:=QT ]89KDRLRVI$:J'
M62H"&Y)OFTA'%RHE),D9(RP0KVS(#73%R$@RZ?;$'I!C08S\;ISCJT:_%TU=
MH%8WA_A8\O7C6JW>W'%_^R,H=CK4KF7 ?@M3V",-E?ITF#P(=Q!TZE<%W[7]
MJ:F7HF@V33K[L2<J(=J/E5Z53%Q$H1F46#5Q9&\L\=_TZD7,;R=7]L)1J(M!
MX*C1C?Q==.,TY^W(E=YGP9QDAVR3LR7N_4+6EIU>G-MT)M]$M@H2\5(W4$E)
MK/BEN;AEGGGEXNH_;!V?;OM\K^J<K52=-:K4%+T1HX;A%22@QW%N*1ATS<XF
M,\L'RP1'X9P<26#L$O"6.<6,9&Z8S/87"*NTB1[(KK&;WO:&/+6-U?K(1IJ5
MHNX2X;V;H?* 72.;O;7;B[VO-DR#83 U\E0@!M<]L!+MNP<D'F=%T6T]I76Z
MGZOZ?:;ZJ:3,VQ3]03J)4^MLUV-4$LG3FN(X7#CF>]DS(NO+J+ !6GI;1K=O
M&I;/MPUO4%Z37[0J%XLT=F9!>;>N53DAQE])<4R-@HA)ZF1[Y%RP6!9670O>
M(;%NU3OU,1>J4XZ3K>/$MF"'G&$3=HF:#&^9\N\<IL;7.CD='N! T<'!<_D,
M58P>8S6&L676_-F2FIQSO8(GR,B:P;W0EK)(=QU<(Y6MD:'>D%J  (]:Z
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MSP2-=5^,>(R%W%9:G?QS&OOUI@ZF#$Z8MLO88H9(XV:.=-&]X?!IJ1,&. )
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MO=_PDIW_ 'U9%OC/N3^&O](Q41</\IG9_P#5YW]T"W=GW)_#7^D8(MT  $0
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M:+,XL"5IYTVYK>6UKM=H8-7$] 21H/;KTL^ :%T+WB_,-1R*F4  !$  !$
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M49ILE_[1'CP"X5GW)_#7^D8(MT  $0  $0  $0  $0  $0  $0  $0  $0
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MY23\MWU^ 6'D0_)1_FV?Z??7YM.'];]"\BT?\60_V0>M^A>1:/\ BR'^R',
M'-E^4D_+=]?@/H3D0_)1_FV?Z??7YM.'];]"\BT?\60_V0>M^A>1:/\ BR'^
MR', '-E^4D_+=]?@/H3D0_)1_FV?Z??7YM.'];]"\BT?\60_V0>M^A>1:/\
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M[L^Y/X:_TC!%N@  B   B   B   B   B   B   B   B   B   B   B
MB   B   B   B   B   B   BZI>QO%:U;./&[4\4&1PX_\ IE<%1DCGUWC[
MWZ,"(FA.T!:=$MBDV1<M-J%OW4S*K+DBDMTR6XPPVW(=>2X4AM@F5&ZUWY8/
M.3\8G*:241DHB41\C(R(R/WR/D8X_P!2*5Q.,=,IW&Y^V]BC<3GU[_AFKGX>
M?/PC2GKSOGBG@L-B+&.C>R2$2M>Q[F..A#V.:[T- =2.IU:>FG28O+XNMBK^
M*R>+GNLM6(+E>Q5OFE-7L5X9X6!X?7M130.YY?(SELD)8T-F8"[7 +6U'I@]
M0JO<*)-5.GT5YMB:HZ/4"=2XZZ;*"0UP=]PM_D9H(RZGTQGG;<VA]-;FKEO6
MW!J4M%9NE,A=&B2*=*8[2F,CB/&I;J$);W4\\*YGX!F#U'I)-K:*E4TFG#(W
M&^PQN&L\YRM'")*S+KWQ&>1&^^(IQM>](T0K5ANPR16^-6&5,1E4S^+=Z26$
M)2;O%/O<I]SGGD:\SLA7;$]]BO(TS5XGM%60$\V=K'.:6S/+?0< -06M<-SC
MMZ*4Q\/"F6DNUH,5EJDL='*WJ\LF=I/8P4L7)8@BD9)C:XF<;4+G/V2,DFB>
M(8F"4![I1 '_ %_?X^H"57#H  "(  "(.*.A453YR54>E*D&>\<@Z=$-\S+H
M9O&T:S,O'G(Y4!4.+>XD:]#H2-?H5" >\ _.N,D42C2W#>E4BF273(B-V1 B
MO.&1%@B-;C2E8(N1<^1<AL>MNW?(%%_%<']@.: 5#W@:![@!W .('[4VM]@^
M@>_J"P#KSINS=NF%Q4&@4"AG5)91CB9A4^,66W26H^*II)(,B+D>2Y]!RN@5
MJ5>S=+K9MZM-MM5&GID$^AMY#R$DMTU()+C9J2?(RY$?(<-M-3IE/T;NZ7 D
MN19379.&^THTK1EY)'@R,C+)'SP?0:;,LV;4-&[1ESY+DJ4[VSB/NJ4I:\/J
M(LJ49F>"Y%SZ"8)L.P.YTK70><]-A:XRB3L_QMY=IMV]-NW77KKW+2'+&0VA
MKA)V77<"-FP2 :;=-==3J#KIITT4@P !"K>0  $0  $0  $0  $0  $0  $0
M  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $5
M;NU/]EOL@?"O;]20 ;4_V6^R!\*]OU)  BE;M#:ITK2?3"Z;FJ/J>\\Q2Y:8
M5/J$F/'3+<<8<02T%(427."HR4:2)6<8\8\PURTNY8>F-I[;EX:ST#4>CT*\
M5,6_L\M4BET]4=-4N!,!9JGLF:Y/"WTR"-QE7N>77(]%>V5I1HAJ!IC4J_K7
M;-0N>CVC!EN0X$&IU"GFX_);43;+G85I-:7'B0DU.$I*"/>R19'F4:T;B:=4
M2D;1=Y[.A/;,]/NF,RU8I:F=H*EFY641($[A-RE/R5*D\.6IKA&:3RA7A!%Z
M[],*\JY;!M*NJI2:*=4H5,E%3$[N(A.0F'$MD:4I3@B7@L)+D1#OXZ+IK<-%
MNBQ;4K5O,'&HLZATURG1C2I)QHY0F>''PLB4?!0:6R69$:]W>\([T"+C:JT^
M_ G-1C,GG:?,:8,CQA]QA:&3SX#WS+!CS07XU$8N+6#9^J=M5]>TK=-UVU5+
M:K"(M26U/IE,JR*G.4S5T-G$ADQ3$GO)*0GBD6Y@SY#TXCB'+?H3T\JJ[1:0
MY5$D9(J3E-AKGH)1;I[LQ3)R"R7(\.%DN1\@14N]T)<T_OW3O3%VOWM6K-@6
M;0U-U&Y(=O52M*I]99@,-18[U,CM*5+-Z>R3)J-"DEG>R99&0MA.=M):I[(4
MFD/W8Y:EP\=<>P]2GZ&U'=F06)ZT$\Y0%MLFP9Q4MEAU&3SGF8M<E6U;TYA4
M:;0Z3,C+/>6Q+IT20TI1'DC-MUI2,D?/W/7SC]K$*)3XS<6#%C0HS2B)N/$8
M:C,-EGHAEE*6T_[*2!%0AI%8&L]A=T?HT?675HM6)TQF3ZF32H[-'*G$FF*-
MPMQCDYOD9%S\7OXOX9]R?PU_I&*B+A_E,K/_ *O/_N@6[L^Y/X:_TC!%N@
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MMY   1   1   1   1   1   1   1   1   1   1   1   1   1   1
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MI3^T4^3 X&_2S2@DE);;4YG!]"Y>$7BL^Y/X:_TC!%N@  B   B   B   B
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M(;2\OYD)D! #01!%MV$$DC: 3J!UUT7Z@ ! J00  $0  $0  $0  $0  $0
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M2]BE9+)(2GW/@SGJ+EV?<G\-?Z1BHBX?Y3.S_P"KSO[H%N[/N3^&O](P1;H
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@8(^I9  1:8+Q%\A!@O$7R#4 117U0BW6YK_HF_2I4)JWF
M/5SU<CNIB]J?WF,1^SFY[>6%>ZX/^T)4"'&KS=H*VEMG]=6J<R-<B/7%Z@P6
MDR3C3#..7'[0;9DP1-IYIXV<^ A,<1M$@V,H ==+K=1S>9I]J5NFW0<GV\OJ
M3\?7TP!U_$C2W$\%$LV;^'9B'=A-3F 9[,-W"<O=YPT(+>U 1[2WLVW6#<X
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M2;,+I)975IQ$7R\O5VL,4@VB-C &C?IU&NNO731  !"K>0  $0  $0  $0
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M-PB]3#-W)1^2LEC&]T\&3ZWSL^Y/X:_TC!/:MT  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M$42=5DU0]HG0HXUK-5. 7J_VVOKD-MN47+!;G#946^[QS[WO#+'4SZ"6PB'J
MR;_LC=!^'=?J6U_E_BVZ4?BG7/:,EAW.6C8]WRY'X<=1+K>+ER5SYXQS^0Q&
MT3]L93OZ76]YC(_W2M\4,](#PE]/74_$+5U_$@_V3P5TC&O#LWQ&W X_[>S'
M\H;.L+G^-+[7V[0X<\3+Z ?.\7/D?+S?OU\X;Y8SSY^;]R$DN0T7T ^=XLXP
M?R?N?T!O%S/!\O-^_P!()HOH!\[Q<N1\_-^_T9#>+F6#Y>8_W^4$7T ^=XL9
MP?R?N7TAO%G&#^0__?Z 1?0#YWRY\E<NO(-XN7(^?F_?Z 31?0#XWTEG.2))
M9,S+!$1<\F?BQX?!X1@>Z=I71ZSKG;M&N73P:VZZEHF8\1^7';<7@DI=E,)6
MRUS/^>M/RD,,]FO6:'V)HH&.<&-=*]K 7.Z!H+B-7'U =5)8W#Y7,S/KXG'7
M<E/'$Z>2*E6FLR,A9H7RO;"QY;&T'5SB  /6L]@/QPI\2H1H\R$^W)BR6TNL
MOLJ2XVM"DDHC)2#-.<&62(^1\A^K>+F>#Y>;]_I&4$$:@@@^L'4?2%'N:YKB
MUS7-<TEKFN!#FD'0@@]00>A!Z@]%] /G?+ER/GTY!O%DRP?+S&*JU?0#0C(^
M@U!$  !$  !$  !%7!M$?9N[('OWE^I$+'Q5UM=W=0K!VN]DZZKI?EP*#3TW
MB<JH,09$QJ.;D0DM\4V$+)O>5R(U?$1B;9Z_:8>L8]1/5][UJ;V/5'L$G?SQ
M>%_W?AD[[OO?<_0.JRU2U-B^%Y(J\TD;L9) U[(WN8Z9V6R)$37 $&0CN8#N
M\%%5)HF6<HU\C&N;::\AS@"&=EK#>0?Z/WW=]"S4 BN6V/H&9$?KQE8,B,O\
MCS^A\R_\H/9C:!_ZXROQ1/\ V0B/,N7_ +LO?HLWA]YXA;?;J?\ :H/SK/#Q
M\0I4=!\DHCY847OD99%<>O\ W0W273VR'Y%F5J37+OJ+K$6B4]=/E14J4Z\E
MEY\W7FTH_BZ5\4D*^N&G=(8,=VNM5M 6K%U&U?N4[WTAU 6HW:QZGM4UZV36
MI"&F"AM(.3+R\Z36\2>B25T,2]3@[-VH(YNS]GDL/EBHU;(DAL7Y(8^9)'5:
MZ/:YX;\1KW,,K@61[G @:DN8I12.9OYC8VL=-+&6OC@;(X-8Z4AVH!/?M#MH
MT+M =5<B BA&VS= 9$>.^F\91%(CLR$EZD3\DA]M+B2/VGQ*(;_LQM _]<)7
MXHG_ +(1)PF8!(.,O:@Z'[6F[^GWOB%M]NI_VJ#\ZSP\?$*5 "*Q[8^@1%D[
MQE<S)/\ X//ZJ/!?^4._5C: TMH5NT"Z*K<APJ)<CG!I,YV(\E,ASB)9W5D:
M2-K+BB26_C)^,8WXK)QEC7T+C'2NVQAU>4%[MN[:P%OI.V]=!UT!/J*N;;JN
M#BVQ"X- <XB1IV@D %W7H"2!U]JS6 V(LEB9&8EQG"=CR66WV7$\R6TZ@G$*
M+'VR5$?QC?$>1IT/0CH0?4MA   1   1   1   1   1   1   1   15N[4
M_P!EOL@?"O;]20 ;4_V6^R!\*]OU)  BLB  !$  !$'0Y>F=C3KE8NZ5;-*=
MN%@EDBJ*AQS?/?0:%;ZC;-3A[IX(UJ,T]2P.^#YWBSN\\^\>/E!%T2LZ9V37
MZ9)I-7M^%/A25I6XV^RTXLC0K?+A.K2I;23/JELTDHCP98'/46W:+;-,8I5"
MIL2EP(^ZEJ-#8:80DL\\\)*249GU/&3\/,<\9DDLGGXBR-MP\H(R\*D_G!%4
M1<'\IE9Y9,RX$\^9F?\ _"<\B\'Q"W=GW)_#7^D8J(N'^4SL_P#J\[^Z!;NS
M[D_AK_2,$6Z  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "(  "(  "(  "(  "(  "(  "(  "**6T5HQ<][U&T=0-/:GZDZB6*Y
M)*@S#;2\A+50-+<PC:=/@JWF<EWZ3QX/".M5>@;5+AV:=-NYMHF$O^N@NPPC
M[69DGA&6?<8//N/!X1-$R(RP8TW2Y>;P9/\ ?Y!&RXN"2::9LMF!\YC=*()W
MQ->^/;H\M;TW.8QL;SWN8 T] NQI<;9*K0QV.FI8;)08IMN.B[*8RO=EAKW!
M*7U1+,TN->.>>>U!$?1BLROF9HXZJ&"+?VJ/52ZEJNYKU/?8C%;K?8H?\6>2
MUA\S/W2]YP\]]RY<NHXUVW=K8[(I<9%XME=J)AJJ$WL,/#L7M1&2";^ME_%\
MIY<_#G(G#NES\_G/]_E#<+&.?+S_ +E] L\U,(<#<R'I->W_ 'R7IO>'DCTN
MCFD:,/>UOHCHL[>.;+3$?,'"AY4M27K@*)WFI6-8,D!9Z<<P=S;#'=)I@)'^
MD-5$&90MII5XP'XMU-IMA$$TS(O8XF7)?9-TE[YF:R_C!;V"+!^'D.KQ[<VN
MBM^Y6G[S;5679#1T)_L,'VA@G\N)-)=ZK+6$EO>+QB<VZ6<\_E/_ -_I#<2*
MNQ3'$GM=\:F0^C;E '-:UI  /0-VZL']%Q)'>J1<<6(F1L& X6=RFTVAS\#2
M>YW8YW3-+RYFKG3;S'8)/PT361OU:T*&[E!VHS:L<F[M;)R.4OUVGV&)_'#5
MCLV.I-[G/.YUSS&VB@;4WKCN5Y=VM^H3T=HJ#'[%#S'>)@R<4:O=*R[A6%%U
M+'0Q,S=+EUY>?]_HP&Z77_F?[\Q7S6SI]MW^CFN_WN33T8^6 >O4'XY'KD](
M]>^P<;60'CS%PN=\<T>OF*EJT37>VES3L]&1CM8(WCJRM\ /04%2MS:^]:,5
M@[T;]<A33.1*[!"PJ)VHC)&Y[DC[/E.]U^,N?9F*#M/)OF'(>NM"K13"4F3#
M[%$RN6<3"5[_ +LL2>^Y<L<N@F)N%C'/Y?W+Z W2SGG\I_\ N+6XIC=GVY?.
MPQ'K;E.[E:Z;M3U#]=)/N]!KW+)+QS9E$P. X49SFWFG9@*3=G;N7N,1#/@S
M7Y?VH0/M?<[EZ;BH.Q;=VMRIMV(?O)I4Y]]D[;<[!"+LK)/&;J3+HO+>"[_!
M^(;TJWMK,_6EV>\6T\ Y'KD/L,,^U$>."1=-S=+/N.I_3-S<+GUY^?\ ?Z<A
MN%RZ\O/^_P!&!08B/33MF1^*&_[Y+KTDYFI.O4Z^B?O/1[E<>.[)=O\ XO\
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M$EMAEIAM)XY-LH)MLN:<GWJ2Z^^-WZ@6E7^J,'_\?\(S, A_.%_^V6OS\O\
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M[GEX^7/ NK9]R?PU_I&"+=  !$  !$  !$  !$  !$  !$  !$  !$  !$
M!$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
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MF5)QR,R+//Q"WAGW)_#7^D8(MT  $0  $0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0?"_<_&7Q_O_P!1]CX7[GXR!!WA0N-BO^RK2]ZY
M(_J-PS+U"X+/'SV/_29XN-[ONGA^,311[GXS^+]_^H@F;]K>S 2R='G>N$FS
M,JH3DKLF#A<\HQV?W/>]>1^(3L1T^,_W_?WQ$XH@]OT.NF1L Z2/DTTV]/3
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MYO(;5Y0=NZ;-[@[3:1KKZ]?4%EE.4WNY3:?+U&S>9=VG37=M&FNI/=Z@N?\
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M:K4  1BVD  !$  !$  !%6[M3_9;[('PKV_4D &U/]EOL@?"O;]20 (K(@
M1   1<;57'VJ?/7&SQD4^:MC'^G1'<4UCS[Y%@>9N^U4.=4-;+]J53N%.U'
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M^D8)[??Z5N@  B   B   B   B   B   B   B   B   B   B   B   B
M B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MK[CC+,F,\\SCBM-/MN.-9Z<1"5&IO/@WB+(KH>_0]P/<>X] ?F)[BFH]J_2
M *(@  (@ /Q2ZC @$E4Z="A)6>$'+E,QB6><82;RDDH\\N1GS%0"3H 23ZAU
M*+]H#X;<0ZA+C:T.(464K;62T*(^AI4G)&1ESR0^Q1$  !$  !$ ?CEU"#!W
M3F38<0EGA)RY3,?>\R>*I.\><=!^AIUMY"7&G&W6U<TK:6EQ"B\:5I,TG\1B
MNA !(.A[CIT/S%-?5ZUN  "B(  "( #\DJ?"@DE4R9$B)5R2J5):CDH_$DW5
M)(_!TR*@$G0 DGU#J47ZP'PVXV\A+C2T.(464K;6E:%%XTK29D9>\/L41
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M6>&(O$ACBE>7L87@ /+6D#=H->]9(H9:T<=><DS0,;%*7-+'<R,;7ZL/5IW
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M?@NORTKI'4;D3JU<NAD9&9*[F.D9%)KRI.4V1N\-&\&1N[3IKV4  <PM]
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MB),NSKCFF41&LBXA-'@TY)?(=IT4I.F%&L"CPM)6(;-G-(65/3%,E'N[W?\
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M*?)&^:S223W=W&[WN!+ 2'$&8HYR^+V/W.K=G@A$\G*YUIT+ Q\\W()BYCG
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M'(V0%S&20O.A;J-LC=#H?4NSX XN/!'$]+B(5K%H58K<+X:UBO5G?';K25I
MR:S4R%=NK)7!XEJ3->S<S1I<'"\_9,J%X5+0JS9=\PEP;@64Q#K*VN$I4-$A
M2(3ZFR2GAF]&W'-TR(TF>#YE@24%*<'9C[J<[#B.HVY(;#;T6.\EMO3FBI0W
MQ6DN<-*$D1)W-[&,%T'Z_8P=U0^[JC?DZI VZD!K5J]<R.F,$,<1E?\ 'D,;
M TO=]\[34^)4!G,DS,9G*Y:.G#CX\ED+=YE&M_(5&V9WS-KPZZ'EPA^QO0=&
M]PZ!70@*7O8P=U0^[JC?DZI >Q@[JA]W5&_)U2!L*+_%^SZ_?3YM;H1H?(NA
MGTZ%GPBE_P!C!W5#[NJ-^3JD![&#NJ'W=4;\G5(!/Q?L^OWT^;7)O=#=0+$L
MN?8\:H636;GO>M=NB4&J06ZB[%M]ITB9FR'F(S;D9X^"HUHXN#(TY2>2$MMD
M"A4NV]!K.I='K,ZX(2>VRRJ4^+(B2%.S7U/O,*8E>W)3&<<-E)JY&E!&GD*7
M=IFR.Z>Z+T*C5F?M;4J[53Y\:$E$C36@N+B]IE-QC4A;C3BD8)PE'NF6<8\X
MD91MF+NH[E+IS\/;>@PHTJ#$F(CLZ<45#;1RF&WS;)""(BW#7@^6<ED^HA*^
M)?#F;>5?-"]L\(AAA96Y3X1I%S"Z5LA$QD=$"YTD>YH#&-<&M(=Z1E>/*U_R
M>8'@>MC,A6FQE]][(9&?+"[5R+P;@JMKT):K7XR*I'<E:R"M:Y4DDEB>9DDL
MK3'=H I>]C!W5#[NJ-^3JD![&#NJ'W=4;\G5($VO-_Q?L^OWT^;6Z$!2][&#
MNJ'W=4;\G5(#V,'=4/NZHWY.J0"?B_9]?OI\VMSZNG0S\Q?]!4EW0B^]/K9N
M&TZ&]9U;K-^7&<F- N2&U4Y$6VF#)*)3RH[#3D9Y2V%&:=[!I-.4\\&.F^Q@
M[JA]W5&_)U2!&C:DT^[IYH;IRY?\[:VI%W*BU.DT\HTC32@K>;]5)[,/?;=6
MRXM.YQ=XR3C))P(O,8^7)T9:D,T==\A9I++7%D-:UP+MK'/9M>YH+6R [HR=
M[>H"[7R?<54^#.)Z>?O8V[E:]6.RTT*65?B'S22PN9"9;,<4YDKQ2ELD]1S#
M':8PP2_!O=K=%LDV[1K5T(LRD4&MSKBIS2)<A-4J$:3%E.O2GC>?:6Q+]O03
M#JU-IWBQA/>\N126%)-"V9.ZC/T6DRX>V_!@QYU-@ST16=.**AMCML9J0;1)
M024D:#<W3Y<S+(Y7V,'=4/NZHWY.J0-RI *M6O6;MT@ACA&T.#=(V!@VASGN
M Z= Y[C[25S^=RDF;S66S$O-,N4R%N_(9G1/EWVYWS.YKH8H(72:O.\Q011E
MP)9&QNC5=" I>]C!W5#[NJ-^3JD![&#NJ'W=4;\G5(&PHK\7[/K]]/FUNA 4
MO>Q@[JA]W5&_)U2 ]C!W5#[NJ-^3JD GXOV?7[Z?-K)#NBFFD"[])8=QII]5
MG5^W:]0E4Q%-?FH-*7JO&XYN,13P\DDED]]*MTN?,A/&U"6BU[;0XA:5IH5)
M0M*R/>2I,".DR7GGO$98///.<BA+:$TS[J5HSI=6+^>VSH=Q(IT^CP_4IS3N
MBFE[U2G-1"=,E(67M)KWR/=/F74AE:@[./=4:O1*35%;<<:,=1I\2;P"T[HY
M\(I+"'B;R1%[@E[O3P"/AQ\<.1N9!I =<@JPO8&@>E6,Q$CG:^D7"4-TTZ!@
MZG7IU60XKM9'A'A[A2>.1T/#V3S=^K8?.YXY>:CQC7U8X"W2!D,F/=,7->>8
MZPXEH+=77;@*7O8P=U0^[JC?DZI >Q@[JA]W5&_)U2!(+E?Q?L^OWT^;6Z$!
M2][&#NJ'W=4;\G5(#V,'=4/NZHWY.J0"?B_9]?OI\VMT!]#]XQ7!MTMHIEP:
M57C<=+J55TXM^/<3=V1H+<I\S>G1B9IG$C14K=<Q(,L&23W<Y$?O8P=U0^[J
MC?DZI CYM/:?=U'T*T;N;4V9MBT^ZFJ$]3FO45_3BB+3*[=*0QOX<;<(N&:M
M[.Z?/!<A'Y.D<A2EJB01.>Z)[)"SF-#X962LWQ[F\R,N8 ]FX;F$C4:ZKJN"
M^)1PEQ%3SCZ;KT4$=RO/6CLFG.^"_3GHSFM;:R8U;4<5A[ZUCE2<F=C)"QP;
MH;)M@:E5AC3RIUA4*?3[7K$MUZVX4\GTO-,%*<-?M<C#J,D9'WQ%DO>$_2Z%
M[Q"@71#2'NI>J&F=M7Q'VT(-!:K<=3Q4IK3JBI1$(C+D24(07///"2YC+7L8
M.ZH?=U1OR=4@78VF,?2KTP_F\B,-+]NT.=WN+6:D,;J3M:"=K=!KT6'B_B)W
M%?$F6S[JHI><K1F96$G.,,8:V.-LDY:PSS;&@S3EC#-+ODV-+]%=" I>]C!W
M5#[NJ-^3JD![&#NJ'W=4;\G5(&\N;_%^SZ_?3YM;H1H?0_>,4O\ L8.ZH?=U
M1OR=4@/8P=U0^[JC?DZI )^+]GU^^GS:R!VZ4-TNX=*;QN6E5*JZ<4"/<3=V
M1H+<I[+TZ,3-,XD>*E;CAE(,C+O#W>H[%L#TJKL:>U2LG"GT^UJQ*<>MJ%/)
M]+S,=,IQ2RX<G#J,DHC(E)+E[QB#^I>@7=1[3LRMW'*VTZ;6VJ5%7).GR=-J
M(ZA_<2I>-UU"TE@T]<9(=.V>M,NZE:QZ5T&_H^V9"MQJJR:E'*D-:=45*(I0
M92XV\E*$(3APT&KDDN8@F87;FGY;M&K7-<1!R@'B5T44)UGW:F'9"US8M@TD
M+G[CKH/3I_*/SO)S6X$&)+9898FOR9N%U=]."_=R489C#"&Q9$V+\L<M_M#C
M)3CBK\D;2X^@XNA>\0U%+WL8.ZH?=U1OR=4@/8P=U0^[JC?DZI G5YC^+]GU
M^^GS:W0@*7O8P=U0^[JC?DZI >Q@[JA]W5&_)U2 3\7[/K]]/FUNA%9>W<J'
M1KYT<O&[*34JKIQ1(=TQ[D9@-3)&Y+GQ%,TKBQHB%K<S)4C=4I.$=<EC)X2]
MC!W5#[NJ-^3JD#@+GV9NZBQ*%5:A+VUZ956Z= E3NR2M-*$\VX<1AQ\D[KR%
MI(SW,$>.I^,1V5HG(TI*HD;$YSX9&/=&)6!\$T<S0^(N;S(W%@:]FYNYI(U"
MZW@?B=O!_$=3.24I+\,-?(5)ZT-OL-A]?)4+&/G=5N"*<U;445E\E:?DR".9
MC'%K@-#-C8'I-<I^BT63/C385,J,ZHR*+#G<8GV8;DYU;>\E_P!M22FE),B6
M2<=,"=!="'GQV>M,^ZEZRZ6T>_6=LZ';J*A.JT(J2WIW1B1'*F37(9+2E*4$
M27>'O$1)(BS@NG+-OL8.ZH?=U1OR=4@9<?3%"E6IAYD%>%D>\C3<6@ D-U.T
M$]S=3M&@UZ+3XLS[N*>),SQ ZJRF<M?GN"JQ_,$#97:MC=*0PRO:W0/E+6F1
MX<\M!=HKH0%+WL8.ZH?=U1OR=4@/8P=U0^[JC?DZI W%SWXOV?7[Z?-K="-#
MZ'CK@4O^Q@[JA]W5&_)U2 ]C!W5#[NJ-^3JD GXOV?7[Z?-K+G;ZH=SU?1"<
MY0T2Y,&!.ILFM0(9.]HE0FIS;CQ(X)&Z9)92O)((\ER&#.Y_M)JNJ.N-Z6K2
M:I1]-*W!M*-;T>H-S&4NS:?")BK&S&F)0MLREI6:C)!;_(\F1\L35G9G[J5$
MI%5FO[<,&6U IL^<J.]IQ15H?['%=?)HT+)23-S<W2R1]1@G9CT_[J+KAIE$
MOV'M@TVTV9=4J\!--C:;T-LB.F3W89NF3;;>>+PM_FGJ?4\<X"?!B;.5\QV@
MM$#6ZP<O<Y[XXK,+-LV\%D99:D,D88X/>V-VHVZ'U3&^4UV/\FN6\G_F=LK\
ME),&906^7%#6M7L+D+#9L>('-M76S82O'4N.G::]>:U&&.YH<WT4EDRY]?\
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MVFVM5:5INFI>H=N-VG"HN^=48X3YJDQ,*,R/"N_STY= !4_'^KYO_K\:MT
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MFE1'@TF6#(R/!E@R'F$[MQM6713)\72>/ZZK/MBT;LL]RJURB0:M+3<Y3:Q
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M@Z95K!M2MW3;]Y5.DLRKBM<I)42I+QQ8)2T;DCA\C/VQ/(^G(=S $0  $0
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M-7NBR+08I%:K;QOS9:GER#)U1J4I45#IJ3$WS4K?X&YO9PK)#/( B$6.1
MB   BT,B/J6?^@Z,WIO9S5SU*\$45A-PU9G@3ZB1%Q)#7!-C=7X3+AF:?C'>
M@!%TRT+ M2Q69<>UZ2S2V9KJGY*&<8==6M3BE'CPFM1JSUR8[F  B   B
MBZ3<&GMI7/7Z)<U:I#$VM6]'J$6D3UX)V&S5&5,34-GC/MS2E)5S+KX1@VT=
MC;9^L>ZV+SM:RG*/7V)4F84N+493;;C\I:G'G)#"'$MO[RE*,B<2O=,^0E0
M(OE*221)(L$E))+WDE@B'T  B   B#IEW6!:E\M1&+GI+-4:A.I?C)=Q[4XA
M:7$J(^N26DC^(=S $4<[NV5M$+VO"-?-QV6U/N*-V8RE)DNM,/\ 9$H1&[7%
M;,F97 2VDF^.E>Y@C3@Q(6-&8B,,QHS:66&&FV6FT$24H;:22$)(DX(B2DB+
MEXAO@"(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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ML)W6HL=B*RGP):CMI:;27F)*2(?I!$  !$  !$  !$  !$  !$  !$  !$
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M6,JZB91$1<B+ (M0  1   1   1   1   1   1   1   1   1   1   1
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M  $0  $0  $0  $0  $0  $0:8(^I$-0!$P1]2R&/HZ  (F"+H6 P77'/Q@
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MC+/IWO(Q;=@C/."R70\<R#=21YP63ZG@LG\?4%1:ERY   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
(  B   B__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>nt10002526x6_linechart3.jpg
<TEXT>
begin 644 nt10002526x6_linechart3.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( F $F@,!(@ "$0$#$0'_Q  ?  $  @$$ P$
M    "0H( 04&!P(#! O_Q !N$   !0,"! ($!P<*$ @,! <  0(#! 4&$0<(
M"1(A,1-!"A0B414R87&!D;$6(S0W=J&U%QDD,SA"4G>TMAHF-E=88G)T=9*4
MEM'3U/ 8)35#4[+!X2=$155S@I.5HK/2\2A45F.#1F2%HZ3$_\0 '0$!  $%
M 0$!              <! @4&" ,$"?_$ %81  $#!  #! 4&" L%!0<%  $
M @,$!081!Q(A$S%!40@4(F%Q,H&1H;'P%2,V-W6TM<$6-4)R<W1VLK/1X1<D
M-&/Q4E568I4E,T."E):B&"935]+_V@ , P$  A$#$0 _ +_   (@  (@P)X@
M?$$T3X>VC<O5;5ZIMH-PB;M^@X<.379:G4LICLDT2G"/Q5H3E*5=59QCJ,]A
M@-OAX=^W/?I LJ)K]0%5V/I]/.K4%"ILF+%CO(D-2UN26F5I:?02V$J,GB-)
M$7NR"J-;&]Z\==Z@GM+TH&A,W79Z-:=KUPZ3Z6WK4FX5%U%J$VHR(CC<B0VQ
M%D*CJA()M+RG6S+F42<*[X+(GKW0[Z--MN6T*M[O#-BZ+(IE*I54AM,R/!34
M6ZJ3?A-H<22C)23<))D1&9*P1]15A](-UST)U%HVE/#1VPVK0[UUA55[?I,E
M-K4R*IRU(U+GT]U"UU"!'<0:EQ6C-:E/)5E*C4?0QW_Q;-%-P&EO!QT>VQV=
M;-8ONZI].MPZ]&AD\^^EUN93I3<5_P )+I],FTKF,B27?&, K]-/)TUMVB-^
M'3K[N_Y]=%[Z9Z59;E:BPI](VD7S4J?/J<:GQYT-BNR8CB9$M$7QVWV:6MI:
M$\_.9DLR(BZ].HGXU"XA&E>D.S=G>!JNV=F6NY1V:C\"SC<*9ZS*(BC0TM*2
MF0:G'E(:,R;RDU=2/!BI1ISOQWT\,?130QW<5L1M6#MF:]2A/UV:U;50F(;F
MO18ZYTP_@YV>VI#KGC))U9&2B,B,C'=/I(.XZVM<]CNT:Z]*Y:&=,M7JW2GY
M,"G%ZK"/PJU2S>AFPT3;:D,.K6WU018+'4$+=EH T"3[7-L$=.GN(Z_2LK=,
MO2A[!N"_[/IVJFWJMZ7Z2WW6':5;.J$Z74)$"<12BB,/DPJ*VAM+SJVR+*R(
MB7G."$XN\[B)Z$;,]MY;B[ZK<69;]1IL"=:\!EPU.W"NI):]68C$P2W#,UOM
MH5RI4:35U+H*T?&>TDT\MO@HZ+U2BVM2:=4[9@67+H]0B0HT>7%?DSZ4X^LI
M++*'C4M?4S->1&SQ+-0+BU V:<(^V;CF2IM*N&KR6*TP\^M;=1:AU>E)CIDI
M-9DZELB(B)PE%Y%Y@JAK7%I (!<6GKUZ 'W_ #_8%/5M\])?L'4/6"QM.]<]
M!JSH5;.I$YR)95[5>5.E1*L1*2AAU"'8K*&_&-QK!&LB+G+J+1M/J$6J0(52
MA.I>A5&'&G1'TF7*]&ELI?9<2>3+"VUH46#/N*4GI*NGMF65LOV<7!;%O4NA
MUBV&[)=I%0I<*-!DL*??H2GE*?C--.K-S)\QJ6><]Q/[9N[Q6W?AAV;N9O&C
M5*\3M*Q[?=FTF U)E3YZ7(T6*VEMN*V_(6:2Y3/D0H_?T!6N Y0X#0Z@C>^[
MQ\^O[E+5DO>7UD-13V<]++TF;9E.?\&'4<G(Z)2DI50[H2E2HQ+,N9?P1A"%
M&GJM1D22,U&>"/$M/" XN=,XJUH:C753M+G=,T6#*B1SB/5-=0=F)EO/-I4L
MG$(4PI)-$9H,B,C/!]@7F"#]_O\ ?X%30 !=>H JH  "(  "(  "(  "(  "
M(  "(  "(  "(  "(  "(  "(  "(  "( ^>7*9@Q)4V2KDCPX[TI]9$9\C,
M=M3KJL%U/E0A1X+J>,# "I<4#9U2ZA-I<S4.8W,I\ER)*;*@5)1(=:<4TZDE
M);,E<JD*+IWQTZ=1F+3CU]OQF%EL]RNQIN0U M]'/5]B)"1&9>P8_LP\M=RE
MV@='7<M;R#,,5Q,4IR;(K+8!6F04AO%RI;?ZR8>0RB#UF2/M3&)&<X9OEYF[
MUL+.>YKIH-GTB77;CJ<6DTJ"VIV3+E/-M(;0DN8S+Q#(E'CR+J, :KQ4-GE*
MKZJ$[J*RMUM\X[KZ84A2$NI/E/!D1D9$HC+)'C'4A$/Q)=[-/W-UZQ='M!KJ
MF2+4J\],*N26695-5.]8?9)HS)WPG2)I2U="R2L>XQF!87!CT95I/&:NJ4[4
M;^J5%3/*NFJ0E4>0_%*0T7A$X:5F2EDA1^6,]\D)LH.&>&8MCMIO/%:XY!:[
MAD,LXMMBM5)&RMI*6"01/K+AZTPEHVYK^Q :X,(T'N)#>8[MQLXDYYF-_P <
MX"VC$[[:<0@I7WK*+Y6RRVVXUM5'VT=OM!HIFM>XM9)'VY<]A>UQ)C:UI?,I
MIOJE8VK-NQ;HL.OPZ]1Y:"6T_'<;-Q)'_P!*R2C<:Z]/;263[9'80J5[3M:Z
MOP^]UUT:/:D73-3IJU+-%8<7XTU,=CD<7"-F.DW5I[I,R;+^Z+S$X)\4[9@G
MD+]4B9[;C32?Z7JG^V/*)*$]6BQ[2L9[$-;S7@_D-BNT;,;H+ME%@N%%372T
M7:@MM3.V6BK&<\3*CL(WLCJ&#Y;-C;2V0-:':&Y\,_2+Q#*,>EDS2[8_@V66
MBY5EDR"P7:\T=(Z"XV]XCFEI/6IF234<A.V/T[D>'Q%[RP.,B8#BMEWI;^H%
MMTR[+7EJG42KM>-!E+:6RIUO&>;PU^TGIUP8Y4(CEBD@DDAFC?%+$]T<D<C2
MU\;VG3F/:=%KFD$.:0""-%=#P3P54$53331ST\\;)H)X7MDBEBD:'QR1O:2U
M['L(<US20000=+8[EK;-N4"LUZ0A3D>BTV;4Y*$Y-1QX49R2\:221J,R;;4>
M$D9GY%V& &Q_B9;<]]E=U+M?2"M^/<>EE1*FW12),>1$E1GSD.QB(FY26UN9
M6RHR-"<&19S@2'5"&Q4(<J%)(E1YL61!?09$9*9EM+8<29'T,C0M1&1]#(4@
M+7C*X8/'_F4-LW*+HMNDJ1.-<J/4Z>[*@4PUKP1$31J];DY/H9<_O'FOH: 0
M[SUL?2-_5W*TQOLXA6@>P&R*->VN5;32H5?F-PJ1')EY]Z8^Y);BDEMIA*G#
MPXZ@OB'W\L&,DM"M9;:UXTMM352U$2$T"[8?KM,)YAYITV#(E)4IMU"'$$I*
MB,N9)9R*9'&;K]<X@G%HVQ[%[7=.J6[8-537[F884EV(41V/#KK!R229M^TV
MV9ES'YG\XS,W6\3+<93MT=L\-7AX6W1*1=.FU!I-+N^\9-2I,"GTQ]%%CNM)
M*/53:BJ-Y32T'R+Z&9F?4%7DZ#S(V?</,_'8^Y5KRI5*/2Z=4:E),TQZ; EU
M"29I/I'AL.2'CQW/#;:CQYC [9GQ%=!-[=V:MV?H]5%SZKH[4&*;=;:H\ADF
M)#[[K"$DIY"27E;2OB&9=.XAUV.\4C<K*W)ZC</[?%1J4C5N1:%P*L^[J;6:
M3-8N V[<G3Y7*S25.1FR9;)*5%S=?+!Y(0@<+S53>=;VX+?1IALQLM,R\:[=
M"I->O8W8;;-N?!]0J$F.E468GP97KB$F@L*+D/K[C! SY77N (/AHG[_ /1?
MH3W5<]/M.VZ[<U2\4H%!ILRIS>1I:W/5X<=R2[R-H(UK5R-*PE)&9GT+K@81
M[&^(AH?ORCW_ "=&SK)HT\JBJ37/A:AU2C_LE$I^(?@%4H[!OI\1A?M-<R<8
M/..HA,X9_%AW,ZOZC;I]H^[J@LM:R:06U49-/G&N(XU4E)HU0G\KD>,V4<DJ
M;8))I4:B,CP8X1PFN*?,3MGWN;@M7K-HUL431.O3(T5FCPZ? 35'SK-2A0TO
M'3H[1J-YYILLK)1Y5G)=P5.0]?=K_P#+N[^_[GP5N?Q"QG"L%_:G_N?T# '?
M9Q$]!=@=#LNO:WU-=-A7Q5&:51U)C2'S<DORV(:$F3"%FG+KZ"RHL?**T-G<
M1;C:[H]-:]O!V_::*AZ$QZG+7;=F$]2'I%?I=.G.QI!M27VO6D&XTSS]$&?M
M]",8Z\:O<IJ/NNV&;.=5-7=-Y.ENH;]]0X=PVA4%G)>8EQ;NIT'QB=<;;)1/
MJ;-XN5.,&1%T!7!AY@#XG1\Q[O\ HKW5CWG2;\M*WKPHJU.TJXZ9#JE/7RJ(
MUQID=N2T?*9<Q9;=2?4<M)1&>,*+YTF0JQ;W>*?JCM?LW:7M"VKT.'<NXC5N
MS:0PW(E3XE-C6LF)1:<^;SSE0Q#=)<9PUD2U)QC!#@FB/%4WO[5-V>D^WKB"
MQ:#7;3US4XBU+^IE;H+Z::^Q&;><CN0J,MPS/QGVXY&ZHLF62!6AI(W\^O'7
MFK;0#Y(,QF?%BS&%<[$R+'F,++LMF2VEUI1?.A18'U@K4  !$  !$  !$  !
M$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !
M$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !
M$  !$  !$  !$  !$  !$  !$  !$  !$  !%H9X(S%>CT@7B97=L4V]1;,T
MFIU8?U=U?ASJ=;M6I--F5%=%88^\U!Q:([#S9*7&=7RFLTF6"-/46&!TQJ9H
M#I)J]*@2]1;(I%UOTWQ/47*G%8E>K>*6'/#)]MPD<Y$6>7&?,%4$ @D;'B%^
M>QPG]]NP;9TZ]KEN M2\M3=VEX54Y5;N:MVI=<Q=(ES9:B;)A,F!)C$7AR.0
MC:-)(Y2[8+%G[B%\2;6RQ-H6DN[K;'HL]J?I[6G#E7G3Y=/;5+HM-3-8:)PJ
M;/A.RE88-:\-LD9$GR,B$K/_  '=K'3_ ,"MFJ,EH62E46FFKF0HE)5S'%,\
MI,LEU\AD!&TZLJ+:*+&:MFD?<FAA<9- =@Q7:<3+A&E2"C+:-@NAF>?#R1]2
MZ@JN.SO[]VNG[ON%1VXIW&.T/XA^Q^UML^A-H5^Y=?-3Y5#@5>TTVC6(A6E/
MBU*)ZR3<MZGIC\IJ\11F@T)+D]PYEQ%.&_KQ;O!.VR4*/;4ZO7YM[]5N>LTA
MC+\Y$6J5B%5E)2TWSN+\&,A>201F7+C!="%MNQMD6U[3N[U7S:.CEITJYE/+
MD%4?@J [R/+,U*6VVN.:6S,U&9<I%@\>X915"E4ZJTZ12JC!ASZ=)95'?@RX
MS3\1QA2#1X2H[J5M<I(/E21H,BZ J\^N7E'<=]3OKK1\!^]?G7[XN)79V^G8
M#MWV1Z+VU=5;UWJTRAV_>-LKMRMQ2MYRBU6GLJ4[+?AI86E;3#B^;F(B(LY&
M5_&(V#:NZ1[!-AEZ6U:$ZXINV7U2M7S&IZ%R94=FKS:7,<+U=A+CBS9;0YSI
M0@U%RGDB%P6S-E>V6PKV=U!M72"U:7=;KZY)U1-+@*-+RS,U+;0<?E;-63/*
M"(\]>XR0N"VJ%=%(E4*OTFGU>D3&3CR:=/BL2HKK1I-'*;#Z'&B)*3,D^S[/
MD"<^M<HZ DZ/CL:T?FZ?:OSV.)=OZM/BR6%LSVI;:K:N>OW]'DT*#?T1ZWZS
M!9M]5"?I7C&[)EPVV%91%>/XY%[/GD7M-NNC%+TVV]::Z45J#!K,6AVG16*A
M J41B9$<D?!T;QFGXTE#K+AM/<Y>T@\&62(AMNF>S?;=I'<TF[K TFMBW[AE
M.K?<J;--A&\EQPS-:F3\#+1F:C/[V:?+W#*$B(B(B+!%T(B[$7N+W$7D7D"H
M7;  &@-^/B?O_P!%T!J+H[I*QIWJ ZSI=IZTXFR;K4EQ-G6Z2TJ^ IRB-"O@
M[*5$99)23(R/L9"J_P"BCH0R]O@89;;:9:U$>0TTTA+;;:$U^K$E"$((DH21
M8(DI(B(B+!"W3J9^+?4'\B+K_0,\5&/12_PO?)_&,_\ S@JP*SQ'P/VA7'2[
M%\Q?8-1H78OF+[!J"J@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M[]*MJG07)KLF Q>L!#4F3%A1&U1"7&)+_P!];2?M&9^9BZA=.Q[:Y>-Z)O\
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M&9GR-QXK;2&\GU,TI01&9]3QU&ZAVZ$ +S0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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MSQY@J+Z0  1   1   1   1   1   1   1   1   1   1   1   1   1
M  1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M  1   1   1   1   1<(U,_%OJ#^1%U_H&>*C'HI?X7OD_C&?\ YP586Y]3
M/Q;Z@_D1=?Z!GBHQZ*7^%[Y/XQG_ .<%6!4\1\#]H5QTNQ?,7V#4:%V+YB^P
M:@JH  "(  "(  "(  "(  "(  "(  "(  "(  "( #0SP1F"+@.HUZVE8=N5
M"X+QETZ)2H,.3*4=12RMIQ;#2W4((GB,C4I2227RF*#.^?<I=.N^[FK:N4"G
M-LT.SKA@*M)B/':;92Q"D(;FF2$M)2XE]#)F7,D^BB,OELD<;O5BGV]I-;FG
M$1Y_[I+M=>.*B-(=CJ;;AOMNNDI3:D\Q*1DL*/VBZ>8K?T72[46XZ.Y7Z'9-
M3J='CM(7(J"*?(Y3Y2+Q%$9L*\7"B/F,C4?F?4=:<$.$UKOV-RY9=+Q+:W5-
M5/;8&U%/"RF?$WD#GPSSS1MF?*\NC(8"6EI:=[(4%Y5Z;N1^BGQ$?:K3PIL/
M$BHO6+LJ8>VR*LAKK715$LL=<:JVVRDK9J5M6R)K8I*H1&6 .=&'1N)5R_8E
MN<LK<;HI9%QP7*3"N[X+8A5JD,,1F9D=R"RB,E2R0A#A^(31J+IV,_+!C.X4
M[N$GJG$T\W41+6N1<J#&NU3C%/2\M]IF,]$CJ2XA4(^5+9FX?+U07O+)BX:T
MI*T$I"N9*B):3]Z5^TD_+N1B&.+6$0X!E]38Z:HJ:JE-/#64]14P=@7LJ 7%
ML>G.;)'&[;!(P\I+2.\%;5PGXF5/%_#J;B#-9K9C\5^K[G)36>UW=MYCMD,-
M6^-M#43\L<T%5!U:^FJHHJAD?9/>P-D:3[  !&2DI?!59R:92ZE4E(-U-/@3
M)RFTD9J<3$CN2#0DBZF:R;Y2(NIF8@@N#CBV/0:_6J$YHU=K[E(GRH*WD4VM
M&VZJ,^M@UH-,$TFE1H-1&GH9=C$]BDI6E2%I)25)-*DJ(C2I*BP:3(^AD9&9
M&1]#(<+=T[L)Q2W7+'M5QQQ1J6M=!I:EK4H^JE*.*:C49F9F9GW/N,C;ZBWP
M&7U^@?6AP;V?)5.I^S()YMZ8_GYNGEK7CM;9B]SQ:VNJ_P"$N-U.0B40BD;3
MWA]I]6+7.,I>64U1VW: L !Y SEWUWT@(O+CTV%3[8K;A:3W!2YCU-FQJ?(J
M+%4A,E(D1W&D.$[)B-H/PUJ2LBYL&:<'W%<2J:4Z[[@K;U4WJ(BU&73+=K].
MJ\^IF2U.^&JJ&<%$=1EXBDLI2A"S9ST3[6"Z";[T@:7=]+AZ7V!:6F<6G6-4
MG)ZJI6K>H##CLPF5-NI;<33X?C,^UE!'S)(_(85Z,<3.G:0;84[96]JM<K%%
MD4V7!JU65'J+?PD[(2OP9#K9PC5]X=7XA)4HSR6",A+-@A;2VJ&Y6*U-]8N%
M1&RHBDK63&.ABD(DV^5T0:^31 8 2"6N=U&EVQPUH([+A5OR_AMA</X3RBZ4
MT%SHJG(*6X.IL=HJIXJP9ZPT38IJKD>T01L<YI,;Y >4!9Z[8N.?0Z'H_:EI
MWA85:NR\;;A)@5:93FY\M:DL)2S'\1N'&>\-26T<N%'^<C&09\=NQ2\+_P "
MMWGXLF/'Z4VN=#D.I:(S_8'0B-63,_+RZ")W@C3KQB;M*U;D?35R78-WS)4N
MN_#]!+P*&V:'I$5I#U3AJ2YDUDCV#(O9ZBY@6F^G_7^D:TU>US9.WZ26#SG_
M /*=TJ[&7GU&LY+%8+/=)*=]G?.96LJ0^.XNC [7VG-,;8GAG*[8:T.(Y='N
M.E$/%NBX8X+F%5:Y<%GN/K<,-U;/296^G8WU[<DD#J6.BG;3&&7M&-C$CP8P
MQS?9<%LVCNI475K3NV[^B4]^EQ[ABE);@R$.-O,$9$?*M#J4+(^OFDAVB/GB
MQ(L%AN-"C,1(S18:CQVD,LME[D-MDE"2^1)$0^@1](6N>]S&\C"YQ8PNYN5I
M/1O-H<VATWH;[]+E^I?#)43OIHG04[Y7NA@=)VKH8G.)9&9"&F0L;II?RMYM
M;T-Z6VU3K"G%[Z?,_P#D.#\SC=-M'U!W4<2[?/6-)J@]3]1]$IMJ7/;[,))H
MEST0XJZM+0VZE25(PU$4DRR?-G!E@?IDU))JAS"(C,S@RTECS,V5X+YS%/\
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MX[FF]#+LU!LR:Q0)D)5.@U1#3Z)U"(E);DL0WDF;2G>56,X,L&0*[0+G\O\
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M[7J'2*K/MVJ2KTJEZRVH4IREL+H\J)58*I3Y-G&3SK:^]\ZRZ]$]@5VNC20
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M3MS'S?!$4<L!>2   B   B   B   B   B   B   B   B   B   B   B
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M\++MQ&X68/;[+<7V<8[4W&%PKVS1T5V9-.'/N=/ZNU\A D[1M,^2/\8SG+7
M$/=^<7%3BU@/HZ^E7QHI6'_:-;+M2X]2,O=M]7?66VZ6VVPP7.S!U5(V%U"*
MYLK=PR#4<<#G1N=S,;G_ *EV_9%N<4VBPM)&6'H155#CT6G&3D=EUQA*W_"4
MWE&/$-9J)&.W7Y+7E,YO48?,1DKU&'S$?DKP$\Q?.1]Q5%X/]!MZ^-R-6N^[
M5R*S=U,7ZQ!DSD/+4AV2RM3ZC4Z1D?-G)9/H70O>=LA..4L=BR18+'1)F1%]
M AGC]5-AOV/XL17SU.'X[0V6KNMPIWT\EUG8WM'5-/VFWS4FG 0SEQ#SSZ)
MYC*'HC0R7'%,PS=L=%;Z#.\VNU^M]AH)FRP6:G+F1]A(UFHXJI[F[E8QC1R-
MB<0">4>0  @1=;H  "+BMSV5:UXLM,7-0*97&F<FTBH0XTKPL]3\,WVG#3S>
M?+C/GD<*_4)TD_K>6P?_ /9Z9_VQAV^ ]&S2L&FR/:/ !S@.I\@==2OIBK:R
M%@CAJJF)@)(9'/(QH)()(:UP'4@$]%P6V=.+'M&2[+MNU:+19#W1U^#3H<9Y
M?+T+[XRRA>.I^>#'.@ 6N<YQVYSG'S<23])ZKREEEF=SS222OT!SR/<]V@-
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M.I\.GLECLU#8;81_\+9#<  %:@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M\CU)/F@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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MJ?=_V_:/( 1   1   1   1   1   1   1   1   1   1   1   1   1
M  1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
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MX>*DDK&<]/<9D/( 5J]?A)]ZO\8QYX+&/(:@"+P2VE)Y+)G\IF?YC'GWZ&
MB]9-I(\^T?SJ,R^KL/9WZ&  B\$MI2>2R9_*9G^8QY@ (N$:F?BWU!_(BZ_T
M#/%1CT4O\+WR?QC/_P X*L+<^IGXM]0?R(NO] SQ48]%+_"]\G\8S_\ ."K
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MQ1%W[8ZX(9_ET_/^<\CKW";O?KU8X:S(\;EQ:X]K+"ZU35D-<]D47*R*;MX
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M(U 36UC0UHUH   >6@- #P    \AI$QC_P"YG]H  O  [D0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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MI-)Y6JC3H50:(SZDW-CMR$)/Y22X1=B!"-??[_4MQ  !40  $0  $0  $0
M$7"-3/Q;Z@_D1=?Z!GBHQZ*7^%[Y/XQG_P"<%6%N?4S\6^H/Y$77^@9XJ,>B
ME_A>^3^,9_\ G!5@5/$? _:%<=+L7S%]@U&A=B^8OL&H*J   B   B   B
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M<GN1H+!S@?BL7L<CZ2A='XL;7U(J:YP'1XE8[9Z%$  $V(@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M]"K1NAZ\+>TNM&EW&^X;JZHQ0Z8EXG#,\K;4F*1H4>3/*3(\]<CN:J4>F5J
M_2ZM3X-2ITEI3,B#.BLRHKS:D\O(IA]#C9I(C/E(TX+RP-S $71EC[<-$=.Z
MU)N&S=,[5H-9EN&Z[48E%IS4@EJ,S4IMQN,EQLS,S^(I.?F'>9$1%@NA%V+W
M  (N$:F?BWU!_(BZ_P! SQ48]%+_  O?)_&,_P#S@JPMSZF?BWU!_(BZ_P!
MSQ48]%+_  O?)_&,_P#S@JP*GB/@?M"N.EV+YB^P:C0NQ?,7V#4%5   1
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M;8VF:II(IIY7: +Y)97.?(]Q+G.)).RB  #>T0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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M4'\B+K_0,\5&/12_PO?)_&,__."K J>(^!^T*XZ78OF+[!J-"[%\Q?8-054
M !$  !$  !$  !$ !H9X(S!%Q^YY5'I]&J55KC%/>I]*@2Y[YU!IAQE"8K*W
MS+[^E2"-1-].F<]A^?)Q%MPM,W(;KKHO"F06HUD4&YJ7"@>H1B;B^!#EMQ:@
M:UL-I023)E9D:SZY/'06C^-3N[3M]VZR[$H$PH]]:G-+@TA;+W+(8;:=)J27
M*D\ESM.'G..GU")?:5L1TFO38)J#6+YN>VVM5]2H;]:HSLZI02J%(?IS[\UY
M"4KD)4I4LC)/M<I]>GD)+PV.&ST;K]7-D(JJB.WT;6AQ(8]P]8J T ^RP>/D
MUP[RU==<!(+?@%CEXF9%%4N;>KG3XM8(H6O=(V"HE;^%;HUC0[<5.QI:7<H)
M[*5@ZN"RWW,7[8M1V';=[(TI*"JDZD/TF.28#;*'WW:;4H13B?Y")TS2YS_M
MORXP+ FAUFQ[$TIL:VHS:6FX% IJS;3T(G)$)EUS..G,2EF1_+D4J.'53[TU
M%UOTIT.N>J+G6Y8]P5M%)A..I=980Q+6Z;C2C4I*R=-DEY3T21EU/ O1T^/Z
MI"AQ2^+&AQ(Z2QV2RTEKR^1/T#8>)M.W'\5PG'&RE\E4Z]955$;)E%VJVTUO
M<_?4N%)1CO\ %QUH+\_)+0/_ -2_I&W-E;^%J*P9):L"M-Q)+R^.U40O%R;S
MENS(*V\".?1Y1)"?'NQ'WN7\FSM%ZS"BN*15K@5'A0$I49+6IUY#*DI(NI\W
M.1'Y$7?N(LF-N.ZJNV'3+910%O6>YF=!@&]';/\ 9+B9?.I9GXAY6HEES>\9
MG;HI;NJ^XO2W2.)E<6ES)$JKH1[22-!-RF?%26"+JCIS>9>>!)Q BIAP84-*
M4I1%B1XZ4DDB(O!:2WT+RZ)(?G5>N']'QJSW,JBY7>\VZR8M#18=1_@:H93"
MNG?&+C?(JGGBE;+$R6:EB=&0&E\/M[Y %)0^?YCK]Q4.FDU@[V+0K%J41UMV
M%9=->),B)S1E$W'-2>8N8O:/V2\BS[LYZS(1/%*-&)_]N]78\7_TOAEXG_Q9
M'OP7N+ZAJ)FX?</:;A]15=#2W[(;U!4OIS&V^UPK/4HZ:(11P40#&-@@Y1UC
M:-=!H!#]_O\ N\$  $AJB   B   B   B   B   B   B   B   B   B
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MV^SNN#FOWUYH8I8H1O6FQ@#IT$O(  )21   1   1   1   1   1   1
M1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
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M>(&5WK*+Q224DU"RW5DLPIW4<%/.UD@C9V;GB0MY7B0<I<&\QYV  /E74*
M B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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M@[%W<02YO0KH0 - :T!K1W-:  /@!H!  !-BJ@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M."(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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MN:(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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MV&GRM;-?K]UOJQ&]3:3+1&MPW4\S7L$Y$D&SS>R7Q2,S(OS$)1O!1YH:/_\
MAI^C\PZ!VS:9,Z6Z36Y0E,)14'HYSY[V,..N3C]:]OJ9G@W,=>HR#'/_  JQ
MNIQ[$*/\*>U?;W+/D-_D.^=]VO#_ %NH8XGKJF:^.E8.H#(6@=RZ"7BE"49Y
M4I3G^"DD_7CN/( $D@ #01  !5$  !$  !$  !$  !$  !$  !$  !$  !$
M !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
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M+*-L^[9R&4.FV?0NJ.;E/Y@5';WU 'N'_4_?IX+[@  5J   B   B   B
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M(9:;9;+"&FT,H+R)#2>1)%\Q%@>T $DM :   -#N'<%N:  "J(  "(  "(
M"(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M"(  "(  "(  "(  "(  "(  "(  "+Q4I*"-2CP1$:C/Y$EDS^@AAG?_ ! -
MJNF-VU6Q[TU/@T>Y:,I":C37([BW(ZG$\R",R+J:BZC,IQLG$J2?[Y"T'\RT
MF1_:(.=ZO"JT)OJ1JMN"JSLW[K95.54%<DJ8AM#L**Z;9>&APF^IH(NB?G\A
MK>3U604= VHQZEH*JHCD<^I9<)9(HVTS(WN<Z,Q]3)S!H /31*D;AI:\ O%]
M?0\0;G?K7;YX8XK=+8*6GJJB2Y35,$44<[:@AK*?LWR.<\;<'-:-':S*_7/-
MEN4$>L$!/B.M,HYX;Z<N/+)MM)<Q%\92B+Z1FY:=VT&]Z!3KFMJ<BHT6JLD_
M!F((TI?:,B,E)(^O4C(4V^%WL TFWE-:G/:AOS4JL6O1D4M*)<M.2CU%U*,^
M$ZDBP3",F9F?N(7!-+-.J1I98MOV+0U*.EV_&3&B&I2E&;:2))9-9FKL1=S&
M"P/(,ER2C%TNU%;:6W5,1=0OHY)73/D9*^*031R.<& <AY=$[[UO''7 >&_#
MF[_P8Q2]9)<\BMU5V=\BO%-2144,$U)3U5*^CGIPUTKW"8B0/8T-T-'8.^Q
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M8&ECF<H#G]20%W<  )'7.Z   B   B   B   B   B   B   B   B   B
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M+K_0,\5&/12_PO?)_&,__."K J>(^!^T*XZ78OF+[!J-"[%\Q?8-054  !$
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M9_163]B4"\@ !(BYZ0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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MT=%)R  #((@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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MA_8/Q?SG"L:N^:YQ9[=8H>)#,DJ*F]Q9!<;NV&HAL4MUJ'6BDLLS6F.AH:*
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M*F[T\,]7:3:G1&U/@BE(B?*^4\TLCVZ<Q@'("W8<N]@ !**@=   1   1
M1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
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MKK\AAS?VJOJ&Q*/M+R >/-\BOJ'D"(  "(  "(  "(  "(  "(  "(  "(
M"(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "( ZBNO7+2NRZP[0
MKGO6CT:JL\OBP94R.T\@E)YDFI"W$J+)=>I?F'&O^$]H619/4F@$62+K4(A=
M5'@O^>]X^1UPH6.<Q]92L>TEKF.GB:YI'>"TNV"/$%9:*PWN>-DT-HN4L4K0
M^.2.BJ7L>QWR7,>V,M<T^!!(*R"&V+J].;6I"ZC34*2?M)7.CI4G^Z2IPC+Z
M2(;53*[3;NMXZQ;-18J4"?"EH@SHSB7&G7#;6A"DJ0:DJPLT]2,^I"K1O0T!
MXBNG5>U6UJCZEU"G:7T]]N7"C-N,X9BJ4LO90EXG,$1D71.?K&!R?(YL?HHJ
MZGM%9>8G<[YC0F,BG@CC[0SR.<==ER@^T%O/#/AY19_>:JR7#+K-AU5&((Z-
MM\;4!UQK9ZEE,V@IF0L+_6>9WR7@: .^JM4_#5,_\YTOR+\/C=S[%^V^?D-T
M0M*TDI"DJ2?4C2HE)/YE%T/Z!2KVQZ:\1C=3:L:_---6*F_0HM6B>/S*:3XC
M,6>E$I!$Z\2NJ6UET+O\@N$:046Z+?TZM2D7A)5+N.#38[-6D+QEV2AE"7%'
M@S+JLE=O>/DQ'+9\ICDJ#8[A;*3L8IJ:JJS&8JMLA</Q+HSUY>79)\PLMQ9X
M447"ZHIZ 9Q8,FNWK=31W.UVIM2RKM$E.R)W^^LG8WE[5TCFM#2?:8X'N79P
MT/H1G\@&9%W/_?YA\TB7'C-&[(?8CM$1FIV2\AAM)=<F:W32DL>\SP-TWKJ>
M@4-@$D  DGH .I/P"C3XG6Z^_P#:;HJW?E@14RJJMU+9H,VTE[4AMK_G<IZD
MH_+Y2%9W<QN/W>[YK1M--S:6U630*.ZB?2JC&;-QJ4Z3S;YF1QV<>RXA*3R9
M^0E^XZ.JNG]5T(BV/2[JI52N=4^-BFT^9'EK+EG,K,EG'=<)&$EY]R+'<2"<
M,FC4F5LMT@=D4FF2'E4^3SN/T^*\XHR>P9J4MI2C/IW,S$(9!0UV9YG=L8CR
M&HH[3%9:6IFIZ813PR3&?EDCD:?DNWR..G<P( T >O:V 7NR<'>#N*\39^']
MNO.656:72W45QN9K**KIZ1E R2&>GD8=/9OMHV$Q.:0Y^B2.E=F)Q.-ZN@VG
M=NZ<5"Q)MIPDQVZ%0ZC,0RDW#E<D)+B4/,HYC;-25$7D9=\GUF%X=VPF-%?B
M;K]?ZF>H>LM[I358BZFV;D>@H<(S;2S'<4[%4:F'4EE*"QRD9]1B]Q_Z?!@T
M[;SZE!A0R7<1DLXD5F,:C*IQ>BC90CF(L=,_%\NXG4VO_B)TU_)^G_+_ .)L
M>\5Q6RR_PSNEHO=RJK_%C%+;IK5Z[RB&GEJ8]F84S!V3I8FM#(GO#BP;+=$[
M'EQ1S*E_V.8OEF%XY:\$JN)MUR*CRLV7M'5=?2VJH8UM(ZX3$U+*6JFD?/50
M1.C9,[E9(','*L@&FD-)2E*4())$E*4))"$I(L)2E!82DB(L%@BZ=.PZ W0?
MB)U+_)ZH?R1X9!C'S=!^(G4O\GJA_)'A,-R_B^N_JE1_A.7(V._Q_9?TK0?K
M42@Q]'U_!-Q'Y0H_2<H6416N]'U_!-Q'Y0H_2<H641I?"W\AK)_,JOUR=3'Z
M3OY[LU_IK5^Q;<@  D%0&M#['\Q_8((>/-^Y>A?X1B?I!@3O'V/YC^P00\>;
M]R]"_P (Q/T@P-+XA_D9D/Z-F_O,4R^CW^>?AW_:.B_O%9Q<,;]Q;H[_ (,D
M?]<9^C +AC?N+='?\&2/^N,_1F,9_)VQ?HF@_58EI_$C\X.;?VIOO[2J$'4F
MN?XI[^_)JK?HZ2.VQU)KG^*>_OR:JWZ.DC(UW_"57]6G_N+6[1_&ML_K])_C
MQJO5P#/ZM-R_Y2%_+Y8LW(^*7T_:8K(\ S^K3<O^4A?R^6+-R/BE]/VF-$X4
M?D/:OZ2N_7)E.GI2?GJRG^@L7[!MJ\@ !(RYZ6A]C^8_L$*/')_<?U?^^8/Z
M09$UQ]C^8_L$*/')_<?U?^^8/Z09&H9]^1N1_HJJ_P ,J6N!'YX>'7]JK3^M
M,61O":_<-Z1?WO4?Y00DB$;O":_<-Z1?WO4?Y00DB'WXG^3&/_H>W_JL2P/%
M+\Y.>?VNR#]J5*#IW7?\4>H7Y.U3^0OCN(=.Z[_BCU"_)VJ?R%\9:N_X.J_J
M\W^&Y:M9?XXM7Z1HOUB-5\^ /_53N3_*1/\ +Y8LV(^*7T_:8K)\ ?\ JIW)
M_E(G^7RQ9L1\4OI^TQHO"K\A[3_.K?UR=3EZ4WY[<L_HK)^Q*!>0  D1<](
M "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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MC1>%7Y#VG^=6_KDZG+TIOSVY9_163]B4"\@ !(BYZ0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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M"M?_ "AC_6 J['FI& $<_P"NK[$/[(*U_P#*&/\ 6!^NK[$/[(*U_P#*&/\
M6 FQY_?[D?2I&!X.$9D1%U]HOM$=7ZZOL0_L@K7_ ,H8_P!8'ZZOL0_L@K7_
M ,H8_P!:";]_WZ?YCZ5&AQ6=F6Y_6[7^Q]0M$[056&+=<>?14BEQVO57B:1X
M2O#=/*L.((^V.F!C\U8O&Y8;999FRTM1V6X[*2.E^RRR@FVD?&+/*A*2^@36
MJXJFQ ^I[@K5^EZ.?YS= N*CL1,C46X&U3(NY^+&P7_^01Q7<-J&KN=PNL-[
MO]NFN4S9ZF.WUPIH7/8UK&^RV/;N5K>G,XD;.M;70]E](R^6K&L?Q>KPK ,A
MHL;HWT-MGR"QON57'#),Z>7\9+5<C3(]_M]FQC3II(V-FO9 X:^_77C7"E7/
MKM2Y5,>JZEJK-]-3&$OT]R.VDHCA,Q5H</VB(L(5UQU,9PLW%Q#N'!4_5J]
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M!!#QYOW+T+_",3](,#,<N*KL16?*G<#;"U'T)"7V5*,_<1$[DS/M@BSD1/\
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MF_6ZGM%NKKI4155+4RP4%--5S,IXZF$/G=' Q[FQ,+FATA :W8V1M1P\ ?\
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M^R"LQBCQT6Z[STTD<-4^:'LFT\ C 9#3,8R/F>9"X#>]@C172U3Q!X-Y]@N
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MG'7V>Z-:(T.O6[8%P2K@D5*C2;HK-22Z[ I;4J.HURY*U$1/%SF1=#['\GZ
M5-81&B0X[18;8@Q&&\GGV&F4(063[^R1=?,0Q:^\*:IZR<270G?6SJ4BDPM(
ME5@W[,.E$\JJ?"<!,,N6?SEX/AFGF^*>?D$U#3?AI0G.>5M#>??R)(L_3@$7
MM  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !
M$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !%I@O<7U#4!X+5REGWF1?
M6>/($6R7'<U M.ER:S<E8IU#I<1!N29U2EQX<=I!%G)NR7&V_F]KY"ZCK33K
M<!HYJG,E4^P-1+9N>=$6;;\*GUBGOR261F1DVPU(6XYCE/)I2K!?3BJ)Z2?N
M0U$NW6';'L8T]N>HVG1M6J^_#OV539+L>1-A,2X;J6TO,+:=:RRXXC+:R/J>
M3[B/O>WM:>X(&Y399K7MMU N>)1]2I%.9O>B5&LU:IQYSLY%.BR%K149;[?5
MV2\O!(/&?F!>@9L#9T7?)'G\3X+]"@!PS3VY&[NL>T+G;<\4J_;5$JCB\8R_
M,IT>0\9ET_YQQ7;IYX',P7F@  (@VJM5NE6]39-6K50BTRFQ$\\F;,>:8CLI
M][CKJD-IS_;*(;J(._2#=:BT>X:^L<F#4GJ97:]\"P*=(CRU0Y"$/5)MB2XT
MZVM#A&2%Y]E6?(%4#9 \R!]*E)+<QH&77]5RQTF;A-X5<M&(_$YN0D8.;\;F
MZ$6.ICN>CUFEU^G1ZK1I\6ITZ6GGC38;S4B.^G^$VZTI;:B_N5&/S9ME6S;A
MDZU:<Z94G63>I>=L:^W?4"GU&W9<N[VH34LYK<J+'35#J+<%1.<Y(]E>.N#\
MR'Z%6U[1^WM"]#[#TSM>O.7+0;=IC:*;6G)2Y:I\=]M#C;IR''7EN<R#2KJX
MHRSWSU!5< #WD_-KX_-ON^^\@P  5J  Z(W(ZPR]"M&[VU.@VY(NN;;%/6]"
MH$4W"?J4I:5%'90IM#BRYG>1.22>,F9]@1<GU!UBTWTO52F[[NZD6RY6GB8I
M;51F1X[TUXUDWR,MO.H6L^=22P@E=3+/N'9#4AA^,S-:<2N.ZPW);>YR)M3#
MC9.I=YL\I(-M1+-7;E^0?F7\2;7#?IN1UUVW:];G[;K^C^EMTZBML:2:>-5E
MQI;,6GW#$B37)+D-<=UU,DD-O$F4W@B49%T,Q>$XB6Y.N[4N&?=>LELRE1KA
MHVE]J0J8_P#'=0]5Z'%AFYS*(\K0EWF-1]35USG)@KN7HWKLN^KN&OBLUJKN
M<T&HMW(LBIZJV?$N9;I,E2UUZE$X3IXPVK,LN51]N4\'G)8R.]XTJ/,8:DQ7
MV9+#R$N-/L.)=9<0LB4E2'$&:5$9&1D9&?0Q^<EHCPQ$[C.%]J%Q%+TU(O%S
M<3/J%1NJWZ^W<-;:;IRJ=6I,E+28;4Y,12%,-H:Y31C'7 L]>CO;O[SW3[$;
M75J-4GJW>UAR:G0ZK6'U&;TQJ%4GH$0U]^I,QB[F9GG)@JENAL'>CIV^FCY=
MYWKS"GZ "ZD1^\ 5B#AE]7_:&G%OR;GO6OT^W*%#4VF14:C*8BL(4ZLFVTDM
M];:5&I9DGH?VCD-8GG2Z55*D3)O_  =39T\F4_&>.'&<D>"G&3RYX?(6"/JH
M?GQ<;3=QO[WA:=ZD5E&F]P:)[0]+KGI=.J-035%L2;TYZTB&R\A2$Q)\9+4M
MHE>QDEDK'Q05S6\Q WK9 W\5^@5:EV6[?%!A7+;%4C5FB5!*EPZC$=0['D)0
M>%*0XVI2%$7O(S'!KCUVT@M2KR*'<>HUJ42JQ.7UB!4*Y3(DAGF+*?$:?E-K
M2:BZES)+/D(\.#K/7%X9FA]2=?D/^IVC7IBWY<AV2\I,9EUTEN/O*4XOHC.5
M*,4D]0:KMGW;\2_=?=F[S<'=FEFF%'K%*@6^Y19EPSHTMQE#T61RQ:/*1ZOX
M3S9$KV"(^Y]@56MV7#KT\0-^('=[_+:_26LS5/3K4!V4Q9EYV_=#L+E]:;H]
M5@5%<?Q/B^*F(^\:.;'3FQGY1V%@O<7U$*^W!-V5;3-!Z9?.K6UO7RH:T6]J
M&4 Y"ZA4ZG)>IR8'.TV2X=2FR78QKR?0T(-1D8L$I+!8+KY_6"M/0D#K\VOJ
M3!>XOJ&H#XY_K7JDLX>#DE$D^K$>.LKPE>!G/3'B<O?I[_E*BZSU'UNTJTH:
M0[J#?EMVL3IX;:J=6@1I"^Q?M#\AMSS(_B]CSV(;M8.I^G^IU-35K#NRA73
M,LF]2:E"FJ;ZX+Q$17G5HR?0N<BSY"J/>O!KW-[XM^^J6J>^JOU].W.,HU6#
M0J;<4FE1#BIA.H<><^")K"FR84EMT_%27;Y\X:<,1RXMEG&QU&V=Z(ZBUJ]=
MN:(TN9683]0F5J%2TT^AR:BRSZ[*D2O#,WD&@\.$9J3UR?8K^4$'1Z@;(\-=
M.X_.KN.H^LNEVDT5J7J%>UOVJR\>&2JM3A1'G3R1'RM2'VW#(C,NQ'CSZ#D%
MCZ@69J-1F:]9-RT>YJ2^66YE)GQ9J2ZX^^>K.N^'U[<^#,40JM:51XS7&0UI
MTDU:NZX&M"-'W'(5(M6DU:HTMDI$FEOI\13E.DQUJ\.4REPB41]L?*.Y^$'>
M^H&Q7BXZP\.=B]ZM<FDE4E1?N8A5>7)G*IS3$%Z?X;;TYU]XC-1I(U$I/;S+
M((6]._J!LC7<.GC]_!7B@'BG)$9&>3R>/FST'D"L3!'W+(X'?6I-B:;4MRL7
MS=5"M>G-EDY%6J4*$:R(\'X2)+S2G,'T/D(S+\PYV99Q\^?G^057^(QPP]Y/
M$"W_ %IL7U<U9I&QVA..')A4FKKIQNM.0T&X3OP?*8FJ)<I*NID?+D^Q%D%4
M $]3H>/^BLAZ;ZY:2:LD]^I[?UM72M@\.L4VK0)$E.>F289?6Z9=#/HGMU^;
MDMZ:C6-IZS&>O.Z:-;+,PU%&<J]0B04O<AES>&J4\T2N4S]KE,\9ZB@UJ#I&
MSPJN,/MXTPV:7_<-0M^^Z@_#O"P55NI7"W&0S"82;D@YLJ82/$\1UWE-)8/)
M?-D1Z3%K#!U W"[/- [AOJJ6/;+L>?+OZI4>?-BOPFY4.',>4]'@/LO/J+G=
M)*2R:<8+N0*\1[+0#T<-[UUUX]-G[5<NI&X/16N5*+2:1JA9M2J4TS3%@Q;@
MI,B1(,NY-,M2UN+/^Y2>!W*DT+22D\IDHB41E@R,E%DCZ>1EU+WBDSPWN'WP
MQ[]W"6#>VWS>'<U[7_8"(\E^T:S.N>G+ESGXK:I328U5J*4R"0XA9%RM+(R(
MC(L=[KT*,B+&C1T*YTQXT>.D\YREEM+:5?+S$G.?/Y05CAHZZ_.-?4OJP7N+
MZB&H ?\ O_O]@*BV.X+DH5K4V15[AJ].HM,BH-R1.J<N/"CM((LF9NR7&V_+
M!95WZ=QU18.X_1+4RJR*+8^I=JW%58SAMN0(=9ISLDU),R-+33<A3CF#(\\B
M3]_814<:+9/NGWPVAIOIGH5J5/T\L!N<ZYJJF I+3U8I:93+W(4I#S#\<FXZ
M74FII>3(S,Q5>W>;:;!X>.\#:50^'?JS<%U:W5&M1XFI=JQ;AJU;;==)R"U4
MUS$RITJ.CV%2G,*07+UQ@R!7M:'?RM$[T.ON[SX K]%2LUNCV[3I-7K52@TF
MFQ6U.R9]0E,Q(K*$D9\RWI"T-EDLX]KJ?;(ZEL/<9HIJ55I5#LC4JU;AJT1P
MVGJ?"K-.>D\Z3,E)::;DJ<<,L&9\B3P74^A"K9Z2)NKU9H.F.U':W9ES3[4K
M6X1N@0K_ 'X+BV93*T_!)S6DOLJ;=2:S>D),VUI,N8R^>,/B#;(U<&67LTW2
M[<=1;JA5^XY5%?U"BS:U5ZC%K"ZVJE)?);,^8ZP6"FNXPWT,^G8@1K-@=>KB
M0T:\M;WY+]$ C(^I=2 =/Z#:BL:JZ0Z=W\R1E]TMK46:_D\FJ4Y38RY"R/!=
M%/*6KSZ#N %8@^*HU&#28;]0J4V)3X49"G'Y<V0U%C,H21F:G'GE(;21$1_&
M40^T_D[B*?BU[=-T&Z+;A,TBVV7S)L>I7#)B-7'4(9-E(<IR);:I"4/FXVXU
M^QC>3EM9'U!/O]]K-FV=S^@MWW*NT;<U4L^J7"AQ3)TUFN4Q3JG$F9*0@DRC
M-:B,C+"",\]!W=4:G3J5">J=1EQX<*.V;KTM]YMMAIOE,^=3JU);)/*62,S(
MC+J/SD>(ML3TGX<UNZ!U#;IK-<<W>Q'N.EG<M*BW/6*I*KLZ75H7K:)%/747
MV(R4MK=Z+:Y>573H+2._37?4G3K@QW%J3JFZ[;^ILVP;;B3DE(*-*]8J+$>,
MATG6C0:%+;62U&1D?,KKUR8*XM'31WOS&O=]OU*70]S&@A&KFU<L=!I<4VHE
M7+1D&E:5<BD&2II&1DKICR/H.X+?N&BW32HU;MZJ0JQ2IA*5&J%/D,RHKY)/
M!FT^PMQI9$?0^51X/H?4?F;[&MJO#;UKTELA6Y#>;>ME:[7S7:E)?MQZ7=YP
M8CSU54[$:.JM5!N":74.HQ[>"R1'V'Z&NRC0NT-N&V[3K22Q+I7>EK6]3W%T
MFXW)KE0748\Y12DN'*=>D.+,DK+HMU1I['@P1S0.XD_%NOWE96@  K4'";]U
M#LS3.@/W-?-Q4RVJ)&4A+U0J4N/%:2;BB0@DF^XV2C4HR+V3,QRJ?.BTZ)*G
M37VXT2''?ERGW5$EMF-';4Z\XI2C(B)#:%*/Y"'Y[_I!>_\ U)WF73?&C>WB
M35E[>=O=4I<?5&]*),DPH58DU22V<-M,QA39_L68TME7A/*ZD9*(L8!7-:7'
M0^E?H!VA>%M7W;T&Z;5JT6M4&>E;D.IQ'4.1GTH5A2D.MJ4@TI/H9D9D6,CJ
MZYMS&A5HW.S:%Q:HVC2[B><)E%,?KE,2\3AXY4.)5*(T*5DBPHB,SZ8$&FS;
M7^I;<. K;>L<"1)DU.V;'N!N))ER')4@I$IZ1$8>4_(4XXM3:S2M)FHSZ=#(
M5U-GG#C5Q -C^X#?AJ_J)=\O6V5.K-PV36F+@K45FA_ E5GN(:1"C3415I4R
MPTW@VRP1$?O!7!@.R3T#@WH.NR?B%^C+!G0ZE%9FP)4>;$D-I<8DQ'FY##J%
M$2DJ;=:4I"B,C_>J/YQ]8K3>C0[O=1-QFT2L6'J56Y%Q7)HU5Y] 769:C5)E
M1T565$B^(M7,M1I8CI21J4HSZF?466"[%\Q K'#E)'DM0 >*CP7?'S^7O,_D
M+N8*BVVLUFF6_39=7K$Z+3J=!:4]*F3'FV([#:$FI2W'75)0G!%TYE$.#Z;Z
MN:=:M09=1T^NJF73"A/*9DR*;*9DMLNH6II2%*8<6G)+0I/4^Y=.XJY>D"\0
MZ_*A%F[!]J#\JMZHW/2ZD]J34J&XKGM*#3XBJBDGY3/,AHY4-+B2RZV9&1YR
M98+X/10YTV-M:U7?JE1J4^339[RI[U2J$F>M,R)-FG.PN4XXI.'VW,D70NW;
M! KN4\O-X?7UUKZ?W*TC=.MNE%F55=$NG4&V*!56B+Q(-3K5.A24<R24GG:D
MR6W"R74N9)9\A]EGZO:9WY+>@6=?-MW+,CX\>-2*O3Y[[7,64\[<60ZM)&1&
M99(LC\Z[>'=&@&[#B^[B5[G]=+GTNT6M251XS$NA3*[*96OX/4RHD0*-*0IO
MD?01*,D%[S]XLF<%/8[LQTMN"ZM<]J>XRJZRTZO^K)E1*C4JNX] *.E4=OQ(
M%4G/N,FLS/NTDSP0(6Z .^\ ]QUH@'O^?W*R@ \4I))8(\]3//SF/(%:@ZVO
M'5S36PI<>#>-[V[;<N3S&Q'JM6@077.4LJY4RGVE'@C+L7N,=C+(C(B,\>T1
M_0D\G\G;W^0_/AXT]X:::[\7^AZ-:T:O5_371:P$.G=E;H4ZK.>J%-HZ'FB.
MGTF0V\]SNI-)&23QW^0%<UO,=?NW]2ODVOK;I+>=5:H=KZAVK7ZL_DVJ=3*Y
M3)LMSD2:E<C$:4XZ9$74\)/!?,/HU&UBTSTGA(G:@WK0+4C.'AHZI5(41UP\
MD1\C4E]M:L&99Y4GCS%7CA!;&N'Q;NNB-Q^U/=+7-6ZE8L&H/RK9J]2K\=XS
M5!>;=S3:O4'%.=$*5UCGR]R+S$>-^T"J<8_C2:G:#ZHW97X6@6DBEPZ?:M*J
MU1IC9ORZ2[]\6]3Y,=Q?ARVB<(EYZECJ"KRC??T V3K1'S'ZO=U5ZZQ-1;)U
M)H[5=L:YZ-=%*=R:9=)J$2<2>N/OI1GG?#R?1/-C(YN*-?"LNB^>'QQC=3>'
M=3KZK%?T:N.1'*@4^KRY=0.GHC4YV<3;;TUZ0^67#(C,C+)%GJ+R2?,LYZ_F
M/J77SZ K2-'S'>#W;'P7D #Q49$77SZ?7T!47#[QO^S;!AMS[QN6DVW#=/#<
MFJSHL%I?4B/E7*=:2>#,NQG@<"@[B]#ZE-C4^!JK9<N;+43<:*S<='=>>4K!
M$EMM$PUJ,S,L<I9]PJ;^E5:L19%4VM:%-WA4K5IUVU:K?=9/I51E0Y$6GQY,
M5QQ:D0WF7G>2/SJ2DC-1F6"+J.C-B?#RX6FJNM.F\G1K>I=-SZGVHBE5&5:]
M9FW324RZGZO'DR8R4U2I-M/DV\A:,I2I*BQW)6 5_*.4.)/7>ARD]WOVKNEV
MZ@V58E/9J=VW/2+=@24DIF75)\2$RZE1%A2%R76TJR1D>4F?0_F'!H&XO0^I
M38U/@:JV7+FRU$B-%9N.CNO/*49$1-MHF&M1F9E@B(SR*E'I2VID%AW:3MZ8
MO.I6S2Z](EP[IJ=+J4J)*8ID!4%*GU)AOM//_L5"G"(C-2C/IW'3NQ'AY<+7
M5;6O3:3HSO3NFZ-3[3;I52E6O69UTTDI=3]7CRI49":I4FV7R;>;6@N5*DJ+
M^Z($Y/9#B3UWTY=]WOVKTR%H<0AQ"B4AQ*5H4DR,E(67,E1&70R41Y(^QD/(
M;?2X3=.IU/@M+\1N#3X<)M>>;G;BL(90LS,S,^<D$>3,\]\F-P!6(/CJ%0A4
MN(].J,N+ AQVU./RYC[4:.RA)9-3CSRD-HZ$>.91%T'UF>"%6#TFG>)JAHSI
M5I'MWTHNIZU*IK_55TRN5R*X33].IL.H1D25D[EM:.:,ZZ?L.)P7GD%4#9 \
MU8AMW<]H+==TKLZ@:J6A4KC0ZIHZ8Q7:8IU3B<Y0@DRC-2B,C+"2,\]!W?4*
ME3J3!?J=2G0X$".T;S\V9):CQ6FDI-1K6^\M#24\I929J(C\O<*!5O\ "ZVJ
M5&7H?3MK.]>HVCN]I#U)N"\JQ.K=3EP[@ESEPZG(ADBHU7X.]EM3T?E;,^IX
MQGH),?2']T&NFW79GH+M\HU[R&[YUK^!+8N*[:>28K\IF%,I\%]]I<=232<E
MEQ:C4TYE7/GF/H"NY07!K23OS&OO]^JLNV=N4T-ONX)%KVGJ?:=:KL9PVG*;
M&K=-<?-Q.24AM")*EN*+!]$I,R,L&.]B,C(C(\D?4C+L9>\O>1^1^8_.@WW<
M/QSA<[?-K.]70?42[:9J@Y+H=7OZ3)KU:GL5[X?G4TW4+BS)KD9LD-R74EAO
M&%="SU%[_9QK*YKWMNTFU2>+]D7/:],<EG_#E,PF$2'#[$1K=):CQYF"HX :
M(.P>G=KJ->_Z%E"  ?3J"M7@M:6T*<6I*$((U*4M1(2E)%E2E*49$DB(C,S,
M\$1=1T#6MT.@=OW4BS*OJO9L.Y%NDR5,57Z4:R=/'*VK]E]%&9D7*?7)F1]1
M@'QMMWES;.]AFJ>H]BRE0;WEQX5'H4M'+S1SJTDJ<\Z1&6#-"7R/.2QU\^HI
M_:'[!]I6N.URAZAZW;PJS;>]W6"IKK-N5E=<K*F;<FIJGK;+;S#5413R2XVZ
MVV2722G!&1%Y KFMV-G>MZZ#9]_E]_!?HWM5&GOP2JC4R*[ -CUDIK3[:XQL
M$@W#=)]*S:-!(]HSYL$7<\#IA[<GH2P\\P_JQ9+#S"UMNM.W'1VUMK;4:5I-
M*IA&1I41D9=R,CSU$7=HQM4ME?"=N2+K!JPUJI<MG615XT;4)M<=KX2BU.*^
MU33)V,\\@E-,K9;YO&-1*ZF><BDKL5T8V#Z\V75[MWB[MKVTZU+O2\+A11Z.
MB9=DN%')^O2FVDKG0IZ(;:%MN-FDUJ))%T+& 56LV"2>@Z= 3_E]_!?I_6I>
M-KWM2VZS:E>IEPTMW)-U"ES(TV*YRGRGRO1G'6SP9&1X5W')A'9PS-L&EVU?
M;%:.GVD.H+VI5D&T],I5T/U"14E36ICQRB,WY,F2[S)\3E-*G<I/H)$P5B
M B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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M%M:U:='I],@,=&VTLLH;6YY94ZI'B*/'4SS[P5SB- ;YM$G?7R UU^&UV4
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MN%J49&LR(QE@"L<=N)'0$H  "H@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (AD1]QH22+L0U $0  $0  $0  $7CRI]P\@ $0  $0  $0  $7CRI]W^_S=
MAY  (@  (@  (@T-)'W(:@"(1$78  $0  $0  $6AD1]R B(NPU $0  $0
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M=_O\W8>0 B   B   B   B   B   B   B   B   B   B   B   B   B
M B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MV^OUJ\41Y >IIUMY"'&SYD.-H=0HNRD+22D*+YTF1CV@O-   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M 1   1   1   1   1!TGN%L*K:EZ-Z@V-1'":J=S6_4J9#7[)D3LN&^PG)*
M,D_&<+N9$.[ !%1!V^\&_C1;3H-X4#;OKZ5AV[=-P5>I3("*/1YGC-2ZG)F1
MSYWG,IY">)73J9]QGALTX"VMMP[EZ!NVXBNM4C6J^+4E)FT.V9=-1$B,2"02
M.9OU=UR,GE4AMSHWU,B['U%LGP4^]?\ CJ_TCR2@D]LG\YF?V@KR]Q\@3WD
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(  !$  !%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>nt10002526x6_linechart4.jpg
<TEXT>
begin 644 nt10002526x6_linechart4.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( FH%7@,!(@ "$0$#$0'_Q  ?  $  @$$ P$
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MQ#E+_P"3Y\9EP\D7*1GW]_=U%AGW@(
M
M
M
M
M                           /4\648/SJ3W=/.*,OA'CB$\178>2DOJ_N
MNE=6V''$E^F:?[924F22^''PB\\9$?0RR,1-=-BVV7<??%G:BZOZ<Q;KNZPY
M*I=KU5Z2\RNFR%J0I2T(;,DJ,S;2?E=.@%FKJK?A8R.LO!V39_?CUKV[[Q_K
M5%[_ $>^*5_A1;J$;I]A)*0^>;T>QV4=QTB_Y3IV>8T),D^G)X+S]1=UB1(\
M*)&@QFR;C0X[$6.V1F9-L1FTM,H(^_R&TDG/>>.HQ2W";'MM6Z.XK-NK6S3R
M+>-<L*4<VUIK\EYE5,DFXATW$);,B4?.VD^OH]\ U;+?I\Z*A&YQH=!+BU\X
M3%TVS:,&15+C@6!8M5@TZ.TI;LEN!3X$R024IRK*$-9QRGGX17DV^\5+;Y97
M PN;;A=EPRH.NUMQ:I:T>PGZ3/1494N957X26VR[$E&9&259))D9=<]<E?<.
MA4I5#3;BX3#U'1344DH+[:7F#@-QBB)84APE)4DHY$CRB,1;W#P4>')=&HRM
M5*QH'!=N]RH)JCCK52E,0'9J'>W2ZNF-$F&K[+Y9I-&,]X$HY$1$5%LCM;+[
M# GP8_;K>&D6P:!<]Z4I^E2-3JA6JFQ39K!LR4Q'JM*>;-UIPDN\KK,@C+G2
M1&1B:&O;)]L%P5:57:SHS:-0JM0D-NS)LBD4]QU]WGSSK4N,I2LF9F>3/.3Z
M#)>VK:H=H4.FVY;E-BTBC4F,U$@4^&TVQ'CL,H2VA*&VDH1[1)9/ER9Y,^IC
M>G.Y/\(W_/("JK=;^W,4?ZYIU96EWA1&@=O6%;E+MBC.1J[S4^E1&(D;_!8E
MEAIAMM)85GS"\$7ME?%] I9ZN?MJ'0#[EKO]E"%TPO;*^+Z *IOZ?0AY   2
M
M
M
M            ;5.KE%IF?5*K4V!CS3)T:,KK_P!5YQ!CV0JM2ZD7-3JC GH_
M=0IC$K'P]@M8OR<1&ZZL?J?'U5U=WZ5K;TW[SR2/!6)R218?*>#UV:_S+ZZ=
M*ML;B  *'J
M                                               'BI9)Z'D_@(S^
M7'< /( 'K[5.<85^">/EQ@ >P ]_S#U]JG.,*_!/'RXP /8/6YW)_A&_YY#V
M#UN=R?X1O^>0 I:ZN?MJ'0#[EKO]E"%TPO;*^+Z!2SU<_;4.@'W+7?[*$+IA
M>V5\7T 0FU>GT(>0  $@
M
M
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M:#[T2I$%AY])_P"JXM1'[Y#? /,
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MOE(T2)"AQ$CR[G0UUGP7V1%][9V:*BGD  ,@,"
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ME:T3K42K77<-1=04F>ZNL0*I)-:I[RW3[-3+J2\H^[!=!:QY2Y>7*L?">?E
MTD9$63+'H,R^@!K+=%1$2V>62=166XFO"(UBU]I6VK<#M[J<2B[E]OMOP(KL
M"7"AU"-<\A%.@PGX[R)V839);C*01K2KVV2P.M-N>T/BWZT[C].KZW,3K6T0
MTRT\Y43;=IMKVE43NM+<=MI*UR*:RVY'4:V2<(SR9&YWE@6M#21XZF6.XR,R
M/Y0Y2,R/KT[NIX B^5LNG>?/"CKBQ8T=;G:''BQXYK)))YU,MI;-9)+HDEFG
MF))="SCS#Z@ "
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MEHWA8GTCO7P3J':LM_)X/T3/N\/:ZG!;LMVWTVK<YIH5&296]6L&5+A$9?\
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M_ ')P_!L^:WU#MB/X:-](_[W!.HV'UK6U[GJ#\SP/R >M:VO<]0?F>!^0&_
M')P_!L^:WU#MB/X:-](_[W!.HV'UK6U[GJ#\SP/R ]$BV+;)IW^YV@_J#QY*
MCP"P9(/I^H&.2CYY/ZB[_ O?T9B%APT_[-F[]%N];<P28CW3\]&VI_VC^=/E
M<$ZBJ!93+,;C=S&(S+,9E$HR0S':0PRG--Z\K39)0G/GP1"V&WW?^RC^:*H%
MH?\ /@3ONO\ _;1:_;[O_91_-&L]&7^RQ9_:ZK?_  '279*K>:T3JN:KHAPD
MJJN:KWD?:N\]@  V@<S@
M
M
M                !H9X(S/S#:O5JF%)\3.I4OQG./%O5"-XSZ<=AVG:9Q_U
M?? &[ -,EC/F[QM3M:IC,@HCM2I;4D\$49ZH1FY)GZ"84X3AG[W+D ;L/6YW
M)_A&_P">0\TF2B(R[CZ__4C\Y'YC'@YW)_A&_P">0 I:ZN?MJ'0#[EKO]E"%
MTPO;*^+Z!2SU<_;4.@'W+7?[*$+IA>V5\7T 0FU>GT(>0  $@
M          ''KN_P4N?_ -7JU_V;)%2;@W_LQ-U_W56?ZO4Q;9N[_!2Y_P#U
M>K7_ &;)%27@WG__ !B;K^_^^JUWEC_S%3_X^ 9KAK_H;$__  TE_B3>VC;]
MZ[3C_9VC)Y5J3O4=+V7^RNO7_P!<6_\ M18N:6%_@?;WWJ@_U9H4R[*Z[K;T
MQ@_[L6^XR/\ _F:C\QBYI87^!]O?>N%W_<S0QS3%_P!9[&__ (5Z(?\ +ZD?
MSJ[$G+1=44YL>XQ_S!AR\  ?-.GP
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M_P!4+:KOBNZE]MZ=9]@#Q0M*TDI)I41^=*B4GXE%T,>0DJ
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MSO$  #U
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M7-FJ33E=F\DEX=2HN;H19'<6M&AF\35[B%;7];:1MGM/:K<MGOKAUVCV_?\
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M6GPJ9I"A<M;]?I:33BUFS)OD.22C6HRY>3&>;!8]$5>K7 #8UCV3:/[/+KW
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M4U&[YK8JHQBZJ(Y(3$9>VM>2(  :E38G0AV\  !(
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M;'E]5R6S<V^LC766V1KCJ?7OQT] U !L@YV
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MQW$7F(NX:D1%W$-0 &AD1]Y 9$?>0U  :$1%W$!D1]Y#4  P1=Q8
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M_LH0NF%[97Q?0*6>KG[:AT ^Y:[_ &4(73"]LKXOH A-J]/H0\@  )
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MJ(CKNU%R?JWU%R=922P  8DFQ.A#JL  "0
M
M
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M[$?4P^@L&?ZFZA2#^ =I9+O\WR?2 -0&G,GTD->\
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M>Y&N>UBNU4<J(JHEU0]@  ,E
M
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M9]O6U>K=1L^%,C2WIQT9B_G9;JV&WTJE&VB&TE983@D$1D9$.^]V.\S0B_\
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M,QQAQL4_8\6C\$K^G4,QQ[:)_P![; W]E:'_ (""2  !L(
M
M
M                !L%R6S1+LI;U'K\!FHT]\T*<CO)2HC-M1*29&HCY<*(C
MZ8R/IHM$I=OT]BETB&U!@QD\K,=E*4(01]_1)$1_">1NP#\_:DJDRZ<[7@]M
MNA-@.F>29RZP&NUVP5BVUUA(]5<C%=JHY56V8   _0 -#(E%@_21_(-0 & F
MZ7AL[5]XE]V+J%KQ93EW5[3J;X_:ZG:E,9C0I/:-N\YQ6U=@[]D:0HB6C'3Y
M,Z:32(%$I5.HU-CMQ:=2X,:G0XK222TU%B,(C,M\I$1'RM-I3G&3QD^\;D
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M<!+T<ED5;INZD_TOF=_   4    #3)>DOE(85[[]Z5D;%-!;@UXOZESZO;]
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M5\7T"EGJY^VH= /N6N_V4(73"]LKXOH A-J]/H0\@  )
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M(IZ@  ;%
M
M                                     &AF22R>?B+( U >OM4^A7X)
MAVJ?0K\$PNG/[>RIUBR\WM[*G6>P!H1Y(C+SC4       R7I   &F2])?*0
MU ,Y[@  !IDO27RD-<X[P  :9+TE\I#7)'W'D   :9+TE\H U !IDN[)9 &H
M -,D?<9 #4     ,@             !DC[CR
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M4BU%SGP8LI$<J=K2D2%!B/6 Y8BJCX-G*]KXC^@#F0  [*
M
M
M           !XJ,RQC]T1'\!GU  U$7F4?ODDS+Y1@5Q$-REW;7-O-?U0LR
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M48K.T]T2J3<6Z+N6W3Z@BJ.&3AIB]A/;(V3>>CKC\R3P1KYO,0^[9UQ3-_\
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M"EGJY^VH= /N6N_V4(73"]LKXOH A-J]/H0\@  )
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MA0H3&PX<.&REJUD-C&HC6L8U$1K6HB(F2(>AO   Z,
M
M
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M3GY;<=+K"C9<)/;\I<F"(D^@R$^9=" AZHKEML]N<   5
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MX  =0
M
M
M                #3!&>?0-0             >!H+T]/0?E%\1'W#4DXZF>
M3_D+X"[B'D      99Z&/#D[NO=W&HB49?&?4>8 #0BQGO//G,\C4
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M   >H
M
M
M
M   #Y9;)OL/-$>.VCO,YQW&ZVI!'\IB@!OPOO<#PY-ZN^-VFZ)UV_H&[R/;E
M'L&^*;$DRUTHXM.=@S.0XL60MI+BI9(5EQ!&1=^.[] G..\<7KEF6C<CS+]P
MVM;U<=CF2H[U6I%/GNL*R1\S;DN.ZI!F9%[4R/H1YR!9JHBYI=%W>5%]!^?A
M)TJU;V=\(*Q] 3T6JMS:W;W[O34IZVHSJY%L,P;P14DNS.6.[[>+,-1=J;>.
M477^'MHO<6@6T;1K3*Z#_P"7*+;\>54$'RY9=J+#<OL5<IF1*:-TT&6<D9'D
MB/H,JZE9-HU9ZDOU*VZ'.<H?-ZD%)IL)YNG<^.;Q1MUE:6<\I=6R1@TD8Y6E
M))2E*22E*4DE*4D1)(B+!$DBP1)(NA$1$1%W %6Z>6Z^W!,CR   J   !HHB
M41I/J1D9&1]QD?I+SEZ2\XX1,TUT^J%0;JU0L2SYM4;5SHJ$FW*0]*)9_P"6
M;SL1;IJ+OYN;/H,<X  ?.Q&9CL%'999992GD2RPTAIE"<8)*&D$E"4XZ8(B+
M'3&!P^7IMI_4*@W5I]BV?-JC:N=%1D6Y2'I1+_=F^Y#4Z:B/J2C49D?<8YP
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M+'_HR'U#Y87]ZQ?N6/\ T9#ZANJ%[QO_ .K/_0TR0  #T
M
M
M
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M3\O#C2TS >CF.:K4145-K(C%35B0W(CX;T5CD144R0  #[(
M
M
M
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M,:?B3U1JL;\J5-6/>RGP)N88USH%-E+I"EY=B+JJK&-=%5-9]DLQN1   ;>
M
M
M
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M(Z1NRSY\^VZD!+U15RSSVKT)[*GEWG*@  *    #+/0QX<GO]WG,B-7X7?\
M&/, !XDDB+'F]\\]XTY.[KW=V2R9? H^I?\ </, !H18+ \'.Y/\(W_/(>P>
MMSN3_"-_SR %+75S]M0Z ?<M=_LH0NF%[97Q?0*6>KG[:AT ^Y:[_90A=,+V
MROB^@"$VKT^A#R   D                         #U]DGTJ_",.R3Z5?A
M&/8 "_M[="'J<+""(O,I/TBI1QG/V55A_?*-]# ML.^U+_63](J3\9S]E58?
MWRC?0P-V=CW^^G0?Z.H?X"8-0]D1_P!7W3!_96!_[@HA9,VI?XA=.OO2Q_0M
MB/O?_P#XY-*#_P#Q9/\ 3,?[Q()M2_Q"Z=?>EC^A;$?>_P#_ ,<FE'WV+^FC
MCBOLNOW&XC_MA2O\_@&=X+_<IAO^HJ1_@I8E\M[]8*)]Z:=_5&1O V>WOU@H
MGWIIW]49&\#;\G_NLO\ T$#^Y89&  !^D
M
M
M
M                               !\LM+JF7DLGAQ4=]+1^ATVU$@^O\
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M<0>59+VQ'GI@7A"]LKXOH JF_I]"'D  !(
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M8*)]Z:=_5&1O V>WOU@HGWIIW]49&\#(I/\ W67_ *"!_<L-]   ?I
M
M
M
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MOB^@"C<K[\_0G2>0  %@                          T,\%D:C0RR6 !
M!QT;YM6DV)IQ:M0GI8N.K2I;](C+(R0\J(\TZX1NGALNB?\ */S^D\#D'#]X
MDFA=#T1H.G>J==8M"X;1B&VDR0N2U/0H^<E(-A/9H-*$EYSYLEUR,XM\NP'3
M+>]1;=A7O(73:I:ZGU4:K-]J:XYR%I4\7(TI'-S$DD]3Z%W=PKD\1K8O:FQ^
MC:;+M2O/UL[L.>U+4IMV,I!0302#YE.*4HE)5Z2\Y8,ATGH^JV!,780I.B_%
MCJM*SGY:B3E'J%-8QSH,U-*D-T&(CT<U8,1JK=7,=955>]U44T1I-T4XMI>(
MX.FO0A6J1/8J7!]8E-)& \7PX\M(SLAAV#,U:!6:%5H%H:/ATR4:R)(QGP'K
M,0/S<2(D=S$[6X@&YZW=Z6OFF%B:6FW.H=O7!'\0JZ4\KU32N7'6^I+*R)U/
M8FA7O"1K=[1_6[<FW2WU.&\NEQZ8A;AERF:EL02,C+O\DR,AAYPE-F6G^IM8
MINO]SN*G52S%$Y3*4HG";2N41MFI:DJ)"S3CF(E$?7)9\XSPW^-H;UBTE0A)
M)0W4FFT)+N2AMV.E)%[Q%@AS-_RA%4I,AHWD-&N'H$Q"I&!*W1I=\::5KH\[
M4IRM2<2:F'.:B7:MT5+-8W6<^S4351,<[&K#,].T>I::<15R7JF*]+\&2J4_
M(2$I%E:?AZFTZ+&E:;28+HSW.F8[834B1XR(K$;R,-L2(](KW2_V]^L%$^]-
M._JC(W@;/;WZP43[TT[^J,C>!23_ -UE_P"@@?W+#IH  #](
M
M
M
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M7Q?0*6>KG[:AT ^Y:[_90A=,+VROB^@"$VKT^A#R   D
M             &,]XK?>$!_K%H7_  ]>_P#="R"*WWA ?ZQ:%_P]>_\ =#/=
M%_[O\*_UO*_^M#]TO_T5C/\ \.](7_LVM&0G!0_Q(U[X(?\ 2+'*=_\ _CDT
MH^^Q?TT<<6X*'^)&O?!#_GK'*=__ /CDTH^^Q?TT<:2_Y0'9CK^V5 _S21-
M=C1^\?H[_J*%_B8I+Y;WZP43[TT[^J,C>!L]O?K!1/O33OZHR-X&3R?^ZR_]
M! _N6&\0  /T@
M
M
M
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MRJTR=2I*C];78'^E:@RP_P!%IQGD(O/Z!^@27ME?%] 'FF_I]"'D  !8
M                         '<*UOA =5IQQ-":04ME526[7E%#2XA3Q%]B
MZJ02N9/0C,LD1"QU7:M$H5)J58GNM,PZ7!E3Y#KKB6T)1%86^:34HR(N8D&1
M=<GYA1'WD:RWCODWC7G7K21*GV1IW*>B4Q*'%KAT_D:7'EJR9]F7:*949&KO
M\PV7HGD7QL:4:><Y(<M3JA)Q8T1WO=:),,A0H=^=SG7Z&J9A0L.S%2PCI9Q
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MF6Q7P).!RW*Q&P(:Q8JMUX36V8QKG+==B)O!DD  -D@
M
M
M
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M-%L.ETV1IS(U!Q2^*R1E8$JV(Y)9FJY[8+&(Y6HJHBK=415&U%X)Z43["5@
M =-D
M
M
M
M               !Z^T+&<+QZ>4P![ &A&1EGS?1\(\>T+T*QZ>4\?* /,>M
MSN3_  C?\\A["//4AZW.Y/\ "-_SR %+75S]M0Z ?<M=_LH0NF%[97Q?0*6>
MKG[:AT ^Y:[_ &4(73"]LKXOH A-J]/H0\@  )
M        ,,=__P"Q3U3^]K7\X9G##'?_ /L4]4_O:U_.&38,_=;AO^O*5_CH
M!A.DG]P&-?[*U[_+HY@=P2O\2%T??%[^N2!-^(0."5_B0NC[XO?UV0)OQE>F
MG]\_&']:Q/[N&8%V-O[RN /ZD;_B(P  &KC>9U/K=_BQNW[VR/Z%0C_X8OZR
MZC??0OZV^) -;O\ %C=OWMD?T*A'_P ,7]9=1OOH7];?'.N+_P#K!Z*?[/XJ
M_P -#)38O1Z4)6  !T40
M
M
M
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M(B61VVR$'L  &QP
M
M
M
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M*^9$/<  .BR
M
M
M
M                   -MG5BETPVBJ-2IU/[8^5KQ^;'A]L><89[=Q':'GIA
M.>ID -R >)*2:26DR4DTDHE),C(TF62,C+H9&74C(\8ZYP-C?N6@QY/B3]=H
M;$PU<I0WZM":E&9]Q=@MXG<^]RY, ;\/6YW)_A&_YY#R0M*TDI)D9'U(R/)&
M1]2,C+H9&74C+H/%SN3_  C?\\@!2UU<_;4.@'W+7?[*$+IA>V5\7T"EGJY^
MVH= /N6N_P!E"%TPO;*^+Z (3:O3Z$/(  "0
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M "95_P"[EB=R=*^@]P  Z((
M
M
M
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MINU=-9I9J25N<Y%XM'4IOHR9(R1]<9](_0]+VROB^@#S;OWY^A/93R   L
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M#0'PTQ2ETZ I1\RE08:E&?G4IA!J/XSZC[ATPQ^NQKT2VLUKK<VLU'6\Y
M%P
M
M
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MN_V4(73"]LKXOH%+/5S]M0Z ?<M=_LH0NF%[97Q?0!";^GT(>0  $@
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MH&X#;Z5^MM.^]\+^KH&X#H"7_P!C#_HX?]VP   >P
M
M
M
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MM.^]\+^KH&X#;J29'3*<9&1D=/A&1EU(_P!+H[C&XCH&7_V,/^CA_P!VP
M>P
M
M
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MOKX#/AY^'X^8E7]DBV8?;[L_YR@_60]DBV8?;[L_YR@_61%1^A?^&K[E[O\
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M_>7_ $[NKK__ +YBNAQF>$CM<V<;K-BFENCT2[*1:NN5=KL*^8:KQN)]4Z/
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M<O=_\?+J^O@,^'GX?CYB5?V2+9A]ONS_ )R@_60]DCV8_;ZM''I*H0\%\?C
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M8?;[L_YR@_60]DBV8?;[L_YR@_61%1^A?^&K[E[O_CY=7U\/T+_PU?<O=_\
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M<H/UD/9(MF'V^[/^<H/UD14?H7_AJ^Y>[_X^75]?#]"_\-7W+W?_ !\NKZ^
MSX>?A^/F)5_9(MF'V^[/^<H/UD/9(MF'V^[/^<H/UD14?H7_ (:ON7N_^/EU
M?7P_0O\ PU?<O=_\?+J^O@,^'GX?CYB5?V2+9A]ONS_G*#]9#V2+9A]OJT<>
MGU0A8^7QC BI3X+_ ,-;G01VM=YD9]2*^[JR99+./T_CY<%_W5NK/X3VURI<
M>&_=C<^#=\C0F@QH#L&@>O&XDK0<F@'/7^F2G=MDG\*ZKQYLXZ@+JEK[_P .
M=<]_J4O-^R1;,/M]V?\ .4'ZR'LD6S#[?=G_ #E!^LB*9/@P'#6/G/UK7?\
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ME7]DBV8?;[L_YR@_60]DBV8?;[L_YR@_61%1^A?^&K[E[O\ X^75]?#]"_\
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M/N//_P!!J/6U[4_]97\IY'L D
M
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MFENP+>O:UJW-85R.0Z;7:7+DI5W8)F/*<<,^_)<G3  YQ@O07R$&"]!?(0U
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MY%ODHR\^,#E@X<J_[+1<2+27=5!*Y7,\M"*J0CJAX3S?WD3_ (T7D^5^I%T
M$-?!AX9%[\..S]8+>O*[DW4[J%=50KL-Q,-N(49J76)]12WRH4KGY42DHR9^
M83ADDB(BP73WB&UU.M4.@L>,5JL4NCQU=TBJU&) 9/X'9CS2#Z^;(V-O433]
MYQ#35]V<ZZX9);:;N>B+<<4KHDD(3--2E*,RP22ZGC! #F."]!?(08+T%\A
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MBZF?0ARZ-*C3&428<EB5'=++;\9YM]EPN_*'6E*0LL=<I49 #W@
M
M
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MQ[,9<,S=;M.W4.&98,UHI$-*C,O,9J(^@%7YHU=ZIFO/9;779[;U.6 ?3J
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M3;-(FO9/F,Y:Z?'7*41X+HI]2SQCH1XR>!W4,$>&W1ZE0]E^A%.JO:>.M6I
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MMW\;;LCE7$"O;6/B@\8J%P]J%JK6K#T4LYQ;=4<HSLEA3QOTQ,P^U=A.L/\
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MQUJ+O,S:274\\W0_. ?FB.O=+JEK(EELG-DI*6  !Y@
M
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M>P KE7HYDV7YP  !4
M
M
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M^\ =H -",E$1EW&1&7Q_3\/G&H
M
M
M
M
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MV+;]QTZ+2:[#H\5=7IT-EAB/$FO,-N2&6VXR4LER.J6D^1)$9ED=X >(
M
M
M
M
M                                                    !\,ZFP:B
MA+<V%!FH2>21-B,RT%Y\DEY"R(\]<D0^AAAF,TAEAIIAI!82TPVAII/O);01
M)27O$1#W  -N72J>N8F>NGT]<M'M9:X;"I:>F/)DFWVJ?B7W#4Z7 .;X^<"G
MG,+_ .UG#8.9W8_OGD[;NZ>W[O>Z#<  &VR:33I<AN3(IU.D/M=6WY$*.\^V
M?G-MYQ"EH_\ 940\IM,@5!+:9D&!,2UU;3,AL2DMGTP;9/(42,8+VN.X;@
M^9<6.XQXLIB.ICEY384RA3!HQCE-DR-LTXZ$1I,O>&T1+7MV#(\:@V_0(4G.
M3DQ*/!CR,GWGVS3"7,GZ>;(Y   $6"P
M
M
D                                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>nt10002526x6_linechart5.jpg
<TEXT>
begin 644 nt10002526x6_linechart5.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( A(%.@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
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MVO-Y&51H#MYC---(;48S[2G6PTA*0GE1Y'H**I:' .: WP()\>!D9^//[UG
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M$NWZHY,ZP28K30D\-26>)W"@0@\]8'H.:RN94./,;+4B/'D-GU:DL-R&B/\
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M1*4I1$I2E$2E*41*4I1$I2E$737W^I=U_@BY?S5RL!KPY_\ XQ[J_P#PD_\
M^R)-9\M]_J7=?X(N7\U<K :\.?\ ^,>:O]C_ %2?^'_[HD45QGLR?L_BL_T>
MGWG])K6M!_I/Z36M%;2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$
M2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*4
M1*4I1$I2E$2E*41*4I1$/^K]-0V[R]CV[_7+5U_--']T$S2[$W$MAO&F;(U.
M0@I82VH^<IU!/4L%7WU,E6TI!^WZ>3_KK)VF[5=FJO3*,4[I3&Z+%52T]7%M
M>6EWZ*ICDCW>KP[;N'@5B[M:*2]4HI*PU(B$K)?Y+53TDFYG3]+3R1R;<$Y;
MNP?$96%=XENR7=UH7MXN^::Q;FIFJF)17X8DXR[9D04NEV6AM!+R'5GE*SU]
MD_#OP*GP\'6[V:'L T9:FWJU1751[H0S)ND5AQL&6> IEQY*D<@]@0"1W]..
M?:>*)M+SG>!MRN^E>!7$6Z]3EQE-OJ2AP ,RD/$%+B@D^ZD^I]>.*Q_+#X+/
MB&XM:HMCQG76[V6S0T!,:W1>AMACL.OH0B2A*>H]_=2/RUV"*Z6O6>BJ>V7W
M4=IL5PI[Y+6;?0!"QU.*9L3,04,,<8)=(\EYRXAF#T"X]);+KHW6D]RL>G+O
M?;?/9(:/=Z<Z9[*AU1WC\SUDLDA:UL;1W8.T;LM\5(5\H3NEJF;38R85TML]
M29L5!9B7&/*<ZUW%@(5Y3+JU$))Y!X^''H*M"V8^'[O;U2VY:>9OIUNYFX)B
M-XAN.6O%F[ U*3;4-E*5I#RGTJ7U*)/)'8@@>E4@RWP0M_>=6Y%KS+6FY9';
MTR&'?8YR6GFN&W4N'W79#B>>03W%91>QS1'(MO6V?3O27+)?ME\Q>+)9FR $
MH#BG7BM/"4$I ">!P"12Y7RWZ2T9;[/I^_6B^UK;Q/43DV]D[&T\T#<$0U\,
MC6N:]H:9&8=SMZ92V6*X:MUE<+OJ"PW>Q43K134\+?3Y*=[YX9VY!GHI8G.:
MYCB1&[+>-W56K;&MG.ZC;_G&07_6W<=*U<LER3'$"TO6=NWIA%MM27"'$NK*
MNM9"N..WI4L"00.">>Y_.:U  ]/]-:UQVZ72JO%6ZMJQ3B9[&,(IJ:"EBPQH
M:,0T[(XP<#DAN3U.3RNQVJUTUGHV45(9S"USG@U-1-52Y><NS-.^21P!Z NP
M!P  E13>,'JYM6THV>9E<MV5AE9=IS-<MS(Q&)<9]J>OLY<U#<*/[=;U!]E)
MEJ:2KCE)2KWNQ(J5FH\?$G\/W"?$2V[7W0_*KLO'9<I4:58\B0RN3\US8<A,
MMEPQ4J2'N7VV^RCQV[BL<LD/J]ZPQ=]<?4?/_#9N>3X)L=Q?;QMAMTRRR<;S
MC]5MDNM_FQ)%W96Q(:"T-WMQ;B_+4KA:E)Z_>KW6_E3EP^3Z;5?;'Y$I;]TB
M0G'WWW''E1GLI@1UI+JU*</+2BE/O<I![5)\]\GPW+:LZ$JV\:_;V)V3Z9XY
MY;>"X['Q5-NC6YF.]YK(D>QO)]KZ2VR1YZ%<%/UFKK=8? [NFKWATZ4[&[GK
M4(LS3.Z(FMYO\R!7MS#-[8NC+'L(6 @AIA+!5R>?QCWHKI< !@Y(<3X],>9Y
M_(P%8;N7V4;;\=\!!_)+1I[;F,EA8IC-TBY&\3(O+,QZ3%>=<3/<ZI !<)(
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M=O\ ;[=.@!SR_;+?,@]?'/1[5'6QU\'UZ>KJX^/'UUB5Y_\ )KM4[EN*U,W
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M''@3@?CQ[O<LV7/=>=,M)L9LF3:G9?:\0MUYML*8Q)N<AF.VXN1':=6$EY:
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M-?\ DKJ('Y-Y_8,U/_AZ3_[4F5+]XB/[4+63^ U_Y*ZB!^3>?V#-3_X>D_\
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MKU:45,_N7#9@QX[+,=H*2U'89CM)"U ):80EMM(X/P2D#GXU8!O@\,O:IO\
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MSJZ_:1CEH#_5SSU!X0P[U<]^>OGGOS7JFFT-(2VVA"$) "4-H2A"0.P"4I
M '8 #T%%4NR,8^9))^'/@H+WOD\7AK/:AG-U:671,5=R^=58PG*[Z+(J;YWM
M(7\V^T&#TB3^$\OV?I^ J3/4?9WH!JIH%)VTY=@T*5H_(@-0!BS)]F8:9CI
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M5&G1(DV.OLY'FQFI3"Q_RFGDK0KCZTFNABX-A=O?$NWXABL&6#R)43'K3&D
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M*'&BMM76WQ+@VGV=I+9*6Y;+R4_B]^ .]1Y^)S@^$0MDNNLB'A>)1)#.-O\
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MHRF(D9A9BQ^5LL--J/X(>JD)23]_UUV=67$$Y#=H\@<_>IM! P3N/F4KXO\
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MY*'0HF;YDTI=Z71VZ>!ZT1K<D \ ^)X^KA9^%INK%VLUKO+!2(]TML*YLDJ
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M"TV">5J7)\M "0?7D^G;IO:C!+5:W-- QTDT]%9H8HVC+GR24%,UK6@=27'
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MZD7))F7J^2<5MER"'93##OM!FMJ][NMMP*22"?C\?JKV31MX+Y-N&M:../5
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M4HL]YDZ1Q+HY?)4:+#O29Z%^>AOK6MR/^&4 WU!1X(Z@>,I%W3#3E^YIO+^
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MX;^&;%MKN(:*7M-MSO(8#LRZ7V]W&V1UA^YW*8JY/K1'D)=2TIN2ZO@M\<D
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M**TE*4HB4I2B)2E*(E*4HB5'OXH7[1_7G^+;_P#(.5(14>_BA?M']>?XMO\
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M1TDCB^21Y<][B27/><ESB>223DDKZ;8QD,3(V-#(XF-8QC1AK6, :UK6CH
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M#!;(\UL$CZZ*Z<[7;PT  ;<  YR,8QSC&<_W<9>Z"2.XX()'Y#QS]];JV(!
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M*"E9V/Z\=AWQI\CWA\&'>?\ 5Q]M%$=1\1]ZL4^3>_VL+2[^,F=?YS3*GRJ
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M< <#R'7\_)76M#1@9^9S]25\7_Z$[_S+O^37VKXO_P!"=_YEW_)J"DHO=/\
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M1;.;>JT-Q(3ES=)MR;LT](:++*NIJ.Z@J=*NRNU%$.&W!'.78=Y$XZ=,?/\
MPLA^4*W[(+_N"V2[&L;R2YX;HMFD^3:[]&M]PDQ3<K9;S 5':7.8=:?5YC?N
M=?F$JZN3R35%/'+\+70+9+LGPK4_;?<<FP.<'L+7F%N_5C?)2\OD2YML3YS:
M'YW+(:<=<<(:2KD$@U>-XO.V*UZVZ-;4LEULU<B[?=[^!Q@QAR941NX,Y!=8
M?L3*RNXAQJW1^L,(Y4XYP>H\D\5$?XK>GF_FZ;.L-RK>EN2QW+H^.77$X."Z
M:6)S'Y<G((CMV@1&GG7;'*>>4I#"67^'FU*3^*>.#12:?8P< $YR>O()^SZA
MSU6:YX4:W'-A^@#CCTA]QS&VUK=E/N2'UE;:%$N.NJ4M9Y/[HFI'*CV\+NR7
M/']CN@ELN\9R)-:QF.XMAU"D+0A]AIQKE*@"/<4GU J0FBLE*4I1$I2E$2E*
M41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4
MI1%335['+WEFFV:8]CTE<2]W>PW*':I+9Z5LS7X3S498(([H>6A7<CTK!/N>
M7>/YX7F09!*N-MO6M.C/S_=;@Q'2(,EYZU2+@_);8]T2I/2AEP-\=^P[ \UG
MVW*XPK3!E7&X/HC0H3#DB2^M02AEEI"G''%$D !*$J42?@*A%W<^.YX=VW.!
M=;3D.H-FS_*8!?CG%H]M-V\V0T5-KC*6AF4@$K'01TGN?2BFTGH&AV<<$>_S
M\%$3MZ^4=;1\^R:Q6#>;ME@Z09W >3'G9'=\/,U)EJ(2IYQ?S.AOGK'/*EGU
MY!K*0VU[M=M&X^QQIN@>=8YD%L,=I;5OM+<6WN1T+0"$&WM^6XC@>H\H?36
M/O4W\2_%1G7#3W:YX>ST.;=I"66,_BQEVM+P+@\N0 JUQTHZQW)\P>M2Q?)Z
M_"-WB;1M9;QKCKQ%NV(8[?66'8.(R;TJXQTI5&6V1Y27U(:Z2L*_H0Y/;[2F
MYC0W).T\8;G/E\_W+-$I6QM)2G@^O4H_E/(K?164K@W!AQ^',;9<#3CL*4RV
MX>.&W'&5);<Y/]PHA7?MV[FN=7 N<5R= G0VW2RJ9!EQ$O)'*F5R6%M)>'<'
MEM2@KCZJ(L.?4;Y//K%N(WM:TZ_9!ND3B]LS*5$7 584L/W2,EMEQE#:G+=-
M3,CE'*4>]T%0![$5:[L\U%W,^%SXLJ]@&<ZQWG5K1S4:UWI$"5<RZX^V8]@?
MF-D!]Z3)1^'<3QW'/'(/'I<%K'IMXOWAQ;TM1=7M$L>O6YS0_426J1"L3EW8
MMS4%267/+0AN2M];26GW4D@(2%]'?GFO8^'+X>.\W=)X@TGQ+M]V)G3IZU>8
M,*P&0[$G!QF5!7;I#8D1ND-AIOH/*FQSP0.**Z"=IW%I:6X XR#P!TYXX^75
M6@^$ZS"C^/GN81?EN*OB[E#?M/G=?F^6_;I+G'?OP&U#U[<"NTWJ>2Y\I;T?
M38PLW-+%W-S\CJ#G/ZFAY?7T=^/HY^ZJZ[^]AF]W9=XD$_Q%=D&GBM5+1EH_
M\X\+CR(D#V$LV\6^-R](ZRZ%*65\!OCMP>U>D\,+8-O3W%^(Q>/$PWOX,K3J
M9&"/U*8G*?BS@\ERWJMTA/F1^CRDM ))!0.H=@:*N0/6W#V-H'CNQTQ[L^6/
M@K7-C'D'Y2EK)\_%SYW#=L^:_.Z^OC]3B_-Z0KOQTGN3\/R5\_%6,-SQ^]LR
M+(%&\INL@W,,=7G=/S?&Z.KI][CHYX[\<?5S5T_B8;!-Z.V3Q%H'B8['L(_7
M)E7'S#E>&1WHL(1PF FW1QYLGK\T. J/9! '8\\UYCP_=AF]W>-XD<;Q%=[^
MG"],+3C2FUXYB4B7$G"2XN!["\4K8Z/*"'$)<'X,#@\#CBJ8^_/VY08X=D8#
M ,9&<C'&./\ !3[>(KA&_+-M(\)A;%=01I_F[-KA?/4Y<"#.+R"Q'+:2B<0@
M$(ZQVY]:QU=W6A7CVVS;WJ).UBW"MWS3IFRK7DUK^9+$P9<5++A=3YC2BXCL
M%]TCX]N]9O3<=MMM#:4]"&T(:0E*B.EMM(2A/(X]$BH_/%!0$[']>>%+'_FV
M_P#NU?\ J'?K^OO]-55MIP1P#R.H5C'R;W^U@:3@>J;OEJ'^_/5,1?I*9:_^
MF\%J^COVJ?*H#?DWO]K"TN_C)G7^<TRI\J([VBE*4HHI2E*(E*4HB4I2B)2E
M*(E*4HB5Y/.<D<Q'#\GR9J(J<Y8+)<KLB&CGKDJ@0GI26$\ GJ=+00. 3RH<
M=Z]97PDLL28[S$EM#L=YI;;S;@"D+:6DI6E8/(*2DD*Y[<<\]J(L)'+_ )63
MG>)9#DMHG;/,BC0[#>[G:1<Y\VX08CR8$YZ(EXOR(3;*0Z&@M/O\>\ #W%<[
M /E7V=YSE^(X[$V>9&Y"R:]VZU?.\*9<9L..B;-9B*?\]B$ME0:\TK5[_'ND
M&KG_ )1].VE89LCU$P;'4X#9M9;L_;W+3:[/&LXNKCB;@AZ6IUZ(E+S*^@E2
MNO@JY(->X^3OSMHF<;$])<.N2=/[UK/8?G!R^VZZQ[-\\,.JFJ=BJ;>E(+[R
M@@=8*"2D <?45WU-F[8>N.IQX<_/GY\+)QQR\+ON,X_?E,*C+O5FM%T7&5SU
M1U7*%'E*95R >IHO%!Y'/*>_>L(3Y2IN0U;UCW-Z'^']I_?+AC./9A=_8<I5
M!E.1U79A]R*ZE2W6UM*2(R'%'I"O> X^-96F[SQ -K^R'!7<HUGU L]H1%B$
M6W'K8\W<[K+=80$1XJ+=;U.RT=2PAM/X'@ ]0' K /\ $>UBW,[Z]<[5XBFB
M.W/)L:TLT>O,>XVK+'$RW9U\@HD-,K=3:GXJ):0ZB/\ !L\)7SZ>A4C'(<>G
M@3TW<8^TA9+FCGR9#8A:- (&+9K9'LMU)O&-Q94C-G9MPCNMW.?"1(:68WG$
M*\AYT)ZNH%71R?6H2?#Y1JOX2/C02-E/ZK[G?M)\YN*TK@R93KL9Z,F$N5!;
M89=>=]F# =1SY83YG2"H>E7]:4?*OM$K=HE!9U$TVNENU=L5B:M)L#B9R),V
MX08HALN=/L@Z%%UI+A3T\DDCL:LR\*W3/<#XJWBHW/Q$]3<.NV+Z:XA.\Z";
ME%=C)?CO1%PX:6 ^VPI:4]#?=L$?8.]%(!X#]^=OB#XG@C'GT\/ERL_J*\'V
M674CA+S+3Z1]"7D!8'?Z.JN37'C,I9:;;0.$---LH'_(:2$)/WA(^RN1164I
M2E$2E*41*4I1%H2 .3_XYJRS<#X@.UO;+DT'#]8]0$8S?KARJ+#5!D2.L-@+
M6>MKW1TI(/>KT'?Q1_A)_36&3XWV+VS,]^^AV)WA*UVN_P!S5"G)2XM'+3R(
MS2A[A!'*5D=O_M[IH33M#J:^?1]RFJ(*1M%6U4CZ4L$W\EA,N&]XU[>0,8(Y
M\PM+UYJ&OTS8OI&VQ4TU4ZMHZ2-E4'F'^53-BR>[<QW&X8.3\"J*^)GNOT-U
MSWN:)ZIZ:Y>Q?L*Q6])DWRZAE; BL!4;E7E.'J5QT*) YYX-7<[]?$.Q3>ED
MNBVS?0/.7X> Y@FSP]1,KC(6@OIMZ(+@AI:/EN(0M2'(Y*%]PHD\C@5?_9O
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M0"/2J,Z;;>M*-)LER_+L(QI%LR+.76'LENCK[LN3<%QNKR?PKY4ML(ZB $*
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MSW27<S/Q3$7=;<E%R,Z_WBZ0')O7'E*C-%-NFK46E^60$D(!)X(][BHI-7O
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M%_FZ:NN_FHOC)][5:;_.R?!OW!>NI2E6E=5O6X._:H6+'(\C3&*J3=5*_"I
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M5;X:G_9>0\8S)=Y['JZ^CJ^'T_ZJU:".[.NLM"Z[/+:>*&<N]'B_2!S@#'M
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ML93;G2X5^>E3(]"5#TJ(7#?E*VU7+,QO#2<1R:-I9:W+BR-3D6:^O6M]=O\
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MQ\1OPGMOWB)6BRR<]8<QW43%E/+Q3/;:Y(CW&T.R%)+JPJ&MEUSJ"4IX4X
M/CQ4JG%..?6B9.<YY_/Y/GXK'RV0?)_M -JVL$/77.\MN>MVI5C4DXO>LA=G
MN?,J0WY)#<>9(DM*/E!*0>$]T@\\U<)XCO@Z:#^(#/QS,[G-?T]U8Q1#R+%J
M#:%2FKA%0\A#2TE,-Z.IP>2@-CK7[HX J8C@#T K7@'U'-$R2<YY4-?AO^#;
MH;X?U^R+4.'=9.I&KV3".+IJ#>5RW+@M,9"FF@V)CSZF^&5>6>A8Y [U)/N#
MT5LVOVD69Z2WZ2J):LQM[L"9(2DJ4VAU"T%7 ()_&YX!'IV^JMO 'H.*40DD
MY)Y_<HX=@?A^:?>'SH9>](,*O#MYLLP7V=(E>4ZTL)GN2I;Z4I4M:@4^>H)Z
M3R2!P!VJ,[PQ=GMUP+Q!]X.NEF:R&/IEDERL:L9D7:=<G&+B^VT^U</9H<YP
M^0EJ0I7XB %#@CD <Y)Q2D@@@$$$$$ @@]B"/0@CU'QKB18$.%U^RQ(D4+/*
MA%CM1PH\DDK#24]9Y//*N>_)^-%3S]_Y_/Q7)0GI3P?B3^?Z^]1H>)%X:^G/
MB+X;AN(:A7IRS1,.N\6[0W6VG'?,=C3H\U*2&UHXY7'2.3R.]294XY]:(J=:
M5:>6_2W3_%,!MCQ?@8M:8=JC.D$%QN'&;CH4022.0V#P2?HYJV+?_LDPK?OM
M\R#0#/+DNU6"_2;=(D2D(6M256Z8W,;'2VI"NZVP/7T]?C5\5*(HRKAX:FFT
M_8 =A#EY<3@9MC=M-U#;OF>4W*$D'HZ_,_&''X_-<?1?PS--=&=BTK8[9;T[
M(PB3%N48W-3;H6E-R?=?</0I9<[*=/[OO4GO ]..WT4X^'PHJY/3/CGY^:@K
MOFTC3/PTO#+U'TKL>F[NX;![,W<I=SP;S'H;MVCWF?(ER7&U%,AU*H0>6Z.A
M)4I20!WK$=TWD>#$QIMJ1J%>'-3\4S*6S?&;-MN,/45R!!R"7[8PRTF2E*8K
MR$W!:'4CR"C@ =DFOTJYL&%<8C\&?$CS8<EM3;\64RV^P\A:2E27&G4K;6"#
MQPI)%6?7/8+M*NN4#+YNB6).7P21*]I1:X#;*GPL+\Q4=$=+2CUCJ/*>YHI-
M=C(.>2"<''B.,8QY_P""Q5/!Y\+#*MS_ (=6485J@_<]+L*U+S2'D5NM\N"]
M[1<+5CV6JNUJ:?8<+#[0]F:93U.)Y5U<\>M90VZO8CIWN@V@O[1+Y*%GPMZV
M8U;C)8:7V&.B-Y;H;:4A7+ZH_40#VZCSS5[MGLMIL%OC6JRVR#:K;$:0S&@V
M^*Q$C,H0D)"4,QT(;'8#N$CGXUVE%0N).??D>X\<_8%%9D_A3:$9IL,MNQ++
M&F;M@EHCANV7=;*T2H+Z)29;;\=85[0V4O(0HA#@)*!R1WJ,;?WH?IAX?_AH
MVS0/4[2:[;J]%;6IZ--EI=G1[MB45^XI7&?CJ83+N3XC]0< ;4D\,\< 5E&<
M#TX[?17G\EQ?'LNM,JR9-9;;?;3,;4W)M]SAQYL9Y"@1P6I#;C?(YY!Z>>?2
MB;CQY;MWES[CX+\S/4FV>$];-GF4HT4O6IFHVXS-Y%KBZ>Z8SK9GYBX7*DSD
M,RHO$]#D)]*4NA/4XRE*?+)''J,V_P #;1++]!O#CT/P?/;:_:,I$:Z7&;;7
MP4N16+C,,R(A0(!Y\AQ)((' [5=OCNPO:?BV5)S&RZ*XG%OR'S(1*5:X+C3;
MRCU>8AA<<MI(5W'">QX/PJ[^-&8B,-1HK+,=AE"6VF6&TM--H2 E*4-H"4I2
MD    #@>E%5SL@ 9\^3DYQCPP/L"^]*4HH)2E*(E*4HB4I2B)2E*(E*4HB4I
M2B)2E*(E*4HB4I2B)2E*(E*4HB4I2B)2E*(E*4HB4I2B)2E*(E*4HB'T//I\
M:QZOE&JMOD/8S>+UJ_.1 RJQW*T733ATLNR%KN<&[1Y8:0RUR%^:^TRWTJ!!
M!XX(YK(4/H>?3BL<GY2IC.E4O8O+S/4%N6[/PB]V&Z6!J+&ES/:/(O<61(C+
M8C)6%"0ED-$K0KI"R>/6BDSVF]>HZ=5"AH+\IAW+XCI5B&,7_9;>LXF6.WL6
MIG)HMH>@,W.VPFFXMN>1&8M7EH_8C;9)')4?>))-3+^%=XT^J._'7:[:59=M
M7NVC]OMZ&U(R&:Q(;:?*XRGN 78,<>Z4])]XU'3MV^4E; ,8TGP[&,VVZP,6
MO>/V6!:WX*L+7<ENF'%9C"4J2FS*ZE20WYQ!42DK(^!J7WPZ/&)V?;X=7)FF
MVB&GL/&LC80E2Y[&*JLZW!Y"GN"^JW13V0D@>^?]%,J3L<_H]O7]8G'3]Q^O
MW*>9"NH<\<=R/R'BMU;4J"AR/I(^\'@UNHK:5H2!W) ^VM:ZV[Q7YEKN<:(\
M8\N3;9T6,^!SY$A^,XVR\!\2TXI*^/CQ1%81N>\4393M!OGZF]<]8+?CE^40
M#:(D=R[3&^0#^$9@EQQO@$*]\ \<_754MK^^+;+O$M,N]: :F6S-(L(-&5'3
MQ#G,>:2$ P7U"3W(XX".P[^E0&:4_)_;#>MV>NFYG?/FS^M&/Y,\Y/QVW723
M(MD"QP&6)'FI 3*+ \IDI[]"">C[ZBM\.7%<2TK^4 YIISLTN-R>VZ6R9Y63
MQ(<V;-L,9:+4Z?+4IQUR,GRY <3VX[@\?113#6D'!.6MR?+KCX_!9CVYGQ$]
MI&T*^67'-?=5(&#WB_AXVN&_&=D+?$=(4[SY0/1TI(/O>OPJENC_ (O&P;7?
M42Q:5Z8:X6[(\WR1;R+/9FH$EM<M3".MT!Q0Z4]*>_<_Z:PW?&JU6V^ZB^,Q
M8\2W).7J[:%Z5>9^JNW6=F[R5253[0A33;;=J0J2/PZ."6T$_$U*?X5V&^!#
MJCK[8,NVK6"X8IKY@;$R19K'?+ADD64ZY[*M4A:(UZ+(<*VFRYT^6HCGBBJ6
M -!]8DMSP.!TQ]_@LD?=)OHVQ[-[) R#<!J5;\,A7%*E0F.GVZ?(2GIZB($=
M1D\#J!_%'([^E=?M3W][5]Z4&YS]O6IL#,DVGRO;X:VU6^X,>:2&^(,E0DJZ
MN"?=0> .2 .*PX<NQ_'/$I^4+W71[6]NY9+HOIPX8\;#?G"9'MY2JR$E*TLK
M"/>=:Y"E(/<C[*XF48?8/"_\?K3?$M (L[#](-3)'LDS#6KA,DVYPL6AIL'R
MWG%(/#KI7^)1-@QCG=MW#I@YQ@?5[_W+/U]:CW\4+]H_KS_%M_\ D'*NFS[6
M[3;2FQ6O(-2,MM>(VZZ0XTF/)NDMB*VXIYI"U!)?<;!*5+ [$^HJ+GQ'-Y.V
M7+=G&M=AL6L>*7&Z7''7D1(4>Z0'7WG#'>Z4-H1(4I75V] 3SQP/H*#>H^(^
M]4U^3>_VL+2[^,F=?YS3*GRJ WY-[_:P=+?H5D.;N(_Y3;F22UMK'U*20H>O
M8U/E15=[12E*444I2E$2E*41*4I1$KP><ZEX'IQ:W[QF^66/&8# !6Y=+G"A
MND<\<MLR'VW%_7T)41\>.:TU,SFUZ<8)EF;WA]+%OQJQW.Z.J5V"G(<)^0TW
MS\.M;83SZ=_0U^=W"M>\WY0YO2U&MMEU"R# =NVGM_D6MUZU27FHM@CMOO1
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MZWBPI:_=))()[BBD0 W+3G)P3C! \OG\>1]DUK+266T-H2E*4(2A"4@)"&T
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M7[I[^_A_*LU)>?3[Q^D5&AO0_K]T]_?P_E6:\VI_\TR_UM/_ -1$LMV*$GM
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M6*_)O>_A@Z4#X,7K,(:/^:B9!)8:Y^OH0GD^I/K4^50&_)O?[6%I=_&3.O\
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M 7=Z**2H]'B?W-/+*(VO,LS(H(GN W;IGEK&L:[(WN(&.2K*=TI'Z^^!]O\
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MG&#T-("B>2._2.35PN@VU#0/;;#F0M'-.++AS<Y05)>BQ8ZY;A"BH?LLM^>
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M#7] 97(ADA;C84AQ!)'-8^'B 0=H5CS7:-)VW9IGVK^0/918Y>IV>W*VY<_
M@S9-UMCS08C7,2(C*5O+<0KV=20GCWAP.*_1]ULV]Z0[A,<_4MJWA-JS&S>B
M(\^.RMUGW@HEA];:G6N2 26U)YX[U1VT[!-IUEPZ#@L#1O'48];I#<J''<BQ
MWI3+[3Z9#:TS7&C(Y0ZD+3^$[<<44VO  Z@CR\?QS\UBV?*27Q+O?A=RHD:X
MSH[QL90N';94UL#FQGE]++:PSQSW\P#@@_1S5WORD2+(F>&5ITU'A2I3RF=)
MR&HD)V0\D)E6!2N&FFU+;X'/4 !QQP>PK(JU"VUZ,:H,X?'SK!K;D3>"! Q8
M36VW3:/+\OI\@N)41QY2/3CT[?5Z+4S133/5S%XV':@XI!R3'8GL8CVR8VVM
MEH02VJ+TI4D@>46D=/ X'2.**(=C9YM)/V@]./+^]84?C5"7;?#6V%9*NUW6
M1:,938;G>G(MNF/N08L.?9Y#SCS#+2W$$--+("P">.U52\8/=#I/O)\&W!LO
MT+N5WR:TV-C3JVW3_@6Y1Y,:5!NEJA/H##[/GK"'V'$\A/  Y]#VR[\]VY:-
M:EZ<-Z59K@MION#-1VXS-CE1V5M,,-A(2VRI2"6N.D?B=//'>J<6+8YMBQO3
M!6C]ITKL\?3U3[<A6.E"'(Q=:D"4VOA22#TO@+';MQV[T50[ ;YM.1Y=0?CX
M>:A+A^&E*\1WPTMJV#-:O9#HZYB^-N*7.MK5P9E2C)3&7TNM1WXKH*.CCA9[
M\]JM;W(>%5*\-+PM-Z;3VM64ZTN9Y;<5+:+C&N<EZV_-LI2?V,R_(EN+4[U<
MJ#:0.W>LNW$L2Q_"+!;L9QFVLVFR6IH,P(#"0EJ.V  $H2D) ' 'H/JK@:@8
M!B6IV*W+#,WLT?(,;NR4(N%JE)2MB2E"NI(6E0*3P>_<&BIO.1Y;LX^>5B(^
M ;X9NS'<ML'P#4[6;1E>29Q.GWQ5PN=T>GV]Z1Y%W>;8ZH+@;Z A"4CNCA0[
M^GKE!8QM[TAV\:*YSB.D&#VO#;&WA.4(]EML9E+SP%DGE(=?;;2\^0?Q0M2C
MR1QWJJ^EVDV :.8O&P[3G'(>,8Y$4XJ/:X+:&V&U.K+CA"6TI2"I9)["JA28
M[,N-(B2$!V/*8=COMGT<9>;4VZ@_4M"E)/U&B.=N)/./ $Y7YS?@O>(AMW\/
M_<SO+N^X25DU@BYMF;QL#[>*7V8E_P!@NEP#_3[+$6..> "3P0>?JJNGB%;L
M;GX[VYK;AM[VD8%DT[3; LH-SRO-YUJNEKAOQVIL2XMJ4BY16&T]*8ZDCA?K
MW]?7,7N'AW;/KI.EW&?HCC,F9.?<D27W(452G7G5J6XLE3)[J4I1/VU732?;
MUHWHI&<BZ9Z>X[B:7."MV!:X+4I7!/ $EMA+P]3Z+XX[<44M[<[@#NP.IXR
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MH;;2/1+3:6TC[ D ?FKZTI5%5<*X06+C#E0I*$N,2V'8[K:QU)4EY"FR2#]
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M93,?"X%[N^9.OI%XFN6Z9X19L<U,T5R%+=M=E1T9 TJ;-1)A(?4F*Z&F8KG
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MYZJ;BE=7 O5IN:WFK?=;7/<C'B0W GQI:V#Z</(8<6IH\@]EA/I1J]6AZ8]
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M>EA$GQP/$JU7W7:Q[>-M.@B=0+AIQ=3"]F3>[;!(:*GO+42^T>ZFVNH=R?\
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M6S>)C*7$**%H+D>WN("DK!203R"""!7=_P"^<<<_XJ>H/_9N0_\ =5%78_\
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MX)X<6HGOS_IP]KN-<V_VBIT[6:KU';Z:E@K;U *H51B?5L<UM(8W;(=T9&9
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M8X<% ?J!O)W[JQ.Z,W';M+QZ!)7'A3KPW>(\A4*'+<#$IT-(;ZE ,+6H\'D
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M\5+!_L->XI117A_UL]./[WN$_P"*E@_V&GZV>G'][W"?\5+!_L->XI1%X?\
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M*?7S-9>*>7>H@<\#GCGM5;_UM=.O[W^&?XKV+_8J]O2LN &M:UH :UK6M &
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M[;M_VX#='HU<M%M,)^I^E&G<V1<V+&W<6H5O=F!+$J.933G+<@(F-)4D/(4
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MK5K6R0II=I7,MC3 @N>SJBOK26W'&OPC9! X'![?313:[&YQ(R> T>8P0>G
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>nt10002526x6_linechart6.jpg
<TEXT>
begin 644 nt10002526x6_linechart6.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( AH$M@,!(@ "$0$#$0'_Q  ?  $  @$% 0$!
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MU7,6\4_??OC%0Z#_ (R]5/P!K_5<Q;Q3]]^^,%>_U;_(;^Q;@  5B   B
MB   B   B   B   B   B   B   B   B  _*[+9:5RK?CH/W./MH5_%4HC!
M%^H!^'S\;_Z5#_\ YIK_ .['Z67FWD\S;C3A>]IQ+B?K29E^/OD$7*  "(
M"(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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M  $0  $0  $0  $7&ZTV\VMMQ)+0XVMI:3[*0XDTK2?R*29D8A>XF?#WTFU
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M  *Q   1   1   1   1   1   1   1   1   1   1!UN[?^;5R?Y-UO\
MH#P[(.MW;_S:N3_)NM_T!X$5"7@H?KW^YS_*)?\ 1YHO\L_%/]^O_.,4!N"A
M^O?[G/\ *)?]'FB_RS\4_P!^O_.,4'H/L'[%?)]8_8W_ &0N4  55B   B
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MDE=_K(\&-2(B[$"=1UK?;[!^WU0B))8+Y3^L:@ *U   1   1   1   1
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MO17)4]S^9/Y!O'YX[S;[33S2N9M]EEYM1=E-N()2%$?N-)D8_0.64(H  "(
M "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "(  "( TR7O+ZPYD^\OK!%J PRW4[Z-!-H9V\UJ[<S=*DW(XMNFQFVG
M9+RC;6E*S6VP2E()/,1^L1=.I#(#2'5FS-;+"H>HUA5-NK6S7VE.P)C?JDLD
M'A9*2H^9)I5TPK!_(,[JUAD+++H9&P2.+8YBQPC>X;V&NUHD:/O]RV4V&RM?
M'5LO/CKD6+N2/BJ7Y()&U;$D>P]D,Q:&/<TM=L-)(Z3\%Z: TR7O+ZR&N2/L
M>1@6M0  $0:<Q>__ '^?L/%-PNO>GFVC22[=9=4*PU1+-M"$J549SA&HN=23
M\NRE)&2C4\Z1-D2<GUS@5?*CZ3W=5:56[HTEV5W5?^D=%F/LKOYB=5(\>3$C
MOK9>ELQO)'XB4)0I9\AF6._0%4-)[@>BMW@(Q^&EQ0=#>)3IU4[LTP>*F71;
M!M-7E9S_ (I2Z!(><6TVTXI]+:W#4M"R,R;+&,GW$FJ7$J,R(TF9=R):5&7S
MD7;Z05""#H]B%O ;.=//R93GW<Q<W\7N-JGDISZR.G<S6DB+W<W['Z< BY0R
M7O$='$3XD6BG#LTIC:@:H2%SZQ6UFS:-K1&WWI%PR4O)96RRN,AQ232XM!9)
M*BR8BZVM>D;:3ZR:W6IHSK1I)6M YU]O*:LRJUY50<CUHC0E;:FU2(D=M'B$
MMK&5G\?IUP1E4-<1L D*RX&?9[1&?Q&N)SHCP[=+Z+?.H+AUJNW>VA=CVG%\
M54NY#6ILL,> EQQ)?=6S(_#5WZ>W&!FQ[T@;2'=+K?3- ]2M.:GH3?US859T
M&O.35IKS7@^8-;;TJ-&:;+P30K!F?QR+ )TG6]=OBK$8#RW5;6&P=&K(K5_W
M_<E)MZW:+37ZD_+J$Z/&\5#3"WVD,)=<0ITWN4DEX?,99$7G#8XP.F_$@U,U
MML?3FTETJC:15")!9N14Q;R*_P"8<=:4XW'6A)LI0IHS2>5$LC(R/'4$T=$Z
M[#U4RH#0CR60,\?29%]8*BU#(@YXCO&VT=V(:B431FC6G.U?UEJZ9"W+$HQR
MTS(2&&DR#-Q<5F09<S!^)U2GL9%DQWKAI\8;1;B&S+EL^!2'].M6[1\NFOZ>
M514CX0BG))2FB)<IIA3F6T\_J-]"[_*5>EVMZ.O7[OC]GS4Q@#0E$99+MU_$
M([.(=Q(-#N'IH[4]2]2*S2ZA6V30FB66S4&OA.KN*=2TM/A,J6^SX?,2C-3>
M,=2Z9,%0 DZ'<E2* ,-MA>[BE[X-LMB[CJ/;R[6I][?""H]&7(.4J.W"DFPE
M1O*2DU>*6%8,B,LXP,R01 '";Z"2I1J;(D]U&XGE+]\K.$_2-"?0:/$)2#3^
MV$LC:_E"]4OEZ] 1<X#B:=0ZDE(6A9'G"FUDM!X]RDF9=/;U&UQ]MO',MM&<
M8\5Q+?-^]YC+/T BYP'%XJ<XRG/NYBYNV>B>Y_[F(O\ ?GQ&6MG.J6WW2*EV
M)]GMVZ]3JK&I<)J><5V"S2%->:?-*4JYR2TM3F#(NB?<8(!OL%** ABT6XO-
MM:N\0*]=A[>G+E*N&RZ?1I<RYSJ2G4.N56D)JBF?*>&1)\ S-DSYNN,^X3+)
M?0:N4UH2KF41)-:24?*>/BYR"+G <#C[;7+SK;1S&6/$<2WS?O>8RR?S#>3B
M35RY3GW<Q9[9^+W/YP1<@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (
MJM/#3X/>INWV/K;M0W*VK1=3-IU7>MR59-3FPJ:S4Y;\!SS\DU3FTKJS9-34
MH]5;Q$M)8QRF.[\4_A^[G-Q3^AFTO;?9M'M/:FQ6(DS4&OL1:2;]%B4*=#J-
M/9:-QI$Y1R'(YM&MI9*^^4?<672+E(\9/'O/(A%XY/$&U(V';7OL@T=IRW]3
M[UF1:1:L]/+R09<F<S!(UFZE3/KJD)QXAD62Z KP7%PUHG8U\-]AO\._ZU+;
MI)8D#2[3BR[!@OD]'M:@4NE>*X]S+==APF8[RS-:E*ZN-J,B,^G3YAZ6EU*C
MP2D'\RTJ/ZB%#.U('I05\6U1;SI59?*E7-&;JM/(FZ!DH<U"9+!<IGG!-.HQ
MDNOUB6CA-VWQKJ5KS6WM_%0=DZ5FAKX,0M-+21*\LHG/[S,W/TXTXS] *A;K
M^,T_8=_#]?K[O@59H ;4<V#YN_,KZL]/Q#<"M52SC )XH^Z?5#6/;MH;3YVF
M6U*QZ&<Z\-26'XJU7%&*EN5 F66%>%,92EUMQA1LK/)*Z]!XCZ(A!*FV?NMI
MO.MURGW%2X$A]:E*6_*AU";'DO*-63RZ\VM?4S^,+6.ZF.RC;[K&XAIEM;UE
M5_Q'&VT-N.&FD3,>*XDB4YCV<QF9=<>T57O1)<? N\7!I/\ Y>*[&1__ #]4
M_=^/Y063>XW#6M%OW^O]2Q:XQM4E[Q.-7H1LWO6LU!W2RVJFZJHT!B5(C19:
M)$*/,6T^F.M/BDI:3+*R5CF/&!YCQ7-NVGO"OW_[+-7=L<>9I_!NFJ0Z;7*5
M!J$Q424EU%-I[BGFE.>$X;GC.+]9!F1JZ&.Z<05IC2;TCG2;4.\7SI-L7-4T
MH@U28GP(9K32F&C04ASD:/[HLDF?/T,QV;TDRXJ!K%N^V(Z;615(=PU]%P4Z
M6_&I$EJH+:8*1291+641;W*7@IYCSC&#S@R,%D;_ .K'N+3OMV^9^';X_$#[
M%ZGZ3AKI7[Y/9'MUI5P3Z=;FKBJ$[>C<&4_&^$T23H\I3;BF'$*Y?T0I/<R,
MO8,<^-WP[]"=B.V3:CN!VY4:58=_6M]BM2K=;I]3GD_6WJD_1W7E2,.IR1$X
MLC)1JSS'WR.X>DD6/.L363AQW]4R=;MJFIMMJ;.4THF(:VF*$POQW<<K6'$*
M2?.9%DC]PR*])BU4L:[=A&VJWK<N.E5JIWC#LJ/2(E-G19LEUQERB-O)4Q&>
M<<0I"B/)*07T J-["+7O+MZ]_IO8^7P]X^U>,<<;>=J!J)PT-D="@7'-IZ=Q
M#-)I%T/PGG(S\QJD3:5$5SO,J0YE2#42S(\JR?-G(\LXG7"\T!VS<+#1S<1I
M'2)5LZLV9'MBX)UV0ZG/1/JDF?/ITIPWE$ZD^AJ61Y49*S[C,>;\972:XK!X
M<_#"J%5@S&85C2FYE><<CNDF$S4JK27F52%<A>$2D'DC6:2,22<:36_3>N\$
MW3VG4:Z*14IUVT&SX%)A1)\5^6^^R_36'6RCM/+>)2'#Q@TD?0^@*C>WE]/H
M9#^T:W]VU.YPD-PLO6_AW:)ZOWE5SD34VW(:K50>/*DLT5!1S<<,S];E99YC
M5D\X/([W(XIFQJ),D0I&O%O-R8DIR+(:4MO[F^PZ;3K:O7SZJTJ0KYC&,? [
MTB*C<*W12P[PB24(N&WZRS4X3I.1G?)U1:RY"/HX@W&'E866#(C(R]XZM.]'
M6X8=3J<^JS-)K@<EU2H2:C,65\7&@G),V0N0^I*2E81SNN*,B+H6< L?L[.]
M^O;6C[_F?AZ*);1?5[3W7#TC&;?.F%Q1+IM>5#2EBJP5$IAPV[:-M7*9&?99
M&0N>)^^_?&*1>U3;%I%M"](/D:/Z'T.3;MBTV'SQ*;+J,NJO-&_;AON9ES%K
M>5EPS/J>/9\A7=$_??OC!5?ZC6]=+=;]=:6X  %8@  (@  (@  (@  (@  (
M@  (@  (@  (@  (@  (M#,B[G_O_P"7M%?SBT\<S13A^O2-)J)1/[J^M%>I
MT^F?8937WD2*8N;&-EI2W(Z'B4HT/$X2321Y(T]3$\ET/NQ;>N"4P9D_&H%8
MD,&GN3S,%]QLR^4EI+'RC^=OP^=/;1WB\=;5FH[DF6KE<M^YGSI="KSQ^%(.
M(U)**;;3ZL8;\%I7*A/K^TO>5[ #LN[AHWH>]8*;-M^&KVQ?>3<V^.^MO=US
M;7U.JRZA4Z=(B5."Q"AO&XWXBYJH9$1,-/FLLF1+Y"(NIC^C+L%W]Z(\0#1R
MG:KZ/UB.^3C)+KE!)2O-4.2I7*;+Z7")PS-PE))1I(CQ\P[EN0VQZ :O:#7S
MIU?VGUH_8@5IU1*232*93C@_!U-?5"6B:AAM3?(IIM9F2TFYR]3/)BF+Z-+<
MM?TOW_[H=#+)G2*CI9]DJV"\)QQRGQ&HKTY;#;2>9;;>%)2GF3CF,L]05SB'
M@NUHM ]^P1L#\.ZO[ .-H\I//[)1?4HR'("Q(  "+'7=/N#HNV#1>Y]8Z_3'
MZO2[:*,I^#'2ZIUWS+I-)Y2:0XOH9YZ)$*;?I#6BSJ>9.G%1;ZJ(RD.2XYG@
MS+U2=C)-7T?B%@'4"P;4U,MB=:%ZTAFN6]4C:\[3I!$;3WAJYD<Q&2B]577J
M0J<<;/0/2;1:^=O<'3BSZ?;D:OU_P*LW%0CEF-'.BHY%$2$F7JJ47M+KV]A=
M-QVOBKLK:5RM-+8D=(YDK)BQC8V1AW26CN7$M=W^8^T33X18K@G)<A%QOD>&
MR5O+79[4U:_6R'T:K#4KT_/,,D(:7/D+H9-/! ]L @@%2F;6.,WI=N?UJMG1
MJ@6-5*55+D.23$]YN;X#9QF3=4?.Y&0V9&18^-[<ED37$HC+/R$?UED8-;9M
MIV@=E6WIUJ#;.GU,I=V-V_3Y#=682@GT.R:>R;Z\D@C^Z&HS/!^WJ8SD470B
M+IG!?5V+Z??[!JLFZ@ZP!CX):\36]+VS2>8XR!QVX'W C7;_ ,AP7,IN+S9;
M7%,9>Q5"&+R9H+]L7)7VHY9 ^9L@ Z8WLZ &>X@GWJ-7BB[K8>U_;3==5AU!
M,>\KDA.4ZVXI*(GG_'YHLGPB[FHD.]#+KW+Y147D;/=:*#MCI.^<GJD3KU?5
M7U-$API;22K1.GES/C&A99Q[D].QC-'C?:K7M<V[6AV!=--EOV-8<Z+,HM)A
MK7*76FUI9E2D''BDMPBRCJ:D*+UL]N_>JKQD-.ZMH([MQ5MED?8RN@MTA,!$
MZ0J0V^B/X?FSIY1S>SXY&]CP\]^N,#N\/4NX[&47T:S;4EZ9EFZX.B]FIK0A
M!>YNR6DDZWIVP?5>I/#W \FXAPOB]OC&&CS-KD^1ARW)Y6S4@UF :TQ18UKK
M$L9+I(I'RN+-AD@>QQ!["P3PX-TE.W2;:[+NU=00_<]-IS5/N*&DR4[%5#2F
M(SXI%@R-9-9ZD7M/J) 13OX$&HVIMN[@[QT^HEO5M&FEU2G)=45/ARX<:A-D
M3\J(RV4II/B$M2R1E&.I9,7#D]"QG/4\?-GH7RX]XXWD%!N.R<\,?3Y3^F:(
M @EC)1U=#@/JEIVW1]P!]Z\[^*_%8>(\URF.J.C-&PYF1I1L>USJ]>Z#**T@
M9L,?7<71!I[EC6O]' K<.-;B4'@U)+/[):4G]1C<OFQZO?)?5GJ(">)F_P 4
M)O5J@%L[2\=BH8EO5@V_(\I(9C$XDS\SZW11*/!'W(6X/$?EN^RA]/H8WKCD
MD^E9*?Z/5;Y;>KI=)IVG/]&#7<]E#V=S'Y#H.O?D^_DNF2./Z-C8/I%D^8[I
MZFQ[;MK?5QWV'=3Y>.C]FW_*H_..1*TK+)&D_P!ZHE?D%$&T-[G%KOS6"I:"
MVM?+]1U4IANM2[=*'3VU,NI;6O'F%%X9^JDSSG LQ\+5W>^Y8=UEO3)TKH2[
M'*B^)Y7XI..>-_>O0_5Y>_RX'4\D\/;G&*)N7,U@K#^FO)'2JVW/N30V?\'/
M%"Z-A=#K;NL$M(&P2N5XUXAU.3WA3J83.5V=4\<ERS4:VG#-7 \R&69DCPR8
M'V?+.G Z!4KH  CY2&@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M_??OC%0Z#_C+U4_ &O\ 5<Q;Q3]]^^,%>_U;_(;^Q;@  5B   B   B   B
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MKI N.EV^D_RF).\5?\K8'^:>"_HRC#PJ_P DYW^=>;_WS%J  (O4HH  "(
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M3FSDQLH6G]EVU/GU.@VM1*//JA\U0F4^FPXLB:99ZR76&4..GU/],4KN8[D
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M.-MO4ODCMDALT*_2TD9%] M:<N.QF7XR+YB/L!)P><F9_*?0OF+L0*[J(!
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M53\ :_U7,6\4_??OC%0Z#_C+U4_ &O\ 5<Q;Q3]]^^,%>_U;_(;^Q;@  5B
M  B   B   B   B   B   B   B   B   B   BV+,TD6.YJ27UF*@_&#JCN
M['BH[-=HU.Q*I5IP-0JK=D-!DIHC:H?PK#.4@NA'EK*.?K[NA$+=54G)IL"=
M/<_2H$"9.<,^Q(B,+>5GV8P@S%/38FQ)W?<9O?!N967G+?T;HZ:=;4O'-'CK
ME6U.ILQ,91>HG+C?*HD'G."P"O9VZC\&GU^)T!^U8/\ !.AQJ=QMMQ5,B)2B
M-2I%.IK:$=$I\C3'HN"(L%_U1^P7]V?BG^_7_G&* G!--1\;[<ZI1Y4=R.F9
MGW/[E.P+_;/Q3_?K_P XP23ZWW#]@/X;U]RY1MYT^_\ $?YA^"KS%4ZE5.>A
MLW5P:=-F(:3W<5%C./);+Y5F@DE\XK$:@\=W5FRKONN@+VZ5LZ=;]3E04U5]
MV4Q%=;8D.LI=-U<4FD$HD$HC->,&74;''XJYDS(VHQKS$&E_5(QF@XD#761U
M>A[#OV^Q=7Q3@_(N:26XN/U(K3Z+8G6!+;K5>D3.+(^GZ3+$'DEI[,V1VV.Z
MM#<Z??\ B/\ ,-PJF4ST@#5>KKAG3-N=6J4>148,)<F!+D3&FTRY3;"EJ<CQ
MG$%X9*,S+)=C%FK2:]I>H.GUK7A-ISE*E5ZG1YCT!WF\2,MYE#AMJYDI5E)J
MQU(CZ"[(8>]C&L=;B;&)"6MU(QYVT D$-<2/7U/JLW*_#_E'"HZDG(:451MV
M26*#R[E6RYSX6L=('-KRR.9H2-^N&[]R]'7\4_H_*0JR>D#K3_=%VR)-:,E<
MJ<ES)RDCJ,/JHLY277.3(BP+1=6J,:DTZ=4YKC;42G0Y,Z0XXM*$I;BM+?5D
MU&1%E*#[]_9U%%OB':W7WOCW.W@]IM3)=<M#2:0X5*;C&MU$1UAI293W.E)X
M,GHZG"STR70;?B-=\F4%G8;!5BD,LCCIK3*TQL;OXN<[8^33]B[[P Q%BWS=
MF8ZF08W!TK<M^W,0R&(W()*5>,O<0T/EEFVT$]PQRF4WU;LKG_N5Z-;.MO<X
MZOJYJO0J13:N_2'"==MV W#A*E&ZZUSH+QH3CIX-:3+'7J)1MB>T:U=I.BE!
MLNG1VI-TSHQ5&[*\I!^<J50G*\XZEYQ9J</P'W5H(N8_;\@A(X#5@6'J)6K]
MUCO2K%=.KEON1(49FIK4J302:\2$IN.B0M6>9I'*?AI29$DA:13@DYZ%G_:?
M;YB[?(,.<>*).&@Z@V*3SK<NBTV;#QU#MZ^5$TAL8]"07=R=K7>)D\?&'/\
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M91AX4_Y)SW\Z\W_OF+4  1>I10  $0  $0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0:&9%W&HBDXH?$)K6PBT;,N2CV25Y.7
M.[,;6P<Y,+RYQEMH3A2DGSFOQ.A%UR0V.)Q5W-Y"MC,=$)KEMY9!$7LC#W!I
M<1UR.:P>RTGNX#LM;E\M2P>/LY3(RF&G5:'S2!CY"UI<U@/0QKGGVG =@?7X
M*5GG3[_Q'^8.=/O_ !'^85(V?2'=:I#+4B/M9N.2P\A*VWV%S'67"41'E#B(
M9H477NDS(?CJ'I%VK%)\FJK[:JK2&Y<^##0Y4IKT)*RE26V%J0J1&;)?(2\F
M23[]!W(\)><$](QM<N].D9&@7;&MC0L;[=]]OM^7"_W6^$@=1R5@-[>T<==#
M?XOO,&OC^L*W4 \5V^ZHR-8])+-U%E4[X+?N>GMS7(/B>+Y<UH2KD\3[['-C
M/R#VH1U-#)7FE@E'3+#(^*1NP=/8XM<-CL=$'N%(\$T=F&*Q$[JBFC9+&[1;
MMDC0YIZ3W&P0='N$  &)94 ;5*))&H^Q=3/L1?*9^PO>9CX97)1%2/*E6J&<
MDCY3CE5H1R"/MCP2>\3/R<H(OO /RR9D>*T3S\B-';5C#DE]MAL^;MA;AI2>
M<ECKUZ8[C\,BN4J*MI$BJ4F.M['A(D5&*RMWM^E)6ZDW/DY<^P$7V R6,^P>
M*Z]Z\:?;==)[KU@U(J[%*M*TZ<[.G2C5XA+-+:ELM-I0?,OQEI)!&C.,Y&"^
MW'B3TO=EM'NW<YHU9[559IB*T5N6^FI);E5ERDR94;UB<(G8WBKCD9&MLBPO
MIDB!/G[E*BE1*+)9^DL#41G\-;>!K5N\TTK]XZS:-+T>J],JDR%"I"ZLW5#F
M,1Y[\9#WB-I3R<[3:','VY\=QGUJ+=+EE6-==V-1O-NV[0:G5T1N;D\=4"$]
M+)KF^]YC:Y<GG&>P(NY>(GW*_BF-Y*(^PI8V1Z2;N_U<K%_PM&-D,W4*%8%<
MJ%)K,F%=*$*C)C3Y$..ZIM+"U&;Y,\Q)(NF>HS0V'^D--Z\;CJ+M8W,:'S-O
MNI5PO+8H956>_+1,=0V;JTD:H[:$X(R3GY2QGH"OZ'?#W;]1Z?9O?O5GU2R3
MT//T$9@2TG\GSE@5;N(?QX]8-J&]25M'TFV\*U9KSC,5ZBN,5YN Y4TOP$35
M^&TIM9ER(61D?7)8/ \ 8])0W :.W'2BW9[(J_I;8E3G1(DB[%UB34(M-1)>
M;92^[X$/DY<N9]91=N_M!4Z':WKM]H_9O:N)#0U$1D1]S^0QX=HMN$TPUUT<
MMS6^Q;EI\RPKBI95-BLO2&HT1A"&2<E(==>6E*#CJYD'SF1F:1 _N2]()TUL
M/>]IAM%T2MZ+JFNX:N_2[VNF#4B9AT!Q)MDQX*B);$WF4I2%>"L^0T]<'T!4
M ).@.ZLI /FTF<=1IU/FJ1R',IT*::<YY3E1T/&C/MY37C/R#Z0*B   B
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MU<&X:GHA=AW;2K;D$Q4*BB&_&CFZMQ;9DPZZDD/D2T*3S-J470C[&,H06-
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M (#4^H  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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M5IA,DI)E[R/H8^\"PH  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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M#8/^,O53\ :_U7,6\4_??OC%0Z!_C+U5_ &O]5S%O%/WW[XP5[_5O\AO[%N
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M$JYE<B%%R]\"7/"VE/DJ_,\=4+#;N\<F@K,?(V+JD?/#KVWD!H !)<2 !W)
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M=OI/\IC4:%_M/\IC40"O0"   B   B   B   B   B   B   B   B   B
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M:Q;0^-!JUL]GZIS]5-.]56Z95F'Y"U/-T0VJ*NK> E*WI!L8<=\/)&WS<O;
MB^U(X</&=I5U:<T.-J_:=_4W0:15(&D5SRKLM!A^CT^JJ-AXU-/5%3KIICI;
M21/*RGEP6!/EP:N%E>>@>JEW;K]UNL%!U7W-7VU!\2/$JE*FRK;3$85%\)LJ
M?-DH,G(JB3ZB4]"S\Y7NUK9<"2/<-$GMK8&M:'W=OBK-:<D1Y//4\?-GH-PV
MI+!=\]3,_G,^HW L2  'TZ@BP8U^V6[0K^JETZQZQZ4VY7JQ$I<JK5FOU1#"
M5NLTN&X^27''&U'DVV30G)YZ]A4(V:;3M(>*GQ0+UU2LS2VF6GM*VUW RS3J
M5"99*%<T\N>/XJ9"&F5GY6I1"<+'/[.PL7<?'<?)V[<.K5VLT2:J#<UQLTVB
M4EU#_@N<M4FII\GD,C)1Y0_C!'C!GW'0?1W-NE+T0X=VG-?<C(;NS4AZK5VX
MI>"\>4J74W9K"G7>JEFE+ZC+)G@@5XV&D[/<](_ G\"HP?2P+^B6KHUMRT0H
M\.I2*?<%0;COTJF4R9.:.G6_,@>!#=**RXA/BL,>$1J+VYR9Y(87[>.(1PZ[
M"=T>THW';$TZ;T&:U1J=$U2K$>=R3JGR0VFY2V'J:@D<\PTGE2\%S9[%D6!^
M*WOMV<[7M6]$[3W6:21[L;NRJN1[7NNH17Y$*BOH>CI6ZZLHKS#9&ZM!GXJT
M)/E/V9Q%?Z2SJWM1U"V4Z7Q=,YUDUF^[FE6\[I]%L^/3'*LSSU"G+-LVZ2@Y
M+*FD*2DR<(L&1XP><%>SN&-+3HD]P=>\=_N(]_W=U\'TH/4B@Q=NFS[2W2R?
MY/2S5.JT_P -BDR5HAS*7\*4UQEE7@*2E?*RZ1*(\XZECN/A\8+9EHGISP:M
M(KVLNU*5;]T:=TJU*Q2JU3HC,6IJE39=-E27'9C+;<ATU+SU<=/&3]_3##BQ
MZ0ZJTKA7\."_[XIU7ER]+IA3KI>?CR79%/@SJS2W(BI2N53B4^721ESXP1'C
MH,R^+[O2T1U+X->D]CV5==*K]U7_ $NU:13*%3I3,JIHDPI=-BR&W8;#BY#9
MDO.26V78P1N_S8'IYAWK[6^OW*?_ (,.NB]0.&/HIJ?>]5??=I-NU(ZS4'O$
M?=3#HQ&CQ#ZJ6YX<=DSP1F?JX+N/P3N/=PPZ?4)M-EZ]/-3*;.DP);?V)UU7
MA2HCRX[[>2CF1DAUM2<EWQDA]'@LZ)/:><,G1#3:]*0]&D5*WZB=7ITE*FG5
MQ*N?B$VM*B2I).,.F1]"^,.ZR^#1P\)TZ54)6@=.<E3I;TR4XJ?)+Q)$EY3S
MSBO6^_<6I1D77KT!8^VW;WZG6M?'YJO/MGW&Z2;J?2&).JVB5R*NNR*A#Y8M
M6.%)@>(;-MFRO$>4A#R<+(R]9)9Z'T%V-/WW[XQ2QT!T+TRVZ>D2R].-(K<9
MM2T(4,E1Z2PXMUILW;;-U?*IS*NJS,^IY^7H+IR?OOWQ@JO]6^OU6^OKZ?O]
MRW   K$  !$  !$  !$  !$  !$  !$  !$  !$  !$&*^]#6*%H5MEU@U)J
M#R([-&M&L1FW7,$E,BH4Z3%8P:OOC=<3RXZ\V,8/J,ISZ$9_(*ZGI)NN,JQ=
MB\C2>C/&W<NLERVM1Z:TV>)+[#=PP69:&R+US3X+Q\Y%T,N^?856C;@/B0/Q
M70_1F](JG2MK-[[B*XPM-<UVO"XIDF4\G[J^Q3+CJ!1>99^LI),N(-.3QC L
MQ&ZA&$J6V1D1=%.)2?U&8P@X<^B*-O>SG1'3)F.4;X.MJ%5'FB02/NM:CL5%
MY1I+VJ6^9F9]<]Q')Q#(G%!<UO??VLNOHTS9BKD+Y#@\B4,1"<?/]$>OT4A1
MX[GCZOMH4_IT_D_2*]7V"[S++_+C[$>SO1]H[[#Y+H^,\?')\H<<<OB<+N&6
M<7,Q9-6I^:U^:$O2\^:_?L-UWT5/SYAK]L:_E4?G'(A:5EE)I/\ >J)7XR%'
MW3;=IQ4-7=2JWI#8-]OUB_Z"MUBHT8HD!HX[R4+41&\L_#5CD/L?7&19CX;C
M&[=C222C=NIQ5]>*9-<_E^;E)]PNGE_4^)CZ1LLE@),9#YLMVE([V"((Y"9B
MV3ZKPTM&V'UW\%UW,_"RYPFC]+O\CXW;L;JEN,HW9),@^"VTNBLLKR0QDURT
M=7F Z((UOU4D"CP7RGT]WSGW+M[Q5_XY&YFJW?<=H;0--I+LJLUZ2IBZ84-P
MUK<6I3+T%"TMY,LFKKU/'7FP+%&MVH\72G2Z\K\F,/R&Z#1ICJ6HZ'''52%1
MG"9-*&DK5A+A),S)/;N9$*2.V'<OH[6-[=Q;G]U=8=3%B5N<=#@RX\B2;A1U
MO1V2-MLE&UX1(1T4@LF0^WB]%SY;.3,+IVX^,NAB8"YTMMP_--#1W/3]8GW'
M1]RZ3P1XW+8O9?F;L?-DX^)4W6,=CX(C/+?SDS'"A"R)NW.$1W,XZ]DACM]E
MU[:7HC2K+WLV!H1NC.51:'#?C37:!,??*FRI#T9J=3S6A"RC+/QC;7A23]8\
M]Q?3HD&F4VE4V!1V68],B4^(S3V8[:&F4Q$,(0P:$H(D]6DHZEW]N3R8I'<4
M7<[MGU\O_3[6K;O6U-ZAT"<U(K9L1)45QYF&ZPF&WSK2A)_<&B21)[ET,6J>
M'QK[+W&;7-.-1*FE]JKR*<4"H-O,K:49TXDPT*RM*27S$WGF+I[NX^OE,=NS
M4QV2GCD@ZFF">M(TL$-C9)>UA]TH!]KO]4#?HN@\<:N=S.!XAS/)5+F,=-!)
MB\KAK43Z[:&68YSW688'C?1?8QSO,<2XMB8TN/99E5FKTRAP':E5Y\6FP6#3
MXTN8\VPPCF/!$MUU24)R?0LF7455^/5=MLW-J#ML<H%=IE71#N(ERET^;'EI
MCH^$(AY=4PXM*"P1GZQETZ^\Q87WD:!U;<MH'=^D5$N>3:%1N),0F*[%\3QX
MGEWB<,T>&MM>5$6.BB%?"3Z/=J+/)LZEN(J536RM2VEU""[,4T9GS?<E2)+A
MMF7O1CW_ "#X.-OQM6PV]<O_ $>6)TK!7\E[^MCX^D/\QO9NBX]M$[;\URW@
MY8X;@\K!RCD/*1BKM":W7BQ)QUJQ])KV:9@%CZ5"'-CZ7S.'06.)Z/=U;5BG
M0+4&R:EIQIW2*?=-$F5)RVZ4A$&-4H;TI2FZ?'):? ;>4[E/8RY>GM+(R+%?
MK9KP>]0]LVOEHZMUC7:M772K;\USV[(*4F*^3[!M)3RKE+:2E!X,B\/!8(6
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M72!<=+M])_E,=EXJ_P"5L#_-/!?T9<;X4_Y)SW\Z\W_OF+4  1>I10  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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M_,HOHST_$.0%B0  $0  $0  $0  $0:'V^DORD-1H?;Z2_*0(JAL'_&7JI^
M-?ZKF+>*?OOWQBH=!_QEZJ?@#7^JYBWBG[[]\8*]_JW^0W]BW   K$  !$
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MJR2!\<S>VNES&EPWHZ'H-%9^  "%E-*   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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M^^,5#H/^,O53\ :_U7,6\4_??OC!7O\ 5O\ (;^Q;@  5B   B   B   B
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M1[:"ZOPEBKP8SD4%4,;6AY5E(Z[8SU1MA8(6Q-807;:& !IV=C2U,B/N6?\
MR&,&L6SK;QKQ7(EQZI:>0+IK$+F*-,DGA;9+225?6DB(90 (RK6K-.435+$U
M:8 @2P2/BD /J.MA#M'WC>C[U)]FK6N1&&W7ALPDAQBGC9+&7-.VDL>'-V#W
M!UV6 /\ P9&ROK_\"]*/)&1D;BC3U+!^K\7V^X9'Z+;=](MOU,FTC2>T8MIT
M^HJ0J7'BGDGC09FDU?,9F?T]/:/;P'TV,QE;<1@M9*]8A<03%/:FEC);W:2Q
M[RTD$=NW;[U\M;#8FG*)JF-HUIF@@2P588I '#3@'L8'#8['OZ(  -<MD@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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MKFM:7[D<\]VL:- Z[;0  :=;A   1   1   1   1   1   1   1   1
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M:U5QD>,9!6\J,>08HR1([S!(_P P]]/ [Z6H  YA=L@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M0FU-T^E0V(,-!JM@U'R,1FVVTY,_8G)GW,7$$_??OC!5?K8UV'2W7O\ 4+<
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MZ24S(COMR&'4GU)3;K:EMK(\E@TF?<?K!5<]SO4_=Z#]2T(B+H18&H "M0
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M^H  (=7H5!67U;_7>Z1^%(_J] LT"LOJW^N]TC\*1_5Z!+WA!_CW,?YBY_\
MW<*\_?V0'^3O#_\ [S>+_P"\E5EZ'_>S'X/'_P!$D?J'Y8?][,?@\?\ T21^
MH1$?4_:?VJ?H_JC[&_[+5UN\O^:-S_Y/UC^KY KK\(?]4=K_ /P\O^D218HO
M+_FC<_\ D_6/ZOD"NOPA_P!4=K__  \O^D21+O!OX/O%+_0<'_Q!R@+Q._A7
M\$/]:<C_ .&1JR4CXI?3^4QN&U'Q2^G\IC<(A4_CT'V#]B   JH  "(  "(
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M-95*T3JK4DX!TJKR4RH463#6PPV9PFR;)+,4D9)/M!?0P'LWIZAZNWH@'0(
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MF0U)J?BU&),=3X7FWI9-I-/Q,)Q@C!7!H!T=$^@T>WWG]_V*4'8/Q"M#-_\
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M(\E].!PR9C46/(DNF1-QH[TEPR41\K;#:G%F>/<E)F*3VCNH''&N+:]<._\
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M#^I64>'-Q)F]_%8UDI3>E%;TU_N35=%*-ZK)FDFM&J8_$\:/YN-'(TEX7/\
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M7JI^ -?ZKF+>*?OOWQBH=!_QEZJ?@#7^JYBWBG[[]\8*]_JW^0W]BW   K$
M !$  !$  !$  !$  ,\%D$7&ZX32%+49$E"34I1F1)2A)94LS/H1)+J9F9%[
MQ4&XPNY34KB [G[+X4^U.IREP9E797KU<]&>-R+3*?$<8J<>,]*:Y6T%(CMO
M,*)+Y&>5$KO@2T\9CB*0MBVW2?%M-]-2UQU/;.VM-;8BFEZH2Y-2>32Y+Z&4
M$XM!Q2EI>YE-D7J&9'TR/#N!EPXJOMETJJFXC7(E5G<MKXX5RW?5*HWXU0ID
M:0^[-I;#3[BG#;-,*4ALR:-.$E@RZX(KF]AU'_Y?M!'W]A^/OVI)]%=D.A6C
M6U.U=K;UHT:9IS1Z3#:J],FHC-1JE4E)0]-?ENNI,G5*G>*Z1NJ5U/H?8=1+
MAW[&$E@M'+!27N3)I22_$DL_,/2-\VG>L&IVW6\+/T+JSM$U$J/D_@BHLFDG
M&N202W\&M2$^LC)=3Q@5!=S-&XA6TRMV9;NJ6K]51/OF9Y*B\JD*YGO%;9Z^
M$\9%Z[B<<W3KCL-]B,*S*M(&0KUY^MS6UY \R.:UH<7@-&M:ZO\ ^TJ4. ^'
M$/.HW,BY7B,5DOI$T46)N"=UR>*"!L[[,;8VEIC#2\'9V/+<=*WQI9LTVIZ5
M7E3[STWTTM"@773O$\C4Z6[3U3&?$1R+Y"823A\R3P>#[#,85N.'YM5XA=GZ
MZ6#J7K-J%.K>EKL1R=.I[ZV.5UF;"2Y$-24O*7W<2?;(L-W=>EM6/19MP756
MH%#H\%E;\F9/DLQDI;;(U+-)/*1SG@CZ)R?8L9[_  Y"E'3L-@@M17NIC3UU
MPX@/)(\O1&RX:'8?$:7,<JXW6X_E8L9CLY0Y*)((W_2<4)71MG=(^,U>E[0\
MS,Z 2 #V>W6UX;NZU_MW;=H7?&IMPO,H;IE)D1X;"W"2X_)FM.1V3;3\91H=
M4DS(B/\ VC^?O=E9N^_+Y=UAO)FH4ZVM0KQCN3*V27FH\N U64H0GG;2E*TH
M85RJ(E*Z=%>T2^<6O?;:V[N_+0T(T>N4G=/Z95RAW)74K5'C5!*Y31.J4V\:
M"-,<R<)*LF2B3DO>>36X?1W:/4.'M1=%[4U&MQV_K HS50I,UE,9$I^9,-N?
M*;4Z3F5J2LC01FM1D>3+V$.XPD/Y#JUG6()?I65F#)-,<75:H[,<\ $-/F.:
M[3M=C\6]O37AE2'AAAL)/F,3>=FN=9)E>V&U9W2X3!Q^Q#8G:V-XCD=:EBF,
M<G22S3BT&-3_ &TVF:?4G0'3:'IFN.Y:2:'$<A.12233DEV,TN89\O=7F#7S
M&>3SW,9)"N?P'-U;MX:<UW;U=E8-VLZ?/>7H"'%&ZN4TZ^ZIQ1.95RD3:4F1
M&9E@\$+%R3)19+YC]G4NXXG+TY:.1M5Y2YY$KG-D=O<C'GK:_?OZ@03\]A>:
MN?<?N\9Y=F\3??)-+%=EFCLR;+K<%EQG@LEQ ZC-&]KG$>C^H;V%N'P[C+_B
M*N'[J)5?F_O)X<EP2WH-"K<V.?+(AT>IRV%=^5Z-#>=:/!].BTD?44LI/$UX
MH&JNM&IVENBLY5UE0*G4:7\$MPJ:T<>&X[)82E3BVSR?@%ZIGU+K\PWG%>(9
M#E!O24[./J18MD$]N;(6?HT38Y9"UI#RQS>Q:=]1:.X[J(>5<OQ_%A0CN5<A
M;ERDDT-6+'UQ8E=)"UKB"SK:X[#AH-#B='LO1N%87_RKNO'3M6'/H^Y21<;;
M+"3Z8]97XS%!#2+2CBD:&ZOW+KM8>DTVGWY<2WIU;J*GHCJ7/"0X;RS:<;-H
MB0DUG@B$LG"DXBN[_<)NEN'2#7JX$RH=#5X4RE>2B-*BO>7<6:#=80E1_=$_
MB[]Q)OB-Q*SF))N08[)X6W2P^"QT=R."^R:RUU6&.O(6QQ->.AT@TQSW-#AL
M_)1AX<\MK8>.#C^1Q>:JW<QG+\E.2>BZ&LX6Y/.C!DE<P]36 >8&M=TGXA6B
M),J-#97(ER&(K#?5;\EUMAE&>W.XZI*$_2HA&CQ5;DMR;L9UL8AW!1);RZ7&
M)#,:JP'W5GXWQ4MM/J4I1$78B,\$.T<4:K5:B[(M9JG1Z@_2JE%@1EQYL9U;
M+[1ID%GD<;4E:3,B]AD>.@J2;.-@&Z3?GI-4KVHNN5?AV^N;*:>HLQV1.9E)
M1-=:Y5^8DJ(R2:3,B,CZ>X<EP?C%&S59RW)YV#$4L/FJ<3V35I9O.>TQV&-#
MXC['F:+1MAUK9[+K><\IO5K+^)XW!3Y:YF,+;E8^&S%$88W]==[BR1NG"/J#
MB \$]@/BI1>#[N&L_;)PXM0]5KNJ,..Q;AU(X\-4ME$UZ?*J$MF"E$4U&^:3
MD*:ZDV98/.2(>S\)G06Z]PVJE[\0_7-#=1KUZ5)T]-X4AYJ6FB0(CK\%:VFR
M4M#1OQ?#5U0A7,?OSB)+<)P:=QNW#0>\K\KVK<V=9%LQD29UK,ME'AS%.K4:
M5+:;>Y#Y'?7R:%>M[2SD32^CW5FJU7:.I,^<[*:ARGV(S:U*-+!-SGD*)"3,
MR3GEZX(LCN.7,Q;,!RWE''<O7OS9[-0T[MB*&5CZ]"=GFG'Q/DZ2'2R,8^Q(
M&ZDC:V, >UOA^(NRDN?XEQ?D6)L8^'!8::Y2KRRQ/99O0O;$W(2L;U MB8]S
M:\9),<A=)L]E/Z\XAEHUN+;;26"-;BTMH3D^A<RS(B(NQ%GYA4X](FD,2-2-
MK!L/L/)3=!9-IY#A)_XRA?&-!GR_3CZ?98,WU6EKC>^VN][<VZ3ETW5>:F#]
MCLM"FDJ;4V^2G\*>-+99;]YBIUJEPN>+1K?)HL_5GFN^;;T@Y%%>>FTQGR#O
MB)<):2)TR4?,A"OH^4<GX64\;6RL'(<AR#$8UE.2U6-&Y.8K4K9JAC;-&"WH
M,8?-HDN!]AP WI=7XJ6\G;Q<_'<?Q_+Y%]R.I8%ZG ):L)BMLD=#(1M_F%L0
MT ->VT[UM7(-!YD5>DNG3:)45;IVO1LMHD-*7_@Z.9X0E9J/'MZ=.Q]1[.*R
MVP/;#Q6-,MPNGT[7FYGY.C%#9DQZG3%/0%(0R44F8B/N3ANGR*2DO5]W?'46
M:"S[?<7U^T</R?$U\1DC#6R^/S,<\?TGZ3CGNDA89)'CR7ES6GS&@!S@!K3A
MW]R[GBV6L9?&-ELXC(8:2NYM;Z-D6-CFD$<,?YY@:3N)Q)#2>^VE:@ #G5TB
M   B   B   B   B   B#0RS[OI+(U $6$_$)(BVEZJ]"_P>R?0L=?$+_9T&
M%_!6Z[>*CGK_ ,82B[>Z>_\ [E[AFCQ"OU)FJO\ !S'^D(87<%;]3Q4?X0E?
MT]X3%B_X%>1'W_VX8W^AKSUF>_\ 9&\0^? ,QO\ ^N8IIR(BQT+./86!J "'
M5Z$'H/L"",KBQ_J/[Y^:#_24"341E<6/]1_?/S0?Z2@=?P#_ #UXM_KW&?TN
M)1_XK?P;\X_FQE_Z*Y;.$S^H^L;_ -O_ *2H2<",?A,_J/K&_P#;_P"DJ$G
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MAO3XQJ(DJ-F2XRIY!FDB+U5EDBP.]I222(DD1$1$1$7L(BP1?070@52XD ?
M:"J5>E:4FK57;GHPU2J/5:NXB]J(;C5,I\J>M"2N.G&:EHBM.FDB+J9J(BP1
MYZ#J/&NHU5E\$O3"# HM5ES$4S3TE0(--E/RT?H^D>(2XK#*GDX3GGR@L8//
M86TKPL"SK\C,0[OMNDW%&C.)<88JL&+-;:6E:5I6A,EIPDF2B)1&DBP99[C;
M7M/;*N6@M6S7;8H]5H3"6B:I,R#%D0FR9,C:),=UI;)>&:2Y<(Z&18P"!VNG
MM]4[^WN#_P E5-W242I%Z-Q$I<6BU150*@6YBE,4V6JH<YU%DU$<%MDY&>YJ
M^Y].Y],CQ-.TK4C=#Z-EIW8MA4N8=_6]YJMP;<J#"J=*GIIMQ(J3S:D3$MK:
M43;&2)2,JSZN<"Y!,T_LV?:_V&R[;I,BV"2E!4-V#%73N5!D:2\HIHX^$F62
M^Y],=,#$3>IM\U/O[:Q=VF.UBZ(FD.H2(R7+.JD"E1)$*&\VX;SS'P<:6XBD
MR\$T?.G!$HS/(*H=Z =M/Z@2?L]?U>JJ7:$\9:ZK:X>]1V9Q]O\ =I[@[2M.
MO6S-@2(%59I*66F)+$B4=2=IY4_U(J%O%E_"B+"<G@8O;+=2ZEIKP.=R+D)-
M0<O*_;_HE.A0Z5$D3'^>LWZY%J;!HB(6I"6"E.(4HR(C2DSZ$,\X>F/'@I>D
MMV[?*[MIM*\*_=12*+*UUCL6739YTV2XZPN:41F*3Z5'#=,S2EXE&><]1-7P
MEN%; V=;1J?I-K:U!OF[J_49%>NF+/A,+CQ:C(JCE6;0A"O&9,V)#AD1H+&4
M$98ST*\N: >P[N:[L=[UW_5Z_9\5B=NET)F:$>C[7#IA3Z7,>FL6?2*R<"%#
M>?EK?N"8U5'#**RA;REDN1E>$FHC+!]A7$TNX7]QVYPLM+>(OH' KD+<G85?
MFUFNP%P)[-5EP(]R$3S;<*0@EH+X-9<3]S9RHO88_I%U:U;>KE .V*O2(-1H
M2H[$55*EQV7H2F(Z4H9;-AQ"FC2VE)$DC1@L="'SZ;8%FTFV3M"G6U1X=M*2
MM)T-JGQ$4U27#,UDJ(EHHY\QF9GEON8*P/+?3WNV?G\C]JJA;MZ_>/&(X*4>
M[--Z;4&]8;5AT9==LJIP9%*E2)MK5&.4L^>H-,$I3IP'5D:4'SFHC]I9PPT9
MXR]TTCAZ5'9O"T!NS[8&U;3K5LU"%)@51BDM,,L2&)$HZD[3RI^$1FUO)/QC
M)6"2G)]1:SWF[8-0+NVQ7W8&T:N4W1?4V<TA^W:Q3*-!=B)D-O&^\TNG\C,5
M92OTLS<29%SF9F?45G&-+^.]$TANK;O7=L]IW37KJ\>BS==8S-F4Z>JG2'7&
M%SBB,1$OI4<1PS4E+O,?4C,_856D:T>G0=U#9((]/N/V>O;OV65OHI)OJVB7
MVN41%+>N6JRI2",L,R9-=GO/L>KT/P7%&C)=^46GKGM>@7A1W:)<E'I]=I4A
M32GZ?4HK$R*]X:B4GQ&)"'&E\IEDN9)B)S@Q<.^N</7:Q3M.[UK/PQJ#7I,V
MKW8]X26DM39\YZ>;)$A:D'X2Y"T91@CP)ABZ$1>X%:X]3B1[RJR.[#A*Z@ZG
M\43;[N.L:Q+;C:(60]557=38M.I$6GO(DP&V(Y/4]+24/$EU)F1&TK!]?;@[
M&5DZ=6;8$=QFT;6H=M%*C16YB*+3(5-1(<8:2DC<3$992LTJSU41]<G[1WO'
M4CR?3Y3Q])=AJ"MW^"@]X_&H>YC3?8%J!7=M::HQ<9.4INKU.C,'*J,&EN5!
MM$\V&&TJ?<YH:GNK19+&>^!4!U%JVQ+4'AQRFM.[3U7U9WRU>.B1>M0JB[_:
MBV_/9ED[*5\'U!M=,=YV_',DMD:>A$1#^E96:-2K@ITFDUJG0JK39;:FY,&H
M1F9<5]"B,C2XR^A;:NAGC*3P?; \8MC;-H3:!U8[>TKLZGG6SS4C*@TI1OF9
MJ,\<T7U<\RL\O?/S@KFNZ==O1P/KK[CV5-NLL5"H^BTPZ1$H]<>K,&H,HETG
MX'GE4VEE=J"4CR'@^95R8/UB:ZI+F["43:13:BSZ/]2(#E+J#$_^Y[<Q'3G8
M,EJ<2U+DX2<-327R4?<B\/K[!84:TETY9M1ZRF[.H:;4?7XKMO\ P=#.EK7X
MGC<WDO!\MGQ#Y_TOXWUC[T.R[6I]N%:<*@TV-;B6ELE1F8D=NGDVO/,@HR&R
M8)*L]2Y,'GK[03J[:U_&+OU^[\%2VX,EF7;/X.6YRWV+<JZ*U+5>7EJ=+I\N
M'*?(JQ5U'X;3[*'5^J>2PD^8C+&2,?#]' W46/;.A^M&S6X*7<U)U>E0M3E,
MTZ=;M8C1E\J:[+P4QZ(B+U:/*,+]<\<I&9BZU;.GUEVA29%$MJV:/1*5+\4I
M-/@T^)'BOD\:C=\5AEI#:^<U*YB4DR/.3R.CVIMYT9LJY)]V6OIU;5%N"I>*
M4VJ0J5 CR'B=0I#I&XU'0K#B5J)9$?K$H^;(IKT^7;[OW 3JV""/77??P _J
M52#T;'2U=\L\1FP+NI%=HU,NZZ%TUUZ;!GTI;C3U7JC*UQ776V%K(DN&KF96
M?3J1]A)#HAZ/7M7VY:P0]>;5K]V3;DMMF[*M&B2;BN*1'>DU6/)>6DV'YSC"
MDI6YT0I!ECHDC["?6TM.[*L9RH.VE;%'MYRJN>+45TN#%AJF.<QKYWSC--FX
MKF,U969]3,^X[FI"%I4E24FE232HC(NJ5%A1'\AET,51SMDGTV /U ?U*@;P
MX] K4UEXV>Z:FZM:<2J_;#=3IK4+X<HLDJ6I,>#(21MOR8WEW,FA.5)4>3[G
MDR%V_37;)H5I*\4[3_3&UK;G(7RMS(M'IZ9*")6"\-],8G4=/:E1'UZCT6BZ
M7Z?V_<$RZ*-:-#IE?GJ)4RKQ*=#8FR5$1D1NR6F4O+/!F65+/&<=AZ "H23K
MY#7ZOW_!45/2=IM1MG>-LVOI%O5ZL4FTZ[4JG4ETFCU"HH:8C.PY"N=4..\2
M,H;419[XZ9&0VMWI)-LW=HS-TCV]Z&7Y=FH==LZ%9],6Y0[A@H1+?I2*3(4I
M4FF):Y4+69ES&18(R,^F1;AO'2G3N_I$65>-FT&Y)$/F*,[5J9!G+9Y_C<BI
M3+II(\=<&1>\?"H^@>C-"FHJ%)TMLB%-:/+<ANV:*2T'[TF4/)'[<D><]2,%
M<'-TT%OU=]P=;WKY'WC[/DH!O1Q=A>J&UC0R_M8-:Z4Y0]2-?JF[7ZC0WR3X
M]+9.H29D="U)QDULR$Y,TERX,L9(8^^E9TBK5/;[H<U2:15JLXW>]%4XU3*?
M+J#B$_9'3#-3B8S3IH219/F5@B+KT(6UH\=J,TEEAIIEI!80TPVEII"2Z$2&
MT$E"2(O81$.IW?8%FWY&CQ+OMNDW%&C.)=CLU6#%FMLN)62TK0F2TZE)DHB5
ME)$?3/L(%0./5U:[[WKT"\&V=-N,[8-&FGFG6'$65026T\VMIULRI<0C2MM9
M$M*B]RB(P&4$*!#IT1B%!C,Q8D9M+3$=EM+;33:2)*4(0@B2E*2(B(DD1$1$
M1 "M7ZC['\QBMKZ2S7M=*;LQATC2RJ5:@VS<5;H])ONN4CQBD4R)/K42(T^:
MXQI?2E"'G%+-*B+E29J/!&+)1]",_D%<_P!)'UMU0TTV32+3TYH'PDO4BI4R
MB5&IJBMR6Z2N358\.,M7B-+2V:ER.CF4&@R)1'T!7,^LWW^T/7[?W_\ %13Z
M,^C"Z!ZBZ9V=>]1WHU>J3[FHM/JTR4W=,]DCE38K,F0P;95PB2MAUU3:R-)&
M1IZD0ETX9?!%TIX?^LM3U2LW7N;J1.GI;2JCR:S(G^#R,*9R:':E++J2N;XA
M=A =H=P#.*%4M++/J] W=W!9])K=/9K<6W(Z_A-JFMU5MN<E"):9YI61D\7J
M%CPOBX+!":;A/\+;>YM!USJM_;@-QE9U1M>6A"6J/.84VTDTQUMY+,ETB]<R
M5T+YO>"N<>WUP[Y ?8/E[NW;[/3:LO(3REC.>IG]9Y&X;$$:2P9YZF?T&?0O
MJ&\%C0 &BCP7;.3(L?."+12B263S]!&9_B&B7$J/!<Q?.DR_**X_%EXU-S;2
M=6K7VI;;--)FJ^X>\EKC,TZ.ZY"327^1MU@U.N,N1G2=;<29Y,B3[3Z#!#2/
MCO;U-M>XNP=$^(]M_>T]INI\R/&HERKJ\:4S#\WX1QR)$)HD.FLY#2#RKU/;
M[<%<&.(V-?9L;]WN^]7*%*))9/M\A9&SQD>Y?\17YA#1QA>)'6=@^TZ'K38%
M+;N*Y[C9H\BV*9YAM@YZ:HY%\-+:UDI!Y;E(QZIGU]X@8M;C7\8N[*9;=PTK
M9569%MW!)I:HM635X_*Y!EO,$](\/RF22AEPUED^I>WL"=)(ZO=Z?;Z>GZU>
M"R6,]B[]>@V$XDSQZQ?*:3(OK,L"'7=SQ08FR+8M1-QFLMM>!J97:3%^"[ <
MD&A^95Y9MQ_!3(0GIX4AY'9!D?M+ @"H7I ?$,T<E:=:][FMLLFB;7=5:RB-
M;]7<K,57E:?(G-1&Y+J&&"DH(O';<3XO+S$7M($#'.&P/Q W]F_57BQH?;Z2
M_*0\QT<U7M76S3:T=3;,FMSK?NZD0ZG"?:ZH)4B.T\ZSGVFRMPVS/VFD>FF9
M="]N2]GR@K54.@_XR]5/P!K_ %7,6\4_??OC%0Z!_C+U5^2 S_JN9BWBG[[]
M\8*]_JW^0W]BW   K$  !$  !$  !$ !Y_J?J?9>D%E5W4"_ZW%M^UK=ANS*
MG4YCB6VF&VT*61$:S3S*5R&DB(\YZ%U!%W_)>_\ W^7W#R;6[6*R-"=,KNU1
MO^LQ:);5ITB9494R6XEM"GF8[KL9A/,HN9;[J$MI(NZE>WL*L&N7I9.AEDW[
M5[6T8T6K6L=#I,UV&_<E+.J-MJ-AQ3;RS99B.<J4K0O!F9DHBR701Z[D^*?=
M''4U-T*V2Z20I>B5DW=6')&JOG:BIIVH1Z7)CU!F&X4KRCC25DTXSRI,C5SF
M2L]@5XC=[P0/>3[A^_R68W#ZTCOWC#[]+DXA&N].F'MSTMKLF/H5:%50ZJF5
M,VENTR?+;:624F12([<A/.THL&1I5V,7-(D6/"CL1HK26(\9AJ.PRV1)0TPP
M@FV6TI+H24MI2DB]Q#PG;)M_L+;)HO8VCFG5(BTBV[3HT..VU&0A)2)BX[9S
M9*UI(E.'(DDX[S*-6>;N?<_?342>_P!1=3^H%:3L_(=@/DMKGQ>^.I9/.,$7
M4S,_<1=3/V"G=QVM<K8N3<;IA9]%>:F5'2RM,2Z\;3O.E"9#T:2DLI,TD9);
M,NG;!Y(S%G'=AN.LW;CH[>5^7)5*>S)IU)E-T^ J8TF:_)DL.,LFB,2_',VW
M5)4>$=B%4'9ALPN+B(3-Q.OFI+DDS?.5.M"7*-P_.%'\X;*&C-19Y"0VDBZG
MVZ'V'7<7ABK.FS-PF.K5 AC/<>9-.1'H=QL-:XDZ^WW*?O!&A2PL^2\1.0OD
MJX3!L;CJSPT]5S(9754QQ D&00UY7R2=.^D.:X]FE3>KXLNWK2_;+I]=*9ZZ
M_>U4H4>FT&QJ:U)E39M0AQV89-NG&;>6R7BDD\K;Q@_<0P[MW0;>SQ0Z_%O#
M<%5:MHSMV5+1*H]ALK)4BLT[Q"7R/2HJX\MDG22A1DZ1]%F788/<'ZR-*J)N
MZN_2?7BUT5#42D5>0Q9!5R2XN'!1%<>-:V8,GFBGXK2$*^+W,C+KU%SN+$CP
MHS4>)'8CQV"2VRQ&;0RPVV6$IY6VR)))Y2+'0NG45R;H,!9?#0@ZK,H$[+\X
M;)T1R^TT5&ZZ1H=C*[;NH'I TK^:S8KPJS%G'\7QGGYJ]&,E#RK*MBL_1J5\
M&: 8"O[<,18QWEF_+US];7>6(NQ4!VL/ 8V]734(]3LBN2+&I].IKJGZ<VB7
M-=EO1XGK/'*4Z2TFXZ@W3];)<WR""'0C8O;VK6^*Y]JDZ\:W$HE!D+9:K/G)
M[OC$B.X_UC'((^G)CE4>.O<6)^)9OHW%;9+XM.VM)-*:G?=(N&-4V*E*A)6:
M(I%'PA2S2P[W-9X[=>A'[17(TNUMW/Z5;FZ[NBI.B]Q3;JK;CC[]).'*0E*C
M96UR^*J*:#Z*ZD1>SWC>8.3-S4;$LMUCA-3(H>9/%UMFZP&EP=[0[ ]W[_4I
M.\,[WB7?XKF+U[DD,[;^ E;Q1US*X\V8<F+/2V683'SHW ->.JT2-%ON(U:<
MV)\+C3#93<MQW=1ZVY=%PUKRZ6IRV7HODR82IM7W-2U)<-:3P9G[C$J)$22P
M7RG]8C#X:6Z[6?=+8ERW#K%8,ZQ*G3'62APYI*)3R7%K2KEYFFOBDDO8??V9
MP)/2'"91UUUV47Y?.M,Z6/>'M>WLT:#7-]D@#]'M[UY<YQ+R.3DN19RJ\,AF
MJ[HZ]JPV>*Q&1'$SRVQ2P?F2QK"T#R^V]^_:Z_=?_-BY/\GZU_5[XJ%\&)IM
M[B&[E2=;;=25Q.='&TN$7W29VYB,B[%^86M-=M4+(TBTNO*\[_KL.@6_ H-3
M;=ERG$D:W9$-YIEMELU)4ZIQQ24))&>IBB%MYOC>3IMK)JEN$VIZ<56O4"\:
MY4I;5;6P<=N3%BRI2?&0U,9P:2;,U9+XR>I'U(Q*?AOC9\AQSG%5LD%7\H4J
M%.M9NRMJU'66V3,8OI$GL=88W9:-N (.EYP\2,G!CN1\(LOCGM''W+URS5I1
MNLVVUC R,2^1'M_07N#0XZ:>_?LK]U>I\,J!73*%#Z4:L'TALIP?DW\85X9=
M?RY["B9MZI^YN?Q"M;8^U.IMT>_?AQQ,F2MB*ZVA!G((E>%+PR7*SG.,>P>L
MVWQ>>)EJ+<M7TXM6AN5ZZXS<B#5:"TQ 2]&)]M;;B5+\)1Y2@U8/'3'3V#('
M@X:*[D:1O8O+576'3B?;)7,\<F=47U_<UO*C.\WJ\B4]%JQTZ9/I[ATN$XW?
M\/\ "<OL9>?!69K6'A^B4G6X;0L$3L>!)5?T.EB<T]3>D.#O4=@2N8S?(Z'/
MLUQ"MB(,[6BJYB7Z7=95EJ& .A\LF.RSK;'*Q[2'DD.:"0>Y7:=X^C7%3C[<
M=3:]KQKF4_3N+"9=K=MIHM+;\^A2E<J2?CGXB";<Z9(NN2Z%V&5_H]E:H5/V
MH36JA6:537#G2$J9FU*)#<YT5!\EK-#[S:D\QEGM[>XF WHZ&UO<3MPU!TBM
MZH_!56NJ.RS&FJ0EXF3;>):O46?*9&73W>_VBH[K)PA-U&TC12\-3V]<JM%M
MVU>:;*HM/2J$W);DOK419C24<I),^IDGN>??G787+8GF/%;G',ED</QR_;SE
M-].&IB_)9,UD;6-_-56M:^1\K@T/DDV- $AO<;',XG*<-Y53Y'C<;F>1T:F#
MMLNRV\GYKX7.DZW:FLN<]C(XV]18QA!WL=^QLM<52XK;E[%M:X\*X*++><I4
M8D-1JM!D.K/Q.R4-/J6KMG!$?080>CND9;1I>2Q_QI-[ECH=2DF(,]G7#]W0
M;]M)JC>]%URKT&WEN/17J),>?GL2E-/N1C-?F)2DGA2.?!I/KGZ+3W"UV67G
MLIT1<TXO.O)K]16\IPI),(CXYI#CQ^HV9IZDOW]^_P GR<CI8;B?#<MQ.//U
M\IECGZEJ:O'7F@?"((C'+&X/ZV.+/9.Q)KOH+ZN-WLSROF>(Y5)Q^QB\2W V
M:L-B2Q%/'-YLK98Y&EO0]O7W :YF^Q)/QE$+L7S%^0:@70B+W (34W(  "(
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M%>[TV.@_'IWL>GQ^?[_"Y"CFP?-WYE?5GI^(;AQMYY3R>3YE=_G[?0.0%C0
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M_P#O)59>A_WLQ^#Q_P#1)'ZA^6'_ 'LQ^#Q_]$D?J$1'U/VG]JGZ/ZH^QO\
MLM76[R_YHW/_ )/UC^KY KK\(?\ 5':__P /+_I$D6*+R_YHW/\ Y/UC^KY
MKK\(?]4=K_\ P\O^D21+O!OX/O%+_0<'_P 0<H"\3OX5_!#_ %IR/_AD:LE(
M^*7T_E,;AM1\4OI_*8W"(5/X]!]@_8@  *J   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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M"K<J,B$E51\1]+;OAL2^8G?"2?,>&U8ZGT%7N5QY]PD#PDU#0RV8ZWE<K:?
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M))1GU,NPZ.;P8\08(Y)9<1 QD<3YGDY+'_X-C>IS@/I.W=@2- [UV]5R%?\
MLBO"FU+%#!GK,DDTT<# W#971ED>R-K2[Z+IOMNT>H@-[;T%8%&*>]0R^ULU
M._@E?^C,>T7G?+EI6([>:J6[/3'IL:H/P6N;Q22\PE]Q*4I)2S4V1F6"29Y+
M'00B;I>*;I/>FF5_:84FC5&/<E09. AB;&FQ%$XDU(</$EE',2>IY[&7;)'D
M:/A'%\]F\S0L8K'3W8:&4I.MR0AKFUVLLQ.<^7V@6L#03U$:[%=)XE\VXOQS
MCV4J9O+UL=8R>%R+,?%8+VNMODJR-8R#V"'O+B&](/4"X; V-]IX(!XTJO\
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M?^*W\&_./YL9?^BN6SA,_J/K&_\ ;_Z2H2<",?A,_J/K&_\ ;_Z2H2<!S_\
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MWI?A'+I^84+5V?C>?XTZM:^C"KR"H*EF<>5')Y\+ ]X=#[?1U;!ZV/&BN4
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M04,";T>(K5JAL\G=#:FDJ?F6LMPM;%]%ZRU\ID_.OTX;!'=<;??RGB&3N8C
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M9%^CY1]3(L?H][OGM](F+%_P*\B'O_MPQO\ 0UYZS/\ TC>('_X S'].8IJ
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MU$-0&B74:'S_ %G^M:8+W%]0U  5?W]=_M0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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MFFU&=),R:CPY#,EQ6/>33BS(B+&<D0]))1&1&6<&1&70SZ'U]A?B',S03P.
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M%A:<S+%7%8ZO/'OHF@I5XI6$M#26R,C#F[&P='N"0>R  #X%MD  !$  !$
M!$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M!$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
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MK/B.-(5_>_M;P9?.0LS.*9=0;;K?B(5T-#C)K0?SI4DR/Z1\[X*HO_9%._\
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MFAQM2*6-X]'LD9$'L<.^BT@]_7UWR@.+QD^Y?\17Y@\9/N7_ !%?F&J6_7*
MXO&3[E_Q%?F#QD^Y?\17Y@1<H#B\9/N7_$5^8/&3[E_Q%?F!%R@.+QD^Y?\
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MBV.G-,)ORZ>O;+A9/MDQ;L!':]G0 ]D>B   K4  !$  !$  !$  !$  !$
M!$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
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M 57>GUCV'Z!'N^/V]O=]X5H9)$1=.N3,\^_)C<-B$\I&6<^LH_K,S&\%B0
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MMV ^E/PG.-QR5-J2T*-:5R)4@U2%F2U&9&M:OG&:0 "IO?<]R@  (@  (@
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M!+B/0:Z7 @D #T]1\^P^U72TD1$9$>>I_7D;AH7S8&H+$@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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,   1   1   1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>nt10002526x6_linechart7.jpg
<TEXT>
begin 644 nt10002526x6_linechart7.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( AH%R@,!(@ "$0$#$0'_Q  ?  $  0,% 0$
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M7E_:5D   XP
M
M
M
M
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MD^5+OVSU[9]W\/P+A   *@
M
M
M
M
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ML_"?$D2%N/+P7;F6> 'N^O+^)G$
M
M
M
M
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M9+'\[7$1?051,B/[ ./.6O@_^Z9U0  +
M
M                                  4>U7UXTOT39IK^I%S,6ZU5O%*
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M9RNX#Y27*6/G/\IF8^AJR;X+L@
M
M
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M\/T<+[T=MK_%+@_?X%?-?!_FC.F  !(
M
M                                '!J!9BR>_P#2<LNAF7^\J'.'"G_T
MK)_%)7_HF+0_7C_QE^92I^I+X$*'<M_5]5[J9_T7T'N?7^FF//N)IMKD7W-6
MZ?\ ]!I!=S_XOC_QB%EN6_J^J[_TOH'[Z8$TZU_]S-N_WBI'\'QQM']H?_!O
MA#_JM+_LNDFB7V.U_P#;+[0?^O$?V7FL-'>@ #5HWP
M
M
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M.PTDDMLL-H:::218)*&VR)""(NA$DB(BZ$!#;:2],_MQ_ WP  (
M   T/L?T'^8:C0^Q_0?Y@!%J]*_^]JW/^.4S^%HXO#]'"^]';:_Q2X/W^+//
M2O\ [VK<_P".4S^%HXO#]'"^]';:_P 4N#]_@1YKX/\ -&=,  "0
M
M                                                     .%/_I63
M^*2O_1,<T<*?_2LG\4E?^B8M#]>/_&C^:*5/U)? A0[EOZOJN_\ 2^@?OI@3
M3K7_ -S-N_WBI'\'QQ"QW+?U?5=_Z7T#]],":=:_^YFW?[Q4C^#XXVC^T/\
MX-\(?]5I?]ETDT2^QW_AE]H/_7A?]LU@[T  :M&^
M
M
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M^CA?>CMM?XI<'[_ CS7P?YHSI@  2
M
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M?R#81(;6XILG&5*3\I"'4*<3GMS((S47V #D
M
M                          QG[R.'A2MTNLNB.M,2[(UKUW2!RLI>ARZ0
MW6(MPPZVVEB3'=:D<S+!E'YVR639G[1*+J0L_P!;=J^V_1[<UH-JOJ3K[9>G
M.G>A*:T_9^D"8=+B27)M;BI^%I+DUIYN4WXTOFE)0Z@\$KE3T+(SRS/'\!_U
M?]6]7?\  _&/#/P?_/R_,(%.LFQ6F;Z.+UN5LC>_J_5--:)29- +2JERJ]-I
ME,N)A^G&J<4=;,Z)%8]722#5^R,^H%X]>[PDGY9>&TGC\?DLDM"/Q1-BY*8C
M,Z^VPI2W6(3""DQS4;BUI89;+XTS/*C2DC]_47ZV[<5'NJC4^OT*:W4*54V$
M28,QHR-N0RXDEH6@RR6#2HC+J(D5/]&(V PYM-J,;7F(IV%4H%0CG^B I1+=
MB2FI#2,'7CYN=3:4\OZ[W'D2J]']/J+I?IS:=BV_-*?1[;ID:GP99/>L%(9C
ML(:0OQN=SGYDH(\\RL^\/C]?L15XZ8_;_85.   @  HMK-N!TBT#H7W1:KWQ
M1[/I9]6W)\N.V^]UY3\*.XXEUS!F1'R)5C/4 5I 6XZ&[K] MQ*)BM(M2J%=
MSD'D]8BQID9$Q'.9DGEBF[XZ^QYY6SP74^@]1K)K]I'H+0#N75:^*-9U)+)I
M>J,R.T\[@R2?A1W'$.N<IG@^1*L=SP QY>968!0G1/<CHON$I3M9TCOZBWE!
M8P3QP)<=<ADS,TI\2,AQ3R<F1XYD%GN0V-;MS.B.WFGQJGJ[J#1;.C2^8HZ9
MTN.F0[RF1*-,93I/&19+]9T+)@,>7F5]&A]C^@_S"D6C^NFE6NUN-75I7>E'
MO"BNY,I-.F1WG6\&:?CF&G%N-9,L%XB4YQTR*NGV/Z#_ # "+5Z5_P#>U;G_
M !RF?PM'%X?HX7WH[;7^*7!^_P 6>>E?_>U;G_'*9_"T<7A^CA?>CMM?XI<'
M[_ CS7P?YHSI@  2
M
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M(H;EK9.8[[;IFI>?:P9&1E@7A <3]W8
M
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M)=U\'[O^#[W\._D9U   +
M
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M2)*4H22$I270B2DNA$1="(NA>0^@
M
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MCB\/T<+[T=MK_%+@_?X$>:^#_-&=,  "0
M
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MO['?^&7V@_\ 7A?]LU@[T  :M&^
M
M
M                       !Q92N5MPS;Y\,O'RXR2\(,_#,_+G^3]8@A[N-
M>=\.T/BF:[:O;3]J]2JEO72_1BO!R.M*V;S]2@&S$6R\]%6F%ZJI2C5X)^WG
M"NHD/\3C<MOWVJ7#9.J6W/1A[6_1ZF^NO:E4"+4(M.DPXI)24=QM2T.2GC^6
MYRLISTQYBP2P_2;=DM0YHVO.G%5TIO)C#56IM4LRJ5-QF4WE#S?KKE)23Q)6
ME1$KG,C+J70#D@GW4>==L>G7S2ZEFM/XZ'%??GTN/*V"UMAF55:9$DR/A5H_
M!8E2V69#_*4+J3;:U+,L^1]?,3$-$;RN.^M+[,NJ[**N@7!7*3%EU.D+/G5!
MDNQVW'&5+))$9H6LTGT+J7D(\MS>DP<,^G4YQZUHLBZ:L19BTN'I[4B<>>_W
MM!*;I*S29JQ@\9+([?;%Q2M[^_?7"RHV@^URJZ<[;(,E_P"ZS46K341ER82B
M(XBFZ14HL:2DE&1HPT18)6<>0$2B^_)RKW^>//K^[\R2^ X\7QR88]8ZN^ S
MXI^9O>&GQ>W]OG_(.0!0           #0^Q_0?YAJ-#[']!_F $6KTK_ .]J
MW/\ CE,_A:.+P_1POO1VVO\ %+@_?XL\]*_^]JW/^.4S^%HXO#]'"^]';:_Q
M2X/W^!'FO@_S1G3   D
M
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ML)'>@ #5HWP
M
M
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MJA%8FQ)#2B4V]&DM)>9<0I)F1DMM:5=^Q@'GSS\\_/N<T  "
M-#[']!_F&HT/L?T'^8 1:O2O_O:MS_CE,_A:.+P_1POO1VVO\4N#]_BSSTK_
M .]JW/\ CE,_A:.+P_1POO1VVO\ %+@_?X$>:^#_ #1G3   D
M
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MX$O&N9RY+>K1CAX[1P7JI/F+/T_D,R_R#4:$1$6"_P!<GD:C4\_0!>_N
M
M
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MT<+[T=MK_%+@_?X%?/Y/_NF=,  "0
M
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MGF5QJ^MW>*E]>UJDLSFG5S3H*4FX4(03;>6P  \090       ,
M
M
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MNF<V&TI/I56>QD7L^70O/Z1>%Z.%]Z.VU_BEP?O\#C\U\'_W?KS,Z8  %@
M
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MG*SV+H]RFUMO9\9/[K4IPE_>[S4XYJU*D5&3I3E--*XE%?0  P.;7
M
M
M
M    ;+[9N-N))7)S-.)(\?)4I)D2O^KW^H1&]]_ 3U)W1[M[WW#T_>[3=.)=
M7=BKH=#8D08,Z@DVQX3B7W$5*/(D>*74O&21I+Y/02Y'FS=0XDE&DUM.((_<
M:TFDE%\Y9R(K.]3@,[H-RVY3476NS=ZUSZ>VY>#D-RGVA$AS7(U*]69Y%I;6
MB:V@_$5[1\J"QY@6B\/.>7WXS^PL_C>CO[E6)=,?/B?<Z(=6I<Q;9U6.1/-P
MIC3ZX^?AO_?TH\/Y^;L)B6B%CS].]+K,LVI7"5T3J!2(D&37B42_A)QB.VTJ
M1S)6LC\0T<^>=7RNYB IO$X/N][8_;E&UHO[>'==T:+T.ZK;1>565(F0ETIN
M768D>&28Z*@<B43[BN51(2?*7RNF1.[VK.4A[0'2UVB7,N[J:Y:])6Q7W$K2
MN>I=/CJ<-1+4I?,E1F1FHS,^N0)GY/F4N_98QC'N7N_>7%   4 ^33G!Y,C+
M./=U]Y=C'T  ^"018^;."+V2Z_,70:FG/G_E(_I(^ACZ  ?*4DG_ $="]W0B
MZ I)'GMU[Y+)']1]!]  -"+'^N"^HBZ$!]C^@_S#4:'V/Z#_ # "+5Z5_P#>
MU;G_ !RF?PM'%X?HX7WH[;7^*7!^_P 6>>E?_>U;G_'*9_"T<7A^CA?>CMM?
MXI<'[_ CS7P?YHSI@  2
M
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M,%%)))+H  !TSZ8
M
M
M                         &P_XOAN>%\OP7>3'_"<A\G_ )L8$1#?54_2
M&F=TVIC6UJ#(7H4EV#]Q2R*C8-LV?YZP4@O&Z.X^5Y#)3Q=[MXJUM5'2U/#I
MM]-:AR"JGW>&I=+3X/*2?4/_ -P2KN>?D>_K\V&#]%;THLU$E-A-F:NQ$NV3
M[%UZ^'_E O%>>8?"37KZ?70M_P!0MFOI#F_&ETK1O<Q-D432*97J+.N=2SHO
M(N-3JDQ-+F;94E;F/"/&,X/ZA-SVU:-M:#:)Z>:5-3%3_N0H,&"]*62B4[)1
M$:1(Z*,S(B=2HBZXQC&1$49U2]**;F4M,RPFTQEU:FIF*)=M8*G',9*>?,3?
MZV,;A].ON,C$PK1&3J%+TNLR1JBSX%^.TF(JY6B\,^2HG';.0G+?L='><O8Z
M= $VWA>SA=E'MY=_KU*M   4            T/L?T'^8:C0^Q_0?Y@!%J]*_
M^]JW/^.4S^%HXO#]'"^]';:_Q2X/W^+//2O_ +VK<_XY3/X6CB\/T<+[T=MK
M_%+@_?X$>:^#_-&=,  "0
M                                                     #3/T_8?
M\09+Y_L/^(,/T^OIK\2,KZ^7\4:@  2  =36JW3+?IDVKU>:Q IU/8<D2I<A
MQ#333;2%+5E2S21J,DF1%G)GT+J+0A*I*,(1<IR:C&,4W*4F\))++;;:223;
M;PNI2I4A1A.I4G&$(1E.<YR48QC%9E*4I-*,8KK)OHEU9OU.HP:3!E5&I2F8
M4&$RY(DR7W4,M--,H-U9FMPTISRI/!<V3[%U,B$17B2:E6ENJW%0J%H/;KUS
M5N@N3&:C5H*'E%67&F>4^;"%)9]6-M1(/FPO&2%RV\G?-J7NNU"7MDVNHG/T
M&=-^#:O6Z=XA%4D(<)+RENX2<5,8R</Y9$X18SU&3#8AP^[-VP6\S7J^TQ<>
MI-89:DU:L3626Y&=<+G4VE+GB)YB):FS-/4^Y_-LUL^QM.!]C2WSNF<Y[PU*
MRJ1VSM&G6E3JT[6Z@H3U#7%#VJ-&46_"MY>UGR=1?S>D7$74[_[3^J5^%VQ:
M=.GP]T;4Z$]Z\0:UO&M0JWME4YZ>E;9\3V;BO&4<5KJF^5I]9*@UX\9FS-VF
MZW;K29^E]&NVHVO#:0N([0YL7QGH9/<W,A"Y)$Y[>3Y>0L]2Y2+H*\[-MEVL
MF[75NGW_ '[$GMV<U4F*K<%RU$G#547&G2D1R2R\9.8)U)(^+YB(C(^W?ZXL
M<6+$WH59J+&8C-JJ5NFIMAIMIM7,48SRAM*4GDS,SZ=<]1*6VMQ(D31#3_U6
M+&BD[18IN%&8:9\0RCMGE?AI3S&9Y,\Y,\C+7$?B/_)78.A;JVUMW2-(UWB-
M8N=_J-"A3C<6KG;4:M6:J0IPG=56ZTO"G6EB$L5)1E)(U\X,\&EOSBQNK8F]
M-W[@W!M7@YJRHZ5H]W<UI6E]&C>U*-&#HU:U6G8T/]CQ\:E;Q3G"3I0G3B5R
MH5(BT&CTRC0D);BTR#%A,I26"Y8S*&241>7,2"/ZQVP -"Y2E.4IS;E*<G*4
MGWE*3RVWYMOJWYL_5^E3A1IPI4XJ,*<8PA%=%&,4HQBEY)1227DD  !4Y
M
M
M
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M6\]/<DNN.ZZY^N]T(  '&           !H?8_H/\PU&A]C^@_P P BU>E?\
MWM6Y_P <IG\+1Q>'Z.%]Z.VU_BEP?O\ %GGI7_WM6Y_QRF?PM'%X?HX7WH[;
M7^*7!^_P(\U\'^:,Z8  $@
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M_BMV5_  &JIOJ
M
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M9#WP?3D^&USH(BPI73F+ $9]>GQ]_P ,DED!\H5S$9F6#)2D_M3P/H"0
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M9)I907BKYL);+K]HS@\2WCH:+\-[4NCZ:WY9%3N.H5=+RBD1$3C0UR-)>_\
M=X[B3YB5CN!22Q\&D_D_4M0]*_Q^EJW/U+^FZ8??_P"JQ_\ \?3T%X?HX7WH
M[;7^*7!^_P 1,N-9Z0#H5Q!=HU=T-LC3RJ4&MU.3 5&J$OX0)MCP9[;ZRP_&
M:;/G)..JC/J)9GHX*B5PC=M>/*+<*?K34<?Y *^:^#_[IG4   D
M
M                     ^5*2A*E*,B2E)J49F1$24EDS,SP1$1=3/R(!VZL
MMQW8'C034?S_ -IGNW]Q6(P7"(_JQ8?]\;@_<2!EGXB?$5TPTYH=SZ)VXAJZ
M[QJ49<*J(8D>&S2C<;/D-3I$IIU1I6?1*DX,C+N8C^;,MR%/VQ:XP-4:C1U5
MJGMRY[TN&3JHRDE.)PO86:5&KPR7G)$><#=3@]LK<ZX0<0Z,](N:=;=%@GH5
M&KR4JE^E;5(J5.%247"%1RCX4JG)&HFG%M=3\S_M$\3-C?\ A#\(+N&X+.M:
M['U6*W1<V_B5Z.E25_0G*G6J48352I2C"3KPH^)*DTXS2::)NU]WY;&G%LU6
M[+LJD>DT>DQW9$F3)<2@O82I1)02C(U&HRY2Y>I=!&5W&;E]:.(WJ@WH9M_@
MU*-IS'J)Q*G4(BG&V:A'2Z7BO./GX9M);)"U$1JPO&"Z8(=+K5N"URXG6J%.
MTHT<@5"D:9MOL%4_5W\-FPYX;CYRG<-F7A\JS22C+FP9)+K@9^=H>T2P-J>G
M\&W;=@QI%QR8S*K@N%3)>LS9'*2S0DU\RFO"4I23Y5>V195G/7'UEIFD<$-,
MHZWN"A:ZKQ,O:7BZ)M^JX5K?;5.<<0U'5(1DXRO5ERH46WRRPX]5*<<NZEKF
MXOM/:U<[9VC=WVA<%-,K^#N7=E"-2VO=Z5J<X^)H^B3J14H:=F/)<W"CB4&W
M4S&4:53I-F.S&P]IUAQ*52XD:H7G/CLN7'<;C)'(D2,<Y(1XG,IHVE*4V:FU
M%SXYE9R+V>P=@&O^L:SJ6OZE=ZOJ]W5O=0OJTJUQ<5I.4ISEV2STA3@O9ITX
MXA3BE&*2-MMM[:T3:.BZ?M[;VGT-,TG3+>%O9VEO!1A"$5UE)]ZE6I+,ZM:;
ME4JU)2G.3;8 !3G4C5>Q-):-]T%^5QFA4K)%ZT\DU)R:B3C!=?E&1>\=*WMZ
M]U6IV]M1JW%>M)0I4:,)5*M2;[1A3@G*4GY))L^I>7EII]M6O+ZYH6EI;P=2
MO<W-6%"A1IQ_6J5*M1QA",5U<I-)>I$OXM7]6I5/[Y6Y^:,)2^V/_P!B&GG]
MY(O[V;$3+B6:B6AJ;NOJ%W655VZU07:A0G$3V4J)LVV"C^*HB/KA'*H_J\A)
M9VA[D=&;IL?3[3N@7I%J%VE266BI2$&ETW&HS?BHR?[#"L_Q#;/C'I6ISX1\
M)Z<;"\<]/TN<[Z*MJS=G&%C:*3NDH?S"CAY=7E71]>C/S]^SCKVB0^T)Q]JR
MU?38T]7U]1TJ<KVWC'4I5-4NG3C8R=1*ZE/FCRJCSM\T?59OS  &HQ^A8
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MH&FH1C\?'?P,.'XV//DS@=L1YZEU(^I&7F
M         TP7N+[!J  X[[:307<O;1V49?KB^<1@[O,_]D"Z=)R9D4.J&63,
M\?T-YZ9[=_(2?WODE^&C]T0B_P!W_P!<#Z=?B54_Q;("'^]?FB4"WV5_='/W
M9C<&VWV5_='/W9C< D
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MSSTK_P"]JW/^.4S^%HXO#]'"^]';:_Q2X/W^!7S7P?\ W49TP  )
M
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MP5R&T$K"T^WX1J+WG[\?6_'9M6]QW'UTYBZA:65*Z-!ZNQ.CW%5.22FG&HZ
MEN,MUYMHT%X3YY21K+)E]0".,X><*#^>>K]RZ/O[OF5UX/=?W(\2_7F_M^&K
M>KLRD:34*6;MEZ,QS29)AQ2?C9E.QGFW&$J2PV[\>PDSS@B,4*W ZQ[M.*KQ
M4+PV4Z6ZS5+0_1#1A^*S5*A38I379"Y$'UEDU$VXS(49/L]C69'GJ>.H]EH'
MI7KEPCN*Q<NEEDV=7:QLOW&''BQ94-$I^FVN46FF2B)E*'C;)R7)P:B\,CY<
M^72D^X+3C=;PMN*C>.\[1C2EG7?2#65RG2ZA;U*KT*/5$**G$TRT]"86_46C
M)Z1C*F4]"-1^8?7U]=B.SRL)->QY]<KIY]>_?R/ ZYR=^NR7B8[2=M-Z[F*Q
MJ)I15:E46+=G.TQ%-55&6V([LMN2VAU;BO#-7*1O*5\WF8GCT%QQVDTI;BS6
MMRD4UQ:C_7.+B-FM9_.H\F/SQ=S.O&Y/<EQ8-E>J^O\ I@[HW2:U5JJYI_84
MBH-5.3!0F/&1.-UY!)?2;B>5PB?21X/!>8_0WMW_ /9J-_>6E?O-H!-=(OIE
MK+QCW=\'>   <8                                !M/?)+\-'[HA%_
MN_\ K@?3K\2JG^+9"4 ]\DOPT?NB$7^[_P"N!].OQ*J?XMD!#[?-?FB4"WV5
M_='/W9C<&VWV5_='/W9C< D
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M*(5#FTV'-I7J1-IC'#E1VWF/"2T7AI+PEH]E/;M@"9K&/9<?^=S9^#Q@]
M!0           #0^Q_0?YAJ-#[']!_F $6KTK_[VK<_XY3/X6CB\/T<+[T=M
MK_%+@_?XL\]*_P#O:MS_ (Y3/X6CB\/T<+[T=MK_ !2X/W^!'FO@_P T9TP
M )
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MF-1J<VVVVVVWEM]6V^[;\VS?Z,8PBHQ2C%)))+"271)+R271+R70  ""P
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M^X '8XD&$Q3H<2#%3R1H,2-"C-_\''BM)991\_*A"2SWZ#:J%+I]59./4J?
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M;89:CME[FF4$V@L^>$I(;J4)3VR?TJ,_SC[ -Y_J   $
M                 &T]\DOPT?NB$7^[_P"N!].OQ*J?XMD)0#WR2_#1^Z(1
M?[O_ *X'TZ_$JI_BV0$/M\U^:)0+?97]T<_=F-P;;?97]T<_=F-P"0    #Y
M4LDX(\GGW$9_F&GB%T(R46?>DR 'V            T,\$9^[ZP(R462S]98
M&H           #11DDLGGZB,S^P@(\D1^_Z@!J          #AS4/+CR$,GR
MNKBR$-'[GE-*)L_J49>740:;"U8T-VD<=?<O7]]L"/'<O*9;ZM*[SN>GN3J-
M 2Q2UIFDPV^P[#42R6VA77H?7OD3H3QCJ, '%VTFX3FM+E/H&]>Z;=M;4" 3
MITBLQI*F*W#YB2ITY'P>XU*4:FR22?%61D18+H!:#ZM-/#6'CNNJ>?Q1BL](
M"WF;!->=NEMZ3Z*/6O?FOU>NRUCL&59M'8B5&E>'<,!Z4HW*6P2CYF/V:B)*
M2^DA*5V+6]=]K[5=%J+?"GU7)$M&DG.]94I3Q(<I\=3"5FHS5[+9I+VNV/>(
MK&TO2;T=/;'J12]1Z9K#"O2\*?4(K-MOUQ=:FLT^:^\AAE*6)S\AM9K=4@DG
M@L'@_<)G%CW-;-WVK0[AM"4U,MNI4^,Y1Y#*/#:<@^"CU?PT8+E237(1%@NF
M"\@)EA))*73+]I8[I=E\OWGK0  *            :'V/Z#_,-1H?8_H/\P B
MU>E?_>U;G_'*9_"T<7A^CA?>CMM?XI<'[_%GGI7_ -[5N?\ '*9_"T<7A^CA
M?>CMM?XI<'[_  (\U\'^:,Z8  $@
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M<M/2[2&N7-JHQMZ^IQI15W5HJ%.E!4YU>9QY:5-8QB"0  'QSTH
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MXO1S<9:K-Y:/7Q2;SH$A/.F3!DLJ>;(SY2\:,E:GFLF1X)Q">W3(##]"N
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M!EDC^L@!] -#,B[ADC[& -0
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MMM?XI<'[_%GGI7_WM6Y_QRF?PM'%X?HX7WH[;7^*7!^_P(\U\'^:,Z8  $@
M
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M07,GT\P  /-GM           ,?7U\$
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M:^626HE?(]PG$>C@$9<(W;9GSC7$?U'4<D!Q^:^#_P"[ZF=4  "P
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MFW:2BDDDDDDDECMT\@  ()Q]?7P0
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MP*^:^#_-&=,  "0
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M;;?5M]6_BS].H*,8Q44HQ22271)8Z)8Z=%T7ECL  !!8
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MI;2:E*2DB\UJ)*2^E1X(A\(>;6232MI1*S@TN)41X[XP9Y^K/SX &\
M   9(^QY          !H9D6._7W%D :@/E2B263,OK,D_E,?1'DL_FZE]H
M/E2B21F9D1%[S(B^T^@^/%3[T?\ >)_C &Z ^25GR,L>\NGU'V,?'BI[<R,E
MW^,3_& -T!\$LCQ\_8R]HOM+H/L  'P2R-7+DL^XU%G]KW'V     VGODE^&
MC]T0B_W@9GZ0-IT63P4*J="/O_0V7<2@'ODE^&C]T0B_W?\ UP/IU^)53_%L
M@(?[U^:)0#:2PKH7ZHYY?VYC<P7N+[!\-]E?W1S]V8W )
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M,BCIO2K7)3CJL9#BG8/B.QFO%0;1I61I\3/123R18,NX[:B^B:TFJT>D5/\
MFQ+[:^$:53Y_A$==^*.9$:D&V1%4\<J#<-)8Z=.Q=A*2U_V0;;]SMY:>W]K-
M8C=U71I=)?EV545S7XQTE^0M"W5I0U[+O,IM)^WVP+JHD2/ BQ8<9)-QXD9B
M)'1GY#$9M+32"SWY4)26?F OSM12BVL9SVZY?UW(;D?T2NE,2Z=*+>/?BO4*
MK3:GR?[?$3GP?+:E$T?^V>,.>%R'GI@^I"6SHQIJG2332T-/$U5ZLIM6E1::
M53D<_C3/5F&V/%7SJ4O*N3F/F4H\F*IY+WE]I#4"KDY=WGZ_J   $
M     :'V/Z#_ ##4:'V/Z#_, (M7I7_WM6Y_QRF?PM'%X?HX7WH[;7^*7!^_
MQ9YZ5_\ >U;G_'*9_"T<7A^CA?>CMM?XI<'[_ CS7P?YHSI@  2
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M<E]KNH[QWGK--T+W<6JIQJQMI.G4J4:$)U;BJI5IPAX]:M<5:DU2A"/)%-,
M ,.&R
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M(9EU^L1/./AHG8^U+A=Z!:3Z+IKEL6?0Y]GR8+#==J3LPGZO6*/,G*=G./\
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MJW/^.4S^%HXO#]'"^]';:_Q2X/W^!'FO@_S1G3   D
M         #PNHFI%G:5VO4;PO>LQ:+0Z8T;LB3(6DCQ@\$VV9DMPS,L>P1X'
M+0H5KFM3M[>E4KUZTXTZ5&E"52I4J3:C"$(13E*4I-)))MMX.O=75M8VU>\O
M*]&VM;:E.O<7%>I&E1HT:<7*I5JU9M0ITX13<IR:C%=6SW0#"3=_&QT*HM=D
MTZWZ,NX*:P^;)5+Q7HOB)0HTK632FLF18/'O%[VV+?;H?N>9.'9U?CQ[D8))
MRZ%(,V76S664DTM\D&][)9/PR/';L/;:OPRWYH6F?IC5=KZK9Z<HQE4N:ENW
M&C&6.65Q&/-.A%Y2S5C!9>'U,8;>XX<*=U:W_)[0=\:%J.KN<J=*SI72C.XG
M'O"TG44*=W+I)XMY5&XIRCE)E[ #S-?O&U[8A2)]>KU*ID:,GG=7)GQFUI27
M4\-N.)49_,1&,>NM7%.VQ:4-OPX5SMW7<#!K25*A,OJYW$9]@GF4+3DS(NI%
M[A\+1-K[BW)75MH6C:AJ=5M)JTM:M6,,^=2I&/ATX^;E.48I=6SU6YM][/V=
M;.[W/N/1]$HI97Z0OJ%"K4ZI<M&@Y^/6FV\*-*G*3?9,R7Y+_3UQ]O8>4N.^
M+3M2#(J%P7!2:7&C)-3JI$^*AQ)$74_#6XE9F7N(C^H1QKTXI&ZO7FJOT+;E
MIA6* Q(,V(M0<9<=0X3GL$OQ)48DI]^25TSW'36]P\]\NYB8Q6-?-1*M:D">
MLGG6F7R41MK,E&E3$5Y&"Y3P7L_5@97H<%7I%.%UQ"W=H&S:/+&;L)7,-4UN
M4>C<8Z?9SEB6.G6H\-]8^3P)=_:7_E#6G8<(^'V[.(ESS2IPU2%G4T3;4)IJ
M*=35;^FFHIYEUI04H)\L^I<1Q/=]>AUY:&7-I!I]>::Y==97';<9B-.DEOU:
M2EQ1>,@^11&G/GC'O\[0>#!5](:9JG>$:_%4MJ\)90ON1D53PO )?@F<PD*D
M8929D?F9=>A'D9-]+.#IMRL^F2F[R9?OBMR(;C1564]*96U)<:4@GN0W%Y\-
M9DLBSU,NO<AB%W(\+S<-HC>E0K>D<&==%J)E.R*54J;).!(I[;BS637(VYXR
M^3F)!9,L\ON/ S#LW5N$NH[0W%PGT+=.JZ-^E)*ZCN'6X4+*GJ%W)T%*-!1G
M34:"^[4H3M:\J=2M2J349.637#B/H''_ $?B+M#C[NG8VB;C_048V,]I;9G=
M:E5TK3X1K\LKM.G<.=TW>5ZE.]M8UZ-O7HTY3C&.#)=QDZWI K0IFFR'J#(O
MYQ7-;7P6J(M]I)2$G*-2HF32DVL8\0R+W#'_ ,*39II=N7?O>Y-5Z&[5Z=;'
MP8=*84Z^S'D*?R3Q)-LR;/E4DN8BR?VBW>PMB&\77N[*?%N>@5N/")]IJ;7*
MM4%O(@QN8DN\L:2X9'S-$HLIP>2S[A*OVG;8K3VN:5T>PK?2B1-;CI56:IR&
MAR?)69.JYR,S/#3BE)+J>2\L8QT=U[BTOA'PN>PMN;T>M[GU*^=S*_TBYY5I
M=O.I2J7$:=2A6J_=HU(4HTHT_&=6<JU6KRQ3Z_4V#L[7?M!\<H\5MY<-X[;V
M1HVF1LHZ1K]FYO6[NE0K4;25:G<V]O\ ?:M*K7E7J5O \"E"WHT7.4L'JM.=
MM6BNE;+3%EV%1Z:AE*4H4[%CRUERE@CYGVUJST+K]&.@KA'B1XJ>2/'CQT=B
M1'9;821%V(B;))?Z^0Y #4*\O[W4*TKB^N[F\KS>9UKFM4KU)/UE.I*4F_BS
M]$M.TC3-(MZ=KI>GV>G6U*/+3M[*VHVU&"PEB,*-.G%+"2[=C0B(NV?K,S_.
M9C4 '4/H))=D   )
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M2JG^+9 0^WS7YHE M]E?W1S]V8W!MM]E?W1S]V8W )
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M822&R;@Q5.$E/1.7?#YSQ@L95]/7J/?$E)$1$1$1=B3[)%Y=BZ#;\='[-O\
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M2@6^RO[HY^[,;@VV^RO[HY^[,;@$@
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MW,Y-*,^^V3;ZT-$IF02S:P@S+))3GR&)#BTZ:Z6Z>Z\05:>)@QI=<-]=QTN
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MJO\ \W-R?]"Y_P G_P!8_6/CB!Q^FX\67_X^[/\  ][^0A^FX\67_P"/NS_
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M$-P&X+53=5J[#U8U3AUN?=54KUO)D/HH$MII;;<R,PGV68Z6N3PR[D6#+KC
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MCUM.COJU'U0A6G O.MG.DJ^%8IMT6 M!1E+-IA2HSJT<[225DS4>3%R'&3T
MTPVM\&*R+2T3H]3L^A5./I[49D5NL5!V0Y+J%4I4V4X4EQWQDI<D/.+Y4JP2
M5$GL0#"Y88[RDUU^2_L[>9*6V9+NQ>W/395ZWRWJ+<BJ81U*[VV&HZ*PLTIP
MZEIE2VT]^R5']A"VGC%:M:@Z(\/K7+4K2VX%VQ>MO4^G/4BM-M$\N(I<LDNF
M3:L$KF1E/7MW&-JTN(O-X>?#'VM7Q$TAN+6)VXK=<2J!37I[TJ*;)1D<SKC$
M>4\HU\YGE>.@MHW*\4.=Q'.&!O0]>T.N#1W[A*9:Q%\-G.,JHFI236OP2F1(
MW5DDF1FDU%C\@B,?:6>W,D^OOPRP393I[QMM\>VJC[C-,MY<JGTRLKK+D:AK
MMJF*Q\%RGF?#]9>=29^(;7NZ>X7S<'WB?;QW]U>KG#\WGU=-W:B6C29_W/W,
MA$-HV76*3+G^,I,(C;<-1-H/E4OV>I=,#%=PH:AQLYFU&AV[LHI#7Z!LIZX(
MU(K#SE$^()^;(;EJ2W/^.(_&6O!^_J73 S7<)3@\Z][?]8=6MZ>\RZ3KNO%X
M4>JR(L'P8^:>LZ9,8>+QXKILN$IMPNGZW!$1 <D\+G3Y>F.5)+.>GY+HT8D;
M UJXIN]??]N0V^Z*[JI5@PK K2&*9&^ 84U+;3IR%H;(WUI_6-D1F9]NXK+J
M5NPXQG!UU'TXN?=EJ$[K;H)>%=9IE9DG IE/3&9=F,PD/.N1?%=9Y5O^(1&:
M>8DXS@:<%)M1\:O>-GF,ON@AJ,RR7=B9[N_T]/M[Y(?2HZA0HVP<Z1.DP?AV
M;<%$11XJW&79SKGW01.8HQ&9O$?4L^&6?+W@OX_F1GVE%QBT\+LD\=LY77IC
MU[=S+7K]Q/\ ;WMZVGVYNBNZK2)- NZWXD^V*?3H,RH/52J28S.(3:8;;KI<
MLUY+)KY3QGF/WE&VX9_%>W:;TN+NN@7M4JA8^C58.8Y0])YT0B=B06J6XY%D
MNR'$-2$^MI)N4E+B"QS<O49P^&SMFTWUDX<NU^E:Z62W<TJV:(].I<*K\ZBC
MN+4U):6\P\1H=3["%))Q!X\N@P<[?J; I/I-VH=+I4"+3*93HD"+"@P8[46+
M'88M<VD);980AI.$)21FE)<W0SZ@5BE[:[M1>'Z8:7UZ?,F]E_E/\YC4:%V^
ML_SF-0.,       -I[Y)?AH_=$(O]W_UP/IU^)53_%LA* >/""S^S1^Z(1?[
MO_K@;3O\2JG^+9 0^WS7YHE M]E?W1S]V8W!MM]E?W1S]V8W )
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MF6WYGTK6RM+*$H6EM0MH2?-*-"E3HQ;PEEQIQBF\)+.,X   ZYV@*+:E;?\
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MK*Z/KY(I0TC2[6K&M;Z?94*L,\M2E:T*<XY6'RSA3C)973HP  .B?1
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ML96L_J-1F0W  "0
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M#TPO"7MP8UNT]K]4-F[*Z]$9J'W%QBEL,E+*&J'+<7E*S=P@D'[&<B/7QO\
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M"*:Z0VFU8^F5@VFVDT'0K3H,-Y!]TR&:7%:?2?7]:ZE9?/CL*E <(
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M/O'KE\L<_'T-X  "@
M            #&>X  -,%[B^P:@      -,%[B^P:@
M
M                      /E225WS]1F0^?"3[U?MC&X  V_#3[U?MC&X
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MX,U))R4:?'7RF9XYEGCRP+BP
M
M
M
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M*U
M
M
M
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MOM?,8%>;*J9>>S7_ $EU7R\R6HGY)?Z^8^A\IZ$1'\_YQ] <8
M
M
M
M                                                          ;;
MK2'4&A:&W$G^M<0E:?K2HC+\@XOJ$;_X6'_]JU__ (#G  /A"$H21$22(NQ)
M+E27T)+H7V#CRH4>822D1HL@D]4E*CMR"2?O23B58/Z!RP '"5!84TEGP(OA
MI(R2WZNT;:,ET-".7"<=^A$(M?$WX3G$(WQZ[7/0:+NAEVSM5NB72S78S%$C
M*1"B1?#5*9.2E]#[J7EDKIR^SGH)4(ZMY2O6<<RL9+ID\=@)C)Q>5C/OZEG^
MPC9A8VQ/;A9&@%D&S,BVS%7Z]5TQR8>J<N2LGY#KI&:EG\>:C+F4?<\>XKS)
M$9F2CPWF6'D'W;?:0\W^T61E^0;Y=B^@OS#4"'UZONS@Q:?%B9]7BQ(Q*QGU
M6,U'YL=L^&E.<#G   XLF(Q+1R2&(\A'["2PV^C]HXE1#Y*%'2PF.4>*3*?D
ML%':)A/7]:T2>4OJ+N.8  XKD1A9((V(RB;SRDMAM1)_ (TF2?GQ@;RVD.-F
MVI#:D&6.12$J09>XT&1I,OFP-P !PHL"+$YO BQ(_-U/U:,TQD_>KPTIR?S_
M .4?$BFPY+GB/PX+ZR,C);\-AYPL>Y:T*,OI'8  -HFD>'X9H0:,8Y.1/AX[
M8)&.7'S8&C+#;">5MMILCZF33:6R^Q)$1_8-X  &T\RAY"FW$-N(5CF0ZA+C
M:B]QH61I/[!N@ .#&I\6(:CCQ8D?F/*CC1FHYJ]V3;2DS\^I]1R7F4/(4VXA
MMQ"L<R'4)<;47N-"R-)_8-T !P8U/BQ#4<>+#C<WRO58S4<U8[<QMI29C>=C
M,NJ2M;+"U)[*<90M2?G2I1&9'] Y  #CN1F75(4IEA9H[&XRA:D_@FI)FGZA
M]/,MO-J:<;;<0K!&VZA+C9D78C0HC29?4-X !U\:F0XBS7'AP8ZC[JC0V6%G
M]*FTI/Z\Y'8   V'H[3Y)\1IESE/)>*TAPB^CF(\'GW#1V,RZE"5LL+)'R2<
M90M)?@DI)DGK[AR  &VII"F_#-"#3C'*I"31T_M#+EQ\V!\M,-LHY&VVVT_L
M6FTMI]_0DD1?/](W@ '7O4V&^[XSL."\[T/Q7H;+CO3_ .8I!J^CKT'.2GE+
M'T%VP1$78B(NA$0^@ '!DT^++-)R(L21RGE)R8S4@T^_!N)49>74NHY++*&4
M);;0VVA.>5#2$MMI+W$A!$DOL&Z  X#U/B//$^Y$A.NI/*778K+CJ?=AQ2#4
M6/F,;_JS7B)<\)DUI[+-I'B%\Q+QS%Y>8Y  #CE&:)[QO!8\3_A"91XO_>8Y
MORC:DP(LLT'(BQ)!H/*#DQFGS0??*%.)4:3SUR78<T !Q5Q67";);,=9-]$$
MMAM1-_W,C2?+]6!\RH,:62"?C1)!-_(*3&:?)'X!.)5R_5CL.8  XJHC"D-H
M-B,9-_(2IALTH_ 3RX1CYB(<CE+&,%C!EC'3!^6.V/F,?0 #KFZ9#;>\=$."
MV[U^-;AL(=R?GXA()>3\^HYCC2'4>&M#;B>GLNH)Q)_2E1&7Y!N@ -MMI#;9
M-H0VA)9]E"$H1U\N1."^GMD?#,=IDU&VTRV:NYM-(;,_PC219^L;X
M
M
M
/                /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>nt10002526x6_linechart8.jpg
<TEXT>
begin 644 nt10002526x6_linechart8.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( IP%O ,!(@ "$0$#$0'_Q  ?  $  @$$ P$
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MLK06)#5#4[478H+")E5G<W2BL__:  P# 0 "$0,1 #\ O\
M
M
M
M
M
M
M
M
M
M
M
M      (B.*YQ6;7X7UGV/=ES6&[?#5Z.S6V8[4]<(XQPEH2H^9+:^?FY_<6,
M 2DV\+J2[@*9Q>5W:8&E*V]M-PRD*22B5!FU&:74B/KYO"<QT/Z?8-LO*\],
M/;M>O5/RK9KJ2^LZ;_\ 0"W9S_LO[BYJ A4X3W&)M3BB2M38UN:75G3P].?@
MSQU54IQ>?_"/-R^'YW&8^]XZ\N>Y$8FJ(\ED"K33PUAFH  $
M
M
M
M
M
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MO1&H  %0
M
M
M
M
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M]2,C^8 :@
M
M
M
M
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MYQC= H
M
M
M
M
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M?S#%1;9Q^N%MYOSVG^@7 )C^U^ZRW4SZI_AK_.,;HVF?5/\ #7^<8W0*@
M
M
M
M
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MF?5/\-?YQC=&TSZI_AK_ #C&Z!4
M
M                                                !F1=P &V3A'V
M)?3_ +)B.3B1\271CARZ,S-1M2)C$RXIS#I6C:*7C1+KLI!^&I"%(YEM>&M2
M3R:.O;)8,4XJUY1IQ/\ 6"L5:\="]#;BB:>PY"WD,1Z>J>R4!"U&A3<I4%7B
M\[19/D,S3[<&0%XPE)973Q;PC]#I*B5VS\QE@_J,>0J@<*+RC"B;HM0Z;MWW
M/6JYI7JK.=.)1JA577&SKDILC5(0ZPMIE$,T8)*2<QS\Q<I&+7+#[<AMMUI1
M+;=;;>;4D\I6VZDEH6DRZ&2DF1E\A@5E%Q>&L>O'H;P  $  &T^^S&:4](>:
M89065NON(::07O4XLR2DOE,R &Z ^? JE.JC:G:?4*?4&TF9&Y F,3&RP>,*
M6PM:2//0R,^_0;3M;I#,U-/>JU*:FJ]6$[4(S<U70C]&*IPGE=\]$=L>\ ?5
M ?#J-R4"CJ2FKUVB4KG]0JE584%:_P %,EYLS^@CZ8'IU"X(KEOUFJT:?!J*
M8='J<V/(I\MB8P;L6(Z\W\8PMQ'KH+VF6?> .3D><E@RQ[R,L_-D:BM'PK^)
M[KYNEWI[L]&-6:A#8L;1ZL4V';[DI<&&RPS*5()?._ALCR3:<>(O\HL@4RXJ
M'6%*12JY1:LI!X<*F52%.4@^Q$I,9YPTG\A_* :QL?;SUQ@_GP>/K[#40CW9
MK3Q&8O%'H&F-#LNG.[+WTJ^%+G56J*F:V?P8ETL4M2BJ:OU9E/1/8C/MWFDG
MU>G4EI+]5J5-IC)I(_&J,V/":SCKA<AQM)]>G?Z@!]0:9ZXP?SX/'U]A\2G7
M)0*PLT4BNT2JF7K)IM5A3EI^=,9YPR^H5P[VXFVXBA\<"V=C$-QO[3-40HY*
M?#C<^4T5,[US3X_WX_\ &_D E)O..Y-_8BRP ^+4+@HM')"ZQ6:12D+21H54
MZE$@<_3TN7SIUK.#QD>Q3:Q2ZPV;U*J=-J;!8^.ILZ-.:Z^]<9QQ/\H$'T@
M
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M&*BVSC]<+;S?GM/] N 6C^U^ZRW4SZI_AK_.,;HVF?5/\-?YQC= J
M
M     R1=SP  #3)>\OK(,D?8R &H
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M[ V([2&FVVVT\J&FFVD%G.$-I)*2^@B(L^W WP,(
M
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MKMUQCYYV\2ZNSZI_AK_.,;HVF?5/\-?YQC= H
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M:DL\N)=<9F)5S%DO>9?4/(:$1)+!>\S^L:CIQYY
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M3S41GGTU1&&35@S_ &1GC'RF.7@
M
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MYOSVG^@7 (BW[RSMRO;Y%NIGU3_#7^<8W1M,^J?X:_SC&Z!4
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MJG1H<%:5;5ZLZ%2$*-RE-NWJRE%*G66'FE)J:[T=K  #J1H0
M
M                     #3)'V,@!J #3)>\OK( :@    9(^QY
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MOYABHMLX_7"V\WY[3_0+@%H_M?NLMU,^J?X:_P XQNC:9]4_PU_G&-T"H
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M,O'3NSUQW9 #P-PB/!DKI\AC3Q4^Y7^B89]>OBA@W 'BE1*[9Z>\L#R
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MW\;Q[4V+;9[\W#7;!.J0K3CL)C4Q+BF3FS)KGFT5OQDI5X9&^I)&9X+KWQU
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MH,U6FT^IQSS'J,&)4&#[99F,-R&CQW]1Q/UCWAQ6Q_[C;0_S5M_]%1!RH"@
M          &VX>$D?_:3CY#R6!N#Q49$19+/4B(OEST %&WCE[O+6V6<2S1K
M7?3'2^IUS5^SG*@JY'V*9-J<:Y(LN"TTE"OU(_$C^;1#-*3+)F?4L&0Y]2/*
MX-,_@V&5:VCW,W54QVTSDHIM6Y#D)0DG5)Q23(N=?,KE(\%GIT&4'&[XF^V+
M:3JY;FGSNV&G[BM<ZRE\GV\<DZA\C*%L\J"B252/.&5%T(CY2[]!""CC&7"Z
MDG&^%$XXA?I)4<#NDRRD^M$SCEQ^4#,EF*;@WX/F2RMO'KWOP7WEL'A,<7^S
M>)Y+U-C6MI#5=,CT[^#/.55*-+CE4/A'FY?#\YAQN;P^7!\O-\N!-D1Y+(K8
M<!;>74]U$[6ENH;25;:"MOX$Y'#C^#]D/G)+S_\ <,//F^.OKX(Q9/(\EVQW
MZ?2!BDL-K&/+.?O74U   @              #9?]1?[V[^88J+;./UPMO-^>
MT_T"X+=+_J+_ 'MW\PQ46V<?KA;>;\]I_H%P"T?VOW66ZF?5/\-?YQC=&TSZ
MI_AK_.,;H%0                                            (O^,4
M?_V>>X3Y*"GI[?V0DWERX\"-(F2W6V(T5AV0^ZXHD(;990;CBU*5@B)*$J,S
M,_8*?'&ZXZNW&/8&J>S33"&YJ5>=?C_!-;J5(5)<;HSZ>;'(VPTZF8K)F@R:
M4?(9'DB,"T$VUA9PUGYGR_)"_P#F#UW_ ,X$?I.:+D9=B^8OR#\T_@4<8'3+
MAL,W+I-K59=;AV[J/6XSAW=4(E1IR*5X\Y;J#5#=BDJ2@SD<IFDRY2+F,R(?
MHNZ,ZRZ?:\Z>6[J=IE<$.Y+1N6&W+IU2B.)4E9*0E2T+01FI"FU*Y#)6#R7;
MKD"U5/G;:V?1_!([4   QFAG@LB.C>UQ&-*MDM1M&G:APWY+UW>>>8FRE]7+
MYH237GPD*[Y+N9"1@RST,8N[@-GFW[<P_2)VLED,77*MYN2=)6[(=9.-XZ?C
M3(D=^;E+OCL/KLI6<;F#OX5:EM[W:1H-*H_=?+AR:6TL9\CGN&JO#]#6+:IQ
M1;7UWHT55^E4--J0I7DI.E)472J5&H1Y:O)*6>L4TB* N/\ [93+F^"97+\J
M9A*_T/!S_O\ 2,H-H_%AT4W<:G_:QL>!)CUCE4HEN(E$G!,J=/JZTA/JI/V_
M0*ZU][=-(:5Q78F@4"UH[.ECDUMM5O<YFDT'")TR\XQXG5SJ9YZBUQH7L,VO
M:!7)'OK2S3N/;ESKBL*54&Y3KJLKCI2H^598ZI49'U]I^\=GU>TX?LK:CV5O
M>=O>6D;FVDZL7"'/CE55;/XI9Z]YNOC_ $'V4<-:+82LM+XD_.G$7#]'6-&J
MU+ZC5MK;Z2UV4;V#Y9.45%\\:?-'IB3,T2/.?D,R^H\#4:$1%G'M,S^D^HU'
M33SL!Z<Z?%IT21-FR&8L2*TMZ1)D.):99:;2:UJ6XLR27*DC/!GU[#YMQ7+1
M;6I,ZN5^I1*52J;'=DS9LQYMAIIII"G%&2G5(29\J3P1*R9]$Y,RS6ZW0[U-
M:-_NI<K:ALI9GQ['3-.FWYJA%0IN/YLE?QQ,*?2@C21)>;^)>Z]#R.0T_3JU
M_4ERN-*WI+GN+FIM2H4UU<I=\GTC!>])[([9PIPAJ'%5U55*=*QTJQ@J^KZU
M>/L[#3+1;RJ5JKVE5DDU0MX9JUYXC"/5KL'>UQ%K_P!9;Z>VD;'XLFYKUJTA
M5)N>]J>2O,Z"RL^5]1.K0<9SXE3J?1=+*DX+KC&2&TCA-Z0Z6:=5$];('VT=
M2+U83/N^N51;OC>=*YI/@M>(MSP_"4ZIO+:B(R273L,FMDFPK2O9Q8T6GT.$
MS6[^J+2)%U7I.;\>=49SA^*X:52/%<8)MQ;B/0<(E%UZ%T&0>IVX71_2.;%I
M5_WI MV=4&GO-&)2DDMWD1E9IYE%V2?;KCIU+IGZ=1UNTL+;Z+85E96,)Q[:
M\JU%1K7=5-*,ZE1RCV=/F_5TDTEE-Y9V_4N)W&E'@[V9VNH4--IU%4N]1M:=
M3\^\1W-O[[O*\K=.M0LJ3BZEM9TVH4X?I*W-/>-/NZ]!])X7%O9T1BVFPUIB
MY-2A=M^)E"B5")Q7QQESX-P^;\@N.Z-Z.:<Z*VA L_3:VHEM4)B.TXF)'(C4
MI3J4N*-QW'.YZ2C,N91XZD6!4 N_5/3N1QBX^IC%T1G+#*:A1W'@O-TEY@E)
M]E<O1?HYYOE%MO2W<=HUJK/^ [#O:GW#5(D:,E^+&4@UM_$I,N;"C/J19[?6
M/KXHU.CC0:$[ZFY7>E6]:G3E<1;N<]*L(\_Z5O\ ]1)Y\>IW+VST.)+C2^!W
M.EK-6RH\&Z77U3M(7D[>E?+GC.K?-ITX7>9<LY5\5=TF]TGD -MU1H0HR+)D
MA:B^=*3,AYD9'V//_P!!J.MGG(KD;O>)]NAT4U^OG3JS=*:S6K7MU47S*KL1
MG5,/H=9\1U1+**LL(,CSZ?;V#%"F\;?=)6)+\.D:9RJG-CDOQ8D-2)#S2TI,
M^5;;+"UI/)8])(M0W[;%M2[7NZ9+MVBRI2K=K*E29%+A/2%J339)I,WG&%.&
M:3QCTLE[,"K9P?:73*CO&UJC5"G09T=JORR:8F1&)+#22>F82AIY"VTEVP1)
M(N@TGQ+:<56/$6CV5OQ?>PH\17]Y"G!6U%1T^G34:T803;=9134%EQ>$F^N#
MV1[.=3]F&M\ \6ZQ>^R;1JU[[/\ 0]'JW%6>IWSGKMQ<3^C5J]5Q45:2G.DZ
MSY(U5F7*EMDFDX;.ZS5C=)8=Q7%JI:$ZTJE3'&41HTUI;:G>=;B5&DEM-]B2
M1]"/O[2[2:$/ETRDTJE-*;I5,@4QM:CYFX,2/$0H\F?I)8;;2?U&/J#;>DVE
MU8Z?;6MY?3U*YHPY:M[4IQI3KRRWS.$&XQV:6$^X\J\3ZIINLZ[J.IZ1HU'A
M_3KNLJEKH]O6G<4;&GR1CV4*U51G47,G+,EGWL   <B<"
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MN]"-ONYW47=!:/GBKXU&?:>JZ7IDQU@C::6UCP7G5L8-+BB,DH(C+N,=]]/
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M"S,CZD><#] !32%&9GS=>^%*(OJ(Q&EQ ^&'H1Q#96ELK65AQYS2NJ?"EO\
M(]);Q(\[9E]? <1S?&,IZ*R7R8SD1&6)1;Z)_P _YD/6C?DR&PNZ;,T_O*XE
MW)7CJ] HE7FPY%RW"J*^]+@Q9;S9,KFJ:)/B.*+!(Y<=NG0IUK/VJZ([1=K-
M\Z5Z&6=#M"TZ98ES(1'8PM]]1T>8M:Y$I1$\]ES*B\52N7/3VC+BS+5IUE6M
M0+5I:<4^WZ7"I4,CR9E'A1FXS635U/XMM.<]<CVKGH$.Z+=KEN3RS"KM+G4N
M663+,>=&=BN]2P9>@ZKJ74"'*3ZMLHP^31:[:.Z*:H[X'-4=0:'9JZI>RO@I
MJIS8K'GQ-5JH^,;9O/(^]D9&>,Y[=,CL#RDO?WHON'TJT\VF[>KO8U-OF]KE
MIT6JP;?8<G*@>%68;K*EN1DO(42DF9GRGA*2/)]Q(76?)>=B-9KE;KKBJY"E
MURISJI+.FUVN4_GD3Y+LEWQ"BS&B7AQU6.;./9@9;;0^ EL*VF7E#U'MRP7+
MHONEN$]2JY<%5J-6\R6?12TQZF[);4H^F#/J1EGN18&3FAS*>9-K&V.])+KG
M_/\ '+KAEZ-W)H'LCT+TRNELVJY1K;BOS&UI22FBJ#3,IM*DD6",DN$1D9$9
M=C+)8%6'RC$B+B/;$C-:2_\ 2V7T6XDCZR:?C!*/Z/FP+S+<=IEEMAI"6VFD
M-MMH07*E"&B)+:4I+H1)21$1%T+'81;[R^%-M^WI:RZ6:TZG,NN7-I34%U&W
MU(=DH2E]:VG#,R:<2@^K*?6(RZ 8XRP\^.<_:2261_<=:'^:M _1<0<J'H4N
MGLTJFTZF1RPQ38$.GL%[F8<=N.V7O]1M(]\"H           'BOL1^Y23^HQ
MY#P7V+Y%),_F(P!2YXRA:2;'.)]H!OIU/^!]2+2K;]3:NK3J:<8UTMMB"U C
MR'6U^,XOE,_."3X/I$G'M&<%/\H?X12H41;DBS8:EQ8ZEQOL'B+\V6;2#4P:
M_@WTO!,S;-6"YN7/M$<'%RVCV7JMQA=&5[M+B31=MFH:I[$%^555*AM.PJ6T
MVIMV&U((XI/2S2CF6E!'G(D8IOD\_""J4*+.A1[-DQI3#3K+WV<1F_%;<;)1
M+Y%5(E)-:3YC29%RYQ[ ,ON-1YG+..[&$LK;[/29)MP_.(SL[WTR+X9VNR:*
M^Y9OF/V1_!5 9HQD<W)QO%-J-'\7U3QGFQ[,>V3HCSU(1A</KAP[/MB<B^7]
ML$>BL.7GYA]D7P57V:R9^9DHHWB$U)D>%W/&>7(D](L=" QO&=LX\^H   @#
M0S(NI_[_ .^!HH^4L_[_ "G] KK\1KCMPMJ&OC.U+0?1V9KWKJ[DI]OTZH/0
M%4LR8*2WSN)9=;7XC)Y+.,8]F0)2;>$L_P /CX?'H6*2,CZE_O\ [Y S(NYB
MN7P\>/#'W0;@5;4-P6C$S0'7 ^4J90ZA4'J@JK&I@Y*R0M3+32#;9Y3/&<Y+
MVCO;BF\9JP.'K4[3TWMNSW-6]<;X.2U0-/J>^\Q+-R.2%'SNLMNFCF;<)PN9
M)%CW@3RRSRXWZX^_X$WQ*(^WU>WZAJ9D7<5LN'IQ]H6Y?7J/M?W&Z.2=O6KU
M4Y5VW3JI4'IGPVE;!RC)#CC333?AL&CIW//;(S/XI/%OTOX;=KVRFHT/[8&J
M%^^,S9.G\*0ZU+J[Z%H09>+'0XIK!.(61K3U+L> '++*CC=]%M_D2^DHC[#4
M5=-E/E#[^K.X.V-NVZK0:=MVN6^UJ59D^K5%^8S4VU-><MDDU1VD),VW&B+*
MNZNYG@A:$CR6I3+4AE9+:?9;D-++U5LO()QM9'[E(4D_I AQ<=FL??\ @:O^
MHO\ >W?S#%1;9Q^N%MYOSVG^@7!;H?,N1?4OO;OM+_$,5%]G'ZX6WF_/:?Z!
M< F/[7[K+=3/JG^&O\XQNC:9]4_PU_G&-T"H
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M0  )
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MHL&-3*33X=,I\1M#4>%!C,Q8S*$))));980VVG!$1'RI+.,F/H  R P1=BP
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M2,GU/E263 )K$L+#Y7OG/>O'RSN6\V?5/\-?YQC=&TSZI_AK_.,;H&,
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MROV\?W'H/_N$RV,UZI_A*_*-P;;7JG^$K\HW!LM=%\%^!YQ   D
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M4MFMTVNT]2UH*;2YD>;&-3:C0M)/1G'&S-*B,C]+N.1
M
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M[^88J+;./UPMO-^>T_T"X!:/[7[K+=3/JG^&O\XQNC:9]4_PU_G&-T"H
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M)="%D<NQ?,7Y!6F\ES+'#=M//_M:X?TW)%EDNQ?,7Y *36)R^+^_<U   J
M
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MW4.8VR-V1#C+?-'(752G#+Y!/41Y+(&.>>9Y6.FW@L+'W&H  %0
M     -E_U%_O;OYABHMLX_7"V\WY[3_0+@MTO^HO][=_,,5%MG'ZX6WF_/:?
MZ!< M']K]UENIGU3_#7^<8W1M,^J?X:_SC&Z!4
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MQ375/,5Y  #L9KT
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M),J3TIO'@F:/4<+V_P"P3'%T(B^0:)222P6?I,S_ "CR @
M
M                                        /!?8C]RDG]1CS&VYV+/;
MF3GZP!2=XONBNC^C?%DT/W/[Q:;#N;;#>CD]FK19<XE)H[D.GM0XRS@M+7)4
MER7A1D322]$\^B8DJHNH? 2J%+@S:?(TQ3$?C,N,)<B,)6AM3:5)0HG$<_,E
M)DD\]>@BBXPFTZ^]Z_%[TAV_:L:@GIUH;=I5#[%JU.=0NGI.'26I$YOPW'FF
MVE.OEX:36I)\RB-/7(R)9\E V=^&V9ZWR7#-M&7&J[+0VX9I(S<2ENJ<A)6?
MI$E/HX/H!FS'$>:4DU%=%MCN_J^\GQV)5S8+6'[S+9B[:KCS7F?V6?8ZTTV9
M9(_-/'\,BSGKRY_V"1_YA#5PL>$GHSPTY6I$G2N^'KO5J#\&_"9.U!^=YK\'
M<Q-8\:7)Y.;/LY?I]DRA%@L 8GUV>?-FH  $  'BI1)[Y^8B,S^H@!Y /$ED
M9XZD?RD9?+[04HDXSGK[BR /(!XI42C,L&1E[R,ORC52B263S]!9/ZB &H#Q
M)9&>,*(_E29?E'D -E_U%_O;OYABHMLX_7"V\WY[3_0+@MTO^HO][=_,,5%M
MG'ZX6WF_/:?Z!< M']K]UENIGU3_  U_G&-T;3/JG^&O\XQN@5
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MT]'L:E./:<16M*6*-Y9M5_<IW&7R+$_J[-[ED<!XI(RSGVJ4?T&?0>0ZZ>1
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M]U&[KWEU5D\RG6N*DJE23_\ JD\+N6P  'TG'@
M
M
M
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MY1N#9:Z+X+\#SB  !(
M
M
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M]>IX(L_*!:,N5],IK#7EZ10MK&I.KG&YXGFW'4?2O2>X++TBT3J,BHUJZ:M
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MO9#_ +*_;Q_<>@_^X3+8S7JG^$K\HW!MM>J?X2ORC<&RUT7P7X'G$  "0
M
M
M
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M0DFWR)HU-F7-RYZYP+J;9F:>OO,B^8CZ?R 4DL-[M]-WUW65D\P  *@
M         ;+_ *B_WMW\PQ46V<?KA;>;\]I_H%P6Z7_47^]N_F&*BVSC]<+;
MS?GM/] N 6C^U^ZRW4SZI_AK_.,;HVF?5/\ #7^<8W0*@
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M^!YQ   D
M
M
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M''
M
M
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M2D0&X:*,NFD>6R6RHVWN;FQS$1=A84(L%@:)22>V>OO/(\@*-N3;?5@  "
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MCJ5_J]Y7U'5+RYU"_N9<]Q>7=:=>XKSPES5:M1RG.6$EF3;PD@  ,Y\0
M
M
M
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M=(TXY>(KO;?5FH  [X:/ VG?5/\  <_-,;HVG?5/\!S\TP)75?%?B5'M1_\
M#2P_\H-?ZB@6V8/WB/\ P2-_-)%2;4?_  TL/_*#7^HH%MF#]XC_ ,$C?S21
MK+V=?K^,O\4WW_+3/1WY0'_A_L>_W8:)^,SW0 !LT\X     P1]RR  #3!>X
MOJ(:X(NQ8
M
M
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MOYABHMLX_7"V\WY[3_0+@%H_M?NLMU,^J?X:_P XQNC:9]4_PU_G&-T"H
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M"/*L/KF9H!H18S\IF?UGD:C<1Y(
M
M
M
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MTCB#6*=*RM]-U:A>:E3;L8MSN;6CS=E3_P"[SBY\\ES.*_:,JP !M0\R@/\
M?OC\@  -,%\OUG_M&N,?^9G^4
M
M
M
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M?\5""))?01#> 0HQ71)?!"4YR6)2E)>#;?@N_P""   L5
M                                                    !G'<:9+W
ME]9 #4!IDC[&0U
M
M
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M,\>4BZD7\ICR
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M0                        'B:R3[S^8L_6/(  'BI1)[Y^@LC4C(^P U
M!XI42NV>GO+  \@    :&9$63&B5$KM]1]# 'D #0S(NI@#4!X\Z??\ R'_L
M'D             #Q4HD]\]?<60YBSR]<_,8 \@
M  >)J)."//7W$9_6 /( &AG@C,_8 -0&V3B3_P 8OG(QYD9'V, :@/ UDD\'
MGZ",QJ2TJ[9^DC( >0 -#,B+)@#4!H1DHLEGZ2P-0  !H9D7?_Q &H#Q)1'T
M(_RCR             !XFHB5R]<_(1F7U@E1*SC/3WD9?E 'D
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M2B_J-O-H  ;A/)H
M                         !\MVM4=AQ33U6I;3J/6;=J$5MQ/X2%.$I/T
MD-O[(*'_ .VJ/_[SA_\ S0!]@!ZL6;#FI-<.7%EH+NN+(:D)+YU-*41?6/:
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MI%0@7A4*!4*OIHBB4YIBA4NJRX3;4;SMI9MR/'B2B+)((T]#[B87B$<9"]=
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MO=F?9=)LJ[X]3N%LY<>*42&W6:?*6X?CGAPO!9<4:2SDBP+)HT,L_P#D1_E
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M>/#29,EE@W3]S9.K2:S_  <@#VP&A&1D1D9&1D1D9'DC(^QD?M(_8?M&H
M      !_OVQ^4          'B:R2HDF9$9]BR7,?S)[G] \@
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M4*73],;OJ5/ERJ'*A1&'D*J24O2$H6RM*65E)?,D*)9&7I]>G0 I=>F[SO\
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M>%%3#C1XR?4C1F(J/E3';2VD_I)("?[*V6%NEOCXOQ/<   Q@
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M$OD1VD/[2)B1Z\F4Q$9=D2'&VF66U.NN.+)#;;:$FI:E+49)+"2,^IB*]GC
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MKS$2>F,#MH8#(
M    'CREGFR>?G/!?,0\@                 #N  #X\BATN6X;LFETF2X9
MY\2138KSAX[96XVI1F7SCZ,>.U&;2TRTTRVCU6F&TLM)_!;01)+ZAO@
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MC)/YTM)21X]@]T                     'BHR(LG[R^O/0>0\%]D_AI_*
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MTT/^G #F@#A?VR-._P!OME_QIH?].&OVQ]/"+/V>69@^Q_910\'_ /CP YF
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M_P"G@"O'NBL_BBUS6/4.)IR<MW3*H&W'H[*'(:$KC.M*;DH(U*YRYB4:3S]
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M !]P
M
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M<6X@N5/*24+0>/E^<">9N,LO/3PSU[OP+,I%@L?[]\C4  H
M
M
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M42T+>O2VYC4ZBW)2H55@2&E$I"FYD9N02",NYMDZ23^4C 2BX]>_HT\HY@
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M-=0_ K%.A5.&\A1*0Y'G1VY+1D9>WD=3D@$HN/7[,;IGUP  *@
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MW@RZ9)#J2/VY[_*$HN.,]_1IY3/O   5
M
M
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M.]+^O\#(P  #&
M
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M)F>4X/)Y(\C(8DDDB2DB21$22(B(B(BZ$1$70B(NA$70O8-0
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M4TM,4E-F9J/U#+J1&,@"(B(B(B(B+!$70B(NQ%[B+V%V+V#4
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M=4\[4(U&IR)!+4HU*4TXF,2VC,U'ZBB'?A$1$1$6"+H1%V(O<7N(O87L&H
M
M
M
M
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M!J
M
M
M
M
M                    "/'BDD1[&M?<D1XMF0>#+)9)APRZ?.0J6>36[ MJ
M.[W1C6"XM?M+*=?-6HMSS40)4AU<=3"7:S.)SD)KE+*DH(O2/'<6U.*3_>-:
M_?YL2?\ 5W17L\D?E1X>WO70Y,F)&Y[HE&GSF2S'R95JH%U)U2<%@^IGVZ>\
M#(OU<OWD8L^4$<(S0S:)I3;V[7:70).E]1L6IPZA7XU)J$PCE+1/C^:X<2ZG
MPTIY#,R3T662,C(Q-!LNXL5M6;P@;(WD:^29]2EVQ13@U%N+$DS9=4>B/%3(
M#1-0VG'LK6VA!K2E7?F49=3'2GE1>N]D6QL*J6FKM9I4NY]0WHL:BTZ'.C2G
MW'8M19YR)##BU%GF+&2+)]"&%VU/7G1_8!P+=+;MW0Z>,ZALW4W-.U=-*J:H
M95B2Y6")GG6II7(27G6EI4XWCV]@)ZPBY9>)X\^5)96?#KOG^GU9WE,^Z:KT
M9[6*TMB%R2-"8DAY2KH>JTJ.3U/:=4V4HXST(GD$I*>?KVSUZ"1RA<=VF:M\
M/:^=ZNB6E;MT5_3%$-5[Z:(J2FY%-.3-.(?-,6V2G.5*''#Y4=,'GY(A;JU1
MXH6Z+9W<5S:6;>+2VX;4IM!J<RG-/.VI54RZ,EEY:S2Z_':DMJ6WT3U-1*41
M%@Q[ODP&E]"UBVL[X=,;FA(J%)N1M^G28BTDIA542NJH\5MOJV2?/?322"QR
MGZ/3 $N,>7.,8DLI2;V?<^[/P[RS-PO>(Y:G$6VS4[76GT9NTJNVB>=R6OYY
MYXY15P7G6E)=>Z&?-X*U=2+&!@-9W'&J6K'$OKFQ73+2$Z[:UK>=+N'4YFKE
MYO 9@T]R?)6Y%-!H+D2TXC'B%DTF70Q7VX7NZT^%5J[Q =K&J\]5'@QV:BY8
MT6?S-MMJJ4:JRF?-$KZ)5EYK!IPHL_*,X?)C-L\W43_A.[T]2HJ_A'5RJ7!#
MM6MS4'S,P'9=5IK[[4A>#2VB,\2C,E$6"+L1&9"KBESONQ[OQ;7?Y=_^6<KM
MR/E$5W,Z[WKM_P!F&W"5N$K=@2&HEQ5F%73IB69)I,W6T,N,K2OD6VXV?*:L
M&6>YX'8&PWR@.?KUN-I^U3<IMYN;0?4^IK-FFKDLU6K09+J6?&63DUJ$F(T1
M)P1&IPB//00O:S\+SB);)=U6J>NW#<U MC4ZFW+6'JS5H$5^V:K-A+><>D.1
MW8LI^7)4?.XX@B4V1ERF6.F!R_:;QD]:],=VUCZ3\0W:W0XFI=U5-NE,ZC*C
M4FG3Z?*(T,-N-1X,%MU?BJ6E)\KG0O:!;EBX^ZE+;KS-273.W3;/^1?9:=0\
MA"T'E*T(<2>,90LB4D_DR1D>#ZD-P?-I$YFI4RFSXZ>6//IL&<P7N9E1VWFD
M_0A9$/I 80
M
M
M
M
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M_P#A00]X  H
M
M
M
M
M                                     &A$1#4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
C                                           !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>nt10002526x6_linechart9.jpg
<TEXT>
begin 644 nt10002526x6_linechart9.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( E($S ,!(@ "$0$#$0'_Q  ?  $  @$$ P$
M    "0H( 0(&!P,$!0O_Q !P$   !0,"! (%!@0/"@D&"0T  0(#! 4&$0<(
M"1(A,1,4"B)!46$5(S)Q@9$6.76A%QD:)#-"5E>3L;.UT=/4&#528G*2EL'A
M\"4F-#93596T\3A#15AV@B@W5'2#E**RTBI$1TAC9&9SEZ.EPM7_Q  = 0$
M @(# 0$              0(#!P4&" 0)_\0 0A$  @$# @,%!P($!0,#! ,
M  $" P01!2$&$C$'$T%182(R<8&1L? 4H7+!T?$(%2-2X21"8A8SDC9#4X)E
M=;+_V@ , P$  A$#$0 _ +_
M
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M)^"VU)47P,@*M-=?SZ'L@  0
M
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M'V &FMVCN8  "
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MS,S,^H%)/.%MMY+"W_=_,^H  !4
M
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M^A=/_/"5@"KV;7J   (
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M",\GG[SQ]PW   V*;2KODOJ,R_B&\ !M2DDE@OSGD_O,"223,RSU]YY^X;@
M&TTD9D9YZ?$P-!&>3SGZSP?V#<  T4DE%@_S=#&U+:4]L^_J9G_&-X #::",
M\GG/UG@_L!2246#_ #'@_O(;@ &Q+:4]LG]9F?\ &-X
M
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MO"=V;7=L7V>6'M_O6OIN.NVPJHJDU-+#<8GCES%R$GX3:E)3@E8Z'U]O429
M8I;MOS;Z?$#@6IEC1M1[$NJR)<@XD:YZ/.I3T@DFLV438KL93A)R1GRDX:L%
MCM@<] ""&_A<\(BQ.&=6M8:Q9][NW8O5NK?*LYMR&N+Y)SS;\KD(UN+Y^KYI
MR6.W8=^\238!;O$/T"G:%7-=CUITN=*@R79[3#DC)PYK4Q*5-(<;YB4;?+U/
MVB1/&.P 2VV\O=F+^SK;11=HNWJPM J!4_EBE6-#=B1JAX'E_,DZOG-1M9,T
MGGXGD==[\=A.B&_W1VH:2ZRT./.C.-G\C5=:5G*HLGF)Q+\=;9DX1^*E*CY%
M)^B1#.0 (SX^/7)4,M;T5*QHU;H</4+<U=-]:4T.I)FQM.)356:@*CM24R&(
MBG53UH-"#0A/5&,%VZBR[1]IVB-"V])VS4VS8$?2=-!70SMPD%Y=33D?P5OJ
M/&5.&L_&YE>MS>T9*X+M@L#4"7)OJ^FY41NOT4S2VH7;6SLO<)<-G:25^L_*
MM2TPBLU-RFO(7,.6]&4X4U+?(MQ2R+YO!$?3X62MH6TO2?9EHI;&B.D-%8I%
ML6W'-M)MI,W9C[IDX^^\ZOYU9N/<SA$M1\O,9$9C*/!=L%@:@')OJ\@00^D;
M?BL]9_RI:/\ /L<3O""'TC;\5GK/^5+1_GV.!,/?C_%'[HR%X+'XN/;S^2)?
M\L)61%-P6/Q<>WG\D2_Y82L@0^K^+^X   @
M                                 #J#5#0K2W6-5,_1&M&!<WR2I9P#
MFMH<*-XIEXG+S)5CFQE6,'CVBE'Q(-+[$LKBC6Q85LV_#I5J2*U16G:/';2B
M,M#J(AN)Y"218/F5GIDRZ&8O;FLB,BYD^SNHL]?ADC_C%(;BE?C=;1ZE_?\
MH/M+_HX>?N]ON&X>QZZN7KFI6[N*SH4^'=6G3H][/NX3Y8/FC#FY8R3;::2:
M;;-.]L-I:K1-/N%;T57J<0Z5"I6[J'>SCSM<DI\O,XN*W3>Z7EL6U-+-J>@M
MD.VG>-L:=T>E7%$HE,=CU2,PTAUIQZGL^*HC)!*)2\F:C(^IG]^5)$1=OJ^P
MNPX];"TE;ENEE/\ >&C]U$1]8#&.G?\ -U'(1JB[N;BYK2G<5ZM><6X1E6J3
MJ245)XBG-MI9;>%MELVQ9VUO:T5"VH4;>$N6<HT:<:<7)PBG*2@DN9X6_E@
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M+S?B> 9=^OB#Y\:[K7FI><@W-;DQN/\ \H7&K=.?1'__ )RF9"R;SUQS\O8
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MD2"RQ'^5(9/OEC.66O&YW2Q@\H)70?;(\]2ZD?4C+V@
M                                   T,R(LF*X?'ZXI6J.QNQ]/]*=N
MK2Y&N&M#\NFV],CDEQ^E/L.M-%RQW$*0]XR7B(^F&RP>>ABQTLC-/3V&1_<8
MI:>DIQ:WH[NMV2[H:U;LJM:96'7JN_<K[,5R9&A,/O0VO%DMM-/<G(25.)\1
M)9,N@%H).23^GGZ>!W?J]Q#]W&P7@Y6A?^XJJ.GO U-BRE43S'ERD-)J50)#
M"TMH(VC44.6VI)8(R(L=^\"$"F<;NQ=!:;Q*$:K5V987GF[@FP73CX33':@7
MB,J@K=-:6U,FILE&R18/)#L;BQ[Z+6XO6X7:1MWVN-5*Z[6MR70VYSD*GS&H
MRB;*F/3VWVS9Y&2BK:>1Z^"5R]"Z";WB^;V-MFR;A]'L9CU)NI:R5RRK=HM/
MLJ/!>\1N;*AQ52")*&U(6M+CIJ/'M+!]0,BRN5<J;F\M-9]G*QMX+K\":+A1
M[T%[Z-FFF>N5324>YZK#?A7%#(^8VYM,=*"ZZ:DD23-UQI:\%V,_;GI)2(!/
M1P](;MTLX;&F*;M@R*9.N&17:HS EMK9D,LS*L]*;YFG"2M"30Z1D:DD1EC
MGZ+H1%\ ,4L<SQTR\&H  $               !!#Z1M^*SUG_*EH_P ^QQ.\
M((?2-OQ6>L_Y4M'^?8X%H>_'^*/W1D+P6/Q<>WG\D2_Y82LB*;@L?BX]O/Y(
ME_RPE9 A]7\7]P  !
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M2=O:O2'Z'?NHQ$HY]68>>BK8?Y7EF\R;3+BS+D>R9]1\/>'PU-\/#<V573N
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MS[RW&:1>L(Y)N&RA1I3X*E_2,BQGX@0\N,<I9Y\=%NL+KC^?@9W[&]#7M..
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M>.R2'22ZWDB5]8_2OH7]ZZ7^2*;_ -U; BK_ -FR3Y=\>9]D  #$
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M]O/Y(E_RPE9 A]7\7]P  !
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M80@E8]F2'T0)E+FQX)))(   5
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MP!1]7\7]P  !
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MF^?"EGJFO W@ #K9V8
M
M
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MP0M;4.D0Z#2*91:>TTQ!I4")3XS3+:6T);B,(829)21)+*4%G!=S,:XUI_\
MI;A6QX<A[&JZ\J.L:ZUM4HVF%+3-.F\)KV6[JM![J4Z::]E&]M$3XIXJO>(Y
M^WI6@NMI&@J23A6NTXK4]1AAX?M)6M&:6\8R:QD]J3!BRN3S$:+(Y,X\S':?
MP9]S3XB58S[<#U?D6F?]64O_ +/C?U0^L URI26RDTO1FRG&+W:6?A\/Z(^<
MS2X##B76H%/:6GLMF&PVX7^2M"$J+[#'T0 0VWNWE^H22V2Q\   ()
M
M
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MN3;;24H27P2DB'EB3(TUE+\23&E,JSRNQ7VY#*L'@^5QI2D'CVX,>R!
M              !!#Z1M^*SUG_*EH_S['$[P@A](V_%9ZS_E2T?Y]C@6A[\?
MXH_=&0O!8_%Q[>?R1+_EA*R(IN"Q^+CV\_DB7_+"5D"'U?Q?W   $
M                                         ?*KC,&31ZHQ4T-.4]RG
M34S$/)2ILXQQUD]S$KIT;-1Y]G?OU%)C<M9-$_1LUEK.CQ2X]@VK/9<ESJ=(
MD16H\B4MSQR)YE:#/F?YRZ*P1="]PM(<0C<!'T$V]W158LGP[DKC":50HR5$
M3SZYRBA.^$751FCQB/*>V1#+<FA):5\,NZ;SN".K\.]27BJM7??0924(7552
M8Q*6HC5@V7"(NO;!%T'HKL5JU^':,M:K5)J'$FMZ9POIMG)ONKJI.O3K7][.
MF_?C94&J<)XPJE?ESNT>1/\ $;1M^+[F'#MO2INKP=P[K'&NL:A%)U[.E&VE
M;Z7IM.JMX2U&Z3JU:;W=*W4O!,Z:V4\/FX-T$&W-3JK>,Q-HQ*@B1.I$U3L\
MY!19*>5*'GW5+;(U-^MR]\GGH)6N*;N8HNR[:6BP+#Y(-\7G BVO9%+@X2^X
M;ZF:=.=;901JR:7N<SY2[G]9;.#_ %&)2-J"JK/=;:ATZ+-G27'5DVVEJ*MZ
M0LU+49$1<K?M/KV$8MM,U?BI\3F7<,AM^;M\V[5?EBM*,WJ=*E/-&A1I/Z"S
M3-C9]I<W; S<5:E?\0\>ZV^(;CGX5X!N;RYC;1ITZ5*2IU(JTL_9BE5N+RXC
M2H\T\S=)22>$?5V::%I/"W9IP]6X:M>[XN[1['3Z->\G4J5Z_-.DW=W<74E)
MT+:SH2J5N2FX051P>&]R4W@Y[0BVX;<H5VW1$5^BCJFIVOW;,EMYF**3)<G0
MDJ=<,W,$U(Q@L=,$>>Q3 CTJ="CTV#$@16T-1H45B'';0DDI0S&:2RV1$1$1
M>H@BP1=B(>Z-!:SJMSK>J7NJ7<N:O>5YUI+PA%O%.E!>$*4%&$(K"48I)81Z
M<T32K;1-*L=+M%BA9V\*47TE4DHIU*L_.I5J<TYOJW)@  <8<J
M
M
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M[L]'M?=O=)W+V9<"4:6U:!/J3%;J++E/2B)3>;S*W&IA-N(QR*Y4K(C5T(B
M.+75-?%8,G,E[R^\:BN9?/I,/#OL[5"78*;LJ-6I].JGR34+IBT.L.TR-))_
MRSG/)9CKB\J'B4GF-XDG@^O43LZ(ZVZ;[A-.+?U4TJN.)<]EW+%*33*I%4GE
M61$1.(6C)J;4A1\IDO!Y(P#375-?+YG;0@A](V_%9ZS_ )4M'^?8XG>$$/I&
MWXK/6?\ *EH_S[' F'OQ_BC]T9"\%C\7'MY_)$O^6$K(BFX+'XN/;S^2)?\
M+"5D"'U?Q?W   $
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M@GN%;I/T   $@
M
M
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M9P64FGAR;>B,L'\D2_Y8Q*P(I^"RHU<.3;T9GD_DB7_+&)6 */J_B_N   (
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MO5A7HU'3JJM"$(\LFXQ65[4FDO6?,NWVG_&8U NGY_SGD!H$] +HO@@  !(
M
M
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M%Z;?^K-0?FVRY4BYI-,@1Y+[+9MD[E2$N1%-D2B2@SP0R$X[Y8V(7[_DPO\
MOJ!R-.\M[#BK@W@W3:D9V6@ZO9O4*]-KEOM;JU:7ZVNVG[4*#_Z:AGW8PECW
MF?9.SN+[A3C+C+4J;A>Z]I-W&PHS]^QT2E2E^BH)87)*XC_U-;'O2G'/1YZZ
M]'TR6S2F=3QXC^,&98_7KI=,"?0NQ?40@+]'T_\ (TIG^6__ -^=$^A=B^HO
MXAT7M!_^L^)'_P#RUTOI-8.^]GO_ -%<-_\ ]7;?_P"34  =-.Y
M
M
M                                                      !H9D74
MSP.C[QW$:-V+?5"TXO"^J/;=VW*4A-&IU7E,0$3C9;YW";D2G&FLI29'T5D^
MW<=X&1&6#$3O$LX3^C_$2HU!J%P5NLV/JC9:93ED7W1JE4HKM(E2,&M;D2#)
MCHE$LT(+E=,R(BZ 2L9W>%YXS^V41O[ZO1WM/=_.X^[]P]1W'R:.=U^37%HM
M*\2>W3"CQR9,X<R).(FR>P2E&SR\WMR,1G?1#=-4MJ\3=/>#:3(R-:U5I)$7
MUG4B+I\3'7==X>_'^VA5%^E;:MQ=0U=LNFJ45+1.A4N,]Y5&?";4N>^Z\KE0
M24F:\F>,CX\.F>E%ZIMOVY4)[EIPEF4:1533;KAM-F?(MPDD:3,R3D\$>>@&
M5.22Q4CA>N'X>&,_V998V>:-:*\*_:7;VCMT:U4FIVY9+CZ%7'6JQ'349*ZE
M--QM!19<YR6XHG%\A)3SGU[$)%+)O:V]0K:IMV6I44U2A59LW($Y*30F0A)X
M-225[/=[_9D5/=!/1]]?]:J_1-0N(_N=N?5)N+.CU1_3:&<VA1"E,.HD(0Y*
MI,Y#3B6WD)5@T*2KEP98%K;3K3RU]+;-H%B6=!.G6Y;<%B#2XANN/FTRRTAH
MN9UTU.+,R01FI1F9F9F9]0,<L9ZY?BUT^1S@  "H               00^D;
M?BL]9_RI:/\ /L<3O""'TC;\5GK/^5+1_GV.!:'OQ_BC]T9"\%C\7'MY_)$O
M^6$K(BFX+'XN/;S^2)?\L)60(?5_%_<   0
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M[33--A2HW\KJG5=S5ISC%0=*FWR-QE*7O/IZF60  U>;1
M
M
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M"\%C\7'MY_)$O^6$K(BFX+'XN/;S^2)?\L)60(?5_%_<   0
M                         $7G$'WZ1MJL*C4&VJ<S<MXW"U,953&Y)-.1
M$D@DY<R1D1J0HU)(R(SZ8ZF),:S)?A4BJ3(R/%D1*;.DL-=C<>8C..M)(_\
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MT:<5LL-K&0/'X2?>K_.,>0!U [D>/PD^]7^<8WD6"(B]@U
M
M
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M9JK9<>^YNEVR:P*&Y5&)<%,=;EU^#27)SK*O <9G-I1,8\,^8U92LRQCH+;
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MDV]$98/Y(E_RQB5@13\%E1JX<FWHS/)_)$O^6,2L 4?5_%_<   0
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MC=Q3?[L  "I<
M
M
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MQ^+CV\_DB7_+"5D"'U?Q?W   $
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MZ\L?VBE_(  "I<
M
M
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MB*;@L?BX]O/Y(E_RPE9 A]7\7]P  !
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MPI]VH1MJRI]Y1C!2ERJG**2;2ZGL$1%VZ?[>H  T<>@
M
M
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MBC]T9"\%C\7'MY_)$O\ EA*R(IN"Q^+CV\_DB7_+"5D"'U?Q?W   $
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M -/FXP
M
M
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M\%DS5PY-O1GW^2)?\L)6 */J_B_N   (
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MH]^@
M
M
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MJI2_U^6K1I]ZY;I0;Y>AET7_ /JG\V1N !Y!/=8
M
M
M
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MS,1E+$=EF.RCHAJ.TAEI!>Y+;:4H3]A$/.!'GJ0 5
M((?2-OQ6>L_Y4M'^?8XG>$$/I&WXK/6?\J6C_/L<"T/?C_%'[HR%X+'XN/;S
M^2)?\L)61%-P6/Q<>WG\D2_Y82L@0^K^+^X   @                    &
M<=P  :9+WE]Y!DO>7WD !G@LB%WBP;_8^WVR2T=TXGMOZO7^P_#C*BO)4]1(
MZ"(I7C(+))5(C+63?B&GOZN3&<.]7=O8VS_1:Y=2KMEL>>CP7F:!2C>)$JH3
MI"5,,&R@LK433ZD*5RI/IWZ=13\VV6;JGQ =U'X<WNY,J-8OFN^>?4_S+8H-
M*ILCQ(K:2/YEHI$%*6SP2.;N>?9N#LLX(M]9NJ_$NOI4>&- C.\NIU5B%W4M
MDJO<K..:G'"[Q+WVX4EO/*T;VS]H-SPYIM'AOAQNXXNXEJ4M,TRC1?-5MYWL
MU1A6:67&>'*4'MR0C.JVE%9FKX/.TV;$HU8W"7I&>E5JOM2WK;ESDJ<?\U+2
M\B<9J>RO'B.>KG)$6"3TP8PVW3\,7?9J/N%U(OBR84==JU^7'=I"UKIN30@C
MY\DXHG"QDNAX(_LZVK=.['HNG5G4&SZ!";@TZC0(\=#+1$2?&)E"9"^A?MW"
M4K_P'-<?7]Y_TCYZW:WQ#;\6:QQ)I;H4OU].-A;T*U/O*=MIEM4B[2A3BI1C
M%PC3BY-;.4I/Q+6'8;PI5X(T+A37:%2^EIU:6J7EU&:C4O-:O*;=_>5)SC)S
MYYU)QAS;JG&"R\(I/_I1_$6Z\T*,KU3(B4[2C]GQ69?F^X3B<(G:?N#VP4+4
MN'KO':8E7 Y2U4?PE1#YBC*<-[/E3,NRB^D)G,%\?O/^D:XQ_P")G_&/FXC[
M6^+.*-(N-%U2=G*SNI495>ZMW"IFA4C4ARS<WCVHK.VZR<EPKV)<"\'ZW:Z_
MHUC6HZC9PK0HU)UHRC%5Z3HU,Q5..<PG)=>JSX@  :P-O
M
M
M
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M,5J^I6T)]+6QBXZ78;-)4ZTU[3/I@ #SP>J
M
M
M
M     /"\3AI439X4;;A(/W.&DR09F?3OCN/,-#QCK_MS[, "A_=%Z:2:&^D4
M:CW-O0;BM6[5Y%++3RO7)&5)H<-948DO>"AY"XCI.+4V2C+HD^N>XF%XQ6[+
MA\S=B>I]#K=PZ<7!/N&DQFK1IM%I]).I/2U'B&49RGH7(:-#BVE8]4S,BZ>[
MR<;?;/PQ=<HM"5NVU,HVDNI\9,C\&[OBK<<K,12B1XBY$>"\U(5ZA()'C8+!
M93[!7:TAX?/!,L>^J+=&J_$"E:M6S1IS,]NTZE#KK<5PXSJ7F&U*<G.(-+:V
MTY(T&1XQCN!F7*^63YDXI+"6<\N,8?YOGTS90]&OMR_*#PT--3N^//BQ)]1N
M210&*@;I/II[M:D.12)M[#B4^64URY(B-)%CI@Q8,+L6>^!B]M OO;W?VA5F
MU7;'4J?4](8L(H-M/TU@X\0VH1)C.&AM1$?,:F_6,^IJR8RB Q-Y;>,9;V\@
M  !!L6KE3GWFDOO,43_2J=9HE9U_VJ:42*55J[2+:JU1G5ZBP:3-F-SVR=BS
M$1EKCL.I^?))M9P>"7VZ"]BK&"S[R(OKST%?K>YO?X>&EV]S3K1_<CI_3)FI
MDV9X-"N^NPG#@09#K+)H,GI,8X3A*YVTJ,W<)]ID!:+P\I9Q_;^9"SM[XHW#
MD;U)TPTBUZV)P]#J;-10Z90;^K422M$^IL-1&6Y?AR*:R25.S.1?K+,DFHNV
M!V!Z59J?'J%C;.-&['G&BRM0ZM3N:+3Y)E"J5+.?3'(31FRHFU(1&<27*9JQ
MDRP78>7TIZX=MU9T1T(I=@.67.U4FUBCOV:BQTTEVHMMO5.G.H\0Z&2G",F5
M)Z.=4IZ'C&"P@XTNG&H]%V'<,O56\H=3<JU@O-2[IGR67W'*?%D5&DG#5+6H
ME&E/@)+E\0R+ &2*]JG+S;6&\]/COX_F3/\ XQ>T#1_3[@L:?5JDV+1:'=.G
M]O6S5:/5H$*-&J+,F<[ E/.NS&&4/O*4K)Y<</'VCIZ^=V%TGZ,A;]3379AW
M/5H2:))JA/N^<.,W740FV2?Y^<DFT?(>%%DL9]A#O3C)[K=*K^X)^G\6EWI1
MJS7=0;=MFET6GPIT5^?(D4]V!%?;7#9>7(94A>4X6T1GW+V#'B^]K5S(]&+M
MR*S1YIU^E14UF53/ =\VB,Y7TS4/>!R^(:/#(U&9(/!=\9(S"/2&?_R>/_Z^
M?S,A]@&S31^I\ ^X*[=5A4297[WMNO5>?6Y4**_4WI,61*E,O-S5LJDM*2XI
M)F:72R?<_:/I^B-ZG56M:0;@=)ZA59,FF:>7,MBA07W7'$0X[]8G<R6><SY?
M5)/0L$9)[>P;^'WNXTI8X MQTZX;XH<>KV#;-<I55I$J=#C5*,_,?DQ6&40E
MO(DNJ6ZDDX0VHR/N1=<^GZ(OIQ4:5I1N'U4FTZ2Q3K^N=;]%F/-.-MRF&:Q.
MYEM&M*4K]4RZEG&3 //)4SUYEZ;Y7\B:?='QO-B6T/6&NZ':R7W5J-?ENE'*
MIP(ULUFH,M^89)YKEDQ&%LKYF^OJJ/W=Q!1QE>-QL3W=[$=1=$M&[]JM:ORY
M:G;/R93Y-LUFGM+\M6&'G>:5*CH91A!&9<ZBR?WBSEK#PY-GVO%\U'4?5'1Z
MDW3>%6)OS]8E&7C/^$V2&\^J?T4]/AU]H@HXZ_#HV?Z$\.K5/4;2_1^D6O>%
M(J=J_)U7BJ(WHOC5IA#O[0L\R3QT,OO K#DYH^]G*\5C.>O0EIX+231PY-O2
M3[E2)?\ +"5<13\%DS5PY-O1GW^2)?\ +"5@"CZOXO[@  "           #:
MI1)(U'T(NIF>")*2ZFHS/!$1%DS,^PK\[^N-3(V>ZY2-)*)IG%OMB.E'B5>)
M76$H0I3!.FE:&C<)*B4?AF1F1D9&)Z+L4I-JW,I*C2I-OUE25$>#2HJ=),E$
M?L,CZD?O'YT5K[<M2-Y>\/4C2ZU*W)5<;MQU8FILYTY:VT-2I3O*E4I:L))M
M/*74B(B^_:O9=PUH6MW.LW_$<H/2M&L8UJ]*I*M3AFM-Q5:5:C.,HJCRM\J4
MN9R2P:I[4N)=<T6VT:PX=52.J:Q?2HT:E.-*I/%",)NC&E6A*$G6[Q)2;CR\
MOCDF>_5*%P9Q^@!USC'R^G^K&=?#YXS3N\O6.7IA7-.8=A,M$GP*G+KC"DOJ
M4PIWD0AXVR4>2))$E2C,S]O00Q_J?7=KG_G&U]+&? A>_'-GF[>T1ZZLZ&Z@
M;!]R=K6O?->F(J5!JD"H3Y=-<7%=?996S+4V90G"-SF:2:"21JSG'M,;3?!W
M97Q!;WNG<,U;.6L2LZM2UG0N+ZO4HRI<LN\5&I54*BSB&&]^?/F:LCQ?VI</
M7-CJ/$M*]CI$;RC2N87%O94*=:-3$>[=6%.4X='/F2S['J?I+(<)1),NI*R:
M33ZR33[%$HNAD9=C+H??L*07$ZBHD\7.%)F,-R*-!J]"75O$)*V&F2CQ3R\D
MR4DT\I'S$OIW(9VUGB^;K-Q3%'TZV3[?Z[-D)IE.I:;\GN/1&O':B,QWI),5
M2*AM?(XE1YYNN,YZF8A0U[/<?:>ZBY*;N87\NZPUPH;]=?3Y=LZ<@XI.L()<
M4S:(T,+)&4&DRY?JSP_9-P1?:9Q%<QUB[L[&M>Z1>V<=/A<TJVJPIW#I0_4R
MM:4I]S"&V56E&?-)+EQEK[.V?C^UNN$XW.A65UJ,=,U.ROW>UJ%2VTBI.WYY
M2ME=UE#O9R7,TZ47%QB_:>R=SZDZC;)"I-'3-58!2T4:EH?(Z73.CJ(3*5DH
M_"ZK)1'S_'KW$'/&::T&OYS129I2JW3BT:15$5WY&BQ(Q9DNM)BF]Y=*35RG
MU3S'[\=.@B:/QB/"5W&Z70S5'>JKS9*,NI$XRI2<)/H99P1%[!UIJS79-!M!
M3K350FE)J--0X<F3(6N-^O&TY-+RE*0:L^XL_'V[7X=[%[#A?6K/7UQ%J=\]
M/G4K?I*]&$:-;FI3I\LW&K.2BN?FVB^GJSSIQ#_B+UWCC1KKA.GPMHVF2UF-
M*SCJ%M<5'<6Z=6E*4Z7>4Z<.=P@XK,U[V5OA.YYPJ]%;5TWVW6Y=5')I^KWK
M&\2J3DM)0MPHCADPDE=3/D3ZO0RS@NIB3\8&\-?KLWT>5GFYZ:ZX9YSU6OF[
M_#/MZ^\9Y#QUQ=?76I<3:Y>7E65:O6U.[<IR>7RQK2A"*\HPA&,816T8I)=#
MW]P1I-CH?"/#NF:=1C0M;72;*-.$5C+G0A.I4EXNI5J2E4J2>\IR<GU   ZZ
M=J
M
M
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M-$]2]19NJ%TVZ<XYMV3R64B=YF4I]'.3CKJOFTF2.JSZ$) @,+ZO?/KY_4
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M6U!;+.P  'Q'(@
M
M
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MD*L.9)+FCS1Q*.<22:>S/6@L+CQ(K3BC4MJ)&969^U;324*4?O,S3G/Q'N
MTVWEMOJ]ST0DHI171))?!+   $$@
M
M
M                                                         ;%+
M))X,C,^4U="SV+/L[#<H\$9_5_&*Z7&;XFNN>QS73:?I_I7"1*HNL5P2J9<R
MUKC))IAJ9$8(_GTJ/Z#RC]7'YNHE)MX75GQ][OI$^A&R_<;>NWJ[=+[@K]=L
MPX93*I#IE6?CO^<8)Y'(['@/-*P1X]59_$11[Q_2<=%]=]"KTTGL+;S<-8N"
M]8"J3!6]1:J?E9,@E,,NDEZE^NM"W$J29&DTXR1Y%LBO[0MK^L[],U(U#TKM
M&XKNN>@4.I5:JSD4]4A]Z13H[Q\ZG6UJ5RFX9$9JY3+H0]*F; =FM'J,2J0-
M%K'9FPG4O1W? I2B0XE1*2HTFU@\&1'U+V 73@L9BVUCQQN8$>COV?K!:'#B
MTUC:L1ZE!EU&=<56I5.JWB^>AQ:E67YC;;B9'SZ4):=0E!+(B(BP1=,%.\7Q
M[CYE'@4RETZ+3Z/$@P:=$:0S&B4YIAF(RVA))2EMN.E#2>A%GE26>Y]1],"C
M>6WC&?!   " &<=QH9D74SP(K.(QQ:-M/#HH],1JE6$5*]J_XI6_9<%+TFH5
M!QDT^(@T0TO/-*PI*D\[?K$?0 DV\+=LE3R7O+[QJ*R6VCTF;:QK1JQ;VEVH
M=IUO1V3=,I,2A5.X(-689F.NFE+)).9$C((G5*01>MCURP8G&W7[K=.]J&W:
MYMQU[2FG[(MR#3J@X\A9J3)CU,T>54V;7,I7B)6E1<A'T,"7%II-/+Z>OP\_
MD939+WE]Y#4536O2M-ECS1.M6O<TA!O&TEV+0Z_)CJPODRA]J IM?O\ 54?N
M$\VW_>MI3KIM5I&[.-)7;6G%2IM2J:Y%5:>A+BL4TUD[XK<Q#+R35R&2"4@C
M4>"2 PUX?C,R\E[R^\:BJK>OI4&TRWM1*I;M LJO7/8E)K'R54-0XD"L_)<=
M;<HXKSKCB(2V"2TZE99-XDJY<D9D>18JVS[E-*]UVD=LZSZ/W#&N*SKGC>/$
ME,F25M.(P3[+K)F;J%-NF;?KD1F9= #BUNUC)D ((?2-OQ6>L_Y4M'^?8XG>
MR((?2-OQ6>L_Y4M'^?8X$P]^/\4?NC(7@L?BX]O/Y(E_RPE9$4W!8_%Q[>?R
M1+_EA*R!#ZOXO[@?&K[CC5%K3C2N1QJC5-QM1?M7$1'5(5]BB(_L'V1\.X_[
MQ5W\AU7_ +F\+T__ '(?QQ^Z*3]V7\+^S*"EYZF[Y-:]Y>H^C.BNI-8GUV16
MI3=$H:'O 0AMA;RUI2XXZ2"Y4%_%CW#(0]E?&V)7*=2K><D7]]HW<SP7_G_>
M8XILQORU]->+[<MVWE4TT>@4^NU<Y4]Q!K0UXC4E".;!EW5T%N=6_#:YS?\
MQG4[Z:>G@J]_QZXZ'_K'IWBG6]=T*MI%IH/"&FZE:5-"TVXJ7,]"G=O]14I)
M5(NK0BHMI0C)I^UEMMO*/+/#.F\-:O2U6YXCXTO-(O:>MZA0I6DM?HV6;6G5
M7=SC1N)\_*W*48R6([<J6V2CMJ_??$6VY:JTG2O4G4FL4?4&;+CQ*?2O'3))
MQZ8I!-$;C;RFO_.(/KT]XL);'.$77+BN&C[E=\=?E:F:DU)F#4Z5;-26[Y&C
M)\%"XZS:0\Y$=\5DVG,>&6,'GJ(CN*IJ99NI7$/T]NZS*LFLV]'KU(?=J+#2
M_ 0TPJ(;JS,RQA)(49Y/V>P3U:S\3A2H%O:.[6+?EZBZ@R;?HE-75XC3S<:D
M2?DV,TLU+6TN,KD,UYYE%U2,_$-/B[5=(X:MN'](M-(OM:TRXK\07MO9T],C
MIU"$Z:G3N+VI&+L;5IN=2,JBJ5.3ECE9B_AT?5>!M U+B*^XDURXUBPTG4J%
M#AJPG>5-6J:O<3C-TY6=A0<_\QNDXJG3E3@Z5/FS/E]Y26:Q;@=%-KMF(G79
M5Z-;]/@1/"IE#IR8_BN> WX;,=$.'ZY&KE2@C-OJ9YZ]<PW7'KIN[XB->E6G
MH?2*IIEHPJ1X%3N=U.')L(UFDG6T2$,2$DHB,\H/]M\!VGH5PU[[U9N2+K%O
M.N:==%<E.HJ#-E..N-1(7-AQIM1QW? 7@N0S+P^Y8,BZ":ZTK-MNR*-#H-KT
M>#1J7!:0RQ&AQVFL(0DDIYUMI2:U="/*LG\1K*6H<)<"9CI*M^,.*H^_K%U3
M<]!TRMMEZ?;3WU&O"6>6YN%W*DE*%.1WF&D\>=J&)Z[*[X X(J8=/0+*JJ?%
M&M6[2PM5OJ3:TFVJ1:Y[*U;N.5N%2I%F$.U;AZ:0[<HL:LR(;=XZ@NDA^I73
M5B7+6[*5A2U(8F&\2.51J(N4_CTR0^CKUP]-!=PE[*OJ^J.J165)2CG;??90
MDDMDV6&V5)06$D1=NW89[=NA .F2XSXIEJU77?\ /-0CJM6$J4KRG<3IU8T9
MXS1I\C2IT=DE2@HPBDDHI)&R(=G7!,-!H\,_^FM)GH="K3KQT^K:4ZE&5>GT
MN*KFI3K7#;<G7JRG5E*3;DVVR)_]*"VI_N?>_P#KDW^L'>^WS8%H;MQO!^]-
M/Z2J)6'TD2W5/ON9(FS;[.*,NQX[#.D!EO..^,=0M:]E>\1ZM=6ES3[JO;UK
MRK.E5IMIN$X2DU*.8K9^1\^G=E_9_I-[;:EIO".A65]9U%6M;JWL*-.M0JQ2
M2J4IJ*<))<R33SA_($6/SG]YY  '4SOH
M
M
M
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M1Y/<  $
M
M
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MUAMYM23R7KH)9IS_ (N<?8/I#YS,
M
M
M
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ML  ;3422,S,B(O:H^4OO/H -P#:2B462,C+_ !3YB_,-P      !G\_V?F
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MC%XWSMX>#)H@$/5H[J]8JC=E#IE1KBDPY4I#4MMZ*VRK"G$),E$HDFGN9%G
ME[A.F_$BO*,E&[&8<-1=E*6VE2CZ=.Y^P5J4Y4VE+&^ZP\_T+1FI]/#J>T
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MJ[]Q(D2B/VD7M+J78^Q_:,<X.$L/XIKHUYHO&2DLKX->3\C< 9(^QY 4+
M^A&?N 'H5.IP*/!D5&IRX\&#%;4Y(E274,LLH21J-2W'%)0DB(C/UE$. 6+K
M!IIJ1(G1+(O6@W-(IJS;FLTRIPI;L=>3+E6B.\XHNJ3+!D7M$)?I$6]%O:SL
M>N2VZ'4%P-0]5W(=$M4XTE3,PU.SVH<DF";43F5(?QDL8/MUSBJ/P>]4-:N&
M[OJT=I^N]2N.%8&YUZ9+4=?J\V7&==.,4B.;7G'G$M<STM."21%U(L8P!=0S
M%O._@O/SW\#]+*5*CPH[TJ2ZAF/';6Z\ZM1)0VVVDU+6I1]")*2,S,^A$748
M^.[K-O3+KK+NKEFM.LN.-.H<K]*;-#C:C2M!DJ66#2HC(R[D98P/O:U3&YNA
MVHLZ(XHFIE@UN=&>:6I)^%*H4J0TI#B3(R/E6DTJ(\]C(?F_\)?AH4KB=:T;
MF*%>^K=ZVHQIY>E1\EX->KKY2$SZQ4%*226I[9(2V22(B]A%T]@",4U)MX4<
M;XSNW\4?I*V?K=I/?CJX]HZAVE79*#(O+0Z]2WI"L]N1IN4IQ?;LE)^T=K<Q
M<O-[,9S[,=\Y]WQ[8Z]A^>'Q'.%#KQP<K?M;=QM>W"WG<%&M>JQI%ST^9)J;
MT:!&*:PUX:T3ISZ)"9*.=.5(]3)F786/;;XLQ.\&\M^$TF7KKBVFJ!(@^,27
M2K)9I3<DSY>4S.07CD6/I%@_>8.&R<7S)O'3#SY8)DM2]Q6B^D9M)U"U(M>V
M77N;DCS*Q3D22Y3Z^(PN0EQ'LZ*26?8/+IGN#T<U=0XK3S42V;H6URDMB%5Z
M>Y),S/IX<=$A3J_CRI,B]HH>\-_A?ZO<:G\-=X.\/6:[HMIUVK27;1HD294X
M<6;$.9(82A'R?,80R45LFRR2,K,NO<S'9NM'!7WV\.;<_I#J'P[;JNS4:UZK
M7F5URARJU+3%I%,9DQTRT/%5);[<CQXQO8-2>9)]CR!/)'=.?M)>6V=ML_G]
M;Q5\ZU:6:<S8U/O>^[>MB9+)7EH]6JL&"X]RD1J-"9+[2E8(R/H1]!P;^ZPV
M[YQ^B_9A_$J_2C3_ )WF\?G$1F^O@S0.)?)TDU)U5O\ N32B\;9H#*:U;](J
M53-M=2D4V.S-4M=.EL-+^?2XO"DF2<X(4T=0^'#3K,XM5+X>D;5R]7[/G22:
M7<GR_7TK(O()F?L!SO$^D?+]+'V 1"*EGVL-++6/!8SOGJ?IHV7KKI)J#5%4
M:S-0;:N2IIZJA4NK0)L@BY35GPX\AQ?;K]$=O"O_ ,.'@86+L"UD=UDM_6"Y
M[TES8K"SI%6FU>0PV:XAMGZLR:^V>><U%A.3QV$_!K;;29<YI(N9Q2C(^B4F
M:E]<=,$1]0*/T>3XMRW9;=H4UZK7/7*70*:PDUNS:K.C064I(C,S)<EUI!X^
M"OL' K!UVTCU,D/Q+&U"M>Y9;"C0Y$I]:ILB3S$9D9(9:DK<7@R//*D^PI1<
M7'7[6;?SQ1;>X<5G:HOZ=Z-6Y)5^&%5BSDTQJ3$7";GO%(FH?BK9Y20ZE/,\
M7?!9(BQS33C@Z:E;>-T^DFI?#PW0INJBT.<Q^B503N]FK&1*)EJ6DH<^K2%/
MFXKS!GX32C0?7ZA?E22;ENUG&.B]7G;Z?#)=JN&Y[?M2G/5:XZU3*'38Z36]
M-JDV/"CH27M\22XT@_L5_&. V+KGI+J/*?A63J%:UQS(ZC0[$I];ILB3S$9D
M9(9:DK<7U(\\J3["FAZ05N5U@UEW:;<.'E9EYU*T:5<:HD'4F11WW&9-2=7&
M@OOK4Y$<:=;+Q%/&7(O!D>"/&!@[OKVC7SP+=<MINN6@VKUU5"BW[.II7/2Z
MC4ZI+CO>;5 8EDMNH3'FSRJ0\7T.AX,NP$J&4M\.67%8SGY^ODDS]&PS(BR9
M]/Z1TS>&OVDEBW?1K%NF^:-2+KKRUMTJB/S(R9LM:"2:DDPIPG2QDC+*2SGW
M8$<F\GBB4O:ALOLS<;3;&J>HUQWK;5%3;MM4M$IUV;7*E&BQ><W(C#QH2W/D
MI</F21$DCR>,BCC5-:MV^MG%JT U%W71*[9ES7A7CJ%NV254?;CTFENH8=B(
M<8B.-,+\2$MHS)UHC(RZES 1&#EE[+'[XQG'P3S_ '/U#&W$.H0XVHE(<0AQ
M!E[4+(E)47P,C(R'D'P+:_O'0\F9G\A4CJ9Y,_UDSU,S[F?M,?? H!P'474V
MQM*K<D75?UR4VV:#&4VEZHU&4Q';2;JR;;))O+02C4LR3T,Q[>H%Y0;!LNY[
MQJ+;CT.VZ//JK[+25K<>3"BNR390E!&LU.>'R%@C[]C'YP/&1XE&[;?S8M5N
M*C:=7-I+M#M6Z#I**D[-E4^1=+L2ME -TDFW#G-)1-9YBQS$LE%UY0+1BY/"
MQ\W@_2'LN]+:U MRGW5:-6C5N@U-*EP:E$<0ZQ(2D\&:%H4I*L? S'*A$OP0
MUN+X:VWA;CTF0I5)G'XTJ0[)?6DY7JFMYY2W%GRX+UE&)7YDMF%&DRGU<K46
M,_*=/&<-1VU.N']B4F8%7LVO(]D,D?8\B'*7QQ]@](O#5JRZ[J8JG5K1]335
MT0T4J>_*-^03G@M18Z$^)+YE-FD_+I7R^TBZ#@&W7T@+A^;@[GN"U*9J*Y;-
M4HJ9+C;5=I51I3DMF*AQUQ:45%J.9&;;9J;1@U+,R)/<LB>67D_/IX?C)S,E
MVSU]P" ^T_2*>';=6M3&C[-_U"G/S:I\CTZNU.WZO3X4V:3OER0R]+8:86DW
M\(2M#BDF1DHNAD)F]1-:=-M+--INK5[733J+8<"EM5A^NOOM%'.$^P4AAQL^
M<B<-UM1&24'G)D0!IKJGN=JY+WC3)>_X?:(!K&](TX=-[:FS]/XE_5.+'CKF
M-1KF7;=;*CR'(*7#?)4\XY0VRYVU(09OX69].IC-C9SQ0MJ^^.[[_LO0N[_P
MAJFG+D?\(<1)+#3*9'.MI277DDA9*2V:CY#/IW --=4U\O,S+N36O3*U+TH>
MG]>NVFT^[[B*0JCT)Q]GSLTHK9.R#;9Y_$,FF_64?+A)=3Z8'N6_J[IQ=%QU
M"TZ!>-%JMPTPT%.I$2?%?F136DU))UAIU3B#,B,S)22["I\FI5'<_P"D(7A4
M(DVI5"S=KEO5A"$1I\E--;>N*T)*3-Z.T[Y=2B=09IYTJY5%DL&61BWP;+KJ
M*N,WO+?K5P515&I=6:>-NH566Y3X<:-$G..*\.0^;#22;09XP7;L!/*\9]$_
MJ7K\E[R^\:B):P^,1M#U2W*2=K.F%TR+UU-@SWH,]BFTV>]3XKS9K-Q+M39;
M<@HY22HO6=+)I,L9Z#L+?)Q3]IFP:GP"UQOEFGW)5V^>EVO"COU&I2#225.I
M7'A$Z^TI*5$9$IK*O8!&'G&'DDGR7?/3W@(&8'I$?#HDZ5LZF3=1YU(:\U%B
M2J)4[?JT&>R[-E(B1O#CRF6I#I.+6E7,EHR(NIG@3*:+ZN6CKIIO;.J-BS#G
MVO=4)$ZE2C;6T;K"TI42N1PB6GHHOI$1@,-=4=I#PO-$ZA:5'@EMK:4?N)Q)
MISC[?>/,-#/'QS_N9_47M @IR7CH7N-VF\="X-0J)IO-O71/=I3JA29E<;;2
M;5-*%;CU.YG7";=5'P[),L*4@E\ID1GD1RZO;G]PO"<U(WC[1E;<Z_J58NN+
MD$],ZW#A2I=.I,BNID2JARL,0Y+#BD2)Y%SK,C0I)J+!]IK^++QCM5M'=>6]
MGNRS2>/JMN)APILJKU-"8JW+/0Q!^44O$_*C/--F[&2M1I)Q!JY3(Q'CHMQ9
M-XU:V9:X[A-:=,*!JQJOH]6[?;F4B1;U">FVY$DUKRM1)4@H+RWN6(VX?-W2
M2,IP8&5<R7,TFL16,[[8Y6L;K^?T1.)Z/GI-J[I/P]=/Z;JY GT:MUFHW#7(
M]$J"UJD4YBKUB14&VU$YZZ"\)])$DTI)))Y2(L8$Z)=B&#G#RWA65O>VNZ>Z
M[V73HU#AW#!4S.H<9*4MTR?!-,68T24H;01%)2X6$H+EP98Z$,XP,<FVVWU;
M   $         !U=K+K!8NA.G%SZHZC5EFA6C:D%Z;5*B_\ 0;)#:UMMXZ&:
MGE)Y$X]I_  =H9+ODL#45$*QZ5SI%%NJ:JC: W'6=(H%:.E2-4&CJI4M+:9I
MPURC24(V>1*R4HLN8,BZ&+-VV/<CIENNT;M+6S26MQZY9UV1"D0Y+*L*:=02
M2D,.-J/Q$&T\9M^N1&K&2 LXRCU6#($0@^D$UI%M\-?5JN.,^.W%FVVRIK/+
MS>8K#+9'GN7*:LF)O<D7<R$$7I&WXK/6?\J6C_/L<9:%>I;5Z%S2:C5MZU.O
M2DTFHU*,XU(-I[/$HIX>S,-6A3NJ56VK+FHW-.="K%-IRIU8N$TFMTW%O#6Z
MZHAZV*<(74O7O;M8FNUJZQ%0*?J#"6\5NKH[4HJ>44R;27BN+(U^(>3R22(L
M&,P(_ WUZ4XZ3NMS+:2(R;7\@Q5&9'TSCF+&/]0E)X+!%^EQ;>L_]4RS]W=X
M\_ZQ*OA'P^__ &C:-/MJ[1*<5"&MQBET4;*S26Z>V:+\<^?[&GKKL![++NO.
MO<\,TZ]:;7/5G=W;G+EY8IR:K++PGOCP*W.T+@G:@;>]T%F[@+BUB_"5-N.2
MUR*5\DMQ_,>88-I*2=2M7ADG.?5+!^T61D(Y$D6<X2E/^:6,_:-2)!=2,OO_
M -HUR7O+[R'2.(N)M8XIO*=_K5RKJZI45;PJ*E2I?Z:E*>&J48)^W.3RUG?&
M<(V'PWPMHO"=B].T.U=G:2J=ZZ/>U*J4^[IT_9=24FDH4XQ44TDET\34!IDO
M>7WD&2]Y?>0X [$:@-,E[R^\@R7O+[R &H#3)>\OO(,E[R^\@!J TR7O+[R#
M)>\OO( :@-,E[R^\@R7O+[R &H#3)>\OO(,E[R^\@!XULM+/F6TTL_>MM*C^
M\QY"(DD1$1$1>PBP7W%T#)>\OO(,E[R^\@!J-JDI41D9$HC[DHN9)_8?0:Y+
MWE]Y!DO>7WD .AM=[(H-;L&O27:)$D3XT93D=UIAM#I&DC49DI"24>.YY^P8
M:[%3MY-;NU$\F"KB9)(A>-RDX7(M:5DV2^N221$?+_&).ID9B=%D0Y!)6S)9
M<9<0K!D:7$&@_N(S$5NI^W[4G2N\Y%ZZ6$Z_ 6^Y*:)@R3Y-2CYED:,GXO.I
M1EU+"2'T4I*4)TG+E<L.+?3*QM\\8_KT,-1-24TLXZ^?YX?4E&K1Q$4FH*G&
MR40H<GQO,FCPN7P5X_9/5Z_M?L]HA;LN\Y%AZV5:Y;1H[M<A19D@_DZ,I24N
MDLW$KZH)6,=3+IU_CYG5[^W/:DP_P4=A34LO\K$DDM)CFX1&2>8W20DRP74_
M6Z]>HS&VT[=4:9T]^N70AJ7<M5)#CK3Z$.>3,LY+*N9*S62NI_?DQ:*5",W)
MQE*2Y>1/X/+QTQ_;P9#;J2CA-*+RV]GO^;^9Q6+O5I*%&W7[/J5&7RKR9LRW
MB)PB/!&:6"Z9[F?UC$R3(K.Z+6I$)4QYBB./$;#9K5X<5EM&5I-HS21^(E.#
MRGH?42YUBT;<JT62Q(HM-=6]'>0E7E(Q'XBVU)2>2;(\DHRP>1$G0JJ]MVU_
MF.5R(IJE><6:U&DT-FU((^4VU8Y3)"5%T3[O>)I.+YW3ABIR[)RSGIG&5_7Z
M=(FI)QYWF.=\+ITZ^GRQZ9,W9>SG2AVWCIL>E$U4RCF2:CXCBC\<D8-7AF?M
M7COTP8PSTVJ%=V]Z[G9\R:ZND2)/A3&W7#2RXA:3)C!*4:6^4E$?3&<'GJ)$
M)&XS2EBB*K7X3QC9\N;J&R3E:G31S$WR_2^GZN<=_AT$:)QJAN7URER*:EV'
M3YCQDN:VE2DQ6V4&3;GB$19\0DD?TB,NP4N>2J=ZWR<N[EG9K'SZ>7H)J*Y7
M#WL[)>/3\_-YDH]7ITAIIUN?!43K;;A$4M@S+G22NQ+/WCVTR&5_0>85_DO(
M5_%D8%KV?77 22J+JI/C*2E/*VMIYS!D7;UWL=#Z>WH/35H1N*HIF5'U1>DI
M3]$EPF\GCL65+/\ W^\8>[@^E6/S4EY?GIT]3)S3_P!C^37IZ_GR9G#=MU4N
MS;?J%Q5AY#$& TIQ:S/)*5@^1!8P>5+]7X&8B\N/<IK/JE7I=.TSB2(4!+JV
MV6VFR=0M*#41*-XT^KS8YBR?M'IZZQ-P5OV>N%J%7EU.W)!D3G(VTU]%98-1
MM'S?2ZXZ^XN@RSV<VY;L+2Z!583<=VI5'G.<Z:$..EX;F&\D9&I/3ZL]SZ#*
MHPIT^\?+4;:2ZN*Z=<KK\D_W*2;G)0WAME^?@S$RG;@=?-)ZM%:O^+(F4];B
M?%CN-I0@V\ESJ\<DF1<I&9XS\/KDUTWU#HNI-L0+DH[R5LR6R-UHCRIAPNBT
MJ+Z7T\EU+KW(=;[DK;MVKZ6W ]5HT4EQ625'DFA#;C:C,SPE6",^8RP99$>.
MWC4_4JRJ;6(5EVL_=,%;W*LDR/"1$2AQ1(-/,2B]<O:6.G<'%5H.<8J$XM)X
M:47G'XOYDY=.7*VY1:V\U^?OG<F5R7Q^X_Z YB^/W'_0(^O[H77_ />H>_\
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MJ.\_1,](Z_9NU+4/4VJTJ3 B:FUZ3-ICLEIQDY+,6KS#0HDN)2>.1:3SCJ6
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MOQ(Z-1JNTY+F0Z>QYVU[DB\\B:^W'CI0<B.DE<SCB2,T^T^N.XG*/A0;#?\
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M>[_= ;AT4O:H3Z"]4&4'1KCILN9%E4B2TX3R7$>3>96LE+2G*><NA>[(SP
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MT;7=I6E6B5Y3BJ-PV9!?C3Y9(0V3JW'#4DR0V9I+I[C/N,W!L29%ZN#+'O\
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M24DXZQ&::4>$Y(O60?;H,CQLR2?5(C/!%W[?:9C4E9/&#(_B7?ZC[& -P
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M!N
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M*;<(E(47P-)D?L'E'';56IVW+==7GG=MZC.+SWYE0&%*S\<F>?B.1 80
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M!]*N8L_:77.4GU2?NZEU&X?(HKBW:;375YYW*53W%D??G7&;4K/QR8^N!A
M          Z*W(ZSQ- =%[^U8FTZ556;0HLN:W3X3+TB3*DHCN*CMMM,-N.J
M,WB06$H/H8[U'HU&GP:I#>@5*#%J,*2DVWXDQAJ3'=0HL&3C+R5MK+!]C28
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MD:#7E)W(:?U>RM2M*$2D7-/JL1^&5:\HY(0Z\TV[&8;)+:(RE9:(R,E9^(K
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M(S+[AN'KQEJ6VVM18-;+*U?!2D$9D?VF/8 P@
M
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M/S8]F )<TT_9]IKE;SMC;P\]O,YPDNGT>7V$7P+H73V=!N  ,8
M
M
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M?XBOZ !Y &U*B5U+/VD9?QC<
M
M
M
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M=6>>Y&+B99ZY+'4_N]_V^T"LEB36,>B>5NO!^)J  !4
M
M
M
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M"'5?1(B3]@LM$6,^W)F?WC1*23VS]9GD_O,;@(;;>7^8   $
M
M
M
M
M                >NX?KE]O\1#V
M
M
1                   !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>nt10002526x6_linechart10.jpg
<TEXT>
begin 644 nt10002526x6_linechart10.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( ;@#L@,!(@ "$0$#$0'_Q  ?  $  @(" P$!
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M0A@F-#=4562"E):R)$-E=;.TM=+3_]H # ,!  (1 Q$ /P"_P
M
M
M
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MHKM.4I1F>Q$DDR#,S,^A$1;[CLJ5$I)*29*2HB,E),E),C+<C(RZ&1^0R[R
MJ<@
M
M
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M,6=,5?<QQK^ =I?J_3P$GF,<^W^)D   "@
M
M                                        'CS%N:>NY>\?Y !Y /$U
M$1D7E/WOTCR  !QS%N9>4O>/](&9)+<]_B+< <@ X4HDEN>_Q%N .0
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MGV_^;N_0'55/4E]E^>_SACCAZT?CY\?.&;3 -6?7?X9]O_F[OT!Z[_#/M_\
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M%64HSD+;BMFAAM:S,EI02T]# ..%G/E^!-6 %[_> %
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M-6?6@89]H/G#OTAZT##/M!\X=^D;3 '6U/7E]I^>[SEC@AZL?AY\/.6:L^M
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MJ4KQE'U,S,=T
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MRT^%+4[159QA"=.$*L)SI581A4<II0J0E%-MYQE-II@  8P9@
M
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MFW65%N*;I\OU%[Q[5.,5;<1 DPBB'+,R8+^4(3S\YD9>+OML!.&NU-?4;;@
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MYPEB?4=/TQ_\X^Y/;7MG\;*V?\SNO\//+HAV>O\ LMY]VH70  &L3=0
M
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M)U'.2SR3C%KBRLD]@#@NI$?O#D:]-B@
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M;\/Z-^L5+%G/%7W,<:_@':7ZOT\"7\F/U_Q,@   5
M       \%IYR,O.E2?\ *+80=ZB.#;;.:,Z7YG<\G/42;=S34B72"IJY"&S@
M15)01+-PDF2MMS/;I[XG''SZG_>4SS^ S/\ V"MO[1WF@;AUG;=Z[W1+ZK87
M52GU$ZU)1<I4I3A*4/3C)8;C'N[C'=S;8T+=FG/3=PZ=1U.QC4596U?BZOK(
MIJ,VHRCEI-XSR[REA8NAVDYGU.U_2G,NUZG4RE5".ZJX6XJENO\ @G\L(B9)
M:5)W-ODVY]B(RZBWQ@3#\'!F*K3QA3YWIE$M:*<5J:ILVS>(]MU<AF9I/<NO
M45_=*?\ X56]_P#\8Z7<?^\G3%FD;7Z;M9U.\U#;EG<W=2K;/;.CZBZ4E'A=
M[=VW_M-QE13XJK2XL/A\$N9HK_#7H>E6&B[NN[.RIV]Q'>NX-,52'$FK&RN:
M:M;?F\<%%-J'+.,Y;-).(41%I%S+T+K07>XMO_%K(0Z^AN?N)Y6_Y?D?]J3!
M,5Q"C_UHV9>[I07=^O=]K7W^80Z^ANNF$\K'T_P_(\O_ *4F?]_?&.Z3_P U
M>ZO_ )[I'_I?E&P]8_YU-J8[%H6K_=.GDLR%W%\!?H'(X3W%\!#D:N-J
M
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MLO-4E;+<=:F5>#$XW_,FGF-O<^HT\3PT.*[C:RI6D'%.IQR/IPE526=,N=-
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MI22V42%F;:NBNI"[$D]]_>4HORF!62YKNY(\@  *@
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MQZIX4:* Y'6MY4>.<B0^GE,W.3[5RELCX .26,=K3[XYSX=_]<^\FJ _>[P
M#C(O^)K8NNZ]L;T*)H:R.G'=YL./*K-25 @3DK9[1"DJ-,\R;22&B7UW^$0
M:*<W\7>X>(8> \I:B?JZQMAV!+J>;:G#H%*1#AI.D+J4"-V\0UH6;RF5LF;+
MFZ%;\W7H+2NM',R,!Z:LL9/6R^\Y0K9J46*F,VXZ\4JI0WHD=QM#25+4IMYU
M"R,BW(T^01$\!O"DDM%EZ:A[B.9-RGJ+?OQ5P3ZFV\FI2&84ZJQJ.RLY)=JE
M"&76T(3T3LDMBV(@+)^B^2\$\+//V]O+^?O(W\F:UN(MK"S#JQR5I9S,O%>(
MM($BAJ@6CZ3P:FF_&E$M%<2J9()+D/94-Y1&9*_G.G=L+#/#*UJLZP=%=@Z@
M[UFTVW*O,55J1="ZA.C1XL:?0Y[E+<??EO*9C-E+=86XDC6G8U&G;NWJJ:=]
M16/=$KG%!P'J%=JEG7U=CT*-9</TEJ,L[F>K*JBIE$-V.P;:^S\):)1H4K8U
M%OMU$JO"HT)53-'!=C8!R%4ZU87JJ5VY*KX8TJ;!JE/A'=$JIP74$RN/*:*2
MPXA7BJ3N1GOOU("TDL>'..._*<5SY=OC]R,2^B6[QM&Y+#TS-V]=-NUYSZOZ
M.?9T>LTZIN;?5'3.]N'(>6DB_P"$1="%I?%7W,<;?@':7ZOT\4!>*[PD[/X?
M4?3[>MNY/N:^'ZM?E%0Y%K=1JTQA')<-/01M(J$R0VGHOKLDMS+WB%_K%7W,
M<;GY[%M57^508"O[0(EC$</*Y\\8[S(   %
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MILX
M                 \20DC,R2DC/RI21'\9D/(      >/*7-S==_A/;Y!Y
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MF.-?P#M+]7Z>*QGHG7^@&F;\/Z-^L5+%G/%7W,<:_@':7ZOT\"S^3'Z_XF0
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M0I*,X*+4;;"C32>'CL48_)[,&VP  U4;9
M
M
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M7W,<;>_8EIF?PG;]/,_RF!66.&.,_P"]V]O:O/9_ID   "@
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MK.YK<$>&'65J%.I/ACEXCQ2>%GD@  .J.U
M
M
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M-K33I3\)+#Y>P]T!XI42NI;_ !EL/(8<9B
M
M
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M5T[-"=O+W><S%GW%7W,<:_@':7ZOT\")/,8<L?*_EY[?ZO(   %
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MBJTZE1QN*L4Y-)+*BDN2[$  !A)FP
M
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MS'&OX!VE^K]/ E_)C_WOXF0   *@
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MFW0
M
M                          ,99BM67>N+[]M:!..GSJ[:U;@0Y1*)/)(D
M4V2RRDUFI!(2MQ:4FHSV21F9]"&31CO+$;PK&>0&BDNPW#M&X5,RF$K6ZP^B
MD2U,N-I;\=2TN<II2@^8SV(O( *8ND[B+7/PD['OG2CF7295*Q=$*OW0[$O>
MW77JZQD-NNU2?,B-SY5(ARV4)::DH8-,A]?*2S(]MC(29<#/%^6+BR?JCUE7
MKB9[!-F:AI5ORK+QUVJ%M1FJ0;S,F3V24,&PJ5S%(6E3"5&I>Q[GU$+>B/C(
M5K2:]DK$>H; =Q9PI5*NZNG;-_5NPY\B2MGTZFNFWS2J-+D.)93R--J[7N21
MI/;86G.&7Q)+-X@5%OE^SL85?&D2P3I[:X=1I,VD,R2G*4E)16)<*$GE1R]>
MR29%Y0.22:R^'PS+/N:Y=W<2ID6Q$0Y  .,KL^B"<ZY]L##V/<2X=LFN7)1,
MJU/>_:W0O"?":-2J//CO.1S*(VM\TU*/VS!\BD[$9&>XKN</K/5F8^XIE:M[
M&>&:I:5OW?9<R W;RSG*ETRL?4>\Q49<Q;S!2%*GSUN2$D\DMC4?*>W4?T-J
MC1Z55B;*ITNF5(FM^S*HP8TTF]_]S\(;<Y-_+R[#3F@: ]-UMZF+@U64JQ:9
M&RU<B(Z*C5FF4)8-,:)X(CL81-E&9,V>BS;01J/<U;GU O&22::[4^>?''\E
MCQ*IF@"];/Q;97%JLG(-6I]K76PQ!>>A5MYF'-FJK151Z"W$:F*:=G*(GD$1
M,I<-)F73J-V^$G@#/V4N"2[C_$^09N)<AWI=%VR+-O-RG')>I##5WS)#KC<!
M\V^=,F.I))4>Q&D]RW(25:GN";HKU2YB7F>^K0G0[HJ<R+,N9-&K53I$2X7(
M)H.&4Z)37F([R6>0B)+J'"V,RVZF)0<78KLG#=A4''&/J*Q;]IVW$3%I=,C%
MRML(2@DJ5N1$:EN&7,M1^,:CW,]P#DFN7;E-Y2:Y+'U_6E[<G\_'BDZ)]<&F
M2-IYK^J#5=)SY;\V^Z*F%0'[=CT?TM,KBIZ5&;[+BU.FM1DOKW=/./Z"F*ON
M8XW/SV-:IE[Q*H, R+XB,B%8OT3HDBL#3,1>2_Z/Y3\MQ4LQ9TQ5]S'&OX!V
ME^K]/ 2>8Q^O^7G_ $P9    H                                 8_
MRC0:Q<UA731*%4U4FJSZ1.:AS$M]HI#AQ72Y"3N75W?DZ'N6^_G%3+3;E"SM
M'6?LI4O4/:SE9JCDV<2)]0B.RR;\*\)-DR;-ETE=NE:=C_Q-R\QBX:-7<C:-
M=.^5[GE7??&/X-7K\SE\)FJ<6R;O*CD3S(;(B,R3Y3Z[C9NP-ZZ9MVSU_1=>
MLKR[T;7[>C&M+3*L+?4*5>VJ*=-TZ\L/JI)R4X-M94<+G+.E^E3HXUG=NH;5
MW%M?4=/L=P[7N[B=M'6:-2[TJM;7=+@K*K:Q4TZ\91@Z=113PY)S6(M5:<>8
MWR'JVU$WU<>FR-.L2GJE-O-S8O:M,P4.)6HE;*[%*R>\A=R=]MN@W.^MU:_?
M_/!5O9;>R3W;[;_WS\?P"?\ Q#IZQ+@MFHQ\96I%MU%5-LYQM*-QQ[LMS1]L
M67.GEW/N,OT#,ZD)(O\ &[R_QE?!Y3&6:WTWZC4O84MO:;IU+2+6VM;2SCK.
MGVNI:@Z=O2A#BKW-93E*3:>$I82Y]K9@NVO\-6DTM.G6W7K&KU]>O;R\OM0E
MM[5;S2-*56ZKRJ1A:V='JXQC&+2RX1;EF.%&,44\,X6%JITM7WCVDY RE5IQ
MW/5F41D]HM)&AF2P3J3[-Y1&2B49=?)\8U\K^6+"Q%Q?:;DK+-4AQ+/I5-I#
MM<G3HZ)K1*D6^RE*G8JB63AJ</?8TJV/K[XECXS&Z<LZ?%%WG7%H/X%RXZ3_
M "#8Z^>#KI2U%52#EF_:"[)N>Y:#1%5&0F;-:)TV*:PVCQ&G"0G8N_8AF>H;
MOTS\F=J:UN2@K=[CT/<NFW=31+"UMYYG>6U",HTH]7"/!2IOAD^)*?;'F87M
M;9.I6V^.D';FV+JK=T=K:YM+4+*GN#4;J[C&"L+BXG%U:CJ3?'7J8DDH9AA<
M7)$.7&PUE:5=2F*[#HF +IHU>K%+=?=J#%,HR*6[',WF5L\RTM-FHR-)F1$9
MD6PG6X+]4J-4T!XC?J4Q<Q]#-2;)U>YJ(D25)2G<S,_%(B3\73H(8^*/PI-,
M>DW2Y<>5,84-Z!=%,<AI8DKF3'R,GYB&E>(\M2"\11D73SF1^43&\$[_ ,'[
MB0_*;=54?PG,68P7=530JG1=IL- G?UK&VW+5I1JZG"E&Z=6=M.K5_V3<>#T
MXI8PWCGG&3<6U:6NTND_4:FOT["C?76VZ565+3)U)VBI0N*-*G_M<2ZQ\,W+
M.4NYHEK  &C3>@
M
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ML4"\+BE]FVR1T6JNT:*^YU0VE3_@_-MOOUV[R ..%X]B?+L;6<>TC@]$Z_T
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M2RN::9Z+M;NWO:%.YM*U*XH5%F%6C4C5IRP\249P;C+ADG%X?)IH  #YSZ
M
M
M                  \%F9)Z>4R+Y3%3OC;65<NK'7;HOT:5W(,RR\.9!DW8
MJ\H\6HNT=%0:IT9J8PAZ='D17$>.1I29N?H%L52>8MM]NI'\AB OBL<'N_\
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M2Q9SQ5]S'&OX!VE^K]/ 2;<8Y>?E=OO,@   5
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MNB)=T;U?"]K(Y  &NS8X
M
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MFU>PZ\JE;&?P"_UBK[F.-R\UBVJG_)H,!/\ 8 DFE%-8?/\ B9    H
M                                 !C#,=_)QECBZKT.&].51:9)=;CL
M$HW%NJ97V:B)"5*V0OE4>Q=Q>0<UO0J75>C;48\56O5A1IQREQ3J24(K+PEE
MM=I\]W=4+*VN+NYGU="VHU;BM/#?#2HP=2I+"3;Q&+>$LON(8N-W6*5(Q_8%
M+8J$-ZI1ZJVM^$U(:<D,I\.C'NZTE1N-EL1GXR2Z$)--$54IU2TX8X]+YT6:
M;%+0B0F.^TZMA9(2G9U#:C4WY=N=*=Q6MQ#AR\^([E[*-W73D15J)ITF0OL9
M[A/-I;C]N4=MF(\ZA*#-+1)4I"",CZF/I:<M6-Y\/S+&0,?SBG9$M>/(;9>A
M-27%-DE@G.S6TM';DR2CV49-[$7<9GY/4NK]'D[[9-IL/2M4I7^[-JR>N7NF
MJC*E"HM65#CM:5U4E&AQT$UPRXWUF,.,.),\0;?Z6*>F])%[TH:YHM;3-C;X
MA';.G:P[B%>=+\12J=7>U;.C&5SPW+AB<'3CU2;<)5>%HM\".;63K$T\V)9F
M4,773D.!2KV1;\Z,JC.I^W)>E0'B802C5MLOF+OV[]B'9M$&MB)K&I%TU6+:
M1VL5M.16S;.6J6;_ (4I9=3,BY31R%T[_.*M^O7"M%U"<8^?B"OU"=!I-WOQ
M&Y;S4N2EILH],0LB[%MQ)'S&9$9$1;]=QJ#:^R9?E1J>D;GE<:55T#3ZVJ7<
M*"HW%6#M'0K<'HRE"2E2GGT)9[%XGI/<&_J%WM+2==VB[76;7<=_3TRRK5^O
MMZ517/7T'-*<85(.-:FX>G%+&7S33,O<"'4SA7 $W4*[E6]H-KIN2XD.4;PC
M9PIK:ZG*4E232K<MTN(/;KW]_E%O:QKYMC(ML4V[[0J;=7M^K(4Y J#1&2'T
MDK8S277N/H*3G%&X56+=$^'J%D&R;@GS*A,?B/.M-N2XA*-F0PHR,R?,E[DH
MRW/RGOMOL,YZ5^.]3].N"K%Q(K 5R7,Y:L)3+E:0]57&IG;&3G,A2(KA&9;F
M1^.KN&:;OVA3WS#\L=G.]U.KJ-Y^#7-K6C0M84(VEM2I.<>MJ1;S*$5\I\VW
MA(Q'9^[Y[&G^1V\(V6F4=/L_PBVN*$J]W4K5+NXG64)]5"<5B,Y-845R2RV7
M'P%6;[)/IWWLMS_Y57_<P^R3J=][+<_^55_W,8#^:O??_453_P 39^S_ +1[
M49]^=78O_7D/_!WWL^@]OW^QEID!6"M7T1Q1KDNZV[6=T^5*EN7!5(=.0]/J
M<R*MHY4EJ/VB6I##:G.4W.8R(C[A9KHU0*K4>E54D=D53IL&H$WOOV938K4D
MD;^7D[3EW\NPQW7MK:[MIVT=;L)63O(U)6ZE4HU.L5)Q4VNJJ32X7./;CM,C
MT'=6A;F5R]%OHWJM'35QPTJU+JW54G33ZZ$,\2C)^CG&.?M^D  ,?,A
M
M
M               !^]W@  B$XR5,UIW;I6KV/-%-KOUC(=YMIAS:E&G,0GJ9
M![=*)32#?,MSEQ%NM\R%)-'?WB''A5XHXF>E"JV3@ZX=%T>@8SN5FOL97RM*
MNJDU*KU!RLM/*.2\IQ"ZDHFWY+II1VYDE/BEL6V]P=2247D^,B/](X).W]78
MO)RE_8!92PL86,Y[_9[?84P,FZ*^(UH]R[JQQII;PTK*V(M7;]"13KN].(%*
M*Q6T)6NNK5#?-3DSG5+>+91I]AT[R%A;ABZ+$Z0=%&/]/M]4ZFUZLQ%U>KW4
MU/AQI463/KDYRJ.,/17DNQG"BO/+;2?(KJ1GOW;23J;0:DF?)NGN-24J-._]
M4SZIWZ;[#S,MDF7O'^@ Y-K#]GW+'\"I5Z);LZT;;L+3,Y;UK6[07/J_HY=I
M1Z+3J:YM]4=,[UPX["U;]?9*/H8M+XJ^YCC;\ [2_5^GBL9Z)U_H!IF_#^C?
MK%2Q9SQ5]S'&OX!VE^K]/ /Y,?K_ (F0   *@
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MRJ3EI^J.4YR<I2?X;%<Y-MODDN;[.1KK8\(4]X](M.G"-.$-1TQ1A"*A&*_
MWR48I)? [*  -6FU
M
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M;_B^D,#E/XT[&!$EB,.:?RNSWKV&0   *
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M3&%G,L9:2S@M@@ #6ILL
M
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M':7ZOT\"7\F/U_Q,@   5
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M0:H<(U'0:<:E*B,'O_(F.O\ -[[_ )??&4?2R%_O*!_T-C]@8ZPH>^+K'/\
M] 4[_J3 RL-<:A*7X?>\W_RJO_\ 5EY^[L-P:/&+TO3FTO\ D-G_ /;TG_$^
M#/IT),26?@4'I!E]T-@C_F5^7DW+^WY14"TQ)2CCR78A*4I2F:YLE"4H26]+
M?[DI(B+W]N\7#*B1^!S#V/;P&67_ .RL4]M,I']?FN[I_MU?_93XV'T=MO3M
M^Y;?_%&\]O\ [^@8%TAI+4-B86/^-EE_Z)+Z^7O+C   U>;1
M
M
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MW'5RJUU07JG/DNRY#Z*?79$5M2WGG''#\1LMB-9[=PG> AK#:\'@   0
M
M                            '!D1]Y$?DZ]>_O\ E'( #0G-7#2T;Z@<
MD1<KY2Q% KU[PY+$M-49DO06Y+\<TFRN9%C&AB9V9H2:2D)<V,N@W<MZWJ-:
MU&I]OT&G1J72*7&:B08$1IMEB.PRVEIM*$-)0C?D26Y[;F?4^H^T/S<=2TE2
MEJ)*4(4XM1]R4((U*/Y",!DT<UHZ!<):Y:79M'S'2UU*+8]5CU>D)0\^P3<J
M/+8FMJ,V%I-6ST=![*/;OW(R,;HT*D1*%1*/0X2#3"HM+@4F(A6^Z8U/BM1&
M"\;J>S3*"W/J?>?457M4^MW7_J7UK9VTW:&+Z;QS;&F.GQZU>5?*%3ZG]4;+
ME)<J_@G8S")4;=,5R/S)4?L]^\2@<'?7I<VN/34W<>1H?@.5+,JE5M^]FN9"
MNVE4RIR*:U*V;2EM'A/@RGN5&Y))9%W[@6:>%SY+GCPXEGZL\B7;8O,7R$&Q
M>8OD(<EU(C\X 5.-B\Q?(0;%YB^0AR  XV+S%\A!L7F+Y"'( #C8O,7R$&Q>
M8OD(<C6G5IJ1MG2G@^[LSW3$G5&!;D=M+%.IT25,ESITLS8A,H9B-//$E<A2
M$*639I21\RO% '8]16![(U+8CNO#>08WA=IW:RRS5(Z7%MJ<0THEI+F;-+B=
MC+R&73Y1\72KIKQ[I'PG:V"<6PE0[,M)4]=,C*<==Y#J,I<M_P"V/&I:MW5F
M>QF>WY! MP?N)9J6UI:M]65.S-'D6C8EEE0Y=F8\DMM*>MZFO1'I"Y#DGD0\
MX<YA")'(ZDC;YN0RW(Q@_/>NKB*ZJ]4NIZQM#U[IQYC;2,W3*G<;R(--JOU8
MQI$-V=*C?RI)+B]F45YHU)YCW7N7=T%N%YX<XQAO+Y<\8_BBW+L1^0OD#8O,
M7R$(O.$MK@J>NG2;;&4[KB>EU^PIM8H5W0>9*S3-HE2>I:I',A*4%X2Y&<>Y
M4]$\VWG$H@%6L/!QL7F+Y"#8O,7R$.0 '&Q>8OD(-B\Q?(0Y  <;%YB^0@V+
MS%\@Y&.LK737+-Q]=ER6Y0UW#7:51YTBDT=MTF53IR(KJXK7:&E1)YGTMEU+
MR]0!W&L4V-6J15:/,;,X=6ILZF2B+H:HT^,[$?+8O&+=IU9;EU\I#2?1AH$P
M?H@8OV/ANEKIZ,A55VK5PE/R'B<DNRWY:C^WJ5R?;7UGRD9>4B+S5D<W:V^,
MAIXQW%UP9=N=JT,7R;^BT).G63&H[DM5)F70W0H[S55(O"WC<CNHE\J&3,MR
M2?G&ZVMSB/:J,JY=TO:2M&-5<QKE'-%IS;ANJ[7HL:H+MYZ!0(U<;8.#-;0E
MQ,PE+92KF+EYN;<P+<+Y<^3^'+GS]V2T$7*?^+L9=Y&0YV+S%\A"!7@^:\<Z
M9OO7/>E353+;J&<-.TFCQ:M<YE'95<Z:R;KC3J(<4NRC]DR@CY2WYMSZD?03
MU$9&6Y 0UAX\\UD;%YB^0@V+S%\A#D (.-B\Q?(0;%YB^0AR  XV+S%\A!L7
MF+Y"'(]>2XZTP\XRUVKC;#SC;>^W:.(0:D-[^3G41)W\FX \U))9&1)W(TJ2
M?DZ*+8]O/Y1H/C?AXX'QCJNR/J]MREN,Y3R;X =PSC?DJ2]Z71E16-F5K-I.
MS2C+Q4D7EZ]X@HU\ZE^+Q95]YTS);MPP-/.GO"]1MT[0HTURA55[*<:HO):F
ML1525-RXQM*3R>(EP]W"Z="&2M3'&"SM;?#[TWWW9-K/6SJ.U+R7J#;K<GD6
M]2Y%-J<>E2ZKV#[26GDOH=.8E"DD7+L23[C LD^Y]O+^>'_I[BT,A*4ER\NQ
M[F?=T,SZGM_://8O,7R$*P&@O71K2Q+KBHVAS6Q=C>4:ED^E1*UC^^#B0:0;
M*7*.BMS(G@,0O'..EY$7F6KKR[[=19^29GOOWD9E\7D/XR AK'\3G8O,7R$&
MQ>8OD(<@!!XFE)D9&DC(R,C+8NI&6QE\9# ]S::,*W=6IE?KUA4FH56=MX5+
M6RR2G>4MB,RY._;Y?*,] /HMKR[LYNI:7->VG*/#*="K.E*4<I\+E"46UE)X
M?>CXKW3K#4J<:5_9VM[3A-3A"ZH4Z\(S2:XHQJQDE+#:XDLI-G2[(Q]:&.Z2
MBB6?1(E$IJ-S*-%:0@MS/F/F-*2-74]^O<8[GRI/R%\@Y <=6K4K5)U:U2=6
MK.3E.I4DYSG)]KE*3;;?BV?10H4;:C3M[>E3H4*45"G2I0C3ITX+LC"$%&,8
MKN221J%J-T-:;M551H=6S99";IFV[VWI4Z<U^-X/X01)=\5GHKF(B+KOW?"-
M*KHX&V@ZMW%1*U$QR5,C4TW?":>B?,44U+I$7*I25)-.WG-)F,T\3[7W:F@G
M3C=617EE5<@R*9)38EIQR6Y4*M.)"FE/LM,I<7RPEJ0^O="D[)ZEL1B*+1UQ
M;,X5+A+Y%UO9S6BNWI0I<J+2XAMQX78NU:M2*;16C-I!)YH_/'0HE)W4I/CE
MU';6NX]?LJ%.VL]9U.VMZ2:IT*%[<4J4$VY-1IPJ*,<MM\EVO)U=SMG0;VM4
MN[O1=-N:]62ZRO7LJ%2K4:2BN*I.#<L)))M\DDEV$^VG?2EA'2O0IMN87M0K
M6I%1)HYD8I+THG%,F9I4:GO&3NI1GMYS&Q^Q>8OD(4KL;\2KB4:?+ETUZBM3
M=Z)O7 6I>O5:*Y8::?38)61";GHA4?\ NC&2;TOPKPEE>^Q&1EL?G%SVAU-%
M:H])K#2>5FK4JGU-HN_E1/BM2DIW\NR72(=9<W-Q>5ZES=UZMS<57Q5:]>I*
MI5J2PEF<YMRD\)++;9V=O:6]C0IVUI0HVUO2CPTJ-"$:=*G%/Y,(12C%9[DD
MLGU-B\Q?(0;%YB^0AR X#F.-B\Q?(0;%YB^0AR  XV+S%\A!L7F+Y"'(X/H1
MG[P <I>8OD&E6M30SAK7+8%,QYF2G+J%!I=4I]5CM(??9Y95.G,U!@^9A25&
M1/L(/J?7R^_HYQR-=&4=$NEHKFPK6(M%RA<U2IU.MJ9)\%43:WZE'B/J)N7]
MJ424/;J,^A$74:><.'-'%,KUXR<G:H,O6S?.#:99TZZ:G2Z4Y:ZY<8FZ [4X
MK#S=*><FH-;R4IW-!>4S+H8%L/'%E+MQSYO&.SXED^RK3I5C6I;]I45I2*3;
ME+ATJ @S4HTQH49N*RGQO&5LVTDNN^^VYCMFR3ZD1?(0I"U[B@<3;)-IY;U\
M8MN[TGTPXFO>%0F,2' ISR;BIZKB50*@\57=3X0QV!-.2-MC,_8]Y;G;HTE:
M@:9J=P!CK-%)C%%C7A2&7GXZ7.U)F<RTA$U)+V+<BDDX7=\8!Q:[?[>\V2V+
MS%\A!L7F+Y"'( 5.-B\Q?(0;%YB^0AR  XV+S%\A!L7F+Y"'( #Q,DEU,B^0
M8IS1B2ULXXVNC&-Y1U/VW=D)<*IM$I:%+96A2%%NV?.GHH^[;SC /$$U6,:,
M-*^1\^NP$U.1;+,.%3(*GB9[:I5A_P  @JYS+H3<EQ#BMR-)$7C=#%?_ $I:
MBN+W<V4L&98JM]VMEW&&8Y]9EW9AJ/5[3IU0QU0XKG-37?"&9"IL\Y$-92#2
M325IY-E=X$I=^4O>\? L5Z/-)6+]%F%Z-@W$,!<"S:',JDZ)'4ZZZ:7JM-<G
M23[1\U+/F><4>W,9$-JB/?SE\);"J;JTURZ]]1&MK*.E71+>18MI^G:AP[@R
M#7B@0JLFM+>H:JVNFFU,278$A<=Z'VJ%'S<W/MN)+N#GK\NO7#I\F3LFT],'
M+>/:G4:!?"4NMN>$2(-2D4]F6:64I0V<E,93W*GHGGV\@$N+QGEW-\^?/FB8
M4 +J1'YP J
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MT:.RA+;3++*$MMMH0DB2E*4)));$1= $I)]BQEY?9VX2Y8^L]L  "@
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M=[PG]1D$NXO@+] Y  *@
M
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M!<13.91K:DT_GBM]DA)>Q</?F^(2UD>Y;@5:QR9R
M
M
M
M  \3]DGWM_T#R  40M3.H9&C'T0%DG4+>UCW75K$B-P$*J%*H58G1U]K0/!B
M[-Z%#?0K99D1\N^Q]Y#OFI_-V3N.QJ3TZ8FPUA6Y+5P=C:Y':W?&0:VQ-@MN
MDU*C5.$A,*IQ8BR)3L8VU&V9F1JYC/H+IE6QS8%=G.5*M61:E9GO;=K,JE I
M4Z2YREL7.]*BNN+V+H7,H]OB(?1HUH6M;W]'[9MZA$?LO2>C4^G*/X50X[)_
ME\H%^+&&ES2PGG[\?'OY9]Q2>UOYCNZ'Q'[FT^:P:]=EEZ2K/LND4'%,"U;7
MJTQRZZDS:345UI=>MR.4UE)U1ME)]N^:32LR]CT'WN 'BJF52X.(WA&[K#K5
M MC(-,B-6S3*_!J"DS8RX=1739?AT]@CD+4AQB0:5+6IM2N51I/J+EUQ8UL&
M[*A$JER69;-=J,%1JBS:I1:;-DLJ/RD]*C.N'W%MXW388.U)XVOQ[#][-Z:V
M:%8^8JG#:BT.XZ?1*8AUH_&:6;J#9;0^2&5%R$ZH^7;9.W< XN7"ECDE[.37
M/L[VLLH*:<\0Y;RSK<QEPIKHCR5XQP!D&X[CG.+<[6(EBK5ARYZ>4AK<T()L
MTH)/.KR%L6Q"7WC V3H_N#5%8>/M3N'KJQE3Z108U+MC5+9ZKCGOQW*918[!
M*<I%MM)>+QFD1R2ZX1*+OZ;B2[A9<*J^],>6<M:J=35]-91U#Y=D0WIM853&
M*:ND)@$XRTAI$<U,J)<99(,V]N[<^I";BZ<?65>L542[+4M^XF5'O_=:DP)S
MJ#WW\1V5'=6C<^_D4G?R] )<N::[DNQXY\FW\>YE0W@.3=2U$U<9BL/'U^7!
ME?1-1#IA6W?-RVW)H,^8T[%=6:=JPTFJO=E*V;,U.*,MMS/8]A<A1S;>-W\R
MODW/8=:MBS+6LR$FGVK;U&M^$DMNPI-.AP4J_P#O/!66N?8^I<V^P[0!1O+S
MC'9_=@  "
M
M
M                                   #A1$HMCW^(S(_E(  '"4DDMBW
M^,S,_P H\@
M
:                               '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>nt10002526x6_linechart11.jpg
<TEXT>
begin 644 nt10002526x6_linechart11.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( E(%&@,!(@ "$0$#$0'_Q  ?  $  @$$ P$
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MJW=M"T>K^LZY3FHDZC$JX%S&39DJ<2E)-FZV9$:%&GR,B/V^T9P@OF*   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MPI936;9AFTJ/3"-)&;3:FD-MF77]"@O8,LP7D?4^WT0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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M@5$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !%M4HD%
MDSP1$9GY82DLJ,_<1"JIQ7N/Y7MK.XBB;5MM5@R=2]2F*_1Z;>#U,6MQRDLU
M.5&(E)82P\3V6'%FKE(^0DF:C(6E:X3RJ75"8SXQTFHDSCOXQQ7":Q[^?&!0
M#V8U[3JQ>/\ ;@:EN?73(]3C5%N7;DJZ6V%PVFF*8^ZI1(G%Z.I1-I0:.;KD
MBY<'W*]@!V2-Z&P/KL?N_P""F7XNW&IO;95MUT;I>GM)2K<3K;1(KL*)ELY5
MMU!3$5QQ#L9QM275.G(P25H29'T+VB""SN-_QA=JUTZ?ZI;LZ!4Z]HK>U4B)
M*)*IT2 T] FR662=5);C\\9,=#Y+22C3XA%@LYZ\6WJ7I2>)+QU+!T[L):;E
MTWM2XHCM+5#^7IYHIS##S_*ALC9902HV#(B2DR(_+H)TOA,%V:#6;P[(FF53
M^Y@]1:A%M2F653*<5..HQI%.D4]F21(B?+QL\A?.2CGP??)@KP .AI:"7^I/
MJ 3[?+0_GU5D/;IKA;6XG1RQM7[2=2[1+RI$6<P:#REM]3#:I+1*/OX3REMY
M\^7([P$/W FIMR4GAD[>(=UH>;JQ4VHJY)!*)U+#DA*HW,2NN/#[9+L0F!!>
M1[$CZKX]P0I-1H-;I\)XXTR?2*E"B2"ZG'DRH;S##Q%TSX3JT.8_N1^?[QAN
M$# VJ[7M8MU^K.I]6U8UON6XHTRCRZ@J8U&MZ))KIH1'CQER'8AD4-U#1\B$
M_-(S(?H,GV/Z#_ *SOPI!2&N'!=IJ2\LO3:1^9-+><ZU>/\ H4$I1]3]@*Z,
MD.;HZVX _4;65G 0D.1>$_H=+;2:WF*)<\I"2SE;K;CCR4EC)Y4LB(L>9]"%
M4&NU;?I*XO&X/<3H9MBG:H7'#G1V*.S<+#+-+::CPGHBG&E5F(Y!D$MI'-A)
M*P9EYX(6NN E+?B\)G0Z="C.29,6W[FE18CJ#:7)D1U..LQU)<+)$^XA+633
MC"^PP8T1^$"Z?6]NUU:V^[PM&X&W%^TJ@IFAW2[2FY?Q_&;)]PW_ $J- :YS
M<90A6%.K,O$P6#!5;O;]-ZO78^F_8>_\_<>/<-+C+W1J1N4K>SK=YM]MS1+<
M;%IU7<MZ=%@4=B3/=9ILF<ZEM^GP(Y-DAI"4Y2YE7?(C2X>4S\6#X1;K/=E[
M1FZK4J#45,TQ%10B8W';.E2&<MH?):"-2$),C)/?WD/2M"Z:/Q(/A!=O:S[9
MJ3.J&D5DIJ,6OWXQ39-.@/E-H*H;:U+<9:;5S.)4DS)9Y/)^8^>S>=O<+KX0
M+>U_Z\HJ%L:-WX<=4>\RITN5 (X]$-+BDK8;4VK+[F/S0LGTZ$"NZ0.H :)C
M!Z>Y+?F._?ZZ^_Y#?,>(_27M+/A#>WZ[[03'HDNZZL;4DZ:VW%2\EJFQFC\5
MN.3:3,TJ/JHNO4^XXWQ"))ZK_"'="=/[O(ZG;MN-TJ7$@2\OQ2?DV_"E+43+
MG,WU>+F/U>I]Q\VX[WH7%%X_>G-Z[=Y=2NC233Z8W+>O+XLF1J>A*J4TL_6D
M-DVCF<94@R)??VCEW&CMJN[->,#MXWG7/1J@O3&IO1X-5KL:'(E1X;--IL.F
M./R#CM.>&DC2I1<YIYL8+(*X>K0?7RSKV/MH?CW[=_7NNR_A0EB4^P=5MANI
M%KP8%%J[->IT?TRF1V(,A:$3:5&)*E1TMK5A"23ZQ]2%HC5_=[!VG[%:'N/N
MZ@S[KC6W95GKF4JFL29$V6<JFPF2-#4-IY]9I,\JY6U9[G[13FXPN[#3CBI;
MMMDNBNU2IU#4)%OU2#,KTV#3)[<6%X9TR:^AY;C7AH\/PW4^L:<FCIG.!?+L
MK3>A(TCLS3ZY*5"KE.I]J6_"G4^J16945YZ-3(K;B7(\A#K2^1U!XYTGV[$?
M8O-W9K-COW.O?7;7]QTJQ2/A4FBJTDK^I\O[JHT_VCN7R,R['2O=V&3_  ]>
M/[;&_?=&_MUM[1:?9T=M'.W<%2FRFI:L1%25>)3);++K75/*7,A.<D99(3AJ
MVXZ%)(__ $26(?JK,O\ 8Q1,="R9=(7<Q4IVST"A6S\)-UQHUM4>!0J/%;I9
M1J;3HS,2*SFW%&KPV8Z&VD\Q]?526?O@GP$.TT@AN^YWWV/^/X?NMD;F=>J/
MMMT9NW6&O4N96*7:B6%2:? 8D293Y//DRGPV8K;KZL&9&?(A1^X>GM5W"T3=
M%HE:>M%OTF=1*5=1SBCTZHQY,66P<.0J.KQ&9;3+Z>92<ESMIR1Y+H.6ZW:G
M:8:/Z:7%?^L$F)$L"B<BJX_-IOQM&0EUWPVO$@^$]XWKF1%\FK'<>#0+5;2C
M6G2^W]0]%9,.7IW6SE%1)$&E_$\99QWE-2/#@>$SX.'2,C^3+F/KUR"\_;^/
MM_/XKN8  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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M:[2O19*V6^:0:4&OQD)\3YO3L"I[?CZ_S_@LE0  5$  !$  !$  !$  !$
M!$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
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M\0C<[NMN+27<W'YZJNV94U]B%37K>EJ:BQ8\5%2CQ)*JHS&01I;C'CQ>N3/
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MW:; 338:C9>4W(\*(EMHFOE25GU"YCZ]<@O/V_C[?S^*[E  !$  !$  !$
M!$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M!$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
M!%TWJ!HEIC?LEZLW9:-/K-29B2#:ER6FUK29,J+!&I*CR9%C_(*T.EMA67.X
MHLVR)EOQ7[13+>2FB*2CT<L1%&73EY>BL*^;Y>\6MI_]B2O[UD_]2L5=M(_^
M%NG_ -^O_P")J$X^$UVX[%^(,9MV>BMPK(.KM\^4-A<US2UT0ZM1N!)TYG21
M[%<S>.^-QS<UX52MH4Q)<\1L6RW(*T/798YAZF3NZ-RM=^TV0N#M#8.E8^L?
M1;333V<_4K/M2GT.9*2CQGXK3:%K(DX21FE"3/!=.OT#M<;4?,3^Q3^ AN$*
M3V)[4GFV)I9Y" TR32.D>0T: +GDN.@-#OV]ET?3J5:4#8:=:"K""XB*O%'#
M&"X_$0R-K6[<1LG6R>Y0RST/J1]#(_,8O;MH45O0'4=Q$2&E::0\9+**R2NK
M+G7F)&<]>Y]?>,H1C1NY_P![]J3_ (&=_P"I6,C@"1F\2 ?7)4M__,1K$\J
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MU[TR0J0YS37GY#CO*M6"YG5<N, K?;U]_3^*R,  !40  $0  $0  $0  $0
M $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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M;'/=^D:9Z6-+G$"Q'O36@DZ^@6O\MECAXSGGRR,C9^A\B"^1S6-!-636W.(
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MF5F@B4DTD9]\9(;1QKAG(^732Q8'&RW!7 -B;J9#6@#CH>9/*YD37'V;U=1
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M:)6?BW]#S$>/<"]W;_\ )MUH:<?N'<G8!_%6G]E%=UMN/;;IO6-PL=<75N7
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M5Z,<_P"Z:NE&8B%+)<E:H?R$8S:3R,&E/JGU[F"I[>WKZ>__ "630  *B
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MBR/:&QOYI?2K^48WB$22223LD[)/N3ZE=*M #6@  !H  &@     /D.P^B
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M#JK7;AO;.-R%R%=FK6C%#N"ODKG548Z$4YYU73UG51$-&X9D19-9F9]<C.L
M3>O1=&Z';<M&MNEL,VCH_8=&LRB,$:2:@1&$R72SS%XTI+:7WL&9F1N+49=B
M'>0 "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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M*Y?0.Q)4H_J]P+Z#U@=NDC0^6^P';MW^BN?[)].=4=*=MNF]BZQ5EVNZA4*
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M$S#,TOJ*5X;9$1)^6YL].I@K5WF  "(  "(  "(  "(  "(  "(  "(  "(
M "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
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M;Z2R9]S;4HB/O]>1[8A@@@Z(((]CV*Z+:06M(((('<=P@  HKD  !$  !$
M!$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$  !$
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MQV!6>WK[^G\5D@  "H@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M1MF6<D9GD35?QG!/%2O4QV SF2QUWAN'95C&1J"1MW"T2#/9CCB/F26&-/4
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M.<35$FL/QI,3T.0I@_$9D,LNIYS3S%S-IZ&"I[>GOZ_P620  *B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MO\R>S9D=+-,_0'5)(XESG: &S\D  'FOD0  $0  $0  $0  $0  $0  $0
M$0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0  $0
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M5T]6;48T5?7^Y><0?7R'NQ9D>6T3T>1'D-'DR=C/MOM&1=S)QLU(Z?2"HO:
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MGW66&D%E3LAU##2?9S..&E!9]N01>92B263S]1&?X!J1Y(C+S$._&&XA=V;
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M^WK[^G\5DH  "H@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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MFU[2^ME6:? 6E,ETFG&N4UF:2Z.%D\F7D,#3X.NUPR,CI+N#(R_LB9YE@_\
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M.57JD7L,%9[?\M_X_P %DT  "(  "(  "(  "(  "(  "(  "(  "(  "(
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M7NQU]F/]>GU#< @[)9._F+L^1R=J:Y<LO,DT\[R][G'V&^S6M'9K&@-:T -
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M&6\G<K"S/:\[+77WK77.6ES3,_1\MO3\#=:;WT@  UY;<@  )I   1   1
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M._8<S %1=+Z+Z Z4: T!ZVM*+0A6C17W%.NP824DVM:UJ<4H^4B[K49_6.Z
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MHYH@/K,B(LFMQ!K,\9,U&>3[C/\ !>)^OJ@  (@8+V  (@8(^Y9  1,$78L
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M;[,=QKG4G)<S2<YSU[@J>WI[^O\ #Y+(\  %1   1   1   1   1   1
M1   1   1   1   1   1   1   1  S(B,SZ$74S]Q#HNY]QVCEGUJ7;]PW
MS2Z95H)I*3"?=:2XT:RRGF)2B/J7N'T5JEJX\QU*T]F1K>HL@B?*X-V!U%K
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MAGK+HG-D8R6NQ_D46O(&W6Y&N V/+VNB<MXBWN<5KV"\-<!9Y!'<@GHV>49
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M=G,M%C\IG*O'JCXIGNR5R-\L,;HV%S(RR,AQ,I'0W1[$J;S[J[8[?=';^?\
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M3#EL-*Y%O0Y3"%%T-*W65H0HO>2E9^H:9=R\ME@JUV-HT6D=-:#8!UZ.F?\
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MC'D $7C\)/M5^^,;R(DE@L_6>1J (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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M/M$3.[3C.[&]F.J4C2#6[4?X@O:*E"I--;ILR6IHG&B>;YEQTJ21J0>>N 0
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M1^:QKK!>>GRVQL#G$R8(02$\I)2@LG@FR)!$7ECEP-Y$1=OPF?X1J Y-7=P
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M #.)YV+.4N?<ND>[(Q9+)59)X&5\Q+&07-R/EQM=.V39Z^HDGN-KV?\ Q_\
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MNN-3MRVJ7M/E2].;==BSY5 )]UJ'(^,*7"J3C;[3:DH=)3F<$M)XSY=1[G$
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MT.:89TWH1RSH3<:K'6V2.0^IV3RU%3CQO_*F9_FA\O8%:N\@  1   1   1
M  1   1   1.P@1XT=9T>ET&S*9<<Y4K4"G^FE;U(CNOI<YGC1XQN> >,FG!
MI)9>MV3UZ%/8H\%T+)X,R+WEU(OK/S%43>BTS>?$K@VYJ":6K7;JM.\-IY[F
MCIY6F30DCSRHYU8R70E9P?L*7/!;'LM<Q_2$EBS!'Q_%W\T]M1W38L-JQAAK
M,/<ZE$I:\ ;+-MV-[4!?TC<J^GX?_HB*I4LR\IS6+XZQ]YA?5J&W-Y@MR#8:
M'0NB#HB\Z:_3]$#1CWM7;/KI>U!<N:V-.JU4:&A"G?35O2(ZC:01F:DM.)):
MN4B\B/F^L<PV\:@,: ZBHN=VV*A*U9HCJH-J4Z5(DQEM39I'%<YVWB\,R)2R
MP;B3(\=!=;M*VK<HML46F46E4QBEMTN AEMB''4TMLXS63-24&ESF+J9GWR8
MK*<6"V;2LS<_I[7;%CPHES5:NP55J-";:P2FI$4F>9ALN1!K+OZA9\\F)PXE
MXLN\1<OD.*Y'"LK4KM.Z^NZO:GV8JT9D?6R#AK<%F)ICF,71L.,?3WVWFKGG
M@2SPDP.)YOB.1R7<CC[^.BMLM4:I:V>W*R..YB6Z.K%29PEKMF\P[:).H%FC
MF%H!L+U0W&7I&U\WFU:94ER'6:C1+"<<4B)&941+CDLV'2:47A^&OUF^O8R$
MX=NVU0;0I$6B6_38M*I<%E+4>+$9;:0AII!)(E>$E)*/E3UR74<:THFU*?IY
M9TNK(Y)SM!IOC)Y2018A,<GJD1$64D1]"(=AJ22B,C[&E1?4HL']X<O<KY1E
MN0W3'=EBBIT'/K4,91:(,90@B<6-CJUV? .S1U2NZI)#\3WDKM;@G"L#Q7'-
MFQT4]C(91L=W*9K)/-G,Y.Q,QLCI;UIX\PD%WPP-+88A\+&-[J/C5WB,;+M'
M;^K.GNI-[4FF7C1#:*J0I%&3)=:-Y/.V2GC:5SFI/7N>!UK^.S</7SU"HQ%@
MSRJW"(L%[S8Q]\8O\1+AT[3U%JCNNU8G'$J3T)MU\E29*"<F(84Q"0VA#J>?
M+W(1\B<?IL$*NVUFT]%=0-P=NV7J\M<#3BY:M4(#<M3SZ4Q&B=6S33-32DJ4
M;YFWC*NY]1D<9AL3D*+[3)\INO$TV SH#?-$8?(R $$OZ='MOL"/F%VGPOPI
M\-.7<:MYV*7EKY<12CERXBK4A')=;6$]J#&AT+G63'T%P:2'=)9L[> K[FVW
M=3H#N:@UR=H9<$&NQ*$J.FK*AP"@DR<@U$SS))".?F-)X[X&4 P.V0['])=F
ME!KT?2M;KT"]&J=-?6:GW24TA!O1E)4XI9&1H=(^A]!G=SE^E7^],:;=%869
M13?+)7V/+?/H2D=(WUZ[;#MCM[:4 \@AP5?+W(N-279<*Q[!2?D(XXKA9Y;/
M,$[(@UC7"7K Z1^J![K> V<Y?I5_O3&AJ(RP:5_O3'RK#+HW63<AHYH+\5?B
MJ7E$M7XZ\7XM])Z^D^#CQ>7]ADL_^8Z,/B.;/2,B_%@I9Y\R0HR^TBP.LN(7
MP]K,WO0;4GW=>,RTXVG\:JS"6RA\DO-.->,\IQ33K)$2$MF?4SP7EW%(S7JR
M=.=.]:;DL6P[CJ%Q65;]6A4TJXB7-;*2A3Y,3UD@W347HZB<,\*//+T&WX+!
M8S+PZ-JTVU&USYXV1-\IC>O3 'N&BYP]O7U/H"N@O"_PQX9X@8_H?F\Y#G:L
M,L^3JUJ,;J5>/SS'7#+4GPNDFCTYL>^HGKU^J2+^=@[W]L^IMUTVR[*U,IU;
MN2JFX4&FLEAQ\VT\RR+)^1#+4C(R(R\R(_J/J0KE<.;A<Z*4>K:5;M[!U2DU
MUIB(_)9ISBI),G(>82S*:<4[)423:=-1>N@LXZ%UR+#RJM3(Q$3U3IC))2E.
M7I\9OYI8_1.%[!@\I6I5K/DT9IYVL:6RF>/RWLF:XAS-:'8=NZC'G&)XUA\Q
M]@XO?R>2@@B,=YV3I_8[$&0CFDCFK^4 -M8UK#U:_6<1[+ZCO-R*Y>_(O'T\
MOJ_?%8/?&_Q6J=N#U'J>BTF3%T?A-QY-&D<T%##49F*;DQS+QDK">4SP9^XL
MBRO*O:SH3:G)EVVU%)!94;M<IB,%]"Y)']X0W\7+?':FD>WFKVII[<M'JE]7
MVDJ?37Z7)BRW(K?C$S)2I4=:TY=:<4DLF1_I3\A]. =.V_''%3AM.L:AZ;,1
M?%&'.!,GR!: >_RVLQX6OR<7*JE2CQ[&9R;+&/'^5FZ#[=.JR2:.22WT_"UC
MH8XW.+R>S.KLJ_\ I5O XFNM=WS[#TSU'>N.ZZ:Z]'E4M,:$PHGV>=+J&UK5
MAWD4A1&:<ET%D7A5-[U&[<U +>&<CXT\6G_<X;_@9Y24YZ7CP?=RYR*FVBM;
MUJV5ZF:.[BYM-F4BD795)LR+*D-\[57CR'T%4W'D.)PCP6W7%%S%D\^K@S%L
M(^-#LBIM!I$J5?4IZJR:=&<J$2%;]2>)J:<=LY*/$C,*2KY8UD70\C:^2UIW
M1LKX[&59Z]AH_P!(JUMS12POT]G7'V:TEOJ?J#W!W._C)ALC-6@Q/#^%8/)8
MC+1M_P"ZV!PWF9*G?Q]CHN5W3U 8X8W/9TZ<W>O,B)ZF$J7K)>TOM(:Y+Z?H
MZB"*O<=_;='-:;6MRZ+D<R9-);H%=9)WJ9%@_0E%UP. 2>.;6*B:TV1M@NJX
M"/HRXLZI#2LS^89DY!3T,S]OO&HMX_F'?^)/9_Z5T<6O3U\QS=>ONH"B\)O$
M&5H<>.6JX/O=EK4M??\ :YH>GU]]*PR:TE[3^@C,=<W_ &_8,ZFRZ_>E"H]2
MC4&#,GG)JT2*ZAA$=A;ZTI<DMJ)'B$WCHHLF8@)E<4_?7>IDFP=FU5CI>,_!
M=?K9-X(_FF:7V"\L=#QW+R&"&]#B+;^J59SFG^K=D'I9$U!:<APFF:C"G37$
MI]1;7+'),ALG.?E,CQDE#[*G&LA+/''YM6)SG=P+<+I P:ZR&1O<XZ;LD +/
MX/P9Y;>R=2I]NP=*>65H=''G\=-=;""#.Z.O3LRS/+(NIQ:T#8!WH+!C=EN0
MM:]M[U3U@M"VH,2S;:N:!"@TF)':3 E,QI*(504I+;1,I27A+7ZR3SY9Z9M.
M0.()L8THTEM/5>3,MRB5RHT.*4>F4BDMOU9V9'BM,R&C*"R;R#4[DN8TEG/3
M/40\[8.%C*U*V"7]J/<%$>+5.\(KE<M1<@E%*@)@279<USPU84OTMHC,N=)8
M,^AF.D^#WI+MXU)UVNO3/<3;C]8OZCU(XUFTZK5*8W'0[ 6Z4PTPEK)CUB9)
M6#1ZWD1C:<C#BKU63I?9<S _Z/,RLX&6>/I8-[<== >'=4AWKI>=:TIQY?1X
M)R; VQ':S4U;PKZ</D:N(EBDMY.B(X6>9U2R%GD-LLE\VR]LCF]$QZ7-+%(C
M=?%&W?;J:BY:6RS0^K0:>\XY&1?,]1QF_"<RDI*8M3C-I/"3S@C[X/)#Y#?"
M-W)ZXT&X-1-UFME9N*[/BR;4*?9,8WH$9$I$9UY$=3L&2AA1$YR)+*.N,$+'
MMH6%9]D4N)2+3MRCT*!";\)EJ# B,K2A/1.76FD+7V[J,S/OD<EG,NN1):&,
MFZY#DMM&H\_*K96EOOY<QE[O:-2_3OV;3,53@H,!&Y2/.M/&QV=._NT'7<1A
MH]>_NH!/B<,.17X-Q_&<7KM<T&\Y@R.<L,#@3Y^3M-<Z(/ ^-M2. #9#3I?G
ME:64S7W:9K<[?E-TN=GW!8=2JC4-B6XTZEF-XCK+;RC?;<;69LI)PC41F1^_
M RTU.XI>ZC=%I_<^D-5L%FOT6K(;CU6.2H7-#-@S-!)4EGG3RJ+] 9$?+]!#
M,G<GL/XG%]:U:CUNR7X)V'79*2I#!1Z,@U15$XEQ/,O#A92KNKKGKY#%BS^$
MUQ); G3ZE9E)C4:H5(UKFON/TJ63[JB49*)#JC2CUE&?J].O0;W]LQ%L16KD
MV)=<9'"87&>3<;ATOTX[!:6N.QT@_%ZE=2MY%P#/LI9[D.0X!-R&"ICY,?-)
ME;G74E;TSNCG/PO@=!,]S@(FO(DV'$ZVLQ. ?9VX2T+UU,9J=%E4C2^4Y"7*
M;D.I6T2S)U3:6$.8-/*\9DKPR+)=3Z=K4Z,\OK>T\?1GH(H^%CH9N?T2T\N>
MD;EW([E>FN,'3E,-06O52XX:^8X7JJ]4TX-1F9=>W82OE[^XCWD%EMO*V96^
M0YNV-#ZY+HY.EC1U]1 +B?0G7LN2?%C-QY_G69OQ.Q<K"Z"%MG$/?+3MB&O&
MS[0V:0!\KGZ^)[@#L:UV0  851PF"/N61I@O87V$-0!$P1=BP  "(  "(  "
M(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "
M(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "
M(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "
M(.D=Q,J\(.B>I\NQ6G'[ICV;<#M*;;,B<-:*3+49MYSZQ$64X(U<V,=1W<.H
MM=;[_$VTEU"O<H"ZDJWK6K4Q$-"36;RVJ=)6DC225\R"4DN=)I,C3DCP"+\^
MGAB\'6PN)A+UEU8W/ZTUFC:AP[RK3-4LZKU2=#G4Y!5N='C&:'Y[#J6ULH)2
M#2WR\O+@L"7=OX*;LK94RXWK"^E;,J-)29W#+,N:.\AU)8.JX/F-./K\Q7LT
M&T"XH_$%UDUFW0;1(]2LNGW+=-1AU-ZEU"/3H2D4FI2X$;FI9.1V&U8;/*O!
M(UJ,U'D^HS5+A<_"("..9ZAUI:43X3KJ/C: 66$2&U/_ /K7_)DK)%]\%[NW
M_P"4:.P^'>P/3M\C^/\ %7MMKNA%M;;M$;)T=M*HG5:#9\14:!.-U3YOH6>3
M/Q5..J7U\S68R$&(FQJQM7M.MLFF5H:YS'9VIU(IZVKFE.N)=<=D&?0U+0I2
M3\^QGGH,NP7@4  !$  !$  !$  !$  !%XW.W[E?\D4T= OSR_KQ^UTK^;BA
M<N<[?N5_R131T"_/+^O'[72OYN*!7-_:_LE6L-S&A=N;CM&+OTANNIR:10[I
M)E$R?%F/0'V"8?)U/))8=9=;RHL>JXG/8QZFU/;_ &SMBT1M/1JT:K)K5!M<
MYQPZC+FOU!]_TR0J0YSRI#S[KG*M1D7,ZK&,#?NCTJOS6C1&\M.]-K]<TTO"
MO$RFE7BU$*:Y2E,ODXXI,8U))SQ$ER?.+'<>GM(TBU"T-T*M#3;5#4-W5*\Z
M"<\ZI>KT,H+E5*3)6\SF,2E$CP6U$W\X\XR"M]O7\/X_)9+   B   B   B
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M0M]3U';M+NZ+A'#,'T#E?-:DL[2&'$<4C.5G!!#?+DR,GE8^#I_5<6OG  [
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MCZ&16;OI5HQ(D*6ZMZDL2&&DH)AA"VY!&\9I)LD]>O3R&57W?\<?_P" &_\
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M=7"4?0S[CZ(%T^_]\\@(P/?NN)2=DGMW)/8:'?OV'L/H@  *B   B   B
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
MB   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MJ;Q@[/T\W&UBI)T-TR*0=XHI2:C+=050I*%LMMQJ7S25&X\DT9;3DNYF"O\
M+!=KOKI#O3OW'W_SZ*X=IAQBN'SK%?M TTT^UVI5>O*YW'&J+268,E#DQ;1$
M;A)6KHGE+VC+K<!NBT0VQ66K4#6N^J;9=L)9)]$N6M)OR&U$6/ BDHGGOG$1
MDVE1]>N!4_X8.W_@.ZN;B+,N;:]5JA3=:[+>6[1Z)7)-QTZ0](<:^7-MFM.L
MI=-:4*4220KO@AC?QL:_6-W7%\V[;'Z_5Z@6E]M3_#J=#C39$5B9%7#BRB9D
M%'<;-PC)!DDUDK&<D9 J=(+M?$.VSU#OKZ#_ !^]6R=LO%&V4;N[B7:>AFL-
M-N6XFE*1\428[E*E.FDC,_";F&A3W1)F7ADKICVB0DC(^I&1_0/SUN,#M4T[
MX5>[S93K9M2A5#3W[I:E3X->I\*HSW8<OG^+(+ZGDN.DTX;WBNJ/F2>#5T%[
M>C:P6E1=%+3U3O>N1+<H<JU;>FU*JU%]MF,R]+IL5Q:G'7E(0GQ'EJQDR[^8
M*UP  (.P?G\_<+N]SM^Y7_)%-'0+\\OZ\?M=*_FXH6:CWX[3%%_NXV;@R4G/
MQS3?,L&?]E>0JV[4;TM+4'X1_K7=5C5^'<UM5%JEG!K,%QMV-)Y+=43A(6TI
M:%<BNAX4?GVP"-'ZW]DJV3NK1KDYH9>B=N;B&M7#)C[EUK*.:27Z07CY*3\B
M?R6?GCT]GZ-?F]!+.1N:=0]K&1S_ +J'$%&2E1>DJ]#P43Y OD.7YGGW'TMT
MFINHND.B-Y7]I78:]2KWHA,JH]G-RTP5U53KY(<24E1*)OPT&:\XZXP/3VCZ
MJZEZSZ$V?J%JYIZYI=?=;.<57LMV:F>NE%'D*:8S*2E*7/&;23G0NF< J>WM
MZ_C_ ,EDN  "H@#B=Z7O;&GUOSKGNVK1J/1J<T;LF7)<0@DH(L^HE:B-9GC&
M$YZB+"\>,5MHMZOR:339BZU'CO>"J<VU)0DS2KE6?*2#(B(R/'7KC)=QL&$X
MKR+D?F_H3#WLDV'_ %KZT#WQQGMIKI-= <=]F]74?DM3Y)SGB/$/)').08S$
M.L=X8[EF..65N]%S(MF1S/;KZ>@'MM2]@,5-O.\31/<E )S3ZZ(LJJ-)2<JD
MNF<>0TI?4B;)_E6]TR?J)/'F0R!N>]K5LVG2JK<M>I=(A1$&X\Y+FQF5I27?
M#;KB5*/W$1C'W,5DL?=?CKM&U6OL<&.J302,L!Q_5'E%O4>K8Z2 0[8UM9;'
MY[#97&QY?'9.C=QDK/,9>K689*I:!MQ,S7^6WI_:#G MT=Z(7V*O/12Z74JD
MX9>'3X$N:LLD6?1F%O$7U\G05+[\GZI<2+=S4[$@5N?3++I54?AL-L/.%&I;
M,8U(D*<0A2$O>.31F7.62]PEJW"<4S12C1:Q8NFD6H:G714H<REIA4J'/\)#
MLAE<<E>DL,N-&2?$S\[!X+.1#AL8UR:VP[H*C4-6*2]:],O6I/2JD<MIPW:4
M4I2W8J2)2"<42S?+FP18(NO3(Z#\+N*\@X]AN6<D.$?%R%F'#N,178F"T[9<
M;=FM2E_KRZ./H,;S$ \GH87=1"Y.\;.<<5Y9R'@G$1R.*;B4G(.GF<N.GD-)
MNA$VC3MY&(?9@R20R^9&R8F, RO#2P.$B%Z\$VPV+&D+M*[Y3%XPH#D@IB6W
MR5+DM-&XI!9=PV9J2:2,C\\EY",?1>+N/K>IJ=E;FIM5LVG2YTB'/:=YY3Z(
MD=:G/DY"G">^7:(S(D*+!*P7;I:"OC=[H-9]@R[WG7Y2W*<NFR'XB&'4//ON
M.L*-ELV6EJ<3EQ24*RDL=<^8J@R-:-6;QW55O<%HOI]/N^YUU!Y%$I4/Q&&4
MD?/&:><EDV;*24CE=PYT/!I/(S? >1\SS6$Y?/RS_2JF+Q\MW%9'.4X'-I9R
M/J%9D!M1-C<0\[+""(BUC1TAVCCN=>'7!X^<^&/'/#;RJ><Y;G:>#R>)P>8D
MJP7^.V71_:Y\A8AL'[+ V,'S;+Y&-?#YLC^KR]BS/MNV$:$;:84:L.PX%?O!
M2">J%U7%(2X;SZBYENDBHK<2C!FK&#QY^P=@ZR;XML.W^*]]WFI-%@*BH5R0
M*4IFH*RDCPTAFGJ7@^A$1$DC+W=A"C"V^<6C=^IE>J^HTK1.R*D1?UIC,0)K
MS<0R(O#\6*XT^1\O3/0^OMZC+C1G@A[=;1FMUS5^I5C5^Y,H>?FU.IU2.RN1
MT4HSC+DN-8-?Z'!$?0NG80)EI_TC;DR')>0SY6[(=N96<ZRX#8U&V60M@A:W
M9 9$WH:.S1I?HI@O"_PM\.J$6-N<@H-CKC1P?!J;;CW/'3U>?EK'DU#*2/CE
MW9>X_$22=KIZ_P#C=/7A,DVMM7T4N#4ZKR73BP:NIFHTN.AQ1\B'.:3$)DRR
M>>JL=._7(AAWX;P-]-V/ITPU\J;MFTVXG&4.6$R<5Q<=F2I"F?&F130LB0AQ
M*_7(O,C\Q=6TYT&TFTII;=(L.Q:!0XC)(2V94V&Z^248Q\NMDWL^_GSG/7L(
M%>+_ ,-35+7G4RU-5= +65<%P5-,E-XM%+;C(:\%I+,%2"?5R(,TI[M$6/;D
M>N#R&$9D(XFT8:L72XLMVY/.E\UH!:7/<6QQ>AT6MWU$:/=2WX8\N\-:W+:=
M-G&*&%H".>2'/9^U^D;PN0Q]=9\DTQAI8\'I=HP0%WF]#1(.K:Y/P]M+-K>F
M&S6IV/?EZVT[=>J-&EJNEJ4]#\<GTH=<IF3-TS);2G$]2,C,R,C/(B5V6ZGT
M/8[O]JEC3YM)K^FER5]QJ35UQHLIKEFK<^+TLN&3QH\-;R$?)J+..OL' /QH
M/?\ ^5@5Q)8^:B[#0E/N2E,HB27T8Z#OG:_P>MT[FO>G\O6JQ9-.T\I]0].K
ME2D5=N8^E<12'XG,XEQ4A7RS:2Z*Z>>"R,[TXN!F6DL9J&W'D(WOEA#X]M>U
MNXS%TR'XFZZ&C7?3=^BE#RN$8^OSVWE/$K'9^KRNG;L7<:VQ2$L=J-CI*LE
M1V9'&> !L,$;6CKU&"?A"N@TN1&GT^%,B<I1)D.-,C>"1-M^#):0\WA*.GS5
MIZCZ)H29&6.Y&GZE%@Q\VBTQFC4JFTJ,1IC4R!$@L),S49-Q8[;"<J,\F?*@
MN_U#ZHBLZV=>FSK?KKVVN&G=/4[I)+>H])/J6[[$_77K]5%EKKPEMK6OVIUP
M:JWS0%2;FN-3"J@\W)DLI6<=LFT'R-+2CHDL=$_3YCJ,N!ELM+/^QE[J1E_9
MT[L?_P"E$U&"/N1!@O87V$,E'F<K$QL<=^RQC&AK&ME< UK0 &@ ^@ T MRK
M>(O.:=>"I5Y3FH*U:*."O#%>F9'##$UK8XV-#M-8QK6AK1V   [+#?:1LFT<
MV<TZXJ9I+3#IT>Y51E5'F>>>4XJ*:C;RIXU'T-1]C&9(8QV ?#-/-8E=-/(Z
M65^B^1YZGN(  ))[GL /P6L9')7\M<FR&3MSW;M@M=/:LR.EFE+6AC2][B7.
M(:UK1L^@"  #R7Q+$?<[LKT)W:_<Z6LMM?'Y6QZ2=)Q)?C&P<GE\;JR9&KFP
M7?MY#$W\9=V,?K<KZ?\ \SF_]H2U /NAR60KQMB@N68HF[Z61RO:T;.SH @=
MSW6RX_F7*\54BHXWD.7HTX2\Q5:M^Q#!'UO\Q_1&R1K6]3R7.T!MQ)/=1Q:.
M\+;:3H=J%0]3; L8Z;=EOJ>539JITIXF3>0:'/DW#-!Y3[2[]A(VE))(B+R(
MB^I)8(;@'A8M6+3@^S/+.]HZ0Z5[GN#=[T"XDZW[+&Y7-9;.3LLYC(W,G8CC
M$,<UVQ)8D9$"7"-KY'.(9U.<[I!ULDZ0?)?HE(DNJ>D4FDR'5_.=?I\9UU6.
MW,XMM2E8]YCZP#P!(]#K[EC0XM[M)!]-@D?W+X?W.4+_ -Q4/^"H?_<CWX=/
M@P"44.%"ADO',4.*S&)6.W,32$\V/+/8>Z KLGU)/XJI>\C1>XCY%Q(_(E
M!16H-#(C[C4 1;>1/L^^?](U))%V+[YC4 1   1   1   1   1   1   1
M  1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M  1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M  1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
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M':U;:6Y*E1X;)(I4M7,_*=2RR@S))D7,XM)=>V1E?\D>4?\ [O9C_P#+[/\
M_P UB1S#BQT/\H</L_\ XA7^G_7_ )_'M+" X_:]S4B\*#3+CH4CTJE5>*U,
M@O\ *:/%8>;2ZVOE/J7,A1*Z^T<@&O.:YCBUP+7-):YK@000=$$'N"#V(*V)
MKFO:U[2'-< YK@=@@C8(/N"/1 'C\1/L5^],/%3[%?O3%%<O( V$LE'@L_61
MD-X(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (
M@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (
M@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (
M@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (
M@  (@  (@  (@  (@  (@  (@  (@  (@  (@X]=J_#M2YG/^3MZM+_>TV2K
M_(.0CT*K 15*74J8XKD;J,"9 6HNO*B9'<CJ5CSP3AG]0N80U["?0.:3]P()
M5DC>ICV_[S'-_,$*DWM>W00-"-UE8U.6EFH4>+=-:CW##)]"7$-KG2(J5X(S
M<+D(S69)+RP?464[BXGFUJG:>/W? O=F94'*>I<6CICOI<5-<:,B:YC0>.5X
MR3D^^,]NHP!=X!FG;=[7%>,+565&7<52E5.5".G.N-\TA]Q]22(WN7U3</!D
MGOU$.&GVAT"].*GJ+P_7:H\Q:MFH@^B7425N%(5*I:IZS* I7JFEPN7!J(=,
M<DS_ (.<RFQ.0S>3S5/(T:=2G9-*B\QW8:[6=,<G4QX8X$N:)6])Z"1WZ01Q
M]QCB/CWX=LSV*XGB^.Y+"Y3(7<C4_2E^..?%V+<GQRQADC/-;KI=Y3NII>T.
MT'%P=ZNJ4UO?7N77:MQ5UBTWM:JH:8D\EMO+IL>CJRRLT)6A2O&:))X498S@
M\BW[L[VQV]MGT!L72!B72KN7;$1U7W2.TF(A^=Z8LG\J4:7%Y;YN0E&XK*2(
M0O7IP!)$8W[RTIU^F6QJC3'D.VK<149;Y4I1+^7249<CPU<Z"Y3$X>T;3353
M2/0>R["UFOU6IFH5#;E-5F\EPFX"JHA3QG%S%;,TH\)DDM]#Z]Q'_BQRO!<D
MR&$;QF2<8O$XB/&Q1/CD@\IL4CNAH:X_%_5]'Q=SVT23M2KX(<$Y!PO#9[_*
MLUY\WG<[+F;L\<D<XFFL0L\QS7M'PM$G5\/;9)(;K6LD66&V"Y6FV6D]N5II
M#:?=@D$7X!Y#;(SSE7<C^<?D><#> B53?I08;Y."S;6]#6V;K'4M4Y%JR9B6
MDG36:8Y(-'A1TL$:9"'4&1GRYR7;R&'7Y&DLO_Y@[B+W%'J)%]1>F"TH WBC
MXC\SQU2M0IYN:&K4B;#7B$-9PCB9KI:"Z$N.M>I)/U6CW?#?AF1N6+]S"Q36
MK<KIK$IFL@R2.(+G$-F#1L_(#U*JVI^#3V6A<9?XOE5>]'G0IOY;IDJ5UAOM
MODA'C25\G.:"29IQT/S%CO1;2]C1_3:U=/8]074VK9@MPD330IKTCPVT()1M
MFH\=$=O>.UP&,SG+^1<DB@AS62DNQUGO? U\<+ QSVM:X@Q1L)VUH&B2/S*R
M6"X?QWC<L\V%QS*4EEC(YG-DF?ULC<7,&I9'@:<2>VO7Y+K?5AEI6G5\.KCQ
M'E(M>N\IR(K+^,TR3_RB5%T\C\N_0R(4G.$QNIT6VJ;E]>+EUGN>/;5)K=SS
M?B^039ODLV)LQ#G*VSGEP9XQ@L%V+L+R=P4:+<-$JU#FEF+5H$JGR?++,MA;
M#GO^8L^V/J[B"BK?!_MH%8JM4JTJ-(.15)\N>_A^:7RTR0N0YV=_3N*_R8\M
MGX-GN.X_$\FP_(I,A'6S<5*-KZ$3)96BO*^1VC(X-:>HM ^%VP7>GJM8YS@.
M19#+\:S''8Z,MC"2W97,OS.CB<ZPR*-@TP%SAH/)T6Z.ED*?&IX?IH6DM762
MRE9%_6Z7YD>/+IG[PJS:YS;-WQ<4.2G2B^%4RV]1Y3*:)>$5*T2(BX,,B4MM
MDEH>R;G0\&62Q]=@/\CU[-_U-*_Z3._[T=KZ(<$?:WH9JG:FJMIL/HK]INO.
MTXU/RU$2GDDE>24X:3Z%^BS]X;1@^0>'/$CD[N!N<BDR-K%VJ4'VVK6? R24
M-?$\AO2.TK(]EP>WI]6G>EJV<X_XC<M_1=+/4N/QX^KE*MV<TK5ADSHHR&S-
M#G;]87OZ>GI=O6G#VPE>X<G$^T+-F9H3NNJ%U0&667H=,F4B*7,DVTK0R;LU
M]9],DGF5CVF0\B]R'&JT&(EZB:*KU0IL/'BS8U1I,-3[+?=1-QD+49J26>F3
M\NXL\-1T-(:0DU$33;;2?6/'*VDD)^\77VC21&9DIY'F6'D?I'V4.I^Q9*+[
MW8:6.?36=#,<?XYE@>SY9L:RI9<#[^?0=6=OZD.[K=AP&&MWQ'(.18<]NF*'
M)/MUFZ]!Y%]MAO2/D"/O5;FA<>.X[44U2]?-L-T6-(:(V9L]GXSJC9*+U5GB
M-"4G&<_-,L>>.F8/+XJNE?$(XGD63&:EQM.M5)+2'6Y+4N+(;.!!0A25,NDU
M)1\KE/5)9Q[!?0N73+3VYX3T.OV5;-49=:<)9/T6FFHRY3YBYU1S66>O7/F*
M85[4*S=...#3:90X4"T[4IE12IN.E34:##-V A:S-1DVT@G%]?+KG!&) \/\
MO@IYN1SX/!V,'E8>-9*82P9*2U6#6")P\J*:/SHY1*(W,/FO #2-*/?$##YV
MO%QR#.9ROG,5/R3'0F*?&Q5;.WN<UPEEAD\J2,QE[7CRV'N"#ZJ79CX/ALX>
M88=./)(W&&'5?EB=W<;2LS_-BZ&9_47D6!!SQ9-A&CVQ^]M"Z=I4EPF[QN6)
M\:-K<?7R>AU*(;/5Y:L_.ZX/H7<^XN^0M5M,BB1"._+5(RB1,E\=TWIAE!?J
MGW=>G3V^RJ+\(EN.@75?VW8K9KM-J[OQI,8)VFS(\PH<N0_&;B.N''<<QRO&
ME1$K!&:1\GAOROEF4YACJ63RV3L49([OFPV7R.@=T5)7,ZP6_LN:UX[[V!KZ
M_5XD<5XGB^(W[N+Q6+KW8I*0BEK,8)6]5NNUX:0XGXF$@Z] 3\NUH[;*7_H-
MTU02FU&BVJ49^&ZE>".!'QG!GU]I=R/R'.-5;RD6)I_==V1(JI<F@TB;4&8^
M#3XRXT9U\D<QD9%DV^_L/Z16/TOT*XSEB6':M6TLUA^Z:WGJ5$DTRBNT^D,^
M#$<C-+98\:0M2E$3:DH+)>78\#S:E;AN,K8MDW-2=4M$3N*@R:3.BU*KM5.D
MM>#$<BNMOR/"CH,U$39J7REUZ>\:M)P9MG)/?5Y+QB\V2X7.@_2?V6<M,VW,
M,=N.$EVMMTUQV>P/NMJCYTZKC(V6N-\GHN92:UMC]%_:8&N$ Z'B2M),.G>G
M N:-#U TNEC^$.:^2:G6(-)T&GU?XMJU1IZOBV6J8I*8<MZ.A2TQV'#1SI;Y
ML&1#S_D@K<OY[:[F+OW:FEV[]X?EY^P>O\'FM>W+PU+W#G==OTVL._&L.1X-
M2BQYB8<N2_*<ELH*0VLBY7E*09IP1FGIY"UM4M&]*D4ZH*38%K$HJ?.,C^)J
M;DC*.X9X_*_?SSY'W&W\LN\$XMG+&$=P2O<=796)L#)VH@\SP0RG^K^/73UD
M?K?%Z]MK3^)TN><IP=;-,YU/3;9?8:*YQM:4L$$[H1_6;9LNZ=_JC0/KM0";
M".-%JKNGW.VCH==.ESEKPZ\<STJ8_.0MZ*<>,;R27&4A#A&I1<I9(A9?%#VP
M-;M--JW%WO+4R_.:CV%;52>2^BGPW9!1_28KK*/"B0T*5\_N2$_3T,65*)QL
M]@-6]&)>I\^"[(YO5D6U5T>'CV\S*<>_IV[>P83Q X9,+^+M<7XW<9C;F%HV
MY&TH;-N*.S.'RR,=+_6'K:PLV.PUHZ&UG?#_ )I#]AR=7E'):;\E4S-RK&Z]
M-6J2OKPF.)CFQ_U8Z'O#RT_%WV-]E+<-#,B(S/R(S^HNXCDIG%?V+UE)JA:S
MPL$:2/Q:?+CGE?0OS5)>T=G4K?MM1N _"IVL% 6IQI9I)V0RSZJD=S-QPL=/
MH$;R<?SL/^NP^3B ]2^E8;K7KO<8] 5),?(<%-KR<QC)2=:#+U=V]]AZ2%;M
M1]_6U;2F\*G8E]ZHP*%<]'-LJA376EFN/XJ>9',HBQU3U]HX1^.?;)OUZZ1^
M\4*DNZ33RQ-W/%JKE@4V[7G[0U E16T7#3YCSD;\J0$FKPFX[W*K"LI/E47M
M,\9(I:6?@V^BSS++IZKU@C=99<,N6H%@W$$KRF>>?]>XD^WPO@6%IX9_(,[F
MZ5[)XNKD37AHLE:SSVCK;OI!;TO#V]+M. &R%%U7FG/<U<S#./8/"W*6,R=C
M'B>:Z^)TGDN^!VNK3NN,M=U-^'OV[!2YM\3O94Z\PRWK12W')#[,=I*67#YW
MGW$M-(Z%^C6I*2\NHSKH=;IMQ4J#6J1)3+IU1CMR8DA/9YEU!.(61?W25$?U
MB@EQ,>'A96PB^-%:3:5W5.XRO6YH12_$?FQSB^A5*(IOY[Z^?GYNN#P+Q.VK
M"=$=-F^="E(MFD\V'DN*+,"/CF,E&9G])F?M(:_S+BV P^'P.9P&1NWZF9=<
M:UUV)D+@*CHV$AC1L;>YP._8 CL5L'#>5Y_,9C.87/X^C0MX9E,N;3E?,"ZT
M'/ +W$M(Z.@@M]"3O:[Z&SG+]*O]Z8ZPUENVI61IG>5TTI!JJ-%HTZ;#+ESE
MZ/%>=1W(RQS(+Z/O"F_1^-[O\NZK5^!9-DS+D.CUFIP7D0(\=\V&8\Y]A@W"
M986:>9#98R1#$<8X1F>5PW+&---D5!T++#[=J.LUIG#BS1D['?01ZCOKYK,<
MGYOA^*34Z^2;<?+>;*Z!E2JZR7"$L#]AC@01U@@:.]'TTKM_.7Z5?[TQJ2LG
MC"B^E)D7VBEJ?%_XGQ$:E:-U\DI(U*/XO+"4EU,S_*O8BZF,H^'1Q:-TFXK=
M[:.AVJE).ETJI'-358SJ8Z'V%LQ5/-DM"6DN),UEC!D0SESPJY+2H7<B^7$R
MP4*TEJP*^2@GD;%$SJ<0R,DGW ';9UI8*EXK<;O7J6/9#EHI[]F*K7-C'2P1
MNEF<UK07R.  V>Y[Z'<CUU:I ,E[0$9J3D ;5K2VE2UGA*4J6H_8E)94?U%U
M&%%]<0O:7IQ=E6LJ\-5J?2+CHBD-U*GNM.<T93A<R"4HL$>2]X^JI1NWWNCI
M5+%M[&]3F5X7S.:W8'46L:X@;(&S[D+Y+=^E08V2[;KU&/=T-?8FCA:YVM](
M,CF@NT"=#OKNLV0$?7XZ%LD_7II'[Q?_ &A[M-XF6S"K5&#2H&L5+D3JB^W&
MAL)9<,WGGEI;;01]2RI:B(OI^@?>>.YX DX;)@ $DFE8T !LD_U?H!W)^2^
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M\Q-6@*424SZ<I1G@DIFQS4?T$3F3,?3(\]2ZD?4C+S @CU!'WJH(/H=_SM
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M:@ V*<2GOD_H(S_ "+> T(R,LD-JEI3WR?T),_P BW@-",C+) 9X(S/R!%J
MVI42BR6?K(R/[#&X$0  $0!M2LE&9%GI[2,OL]HW B   B   B   B -IJ(C
M(L'U]A&8$LC5R]<_0>/M!%N  !$  !$  !$  !$  !$  !$  !$  !$  !$
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MF5TVSF)1PW:JIY\FUI3(Y5<GAI/G[=2Z>\>GM*UGO;7W0JT-4-0M/'M+;JN
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M\=8 WE)(R1L=]25F@ []SKZE2&><R=.I.)\NC);LD8MDC6^FP#%8=O\ #O\
M-1;ZM:V[^=7]]&INA>A.IM1D5152Y*#;Z$-LI:;:2XZXDG'%DGHA.<G]0[H/
M:CQTB_\ ;M2[D7]F0LY/IV\;_4AUEPPI6H,GBW0Y.JC'H^H[DJH_=2P7(OPW
M_0'B01&R7A]?6R:.GO%Y=3F#Z<WSB+YAGYX/[?J^DA)7->5/X;<Q.)H8/C%N
M(X+&V))Y\;%8=+,]A8]S)F^6'QN\IKFN+>IP=U$]]*-.$\5CYC4RN5OYSDM2
M1N<R%>*"#(R5VQPL>R2-CXGAY9(SS.ES0=-+>GMKO0A/67B(;?\ =3IEI)KG
MJ?4J;59U=B-3J,I+3Y/LK?84:#<96I.#;6>>_P!(OD6[(6_0*$\^I2WGZ+2G
MG5F1^LX[":6M1^PU*,S/Z<"D]QFJM6J%Q);/K=MTXZO<-+G19%)I>2:.<^W&
MCK2T3BLD7,M*4Y,C+KY"0.W.*!Q'Z2BF1YNRJHS:;"IL)E'+<#*"?8:BMMLO
M$:6,EXB$I<QW+/?L/GYG@+?*L/Q#+8^K@\?-9Q4MB[&R>CB6/EDE;KRHYY(G
M2M ![]3^DG1</1?5PSD%3BF8Y=B<A9SEZ"ME8:].5T%[*O9%'&[8D?"R01N)
M.]:;U@;#3W*G=W?ZKW#HQM\U"U'M5'/7+;IY28*3).#7U_3D:?+S(Q4CM3C<
M<0J^69TBS;"J%RL09TN.^[3HS#R64-2%M-<YLQUD7,22QD\_8,E-TG%-W;ZD
MZ,WYI]>.T*K6?2*M ./4:\Y5U/MTU'*OUS3Z.1++)Y^=Y?6.TO@W-*I=0TXU
MJ.?3J=4%?&<)XE384>4II;\N2XXT1OMK,B0H^56,9P6?(>6&X_4XCP[-9KD>
M Q.:M09"DVK&Z[#9;Y,X;&\>=3EE$?2\AP8X;<0#Z=UZYGD-OEW,<)AN.9_+
M86I/C[C[,C:<]9WG0GS6_P!3;CB,FVCI+QV;K7J"L1#XOW$]22E*T=N%*$)-
M2U' +"4I+*E'^5.Q$1F8S&X8W%8W,;H-TT31W52F^@4KED%-96F,EQEQJ*MT
MDJ2A"7"/G3CKY^T63KBMBVDT&NXMV@=*)53R5(IY'DH3W8R8^OR]HH@Z"[B9
M^UOB1:I:D4BPY=_.Q:W,;;MRE&XPX9+*2R?AE':<Y>4CY\$V?;Z![8-^ YQA
M^4UZ'"\3C,A1Q?FT98)GE[K$CQ&W3YBR./IUL.<=;['YKPSD?(.#Y?BT]_F>
M5R>/O90178IX6M8VO$UCW[CA\R20.!T6AO5Z:'97]R/.?<9E_K]0USC_ ,C/
M\ KI?CY]\EG&T*[2ZGT],J'M\_RB77V].XX]4..MK"B0::;LON>1&Z<KJI]0
M)2O;T.&6/L^D1NWPYY<XZ&.A']K)8UH]O<VA\_W%20[Q'XBT;_2,Q[CLW&Y)
MQ[Z]A5[>OUU^(5CVJ27(L"<^U\]B!,D-]/T;,=QQ&<]"]9)=Q35UTXN._JF[
MGM1]'-)%.5Q%"J)1Z)2(T*&X^MLC<-9$?A+</"4YZD,U9O'1UOE0YD=>RNY6
MT2(<EA2SJ$XR03S*T&YDH><((^8R[=.HC(X8=Z2=5N+2W?5;MY-$E73*J+\R
MW9S:9)T\TP'C)"TO(P?SCP9H(R/W]M^X;PV?!5.397DV"QU^*CAI+5.&Q9JV
MV&>![7ENJTTKH^I@+2\@=CH':T'F7,8<_:XQB^,Y[(X^2_F&5K<]>M;IR-@F
M:&!W^DQ1-EZ7N!# X]^YT NR_P <HXQ?ZWE8_@V+_F@]*Q.+]Q#(6N^G^FFJ
M1.6^=>J\>)4:9*@PD.FRX^TD^[*%_,69]"^ON+H*K?H>>E%HOSDE_:J'YF7<
MS9_R^\A2:XQ5=187$JLZYX%(;F_<_/AS&J/!93'.:I,:.[X:2827K&:<9))G
MUR1#[N'9?CO,<C;Q'^0V!HN_15ZQ%/$USY!-%#_5 "331\9!ZB1KU[>WQ<PP
M_(N'8^IE_P#+G/WF'*4:TL$SFM8899097'RR7.TQKATCU"NVT.6[.H](EO\
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M//TE]76%G035.T-S7&$MW4R#0\6G><Q]35%JL97:- Y#](C36R7U5ZQ>(W]
MF+A7!)Z+\Y?Y=QN::E0PEFY7BLO="R2S 8Y1&U\4G4'/B#P"00!LD; 4-\UY
MW#>;@Z'$>20Q7;V:K4[$E9HE?'7G!CZW-ECT6MD<QV@02>V]$K*_\D#[G?\
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MXXW1_I(%;IGS=^7W;]_O_+\YIOQP3:%^OG9_\+4[_. _'!-H7Z^=G_PM3O\
M.!"S^1;-AGZLO+^.-T?Z2#\BV;#/U9>7\<;H_P!) FF?-WY?=OW^_P#+\YIO
MQP3:%^OG9_\ "U._S@/QP3:%^OG9_P#"U._S@0L_D6S89^K+R_CC='^D@_(M
MFPS]67E_'&Z/]) FF?-WY?=OW^_\OSFF_' ]H9]M<K0,_855IYG]A2#,P_'
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MY8]KJT+8B2(9"SOT[!WON=^IWM_"^&1<?P4>-R[<?D+C;-J=]B.L'L+;$WF
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ME">A'W'YPFT/9YK5QP=\NXO72FZ@5O3*';EQE&9O>72)3JX[#3\J)$7$:?\
M!7A:&D),V5%W(U#]*&_K"M?4NU:K9EXTQ-7MVLM>#4:>M:FTR6_TIJ3@RSYX
M[^\=6:"[7=#]M4&KT[1FPZ=946N.I>JJ(24\TQQ*U.$IU9))2C):E*]8SZG]
M *YKND'7J1KT]MC^_P"Y4I-_'P=/7_3C;G=VKE9W7U[6VI:;,,5>BVA*HTDG
M5E%<\=2HS[LA\V?#\$EGX9%G!#*KA[[T).Y7@DZVZ:7$FJNZA:(V]4*%<13H
MDM,Q:'I$N-$;2AYLENDVA@B+DYL%[",A<<KUOTBY:1/H=;A,U&EU*.Y&FPY"
M26T^RZ@VUH4E9&G!I49=NF3,AC!ISL=VRZ54F^*'8NF--H-*U#/FNV"PKY"K
MGS.+^4;P2"]9Q9_-\_H!5ZR1H]]$$?/MH?EH?)4/^ UQ=]M?#HTOU7L_7!NX
MXE5N:Y:@Y!2W;M;>)THU9F+61FQ#<(B(E>9EY&1^WF'$HWPW-QW];=!]M&TK
M36Y)%CV_<;4JN7+)IM2A0YD1,V+-<<=5/BM(:\%MI9%E9<QETR8N6%PH]A_K
MYT MQ9N/.OK-;;2S-UY9N.*]9!]5+,S/WC);1?:QH)H"PZQI1IG;=I>+CFD1
M:9".66#/'ARO )]'<_FK+IT/H"NZV[+ND]7J"3V_+_':K8<;7A7WU?7#GT0I
M.C\-VNWIM<HU-J<*BQF_EYLE:H,RHI;,\JS'5&<[$HU&70L&0ZEX>GPC[;CI
M'MIM[2C=7#N2R-7=,J:_1Y4*70:T\JJRJ>2H[#"?#A)2WGP$H)9&HC)1'@7)
MY,2-,CNQ94=F3'>0IMUB0VEYEU"B,E)<;62DK29&9841]Q'UJEPL]C.LETR+
MQO[0:W*G7Y+I//2XS+4%#CI'GF-J,VV@SSU/)=<F"M#AKI<"='8(.CW]1^*K
M4[#^(EO^XE/% J-ZZ)SZ]8NS2FS237*94*,OT3T-$4VXKC,B>RTZYZ2XWSJ)
MHSY.;!GDA;2W3$XG;IJR3JE.K38]:2M2$&I3CB*/*)Q9(21GZZR-7*1>XARK
M1G;_ *1Z VVQ:FD]CT:SJ+'22$L4^'';?6DCR1.R6VD/.\IGT-:U>PAVE7*)
M3+BI4^B5>*B93:E'=BS8R_FOL/(4VXVKW*0I1'](*TD;V!H#6A]WS/S^O94F
MO@D:R5>>]?\ *\]G%YEUF0I$3F_KU4,\AOMH)?TIR+"W%%X6-E<3.VK#M^\;
MZJ]DM60Y/<C/4I^<RJ2<Y2#43GH4B.:N3DZ<YJQGH,U]"MJ6A.W&1<4K1ZPH
M%FOW5(]*KKD+&9[_ (BG?$<P1=>=:E?6>1D=@O8"JYW4XN]-Z_NT?P_@JS.B
MWP?RQMIFC&Y*@V+J17+YJ.J=J+2S JK]0?0Q(I%-E>"AKTV6^GF><-)%@B,S
M/V]!!_P2N(+HOPKRW/;;]X<"L:=7053K14:4[;U2E_'!.2:F_&9)UF&I+K;J
M%M(QSJ+"R\NA_H2&E)D9&DC(\D98Z&1E@R,O,C+H9'T,NXP9UUX<.SG<?<Z;
MOU;T8H-QW"AQ+GQDVTW"==6G&%.G&;1XI]"^?S>>050[U#AL'7IV/;7]X&E4
M-X.FE-S;T]Z&^S<];5L5.V=&;WH\YB@*D0)-.BUU9T:J0HSC;+S4<EFN0MM6
M"0HR-77J.G^$%O@TZX1NJV];;[NXC5RQ'J_5*S(M26NBU26U,5(>JLN(EAR/
M&4VLG?&93T4>.?N1D0OT:2:,Z::'VA!L;2^T:3:5MT]!MQX%.B,,F:#/)D^\
MVVAQ_KV\4U8(8YZ]\.[:'N7N*-=6L6CM#NBO1'"<;J1--PWG%EC!O*CH2I[Y
MI?FAJ\_:"J'-V=@])UH;[C6M=_[_ /@JFWP>/2^[=QW$#W.;YCHM5I6G\NML
MKM:=4X<J*57B/'+BDXT4IMM9X2:%8(CQD65^,L1EPY]Q!<CSAJH:,)9:6^Z9
MJ6>.5MLE+/OC!$,_])-&M-M#K0@6-I?:5+M*VZ<@VXT"G1F&3Y3//RSK;:''
MCSV-PU8\NX^YJ#I]:>J%I5:R;WI#-<MJM-$U4J8_^926RZDE70_,%:7;=O78
M:T/H/157_@G27(>S6]R?CRV%,UJI.K3*BO1E835IR^B7DH,\D7D7F)2+(XQ&
MA]Z[]Y>PJ#1I[.HL1Y3)SWH\UMAU3<0Y2O"6XREAS"$X/E69%T]PD5T3VXZ0
M[=K;F6QH_9D*T*++-UU^!$QR/.+4IQ6>A?/6I7T<QGY"*"R-@-[W'Q1:INZN
M&PJ?IW:.GBC^Y*>PY#FR+].J4\XLMUY3*2?AG!7A1$[GG_0@F^HDGY?O_P":
MG7]PZCUVQ^([J?T4K_83<AX21J4?]9IGS2ZF9^PB^HAVV6?/O^ O(O>/2J=-
MAU>GS:94&$R(4^,]$EL*^:\P^VIIUM7N6A2DG[C!6JC'\%37S;E-[WY6J#/^
MS3YTN#)BH5FJ5'YBGFT$LL^:3/IW%Z+_ (O_ /2?_P!PQRT2VD:!;>JO<E=T
MDT^IUH52ZY'I5>E0\<]0?\1;G.Y@BZ\[BE>WKU]^2F",L8Z?ZF"N<>IQ(].W
M[@!_!47_ (1.E9\2C8NXF-.>2W=<KG7'@R)+2,R(&/$6TVI""]ZC(O>,N_A1
M3+LG87I TRQ+?<7]Q)DW&C/R%X3)HRCYD-)4:<>>2^GL+*6K&TK0/6N[[:OK
M4G3^GW-<]I/JD4"J2<>+ >4:%&MOH9Y,T)]G8?=UIVW:.:_VQ L_5:S(=V6_
M3#C^A4^5@FV/13;4QRGCLV;2#(NWJ@G5V;[]/\A0):EY/X/I,(V9)J_$WA)-
MDHKIO\W*A./1^0W/JY2]IB*/AZZ#7GN1^#RZVZ.V52YS]U5%^IU"!!<C.QY$
MA-,N*;/<)+;J$J5\FCHDB/)="(77I>@^EL[2M6C,JU8CNG*H:82K;5CT8XR,
M<K7;L6/8,<-0]OM2T$VN7[9.R>W*?8UYM4^3,M:$TS&DL.2LNR9#*FI2?1U%
M*49H,EI,B-7GG!E4/(].VW!WY=Q^7[U4=X._&HT?V3;3*IM*W"VO=MNZJ6!]
MT='M^C)MBO.N5^;)E3&TH2IF I"$<W)\IU(R,E9QVQPX1VMCMY<4W=EN$NZD
M/6;Z?;EP5!5)DDOTB TFV*HJEK6A:4.\\E/A+(C22DFK!EDAW)8&_G7[2#4"
M\9>\WAJLZEZ\4F15(-N7K"B1(T1YU\Y$:/,5$IM*7"6I39LK]<SZ]<Y&47!5
MV&:\:Y;IMP^\G<[I6YIG8NJJH**/9+BT-IG4U$>1#..7HZ&%QTM,N)2HO#0:
MB(\^0*\]@\Z #@-_$#LD@Z:/E\_IM9>?!P[&J=RVGNFW75N,^N7KG=E;C1)T
MQAQ#[D6VJS58*.4WDDOE-M",&73E/!=! G<&S*T-]?'MULT0O]52AVG/492C
M]!FMQ9DANBO/1#.6@D((FWR2?19D>.ON_0LT3T)TOV]V!#TSTFM>-:=FP7Y\
MB-2(Y\Z4.U%]R1+6IP\J4;KKBUGS&>,C@]O;1= +6U@J&NM#T]I\'5"IJ)4V
MZ6^7TIY7A&UD^G_)F:>_M!6!Y!<1ZD:^7R[_ +OK_%4W^'#J3>O!YXF&H6P;
M5Q^J1M ]4YC,'3^N*@29%,@I3%==+P7&D+;^5=?;3S>(74_>.G=U%TW)PJ^.
M:6\'4"TJ[7]"]0'&IL:Y*?2Y\UA<)ZCH1XREPX[RF/#)\E<BE)-6,>X7?-7]
MH&WS7"ZZ!>VI.G5.N&Z;:?*31ZWA,>=$>YD*Y_2&B2\O!H2>%+,NF,8%:_C#
M:F;\]"]P=/?5MZA;C=F$E$:-!M<H-*.= APHK+3C13RAR:FG+A=>I&9)QDR,
M%4.V[9'J.EW?6_0;]^^^Y_YJ(OCX<5'3'B#V7HM0]"+>KDG3Z@W117ZU>M4I
ME2IC!/2JS <2Q':J,5CQ/#?)3*C;69YZF>,$+R'#^_WHVB'L*TZ81'[2* P1
M']8HX;G:WKEQ3V-!MK6V78<_H#8=IW#!G7-6"Y&UN(;J<2HON.OR($5USPS:
M=-)&XKV%@7\=NNEZM'=%].=.7'O'?M:V:3!DN8P92FX$=N0WC)_,=2M.>QXS
M[ 1VNEH]""[ML'0.O4_77R7>   +S0  $0  $0  $0  $0  $0  $0  $0
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MR-X "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(  "(
M"(  "(-,%G/G]8U $0  $0  $0  $0:&62,C\RP-0!%QN3:%KS73?FVQ;<Q\
MSR;\JB4Y]XS]IN.QEK,_K'V(4")3VB8AQ(D-E/S68<=J*RDO83;*4(^\/< $
M0  $0?.J%)IM50352IU/J+19PU4(4>8V6?8B0VXDO?@A]$ 1? @VQ;U,=)ZF
M4"@TUTL_*P*1 B.]?8XPPVHO?U'WP $0  $0  $0  $0  $0  $0  $0  $0
M  $0  $0  $0  $0  $0  $0  $0  $0 &A]C^@P18*\0S?%8VP7;9>>O=Y-
MMSSH49M%(H:GS8=JLZ6OT>.VVLB-1<KZD9P7F1'TZBIS'X_W$PL>A6YNPU*V
MSS(^TNZJX3,*=\;1,1Z2Y44P4RG/#C^DI22'$ND2S2:L8SYC)_X7-<-1@Z!Z
M#VPP\\BEW'=D9JI,H6HFGD,UNG<I.I(^51=3QS$>.H[MWC:=6Y(^#Q2Z4Q"@
M1(].LFWIL8U16.9#IK8=5X;AI)2%J67,9I/)^?8@7HT !I(WU.Z?N';ZCOZ_
MXJP[M8W%6;NJT-L/7&PI")%N7K3&I<<VU<Q,R4H04I@S/KEIXU-GDL],^8R(
M%<SX,?7:K5>&?IW'GRW)#-/EUUB*AQ1J\)**N^CU3,S/!DDL8Z$0L9%V+Z"!
M6.'2XCY%:@  J(!]",_8 VJ,R+H6>Q?4?0$4*7&SXCMX\.S;I#OW3VCHK=[U
MZ6S%H5.4^VRN0ZJ8S'4VCQ4J2HU>*1?-/W%DR%?2VN.)QC;A.V9T;:%<"Z'7
M)]%251](:Y?B^?)CI=D<IPBRDF'361D?4NQC,?X3+H=NNW*7%MEL';[I5.O:
MF4>L3IU7EQY266&);,N-*I[CZ5I-!I0^VD^57JF2<*Z&,(M0]\7&+X7;FDEZ
M;N[$MRX= 9IT6BO45FCVLGXI@(]#I[2GYD**M\G&DJ0LS69+-2?:8+U: 6#0
M!<2??1[:T!_/[E=XT2NFYKRTNLJY;OIJZ3<=9HT*95J<LR-<64]&:<=;49$1
M90XI23Z%V'; Z(VV:X6MN*T6L/5^S30= O*C19T9+2>5#3QL-G(:26$EAIY2
MVRZ%T3DAWN"\D  !$["-+B*\3#0;8!I3<=SWQ=5-?OOXLE%:]ELR$O5.=4#9
M6EDUQV#<>8)MTVU_*MD2B]PDM%;/B0<'W1+4>]]P>]W5VKU&^JPJV'I-IV8_
M+G,4NV'X='D,+6VR4@X;RGEH0Z>6"Y3+OGJ"N;HD=6]?3U*^]P">)KKEQ&Z!
MKK<&L<5$-JS:M"*VHZ3CGR4^?+D^"2C92D\^CH:^>62//GD<GXR/&-G;#IMA
MZ)Z*6?\ BE;@-4GWX5"H<>649ZF26EM$CG)2'&U^(EY*_721$1?6(Q?@A?\
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M#12UJ9<J'W)+<]=/AOI;><,U*6VTXPI"#YC,RY2+!XP"-+1HD$D'8T??Z_\
M!8I\$#;%>^U;A\Z/:;ZC1':=>'H<RIU.F.J(U0T5.1Z<P@\'C/ANEDL$9=CP
M?02^CQM--LMI::0AMM"20A#:20A"$EA*4(21)2E)="))$1$/("L/?N@X[=M%
M<N*UKEH#3YQG:Y0JK26Y)9,XZJA!?B)=21=<MF[SX(RR9#D0 BI.)^#0;G[
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MB+D8;;29].IF6<]3Z@JEX(.FZ+M;.^W;7H/O^JY0A/*GZ3-7[X\C>  O-
M1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M1   1   1   1   1   1   1   1   1   1   1   1   1 R1=SP-JE$D
MLG[2+[3P(?>(-QDMM'#PO:U+'UFD/-52[2EJIQ-L2WN;T-M+CO\ 8[:RSA1$
M1'U[?450"3H#9^BF#R7M+[2&HK$43X4WP\JA468D^K5>F1G'"0Y-<H-<\)HL
MD7,9G$))E[^;!B;/:-OIVW;V;1<O'0"_X%VP(Z6SFQD_E:;$-PS))+B/*)\L
MJ(^Z??V!5+7#U!'WC^?FLQ &F2QG/0;26DSQU+Z2,@5JW@-#,B[C4$0!IDLX
M\_H,:*42>_V%U,$6X!M2HE=OL/H8W B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
M  B   B   B   B   B   B   B   B   B   B   B   B   B   B   B
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MW]5]X  %:@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M(@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
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MZW(62/*CQ[5&9?8-X*I<7:W[=@ -:0  %:@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@
M (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (@  (O&Y\P_]?(QM9ZI
MZ_Z]3_H( !%Y@  1   1   1   1   1   1   1   1   1   1   1   1
M   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
M   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
A   1   1   1   1   1   1   1   1   1   1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>nt10002526x6_linechart12.jpg
<TEXT>
begin 644 nt10002526x6_linechart12.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( DX$Z@,!(@ "$0$#$0'_Q  ?  $  @$$ P$
M    "0H( 0(&!P,$!0O_Q !S$   !0," P(&"0P-!P8)" L  0(#! 4&$0<(
M"1(A$S$4&2)!4=0*%59787&1E=(6%S)8=8&2E):AL=,8(S,W.#I4=+.TM;;1
M&B0U0E)RDR4T-D-B\"<H.415=H*RP28I15-SHN'Q*D=C96:#A8:CI*7_Q  <
M 0$  @,! 0$              0(#!@<%" 3_Q !?$0 ! @,$! 8*"PT%!@0'
M     0(#!!$%!B%A$C%1\ <B06)QD1,6%U97@966H;$4%3(W0E)C=K/1X1@U
M-E5R<W1UD[2UP=(((S.4\20T1%2RTR4X=X(F)T-%99*B_]H # ,!  (1 Q$
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MDSJ5-I3B95.F/09*"8FMMN&29#*TDHBPHBR73 $&2X
M
M
M
M
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M^V2:@^FH92^E*S_STGLGC!GG'0"AF>
M
M
M
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M>3>AF4
M
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MCPJTDI_SIK+)OED\^=HC7W=Q=_I R6 :&HB\X$9'W& -0
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ML1_5O9WNIM_YW@_KP^K>SO=3;_SO!_7BNYXG_<'[_P!7?PIGK0>)_P!P?O\
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MRHU%KCBJTP5*42M5Y=A<7(R,LD-1M1RX/E[N91]V.IGU(;@,8
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M9FRM2Y[KSK?+S*+HOKGJ)(L$?>60 BJTI7#?>@(L="   @
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MJU0;N-Z/X.;34^HOS&HA)[5W/@S;J8^>8NC>< 5Y.K#KW\9F\ $
M                                                QYW2?O%ZB_<6
M1_5W!$EP-_\ HSK+]W4_U^2);=TG[Q>HOW%D?U=P1)<#?_HSK+]W4_U^2.O7
M=]Z*_P!^N+N_3./GV]GO^\%GS=O5]##)\P !R$^@@
M              -#[C^(_P! U&A]Q_$?Z ! QQ]OX)B?NA!_M*.,T^%1_ ;T
M7^YTS^G,86<?;^"8G[H0?[2CC-/A4?P&]%_N=,_IS&SQOP5E/UG&^B:=JM+W
MBKO_ #XM'^'M)%0 !K!Q4
M                            &<=X
M                9(N\\   TR7I+Y1J  !G'>&<]P
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M2?@\5;3'-_K<F3[P,>W?JW0S;
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M*+;-BVE9<..YS(+YZ3CRS(CVHCG-8Z*QJ.<C5151,413F@  _*>(
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MC3DQ(D3DIBZD^JG-\L3+9]G!-E&3ZGC)]0*[^O?J,X@ OA[P
M                                            &/.Z3]XO47[BR/ZN
MX(DN!O\ ]&=9?NZG^OR1+;ND_>+U%^XLC^KN")+@;_\ 1G67[NI_K\D=>N[[
MT5_OUQ=WZ9Q\^WL]_P!X+/F[>KZ&&3Y@ #D)]!
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M%$=(J%K4&13B+F\B,Y3(JV6SYB)66VE(09GW\H%7HG%5'.<BUQ7+"F^1S0
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M^:)ALN>"3*\'UZ^G(%.3JZ>7=?$9Q@!?#W@
M                               ,>=TG[Q>HOW%D?U=P1)<#?_HSK+]W
M4_U^2);=TG[Q>HOW%D?U=P1)<#?_ *,ZR_=U/]?DCKUW?>BO]^N+N_3./GV]
MGO\ O!9\W;U?0PR?,  <A/H(
M                   #0^X_B/\ 0-1H?<?Q'^@ 5M?9$?[VFC?W?3_:<(3(
M['/X+^DOW!C_ -$V(;O9$?[VFC?W?3_:<(3(['/X+^DOW!C_ -$V-HG?P8LG
M],G/5#.U7B]Y6X7S@O!ZX9ET  -7.*@
M                                    &AEDC(_./AR+<HDMXWY-%HDE
MXSSVTBE0GGLEW&;CC2EY^'(^Z  \3++;#:6FFVVD)Z);:0EMM)>8DH21)27Q
M$0\H                            T,LF1Y/IZ#/!_&7G&H
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MZ#:CJ?HO8%RRK2NRZX44J/782EHD0Y$1XGT\BD+;47:*223,EE@C%,*A1O9
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M*](+Q:K%6BL4%=49JIOP(U1?8A2>V8)*4^$1$-O\IEY//R^8"AFV
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MF/\ P 53?Q?6AN .\ )
M    T/N/XC_0-1H?<?Q'^@ 5M?9$?[VFC?W?3_:<(3(['/X+^DOW!C_T38AN
M]D1_O::-_=]/]IPA,CL<_@OZ2_<&/_1-C:)W\&+)_3)SU0SM5XO>5N%\X+P>
MN&9=  #5SBH                                    BO3U+]0   D
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M?"!4S> "
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M,3D[8-E34U'>C4=&F(\E!BQ8CD:C6HKWN<Y4:U$15P1$   \,V8
M                                T/N/XC_0-1H?<?Q'^@ 5M?9$?[VF
MC?W?3_:<(3(['/X+^DOW!C_T38AN]D1_O::-_=]/]IPA,CL<_@OZ2_<&/_1-
MC:)W\&+)_3)SU0SM5XO>5N%\X+P>N&9=  #5SBH
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MNK>6M#-;DMH6:W%*4?.E)*(\]<YZ@55&Z-45?=4QZ%6I8I :%W%\1?H&H%
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MX@*]SUKIV-?7%;T8=N:$;_M_[<^ ^T29K?:\GM]@B3X(:_L.N.[S#]2JV_;
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M/*YLY,CR!CY.K'KW\1F^ %UZ@
M                     / _'9DH-M]EEY!]Z'VD/(/X#0LC3C[P\$>FP(BC
M5%@PHIGWG&B,L*/XU-)28]X!.DJ(J(JHBZTJM%Z4U*46&Q7(Y6II)@BTQ35J
M76FKD]8  $%P    ATXS/\&-[^=P_P"O-"8L0Z<9G^#&]_.X?]>:&^\%_O@7
M4_7,G]*TY9PV>]7?C]03GJ:91<-W^!]I1_,)?].,Z1@MPW?X'VE'\PE_TXSI
M'BWP_"N\?Z[M/]\BFQ\'OX"7.^;-B?PZ7   UPW
M                     T/N/XC_ $#4:'W'\1_H %;7V1'^]IHW]WT_VG"$
MR.QS^"_I+]P8_P#1-B&[V1'^]IHW]WT_VG"$R.QS^"_I+]P8_P#1-C:)W\&+
M)_3)SU0SM5XO>5N%\X+P>N&9=  #5SBH
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MI?*2E&99,^I_ )<Y%2F==5$3#DQUZZ\B]1V.7<7Q$-0 "@
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M5X]]IF<
M                 ATXS/\ !C>_G</^O-"8L0Z\9DC/;&]@L_YW#_KS0WW@
MO]\"ZGZYD_I6G+.&SWJ[\?J"=]33*'AN_P #[2C^82_Z<9TC!;AN_P #[2C^
M82_Z?_O^@9TCQ;X?A7>/]=VG^^138^#W\!+G?-FQ/X=+@  :X;@
M                                :'W'\1_H&HT/N/XC_0 *VOLB/][3
M1O[OI_M.$)D=CG\%_27[@Q_Z)L0W>R(_WM-&_N^G^TX0F1V.?P7])?N#'_HF
MQM$[^#%D_IDYZH9VJ\7O*W"^<%X/7#,N@ !JYQ4
M
M       #3!>@OD&H         TP7H+Y!J
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M8:H%1JMIT&9-BJ/)MR7Z5%>>[B21$IQ:C)./)+H!+T2C51NC5-6/)3:<_
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MS)
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MZT/V+7%=]VLK_BP/UH\?N8V)X2[F\G_%1^71^2YWH/?3AJO)A_\ )OA#Y/\
MA);F?*[UZ2RW[90OY7"_'&/I#VF7FGT$MIQIU)_ZS3B7$_A(,R%5;572SB9:
M-6+6M0[UOV9&MRALDN<^2HCAMDX9H0?(VX:S+FP7<):>%1J->^I6W6!7[YK[
MMPU=;TA"YSJ>11\DMQO&,GW$6/O#SKQ\&[;#NZ^\DG>:Q;>DH<_!LZ)[5OC1
M-"8C0W14:Y[V-:BM8E5;72HJ+2A[-T.&!]Y;V0KH6C<R\=U[2C67'M:%[=ME
MX21)6!$AP5>V&R(Z(J.B.5K74T:M<BT4E%  ',#M:8X@
M                 :'W'\1_H&HT/N/XC_0 *VOLB/\ >TT;^[Z?[3A"9'8Y
M_!?TE^X,?^B;$-WLB/\ >TT;^[Z?[3A"9'8Y_!?TE^X,?^B;&T3OX,63^F3G
MJAG:KQ>\K<+YP7@]<,RZ  &KG%0
M
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MH!CW]>_69G@
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M_/>5_AS3Y^M#_P R-A?^FT]_%R7P  <@/H!-2=">H   2
M               :'W'\1_H&HT/N/XC_ $ "MK[(C_>TT;^[Z?[3A"9'8Y_!
M?TE^X,?^B;$-WLB/][31O[OI_M.$)D=CG\%_27[@Q_Z)L;1._@Q9/Z9.>J&=
MJO%[RMPOG!>#UPS+H  :N<5
M
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M^[H\I<R/,ES'ZE'8D.J-:G&X<PEQV_*,S(DH\D\>@C$C5Q6;;5U6W-M*X*-
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MR%-5]ZO%[8RJ@_(GD<EY]]23*8XZ7)S829<GFP!7DWH9D
M
M     # KB7_P.M4_YM!_IS&/'!L_@N4[^=2_Z\Z,A^)?_ ZU3_FT'^G,8\<&
MS^"Y3OYU+_KSHZ_)^\G:OSWE?X<T^?K0_P#,C87_ *;3W\7)?  !R ^@$U)T
M)Z@  !(                             !H?<?Q'^@:C0^X_B/]  K:^R
M(_WM-&_N^G^TX0F1V.?P7])?N#'_ *)L0W>R(_WM-&_N^G^TX0F1V.?P7])?
MN#'_ *)L;1._@Q9/Z9.>J&=JO%[RMPOG!>#UPS+H  :N<5
M
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M!8P0KMWKTF:
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MN &('[.G:Y[[5"_X[7ZP/V=.USWVJ%_QVOU@UGV#.?\ *S'[&)_2<7[7+?\
MQ+:G^0FLODL_0IE^ Q _9T[7/?:H7_':_6!^SIVN>^U0O^.U^L#V#.?\K,?L
M8G]([7+?_$MJ?Y":R^2S]"[#+\!B!^SIVN>^U0O^.U^L'OTG>MMJK=4A4>F:
MHT>74:@Z342.VZVI3SAG@DEASSGT!9*<3%9681$Q55A/P_\ Y*NN];S6JYUC
M6FUK45SG+(S2(U$2JJJK"HB(E5556B46IE@ \;3J'VFWFE<S;K:'6U%W*0XD
ME(47QI,C'D'Y3QP
M
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M^,SA
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M+=_U*  !!0
M
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M1R$4(V8\ZHR);$3LR<<(RC,NHCYYNI(S@"N_K,W"
M
M            0"\<?_0VB'W>/^T8HGZ$ O''_P!#:(?=X_[1BCI_ W[X]V_S
M\S^Y3)Q;^T+[T-[_ ,Q9_P#%9(F!VT?O)Z>_<*)_5VAWR.AMM'[R>GOW"B?U
M=H=\C0;7^^MH_ILS],\Z?=S[P6-^J[/_ '2"  !YQ[0
M    !I@O07R$&"]!?(-0        !XW?L2_WD_I%1CBF_P#E,]#/NVW_ .Y%
M%N=W[$O]Y/Z148XIO_E,]#/NVW_[D4;/=3[XQOT";^C.T<!7X83_ ,U;Q_N#
MRV?;G^@J%]PZ5_4V1]P?#MS_ $%0ON'2OZFR/N#65UKTKZSC43_$B?EN_P"I
M0  (*
M                                                           =
M;:N:I67HUIY=.H^H%4CT>U+8ILF=59LHB-E+;3#CA-*)717;<O9DD\YYL"O7
MM#U&X>G&ZO/7*IU#;+1W:7I)48T6->2&5TY-UJ<?=8>>;)B+'QV2F.\C7SYZ
M_#FCQY*%==Q<,;<!3+-C39E8./17E1Z?VOA2X<>?VLWE[ NT-)1R4;G+WI[\
MED1F\ W>?P^='-C]JV_'O>W;"U08>J#&I<.<A$6H/36J@ZECPDY*FUNF2N<^
M[IU,S,LX%T3B*Y*UK1*<FI<:;=2'(=&N)/L3V7\0>X=@E&V]TS1QB/,@4^@Z
MG28IN^W,B3&)SDCO/PVS0:'%I9,T2/*-7G\]I2'+CS8T:7%63D>7'9EQW"^Q
M<8DMI=:<3\"D+(R^,4-N/UKEM!W&ZV;;:3M8J%,O/<L]>M-=G5JU8JBG1F&J
MO3W%*E/0T&E[,5*\\RS)*<]<Y,7@]&8M;A:4Z<1+A<-RLQ[+MMNH*41$KMD4
M:$E25X/[)*B,E9R9&1YZ@'(E&KBBJE%1=J4QVXG9X  % .,WA==&LBVZU=5P
MSHU-HU!ITNISYLMU##+;,-A<A25..&E)&M+9I26<J,R(NHY(H\%\)F1%\9]"
M%13V0SQ"ZJ5S6/PZM++K1:==U6JL2/J5=?;MQ56]1XTJ-+6DUNK:YDS(*WD*
M)#J<%G.>@$HBJM$(M]S'&TU^W(<3S3ZT=";\GVCH'1[R*B0HZ(QN1KF)J6S#
MJ'(^LD&:6GVW/*3S$>>A$+3G%UXAU1X?^R5S5*WR3-U*KU!M^%:;*E(0IVI5
M)J+%=D%SI4A1I>DI=P9=Y"EIO#L[:WMNW;;#;-T-NRC5NV+(FKJ&H5VP7FG6
MWZE4T0)DIV:\3B^J9BG_ +-P^N<"7?V4)J%0M1]H&T.Z["KD>OV96YU$+VQ@
M.$[#D*BSJ0RM"EI,T<S3J%(463ZE@C RZ+5=#1$HBZ\Z=.^LPON/7'C6;>]O
MEG\2^[->9M?L2XJM&J5<T[51:>TW3Z++JC3#;)R2SDCAN_9$V1]/.>1=PV"[
MIH.\G:QI=K] 91'^K"E$<Z.ATG3:GPT-L3%*,BZ<SY+5C!%UZ=! YOP;BG['
MA<YD,839UM&UE+?*2^9C['IWF>,\O4=C>QTYFI#G"8H!6T3KUQ,0;F^I)MTR
M))S_  R7X.E)N^1@WNS+)^21=Y<H%7<9JNI14=3!*)2B8=*>HLT$O)XY5??2
M9%\HJ)V9_&6M2OYC2_[K#V9]P^R4_;6IE!LZ"=/*K5 J<9SK6+FIQ3'? E*Y
MN[,;LS/FZ]>O<,+>&Q)W12^.I=+V\:$U3];E18_MW&87$<;0DJ OP;E7 _S8
MR./R_89 (W!RU1>*NI>@O'W;2ZM6;5N.DT.J>TU7J-+J<.FU0FB=.GS),9YJ
M/*)L^CG8.K0YRGW\N!B9L<T,UVT(TODVMKSK.O6BZ7JQ5IK%Q+IC5,4Q#EU&
M1)B1>R:4I)E'C.-Q\YR?9\QEUZY9W;!K=2M6XX%NU'VJKLRE5./2*EV27? :
M@]&>;B2.S/HYV+ZFW.4^A\N#[QB7L;TNW+Z5Z7RJ#N;U7/5B]7*Q5I,>NJID
M>F&S3Y%1?>@Q^QCFI"NPAK:9)7>?)S'W]!C,W
M
M         $ O''_T-HA]WC_M&*)^A +QQ_\ 0VB'W>/^T8HZ?P-^^/=O\_,_
MN4R<6_M"^]#>_P#,6?\ Q62)@=M'[R>GOW"B?U=H=\CH;;1^\GI[]PHG]7:'
M?(T&U_OK:/Z;,_3/.GW<^\%C?JNS_P!T@@  ><>T
M             >-W[$O]Y/Z148XIO_E,]#/NVW_[D46YW/L2_P!Y/Z144XIK
MK7C--#R[5KF;K;7:$;B"-O*8I%S]?(SYN;&?,-GNI]\8WZ!-_1G:. K\+[0^
M:MXOW!Y;3MS_ $%0ON'2OZFR/N#X5N&7M%0CR6#H=*P?IS#9QCTY'W1K*ZUZ
M5]9QJ)_B1/RW?]2@  04
M
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M
M                              (!>./_ *&T0^[Q_P!HQ1/T(!>./_H;
M1#[O'_:,4=/X&_?'NW^?F?W*9.+?VA?>AO?^8L_^*R1,#MH_>3T]^X43^KM#
MOD=#;:/WD]/?N%$_J[0[Y&@VO]];1_39GZ9YT^[GW@L;]5V?^Z00  /./:
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M)-$
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M)ALNUA)9<(C+)<V#ZY CD75R=/+J_GXC-\OA[P  (
M
M          @%XX_^AM$/N\?]HQ1/T(!>./\ Z&T0^[Q_VC%'3^!OWQ[M_GYG
M]RF3BW]H7WH;W_F+/_BLD3 [:/WD]/?N%$_J[0[Y'0VVC]Y/3W[A1/ZNT.^1
MH-K_ 'UM']-F?IGG3[N?>"QOU79_[I!   \X]H
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MCEW%\1?H'J7F^_D_^<9]%#-YX:??,O3^F0OW6 :@ #P3EH
M
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M.@Q\F]>K[#-L
M                                           ! +QQ_P#0VB'W>/\
MM&*)^A +QQS_ .1M$2__ '\9_P#_ $8HZ?P-^^/=O\_,_N4R<6_M#>]#>[\Q
M9_\ %)(F!VT?O)Z>_<*)_5VAWR.A=M!YT3T]^X<0NO3_ ,W:_P#AU'?0T&V/
MOK:/Z;,_3/.GW<^\-C?JN0_=((  'G'M
M                    !B)OD_@OZL_<*1_0NC+L8A[Y#_\ %?U9^"A2/Z!T
M?JDO]\E?TB#_ -;3V;N_?VQ_UG(?O4$AS]CN_O8:P_\ K [_ &I+%D<NXOB+
M] K<>QWOWL-83R6/J@<_/4YABR.7<7Q%^@>I>;[^3_YQGT4,WGAI]\R]/Z9"
M_=8!J  /!.6@
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M4I$-,K)L,=)*6DO_ &)_9]Y]X%=_69P !
M
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MZ@/V2W%F]R<G\7@?J [CEL=\]R/.*7R^3SWPJ^Z&L#O+X1O-68R^5SWQI9I
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MFD!66_9+<6;W)R?Q>!^H#]DMQ9O<G)_%X'Z@.XY;'?/<CSBE\OD\]\*ONAK
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M3T  <O.L
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MDZL>O?Q&;0
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M8^*Z,^7DY6$L>/HQ(SXBM;34  ::;*
M
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MD!]A%N.VV13850?B2S.([%BJ7S2FG3[3D/G^RR9'D#'MWITF90
M
M
M
M
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MQ^F(]LFJ@^W4/VE]MM:C\-2[Y6#R?4CP!4S,
M
M
M
M
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MP69(F-^V2Z@^NH9<D+6LC\--[*<X(^A 8^3JZ.7=/&9F@
M
M
M
M
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MC$MUTN3G(D_8D1$6 *F9(
M
M
M
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M+F&GLG7E(Y"<+E(N7!8("O)_+D]?\C-<
M
M
M
M
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M=?LZ=UP<3G>@X%X_?A?>_P"N?DG7?5QY3X^7"^)LG/V02#S_ -6FVZNIXO\
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M
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MC39CT';:2QGX5&?RGD;AM2HEI2I)D:5$1D:3)23(^I&2BZ&1EU(RZ#<!
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MH2F8:E*Z=R2,\]/..W#?92T<A3K26N3G-U3J29)O'-SFX9]F2>7RN;.,9/.
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M;:0@BSS+<6:4)219/)F1&74=51-==()UR.6G$U*LV1<+:R;53&[BI"WNT/\
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MR/!D8W@
M
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M(8J3]9<ADZ2B(TE5'3R@E=,&2B/IWYR+$Y=Q?$0&)R4<J9KJU&H  $
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M[B^(OT 8WHB.<B:JFH  %0
M
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MF:EDFE2YLHD/3%J+)G_SGG,CSZ<=.@R[Y"QC*L?&8W@2YZNP6FNN"4Q76H
M J                P  0Q<97A@SN(]HS1:;:-\5BQ-4=/'55&QZQ2Y<R.D
MYGA#<M3;[4>2PVZ3BVDH_;N8B)1]Q"O[<?#"XWNZ2Q;.VD[B=2G*5MYH<R+#
MK%>-ND2GZQ1Z?*9<80^VP[X69K99)&5*,RYLGYQ>>,B46#_,>!H:",L95^$?
M7XP+(]41$PP6J53%/&0YZF\(C2.\^&LSL ISK%/HM'H2$T.N''4IR-6VS*<X
M^ELE<Q^$3T$9DH\)/!ETSFM6O@\<:&X=*:7L0N'4I:=H]-KJ4IG]C2C<50T5
M8IA-FVE[PLR4RGDZJ,R(Q?AP6,>8;>0L8RK'^\8!'JFQ<=+%-2[4,2]D.U*U
M-F.V[3S0"T%MO4VSJ<2'Y:6NR5*FR4H=F+463/K(YSZG\(RW  *@
M
M
M
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M),C[C)1=#(RZD9=#+N&X
M
M
M
M                                                !QN[/^CEP_\
MJ[6_[/?'Y\W"(_\ +^ZL?=VJ_P!4F#]!F[>EN7$?_P##M;[ON>^/S+]K&\K2
MG8YQF-9M;M8'ZE!M"GW#4&Y$AFF3G\&\W+83RDPRX:LK474B,O.(Y:Y+_+ZC
M)#151Z)BJM_F?HF;RK)MW4';5J_;=T-1I%)DVG677$2VT/-H<C4^4ZU@G242
M3YTEC!%@Q2V]BM5FOT37+>G8MO5!Q$(ZI5(U)01GX.B8ARJII[A)5^UI2R^3
M2NN$].I^<96[]/9,>W'4S;U>>F>VBF7'=NI%]PW*13T1:-6VEQ%2S5&/F2N'
MRK[9#O?DB3DS^+Y? FV<Z[[4]CNYW==7+0FTS5/5VB5*NV;!DH-%1@FVBH//
MO=@M).&OLWDN$E:"ZXY<B24:K8;M+#2HB(N%<46O5MU'5.K/"RU;U5UHU;U>
MXB>^4K&H3M0FR++H]+K[*'O 4KD$RU[7T2KMNH4RSV)86R1J,L]YC"_A.:VW
M'MWXN$+;/ION K^JFW.\VJW1G9M454%)J_/2'V6E-)GR'WHIQ9#N24@RYS22
MB[B,=3\,FY=D^X+5?7J^^*[J7>55OND7%556M;%3J%V4R,\;,Z:DX[<.%(;9
M(D)0VA!=D9+Z8+!CS;,KBV\2>//I]4]%Z%5+;T-?J4]BPV*C"J;).E'IW9/K
M[6H--O*);I)4E3AGS$9&1GDP+TIIM6KJ-K@B4Y%317%?J34AG78FI>H?#7X^
M$_3R]+QN*IZ*ZMU@G:5&JM2GN4\G)T(WDHC>%/.M)Y)$HBPV1%DBR7F'=_LE
M3=+?.IFNFU_9KH;<M8HE>N:O07[G*@SI3$MRGSI5/GH4X<1QM9)*(ZH^\B-.
M?,.Y?90^V&H-6;HWO5TXI3C5QZ,3F:E6:G#;/MW4R)41,(W5H+F)/(@BRHS(
MBSYNZ,C@U4N^>*)Q1F]U^KM->JE*T@IE%B2F7R[6(A94)NGQ5)61&TE7-'29
M\I9YN\"&THD3XJ+7;I)2F'CZO$=L\=?4W6?:Q9.RG:1!O.[+0T1ET9I6H]ZQ
M/;.4_66I<2G3)2Y,UE9RXZHBW7T]9!&LRP0ZEM;9'M%UA@6!<VP?B*5FB:RP
M54R;-AUNH5AMF34C7&=ELK37:LB.1-NDZ@R-/*KT";OCD;V=M6CMY:>Z%[NM
MH\G5322Z%*IT/49F5-;3;D9*64.OY@Q'76DM<W1)NIYNS,B[Q6?XAFV'A&V/
MI!(UJV5Z^W! U$J"*=-M73>WV;G;EO5*0XTI<3MV7R4V<1Y?*9J0DE\OQ@0W
MC(B<9M:I5$JBK5->S%<N1.1#]%7:#;^J5K[?=/J#K+>\;434"F4Q$>L7=#*(
M4>K)0E*(SB/ EN1_)9(DJ-"U&?>9Y,9,B"?V/54]PE4X=6ETG7DZLY439G^T
M;];[7VT=@E-5V)O^$_YU^X=F9=L?7.2\YG.P7<6>_P X&)4HJI6M.5   !
M
M
M
M
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M "
M
L                                                       __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>nt10002526x6_linechart13.jpg
<TEXT>
begin 644 nt10002526x6_linechart13.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( A(%+ ,!(@ "$0$#$0'_Q  ?  $  @$$ P$
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M8[.QTTFLRNS<NFZAI6N$W)O)FEK2K_PDF*JABIF;EZ350P "BH;L8+\(F?\
M%'T27(J?0-:V2VPE"U6U[9!M14T"0)G!$[[R#F6/9RF4QA,4?+D:K 4<"(B
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MX^CC[!BJ!)-;->:.?"-LU-K:E<IUA659U=*Y=4RZAGH2,JE:+-%5U?, H14
M(N)@*H;L0"E (SL\,/5SJ7N7=JY]H+XS$EQ9)3\MIF9TK<MN5FR*^&=2\LP>
M-E9<U QD?*&4!L!E1#?M Q?A"FO7\"1^K0_>*G4A&PA]X? 0$0[#Z#],;@$!
MX#O]L*I6L(TR CCU^V&X,XSS"E:PC3(9QZ_;#(9QZ_;"E:PC3(9QZ_;#( ./
M7[84K6$:"8 ''K]0P$0#@>_VPI6L(T$0#O\ ZX"(!WA2M81H(@'> B =_P!
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M*)D,<!(4#% 0$,1E=(];0VO\-FD]1M+6=?MDI3*6TL86Y1!P#I%JU43EA2B
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M"85^1:_Y*V/_ "7KEK>O_.?OGY5Y_7[HOYHN_P!QISRQZ7C%Q'^MMQ)_NA\
M/[H'B>'RX\AR%B_O3X<]5%C='Q*ZHH'7-)=)K:TDUF<FFBB!#5LGYKR2/6:)
MN!$=J I>R8XE_&ASQWXCU[[>)C5-H]85)Z:65HYI/)542C0BM7(BY\LU!PV1
M7$1 B!DQVBJ)1R? "'..(E6=V_HU[/TZF=4U*7$^3$!)-E&38[TN"@7(.#)"
ML @' 8.' ?1&DPM[1<TG2-0/Z9E#N<M\"C,UF+51VGM "AM7.D*I=H  !@X<
M!%KMKR%29(;R -J<NK4IA7D65>!;4E/B6[15]H5@*'F#I:=[ /Q](.?]%&'[
M"Y,Z+KF-0.G<S';RS];KDU[8SEU"DQ<W"DM;BIBJ*5>QV]Q7..E*T>\5&ISQ
M,JKL-J8M_8F76BFE22^L3LRN*D0,Y!!AYI!NJ(F!- Z?L=82\F+R$>35[XE]
M5:;+W6KM5*[1S6K&=P3L"N9TU%R"4L!XFV.(J FB<OL=<0')B\EY]8E2FMO:
M+G4U;3J:TS*7\T:"46S]RQ:JN4=H  ;%E$C*%P !C!B]@A.K>T94#]I,YS34
MIF3]CM%H[=L6JRS<2@ %Z2BB1CI[0*7 E$N,  11^UY$M-P#60AI4B='?@GR
M#*_)1&^'CQ""1XY>TK[5?O(V- ZI:>H'1.(]A:[GT65<FK+BMYM65M#+;E'^
MM.1S4."U9&%(;)MWLM2D*\@QR9D^'I9'(U%UK:\2:I]*MPK.49*+336LT+FF
M8%=/VGFNG*!>%:&'K=%!0/8%P8!W"4?8Y]<]^Z@_$(LSIIGUI*;N<[-*YG=%
MLV4;I]-<XL%G*#90B)P(7VQ$[@"<B&T0YP,9E3ZW]&U*Y9/)[3<IFKF7;19+
MO&35PHVV;=G1,LD<Q-NT,;,8P&/HC2\2*WVC.22>E;ZZH:?%^RH)RF>5J)JO
M"[%3K(I([2M,[03.4F  N!P6/&YIOUMCWFX-WB!X97$>B)N3/@Q+;%9X^>\5
MYO:W?%1R4E2@.!&O2LK@+_1O-KSTPPZX],\O1,:BY';<EE81<S=,BSF_W0.'
M%/(6R>$1('LZ06([S+)5YIODI>CVJ4J23EA4$IETYEJP.&$S:(/6BP?\8BX2
M*L0<>GL'+P.(Y:,?=+]T[=WDLK1]>6M X41,&AD)("G5W%;L]J  /6 %. *'
MO!F,@HVF,\B1'8?0M#B'F6W4N-'DVM+B H+;5\4*!VD_%)!KGZ^6R39;S=K/
M,B2X$NUW&9;Y,*>WX4Z(]$D.,.1IC7^3DLJ04/H_HN)4/A2-HF /I^J.L;I7
MCMQ9JGW-37%JF6TW*FJ9U3J.W*)%CE( Y!) 5"JJB&.Q"C],5Y-77CT2"5#-
MZ/TT24:A>%!5LG69E!0(U4#)15(T<I[5  V>W'&?@$82^Y38\<:+ETG-,KT2
MB,D^)*=[; ;83M9W_G$!(^)%2MTA^CWU9ZX7)$'I]B5PN<8.)1+O;Z#"L%O3
MR2E:YEVDA$1' *Y>$A;DA8!#;*U=JLQ).VZJJB)'#<ZJ6.HDFLF=5//8%$RF
M$Y,^FX"_5'LQ6@\'O6)7%?'U'7=U'W".]EDK/(EU'CH@)-94185  A$R#T\8
MP7V0#(AD>\3NTYJ>LI5-N9E=625JT>T+*0$7\]*7"+< 4%,=P9$?? 0X'ZN8
MI8LEM]]MT>X-J$426Y#[<>2ZTE\1V'EM%Y: HZ0>'(D;2C>E*W7IU?Z#9ITB
MSB]83.C/7]VPRK):IMYLD"<]9UWN\VN'<F;5'DK83XDK4L---*2AU_CS0UQ(
MK(*$8^T?J@LE7=#3BXU+UJSF=(2(##-)NF @DUVG,0VX!'/O$,'V<=X4#J@L
ME<RE9]6E%UJSG%.4T!C3J8I%$",@(8Y3"<!R/=,P?9QS&63<(*RT$S(RB\TI
MYD)?;/BLH^^ZWI7OMI^*D[ ^=1J_AN6QDSUR,9OK"+7.8MER4[:IK:8%QE$"
M-!F%3($:6^2 TP[P=<)TE)-9!0CH"VVIVREV9)4E04%6C.>RFD@.:?NT0P67
M@F)P-U $?04S!]D:VNU-65O&UJ=Y;NM&=0MZ/ZGX0J-PXEX)=3>*F1'W>D</
MIV^L51/A.%D-RXRS)2M4?B\VKQDM[\136E'F$:/,IWQ^.J2<.RR$+JJ9C=\B
MBQNQ6+R9%KFM"U/3BD0FK@5LI\HY**TB.A_@7BH!L*)%=_0C'^UNIVR=Y'52
M,[=5JRJ)Q276^7TF^<L.AU!5ZG(^Z"2F>P<1X[:ZH[(7:G50T_0-;LY]-:7%
M8)VT0#VF0MP4%7?R.=H)*"./A]4$3X+@9*)<98DJ6F.4O-D/*;_G UI7VA1_
M3"=\?CJJR,-RV&JZHE8U?8RK&U$?O*7[5.:-J9G\?).W +83Y-N7S3Y=;_AI
M>V/#*MC>0D(QWH#5/8VYU4SNC:*KAE.JBIX50FTO1 =[442G,J!OCL!,XCCX
M"'T1I1FJFQE?UQ-+=4I7+*:U?)A5+,92F ]1 4BF.H CV':4AA''; YBB;C
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M3L:0?>[^E&L+R]Y45#6,7YQ<ZUN7N$E%IG*5*L[()=ND<!@EVWM@$KEHVPD
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M1/#CMWI+E5W)72L\>3,EV2N2S<[A1T/EP<>8W=,%E3B7 .#![ E[!VXQ)+@
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MBH=UTT?.)+)*  G5,0W"QA#!0QCB).\ '8 C7 ?"*-8U8V1$2W;F$B#*=FQ
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M4";1W!@2"/?Z8M&SMV>7R6;OTD>NHRE;]VFA@!ZQVS558B6,<]0Q )C YSC
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M^S](1NC:?W1^S](0I52+QP?XS?PT?RW67\VWBV'3W\#R?\BRK]32BIYXX/\
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M3=YT![YZ'];CWR.(4O2NO1+PZ9Q(9R[6-JN,G^\'&YIU .+TPB("!O+_ -;
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M)> ^F(V=9])>(=-K_P!I7NGYTNG;%LI+_P -P3,S*7:5)J#K<"P]0<G!?@O
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MQ(9IDYBF:=?=UQ !'!7'N?9Z1ZVM^E/$ F]E[)-=.KE9.X#,C4+B"F=H0QS
MJUZV16'9[H+".W/^L$K(78QN@%DN[_LUB(^@LQ@L3C)"26H?O#Q'6.7VR3QX
M:/K5+!T4@WQKI^ZOJKTVM1SF\9#:I#=SO2V',2385.I;N&3#P2(,&\>%RM;P
M*_'#B"0G=3*G73(4#&42*!NQC*$ OV"(@ _8,#+IE(!Q42*4>QC*$ OV&$0
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M1.NL? <CM33,. [XB&RI?'5T&4U4,XIUY<0QGDF>+L7>V7/APY;JG26(&""
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ML$I8_4>D'L9H1JJ9P7_K(@</MB(C0K=O0W6U[;FR?3O2*<DK^7S,Z=6/2@[
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MS^EIE77G*E</VRJ<GGS%\J=%N^<'8M]K=)81!L4N[Z1P$6F+?2AY(:$HJ23
MNQ_)J5D,L?$R [7;&5-6S@H"' X62.&0X^'$;DZ^HA<X)-ZTI%=?..DG4DH.
M?(]@ A'AC9'X8Y&/JD5DUTRJ)'(H0X )5$CE43. @')3E$2F ?3 C"A)/K^/
M]=?*UY4<AI.D*CJ.IM@R*2RE_,9F4Z77*HV:-55U4A1 IQ4ZB:9B; *(CG&.
M8I>2W6+I_P#$EUF21&XE3JVBTLV+JY9G0]NT*(=)I7)G"[_HKJE<MV;=:6^1
MFZ!5Q.<@@MNW";;S%UBH:?E53R=](YTT*]EDQ1,@\:F$0*ND8HE,0W]Z8HB
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MJB*9B.TT#J@)2E >FHB.U0/7(1"8&SZ_B3^%=,Z"1H#\ /X_C5?,VDIFJ_%
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MYPD1=1ZFDT%1H'4 4E%SI*@;?P(E^D "()]?H?\ RW=*_E64?G8MLQ=0D/\
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MJYHY.,/]6.KRU&F&D'CZMINC\M3!DZ0E$B((F</5#I&3$!Z>XZ0%$P"&XN1
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M-RET\G7 #D'/NAS"@&_ZOZ_2KCRBI$@ 3G(0!]3G*0/O,(!!-5-7W#IG_P
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MJI*J_P#U9#&/]D1":$M(5@;'7MN96-M+O)UQ4%1311U-9(5=1096L=58QDQ
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MP$=MP/@0.'/H$=AZ\[[UMJRO))]$FGYTX48JOTT[EU!+E#&0;MDC)NBI&6(
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MWM)^!T:H?:D*]\:/3I)JCN/=NJIA35%MYL]$LTQ+W!2LU'RB;+"*([@ 2"F
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M^*G:#2!+UZ5D9T[C7FF93-*>H61G4>+'?K!TTA578E7*CTS'(H(*@'; XYB
MRNO#G\17Q+EV=_+S3I6CTIBH=[2%)N46:HR=FJ;YK E,F)3"CTAR<A!R';,3
M;TJLZK!>;;F>13(]ALC0DMQ'IZE-OW%Q^,ZSJ'' +SC;?B!3CW$-=M!1/I!7
M5N\(R.RW+"L;B2+_ 'QQ4-Z4S;TAQBWM,2V)&IK_ ';0XX&BE#(//OM02./*
MPKI_M?IM=Z6J5<S&46W/-!MZ]4,9PM3X.Q<C)#"(FWF!85"FY#=[0&[\YBIK
MX?.DFU6K#7E<JWMQFZ[JBI74LQ,66RUZX9)ND0<.U2)E78J)^P&P #D2[1Q&
M-EV--^H^RFIZ5Z29I=2I#U*\609(.$9H\3;ID<HD/M*@DZ!#8*9P*)0P E],
M19 \*KPGKUZ0K\.[L5[5'RY+)NT;NMQD$2**"X9"/M' YSB8#*!D1$><_&)#
MD,P>GV/9/<&<W$R;EMK3,L*6VY+#P;\PIP.QG%.._>#O%)^S5[I(J.(K\[J+
MD6+6][!/(0L/NGDKZMQ;3[:W/#8;6F0A##(''P%%25%:2%$$_!4U%BM$6F;3
MPQ(QM?:Z1RDB92D\P_;(39T82<;^N]255W"(9R!L\]XRL;LV[5($6Z"#=(,
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M%]@AN\?,:2]=MAM9DMJ::V9FDY?,J32:KS=6<T_-9"!$G91.BHE\J-T!6+L
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MI*D3 ':* F(8HA[102-@V/B'H%TS3E.;).*$84_8Y[*7-,4\W1:@26%3*)#
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M#F.@#SK6[XU%7I-94C.+$:1BN4A?JE,87$Y9 8HG2(;]ZO\ :H<ABY*)@VF
M?=BPYI'T361T>4.TI&UU,,6SKH)!-9^X2!U,IDY -RBXNG('<E$ZHG.(=3G.
M!B/$VRP8"E,B_)CW[*@ IC'VW [;+2YH$+O+S9U(D(/<06E<!K3RR"!4DJNF
M0=05&/CZI%@Q-7NOY"M"F[E=4=MMVAE8W'CK1L>=='(\@4(!2I)P T#^$31]
MD9DG>S4,_4N[?R<"69N9O/.JJA)7B_SBJ:3-PHX:FV]04P$I"@&P!#M$W2#1
M!LDDB@DF@BB4"I(H$!)%,I0 "E*F0 (   8X (]@  .T:QH=\O\ =<BFKGW6
M4N0\0$MH[(8CM)^XQ&91IMAE &DMMI 'KW.S4@6+'K5CL)$&UQ4,-CWG'/OO
MR'-#D])?5MQ]U6NZUDGX)"4@ 4E=?I0_=NZ5#GF:RGU^+)L/_P"*+J$@  E,
MI'GF42SU'T:)>G]/OBEAK]_CNZ5_*LH_46T74)#_  1*/R1+?U1&)*ZG?\@=
M-1\L18 _VVZC'I7_ ,O]2O\ 6N3_ -=ZN9A"$0Y4TTA"$*4B)KQL/XO*\_(?
MUO+ ^O\ ?9>WW1*G.9HVDLHFDX=B(-95+W<P<"!1,/19MU'"F"E 3"(D(.
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M"$*4A"$*4C'C5/:ZJ;R62JZWU&U M3,_G:3<C.;MP$54.DKO.4N#%$.H'LY
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M"B[40*8PDX* >SD/2)L9?*V$J:),9:R:R]H@F5)%LR02:H)D(4"E*":!2$X
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M!*8KLO.#-%$%5A42$P)G$@ (=/(B(&$0''QZ#:5E)-3?B5R2KK0RY!E)'DU
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M3_L@+^P0K#_I&'Z\G'TO@)_V %M_KF7Z\,?-?L@+^P1K#_I&'Z^G'TO@*?V
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M4SF4P40SLQWBT73K]U-)!))D^9_)[Q_*V#QVPW;O).'#5-99KNP&[H*&,ED
M#W>T5\K.^/?ION!<VG*4JZU\RMW1E831>6TK7\TIR8$E[]1)?H)**>8EJ*30
MJZHI@D994H'W@)1&+#4O>M9BQ9OV*I%F;UHW>-%4\;%6SE(BR"A,<;3)'*8
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ME'6VD:21491+45'2A$@(=9X[2(NZ%0<;C""YC^\(_'UY[\CEHG9_#T'Y"NZ
M-#\3W/YFD(0BE5I"$(4I"$(4I"$(4I"/2F$Q8RIFX?S%VW8LVR9E%W3I9-!%
M(A2B83'45,4A> SR(9C']75;I_2552/=*F0.DH9,Y0FC$<'(82F+_7']J("$
M?0Q$DR>7EX[SX3H*+33CG'?IO@E6M_#?K7RR)L2)Q$F2PP5[XAYYMHJUK>@X
MI.];&]>GQK(V$=!R74S8R?S1I*)5<NFW<P>&V-FQ9HQW*F[;2_/]Q$0 /B/
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M#5J=7:0 #<*"*8C@!QR(QV)'A0]PG_1I?]P(\T<ZN.N/+*W7%N+( *UJ4M1
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MI"$(4I"$(4I"$(4I"$(4I"$(4I"$(4I"$(4KBIZY79R2<.VJ?6<M97,'+=(
M 1470:*JI)@ \#O4*4N![YQ$-^@75GJ0O5?2Z%'W6MLI2E-4[-%&TFF1F"+8
M'B +."E4!5-LD90#%(4V1,;OW]8F1GCM5A)9N^02ZZS.5OW2*.,]55NT5633
MP/?><@%QZYB'705K7O#?^^=T:#KJT)Z'DM*311I+9P:7)M F*155R@H"Q6B
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MRR329FBV;H-R 0HG(F4BJIL  B94Y1..?41C&/7M15RZZTY5Q*+85D6D)X#
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M,%P*N[.X5'*BF'(J" G.;&X<<8",.O"J\/ECI&MD-95PD6<WQN00L[K2H'H
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MD(0A2D(0A2D(0A2N,G;PTODTW?D1\P=C+'[PB&,]8S9JJL5+'KU!(!,<YSC
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M9'YJV:_'B]*MR[Q=%6A#C=J5<)BK<AW^<1!,APQ4KV2>26> .R>XK03 7O\
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ME#.00'[>QT[AVF'"LLC92NZN1BVJY2D%*0IUH,J3'0I*@UR"DD*!)^R(4"%
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MCMND  EY<Y"F1%,"@!03%,2[0+[(!@ XA52-? C\_P#@*]B$(0JE:" #W@
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M7K$-@#@!> &.O_'0T3Z<M,-FK;S.SE ,Z7F;QP1H^>)KJKG=%1<-D14,"PG
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M_P"HZU_Y34_76T60J]KRE[:TK-ZSK&9IRBG9(@9Q,I@J&XC=( $1$0#OD X
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M$FZ93!F9#(OL)0?LL"\0RPJSQ%2D*XJ\1L!(4C;3@+QV0ILG]$PHY#T^C Y
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MYHHF("04G*!%B%#' ;2G N/H^_G(G".A+3#+:%%:$--H2M1Y%24H"4J)^)(
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M(=R\1K@]=BH1>&]K3M*5D.$ <?=.^Z>Q(4(^/ZHNTEAD?)N<  CP1[G@,_\
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M/.<VFB$@MMJY;0@CL4I('X5,.-9+D+?T?<PE-WRZHDP,GLL&$^F?)#T2&IE
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M9469N*7J1E,9L!G"*'2;(S1FY.;YTQ=V$DCC@.>,=\Q+\ 8^(Y^,:PIOOO\
MX5UVI1ZLWMLWHU^N=FLXHYA(7:R1A [=<LI(R7,0Q! <IGW" E$!R&0&(V[;
M^&!3UL[*Z@;5M*_G%2EO.V=+"O,UGKL9<\(+MPU31*\=*[2BNL4@[!*!0#D!
M"):(TP'PQ]7$*;(_CY54VTP>&[JV:7&TMVTKFV@VRH72C4=>S']N&7SAHLM<
MEI5LP5?-".Y8T.19/R2>Q O7.IG=Q@,QFMX@^D34C*M2MK-66EZC1NG4$DI^
MHZ8JZC3OFTJ%TE/9(-/I/RO7)A /*IJF=B0I<G$HD'TB?+'TB..W_G\8U$/4
M!Q^C[0A5>1W\/CV^'?UW48?A8:1JRTH:99;2%R3%_#V?3B=3^I&0@F<C!2;S
M=>:$:;TS&35\OY@4MP![0%W>L=-L]'MY6WBE.]2Q9*FG:A5 A$WY%FY0W?)/
ME3"#<H@H&5N!]GGN,30@&/\ SYA"J;.R?GL?KK!^\U^+J4#J>L%:FF*&6GU"
M7)-4 U94I%@(E3WR<W!5J*B>PV_KGR <EQB,MZRD):JI&IZ;5*&RH*=F\IR/
M/3/,)<X:$-P(9$AEMP8'G 9X$8Y=:3RUP^;S)9FW5?-=WEG*B1#JH[PP;I',
M43)[@[[!#/K')0JE5'Z*\-?6NYG=L=)52T>5AIQM97%0U4UNYYYDI\I$G4_-
M41$?D<AO,)=)80;;L^U[V [#8]N?-;XT9,[3T]:FBB5;3A6:4KK2:F?MV0RE
MO+F[=LV6*BM[2W6 AS8)[L918 >!S]X_TX](UA52=_+_ '_/\ZBF\6#3!=/5
M-IJ1H.U$E0?U@I4E'31PB)VR"@(2R>,7[[+A42@;I)(J_P!L.<<=XS+K^CJY
M<:<D*/I1) U;2^B9#+V[5PF@X16F,KE+9%9H<BX&0$%5D3(B8P"4-V8R.A"J
M?A_'P_LJM19W23JYOCJVTWW;O78]GI^E6FU]6'GIK(YC+54;E(S\ATFB[EE*
M0;D0%L4A#@"I3B(G^.8L>S9DLXE,Q:(!N57E+YFESW55:'12Y'^480[]LQS.
M/I'CZ?T_&-854G?X:[=JJYS'PP-0TTM3KAII_1$M=3N]%<VSG-#BJ:6G6=R^
MG:E3F$U,5P8!,AL:%$1*8Q>H'&!S&65&:%+NTKKYLA>MA2[*6VTHFETI=.W3
M,S)ML>?@TWEZ@*I(@11P/FTSAD0, =P'GB=J$*KR/[?ZP!^ZH!O'2M^5U;6U
M5WV,^7:5%:NH4G,FIT):K,&51>?FK7JHO VG;)%(0F ,X(8"B;<7&(PL\+BK
MZWNUXFNHBY4^H8M+BI3E"(J,V+9,DN2,TIDK=(Z3QJBFU6%T)0,<I!'I&-@W
M(#%H:Y]JJ$N_2[NC[@2!M4,A>;>NR6 "B.TVXHIJ@&],0, #DHASS'RUG-/-
MI+$M'K2V5(M:=+,-GG%\^9>.>F(],%7:H&<'*3."E,H(%+P&(4W[NOC\/P&P
M?VBL$+%Z>;H'U0:Q+VU_30,$J_D;656Q,HNDL *$DSN7+&2 ,](%#&(&#;??
MR.0#F%33[X.^J+3;=26ZOJ.I\'=[FM;SA[.:2=O&KME.)--YVJ0KAN#DZC%B
M9K*UA7,"*93*&# ^U%P@  .P &?@&(UA3D1O\= _B!\*KN^-E3DTE[33!J :
MS$Z=<VF75<,Z*-+O/RVH'LY\BE,6[M0Q%&2!62O4 AETQ+D,DQB.CO![JRM;
ML>(/K2NC4](%II2<RNVA%6[-HFA+4O*R0J)1;.&R*;1QO$,J%1$>F8<&QB+(
M-U[-V[O33:M*W&IQO44E4P(ME1Z:A! P& 4EBAU$QW  Y((9QR,<;9^PMK+&
M2IQ*+:4HUIQJ[V^:.4>N\= 01$@.'B@"NL!,^P"BAMH<!C$*;[:_4?T@_NKN
M%,,%^T1^\1[QOA"%6TA"$*4A"$*4A"$*4A"$*4A"$*4A"$*4A"$*4A"$*4A"
M$*4A"$*4A"$*5QLY!D,HFH3(<2X9:^!^//#(6JH.AXYX0ZG;F(EM#\F\.]A>
MRYJ^EY\1S<U69&&N$R^=R1Z"BV0'S ]/('ZON_GB6B=)LUI--DI@;:P5EC]-
M\;^2S.U5*Y-QS[*(G'CGB(C-"]MM!5*7MN=---M3$FUQ'\S,I6#0HO,H/!47
M$Q?GSF)[PGQM  X^V-:O 6;OCY2U9EI$B3R7<% 3VP61HVH?TG2>SP[_ &?>
MIUZ:.QT=->LR';AU.BNN6>PAB+AK*G,/G$7-14CJ&M*5!NWMC2[65%(,PJ&]
M]C,(7&/9[9'^G]/TQNC:4  /9[?ZXW1LM056P_N_;S_3ZXK(^,H5M(=6>D^J
M[BH'5M:SFTT-,#KD.JP1'<V AG 8,F4 5#.#X <19QC&35!I0M)JQH92B+JR
M).:LRE$&+K>HDX8'$P'$R*J(E5+N, ".TP<A&MY7:)%[LK\*(MI,H.QI,</[
M\!QV)(:D):?T"?"=\/@H@=M[T:G3Z.74RS=)NJEGRO(XTZ18%V^_6&\+M(;]
MKPH&1V:999%QM1=6VWYZ B9YI@*6CF6R@+25<A6*\0&Z=.ZSM6&FNP5FW+>?
MTA32C!51"3MRDEZ:1$&+I4JB3<H(EP"8[MP9'USWC)[QHJJLM)+'VPL-3@2=
MQ=*7.:2;2^52I! 9@Q53=2T7'4\L3>4Q]IA$#??G(Q)]I-\+;3CI/J=W6M'R
M8TRJM4IR,IN^7<NE6!#D,D8$_-'5'\6;;P(8P'$?'+^$S92?:J)UJ:KIZYJV
M93!VU>2ZGWBCH6LM6;$ I3$!14Z(Y,!3@ )@''UQH;N*9,_;KR7F;:NZY3,8
M9G*#RE1[3:V&@VWY<J0%/NHX[2D)2 I85\#78,#Z1?06T9KTJ:M-RSICIY]'
MG&+M=<0:7;&&;UU%ZAW>X>=E^UT,S%QK5 D*=2'GW7'EK98=;[>*G>;6E25S
M>3V!M@PG::B4Q1IN6BNFJ)A4*!F:!B ;=S[H@.![!&1<>NU:H,F[=HV3*DW:
MH)-D$R@ %310(5-,A0#T*0I2_4 1[$2U'9$=AE@$J#+3;7(^JO#0$[/YZW7Y
MO7NY*O-YNMW4VEE5SN,V>IE'W6C+D./EM/X(\3B/RI&'VMV^-X-/UB:BN+9*
MTBUYZZE8M0EU$(3$LL4F ++E35$'1BG G23$5!XSCB,P8Q!UL2O4C.+&5"RT
MM3-"4W8.9M\C/'+1F\2( +AU\HO@%N;*60]KX\9&/:L6/XW4 \T\;OQ!Z)?T
MJM=+P\GU#TK/YS+96ZJ-U6Z*K>7%?/4&8JJ@*)2AM,MP!CE$PA@(M,TO-5I[
M3=/SM=$K=:<266315 BA52('?LD71DBJ%X4!,5=@&#@<9BJ76NA7QE=6"TCM
MEJ%O=+)'9US.Y/-*G;-*6IX'*Y),_;S!%))VR CI#J*([1,B;G=SD(M24+3)
M*.H^F*6(N=R%/R.62H7!Q$3+G8LD6IU1W")@WF2WX'MG'I"KE:[:UOXZ)(_/
MO^ZOK80A"K:0A"%*0A"%*1M/[H_9^D(W1M/[H_9^D(4JI%XX/\9OX:/Y;K+^
M;;Q;#I[^!Y/^195^II14\\<'^,W\-'\MUE_-MXMAT]_ \G_(LJ_4THH/4_G^
MX5<?NI_3^VN<A"$5JVD(0A2D(0A2D(0A2D(0A2G;_P#%G\P<QMW!\#?Y!_\
M^V,0=:]X;F65LK.ZPM;2J]35(UZ/10;F^<1*=4"&/T]A]P 4=P\< 'T17SF_
MB]ZKY [!A.9(5@]W !FZAFHG(8P\$/D@"7D<>T =O2)2PCI#EF?V]RXV!5J4
MRW)<C%J5<F&))6VAM:E".2IP-Z< "U) )!UNH)ZF_2%P/I1=6+1E*;XE]^*U
M+2]"M#TF($/+6A"#)Y(;+I+:MH05<1K9Y$"K9(G*'?(?64P?I  B-/7GKB8:
M?I&C05!D+4EWJR*I+)#)6!P6<-%5L(&55!,JFP2E5!0-X% -O>(@9)XQ&I"7
M//)5%1YIL>>HJ,I.U060ZH.7*8H(JE(BF)S;%5"'["  '/$9EZ1-,X4R$YUK
M:R9DDI5[PJLYE+2>+$Z,@:X4.DFFW5.*1S*MQ3*&$P-G'&1"-N3TK3TW4K).
MI9@O6^(E*[-9+?.:DNY)<NY1%Y-GDQ!BK2E=P>4D>X4M-\EK[1ZOKNYUD2UA
MO1A%S8NT]Q3>19+=+:]$CX;9CX8<G!+@4W)N<UM:V[5'2LGQ.3SG!+==F:)]
M(C6STLFVJ/5 ]0=W/G:2D\4<SQ4ADZ;;&!18A4RKG,@<QVQP*   & Q0#&>(
MQEOOJ1O-XA]S'FG72VL_D]GY>^395S<!LF=)%\V*?)DT.J5,P$*!%41%!7 @
M/W\/<2Z-\?%&N8[M+9?Y1I+3;3\P2;5/5R)3HISIJBH&$D"F!!8";T3HY0./
MLF^&(G!TZZ;;;:;J%EM%6_DC>7HMVZ0/WP$ [M^ZP4RRRK@X=<1,MO/[1S8S
MB(BR?)KGE=W?O%U<2IYSBW'C-CA$@1&AQCPXC(]UF.PV EMM('Q6HE:B3T-@
M^$V3 [!%L%C94EAKD[,FOD.3KK/=(5*N%PD$!R1+DN;6XXL]AIM(2A"4B%F=
MZHM/?A@.9EISIRVSRH:K-*%6]3U:1)YUWSZ8,3'$XKG;JF.4%5C[BE5$!Y"(
MI-)>L:0Z<M1%97JF=+3.:R^I'SE\E+RMG:)D"J L;:"@("(_C.^WT^O%P:X^
ME^R%UIV%0UW0DNGLW /Z^5(0%C>R!/;,!=QL%X#<(_HCKW_@(:6^?_BLEG/?
M//Z8U\*&NX))UOOZZ_C_ 'UMY2=]B !Z?U?V?C7@T9ZP:7U?V_6KBG9*\D/E
MU!*Z8.TG!13$53$)M473)U,[<CM 0#/I&9<=?6YM?0UJI$G3E!T^TIZ4)"82
MM6J9"@.XPF$3F* &-SS[6<9XCL&+#K?;TJ\;UW]:0A"%*0A'"5%44EI64.YY
M4$R:RF5,B;W+YXJFB@B4>V]14Q2!GL&3!D8JE*EJ"4@J4HA*4I!)))T  .Y)
M/8 5:I24)4M:@E*05*4H@)2D#9))[  =R37-PC&#_AAZ<>?_ (UZ;X,8@_\
MI!K[Q1P8/QWH(1]!2^IRQE83MI3].W(I^93=\)BM62<P:=182ADP$#K9$<?
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M7?JB44X==YR_NT-(B!R>S-)< ^T @'[S;^]\!],?&+CLB$/DF5<A_!,N]?\
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M[KU-^.'I<MO)Y])+;S5>OZL,Q?,6Y46CYFS1<*H*HE4(^,F+904S& X8-@1
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MRI@  R(B(%'  &?A =^P]350"2 !LD@ ?,GL!6!/B>?V%-Y_R6G_ -X8BO\
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M4Z\I";S[/V\U*<CIVRV%<P P5I#9<WP>F_\ !#3KJ\)(M4#9%TPM^9ZH1RY
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MI#4S4MO-/M5:67%I#+_AH1J#^:O$ 1FY#MU1<I=-LLW!\!LF[)X$V.>8FF\
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M:*%?^?D<IE$W75;)H2D\VF:+ [LY7?S)@2*MU1WB 8((>N84 V0/GVJ2@5
M<#M ?@)RY^Z/)%3^A['>,_5$RHVL7WB*4<O))RO)9S,9*DPHPQAE[L[9XO+
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MUY;1E2KBCGG2(<%W]/*L7;E( 4,!4_/+,MF3#@@*9](EYV!\38^&X<?=&X0
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MW56WSN5^%&J&LS$?$I9$YGB-.)F5!4J)W+559D03,U  0,!!R&,9XB-LK]L
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M!R/.!W ,9A$L/:IE2<VI24T)3<METSE;R7&!&4,"JD*X;*(%."Q$"J@8F_<
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M"=BLQX1P1JDD28;E)Y(TR_RCS5D4/O%;'YX\(U=2Q RK4].$#XC.Y<4/O,X
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MR4A]H=\XQB-QQ''X\62Y=V[DBZ"VI4HQK<A]16^I!#8!<2VEPZY%*0#WT3H
M[G+HETTMMGNTS-XV4QLP1B;+CQM&+Q[DXM^Y/,K3%;2J4Q%;E*X>(4-MI6"O
MCR4$@[L5>&9K\T?TCI:I27WG)3E*UG;])PFY=KR5"83%WU%A!(Y!3;"L8P$(
M4<@81 1[AB,@+@^._ISE;@[&U--5)<UZ4>F@BTD<Z9)*&#V4RE4!F=,"CP'
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MU6Z^3/'2G#LI1G+>GFVT=QP2D#@!$2^I0$.P]O7ZHZSNC2WC!VZH*KKFW%U
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M_JQQ:%&4@V5(NVI2G6ZZ?*:R4DEA%"#QR0Y&X&*/T@(1]*         8  X
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M%BP;$* $*.,B<P%*)Q$0SD^1SSWC%]2NN,/,,::Q^RVEZR-IG-RSY8LQ6$A
M65@-1P I3JE[5O0V-]R:V/I1]'>R]#\L<S7%.I.49'?IUMDV>=-NEO<MD\6]
MY+&F$3VKS.<4R?"2E;'AH20A.UD )'R5(Z=;+T4FDG3UN:;9E2 -G4E;%<0
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M(J)2[S"8P"8#@!P$1'@0P'I'NU)?:!2V^\T"=GPUJ2"?Q"2-_@?W5]T2YW&
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M3VZL[/4+>4F:)S1B=XRVMW10.IPF<,)9X#VH4T=Z^-3F;@P)A$   $1$>
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M9U(A1! 61@$  G2!-("9[XV%XC(:,?M,%U7-Z+)45<=W304BO4;,7"D@!$$
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M- PP2DJ(UWZ2MEXA%G[V6"N->>C'2X2*D)7, <+=!P4Z3H4G*#<X$.3<.%R
M;V0XQR/,1N>#Q?W4QJ.NO>>L*VK!S4EJ9?.3)T^FN@1N#1$7#E($RE'YPV-I
M0Q\ SVB8VWVC+3U:ZW506JHNAT931%3E.6=2@KI50KL#G.H;*A\G+DRAAR'/
M/$?16#TNV6TS2N:2>SM*)TM+YRN+B8(IN57 +JBH=7=E7DOMG,. 'UC'BT9)
M*N.-S+A<8Z&K8S*5<V("Y#")DQU 0T0V04.1D#9X.Z4%^\*VX]2>B&/81UPQ
MC#,+O4FX9Y<[#%P2Z9;%M%RDXSC%N>\S/YRFW _"O<IWD@2('-I;!#;OW>^0
M1,XY^SZHW0A&ZURS2$(0I2$(0I2$(0I6TQ<^N!P(!]H8BKUK?_8]-2:L-7M9
MZJ)/J7FE&.ZF48J,Z:4ESF8R^6F9M@0':W4<>5.!\;A#I!SWBT/&@E >X?G&
M%5!*>X.OA59ZV?@RZYK73&0FI?7Q*9?(I3,&2[F5IVHDO6>,VSA)15J+S8"I
M!61(9+J 83!NW=PBR9(F3R72642]^\\^^8RYDU>/M@)^<<MVZ:2[GIAPGUU2
MF5V!P7=M#@(Y3:7X?G'_ &QNA0DGU_=2$(0JE(0A"E(0C01P&<"/U!D?S0I6
ML(T 0$<<_: @ _5GO&A_='T[?1SD(4JKKXC&L#4E9#4Y6=K:+K!:1T]7*3=K
M3\J,W35/,B$9X=D9'4]L<"<0-T0$0$W(9",2?#CHN^W_  ^;9S:I;>SAC(.M
M.'<]J5\1<4U3NVAE4SF%9+@#G-[(;L<\1W#XX"9 \37PURE "D<SFL0<D( %
M*Y I&VT')0#"X%#W04 VT.WT6L:7D\H:RZ3N&\KE;=8)+*Q!9!@U17 19I9^
M=32*?GZ\Q.D;K68.&2\0@8A8X"KA946>Y7B+S;GW%*(_EQ)E%"$AQT)VK2E'
M9WM7>N8WOHU1IG4:'U"O&>9->S;,@?O]DQ^XK2]:K&X_,\TN/ 0ITE#23I*"
M$IT->X>(U]<!0#_)*'W?1]@1NC3(?$/O"&0^(?>$0773E:PC3(?$/O"&0^(?
M>$*5K"-,A\0^\(9#XA]X0I6L(TR'Q#[PAD/B'WA"E:PC3(?$/O"&0^(?>$*5
MK"-,A\0^\(9#XA]X0I6L(TR'Q#[PAD/B'WA"E>-5!%<O36236(.0$BI"J%$!
M[A@^0^\!CHROM.MM*_(LK,)(FTF)\BD^9',T,F<>Q]K?9GG \XS'>^0^(?>$
M,E^(??"E0AW%MV>G+O2^UTPJ!T[I]-TD1!5RJKTTDE!*<R8@H<=V0'8 ^GI&
M4M]-.-KJ:M0>?R%)O+)K+&C=5-T1?>=VHJ!<B0N\!X$?[7(_5'96I73>O<Q5
MO55)K>5JECD^T@X,\,& )[8F "; #/TQBJ:Q&I>MA94O5+EPE(61RI]4RR9B
MD1W!D3% _P Y[(< ;..?MOWO7O:UZ_QWW^G\]4K[C3/J8IVB:/)3%=3!Z0K0
MXD8+^5<NBB45!W"*J93!@ Q@!-QCF,SI3J,M'.A(5G5*0&/CV5D3H8$?CU0#
M$<?0^GF@J8H]A34PE36;+(I?OIXH0I553GP8W)LF#!A$ Y^WTCT)OI4LS-BF
M$:>,V6-D>H@^<)8$?H(< X^B*'B3\1_7_5V_;2NZY;6-,38@*,9[+5BF !#]
M^-RCS] J ,<X1XU5_%.FJ@?WCA,W_=$8PJ?Z+*7*<3T[4DRDI@Y)AT[6V_#@
M5\<<?7\(X%;31>*G<GI2[3DY4^4T5&F\>.0 154'X8^F*:'S_6/[-TK/O "
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M7:JH0 95<"F'.[ @!IS+4S#GMP=R _FB.BI/!FT53O>>6TG-)0H;(@=M4TW
M"B.<8!-R4./3_5'2<V\#>T &.I1]PZJIHX_BA+.9TY!/X8 S[G'^KZ>'G^H,
M?^>L-BG >IB79]@GT]$R(A ^/;E_73V#T#GC^2YWG%D4?A=L3A3T(].RG+?>
M$*(_$-#?]52Y76O!(* MW5-9LIE)ITM))6Y=-V32;L5#K*D04,D'S:QQX.4.
M #G$53V_C.ZSJQJ:=L:$I169@A,GZ#:5M@;++(MVKA4@&P5(RA@Z1 ,(B7@.
M1'UB0::^#%<Z6,G*5+:KYXQ8J(JE6:/Y>Z>)&1,0P&*;S+HQ3>R(AD?_ #B#
MNKI57_AN:EWAJ>GC6LE6R<P0^5W+)J5G-SOVBB2ZA4EP413,@*AAP&1$V/7F
M(ZSV^YJT;9,DQ;GBEG9?\O<94"5$G;+ZDAMW[(A9X<5!*%I0DDZ!*B .B.A&
M#=%Y0R:SV^YXWU4S"5!3/QVUWRV7BQ!*8*5&3'5YD*91XJG&U*=9==<2$[*0
MA*C4C.F[QBM2]0ZA*,MS<REU',MG3T[.:2U,$>NU,;!2"8$$A5#:8V1]..>T
M6KV3KS;1JZZ9B Y:MW(%$!R7KI%4V" AW+NQSZAS%%G1]:/4O?N[\WOI9YZT
M85VT=JO63ERW8&;KJ.14$Q$4'>&_S>1+D@"' #Q$QQG'C821LF(-6\]% 0*)
M2?(2/63*."X*4!V^R =O3F/KP'++]%M<A^]0<HOC$N0IZV3&K<) ,-.FPKQ$
MK2LEPI*N 04I(/%1WVQ/7CI3@URR:!!PR]],<)FVBVLP\EM$G('+>I-X<)?6
MV([K#K2$L-N);#I?#C@*?%;;XU8A%0 [@;_)&-.J7^^_R1BO(%[?&+IUWLF5
MDOEM,4]P%+-I0CC:7)A$2E]1 >,QZW_#H\3FGFAQGFE!T],W4 %EB3]H&X-W
M8"$2$>0#&0^G'T;W]?[:C^?M.2Q] D^+89YUK7Q;;6/B3^7X^L%_W!\B=X^1
MRKIS<>13KRN=6!)5R]-)D2F3O?;1&]D:!J6S5GK+M)I!IN65!="9 S"<BH$L
M:@FJHHZZ1RE5VE2 38)GOM](C^_=T=)';Y07R!=PAY1[\,]^G$/WB,WJU%ZH
MZ5I=W<O39,K=K4:F[.G/5)L>8HG\SM$^YH5,$_00#(<=_C&$@U7IK'2B$G"B
M$_\ A%[Q2-/.LMG(.]O];;>@(]#V<=\^@C$8Y'U1OK5XG-6=^!"M;$$2XJKO
M;YS#\M;:4>,PTEU+2R^7%E+:. 00GNON:Z8Z>?1BP>5A]DEY=#OUZR:X7TVJ
MYMXE?[).@6AF0ZYY2=)<B.2FT04,-A<A[QB\E2]>!Q'>[%I.UCVCU>4N_J.U
M\U*]+*A(69LQ(HFJT%0QBI[RJ@!_;$H\[0#M&6V0^(?>$4TO#9UD4UHMHBH7
M+VU%1U)4-5 U/,YFS;S8&X%;'$4]J*#91 OLFP.W&>_/$2FMO')M*#(CF9VT
MJM@IV62&4SLX)_\ 7!C@?6-YQOJ59Y%F@/7^YPXEV<9YRV4MOMMH5R(&N39
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MXB*4=9I2N#YQG4!=S%L$@71DK\;DG8\+P@>0:5XFR0T?0.Z[UU0[]#FV-^/
M'4G=_8Q@Y,;<<9FI8\IX?NJ,OS!3P5)2J/Q"#*WW\MOW1^@2 @/(" @( ("'
M.0'L/U#Z1K&$DDUU:8FLFE#9_=R3J3!"4RY-ZJ8Y"BJY(T2*L80ZF-W5 ^X
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MY6EZLS,5T(NE.@0$TE'8+J;CAGYL@X 0YY")0?!<U/U-)YA<@EX;IIA1Y#,
MER<\>)]01#>50R9W2XK<J8$=O.!QZ1HUCZKHNEUMENEV*1;&[JRN1&F/2V%M
M%E"5D/$:1]F5H4C94#R'9)J;\U^BN]C&+Y-D-JSFW9+)Q68Q;[E:(=JGLRA-
M><82J&DJ+G*2A$A#W!*5)+1Y<QVW:KA&,@:O-/&.;I4__P#?6WV?\</]/O'@
MIAK@TQ2M?RSNZ\C(L'<I%T5 #C/(E4$.T2:J\VE(VJY04CTV93 'P^)<_']M
M<U-XCE#RN#6.WIQ6M\46N:HZ&MG08WH;_;67$(PV'7II8 <?ML2@?J,00^\#
MXC3_ (>NE?\ NKRG[R__ -\>?MVR_P#\5M__ />1_P#_ *?QK\M^_P!1\Q__
M )6R#_\ Q$_\/_4?C_';>9(B <B(   (B(\8 .X_4'K'5$\O7:ZGIFXE$YKB
M12^8M1 '#1:9,R*)";D .4RP" B'Q /A&,U4>(7I-92Z8,S7=EB+YY+7Z+)0
MB1E>FX4;*D2/\V(AN*H)#!GCCOS%-NKV3B]>K^?TW.[OS<DLK&<+"A72;YXB
MS3;[S&;@#%-R5(@$(<J?]J [<XS&E9AU$CX^FW(M34.]29\ORI;;N##:6%$)
M+?B*27"GQ%*XI4H! T2I0[;F;I']'RX9\YD+N42KOAENL5I-T2_(Q^=(=G(0
ML^.(S:Q'2X(S25+<0VM;ZB4!IM?O%-[)A?FTDQ>MV#*OZ?<.W1MB")9DR$RA
MAP %* +\B(B& #G,=PD.4Y2G((&*<I3E, Y 2F#)1 0[@(<@/K'YYEWZ#6T\
M:AV5!4Y=^>5/^"\SD+U6L6[]^9%)!PHV=JX:E<J)K%(GN*8H"/; Q;*I+Q7M
M'M(4524HJF[[J>3YK)9>A,725-S(ISKI,T2'*8A$A 1(8HE$P"(CC,?-B_4N
M-=7[K&OS<"P/6QU#)+URCK;=<)6EU"%*+?(M*3W+8<1I0VH; .2ZG?1MN6*P
M<4N>#2;YGT/)H;TT"'C5P8D18Z4L.1GG66Q(+:)+;VTHD>"\"A7V9'I+7&F0
M^(??$2TW\9S1,P,B1M64W?"IG($IJ<Y+CX #<1'(=N/O]/C)OXV^DAFHBG+7
M%13(5<@;934]()<!Q@/*9'/H,;4O-\1;WRR*T]NQ"9C2CWUK7%1WZ_+_ 'Q<
MQT5ZLR DM]/LJTL$@KL\MH:3O>RXVD#T^.JE*O#>2W]C*(F5P+D3UO(:9E0)
MB[=JB!C84-L*":11WJ9,( .P!C DOC!:&S!G]M @<F  -+G@".T<< (<Y],1
M$QXB'B(6"U;6.FEMZ6E-6&J,W3/*52R>H&R)#)JE64ZP"W(D8,%#\9D SQB(
MC;)273*\LU=1_=U!0EU) DQ3H9N*CM,SY14YRKB)$\$(*1 ((@H&1$/C$9Y+
MU3FL7M$#&W[#(@&"N2J;,<>4V7F4...L>(VI"4N<$ -(TKQ%*'O D"ND^G'T
M7K-.PMZ^]1X.>VZ^"^Q[:W9;/%A)?3#F.1H\6=X$A+KCD?QWEF5(Y-B.VVH^
M&H)*S=JT\ZV]/.IV83:56DK1">S&2](7S0Z*C54.L BGTR+X,IP B.P!QZ_1
MEMO+C.>,B'8?2*)?AQ7HG6F6OYY=5I:>H*_.Z.;Y((P5F#=JDD4JB)2G,@DH
M@ME,2@ GW8$/00S$TIO%]U&S1DJK(M'4\4%13#=4\U<)B;)L![)VP#@<AWY[
M8XC-XMU1@SK0S(O_ "BW):W>3$&WW&0V64J^R<^S8>"2M.O=\17P.QO0TKJ?
M]&2^6++IENP1*;GC;+4,-S[W?L>@/HE.M),EA7CSHJG$M.;]XQVB!M/$\>:K
M!PJ%#XC]0",:=4OP-_DC%>ASXD6OZ=^32I_1U,&RBV1W'J!$ .4>0SU$<%''
MQ /7F/&&K[Q5Z@?F3D^EY:7I@7E,\_EY@R)>!WG3 .^!^OZ.(V#^Z#9E=F8=
M^D'W0/"L-S.R0-ZY1T@:W\?T UH Z!YBWWFWC!+>.)4?-YUC*2 %<>X;N+A[
MGTT"/GJK#@' >Q3?Y(_ICT)LLX0ELR6:@(N$9<]6;@ #D7";<YT0#(8]\"XR
M'>*]J5U/&<GR3E9E:<DJ P@"133&3JBB B(9Y*&[']/7&Y1'QL)HV('F&TE,
MID55#!(E.D01R(&*/ E @CW#T^^ASIM8/@XUECH([*39W&_4Z!'C+;'QW^';
M>J]$=$7VEI,KJ1TJC%*T\D.9A&?]-*5R\FS([=]'YGLG=1DZ@O$;UW4_J!KZ
MA977+R3J,)J+>52 98@)RH]0Y4BD.8@"?>0"B& 'WNT=45%XDGB&4>[8LJGK
M^82:8.7C(K=DYE*!5ERK+)@4H)J$*;YPIPQ[/8<YCD]:=C-3-G*^DNHR\U12
M2<UF]?-W;D\O5DQU$U6*J0 1>7L5#XW[0+[9.W(AWCS65=SCQ#M9U#3*Y;B4
M4Y3LI&7FF*2WD9>S2^3&B/EQR H)'%<R "(!_;&P/,<YRY>3+O$FV>W,FAW6
M9=F6[;!D2'&4JAS'%J\>0I+ZD,EA!3M""4D>G$).OT/M-HZ:,XC:\F&#=-;O
MBMIQ27(R2^VZWQY;B+U9H\=M4* AV"AV:B<]ST^XE+@(&P2M!-N[1E7=?7&T
MYV[K&YO4_#*<2\ZTS%5,$CJ"'XDYDR@4"[R8-C =XQ\\2C4+=S3U:N653:>B
M!K::K/$D7#$K-)Z*8'=)(A\VHBOW V1$"<8S]4A-+,)1*I!*9;(SLS2J7,&K
M)F9B9(S8Q&R":.Y,R(BF;=LR.!'(B(YCD)C+V4Q0,DZ9,GP 0XI)O&R#I,JN
M!%,>FN0Y.#@40X[_ &#'6#EOENV1-N;N3S,SR34<7-*4NO!U*$),G2]I6M1!
M5[QTHG9^=?E[8,JL5FZBQ\LN6(0+[C\>^OW)_#I+ST*WRH+CSJTVQ;T<>,PR
MVA:4)+:=H"!I/;58[Z3KEU5<RQ]#55<&3M:4K2<M#K32FQ6;)N&8[@Z8>63!
M,Q1.00-MZ91 /3TC(\7K8J_ES.6H+#_Q(N$@6_S0F _;GW?]L0GRK3IKE:^(
M@WNVXJ8__!X46."\B0!HW9H($9])(I&R1RB'M_R4PCE*_L7KHF'B&,+E4[4;
M@FFTBB)G$J!5N"12E9$(ID@J=4<K@8>"?5&(CWRX1X;2';)=I#K-T:M"G%(:
M#DAD)0E5Y*4J"4Q5=U+X]TDZ"?@)4O?2?#KMDDZ3!ZJ]-[1 NG3^?U+9AQYL
M]<&T7)Q];K?3)EV0V7W<@CH6&& Y[CJ$)45[5NIFSO6Q%@0,Z:$5'LD=PD54
M?J3$X''[ ^_UT4>MDE 04=M2*F[)G<)$5'U]E,QP,/V!$+M[;$ZZY[KHIZOZ
M$J%PC8%NHS&8R\JS<$BD(U2(L D,H"IMRQ3C[O&?AV\6I:Q&NZJ=7M$5E:ZH
M'#:S+)1B,\:E6;$3 B3=N5SN(90%#[U2*>Z ]^.(]W<AF-HEJ3C]U<,:Z-6]
M"4MH)D,N%(5/9[C<5L':U*TKU[5C+?T6QJ<_CC3G63I[$3?,!G9E*>D2Y ;L
MERAHYMX?<2$;1?Y9'%EE/N$D:/IO*;7EH3H+6O3<CD=0U QI:?2+K_)4Z%-)
M5T0'0@*H D!B**;BAM#.< /'$?5:*M'-!Z*+=%H603=E-)J]P,SGRW29N9D)
M5#'2^:5/O'8!L!@1SQ&%VL&Q6NRLM1MLJGLS4"S"V4K4EPU2B5PV23$J2+8'
M6XJJA#FWG(MV#^V''I'L:X+%ZZ+A7=LY.K U&M+Z+DRDL&M"(KM@(L5$C0'8
M&!10HFW&37Y* \C&%>\E'N]TR%O$9[UWB/1;>B8VA/BSX[X0E3\8*6$%MA&@
M\X4ASBDIV1Z;A:L6E7C%L!Z>R_I 83;L1RBT7S*IEJFS'41,1N=I\5QBT7Q2
M&2^W.NKH)@QDN*94ZL+X!1!,T*SQNW$A5G35(5,; 6722,?/;8!S%$_T8[QJ
MN\;-P(*SEJCU,;16732 ^?Y&\Q=V?3&<Q#9X@=C-<ER*NL6\TX5(O*9-3XRW
M]L B2C<@.>D5D#K<"RA!'<*:X^SGOW[9]GQ"K'ZW[E,K!$TVU&XE"].%8!<7
MI*-D_-BGY/S&[K'+NR*:_N9[]_CG)5_EQ_:_"P721[,5$#'A(;/M+S/'Q#$V
MKOY;E]KRUZ'6ZTBP=&\;O!Z;B3U@P"S_ %Z;R1RZF?*DH&#FPASRC>2\6CX*
MK[X8%L\+GS+B.?$5,2X=MT2)F4<M42J8VF6723*?D.""<Q0-]&W.8B6U@>&3
M3&LS4M:.[=[JY3F]I+7#-3-;7G,+%":*S-N5,#_*:2Z9@%%P4%@QSG@! <#'
M Z\[(:W;A6YL++=/=0.)=4M.D:A<0Z:K=,7ABG:"J)A54( \$5SM$8];6;8[
M7!6]B[+R"R$^<,Z^D*: 5PJFLW3,Y,"C85-QSJ%*.TI%>PCGZX2;_+CFYA%A
MNCXM\:*^TIM"")ZY 25L1?>VIV/O3H4 !KM^-+%T=QV[LX$Z_P!7\!M"LQO>
M06FY-SY4A"\0CV53J8UTOVF]-0KR&DJMZV]E0>1S([ZWT!X3%K=/FKBB]3>G
MVIQMY(&I'9*\HMP]6F*-8D%IY27 I,7KHW3!B [B>T;("!0Q'TGB >']</5#
M=VQ-_+0WW:V9KJR/RX:23525M9NBX/.TBHJF#KJ%1^;*'KG(C],?*ZI+':X:
MKTMVLI2U$]<(79E":85<Y(LW3.X-UT!,(G44!,=J93^Z(B/:-]^+':X*AT6T
M#0U 3YPE?*7)E+43TJS<BBIO,I'$14,H"8[4@,'!A >WT0=O\MI4U*;#='?*
M6UF<@H;01*=="2J"Q[W>2WO2P?=!'K5UNZ.X[.8Q9YWJ_@,->09M<L2EM294
M@+L-O@K6EO*KJ/#]RQSDI"HSP]]0<3L>NON='/AX/;'7:K;4S?\ NVA?._%;
M%8$6KE9FC(VTO38H&:D*W:)+"T#J-A!,PI[<X$PY' Q]EX@&@F6:QF=!5S2M
M>M[77GM,L[=6WN6BD1Z62+/U"&> 9 %2(N"N"D!(05,(!D?3B.G+E60UNS/0
M%3%N:6J!PGJ*:I_^E9F"K<JIS><(< $YE.E[* "'!QS]\>W.[(ZV7'AR,+8,
M*C7)J<33'S$YZC?JB;SW4#V^H"/];\>_CXA%3?I86ZCV%<R&[,FZ!80CBX^K
M6[6CWM^=3ONDCB==C7FUT@QUQBWOJZO8$A<WJ<[@#K1DR0Y"M#:BD9[(2&O=
MQ=P)Y(>'VQ2H>YZZ\FCCP][I6HO#.-2&I74:[OI<9V@U:29<B(R"325!HV\B
M(BR:N/DY<7#<"Y$R>0-SG/(YL:O[ MM5&GRM+.%J9K3J-5*R]09X44G237R+
MM-U@0 X$'>)-O)N,QA%3=D=;#3PYII;&9U$N?4TJ0 :3D5&XK /GA4'VNH*0
M!T, 'M?;'JVOL?K=E6@>JK=U74"ZFH=VGB4S,56YE"&\X<_!P4%, %$2EY-G
M'V03?I96RDV*Y@.V95T*BA&FGTC8MCG??G%?!(]T?.CW2#'6V;D^.KN!.JM_
M4UC 66429/.=:'5(2K/(P+7?%VN14IX_; ).T>FY ]+]EV=@+&TA:C\(6U1(
M4JU=-E)N0R223DKDQA/G:<2I\")?>^F/F:?T>:<I#<JI[S2"D6K6O:I9.V,[
MJ%.;G73<H/&:K%8#) J9%/*"QR?VO?MQ&#5@K':X:>T8W H>X4_<+7OF*9RT
MX],JW.HD;S*QL@H504PW)"0/:-CZ,B$;=*MCM<-):8;JTK=N?.'%U9PFJ%'N
M#K-U#MS"LN8NU0B@DP8AD_>,&/O"+6;_ #'500JP7-L2[<].<*T( B.M;XPG
MO>.I#OHA(!!)]:]+ET<QV"SE3S76# 9JL>S6V8I$:C2Y"EY! N"VTNY3:P6_
MM+) YJ5)=5[R0VKMZ;QTG?@J3285U5%,T[?.7R_2E6=3,*HJ*T:4C:.5?E"6
M3(LY1$M0@<7:&Z9@*QMAR@/)>P1GKK?T%RG5C;:A931=;(4'<6TDN:L+>UN@
M5.:&D)$6[=JL)FP*"4X*HM2$$%3>D=,:++'ZX*&LC>J17RGSAY7<^3<!0JBB
MS=4S4QCNA()3)J&*&2G3QN$,<1[&@FQ^MRWMO[^2[4/4"\QJ*HRN@MV=15N<
MS,QA=BD)12.8 ]]$<&$O(8BL6_RY"K6%V&YL"X1I3[Q=2@" J/O@Q*][W7)&
MM-!.P21OC5+[T>QZSM9Z[&ZOX#=U89><?M=M;@2I"UY@Q>E,(E7.P;;T]#LP
M=4JXK<(*4LKX;T-]P^'IH;<Z3&]P:OK:X[>Z=XKH_)9:^K5-!)D$Q)(BF1E0
M&:(J'21Z#<0)[.W(ADW,?1:F=%K74AJ2TTWZ1KEM*#:>5:C5/(TDTG@SH9XD
M!! ZI#CY7H8SR'/T1CSX>=C=<%M$K^%U)U&O-S5&68!;KJJ-SBSZGG?+;>DH
M?&-Z'OXQ@.?AZF@"Q>N6W%:WR?:C*C<361S\TS_ !-51L<&P*D> UV@DH82[
M1.A[P!R 9&$:_P N0+1SL%TC^TE2TOAU" ;;Y;?!4O2NPDZ'@\=D[&]56_\
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MY4=5U2FPW20+<S#=9+*$$7$RN/-N(2>ZXW(^+R UQ.J\K#T?Q^\M=/''^K^
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MI@ 2<4G4+)=7;V\NBHR345'@,@F4PA]L<(OXXO@ZN3;UAJ_</ B2CZQ(&/\
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M8B8 W8#MS$5:_BI:&+0SF;4O6UV*ME,Z*IU"_)E%U.Z04%415QU&38R6" ;
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MI*6MRA*YPPEK-1JZ:G66<$,"N,I$3 1^O@1^G'$8^[X!BUTMTJ W:(%N<D(
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M5N^\N9,X*"U.?;CD0$0CLS4KK+L+I*0D3F]E1S20(U(5T:5&E\@FL\ZI6?\
M7!E?DY%;H%3#D14VACG,5,--+^BIK<SPFY9:1)4*XE507N"OR,6ZZ+])<[U4
M0&HE2E*J;<(*BW\^(AC/3BR;XH-S9'9+2/65SIM3TLG\_8(R>FY(D_ES>8*H
MN*J72DSA1N5=!;8)#.1.80P.0 0QW!0C1 ^?X_CKY?I]*R TQ:T-/>L"5SN<
MV%K)2KI?3QT235<\L>RX&YUC&*0N'9"[S;BF P%R)1 0-@0C*@1 H9SP. [B
M/?[XC9\,#3%)M-.F"E6:4I10JRL$7=3U(^3)TE'P3=4\V8I'( ;2%13= F4
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M?B?^'[15\F_=^+<Z;;75%>&ZLY&1412Y4!FTR!)5<4?,K @@!44LG.8Z@@4
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M+]0%  B)VWGC(Z-+CWT;6.D59.OEJ:S!Y*Y%.'$IF#>439]+S&2>HH3-9$K
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M=XC/TS^,/IDU374DMK[8C/Y@_GSZ:R^7S,U/SI&6*+2A11)UE^JT!F4"J)F
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M\AH2FYQ5E2O08221LUWTQ=B43]%!ND=50VP.3#L(."AR(\0I7TAB$.!BF !
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M[4HM3;U:?S>93F:3.4LYFE3TZ^3#.I4NHW= 9^+4690*JF8N3+8$>PPJO?\
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M=K-9.NH:7I&7.85#=-(N3#N$1&)-TTR)%*1,H$*0A2%*4, 4A  I2@ < !0
M   XA5RB#K7X^OXG=;X0A"K:0A"%*0A"%*VG+N  'T,4?N$!Q]L5F-<VD9A=
MK6Y4UY:.UC4[:FZMKI"_G,EH.J*4EDU: 9O(57*K5LM.C@T7.^30 F$R&$#G
M ,"(A%F@0 >_H.?M"(ZM47A?Z4]6=;,+B72I6;+U>Q4*?Y5E513>4"Y* $(*
M;A*7N$2+$Z9.F)5 $!*.!#$*J#K]6OA^^NH?!IU27#U0:2I34]RY*@TJ223N
MHI&XG327-Y0QGY95.G4N(\;2]H@@W0*H1N"OS11*8#@.1# C+H'( /QCJRS=
MFK>6%M_)+9VPI]O3E(2!(R<OEJ'M;14$#K***#[:JBJF3G,<1,)A',=IPH=$
MG0T/@*0A"%4I"$(4I'7]S;?2JY]%SJB)RJX1E<^2*V?&;+*H+BW,.U4B:J)R
M*$%0@F+DI@QGT[QV!"%*J4:%;"VVTT>-9J,M9:N6.9933 ) [ CUZYF+I5>8
M291VX.J\=G57/E90Q@*900)G!>,1]WJ\!DT\:*S+FZ9FI*/5HFYOX)GJ $0D
M)#%HIT#P!,__ '@50Q^$^H('%3&SVHG\DFD"QM/:@:HU,RNE^A=RKR,R3VH/
M-+#YHK)MY1O^]Q'I%V(^QP'T_"/BM7F@C3GK5ETB:WMI-::OJ:.J:13B6S%W
M)YBQ*X,!G297DO.DY,1P4NPY14P)!$HY#(0J[EW[_%.OQ]!^O^RHB_V/J2:&
MIK48Z9 Z"WR]:3#\#LD4(Q$"SV9 \%B!OF^F*F,"E[(EY+Q%D@.P?4'Z(Z0T
M^Z>K6:9;:R:U-HJ;1IND)&0X-&A3BNN<RQNHJHNZ4#KKG.IDXF5,8<CD!CO"
M%4)V2:0A"%4I"$(4K:<,E-@<#M, #\,AWBI+X]VE6TM'3ZVVHQM+G[FZ-2UU
M3)7$V<S-ZX9-P0G\O;E!M+%53LT,HFV&Z29!$<F',6W(QIU&:3;*:II3(Y+>
M.FOPCE].OV\RE:7FE6W0=MG*3M%3*0@)MJZ)#X'CC';LJJ3H[KI+6'3$FK70
MM,Z<J&OC6RE<[H:C&;NLR,C3#Y)*XES$FX6A! 3D4%02&#(% HB(\9B #3P\
MN9X;^HW1A9*@;XTGJ?LU?=Y6BHLY%2$AE\VI;R8"Y4.\FK))Q,DCJK+B;]\*
M)YVB7 ]AM;5_:.A;F6X>VIK"4?*E%OY4VD[B5]91$3,F:!6[8A5DQ!0IDDR%
MP8!SD &,(M-?A4:0M+=P!N3;6BGP50V7<.).\G4]FD["2G=[_->02F:ZZ;8%
MMX@((E+P ?"%5! &C^/;MH]OGZBI(&JXN$$%1)TQ5;HK"0>Y!53*<2#])1''
MIVCV88 .P8_\H0JVD(0A2D(0A2HH_%/O7I/TWVSDM\=1,AEE3512!7;:ULCF
M2@B5[.IP8C-/:U$IT5BD=G0$PK)F*0.1P&8PQ\).QL_51U*ZR;BS2GV5UM2M
M-J.$+=4\_EJR-%RF22IZA(\-Y.MY8%GTO.V4P9!,Y39R&\.)3-87A]Z:M<R%
M*M-1%(K5:SHXSD\B:DF;Q@B@=T8#J'43;'*58P'*!B"H [!#)<#C'I:4?#NT
MU:-IC4DSLG3TYE#BJ4FR$U),ZCF\Y;&1:D%)%-!O,'"R38@)B)3%1*0#!W"%
M7;''7??]6OEZ_/O5/9XM2;/0[XC,MK0[/]N(;HVXZJ<R(G^%2FZNQ-+AE8+A
M\IG*5+IB?R>0*GC?[,7--"B53HZ5K-)U=YCY:"F)<*_FMW7Z LT!:[^I[7XG
M9C/,=#W,\)'19=:^)+^59;E5>M5GJ$PFB;:</FDIFSMF)#,EGDI0.67KBW4(
M!R=9(^# (@(".8DLE[!I*V+*6L4"-F4O:H,VB"90*1%NV2(BBD4    ")D*7
MCX0H2#Z?QV [?J_"O<A"$*MI"$(4I'6UVF%"S&WU5(7'Z(44G*W3NH16<>62
M\BT0476 RH"4>4B'#: Y-[O.<1V3'75U+84K>&A9_;NLVRSNFZD;"TFK9!RL
MT46;F 0.0JZ!BJ$ Q1$!VB&0$<\0I52BW+>S/B-:P;9R.Q#.D[8:0])%23GY
M/GJ,PEC.;W%FLY<F%X1,ISMIP7R$W0.01 504 ?Y,22>*OI5I34G=S2W(%=2
MTKLA4E"RJI7%&RZ=2%I-994IVLM(J"CAQ,E$V(=($$SE!<P[\@!<C'>EM? Y
MT 6EJN25?0=NYY(9K()BO-& ,ZNGJ+87KE;S*ZKEJFY(@ZWK#O %B' ![1E=
MJOT$:>-8LHIB6WCIQ_,7%&H&:TU,Y;.IC*'LM04*5-=,%Y>LBJIUDB 0PF-V
M^V%7%7<:)[?,;/[>^_T:J.GP:-1EX+@U;J2T^W4FDHK8+ .Y!+I-="1R"6R"
M6U@A,C+ 7HH2M C4_DDDBIG,117DN1Y&)[ [<]XQGTQZ3+*:2J*"AK,4P$@E
M)\"\76<K/Y@_.!A.!G;]R)G3@2F,.WJJ&VY$ [QDQ"J$[/8:%(0A"J4A"$*5
MH(@ #SC@1^X(KO\ BDRRU-V:!U)TI8VZ%(T'?.G24],;PMY])9:O,YTR9B#Q
MHREKB= 4Q5%F*2B&^6&,<HJ%$0W $6(>\1HZF?"CTA:JKE(W5NA1LS7JTRZ"
M\T>RNH9M*$YP9KL!N5^WEZZ2+@J8$ -JQ3@(".0Y'*JC0.S\/E^=0\U]6*%Q
MOV/1\NVSIV<4ND6:2F7*RDJCY=\(RFLT6L[=@<X Y\N]Z:KK !TRHGP4=@1T
M8P=4'--5/@YI6&-*S3MK+;C!5PTZFW*JFY"5MP6^7A9!D%!."G3\\.1-G;S%
MKN5:>[326T!+&2ZDF"%LTY8>5EIL$R"V\NH38<1R'*IA'J"J(=3?[>[<$8G:
M9?"STAZ4;BS.Y]IZ%<,:K?.5G35[,9O,)J64J.1.+GY-2>J*)LRK"H;)6Y4P
M$.X<0JNQW]?4D=^W<:[_ ![5(HV!4$D@5_& @B"N?^5V!O\ _P +,>S#M"%6
MTA"$*4A"$*5@9K/G^GAB:CY!=V?2>G:[J)E/&EK)K/9>1]+&<R,V%-5=P#HH
MRXO35.D</.&*4VWV>0B'KP7)@[MQJUUR67K*9-JWN7+W%,S"H+J2)!!K3\^E
M[Q!R]DB3)C+ -*6_R:Q.F@IY0P&5,0!/[7$3G:J]'%CM8M%IT1>NG%IW+&PB
M9@NSF#N5OF)C'*<QF[QD=-REN,4N=APSC QPFDO0UI^T9R";22RU*J2E2?@D
M2>S=^_=3::30C?(-R.7[\ZKM0J)3"0H&4$ #CL !"J]M'YG\!\]^M5M=6-C)
MM;B]VL'6G9?6%3);D2B8T6O4-KZAHB33%TW304*@BP:'G(G44,[1(9,#MD1,
M03 8?2+&GAZ7VJ;4?I.M==FKZ>_!FH)^U=-YA*_+%:E!27+"T\V1N1)$B17G
M3\P4I$RE I\ &(Z8O'X1.B^^%W75Y:WH6:N*KG#QH^J(K6I)NSE\[<2\2F8&
M<RYLN1F8J!B%':=,P&YS$CU)TG3]$4]*J7IF6-Y3)),U29R]@V(4B2"*)"ID
M  (!0$PE*&XPAN,.1$1$1&%5)! ^8^/X:]/Q[U])"$(5;2$(0I2.AM2ETIM9
MVRM?7"D5/N:FG$@DKL\MD[0Q@7</%6ZA$#EV$4,/25V'V@7)L8SSF.^8\#AL
MW=HG0=((.4% PHBX2(LB</@=-0#$,'U@,*5^>!0M_I*&OO2AJ;N_+:J4OS6=
M75FRKUE,I5.2?)#8CTTOD!&*2B'04*+,Z953LR & W*8]9ZO%'=RT_B(>&A/
MKBG1"T[F27#<O1F1"_(:1G,@252+-2KAY0A^HH'3!V&=V-G(Q-Y</1YI_N?<
MJV]V*LM[3[JL[5*3%6CG[>7M&A&:DS*!79ET$$"INS&  $HK%,)!#)<1Z.JC
M1E8C6%13:A[TTM\N2M@79+'#5TO+7TM*(EWE9O&9DW" * 0"F!(Y0$H  \0J
M_D-@ZUKM_P /RJ&+P<3M'.NOQ&7M%BF-KUW5O/P:,Q3 DC.8K50%QE?1 &@X
M/NZHM_7._O%DH,XY[QC!I:TAV2T@4(6@+*TS\@R8?ZY67=+OG[T0.)RBZ?N1
M,Z7V"([>JH;&<!Q&4$*M)V?U>OKZ4A"$*I2$(0I7C4-M*(]@ #&''(X*&1#'
MTAQ%)#QMK]3&]UW[OVEO53M3R:S%CEY"ZHDK1G-3RNNG#XJ;I<[ARS1!%+Y.
M=ID$H.#' XX H!B+N<=,W?L#:F^='SNB+C4=))U(Y_T/E,#R]H1XX\N<%$A,
M]*CYC)1#OOY#C@(5<DZ._P"!^-0Y:%[A4I>?PAY4BWJMY0$N+3\WD3RH%)4Y
M.:3LSKJLT5 ;&(F9<O0R!L!V+DWQB*.T*]P_#,K[2-(;0W]I?4[::\E4UJ9[
M34OHJ1M)VQ,>9F.J*TS23<S9N*"S@YQZ@I[@(/&.8MJTKIKM#1MF_P!H>0TL
MU96U%FZ9&D3<>D0R#S?U@ZI *;<.\P@?WBYX',8?6%\)'1CIWN<E=6@*!??A
M++G;M]3_ ,L3Z9SEI)'$P,<[XS1G,55FR?7.<1PFF4"CC'8(4"AW^1)[=OT?
MEK\-U)1*'IW\NESQ1+H&>2UB\,B/=$[ENFJ9(> _%B?:/'IV".3C0I2E  *
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<$(4I"$(4I"$(4I"$(4I"$(4I"$(4I"$(4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>nt10002526x6_linechart14.jpg
<TEXT>
begin 644 nt10002526x6_linechart14.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( DX$X@,!(@ "$0$#$0'_Q  ?  $  @$$ P$
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M=]G-EOY3OP  "H
M
M
M
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MT  "@
M
M
M
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M*T  "@
M
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M51JS,K,2Z.R:L:#$A(ZUERUVMODJ+ERGE  #*?F
M
M                                 "'#BW;P=SNWRU+-TOVFZ-SM3=5M
M8X5=BT^LQY91(]HQJ<RKPN9(4ZTN,I2HZEN(2ZM!Y07+XV#$QX^5NRGP)5)J
MLB3!A2)$:AUGP>3(BL.R(W-!>)7@[[B%.,\W<OD4DE%W]P$IDM[7X*49?4ZU
M1UI5Q'-U--USN>M5K4=J919-T,S:E)D0XK\N+(>1%8BF\Y$:*/S&T9LI22C2
M1G@9(<?/6[5'73>KMBX>MD7=5+.LV_ZI46K^72Y#\:14XC!1IK:"D1W&7VL(
M4M.4.=Q]>@Z_X)Z<<9'?>>4F7KY0B+QB,^C$OIW^0AZ?BXO_ -C#CG;-]2+N
M+UKM*H52K1X]7E%V4+M%0HT?"I#A)91]$42<K67RAX/]%^DR(MWW7:C45+<N
MJEES.K*II_=G!=XJ&V*S]++[N2?HQKHE,>Y+9K%4J55:>E,4N*E;B5U*3)6C
M,R0IW""(NN/(0[BXA%;U'XD?&7L+A_56_:U;.AUM4QBH5RGT>9,IZY::S;S%
M6;);\!YB1]"=/IE9].G=W>JXRERTK67BR</JQM/YL.XZO1Y+TR:FCR6:B3#+
M\"G24*>5$6\E'T//OL=Q^8>9!JU/TF]4YP9U\S&*#3+HMR@1:54ZJM$&"\[#
MLF.S(),J0IMG+;A<I^/T,CZ=0+;41=KDAWXHJ*EN?+EXC9))OCA?\:R7L4H-
M_5ZXM!-36XY4FF5B;,J*X:X%&\,=-#T]^2^GFD+)2L*(OE(A;2U'WL[9-)KJ
MF67?NKMMV]<L%+:Y=)E3H:9$9+Z"=;)Q"GR4G*%$9$HB%3?5*6SJ[ZIQTZ;L
M*3%N"/93<GU[J%*D-3X+#<VVTFCGEQU.QT\R2,B/M"^7H),MZOJ<O;_O(W$W
MEN#N'46YK;K=YHIY5"EQ*I6BCM.08J6"[-#$UME!*P9^(@N_KY@*.LJM5V5V
MHJKR\;6VKMSVD9/JEO7C2?=):VV:U=#+WHM^UV%=B9TN'2Y<=UQF-%K$"0\X
M[V;B^3E::6LB\I%@C,Q/OM>XANU/3_0/2RT[HU%;@U^AVM2853A> 25G%D,T
M^,TX@UI+E5A:5%DL]PJ(\5#A4Z3\(FHZ#ZIV%=-:O9ZZZXY29D*K3:D\V@Y4
MV- ;<:\-DR"3R^$<YDE*3,T]QF)U=(>#54]7-,K)U)CZLKIWLPHL"J*II4PU
ME"*3$9?)LG#67/@G,9P7=GKD;@T>4'1+5:5.1L?8JJE"JD.?2'*2TC!=%AQ9
M+M,)W;GVDIG5<L98C,WMNB)W.Q3G73'BK3]0:W3);1-@6B8IH46F+&GYZJ3#
M(,:!4_-,1CI:&UU4D;PTEFPHE^UNS>O=_P U)FO;0]FGPH-^C9?YH>VA[-/A
M0;]&R_S1%?[1#7/AD<]%%^D#VB&N?#(YZ*+](/?^@[L:_P 8N(MWK-_N/BGB
MII_TQ>S1_$]A'Y=!X?UAZVY[2H>VA[-/A0;]&R_S0]M#V:?"@WZ-E_FB*_VB
M&N?#(YZ*+]('M$-<^&1ST47Z00F#NQKR^R-B+=ZS?[CXIXKTCTQ>S1_$]A'Y
M=!X?UAZVY[2H>VA[-/A0;]&R_P T/;0]FGPH-^C9?YHBO]HAKGPR.>BB_2![
M1#7/AD<]%%^D!,'=C7E]D;$6[UF_W'Q3Q7I'IB]FC^)["/RZ#P_K#UMSVE0]
MM#V:?"@WZ-E_FA[:'LT^%!OT;+_-$5_M$-<^&1ST47Z0/:(:Y\,CGHHOT@)@
M[L:\OLC8BW>LW^X^*>*](],7LT?Q/81^70>']8>MN>TJ'MH>S3X4&_1LO\T/
M;0]FGPH-^C9?YHBO]HAKGPR.>BB_2![1#7/AD<]%%^D!,'=C7E]D;$6[UF_W
M'Q3Q7I'IB]FC^)["/RZ#P_K#UMSVE0]M#V:?"@WZ-E_FA[:'LT^%!OT;+_-$
M5_M$-<^&1ST47Z0/:(:Y\,CGHHOT@)@[L:\OLC8BW>LW^X^*>*](],7LT?Q/
M81^70>']8>MN>TJ'MH>S3X4&_1LO\T/;0]FGPH-^C9?YHBO]HAKGPR.>BB_2
M![1#7/AD<]%%^D!,'=C7E]D;$6[UF_W'Q3Q7I'IB]FC^)["/RZ#P_K#UMSVE
M0]M#V:?"@WZ-E_FA[:'LT^%!OT;+_-$5_M$-<^&1ST47Z0/:(:Y\,CGHHOT@
M)@[L:\OLC8BW>LW^X^*>*](],7LT?Q/81^70>']8>MN>TJ'MH>S3X4&_1LO\
MT/;0]FGPH-^C9?YHBO\ :(:Y\,CGHHOT@>T0USX9'/11?I 3!W8UY?9&Q%N]
M9O\ <?%/%>D>F+V:/XGL(_+H/#^L/6W/:5#VT/9I\*#?HV7^:'MH>S3X4&_1
MLO\ -$5_M$-<^&1ST47Z0/:(:Y\,CGHHOT@)@[L:\OLC8BW>LW^X^*>*](],
M7LT?Q/81^70>']8>MN>TJ'MH>S3X4&_1LO\ -#VT/9I\*#?HV7^:(K_:(:Y\
M,CGHHOT@>T0USX9'/11?I 3!W8UY?9&Q%N]9O]Q\4\5Z1Z8O9H_B>PC\N@\/
MZP];<]I4/;0]FGPH-^C9?YH>VA[-/A0;]&R_S1%?[1#7/AD<]%%^D#VB&N?#
M(YZ*+]("8.[&O+[(V(MWK-_N/BGBO2/3%[-'\3V$?ET'A_6'K;GM*A[:'LT^
M%!OT;+_-#VT/9I\*#?HV7^:(K_:(:Y\,CGHHOT@>T0USX9'/11?I 3!W8UY?
M9&Q%N]9O]Q\4\5Z1Z8O9H_B>PC\N@\/ZP];<]I4/;0]FGPH-^C9?YH>VB;-/
MA/;Z$9_X.E=Q%D_((K5<"*N$1?\ VR.8R1'_ .BL]#/!_P#M/C_V"+[>1M+=
MVCZ@4RQ9%SKNHZHEQ"9Q,JBDCF;(S^ADHR/JKYR(??PUHGT#XNJ<.C8?QQB2
M?J,2%%C,ET@L@JL. QKXKM>/3(</N6W6RNNN=D4\IC/3YV5>CZB1,18MT88/
MI-'@QY>6B3;H[YA&QIEZ,@L[5*UR-%76<EM9&6;;NE:64)_&7X?M-EO09FL[
M34J.?*ZWZT3%<I_*7>/$]NDX>GPU-^AIHI#2=J;UYZLT^W4W$Y$5=,^+'0_V
M:E%&\(6A'-RY\;E)SR^8\]>@FUA>IE[AFPH,Q&X)7+-@Q)A$5#]YX4PA[D_9
MOW'/R_,/&3N#=!DE.3,G&QM7&Q9:8C2\1OF?65L2!%6$]JJVFJBJCFJBJBVV
MVW&\J3CK3]5*73:E#P%0EAU"0DIZ&YL=&M<R;EX,=CFM?4T<C5:]%1%[I$5$
M7.UIQ/;I.'I\-3?H::'MTG#T^&IOT--$(GN8ZX_K@5^@B_3![F.N/ZX%?H(O
MTP_-Z&-!'MWKF[UL[W/Q;Q\? ^CZ*^R!R^L*A[O7#/<_&G7=M2TW?MTG#T^&
MIOT--#VZ3AZ?#4WZ&FB$3W,=<?UP*_01?I@]S'7']<"OT$7Z8/0QH(]N]<W>
MMG>Y^+>/CX#T5]D#E]85#W>N&>Y^-.N[:EIN_;I.'I\-3?H::'MTG#T^&IOT
M--$(GN8ZX_K@5^@B_3![F.N/ZX%?H(OTP>AC01[=ZYN];.]S\6\?'P'HK[('
M+ZPJ'N]<,]S\:==VU+3=^W2</3X:F_0TT/;I.'I\-3?H::(1/<QUQ_7 K]!%
M^F#W,=<?UP*_01?I@]#&@CV[US=ZV=[GXMX^/@/17V0.7UA4/=ZX9[GXTZ[M
MJ6F[]NDX>GPU-^AIH>W2</3X:F_0TT0B>YCKC^N!7Z"+],'N8ZX_K@5^@B_3
M!Z&-!'MWKF[UL[W/Q;Q\? >BOL@<OK"H>[UPSW/QIUW;4M-W[=)P]/AJ;]#3
M0]NDX>GPU-^AIHA$]S'7']<"OT$7Z8/<QUQ_7 K]!%^F#T,:"/;O7-WK9WN?
MBWCX^ ]%?9 Y?6%0]WKAGN?C3KNVI:;OVZ3AZ?#4WZ&FA[=)P]/AJ;]#31"&
M?J8ZXR__ ,@EXR63]8RZ$9XS^S>01%\2+AS2^'M<-C4*;?CE]>S54I+<DHAP
M/!#B\AGXI*5SYYC+)^8?5HFCS0WB*HP*31\75R;J$PU[H,#M+86ND*'VV)W<
M6GL8EH;7+977VV38?%KVDK3;AJF1JO6<&4*3D)=838LPL18J,=&>R'"34A5)
M[UUGJC;HVR71=EK70V>,5L$DMI>9UB96VKN5ZTRRSCYC'+[<'L)^&!GT3+_(
M*YNSO@<UC<QM[L;6:)K NWV;L:E.(I'K9X2<8H[QM9[4W"YB5W]W?\@R;]S?
MW%\/+OH7_P X:^J>'< 4ZI3]/=7*@CI*<F)5R.AW<BP(RPEUE;*ZJNR6ZMRO
MLX_TDP-0NQ\KV"\)UNO8]K<E6ZMAZCU&KR<K*1%EI2I3DC+QYR7@*M+BJL*#
M'B/AP[Q(BZJ)=SEVS+^W!["?A@9]$R_R![<'L)^&!GT3+_((:/<W]Q?#R[Z%
M_P#.#W-_<7P\N^A?_.'X?.G1_P#AV>W?>W>Y^"\5\'?]5Z#>QF_&/B+Y&_A\
M3\>N5YE_;@]A/PP,^B9?Y ]N#V$_# SZ)E_D$-'N;^XOAY=]"_\ G![F_N+X
M>7?0O_G!YTZ/_P .SV[[V[W/P7BO@[[T&]C-^,?$7R-_#XGX]<KS+^W!["?A
M@9]$R_R![<'L)^&!GT3+_((:/<W]Q?#R[Z%_\X/<W]Q?#R[Z%_\ .#SIT?\
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M\T1#>YZ:]\-Z_0ZOT@>YZ:]\-Z_0ZOT@)B#3!E]:5)W??F^X^'<? G($T?\
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MR6Y4H4JE56CN2%&EI+T*H(9E^.:5=393T+/=@!9;7LMN6V1GB  !
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ML_RC4 %DY.O5$Z#3!?']L_RA@OC^V?Y1J "R<G7JB=!I@OC^V?Y0P7Q_;/\
M*-0 63DZ]43H-,%\?VS_ "A@OC^V?Y1J "R<G7JB=!I@OC^V?Y0P7Q_;/\HU
M !9.3KU1.@TP7Q_;/\H8+X_MG^4:@ LG)UZHG0<;A%R^7H:?*9_NB\XJ@<:?
MZ86T_E<_F61; <]Z?RI_E$*G_&G^F%M/Y7/YED=!]C+]U&2_)56_9CD/LV?N
M'U'\NT1.\DP1@V5],/IV7_[S2_*?_OHQ_A_\!?EMQ)';]!,_]"4G^A,B@U97
MTP^G?\,TO^>C"_-;?^+U!_@2D_T%D:<Q5_&2O?EJJ_ML8Z0P)_$O"/YKX?\
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M2HD3M*C55+2RSGLF$F?[E"2\WD'Q&I[MX,^IH-(/8T<XK:7J-5?9P=(-PG/
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M[][DN21ME@CP>2YE']LS&\:$1%T(L#4#&
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M=O7D*<7JM[]K7:]]G$7\?TP6<]E/TK^B_P!AE#_%D45C/5;W[6NU[[.(O?\
MP_3!9SV4_2OZ+_890_Q9% LOJ&<[_P!TRM   H
M                      ;'/>G\J?Y1"I_QI_IA;3^5S^99%L!SWI_*G^40
MJ?\ &G^F%M/Y7/YED=!]C+]U*2_)56_9E.0^S9^X?4?R]1/UY&#97TP^G?\
M#-+_ )Z,+\UM_P"+U!_@2D_T%D4&;*^F'T[_ (9I?\]&%^:V_P#%Z@_P)2?Z
M"R-.8J_C)7ORU5?VV,=(8$_B7A'\U\/_ /Q,J>[  'GSU@
M    ;5^]/YOPD*:7JF?]L+0+_E:Q_P!R+EJ_>G\WX2%-+U3/^V%H%_RM8_[D
M;>T%_=)HO]S4/V*,:8T]_<TK7_N:9^WRI/KP>?\ )_Z(?\QJ?]-4).A&+P>?
M\G_HA_S&I_TU0DZ'A<8_QLQ+^7*I^V1CW^"/XG86_-^D?L,   #S9Z@
M             (A.-I](?J7\M+_IQ"./U-O_ ('UY^6@?REB1SC:?2'ZE_+2
M_P"G$(X_4V_^!]>?EH'\I8V-(?<ZJ_Y49_\ BG4F&_Y+N-_SLE?UU'+2Q=WS
MG^$QJ-"[OG/\)C4:Y.6P
M                                     &"/O+(   8QW   8+S=_?\
M&   -,%YB^T-0  ,$?>60
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M7*18+)F>!9YV4_2OZ+_890_Q9% /6[6+9$S=DFS^:96@  8P
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M/PGD[*.;Q?0N4LYY<=_?U[AYI6JF:IXCVFLU=_C)H@#_ ,?O= %2P
M       &U?O3^;\(II>J9_VPM _^5K'_ '(M#[KMV^E.T/3]6HNK%253;?0X
MVDWDLO/'XSJ6_>,I4KWRB+N%*[C4[X]$=ZEWZ55;1BK2JS$M54YRJ.G ELDA
M,I+9MX)Y"25G!^][O*-Y:"J)5WXUI%:93IMU)AI4(,6H)!>LJR(LG$1&.C6U
M$<KGL;95O=R)S:"T_5VCP\$5>BOJ,HVK18E-C0Z>L9OFJ)#2=@.<]L*^LK48
MQ77ML2ZKFA:^X/)E[7]HAU+^\:F7_P#6J$G8JS\./C![1]#=K^D.B-ZW-)A7
MK2WW*9*AJITXT(D5*>E$8B<)OD,S4ZDC,E8+S>46@*#6H=PT:E5R OGA5:#%
MGQ%X,N9B4RAYI6#(C+*%IZ&62R/"Z0*)5Z7B6L3-1ITW)2]0K%4BR4:8@OAL
MFH:33W:\%SD1'MU7L==M\G-7>>_T<UZC57"]$E*;4I2=F:;1*1!GX,O&9$B2
ML7S'#9J1FM6['*YCVHCD2ZM<FU%/<  #PY[X                #:H\%]XO
ME, 1#<;3Z1#4KN[Z9_3B[A''ZFW_ ,#Z\_+0/Y2Q]7QW-RTJN)LW9[IZ\=2N
M:^Y1Q[@@QOHCK"VWF7H25H22C+GYR//3!9R8BHVH;L=5^$?JO?EAWS8+M><K
M\*C2:C1')281)0N&4B,I$@DF3AFEU*U$C/*9X5CO&UZ12IN9P/,T^$C%G:C'
M6?E)9ST9$BR\*)+L<]$>K4LJM6R[%RS.S\$8,K57['NK88DF0'X@Q34'8BHE
M*BQX<O-3E+D9RF08TRQL96-1BO@NU'.5&.16KK=TA? )2<=_E/S^4S&O.GS_
M 'C_ ""J47JD9XLD>@BLY,\>ORLD6>A?L7D[AK[I&=^ -7IY7Z(>7] F*/P=
M_B)?A[[QZY7T]]3KI=]JSOG&F\/A7'P*6M.=/G^\?Y YT^?[Q_D%4OW2,[\
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MT/"NA]# @\L                      >',@Q9[9M2XL66T?>U,CM26C_\
MXW4J3]X>8  \&%3XE/1V4.)#AM>1J'&:BM_<,I0G[PW3(,6<T;,N-%EM*QS-
M2X[4EH\>=MU*D_>'F  /#A0(D!LF8<6)$:+N:AQFHK1?_P ;*4I^\/+/N/Y#
M_ -1H?<?R'^  4X/5;W[6NU[[.(OX_I@LY[*?I7]%_L,H?XLBBL9ZK>_:UVO
M?9Q%_'],%G/93]*_HO\ 890_Q9% NOJ&<[_W3*T  "@
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M(/IQQ/$1&Q'M38U[D3F1RHAW?"<KH4-RYJZ&QRKQ5J*OA   H9
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M/#YTVN^OZG7M5;XULU:E)JM^5"H2I3C,>6F4[*0TQ'<D/1FR3VRD'V"4$9)
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M,C(\=1*3O(VV4;=MMQU)T(N"5X)!O6E.LMR3;[3L9D9"W8*S21EDBDDV?DP
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M1@O\VS:(D_E338I&!9R*C&72V;MO_296@  8P
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M/^)EH_8Q0/Q5$'TXT!&^VQ?[Q_Z2G1<#[1!_NH?Z"   8S*
M
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M,H?XLB@6<JJQEUOF[;_TF5H  &,
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M\ZY+]GC'Z"MD_P")EH_8Q0/Q5$'TX^8LG_$RT?L8H'XJB#Z<:&C?;8O]X_\
M24Z$@?:(/]U#_00  #&90
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M_1?[#*'^+(H%U]0SG?\ NF5H  %
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MW@ME:N2(N66_=Y24R5.Z54WKG;KL+(X#8A:5ET4DS+OY5$K\!G@;QC,FT
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M*';H_P ]O_M4?E'F++R=>JITGJ[IR]>JITG, X>W1_GM_P#:H_*';(_SV_\
MM$?E"R\G7JJ=(NG+UZJG2<P
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M5]*]U^VYFU](Y#3J[<W!LV][*7*OV=.-YUIV+!ILB0U]$Y8I&Z\?-S9+ID8
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M-.H6CU5:I7L7HK,& A%.)J$A$I!&Z\A:S4X6#-2<Y+S 55+JW8V[45=R<_\
ML==>JUIT.7IKM=*-+B25>S>*:BC267^7_P!/4W_W:E9+)&6?PBS]LI^E?T7^
MPRA_BR*/SA>*5M2XC^WBD:-U'?!JM*U#H-4O&C)MJ(^S$;*$IJNP2D]8SKAF
M:E&D_&(N[Y!^CULI^E@T9\QV?13+]Z=.BF7W@)<EF,2Z+F[-/^DRM   Q@
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M5J,S#JJS$]4)F+-S<;M=7G(</ML>,Y\2)J0VM8W6<MFM1$R0  #41T,
M   ;5^]/YOPD-PVJ+)&1?[]0(7Z4\:%1_C_$2MT.SQ"DDM*KI?)2%$2DK(Y\
M C)23R2B,C,L&7E%IJR[5ME=G6@I5M6\I2K8H1J,Z-3S/F.E1#/KX/W&?RF*
M[?'&V>[H=P>I^AEW[?K%<NEZQY-2G/RT3&(Y09)J9=BJ-#WO_HK1'CKU+KT&
M+T&^_5"5.APH$6@O(C4Z)'@Q49HIDB/%:0PTG)I,SY&T)+KWX&_(U"A8KP-@
M2!)8GPW3)BDRU79.2]4J[)*,UTU/]M@IVM&O=ZAJJNMJJB.1;*BW3G:#B&-@
M_'^/X\]A7%%5EJQ-4=\E,TFC1)V YLM(I#BKVURL;ZIZ-[A79M5,E0P3XI5]
M:CZ/<5"_;PT1)5(OJC'3SH7K-34.J:4[34I=[&!':Y%&:._E;Z'U'P:N)?Q8
MC/K<]X9Y2+'L,?+Q2(B+IX)YL=<"0S9]LUX@MX<1*Q=R>ZS3)J4PXY+5=%;G
M/4Z3&/EA=A&[2"E"FEXZ$7B],$8M]IL2RC(N>S;5,^1!&I5OT@SR22+!YB'W
M=1ZS$>/\-X4EL,T28PYAK&LS(X=D)>8JC9F7FV0HL'6AOEF15EXZJQ%9VUNL
MK7?PE]5%6Z^.PMHZQ/B^9Q17I;$N)\#2T_B6?F)>E/E)J4?&@QNUQF342$DU
M+HCU:_M2ZK7I_!JB/L?G[^V6\6+ZI[P_U,?_ %0/;+>+%]4]X?ZF/_J@_0+]
M@=C_ %&6I_J[2/U,/8'8_P!1EJ?ZNTC]3'E_3CPM^*S#?1+</B_AURMZWTD\
M6_C:Q+NW37N?C'KGQM^?I[9=Q8OJGO#NS_B8_P!Q=Y_WIW$.?3[BQ<0YW5FQ
M[4NK5J?$3.N*E0ZI2Y=#CQG^PD3F&EMN-N(0ZWSMK419(N\O.+_LBQK)2VZ:
M;-M5)]@]XQ6_22,O$5T+$0OG'Y]O$%B1(/%@N"+ BQX45N\K/[.-$9;CL-YE
M13/D:92AM.3ZGA)9'O,!8IPKCV:JU-71]AZEK)T::GVS$.!+1W*Z&L.$C4:L
MI"U5O%1R.1UT5B9<FO-(>$L7:/9.CU/TQL159)RLRL@^7B1YN7:UKT6*KU<D
M[%ULH6JK5:B+KJNZQ^A-:LI^=;%N392^TDS*#1Y4AS&.=^13X[SJ\>3F<6I6
M/C'OA\S97^)MI?8S0?Q5%'TPY'BI:+$1,D2(]$1-W=*=FP558,)56ZK#AJJK
MFJJK4NJJ  !C,@
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MD][TPF7:!$9H=/GTR67A*7I41<*2E,-/;MD;9J4W@N<U=Y"2P:&1*+!Y^8\
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MSN&O>"T:(NF4-+SAIC2%)AN$XM*$F1GW@6:B*JWO9$OEP5.CG*_]YZ#WAO\
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M[#*'^+(H%E]0SG?^Z96@  4
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MML7^\?\ I*=#0/M$'^ZA_H(  !C,H
M                                           &U:DH3S*,B+SJ,DE\
MYGT+YQXOAC/_ +^+_&&_S@NB;5L2B*NQ%7F15/, >*B4TM1))YA1GW$AY"E'
M\B2,S/YB'E!>^PA45-J6YP     .%]YN.TIUUQII"??./.):;3^^6LR27SF
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MD(+XU+5A)%\IC@BS(\M)JCR(TA)'@UQGVY"2/.,&ILU$1_*?X !Y8
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M3RH/T+4"VB8.KV95XLRGU)DI*36R:6:@TPZYS-EVGBM]$]3$KQF1DK!^<OG
MA45,ER*</JM[]K7:]]G$7\?TP6<]E/TK^B_V&4/\6116,]5O?M:[7OLXB_C^
MF"SGLI^E?T7^PRA_BR*!=?4,YW_NF5H  %
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MT'\511],-#QOML7^\?\ I*=#0/M$'^ZA_H(  !C,H
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MHRR62[M]_P"B96@  8P
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M"L1KH\5<F(K6]T]S&K]QP(&VWD:R]JTVYUHY_1&T+,LFOH7,1X^86+? 8_\
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M  83]
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MHJVL]J:6SYDS3>Q:I%FQXENHE.<_9(==E/(D$V:&N4UHZ=F6,&+,H8+S=W<
M152^>T^?JEO1*A;%3M=O^YX4^@2[?;))9*/$DTYRG)))>4FFG"P73WHC+X=/
M##L7AZ2]:YMJ76[<9:QU9=8JA*BN,' 5X3*E*27,M9KZR5$1IP>4]W42J#3!
M=>A=>_X_E B^U.7:5V-J6TV_+8XMVY[7&@5*XI6F-3=M\Y'KC.J/K8ZZ5,<9
MQ!AS'393R/F9*\';P?>8L!W-:U(O&VZU:U?AM3J17H$ZFU"(\DE-O1IK#D=Q
M)D9*(OH;JL&19(^H]VS"BQW77F(T9AQ[':K98;:<=,NXW5H2E3F/)SF>,GC
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M9SO_ '3*T  "@
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MXOU%W?.?X3&HT+N^<_PF-1R0=D)L3F0   2
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M_%D4"5]0SG=^Z96@  4
M                  ];5"_N"=_S";_1U_E%+ZZ?\HU)^RN-_.I%T*J_WA._
MYA._HZA2]NG_ "C<G[*XW\ZD=0]C3]NTA_F=.>,X=[-'[1HA_P#N)(^*"7/J
M)_@FE?P53OZ,D>U'JJ)_@FE?P53OZ,D>U',,3[9$_MN_24[;EOM$/^PS]!H
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M<_PF-1H7=\Y_A,:CGXZ,38G,GB   $@
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MNF5H  &,
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MM*OW3]%/Y1B?M4F7ZB[OG/\ "8U&A=WSG^$QJ.?CHQ-B<R>(   2
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M!O5M2P-3-X>AL2I:L-T]#U1BO5)WFI4QUELGFN>/AM>%$:?%(B/ D\\%;_\
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MY,X$[VX7:_HONGLA[3W7&T&;RM1]?.Y2WWW&$JY7>U3X[9DKWQ$>/B+R#O\
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MO_=,K0  *
M      &AG@L_(7VS(O\ : 5;9J>JK;S3%,J#K[K;#2*?--3KJTMH3F.OO6LR
M27=Y3%+JZ)<0^(E(EE*CJB^RJ/\ W23S9L='DY^C<W9__P#7?T$PW%6W1ZCT
MNOV?MLT=FNP;BOB0N#6I$=1$\VTI31MF7<I)=FXK/*?48^M\%:Y)&G'LVD:I
MR4ZGKIWKYV!Q#4X4GLO#"1X4;_OC[NG=\N2'6>AR%1='E"F<0XSKLO1V:0*5
M-4BB222\Q-3/F98JPG52:;!:O:99(B:K47U;>ZUL[' 79%S.)=+V*9+"6CG"
MLWB!^B6N2=?Q+473<M(R;YWM,..RBR3IAS?-,VL)MXBPW*K'W9J+:ZV/+>D,
MR:-278[K3[2J53N5UEQ+K:O[E;[EH,TGW^0_(/=BM3LBXC$S;O-NS1#=37Y)
M,6E(3"HE4>0M]UEMM;A+YTM)4M9.)06.91\O[DQ-AMQW>:.[H2KYZ5ULZN5N
M=AZXF<=YCLRD9[(_HJ4FKFP?=G'E/(TIC71ABK!\U/Q9FGS,[1)=8,:#B&4E
MXSZ3-2LXC'2L=DSJZC>V]M:U6.==C^YSR5>EM&NF_ FD*2I,O)5>3IN)IQ)B
M7F,(S\W!AU^3GJ?KLG9=\GK)%B)!6#$>V*QB-?!37LU4>B93  #6YN<   #$
M3?%]+)JA_!A?_$*\' \_;^OW^$'?Y3XL/[XOI9-4/X,+_P"(5X.!Y^W]?O\
M"#O\I\73U"\_D*.VMY_I0MK->]/]\K\(Y!QM>]/]\K\(Y!0N
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MAT:LTZIO@-:^*V2FH4PL-KK(CGI#<[5179(JVW'W@  ^(?>
M
M                              TP7F+[0U      #&>\:8+S%]H:@
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ME<D)2<I)#[*F\DHR47C$>,#M;B:<9Z@[)=2+1T!TGTV>USW 7B4KP6PX,UV
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M_P#1Y#*T  #&
M       !H9&9=.G4C^T9&-0 *ERNEQ7M-KVTRUJTYW0VM2I-8IE'FF]7/!VE
MOG#9;-EDLMI0X?T1!*Z\G3.?(,AVN,;MQ/2M-0<>DHOCUB\!5:W@TLW/"RA^
M#_L_9<O5SQN7&2+I\8F#NFT[?O2CRZ#<M+BU>E3FS:DQ);+;J%H46#(NT2KE
M/!GU+KGJ1D?482GPRMGIU[V0?V+XWAG;G*-'ACY-=L:NTSV>>3'/UY?>^3N[
M]YTG'> JQAO#]%TA4:N3,WA-L67I-0H,S+PEG*?$B]O;(5"',61K61%5K8L%
M==&+E9;ZW+E?T7:5L.8RQ7B/1'B3#,I3L=O@35>I.*I2;C-IU4A04@/JE)BR
MJ.5\6*SNW08_\'VSU37M1J-J^W#HY>^M]F:T;M[AA2+>MZ).C/TV/*C*3ZZ,
MRI:V4\G.E"DDTDTF>$GGOP)3N W@V=9U$DBR=&[BQDB-S S?XFEH6Y9&QR][
M?M>DQ:/283=/:CPXK3;24H*2DB)1H2GG/H756?MF,'^ U_>^LO\ U/\ A<&Y
MZ[C:-CK0+CRIK*MD)"3KE+I='I['(])*F2;Z.V7@NBV1T6(MW1(D1?YSE1O<
MHAS7A;1I+Z+>RMT6T))Z)5:K/X8K%<Q#5HC59YY5JH0:Z^:F(<&ZI @HU&0H
M4-MNY9KN[MSBQD  .)3^FR;$YD\0   DQ$WQ?2R:H?P87_Q"O!P//V_K]_A!
MW^4^+#V^11)VQZHF9D1>MA=5&22\OE,5X.!Z9%N OM)F1&JH/&1&9$9X4_W$
M??\ ,+IZA>?R%'>J;S^0MKM>]/\ ?*_".0<;7O3_ 'ROPCD%"X
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MJ9 26D)+M,*6@(Y[TA0TCMLU'1'/>O.YRJ9F  #G$Z<
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M1F>"/.,BT+LI^E?T7^PRA_BR**QGJM[]K7:]]G$7\?TP6<]E/TK^B_V&4/\
M%D4"R^H9SO\ W3*T  "@
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M_"8QN2RJG-XB[554SVY]"6\IN  $%@
M                  XW?>E^^3^$<@XW?>E^^3^$2FU.=/&"B=ZH5^G%M+^%
M:5_.11;IV#?2I:1?P&U_-MBHMZH5^G%M+^%:5_.11;IV#?2I:1?P&U_-MC?V
MD'[E&C3^Q,?JT.<]''W7-)W]Y"_7M,S  !H Z,
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M"%=_1R1.O7_4&-^B6W*W=&Y52GP9:JA.J'9DM_E4T2.SR1>)DR/)&?\ XC)
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M^+(H%U]0SG?^Z96@  4
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M^4\+4Z/>E\_X3%5C@1?MI:L?\YB_RGA:G1[TOG_"8E_JE[WB0JW8WF=XT-P
M J7                                                #C=]Z7[Y/
MX1R#C=]Z7[Y/X1*;4YT\8*)WJA7Z<6TOX5I7\Y%%NG8-]*EI%_ ;7\VV*BWJ
MA7Z<:TOX5I7\Y%%NG8/]*EI%_ ;7\VV-_:0?N4:-/[$Q^K0YST<?=<TG?WD+
M]>TS,  &@#HP  TR7G+[8 U :9+SE]LAJ
M                                                   -.4N;FZYQ
MCOZ?:&H          .-QM+B32HDJ2?>EQ)+0?RI5DOO#D  >.S':8+#;;31?
MYK+:6B/Y2019'D      #Q%1&5N$XIF.I9=SBF&U.%Y\+-)J^^/*(L%@:@
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MP
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MQ/AV;6>HM7EWS%/FU@Q9=8T)(KH2N6#'8R-#L]CDL]C5RO:RH;@ !\<]$
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M1X<Q%CB#CWT)8JC428AQ,.OK4.+2H$Q#5%2;ARS&.=&5%]D<J(U4S;9<B:,
M :F-R
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ME?T7^PRA_BR*!=?4,YW_ +IE:  !0
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M*56"E&[-\,:=-OL(YNI\1*24>5%C[>18$%514VED5%V   02
M                        !H?<?R&*W'JC*D5RJZ!6"5%HU2J[T.K%-4S3
MH4F8X7@L^,^E*D1FW%%S\F",RZ=XLD#TM9MR@7"RF/7:-3*PPCWC-2A1IK:>
MN?%1(;<27QX(AZ'"E=]#.(*97%EO-B4^82,LMVSM/;DU7-5G;-5^I=';=1W,
M><Q;078FP_4J(R:\Q/GX*0F32PNWI!<V)#B(]86O#U[*RUM=-M[Y%//1#CL:
MIZ,Z3V3IDSM*NRJG:=/8B+JN*JT4XD--I(^Q\!5V?1/=G/7OR,$]S6Y*ZN)%
MNQT8K-V:#W/95NLU8HE3I3T.JR&I+$E;$=SM)1Q$DR7(:CR9I[Q?4_L6Z;_4
M':?^K])_5ARL:9Z>QGVY,>R+78D,F2FGFJ%2VW&S(\Y0M$<E),CZY(\C9LEI
M/PG2IZ9JU(P$LA5H\*<8V>;7YR*Z&^=8YL6(V'$@K#1=9ZO2R)JJB(U6[35$
M[HJQE5I&6I%8TA-J%'EXLFY9")AV4ALB0Y-S.UPW/9%:^VJVUU547:Y'64B^
MI'!7X?,ZE4F6_HPVV])I%,D/EZZS2_NAV(TMY1DI62-3BE&9>0SP/9>TF\//
MX'6_2TO\X2SI2E)$E)$E*2)*2(B(B2DL$1$7<1%T(NXAJ-<KC;%ZJJIB:O-1
M5541*I.99WM]MW6ZY&S&X"P6B(BX5P^JHB77SJD\URNOVK?9>GGO"CJYP:=A
M5N:97Q6*%HV2:S3[?J<FFO-U.<MQJ4S"?6T:&R,^T/M$IZ8/)].HK4<.S?YJ
M3PYY6KU$INWRZ[[B7=7Y,:.LH55A%!C4FHR6XQ$?@2NU(V^4B5G!D18/J/T
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MU:5!I_:X#IB',(MX$16KJO:[)67777NNYL>R  &LS:X
M
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M:  !0
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M]*E6;._]"   4+@
M
M
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M\TRM   Q@
M                      $-7&A^EDD?OV_Z2@3*B&KC0_2R2"_X[?\ 24?E
M&R]#OW3L%?EV3_3-*]D3]Q32-^;,_P")AUIP-?VI;U_Y2!_+=$\ @?X&O[4M
MZ_\ *0/Y;HG@'[].?W4\7_E+_P#'@'R>Q<^X3H[_ "/$_;(X  &I3H #KK5?
M]KF]OL<JO] D#L4==:K_ +7-[?8Y5?Z!( %1'A8_3_4K[(;K_G)8N9BF9PL?
MI_J5]D-U_P Y+%S,7?M[WTJ49L[_ -"   4+@
M
M
M                                    !M-)'\7X#^4NX_BR-P #:22+
M_?!%\A%T^4:GW'\A_@&HT/N/Y#_  *<'JM[]K7:]]G$7\?TP6<]E/TK^B_V&
M4/\ %D45C/5;W[6NU[[.(OX_I@LY[*?I7]%_L,H?XLB@77U#.=_[IE:  !0
M
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MZGV[7_O6?^U2';M?^]9_[5(IB_VZ/$4_TW='^KC_ .@#^W1XBG^F[H_U<?\
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M (2U_L5_N0>'1^F9,3^,M?>\8:$.L$SS/- ;4J):24DTJ(^XTF2B^8RZ&-P
M
M
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MU?&8O\[*?I7]&2_S;.HJ3^5--BD!9R68Q%Y7?NF5H  &,
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M3+^"6_YML95#&738G,GB   $@
M
M
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M4"5]0SG=^Z96@  4
M                                            -I())F9$19\Q8/YS
M\OS]WD&X  $?W$]^DRU4_P"2IG]*$4/ D_QBUA_?TK_O1*]Q/?I,M5/^2IG]
M*$4/ D_QBUA_?TK_ +T=/8-_DVZ1OSBD?UE'.&=(W\L[0[^:,[^A72RTOWO_
M $__ (C%1GC:_3)V;_",+^7'%N9?O?\ I_\ Q&*C/&U^F3LW^$87\N..9&;>
M]]*'<3O4-[WB+(.S'Z7'3+^"6_YML95#%79C]+CIE_!+?\VV,JA0NFQ.9/$
M  )
M
M                                                      \65+8B
M(-R0_'CMEWN27FV&RS_QW#2G[X \H:'W'\A_@'C19D>8CM(TB-)0?<Y%?;D-
M_=MJ47WQY)]Q_(?X !3@]5O?M:[7OLXB_C^F"SGLI^E?T7^PRA_BR**QGJM[
M]K7:]]G$7\?TP6<]E/TK^B_V&4/\610+KZAG._\ =,K0  *
M
M                   1_<3WZ3+53_DJ9_2A%#P)/\8M8?W]*_[T2N\3X_\
M[F>J9>=JF_TD11<"0C]D6L/[^E=_?_[3R=_E\PZ>P;_)MTC?G%(_K*.<-:1D
M_P#&=H=_-&=_0KOD4LM+][_T_P#XC%1GC:_3)V;_  C"_EQQ;F7[POWY?RC%
M1CC;'_\ >3L[XJC"_E1S',C-O>^E#N%WJ&][Q%D+9C]+CIE_!+?\VV,JABKL
MQ^EQTR_@EO\ FT#*H4+IL3F3Q   "0
M
M
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MUO3]+_6P]FUG_5=:WI^E_K8I!^YUN)7]?5=?\4?_ *P#W.MQ*_KZKK_BC_\
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M0?N=;B5_7U77_%'_ .L ]SK<2OZ^JZ_XH_\ U@ U6^R-Z%\G'K92[Y[-K/\
MJNM;T_2_UL/9M9WU76MZ?I?ZV*0?N=;B5_7U77_%'_ZP'0>YW@I\0W;%H;?>
MN%P[V;LK--L6"4U^D$S)8.<@R49I[5,\S;Y>7OQY0",:OWQO0O7?UL?H%TVN
MT:KFOUJK%)JG9X[3UMJ,6:;>>[G*,Z[RY\G,99'MA3X]2P6]KG>.FNI>O6HF
MLM9N^W+HFM0:5:E3)^3ZWJI$N1!D+1,D/.*^C+;-PR)/3N%P5)&1=3SGK]OJ
M!5R:JJE[V-P  %0
M
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M="Y3,B 7NB)R7\/7KOYNR3YU?=&'9)\ZONC'( $''V2?.K[HP[)/G5]T8Y
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M-]Y?[QIMU2U?,1@2JW557>>\   @
M
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MLW%<[U/=<2I*7VSN&<KF1S$64\JDF6.F,=_>=FTNXOD("KTLYR)DE]G(:@
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M:/W!4;HTOT^N"K1EQ:E5[0M^9.96>5>$OTF(ZZXK.#RXXI2S[\9,AV6!B
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M4>GH,M^=2*3+DY)^72*;+?298-+\B(VZZ1EY#):CZ#W &(
M
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M&VD-(2VA))2A"6T$18)*$$24)+'<24D1$.0  J
M
M
M                                                 &F2+O,AHI1)
M+)^<B^V>!"#Q"N-]MZX>VJM%TJU.I4J?6ZTETXW@Z);BU=DTEXTH;CLN&L^5
M1="ZF>, $15R0F_R7G+[9#457J?ZJCV8G48+%>M6[*!39,AMIZK3;=N-F-&0
MXM*"=4X[3D(-/7F(^;!D7?YK#NVK<[H]NPTQHFK.BMV0KKM&ML$ZQ)CK2E]A
M18);<B,:C>:-*\H+M$I,^7H0$JU4VHJ<YD( V<Y9,B)1X\R3Q_O\0U)1&1G@
M^G>6#S]H"#< VI42BR6?G(R_"'.7-RX5G]Z>/M]P W -G.63(B4>/*1'C[?<
M-4J)6<9+'G+  W
M
M
M
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MI_\ T_W_ /$:@8P
M
M
M
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MP  !
M
M                                                         ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>nt10002526x6_linechart15.jpg
<TEXT>
begin 644 nt10002526x6_linechart15.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( DX"C@,!(@ "$0$#$0'_Q  ?  $  @$$ P$
M    "0H( 0(&!P,$!0O_Q !N$  ! P,# @,$!0,,# <+!1$! @,$  4&!P@1
M$B$)$S$4(D%1"A5A@9$C,G$6&#935G:3H;&UTM,7&20S.$)2<I*ST? E-'64
MM,'A)B<U.4178G-TLO$:*$-458*5HJ,I149D@]1'6&6$I,+#_\0 '0$!  $%
M 0$!              (! P8'" 4)!/_$ $T1  $# P," P4%!08$ P0+  $
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M8UW9.KS$F#)S:Q1[=)+U@5Y2U,E;P?"2%-I4HD=/'3S\ZMKWC_B%P_Y,G_\
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MXK*_LYVNY3]3;#<X:"LFM](^NCJJZ.GE?24[Y+=4B-D]0&F*-SR0&M<X$D@
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M@?;^)_VUL+1_5+6VA*.IH--7;V&CJZ@54T+J2DJ&NG#&QF0&HBD<TF-H:=I
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M910P7%!///N]N]6$KQLKVL7J^-WJY:+X,Y=0Z74+^J+0R2YU=1(CB*GJ[]R
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M,;H/#]_Q [:6>\#A=8;BM?<-V[Z;7W/\NN#$5BWPW%0HZU@/2Y*DJ0REIO\
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M0\)7<%X?.J^ :M9+DELW&M2I^K&.7B=<)L:>_/B0765)%PDOMLAIR<XL)90
M1P...U$V'S.#D@#'? !_FKS-VR3'K#T&^7ZR65+G9M5WNL&W!S_U?MDA@*X/
M8\$U[T"XP+I'1+MTZ%<(KG=N5 E,RX[@^:'F%N-J^Y1[U2ZW.(U"\3'Q;\ZV
MM7_42_6'131?#(%]8M5DFS;=YUQO^'?7#"G'[>_'>*8\\)6$J)2>.D=C60?@
MA[PLDT2.\O0#<CJ/*NVGFU*ZVIJTYA=O,==B6Z\2Y3B$/%:W)#W0RA".7'"K
MW0>>Y%$V<9SS@''P=V/Q[C\58JWF?X,NLO[S+[_-DJJOWT2']@6ZW]_3_P#/
MUSJ1W<WXW?AKYUH-JGBV,[@;?<+W=L;OEKA0T6R6E;\[V*5&2TDJ]WN\0CD_
MIJ-[Z(VZA_3O='(;/4U+S 36%?Y<:7>+@^PY]@6TM*@/MHI $1OR".W<>I:?
MY?F%<JI2E%:2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4
MI1$I2E$2E*41*]>7'3+C28RR0F3'?CJ(YY"7VRVHCCX@'M\:]BE5!(((X(.1
M\PJ.:' M<,@C!'J#Y*LWO=\*M_'W-3=?K7J+(7:TJ;G_ *GG8SBU\N*65H$I
M;JE=(4>1\$^G;O48^S;:+.W=YG?,/M^3N8JJS.AIV86E2_,!ZP3T%0Z3PD^G
MSJVOOR'&US4_[;>T?_PQ4"7@CE*=;M0"H\ /\\D\  ><22?@ .YY[<<\UV_T
M_P"IFLJGHOK>^374R733!H:.SU+J6E)IH&QTD;6N8(O#G.UYRZ9KW>97S"ZM
M=%NG5']I'IGIBGL;HK+K87"XZBI&UU9BKJ7S5<CGLE=,Z6E:7-;B.GDC8T<
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M_E^GRN?AZFN_-Q.YK%O%'UY\,C1W;I#R+([[I3%DP]5I<O';M:8V,R;;!MJ
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M'/J.#Q6.7T1EE$;3C<_$;'#4#*VK<P.>>(\&[7",P/N;;2.>Y/'K5H?>8/\
MYLNLW[S+[_-<JJOWT2']@6ZW]_3_ //USHI DQOR2>V,G..1_57)J4I16DI2
ME$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4K0J"05*(
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M02<#!(\YY]D&W:][9]#;%IWD60R+_=8/M"I,I\KY1YCRG>GE;B^ D*Z3[W
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MTNAM39".. >X]*MC[Y(46W;4=2(4)AF+%C6N.RQ'8;0TTTVV4H0E*&P$CA(
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M?PJ,OBY/JCK_ &W4:>_8GO+GKM"P[[@2E2E(2ZI\J ![=N/7] J*O:7M1O\
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MS=)IYK'E.,Z681-:NDK!')[=ZN3+G4PAV8$E"&U ="N%H*3TJ/!YYHS]X<9
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M^2(:WVD.^S@^>GAOS KI[)'!3P1QZU9 WL_X-6I__)2O_=75<[P0O\(G-O\
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M;'>M9(,O,\P?CM2KHU-GS.&GW4I<#9Y=6A705=)[#T[T<&@Y)//D/U1I<1@
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M<'S^&#_11[9EC>F-DUQG8I9[PS,TNAWABW?7J8Y'4V9 COK2UW<*4*YY/)'
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M<)S4VY]5/"71^PW"E<RNF]G&9'0[3)S%GAW/Z!?A];Z<;WPZ3C-K?;6\?R2
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M7IR5(;MCB&B&B.I2RH+>7\. .*_93Z$O,UMJJ^1GL\M/XFVBE8\5$S8@"XM
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MMM"&TI]$MH2A _0E( 'W"O)7QTWRUD<_6EJ[]Q_PC%[I/=)_OOQ%:_7=K_\
MM2U?_?"+_6UY.UW^4_@5AGA2?Y'?Z2OKUM4D*]?XCQ7R3?+4D=2KK:4I'JHW
M&*$C])\WBOAW[.\8L-FNMYF9!8FXMKM\R<\OZUA'@18[CP2!YW)4OHX  [DB
MJACW$ -<23@8![_1"JR"9[FL9%(YSG!K0&.)+G$  8'<D@8[KEI" >.5_+GO
MQ^->5*0GTY^\DU4DU%^D Z@V;6V[V3&L%1.TVMV1Q[.U=!/:3Y[/MPARG@@H
M+G#?"E^O!'<&K1.CFJN.:QZ=XKJ!B\V/-MF16R-*26G4J\N0IEM4AH@$JY;>
M4I!Y'PY[<U[-UT]=+-#2SUT CCJVYC<U[7X.UKMDFW.Q^'?NNP>#Z%9WK'IC
MK#0E#:;AJ.W"DI;S&7TCV31S['".*4PU C<XP3[)6GPY,.X=C.UV.U*5L*PD
M\$*_ \5IYJ."2> D%1Y''8#DGO\ (>M>(M?KR4KI:X;@=(+9DJL3G9]8HV0(
M=0TJVN3X@>2XOCH04E[D*5R  0"2>..]=RMNMNMH=0I*D.(0XA0(X4A8"DJ!
M]"""""/A4WQR1[3)&]@<,M+FN:' ^;<@9'Q"OS4M33"-U13S0-F;OA,L3XQ*
MSCWHR]H#V\CEN1RO)2M.1\Q^(IR/F/Q%05A:TK3D?,?B*ZYSS5?3_341%9ME
M-KQX3NOV03I<=A;WE_G]*77$*/3\> :DQCY'!C&N>X]FM!<X_(#)*NPP35,C
M8:>*2>5^=L<3'22.P,G#&@N. "3@<!=CTKBV(YEC6;V=F^XM>85[M,CGR9L-
M]IYI7!X(*FU* X/;U^RN4<CYC\15'-+26N!:X'!:X$$'T(/(/S49(WQ/='(Q
MT<C'%KV/:6O8X<%KFN +2#W!&0M:5P;4;4;$=*<.O.=YQ=6[-C-B8\^Y7%T=
M2&$<>[R!ZE1[ #XFHN7?&WV'MNOMIU)*PR\ZP5IMDXI4MI:FU]/"#R.I)].?
M^NOW4EKN->USZ*BJ:EC'!KW0POD:UQQAI+6D X.<=\+W[+I'4^HXIIK%8+M=
MX8'MBFEM]#454<4CAN#'OB8YK7EOO;2<XYPI?Z5$YBOC-;&<JR*TXY#U+#4V
M\26XD13MOEMH4^ZM+;2"MU*4CK6M*>Y^-2K0KA$N$&'<8;H?B3XS$J*ZCN'6
M)#27FECCM[S:TG[ZA5V^NH"P5M)44ID!,?CQ/CW@8SMW 9QD9QVR/4*S>M,Z
MATXZ!E^LURM#JEKG4XN%)-2^.UA >8O%8W?L+@'[<[21GN,^[0D#U/'Q[_(>
MI^ZO'YB?DK_1->"4R9,>0T%%KSHS[/F$<%!=;4@+[\?F\]5?C7ACN,G \SWQ
M\5C]G>ZO073B_/XUE^H]EM-YC<>?!7)96XSU)Z@%A+AZ3Q\^*X8=]&UT?_Q9
ML?J!_?F_CV_;*JM>+!X=VHNEFH&INY:[ZF3KAAM[DQ'H-O\ K%V.ON?*+;#*
M97F<(4O@]"#Z=^*A_P!#=(;KKMJ18M,+1E5QL-VR0O-09\N]24,(4A'5U+7(
ME(:1V(XZU#N1VK:5MT-9;A;67%EZF=&V(/J7,@&R&01M?*SWCN/AYYX*["TK
M]GG0FI=*0:HAU]624D5&V>ZS06QHAH:F.FCJ*V!PD?XI]EW%K]K7<#/GA?I:
MX1G.*ZAV")DN'WN%?K+-"E1YL-]IY"@D])ZO+6OIX(/YW%<CG.O,Q9+C"/,>
M;BR'&6_3S'FVE*;1S\.I8 ^^HK?#3V_L[*M H>":C:P62_WIX*?>3.O\!Q<)
M*WE/("5N37>KK2L @$<<5F]>MS>A5AZTW/4W&62@'J";I <'8=^ F0>>WPK7
MU91"*MJ(*%TE;3Q2N;#.V%X\5@/NNVX.,_\ 7LN9+W88Z2_7*@T]+5:@ME+6
MRPT-QBH:A@K:=C\,F\+82T/'QY[C@@JJ5O<\2'Q%=.]Q6HN,V)R^85AN/RFD
M6B,S8S/A)86E7Y0STQBW[Z0%^\OMSP*P^MOBV>(C>G5Q[+J/<KO*;Y)8MU@:
MF.I6GNE"VV&7%#J4.#R.1\O6IW/%BW[[?;?MSR7$M-)6+9?J!G#;<:/,B0(#
MLN,EA\)>4N4EI:^2T2$DN?#L.]5SO#@W.8OM6W&6?-,[ML.YX+=G93N3^WPV
M9:(I=:5Y1;:?:>YX<62 VGCL.U;CL<%/5V&2L?I6C;4TL0C@@?$SQ*UT,;=[
M\R1;VE[@=N0XO=D97=O3RV6J]=.*J^U'1JPQW2STHIK?;JBDB]JU#+04T7M%
M1NJ:(SPOJ) X1AXG=+,'-W*X9X5VN^X/7K;E:\OW!V:5 R=2GDLW*:T(K]S0
MF0IOJ5#\MM3/0A('O)[\]OG4GO4..2?ESQ\*@'R+Q[]F^)MF#AL&5=6&DA3,
M6UV2?"8\QP=3B$-QH:6QPLD'I2 ?6ND+U](FQ]_K9P?;[DU_6>0TXEN[-!7^
M2>/8@.Y/I\/2M=U.F+_<*NHJ8+%)0PSR.D9 =L4<+7=F RN9P/D!Z =ERY=N
MD/4K4MXN-WMW3JJT_0U]7+4T]M=X5%24,4KMS88W5LD&&,!_RL'?:T-PT692
MXD?Y1_0#7S;M)9C6ZX3'U>5'B6^:^\ZOW$H;:CN+6HD\#LD$^M54KKXV^\3-
M%*3IUM8R*.E[M'<<7) '5V3_ 'Z&!\>>_P#(.*Q8W%^)_P")-;<0>A:B8S+T
MOQ_+XLF+%=>3%==D1EI4S(;;/E(<3[CA02#WY[_*KU-H2\RRQQR24$#GN;[C
MZV!TO<9VQQN>YQ YP!\\<X_;;/LYZ[K*NFI:JHTW;IIY&M$%1J"WRU1 PZ01
MTM)+/-(]C-SMK6YX.<8RL+=V.IN*W+Q%,KU*MLQ,S%X6:6%MR:CGH4IB<TP_
MP>3R&EH5R0>W'>K^&D&9X]GVFV%95C,Y%QM%RQZTIC26B"A2VH+"'4=B1U(6
M%)/?MP:_,_9QB1?,:R/-95X29,.5[8_"?(,F?*GR%.EU*UJ\SW'5]? Y ]*M
MC> ?N_7FVG-UVY9?=5KOF"!HXX'E*<=EMSE+D/("CR4AEL =R?3C@#TS#7=E
M+[-0U%,YTILC&4D[<?\ R2R)GB$8[M<&$XXVOSG@K>OVCM &;06G;E:I9:L]
M/X(++7LVNW.H9(*2+VHMV\NCECA=(6^YLGR7?W95D:E;4GJ'/W'](]:W5IE<
M&)6(6^F^:"X[MAU,O&Y6&FX:/P;<AW)X*GGF!,Z"51(X<9_*@NOA+8Z.>2?2
MLO:C)\7O0C.-QVPG672_3N(Y.RN<FS7FW065=+DY./ST71^+SR!_=#3*FE \
M\A7H?2BJ.X^:IE2M]O@Y/7.9 Q_PY\@ND4R;F+:_&O>3QW[LU%<=\^3'CHB!
MUU"D)+JRA*P$JYYX[U9:\!/6K;7K3ISJ??-M&W*3H%AL>1;VUM2[Y-NS]]<2
MZ\A?F,SDI?B*C.A0(*1U<U#AD=TS[0/0G9!OKE[18[C>DEOU,Q;6+39FVQWY
MMR]M0YC=KEO--V];[Y>*3*0I+*RGJYY^-28_1X[CJ5G;NYO6&ZZ;R]*-'=1;
MI99^E^%RXBHB[:4OR5WGI2ZQ&?(<?<*@'&T@<CI'%%<=C:2,^G+B>0>>/P*L
MWTH/04HK24I2B)2E*(E*VJ4$^OX#N:U!!]*(L6]YG^#+K+^\R^_S9*JK[]$B
M!.!;K>5+5SG,@>\M2N!]?73TY/;U^%6@MYG^#+K+^\R^_P V2JJ_?1(?V!;K
M?W]/_P _7.BN#_#?]WZM_J5<F X'%*4HK:4I2B)2E*(E*4HB4I2B)2E*(E*4
MHB4I2B)2E*(E*4HBZKUITFQK6[37*--,NCB38\E@.19#9)'2[Y:A'=['D^4\
M4.!/Q*>#ZU65N7T<2YN7&XKMVNABVY^=*DPXXLG>.R^^MU+/5YH4>A*DHY/K
MQS\:M?5MZ$_+^,_[:]JU:ANUE;*RW51A9,X.>PL9(TN;P' /:[:['!+<$COE
M9]H[J=K304-93Z8O#Z"GKI(Y:B%T%/4Q.EB!:V5K*F*5L<FUQ:YS "X!H=G:
M,5Q=J?@,671+6K%]4,_U(3GEKQAY;\:P*M?L:775)]Q2GT+5W0X$K]X=^/M[
MV(_J&T^4TPJUVUUEEEJ.TA^#'>X:90&VTDK;)/2@ >OI7UPD#N!_+6ZK-TO-
MQO$S)[A4.FDCC\./AK&L9DNPUK &C).2<9/'H%Y^KM=:HUS74]QU+=)*^II:
M<4U.X,BIXXHMQ>0R*G9'&TO>2Y[@W<XXW$X"X/>--\"OC)9NF&8U,0H'JZ[+
M;>3SZCJ,;J/-8\9GLCVR9>S+7>M(<?FN*8?<2EN+'C>8ZAM2T-CRF4\%:N$@
M_#G]/.7]" ?6OQQ5=5 08:B:(C_)*]G^UP7ATEXNU X/H[E7TK@<YIZN>$_C
M'(TK\Y+Q"<2MNG>[747$;9@#NGM@LUP@&U6)E#DEIZ, %O!N0EM/5YZ4]1X)
MZ.OOZ=\6,XR;'<BGPY6.8W,QEA BQ7(;/M+[DB0I*&>I#B4A:%.N\J]TCCD#
MX5^BKK+L3VPZ^9.G,=4=-8.19$D<?6)><BN+]T(_*>21U\)  Z^:ZH9\*C8Y
M'D,26M&8(>C/M265&?((2ZPXEUM125<*X6D'@@BMM4/4:V0TE''445<ZHIZ=
MD4CF2-<Q[PUK7N]^3<[=MW OW.!/'GGM?3OVIM)V^RV*FN5AU#+<[7;(:.>2
M"JBEIIIVPQQ32EU14^)-XIB$@?4-?)&YSMIY)= SM&\$*V;AMON%ZM7C4G*=
M.\DR9F0^NV*EW=Y;26W"AI:A[4WP'$<+2.GL.P''-=O7OP!M5<=2Z_A>ZW)V
M?(0IQH*3<CTH2"I9/F3>_2D>G')X^)JT+8+!:,9M$"QV2"S;[7;&&XT*&PA*
M&F&6DA"$I2@)3^:D<GCDGU)KZCC*'4J2L<I6E2%#D\%"P4K'WI)%8=+KF_OJ
M)I(ZH-A?*]\<$D$$S8XRXEL>7QDG:W SG[UHFN^T+U*GN=;54UZ#*">KGFIK
M=54%NKHZ6FDE<^*F#ZFDD>]L3"(P7..0.?A^;YNZL.I&D>I]]T&RO5V[:G0<
M2D16'WYADLMI,H)6I:F'7EI7Y1Y/QYZ>?E70\E^;IK?[+?L'RQU5XC!"XUXB
M(5'<MJW$H*A[B@I?3SP>XY //-6[M['@>63<GK3=-6\'U _4&]D*D+OMO]@5
M/]I6TUT-*#CB_<X45*X ^7-8BM?1P[]YS >UW*XXDQUR$*L7)<CH=2MUH'S.
M4^:@%'(/;GGX5LNWZUT\:&E]IKFQ2F >UP&D+0^9S0)=S8XMG+MQ]PX<#@_#
MK/377SI>[3UG;=M0Q4E:ZW,_;5 ZR21LGKI(8VU?BQ4E$:7#I6O<UL)\.5C@
M) >PZ(T"VL>)=N0TPQ[5?3[<5='L=R!MP14>RLI\D15>44\NOA2N".GGX^M=
MS_VN#Q9__P"8*Z?P$7^OJROMEV]XKMGT?Q;27$>KZJQ^,6U.E3G]T/N<*?=
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MKIYK[5-FTY?.E^EK2;I4B%UTM]RN-KB@>UCI&X@;*^)[Y'L\..,NC:Y[VMW
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M3VMK]NC?PZ/Z546OUOGTH?\ =VY^&/\ ]93];Y]*'_=VY^&/_P!91-G\3/\
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M439_$S_5\OA\?R*O2^UM?MT;^'1_2I[6U^W1OX=']*J+7ZWSZ4/^[MS\,?\
MZRGZWSZ4/^[MS\,?_K*)L_B9_J^7P^/Y'T5Z0R63ZNQOX=']*M/:&/VV-_SA
M']*J+GZWSZ4/^[MS\,?_ *RGZWSZ4.2!^KMSO\?^Y_C[_P I1-G\3/\ 5\OA
M\?R/HKTGMC/[?%_YPW_2K7VMK]NC?PZ/Z5?FN91NQ\=K#]U]LV67O69]G7:[
M'IAV$0+2M#A$82^?:DJ,?@,D*Y)[_IK/Q.W_ .E"K"5)SMPI6A*TJXQ_@A8!
M'?S/7@^E%4QXQ[S.>W/EQSV^/Y%7I_:VOVZ-_#H_I4]K:_;HW\.C^E5%K];Y
M]*'_ '=N?AC_ /64_6^?2A_W=N?AC_\ 645-G\3/]7R^'Q_(^BO2^UM?MT;^
M'1_2I[6U^W1OX=']*J+7ZWSZ4/\ N[<_#'_ZRGZWSZ4/^[MS\,?_ *RB;/XF
M?ZOE\/C^1]%>E]K:_;HW\.W_ $J^;<XEFO45<*[1;3<XB^.N--3%E,JX].II
M\+0>#W[BJ)^3:0?2<\0Q^\9/>M0'6+58H,JY3W>BP**(L-EQ]]82'.5=+;:C
MV!]*PZV=[CO'NWVO9XQMZUA?R%>F\_ZMRGKA6B)[)*]H=BA',E0"^7FEI]SD
M<@4!(.0<$=B."I-:X$.:\-+2#N#B"TG&#N'(.?PPOT3?['FFOI^HW$/_ +UV
MC^HKD=HME@L+!C62W66T1R>2S;VH<-!_SDQTMI5^DCFJ./ZWSZ4/^[IS\,?_
M *RGZWSZ4/\ N[<_#'_ZRIF1[AASWN'?!<2/P)4WRSR#;)4N>W@[7S/</+R<
M2.,_D?17I?:VOVZ-_#H_I4]K:_;HW\.C^E5%K];Y]*'_ '=N?AC_ /64_6^?
M2A_W=N?AC_\ 65!6MG\3/]7R^'Q_(^BO2*DLK2I*G8JDJ!2H%YL@@C@@@G@@
MCL0>QKA+V!:=/NK??Q'$77G5%3CJ[9:"M:B>2I2BQU*))Y))Y^^J2/ZWSZ4/
M^[IS\,?_ *RL/-X>M/T@+8IA=LSW<'JZ]CV.W>8S!B/HB6>6HR)$EN(V%(CJ
M*T\NNH'?@<'GTJ37.;^ZYS<]]I(S^"N1NEC)\*<QD]]DKF$^?.W&<9\_BOT/
M;9B.$6>4B=:,<QFVS$<]$J'!MD=]'(X/2\RTEQ/(['@\_;QZ<K]K:_;HW\.C
M^E5!32C$?I*^M6 8YJ9@>H[MPQ7*HB)MHD^58FU.1UH2M*E-K6%HY2H'WA]G
M>NQOUOGTH?\ =VY^&/\ ]95"YSN7.+CVY)/ZJCS)(=TDV]W;,DCG$#CC+LGC
M/;X%7D+U LV06R7:+S'M]QMLUM34J')6PZR\A0Z2E2'.I!['L2.WJ.]8L.[(
M=K#SKKR]+,;ZWG%NN$.14@K<45+/ 1P.5$GM51;];Y]*'_=VY^&/_P!93];Y
M]*'_ '=N?AC_ /65>AJ:BGSX$\T()!(CD<P$CL2&D9^]?MHKG=+:'MM]SJJ)
MLI!D;2U<U.'D8P7B)[0X@'&3G SA6^[%LXVS8Y=X5[M.F6-Q[E <\V*^3$<\
MI8((4$K04D@@$<]^W;T[93-.QF&VV6EQ&VVD(;;0EYM*4H;2$H2D @ )2
M/2J+WZWSZ4/^[MS\,?\ ZRM#M]^E#C_].G/4#TQ_X_\ [2J2U$\Y!GFEF+1A
MIED<\@>@W$X^Y0K:^X7)S'W"X5%:^-NV-U54RSEC202&F5SBT$G) P,@^BO2
M^V,_M\7_ )PW_2K7VMK]NC?PZ/Z5?FL:L;M_'6T5W)8KM0SK6=Z%K#F3JF;'
M9T0+2ZB0M#27E?W0THL#I;6D\J5\:S]9T"^E!R&F7F<\<6T^RT^VL#'^%-O(
M2X@_WSU*5#D?#N#WJROQ^&>,N8,X(R>X/W>7FKS$B):I3A=D1K-(</JY(9AO
M.?Z:TJ41^DUX/JRQ_P#V?C__ #2!_5U1S_6^?2A_W=N?AC_]93];Y]*'_=VY
M^&/_ -95=SAV)_$_7D%(%X  EP/(>(0!V_K^1]%>@9=C1VTM,JA--I_-;96R
MTVG_ #4(Z4@?H%>7VMK]NC?PZ/Z546OUOGTH?]W;GX8__64_6^?2A_W=N?AC
M_P#6510V9_YV<^KO7'?CX\_(J\G(B6J2X79$6ROK/JY(9ANN?>M:5*/WFO +
M;8_A;\?^Z+ _JZHN7[1CZ3OC-DNV0W7/G&;;9(,JY3G.G'U%$2&PY(D+"0X2
MKI:;4>PY^^L+]H&Y3QZ]\]TS^S[?=8G\@F:9S_JW*T+A6B((<KSW8W1U25 +
M'FM.)Y3V[#YU7<>V3CYE3'B8XEP!CL]V!G&.W;OCTX*_2'9=C1VTM,JA--I_
M-;96RTVG_-0CI2!^@5Y?:VOVZ-_#H_I51:_6^_2A_P!W3GX8_P#UE/UOGTH?
M]W;GX8__ %E44-F?^=G/J[UQWX^//R*O2^UM?MT;^'1_2K@N<8#@FHT%%OS.
MPV3(8K9);;G)B/%HD\DH6\E93S\0GUJDI^M\^E#_ +NW/PQ_^LI^M\^E#_N[
M<_#'_P"LJ37.8X.8YS7#D.:2"#\".5<A?+!(R:"?P96$.9)'(YCV'CEKFX+3
MSW!\BKBOZU?;Q_YM,4_@;?\ U5<^P7232W3>1)E89BF/6"3*Z?.DQ6X2'E=(
M( #J$)<3V)YX5WJE9^M\^E#_ +NG/PQ_^LK%?=MJ1](4V2:8R=6]>]5WK#AL
M=QF,Y,3%LTI2)$MY,6,"W'67.[ZT#T X/-77U53(TM?/,]I&"UTCRTCC@@G!
M[#NOVRW.Z5,;H9[G5S1/P'12U<[V.Y:0',<X@\X[CN"OT54+"TA22D@_%"@I
M)^?!';UK?4)G@5ZC[M=8-F&*ZG;J<P.87S*T/2;#/5&BQG#'3)7W*(Y^+10/
M>X/;X$5-F/0<^OQJPO,(P2.^/KS7H7%IYZ)+;8_OCD*6TV>>/RKC*DM]^W'O
M$=__ (C\Z3Q/-HWB78;O3U=U0EV;/9VW^_SH;]KEV/(;DIMJ&TV0^MF!;GU.
MIZ222E* 2?2OT8)<D16)#Y3U!B,_((^88;4X1]_''WU2L\0WZ1;JEA>Y+4+:
MKI'I!"ML_#9,>"YG-U$.YQE&4@J#Q@W&*XR0WP?=YX)^=%*/.3M .!SG' X]
M?N^*B7TBL>T/*ULV+6+>]JMH'DSJ?)?M]\L.=K:1)4GI<2F5+?8:4$KY]Y)X
M^-7!?!8T$TFT6TTS5[2?=')W,67(U0'E7B490>M*6EN*0E34N7)<1YW5QP2D
M]N_-5$LVQ+'-_P!<8>0;UM\^,:<VY!6^+)8M++7&>CMN@*6TJ98FF'5E*?="
MR>1Z^OI:N\!W0+9GH-I9GMDVDZTSM9XTI5M&5WN9&ND1++K2W/9RU&N#KH;"
MU%?(9X';@T4G]CR?+C''EYX^?FI_Z4I16DI2E$2M#W_W_P!_T5K2B*!O?MX-
MMRW%:^QMU&W/6AW;YKL[%E6_(LFCV@WGZ_A3(7U:XV[&<6AA'1!4ML*(*@5=
M0/-92^&7X:^'^'EIW?[-#R-6<ZC9U)]OU SUV.N+(R&;[2[);<6PM2_*#:W5
M@)2L@=N/2I/B ?44[#[!15W'&,\>GU^7HN@MS>(7[.=!]4L5QQA4R]7C$KU%
MML8*""_(<MDE#;043P"XLI2.?B?0U7N^C3[0=PNU7!=Q#.O."/X/(RS,94NP
ML/26Y!EQD7JX.^:"C\T*:<0L<]SU?95@W<CN=T8VI:<7/5+6[+8V)XA;$I\^
M4X@OR'E.+#:&X\-!\^0I2R$E+2%'OP1W%8S[/_%"V<;T;[=<4T)SL3\FM*@9
M=AN-DEX].<2X%+;<8CSVH[TA*D N=33:ATD*Y(-%7)VD>1(SQYCXJ1D<\#GU
MK6@/-***4I2B+0^AX]>*K&_24]HNOVZS171ZVZ&82_FD_'<LMLJ[Q6'VV5L,
M&]0'2X?,/O!+:%K/Z._VV<BH)')^8'WD\"H^MU?B:[,-GF36G"MPFHZ<;R*\
MAURW6EJPS+[(>$= =<(9AMO+24)(5^9S\:*H)!!'<=O-=R[.<%R;3?;=I)AN
M61%0+_9,5M<:YPRL++#R8,=*FRI)*3T*!3^D5E#6'>TO?=MJWM6O(+MMVS*7
MEL#%E1V[PN58KC9#%5)*DL)2W<&FE+ZBD_F#@?&LQ**B4I2B)6T\\@\]OE^G
ML/\ ?X5NK$C==O:V\[-,08S/7;.K?BULESX5NB1RM,FX294^6W"CH1!969)!
M>=0"0V0 >31%6_U#V-[G+O\ 2(,<W*0=/WWM$TJ6M[-C+:2TT!8DLD&.??/Y
M7E'//PJWBRA2$H23STMH0>_;J2D _P"_:NF;CK?I;9]*AKK>K[;[7I^+,U?%
M9%+:;9Z(#\<2&E];G2X%N-D=*.>HD](!-8'[?_&<V%[DM5&=']-]5'G\RGRY
M,*SQ[K9+C:(=W?AJ4F4F%.N"&8T@-*0>[*U@]OLHI$EWW #@>0]5*Y2MJ%I6
MD*00I*DI4"#R"E0Y201V((/((/%;J**4I6QQ:6D*<6I"$I'*EN*"$)2.Y4I1
M[  =R20*(L:-WV#Y)J+MSU:P_%8BIU^O6*W6-;(@6$E]Y4"0E+84H]*>M1"?
MTFH(/HU>T37_ &J:/:T6_73"7\*G9+EMPE6>,_(0\N0P+W/>#HZ#[H4VXA8Y
M_P H?;4SD?Q =LD_= SM#MV>P;IK2^ATKQZ"CVQEH-Q#*6ER8PIR,#Y//*5*
MYY!21S7T=UN^O:_L;MV/7#<-G#&#1,K7)38D1K2_.>GJBJ ?\N+!07%%*E#G
MA*N]%(;L;>>><8[_ !"S+'H.?7BM:P!VK>)ML^WFY+>L1T U!GY5?; EA=TB
M2\:N]E# DH*V2ERX,-(<ZD#GW.>/C6?H(4.1\R/PHHK6E*41:'T/'KQ5=?Z1
MMM7UOW2[/8&+Z)XF]F%_@9!9'I%M8>0TYY:;W$=4L%SU#;:%*/'RJ6C=MOHV
MW;)\;@Y+K_G+6+QKKY@M4&/%>N5SN*F5!+@C6^&%RW>@J'/0VKYUUCM,\339
M_O=FW:P:*9\F]7^R);=NF/7RSRK//:;6E3C;HA79#3RQY:2[U);/"?>].]%4
M9'O#/'.<+D/AMZ89IH]LUT4T^SZV*L^56"P-,W:W+<2M4=Q339""I/NJX^/'
M\M9W5$WKGXT&P7;OJJ]HUJ#JH[&R^VRXUOO#5KL-PN=NL\B6I*(J)<^ V[#C
MAQ2P.77$ $&I,-/M0<2U0Q&RYQ@]XC7[&+_%;EVNZ1%I<9DLN)2L$*05 * 4
M I)5U \@]P:*F#Z+FE*4HB5H>W?GMZ<?]O\ OZ44I*02HA( *B20  D<DDGL
M !W)/H.]15[E/&2V)[6=1)>ENIFI\@YG:W&FKQ;K!8[ED"+47@%(,R1:6I+4
M<*2>KETH X/)]2" $]AGY*%K7'8UN>R?Z0CI_N0L^GK\C19A3JY.:>UM)9C)
M;L:&2%,'WCRZ"@=QZ5;RCMK;::0H_F,-((Y_QD( 5V]/45BYIYN_VZZIZ**W
M(87G%KO&E\>&[.D9(F.@/Q&& ?/\YHDR6EI*%)Z%]*B4]('-806'QX?#1R7)
M;?BEDUJN,Z\W2[*LL)#.%W]<5ZXIE"&ID341U1^!(/05^9TCU)HI'+L<=@!P
M/3U4Q5*]6#-CW*##N,19<BSXL>;&<*2DKCRF4/LK*3W25-N)/2>XYX/>O:HH
MI2E<7S',L;P+&[MEN676-9K!8XKLRYW&4M+;,:.RA3BU*4LI3STI/2GGDG@
M<T1<0UNQZZ93I+J-C]G07[I=<1O\2 P%!)>DOVJ6TRRDD\ N.*2@=O4U6O\
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M0?Y:WTHB\;326DA*4I0!Z);2$('Z$IX'?X]O6O)2E$2E*41;%H"TE) (/P4
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M4/6+KO/ICJC=--T=599J.+3L%LHGTD]08)&.\2O<6U,+:IS@Q\C,OB!+F'
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ME#7O."AK3>&PA+\I]V))0)Q9C*2KS2&E<'E)X'/;FB 9( \U-!6G?GT[?/\
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MS C,(3/N0:'M-P?X"ENK=4"Z.7.I025<)!X'H*GOX^/US]?]XAG//8?G]?\
M;U4)3?@T:]I>AJ_709 $LR8,A9\J9P1'=;<6T?[KX[A)1SP14_>D^$W#3W <
M;Q&Z7IV_SK+";C2+JZDH<EK2A*>M25%1^'?D_$]Z[&Z$_+^,_P"VMU0))[J0
M:!V6A]/O'\HJG'F2;:_](CU"BWE-P8LTC"KPQ=)K4*6IJ/#>P.2V^\T^TCA:
MVFE*6E+:NM2@$@=7%7':Z =VR:*OZN/ZX.X/ <U+DLKC/Y*L)4^ZRY&,1:%I
M*2%)5');(42"#Z<U13!QGX@A4$,C8:VRZ=:HY?H)J\SN&T!@ZEIE7G2.\8FB
MR9:F5)R]Q;[$:[71M60.)9FJ<*5,@CRT@I]PUGAO8U0M&H.L_A8ZU;A<'R+"
M=IUPAY0F^XAS=9\&POL083$%5Z\A'4ZA^< XV)J.A(!Z3P*LY7[PN=E.1ZBK
MU2NFC\9S+')J9[JX]PE1K2]+0X'$O/69E2+<Z0L=?OL*Y5W]:R8U5VX:,ZSX
M"WIIJ)@=FOV'-1FH<:UF)'8]B8:2E*4PWFVPY%/"1U*CELJ(Y5R:*>\<<<^9
M^8QY?]/3LJEL&]:+ZB>-+H_-V519SN"1,'S)O7%VT0I\?%Y$=["'48ZV^SY:
M+:ZX!RGW4J6'#[PZ^:\O@Y8OH/D6Y+Q'= LJL\-C,<S<>BXS8KC:W8[[DAZ/
M=E..V]];*>EP.+0X"DA)'KZ@U:6V\;+MN6UR)<(>B^G-OQ<7,$39CRC<;B\E
M75[OM\L.2DIX44](<Z>CW>..U=99?LJTBP?-<QW*:,Z70V-Q<J#(=MMXCR_9
M47"?[*XRTEV-[L105RE!+J2._/IS14+AC&#V !\^#GGZS^BI,2[_ *P+<1X&
MST2[JE(U1;OS:RN1U"UC+DY7Y941^9[&/+X+G'3VX^%9K;][5H+H[XN6Q?%M
M9[.ZWI+AN.OV^XQ(R9;K#$MO%X#+CDAB(%%Q*Y:%*7UH('))[ U)[X>OAP[E
M+COAU,\0#>O#@VC4NXSTMX-C335O?-KA,M/6\NB9 ]QQ3\0-.^\ 4$\#N*[,
MW+^&=GFOGB?Z.[B,BM<:]Z$XW&OT;+;8_P"S\OHN%H]B8Z%*)D-E+I/"FQU
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MH(2[PI]'M*&W>H("^E/'%$!&WY!P \^?7ZQ_*T-#_O+'_LL?_5IKW*V(0E
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MEXT@V_>*7@&AN07\Z3X3<,#MND:[E*N*I=@M^2W!]FZALW)PS$I>;?X25E)
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MH6E2%I4 I*DJ!"DJ![$$'@@^HK]U'<JRA?$Z">5K(I6R^")7MB>6N:XAS&N
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MM3B^ WP2'TD\CL2.P[5FA8;#:<:M,*RV6$U;[9;VDLPX;*4I;8;0D)2A 2
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MX5&"2\9P@W'5O YEDMMWQQ$J.7&V+M>HT5]25D+;<*(ZW5^ZDGM\S4\Q]/\
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,E*(E*4HB4I2B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>nt10002526x6_linechart16.jpg
<TEXT>
begin 644 nt10002526x6_linechart16.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( DX"> ,!(@ "$0$#$0'_Q  ?  $  @$$ P$
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M=+0U.'.")D-$4F-E=__:  P# 0 "$0,1 #\ O[DA(*E$)2D$J42   .223V
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M3-)FEVZ6T;L,&1A6M6T^!:5YC:S<&Y)ND[(VWEV=E*XZ/(;ZBE".6PK\+O\
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M9]S6]&DZSD36WTRCJ*3#:6^V%NM-H<BLD*:C%G>@I0I2EJ<4M1_12E>">/\
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M"<'<1QG"M">TWTQU^U?Y%LF7*WQM-6M5XN<J]0#!C-P6U)0XXE[Q'&U+2I0
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M''G%J#L7?E++*"\GW&@MV%/6!05XC%P5U(*1E%L *"D-A*7&PD)*?=  'PX
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MXZW07[E(D8SH1A*;8S)MS<L.M1&6F&FU(<:0M#D@2UL$#J2KR^>0*Y2.$YX
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M)'/PXK-W<[H;C^S?*8VTC;5F<W/-6=7&K"UGLNSHD1E6YN6U'D,)4VRXXTX
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MR^SI,F2L(0'&F9SC#?<IZO,<2$<#GU_)7?>W/$<K\5OQ"L@UHS&+*D:,::Y
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M*/PA=%KEA&V^[:@K8$3)=2V[C,;><0DO(E(<DJB+)5W(\UU"N_8^GIV%?OQ
ML;W 6/<-D,K7]^?<'YERZ[!/=4H09%M2LE3;#39,9LIBE*"4@$J[GO5T?2+"
M+9IKIGB6)6U*68=GLL)2@E(;2A1B-KD*('' "^H^GJ*JU^,7KXWJ_KC"TQQA
MMBXVW34NBY2XC*%*6N:RE?#CZ$%?WM8(]Y7V5T.M-0NZIU;?KZYR+C<9+S0/
M=N,E?AQ6N?1IA#;8'P3Z=JRWIII)G0V@-*Z6: "K19X;$A2<8>G+;2[/?.T
M;GI;C[A^:C444J!$R?+[-:]++')<G3)4!-MMK"'93BIZ%-<NDE*RE*9 #A!
M3Q_T:O!;'L:UCQ?;YA5KUMD(7F3,!)<80PPP(T500J(@HCI2CGV?H!Y'//)(
MYJOYX(> XGE6L6=Y#?K/%N=SQ4P/H1Z2VAUN&I]E:7B&G$J0I1X]2.01S5L%
ML ) ' 'H !P D=@D =@ /0#@?(5BJSSCX>M9T@>OW8_7Z_&M=0$>.9OEUPV=
M8CI@SHO=!99N<IO3-SN)98D%IN,4MI2&WDGGJ2I0Y'ISS4^]5/\ [IVY^K6W
MT#GGJR+CY ^8CX^E9_TLM=OO6N[#;;I%:FP9+LA+\9X$MNI3#?6D*"2D\+2E
M0Y[BH[ZMW:XV/I_?[I:9;L*?&;BEB2R0'&BN;';44D@CE"E)/'8U5HR/6;4#
M*M6)>METFSGL_G/)DOWQ%O<4QYY3T]?6ALQTD? ]0X^!["IP/ EL<37K>CEN
MJ>JH^MN98\W!^C[E<B7@WUPUM@>4[YB?<0D!(_8\<#CCMUOHOJ]L%M?AS7C!
MLV,!.Y=R(XF(E<%]R4\ZJ2M3?3*2CRT=+)3^R//?CY#N'[G!_P",9JAS\78R
MD=^?O2D2"WZ?] I^W[!WK:O6=P2]H;6Z6+++LB[''^@HDA]LM&7;T.L(!A.$
M!:H3B?=P%*2H8"B:U'T+;U,Z\T.I^^Q+ZB_/IOLV*R]XWE+@M#B]LUKE*9C:
M_>.1E)Y ]:N\M !    3[B0!P$I3V2D =@ .PXK<X'R'YJT-?@G_  E?RUN5
MHE6_X[#[!^5>. /0"O-*4JM:5$\=ASR0/S]N:J;_ '0'NSD3;QC^V#&9$J*P
MSYKF:A*G&VW^I*)< <\)"PGC]@5=R>?E5L-]U#3:G%J"$-)4\XL^B&V@5+43
MZ<!()-4?_&9SO%]?MW;^+:26-%YO>"H=3E5\@+4ZW,ZX8* Z0"E!CI0I/X7<
MI^'<5FV@(S;]_;=>:*VXK+K_ (F0&V7$@!MQPGC&XX2,@[RDCM6P/LUVJ+/Z
ME1)DZ&N1$LT"9<C(*D(BP)#: B-*E*<PG:EQ>UI.0KQU-*&0DU#MA67W73C,
M\4SK'WTHNV-W2#)844I4$L(DLF4"E7*25M)4._?OR._K]&;9EKU;MR&WG3W5
M.W(4VF[VIJ+*0I*D],BW-MQ'E#J2GD*=0H^Z/C\A5%;P_MG$7>QK-(TPG92K
M$HEIFL.3)B8AF%\1E><]&Z.4]/F>4IDJY[<\GFK]>W_1?%MO^E.+:4X<REBQ
M8Q%,9@)!^_.JX,A\]7<><Z%.<'G@*X!K)>IDJWK\G%&XW)A162 0E$9U 4 I
M6,**E84@ G;[Q.,C,K>UK>-,R%6&S)\1S5EN<4^XM+2T-L6B8R%I;==4-KJG
M7DH6TE"B6@'2K&\9[G("AP?]1XK1Y2?FK]\:W*5$E:45I2D)].>_S/-:J4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*ZPS_6#3C3,Q1FV6VNP
M+E]7L[4J4PAUSI/O?>U.!?;M^Q].]=:?UW>WK_\ >=8_X4Q_\6OC=N$%A9;>
MF1FG!C<AQ]I"DYQC*5*!'!SV[5VT:PWN:RB1$M-RDL.9V/,0I+K2\*"3M<;;
M4DX/!P>,&LD)<V+!;\V7*BQ&AZNRI#4=L?C6ZI*?Q=_6O6?6?'/VP6+^-X'_
M ,:H??$^MVO>OVA-AN&S_(!?8K:I"\@;LD]A#TEL/(\GEUMWS&O+ 7Z'OZ>M
M54,CS/=#B.:KTYR/,\CMN9L/,17K*JXRUK1(?X2TWY@?XY6H@#L/7YU&VK>I
MATO<$Q#I^;.BN(94Q<6W4MQ)"WAN#;"]BTN*&,$!6<YXQWV/Z3^S4GJA87+H
MG7UDLESCO3$3=.OQW)%VM[$1:$*DSHX?9<CMK*LI4ILH"2DE>24CZ'\.Z6ZX
M%7L%P@3@CCJ]CF,22CGGCJ\E:^.?ASQ\:_?5<_P@M(M[V%9YE-ZUM>NL+3ZX
ML0)$.)<Y8F^V-N,%;;C:G7%N-\E:5GCN>>#5BY ('O>O)_-S6;::O3U_M3-R
M?MDNTN.K<28<Q.UT!"MH6,A)*%CWDDI3D>GK4+=1]&P]!ZIEZ=@ZEM.JX\9F
M,X+O9UA<1:GVDN+9.U;B4O,J)0XE+C@!'ULY U4I2N_K Z4I2E*4I2E*4I2E
M*4I2E*\'T/XJ@P\</;_CVOVA^,8[?]RD+;8W$F&3'RR1:6;D^X\U+9>08ZU.
M-.,="T)"_+<3U \'GTJ= ^AY]/C41_BR6+P[KYI58&/$'G7&#@"77C:%V^3>
MHSA<\ULN<JLQ\X_?0CCJ[?+M2JIX(_@,GY\'@\56NQO;QJ/ N&+1HWC;LRHE
MON=A;;MPPR.5S8\>5&2F"%?2!6?:6T^1U<'CKY_'=^TJCNQ=/</COW\Y,\S8
M[<VY?BWY1NRDPV4F;Y?*NCV@CSN.>P7QS\Z#V\_$O 2QK2FTY-M!NF87G76S
MY9AYQ''(T[.9"[YYM]A)>"_/)::2RQ[QZPI)23SQ5[#;;=W[WH;I=<G["[CC
MC^(6(?1+SJWG8Z$VN*E"G'%@+*G$@+(4.03P:5>OG'?'.,I ^&>W\_PKO2E*
M4KCI2E*4I2E*4K\<S]9?_P ED?S:JHM[:_[I_P!0_P#&?[..U>DF?K+_ /DL
MC^;55%O;7_=/^H?^,_V<=I5Z.R_[A_--7L*4I2K*4I2E*4I2E*4I2E*4I2E*
M4I2E*5U)KCJI$T7TRR?4:=!=N+&/1"^8;(67'UJ!#:!Y:5*'*^ 2!V'<]J[;
MKI?<%DV+8CI%FM^S*$S<+!"M,GVN&^ 6WUN,+2PD]0(!+A ';U^5=A:6FW[I
M;F78KDUMZ;%;7$97X;LE"WT)4PVO!VK=22A*O0J!KIM0R'8MBO$EB<S;7F+7
M.>9N$A'B,0G6HSBT2WD?UVHZ@'5H_K)214!+_CJY294PLZ.J3'2_+CL)7=DH
M4 VXMMMQ25-A0/8*X/XJPRT0W--ZH;_L6UNU$L+\T7V<6H]J!<DHMJBRF,W[
MS25!7=23STC\'X"L.7L=R77C4O)UZ580XXF5<;B]&L$5TK1"CQG7G%NE[HX]
M]M)< /![\ &LI/#VS3%]*-T6/XYJAAS<V3,G+C(D3'.A6/R6D^626E(^^^8X
M/PB!T\?EKT>E: T-I+3&K)6FM-)8OK^D935PM<2ZJ<NK4*7'*G$9>DO>'A2"
M5.-)'C>$I#97PD^-4#JQU/U_K?0D/6>M')6EHVOX+UIO,^R--61VXP):$,O8
MCPF"^2A:4AEU6(X?2MT-8*TVFMW&OUFT V^Y7J++?9C/)L*6[5&6L)<=<N$4
MLM);2>Y4T74]@.00/3FJV&A&AEPR3:CN0W99_$>F7K+)+$C&),Q"E.-LF>^R
MYT*7R>S2DCT'I\*R2\4?5*Y[EMQFF6T? %K?B0ID1[(6X+A6R[#?$::V'0WR
M@I;8ZN>H]@/AP ,R=W&1Z(:(;),DVZ63)K6QD=IL%H:38F%-J?\ :WTM/R>H
M-K/O=?5SU=^>U>:N<'CC<K/?)"<\#Y_;]M>U(S@;B#M0!D#:-V!R!Z9/;T[8
MK [P&^^H>KY^<B$?Q<EX_P"KGBK2R/P1^7^4U4D\%_5? M*L^U+?SN_QL?:O
M$J"BWKED)1()4M  42 />4!Z\5;&M-ZMMYM<>[VN:Q-MTIHOL2V'$+94UQU]
M8<0I2.E*3R3SV^-6K'O?;C'X"KTGW?LK?NERA6>WS+G<9+,.# C/2Y<E]Q+;
M3+$=M3KBE+64H'"$D\%0Y]/B*I3>)1K5?_%8W@X=M?V_6]V\8_I]*NS!RF*D
MKBK^]%V<MTJ3Y;086RX 5N#KZ3TUG)XRWB.9#,O+.R;;-*?O.HN82FK1E-QL
M;A>>M:9#C8;"5LA04%M.*#G0L=(!"O2L;;I:+MX(NVC",RAZ=/Y[K[KG#F3,
MGRE*%O/XXX"'$A:_+D)0IYF24*'4@\]CW[5/_3K3DC3;4#43C*'=77Y#\?15
MG?<0UM"V5AZ\S0XI.V.VR5^"A6/%SP#O21KOU(U+'U2]/TTTZXUI"PK8?UM=
MV6U.A:@^WY>S0RWDJD./[$NK3E+2@2HA+2TJ@0S;;&]A.['^MBEWWVB6Q<[7
M;)-_\C@MNS0V'?['!X/D+4I/8GGIY[_&YMX9WA$HV,9U=]2VM5%9LUEUMM$Q
M, VGV'V4N00I3?F%1Z^DN\<\>@[52ER[</EF8;B9&X^?9;LWE,JYQKJN#]&R
MR/.84E:4^;Y/1ZI'?CM\O@+D'A ^*3J3O0O^4Z?Y_I_/LIQ*%:(MOO3B'4,.
MH3&Z.X+"$ D- ?A?C[\U)?65&NAI*&MB2R;6BT--ZK0DQ<NRBN/[S6Y'B%(=
M"CF.I*<'MZ"+>B0T(=834R(<E-S5=5KTHXH2PEJ*$/>Z[X:_#)4V4#]NE6%
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M=AQWJM3O00E/B:7Y(2@)&68T.E*0E'!>8[=( ''S[?/YU>8?_673_P#BKO\
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MY2]H&" G:,$E8.U)E!1X0>H#SL9LZZXO'3[7&45Q;]98Z@$/)4?UFX!2CP.
M/7Y>M9W;T=Z<#PU]H>)Z"8=EC><:XWRUOV:PR(DI$R0'9A2RZ5>6J1ROH?X;
M4I8X !'SJE-#RS4)V-)N;>H&7-?1;K3H2O)+ORIQ"PILA*IHZ@E20>."#Z'[
M;!_A";#-0=YFH]IW/;F)ERR33[#W6',5CWA;[K60+9 8Y0'5J+0ANLMJ)Z3Y
MG'?GFI=G='=/Z#"=2ZDU FZVFV+*W+9Y/RKMPF!*50X;9+S@<2\OEX<;6DJ)
M.W<H0W;NMFH>H2E:6TUIU5HN]T2&V[F)AE-0(15MF3'!X+1;+3?#2\GWU# 4
MK:E6>_@P^'%?84U_>;N3@O7C4_,Y#MWQJ%>T%]^T(D..*<4I#_6%AQEQ);ZT
MCH '3QZU8;U4T5TTUHL"<;U)Q2WY/:4\=$:6RV2T 00&7"DJ;'('(00"!W[5
MV1;K?$M<&);X$=J+"A1V8L2,RA*&V6&&TM-I2E 2D<(2!V2/3[37[J@C4FK+
MIJ.^.WQ]Y<=T*"(+4=:FT6^*U[L>-&V$%M#2,#*<%2LJ/))K8+3.C[3IJPM6
M)AE,EI22N>[)0EQ=QDN %]^4%A06IQ0X2K(0D!"< "L%?U.'9Y_^YNS^G'K\
M/WM=]:/;=M']"(\^/I=A5MQ9%R*#,7&:;+SWE\E'4]T!SA//8=7'P^%=X4KJ
MI%YN\MHL2KG/D,*P5-/2WW6U;<8RA;BDG!&1QP:[>-8[-">3(B6JWQGT A+S
M$..TZD*&%;5H;2H9'?!Y_"N&Y[GN+Z:8G>,TS"Y-VG'K''7)N,YP<H90E)5Z
M?$GC@?,U$O*\<G8PQ*E1TYTI],:0]&+J+?-(4MAQ3:^.$'T4GCG\OQXJ3K77
M1_'M==+LITORA3B+-E$7V:2MM;B%MJX/EK"FE)60A?"ND$ \<'D'BJ./B<>'
M=CFP:YX0QC^6?6F+G<R\/^4Y!,9=O2T]YB4=2U++O(<XY)^'VUD6D+18KRZN
M'<7Y:)SB_P#16F,);6VE!6LJ<*%@*&#P<# [DG%;(=$=%=.M=SGK'JFXWJ/J
M&5(VV>';PVW&?C-1W'Y"W'U,/A+J?#.$K\-.T )*E*P+36D'C ;-=8L\L^GF
M-YVE&07YPM6MEZ'):3(<2.2GK=2E"3WX]X_'MW]>HO&8WJM[?-!#I_ALP+U'
MU7:;M]A3#>)EQVGW&V5GRD<J'GLR!Z@=E CBHP/#L\,31^1I3I]OGU+SP,VZ
MP1+S>7,=]F7$;9?MX48R%SVW$?ANM)(YYYYX(K@6A>+7_P 53Q%+EJ3>6)3V
MA^D]T8C0HSO6]!;3;VQ&C%KJ(0OS78B">!ZGWO6NX;L>GXUW>EQG9+ULL3:G
MKCYD#:N:TLI9B-*V(\0N+3DC!! QDYK/(_3SII:=:W"]VJ9=9NDNG,9^=JH7
M=M*6WM00Y*VK?98;OA,>9,F0VDN)#:D%*2 I25\2X^"YLN&W_0U&J.8Q/_E,
MU3)NUW7,9)F1 IY<AHAQP%0\UM[X=/8^E9Q;\LDQ^W;:-58$Z^6F).<LSB6X
M;]QB-3'%%M9X1&<=2\KG[$'YGM69%KMT>UV^#;83;<>);X;$*,TTVE"$-QF4
ML(*4) 2!TH3\/A55KQ2?#NWS:\;E[_G>F+UWRK3R\)8%LM<>[?1D2V):C);=
M0N,'PA\.+_OVST_#M6/V]QO4&HG)MSN+-O!<\V'7_J?L7$>%&024I3A'NIR1
M@)X!/%1EIF5%ZF]3Y-^U=JF!IA+DKZ93*N.#'4(<EA46TL*6XRVUAA(;;*U@
M)0T<)6K@X7> [>+39-V.52+Q<X-JCO7:XEM^X2F8;*P52N"'9"VVSSR./>^5
M7>+;/A7**F7;Y<6=%<4KRY$.0W)87P>#TNM*4A7Y%&J%<+P=_$.MCI?M.G\^
MUR5J']D6_(&8;P43^NEQAUM:B@GJ(*CS^>K;7AI:'ZU:";8L3P/7&^R;KF4)
M,DR&9:P^]"2Z^IQ"%R>MPO'H(3R5'T_(.\U\W;9;R;M$N\22ZOP8QALK2XL)
M0@Y=WH6KW1C!!2.XP?2I"]I.)I.]7!K6UCUM9;O*D"#:E6&"ZW)D-LL,.;IO
MCLO+&P$)2I*VT %8VK4<BI"J4I4;5JG2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E;9<2/[X_B!H'$G^^'XP:4K<I2E*5PO43_>'F7^C=Z_[L?JE+X:?_
M "D6/?Z49;_.S*NM:B?[P\R_T;O7_=C]4I?#3_Y2+'O]*,M_G9E0MU._VGZ=
M?[Y/_N8-;F>S1_Y9>T3_ ,%H_P#8WFKP#_ZP[_DKO\S5&G>E_P IM?\ _2S&
MOYYBKR,Y]B-$?>DOLQV4Q72MY]Q#33?WH]UN+*4)';U415&;>9,B2/$NOTN/
M+C/Q#E>-J$ME]IV-PEYCJ/GH46^$]^H]7;@\^E5ZTJ'T18!D9&H8IQG' 0OO
M\!SW[53V,P?Z4Z].U6#H"[#.#C/CQ>,XQGY9S5XW%/\ >MC?^8+/_P!W1J]_
M7%,)N$"X8IC;D";#FMBP6<%R')9DH!%OC@@K96M(X/;N?7D5RNID:(+;9!R-
MB.1V/NCL?6M.I*5)D/I4"E0><!!&"#O/<&E*4KDKAI2E*4I2E*4I2E*4I2E*
M4K\\R2Q"B2IDE8;C1([\F0X?1MAAI3KJS]B&T*5^2H&?$3T;TE\4/2N&K;KK
MOB]CUVT9N3LC!KLY.MB9L&ZM34KDQ?H^9+:4LONQ1'/4V>.2>*GBN$&-<X$Z
MW3$E<2X0Y4&4@*Z>N-+96P^GJ'=)4VM0"AZ<\U5QW5^ SMUQ_,LEUKT'W0O[
M4<LE2I-\N$Z7E$BYQE3BM<I2_HN;=V63U.E1\M+/'O<<4JJ>"#G&/EG]?"L;
MW]C7C7[V)&%:#[Q,]BX[MSLUSM3F3S(<:Q2D97"QV7&D6I2D6U8?9ZO9&SU
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MRSN6X\\LN.+43R5+6HD\YYK9B%%CV^+$@0VDQX<*.Q$BQV@$MLQX[:666D)
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M2&RA));2"H$@<\XKT#^BG]?ZFF6"#+A6-VT!,%J6?$=; ?A^(E3FY8)+B5J
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MBJ&7Q9M_FH6PN+HUF>/6AF;@>07I4+/;B]+89%LC.S8L9A[H>Y6Z '5J(;]
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MVD6>SV54,&TMQ;+%\K'<:@//-H?>&279+@.''#CW4H0$A*!5?3Q^?^ ?%?\
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M[UL;_P P6?\ [NC5[^N/XH?_ &8QH?/'[/Q_%T>N05,C?^K;_N)_Y16G3_\
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M#,>.P@-M,,-I98;0D )2AI 2A/  ] *A4\:#+MW^*:98@[M;1.3&DF<WF4J
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M+=I<5CVJ5%MDZ0Q&*@D/.-1G'$H4I0Z0%*2$GGMP>_;T 9X')/  ]:$@#)(
M'<G@ ?$FJ\FX'QI\LTZU<RW <9TM>E6_&9*8PFR)QC+DGNE2@T\VE0 4DD<>
MHKHR?XXVJ]VM=PMK&F(@R9L5^*U.%S;68ZGVE-!:6PCWU#K!2..>0/F*CKW-
M9)E^M^YK,'I6,,6W+KE>OHZ+88:V%(4IIY45@^='0&E*='2LGCL5'JX/>NM-
M4]'-2M",@M=FU+QI>/79YZWSX453J7TRTA34IE'6GE(#B2@*YYXZ^X'QVYT#
M[.;#Z]-7/5=_A,R9[35Z1I)D)\_/M[24/^$7EO-E)7N:#Y::6AI*U(4L')'G
MUU8]L>1$1K2Q:"TG<Y$6UO/::<Z@2%+%JM=W?6J,9*([4=P*2C:^88?DMN/K
M;#B&BGA4F.RC87F^\7.).N6N"IT;!Y5V;NG3.2YYN1K1*+K30ZBEYA$1P)1_
M>K'V5AG]T)8O9,*UNT?QG'+?&MMGMK+MOAQ8S+;(0A4>-'ZU%"05G]D2KGOW
M)J=G'/$MTIVP[*L(SS5N/:<?RV5:Y+.-X5;Y4>1(O#T,^0VIU,$*5%)(0O[\
MA/5U$\_.I9OHW#:V[Y\S?W Y1BJ+#@EODN?5>$N9'<=B,E?D!Q*!TO.>:$H7
MW1RCYCM7+I-_4NI>J$S6][BILECMAFV&WLRG$1HT-J.%0XMK@)64AY3902\I
MK+9<WG=N(367R-/6#372*R=--&&9K#5-^%OU)<%6>')NETO4RX);GS+M.3&0
MZ^GQPZE,=MP%U#(;!1@%5=M:I>%_!TYV0V[>"UK!;[M*G1D2'L#0S&3)C^8^
ME@ .ATN*XZ^KLW\#S]LL_P!S(6*S2X&O5\D6R*]=8RK![+.=8;<D1PXIQ*O(
M=4E2VNH'@]"D\_'Y55^GZ@ZOW3%483<<KNLO$&TE+=@<?>,-">RA[A<\O@*
M/X/;@?*I4?"TW_9AL4L.I%LL&CMYU'FYS]'".]!3,2U$5#4LCEQF.ZVKJY '
M*NQ';TK)NH$2\RNGNHK;(OL2^7&9=&'H(87'BEFWF9'6F(H)6D.> A*BIQ62
ML9R3BLIZ,](]:WKJ]H]FR]*]5Z<83:Y3,MV]VVXPH+EP9MLE3\UVXW5F/$BA
MW *$*>0 L;6QE0%?0$#B1V 5^]/_ *^RL>]TVEV0:RZ&9YIUB]]=QJ]Y';U,
M0+LUR'6' DGI'"D%/F=D%74.GGGGMQ5;29XN'B*ZDN*;TSVTWNU!XGR')#G
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M)Z6T^^KWB![O/K5)[Q,-P&G&XW<XUJ/IE=A>,6;NEGD>W*:6P5,PE,>:H-N
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MP-N.*_-;67V8,%F3PI]J!$9D*[<+?;80AT\=P 5A7;TKJK*] ](\SNSMZR7
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M"E+!*%'@@\U%O4W4FH-,PX<VSR+4PP5.ID)G'=)><&PM(B,E20X<>(I8&2,
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M,N8Z4@$N7 )E]"N"0"V7.GCUY!YX[5EI6RPA"$)0VD)0VD--I'HEML=*$C[
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M\OW-PNI]J6\[YI(9<4KRN%$]A\#65%3E;5SG($-=S::9N"X[2IC3"BMIN04
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MV[:=M,VF3<DG:(Q,=QB5E:F#>W',IC3%RC%Y#7/GRE='1R1[O%9;?6_%A_\
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M\CJ6TM"B!R>.37/OK?BW[9\:_CRW?I%4;_U!7Q<_W;>2_P $'Z=3]05\7/\
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MD!FOZL1^J'?7[_V)"NOZI>P(Z^?HKV+^V^OS/USWN.GU[>E6%0AM2O\ W@/
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M>AFFT3%)E^=\ZY3GI+MSFN+ZUK'E2IOF/LI!6I(2VM("2$@=-9B4JTG.,=@
M*4I2E4I2E*4I2E*4K2M7 /Q]U1X^? YXJN3XC>YC9%N:EZ];*=;\VO.F&5Z=
MV<7+VZ/$O-N1?+@F [=K<PS<(OLK<T%]AMM3:'G@>HH4.#TU8X]:PAW$^'AM
M+W3Y#;\IUGTLAY%?[8\A]BZQ)+UIEO.(*"GVQZ 6G)B1T !,A3@Z>4\ 'BE5
M&,\Y^[_&J7&4W;5?4_P6L;R&ZXA<OJ#HCJE:6;!>V;6['D7JR-:C1VC-7:FF
M$R"EJ'&2\IUQ"NL<ND\'JJ0+4+63 ]XOBK>&>]H'<I.9QM,\-G1LVF1X,AF)
M87SA]O:#<J2I):;476G$<*4D\IXXY]+6S.WG1]C24Z(M8/:4:9F%]'G%A%8]
MD5'Z>CE0\OA3O[+SBGS KWN>>]=.;<-@&U7:C>;S?]$-,8F+7B^O&1<+D])>
MN4KS"I2C[,],+CD5)*U)Z&%(3T^[QP!2KMPY.#G*L?#W@!S\?7/H?@*S'C-J
M:;:0KU0PRV?C[R$ 'OZ'N/6OTT]*4JRE*4I2E*4I2E?AN+DAJ'+<BM^:^U#E
M.QV^PZY+;*U,-\GTZW D<GM\Z_=2E*H8[ZH&_)C7W=GKGK+M.F:DZ?1V8,;2
M?(I&1L(AX!%]D?ASY$:TA+B)AGIZ'. V"V0"#SQ6/>57_6/-_"4VR9OF&DMT
MQ33[1O4=R8C(T.O7)=\9NN>QERBJV--%^&W;>%))4GI*4]8X37T&LXT[Q/4;
M'+KB67V:'=[!>FPU<H+C*$B2@>@4L)ZOB>Y)/%=9,;7=#X^C#F@*,$MJM*7$
MR4'%'6T.1A[6ZIY]2%+2HH6IU:EA:0%I/!!'%*Y-_ X'!';/8#'Q]>>_[ZJV
MV_5/#=U7C2[)\ET2GR,NL&F&%EG-;O%A26X-F>E85!9::=DE!9*BZVML@K!!
M3P>#VJXHGU/R[#\H'!K#[;3L/VP;29-YEZ&:;1,4F7YWSKE.>DNW.8XOK4L!
MF5-\Q]E(*U)"&UI2$D) XK,2E6$YQCL !2E*4JE*4I2E*4I2E:5'COQR>%$?
MD%55-V&G?A+ZG;WMQ W!/9!:MPMMQIZ3+E)N&3X_&7/8QV4[:UP;C&7'AR5(
M4AI1;C.+ZE -J[FK5A /K6%6XOP^-J.ZF^VS)-:-,(F0WVTN!Z+=H4IZSS7%
M<I/$N3;RR]+2.D)Z)"W$]/(]#Q2J@X/K]U4>+BYK9G'A/Y->[FK)\NT2T=U>
ML2]/[Q<XMQD7+Z%_JDM&4ORY:7+A*:C1F1PXYU#RT=8(3WJ3G4+63 ]XOBK>
M&>]H'<I&9QM,\-G1LVF1X,AF)87SA]O:#<J2I/E-J+C3B.%*3P4D<<\5:N@;
M;]&;;I$K0V'@EH:TP5#5!7BPC,&*XPH<$N<M^^[R2H.J27 KW@KGO74NW#8!
MM5VHWF\W_1#3&)BUXOKQD7"Y/27KE*\PJ4H^S/3"XY%22M2>AA2$]/N\< 4J
M\K'PP?>Q\/> '/Q/?TY[&LQXS:FFVD*]4,,MGX^\A ![^A[CUK]-/2E*XZ4I
M2E*4I2E*5H4/3OP#RGG[5#@5KI2E42=TVENC\;QOM?!NSG7W&M*LXQ\RL4GQ
M95XM,:^3;7BLAUI8N]N6P4*AS T0T7B72/+^/%=&WV\ZOZJ>%!N-LL:5D6<Z
M+:.:GX3)TON\R!.,Y^RG4)M^XJ0F0AR=.1#C,<%U9<]Q'7SQWJ[9N8V,;9MW
M2;4G773B'ECME<+ENFL/N6N>TI2DK4%SH1:DK2HI *5.$%/*2.GM78.([9]%
M,(TC.A^.8%9X.F9ANP5XV8S+K4AAT%*_:'%ME3[G<E#CG4M*CU)4%=RKDW]N
M,D;>_;W?Y]OLJHUK[K)@F]#=EX6.);?KC*S6]8)A>46_+V8T&2PU8I8QJ$P&
MI<A2"VPI;K2T .*05%)'%*M";>/#RVF;6\JO&::+Z71,8R2^/KDS;F]*>N+S
M;JU*6HPS+\PPPHK4"F,4 CMZ 4I5I/8#L/CC/QK-RE*4JVE*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2O!('<]OA^>L(MQ_B(;3-J&16S%-<=36<1O]W#AM
MUM]@E39$D,H#CA;;C)4M72@@G@&LV7OP!_AH_P"L*IN^*5IWB.J?C>[(L'SF
MV+O>,WIS+T7&U*D.-,2DMVAHH#B4GI/2>_=)I5R1DXY[9XJQ/H1XG6R[<AEJ
M,(THUBMUWR=P]+5JN49ZS.OGCJX:%Q\DN'CX(!/IZ$UG[YB>W!Z@H @H'4""
M.001VX([@^AJF1X[NPK0[9OIAIAN^VQV:1I;J;@F78NT[,M5XN 1=6+Q?;;"
MD(>A^>AASB.XXGNVK\+\$?&0S<=NJ\0"]8QMYM^@%OL> 8;DN!,7#*M8+K?K
M"9*Y$#'HLM 3CUS=;D.*D2 MDEM)/*NLDTIM'!!X.1SQC&/Y^E6*^L<$\*[>
MHZ3S_)7DJ 3U=^/L!)_-51O;5XOV[W5C0_>3AC=G3D^O^UUS'7X-YC&&E.6P
M)LEU^Z/-QVD&/'$>WL.*[=74.X-9":G^-?>[1X5F [L,/MK,[6K4#(X^*6O$
MT26C+3<H^3LX[<U%!!/WIQ2UD*:XX3\O10I(]/EQ]F?R_P :LO\ F)[=E'GX
M!))[?.O(4%<C@CCY@BJC>ZSQ:]VN!:A[?MLHEO:.Y_G=@=O65ZHS[<Q-M+2Y
MEJCW>UQE^T,HMZ>M+R8O4'AP3U'OZ2P^%IN#W<ZOQ,ZL^Y&%8;Y:[ J%]4=2
M;/D%CFJRIJ05EYQVT6IUQ=O+20D!+H'5SSWI3:0,U,+2@^T<?92E6TI2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5MN@E(X]>I)_
M,H54L\6?1#>!9_$JVT[LM ]!9&L=BTI.0N7" W=V+4'3<;>W';'G. E/O \$
M"K:]?F>BLOD*<9CN$>A=9;<(_$5))I50<'X^G/PJG%N%TU\3SQB,WTRTLU<V
MVO;9]O.)WZUW3,YSF10;^+PBV3HMPBI4R@-OI^^Q>GE)/X7/'' /X]_NUO='
MB&^[!+M=M$\DU\VEV3&[=CV#X?9,NF8I&LTV-CT:UR)#SMO=2[(2_<6TO]+Z
M>!P1Z&KE3,9ID$-MLM)/J&6D- _X00!S6W)@QI909$:+(*#RGVF.T_T'YH\Q
M*N@_:/C2J[NW P!C'/KW(YSD_&JDOA ;-M>M$-TF\_(-;-$4:2:9:S6*W1,:
M9NM^CW2+#ANV67&4'YKQ"5E"9".5.KY!!/J#43FV;:9EV>^+?(V0?6)&1[:M
M#<PG90J' =;N%DB2,@?=R1L%V,XZP3[;W'?D*'H#5\W<?HH->='LOTM8O[N)
M.Y3%;B_3\%M294)*3W*%,*;=Y*24CI6" >!\.,)?#N\*?1'8"]F63XM)D9AJ
M5GTA$C*<ZNKLJ1/GJ8<<5' ]M=?6UY2%^7PA?! XX I5P7]8^I  &.V,<Y.?
M3/\ EVC4\6;2K5B[ZN8G%R_9R-S&V.':4VE4NTY$SBEZQM,*W-0XI1.M[8N[
MWG2&T_@NCI XYZ?7KSP,]E&XW1W<3K5J\O%\CT0VR90JTKP#26^Y%,RHI0RR
MXW,2B?<'W)+71((=]Y(Y]!5KF3"C2VRU(CQY#9/):E,HD-'OS^ Z%)]?L^VM
M<:*Q%;#3#++#:?1N.TAAI/SX;;"4CG\5*MW'&/0]_7\^Q^8K=0"$\*]>2?Q
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M4KU\JZVR"H(FW&WPU*_!3*FQXZE?B2ZM)/Y.:4KV%;8<0I90%)*AZ@*!4/\
M"3ZI^SGCGX5BYN9W7:9;;-.KIG&3WZVONM1G?HJVQ9C,AZ=*(*&DI#"EJ #I
M3WXXXJNAH]XQ.J]LW"W'+=1EN2=*,GN3<<X^ A(L,1*_(COI?0@K=\T*2Z0$
M\IX]ZK@DD9'^=6E0!P?\JMK4KK/ -7< U(Q*T9GC&3V>99KS%;D1GEW",RI*
ME(2IQI3;KB5I+:B4'J ]#\*[!B3X4Y!<A3(DQ ]5Q)+4E _&II2@/SU;5U?K
MI_Z]/_'TK2H\ <#GD@>O'J>*P7N6Z?.(&[BV: ?U/[><,F,2'9.<+R&&W(C)
M9@F7R;0I0?*>H%"E< ) *R>.]*5G52NC(.XW1>XYB<&B:@V%W(P\IE,+Z0AA
MIUU'93;4@O!EU8XX4E"BH*[$<]JY'J%K'III='CR,ZS*R8XB64B,B;<(C3[_
M %$#J;9<>2XM'O ]24E(3[Q/%*5VA2L$]W._[0O:7H$YK]E626V\XLN;:X5N
M5;Y:)34]=RGLP H/1%.A/DN/#K[]B/>X[\=MZ,;HM)]:;+BEQQG*[.[<,MMS
M=QMUF;G1ER5M+CHDJ#;?F^8X6VU@KZ4DI /5QQ2F#C/IVS\ZR1I74D_7'2NV
MS<@@3<XL<>3C"HZ+^A<^(!:52SQ'$Q1>X8+I[)\WHZCZ<U^?&M>](LNR-S%,
M=U QRZW]M*2+9'ND%;SP6CK'LZ$/J4_PGWE>4E73\>*4KN.E=/Y/KOI+B&2P
M<2R+/,?M>07!9;CVY^Y0DNA?;A+X4^"P5\CH#H25$\)YKMEB2Q)9;D,/-.L.
MMI=;=;<2MM;:AU)6E:24J24]^0>.*4K?I72E^W"Z-8UE;&&7S47&;;D;[@:3
M;9%V@(6AQ7'2AXKD -+7R D.=)43PD$U[_.]7]-]-K9&NV:9C8[!!FA*H;LN
MXQ$*EI7T\+C(6ZE;R % E306 D\D\4I79E*ZT1J[INYAOU^;S*Q.8@/*"K^U
M<H:X+9>6&VP](2\66E*60D!:TGGMQS7HK/N"T=OV1KQ:T:@X[<+ZB.N4+='N
M<%QUUEM@R%KCI0^I3W0T"M7EA72/PN*4KNBE1KZ-^)OH#K/N:U@VTXU>H:,C
MTC5 3=)LA\,^V&9'7(7Y2'NA*DL!"NHMJ4 !R2*S L6X'1_);PU8K%G^.W.Z
M.^T@18MS@O%/LO4J1YI:D*\KR@A1/7QP ?AS2G;]W[^1^ZNZ*5TMCVX+1S*<
MID8;8=0\:N611W/)7;6+M 6XXX#[S<?ID'SUH/(4EKJ*2."*POP/Q"?KGO[U
M8V5?4;V3^IHS9G?K;[=U_2'TM;O;^/8^G[WY7ZWSSW/>E*DYH#SW%=$[C-=\
M9VY:-9QK'EJVT67#;:_+<0ZYY:9,E+:_98H7ZA4EY*6DD<GE7(!XJ.SPI_%A
MQWQ*,5U!N"<'7IQE.G\Z1'GXS-EN.2WHOM4AJ%*0'TMK4F4PTF0.A!X0OGT'
M-*K@XSZ"IB"H#U/^HUY!!]*KFY[XR^X^?NVUMVM[=-H"M8[IHH+>]?;FG+V+
M1UL38JYO5Y3Z#P0TVKA*22?E68FRWQ6M/=SF :R7;/<<_J/ZCZ 1#(U9P&X2
MG)+N/.+1(7#:3*=0@2O:TQU=):21W'?BE-I^'P_?V_&I;.I//'/]'Y_2M55E
M7O&SW59SC]XUZT-V37#/MK>+7M^U3=0FLH3%DW2.Q<5VR7+C65;/MS@BNMN+
MZ&FU=0'RJ>G:_K[8]S>BF':RX[;IMIMN5QG7/HVX1I,25"DQE^3+CN,RVVGQ
MY4@+;2I2 %A/4GL:54I(Y/Y@_D>/OK(&O'(//V>M<(U&U#Q?2W#KWG.8S_HW
M';!$<EW&8&UO%I"$*4$I:;"EK6OIZ0E(YY(^-1,["_%[PK?EN1URT:T[PN9!
MQ'263;8MNS.:J3%>R%<Q+AD*^BY;3;T9++C92DD<.)/4DD=Z5;@\_+O^53/4
MKBN69IC&$6=R^97>H-AM32TH<G3Y#,:.A2U]" 77EH;'4HA(Y4"3Z5UO#W':
M)SU7A,74K%7%V-MIVY-F\6Y*V6WD=;:D(5)!="DCJ/1SP.]*5WE2NNL:U6T\
MRW&'\PQ_,;#<L=C)>5)NS=SA>RQDLE07[0Z'RAK@I4$^8I/41P.:X=8]R6B>
M1R(D.R:CXU<)<V0Y&AQF;I 4_*>:<\MU#+27RXZ4+'!Z$GC\5*5WJ2 >/C^(
MFO-0L[L/%0N6W[6;--/,<T[.96[36/"?S*<W<1'3!%UBB1;_ #!TJZ?-)X3W
M'(K,+;!O:P77G1K3#4K(7[=A-]U,>N[5IQ%=P9EW!?T5)4RXI#74'E)Z0'"K
MRR$@GGL.:57! SZ&LY*5TG>MP^C./Y ]C-XU%QF!>XR4*D07KM 0N.'4!;8?
MZY"?*4M)' <Z23V ]*[1Q[(K-E5IC7NP7&-=;7,Z_9IT1Q#K#P0HI46W&U*0
MH CCE*B.U*I7NZ4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E:5 D< \
M=Q_J-1)[[MC^N^XS-K!DNFNM-PP>UV\/B19HD=92HN-A"27$O-\^\"KT/'8?
MCENK2I(5Z\_D)% <<BG>J:N\SP^]SVB.(Q<UR[,KWJOC$(.&>XKSP+,%*"4*
M,1+KQD>83R3T>X!R>W>HTEW"'=;)9,=MN/.JOH?5'7-9+CTBY/R'@EEL1$(+
MC9:40WSQ[O!)XXKZ'61XS9LJLUPL-]@1[E:[G'=C2XDII#S;C;J%(/NN)4 4
MA1(([CX'M46^E'A-Z):::^WG6%*6;I:US!-QK%7VEJCV9]SJ5*5UN$H?\QY7
MF)"D^YQPFN0+XY[_ )UQE'P[>OX]_P!8J*+0#PO-WF7::6>_L:M7S36)<HZG
MH>+DNR?9FG.%-JZO:$]'F)4%\=(XYXJ<?87MDU3VUX3=[%J?J5+U#GW%;:HK
MTME3:H00M:E@*4XX5]?(^/8 5GHQ$8C,ML,MI:990EIIMH!M"&T )0E*4\ <
M) 'IQ7Z  !P*M*B?L^%7!(%;;WX(_P -'_6%56-=Y\K]6I?M[UZOMFMDC#,I
M8?N3#5PD0;8A["Y*#)1':^\NK:YZTI2.HK2..%<5:K(!]1S_ .5=+7#;[I+<
M]1QJM.P^#)SKV=^+].N)2IXL28RHCS:DJ!!"V"6SS\#5M7@XS\P1^-4*\*N]
MNVQ9;I]E>36W)MSFGBM4[PU9,^8OUVQ^^1I%TRU3*VI6.,NKN:V84AX,I+[?
MEEIOJ'WL\U(5N#E:9ZI>*AF^/;X9>36;12)I]9;AH7:!-OL"T<2\'1+NB5S;
M>XRRX]'=4WP)*O,+J>![QJR39/#BVAV#4@ZJV[2F.G+C,7.#LB=(DVIN4XLK
M4\W9WE+M[:RX?,Y0P#U^]SR.:[&U_P!FVWC<S&M476'3V#D@LW0+=*CJ-MG1
MT-]'0V9D0-R%-@(2CH+G3T<HXZ>P5?O&?7L1^/P_7Y51KS##9^>>'EO+9ALY
M/D^V'3'/]/TZ'W.Z"[+D1[7/S- R@,)F]<^8VE*5I2ZLJ\M "D* ],]=?;)I
MGLKTGV1>(QMAB7[^I5IKA]_@ZC1TW>Z2XMQNV06ABSQ/:(TAQP-EBXN**$%O
M@$< #BK7HVMZ')T9>T#1@-K1I9(81&D8PVTVAI]I*^L*?=".MYP+]\..=2^>
M_/-1$[\O#8UBU<TNP;9QMKN,?3?:U/O+-PSVWNQXUXZ&(5S9NC;#*YQ5*;$A
MU"T?>B E*O3@4H% D9X&>>>,$ '[^..*A7R+ LGR/PH=XV_')KK?XM^W.9'I
M],@ W2X-/VNUV;)TQW_8VP\E4<.0U$'RDH\SCXD5U]=HNBF)7C8-F6RN^99.
MW'WFSY2O(FT7'(IPN<EJ R'?I2-,>=AL>2@N>3YZ %_L*M#[J_#L:U,\.U6R
MC2JZ-8FAEO$6XUP1%0\T#9YT67<S[.LA'$PM.^I]WJ[5V'M,\-_0';A$Q#*8
MN$PI.JMFM<>).RA]1>!?;BHCNNQ8;O6Q$\T!14& CJ)Y5R:50*&.<YR>!VQ@
M  _Y53X?M<O5O,]Y]PW$WC*+%K/;+CINNRY0]<[M#7B<WSVR@VJSM/,MW(2U
M!"7DQ4$)'=P5<FV7MY_;=C>+HRW*Y>:9O#P/)#%R*3#7"E3ELVN2;03&5[R5
MMH3'2DJY*R.:Y5JIX?\ M6UDU!C:G9[IC%N>8Q)#,D7&)+>MS,IY@I+*YL2*
M6V)A:Z$E/M"'./A67]ILULLEKAV>V0V8EM@QFXD:(VA(:;8;;2TEOI "2.A(
M2KD>]\?6E4*LC]<< 8'YU1$VU-;+\WL.XG-O$1R;-K?KQ;=2[4W(?3*RUB="
M"<M=9Q]NV6RVNMB0T['3'#IBM% ;/+GNUD/N GZ7ZC>(_@.%[JKSE3.TZ#AK
MJM#O,>O]J@7.&,3;<G.SY41;*D/-*2TML3EE:G.R>5'O9QS;P^-INH.J<;6/
M*M)K5<,[BR$2DW!M1CPGY#?'ENRK:T$PY*FRE*DEYI92H=0X/-<ZUVV?[?-Q
MUDM./:LZ>V[(+=9&T-6HQN+;,@M-A 2TS,AAN0A!2A"2E#@2I(*2..:57<,Y
MY[8/RSCM^%4H)EYR"%LN\2C%=*;SF4S:39LSTEA:/W-U=[]M8:FY2AJ^HMTJ
M2I5S>;]H44*4VX4I1WYZ>:R/S;;Y@>W?77PF\TTS3EUJR;5&S9JWFUP=N]_N
M#-Z#EJC--IN$:0^XPP4H>4E'F)!Y/(JVW VFZ"6W1T:$0]/+2SICYD9U>.):
M;XD.1)"94=R5("/-DK:?0E:5/%9!'Y:]U?-MNC>0R]/9MWPJ#,DZ7I>1A#J@
MGFQ)D)0AX1^0?PTH2#Z=A^.E-W/RYR/CP ,_QJI=H=HYMZP;Q-?$FC9?;+I:
M-2+3@EBN.E"6Y=S92Y*N.&2Y5X=;6TI#4Y14KKZ5%9:4>E/':NJ]K.W\XKX/
MFJN[K22%F,[=#)S+)8B+_*NE]DRX]C5F-PM]U,>TRW5M@(LQ=2DMM\@ *3WX
MJWE?ME^W7)-77=<;MI_&?U*?AK@2,A1(<:5*BN0S 4U*900V^GV4EI/FA?2#
MV ]*[2P#1'3'3/!WM.L-Q*VVK#GU3U/6(L-/PW%7%QQR65M.(+:BZMU:N2GL
M3SZCFE-WVY]W/W#&/L_1[51,R*W[=L4V^[2]0=I>29I(WGWC,@N0VF;E$N7<
M9#V20QE*+I;Y3JV(J&6%S W[4VE/3W:[5,#M9?FR/&^U^=ND:8W>'L,TN=NZ
MW(KP8,]>$QE2N))0&EJ,@K*@E1(5V-3:Z=>'UM0TLU,D:N85I1;;9F\F0Y*^
MD'7%2HD9]WJ\QR';WPN+%4LJ*B6&T$JX4?> KO6V:$Z76?4V]ZNV_%(<;4#(
M$QT7;(D "1+3%9##"5\#T;:]Q/?L*4*@?W]_F0?X8JN9]T2Z]9]?K1HOL=T1
MM-QS34+6S($W"XXM;TOL)EQL4N<6[*BRK@E'E1TR8Z%MDK6$E*QR#W%8!Z.Z
MB:[[+O$>T/U!U9VTR]L6C.M%D:L&30;9=1D,"Z3K+8&+3%E2DV]H(C+D3E>=
M]\2"5K/)/%7(+QMVTBONJ=EUENV'0;AJ)CX>%GR&6 ^Y ]H:\E[R&W I+96V
M.DE''\E?JU9T$TKULC6J+J3B<')6[*^F1:U/(2AZ$ZEQ+H4PZE/6V.M"20A2
M>>.]*H%#&,<<YY^..<=N,?XU4_VJ;F=%MM_C(>('?M6<CD8Y9\A@X'=+/+?L
M\Q^/<(CEA7*4&G4-%"N&G "A))Y/21\^N=,<0RC>7K!XKNN^WJVW5.F&:P,*
M?Q"2W;9-D9RU&/P92+NF/&>:CJ^]+;6E70E?F<\\'FK0.H/AQ;0=3<GEY?F&
MDD*YY%-:ALR[HB4[&D26H#268K;RVBE3B6FD)0 M2AP*R?TSTAT[TBQ*/A.G
MV*6K&\<CM+93;XD2.CS6W.0M,I:&TJD]0)'WXK[$_ TJNX=QG.$@Y[>[M^']
MWU_.JS'AZ>*5M-VU>&U:,:U%0NW:@::W?(;;D^E,W&)SDN7<9F026(:/)<A*
M]L$ISI7YJ6G D*Y(Z>]3/:"[]]',DTHT,R3-K2SHM=]<W+U]0L#-O4R'VK9(
MZ5.A#4:.U%]H;6A_AQM!)7\37*\L\.'9[FNHZ-5,@T=M,K,&Y2)GM+*O9K>[
M(0H*2X]:V4HA/$* 5RXRHD]_4FOW:\[+,$UQU%T*S"Z)9MELT17<56BS061%
M8<$UMI"$-"-Y;;*6?*3R />-*H2D^AR3DGO]P''K64F<85BFI^*S,5RN F[X
M[=VV'Y4,K6VF2A'2^QRI'?@D))'H1V/KQ5;WP_<8L&%>,OOUQ3%K(+'8;2,!
M1!A1K>J+";"K.HJ+3J6FV7BKU6I))ZNZB3ZV<HT9N*PRPV.$,1VHR >Y#;*$
MMI'/J?=2*ZJQ[0W3#%M1<IU4L>+1(&=9E[+]8K\V![1<O8V_+C^:> ?O2/='
M<]J53/!'Q_F*B)^Z &)$W8+?[9'EW:"JY9I@<)V39US&YB8\G+8#+Z$JA*2^
MD.-+4E2DGL">>U1,:G[#=%\1\1+93IQ9&LSC85J=I9DMSU(LZ,BR-<;)9<+
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M2VVT04C@]N>]1%;-LV\4??/:]QVIF&;T7,"&DUZO3^.X><-M]P;N<6U3K@3
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M5]'  L<8S;P0MM39!$1@$=) ( ((!XX(';FLOZX[BN,6;#L>L^,6"&B#9['
MC6ZW14#W68\1E$=L<_$]#:>2>Y/)/K7(J592E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
..2E*4I2E*4I2E*4I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>nt10002526x6_piechart1.jpg
<TEXT>
begin 644 nt10002526x6_piechart1.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( O8$Z@,!(@ "$0$#$0'_Q  ?  $   8# 0$
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MX9)4TE?)RR\CFQQN!(>00X'(Z(HD[MQT.?NV*Q=V[VSUS+Z5K=C::FW-O+;
MU](ZH#I:J6(4]7;GS3P10/GY8B]CGQAS ""<^2J?C+V:HN CBNX:=SMD+]?;
M9!KZ]W.FUC::R[W&XT]TD+X(/%\.LJ)8HQS3/D#6MP,@#L%7FU%XM=1Z:_>'
MP*V%X<RU-$G.WP7N_@SLMCESR/(/LD-)(/15)Z:ZXT$>Z/"!&^IC,C=47 N9
M&]LAC!KJ+!E#23&T^1?R@X12X&#CN=MU\AW;_7BO0+9*J2NM%IKI#E];:K?5
MO^$E12Q2O^\N*[1QY1GZ#YGLJ?TC)'-I?3<D4C)8W6"S<KXW->T_]WP=G-)'
MXKOWCF;\B#]Q15%IO](OQ&ZLAW=V.X3MN+XZT7;>"OK6ZDN,/*)J*BM+X:E\
M(ZAP]:I^>/F:X%O-D=@KD\2' 9H&^;%72?;P7?2NY6E+#'?+%JF"]72=T=PH
M:45]<^6!U3RSBKEA<"V3+6<W0<HPL /2V:+U-LWQ2\./%U04%=<=(:6NU73Z
MMJ*2*:<6J.XOIZ""1\<39'\IYBYQ   &78'5;J[QOOME=.'RZ;CT^JK;4Z?N
M>A:EL4T4\4M0ZLK++)"RF]4:\S^)ZS((RWD+@[/3"*7^]D_I@8'3/GW]Y6#G
MHIN*74O%=L+?M%[K.DN.M]NJZJT[J6X"3P9:^GCKIZ&C=_5<OAN]6@!R'<QS
MG*UX:LV#VU_]L)HW;O\ A==_1:XLN-154G\6KC4/D=:#4GEK#+ZPQIE.<-?T
M'0=.BS.]"OL=J;;O;/<C=&_TLMNI]UM37"MME+5-,$K*:BO%9R2NCD#7L;+&
M]KVES1D'IE8_:RU#98?3?:!$EP@8&05\;Y2]GJS'.L7*T/J.;PFDNZ8+@<],
M912D9#"?+KWYQ]?6%Z#-!;>Z8VUL%/IG2=+/26BF+S##4U<];(WG<7.S/4.?
M*[J>F7'"QLX\?_H:=;?_ %PL/_Y3IUF/')'*T/B>R1AZA['![#\G-):?H2L*
M/2 W6W6KACUQ/<*N&FC;7V$Y>]H>?^\X.S"X./0$] >@)[(ISL#W;?<M?_&+
MP#?_ #I.&?0>XVW;A9=\-M[6+UI:[6^,4]56/IVQ5,T,DL3HB]SHH/# >7=#
MTR>_:^C7](#4[W;=:NV WL=_1[?G;6PWBSW*DNCS!4WR.FH:N&&2%DC6-+FT
M\#7^QGF!R3U"VB<-=UME\V8T34VVL@K:>2VM;S1O9)D<C6N:]K2>7/4$.&/>
MM*WI5N![6&E-0?\ SU.%Z*:R[E::@JCJRUVB/PQ?*6KA-(]SZ>+EB=X-*9'D
M^&XG).<E% [>T/+(\1MYXV'@LN=@-YJ#8/@0U;NI<6<T&G+CJT0 NY!Z[57:
MNBHW$D=FSEAQV/0=N]-\".T=+Q4;('B W]JJ_56IMS:V\LBIV5]7116N@I*Z
MHI*/P64LS(032F/JT Y;S.Z]5:#9/;[57$WZ(2Y:9IX)CJS4U'>*R>!S##.Z
MOM%?/55##&0TASI8WM QU/;(59>A=W[M-9PZMV#U=41Z=W&VDN=SH;S9KR\6
MZ41U-TF-/)"ZK,0G:Z%@?_5!X .43O;G^[M\>I5A-#[CZWX"?2(6CAR.H:^[
M;"[Q5,[M+VRX325,FGI*.E-3.UE54OFJ)1-42C^T W&!TPNN]-;IS4]CUAL-
MK#3&M[M:1J6_PQ3T-+/4P0OYZVC9"]S8IFL>&"0.Y2WK@C'7K6W$)MQ+Q)>E
M/V7_ *)N?6639^6YSZUO%-&9:&A-PM[)*%K*I@,,YD<SE/A2'E=T*@^G"K+?
M057#!;GU3?&CU1!$UC,/?RPW*WLYI&M),;?9SEV!\>B*!V:X=P/0_(JI..;@
M=T^.%6X;W5>KM05>]&F[#IB\V[5U/=;G101NCAI9S&;9#5-IG Q-$1+F>U]H
MC/?,_P!'_P 1D&HN"/:W=#=W5%+05<[+E;*N[W*HB@;.+75F@B<7RO8W);&W
M))))^)7<<=EQH(^ W5\KZNG\*30VGFL<V:-WB'^'T_1F''F/P;DCW+#WT?7#
MIM/Q5^C4VOV\W.IJFY6.*Y:E>ZEH;I56NKBS>YI6^(ZBEBJ&!S@"T/QD>\(H
M_P 7_+X]>G^G?T6URU\2>R5YN-):K9N-8*RX5K@VEI8;A2/EF=TZ,:V8EW?R
M^BT<>GCGJ!J7A/GML8J:S^DE9+1PY#1,\U]$Z(<QZ .=R]3[UGKH?T17"!M]
MJZPZVT]IS4$%[TY()K=--JN^SQ1O;R_;AEJG1R#V0?;![+7MZ<V_Z?I-P>$&
MRQU\3ZFCU))$^&%PG,$4=?0-C\=S"[P_9;W?C/4E$=GE.<=WYCX+:1I_7W%X
MW3FFVTVT<3Z=MALK8G-O5#[<3:"G#7. .07- )SU&>I\EI2X_+[NC>N.SA!E
MW.TJW2]1%=KO_#H6UD-8*@EM.)3S1?9Y<>??/1>HK1E525FC=*STU3#41'3M
MC(D@F9(S'\-ICDNC<6C!Z.Z],8/9>;KTLVI;%0\>/!S/47"/PZ"\7EM8^$B9
ME,Z;U9L0G,;G"'F)P"\MRB'..N.GAXCR^?<LZO24<3VK-KK)LOL=MS<?X1K7
M>O\ A]'%=8RUTM#04!H_7F<CB 344LDC 0X%N01U5V=QN 3:_5FQ4ULMLEXM
M&NJ+3++_ $&K&7FZ.GCO<="+G+(8FU(#VRUC<!CB6@. ^SD+7OZ9/;S4M!4<
M-'%)I"CJ;[9=K9K?)J3^'<U4:>CN3K?"V9L=/XCG-$69'%K>F#GH%N7T-O\
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M9<TD$Y699('=<HBM!M9L;MSL[3U,&B+$R@EK>0UU=42OK:^J>S)#I*NHYYR
M2<!SSTP%;O>+@YV$WZOM%J+=+2!U-<K;*V:W235]3"RCD:6GGBBC>&-/,UIR
MT Y *RC1$6/6K.&':37&A*/;34]DJ+GHRAA\"*TR7&K:'0C'*R242<\C6AH
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MLOCM@CU;?!3AY?SG$ JA&&\W]D#EQT"SFT)H#2NW-BI=.Z1M$%HM=(P,BA8
M^9S1C'C5!'BS'W&1SB/O10 \0-N\? ?Y_#\58+:S@JX>]F-15VJ]M]&OT[>K
MG)-)<:F.XUDHK73<W,Z>-[^63H]W+S XS]_277@&X8[QN)4;K5>@W,U[4RMG
MGO\ 272LI)Y)6C#7/;3R,#\#IAV00LS$11P/ ;=%AWK/@1X;MPM16O5FL]&3
M7S4-E<UUKN4]TK!+1.8&AKH0)#RG#&Y(QS8Z]U!O' 5PT:@U=;=>WG1,M;JZ
MT>$;=>GW6M%12> UC(Q$0_+0&,:TX(Y@.O=9E+C(&![^R)@> ^Y8T;L\)&R&
M^-OM]JW/TO)J6W6IL;:&CEN%5%#&(N7PRYK7XD<PL:6N=U!&>ZNIMKM;I#:7
M3M/I31-#+;;#1L$=)125,U5X+!_9;),XNQ[AY!7$1%'S4A<K?!=**>@J0XP5
M#"R0-<6.Y2,'#AU;T\PL*-5>CFX3];ZBFU9JG;Q]VU)42>+)=Y;Q<&U;7@]#
M'*V7GB]WL.'19RY'O'WA,CWC[PB+""3T=_"W)"Z!^C[R8GL\)S?Z67WJPCDY
M?]*Z#'14O7W_ (+_ $;MLHK56U(VUH]=22.@DE]>N\MS?2/+G^-52%\N6.><
M<[R>N&A;"%C9Q#<)6QG%)262BWGTC_2B#3TKY;4!634;J9\CVR/]J$AS@YS1
MD>[HBACPQ]8_3]%A-MQJ:Q<:G%-:]UM-PB[;7[)A[M*WZJM[X([V^^4G)4NI
MQ4Q-D IY6]2WF^8\MH.K]'677.G:[2]_ADGM%PB,%5!#-)3O?#@M\/Q87!S0
M6D@X."#C"ZK;3;#1.T>E+?HO0-BI;#IZUQ"&DI(&-+PS_P##38\28^XR$D*X
M"*/T5BGM/P7\/^R%VK;WMEH]^FJ^Y.E=<)(;E5R,JWR\W,^6-SRQQR]Q!(R#
MU73W3@1X;;UKZ+<^Y:*EJ-=0U J8M0?Q6N;4Q2@@@QXD]@'&"UIP1T/19B(B
MA@> 6,>\/"'L9OS#;Z?=32TFIJ:TM8V@IIKA510Q>$&ACG1L>&R.;R-<"X$Y
M&<Y6E;TSF@="[;;.;#;:Z9IV4.F*/4M)1PVN2M=4S14T]XHQ(PR2O,S0&N(:
M[IR@=.R](JQ"WSX)-A^(V\TUXW<T[/J62@E;/;8C<*JEBI)F$/$C(XG\A(>U
MKNWEU10(R#CJ<?@J&T3P4[$WG0NB89+?6UVGW:?T_6FU,OM=-2R5)H*2I<7.
M9.Z,M$YYG,/3&6D=UF.W0VG(=*?T+H[=%;]/"D]29040%*QE/R>&YK3 &8<]
MGVG@!Q))))ZJ2VZV_LNVFFZ+2VG_ !FVFW1MAHXIYI:A\4+  QGBRN<]P:T-
M:,G& J\13?)8C:!X'>'3;#6=5N!HC1DEFU972R35MU9<ZR22KDD#N9U0US\2
MXYW<O/GE\L*'K;@:X<MQ=:TNX>L-&27;6%#,V>CO#KI61RTDC>4AT#6OQ'GE
M',&8YNQ67J(H8'3 PK*;C</NU>[&AH]O->Z8IM0:;BB9%!#4./K=.V'E\(P5
MO6IB<TM:<QR-)QU5G-%<"6P6BJB@EH[!77&"SR>):**YWFOKZ2D/-S>W!5S2
MQ3!I Y ]AY,#EPLSD1,#P"H76FW>F-?:6J-&ZAHW3:?JJ=M+/0TLLE&'4[6\
M@B:Z L<QO)[)#< CX=%93:/@WV%V+J*ZIVNTD_3+[GXIKV0W"JDBJ'2A_.]T
M;WE@<3(YV<9R?>LI4116'9X$>&TZ_&Z)T5+_ $\%1ZT-0_Q6N]:$N<]_$[>1
M';EZ*H=X>#G8;?JJH*O=323]3R6KPOX>R:XU<,5.8>4,>(HWAA<.1KLD$\PS
MW64:(F%AON)P&<,^ZNEM.Z.UOH0W:SZ4#FV!_P#$JJ&X6]KG-<6QW!CA58]A
MK1[?1H & OF_\!'#!JC;ZT;8WW;QEPTG8WQR6V"HN$\M?"^.5L[";E(7U;L2
M,:>LF,=.@692(H8'@%2.AM#Z:VYTS;-(Z2MXMEBM$(IZ&C#W2F*)H #3(\E[
M^@'5Q)57(B**(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B^7$@9 SU'XE8";N<46\&A.*':W9G3FS55J70VLWW%M[UTRO\&"RBEIVR
M1ND@Y"'>(X\HRYO99]O>(V/>[[+&N>< GHT9/;X#MW/DM:.O?20;,:4XE])<
M.C+2^YZUOTE;'ZW44$U.^A]4A\:0P32P?UN69R(Y,]//*(?NZ?G^O1;+(GE[
M&N<WD<YC'%N<EI<T$M_]).%]Y';(RM7=^]*;L78^(J'A_<RM?=F02ON=Q-'6
ML?1RMH_688HJ8PYJ/%/]671Y#?M%48/2OZ#L>]>G]L-?:&N.C=/:OK9*/2VM
M*T58@NCXR&DF%\#!!S2.8QO._KS>:*&1X_77Z*V\(I>EJ8:RFIZNG>'P55/#
M4P/'9\,\;9(WCX.8YI^H5([B:EKM(:.OFHK;:G7NNM=%/4TUK9)X3JN2.)SV
ML$@!+?:;U./GT1150F\VYU9-;8JNGEN,+"YU$V:/Q@[D+FM<P.+V\_3&6_%:
MJ-Q_2/:BT/QA[?<+53M7+2#6=1711:FDN8+',HX1-SLIRP9]D]N8K!7@PXU-
MW=R.,+B#O&K="5\LD5UL5OHM*LN#WQ:9A:74IFYV QR>LL FQR#'XKM./2\V
MVQ>DTX0-1W5S:&CABU)5ULK8>>6,OM<4@C<&-YY7 DL'GGL$4O-D;>('X^?Z
M;]%Z.Z>4RQQ.(P7PQ2$=\%[ XC/P)4=:?];>E@T)MENAI[1^K]#72U: O\]+
M;;9N)4LK8Z::H=X4 #Z5T $0-0]L;2]S0[.02%LBW"WLT%MMH*+<+4MXAI['
M5T='56]T?]=-7&XL8:2.""/,LGB/EC:XQAW)S9=A%-GKY=5=[(]Z+5AN3Z1F
MOV79:=4[K;/7#2VTUUJ88HM>^N2UC(HJF5D5-/-0Q0^+"V5TC#[9& [/8%;&
M=O-P=*;HZ0LNM]%W6"\Z=OM*RJM]?3N#F2L>UKB.A.',+N5P/4'H>J*&0=OK
MZW^:JRMFG@II9::#UF=K"8H.;D\5^#RLYCT',<#/DM2N\?I2[/LOOM:^'[56
MVE0S7M_JVTUBHF5[Y&W#/*XO$L<9C: Q[7')\^O1;<)?LC_>;^:\M?'_ !QG
MTM'#-F*%Q=6W/F+HF.+O\C@QDD9..XSV10<<#YA>FW1UZN]^L%#=+W9?X#75
M=-%4OMWK#:CPF31MDC'B-Z$EKAD=QV(ST6'W%#QC5O#37V*.];>2W>UZCK(Z
M&TW&.OY?'F?-'" Z)C'.C DD R[ /?LLV;9_H%%_];J/MT_^EV+5OZ3)C7V[
M:?F9&_&H:?'B,:_'_>-+U&0<?1%$[?A^>_X+9/H34%ZU+IVW7B^V$:=JZ^DI
MZQMO]9;5%D53&V:(^*W )<QX)&,@Y!ZA5GD#N0M;?%%Z0[:;@^M^A[-K"GJZ
MV]WNWV&EHZ04U5'3$34])&]XJVQ.A'ALEY@WGZD8[JV^]WI4=(;4V^TZHM>W
MUWU7HB6.VR:AU,R*MIH;*RXB'PW>$:=WK#6F4@ECL8;S'HB9'CX?BMJ>HKC5
MVFPWJYT-&:^LMUKKJVEH@[D-7/34LDT4 =Y&5[&L!Z]7=%AGP5<2FZG$-8-6
MW/<_:BIVNJ;#=*NCMT%56^M&YT\%9/ VH!+&>&UT43),8[/^"N/1<5NUESV
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M/D:=F/O\EK']([02W8;16RF<!53WUDD3 07N$-?3/?RL[NP!UQV[KI-NN/\
MUM0:8H+'NGLC=],:_M=#3VVIM,4M57QU=310MIVR"K@IS"SU@Q^)G)#>?JNT
MT+I#>GBKWHT?NUNOHQ^W.VFW4E7+I?34]5'7.U/Z_'R.FF=&&2TWJ\C62@2-
MZYY1C!11R#L/+[C_ #'S6'GIPK50R[+;(/J*.GDJ6W;2].Z=T,9J WU^TQN8
M)BWQ ,$C',M@W$%H;24? C>+:+!;/5!MO:JCD=1TSG^,+-%*)#(8BXN#_:!)
MR.V5AUZ8G;7=[>FQ[;Z'V?V_GU;+8+Y05]VF94BF90TM'<*2J'*9!RO_ *F$
M_9)(Q[^V7.]-\U=J3@KFTY9M&557K:YZ-H[%#IH2N:X5=-0,HI&F<MY1B0$]
M>F/HBEZ.=D=PQMUVW _#98S^B0(NWHWWT=S;%7TL%#N7'%!5QLJ8XV,FNH8T
M,F#QA@:.48Z$=,86&?HQ((6\+G&%"R&%L<<NI R,1,Y&8J[K@-9C [ 8 '8>
MY9:>CNMF[&P?!1J#:W7^V]5:]=T5+JQE#9O6#,*]^H9J]U.!/&PQLY6U#"??
MYJS_ *-K8C>_1FU?$5MCN7H2HT5>]Q1?9=-O?4-JV57K4EPGA&6CD9D3L'M.
M&.9%'^[_ (?QV\=@?BJK]$#<)++P#:[O-)&SUZB_[0WP3"-IF816W;V@_'/[
M.,CKT(Z=<8GO156_<3<W96_:OTSNQ#9[W6ZGU%'>Z6>T4]RK&MAOE9' VHJ)
M^:;EY&X:U_3EZ#H%T7HS=%<2^T.E=5\*VO-F);18#<=2PU^X4ESADB?17NLK
M9XI&T( #LPU'+AKB>OO6/E/M3QP^C"WYUK<MB= U6\FP>N[DVX?P**K@H!3S
MN<^><1ND$DL7/53.ZM#<HH XY=CT(Z=.GX>"V/T?H\X= \4%PXT+ON@RLUM0
MZ?OM74V:EML=KAN\\%DJ(J=SH8'LBD="6AX/A/()R<=5C/Z';4K]Y=YN++=W
M5_+<]8U>HJ&C9/6$2S6^"AJZNDB]69)GU8/BC8"8@T/'?)67G#C/Q.\3^JH]
MTM]M%S[-:,MEOK:.P:"-=%<S<V72D?1UCIJF'D>WP7/,C1*#G[(6NJFV7XI/
M1K<6>NMR-HMOZK=?83=>X155YM='616\VUT8>YIY<2S./K$SCT;UQY@HG]T@
M'&_GU 'Q_P!/@KC>FDM5N9O1P<W6.CIV7%VIKDQ]9'#&R:1HK*,#Q)&M#WX'
M0<[G8'1>@#2_73FG2>YL%I__ !&G7F\X]K=Q6<6.K^&G6.C]A:JCH],7:JKH
M[<^ZQ%TS75-/).)I'L:8?###CG SC '3IZ)-L:O4=;H?3<VK+!_1F^1VB@IJ
MVS>LLJ_59*>FBB</'9[+^8M)Z#H, HHCJ[KW=Q\ J[>]L;'/><-8USW'W-8.
M9Q^@&5B5O%LWP[<8VG;_ *#UW9;;JR*U1FGJG.8(:VV33APC>*AH\<$/ < '
M#.%EA5-YH)ACF!@G!'OS&X8^N<+2)HV\<6&PW$]OQK2EVKJM9;$ZIJ;.^DJ!
M<HJ=UH;2QN;/)#3EKIYO$D)=AC?AT11/PRM:O$5P \3?HT[E5\0G";N%=[IM
MQ9JQE??-,.=)+#;;>9QS0MBJIY?$:^(O:7LC]D=3U6_G@MXHJ3B\X5+;NI-2
MMH[S7:=O5)?+>_$HBK*.EFI97EY'*?$EB>X@#IV6,?$7Q';@\0NV]]V7V;VE
MN%XU-K&.*W5\]:Z2DI;/!(X1U4A]=@$,YCA>]PP1GEZ'J%E=P2<*<7"OPR6C
M9YLHJ[Z;??)[M78+"^OOAGJ3#R9+,4\U0Z(%I /*3T10 P3CIWCS^?E]=%K*
M]#534\F^G&EXL,+PW4%G#>>)AY :NJSRD@\O3N1CX]EE#=W; [3\8.N+YM!I
M@[B<3FO76]FH+/'5U BM#:2FY('R5DADI*7-*2_DS'S\O)U*Q!X1MO.*?A3X
MI.(/1T>S<NI-.[Q7&F?:==MND5-#;(8S/(^;U8 ME+!,",N!RT$=5T&AM)\6
MW!MQP[LZTCV=J=X]+;S5%G?1:EDN45*^V/I*?$L<(D;-)"V*24QNY"P2!F3T
M12Y.&CEQOX=-_/QSU^*Z/31U@_TT6CZO6]-'07JMAKI)*&G$313YLI>(Y9(
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M<YSX8'+G/7..^4;24['->V" .;]ES8(VN'R<&Y'T4RB(N" >_N(^_P!X[$?
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MX8]OFZKHG]/]/551?RRB?98[W)IBM8:6/F91U%IG947.EB#3S""JE=)-3X
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MX]%IOK8]>;6-B:T,G9*V'G>YH$;FEK"][G/.S0"XN)/7.5N I#ZBZC=*7.?
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MQ+K.TPT-'<G"J?1US;<:>:*'M.9URE,5,PL:XO#W/:0]O+F/O\MI>1\?N/\
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M=GFC>RFC:YIR!V/PZ+L_X?0EC8S149C9U:SU6'D:?>UO+RCZ *;:T- :T!H
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M'PRPT[IR30M:'BE:QF'3<XY3MR <I/H.K;I;;=R>OW"@H?$SR>NUE/2\^/\
M4\9[.;&>N,X5&:MTQH/=:PUNF+^+;J.SU(:*R@IJ^"=CP#EHE%/(['7MS#KY
M?'SX^D0WIT!NQQ(G9_4G$/<]E:';][(6U=#:Z^LI[C+<X XE\M,Z)C1 _L7.
M.2%L9]'#P\V7:325]U3:=]I-]:75[:22EO4ADB]193D^R:9]3,8B\.Y?:#>W
M8J^K]'"QZ;H-0U=TK*2YU<=/54-O^R+A'&YLSPZ&2.[EK:/F$&)\-?SC/( 7
M JRHM8?;>HJ[3]+:Z6KMM+)/35E>;K02/:86!LK9+4"ZKY#-F %S.1WO$AIW
MSFVSV>V]VAMU1;= V"'3U!4>U+2PR'P,@EV0P^PS)ZN(:,]SE5S#?[+45;Z&
M&ZVZ2L8<.IF5M.Z7/N;&'E[C[P&Y'FL2^/;?*Y\/7#)N!N/8JAL-[H8*:BMK
MC@N;)<IO5"]O," 8_$YAG!SVP>HT:;@[AZZV@X.-@^**VZEN#MT+KJ.IEU!<
MWU,[H[K27&_PPMB=2OE-/&(:29T8(9U SW4-/Z+N.JX(;E+7\C[I>18Z)\_/
M/+57(TCZLF9[G99"UC8XW2Y>X/E:>4M:XB:^ZQMVEII+=#0!T=ML_P!M5K(#
M'!%2V_UN.E;V,;6XDF<YTDC(\,!9$[V@YS0?4E--%!&Z::2.*)@+G22O;'&T
M#S<]Q#1]2I"AO=HN;G-M]RH:QS"0]M-503/:02,%D;W.';ID#*TE^D4XP]7Z
M=X>-CJ?0=PDLM[WMDT]%-<8R'2PLCJ;<RYM9T:3ZPV:5F006\P[X5L]V-RKO
MP@\7/"Y:-)72N.E-T[8R36]IJ:J>ICKJN6U4;XY0Z>20Q?Y3.^3EBP#D ],*
MI;N'=QKZ*FF,[(:RX1Z@EM]&6%W;-TY$V2N[20. B+W=I%!@/YI8W!W*TARI
MW#B#;Z*MJ(&P/FI*%]ACKZL/#.Q=J&0QT79QD$RA@Y)9]VEL;QR!Y!"] ]=<
MJ"VQ>-7UE-1Q?^94SQPM^AD<T'XX/1<T=?17"(34-535<)[24T\<[#_ZHG.
M^]:-M_M[M3;O^D/VEX7X[E44.WU/;+G6ZKME+,^%]U-791<*+FFB,<L7J[SD
M$'K]%%X+M]]0Z0XX]^.%RLN-3<M%VN:U#1M-52OF?:P:5]36 2RN=+)XCO\
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M_72V^ZTLE+41$C#P>21O<^)_1[#U!!^*]86F\6^^445?;:F.III0"',.2UV
M2Q[>K7-S@@@;J*B(L0LFB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B^'O;&QTCW!K&-+W.<<-:UHRXD]A@=5\SSQ4T4D\
MTC(HHF.DDDD<&L:Q@YG$N) &&@GJ5H]](GZ3*T;56RLV_P!I+M%<-5U,=125
M]73/:X49<TL.#@L)+21T.1CY!;#IG3%VU7<X;7::=TLLCAVDI!$-/&3O+-)@
MAC0,XS[QV&ZQEVN]%9:.2MKI1'&P$M;D=I*[N9&WJYQ..@VZG95!Z13TD^G-
MF++>-M=NKC%7Z]JX9*9]13R!WJ!<TAQR/8)Y2>Y!!'1>3K6.M=2Z[OE=J'5%
MVJKM=+A/)//45$CWC,CW.#6-<YS6AH=R^R!G 4OJW5E\UMJ"Y:EU#737"[72
M=\]54S/<\N<]SG  .)Y0WF(Z=_DJ;7OC0.@+5H:V,IZ6-LUPF:UU=7O:#+-+
MRC+6'&60M.>5@..\[]/,>J-45NHZQTDKG1TL9<*>E:3R,9G8N'1TAQ[3O/ P
M$1$6_K5D1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1%$A_TBF_XB'_K"STM/_A=!_P[/^EJ
MP+A_TBF_XB'_ *PL]+3_ .%T'_#L_P"EJL*[I'\7?D%KFH.E-\9/R:NP1$6.
M6M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B*6DBFCJ*:OH)WT5RHIHYZ6K@<Z.5CXWAX]
MIA:2"6@=3VZ=EO*X+/2.6^.UV/;+>&<P7* QT5%?9WEWK0)#(PYK?L\HY6^T
M[KWS@K1\H,L;W<LD,CH*F)S9()V$A\<C#S,(<.H]H#L?JM(UKH:U:SH#!61]
MG5Q!SJ2LCPV6*0C8%V/:C)QS-.W>,'KNNC-;7/1]<)J9W:T4I:VKI'DF-[,C
M+F#.&R 9PX;]QR-E[B;=<*.ZT5+<*"HCJ:2KACF@GB<U[)&2,#VD.:2.QZC/
M3LIU>=W@#](96:5N5#L_O7<S'9^=E+8+[5$D1%V,,=CJ026LR]W0?!>A2VW&
MBNU%37&W5,-915<3)J>H@>V2.2.1H>PM<PN:?9<//YKP_J735STM<YK;<HBU
MS'$PS 'LJB+/LR1NQ@Y&.9O5IV/<5[.T]J&W:EML-RMTK7QR-':1DCM89,#F
MCE;U:X'IM@C<*>1$6O+.HB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(N"0 2>PZG/3 '<_0=5RL"..KB_L?#+MS72PUE.[5EUI)XK7
M3"5AEA>6ECG.9[1_M<PR!Y$?#)6FU5U[N-+:[="Z>KJY&QQ,;YG=[CW,8/:<
M3T 5K6UE/;Z6:LJI!'! PO>X^70#Q<X[-'>2L5O27>D#T_LWIJ];5:.K65.M
M[E ZFFDII</H0YGM'F;EN3&X],CMV[+R17_4%TU)<ZR[7:LGK:VMJ):B6>>1
M[W.,KW/Q[9. WFP/Y=JQW8W-U'NQK*\:PU/6RUUSNE7+-))*XNY6&1QC:T9(
M;AA#< 8P/BK9KZ"\/-"4&B+-%2PL:^X3M9+<:H^TZ:HY '-82 6PQG(C:,9'
MM'<[^7=6:FJ=1U[Y7'DI(G.92PC(#(\[.<,X,C@/:/R"(B+H*U-$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$11(?\ 2*;_ (B'_K"STM/_ (70?\.S_I:L"X?](IO^
M(A_ZPL]+3_X70?\ #L_Z6JPKND?Q=^06N:@Z4WQD_)J[!$18Y:TB(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(NGNUIAN4;#ET=1 ]LL$T;W1O8]C@]I#F$.'M =B%N
M_P#1R\=E!106;8C<JL-/6PGU:RW2MJ"1(,Y+'/D=@].5K>9WR6EA4]>Z.L;X
M-VM%1+1WBVR,J:.J@>Z.1CX7"0>TPM)R6@$$G/;LM%UWHJ@UC:I*:=O9UD(+
MZ.I:!SQR@' /BQW1S?!;SH;6E;I"YLFC)DH9RV.LIB?9='D>VT=!(T>Z?D=E
M[K(9HJB*.>"1LL4K&OCD8X.:YK@'-(()!R"#W45:@_1?<;O_ &Z:0.UFMW"'
M7^C88J5U7-+_ %UYC=GP^6)V,&&%@R6Y)[E;?%X2NUKK+-<*FVUT3HJBFD=&
MX$;. /LO;XM<,$?'!W7MFVW&ENU#37"CD;+3U,;9&.!!QD;M=@G#FGV7#.Q"
M(B+'*^1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$7Q)(R)CY
M)'-8QC2][G' :UH)<23[@"416XW<W'LNU.@=1:WOM3'345FH9I2Z1[69F=&[
MP0W)R?ZS'0#K^*\.?&!Q(:CXA-S;SJ.Z7.HJK<RMJ(K9 9'"%D+'NC&(P[EP
M6L;_ &5MR]+OQBR7>XU&R6CKEB@H"8[K5TL^8ZIS@) QX8<?U9YF>>>G9>=.
MIF,TA<3YDGXN/VC\<GKE>S>!.@_LFVNU)<80+A<V--&'M'/3T) ((R,M?4$\
MQQ_  ",YSP+B5J;URJ%GI),TU([-06G:6IV]G;JV+S_BRI=$1>BUR1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$11(?](IO^(A_P"L+/2T_P#A=!_P[/\ I:L"
MX?\ 2*;_ (B'_K"STM/_ (70?\.S_I:K"NZ1_%WY!:YJ#I3?&3\FKL$1%CEK
M2(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(>O0]BB(BE]%;AZLX?=R+'NSH*HDH[C
M;:R-U='$?ZNHII'LCF$D9]AV(2\#F:<=PO87PO[_ %AXB=J[!KJT3Q.J:JDC
M%RIF2!TD%2QK8Y#(W/,WQ) YP! '7HO'C6TL5932T\K0YCV.&#[R"%D9Z._B
MNU'PW[^VS;B_WR2DVVUM5B"K=/[5/0R1]*=K X]/%F>!EA'R*\_\:=#,N5 =
M0T$0%=1M_K/*-YJ9HR0<#+G,W<WR!'>N]<'=:NH:P:>KI7&DJS_57..1#4$@
M 9)V;)TP.CL'Q*]AZ*3M];!<:*EKJ9XEIJNGAJ()!_[R.:-LC'#YM<"IQ>1U
MZF1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$18K\8>[M%L_LCJ
M^_R7!E%<W6^2*VM+@U\SY6NB?X?4'+>;/O64[B&@N)P!U)/0 #N2?<!U/P7F
M:],GQ#2W?5%MVIL]8WU:RMG];=3S!T<QF8V7^L##@X(P,]>_GA;QP[TT_5&J
M[9;^4FFCE%76.P"UM-3D2/#L[>V0&8_XL]RU_4]V;9K-5U9=B4L,5..]TTGL
MMQ_A!+C\%H:W*UA7ZOU)>;[<:J:IJ[G7U,KWS/+W\IF>6C+B3CE/;MCR]ULE
M-ULYGJ'O^.,?$=S]ZE%]&::%D$$<4;0UC&-:UK1@-:UH#6@>   7DR:1TTKY
M'GF<]Q<YQ.223DDGOR23E$1%75)$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$3('<X3(][?\ F;_-$1%QD>\'Y$'\
MD]KR9(?]V-Y^G9$7*)A_E!5GM]FEF=W^32IZ"UW.J<&T]NK9'.QRCU:89S_Z
M%0FJ:>F89*B>&GC:"723RQQ,: ,DE[W!H [R3@=_<JC(I)"&QQOD<<8:QCG'
M?I@-!)^0/0J1155!H7654YK:>P5LA=]D>%(,_P#VN>GG\?@J@H]G-T:\CU;2
M%6]O]IY+VAO7'8MZ_>M0K^)7#JUY^T]?:*M_*,N%=JFQTI SCI/7,/7(&VYV
M&ZS%/IG4=7CU6P7NIR<#U>U5TWAWQP.'?\N_JK:HK^VSALW4N,@8[3]13 X]
MIW7O_P"GW>7S^2N!:>#/<NY2B-_/1AV!SNC8<9_WCY?OLN5:E]+CT:-(]K]O
M\:M T?8L[23LK[3U_*S;?_N\U7-UZ-R?);5;.$7$R[\GV?HG4$_.[E:'4$L&
M3X?U@1 ?$[#O6(29QW6P2C]'WKN7DDGU$UK7=2SU>/I]<^_[C[L%5A;/1]5S
M?_$[X)/>!$ /P=G\>APN*7G]IOZ$=GADD_[<K#='Q[&GM-!>*J=Q&Q#6OH(6
M.P>_GP00MXHO1@XX5KVL&A:^F#L8?5U%%$P#;<D5#R/ARY6LO(/FW[P/S*9'
MO!^1![?(E;;+7P!:1B'->;ESM'5V6N;T'?\ M^[IV]WU[67A!V+T]S2R3MJ9
M&_:9F;N!@YZG'TZ]_-<_I/VLGHKWNZ&RZ.CXGZVN;G<D46F]"5=73O<2 WM:
MM]5%'31N)VEJ Q@WR1C;8G^B/Q8I*=M5=QIFRTYW+KE?(HI , GEB9$\R. Z
M,82XG8 [+4%!GQZ?V)"/6(>H8XC_ #C>YQ@=/?A9Z6C_ ,*H/^'C_P"EJN'J
M+;/:^VM%!8K9&X1OSXV7$Y!YA]H9QS#K\0NFEM#(HFMIQRLC;AC>_0=!^ ZX
M6[:;_:#\%]2ZDI=,WFFOFBJJ>::$5%_CIS3TTP>R.&"ODHY)F4LTV2<!\K(L
M#G?OM<:H]!GC8[1@UE9Z&AOU/3M%0+;02O;<JJD?'SR55)3SMC,T<?*,-(9)
M('>RS;!Z5%]O8Z,\KA@A?"]K45;1W&E@KJ"JIZVCJHV34U52S1ST\\3P',DA
MFB<YDC' [.:2"O#-;15EMJYZ&X4M115M+(Z&II*J&2GJ()6'#XY896MDC>T[
M%KF@_)$1%=*U1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$16EW*LDKXJ6^T#7,N%IJ
MJ>N@EB/)(V2EF;.W#FD$>TP9Z]?DKM+K[I3-JZ"H@<,A\;A^!5M64\=7334\
MC0YDL;F$. (PX8/7R5S1U,E)4P5$3BR2*1CVN:2""UP.Q'P7I_\ 1I\3U)Q
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M:HZAK@XXZ=.W7_'Z*S-=J2\7#F$]6\QN[L'08]W0_OXJDZ^XP4$3I9G@N.2
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M_P"'DN$1<#)+B7.)<XDDN<27$GJ23DDGO).2O536M:T-: UK0 UK0 UH&P
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M<[\AT6[RBX*-KZ5T9F8*D,[@MD'/\SD@>>?WFMK=PH[,T+^>734=4.F&F60
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M:P-=B*W8= QX.,2U#RU@]K9P;EP&X!Z*]UVUI9K4UX=,)96]F-]_7'5I/?\
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M[)RO(?$6XNJJ6:0NR):F.-HR?=#BXX_Y@/O^[U?P]H12SL:UON4KG/<>XNY
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MW@]_U'G[_CYA<]XA\2M.<.+2ZXWJH#ZF0%M#;(7-=65DO<UC,Y9&.KY7#E:
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MLMPJ)#":@V820MY&<ID#1*!G/*?<3TPJXT#JNIU9IV&\U]$;7/))-'+22O\
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MN%]+]"\,=!\-;5!9M$Z8M5AHZ=C6!U+31^MS<NX=55KPZJJ9 2?;FE>X9P"
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M(ZY/N_?U^*[^M):<$;_7X?6^%K_W[TI/:]22W>.+%#5G+7@="0W!^&<Y_16
M/8_(_DMC>\.FY-1:2JFT\ GJJ5A?"WH'=RXX=\@?WT6N>6*6%\D$S>2:-SV/
M;_JD$@#/TZKXS>EAPX_H)Q/K:ZCBD;9]5A]YI7EA$3*N5Y]>IHW^[B.7VFL]
MX,<"5[7X3:D^WM+P0S/::RTXHIAGVW1,:.PE<.OM,V)Z9&%*HB+S*SI\_P!
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M9_@3%AY',<YQ;[6 .C<#J>^%3*V?;@[;6;6]FJZ1\$<-P<QSH:L %Y>W+AU
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M]%1LD9C.#^_W^*Q]UM5NO=OJK7=:2"NH*V)T%335$;9(I(WC!!:X$9'4'J"
M0KVAKJF@J8:JEF?!4P/:^*6,EK@X';<>/0CH1U6G;5EMK]#Z@FTY?XGTTK9'
MMI)W-(9.S)Q@@8'L@>?<KK1[^^1^8Z']5M'W'VDTCN52O_CE V2XQ1O]2KFN
M+'P2%IPXAF.?J!W*ULZ\T)?MKZR:"ZQRU-GCE+8;B(W<OAN<0P'E![ @=^W7
MHOECQV]&.[Z%J*S46DX9+II:1\L\D$8YJJUL+L\CV >W P.PU[0<-'M8[_5F
MA.)U%?XHK==GMI;HUK&!SO9BJW# YF.)V>XC=IQN=EB/N!&6ZAJG$8#BW'3I
MCEQ^GX*@I/+Z_HKE;BB)]SCJ(7A[)AS @CW=CCS_ "[*VLGE]?T7OW@#7/N/
M![0E2\%KA9F4Q!SD>IRR4N^=^D0_D%YUU[3^K:POT0.1Z\^3_P#M:V7_ .[S
M^*@O^R?I^84J_P C\_T4T_[)^GYA2LGE]?T79F=/G^@6F2=WS_12A&"0H;^W
MU_0J*_[1^GY!0G]OK^A4).[YJFH2@'N?F?S4=07#!/W_ 'JFBAN&0?AU^Y2S
M^WU_0J:/8_(_DI5_;Z_H412K^_T_4J"[N/D[\E,/[#YJ6?Y?7\>BB.H^*CW.
M^'ZA6POS,7&;'<D9^6//Y]#A4])Y?7]%56H(PVM<[_6_3]^7\E2S^P^:^<&N
MH#3:RU+$?_W>LD&^=II72=?^;Y+Z>\/*@56AM*S YS9:*/.W^YA9%W>')CY?
M-2[QTS[OU7P)I(P7,>YIZ=B?>HC_ +)^GYA0'#(*U48R,],C*W(>77NPNXI=
M2W6D']7._P"&'$8^'R566W="]TG1T\HP1C#STQC)^)[]/BK:*75.2V4-0?WM
M/&[OSR@'N&Q[OK*N8KA6TY)BJ)6\O+@<QP1X'Q'^>5DY9=^;I2N:TUTK.7_;
M?[QC/7/<?I\%>S3W$W<Z;P\W)QQCN_W>_K]W[*UX$%I3QY8B"Q[FGW@G\.JQ
M<^E+?)DQ&2%QZ<AV61BU-7MPV=L52T#I*P..V/';Y;!;B].<5$KC&*BK:YN
M""YIS].O7.5>^R\0^G;HQC*Q].YQ^T2&]///4>??O_-:%(=1W2D<'1U$G3!
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M^0\AV"Y:TN/*WNJ@M=IEJ'M]DDYQV_?X9]_;JN53SS5,KYIY'22/)+G.))^
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M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$)PN
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M*X9CJZR,N=SN(<2!GKG'YDSTQW@G<'NQW=_U\]M7!5Q.7'BBVO\ Z>7+3_\
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MFM[QYC]"5;-XZY]_Z+Q/Q_A+-<Q2XP)K-2'.V[FOF#A\AR^?5>[_ $<*CM=
M31$GFI[W6MQW!CHX"T_$GF^BI12ZF%+KAZ[^H+OM%2[_ +1^GY!3#_M'Z?D%
M+O\ M'Z?D%<,_A^2D?O]Q_-J@R>7O_?]R@/[?7]"H\GE]?T4(C(PKA43W?'\
M\C\RI5_;Z_H5)N[GYE3C^WU_0J4>,'Y]559T^?Z!4%*J$_O]/U*BJ$_N/DKM
M47?P_P"$+X4%_P!H_3\@HR@O^T?WY(J,G=\_T4JH![GYG\U'4 ]S\S^:NV=?
ME^H4@Z'X?J%+*5<,CX^2FE+J=GNCY_F5:.V&?A^84NH;OM?^D_D5$4-WVO\
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M4.Y51#JO4]"YDL7BQ.;$][3EV8@7PG('F%N6G=+7:MKJ&HDI)(*%E3#++/*
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M]S\S^:FG]_I^I4J>Y^9_-5U1?[Q^7Y!0I/+Z_HI5_P!H_3\@IJ3R^OZ*5?\
M:/T_(*X1_O'Y?D%"D^P[Y*0?]D_3\PI^3[#ODI!_V3]/S"JLZ?/] J;OX?\
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MWFU!H?4!TE/>-.V^Z37%M,RJ=%/#8'U) C?@G,F6].W=% NW&/$?,'!^M_\
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M3U'0,YLCY=%CI>'NJ(<E]LJ6@9W,;L8 '\S\ED(N)6E*@AK;G39(QCM6$@[
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M=<9Q^:LS=][;4-K:#<33-#+?WWNW05-EM<39&.JZBHB86P&3D=X89*]K"YP
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M,499GH6DJBRGT]HQE75-,D!O]W[=[7/DJ)*RZUV 13QN+B'RAF>S9B,-CYB
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MP((!Z]0M1?I"M#?_ #BK[MUPY:'H*2KKJFZ1UFIKC34\3&:=IZ"I@KXFR/#
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M4-!'1W+G.,!862\%.]M\V TWPB76WB+15DU#-<I==^) ?&H_XT+I#!ZB#SM
MC:(,AV?[1^-"IT1J*AM%'3/I)JJ:IX83:6#( 913WA]9!.R&4MR(V/8]S3,<
M1-$!YG <N;FEXCZ3N5]KZUE;!1T])QGI=:F2I(@-38(Z"HII*B!K@'2RQR0L
M>*9H,[O6F\K#AV-AO W4U57PQ;6SUKY))S:F-+Y>;G+0QH;GFZG &!\NBR[5
M%;?:*M>WVC=.Z/M$0BH;%;:2CC#>@=)% R.63'<<[VE^#[U6J]#6:DDH+3;*
M*9P?+24%)3RN'1TD,#(W$$[[EJ\JW^NAN5\N]PIVED%=<JVJA80 6Q3U$DC
M0-@0UPV'1$1%DEB41$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$7QR#_6?_ ,Q1$1?6/G]Y_FF ?I\T1$5'W[1.G]172UW:\TAK*BT.D=0M
M?([P6&3',7PY\.0CNWG:>4]1A5>UC6AK6C#6M#6CR#6C &.V ![D14VQ1L<]
M[6-:^0ATC@ '/(:&@N/4X: !GH-E4=+(]L;'R.<R(%L;2XEK 27$-'09))..
MI7U^^^?S7&/G]Y_8^B(JF!MY=%37(&.@7'*,8\OF41/KZ^Y%RB(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
&(B(B+__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
